[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-post-Teva":3,"tag-alerts-Teva":642,"tag-art-Teva":766,"tag-health-Teva":767,"tag-material-Teva":768},[4,18,27,36,45,54,64,73,83,93,103,112,122,132,142,151,161,172,182,192,201,211,221,231,241,251,261,271,281,291,301,311,323,332,341,350,360,370,380,390,399,409,418,429,439,449,462,473,484,493,503,514,527,539,548,557,568,578,588,597,607,618,627],{"content":5,"subtitle":6,"type":7,"timestamp":8,"id":9,"slug":10,"imageUrl":11,"link":12,"user":13,"tags":14,"title":16,"videoUrl":17},"\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Boicot a la farmacéutica TEVA, y todas sus marcas, Tevagen, Dalvur, Belmac y Ratiopharm\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Boicot Teva\u003C\u002Fstrong>\u003Cbr>Por qué? \u003Cbr>-porque genera millones de dólares en ingresos para el régimen militar y colonial israelí, siendo así facilitadora del genocidio y del régimen de apartheid\u003Cbr>-porque se aprovecha de la ventajas de la ocupación, el monopolio y la explotación de los palestinos. \u003Cbr>-porque vende sus fármacos a palestinos por encima de su precio de mercado\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Teva es el mayor proveedor farmacéutico y empresa comercial de Israel, además de ser uno de los mayores fabricantes de medicamentos genéricos del mundo. Proporciona millones de dólares en ingresos fiscales al régimen colonial israelí y a su ejército. Este dinero financia directamente la maquinaria asesina utilizada por las fuerzas israelíes para destruir vidas palestinas, y que actualmente se está utilizando para masacrar a decenas de miles de palestinos, básicamente mujeres, ancianos y niños.\u003C\u002Fp>","Boicot a Teva, Tevagen, Davur, Belmac y Ratiopharm, a sus medicament¡No prescribas, ni dispenses, ni consumas! Tu dinero acaba derramando sangre, matando y destruyendo Palestina","post",1735228549795,"m55i2t3fuhv19vaoeuq","boicot-a-teva-tevagen-davur-belmac-y-ratiopharm-a-sus-medicamentos-y-productos","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1735228543\u002Fhzmsc4m2y24yurjlxua4.png","","jjgervas@gmail.com",[15],"Teva","Boicot a Teva, Tevagen, Davur, Belmac y Ratiopharm, a sus medicamentos y productos. ","d9mazC2-vsw",{"content":19,"videoUrl":12,"imageUrl":20,"type":7,"slug":21,"link":12,"tags":22,"user":13,"title":23,"timestamp":24,"subtitle":25,"id":26},"\u003Cp>Teva. Un gigante farmacéutico cuyas ganancias dañan la salud de la población de Palestina. Teva en España (y el mundo). Datos y nombres. La fábrica de Teva en España es una de las principales del mundo. Además de la fabricación, Zaragoza es responsable de la gestión integral del almacenamiento, empaquetado secundario y distribución de medicamentos en investigación destinados a ensayos clínicos en todo el mundo. \u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref1\">INFORME COMPLETO EN NOGRACIAS\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">\u003Cstrong>Teva en España, KOL, profesionales que recibieron 10.000 euros, o más, en 2023\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Teva declaró pagos (transferencias de valor) a casi 1500 profesionales de la sanidad en el año 2023 (la amplia mayoría en torno a los 600 euros). Destacan como KOL, key opinion leaders, con pagos de más de 10.000 euros:\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Patricia Pozo Rosich, Barcelona, neuróloga, 31.654\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">José Miguel Laínez Andrés, Valencia, neurólogo, 14.619\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Roberto Chacón Puig, Barcelona, farmacéutico, 14.324\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Rogelio Leira Muiño, Santiago de Compostela, neurólogo, 13.720\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Pablo Irimia Sieira, Pamplona, neurólogo, 13.173\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">María Carmen González Oria, Sevilla, neuróloga 13.629\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Mariano Huerta Villanueva, Barcelona, neurólogo 12.502\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Roberto Belvis Nieto, Barcelona, neurólogo, 12.417\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Julio Pascual Gómez, Santander, 11.914\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Samuel Díaz Insa, Valencia, neurólogo, 11.834\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Sonia Santos Lasaosa, Zaragoza, neuróloga, 11.130\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Jaime Samuel Rodríguez Vico, Madrid, neurólogo, 10.624\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">\u003Cstrong>Teva en España, organizaciones que recibieron 10.000 euros, o más, en 2023\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Teva declaró pagos (transferencias de valor) a 45 organizaciones, en torno a los 3.000 euros. Destacan:\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación SEN (Sociedad Española de Neurología), Barcelona, 149.645\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundació Hospital Universitari Valle D'Hebron. Institut de Recerca, Barcelona, 112.850\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Sociedad Española de Farmacia Clínica, Familiar y Comunitaria, SEFAC, Madrid, 90.985\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación Investigación y Formación de la SMEG (Sociedad Española de Médicos Generales y de Familia), Madrid, 87.483\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundació Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, 53.800\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación para la Investigación del Hospital Universitario La Fe4, de la Comunidad Valenciana, Valencia, 43.024\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundació Privada Mon Clinic, Barcelona, 42.350\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Respira, Fundación Española del Pulmón, SEPAR\u003Cspan style=\"font-style: normal;\"> (\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"font-style: normal;\">Sociedad\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"font-style: normal;\"> Es\u003C\u002Fspan>pañola de Neumología y Cirugía Torácica)\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">, Barcelona, 30.008\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundació Privada de la Societat Catalana de Neurología, Barcelona, 18.416\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación para la Investigación Biomédica. Hospital La Paz, Madrid, 14.092\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación de la Sociedad Española de Alergología e Inmunología Clínica para el Fomento de la Investigación, Barcelona, 12.100\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Sociedad Aragonesa Aparato Respiratorio, Zaragoza, 12.100\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación Sociedad Andaluza de Neurología, Sevilla, 11.566\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, Soria, 11.353\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Sociedad Española de Neurología, San Sebastián de los Reyes, 10.865\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación ISA (Instituto de Investigación Sanitaria, Aragón), Zaragoza, 10.587\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Institut Catalá de la Salut de Barcelona, Barcelona, 10.000\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>¿Por qué proponemos el b\u003C\u002Fstrong>\u003Cstrong>oicot a la farmacéutica TEVA, y todas sus marcas, Tevagen, Dalvur, Belmac y Ratiopharm? \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">¿Por qué?\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque genera millones de dólares en ingresos para el régimen militar y colonial israelí, siendo así facilitadora del genocidio y del régimen de apartheid\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque se aprovecha de la ventajas de la ocupación, el monopolio y la explotación de los palestinos\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque vende sus fármacos a palestinos por encima de su precio de mercado\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp> \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1735808655\u002Fr1qqfqa9vrcjzsnqin4m.jpg","teva-en-espana-y-en-el-mundo-datos-y-nombres",[15],"Teva en España (y en el mundo). Datos y nombres.",1735808665188,"Teva. Un gigante farmacéutico cuyas ganancias dañan la salud de la población de Palestina. Texto completo","m5f3b4vfwyped48pojq",{"videoUrl":12,"tags":28,"user":13,"link":12,"timestamp":29,"content":30,"id":31,"imageUrl":32,"title":33,"slug":34,"subtitle":35,"type":7},[15],1735809586462,"\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Press release\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Report just published, \u003C\u002Fstrong>\u003Cstrong>Teva a case study:\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref1\" target=\"_blank\" rel=\"noopener\">“\u003Cstrong>Teva in Spain. A pharmaceutical giant whose profits harm the health of the people of Palestine”. \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cbr>\u003C\u002Fstrong>\u003Cspan style=\"font-weight: normal;\">Free access to the full report at: \u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fa> \u003C\u002Fspan>\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Author:\u003Cbr>\u003Cstrong>HealthWorkers4PalestineSpain (HealthWorkers4PalestineSpain, \u003C\u002Fstrong>\u003Cstrong>HW4PalestineSpain\u003C\u002Fstrong>\u003Cstrong>)\u003C\u002Fstrong>\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote1sym\" name=\"sdendnote1anc\">\u003Csup>i\u003C\u002Fsup>\u003C\u002Fa>\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Contact: hcw4palestinespain@gmail.com\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Introduction\u003C\u002Fstrong>\u003Cbr>Teva was founded in 1901. Its headquarters are in Israel. It has a plant in Zaragoza, Spain, with 600 workers, where many medicines marketed by Teva worldwide are produced\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote2sym\" name=\"sdendnote2anc\">\u003Csup>ii\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote3sym\" name=\"sdendnote3anc\">\u003Csup>iii\u003C\u002Fsup>\u003C\u002Fa>.  Zaragoza is also \u003Cspan class=\"ryNqvb\">responsible for the comprehensive management of storage, secondary packaging and distribution of investigational medicinal products intended for clinical trials worldwide.\u003C\u002Fspan>\u003Cbr>\u003Cbr>\u003Cstrong>About Teva and its medicines\u003C\u002Fstrong>\u003Cbr>Teva forecasts revenues of over $16.4 billion in 2024, relying on generic medicines (which have lost their patents) that are sold only under the name of the active ingredient, such as paracetamol, omeprazole, enalapril, metformin, budesonide, monteluskat, etc. In Spain under the names Teva, Tevagen, Davur, Belmac and Ratiopharm. Teva is the world's largest generic drug company.\u003Cbr>It also markets other drugs such as Austedo (deutetrabenazine) for Huntington's disease and various GLP-1 drugs (gliclazide, sitagliptin, liraglutide, etc) for diabetes-obesity. \u003Cbr>Its ‘star’ products are Ajovy (fremanezumab) for migraine, Copaxone (glatiramer) for multiple sclerosis, Uzedy (risperidone) for schizophrenia and Azilect (rasagiline) for parkinson\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote4sym\" name=\"sdendnote4anc\">\u003Csup>iv\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote5sym\" name=\"sdendnote5anc\">\u003Csup>v\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Teva and corruption\u003C\u002Fstrong>\u003Cbr>To promote sales of its medicines, Teva has engaged in corrupt practices that have been discovered and condemned. \u003Cbr>Thus, a fine in 2016, in the United States, of 519 million dollars, in relation to bribes to sell Copaxone\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote6sym\" name=\"sdendnote6anc\">\u003Csup>vi\u003C\u002Fsup>\u003C\u002Fa>.\u003Cbr>In 2022, also in the United States, Teva was ordered to pay $4.25 billion for off-label promotion of its opioid drugs, which contributed to the epidemic of overdose deaths\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote7sym\" name=\"sdendnote7anc\">\u003Csup>vii\u003C\u002Fsup>\u003C\u002Fa>.\u003Cbr>In 2023, Teva was fined $225 million for its corrupt practices with pravastatin (for ‘cholesterol’)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote8sym\" name=\"sdendnote8anc\">\u003Csup>viii\u003C\u002Fsup>\u003C\u002Fa>.\u003Cbr>For bribery, also in relation to Copaxone, a US fine of $450 million in 2024\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote9sym\" name=\"sdendnote9anc\">\u003Csup>ix\u003C\u002Fsup>\u003C\u002Fa>.\u003Cbr>In relation to the same drug, Teva was fined 462.6 million euros by the European Union in 2024 for abuse of dominance\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote10sym\" name=\"sdendnote10anc\">\u003Csup>x\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">Between 2010 and 2024, Teva paid US$9 billion in convictions and fines for corruption proven in courts around the world\u003Csup>\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote11sym\" name=\"sdendnote11anc\">xi\u003C\u002Fa>\u003C\u002Fsup>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Currently, at the end of 2024, Teva is under investigation in the US for increasing prices and impeding competition by making changes to its generic asthma and COPD (chronic obstructive pulmonary disease) medicines\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote12sym\" name=\"sdendnote12anc\">\u003Csup>xii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">\u003Cbr>\u003C\u002Fspan>\u003Cspan lang=\"en-US\">\u003Cstrong>Teva, sales in Spain\u003C\u002Fstrong>\u003C\u002Fspan>\u003Cspan lang=\"en-US\">\u003Cbr>In 2023, in Spain, Teva was, by volume of sales to the Sistema Nacional de Salud (the public health system), the third largest pharmaceutical company, with 70 million packs and spending of more than 500 million euros.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Teva's advertising to professionals in Spain in 2023\u003C\u002Fstrong> \u003Cbr>Industries call the financing of their marketing activities with payments to professionals ‘transfers of value’, including travel, accommodation, meals and remuneration for consultancy, conferences and other activities.\u003Cbr>In Spain, in 2023, Teva declared €2,010,412 in ‘transfers of value”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote13sym\" name=\"sdendnote13anc\">\u003Csup>xiii\u003C\u002Fsup>\u003C\u002Fa>.\u003Cbr>Payments to healthcare professionals €961,819 \u003Cbr>Payments to associations: €811,811 \u003Cbr>Payments related to research: €236,782 \u003Cbr>Teva reported payments (transfers of value) to almost 1500 healthcare professionals in 2023 (the vast majority at around €600). There wre 12 professionals with ‘transfers of value’ of more than €10,000 in 2023. Stand out as the best paid:\u003Cbr>- Patricia Pozo Rosich, Barcelona, neurologist, €31,654. \u003Cbr>- José Miguel Laínez Andrés, Valencia, neurologist, 14,619 €. \u003Cbr>- Roberto Chacón Puig, Barcelona, pharmacist, 14,324 €. \u003Cbr>- Rogelio Leira Muiño, Santiago de Compostela, neurologist, 13,720 €. \u003Cbr>- Pablo Irimia Sieira, Pamplona, neurologist, €13,173 \u003Cbr>- María Carmen González Oria, Sevilla, neurologist €13,629 \u003Cbr>Teva declared payments (transfers of value) to 45 organizations, around €3,000 each. Of particular note are: \u003Cbr>- SEN Foundation (Spanish Society of Neurology), Barcelona, 149,645 €. \u003Cbr>- Fundació Hospital Universitari Valle D'Hebron. Institut de Recerca, Barcelona, 112,850 €.\u003Cbr>- Sociedad Española de Farmacia Clínica, Familiar y Comunitaria, SEFAC, Madrid, 90,985 €.\u003Cbr>- Fundación Investigación y Formación de la SMEG (Sociedad Española de Médicos Generales y de Familia), Madrid, 87,483 €. \u003Cbr>- Fundació Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, 53,800 €. \u003Cbr>\u003Cbr>\u003Cstrong>Why do we propose a boycott of the pharmaceutical company TEVA, and all its brands, Tevagen, Dalvur, Belmac and Ratiopharm? \u003C\u002Fstrong> \u003Cbr>Why?\u003Cbr>- because it generates millions of dollars in revenue for the Israeli military and colonial regime, thus facilitating genocide and the apartheid regime\u003Cbr>- because it profits from the advantages of occupation, monopoly and exploitation of the Palestinians\u003Cbr>- because it sells its pharmaceuticals to Palestinians above their market price\u003Cbr>Teva's profits come directly from decades of colonisation and exploitation of Palestinian land and people and help finance Israel's illegal and criminal activities. It is our duty to do all we can to ensure that our money is not used to further genocidal and colonial oppression\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote14sym\" name=\"sdendnote14anc\">\u003Csup>xiv\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Teva drugs\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">‘The Health Authorities do NOT warn that this medicine seriously harms Palestinian health’.\u003Cbr>Boycott Teva, Tevagen, Davur, Belmac and Ratiopharm, their medicines and products.\u003Cbr>Don't prescribe, don't dispense, don't consume\u003Cbr>Don't help kill Palestinian women, children and the elderly.\u003C\u002Fp>\n\u003Cdiv id=\"sdendnote1\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote1anc\" name=\"sdendnote1sym\">i\u003C\u002Fa>Profesionales de la sanidad por Palestina, España (HW4PalestineSpain). ¿Quiénes somos? \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fsobre-nosotros\">https:\u002F\u002Fhw4p.es\u002Fsobre-nosotros\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote2\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote2anc\" name=\"sdendnote2sym\">ii\u003C\u002Fa>Teva Israel. \u003Ca href=\"https:\u002F\u002Fwww.behance.net\u002Fgallery\u002F117083769\u002FTeva-Israel-Brand-Presentation\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.behance.net\u002Fgallery\u002F117083769\u002FTeva-Israel-Brand-Presentation\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote3\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote3anc\" name=\"sdendnote3sym\">iii\u003C\u002Fa>El consejero de Sanidad visita la planta de Teva Pharma en Zaragoza que produce 8.700 millones de dosis de fármacos al año. \u003Ca href=\"https:\u002F\u002Fwww.aragonhoy.es\u002Fsanidad\u002Fconsejero-sanidad-visita-planta-teva-pharma-zaragoza-produce-8-700-millones-dosis-farmacos-ano-96176\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.aragonhoy.es\u002Fsanidad\u002Fconsejero-sanidad-visita-planta-teva-pharma-zaragoza-produce-8-700-millones-dosis-farmacos-ano-96176\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote4\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote4anc\" name=\"sdendnote4sym\">iv\u003C\u002Fa>Teva banks on blockbuster Austedo sales as COVID-19, Copaxone generics take their toll. \u003Ca href=\"https:\u002F\u002Fwww.fiercepharma.com\u002Fpharma\u002Fteva-banks-blockbuster-austedo-sales-as-covid-19-copaxone-generics-take-their-toll\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.fiercepharma.com\u002Fpharma\u002Fteva-banks-blockbuster-austedo-sales-as-covid-19-copaxone-generics-take-their-toll\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote5\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote5anc\" name=\"sdendnote5sym\">v\u003C\u002Fa>Teva eleva sus previsiones, aupada por los fármacos contra la enfermedad de Huntington. \u003Ca href=\"https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-eleva-sus-previsiones-aupada-por-los-farmacos-contra-la-enfermedad-de-huntington\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-eleva-sus-previsiones-aupada-por-los-farmacos-contra-la-enfermedad-de-huntington\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote6\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote6anc\" name=\"sdendnote6sym\">vi\u003C\u002Fa>Teva agrees to pay US$519m to settle corruption charge. \u003Ca href=\"https:\u002F\u002Fpharmaceutical-journal.com\u002Farticle\u002Fnews\u002Fteva-agrees-to-pay-us519m-to-settle-corruption-charge\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fpharmaceutical-journal.com\u002Farticle\u002Fnews\u002Fteva-agrees-to-pay-us519m-to-settle-corruption-charge\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote7\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote7anc\" name=\"sdendnote7sym\">vii\u003C\u002Fa>Opi­oids Mak­er Teva Agrees to $4.25 bil­lion set­tle­ment: Pre­lim­i­nary Agree­ment Will Pro­vide Cash and Nalox­one to Address Opi­oids Crisis. \u003Ca href=\"https:\u002F\u002Fwww.texasattorneygeneral.gov\u002Fnews\u002Freleases\u002Fopioids-maker-teva-agrees-425-billion-settlement-preliminary-agreement-will-provide-cash-and\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.texasattorneygeneral.gov\u002Fnews\u002Freleases\u002Fopioids-maker-teva-agrees-425-billion-settlement-preliminary-agreement-will-provide-cash-and\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote8\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote8anc\" name=\"sdendnote8sym\">viii\u003C\u002Fa>Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges. \u003Ca href=\"https:\u002F\u002Fedition.cnn.com\u002F2023\u002F08\u002F21\u002Finvesting\u002Fteva-pharmaceuticals-price-fixing-settlement\u002Findex.html\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fedition.cnn.com\u002F2023\u002F08\u002F21\u002Finvesting\u002Fteva-pharmaceuticals-price-fixing-settlement\u002Findex.html\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote9\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote9anc\" name=\"sdendnote9sym\">ix\u003C\u002Fa>Drug Maker Teva Pharmaceuticals Agrees to Pay $450M in False Claims Act Settlement to Resolve Kickback Allegations Relating to Copayments and Price Fixing. \u003Ca href=\"https:\u002F\u002Fwww.justice.gov\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.justice.gov\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote10\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote10anc\" name=\"sdendnote10sym\">x\u003C\u002Fa>Commission fines Teva €462.6 million over misuse of the patent system and disparagement to delay rival multiple sclerosis medicine. \u003Ca href=\"https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_24_5581\">https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_24_5581\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote11\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote11anc\" name=\"sdendnote11sym\">xi\u003C\u002Fa>\u003Cspan style=\"font-family: Arial, sans-serif;\">Violation Tracker Global: Current Parent Summary. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fviolationtrackerglobal.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\">\u003Cspan style=\"color: #000080;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cu>https:\u002F\u002Fviolationtrackerglobal.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-family: Arial, sans-serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote12\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote12anc\" name=\"sdendnote12sym\">xii\u003C\u002Fa>FTC opens investigation into Teva, escalating patent fight with pharma industry. \u003Ca href=\"https:\u002F\u002Fwww.washingtonpost.com\u002Fhealth\u002F2024\u002F07\u002F01\u002Fteva-patent-pharma-generic-inhaler\u002F\">https:\u002F\u002Fwww.washingtonpost.com\u002Fhealth\u002F2024\u002F07\u002F01\u002Fteva-patent-pharma-generic-inhaler\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote13\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote13anc\" name=\"sdendnote13sym\">xiii\u003C\u002Fa>Teva, Spain. Transparency. Informe de transparencia, 2023. \u003Ca href=\"https:\u002F\u002Fviewer.tevapharm.com\u002Fview\u002F385844187\u002F\">https:\u002F\u002Fviewer.tevapharm.com\u002Fview\u002F385844187\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote14\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote14anc\" name=\"sdendnote14sym\">xiv\u003C\u002Fa>Israeli-owned big pharma is now being targeted by UK activists. Complicit in genocide. \u003Ca href=\"https:\u002F\u002Fwww.thecanary.co\u002Fuk\u002Fnews\u002F2024\u002F03\u002F05\u002Fteva-uk-protest\u002F\">https:\u002F\u002Fwww.thecanary.co\u002Fuk\u002Fnews\u002F2024\u002F03\u002F05\u002Fteva-uk-protest\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>","m5f3x2ksj5kupuro23","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1735809574\u002Fcbpdo4czqhjarrhkrrey.png","Teva, corruption in the world. A case study: “Teva in Spain\". ","teva-corruption-in-the-world-a-case-study-teva-in-spain","“Teva in Spain. A pharmaceutical giant whose profits harm the health of the people of Palestine”. ",{"videoUrl":12,"link":12,"timestamp":37,"user":13,"tags":38,"imageUrl":39,"content":40,"type":7,"slug":41,"title":42,"subtitle":43,"id":44},1736001338305,[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1736001332\u002Fer4summteojkivusotct.png","\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Sanciones a Israel\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>Podemos pedir sanciones internacionales contra Israel por sus crímenes en Palestina. Debemos hacerlo, y presionar además con manifestaciones, escritos, denuncias, huelgas, agitación y demás medios.\u003Cbr>Pero también podemos sancionar a Israel nosotros mismos, sin tener que esperar a ninguna decisión internacional.\u003Cbr>\u003Cbr>Nuestra mejor arma de «acción directa» es el boicot a los productos y medicamentos de Teva. \u003Cbr>\u003Cbr>Teva es un gigante farmacéutico, la mayor empresa de medicamentos genéricos del mundo. Teva prevé unos ingresos de más de 16.400 millones de dólares en 2024, basándose en los genéricos.\u003Cbr>\u003Cbr>\u003Cstrong>Hay tres argumentos éticos para el boicot: \u003C\u002Fstrong>\u003Cbr>\u003Cstrong>1\u002F Los beneficios de Teva sirven para pagar impuestos en Israel y financiar su actividad terrorista, \u003C\u002Fstrong>\u003Cbr>\u003Cstrong>2\u002F Teva monopoliza el mercado palestino de medicamentos, e impone precios abusivos y \u003C\u002Fstrong>\u003Cbr>\u003Cstrong>3\u002F Teva es una empresa corrupta y corruptora; entre 2010 y 2024, Teva pagó 9.000 millones de dólares en condenas y multas por corrupción probada en tribunales de todo el mundo.\u003C\u002Fstrong>\u003Cbr>\u003Cbr>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\">Tienes información general sobre Teva en el mundo, y el estudio de caso concreto de España: 'Teva, corrupción en el mundo. Un estudio de caso: 'Teva en España' \u003C\u002Fa>\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Hay que conseguir un boicot a Teva en las farmacias hospitalarias y comunitarias. Hay que conseguir la no prescripción (médicos), la no dispensación (farmacéuticos) y la no utilización (pacientes y familiares) de medicamentos de Teva y sus empresas filiales (en España, por ejemplo, Teva, Tevagen, Dalvur, Belmac y Ratiopharm).\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Hay que emplear la información de transparencia de distintos países (Physician Payments Sunshine Act \u003Ca href=\"https:\u002F\u002Fwww.medispend.com\u002Fresources\u002Fsunshine-act-open-payments-overview-1\u002F\">https:\u002F\u002Fwww.medispend.com\u002Fresources\u002Fsunshine-act-open-payments-overview-\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fwww.medispend.com\u002Fresources\u002Fsunshine-act-open-payments-overview-1\u002F\">1\u002F\u003C\u002Fa>   para denunciar a los key opinion leader (KOL) que reciben mayores cantidades de Teva, y a las asociaciones de profesionales y de pacientes que reciben también grandes cantidades de Teva.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>Se trata de lograr un movimiento social, no solo de profesionales sanitarios ni de \"palestinos\". El boicot a Teva es cuestión moral profunda, por las tres cuestiones éticas mencionadas. Por ejemplo, la denuncia de las farmacias comunitarias y hospitalarias que cooperan con Teva como si fuera cooperación con un \"cartel de drogas ilegales\", cuestión profesional pero sobre todo social.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>Tenemos una potentísima arma en nuestras manos. Un arma no-violenta. Un arma de aplicación inmediata. ¡Tenemos que utilizarla YA!\u003C\u002Fp>","sanciones-accion-directa-social-contra-israel-boicot-a-teva-arma-no-violenta","¿Sanciones? Acción directa social contra Israel. Boicot a Teva, arma no violenta.","Tenemos un arma de aplicación inmediata, por profundas razones morales. ¡Tenemos que utilizarla YA!","m5ia1a6l6lkxaiabl48",{"imageUrl":46,"timestamp":47,"link":12,"tags":48,"user":13,"id":49,"videoUrl":12,"content":50,"title":51,"subtitle":52,"type":7,"slug":53},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1736001730\u002Fzjufdlxmpjxow99n5xzl.png",1736001853028,[15],"m5iadug6pf9z57x133","\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Sanctions on Israel\u003C\u002Fstrong>\u003Cbr>We can call for international sanctions against Israel for its crimes in Palestine. We must do so, and we must exert pressure with demonstrations, writings, denunciations, strikes, agitation and other means.\u003Cbr>But we can also sanction Israel ourselves, without having to wait for any international decision.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>Our best ‘direct action’ weapon is the boycott of Teva products and medicines.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>Teva is a pharmaceutical giant, the world's largest generic drug company. Teva forecasts revenues of over $16.4 billion in 2024, relying on generic.\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>There are three ethical arguments for the boycott:\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>1\u002F Teva's profits serve to pay taxes in Israel, and finance its terrorist activity,\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>2\u002F Teva monopolises the Palestinian drug market, and imposes abusive prices and\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>3\u002F Teva is a corrupt and corrupting company; between 2010 and 2024, Teva paid US$9 billion in convictions and fines for corruption proven in courts around the world.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\">You have general information about Teva in the world, and the specific case study of Spain: ‘Teva, corruption in the world. A case study: ‘Teva in Spain’\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>A boycott of Teva in hospital and community pharmacies must be achieved. It is necessary to achieve the non-prescription (doctors), non-dispensing (pharmacists) and non-use (patients and relatives) of medicines from Teva and its affiliated companies (in Spain, for example, Teva, Tevagen, Dalvur, Belmac and Ratiopharm).\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>Use the transparency information from different countries (\u003Ca href=\"https:\u002F\u002Fwww.medispend.com\u002Fresources\u002Fsunshine-act-open-payments-overview-1\u002F\">Physician Payments Sunshine Act\u003C\u002Fa>  https:\u002F\u002Fwww.medispend.com\u002Fresources\u002Fsunshine-act-open-payments-overview-1\u002F  ) to expose the key opinion leaders (KOLs) that receive larger amounts from Teva, and the professional and patient associations that also receive large amounts from Teva.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>The aim is to build a social movement, not only of health professionals and ‘Palestinians’. The boycott of Teva is a profound moral issue, because of the three ethical issues mentioned above. For example, the denunciation of community and hospital pharmacies that cooperate with Teva as if it were cooperation with an ‘illegal drugs cartel’, a professional but above all a social issue.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>We have a very powerful weapon in our hands. A non-violent weapon. We have to use it NOW!\u003C\u002Fp>","Sanctions? Our best ‘direct action’ weapon is the boycott of Teva products and medicines.","The boycott of Teva is a profound moral issue.","sanctions-our-best-direct-action-weapon-is-the-boycott-of-teva-products-and-medicines",{"content":55,"slug":56,"imageUrl":57,"type":7,"id":58,"timestamp":59,"videoUrl":12,"title":60,"subtitle":61,"tags":62,"user":63,"link":12},"\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>To: \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Primary Care profesionals, patients and relatives\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>\u003Cstrong>Subject: \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Raising awareness of ethical challenges related to the pharmaceutical company Teva.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cbr>Who we are\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">We are a group of healthcare professionals\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote1sym\" name=\"sdendnote1anc\">\u003Csup>i\u003C\u002Fsup>\u003C\u002Fa> moved by the humanitarian catastrophe and the total destruction of the healthcare system in Gaza. We cannot remain indifferent to the suffering and death of tens of thousands of Palestinian children, women and civilians for more than a year, nor to the targeted killing of healthcare professionals. We therefore write in the hope of engaging together in concrete action aimed at reducing this suffering, or at least not contributing to it.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Teva\u003C\u002Fstrong>\u003Cbr>The large Teva industry, responsible for the manufacture of the branded drugs Teva (and Tevagen, Ratiopharm and Davur in Spain), is among the largest generic drug companies in the world\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote2sym\" name=\"sdendnote2anc\">\u003Csup>ii\u003C\u002Fsup>\u003C\u002Fa> and generates millions of dollars in revenue for the Israeli military and colonial regime, thus being a facilitator of genocide, of the apartheid regime and directly responsible for health apartheid in Palestine. Headquartered in Tel Aviv, Teva has four production sites in Israel and also operates in illegal settlements in the West Bank.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Teva is a corrupting pharmaceutical company that has been condemned up $ 9 billions to fines and penalties for its irregular activity\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote3sym\" name=\"sdendnote3anc\">\u003Csup>iii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>The market position of Teva\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Teva Pharmaceutical sees more growth in 2025 after beating third-quarter profit forecasts, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease. For examplo, in U.S. sales of Uzedy rose to $35 million in the third quarter from $2 million a year earlier and were on track for $100 million in 2024. Sales of migraine treatment Ajovy rose 21% to $137 million, while Huntington's disease drug Austedo jumped 28% to $435 million, with an expected $1.6 billion in 2024. Generic drug sales in the United States climbed 30% to $1.09 billion, led by a copycat version of Revlimid that treats multiple myeloma. Generic sales in Europe grew 10% to $973 million\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote4sym\" name=\"sdendnote4anc\">\u003Csup>iv\u003C\u002Fsup>\u003C\u002Fa>. In Spain, prescriptions dispensed in community pharmacies accounted for an expenditure of over €13 million in 2023\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote5sym\" name=\"sdendnote5anc\">\u003Csup>v\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Boycott\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Since October 2023, while the state of Israel commits genocide in Gaza, voices have been raised around the world calling for a boycott of Teva, such as the campaign “Teva j'en veux pas” in France\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote6sym\" name=\"sdendnote6anc\">\u003Csup>vi\u003C\u002Fsup>\u003C\u002Fa>, “non à Teva” in Belgium, “Teva, no grazie!” in Italy, “Boikot Teva Israeldar Farmazeutikarik EZ!” in Euskadi or the protest action in front of the Teva factory in Zaragoza (Spain) and elsewhere.\u003Cbr>Boycotting companies from a country that disregards human rights is a pressure tool that has proven effective in the past; for example, the boycott movement, which urged world citizens to avoid buying products from South Africa, played an important role in the fall of South African apartheid in 1991\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote7sym\" name=\"sdendnote7anc\">\u003Csup>vii\u003C\u002Fsup>\u003C\u002Fa>. \u003Cbr>From our point of view, as prescribers and consumers of pharmaceuticals, but also as simple individuals, it is our collective responsibility to participate in the boycott of companies like Teva, which support Israel's position despite ongoing war crimes.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">According to the recent declaration of the International Court of Justice, Israel illegally occupies Palestine and UN member states have an obligation to avoid aiding Israeli activities, thus reinforcing the legitimacy of international calls for boycott, divestment and sanctions (BDS)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote8sym\" name=\"sdendnote8anc\">\u003Csup>viii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>What to do? No prescribing (physicians), no dispensing (pharmacist), no consumption (patients)\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">In primary care we can exercise a key role for health and human dignity and therefore we strongly encourage you to adopt an ethical attitude, avoiding prescribing Teva medicines or those of its subsidiaries Tevagen, Ratiopharm and Davur. \u003Cbr>To do this, we can carry out different actions that can facilitate the boycott of this brand:\u003Cbr>1.-Appealing to pharmacists: through the dissemination of a letter addressed to community pharmacies\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote9sym\" name=\"sdendnote9anc\">\u003Csup>ix\u003C\u002Fsup>\u003C\u002Fa>. Also from the local prescription application, writing an annotation to the community pharmacy urging them not to dispense these brands, or prescribe another brand and indicate that it should not be changed. This video explains how it is done in Andalusia (Spain)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote10sym\" name=\"sdendnote10anc\">\u003Csup>x\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">2.- Appealing to fellow health professionals: by disseminating this letter, informative material, such as the posters that we include in our web\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote11sym\" name=\"sdendnote11anc\">\u003Csup>xi\u003C\u002Fsup>\u003C\u002Fa>, or this video that we have made\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote12sym\" name=\"sdendnote12anc\">\u003Csup>xii\u003C\u002Fsup>\u003C\u002Fa>. We can focus our boycott on the drugs most frequently prescribed in our country, given that 9 of the 10 first on the list are available under the Teva, Tevagen, Ratiopharm or Davur brands.Here you can see an excel with advice on how to avoid prescribing Teva brands for these drugs\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote13sym\" name=\"sdendnote13anc\">\u003Csup>xiii\u003C\u002Fsup>\u003C\u002Fa>. \u003Cbr>3.- Appealing to patients: explaining in consultation, also from the prescription application, writing an annotation for the patient recommending that they reject Teva brand drugs, with information leaflets or posters hung; distributing information in demonstrations for Palestine; explaining in other spaces of activism for Palestine. \u003Cbr>. \u003Cbr>We hope to join efforts in this important humanitarian cause. \u003Cbr>Thank you for your solidarity.\u003Cbr>Health Workers For Palestine Spain\u003Cbr>hcw4palestinespain@gmail.com\u003Cbr>Health workers 4 Palestine - Spain | \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002F\">https:\u002F\u002Fhw4p.es\u002F\u003C\u002Fa> \u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cdiv id=\"sdendnote1\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote1anc\" name=\"sdendnote1sym\">i\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002F\">https:\u002F\u002Fhw4p.es\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote2\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote2anc\" name=\"sdendnote2sym\">ii\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fwww.timesofisrael.com\u002Fteva-ceo-says-production-and-distribution-in-israel-remain-largely-unaffected-by-war\u002F\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.timesofisrael.com\u002Fteva-ceo-says-production-and-distribution-in-israel-remain-largely-unaffected-by-war\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote3\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote3anc\" name=\"sdendnote3sym\">iii\u003C\u002Fa>\u003Ca href=\"blog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote4\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote4anc\" name=\"sdendnote4sym\">iv\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fwww.reuters.com\u002Fbusiness\u002Fhealthcare-pharmaceuticals\u002Fteva-pharmaceutical-third-quarter-profit-revenue-top-estimates-2024-11-06\u002F\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.reuters.com\u002Fbusiness\u002Fhealthcare-pharmaceuticals\u002Fteva-pharmaceutical-third-quarter-profit-revenue-top-estimates-2024-11-06\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote5\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote5anc\" name=\"sdendnote5sym\">v\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote6\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote6anc\" name=\"sdendnote6sym\">vi\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fwww.ouest-france.fr\u002Fnormandie\u002Falencon-61000\u002Fa-alencon-des-militants-pour-la-paix-a-gaza-appellent-au-boycott-de-lentreprise-israelienne-teva-e4a695d6-e505-11ee-b685-1479f5265e87\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.ouest-france.fr\u002Fnormandie\u002Falencon-61000\u002Fa-alencon-des-militants-pour-la-paix-a-gaza-appellent-au-boycott-de-lentreprise-israelienne-teva-e4a695d6-e505-11ee-b685-1479f5265e87\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote7\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote7anc\" name=\"sdendnote7sym\">vii\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fwww.aljazeera.com\u002Ffeatures\u002F2016\u002F2\u002F23\u002Fbds-movement-lessons-from-the-south-africa-boycott\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.aljazeera.com\u002Ffeatures\u002F2016\u002F2\u002F23\u002Fbds-movement-lessons-from-the-south-africa-boycott\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote8\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote8anc\" name=\"sdendnote8sym\">viii\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fhudoc.echr.coe.int\u002Feng-press#%7B%22itemid%22:%5B%22003-6718555-8953654%22%5D%7D\">https:\u002F\u002Fhudoc.echr.coe.int\u002Feng-press#%7B%22itemid%22:%5B%22003-6718555-8953654%22%5D%7D\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote9\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote9anc\" name=\"sdendnote9sym\">ix\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fsesion-virtual-12-diciembre-boicot-a-teva-ratiopharm-tele-encuentro\">https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fsesion-virtual-12-diciembre-boicot-a-teva-ratiopharm-tele-encuentro\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote10\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote10anc\" name=\"sdendnote10sym\">x\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=yXy6BhNm1gg\">https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=yXy6BhNm1gg\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote11\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote11anc\" name=\"sdendnote11sym\">xi\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fmaterial-docente\">https:\u002F\u002Fhw4p.es\u002Fmaterial-docente\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote12\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote12anc\" name=\"sdendnote12sym\">xii\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboicot-a-teva-tevagen-davur-belmac-y-ratiopharm-a-sus-medicamentos-y-productos\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboicot-a-teva-tevagen-davur-belmac-y-ratiopharm-a-sus-medicamentos-y-productos\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote13\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote13anc\" name=\"sdendnote13sym\">xiii\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fdocs.google.com\u002Fspreadsheets\u002Fd\u002F16VsDIivKGAvK-TnDKwf4vZmutj_HoCVg\u002Fedit?pli=1&gid=1565498314#gid=1565498314\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fdocs.google.com\u002Fspreadsheets\u002Fd\u002F16VsDIivKGAvK-TnDKwf4vZmutj_HoCVg\u002Fedit?pli=1&gid=1565498314#gid=1565498314\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>","teva-letter-ethical-challenges-in-primary-care-eng","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1736088033\u002Fkmfqzsn6e00vlihzojtc.png","m5jpr64uaehv9mut3ap",1736087724397,"Teva. Letter. Ethical challenges in primary care. ENG","To:  Primary Care profesionals, patients and relatives",[15],"me@unai.me",{"videoUrl":12,"content":65,"title":66,"imageUrl":67,"slug":68,"type":7,"tags":69,"user":13,"link":12,"id":70,"timestamp":71,"subtitle":72},"\u003Cp lang=\"ca-ES\">\u003Cstrong>\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">CATALÀ\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"ca-ES\">\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">\u003Cem>\u003Ca href=\"https:\u002F\u002Fmalarrassa.cat\u002Fdestacats\u002Fcap-empresa-genocida-a-la-nostra-ciutat-campanya-de-boicot-contra-la-farmaceutica-israeliana-teva-impulsada-per-terrassa-amb-palestina\u002F\">El col·lectiu terrassenc de solidaritat amb Palestina i lluita contra el genocidi \u003C\u002Fa>treballa en l’impuls d’una campanya de boicot a l’empresa farmacèutica israeliana Teva, que subministra medicaments, entre altres, al Consorci Sanitari de Terrassa. En l’article que segueix, Terrassa amb Palestina explica i argumenta les raons de la campanya i crida a augmentar la solidaritat contra el genocidi que l’estat israelià està portant a terme a Palestina.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"ca-ES\">\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">\u003Cstrong>Cap empresa genocida a la nostra ciutat\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"ca-ES\">\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">Teva és una companyia farmacèutica israeliana que opera a tot el món i distribueix medicaments. Va ser fundada l’any 1901 i la seva seu central està a Israel, tot i que actualment opera en 33 països. Sota la denominació \u003Cstrong>Teva, Tevagen, Davur, Belmar i Ratiopharm\u003C\u002Fstrong>, està especialitzada en medicaments genèrics i medicaments que han perdut la patent.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"ca-ES\">\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">....\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"ca-ES\">\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">\u003Cstrong>Teva en la contractació pública del Consorci Sanitari de Terrassa\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"ca-ES\">\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">Recentment, la plataforma Terrassa amb Palestina, en col·laboració a altres grups a favor de la causa palestina com Healthcare Workers For Palestine España, va trobar dins la web de la Plataforma de Serveis de Contractació Pública de Catalunya diversos contractes del Consorci Sanitari de Terrassa amb aquesta farmacèutica, amb un valor que supera els 90.000€. Es tracta de contractes que es van iniciar al novembre de 2023 i van finalitzar el passat novembre de 2024; però també hi ha contractes iniciats l’abril de 2024 i vigents encara, com és el cas del subministrament de Teriflunomida i Ferro Carboximaltosa amb data d’inici d’adjudicació de 7 de març de 2024 i data final d’execució de 7 de juny de 2026 per un import d’adjudicació amb IVA de 4279,76€ amb un valor estimat del contracte de 72426,82€.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"ca-ES\">\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">....\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"ca-ES\">\u003Cstrong>\u003Cspan style=\"font-family: Liberation Serif, serif;\">\u003Cspan style=\"font-size: medium;\">CASTELLANO\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Fmalarrassa.cat\u002Fdestacats\u002Fcap-empresa-genocida-a-la-nostra-ciutat-campanya-de-boicot-contra-la-farmaceutica-israeliana-teva-impulsada-per-terrassa-amb-palestina\u002F\">El colectivo terrassense de solidaridad con Palestina y lucha contra el genocidio\u003C\u002Fa> trabaja en el impulso de una campaña de boicot a la empresa farmacéutica israelí Teva, que suministra medicamentos, entre otros, al Consorci Sanitari de Terrassa.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En el artículo que sigue, Terrassa con Palestina explica y argumenta las razones de la campaña y llama a aumentar la solidaridad contra el genocidio que el estado israelí está llevando a cabo en Palestina. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Ninguna empresa genocida en nuestra ciudad \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva es una compañía farmacéutica israelí que opera en todo el mundo y distribuye medicamentos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Fue fundada en 1901 y su sede central está en Israel, aunque actualmente opera en 33 países.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Bajo la denominación Teva, Tevagen, Davur, Belmar y Ratiopharm, está especializada en medicamentos genéricos y medicamentos que han perdido la patente. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">....\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva en la contratación pública del Consorcio Sanitario de Terrassa \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Recientemente, la plataforma Terrassa con Palestina, en colaboración con otros grupos a favor de la causa palestina como Healthcare Workers For Palestine España, encontró en la web de la Plataforma de Servicios de Contratación Pública de Cataluña varios contratos del Consorcio Sanitario de Terrassa\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">con esta farmacéutica, cuyo valor supera los 90.000€.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Se trata de contratos que se iniciaron en noviembre de 2023 y finalizaron el pasado noviembre de 2024;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">pero también existen contratos iniciados en abril de 2024 y vigentes todavía, como es el caso del suministro de Teriflunomida y Ferro Carboximaltosa con fecha de inicio de adjudicación de 7 de marzo de 2024 y fecha final de ejecución de 7 de junio\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">de 2026 por importe de adjudicación con IVA de 4279,76€ con un valor estimado del contrato de 72426,82€.\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv id=\"ow17\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">...\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">....\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"El colectivo terrassense de solidaridad con Palestina y lucha contra el genocidio trabaja en el impulso de una campaña de boicot a la empresa farmacéutica israelí Teva, que suministra medicamentos, entre otros, al Consorci Sanitari de Terrassa. En el artículo que sigue, Terrassa con Palestina explica y argumenta las razones de la campaña y llama a aumentar la solidaridad contra el genocidio que el estado israelí está llevando a cabo en Palestina.\n\nNinguna empresa genocida en nuestra ciudad\n\nTeva es una compañía farmacéutica israelí que opera en todo el mundo y distribuye medicamentos. Fue fundada en 1901 y su sede central está en Israel, aunque actualmente opera en 33 países. Bajo la denominación Teva, Tevagen, Davur, Belmar y Ratiopharm, está especializada en medicamentos genéricos y medicamentos que han perdido la patente.\n\nTuya en la contratación pública del Consorcio Sanitario de Terrassa\n\nRecientemente, la plataforma Terrassa con Palestina, en colaboración con otros grupos a favor de la causa palestina como Healthcare Workers For Palestine España, encontró en la web de la Plataforma de Servicios de Contratación Pública de Cataluña varios contratos del Consorcio Sanitario de Terrassa con esta farmacéutica, cuyo valor supera los 90.000€. Se trata de contratos que se iniciaron en noviembre de 2023 y finalizaron el pasado noviembre de 2024; pero también existen contratos iniciados en abril de 2024 y vigentes todavía, como es el caso del suministro de Teriflunomida y Ferro Carboximaltosa con fecha de inicio de adjudicación de 7 de marzo de 2024 y fecha final de ejecución de 7 de junio de 2026 por importe de adjudicación con IVA de 4279,76€ con un valor estimado del contrato de 72426,82€.\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"YJGJsb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"kGmWO\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"OwOEge\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cnav class=\"VlPnLc\" aria-labelledby=\"ucj-38\">\u003C\u002Fnav>\n\u003Cp> \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>","Terrassa. Teva. «Cap empresa genocida a la nostra ciutat» CAT\u002FESP","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1737139549\u002Fqfct0tyl0rjeho4ixirq.png","terrassa-teva-cap-empresa-genocida-a-la-nostra-ciutat-cat-esp",[15],"m613pvzpn8yaxl6n9h",1737139763627,"Campanya de boicot contra la farmacèutica israeliana Teva, impulsada per Terrassa amb Palestina",{"content":74,"subtitle":75,"id":76,"slug":77,"type":7,"imageUrl":78,"user":13,"tags":79,"link":12,"title":80,"timestamp":81,"videoUrl":82},"\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref1\">\u003Cstrong>¿Por qué proponemos el b\u003C\u002Fstrong>\u003Cstrong>oicot a la farmacéutica TEVA, y todas sus marcas, Tevagen, Dalvur, Belmac y Ratiopharm? \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">¿Por qué?\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque genera millones de dólares en ingresos para el régimen militar y colonial israelí, siendo así facilitadora del genocidio y del régimen de apartheid\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque se aprovecha de la ventajas de la ocupación, el monopolio y la explotación de los palestinos\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque vende sus fármacos a palestinos por encima de su precio de mercado\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Why do we propose a boycott of TEVA pharmaceuticals, and all its brands, Tevagen, Dalvur, Belmac and Ratiopharm? \u003C\u002Fp>\n\u003Cp>Why?\u003C\u002Fp>\n\u003Cp>because it generates millions of dollars in revenue for the Israeli military and colonial regime, thus facilitating genocide and the apartheid regime\u003C\u002Fp>\n\u003Cp>because it profits from the advantages of occupation, monopoly and exploitation of Palestinians\u003C\u002Fp>\n\u003Cp>because it sells its drugs to Palestinians at above market price.\u003C\u002Fp>","Acción directa, arma no violenta contra Israel","m6cbvdezddw7e7v85jm","en-imagenes-gif-boicot-a-teva-tevagen-dalvur-belmac-y-ratiopharm","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1737818323\u002Fkoresdcmgr4owxtwbs9y.png",[15],"En imágenes GIF Boicot a Teva, Tevagen, Dalvur, Belmac y Ratiopharm",1737817924179,"\u002FvOSvHhMP6zs",{"imageUrl":84,"link":12,"tags":85,"user":13,"content":86,"timestamp":87,"id":88,"videoUrl":89,"title":90,"subtitle":91,"type":7,"slug":92},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1744014906\u002Fch51pfz58ranfat1kpqs.jpg",[15],"\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cstrong>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"background: transparent;\">ESPAÑOL\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cstrong>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"background: transparent;\">ACTUALIZACIÓN 10 ABRIL 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"background: transparent;\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El pasado lunes 8 de abril, un grupo de psiquiatras en formación se entrevistó con el ahora exvicepresidente de la EPA, Geert Dom, por la hipocresía de invitar a Teva —una compañía farmacéutica cómplice de la opresión israelí contra los palestinos— como patrocinador, mientras promovía temas como la responsabilidad social en la atención de la salud mental.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> También criticaron haber sido silenciados (se les retiraron las credenciales y se prohibieron los folletos) a pesar del supuesto compromiso de la conferencia con el diálogo abierto.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"background: transparent;\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Dom defendió la colaboración con las compañías farmacéuticas, citando controles éticos, y sugirió que el grupo debería presentar una queja formal y una carta de protesta en lugar de protestas.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Cuando se le presionó sobre el papel de Teva en el genocidio, eludió el tema mencionando otros conflictos globales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"background: transparent;\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los activistas enfatizaron la urgencia del sufrimiento palestino, mientras que Dom reconoció sus preocupaciones, pero no ofreció ninguna acción real, terminando con un aliciente para \"seguir luchando\".\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"background: transparent;\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Para ser readmitidos en el Congreso tuvieron que firmar un texto (abajo, al final del todo) en que el Congreso declaraba ser \"estrictamente apolítico\" pese a haber incluido en el propio Congreso cuestiones sobre China, Irán y Ucrania (y haber aceptado dinero de Teva).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cstrong>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"background: transparent;\">7 de abril de 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Health Workers For Palestine Spain denunci\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">a\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\"> la expulsión de tres \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">residentes de psiquiatría holandeses\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\"> asistentes al \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fepa-congress.org\u002F\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">33º Congreso Europeo de Psiquiatría (EPA 2025) \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">que se celebra en Madrid del 5 al 8 de abril \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">y cuenta con patrocinadores industriales (entre los “platino”, los más generosos, Teva, el mayor productor de genéricos del mundo)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Ca href=\"https:\u002F\u002Fepa-congress.org\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">https:\u002F\u002Fepa-congress.org\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 129%; margin-bottom: 0.28cm;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">El hecho sucedió durante una sesión patrocinada por la \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">industria farmacéutica TEVA\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">el sábado 6 de abril sobre “Through the looking glass: Tardive dyskinesia in the age of modern psychiatry”, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">cuando \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">el\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\"> grupo de médicos residentes holandeses distribuy\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">ó\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\"> pacíficamente folletos en los que se explicaban la contribución de dicha industria al régimen colonial israelí y al genocidio que está llevando a cabo en Palestina.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 129%; margin-bottom: 0.28cm; text-decoration: none;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: transparent;\">Teva, empresa israelí, genera millones de ingresos anuales que contribuyen al régimen militar y colonial de Israel, financiando el genocidio y el apartheid. Además, limita el suministro de medicamentos en Palestina, contribuyendo así al empeoramiento de la salud del pueblo palestino. TEVA también disfruta del acceso total al mercado cautivo tanto en Cisjordania como en Gaza, donde las empresas farmacéuticas palestinas no pueden operar a causa de las restricciones legales del régimen de apartheid israelí. Además, está implicado en varios casos de corrupción. Teva es una empresa farmacéutica que ha tenido juicios varios y cuantiosas multas por sus práctica corruptoras con médicos.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 129%; margin-bottom: 0.28cm; text-decoration: none;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Calibri, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 129%; margin-bottom: 0.28cm; text-decoration: none;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Calibri, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-en-espana-y-en-el-mundo-datos-y-nombres\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-en-espana-y-en-el-mundo-datos-y-nombres\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 129%; margin-bottom: 0.28cm; text-decoration: none;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"background: transparent;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref1\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref1\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; line-height: 129%; margin-bottom: 0.28cm; text-decoration: none;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: transparent;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Esta expulsión de la sala donde se impartía la sesión y también del \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">C\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">ongreso, constituye un ataque directo y grave a la libertad de expresión de profesionales de la sanidad comprometidos \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">con la paz y la solidaridad, con un sistema sanitario libre de corrupción\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">. Estas personas informaban de forma pacífica y justificada, dado la complicidad que comporta que una empresa que participa activamente en un genocidio en curso sea patrocinadora de un espacio de formación, en este caso un congreso europeo de psiquiatria.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; line-height: 129%; margin-bottom: 0.28cm; text-decoration: none;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: transparent;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">El boicot \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">y la denuncia son\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\"> herramienta\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">s\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\"> legítima\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">s\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\"> que podemos y debemos aplicar ante la ocupación, el apartheid y el genocidio palestino \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">por Israel.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>UPDATE APRIL 10TH 2025\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Last Monday, 8th April, a group of psychiatrists in training confronted now ex-vice president of the EPA Geert Dom about the hypocrisy of inviting Teva—a pharmaceutical company complicit in Israel’s oppression of Palestinians—as a sponsor while promoting themes like social responsibility in mental healthcare. \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">They also criticized being silenced (badges revoked, leaflets banned) despite the conference’s supposed commitment to open dialogue. \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Dom defended collaborating with pharmaceutical companies, citing ethical checks, and suggested the group should perform a formal complaint and protest letter instead of protests. \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">When pressed on Teva’s role in genocide, he deflected by mentioning other global conflicts. The activists emphasized the urgency of Palestinian suffering, while Dom acknowledged their concerns but offered no real action, ending with an encouragement to \"keep fighting.\"\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan class=\"ryNqvb\">To be readmitted to Congress, they had to sign a text (see at the very bottom) in which Congress declared itself \"strictly apolitical\" despite having included issues regarding China, Iran, and Ukraine in the Congress itself (and having accepted money of Teva).\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>APRIL 7th 2025\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Health Workers For Palestine Spain denounces the expulsion of three Dutch psychiatry residents attending the 33rd European Congress of Psychiatry (EPA 2025), which is being held in Madrid from April 5 to 8 and is sponsored by the pharmaceutical industry (among the \"platinum\" sponsors, the most generous, is Teva, the world's largest generic drug producer).\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"https:\u002F\u002Fepa-congress.org\u002F\">https:\u002F\u002Fepa-congress.org\u002F\u003C\u002Fa> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The incident occurred during a session sponsored by the pharmaceutical industry TEVA on Saturday, April 6, on \"Through the Looking Glass: Tardive Dyskinesia in the Age of Modern Psychiatry,\" when the group of Dutch medical residents peacefully distributed leaflets explaining the industry's contribution to the Israeli colonial regime and the genocide it is carrying out in Palestine.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Teva, an Israeli company, generates millions in annual revenue that contribute to Israel's military and colonial regime, financing genocide and apartheid. Furthermore, it limits the supply of medicines in Palestine, thus contributing to the deteriorating health of the Palestinian people. TEVA also enjoys full access to the captive market in both the West Bank and Gaza, where Palestinian pharmaceutical companies cannot operate due to legal restrictions imposed by the Israeli apartheid regime. Furthermore, it is implicated in several corruption cases. Teva is a pharmaceutical company that has faced several lawsuits and hefty fines for its corrupt practices with doctors.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-en-espana-y-en-el-mundo-datos-y-nombres\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-en-espana-y-en-el-mundo-datos-y-nombres\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-health-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref1\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-health-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref1\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">This expulsion from the room where the session was held and also from the Congress constitutes a direct and serious attack on the freedom of expression of health workers committed to peace and solidarity, and to a corruption-free healthcare system. These persons were reporting peacefully (see the video) and with justification, given the complicity that comes with a company actively participating in an ongoing genocide sponsoring a training event, in this case a European psychiatry conference.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Boycotting and reporting are legitimate tools that we can and should apply in the face of Israel's occupation, apartheid, and Palestinian genocide.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FGoMWsg7WAAA9fhS?format=jpg&name=large\" alt=\"\" width=\"1200\" height=\"1600\">\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cimg src=\"blob:https:\u002F\u002Fweb.whatsapp.com\u002F82957735-73d3-4e16-bd4d-687d676bca2d\" alt=\"\">\u003Cimg src=\"blob:https:\u002F\u002Fweb.whatsapp.com\u002F82957735-73d3-4e16-bd4d-687d676bca2d\" alt=\"\">\u003Cimg src=\"blob:https:\u002F\u002Fweb.whatsapp.com\u002Fc4cc7268-6dd3-47d9-aa29-396495bee31f\" alt=\"\">\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FGoMWsg-W0AABjVO?format=jpg&name=large\" alt=\"\" width=\"1200\" height=\"1600\">\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 129%; margin-bottom: 0.28cm; text-decoration: none;\">\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>",1744015309217,"m96t6f71lrl9gaprbj","j6lZhUCUPaI","TEVA Protesta, expulsión Congreso Europeo Psiquiatría. Protest, expulsion European Congress Psychiatry ESP ENG","Madrid (España. Spain). Protesta pacífica patrocinio TEVA. Peacefull protest TEVA sponsorship","teva-protesta-expulsion-congreso-europeo-psiquiatria-protest-expulsion-european-congress-psychiatry-esp-eng",{"link":12,"user":13,"tags":94,"id":95,"subtitle":96,"title":97,"timestamp":98,"videoUrl":99,"content":100,"type":7,"slug":101,"imageUrl":102},[15],"m9e9coposi3vtawai1","Copaxone, a treatment for multiple sclerosis. Esclerosis múltiple. Sclérose en plaques","Teva €462.6 million EU UE Fine Multa Amende  ENG ESP FRE",1744467023173,"M9Mu9-sRJ98","\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.crai.com\u002Fengagements\u002Feuropean-commission-fines-teva-e462-6-million-for-antitrust-abuse\u002F\">European Commission fines Teva €462.6 million for antitrust abuse \u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>On 31 October 2024, the European Commission fined Teva €462.6 million for delaying competition for its blockbuster drug, Copaxone, a treatment for multiple sclerosis in seven Member States (Belgium, Czech Republic, Germany, Italy, the Netherlands, Poland and Spain). \u003C\u002Fp>\n\u003Cp>The Commission found that Teva had abused its dominant position by engaging in two types of conduct.      \u003C\u002Fp>\n\u003Cp>First, it misused the patent system to artificially extend the patent protection of Copaxone. It did so by filing multiple divisional patents1, thus creating what the Commission described as a “web of secondary patents” around Copaxone. When challenged by rivals, Teva strategically withdrew the patent being challenged to avoid a finding of invalidity which would have put into question its other divisional patents. Thus competitors were forced to start lengthy proceedings anew, facing prolonged delays in entering the market.     \u003C\u002Fp>\n\u003Cp>Second, Teva engaged in a systematic disparagement campaign, by disseminating misleading information about the safety and efficacy of a competing glatiramer acetate product, despite the relevant health authorities having approved the rival product as safe and therapeutically equivalent to Copaxone.  This is the first ever Commission fine on these types of conducts. A CRA team led by Raphaël De Coninck and Elina Koustoumpardi advised third parties on this case culminating in the Commission’s decision against Teva’s conduct.  \u003C\u002Fp>\n\u003Cp>Further details can be found on the Commission’s website. \u003C\u002Fp>\n\u003Cp> 1 Divisional patents are based on an earlier ‘parent’ patent application, but may focus on different aspects of the invention and are treated independently when it comes to assessing their validity.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.eleconomista.es\u002Fsalud-bienestar\u002Fempresas\u002Fnoticias\u002F13062352\u002F10\u002F24\u002Fbruselas-multa-con-4626-millones-a-teva-por-obstaculizar-la-competencia-en-el-mercado-de-la-esclerosis-multiple.html\">\u003Cstrong>Bruselas multa con 462,6 millones a Teva por obstaculizar la competencia en el mercado de la esclerosis múltiple      \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>La israelí alargó la patente de Copaxone y propagó información engañosa sobre un producto rival    \u003C\u002Fstrong> \u003C\u002Fp>\n\u003Cp>La Comisión Europea ha impuesto una multa de 462,6 millones a la farmacéutica Teva por obstaculizar la competencia en el mercado de la esclerosis múltiple. En concreto, ha alargado de forma artificial la patente de su medicamento Copaxone y ha propagado información engañosa sobre un producto rival.  \u003C\u002Fp>\n\u003Cp>Según un comunicado de Bruselas, el objetivo de la israelí era obstaculizar la entrada en el mercado y aceptación de un medicamento similar de la competencia. El abuso de su posición dominante se produjo en Bélgica, República Checa, Alemania, Italia, Países Bajos, Polonia y España.  \u003C\u002Fp>\n\u003Cp>Teva tuvo la patente de acetato de glatiramer (el principio activo) hasta 2015. La Comisión Europea apunta que cuando la patente estaba a punto de expirar, la empresa hizo un uso indebido de las normas y procedimientos de la Oficina Europea de Patentes (EPO) sobre patentes divisionales. Presentó múltiples solicitudes de patentes divisionales de manera escalonada.  \"Los rivales impugnaron estas patentes para abrirse camino al mercado. A la espera de la revisión de la EPO, Teva comenzó a hacer valer estas patentes contra los competidores para obtener medidas cautelares provisionales\", ha indicado el Ejecutivo.\u003C\u002Fp>\n\u003Cp>\"Cuando parecía probable que las patentes fueran revocadas, la farmacéutica las retiró estratégicamente\", ha añadido. Esto obligaba a las empresas competidoras a empezar de manera repetida nuevos procedimientos.  Por otro lado, el laboratorio puso en marcha una campaña \"sistemática de desprestigio contra un medicamento competidor con acetato de glatiramer para el tratamiento de la esclerosis múltiple, difundiendo información engañosa sobre su seguridad, eficacia y equivalencia terapéutica con el Copaxone.\u003C\u002Fp>\n\u003Cp>Cabe destacar que el producto rival ya había recibido la aprobación de las autoridades sanitarias relevantes.  \u003C\u002Fp>\n\u003Cp>La actuación de Teva duró entre cuatro y nueve años en función del Estado miembro y \"podría haber impedido que los precios de catálogo disminuyeran, con un impacto negativo en los presupuestos de salud pública\", ha afirmado Bruselas.\u003C\u002Fp>\n\u003Cp>\u003Cimg src=\"https:\u002F\u002Fwww.laboratoriochile.cl\u002Fwp-content\u002Fuploads\u002F2016\u002F03\u002Flaboratorio-chile-copaxone-solucion-inyectable.jpg\" alt=\"\">\u003C\u002Fp>\n\u003Cp>\u003Cstrong>FRANÇAIS\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.lemonde.fr\u002Finternational\u002Farticle\u002F2024\u002F10\u002F31\u002Fl-union-europeenne-inflige-une-amende-de-460-millions-d-euros-au-groupe-pharmaceutique-teva_6368918_3210.html\">\u003Cstrong>L’Union européenne inflige une amende de 460 millions d’euros au groupe pharmaceutique Teva  \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>La Commission européenne lui reproche un « abus de position dominante » pour son médicament contre le traitement de la sclérose en plaques, le Copaxone. \u003C\u002Fp>\n\u003Cp>Publié le 31 octobre 2024 à 12h38  La Commission européenne a infligé, jeudi 31 octobre, une amende de 462,6 millions d’euros au groupe pharmaceutique israélien Teva, lui reprochant un « abus de position dominante » pour son médicament contre le traitement de la sclérose en plaques, le Copaxone.  \u003C\u002Fp>\n\u003Cp>Dans un communiqué, Bruxelles a notamment accusé Teva de « diffuser systématiquement des informations trompeuses sur un produit concurrent pour entraver son entrée sur le marché ».  \u003C\u002Fp>\n\u003Cp>La Commission reproche aussi à l’entreprise d’avoir « artificiellement » étendu le brevet du Copaxone, pour mettre des bâtons dans les roues de ses rivaux. Teva est avant tout un grand groupe industriel spécialiste des médicaments génériques, mais il vend aussi ses propres traitements, tels que le Copaxone.  \u003C\u002Fp>\n\u003Cp>Il y a une quinzaine de jours, le ministère de la justice américain avait annoncé que le laboratoire allait payer 450 millions de dollars pour mettre fin à des poursuites civiles aux Etats-Unis, liées au versement de pots-de-vin pour augmenter les ventes du Copaxone et à une entente sur le prix d’un médicament contre le cholestérol, la Pravastatine\u003C\u002Fp>","teva-462-6-million-eu-ue-fine-multa-amende-eng-esp-fre","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1744467087\u002Fqwjcrwsm1kvddeqibk7l.png",{"subtitle":12,"content":104,"type":7,"slug":105,"imageUrl":106,"link":12,"user":13,"tags":107,"timestamp":108,"title":109,"id":110,"videoUrl":111},"\u003Cp>\u003Cstrong>Updated 21 August 2025\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Ftwitter.com\u002FSMaurizi\u002Fstatus\u002F1958463788266512471\">\u003Cstrong>Stefania Maurizi\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>\u003Ca href=\"https:\u002F\u002Ftwitter.com\u002FSMaurizi\u002Fstatus\u002F1958463788266512471\">\u003Cstrong>@SMaurizi\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>1. This thread does NOT necessarily reflect the opinions of my newspaper.\u003Cbr>Based on info available atm, a doctor and a nurse working for #Tuscany's public health system,@Usltoscsudest , have boycotted #Teva drugs to protest against #Israel's #genocide. They're at risk of being fired  \u003C\u002Fp>\n\u003Cp>2. If the doctor+nurse caused damage by throwing away #Teva drugs paid for by our #PublicHealthSystem, they should reimburse it, BUT their non-violent protest is part of the great tradition of #CivilDisobedience. It's Emmeline Pankhurst, Ellsberg, Manning\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>FROM ITALY\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>14 April 2025\u003C\u002Fp>\n\u003Cp>Please without our name\u003Cbr>Because from 3 days a temporary law has gone into effect for 60 days that prevents peaceful dissent, passive resistance or contradicting government decisions.\u003Cbr>In Italy in the Lazio region where the capital is Rome...Teva has obtained the monopoly of some new generation antipsychotics...including paleperidone...so there is no other brand or other generic type of drug...and we are forced to use that...or go back to old antipsychotics with greater side effects.\u003Cbr>In the Lombardy region with Milan as its capital...same thing for a type of anticoagulant. Furthermore the assignments of tenders for the supply of these drugs both for hospitals and for the territory are based only on the lowest cost...and not on the effectiveness of the drug.\u003Cbr>there is no competitive market since they take an absolute monopoly... after a while the drugs become unavailable... creating great difficulties for patients and their healthcare facilities... after a while they become available again with increased costs... this is what Teva does in Italy... in addition to other illegal and unfair practices to convince doctors to prescribe its products.\u003Cbr>We are boycotting about Carrefour, L'Oreal, Coke and all their drinks, Mc Donalds and other food...but for a relative suffering from bipolar disorder with aggressive aspects when it decompensates that we worked so hard to stabilize him ... unfortunately we have to accept to use the paliperidone Teva because with other antipsychotics he was not sufficiently stabilized and became aggressive and unmanageable ... with the \"older\" molecule risperdal unfortunately he gained too much weight and was anhedonic. \u003Cbr>We do not want to be complicit in the crimes of Israel ... but Israel has created an economic system and control of every country in the world through trade, computer security, banks, insurance, drugs ... that managing to make a complete boycott is impossible.\u003Cbr>We think we must ask at us country don't fall in these imperialist trade and control network...but unfortunately the current Italian government is complicit and does not listen to our protests against what is happening.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Actualización el 21 de agosto de 2025.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Ftwitter.com\u002FSMaurizi\u002Fstatus\u002F1958463788266512471\">\u003Cstrong>Stefania Maurizi\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>\u003Ca href=\"https:\u002F\u002Ftwitter.com\u002FSMaurizi\u002Fstatus\u002F1958463788266512471\">\u003Cstrong>@SMaurizi\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>1. Este hilo NO refleja necesariamente las opiniones de mi periódico.\u003Cbr>Según la información disponible hasta el momento, un médico y una enfermera que trabajan para el sistema de salud pública de la Toscana, @Usltoscsudest, han boicoteado los medicamentos de #Teva para protestar contra el #genocidio de #Israel. Corren el riesgo de ser despedidos.\u003C\u002Fp>\n\u003Cp>2. Si el médico y la enfermera causaron daños al deprescribir los medicamentos de #Teva pagados por nuestro #SistemaDeSaludPública, deberían reembolsarlos, PERO su protesta no violenta forma parte de la gran tradición de la #DesobedienciaCivil. Es Emmeline Pankhurst, Ellsberg, Manning.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>DESDE ITALIA\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>14 abril 2025\u003C\u002Fp>\n\u003Cdiv class=\"pGxpHc\">\u003Cheader id=\"gb\" class=\"gb_Fa gb_2d gb_Pe gb_rd gb_Wc\" style=\"background-color: rgba(255,255,255,1);\" role=\"banner\">\u003C\u002Fheader>\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cdiv class=\"zXU7Rb\">\n\u003Cdiv class=\"akczyd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"akczyd\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\n\u003Cdiv id=\"ow10\">\u003C\u002Fdiv>\n\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Por favor, sin nuestro nombre. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Porque a partir de 3 días entra en vigor una ley temporal de 60 días que también impide la disidencia pacífica, la resistencia pasiva o la contradicción con las decisiones gubernamentales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En Italia, en la región del Lacio, cuya capital es Roma, Teva ha obtenido el monopolio de algunos antipsicóticos de nueva generación, incluida la paleperidona, por lo que no existe otra marca ni medicamento genérico, y nos vemos obligados a usarlos o a volver a los antipsicóticos antiguos con mayores efectos secundarios.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En la región de Lombardía, con Milán como capital, ocurre lo mismo con un tipo de anticoagulante.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Además, la adjudicación de las licitaciones para el suministro de estos medicamentos, tanto para hospitales como para el territorio, se basa únicamente en el menor coste, y no en la eficacia del medicamento.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">No hay mercado competitivo, ya que tienen un monopolio absoluto... después de un tiempo, los medicamentos dejan de estar disponibles, lo que crea grandes dificultades para los pacientes y sus centros de salud... después de un tiempo, vuelven a estar disponibles con precios más altos... esto es lo que hace Teva en Italia... además de otras prácticas ilegales e injustas para convencer a los médicos de que receten sus productos. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Estamos boicoteando Carrefour, L'Oréal, Coca-Cola y todas sus bebidas, McDonald's y otros alimentos... pero para un familiar que sufre trastorno bipolar con aspectos agresivos cuando se descompensa, nos esforzamos tanto por estabilizarlo... desafortunadamente, tuvimos que aceptar usar paliperidona Teva porque con otros antipsicóticos no se estabilizó lo suficiente y se volvió agresivo e incontrolable... con la molécula \"más antigua\", risperdal, desafortunadamente, ganó demasiado peso y sufrió anhedonia.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> No queremos ser cómplices de los crímenes de Israel... pero Israel ha creado un sistema económico y el control de todos los países del mundo a través del comercio, la seguridad informática, los bancos, los seguros, los medicamentos... que lograr un boicot total es imposible.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Creemos que debemos pedirle a nuestro país que no caiga en estas redes imperialistas de comercio y control... pero lamentablemente el actual gobierno italiano es cómplice y no escucha nuestras protestas contra lo que está sucediendo.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\n\u003Cdiv>\n\u003Cdiv class=\"zXU7Rb\">\n\u003Cdiv class=\"akczyd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"ow26\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\u003C\u002Fdiv>\n\u003Cdiv class=\"akczyd\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\"> \u003C\u002Fdiv>\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">ITALIANO\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">14 aprile 2025 \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"ryNqvb\">Per favore, senza il nostro nome. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"ryNqvb\">Perché tra tre giorni entrerà in vigore una legge temporanea di 60 giorni che proibisce anche il dissenso pacifico, la resistenza passiva o la contraddizione con le decisioni del governo. In Italia, nella regione Lazio, il cui capoluogo è Roma, la Teva ha ottenuto il monopolio su alcuni antipsicotici di nuova generazione, tra cui il paleperidone, per cui non esiste nessun altro farmaco di marca o generico e siamo costretti a usarli o a tornare ad antipsicotici più vecchi con effetti collaterali più gravi. In Lombardia, con capoluogo Milano, sta succedendo la stessa cosa con un tipo di anticoagulante. Inoltre, l'assegnazione degli appalti per la fornitura di questi farmaci, sia agli ospedali che alla regione, si basa esclusivamente sul costo più basso e non sull'efficacia del farmaco. Non esiste un mercato concorrenziale, perché hanno un monopolio assoluto... dopo un po' i farmaci diventano indisponibili, creando grandi difficoltà ai pazienti e alle strutture sanitarie... dopo un po' tornano disponibili a prezzi più alti... questo è quello che fa Teva in Italia... oltre ad altre pratiche illegali e sleali per convincere i medici a prescrivere i loro prodotti. Stiamo boicottando Carrefour, L'Oréal, Coca-Cola e tutte le loro bevande, McDonald's e altri alimenti... ma per un parente che soffre di disturbo bipolare con aspetti aggressivi quando si scompensa, abbiamo cercato con tutte le nostre forze di stabilizzarlo... purtroppo abbiamo dovuto accettare di usare paliperidone Teva perché con altri antipsicotici non si stabilizzava abbastanza ed era diventato aggressivo e incontrollabile... con la molecola \"più vecchia\", il risperdal, purtroppo, ha preso troppo peso e ha sofferto di anedonia. Non vogliamo essere complici dei crimini di Israele... ma Israele ha creato un sistema economico e un controllo su tutti i paesi del mondo attraverso il commercio, la sicurezza informatica, il sistema bancario, le assicurazioni, la medicina... per cui un boicottaggio totale è impossibile. Riteniamo di dover esortare il nostro Paese a non cadere preda di queste reti imperialiste di commercio e controllo... ma purtroppo l'attuale governo italiano è complice e ignora le nostre proteste contro quanto sta accadendo.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 BwTYAc leDWne\" aria-hidden=\"true\" data-location=\"1\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne uE8p1 sMVRZe\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"r375lc\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"\" data-crosslingual-hint=\"undefined\" data-location=\"1\" data-enable-toggle-playback-speed=\"true\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","teva-italy-monopoly-monopolio-en-italia-eng-esp-ita","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1744637673\u002Fvuy6hkfmpbdzytzqjiuq.webp",[15],1744637686226,"Teva. Italy monopoly. Monopolio en Italia ENG ESP ITA","m9h3jsksuhw7l6lcplr","s8eWKfeaR48",{"subtitle":113,"timestamp":114,"type":7,"slug":115,"content":116,"title":117,"imageUrl":118,"link":12,"user":13,"tags":119,"videoUrl":120,"id":121},"Un gigante farmacéutico con pies corruptos. A pharmaceutical giant with corrupt feet",1744816610545,"teva-2024-ingresos-revenue-16-5-billions-deudas-en-espana-treasury-debts-in-spain-esp-eng","\u003Cp>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fen.globes.co.il\u002Fen\u002Farticle-teva-falls-sharply-on-disappointing-2025-guidance-1001500783\">Teva, ingresos, resultados 2024.\u003C\u002Fa> \u003C\u002Fstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">Los ingresos para el año completo de 2024 fueron de $16.5 mil millones, en el límite superior de la previsión de $16.1-16.5 mil millones, y un 4,4% superiores a los ingresos de 2023. El benefici\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\">o por acción no GAAP en 2024 fue de $2,49 (la previsión de la compañía era de $2,40-2,50).\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\"> \u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El precio de las acciones se vio impulsado por los resultados positivos de duvakitug, para el tratamiento de la enfermedad de Crohn, que está desarrollando junto con Sanofi.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.eleconomista.es\u002Factualidad\u002Fnoticias\u002F13304244\u002F04\u002F25\u002Fhacienda-exige-36-millones-en-impuestos-no-pagados-a-la-farmaceutica-israeli-teva.html\">\u003Cstrong>Teva España. Hacienda exige casi 36 millones de euros en impuestos no pagados a la farmacéutica israelí Teva. \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>La compañía, según figura en las últimas cuentas disponibles en el Registro Mercantil, tiene aún pendiente un procedimiento en los Juzgados de lo contencioso-administrativo tras recurrir las actas fiscales que la Agencia Tributaria remitió al finalizar sus inspecciones.  \u003C\u002Fp>\n\u003Cp>Hacienda en concreto investigó los ejercicios del 2008 hasta 2013 e interpuso sanciones superiores a los 13 millones de euros al margen de la reclamación fiscal que, tras la disconformidad de la compañía, todavía se encuentran recurridas por vía judicial. Situación que, junto con otros recursos aún pendientes de resolución, ha llevado a la farmacéutica a presentar avales bancarios por 33 millones de euros a favor de la Agencia Tributaria.  \u003C\u002Fp>\n\u003Cp>En cualquier caso, la Agencia Tributaria tiene aún en revisión los pagos del Impuesto sobre Sociedades correspondiente a los ejercicios de entre 2011 y 2013, así como de entre 2019 y 2022; el pago del Impuesto sobre la Renta de las Personas Físicas (IRPF) entre 2019 y 2023; el Impuesto sobre el Valor Añadido (IVA) de los ejercicios de 2019 hasta 2023 y otros impuestos del mismo periodo.  \u003C\u002Fp>\n\u003Cp>El grupo mantiene también otro conflicto abierto con Hacienda desde 2015 después de que la Agencia Tributaria concluyese que no cumplía con los requisitos para tributar bajo el Régimen Especial de Consolidación Fiscal. Desde entonces, la compañía ha pasado a declarar sus impuestos en régimen individual hasta que se resuelva el recurso que mantiene ante el Tribunal Económico Administrativo Regional de Madrid.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fen.globes.co.il\u002Fen\u002Farticle-teva-falls-sharply-on-disappointing-2025-guidance-1001500783\">Teva world 2024. \u003C\u002Fa>\u003C\u002Fstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fen.globes.co.il\u002Fen\u002Farticle-teva-falls-sharply-on-disappointing-2025-guidance-1001500783\">Revenue in full year 2024 was $16.5 billion,\u003C\u002Fa> at the upper end of $16.1-16.5 billion guidance, and 4.4% higher than 2023 revenue. Non-GAAP earnings per share in 2024 was $2.49 (the company's guidance was $2.40-2.50). \u003Cspan class=\"HwtZe\" lang=\"es\">The share price was boosted by the positive results for duvakitug, for the treatment of Crohn's disease, which it is developing with Sanofi.  \u003C\u002Fspan> \u003C\u002Fem>\u003C\u002Fp>\n\u003Cdiv class=\"pGxpHc\">\u003Cheader id=\"gb\" class=\"gb_Fa gb_2d gb_Pe gb_rd gb_Wc\" style=\"background-color: rgba(255,255,255,1);\" role=\"banner\">\u003C\u002Fheader>\u003C\u002Fdiv>\n\u003Cdiv class=\"T4LgNb\"> \u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cdiv class=\"zXU7Rb\">\n\u003Cdiv class=\"akczyd\">\n\u003Cdiv class=\"X4DQ0 zWsGpc\">\n\u003Cdiv class=\"VfPpkd-AznF2e-ZMv3u\" role=\"tablist\" data-use-automatic-activation=\"false\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"akczyd\">\n\u003Cdiv class=\"X4DQ0 zWsGpc\">\n\u003Cdiv class=\"VfPpkd-AznF2e-ZMv3u\" role=\"tablist\" data-use-automatic-activation=\"false\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"AxqVh\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\n\u003Cdiv id=\"ow9\">\u003C\u002Fdiv>\n\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva Spain. The Treasury is demanding almost €36 million in unpaid taxes from the Israeli pharmaceutical company Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to the latest accounts available at the Commercial Registry, the company is still facing proceedings in the Administrative Courts after appealing the tax returns issued by the Tax Agency upon completion of its inspections.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Specifically, the Treasury investigated the years 2008 through 2013 and imposed penalties exceeding €13 million, in addition to the tax claim, which, following the company's disagreement, is still being appealed in court.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This situation, along with other appeals still pending resolution, has led the pharmaceutical company to submit bank guarantees for €33 million in favor of the Tax Agency.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In any case, the Tax Agency is still reviewing the Corporate Income Tax payments for the years 2011 through 2013, as well as those from 2019 through 2022.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">the payment of Personal Income Tax (IRPF) between 2019 and 2023;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Value Added Tax (VAT) for the years 2019 to 2023; and other taxes for the same period.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The group also has another open dispute with the Treasury since 2015, after the Tax Agency concluded that it did not meet the requirements to file taxes under the Special Tax Consolidation Regime.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"QFw9Te BLojaf\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Since then, the company has moved to filing its taxes individually until the resolution of its appeal before the Regional Economic and Administrative Court of Madrid.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 BwTYAc leDWne\" aria-hidden=\"true\" data-location=\"1\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne uE8p1 sMVRZe\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"r375lc\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"en\" data-language-name=\"inglés\" data-text=\"\" data-crosslingual-hint=\"undefined\" data-location=\"1\" data-enable-toggle-playback-speed=\"true\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","Teva. 2024 Ingresos Revenue $16.5 billions. Deudas en España. Treasury debts in Spain. ESP ENG","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1744816570\u002Fpa4yyfkqua3exiqu8ltq.png",[15],"N4d7Gv0cur0","m9k1k6yttkjwvzpzihl",{"id":123,"user":13,"tags":124,"link":12,"subtitle":125,"content":126,"timestamp":127,"videoUrl":128,"imageUrl":129,"slug":130,"type":7,"title":131},"mabcnjemkq929x80f5",[15],"An entry point to health justice. Contra el genocidio en Gaza, boicot a la empresa israelí, Teva","\u003Cp>\u003Ca href=\"blob:https:\u002F\u002Fweb.telegram.org\u002F254ebbf0-5928-4721-80a5-fcc879af95b1\">\u003Cimg src=\"blob:https:\u002F\u002Fweb.telegram.org\u002F254ebbf0-5928-4721-80a5-fcc879af95b1\" alt=\"\">\u003C\u002Fa>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fsamajournals.co.za\u002Findex.php\u002Fsajbl\u002Farticle\u002Fview\u002F1961\u002F813\">Healthcare and genocide: BDS as an entry point to health justice. (2024).\u003C\u002Fa> \u003Cem>South African Journal of Bioethics and Law\u003C\u002Fem>, \u003Cem>17\u003C\u002Fem>(1), e1961. \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.7196\u002Fsajbl.2024.v17i1.1961\">https:\u002F\u002Fdoi.org\u002F10.7196\u002Fsajbl.2024.v17i1.1961\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>To the Editor: On 26 January 2024, the International Court of Justice\u003Cbr>(ICJ) found that there was a prima facie case for genocide by Israel\u003Cbr>in Gaza. Provisional measures were issued for Israel to ensure that\u003Cbr>its military does not commit and takes all measures within its power\u003Cbr>to prevent acts of genocide, as defined in the Convention on the\u003Cbr>Prevention and Punishment of the Crime of Genocide.[1]\u003C\u002Fp>\n\u003Cp>The Israeli government has denied accusations of genocide, claiming that it has\u003Cbr>the right to self-defence. South Africa’s (SA) case included numerous\u003Cbr>detailed reports of attacks on healthcare workers and hospitals. Such\u003Cbr>attacks have also occurred prior to the events of 7 October 2023.\u003Cbr>[2,3] The crippling of Gaza’s healthcare system has left it unable to\u003Cbr>cope with the sheer number of injured patients. This, along with the\u003Cbr>worsening man-made public health catastrophe which has paved\u003Cbr>the way for malnutrition and wide-spread infection, should be of\u003Cbr>particular concern to those in the healthcare sector.\u003Cbr>While SA’s initiative in filing the case has been met with mixed\u003Cbr>reactions both in SA and internationally, the action was in keeping\u003Cbr>with the responsibility of all countries to protect populations from\u003Cbr>genocide, war crimes, ethnic cleansing and crimes against humanity.\u003Cbr>Healthcare workers across the world may be physically removed from\u003Cbr>the ongoing and deadly military assault on the civilian population\u003Cbr>of Gaza and may not have any legal obligation to act. However, the\u003Cbr>ethical principles of beneficence, non-maleficence and justice compel\u003Cbr>healthcare workers to take action where they can.[4,5]\u003Cbr>Taking our cue from SA’s historical dismantling of Apartheid, we\u003Cbr>note that while the domestic uprising was a major component of the\u003Cbr>anti-Apartheid struggle, another element was the pressure exerted\u003Cbr>on the Apartheid state by the international boycott, divestment\u003Cbr>and sanctions (BDS) movement.[6] Academic, sporting and cultural\u003Cbr>boycotts meant that upholding Apartheid carried more than an\u003Cbr>economic cost.\u003Cbr>Inspired by the SA anti-Apartheid movement, the Palestinian BDS\u003Cbr>movement has called for the boycott of Israel since 2005 as a form\u003Cbr>of non-violent pressure for it to comply with international law and\u003Cbr>numerous United Nations resolutions.[7]\u003Cbr>Boycotts take different forms. Targeted consumer boycotts call\u003Cbr>for complete boycotts of specific brands. They are initiated by the\u003Cbr>BDS movement following in-depth research on the impact of such\u003Cbr>a boycott. In contrast, organic boycotts are consumer-driven, often\u003Cbr>arising spontaneously following a public misstep by the company\u003Cbr>involved. Pressure targets are another technique where a full boycott\u003Cbr>is not called for, but consumers are asked to apply pressure by using\u003Cbr>alternative products where possible, as well as lobbying, peaceful\u003Cbr>disruptions and the creation of awareness through social media\u003Cbr>campaigns.[7] This technique is more appropriate for the healthcare\u003Cbr>space, where care must be taken not to cause harm by disrupting\u003Cbr>patient care through creating supply chain failures.\u003Cbr>\u003Cstrong>Teva Pharmaceutical Industries is listed as a pressure target by the\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Palestinian BDS National Committee. \u003C\u002Fstrong>Teva is an Israeli pharmaceutical\u003Cbr>company and the world’s largest generic drug manufacturer. Teva\u003Cbr>benefits from Israel’s illegal occupation of and the building of\u003Cbr>settlements in Palestinian lands allowing the company to exploit the\u003Cbr>captive Palestinian market.[7,8] Teva is already subject to boycotts in\u003Cbr>the United Kingdom[9] and other countries. Table 1 suggests actions\u003Cbr>various role players in the healthcare sector can take to exert pressure\u003Cbr>on Teva and Israel as part of a broader BDS campaign.\u003Cbr>The Palestinian BDS National Committee (BNC) also calls for an\u003Cbr>academic boycott of Israeli universities. The boycott is directed at\u003Cbr>institutions and not individual academics. The BNC reported that\u003Cbr>Israeli universities are ‘accomplices in Israel’s regime of occupation,\u003Cbr>settler-colonialism and apartheid… involved in developing weapon\u003Cbr>systems… deployed [by] Israel [and] justifying the ongoing\u003Cbr>\u003Cstrong>Healthcare and genocide: BDS as an entry point to\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>health justice\u003C\u002Fstrong>\u003Cbr>\u003Cbr>1. Application of the Convention on the Prevention and Punishment of the Crime\u003Cbr>of Genocide in the Gaza Strip (South Africa v. Israel) (Provisional measures).\u003Cbr>https:\u002F\u002Fwww.icj-cij.org\u002Findex.php\u002Fnode\u002F203447 (accessed 2 February 2024).\u003Cbr>2. Mahomed S. When sanctuaries of humanity turn into corridors of horror: The\u003Cbr>destruction of healthcare in Gaza. S Afr J Bioethics Law 2023;16(3):e1732.\u003Cbr>https:\u002F\u002Fdoi.org\u002F10.7196\u002FSAJBL.2023.v16i3.1732\u003Cbr>3. Soni A. Israel desecrates the sanctity of healthcare with its attacks. S Afr\u003Cbr>J Bioethics Law 2023;16(3):e1656. https:\u002F\u002Fdoi.org\u002F10.7196\u002FSAJBL.2023.\u003Cbr>v16i3.1656\u003Cbr>4. Soni S. Gaza and international law: The global obligation to protect life and\u003Cbr>health. S Afr J Bioethics Law 2023;16(3):e1764. https:\u002F\u002Fdoi.org\u002F10.7196\u002F\u003Cbr>SAJBL.2023.v16i3.1764\u003Cbr>5. Hanbali L, Kwong EJL, Neilson A, et al. Israeli necropolitics and the pursuit of\u003Cbr>health justice in Palestine. BMJ Glob Health 2024;9:e014942. http:\u002F\u002Fdx.doi.\u003Cbr>org\u002F10.1136\u002Fbmjgh-2023-014942\u003Cbr>6. Wikipedia contributors. Anti-Apartheid Movement.Wikipedia, The Free\u003Cbr>Encyclopedia; 2005 Mar 4. https:\u002F\u002Fen.wikipedia.org\u002Fw\u002Findex.php?title=Anti-\u003Cbr>Apartheid_Movement&oldid=1195203572 (accessed 2 February 2024).\u003Cbr>7. The Palestinian BDS National Committee. Act Now Against These Companies\u003Cbr>Profiting from the Genocide of the Palestinian People. https:\u002F\u002Fbdsmovement.\u003Cbr>net\u002FAct-Now-Against-These-Companies-Profiting-From-Genocide. (accessed 2\u003Cbr>February 2024).\u003Cbr>8. Teva Pharmaceutical Industries. Who Profits Research Centre; 2012 Jul. https:\u002F\u002F\u003Cbr>www.whoprofits.org\u002Fcompanies\u002Fcompany\u002F4212?teva-pharmaceutical-\u003Cbr>industries. (accessed 2 February 2024).\u003Cbr>9. Annabelle Collins. Teva links to Israel prompt boycott by UK contractors.\u003Cbr>Chemist+Druggist; 2014 Aug 4. https:\u002F\u002Fwww.chemistanddruggist.co.uk\u002F\u003Cbr>CD017184\u002FTeva-links-to-Israel-prompt-boycott-by-UK-contractors. (accessed\u003Cbr>2 February 2024).\u003Cbr>10. The Palestinian BDS National Committee. Campaign Area: Academic Boycott.\u003Cbr>https:\u002F\u002Fbdsmovement.net\u002Facademic-boycott. (accessed 2 February 2024).\u003Cbr>11. Savo Heleta. The deafening silence of South African universities. Africa is a\u003Cbr>country; 2023 Oct 10. https:\u002F\u002Fafricasacountry.com\u002F2023\u002F10\u002Fthe-deafening-\u003Cbr>silence-of-south-african-universities. (accessed 2 February 2024).\u003Cbr>12. Sathar MA. The war on Gaza. A test of our humanity. S Afr J Bioethics Law\u003Cbr>2023;16(3):e1734. https:\u002F\u002Fdoi.org\u002F10.7196\u002FSAJBL.2023.v16i3.1734\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Salud y genocidio: El BDS como puerta de entrada a la justicia sanitaria.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(2024).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Revista Sudafricana de Bioética y Derecho, 17(1), e1961.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">https:\u002F\u002Fdoi.org\u002F10.7196\u002Fsajbl.2024.v17i1.1961 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Al Editor: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El 26 de enero de 2024, la Corte Internacional de Justicia (CIJ) determinó que existían indicios razonables de genocidio por parte de Israel en Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Se emitieron medidas provisionales para que Israel garantizara que sus fuerzas armadas no cometieran actos de genocidio y que tomara todas las medidas a su alcance para prevenirlos, tal como se define en la Convención para la Prevención y la Sanción del Delito de Genocidio.[1]\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El gobierno israelí ha negado las acusaciones de genocidio, alegando su derecho a la legítima defensa.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El caso de Sudáfrica (SA) incluyó numerosos informes detallados de ataques contra personal sanitario y hospitales.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Este tipo de ataques también se produjeron antes de los sucesos del 7 de octubre de 2023. [2,3] La paralización del sistema sanitario de Gaza lo ha dejado incapaz de atender la gran cantidad de pacientes heridos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Esto, junto con el agravamiento de la catástrofe sanitaria pública provocada por el hombre, que ha propiciado la desnutrición y la propagación de infecciones, debería ser motivo de especial preocupación para quienes trabajan en el sector sanitario.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Si bien la iniciativa de Sudáfrica de presentar la demanda ha generado reacciones diversas tanto en Sudáfrica como a nivel internacional, la acción se ajusta a la responsabilidad de todos los países de proteger a las poblaciones del genocidio, los crímenes de guerra, la limpieza étnica y los crímenes de lesa humanidad.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El personal sanitario de todo el mundo podría verse físicamente aislado del continuo y mortal ataque militar contra la población civil de Gaza y podría no tener ninguna obligación legal de actuar.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sin embargo, los principios éticos de beneficencia, no maleficencia y justicia obligan al personal sanitario a actuar siempre que sea posible.[4,5] Siguiendo el ejemplo del histórico desmantelamiento del apartheid en Sudáfrica, observamos que si bien el levantamiento nacional fue un componente importante de la lucha contra el apartheid, otro elemento fue la presión ejercida sobre el Estado del apartheid por el movimiento internacional de boicot, desinversión y sanciones (BDS).[6]\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Los boicots académicos, deportivos y culturales implicaron que mantener el apartheid conllevaba un coste más que económico.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Inspirado por el movimiento antiapartheid de Sudáfrica, el movimiento palestino BDS ha llamado al boicot de Israel desde 2005 como una forma de presión no violenta para que cumpla con el derecho internacional y numerosas resoluciones de las Naciones Unidas.[7]\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los boicots adoptan diferentes formas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Los boicots dirigidos a consumidores exigen boicots completos de marcas específicas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Son iniciados por el movimiento BDS tras una investigación exhaustiva sobre el impacto de dicho boicot.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En cambio, los boicots orgánicos son impulsados ​​por los consumidores y a menudo surgen espontáneamente tras un error público de la empresa involucrada.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Los objetivos de presión son otra técnica en la que no se justifica un boicot total, pero se pide a los consumidores que ejerzan presión mediante el uso de productos alternativos siempre que sea posible, así como mediante la presión, las interrupciones pacíficas y la sensibilización a través de campañas en redes sociales.[7]\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esta técnica es más apropiada para el sector sanitario, donde se debe tener cuidado de no causar daños interrumpiendo la atención al paciente mediante fallos en la cadena de suministro.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva Pharmaceutical Industries está catalogada como objetivo de presión por el Comité Nacional Palestino de BDS.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva es una empresa farmacéutica israelí y el mayor fabricante de medicamentos genéricos del mundo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva se beneficia de la ocupación ilegal israelí y de la construcción de asentamientos en territorio palestino, lo que le permite explotar el mercado palestino cautivo.[7,8] Teva ya es objeto de boicots en el Reino Unido[9] y otros países.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La Tabla 1 sugiere medidas que diversos actores del sector sanitario pueden adoptar para ejercer presión sobre Teva e Israel como parte de una campaña más amplia de BDS.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> El Comité Nacional Palestino de BDS (BNC) también llama a un boicot académico a las universidades israelíes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El boicot está dirigido a instituciones y no a académicos individuales.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El BNC informó que las universidades israelíes son cómplices del régimen israelí de ocupación, colonialismo y apartheid… involucradas en el desarrollo de sistemas de armas… desplegados por Israel y que justifican la continua atención médica y genocidio: el BDS como puerta de entrada a la justicia sanitaria. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">1. Aplicación de la Convención para la Prevención y la Sanción del Delito de Genocidio en la Franja de Gaza (Sudáfrica contra Israel) (Medidas provisionales).\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> https:\u002F\u002Fwww.icj-cij.org\u002Findex.php\u002Fnode\u002F203447 (consultado el 2 de febrero de 2024).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">2. Mahomed S. Cuando los santuarios de la humanidad se convierten en corredores del horror: La destrucción de la atención médica en Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">S Afr J Bioethics Law 2023;16(3):e1732.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Español: https:\u002F\u002Fdoi.org\u002F10.7196\u002FSAJBL.2023.v16i3.1732 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">3. Soni A. Israel profana la santidad de la atención médica con sus ataques.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">S Afr J Bioethics Law 2023;16(3):e1656.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">https:\u002F\u002Fdoi.org\u002F10.7196\u002FSAJBL.2023.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> v16i3.1656 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">4. Soni S. Gaza y el derecho internacional: La obligación global de proteger la vida y la salud.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">S Afr J Bioethics Law 2023;16(3):e1764.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">https:\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">doi.org\u002F10.7196\u002F\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> SAJBL.2023.v16i3.1764\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">5. Hanbali L, Kwong EJL, Neilson A, et al.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La necropolítica israelí y la búsqueda de\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Justicia sanitaria en Palestina.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">BMJ Global Health 2024;9:e014942.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">http:\u002F\u002Fdx.doi.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> org\u002F10.1136\u002Fbmjgh-2023-014942\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">6. Colaboradores de Wikipedia.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Movimiento contra el apartheid. Wikipedia, The Free\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Enciclopedia;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">4 de marzo de 2005. https:\u002F\u002Fen.wikipedia.org\u002Fw\u002Findex.php?title=Anti-\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Apartheid_Movement&oldid=1195203572 (consultado el 2 de febrero de 2024).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">7. El Comité Nacional Palestino de BDS.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Actúe ahora contra estas empresas que se benefician del genocidio del pueblo palestino.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">https:\u002F\u002Fbdsmovement.net\u002FAct-Now-Against-These-Companies-Profiting-From-Genocide.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(Consultado el 2 de febrero de 2024).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">8. Teva Pharmaceutical Industries.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Centro de Investigación Who Profits;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">julio de 2012. https:\u002F\u002F www.whoprofits.org\u002Fcompanies\u002Fcompany\u002F4212?teva-pharmaceutical- industries.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(Consultado el 2 de febrero de 2024).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">9. Annabelle Collins.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Los vínculos de Teva con Israel provocan un boicot de contratistas del Reino Unido.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Chemist+Druggist;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">4 de agosto de 2014. https:\u002F\u002Fwww.chemistanddruggist.co.uk\u002F CD017184\u002FTeva-links-to-Israel-prompt-boycott-by-UK-contractors.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(Consultado el 2 de febrero de 2024).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">10. El Comité Nacional Palestino de BDS.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Área de campaña: Boicot académico.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> https:\u002F\u002Fbdsmovement.net\u002Facademic-boycott.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(Consultado el 2 de febrero de 2024).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">11. Savo Heleta.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El silencio ensordecedor de las universidades sudafricanas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">África es un país;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">10 de octubre de 2023. https:\u002F\u002Fafricasacountry.com\u002F2023\u002F10\u002Fthe-deafening- silence-of-south-african-universities.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(Consultado el 2 de febrero de 2024).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">12. Sathar MA.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La guerra en Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Una prueba para nuestra humanidad.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">S Afr J Bioethics Law 2023;16(3):e1734.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">https:\u002F\u002Fdoi.org\u002F10.7196\u002FSAJBL.2023.v16i3.1734\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"FFpbKc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"\u002Fdoi.org\u002F10.7196\u002F\nSAJBL.2023.v16i3.1764\n5. Hanbali L, Kwong EJL, Neilson A, et al. La necropolítica israelí y la búsqueda de\nJusticia sanitaria en Palestina. BMJ Global Health 2024;9:e014942. http:\u002F\u002Fdx.doi.\norg\u002F10.1136\u002Fbmjgh-2023-014942\n6. Colaboradores de Wikipedia. Movimiento contra el apartheid. Wikipedia, The Free\nEnciclopedia; 4 de marzo de 2005. https:\u002F\u002Fen.wikipedia.org\u002Fw\u002Findex.php?title=Anti-\nApartheid_Movement&oldid=1195203572 (consultado el 2 de febrero de 2024).\n7. El Comité Nacional Palestino de BDS. Actúe ahora contra estas empresas que se benefician del genocidio del pueblo palestino. https:\u002F\u002Fbdsmovement.net\u002FAct-Now-Against-These-Companies-Profiting-From-Genocide. (Consultado el 2 de febrero de 2024).\n8. Teva Pharmaceutical Industries. Centro de Investigación Who Profits; julio de 2012. https:\u002F\u002F\nwww.whoprofits.org\u002Fcompanies\u002Fcompany\u002F4212?teva-pharmaceutical-\nindustries. (Consultado el 2 de febrero de 2024).\n9. Annabelle Collins. Los vínculos de Teva con Israel provocan un boicot de contratistas del Reino Unido.\nChemist+Druggist; 4 de agosto de 2014. https:\u002F\u002Fwww.chemistanddruggist.co.uk\u002F\nCD017184\u002FTeva-links-to-Israel-prompt-boycott-by-UK-contractors. (Consultado el 2 de febrero de 2024).\n10. El Comité Nacional Palestino de BDS. Área de campaña: Boicot académico.\nhttps:\u002F\u002Fbdsmovement.net\u002Facademic-boycott. (Consultado el 2 de febrero de 2024).\n11. Savo Heleta. El silencio ensordecedor de las universidades sudafricanas. África es un país; 10 de octubre de 2023. https:\u002F\u002Fafricasacountry.com\u002F2023\u002F10\u002Fthe-deafening-\nsilence-of-south-african-universities. (Consultado el 2 de febrero de 2024).\n12. Sathar MA. La guerra en Gaza. Una prueba para nuestra humanidad. S Afr J Bioethics Law\n2023;16(3):e1734. https:\u002F\u002Fdoi.org\u002F10.7196\u002FSAJBL.2023.v16i3.1734\" data-crosslingual-hint=\"en\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",1746467980806,"KIVVUC5wl2Y","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1746467814\u002Fs9jbdpcpcp96gjunymhi.jpg","boycott-teva-healthcare-and-genocide-boicot-a-teva-puerta-de-entrada-esp-eng","Boycott Teva. Healthcare and genocide.  Boicot a Teva, puerta de entrada. ESP ENG",{"title":133,"videoUrl":134,"imageUrl":135,"type":7,"timestamp":136,"slug":137,"link":12,"tags":138,"user":13,"content":139,"id":140,"subtitle":141},"Miles de personas en Madrid denuncian \"el genocidio en Palestina\" y el comercio de armas con Israel","Yl-Y2dg5g64","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1746903488\u002Ftdzgwmv7c6hq72ig8qre.jpg",1746903713398,"miles-de-personas-en-madrid-denuncian-el-genocidio-en-palestina-y-el-comercio-de-armas-con-israel",[15],"\u003Cdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh xsag5q8 xz9dl7a x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s x1q0g3np xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1iyjqo2 x2lwn1j xeuugli x1q0g3np xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1iyjqo2 x2lwn1j xeuugli xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cstrong>\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Health Workers 4 Palestine Spain\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">\u003Cstrong>Hemos estado en Madrid junto a toda la ciudadanía\u003C\u002Fstrong>, pidiendo por el fin de la ocupación, la barbarie y el genocidio del pueblo palestino.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Con dos ejes principales: 1\u002F boicot a Teva y 2\u002F denuncia del silencio de organizaciones médicas (Colegio de Médicos de Madrid y Organización Médica Colegial, OMC)\u003Cbr>Como profesionales de la sanidad, nuestro juramento hipocrático nos obliga a posicionarnos contra regímenes genocidas y que vulneran absolutamente la legislación internacional y los derechos humanos.\u003Cbr>Es nuestro deber como, ciudadanas y como profesionales, gritar por nuestras colegas sanitarias que están siendo secuestradas, encarceladas, torturadas y asesinadas impunemente por el estado de Isreal.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Y lo seguiremos haciendo hasta que Palestina sea libre.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FGqp-cYCXwAAVNEB?format=jpg&name=large\" alt=\"\" width=\"1536\" height=\"2048\">\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">\u003Cstrong>Miles de personas se manifiestan en Madrid para denunciar \"el genocidio en Palestina\" y el comercio de armas con Israel      \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Belarra ha acusado a Sánchez de mentir en el Congreso al decir que España no comercia armas con Israel     \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">La protesta ha sido convocada por la Red Solidaria contra la Ocupación de Palestina bajo el lema \"Muévete por Palestina\"  10\u002F05\u002F2025 \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Miles de personas —10.000, según la Delegación del Gobierno— se han manifestado este sábado en Madrid para denunciar \"el genocidio en Palestina\" y el comercio de armas con Israel. La protesta ha sido convocada por la Red Solidaria contra la Ocupación de Palestina (Rescop) bajo el lema \"Muévete por Palestina\" y coincide con el 77 aniversario de la Nabka (catástrofe, en árabe), que cada 15 de mayo evoca el éxodo palestino como consecuencia del nacimiento del Estado de Israel en 1948 y también con la intensificación de la ofensiva israelí en Gaza y Cisjordania.  \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Saida Ghodaieh Curiel, presidenta de la Asociación Hispano Palestina Jerusalén, ha denunciado que desde entonces \"lo único que hemos vivido son desplazamientos, asesinatos, limpieza étnica, apartheid y crímenes de lesa humanidad contra el pueblo palestino, más aún hoy en día con un genocidio que está siendo televisado y de manera impune con la complicidad de los países occidentales\". \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Greenpeace tiñe de rojo la fuente de Neptuno para exigir el embargo de armas a Israel\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">La marcha ha discurrido desde Atocha hasta la Puerta de Sol, donde ha acabado el acto con la lectura de un manifiesto y de unos poemas por parte de los actores Alberto San Juan y Elisabet Gelabert.  \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">\"Boicot a Israel\", \"Esta bandera (en alusión a la de Palestina) es la verdadera\", \"No es una guerra, es un genocidio\" o \"Vosotros sionistas sois los terroristas\" han sido algunas de las consignas más coreadas por los asistentes. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">IU y Podemos se suman a la marcha.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">\"Después de 19 meses de una brutalidad sin precedentes en el genocidio que Israel lleva cometiendo sobre Palestina desde hace décadas, hemos decidido hacer esta manifestación, ya que nuestras exigencias no están llegando al Gobierno español con la suficiente claridad y hemos venido aquí desde los diferentes territorios del Estado para unir fuerzas, porque solo la unión nos da la fuerza\", ha indicado Lidón Soriano, una de las portavoces de Rescop.  \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Antes del arranque de la manifestación, Antonio Maíllo, coordinador general de IU, ha restado importancia a su presencia en la manifestación, junto a otros compañeros como Enrique Santiago, a pesar de que su partido forma parte de Sumar, socio del Gobierno de coalición, y la protesta también iba dirigida contra el Ejecutivo por seguir comerciando con Israel. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">\"Hay miles de militantes que son el orgullo de nuestra organización, que están trabajando desde hace decenios de años en favor de la población Palestina. Y esa es la legitimidad que nos pone en presentarnos con esta posición, que es una posición que nadie cuestiona en nuestra organización\", dicho. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">El Gobierno adjudicó 46 contratos de material militar a empresas israelíes desde el inicio de la guerra en Gaza. \u003Cbr>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi x1wdrske x8viiok x18hxmgj\" style=\"line-height: 18px;\">Por su parte, la líder de Podemos, Ione Belarra, ha llamado al presidente israelí, Benjamín Netanyahu, \"Hitler de nuestro tiempo\", a la vez que ha lamentado la \"lección de historia terrorífica\" que está dando el sionismo, \"haciéndole al pueblo de Palestina lo mismo que los nazis les hicieron a los judíos\", y ha acusado al presidente del Gobierno, Pedro Sánchez, de mentir en el Congreso al decir que España no comercia armas con Israel.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s x1q0g3np xqjyukv x6s0dn4 x1oa3qoh x1nhvcw1\">\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FGqroU0RW0AASaFJ?format=jpg&name=large\" alt=\"\" width=\"1600\" height=\"1200\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"x78zum5 xdt5ytf x1iyjqo2\">\n\u003Cdiv class=\"x1iyjqo2\">\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x6s0dn4 x1oa3qoh xl56j7k\" style=\"height: 100%;\">\n\u003Cdiv class=\"x9f619 xjbqb8w x78zum5 x168nmei x13lgxp2 x5pf9jr xo71vjh x1e56ztr x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Ch2 class=\"x1lliihq x1plvlek xryxfnj x1n2onr6 x1ji0vk5 x18bv5gf x193iq5w xeuugli x1fj9vlw x13faqbe x1vvkbs x1s928wv xhkezso x1gmr53x x1cpjm7i x1fgarty x1943h6x x1i0vuye x133cpev x1xlr1w8 x5n08af x2b8uid x4zkp8e x41vudc x10wh9bi x1wdrske x8viiok x18hxmgj\" dir=\"auto\" style=\"----base-line-clamp-line-height: 30px; --lineheight: 30px;\"> \u003C\u002Fh2>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","maikvd2f1jrebdknt91","Manifestación, 10 de mayo 2025",{"slug":143,"type":7,"title":144,"content":145,"timestamp":146,"id":147,"subtitle":148,"videoUrl":89,"imageUrl":149,"user":13,"tags":150,"link":12},"200-profesionales-hospital-contra-teva-200-health-hospital-professionals-againts-teva-gurutzetako-larrialdietako-berrehun-esp-eng-eus","200 profesionales hospital contra TEVA. 200 health hospital professionals againts Teva. Gurutzetako larrialdietako berrehun. ESP ENG EUS","\u003Cp>\u003Cstrong>Actualización a 21 de julio de 2025. \u003C\u002Fstrong>\u003Cspan class=\"inline\">\u003Cem>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-no-ni-hp-390-profesionales-de-la-sanidad-vallecas-madrid-390-health-professionals-vallecas-madrid-spain-esp-eng\">390 sanitarios piden al Gobierno de Ayuso \u003C\u002Fa>que los hospitales no compren más material a empresas israelíes\u003C\u002Fem>\u003Cstrong> \u003C\u002Fstrong> \u003Cem>En una carta dirigida a la gerencia de dos hospitales de Vallecas y, en última instancia, al Gobierno de la Comunidad de Madrid, los sanitarios solicitan que investigue a las empresas contratadas y ponen como ejemplo el material adquirido a HP y la farmacéutica Teva.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Actualización a 17 de junio de 2025\u003C\u002Fstrong>.\u003Ca href=\"https:\u002F\u002Felcierredigital.com\u002Finvestigacion\u002Fgolpe-farmaceutica-israeli-teva-boicot-sanitario-tumba-intereses-espana\"> Golpe a la farmaceútica israelí Teva: El boicot sanitario tumba sus interes en España\u003C\u002Fa>. 200 profesionales vascos han desatado un debate al pedir que no se compren productos a esta polémica compañía israelí\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL. 11 de mayo de 2025\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Acción directa. ¿Cómo ayudar directamente a Gaza?\u003C\u002Fstrong>\u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.naiz.eus\u002Fes\u002Finfo\u002Fnoticia\u002F20250508\u002F200-trabajadores-de-cruces-piden-la-retirada-de-los-productos-de-una-farmaceutica-israeli\">\u003Cstrong>200 profesionales de las Urgencias Generales del Hospital Universitario de Cruces han reclamado a Osakidetza que retire los productos de la farmacéutica israelí Teva y los reemplace por «una alternativa que respete los Derechos Humanos».\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>Han pedido al Servicio Vasco de Salud que elimine de sus farmacias y dispensarios todo fármaco y material de la farmacéutica Teva y de todas sus marcas: Tevagen, Ratiopharm, Davur y Belmac. Además, han reclamado que se retire la subvención a los mismos y se «rompa toda relación con empresas e instituciones que defienden y apoyan el genocidio, tanto académica como económicamente».\u003Cbr>Según han explicado en un comunicado, en este momento Osakidetza cuenta con numerosos medicamentos de Teva en su red de hospitales, medicamentos tan habituales como el Omeprazol oral o algunos inhaladores, «fáciles de reemplazar por otros genéricos de otras farmacéuticas cercanas». En el caso de Cruces, cuentan con 35 medicamentos y productos sanitarios de Teva desde 2024.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH 11 May 2025\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Direct Action.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">How can we directly help Gaza?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Ca href=\"https:\u002F\u002Fwww.naiz.eus\u002Fes\u002Finfo\u002Fnoticia\u002F20250508\u002F200-trabajadores-de-cruces-piden-la-retirada-de-los-productos-de-una-farmaceutica-israeli\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">200 General Emergency Room professionals at Cruces University Hospital have demanded that Osakidetza withdraw products from the Israeli pharmaceutical company Teva and replace them with \"an alternative that respects human rights.\"\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Specifically, they have asked the Basque Health Service to remove all drugs and materials from the pharmaceutical company Teva and all its brands: Tevagen, Ratiopharm, Davur, and Belmac, from its pharmacies and dispensaries.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">They have also demanded that subsidies to these companies be withdrawn and that \"all relations with companies and institutions that defend and support genocide, both academically and financially, be severed.\"\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> As explained in a statement, Osakidetza currently has numerous Teva medications in its hospital network, such common medications as oral omeprazole or some inhalers, \"easy to replace with generics from other nearby pharmaceutical companies.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In the case of Cruces, they have had 35 Teva medicines and medical devices since 2024.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">EUSKERA\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"eu\">Ekintza zuzena. Nola lagundu diezaiokegu zuzenean Gazari?\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.berria.eus\u002Feuskal-herria\u002Fgurutzetako-larrialdietako-berrehun-langilek-osakidetzari-eskatu-diote-israelgo-enpresa-bati-botikak-erosteari-uzteko_2141457_102.html\">\u003Cstrong>Gurutzetako ospitaleko (Barakaldo, Bizkaia) larrialdietako langileek argi dute: ez dute harremanik nahi Israelekin. \u003C\u002Fstrong>\u003C\u002Fa>Ez dute harremanik nahi genozidio bat egiten ari den herrialde batekin. Jakinarazi dutenez, Osakidetzak Israelgo Teva Pharm enpresaren produktuak erabiltzen ditu. Horrekin ados ez, eta sinadurak biltzen hasi dira: larrialdietako berrehun mediku, erizain, teknikari eta zelarik Osakidetzako zuzendaritzari eskatu diote ez dezala erosi enpresa horren produktu gehiagorik eta ahalik eta lasterren ordezka dezala «giza eskubideak errespetatzen dituen beste batekin».\u003C\u002Fp>\n\u003Cp>«Hilabeteak dira Palestinaren aurkako zuzeneko genozidio baten lekuko garela», gogoratu dute osasun langileek. Salatu dute hildako kopuruak «beldurgarriak» direla, eta erasoek herritarrak izan dituztela helburu, baita ospitaleak, anbulantziak eta osasun langileak ere. Jakinda horrelako ankerkeriak gertatzen direla, beharginek uste dute ezin direla «besoak gurutzatuta» geratu. «Gure lanaren berezko parte da bizitza eta giza eskubideak defendatzea».\u003C\u002Fp>\n\u003Cp>Nazioarteko hainbat erakundek eta osasun kolektibok hilabeteak daramatzate palestinarren aurkako krimenak salatzen, «baita urteak ere», sinatzaileen arabera. Esaterako, nazioarteko kanpaina bat abiarazi dute, «genozidioaren konplize diren enpresei boikota egiteko eta desinbertsioa ezartzeko».\u003C\u002Fp>\n\u003Cp>Hain justu, konplizetzat jo dute Teva enpresa. Israelgo merkatuko merkataritza eta industria enpresa handiena dela ohartarazi dute, «kapitalaren, mozkin garbiaren, diru sarreren eta merkatu balioaren arabera». Israeli eta haren armadari «565 milioi dolar» ordaindu zizkion duela bi urte «metatutako zergetan».\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>",1746958125406,"majgnnz9c0kx7rqvbc","País Vasco (España), Hospital de Cruces. Basque Country (Spain) University Hospital, Cruces. Ez diezaiola botika gehiagorik erosi Israelgo enpresa bati","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1746957689\u002Ffhlblvbqua1bqipx3yzj.jpg",[15],{"subtitle":152,"content":153,"slug":154,"type":7,"tags":155,"user":13,"link":12,"timestamp":156,"id":157,"imageUrl":158,"title":159,"videoUrl":160},"No prescribas, no dispenses, no consumas TEVA","\u003Cp>En un minuto y diez segundos, una llamada de atención para poner en su sitio a TEVA y su apoyo al genocidio palestino por Israel. Para pasar a la acción directa y rechazar el genocidio al rechazar los productos y medicamentos de TEVA.\u003C\u002Fp>","boicot-teva-no-seas-complice-de-genocidio",[15],1748367560310,"mb6sot0ueqm9ioatwvm","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1748367414\u002Fpmgewx1uthqh4genysjq.png","Boicot TEVA. No seas cómplice de genocidio","B4t0KwAOCdI?si=9FGcsB_PYZL7Lv7w",{"link":12,"content":162,"user":13,"tags":163,"subtitle":165,"imageUrl":166,"timestamp":167,"id":168,"type":7,"title":169,"videoUrl":170,"slug":171},"\u003Cp>¿No lo habías oído?\u003C\u002Fp>\n\u003Cp>Mantén los oídos bien despiertos.\u003C\u002Fp>\n\u003Cp>Cuando abres una caja de Teva, llega el sonido del genocidio en Palestina.\u003C\u002Fp>\n\u003Cp>No prescribas Teva. No dispenses Teva. No compres Teva. Teva. Tevagen. Belmac. Davur. Ratiopharm\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Teva’s Subsidiaries, Affiliates, and Joint Ventures\u003C\u002Fstrong>\u003Cbr>The following includes a list of Teva’s current indirect parents, subsidiaries, affiliates, and joint\u003Cbr>ventures. Teva made reasonable efforts to identify all current indirect parents, subsidiaries,\u003Cbr>affiliates, and joint ventures and believes this list is complete.\u003Cbr>1. 10009474 Canada Inc.\u003Cbr>2. 1453350 Ontario Inc.\u003Cbr>3. 9985247 Canada Inc.\u003Cbr>4. Abic Investment (1959) Ltd.\u003Cbr>5. Abic Ltd.\u003Cbr>6. AbZ-Pharma GmbH\u003Cbr>7. Actavis d.o.o. Belgrade\u003Cbr>8. Actavis Dutch Holding B.V.\u003Cbr>9. Actavis Elizabeth LLC\u003Cbr>10. Actavis Finance LLC\u003Cbr>11. Actavis Group PTC ehf.\u003Cbr>12. Actavis Holdco US, Inc.\u003Cbr>13. Actavis Kadian LLC\u003Cbr>14. Actavis Laboratories FL, Inc.\u003Cbr>15. Actavis Laboratories UT, Inc.\u003Cbr>16. Actavis Limited\u003Cbr>17. Actavis LLC\u003Cbr>18. Actavis Mid Atlantic LLC\u003Cbr>19. Actavis Pharma S. de R.L. de C.V.\u003Cbr>20. Actavis Pharma, Inc.\u003Cbr>21. Actavis Pharmaceuticals NJ, Inc.\u003Cbr>22. Actavis Puerto Rico Holdings Inc.\u003Cbr>23. Actavis South Atlantic LLC\u003Cbr>24. Actavis Totowa LLC\u003Cbr>25. Actavis Ukraine LLC\u003Cbr>26. Actavis US Holding LLC\u003Cbr>27. Anda Holdco Corp.\u003Cbr>28. Anda Marketing, Inc.\u003Cbr>29. Anda Pharmaceuticals, Inc.\u003Cbr>30. Anda Puerto Rico Inc.\u003Cbr>31. Anda Veterinary Supply, Inc.\u003Cbr>32. Anda, Inc.\u003Cbr>33. Andrx LLC\u003Cbr>34. Anesta LLC\u003Cbr>35. Arana Therapeutics, Inc.\u003Cbr>36. Asaph II B.V.\u003Cbr>37. Assia Chemical Industries Ltd.\u003Cbr>38. Auspex Pharmaceuticals, Inc.\u003Cbr>39. Balkanpharma Dupnitsa AD\u003Cbr>40. Barr International Services, Inc.\u003Cbr>41. Barr Laboratories, Inc.\u003Cbr>42. Barr Pharmaceuticals, LLC\u003Cbr>43. Cephalon (UK) Limited\u003Cbr>44. Cephalon Australia (VIC) Pty Ltd\u003Cbr>45. Cephalon Clinical Partners, LP\u003Cbr>46. Cephalon Development Corporation\u003Cbr>47. Cephalon LLC\u003Cbr>48. CIMA Labs Inc.\u003Cbr>49. Circa Pharmaceuticals West, Inc.\u003Cbr>50. Cobalt Laboratories LLC\u003Cbr>51. Copper Acquisition Corp.\u003Cbr>52. Coventry Acquisition, LLC\u003Cbr>53. Cupric Holding Co. LLC\u003Cbr>54. Cybear, LLC\u003Cbr>55. Doral Manufacturing, Inc.\u003Cbr>56. East End Insurance, Ltd\u003Cbr>57. FEI Products, LLC\u003Cbr>58. Gecko Health Innovations, Inc.\u003Cbr>59. GeminX Pharmaceuticals Canada, Inc\u003Cbr>60. Genchem Pharma LLC\u003Cbr>61. Goldline Laboratories, Inc.\u003Cbr>62. Inmobiliaria Lemery, S.A. de C.V.\u003Cbr>63. INSPIRE INCUBATOR, LIMITED\u003Cbr>PARTNERSHIP\u003Cbr>64. IVAX (Bermuda) Ltd.\u003Cbr>65. IVAX Argentina S.A.\u003Cbr>66. IVAX Far East, Inc.\u003Cbr>67. IVAX Holdings C.I.\u003Cbr>68. IVAX International B.V.\u003Cbr>69. IVAX Laboratories Puerto Rico, Inc.\u003Cbr>J-2\u003Cbr>70. IVAX LLC\u003Cbr>71. IVAX Pharmaceuticals B.V.\u003Cbr>72. IVAX Pharmaceuticals Caribe, Inc.\u003Cbr>73. IVAX Pharmaceuticals Mexico, S.A. de C.V.\u003Cbr>74. IVAX Pharmaceuticals NV, LLC\u003Cbr>75. IVAX Pharmaceuticals, LLC\u003Cbr>76. IVAX Specialty Chemicals Sub, LLC\u003Cbr>77. IVAX UK Limited\u003Cbr>78. Kilburn B.V.\u003Cbr>79. Laboratorio Chile, S.A.\u003Cbr>80. Laboratorios Davur S.L.U.\u003Cbr>81. Labrys Biologics, Inc.\u003Cbr>82. Lemery S.A. de C.V.\u003Cbr>83. Limited Liability Company “Teva Ukraine”\u003Cbr>84. Maancirkel Holding B.V.\u003Cbr>85. Marsam Pharmaceuticals LLC\u003Cbr>86. Med All Enterprise Consulting (Shanghai)\u003Cbr>Co.,Limited\u003Cbr>87. Mepha Investigação, Desenvolvimento e\u003Cbr>Fabricação Farmacêutica, Lda.\u003Cbr>88. Mepha Pharma AG\u003Cbr>89. Mepha Schweiz AG\u003Cbr>90. Merckle GmbH\u003Cbr>91. MicroDose Therapeutx, Inc.\u003Cbr>92. MORIAH BIOTECHNOLOGY LTD\u003Cbr>93. Norton (Waterford) Limited\u003Cbr>94. Norton Healthcare (1998) Limited\u003Cbr>95. Norton Healthcare Limited\u003Cbr>96. Novopharm Holdings, Inc.\u003Cbr>97. NT Pharma Canada Ltd.\u003Cbr>98. Nupathe Inc.\u003Cbr>99. Nuvelution TS Pharma, Inc.\u003Cbr>100. Odyssey Pharmaceuticals, Inc.\u003Cbr>101. Oncotest Teva Ltd\u003Cbr>102. Orvet UK\u003Cbr>103. Patient Services and Solutions, Inc.\u003Cbr>104. Pharma de Espana, Inc.\u003Cbr>105. Pharmachemie (Proprietary) Limited\u003Cbr>106. Pharmachemie B.V.\u003Cbr>107. PharmaPlantex Limited\u003Cbr>108. Pharmatrade S.A.\u003Cbr>109.PharmNovo LLC\u003Cbr>110.Plantex Ltd.\u003Cbr>111.PLIVA d.o.o. SARAJEVO\u003Cbr>112.PLIVA HRVATSKA d.o.o.\u003Cbr>113.PLIVA Ljubljana d.o.o.\u003Cbr>114.Pliva Real Estate GmbH\u003Cbr>115.PLIVA SKOPJE d.o.o.\u003Cbr>116.PLIVA, Inc.\u003Cbr>117.Plus Chemicals, branch of Teva\u003Cbr>Pharmaceuticals International GmbH\u003Cbr>118.PT Actavis Indonesia\u003Cbr>119.Rakepoll Holding B.V.\u003Cbr>120.ratiopharm - Comercio e Industria de\u003Cbr>Produtos Farmaceuticos, Lda.\u003Cbr>121.ratiopharm Arzneimittel Vertriebs-GmbH\u003Cbr>122.ratiopharm España S.A.\u003Cbr>123.ratiopharm GmbH\u003Cbr>124.ratiopharm Immobilienverwaltung GmbH &\u003Cbr>Co. KG\u003Cbr>125.ratiopharm Kazakhstan LLP\u003Cbr>126.Representaciones E Investigaciones Medicas\u003Cbr>S.A. - also called RIMSA\u003Cbr>127.Rise Healthcare Ltd\u003Cbr>128.Royce Research and Development Limited\u003Cbr>Partner I\u003Cbr>129.Salomon, Levin & Elstein Ltd.\u003Cbr>130.Sicor de México S.A. de C.V.\u003Cbr>131.Sicor Inc.\u003Cbr>132.Sicor Società Italiana Corticosteroidi S.r.l.\u003Cbr>133.Sindan-Pharma Srl\u003Cbr>134.TAGCO Incorporated\u003Cbr>135.TAPI Puerto Rico, Inc.\u003Cbr>136.Teva API B.V.\u003Cbr>137.Teva API Inc.\u003Cbr>138.TEVA API INDIA Private Limited\u003Cbr>139.Teva API Japan LTD.\u003Cbr>140.Teva API Services Mexico, S.de R.L.\u003Cbr>de C.V.\u003Cbr>141.Teva B.V.\u003Cbr>142.Teva Biopharmaceuticals USA, Inc.\u003Cbr>143.Teva Biotech GmbH\u003Cbr>J-3\u003Cbr>144. Teva Branded Pharmaceutical Products\u003Cbr>R&D, Inc.\u003Cbr>145. Teva Canada Innovation G.P. - S.E.N.C.\u003Cbr>146. TEVA CANADA LIMITED \u002F TEVA\u003Cbr>CANADA LIMITEE\u003Cbr>147. Teva Capital Services Switzerland, branch of\u003Cbr>Teva Pharmaceuticals International GmbH\u003Cbr>148. Teva Czech Industries s.r.o.\u003Cbr>149. Teva Denmark A\u002FS\u003Cbr>150. Teva Digital Health, Inc.\u003Cbr>151. Teva Farmaceutica Ltda\u003Cbr>152. Teva Finance Holding B.V.\u003Cbr>153. Teva Finance Services II B.V.\u003Cbr>154. Teva Finance Services LLC\u003Cbr>155. Teva Finland Oy\u003Cbr>156. Teva Global Products Limited Partnership\u003Cbr>157. Teva GmbH\u003Cbr>158. Teva Health GmbH\u003Cbr>159. Teva Healthcare India Private Limited\u003Cbr>160. Teva Holdco US, Inc.\u003Cbr>161. Teva Holdings GK\u003Cbr>162. Teva Holdings Ltd.\u003Cbr>163. Teva İlaçları Sanayi ve Ticaret Anonim\u003Cbr>Şirketi\u003Cbr>164. Teva India Private Limited\u003Cbr>165. TEVA INVERSIONES Y\u003Cbr>EXPORTACIONES SpA\u003Cbr>166. Teva Investments (Pty) Ltd.\u003Cbr>167. Teva Israel Ltd\u003Cbr>168. Teva İstanbul İlaç San. Ve Tic. Ltd. Şti\u003Cbr>169. Teva Italia S.r.l.\u003Cbr>170. Teva Laboratoires\u003Cbr>171. Teva Limited Liability Company\u003Cbr>172. Teva Logistics Services B.V.\u003Cbr>173. Teva Medical (Marketing) Ltd.\u003Cbr>174. Teva Medical Ltd.\u003Cbr>175. Teva Nechasim Ltd.\u003Cbr>176. Teva Nederland B.V.\u003Cbr>177. Teva Neuroscience, Inc.\u003Cbr>178. Teva Norway AS (f.k.a. ratiopharm\u003Cbr>Norway AS)\u003Cbr>179.TEVA OPERATIONS POLAND SPÓŁKA z\u003Cbr>OGRANICZONĄ\u003Cbr>ODPOWIEDZIALNOŚCIĄ\u003Cbr>180.Teva Parenteral Medicines, Inc.\u003Cbr>181.TEVA PERU S.A.\u003Cbr>182.Teva Pharma - Produtos Farmacêuticos Lda\u003Cbr>183.Teva Pharma (MS) Pty Ltd\u003Cbr>184.Teva Pharma (New Zealand) Limited\u003Cbr>185.Teva Pharma AG\u003Cbr>186.Teva Pharma Australia Pty Ltd\u003Cbr>187.Teva Pharma B.V.\u003Cbr>188.Teva Pharma Belgium N.V.\u003Cbr>189.Teva Pharma EAD\u003Cbr>190.Teva Pharma Holdings Limited\u003Cbr>191.Teva Pharma Iceland\u003Cbr>192.Teva Pharma S.L.U.\u003Cbr>193.TEVA PHARMA UK LIMITED\u003Cbr>194.Teva Pharmaceutical and Chemical\u003Cbr>Industries India Private Limited\u003Cbr>195.Teva Pharmaceutical Finance Company B.V.\u003Cbr>196.Teva Pharmaceutical Finance Company LLC\u003Cbr>197.Teva Pharmaceutical Finance IV B.V.\u003Cbr>198.Teva Pharmaceutical Finance IV, LLC\u003Cbr>199.Teva Pharmaceutical Finance Netherlands II\u003Cbr>B.V.\u003Cbr>200.Teva Pharmaceutical Finance Netherlands III\u003Cbr>B.V.\u003Cbr>201.Teva Pharmaceutical Finance Netherlands IV\u003Cbr>B.V.\u003Cbr>202.Teva Pharmaceutical Finance V B.V.\u003Cbr>203.Teva Pharmaceutical Finance V, LLC\u003Cbr>204.Teva Pharmaceutical Finance VI, LLC\u003Cbr>205.Teva Pharmaceutical Industries Ltd.\u003Cbr>206.Teva Pharmaceutical Information Consulting\u003Cbr>(Shanghai) Co., Ltd.\u003Cbr>207.Teva Pharmaceutical Investments\u003Cbr>Singapore Pte. Ltd\u003Cbr>208.Teva Pharmaceutical R&D LP\u003Cbr>209.TEVA Pharmaceutical Works Private\u003Cbr>Limited Company\u003Cbr>210.Teva Pharmaceuticals Australia Pty Ltd\u003Cbr>211.Teva Pharmaceuticals Colombia S.A.\u003Cbr>212.Teva Pharmaceuticals CR, s.r.o.\u003Cbr>J-4\u003Cbr>213. Teva Pharmaceuticals Curacao N.V.\u003Cbr>214. Teva Pharmaceuticals Europe B.V.\u003Cbr>215. Teva Pharmaceuticals Finance\u003Cbr>Netherlands B.V.\u003Cbr>216. Teva Pharmaceuticals International GmbH\u003Cbr>217. TEVA Pharmaceuticals Mexico S.A. de C.V.\u003Cbr>218. Teva Pharmaceuticals Panama, S.A\u003Cbr>219. Teva Pharmaceuticals Polska spółka z\u003Cbr>ograniczoną odpowiedzialnością\u003Cbr>220. Teva Pharmaceuticals S.R.L.\u003Cbr>221. TEVA Pharmaceuticals Slovakia s.r.o.\u003Cbr>222. Teva Pharmaceuticals USA, Inc.\u003Cbr>223. Teva Pharmaceuticals, Inc.\u003Cbr>224. Teva Puerto Rico LLC\u003Cbr>225. Teva Respiratory, LLC\u003Cbr>226. Teva Sales and Marketing, Inc.\u003Cbr>227. Teva Santé SAS\u003Cbr>228. Teva Sweden AB\u003Cbr>229. Teva Takeda Pharma Ltd.\u003Cbr>230. Teva Takeda Yakuhin Ltd.\u003Cbr>231. Teva UK Holdings Limited\u003Cbr>232. Teva UK Limited\u003Cbr>233. TEVA Uruguay S.A.\u003Cbr>234. Teva Women's Health, LLC\u003Cbr>235. Tevamiri Limited\u003Cbr>236. TEVAPHARM INDIA PRIVATE LTD.\u003Cbr>237. TEVCO Incorporated\u003Cbr>238. TPI U.S. Holdings, Inc.\u003Cbr>239. Transpharm Logistik GmbH\u003Cbr>240. UAB Teva Baltics\u003Cbr>241. Valmed Pharmaceutical, Inc.\u003Cbr>242. Watson Laboratories, Inc.\u003Cbr>243. Watson Laboratories, Inc.\u003Cbr>244. Watson Laboratories, LLC\u003Cbr>245. Watson Management Corporation\u003C\u002Fp>",[15,164],"Boicot","No prescribas Teva. No dispenses Teva. No compres Teva. Teva. Tevagen. Belmac. Davur. Ratiopharm","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1750355598\u002Fvs4krrl3djvjkhlfkyms.png",1750355707710,"mc3obqd3ti374lq5ka9","Vídeo. Al abrir una caja de Teva, oyes el genocidio en Palestina","24wAeIbrC5s","video-al-abrir-una-caja-de-teva-oyes-el-genocidio-en-palestina",{"imageUrl":173,"content":174,"link":12,"user":13,"tags":175,"videoUrl":176,"type":7,"subtitle":177,"slug":178,"timestamp":179,"title":180,"id":181},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1750414478\u002Fys1nooo5phflmp9iqrpl.jpg","\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Haven't you heard?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Keep your ears open.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">When you open a box of Teva, the sound of genocide in Palestine comes through.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Don't prescribe Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Don't dispense Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Don't buy Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Tevagen.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Belmac.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Davur.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ratiopharm,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cbr>Teva’s Subsidiaries, Affiliates, and Joint Ventures\u003Cbr>The following includes a list of Teva’s current indirect parents, subsidiaries, affiliates, and joint\u003Cbr>ventures. Teva made reasonable efforts to identify all current indirect parents, subsidiaries,\u003Cbr>affiliates, and joint ventures and believes this list is complete.\u003Cbr>1. 10009474 Canada Inc.\u003Cbr>2. 1453350 Ontario Inc.\u003Cbr>3. 9985247 Canada Inc.\u003Cbr>4. Abic Investment (1959) Ltd.\u003Cbr>5. Abic Ltd.\u003Cbr>6. AbZ-Pharma GmbH\u003Cbr>7. Actavis d.o.o. Belgrade\u003Cbr>8. Actavis Dutch Holding B.V.\u003Cbr>9. Actavis Elizabeth LLC\u003Cbr>10. Actavis Finance LLC\u003Cbr>11. Actavis Group PTC ehf.\u003Cbr>12. Actavis Holdco US, Inc.\u003Cbr>13. Actavis Kadian LLC\u003Cbr>14. Actavis Laboratories FL, Inc.\u003Cbr>15. Actavis Laboratories UT, Inc.\u003Cbr>16. Actavis Limited\u003Cbr>17. Actavis LLC\u003Cbr>18. Actavis Mid Atlantic LLC\u003Cbr>19. Actavis Pharma S. de R.L. de C.V.\u003Cbr>20. Actavis Pharma, Inc.\u003Cbr>21. Actavis Pharmaceuticals NJ, Inc.\u003Cbr>22. Actavis Puerto Rico Holdings Inc.\u003Cbr>23. Actavis South Atlantic LLC\u003Cbr>24. Actavis Totowa LLC\u003Cbr>25. Actavis Ukraine LLC\u003Cbr>26. Actavis US Holding LLC\u003Cbr>27. Anda Holdco Corp.\u003Cbr>28. Anda Marketing, Inc.\u003Cbr>29. Anda Pharmaceuticals, Inc.\u003Cbr>30. Anda Puerto Rico Inc.\u003Cbr>31. Anda Veterinary Supply, Inc.\u003Cbr>32. Anda, Inc.\u003Cbr>33. Andrx LLC\u003Cbr>34. Anesta LLC\u003Cbr>35. Arana Therapeutics, Inc.\u003Cbr>36. Asaph II B.V.\u003Cbr>37. Assia Chemical Industries Ltd.\u003Cbr>38. Auspex Pharmaceuticals, Inc.\u003Cbr>39. Balkanpharma Dupnitsa AD\u003Cbr>40. Barr International Services, Inc.\u003Cbr>41. Barr Laboratories, Inc.\u003Cbr>42. Barr Pharmaceuticals, LLC\u003Cbr>43. Cephalon (UK) Limited\u003Cbr>44. Cephalon Australia (VIC) Pty Ltd\u003Cbr>45. Cephalon Clinical Partners, LP\u003Cbr>46. Cephalon Development Corporation\u003Cbr>47. Cephalon LLC\u003Cbr>48. CIMA Labs Inc.\u003Cbr>49. Circa Pharmaceuticals West, Inc.\u003Cbr>50. Cobalt Laboratories LLC\u003Cbr>51. Copper Acquisition Corp.\u003Cbr>52. Coventry Acquisition, LLC\u003Cbr>53. Cupric Holding Co. LLC\u003Cbr>54. Cybear, LLC\u003Cbr>55. Doral Manufacturing, Inc.\u003Cbr>56. East End Insurance, Ltd\u003Cbr>57. FEI Products, LLC\u003Cbr>58. Gecko Health Innovations, Inc.\u003Cbr>59. GeminX Pharmaceuticals Canada, Inc\u003Cbr>60. Genchem Pharma LLC\u003Cbr>61. Goldline Laboratories, Inc.\u003Cbr>62. Inmobiliaria Lemery, S.A. de C.V.\u003Cbr>63. INSPIRE INCUBATOR, LIMITED\u003Cbr>PARTNERSHIP\u003Cbr>64. IVAX (Bermuda) Ltd.\u003Cbr>65. IVAX Argentina S.A.\u003Cbr>66. IVAX Far East, Inc.\u003Cbr>67. IVAX Holdings C.I.\u003Cbr>68. IVAX International B.V.\u003Cbr>69. IVAX Laboratories Puerto Rico, Inc.\u003Cbr>J-2\u003Cbr>70. IVAX LLC\u003Cbr>71. IVAX Pharmaceuticals B.V.\u003Cbr>72. IVAX Pharmaceuticals Caribe, Inc.\u003Cbr>73. IVAX Pharmaceuticals Mexico, S.A. de C.V.\u003Cbr>74. IVAX Pharmaceuticals NV, LLC\u003Cbr>75. IVAX Pharmaceuticals, LLC\u003Cbr>76. IVAX Specialty Chemicals Sub, LLC\u003Cbr>77. IVAX UK Limited\u003Cbr>78. Kilburn B.V.\u003Cbr>79. Laboratorio Chile, S.A.\u003Cbr>80. Laboratorios Davur S.L.U.\u003Cbr>81. Labrys Biologics, Inc.\u003Cbr>82. Lemery S.A. de C.V.\u003Cbr>83. Limited Liability Company “Teva Ukraine”\u003Cbr>84. Maancirkel Holding B.V.\u003Cbr>85. Marsam Pharmaceuticals LLC\u003Cbr>86. Med All Enterprise Consulting (Shanghai)\u003Cbr>Co.,Limited\u003Cbr>87. Mepha Investigação, Desenvolvimento e\u003Cbr>Fabricação Farmacêutica, Lda.\u003Cbr>88. Mepha Pharma AG\u003Cbr>89. Mepha Schweiz AG\u003Cbr>90. Merckle GmbH\u003Cbr>91. MicroDose Therapeutx, Inc.\u003Cbr>92. MORIAH BIOTECHNOLOGY LTD\u003Cbr>93. Norton (Waterford) Limited\u003Cbr>94. Norton Healthcare (1998) Limited\u003Cbr>95. Norton Healthcare Limited\u003Cbr>96. Novopharm Holdings, Inc.\u003Cbr>97. NT Pharma Canada Ltd.\u003Cbr>98. Nupathe Inc.\u003Cbr>99. Nuvelution TS Pharma, Inc.\u003Cbr>100. Odyssey Pharmaceuticals, Inc.\u003Cbr>101. Oncotest Teva Ltd\u003Cbr>102. Orvet UK\u003Cbr>103. Patient Services and Solutions, Inc.\u003Cbr>104. Pharma de Espana, Inc.\u003Cbr>105. Pharmachemie (Proprietary) Limited\u003Cbr>106. Pharmachemie B.V.\u003Cbr>107. PharmaPlantex Limited\u003Cbr>108. Pharmatrade S.A.\u003Cbr>109.PharmNovo LLC\u003Cbr>110.Plantex Ltd.\u003Cbr>111.PLIVA d.o.o. SARAJEVO\u003Cbr>112.PLIVA HRVATSKA d.o.o.\u003Cbr>113.PLIVA Ljubljana d.o.o.\u003Cbr>114.Pliva Real Estate GmbH\u003Cbr>115.PLIVA SKOPJE d.o.o.\u003Cbr>116.PLIVA, Inc.\u003Cbr>117.Plus Chemicals, branch of Teva\u003Cbr>Pharmaceuticals International GmbH\u003Cbr>118.PT Actavis Indonesia\u003Cbr>119.Rakepoll Holding B.V.\u003Cbr>120.ratiopharm - Comercio e Industria de\u003Cbr>Produtos Farmaceuticos, Lda.\u003Cbr>121.ratiopharm Arzneimittel Vertriebs-GmbH\u003Cbr>122.ratiopharm España S.A.\u003Cbr>123.ratiopharm GmbH\u003Cbr>124.ratiopharm Immobilienverwaltung GmbH &\u003Cbr>Co. KG\u003Cbr>125.ratiopharm Kazakhstan LLP\u003Cbr>126.Representaciones E Investigaciones Medicas\u003Cbr>S.A. - also called RIMSA\u003Cbr>127.Rise Healthcare Ltd\u003Cbr>128.Royce Research and Development Limited\u003Cbr>Partner I\u003Cbr>129.Salomon, Levin & Elstein Ltd.\u003Cbr>130.Sicor de México S.A. de C.V.\u003Cbr>131.Sicor Inc.\u003Cbr>132.Sicor Società Italiana Corticosteroidi S.r.l.\u003Cbr>133.Sindan-Pharma Srl\u003Cbr>134.TAGCO Incorporated\u003Cbr>135.TAPI Puerto Rico, Inc.\u003Cbr>136.Teva API B.V.\u003Cbr>137.Teva API Inc.\u003Cbr>138.TEVA API INDIA Private Limited\u003Cbr>139.Teva API Japan LTD.\u003Cbr>140.Teva API Services Mexico, S.de R.L.\u003Cbr>de C.V.\u003Cbr>141.Teva B.V.\u003Cbr>142.Teva Biopharmaceuticals USA, Inc.\u003Cbr>143.Teva Biotech GmbH\u003Cbr>J-3\u003Cbr>144. Teva Branded Pharmaceutical Products\u003Cbr>R&D, Inc.\u003Cbr>145. Teva Canada Innovation G.P. - S.E.N.C.\u003Cbr>146. TEVA CANADA LIMITED \u002F TEVA\u003Cbr>CANADA LIMITEE\u003Cbr>147. Teva Capital Services Switzerland, branch of\u003Cbr>Teva Pharmaceuticals International GmbH\u003Cbr>148. Teva Czech Industries s.r.o.\u003Cbr>149. Teva Denmark A\u002FS\u003Cbr>150. Teva Digital Health, Inc.\u003Cbr>151. Teva Farmaceutica Ltda\u003Cbr>152. Teva Finance Holding B.V.\u003Cbr>153. Teva Finance Services II B.V.\u003Cbr>154. Teva Finance Services LLC\u003Cbr>155. Teva Finland Oy\u003Cbr>156. Teva Global Products Limited Partnership\u003Cbr>157. Teva GmbH\u003Cbr>158. Teva Health GmbH\u003Cbr>159. Teva Healthcare India Private Limited\u003Cbr>160. Teva Holdco US, Inc.\u003Cbr>161. Teva Holdings GK\u003Cbr>162. Teva Holdings Ltd.\u003Cbr>163. Teva İlaçları Sanayi ve Ticaret Anonim\u003Cbr>Şirketi\u003Cbr>164. Teva India Private Limited\u003Cbr>165. TEVA INVERSIONES Y\u003Cbr>EXPORTACIONES SpA\u003Cbr>166. Teva Investments (Pty) Ltd.\u003Cbr>167. Teva Israel Ltd\u003Cbr>168. Teva İstanbul İlaç San. Ve Tic. Ltd. Şti\u003Cbr>169. Teva Italia S.r.l.\u003Cbr>170. Teva Laboratoires\u003Cbr>171. Teva Limited Liability Company\u003Cbr>172. Teva Logistics Services B.V.\u003Cbr>173. Teva Medical (Marketing) Ltd.\u003Cbr>174. Teva Medical Ltd.\u003Cbr>175. Teva Nechasim Ltd.\u003Cbr>176. Teva Nederland B.V.\u003Cbr>177. Teva Neuroscience, Inc.\u003Cbr>178. Teva Norway AS (f.k.a. ratiopharm\u003Cbr>Norway AS)\u003Cbr>179.TEVA OPERATIONS POLAND SPÓŁKA z\u003Cbr>OGRANICZONĄ\u003Cbr>ODPOWIEDZIALNOŚCIĄ\u003Cbr>180.Teva Parenteral Medicines, Inc.\u003Cbr>181.TEVA PERU S.A.\u003Cbr>182.Teva Pharma - Produtos Farmacêuticos Lda\u003Cbr>183.Teva Pharma (MS) Pty Ltd\u003Cbr>184.Teva Pharma (New Zealand) Limited\u003Cbr>185.Teva Pharma AG\u003Cbr>186.Teva Pharma Australia Pty Ltd\u003Cbr>187.Teva Pharma B.V.\u003Cbr>188.Teva Pharma Belgium N.V.\u003Cbr>189.Teva Pharma EAD\u003Cbr>190.Teva Pharma Holdings Limited\u003Cbr>191.Teva Pharma Iceland\u003Cbr>192.Teva Pharma S.L.U.\u003Cbr>193.TEVA PHARMA UK LIMITED\u003Cbr>194.Teva Pharmaceutical and Chemical\u003Cbr>Industries India Private Limited\u003Cbr>195.Teva Pharmaceutical Finance Company B.V.\u003Cbr>196.Teva Pharmaceutical Finance Company LLC\u003Cbr>197.Teva Pharmaceutical Finance IV B.V.\u003Cbr>198.Teva Pharmaceutical Finance IV, LLC\u003Cbr>199.Teva Pharmaceutical Finance Netherlands II\u003Cbr>B.V.\u003Cbr>200.Teva Pharmaceutical Finance Netherlands III\u003Cbr>B.V.\u003Cbr>201.Teva Pharmaceutical Finance Netherlands IV\u003Cbr>B.V.\u003Cbr>202.Teva Pharmaceutical Finance V B.V.\u003Cbr>203.Teva Pharmaceutical Finance V, LLC\u003Cbr>204.Teva Pharmaceutical Finance VI, LLC\u003Cbr>205.Teva Pharmaceutical Industries Ltd.\u003Cbr>206.Teva Pharmaceutical Information Consulting\u003Cbr>(Shanghai) Co., Ltd.\u003Cbr>207.Teva Pharmaceutical Investments\u003Cbr>Singapore Pte. Ltd\u003Cbr>208.Teva Pharmaceutical R&D LP\u003Cbr>209.TEVA Pharmaceutical Works Private\u003Cbr>Limited Company\u003Cbr>210.Teva Pharmaceuticals Australia Pty Ltd\u003Cbr>211.Teva Pharmaceuticals Colombia S.A.\u003Cbr>212.Teva Pharmaceuticals CR, s.r.o.\u003Cbr>J-4\u003Cbr>213. Teva Pharmaceuticals Curacao N.V.\u003Cbr>214. Teva Pharmaceuticals Europe B.V.\u003Cbr>215. Teva Pharmaceuticals Finance\u003Cbr>Netherlands B.V.\u003Cbr>216. Teva Pharmaceuticals International GmbH\u003Cbr>217. TEVA Pharmaceuticals Mexico S.A. de C.V.\u003Cbr>218. Teva Pharmaceuticals Panama, S.A\u003Cbr>219. Teva Pharmaceuticals Polska spółka z\u003Cbr>ograniczoną odpowiedzialnością\u003Cbr>220. Teva Pharmaceuticals S.R.L.\u003Cbr>221. TEVA Pharmaceuticals Slovakia s.r.o.\u003Cbr>222. Teva Pharmaceuticals USA, Inc.\u003Cbr>223. Teva Pharmaceuticals, Inc.\u003Cbr>224. Teva Puerto Rico LLC\u003Cbr>225. Teva Respiratory, LLC\u003Cbr>226. Teva Sales and Marketing, Inc.\u003Cbr>227. Teva Santé SAS\u003Cbr>228. Teva Sweden AB\u003Cbr>229. Teva Takeda Pharma Ltd.\u003Cbr>230. Teva Takeda Yakuhin Ltd.\u003Cbr>231. Teva UK Holdings Limited\u003Cbr>232. Teva UK Limited\u003Cbr>233. TEVA Uruguay S.A.\u003Cbr>234. Teva Women's Health, LLC\u003Cbr>235. Tevamiri Limited\u003Cbr>236. TEVAPHARM INDIA PRIVATE LTD.\u003Cbr>237. TEVCO Incorporated\u003Cbr>238. TPI U.S. Holdings, Inc.\u003Cbr>239. Transpharm Logistik GmbH\u003Cbr>240. UAB Teva Baltics\u003Cbr>241. Valmed Pharmaceutical, Inc.\u003Cbr>242. Watson Laboratories, Inc.\u003Cbr>243. Watson Laboratories, Inc.\u003Cbr>244. Watson Laboratories, LLC\u003Cbr>245. Watson Management Corporation\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>",[15],"lJtm7Ghb3F8","When you open a box of Teva, the sound of genocide in Palestine comes through.","video-55-sg-the-sound-of-teva-genocide-in-palestine",1750414549241,"Video 55 sg The sound of Teva (genocide in Palestine)","mc4n823abkza3gx36mu",{"timestamp":183,"slug":184,"videoUrl":185,"type":7,"content":186,"imageUrl":187,"title":188,"id":189,"user":13,"tags":190,"link":12,"subtitle":191},1750601191112,"navarra-espana-spain-campana-campaing-stop-teva-esp-eng","B4t0KwAOCdI","\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cem>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #274e13;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">ESPAÑOL\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #274e13;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">PETICIONES AL CONSEJERO DE SANIDAD SOBRE LA FARMACÉUTICA ISRAELÍ TEVA Y LA RUPTURA CON TODO TIPO DE PRODUCTOS DE ISRAEL EN LA COMPRA PÚBLICA DE NAVARRA \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #274e13;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">(ESPAÑA). 20 junio 2025\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">\u003Cbr>Recientemente, tras dialogar con Yala Nafarroa con Palestina y Nasaf, tres grupos parlamentarios de Navarra registraron la siguiente pregunta en el Parlamento de Navarra dirigida al Gobierno de Navarra y al Consejero de Salud, de enorme importancia para un aterrizaje en hechos concretos en la línea de ruptura de relaciones con el régimen de Israel, tal como demanda la Corte Internacional de Justicia:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; margin-left: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">«TEVA es una compañía farmacéutica israelí que opera en todo el mundo y distribuye medicamentos bajo las denominaciones Teva, Tevagen, Actavis, Davur, Belmac y Ratiopharm. Está especializada en medicamentos genéricos y medicamentos que han perdido la patente.  \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; margin-left: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Según la ONG israelí \"Who Profits\", especializada en verificar qué empresas se benefician del apartheid y la ocupación, Teva es cómplice de la ocupación ilegal de Palestina, de apartheid y de genocidio contra el pueblo palestino. Teva empeora de forma deliberada la calidad de vida de las mujeres palestinas, ya que colabora en la restricción de forma severa del acceso a los servicios de salud y los fármacos por parte de las mujeres embarazadas. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; margin-left: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Teva disfruta del acceso total al mercado cautivo tanto en Cisjordania como en Gaza, donde las empresas farmacéuticas palestinas no pueden operar a causa de las restricciones legales del régimen de apartheid israelí. Israel tampoco permite que los productos farmacéuticos palestinos se distribuyan en hospitales y farmacias de Jerusalén. Los medicamentos israelíes son más asequibles económicamente a causa de los impuestos que impone Israel a los productos que ingresan en Cisjordania.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; margin-left: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Hemos tenido conocimiento de que TEVA forma parte de la lista de empresas admitidas en algunos de los acuerdos marco de contratación desde el Servicio Navarro de Salud para contratar productos farmacéuticos.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; margin-left: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Por todo ello, preguntamos;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; line-height: 138%; margin-left: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"background: transparent;\">    \u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">1. ¿Se plantea el Gobierno de Navarra indicar al Servicio Navarro de Salud que deje de comprar productos a TEVA -los cuales tienen en su inmensa mayoría sustitución en el mercado- como modo de no contribuir a la normalización de las relaciones con Israel mientras sostiene un genocidio en GAZA y aumenta la espiral de violencia en toda Palestina; mientras amplia la ocupación ilegal en zonas como Cisjordania donde TEVA también sostiene parte de la infraestructura; mientras se sostienen las políticas de apartheid? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; line-height: 138%; margin-left: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"background: transparent;\">    \u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">2. ¿En qué plazo y con qué agenda puede trabajar el Gobierno de Navarra para suspender todas las relaciones con la empresa israelí TEVA?\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-left: 1cm; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\">    \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">3. ¿Con la actual ley foral de compra pública y los aspectos apuntados en materia de Derechos Humanos, acaso no se puede considerar en los futuros pliegos y licitaciones un supuesto de exclusión atendiendo a los dictámenes de la CIJ y otros organismos internacionales?»\u003Cbr>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: -1cm; margin-bottom: 0cm; border: none; padding: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">El Consejero de Salud, Fernando Domínguez (GB) no demoró la respuesta que citamos: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; margin-left: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">«(...) Tal y como se ha manifestado públicamente en los últimos días, desde el\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Departamento de Salud se está llevando a cabo un análisis de los contratos que se\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">tiene con empresas farmacéuticas de origen israelí que tengan vinculación con el\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Gobierno de Netanyahu.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">En el marco del plazo estipulado de vencimiento o prórroga de esos acuerdos, se\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">procederá al recambio de los productos y al reemplazo de los servicios referidos\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">priorizando en todo momento que tal sustitución no perjudique a la ciudadanía\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">navarra.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Es cuanto informo en cumplimiento de lo dispuesto en el artículo 215 del\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Reglamento del Parlamento de Navarra.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; text-indent: 1cm; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Pamplona-Iruñea, 5 de junio de 2025»\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Desde Navarra Sanitaria por el Alto el Fuego (más de 600 sanitarios firmantes), Yala Nafarroa con Palestina (más de 225 colectivos y 1700 particulares), Health Workers 4 Palestine-Spain y Plataforma Navarra de la Salud, plataformas que impulsamos la campaña STOP TEVA que entre otras cosas incorpora la recogida de firmas digitales que alcanza 3400 firmas en el momento de este escrito y que está dirigida a Osasunbidea y la Consejería de Salud para dejar de hacer Compra Pública a TEVA queremos manifestar lo siguiente en cuanto a las preguntas parlamentarias de TEVA y la respuesta del Consejero:\u003Cbr>\u003Cbr>1) Celebramos el «análisis de los contratos que se\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">tiene con empresas farmacéuticas de origen israelí que tengan vinculación con el\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Gobierno de Netanyahu». Que nos cuesta pensar que alguna farmacéutica Israelí que opere en territorios de Israel o de los Territorios Palestinos Ocupados (como es el caso de alguna de las plantas de TEVA) no sostenga ferreos lazos con Israel y que nos reafirmamos en el dato contrastado de que TEVA proporciona muchos fondos vía impuestos y otras transferencias de valor que sostienen el régimen focalizado en el genocidio y la ocupación y que se beneficia de la ocupación de Palestina. \u003Cbr>\u003Cbr>2) El análisis de los contratos no debería demorarse, merece un tratamiento de urgencia y basta con revisar la exposición actual a medicamentos y otros recursos hospitalarios de origen Israelí en las bases de datos de Almacén, Farmacia y en las licitaciones públicas. En cualquier caso nos parece buen criterio que la Consejería de Salud no limite solo a TEVA esa revisión de relaciones con Israel.\u003Cbr>\u003Cbr>3) No es suficiente que todo se limite a vigilar la finalización de contrataciones. Pensamos que el Gobierno de Navarra puede tener más herramientas de sanción a empresas Israelíes en concordancia con la Corte Internacional de Justicia. Y se nos ocurren varias líneas que nos permitimos ofrecer al Consejero:\u003Cbr>\u003Cbr>3.1.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Recomendar a centros públicos y privados que reconsideren sus alianzas de investigación\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">en temas sanitarios y se sugiera desvincularse de Universidades y Centros de Investigación israelíes que no estén firmemente concernidos contra el genocidio, la ocupación y el aparthid.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Que se congelen las futuras ayudas públicas si determinados centros públicos o privados sostienen en el tiempo este tipo de nexos\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">con entidades de Israel.\u003Cbr>\u003Cbr>3.2. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Recomendar de un modo activo a médicos, farmacéuticos o almacenes de farmacia que se abstengan en el futuro de utilizar insumos de Israel\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">siempre que procedan de entidades que no se hayan posicionado frente al genocidio, la ocupación o l apartheid de modo expreso. Pese a que el Gobierno y el Consejero no tengan potestad legal para determinar qué dispensa una farmacia o qué receta un médico, si creemos que el Consejero puede tomar un liderazgo moral en clave de Derechos Humanos y Justicia Internacional.\u003Cbr>\u003Cbr>3.3. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Instamos a tomar desde Gobierno de Navarra y Osasunbidea una decisión rápida respecto a la ruptura con TEVA\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">y trasladarla a centros de salud sanitarios. Una decisión que sea más rotunda que esperar a que venzan los contratos. Seguir sin demora con el resto de nexos con productos y servicios de origen Israelí.\u003Cbr>\u003Cbr>3.4. Por último y no menos importante que la ruptura no se condicione solo a un alto el fuego (que siempre incumple Israel) sino que vaya condicionada al fin del genocidio, e apartheid y la ocupación n los términos solicitados por la Asamblea general de la ONU y por la Corte Internacional de Justicia.\u003Cbr>\u003Cbr>Todas estas solicitudes las hacemos con carácter de urgencia como modo de responder a una sociedad movilizada, ser consecuentes con las declaraciones parlamentarias o las mociones en más de 45 ayuntamientos de Navarra, pero ir a la acción, a los hechos por justicia;\u003Cbr>- frente a los 1.500 trabajadores de la salud asesinados y los miles de pacientes y sanitarios desaparecidos, heridos y con trauma permanente \u003Cbr>- frente a las decenas de hospitales y centros de salud atacados y destruidos\u003Cbr>- frente a los dos millones de gazatíes privados de tratamiento médico, medicinas, alimento, agua o energía.\u003Cbr>\u003Cbr>Pedimos una reacción rápida y señales a la altura de la sociedad navarra, hacia el pueblo palestino y hacia la Corte Internacional de Justicia y no un estudio vinculado a “vencimientos de contratos”. Más gallardía, celeridad y profundidad en las medidas. Israel no para de jugar con la seguridad de Palestina e incluso con la seguridad global con ataques unilaterales en coordenadas mundiales (Líbano, Siria, Yemen, Irán…) y Navarra puede y debe ser referente en un aislamiento a Israel como en su día fue el aislamiento a la Sudáfrica del Apartheid. No hay otra vía de detener al régimen sionista.\u003Cbr>\u003Cbr>Por todo esto los colectivos que impulsamos la campaña #stopTEVA la sostendremos en el tiempo sumados a los cientos de trabajadores sanitarios de Cruces o a la importante campaña frente a TEVA en ciudades como Terrassa y otras. Pedimos a la sociedad Navarra que se sume y firme en la dirección: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"http:\u002F\u002Fstop-teva.yalanafarroa.com\u002F\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #1155cc;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cu>\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">stop-teva.yalanafarroa.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"font-variant: normal; font-style: normal; font-weight: normal; line-height: 138%; margin-bottom: 0cm; text-decoration: none;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"background: transparent;\">Pedimos a los médicos que no receten TEVA*, a los farmacéuticos que no dispensen TEVA, a los usuarios que no consuman TEVA y al gobierno que trompa con TEVA y otras empresas israelíes de productos, materiales o servicios sanitarios con la contundencia, celeridad y diligencia en los términos que hemos expresado a lo largo de esta petición.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Chr>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #666666;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">*Recordamos que en todo caso nos referimos a cualquier producto de estas marcas operadas por TEVA: Teva, Tevagen, Actavis, Davur, Belmac y Ratiopharm. Pueden encontrar un dossier completo y más recursos de la campaña en: \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"http:\u002F\u002Fyalanafarroa.com\u002Fstop-teva\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #666666;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cu>\u003Cstrong>\u003Cspan style=\"background: transparent;\">yalanafarroa.com\u002Fstop-teva\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #666666;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">\u003Cbr>\u003Cbr>\u003Cbr>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap Condensed, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">FIRMANTES: \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">\u003Cbr>- NASAF\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">(Navarra Sanitaria por el Alto el Fuego),\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">- \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Yala Nafarroa con Palestina,\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">- HW4P\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">( Health Workers 4 Palestine-Spain)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">- y Plataforma Navarra de la Salud\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">\u003Cbr>\u003Cbr>\u003Cbr>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap Condensed, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">CONTEXTO DE CAMPAÑA #STOPTEVA\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 138%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">- Campaña digital de firmas: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"http:\u002F\u002Fstop-teva.yalanavarra.com\u002F\">\u003Cspan style=\"font-variant: normal;\">\u003Cspan style=\"color: #1155cc;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Asap, sans-serif;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cu>\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">stop-teva.yalanavarra.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cdiv class=\"VjFXz\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"hgbeOc EjH7wc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"cWQYBc\">\u003Cem>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">PETITIONS TO THE HEALTH MINISTER REGARDING THE ISRAELI PHARMACEUTICAL COMPANY TEVA AND THE BREAK WITH ALL TYPES OF ISRAELI PRODUCTS IN PUBLIC PROCUREMENT IN NAVARRE (SPAIN) 20 June 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Recently, after discussions with Yala Nafarroa, Palestine, and Nasaf, three parliamentary groups from Navarre submitted the following question to the Parliament of Navarre, addressed to the Government of Navarre and the Health Minister.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This question is of enormous importance for achieving concrete action on the path to breaking relations with the Israeli regime, as demanded by the International Court of Justice: \"TEVA is an Israeli pharmaceutical company that operates worldwide and distributes medicines under the names Teva, Tevagen, Actavis, Davur, Belmac, and Ratiopharm. It specializes in generic medicines and medicines that have gone off patent.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to the Israeli NGO \"Who Profits,\" which specializes in verifying which companies benefit from apartheid and occupation, Teva is complicit in the illegal occupation of Palestine, apartheid, and genocide against the Palestinian people.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva deliberately worsens the quality of life of Palestinian women by collaborating in severely restricting pregnant women's access to healthcare services and pharmaceuticals.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva enjoys full access to the captive market in both the West Bank and Gaza, where Palestinian pharmaceutical companies cannot operate due to legal restrictions imposed by the Israeli apartheid regime.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Israel also does not allow Palestinian pharmaceutical products to be distributed in hospitals and pharmacies in Jerusalem.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Israeli medicines are more affordable due to the taxes Israel imposes on products entering the West Bank.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We have learned that Teva is on the list of companies admitted to some of the framework contracting agreements with the Navarre Health Service to contract pharmaceutical products.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Therefore, we ask: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1. Is the Government of Navarre considering instructing the Navarre Health Service to stop purchasing TEVA products—the vast majority of which have substitutes on the market—as a way of not contributing to the normalization of relations with Israel while it sustains genocide in Gaza and escalates the spiral of violence throughout Palestine;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">while it expands the illegal occupation in areas like the West Bank, where TEVA also maintains part of the infrastructure;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">while it upholds apartheid policies?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2. Within what timeframe and within what agenda can the Government of Navarre work to suspend all relations with the Israeli company TEVA?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3. With the current regional public procurement law and the aforementioned human rights issues, can exclusion be considered in future specifications and tenders, taking into account the rulings of the ICJ and other international organizations?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Minister of Health, Fernando Domínguez (GB), did not delay the response we quote: \"(...) As has been publicly stated in recent days, the Department of Health is conducting an analysis of the contracts it has with Israeli pharmaceutical companies that have ties to the Netanyahu government. Within the stipulated period for the expiration or extension of these agreements, the products will be replaced and the services referred to will be replaced, always prioritizing that such replacement does not harm the citizens of Navarre. This is all I am reporting in compliance with the provisions of Article 215 of the Regulations of the Parliament of Navarre. \"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Pamplona-Iruñea, June 5, 2025 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">From Navarra Sanitaria for the Ceasefire (more than 600 healthcare workers signed), Yala Nafarroa with Palestine (more than 225 groups and 1,700 individuals), Health Workers 4 Palestine-Spain, and the Navarra Health Platform, platforms that promote the STOP TEVA campaign, which, among other things, includes the collection of digital signatures. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">At the time of writing, the campaign is directed at Osasunbidea and the Regional Ministry of Health to stop public procurement from TEVA. We wish to state the following regarding the parliamentary questions about TEVA and the Regional Minister's response: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1) We welcome the \"analysis of the contracts held with Israeli pharmaceutical companies that have ties to the Netanyahu government.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">We find it hard to believe that any Israeli pharmaceutical company operating in Israel or the Occupied Palestinian Territories (as is the case with some of the TEVA plants) does not have strong ties to Israel. We reaffirm the proven fact that TEVA provides significant funding via taxes and other value transfers that support the regime focused on genocide and occupation and that benefits from the occupation of Palestine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2) The analysis of the contracts should not be delayed; it deserves urgent treatment, and it is sufficient to review the current exposure to medications and other hospital resources of Israeli origin in the Warehouse and Pharmacy databases and in public tenders.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In any case, we believe it is good judgment for the Ministry of Health not to limit this review of relations with Israel to TEVA alone.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3) It is not enough to limit everything to monitoring the completion of contracts.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">We believe the Government of Navarre may have more tools to sanction Israeli companies in accordance with the International Court of Justice.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">We can offer several guidelines to the Minister: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3.1.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Recommend that public and private centers reconsider their research partnerships on health issues and suggest disassociating themselves from Israeli universities and research centers that are not firmly committed to combating genocide, occupation, and apartheid.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">That future public aid be frozen if certain public or private centers maintain these types of ties with Israeli entities over time.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3.2.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Actively recommend that doctors, pharmacists, and pharmacy stores refrain from using Israeli supplies in the future, provided they come from entities that have not expressly taken a stand against genocide, occupation, or apartheid.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Although the Government and the Regional Minister do not have the legal authority to determine what a pharmacy dispenses or what a doctor prescribes, we believe that the Regional Minister can take moral leadership in terms of Human Rights and International Justice.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3.3.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">We urge the Government of Navarra and Osasunbidea to make a swift decision regarding the severance of TEVA and extend it to health centers.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">A decision that is more decisive than waiting for the contracts to expire.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Continue without delay with the remaining ties with products and services of Israeli origin.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3.4.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Last but not least, the rupture must not be conditioned solely on a ceasefire (which Israel always violates) but rather on the end of genocide, apartheid, and occupation under the terms requested by the UN General Assembly and the International Court of Justice.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We make all these requests urgently as a way of responding to a mobilized society, being consistent with parliamentary declarations or motions in more than 45 municipalities in Navarre, but also taking action, taking action for justice;\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> - in the face of the 1,500 healthcare workers murdered and the thousands of patients and healthcare workers missing, injured, and permanently traumatized; - in the face of the dozens of hospitals and health centers attacked and destroyed; - in the face of the two million Gazans deprived of medical treatment, medicine, food, water, or energy.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We call for a swift reaction and signals from Navarrese society, to the Palestinian people, and to the International Court of Justice, and not a study linked to \"contract expirations.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">More courage, speed, and depth in the measures.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Israel continues to play with the security of Palestine and even global security with unilateral attacks on global scales (Lebanon, Syria, Yemen, Iran, etc.), and Navarre can and should be a leader in isolating Israel, just as it once isolated Apartheid South Africa.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">There is no other way to stop the Zionist regime.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For all these reasons, the groups promoting the #stopTEVA campaign will continue to sustain it over time, along with the hundreds of healthcare workers in Cruces and the important campaign against TEVA in cities like Terrassa and others.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We ask the Navarrese society to join us and sign at the following address: stop-teva.yalanafarroa.com \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We ask doctors not to prescribe TEVA*, pharmacists not to dispense TEVA, users not to consume TEVA, and the government that attacks TEVA and other Israeli companies that produce healthcare products, materials, or services with the forcefulness, speed, and diligence we have expressed throughout this petition.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">*We remind you that in all cases, we are referring to any product of these brands operated by TEVA: Teva, Tevagen, Actavis, Davur, Belmac, and Ratiopharm.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">You can find a complete dossier and more campaign resources at: yalanafarroa.com\u002Fstop-teva \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">SIGNATORS: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- NASAF (Navarra Sanitaria por el Ceasefire), \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- Yala Nafarroa con Palestina, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- HW4P (Health Workers 4 Palestine-Spain) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- and the Navarra Health Platform \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">#STOPTEVA CAMPAIGN CONTEXT \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- Digital signature campaign: stop-teva.yalanavarra.com \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- Campaign resources, dossier, poster: yalanafarroa.com\u002Fstop-teva\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1750601153\u002Fp9l42xbbjo2jfewr0aav.png","Navarra (España, Spain). Campaña Campaing Stop Teva ESP ENG","mc7q0y1mzpso46a18z",[15],"Peticiones al consejero de Sanidad. Letter to the ministry of Health",{"imageUrl":193,"content":194,"link":12,"tags":195,"user":13,"videoUrl":12,"subtitle":196,"type":7,"slug":197,"title":198,"timestamp":199,"id":200},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1751738198\u002Fj2njz6beivkunfj07p0r.jpg","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cem>Teva. Gaza sí nos incumbe como personal sanitario\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>5 julio 2025.\u003Ca href=\"https:\u002F\u002Fwww.noticiasdenavarra.com\u002Fopinion\u002Ftribunas\u002F2025\u002F07\u002F05\u002Fgaza-incumbe-personal-sanitario-9840984.html\"> Tribuna en Noticias de Navarra\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Miriam Bravo Izco y Jaxin Gómez Viniegra \u003Cbr>Miembros de Nasaf (Navarra Sanitaria por el Alto el Fuego) y Yala Nafarroa con Palestina, respectivamente \u003C\u002Fp>\n\u003Cp>\u003Cbr>Desde Yala Nafarroa y Nasaf (Navarra Sanitaria por el Alto al Fuego), hace unas semanas nos pusimos en contacto con tres sindicatos con representación en Osasunbidea para que propusieran a la Comisión de Personal que aprobara un texto en el cual se llamase a la ruptura de relaciones comerciales de Osasunbidea con la farmacéutica israelí Teva y sus filiales.\u003Cbr>La Corte Internacional de Justicia, en su dictamen de 19 de julio de 2024, declaró la ilegalidad de la ocupación israelí de los territorios palestinos y se dirigió a los estados miembros de la ONU recordándoles que no deben prestar ayuda a Israel para mantener esa presencia.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Creemos que ya basta de desoír esta exigencia por parte de nuestros gobiernos, por lo que abogamos por el cese de todo tipo de relaciones con empresas y organismos israelíes. Por eso, teniendo en cuenta el gran peso económico de Teva en la economía israelí (es su principal empresa) y en la financiación de su maquinaria de destrucción, entendemos completamente necesario dejar de financiar la barbarie comprando, prescribiendo o dispensando sus medicamentos.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Recientemente, tres partidos del Parlamento de Navarra se dirigieron al consejero de Salud solicitando la interrupción de compra pública con Teva. El consejero, Fernando Domínguez, dio una respuesta favorable y afirmó que se revisarían todos los contratos con productos de Israel, incluida Teva Farma, eso sí, “conforme se produzcan vencimientos de contrato y mientras persista el genocidio”. Si bien esta postura nos parece insuficiente, demuestra claramente que el genocidio nos interpela directamente como sociedad y como personas y por ello debemos decidir y actuar en consecuencia.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Lamentablemente, la Comisión de Personal de Osasunbidea no parece entenderlo así. En su reunión del 26 de junio, el sindicato LAB se hizo eco de nuestra demanda y la presentó al resto del sindicatos. Sólo ELA apoyó la iniciativa. El resto se movía entre el silencio y el rechazo a la misma, alegando que ese organismo, la Comisión de Personal, se debe ocupar únicamente de las problemáticas laborales de la plantilla.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Se ignoró de esta manera el sentir de tantos y tantas profesionales de Osasunbidea que se sienten totalmente concernidas por el asesinato de más de 1.500 sanitarios y sanitarias en Gaza, así como por el ataque a toda la infraestructura sanitaria y por el bloqueo de suministros básicos. De hecho, cada mes, desde el inicio del genocidio, se organizan concentraciones a las puertas de distintos centros sanitarios de Navarra reclamando el alto el fuego y el respeto al Derecho Internacional Humanitario en Gaza, en las que partipan cientos de sanitarios y sanitarias. Ignoró del mismo modo la Comisión de Personal de Osasunbidea el hecho de que esta situación también afecta a las condiciones de trabajo de su plantilla al verse obligada a colaborar en su desempeño laboral con una empresa como Teva, sin posibilidad alguna de poder hacer objeción de conciencia al respecto.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Queremos poner de manifiesto que la campaña Stop Teva en Osasunbidea, que ya acumula cerca de 4.000 firmas, muchas de ellas procedentes del ámbito sanitario, está sostenida por Health Workers 4 Palestine-Spain; por Nasaf, que cuenta con la adhesión de cientos de profesionales; y por Yala Nafarroa con Palestina, donde participa la mayoría sindical de Navarra, sin objetar en ningún momento que se trata de un tema extrasindical.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Por todo ello pedimos públicamente esta vez:\u003C\u002Fp>\n\u003Cp>-A la Comisión de Personal de Osasunbidea, que reconsidere su postura de no apoyar pública y activamente la campaña Stop Teva.\u003C\u002Fp>\n\u003Cp>-A los y las trabajadoras de Osasunbidea, que exijan a su sindicato este pequeño compromiso para frenar el genocidio y la ocupación por parte de Israel.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>La neutralidad no es una opción. \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Gaza does concern us as healthcare workers. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">5 July 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Miriam Bravo Izco and Jaxin Gómez Viniegra Members of Nasaf (Navarra Health for the Ceasefire) and Yala Nafarroa with Palestine, respectively \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">From Yala Nafarroa and Nasaf (Navarra Health for the Ceasefire), a few weeks ago we contacted three unions represented in Osasunbidea to propose to the Personnel Commission that they approve a text calling for Osasunbidea to sever commercial relations with the Israeli pharmaceutical company Teva and its subsidiaries.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> The International Court of Justice, in its ruling of July 19, 2024, declared the illegality of the Israeli occupation of the Palestinian territories and addressed UN member states, reminding them that they must not provide aid to Israel to maintain that presence.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We believe that our governments have had enough ignoring this demand, and therefore we advocate for the cessation of all relations with Israeli companies and organizations.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Therefore, considering Teva's significant economic influence on the Israeli economy (it is its main company) and the financing of its machinery of destruction, we believe it is absolutely necessary to stop financing this barbarism by purchasing, prescribing, or dispensing its medications.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Recently, three parties in the Navarre Parliament addressed the Minister of Health requesting the suspension of public procurement with Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The Minister, Fernando Domínguez, responded favorably and stated that all contracts with Israeli products, including Teva Farma, would be reviewed, but only \"as contract expirations occur and as long as the genocide persists.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">While this position seems insufficient to us, it clearly demonstrates that the genocide directly affects us as a society and as individuals, and therefore we must decide and act accordingly.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Unfortunately, the Osasunbidea Personnel Commission does not seem to understand this.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">At its June 26 meeting, the LAB union echoed our demand and presented it to the rest of the unions.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Only ELA supported the initiative.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The rest hovered between silence and rejection, arguing that this body, the Personnel Commission, should deal solely with the workforce's labor issues.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> This ignored the feelings of so many Osasunbidea professionals who feel deeply concerned by the murder of more than 1,500 healthcare workers in Gaza, as well as the attack on the entire healthcare infrastructure and the blockade of basic supplies.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In fact, every month, since the beginning of the genocide, demonstrations have been held outside various healthcare centers in Navarre demanding a ceasefire and respect for international humanitarian law in Gaza, in which hundreds of healthcare workers participate.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The Osasunbidea Personnel Committee similarly ignored the fact that this situation also affects the working conditions of its staff, as they are forced to collaborate with a company like Teva in their work, without any possibility of conscientious objection.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We wish to highlight that the Stop Teva campaign in Osasunbidea, which has already accumulated nearly 4,000 signatures, many of them from the healthcare sector, is supported by Health Workers 4 Palestine-Spain;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">by Nasaf, which has the support of hundreds of professionals;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">and by Yala Nafarroa with Palestine, where the majority of the unions in Navarra participate, without objecting at any point that this is an extra-union issue.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For all these reasons, we publicly ask this time: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- That the Osasunbidea Personnel Committee reconsider its position of not publicly and actively supporting the Stop Teva campaign.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-To the Osasunbidea workers, please demand this small commitment from your union to stop the genocide and Israeli occupation.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Neutrality is not an option.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",[15],"Profesionales de la sanidad: Teva es parte del problema. Health workers: Teva is part of the problem.","teva-y-genocidio-en-palestina-no-a-teva-en-navarra-teva-and-the-palestinian-genocide-stop-teva-navarra-spain-esp-eng","Teva y genocidio en Palestina. No a Teva en Navarra. Teva and the Palestinian genocide. Stop Teva, Navarra, Spain. ESP ENG ",1751738851508,"mcqj8vygt9b2m1xwk2c",{"subtitle":202,"title":203,"link":12,"user":13,"tags":204,"content":205,"timestamp":206,"type":7,"imageUrl":207,"slug":208,"videoUrl":209,"id":210},"Ask for non-Teva medications. Pida medicamentos que no sean de Teva","#BoicotTEVA In the consultation room. En la consulta ENG ESP",[15],"\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>#BoycottTEVA \u003C\u002Fp>\n\u003Cp>Global Health BDS for Palestine \u003C\u002Fp>\n\u003Cp>22 jul 2025 #BoycottTEVA\u003C\u002Fp>\n\u003Cp>It's really great to see you again, Mr. Bonnie. \u003C\u002Fp>\n\u003Cp>How are you feeling?\u003C\u002Fp>\n\u003Cp>Much better, thank you. Thank you so much for the painkillers. I was in a lot of pain before I came to see you and they've really helped.\u003C\u002Fp>\n\u003Cp>You're very welcome. Is there anything else you'd like me to do for you?\u003C\u002Fp>\n\u003Cp>I don't think I need any more medicines for now, actually, because I feel so much better. But I noticed that the medicines I received are made by a company called Teva. \u003C\u002Fp>\n\u003Cp>Yes, they do make a lot of medicines. Was there anything wrong with them?\u003C\u002Fp>\n\u003Cp>I didn't notice anything wrong with the tablets, but I know that Teva is a company that supports the Israeli army, and I don't want to support any company that upholds war crimes or genocide. Do I have a choice in which company's medicines I receive?\u003C\u002Fp>\n\u003Cp>Yeah, you certainly have a choice. Um, is there anything that I can do to help?\u003C\u002Fp>\n\u003Cp>I'd like to exercise this choice please and ask that I don't receive  medicines in the future. Can this be noted on my medical records?\u003C\u002Fp>\n\u003Cp>Yeah, certainly. Uh Teva mostly specializes in copy drugs, so nearly all of their medicines are made by other companies. However, a small number of their medicines are exclusive to them. So, I might not always be able to use an alternative.\u003C\u002Fp>\n\u003Cp>I understand. But wherever possible, I wish to avoid having any Teva medicines if that's okay, doctor.\u003C\u002Fp>\n\u003Cp>Yeah, of course it's okay. It's your right to refuse medicines from any specific company and we can usually accommodate these requests without any trouble.\u003C\u002Fp>\n\u003Cp>Thank you. Will this impact on any of my future healthcare?\u003C\u002Fp>\n\u003Cp>Oh no, not at all. As I mentioned, there might be a small number of situations where there are no alternatives to using Teva medicines and we can discuss that if the issue arises. Anything else I can do?\u003C\u002Fp>\n\u003Cp>No, that's all. Thank you, doctor. Do please ensure that it's on my medical records that I want to avoid Teva medicines, please.\u003C\u002Fp>\n\u003Cp>Yeah, I'll add that to your notes right now. Thanks for reminding me. \u003C\u002Fp>\n\u003Cp>No problem. Thank you again and have a great day.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>NOTE \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Teva is a medicines company based in Israel and is one of the largest medicines companies in the world. Teva has proclaimed its support for the Israeli government since the start of the Gaza genocide in 2023 and supports the Israeli government through taxes and by providing direct assistance to the Israeli military.\u003C\u002Fp>\n\u003Cp>Nearly all Teva medicines are made by alternative companies since Teva specializes in copies of existing medicines. By refusing Israeli products, you can help to remove all support for the Israeli military. Ask your doctor and your pharmacist if you are receiving any Teva medication and ask for alternatives.\u003C\u002Fp>\n\u003Cp>Boycott Israel. Boycott genocide.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">#BoicotTEVA \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Salud Global BDS para Palestina \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">22 jul 2025 #BoicotTEVA \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Me alegra mucho volver a verlo, Sr. Bonnie.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">¿Cómo se siente?\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Mucho mejor, gracias.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Muchas gracias por los analgésicos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Tenía mucho dolor antes de venir a verlo y me han ayudado mucho.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">De nada.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">¿Hay algo más que quiera que le ayude?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La verdad es que no creo que necesite más medicamentos por ahora, porque me siento mucho mejor.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Pero me he dado cuenta de que los medicamentos que recibí son fabricados por una empresa llamada Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sí, fabrican muchos medicamentos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">¿Tenían algún problema?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">No noté ningún problema con las pastillas en sí, pero sé que Teva es una empresa que apoya al ejército israelí y no quiero apoyar a ninguna empresa que apoye crímenes de guerra o genocidio.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">¿Puedo elegir qué compañía de medicamentos recibir?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sí, por supuesto que puede elegir.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">¿Hay algo que pueda hacer para ayudar?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Me gustaría ejercer esta opción, por favor, y pedir que no me den medicamentos de Teva en el futuro.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">¿Se puede registrar esto en mi historial médico?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sí, por supuesto.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva se especializa principalmente en imitaciones de medicamentos, por lo que casi todos sus medicamentos son fabricados por otras compañías.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sin embargo, una pequeña cantidad de sus medicamentos son exclusivos de ellos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Por lo tanto, es posible que no siempre pueda usar una alternativa.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Lo entiendo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Pero siempre que sea posible, quiero evitar tomar medicamentos de Teva, si le parece bien, doctora.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sí, por supuesto que no hay problema.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Tiene derecho a rechazar medicamentos de cualquier compañía específica y, por lo general, podemos atender estas solicitudes sin problema.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Gracias.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">¿Afectará esto a mi futura atención médica?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Oh, no, en absoluto.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Como mencioné, puede haber algunas situaciones en las que no haya alternativas al uso de medicamentos de Teva, y podemos hablarlo si surge el problema.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">¿Hay algo más que pueda hacer?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">No, eso es todo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Gracias, doctora.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Por favor, asegúrese de que conste en mi historial médico que quiero evitar los medicamentos de Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sí, lo añadiré a sus notas ahora mismo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Gracias por recordármelo.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">No hay problema.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Gracias de nuevo y que tenga un buen día.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">NOTA \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva es una empresa farmacéutica con sede en Israel y una de las más grandes del mundo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva ha declarado su apoyo al gobierno israelí desde el inicio del genocidio de Gaza en 2023 y lo apoya mediante impuestos y asistencia directa al ejército israelí.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Casi todos los medicamentos de Teva son fabricados por empresas alternativas, ya que Teva se especializa en copias de medicamentos existentes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Al rechazar los productos israelíes, puede ayudar a eliminar todo apoyo al ejército israelí.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Consulte a su médico y farmacéutico si está tomando algún medicamento de Teva y solicite alternativas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Boicot a Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Boicot al genocidio.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>",1753210857918,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1753210849\u002Fjunzeijxytvfr3awp0gm.png","boicotteva-in-the-consultation-room-en-la-consulta-eng-esp","WyLoPpOUmRc","mdevfbojqb6zm4b5i4s",{"subtitle":212,"link":12,"title":213,"user":13,"tags":214,"content":215,"timestamp":216,"type":7,"imageUrl":217,"slug":218,"videoUrl":219,"id":220},"No a productos de Teva, ni de HP, Hewlett-Packard. No to Teva and Hewlett-Packard products","Teva no (ni HP). 390 profesionales de la sanidad, Vallecas (Madrid). 390 health professionals, Vallecas (Madrid, Spain)  ESP ENG",[15],"\u003Cdiv class=\"desktop:ml-[64px]\">\n\u003Cdiv class=\"published text-sm text-warm-gray-700 dark:text-cold-gray-200 mb-3 desktop:mb-5\">\n\u003Cp class=\"desktop:inline\">\u003Cstrong>\u003Cspan class=\"tablet:mb-3 tablet:block\">ESPAÑOL\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"desktop:inline\">\u003Cspan class=\"tablet:mb-3 tablet:block\">Para Público, Emilia G Morales Madrid\u003C\u002Fspan>\u003Cspan class=\"mx-2 tablet:hidden\">-\u003C\u002Fspan>\u003Ctime datetime=\"2025-07-21T21:30:00+02:00\">\u003Cspan class=\"tablet:block inline\">21\u002F07\u002F2025 21:30\u003C\u002Fspan>\u003C\u002Ftime>\u003Cspan class=\"mx-2 tablet:hidden\">-\u003C\u002Fspan>\u003Cspan class=\"mr-1\">Actualizado a \u003C\u002Fspan>\u003Ctime datetime=\"2025-07-22T07:57:06+02:00\">\u003Cspan class=\"inline\">22\u002F07\u002F2025 07:57\u003C\u002Fspan>\u003C\u002Ftime>\u003C\u002Fp>\n\u003Cp class=\"desktop:inline\">\u003Cspan class=\"inline\">\u003Cstrong>390 sanitarios piden al Gobierno de Ayuso que los hospitales no compren más material a empresas israelíes \u003C\u002Fstrong> \u003Cem>En una carta dirigida a la gerencia de dos hospitales de Vallecas y, en última instancia, al Gobierno de la Comunidad de Madrid, los sanitarios solicitan que investigue a las empresas contratadas y ponen como ejemplo el material adquirido a HP y la farmacéutica Teva.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"body-modules\" class=\"body-modules w-full\">\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">El pasado 7 de junio, \u003Cstrong>un total de 390\u003C\u002Fstrong> \u003Cstrong>médicos, enfermeros, celadores, administrativos y otros\u003C\u002Fstrong> trabajadores del sistema sanitario público del distrito madrileño de \u003Cstrong>Vallecas\u003C\u002Fstrong>, firmaron una carta pidiendo a las autoridades competentes que \u003Cstrong>evitaran la compra de material médico o la contratación de cualquier\u003C\u002Fstrong>  servicio a empresas que, \"directa o indirectamente\", estén relacionadas \u003Cstrong>con la ocupación de los territorios palestinos o el \"el asesinato sistemático de su población\"\u003C\u002Fstrong>.\u003C\u002Fp>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cem>Público \u003C\u002Fem>ha tenido acceso en exclusiva a dicha misiva, en la que también se pide acabar, \"en la medida de lo posible\", con cualquier acuerdo económico que sostenga al régimen israelí,\u003Cstrong> cuyos principales representantes están siendo investigados por \"crímenes de guerra y contra la humanidad\"\u003C\u002Fstrong> por la \u003Cstrong>Corte Penal Internacional\u003C\u002Fstrong>. A la cabeza de todos ellos se encuentra el primer ministro, \u003Cstrong>Benjamín Netanyahu\u003C\u002Fstrong>, sobre el que pesa \u003Cstrong>una orden de busca y captura interpuesta por la fiscalía de la CPI, el pasado mes de noviembre. \u003C\u002Fstrong>Ello no ha impedido al mandatario viajar recientemente a Hungría sin ser detenido, pese a que el Alto Tribunal tiene jurisprudencia en aquel país.\u003C\u002Fp>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">El personal sanitario de Madrid ha dirigido la misiva a la \u003Cstrong>gerencia de los hospitales Infanta Leonor y Virgen de la Torre\u003C\u002Fstrong>, así como a la \u003Cstrong>dirección médica \u003C\u002Fstrong>y a la \u003Cstrong>comisión de compras \u003C\u002Fstrong>de ambas instituciones. Entre el 2017 y el 2023, la gerencia de los hospitales madrileños se designaba por concurso público. En 2023, el Gobierno de \u003Cstrong>Isabel Díaz Ayuso\u003C\u002Fstrong>, aprobó por vía de urgencia un decreto que abría la puerta a recuperar el nombramiento a dedo\u003Cstrong> \u003C\u002Fstrong>en esos puestos. Sea de uno u otro modo, una de las personas que ha redactado la carta, y que prefiere no dar su nombre, asegura a \u003Cem>Público\u003C\u002Fem> que desconocen \u003Cstrong>\"quiénes son los responsables últimos de las compras\" \u003C\u002Fstrong>de materiales y servicios para los hospitales.\u003C\u002Fp>\n\u003Cdiv class=\"related-intext bg-warm-gray-100 px-5 -mx-5 py-5 mb-10 desktop:bg-lightmode desktop:border-t-2 desktop:border-b-2 desktop:border-warm-gray-300 desktop:dark:border-cold-gray-500 desktop:mx-0 desktop:px-1 desktop:mt-6 desktop:mb-12 dark:bg-cold-gray-700 dark:desktop:bg-darkmode\">Por eso, en el tercer y último punto de la petición, solicitan a la dirección de ambos hospitales que eleven la petición \"\u003Cstrong>a aquellas instancias o autoridades que sus destinatarios consideren concernidas por su contenido\u003C\u002Fstrong>\".\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">Los sanitarios que han firmado la carta no saben cuándo se realizaron los contratos ni a cuánto ascienden. Pero cada día, al llegar al \u003Cstrong>Infanta Leonor \u003C\u002Fstrong>y al \u003Cstrong>Virgen de la Torre\u003C\u002Fstrong> encienden sus ordenadores de la marca \u003Cstrong>Hewlett-Packard\u003C\u002Fstrong>, más conocida como \u003Cstrong>HP\u003C\u002Fstrong>. En ellos, toman nota de los síntomas de sus pacientes, gestionan internamente el hospital y registran la administración de uno u otro medicamento. Algunos de ellos son elaborados por el laboratorio israelí, \u003Cstrong>Teva Pharmaceutical\u003C\u002Fstrong>.\u003C\u002Fp>\n\u003Cdiv>\n\u003Cdiv class=\"subscription-claim-intext [&_>*]:mb-7\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">Tanto HP como Teva, han sido señaladas por varias organizaciones no gubernamentales debido su vinculación con el \u003Cem>apartheid \u003C\u002Fem>y la colaboración con lo que la relatora de la ONU, \u003Cstrong>Francesca Albanese\u003C\u002Fstrong>, describió en su último informe cómo \u003Cstrong>\"economía del genocidio\"\u003C\u002Fstrong>. La abogada italiana define dicho sistema como la metamorfosis de las infraestructuras económicas y tecnológicas de los \u003Cstrong>sistemas de control, explotación y despojo \u003C\u002Fstrong>de los palestinos preexistentes al 7 de octubre, en infraestructuras que ahora reproducen una violencia masiva -genocidio- contra los palestinos.\u003C\u002Fp>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">En cumplimiento de la misión que le designó Naciones Unidas -vigilar e investigar las violaciones de derechos humanos contra la población palestina en los territorios ilegalmente ocupados-, Albanese realizó una investigación en la que puso nombre y apellidos a estas empresas. \u003Cstrong>Entre ellas, se encontraba HP\u003C\u002Fstrong>.\u003C\u002Fp>\n\u003Cdiv class=\"related-intext bg-warm-gray-100 px-5 -mx-5 py-5 mb-10 desktop:bg-lightmode desktop:border-t-2 desktop:border-b-2 desktop:border-warm-gray-300 desktop:dark:border-cold-gray-500 desktop:mx-0 desktop:px-1 desktop:mt-6 desktop:mb-12 dark:bg-cold-gray-700 dark:desktop:bg-darkmode\">\n\u003Cdiv class=\"pb-2 text-xl4 font-serif\">\n\u003Carticle class=\"flex result-page listing-item\">\n\u003Cdiv class=\"article-details mr-3 desktop:mr-4\">\n\u003Cp class=\"font-sans text-base text-black text-balance dark:text-cold-gray-300\"> \u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Ca class=\"page-link hidden desktop:block w-28 min-w-28 ml-auto desktop:w-48 desktop:min-w-48\" href=\"https:\u002F\u002Fwww.publico.es\u002Finternacional\u002Fcasi-90-gaza-sometida-ordenes-desplazamiento-control-militar-israel.html\">\u003Cpicture class=\"relative z-10 object-cover aspect-square desktop:aspect-interior\">\u003Cimg title=\"EuropaPress_6862273_17_july_2025_palestinian_territories_gaza_city_palestinian_mourners_take\" src=\"https:\u002F\u002Fwww.publico.es\u002Ffiles\u002Fimage_horizontal_mobile\u002Fuploads\u002F2025\u002F07\u002F21\u002F687dfdcc7f631.jpeg\" alt=\"Los palestinos retiran el cuerpo de un ser querido para enterrarlo en el Hospital Árabe Ahli en Gaza.\" width=\"480\" height=\"270\" loading=\"lazy\" data-full-src=\"https:\u002F\u002Fwww.publico.es\u002Fuploads\u002F2025\u002F07\u002F21\u002F687dfdcc7f631.jpeg\">\u003C\u002Fpicture>\u003C\u002Fa>\u003C\u002Farticle>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">Según sus pesquisas, la tecnológica, de capital mayoritariamente estadounidense, era la encargada de mantener la base de datos central de la \u003Cstrong>Autoridad de Población e Inmigración\u003C\u002Fstrong>, dependiente del Ministerio del Interior israelí. Esta agencia es el corazón de la burocracia del \u003Cem>apartheid\u003C\u002Fem>, al administrar el acceso a lo que considera territorio de Israel. La Autoridad de Población cumple un \u003Cstrong>papel fundamental en la detención de personas \"ilegales\" en Israel\u003C\u002Fstrong>, para lo que colabora con los servicios penitenciarios sionistas, así como con las fuerzas y cuerpos de seguridad del estado israelí.\u003C\u002Fp>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">Según las pesquisas de la relatora de la ONU, la filial isarelí de HP \u003Cstrong>continúa suministrando servidores para la base de datos\u003C\u002Fstrong> de la agencia, lo que permite la\u003Cstrong> recopilación, el almacenamiento y uso de los datos biométricos\u003C\u002Fstrong> de los palestinos. Esto, explica Albanese, sostiene el régimen de permisos de circulación de Israel, extremadamente discriminatorios para la población palestina. Además, la opacidad de la\u003Cstrong> estructura comercial \u003C\u002Fstrong>le ha permitido ocultar información sobre siete de sus filiales en Israel, por lo que podría tener otras funciones desconocidas en la actualidad.\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">Entre otras fuentes, Francesca Albanese utiliza las informaciones recopiladas por la organización \u003Cstrong>Who Profits\u003C\u002Fstrong> y el movimiento  \u003Cstrong>BDS (Boicot Desinversiones y Sanciones a Israel).\u003C\u002Fstrong> Ambos llevan años investigando la complicidad de estas empresas con el \u003Cem>apartheid\u003C\u002Fem>, la colonización y, ahora, el genocidio. Ambas organizaciones han señalado la vinculación de \u003Cstrong>Teva Pharmaceuticals\u003C\u002Fstrong> con la precarización del mercado palestino.\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">Esta empresa es la mayor distribuidora de fármacos genéricos del mundo. Según \u003Cstrong>Who Profits\u003C\u002Fstrong>, su enorme cuota de mercado y el libre acceso -sin aduanas ni controles- al mercado palestino, ha impedido el desarrollo de la diminuta industria farmacéutica gazatí. Desde el 7 de octubre, esta ha quedado, además, sepultada bajo las bombas. Teva tiene \u003Cstrong>el monopolio de la distribución de medicamentos en los territorios ocupados\u003C\u002Fstrong>, pero no la obligación de etiquetar sus productos en árabe.\u003C\u002Fp>\n\u003Cdiv>\n\u003Cdiv class=\"pb-intext-papel [&_>_*]:mb-7\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">Pese a que Teva no aparece en el informe de Francesca Albanese, los sanitarios madrileños han pedido a las autoridades competentes que apliquen \u003Ca title=\"Francesca Albanese: "Ya que no hemos podido parar el genocidio en Gaza, hay que exigir que quienes han contribuido rindan cuentas"\" href=\"https:\u002F\u002Fwww.publico.es\u002Finternacional\u002Ffrancesca-albanese-hemos-podido-parar-genocidio-gaza-hay-exigir-quienes-han-contribuido-rindan-cuentas.html\" target=\"_blank\" rel=\"noopener\">la estrategia propuesta por la relatora\u003C\u002Fa> para esta y otras empresas que se lucren del genocidio: exponer a quienes han contribuido con el apartheid y el genocidio para que rindan cuentas. \"Pedimos que no se hagan contratos con quienes no estén libres de sospecha\" y que \"se investigue antes de contratar\" a una u otra empresa, aclara a \u003Cem>Público \u003C\u002Fem>uno de los firmantes de la carta. Para ello, dan como referencia el informe de Albanese, así como las bases de datos elaboradas por BDS y Who Profits.\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">De momento, ni las autoridades hospitalarias ni la Consejería de Sanidad de Madrid se han pronunciado sobre las peticiones de los sanitarios, según los firmantes del escrito.\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For Público, Emilia G Morales Madrid - July 21, 2025, 9:30 PM - Updated July 22, 2025, 7:57 AM \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">390 healthcare workers ask the Ayuso government (Madrid, Spain) to stop hospitals from purchasing supplies from Israeli companies. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">In a letter addressed to the management of two hospitals in Vallecas (Madrid) and, ultimately, to the government of the Community of Madrid, the healthcare workers request an investigation into the contracted companies, citing the materials purchased from HP and the pharmaceutical company Teva as examples.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">On June 7, a total of 390 doctors, nurses, orderlies, administrators, and other workers in the public healthcare system in the Madrid district of Vallecas signed a letter asking the competent authorities to prevent the purchase of medical supplies or the contracting of any services from companies that, \"directly or indirectly,\" are related to the occupation of the Palestinian territories or the \"systematic murder of their population.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Público has had exclusive access to the letter, which also calls for an end, \"to the extent possible,\" to any economic agreement that supports the Israeli regime, whose main representatives are being investigated for \"war crimes and crimes against humanity\" by the International Criminal Court.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">At the forefront of these investigations is Prime Minister Benjamin Netanyahu, who is the subject of an arrest warrant issued by the ICC prosecutor's office last November.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This has not prevented the president from recently traveling to Hungary without being arrested, despite the Supreme Court's jurisdiction in that country.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Madrid healthcare workers addressed the letter to the management of the Infanta Leonor and Virgen de la Torre hospitals, as well as to the medical directors and the purchasing committee of both institutions.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Between 2017 and 2023, the management of Madrid's hospitals was appointed by public competition.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In 2023, the Isabel Díaz Ayuso government approved an emergency decree opening the door to restoring appointments to these positions.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Either way, one of the people who drafted the letter, who prefers not to give their name, assures Público that they do not know \"who is ultimately responsible for the purchases\" of materials and services for the hospitals.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Therefore, in the third and final point of the petition, they ask the management of both hospitals to forward the request \"to those bodies or authorities that the recipients consider concerned by its content.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The healthcare workers who signed the letter do not know when the contracts were made or how much they amount to.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">But every day, when they arrive at Infanta Leonor and Virgen de la Torre, they turn on their Hewlett-Packard computers, better known as HP.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">They use them to take note of their patients' symptoms, manage the hospital internally, and record the administration of certain medications.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Some of them are produced by the Israeli laboratory Teva Pharmaceutical.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Both HP and Teva have been singled out by several non-governmental organizations for their links to apartheid and their collaboration with what UN rapporteur Francesca Albanese described in her latest report as the \"economy of genocide.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Italian lawyer defines this system as the metamorphosis of the economic and technological infrastructures of the pre-existing systems of control, exploitation, and dispossession of Palestinians that existed before October 7 into infrastructures that now reproduce massive violence—genocide—against Palestinians.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> In fulfillment of the mission assigned to her by the United Nations—to monitor and investigate human rights violations against the Palestinian population in the illegally occupied territories—Albanese conducted an investigation in which she named these companies.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">HP was among them.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> According to her investigation, the technology company, majority-owned by the United States, was responsible for maintaining the central database of the Population and Immigration Authority, under the Israeli Ministry of the Interior.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This agency is the heart of the apartheid bureaucracy, managing access to what it considers Israeli territory.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"paragraph text-xl pb-7 w-full text-pretty [&_a]:text-link-normal dark:[&_a]:text-link-dark [&_a]:decoration-1 [&_a:hover]:underline [&_a:hover]:text-link-hover [&_a:hover]:decoration-2 [&_b_a]:text-link-normal dark:[&_b_a]:text-link-dark [&_b_a]:decoration-1 [&_b_a:hover]:underline [&_b_a:hover]:text-link-hover desktop:leading-relaxed break-words font-serif\" data-original-text-size=\"text-xl\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Population Authority plays a fundamental role in the detention of \"illegal\" persons in Israel, collaborating with the Zionist prison services, as well as with the Israeli state security forces.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> According to the UN rapporteur's investigation, HP's Israeli subsidiary continues to supply servers for the agency's database, allowing for the collection, storage, and use of Palestinian biometric data.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This, Albanese explains, supports Israel's travel permit regime, which is extremely discriminatory against the Palestinian population.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to her investigation, the technology company, majority-owned by the United States, was responsible for maintaining the central database of the Population and Immigration Authority, under the Israeli Ministry of the Interior.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This agency is the heart of the apartheid bureaucracy, managing access to what it considers Israeli territory.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Population Authority plays a fundamental role in the detention of \"illegal\" persons in Israel, collaborating with the Zionist prison services and Israeli state security forces.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> According to the UN rapporteur's investigation, HP's Israeli subsidiary continues to supply servers for the agency's database, enabling the collection, storage, and use of Palestinian biometric data.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This, Albanese explains, supports Israel's travel permit regime, which is extremely discriminatory against the Palestinian population.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Furthermore, the opacity of its commercial structure has allowed it to conceal information about seven of its subsidiaries in Israel, so it may have other functions that are currently unknown.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Among other sources, Francesca Albanese uses information collected by the organization Who Profits and the BDS (Boycott, Divestment, and Sanctions against Israel) movement.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Both have been investigating these companies' complicity with apartheid, colonization, and now, genocide for years.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Both organizations have pointed out Teva Pharmaceuticals' connection to the precariousness of the Palestinian market.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This company is the largest distributor of generic drugs in the world.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">According to Who Profits, its enormous market share and free access—without customs or controls—to the Palestinian market has impeded the development of the tiny Gazan pharmaceutical industry.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Since October 7, it has also been buried under bombs.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva has a monopoly on the distribution of medicines in the occupied territories, but is not required to label its products in Arabic.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Although Teva does not appear in Francesca Albanese's report, Madrid healthcare workers have asked the relevant authorities to implement the strategy proposed by the rapporteur for this and other companies that profit from genocide: exposing those who have contributed to apartheid and genocide so that they are held accountable.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"We ask that contracts not be made with those who are not above suspicion\" and that \"investigations be carried out before contracting\" with one company or another, one of the signatories of the letter clarifies to Público.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">To this end, they cite Albanese's report, as well as the databases compiled by BDS and Who Profits.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">At the moment, neither the hospital authorities nor the Madrid Ministry of Health have commented on the healthcare workers' requests, according to the signatories of the letter.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",1753359656000,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1753359161\u002Fst705oooomlqdf8kmpwv.png","teva-no-ni-hp-390-profesionales-de-la-sanidad-vallecas-madrid-390-health-professionals-vallecas-madrid-spain-esp-eng","ogZmnc9f1Kc?si=SanUZ0OglCzGONTx","mdhcj7xj69h005r630q",{"videoUrl":222,"content":223,"user":13,"tags":224,"title":225,"link":12,"imageUrl":226,"id":227,"slug":228,"type":7,"timestamp":229,"subtitle":230},"r7UKaS4Zmco","\u003Cp>ESPAÑOL\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>El Israel genocida, un peligro para la Humanidad. ¿Qué podemos hacer desde nuestra pequeñez de profesionales de la sanidad en España?\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote1sym\" name=\"sdendnote1anc\">\u003Csup>i\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-weight: normal;\">Juan Gérvas, médico general rural jubilado, Equipo CESCA, Madrid, España. Exprofesor de salud pública, universidad Jonhs Hopkins, Estados Unidos y Universidad Autónoma de Madrid, España\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"mailto:jjgervas@gmail.com\">\u003Cspan style=\"color: #000080;\">\u003Cspan style=\"font-style: normal;\">\u003Cu>jjgervas@gmail.com\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Ca href=\"http:\u002F\u002Fwww.equipocesca.org\u002F\">\u003Cspan style=\"color: #000080;\">\u003Cspan style=\"font-style: normal;\">\u003Cu>www.equipocesca.org\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cu>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fu>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">@JuanGrvas\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cdiv>\u003Cspan style=\"background-color: #ffff00;\">NOTA:\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv>\u003Cspan style=\"background-color: #ffff00;\">En la imagen, un aguafuerte de Francisco de Goya titulado \"Las mujeres dan valor\", de 1863, de la colección \"Los desastres de la guerra\", respecto a la invasión francesa y la respuesta de la guerrilla española.\u003C\u002Fspan>\n\u003Cdiv id=\"watch7-content\" class=\"watch-main-col\" itemscope=\"\" itemtype=\"http:\u002F\u002Fschema.org\u002FVideoObject\">\u003C\u002Fdiv>\n\u003Cdiv id=\"content\" class=\"style-scope ytd-app\">\n\u003Cdiv id=\"masthead-container\" class=\"style-scope ytd-app\">\n\u003Cdiv id=\"ticker\" class=\"style-scope ytd-masthead\">\u003C\u002Fdiv>\n\u003Cdiv id=\"interstitial\" class=\"style-scope ytd-masthead\">\u003C\u002Fdiv>\n\u003Cdiv id=\"background\" class=\"style-scope ytd-masthead\">\u003C\u002Fdiv>\n\u003Cdiv id=\"container\" class=\"style-scope ytd-masthead\">\n\u003Cdiv id=\"start\" class=\"style-scope ytd-masthead\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"content\" class=\"style-scope ytd-app\">\n\u003Cdiv id=\"masthead-container\" class=\"style-scope ytd-app\">\n\u003Cdiv id=\"ticker\" class=\"style-scope ytd-masthead\">\u003C\u002Fdiv>\n\u003Cdiv id=\"interstitial\" class=\"style-scope ytd-masthead\">\u003C\u002Fdiv>\n\u003Cdiv id=\"background\" class=\"style-scope ytd-masthead\">\u003C\u002Fdiv>\n\u003Cdiv id=\"container\" class=\"style-scope ytd-masthead\">\n\u003Cdiv id=\"start\" class=\"style-scope ytd-masthead\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv>\u003Cspan style=\"background-color: #ffff00;\">Puede ver \u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=LDFOVnMGOng\">aquí\u003C\u002Fa> los 8 minutos de síntesis del escrito en el vídeo de dicha sesión, desde el minuto 1h16 min al minuto 1h24 min. En la locución por favor, corrija y \"oiga\" correctamente \"cárceles israelíes\" (no palestinas), \"75%\" (no 82%), \"Teva, Tevagen, Dalvur, Belmac y Ratiopharm\" y \"millones de dólares\" (no pesetas).\u003C\u002Fspan> \u003C\u002Fdiv>\n\u003Cdiv>Comentario periodístico en ABC\u003Ca href=\"https:\u002F\u002Fwww.abc.es\u002Fespana\u002Fcastilla-la-mancha\u002Ftoledo\u002Fcolegio-medicos-toledo-rechaza-barbarie-gaza-asesorara-20250801180645-nt.html?ref=https%3A%2F%2Fweb.telegram.org%2F\"> \"El Colegio de Médicos de Toledo rechaza la «barbarie» en Gaza y asesorará a médicos que deseen trabajar en zonas de conflicto\"\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>Situación global\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Israel ha bombardeado y masacrado la población gazaití desde el 7 de octubre de 2023. Ha destruido el 92% de las viviendas (la bomba atómica de Estados Unidos contra Hiroshima \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-weight: normal;\">arrasó el 70%).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\"> Entre dicho mes y el de septiembre de 2024, mediante una matanza indescriptible, Israel ha logrado disminuir la expectativa de vida al nacer en Gaza de 76 a 41 años\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote2sym\" name=\"sdendnote2anc\">\u003Csup>ii\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Israel ha asesinado impunemente a unas 400.000 personas en Gaza, la mitad niños\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote3sym\" name=\"sdendnote3anc\">\u003Csup>iii\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote4sym\" name=\"sdendnote4anc\">\u003Csup>iv\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote5sym\" name=\"sdendnote5anc\">\u003Csup>v\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Israel ha “producido” 40.000 huérfanos en Gaza\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote6sym\" name=\"sdendnote6anc\">\u003Csup>vi\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Israel ha sometido a un asedio medieval a Gaza, bloqueando la entrada de comida y agua, de productos sanitarios, repuestos y combustible y está matando de hambre a la población gazaití, con mayor afectación de la infancia y la ancianidad.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"font-style: normal; line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>¡Muera el Ejército de Israel!\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote7sym\" name=\"sdendnote7anc\">\u003Csup>vii\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">El “¡Muera el Ejército de Israel!” es expresión que firmamos personas de buena voluntad pues dicho Ejército está formado por militares cobardes que asesinan a población civil indefensa, día tras día, con maldad inusitada como el disparo al “blanco” de niños por francotiradores, el asesinato a mansalva que quienes acuden a las fuentes de agua y de avituallamiento, o el bombardeo que provoca la muerte por quemaduras de familias que se alojan en chabolas de plástico. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">No hay defensa aérea ninguna, no hay tanques, no hay misiles, no hay sirenas, no hay aviones, no hay drones, no hay artillería...No es una guerra. Hay sólo una increíble guerrilla de liberación nacional frente al ente colonizador: la Resistencia Palestina (a la que es incapaz de derrotar el Ejército de Israel).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"font-style: normal; font-weight: normal; line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>No es sólo un Gobierno cruel, es una población que lo apoya\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">La crueldad y maldad del Gobierno sionista de Israel expresa bien los sentimientos de la población judía sionista de Israel. Una encuesta reciente (de marzo de 2025) entre judíos israelíes demostró que el 82 por ciento de los encuestados apoyaba la expulsión forzosa de los palestinos de Gaza, mientras que el 56 por ciento apoyaba la expulsión de los ciudadanos palestinos de Israel\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote8sym\" name=\"sdendnote8anc\">\u003Csup>viii\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Otra encuesta de la Universidad Hebrea de Jerusalén\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote9sym\" name=\"sdendnote9anc\">\u003Csup>ix\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">, de junio de 2025, arrojó una estadística escalofriante: una abrumadora mayoría (75 %) de los judíos israelíes está de acuerdo con la idea de que \"no hay inocentes en Gaza\". Es decir, que estaba justificado matar incluso a los recién nacidos (no digamos, claro, también a sus madres).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">No es extraño que la crueldad israelí lleve al extremo (en la actualidad, en pleno verano boreal de 2025), de prohibir bañarse en el mar y de pescar en el mismo a la población alojada a la orilla del mar en instalaciones axfisiantes. O al envenamiento de sacos de harina con pastillas de oxicodona, un potente opiáceo.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Lleva ya tiempo la prohibición de Israel de recoger y utilizar agua de lluvia a la población palestina en Cisjordania.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"font-style: normal; font-weight: normal; line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>Israel, país sionista, racista y terrorista\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Israel es un peligro para la Humanidad, un satélite de Estados Unidos y otros países “occidentales” para controlar las reservas de petróleo del Oriente y el Canal de Suez.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Israel ha bombardeado sin declaración de guerra Irán, Líbano, Siria y Yemen. Nada le impedirá utilizar sus bombas nucleares si se ve en peligro, incluso contra sus “aliados” con los que comercia, como España.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>I\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">srael es un país sionista, es decir, racista y terrorista, con decenas de leyes que discriminan al 20% de su población, que es palestina. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Israel nació con el terrorismo, cuyo ejemplo clásico es el atentado el 22 de julio de 1946 contra el Hotel Rey David en Jerusalén, que albergaba el Gobierno Civil del Mandato Británico de Palestina, el Cuartel General del Ejército y la División de Investigación Criminal. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">91 muertos fue el resultado. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"font-style: normal; font-weight: normal; line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>Un poco de historia\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Los problemas se arrastran desde hace más de un siglo, con la ideología de un fanático y su “biblia” publicada en 1896 (“El Estado Judío”, en alemán original “Der Judenstaat”). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">También nació con la “Declaración Balfour”, en 1917, durante la Primera Guerra Mundial, que anunció el apoyo británico al establecimiento de un «hogar nacional» para el pueblo judío en la región de Palestina, que entonces formaba parte del Imperio otomano. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">La Declaración fue firmada por el ministro de Relaciones Exteriores británico Arthur James Balfour, dirigida al también británico Lionel Walter Rothschild, líder sionista y banquero (el de la Banca Rothschild, que había financiado la construcción por el Reino Unido del Canal de Suez).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Tras la primera Guerra Mundial, y el romanticismo de Lawrence de Arabia que engañó a los árabes, británicos y franceses acordaron el reparto de la Palestina otomana y el Reino Unido se hizo cargo del Protectorado Palestino. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">La actividad terrorista sionista llevó a la declaración de la independencia de Israel en 1948 y al comienzo de su actividad como potencia colonial ocupante que se apropia desde entonces de bienes y recursos, y expulsa a la población autóctona. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"font-style: normal; font-weight: normal; line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>La legitimidad de la Resistencia Palestina\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">El 7 de octubre de 2023 fue un día de humillación del Ejército de Israel, apenas un ejemplo de la necesaria y legal Resistencia ante el poder colonial ocupante. Por ello, por no ser atacado por un Ejército de otra nación sino por la población autóctona, Israel carece de “derecho a la defensa”, y la Resistencia no es terrorista. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Por ejemplo, la Resistencia no fue “terrorista” en la Francia ocupada por la Alemania nazi. Tampoco fue terrorista el general Charles De Gaulle promoviendo la Resistencia francesa en su alocución por radio el 18 de junio de 1940.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"font-style: normal; line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>Ensañamiento con lo sanitario\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">La destrucción de Gaza se acompaña de la destrucción más silenciosa de Cisjordania, y en ambos casos hay especial ensañamiento con los establecimientos sanitarios (hospitales y centros de salud), las ambulancias y el personal de sanidad (y sus familias)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote10sym\" name=\"sdendnote10anc\">\u003Csup>x\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote11sym\" name=\"sdendnote11anc\">\u003Csup>xi\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Como botón de muestra, esto del 23 de mayo de 2025: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\"Israel sabía que allí estaban sus 10 hijos, sabía que era el domicilio de la pediatra Alaa Al-Hajaar. Cuando su marido, también médico, regresó, tras dejarla en el Hospital Nasser, bombardeó su casa y mató a 9 hijos. El décimo, uno de 11 años, ha sobrevivido pero esta herido grave y el padre esta en la UCI en estado crítico\". \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">También como ejemplo de comprimiso, ética y solidaridad, ese mismo día la doctora Najjar continuó trabajando a pesar de haber perdido a nueve hijos, aprovechando para revisar el estado de su esposo y de su único hijo superviviente \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote12sym\" name=\"sdendnote12anc\">\u003Csup>xii\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote13sym\" name=\"sdendnote13anc\">\u003Csup>xiii\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">La paz y la solidaridad fundan la sociedad, y el sistema sanitario es la mejor expresión de tales anhelos. De hecho, el sistema sanitario es un determinante social y si se quiere destruir una sociedad no hay nada más fácil que emplear de objetivos a destruir los centros sanitarios, y matar, encarcelar y torturar a sus profesionales, lo que está haciendo Israel en Gaza desde el 7 de octubre de 2023.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Hay tres profesiones e instituciones de Gaza selectivamente asesinadas y destruidas: de educación, de periodismo y de sanidad. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">La destrucción de la infraestructura civil de Palestina, la matanza general y el asesinato selectivo de mujeres e infancia y de profesionales de educación, periodismo y sanidad reflejan las clásicas políticas coloniales de las naciones “occidentales”, de la que Israel es alumna aventajada.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"font-style: normal; font-weight: normal; line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>¿Qué podemos hacer desde nuestra pequeñez de profesionales de la sanidad en España?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Dos cuestiones son centrales como “acción directa” en España para hacer verdad aquello de “mucha gente pequeña, en lugares pequeños, haciendo pequeñas cosas, puede cambiar el mundo”. Por favor:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Col>\n\u003Cli>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Pide la reprobación y enjuiciamiento de la actual ministra de Sanidad en el Gobierno, la médica anestesista Mónica García, de MásMadrid. Tal ministra apoyó y aprobó la enmienda de Israel en la Asamblea Mundial de la OMS (Organización Mundial de la Salud), en 2024, que dio cobertura moral internacional al derramamiento de sangre palestina sanitaria. La enmienda dice que la OMS: “...\u003Cbr>“(…) pide la liberación inmediata e incondicional de todos los rehenes retenidos en Gaza, entre ellos niños, mujeres y personas mayores, y condena el uso, por parte de grupos armados de los establecimientos de salud, incluidos hospitales y ambulancias, que pone en peligro a la población civil”. Es decir, admite la tesis israelí de la infiltración por la Resistencia Palestina del sistema sanitario y por tanto legitima su destrucción y el asesinato, encarcelamiento y tortura de profesionales de la sanidad (y sus familias). Además, se olvida de más de 10.000 rehenes palestinos en cárceles israelíes, maltratados, mal alimentados y torturados. Los “rehenes” son sólo los israelíes retenidos por la Resistencia Palestina. La ministra de Sanidad apoyó con su voto tal monstruosidad, y no intentó modificarlo en la Asamblea Mundial de 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote14sym\" name=\"sdendnote14anc\">\u003Csup>xiv\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">. De alguien así no es extraño el ejercicio de propaganda alrededor de cualquier paciente trasladado a España desde Gaza: en la actualidad, precisan traslado urgente fuera de Gaza 12.000 pacientes. España cuenta con 45 pacientes que hayan sido evacuados ¡en 685 días de genocidio! \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">Haz boicot a Teva y sus varias marcas (Teva, Tevagen, Dalvur, Belmac y Ratiopharm). Teva es un gigante farmacéutico israelí cuyas ganancias financian el genocidio en Palestina\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote15sym\" name=\"sdendnote15anc\">\u003Csup>xv\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">. Teva tiene una inmensa fábrica en Zaragoza, que habría que cerrar o nacionalizar. Teva tuvo ingresos en 2024 de más de 16.500 millones de dólares, básicamente por sus medicamentos genéricos (copia de otros cuya patente ha caducado). En 2023, en España, Teva fue, por volumen de ventas al Sistema Nacional de Salud (el sistema sanitario público), la tercera compañía farmacéutica, con 70 millones de envases y gasto de más de 500 millones de euros. Teva es una empresa sionista “ejemplar”, en el sentido de ser corrupta y corromper. Entre 2010 y 2024, Teva pagó 9.000 millones de dólares por condenas y multas por corrupción. En 2023, en España, Teva “regó” con “transferencias de valor” (dinero) a múltiples profesionales y sociedades “científicas”, con un total de más de dos millones de euros. Destacan Patricia Pozo Rosich, Barcelona, neuróloga, con 31.654 euros y la Fundación SEN (Sociedad Española de Neurología), Barcelona, con casi 150.000 euros. Hay que boicotear a Teva porque genera millones de dólares en ingresos para el régimen militar y colonial israelí, siendo así facilitadora del genocidio y del régimen de apartheid. Además, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>porque se aprovecha de las ventajas de la ocupación en Palestina y del monopolio para la explotación de los palestinos y porque vende sus fármacos a palestinos por encima de su precio de mercado. No prescribas Teva. No vendas Teva. No compres Teva. No consumas Teva.\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">También podemos presionar en otros apartados. Por ejemplo, lograr la expulsión de Israel de la WONCA (Organización Mundial de Médicos Generales\u002Fde Familia), ¡presidida en el momento actual por un médico sionista!\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">También, lograr la expulsión de Israel de la Asociación Médica Mundial, de la Organización Mundial de la Salud y de otras asociaciones y sociedades europeas y mundiales. Así mismo, rechazar la presencia y participación de profesionales e instituciones israelíes en congresos, cursos, proyectos de investigación, etc.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">Así pues, en síntesis, hay mucho pequeño por hacer por gente pequeña, que puede influir en el establecimiento final en Palestina de un Estado de Palestina (los israelíes, claro, tendrán todo el derecho del mundo a hacer sus maletas para volver a sus países de orígen).\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Referencias\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv id=\"sdendnote1\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote1anc\" name=\"sdendnote1sym\">i\u003C\u002Fa>Se presentó un resumen de este texto en la sesión virtual sobre «La asistencia sanitaria en zonas de conflicto: una mirada a Gaza», organizada por el Colegio de Médicos de Toledo el 31 de julio de 2025. Puede ver la presentación oral del firmante desde el minuto 1h16 min al minuto 1h24 min \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002Flive\u002Fr7UKaS4Zmco\">https:\u002F\u002Fwww.youtube.com\u002Flive\u002Fr7UKaS4Zmco\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote2\">\n\u003Cp class=\"sdfootnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote2anc\" name=\"sdendnote2sym\">ii\u003C\u002Fa>Life expectancy losses in the Gaza Strip during the period October, 2023, to September, 2024. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(24)02810-1\u002Fabstract\">https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(24)02810-1\u002Fabstract\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote3\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote3anc\" name=\"sdendnote3sym\">iii\u003C\u002Fa>Counting the dead in Gaza: difficult but essential. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(24)01169-3\u002Ffulltext\">https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(24)01169-3\u002Ffulltext\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote4\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote4anc\" name=\"sdendnote4sym\">iv\u003C\u002Fa>The Israeli\u002FAmerican\u002FGHF “aid distribution” compounds in Gaza: Dataset and initial analysis of location, context, and internal structure. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fdataverse.harvard.edu\u002Fdataset.xhtml?persistentId=doi%3A10.7910%2FDVN%2FQB75LB\">https:\u002F\u002Fdataverse.harvard.edu\u002Fdataset.xhtml?persistentId=doi%3A10.7910%2FDVN%2FQB75LB\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote5\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote5anc\" name=\"sdendnote5sym\">v\u003C\u002Fa>HARVARD REPORT: The Hidden Numbers Behind Gaza’s Real Death Toll. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002F21stcenturywire.com\u002F2025\u002F06\u002F23\u002Fnew-report-the-hidden-numbers-behind-gazas-real-death-toll\u002F\">https:\u002F\u002F21stcenturywire.com\u002F2025\u002F06\u002F23\u002Fnew-report-the-hidden-numbers-behind-gazas-real-death-toll\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote6\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote6anc\" name=\"sdendnote6sym\">vi\u003C\u002Fa>Gaza faces ‘largest orphan crisis’ in modern history, report says. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.aljazeera.com\u002Fnews\u002F2025\u002F4\u002F3\u002Fgaza-faces-largest-orphan-crisis-in-modern-history-report-says\">https:\u002F\u002Fwww.aljazeera.com\u002Fnews\u002F2025\u002F4\u002F3\u002Fgaza-faces-largest-orphan-crisis-in-modern-history-report-says\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote7\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote7anc\" name=\"sdendnote7sym\">vii\u003C\u002Fa>\"Death to the IDF\" \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NGVe62pT1uU\">https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NGVe62pT1uU\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote8\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote8anc\" name=\"sdendnote8sym\">viii\u003C\u002Fa>Nearly half of Israelis support army killing all Palestinians in Gaza, poll finds An overwhelming number of Israelis, including seculars, back the forced transfer of Palestinians from Gaza and Israel. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.middleeasteye.net\u002Fnews\u002Fmajority-israelis-support-expulsion-palestinians-gaza-poll\">https:\u002F\u002Fwww.middleeasteye.net\u002Fnews\u002Fmajority-israelis-support-expulsion-palestinians-gaza-poll\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote9\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote9anc\" name=\"sdendnote9sym\">ix\u003C\u002Fa>Poll: Overwhelming majority of Jewish Israelis share genocidal belief there are ‘no innocent people in Gaza’. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fmondoweiss.net\u002F2025\u002F07\u002Fpoll-overwhelming-majority-of-jewish-israelis-share-genocidal-belief-there-are-no-innocent-people-in-gaza\u002F\">https:\u002F\u002Fmondoweiss.net\u002F2025\u002F07\u002Fpoll-overwhelming-majority-of-jewish-israelis-share-genocidal-belief-there-are-no-innocent-people-in-gaza\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote10\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote10anc\" name=\"sdendnote10sym\">x\u003C\u002Fa>Documenting the Targeting and Destruction of the Health Sector in the Gaza Strip Key statistics – July 26, 2025 \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fgazahcsector.palestine-studies.org\u002Fen\">https:\u002F\u002Fgazahcsector.palestine-studies.org\u002Fen\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote11\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote11anc\" name=\"sdendnote11sym\">xi\u003C\u002Fa>Attacks on health care in the West Bank. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.emro.who.int\u002Fimages\u002Fstories\u002Fattacks_on_health_care_WB_30APR25_copy.pdf\">https:\u002F\u002Fwww.emro.who.int\u002Fimages\u002Fstories\u002Fattacks_on_health_care_WB_30APR25_copy.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote12\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote12anc\" name=\"sdendnote12sym\">xii\u003C\u002Fa>Israel a la caza y asesinato de familiares de profesionales de la sanidad. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fisrael-a-la-caza-y-asesinato-de-familiares-de-profesionales-de-la-sanidad\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fisrael-a-la-caza-y-asesinato-de-familiares-de-profesionales-de-la-sanidad\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote13\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote13anc\" name=\"sdendnote13sym\">xiii\u003C\u002Fa>El drama de la médico Al-Najjar: se fue a trabajar y perdió a 9 de sus 10 hijos en un ataque aéreo israelí contra su casa. \u003Ca href=\"https:\u002F\u002Fwww.elespanol.com\u002Fmundo\u002Foriente-proximo\u002F20250524\u002Fdrama-medico-al-najjar-trabajar-perdio-hijos-ataque-aereo-israeli-casa\u002F1003743773116_0.html\">https:\u002F\u002Fwww.elespanol.com\u002Fmundo\u002Foriente-proximo\u002F20250524\u002Fdrama-medico-al-najjar-trabajar-perdio-hijos-ataque-aereo-israeli-casa\u002F1003743773116_0.html\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote14\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote14anc\" name=\"sdendnote14sym\">xiv\u003C\u002Fa> No son bases militares sino necesarios hospitales ¿Volverá España a apoyar al Estado de Israel en su destrucción del sistema sanitario de Gaza? \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fahoramqnunca.blogspot.com\u002F2025\u002F05\u002Fvolvera-espana-apoyar-al-estado-de.html\">https:\u002F\u002Fahoramqnunca.blogspot.com\u002F2025\u002F05\u002Fvolvera-espana-apoyar-al-estado-de.html\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote15\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote15anc\" name=\"sdendnote15sym\">xv\u003C\u002Fa>Teva en España. Un gigante farmacéutico israelí cuyas ganancias financian el genocidio en Palestina. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina\">https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\"> \u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\"> \u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Genocidal Israel, a danger to humanity.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">What can we do as small healthcare professionals in Spain? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Juan Gérvas, retired rural general practitioner, CESCA Team, Madrid, Spain.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Former professor of public health, Johns Hopkins University, United States, and Autonomous University of Madrid, Spain \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">jjgervas@gmail.com www.equipocesca.org @JuanGrvas \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"ryNqvb\">NOTE: In the image, an etching by Francisco Goya titled \"Women Give Courage,\"  1863, from the collection \"The Disasters of War,\" about the French invasion and the response of the Spanish guerrillas.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Global Situation\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel has bombed and massacred the Gaza population since October 7, 2023. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It has destroyed 92% of homes (the US atomic bomb on Hiroshima destroyed 70%).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Between that month and September 2024, through an indescribable slaughter, Israel has managed to reduce life expectancy at birth in Gaza from 76 to 41 years.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel has murdered some 400,000 people in Gaza with impunity, half of them children.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">iii, iv, v. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel has \"produced\" 40,000 orphans in Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">vi. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel has subjected Gaza to a medieval siege, blocking the entry of food and water, medical supplies, spare parts, and fuel, and is starving the Gazan population, with the greatest impact on children and the elderly.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Death to the Israeli Army (IDF)! vii \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"Death to the Israeli Army (IDF)!\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">is a statement signed by people of good will, because said Army is made up of cowardly soldiers who murder defenseless civilians, day after day, with unprecedented cruelty such as the \"target\" shooting of children by snipers, the indiscriminate murder of those who go to sources of water and supplies, or the bombing that causes the burns to death of families living in plastic shacks.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">There is no air defense, no tanks, no missiles, no sirens, no planes, no drones, no artillery... It's not a war.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">There is only an incredible national liberation guerrilla group facing the colonizing entity: the Palestinian Resistance (which the Israeli Army is incapable of defeating).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It's not just a cruel government, it's a population that supports it. The cruelty and evil of Israel's Zionist government well expresses the feelings of Israel's Zionist Jewish population.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">A recent survey (March 2025) among Israeli Jews showed that 82 percent of respondents supported the forced expulsion of Palestinians from Gaza, while 56 percent supported the expulsion of Palestinian citizens of Israel. 82 percent of respondents supported the forced expulsion of Palestinians from Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">93 percent of respondents supported the expulsion of Palestinian citizens of Israel.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Another survey by the Hebrew University of Jerusalem, 95 percent, conducted in June 2025, yielded a chilling statistic: an overwhelming majority (75%) of Israeli Jews agree with the idea that \"there are no innocent people in Gaza.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">That is to say, it was justified to kill even newborns (not to mention, of course, their mothers).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It is not surprising that Israeli cruelty goes to the extreme (currently, in the middle of the northern summer of 2025), of prohibiting bathing in the sea and fishing in the sea for the population housed in suffocating facilities.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Or to the poisoning of sacks of flour with oxycodone pills, a powerful opiate.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel has long prohibited the Palestinian population in the West Bank from collecting and using rainwater.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Israel, a Zionist, racist, and terrorist country\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel is a danger to humanity, a satellite of the United States and other \"Western\" countries seeking to control the oil reserves of the Middle East and the Suez Canal.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel has bombed Iran, Lebanon, Syria, and Yemen without declaring war.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Nothing will stop it from using its nuclear bombs if it finds itself in danger, even against its \"allies\" with whom it trades, such as Spain.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel is a Zionist country, that is, racist and terrorist, with dozens of laws that discriminate against 20% of its population, who are Palestinian.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel was born with terrorism, the classic example of which is the July 22, 1946, attack on the King David Hotel in Jerusalem, which housed the Civil Government of the British Mandate of Palestine, the Army Headquarters, and the Criminal Investigation Division.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The result was 91 deaths.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">A bit of history \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The problems have been dragging on for more than a century, with the ideology of a fanatic and his \"bible\" published in 1896 (\"The Jewish State,\" in the original German, \"Der Judenstaat\").\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It also arose with the \"Balfour Declaration\" in 1917, during the First World War, which announced British support for the establishment of a \"national home\" for the Jewish people in the region of Palestine, which was then part of the Ottoman Empire.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> The Declaration was signed by British Foreign Secretary Arthur James Balfour, addressed to fellow Briton Lionel Walter Rothschild, a Zionist leader and banker (of the Rothschild Bank, which had financed the United Kingdom's construction of the Suez Canal).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">After the First World War, and the romanticism of Lawrence of Arabia that deceived the Arabs, the British and French agreed to divide Ottoman Palestine, and the United Kingdom took over the Palestinian Protectorate.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Zionist terrorist activity led to Israel's declaration of independence in 1948 and the beginning of its activity as an occupying colonial power, which has since appropriated property and resources and expelled the indigenous population.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>The Legitimacy of the Palestinian Resistance\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">October 7, 2023, was a day of humiliation for the Israeli Army, just an example of the necessary and legal Resistance to the occupying colonial power.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, because it is not attacked by another nation's army but by the indigenous population, Israel lacks the \"right to defense,\" and the Resistance is not terrorist.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For example, the Resistance was not \"terrorist\" in France occupied by Nazi Germany.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Nor was General Charles de Gaulle a terrorist when he promoted the French Resistance in his radio address on June 18, 1940. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Harassment to Healthcare \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The destruction of Gaza is accompanied by the more silent destruction of the West Bank, and in both cases there is particular cruelty toward healthcare facilities (hospitals and health centers), ambulances, and medical personnel (and their families).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">As an example, this from May 23, 2025: \"Israel knew that her 10 children were there, knew it was the home of pediatrician Alaa Al-Hajaar. When her husband, also a doctor, returned after leaving her at Nasser Hospital, he bombed her home and killed 9 children. The tenth, an 11-year-old, survived but is seriously injured, and the father is in the ICU in critical condition.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Also as an example of commitment, ethics, and solidarity, that same day Dr. Najjar continued working despite having lost nine children, taking the opportunity to check on the condition of her husband and her only surviving son.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Peace and solidarity are the foundation of society, and the healthcare system is the best expression of these aspirations.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In fact, the healthcare system is a social determinant, and if you want to destroy a society, there is nothing easier than targeting healthcare facilities and killing, imprisoning, and torturing their professionals, which is what Israel has been doing in Gaza since October 7, 2023. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Three professions and institutions in Gaza have been selectively murdered and destroyed: education, journalism, and healthcare.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The destruction of Palestinian civilian infrastructure, the widespread slaughter, and the targeted killing of women and children, as well as professionals in education, journalism, and healthcare, reflect the classic colonial policies of \"Western\" nations, of which Israel is a shining example.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\"> What can we do, as small healthcare professionals in Spain?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Two issues are central to \"direct action\" in Spain to make the saying \"many small people, in small places, doing small things, can change the world\" a reality.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Please: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1. Call for the rejection and prosecution of the current Minister of Health in the government, anesthesiologist Mónica García, of MásMadrid.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This minister supported and approved Israel's amendment at the 2024 World Health Assembly of the WHO (World Health Organization), which gave international moral cover to the Palestinian health bloodshed.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The amendment states that the WHO: “…calls for the immediate and unconditional release of all hostages held in Gaza, including children, women, and the elderly, and condemns the use by armed groups of health facilities, including hospitals and ambulances, which endangers the civilian population.” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In other words, it accepts the Israeli theory that the Palestinian Resistance has infiltrated the health system and therefore legitimizes its destruction and the murder, imprisonment, and torture of health professionals (and their families). Furthermore, it ignores the more than 10,000 Palestinian hostages in Israeli prisons, mistreated, malnourished, and tortured. The “hostages” are only the Israelis held by the Palestinian Resistance. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Minister of Health supported such a monstrosity with her vote and did not attempt to change it at the 2025 World Health Assembly. From someone like this, it is not unusual to use propaganda around any patient transferred to Spain from Gaza: currently, they require urgent transfer out of Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">12,000 patients.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Spain has 45 patients who have been evacuated in 685 days of genocide!\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2. Boycott Teva and its various brands (Teva, Tevagen, Dalvur, Belmac, and Ratiopharm).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva is an Israeli pharmaceutical giant whose profits fund the genocide in Palestine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva has a huge factory in Zaragoza (Spain), which should be closed or nationalized.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva had revenues of over $16.5 billion in 2024, primarily from its generic drugs (copies of others whose patents have expired).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In 2023, in Spain, Teva was the third-largest pharmaceutical company in terms of sales volume to the National Health System (the public health system), with 70 million packages and spending over €500 million.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva is an \"exemplary\" Zionist company, in the sense of being corrupt and corrupting.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Between 2010 and 2024, Teva paid $9 billion in convictions and fines for corruption.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In 2023, in Spain, Teva \"watered\" multiple professionals and \"scientific\" societies with \"transfers of value\" (money), totaling more than two million euros.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Notable among these were neurologist Patricia Pozo Rosich, Barcelona, with 31,654 euros, and the SEN Foundation (Spanish Society of Neurology), Barcelona, with almost 150,000 euros.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva must be boycotted because it generates millions of dollars in revenue for the Israeli military and colonial regime, thus facilitating genocide and the apartheid regime.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Furthermore, it takes advantage of the benefits of the occupation in Palestine and its monopoly to exploit Palestinians, and because it sells its drugs to Palestinians above market price.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Don't prescribe Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Don't sell Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Don't buy Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Don't consume Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">We can also exert pressure in other areas.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For example, achieving Israel's expulsion from WONCA (World Organization of General\u002FFamily Physicians), currently chaired by a Zionist doctor!\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Also, achieving Israel's expulsion from the World Medical Association, the World Health Organization, and other European and international associations and societies.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Likewise, rejecting the presence and participation of Israeli professionals and institutions in conferences, courses, research projects, etc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">So, in short, there is much small work to be done by small people, which can influence the final establishment of a State of Palestine in Palestine (the Israelis, of course, will have every right to pack their bags and return to their countries of origin).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>References\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv id=\"sdendnote1\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote1anc\" name=\"sdendnote1sym\">i\u003C\u002Fa>Se presentó un resumen de este texto en la sesión virtual sobre «La asistencia sanitaria en zonas de conflicto: una mirada a Gaza», organizada por el Colegio de Médicos de Toledo el 31 de julio de 2025. Puede ver la presentación oral del firmante desde el minuto 1h16 min al minuto 1h24 min \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002Flive\u002Fr7UKaS4Zmco\">https:\u002F\u002Fwww.youtube.com\u002Flive\u002Fr7UKaS4Zmco\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote2\">\n\u003Cp class=\"sdfootnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote2anc\" name=\"sdendnote2sym\">ii\u003C\u002Fa>Life expectancy losses in the Gaza Strip during the period October, 2023, to September, 2024. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(24)02810-1\u002Fabstract\">https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(24)02810-1\u002Fabstract\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote3\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote3anc\" name=\"sdendnote3sym\">iii\u003C\u002Fa>Counting the dead in Gaza: difficult but essential. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(24)01169-3\u002Ffulltext\">https:\u002F\u002Fwww.thelancet.com\u002Fjournals\u002Flancet\u002Farticle\u002FPIIS0140-6736(24)01169-3\u002Ffulltext\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote4\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote4anc\" name=\"sdendnote4sym\">iv\u003C\u002Fa>The Israeli\u002FAmerican\u002FGHF “aid distribution” compounds in Gaza: Dataset and initial analysis of location, context, and internal structure. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fdataverse.harvard.edu\u002Fdataset.xhtml?persistentId=doi%3A10.7910%2FDVN%2FQB75LB\">https:\u002F\u002Fdataverse.harvard.edu\u002Fdataset.xhtml?persistentId=doi%3A10.7910%2FDVN%2FQB75LB\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote5\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote5anc\" name=\"sdendnote5sym\">v\u003C\u002Fa>HARVARD REPORT: The Hidden Numbers Behind Gaza’s Real Death Toll. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002F21stcenturywire.com\u002F2025\u002F06\u002F23\u002Fnew-report-the-hidden-numbers-behind-gazas-real-death-toll\u002F\">https:\u002F\u002F21stcenturywire.com\u002F2025\u002F06\u002F23\u002Fnew-report-the-hidden-numbers-behind-gazas-real-death-toll\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote6\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote6anc\" name=\"sdendnote6sym\">vi\u003C\u002Fa>Gaza faces ‘largest orphan crisis’ in modern history, report says. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.aljazeera.com\u002Fnews\u002F2025\u002F4\u002F3\u002Fgaza-faces-largest-orphan-crisis-in-modern-history-report-says\">https:\u002F\u002Fwww.aljazeera.com\u002Fnews\u002F2025\u002F4\u002F3\u002Fgaza-faces-largest-orphan-crisis-in-modern-history-report-says\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote7\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote7anc\" name=\"sdendnote7sym\">vii\u003C\u002Fa>\"Death to the IDF\" \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NGVe62pT1uU\">https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NGVe62pT1uU\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote8\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote8anc\" name=\"sdendnote8sym\">viii\u003C\u002Fa>Nearly half of Israelis support army killing all Palestinians in Gaza, poll finds An overwhelming number of Israelis, including seculars, back the forced transfer of Palestinians from Gaza and Israel. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.middleeasteye.net\u002Fnews\u002Fmajority-israelis-support-expulsion-palestinians-gaza-poll\">https:\u002F\u002Fwww.middleeasteye.net\u002Fnews\u002Fmajority-israelis-support-expulsion-palestinians-gaza-poll\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote9\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote9anc\" name=\"sdendnote9sym\">ix\u003C\u002Fa>Poll: Overwhelming majority of Jewish Israelis share genocidal belief there are ‘no innocent people in Gaza’. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fmondoweiss.net\u002F2025\u002F07\u002Fpoll-overwhelming-majority-of-jewish-israelis-share-genocidal-belief-there-are-no-innocent-people-in-gaza\u002F\">https:\u002F\u002Fmondoweiss.net\u002F2025\u002F07\u002Fpoll-overwhelming-majority-of-jewish-israelis-share-genocidal-belief-there-are-no-innocent-people-in-gaza\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote10\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote10anc\" name=\"sdendnote10sym\">x\u003C\u002Fa>Documenting the Targeting and Destruction of the Health Sector in the Gaza Strip Key statistics – July 26, 2025 \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fgazahcsector.palestine-studies.org\u002Fen\">https:\u002F\u002Fgazahcsector.palestine-studies.org\u002Fen\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote11\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote11anc\" name=\"sdendnote11sym\">xi\u003C\u002Fa>Attacks on health care in the West Bank. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.emro.who.int\u002Fimages\u002Fstories\u002Fattacks_on_health_care_WB_30APR25_copy.pdf\">https:\u002F\u002Fwww.emro.who.int\u002Fimages\u002Fstories\u002Fattacks_on_health_care_WB_30APR25_copy.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote12\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote12anc\" name=\"sdendnote12sym\">xii\u003C\u002Fa>Israel a la caza y asesinato de familiares de profesionales de la sanidad. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fisrael-a-la-caza-y-asesinato-de-familiares-de-profesionales-de-la-sanidad\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fisrael-a-la-caza-y-asesinato-de-familiares-de-profesionales-de-la-sanidad\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote13\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote13anc\" name=\"sdendnote13sym\">xiii\u003C\u002Fa>El drama de la médico Al-Najjar: se fue a trabajar y perdió a 9 de sus 10 hijos en un ataque aéreo israelí contra su casa. \u003Ca href=\"https:\u002F\u002Fwww.elespanol.com\u002Fmundo\u002Foriente-proximo\u002F20250524\u002Fdrama-medico-al-najjar-trabajar-perdio-hijos-ataque-aereo-israeli-casa\u002F1003743773116_0.html\">https:\u002F\u002Fwww.elespanol.com\u002Fmundo\u002Foriente-proximo\u002F20250524\u002Fdrama-medico-al-najjar-trabajar-perdio-hijos-ataque-aereo-israeli-casa\u002F1003743773116_0.html\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote14\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote14anc\" name=\"sdendnote14sym\">xiv\u003C\u002Fa> No son bases militares sino necesarios hospitales ¿Volverá España a apoyar al Estado de Israel en su destrucción del sistema sanitario de Gaza? \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fahoramqnunca.blogspot.com\u002F2025\u002F05\u002Fvolvera-espana-apoyar-al-estado-de.html\">https:\u002F\u002Fahoramqnunca.blogspot.com\u002F2025\u002F05\u002Fvolvera-espana-apoyar-al-estado-de.html\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote15\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote15anc\" name=\"sdendnote15sym\">xv\u003C\u002Fa>Teva en España. Un gigante farmacéutico israelí cuyas ganancias financian el genocidio en Palestina. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina\">https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv id=\"ow25\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv id=\"ow25\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",[15],"Israel potencia ocupante. Destrucción, muerte y Resistencia. Israel, a colonial power. Destruction, death, and Resistance. ESP ENG","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1754216916\u002Fpkyy236uaw0bt4wcggje.jpg","mdvhw4vl30esd8r6c4i","israel-potencia-ocupante-destruccion-muerte-y-resistencia-israel-a-colonial-power-destruction-death-and-resistance-esp-eng",1754216487198,"Gaza. Situación general allí y acción directa aquí. General situation there, direct action here.",{"link":12,"user":13,"tags":232,"timestamp":233,"title":234,"subtitle":235,"videoUrl":236,"content":237,"imageUrl":238,"type":7,"id":239,"slug":240},[15],1755793014180,"TEVA, no gracias. TEVA, ez eskerrik asko","Es Teva y sus muchas marcas: Teva, Tevagen, Davur, Belmac, Ratiopharm...","plj1xAN5mxY","\u003Cp>\u003Cstrong>Vídeo de Alberto Villarreal, sanitario de la plataforma Al Ahli Arab Taldea \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"css-175oi2r r-eqz5dr r-1wbh5a2 r-1wron08\">\n\u003Cdiv class=\"css-175oi2r r-1wbh5a2 r-dnmrzs r-1ny4l3l\">\n\u003Cdiv class=\"css-175oi2r r-1wbh5a2 r-dnmrzs r-1ny4l3l\">\n\u003Cdiv class=\"css-175oi2r r-1wbh5a2 r-dnmrzs r-1ny4l3l\">\n\u003Cdiv class=\"css-175oi2r r-1awozwy r-18u37iz r-dnmrzs\">\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-adyw6z r-135wba7 r-1vr29t4 r-1awozwy r-6koalj r-1udh08x\" dir=\"ltr\" style=\"color: #0f1419;\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Alberto Villarreal\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"css-175oi2r r-1awozwy r-18u37iz r-1wbh5a2\">\n\u003Cdiv class=\"css-175oi2r r-1wbh5a2 r-dnmrzs r-1ny4l3l\" tabindex=\"-1\">\n\u003Cdiv class=\"css-175oi2r\">\n\u003Cdiv class=\"css-146c3p1 r-dnmrzs r-1udh08x r-1udbk01 r-3s2u2q r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-a023e6 r-rjixqe r-16dba41 r-18u37iz r-1wvb978\" dir=\"ltr\" style=\"color: #536471;\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">@yugovaz\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-dnmrzs r-1udh08x r-1udbk01 r-3s2u2q r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-a023e6 r-rjixqe r-16dba41 r-18u37iz r-1wvb978\" dir=\"ltr\" style=\"color: #536471;\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina\">TEXTO DE HW4PS, publicado en Sin Permiso el 26 de julio de 2025\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Teva en España. Un gigante farmacéutico israelí cuyas ganancias financian el genocidio en Palestina.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Profesionales de la sanidad por Palestina, España (HealthWorkers4PalestineSpain)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote1sym\" name=\"sdendnote1anc\">\u003Csup>i\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Introducción\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Quizá a usted no le suene el nombre de Teva como le suenan otras compañías farmacéuticas internacionales tipo Johnson&Johnson, Roche, Pfizer, GSK, AstraZeneca, Lilly, Sanofi, Janssen, etc.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Sin embargo, Teva es un gigante farmacéutico, la mayor empresa del mundo en el campo de los medicamentos genéricos (medicamentos producidos por compañías ajenas a las que desarrollaron el original, al acabar sus patentes).\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Teva fue fundada en 1901. Sus oficinas centrales están en Israel. Tiene una cartera de más de 3.600 medicamentos que produce en 53 plantas, en 33 países, incluyendo una planta en Zaragoza, España (con 600 trabajadores\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote2sym\" name=\"sdendnote2anc\">\u003Csup>ii\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote3sym\" name=\"sdendnote3anc\">\u003Csup>iii\u003C\u002Fsup>\u003C\u002Fa>).\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Zaragoza concentra el grueso de la producción de Teva en todo el mundo (produce el 87% del total de sus medicamentos).\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Sobre Teva y sus medicamentos\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Teva tuvo ingresos por encima de los 16.400 millones de dólares en 2024, apoyándose en medicamentos de bajo coste pero alta demanda como los genéricos, medicamentos que han perdido la patente y se venden sin nombre de fantasía, sólo el nombre del principio activo, tipo paracetamol, omeprazol, enalapril, metformina, budesonida, monteluskat, etc bajo la denominación Teva, Tevagen, Davur, Belmac y Ratiopharm.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">También comercializa otros medicamentos como Austedo (deutetrabenazine) para la\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> enfermedad de Huntington \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">y\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">varios \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">GLP-1 \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">(gliclazida, sitagliptina, liraglutida, etc)\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">para la diabetes-\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">obesidad.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">Sus\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> productos “estrella” son \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">Ajovy (fremanezumab) para la migraña,\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> Copaxone \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">(\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">glatiramero\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">)\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> para la esclerosis múltiple, Uzedy \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">(risperidona)\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> para la esquizofrenia y Azilect \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">(\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">rasagilina\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">)\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">para\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\"> el \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">p\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">arkinson\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote4sym\" name=\"sdendnote4anc\">\u003Csup>iv\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote5sym\" name=\"sdendnote5anc\">\u003Csup>v\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Teva y la corrupción\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Para promover las ventas de sus medicamentos, Teva ha realizado prácticas corruptas que le han llevado a condenas judiciales.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Así, una multa en 2016, en Estados \u003Cspan style=\"color: #000000;\">\u003Cspan style=\"background: transparent;\">Unidos, de 519 millones de dólares, en relación con sobornos para vender Copaxone\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote6sym\" name=\"sdendnote6anc\">\u003Csup>vi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"background: transparent;\">En 2022, también en Estados Unidos, Teva fue condenada a pagar 4250 millones por la promoción fuera de indicación de sus medicamentos opiodes, lo que contribuyó a la epidemia de muertes por sobredosis\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote7sym\" name=\"sdendnote7anc\">\u003Csup>vii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"background: transparent;\">En 2023, Teva fue multada con 225 millones de dólares por sus prácticas corruptas con pravastatina (para “el colesterol”)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote8sym\" name=\"sdendnote8anc\">\u003Csup>viii\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Por sobornos, también en relación con Copaxone, una multa en Estados Unidos de 450 millones de dólares en 2024\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote9sym\" name=\"sdendnote9anc\">\u003Csup>ix\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">En relación con el mismo medicamento, la Unión Europea multó a Teva en 2024 con 462,6 millones de euros por abuso de posición dominante\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote10sym\" name=\"sdendnote10anc\">\u003Csup>x\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"background: transparent;\">Entre 2010 y 2024, Teva pagó\u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\"> 9.000 millones de dólares por\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> condenas y multas por corrupción demostrada en tribunales de todo el mundo\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote11sym\" name=\"sdendnote11anc\">\u003Csup>xi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"background: transparent;\">A finales de 2024, Teva fue investigada en Estados Unidos por incrementar los precios e impedir la libre competencia al introducir cambios en sus medicamentos genéricos para el asma y la EPOC (enfermedad pulmonar obstructiva crónica)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote12sym\" name=\"sdendnote12anc\">\u003Csup>xii\u003C\u002Fsup>\u003C\u002Fa>, lo que se confirmó en mayo de 2025, con la correspondiente amonestación\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote13sym\" name=\"sdendnote13anc\">\u003Csup>xiii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Teva, ventas en España\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">En 2023, en España, Teva fue, por volumen de ventas al Sistema Nacional de Salud (el sistema sanitario público), la tercera compañía farmacéutica, con 70 millones de envases y gasto de más de 500 millones de euros.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>La propaganda de Teva a los \u003C\u002Fstrong>\u003Cstrong>profesionales\u003C\u002Fstrong>\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">La propaganda de medicamentos se hace a los médicos y otros profesionales, especialmente a los médicos “principales”, a los “key opinion leaders” (KOL), los que crean opinión, los influyentes que son especialmente eficaces para transmitir mensajes a sus compañeros, a quienes se financian estudios y publicaciones y a quienes se promueven en todas las actividades docentes financiadas por las industrias (congresos, jornadas, cursos, encuentros, etc).\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Las industrias llaman “transferencias de valor” a esta financiación de propaganda que incluyen viajes, estancias, comidas y remuneraciones por asesoría, conferencias y otras actividades\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote14sym\" name=\"sdendnote14anc\">\u003Csup>xiv\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote15sym\" name=\"sdendnote15anc\">\u003Csup>xv\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">En España, en 2023, Teva declaró 2.010.412 € en “transferencias de valor”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote16sym\" name=\"sdendnote16anc\">\u003Csup>xvi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Pagos a profesionales sanitarios 961.819 € \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Pagos a asociaciones: 811.811 € \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Pagos relacionados con investigación: 236.782 € \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">\u003Cstrong>Teva en España, KOL, profesionales que recibieron 10.000 euros, o más, en 2023\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Teva declaró pagos (transferencias de valor) a casi 1500 profesionales de la sanidad en el año 2023 (la amplia mayoría en torno a los 600 euros). Destacan como KOL:\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Patricia Pozo Rosich, Barcelona, neuróloga, 31.654\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">José Miguel Laínez Andrés, Valencia, neurólogo, 14.619\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Roberto Chacón Puig, Barcelona, farmacéutico, 14.324\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Rogelio Leira Muiño, Santiago de Compostela, neurólogo, 13.720\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Pablo Irimia Sieira, Pamplona, neurólogo, 13.173\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">María Carmen González Oria, Sevilla, neuróloga 13.629\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">\u003Cstrong>Teva en España, organizaciones que recibieron 10.000 euros, o más, en 2023\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Teva declaró pagos (transferencias de valor) a 45 organizaciones, en torno a los 3.000 euros. Destacan:\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación SEN (Sociedad Española de Neurología), Barcelona, 149.645\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundació Hospital Universitari Valle D'Hebron. Institut de Recerca, Barcelona, 112.850\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Sociedad Española de Farmacia Clínica, Familiar y Comunitaria, SEFAC, Madrid, 90.985\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundación Investigación y Formación de la SMEG (Sociedad Española de Médicos Generales y de Familia), Madrid, 87.483\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"display: inline-block; border: none; padding: 0cm;\">Fundació Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, 53.800\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>¿Por qué proponemos el b\u003C\u002Fstrong>\u003Cstrong>oicot a la farmacéutica TEVA, y todas sus marcas, Tevagen, Dalvur, Belmac y Ratiopharm? \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">¿Por qué?\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque genera millones de dólares en ingresos para el régimen militar y colonial israelí, siendo así facilitadora del genocidio y del régimen de apartheid\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque se aprovecha de la ventajas de la ocupación, el monopolio y la explotación de los palestinos\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">porque vende sus fármacos a palestinos por encima de su precio de mercado\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Conclusión\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Es nuestro deber ético y moral promover el boicot a Teva y sus productos y hacer todo lo posible para asegurarnos de que nuestro dinero no se utilice para fomentar la opresión genocida y colonial de Israel\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote17sym\" name=\"sdendnote17anc\">\u003Csup>xvii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cdiv id=\"sdendnote1\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote1anc\" name=\"sdendnote1sym\">i\u003C\u002Fa>Profesionales de la sanidad por Palestina, España (HW4PalestineSpain). ¿Quiénes somos? \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fsobre-nosotros\">https:\u002F\u002Fhw4p.es\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote2\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote2anc\" name=\"sdendnote2sym\">ii\u003C\u002Fa>El consejero de Sanidad visita la planta de Teva Pharma en Zaragoza que produce 8.700 millones de dosis de fármacos al año. \u003Ca href=\"https:\u002F\u002Fwww.aragonhoy.es\u002Fsanidad\u002Fconsejero-sanidad-visita-planta-teva-pharma-zaragoza-produce-8-700-millones-dosis-farmacos-ano-96176\">https:\u002F\u002Fwww.aragonhoy.es\u002Fsanidad\u002Fconsejero-sanidad-visita-planta-teva-pharma-zaragoza-produce-8-700-millones-dosis-farmacos-ano-96176\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote3\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote3anc\" name=\"sdendnote3sym\">iii\u003C\u002Fa>El origen de la planta en Zaragoza es la aragonesa Industrial Farmacéutica de Zaragoza (INFAR), promovida por el farmacéutico Julio Gracia Zatorre en los años 40 del siglo XX, quien industrializó las fórmulas magistrales que habitualmente dispensaba desde su oficina de farmacia Zatorre, ubicada en la calle Balmes 3 de Zaragoza. La compañía se asoció después con la compañía alemana NATTERMANN GmbH. En 1973, construyó en el polígono de Malpica de Zaragoza una planta de fabricación, con 70 trabajadores, donde mantiene su ubicación. Después, ha pasado por diferentes dueños hasta su adquisición por TEVA.\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote4\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote4anc\" name=\"sdendnote4sym\">iv\u003C\u002Fa>Teva acelera en España: crece un 10%, hasta 160 millones en el primer semestre. \u003Ca href=\"https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-acelera-en-espana-crece-un-10-hasta-160-millones-en-el-primer-semestre\">https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-acelera-en-espana-crece-un-10-hasta-160-millones-en-el-primer-semestre\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote5\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote5anc\" name=\"sdendnote5sym\">v\u003C\u002Fa>Teva eleva sus previsiones, aupada por los fármacos contra la enfermedad de Huntington. \u003Ca href=\"https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-eleva-sus-previsiones-aupada-por-los-farmacos-contra-la-enfermedad-de-huntington\">https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-eleva-sus-previsiones-aupada-por-los-farmacos-contra-la-enfermedad-de-huntington\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote6\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote6anc\" name=\"sdendnote6sym\">vi\u003C\u002Fa>Teva agrees to pay US$519m to settle corruption charge. \u003Ca href=\"https:\u002F\u002Fpharmaceutical-journal.com\u002Farticle\u002Fnews\u002Fteva-agrees-to-pay-us519m-to-settle-corruption-charge\">https:\u002F\u002Fpharmaceutical-journal.com\u002Farticle\u002Fnews\u002Fteva-agrees-to-pay-us519m-to-settle-corruption-charge\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote7\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote7anc\" name=\"sdendnote7sym\">vii\u003C\u002Fa>Opi­oids Mak­er Teva Agrees to $4.25 bil­lion set­tle­ment: Pre­lim­i­nary Agree­ment Will Pro­vide Cash and Nalox­one to Address Opi­oids Crisis. \u003Ca href=\"https:\u002F\u002Fwww.texasattorneygeneral.gov\u002Fnews\u002Freleases\u002Fopioids-maker-teva-agrees-425-billion-settlement-preliminary-agreement-will-provide-cash-and\">https:\u002F\u002Fwww.texasattorneygeneral.gov\u002Fnews\u002Freleases\u002Fopioids-maker-teva-agrees-425-billion-settlement-preliminary-agreement-will-provide-cash-and\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote8\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote8anc\" name=\"sdendnote8sym\">viii\u003C\u002Fa>Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges. \u003Ca href=\"https:\u002F\u002Fedition.cnn.com\u002F2023\u002F08\u002F21\u002Finvesting\u002Fteva-pharmaceuticals-price-fixing-settlement\u002Findex.html\">https:\u002F\u002Fedition.cnn.com\u002F2023\u002F08\u002F21\u002Finvesting\u002Fteva-pharmaceuticals-price-fixing-settlement\u002Findex.html\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote9\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote9anc\" name=\"sdendnote9sym\">ix\u003C\u002Fa>Drug Maker Teva Pharmaceuticals Agrees to Pay $450M in False Claims Act Settlement to Resolve Kickback Allegations Relating to Copayments and Price Fixing. \u003Ca href=\"https:\u002F\u002Fwww.justice.gov\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback\">https:\u002F\u002Fwww.justice.gov\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote10\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote10anc\" name=\"sdendnote10sym\">x\u003C\u002Fa>Commission fines Teva €462.6 million over misuse of the patent system and disparagement to delay rival multiple sclerosis medicine. \u003Ca href=\"https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_24_5581\">https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_24_5581\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote11\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote11anc\" name=\"sdendnote11sym\">xi\u003C\u002Fa>Violation Tracker Global: Current Parent Summary. \u003Ca href=\"https:\u002F\u002Fviolationtrackerglobal.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\">https:\u002F\u002Fviolationtrackerglobal.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote12\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote12anc\" name=\"sdendnote12sym\">xii\u003C\u002Fa>FTC opens investigation into Teva, escalating patent fight with pharma industry. \u003Ca href=\"https:\u002F\u002Fwww.washingtonpost.com\u002Fhealth\u002F2024\u002F07\u002F01\u002Fteva-patent-pharma-generic-inhaler\u002F\">https:\u002F\u002Fwww.washingtonpost.com\u002Fhealth\u002F2024\u002F07\u002F01\u002Fteva-patent-pharma-generic-inhaler\u002F\u003C\u002Fa> \u003Ca href=\"https:\u002F\u002Fwww.saludyfarmacos.org\u002Flang\u002Fes\u002Fboletin-farmacos\u002Fboletines\u002Fago202407\u002F14_co\u002F\">https:\u002F\u002Fwww.saludyfarmacos.org\u002Flang\u002Fes\u002Fboletin-farmacos\u002Fboletines\u002Fago202407\u002F14_co\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote13\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote13anc\" name=\"sdendnote13sym\">xiii\u003C\u002Fa>Improper Orange Book Patent Listings for ProAir HFA, ProAir DigiHaler, ProAir RespiClick, QVAR 40, and QVAR 80 \u003Ca href=\"https:\u002F\u002Fwww.ftc.gov\u002Fsystem\u002Ffiles\u002Fftc_gov\u002Fpdf\u002F2025-05-21-teva-branded-pharm-orange-book-warning-letter.pdf\">https:\u002F\u002Fwww.ftc.gov\u002Fsystem\u002Ffiles\u002Fftc_gov\u002Fpdf\u002F2025-05-21-teva-branded-pharm-orange-book-warning-letter.pdf\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote14\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote14anc\" name=\"sdendnote14sym\">xiv\u003C\u002Fa>Los pagos a profesionales y organizaciones sanitarias: el mercado de pulgas de las multinacionales farmacéuticas. \u003Ca href=\"https:\u002F\u002Faccesojustomedicamento.org\u002Flos-pagos-a-profesionales-y-organizaciones-sanitarias-el-mercado-de-pulgas-de-las-multinacionales-farmaceuticas\u002F\">https:\u002F\u002Faccesojustomedicamento.org\u002Flos-pagos-a-profesionales-y-organizaciones-sanitarias-el-mercado-de-pulgas-de-las-multinacionales-farmaceuticas\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote15\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote15anc\" name=\"sdendnote15sym\">xv\u003C\u002Fa>La red oscura que las multinacionales farmacéuticas ocultan tras los pagos a profesionales sanitarios: sus líderes de opinión en el SNS y su red de intereses al descubierto. \u003Ca href=\"https:\u002F\u002Faccesojustomedicamento.org\u002Fla-red-oscura-que-las-multinacionales-farmaceuticas-ocultan-tras-los-pagos-a-profesionales-sanitarios-sus-lideres-de-opinion-en-el-sns-y-su-red-de-intereses-al-descubierto\u002F\">https:\u002F\u002Faccesojustomedicamento.org\u002Fla-red-oscura-que-las-multinacionales-farmaceuticas-ocultan-tras-los-pagos-a-profesionales-sanitarios-sus-lideres-de-opinion-en-el-sns-y-su-red-de-intereses-al-descubierto\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote16\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote16anc\" name=\"sdendnote16sym\">xvi\u003C\u002Fa>Teva, informe de transparencia, 2023. \u003Ca href=\"https:\u002F\u002Fviewer.tevapharm.com\u002Fview\u002F385844187\u002F\">https:\u002F\u002Fviewer.tevapharm.com\u002Fview\u002F385844187\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote17\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote17anc\" name=\"sdendnote17sym\">xvii\u003C\u002Fa>Israeli-owned big pharma is now being targeted by UK activists. Complicit in genocide. \u003Ca href=\"https:\u002F\u002Fwww.thecanary.co\u002Fuk\u002Fnews\u002F2024\u002F03\u002F05\u002Fteva-uk-protest\u002F\">https:\u002F\u002Fwww.thecanary.co\u002Fuk\u002Fnews\u002F2024\u002F03\u002F05\u002Fteva-uk-protest\u002F\u003C\u002Fa> Teva crea valor para sostener el genocidio en Palestina. Teva creates value to sustain genocide in Palestine https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cp> \u003C\u002Fp>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1755792980\u002Fldzzcavs279x4m064klb.jpg","mell4zgaq0vk83ug79c","teva-no-gracias-teva-ez-eskerrik-asko",{"type":7,"title":242,"slug":243,"id":244,"subtitle":245,"videoUrl":246,"imageUrl":247,"content":248,"link":12,"timestamp":249,"tags":250,"user":13},"¿Sudocrem para bebés, pieles irritadas? Daña gravemente la salud en Gaza (y toda Palestina)","sudocrem-para-bebes-pieles-irritadas-dana-gravemente-la-salud-en-gaza-y-toda-palestina","meqre8j0qm56vr6clkh","Sudocrem es de Teva, una industria israelí que financia el genocidio palestino","k_kMXqngvCQ","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1756105900\u002Fhnrgcvwgpxyhoiqs57be.png","\u003Cp>\u003Cstrong>BOICOT TEVA, SUDOCREM\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>La propaganda de Teva dice que \"Sudocrem® es una crema protectora y calmante ideal para tratar dermatitis del pañal, erupciones y rozaduras en pieles delicadas de bebés y adultos\".\u003C\u002Fp>\n\u003Cp>En realidad no se suele precisar Sudocrem (ni ninguna crema) para evitar o tratar la dermatitis del pañal y otras por irritación local. En la mayoría de los casos, suele ser suficiente con “airear” la zona y cambiar el pañal con frecuencia, además de limpiar y secar cuidadosamente la zona, sin irritarla.\u003C\u002Fp>\n\u003Cp>En todo caso, Sudocrem lo produce Teva, una empresa israelí muy corrupta cuyos ingresos acaban financiando el genocidio en Gaza y el régimen de apartheid en toda Palestina (Israel incluida). Sudocrem, pues, daña gravemente la salud en Gaza (y en todo Palestina).\u003C\u002Fp>\n\u003Cp>Es nuestro deber ético y moral promover el boicot a Teva y sus productos y hacer todo lo posible para asegurarnos de que nuestro dinero no se utilice para fomentar la opresión genocida y colonial de Israel\u003Ca id=\"_ednref17\" title=\"\" href=\"https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina#_edn17\" name=\"_ednref17\">\u003C\u002Fa>. Más información sobre Teva, sus multas por corrupción y más en:\u003Ca href=\"https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina\"> Teva en España. Un gigante farmacéutico israelí cuyas ganancias financian el genocidio en Palestina\u003C\u002Fa>\u003C\u002Fp>",1756105906873,[15],{"title":252,"content":253,"videoUrl":254,"type":7,"slug":255,"imageUrl":256,"timestamp":257,"link":12,"id":258,"tags":259,"user":13,"subtitle":260},"Sudocrem for babies, irritated skin? It seriously damages health in Gaza (and all of Palestine)","\u003Cp>\u003Cstrong>BOYCOOT TEVA, SUDOCREM\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Teva's propaganda claims that ‘Sudocrem®\u003Cspan class=\"kY2IgmnCmOGjharHErah\" style=\"-webkit-line-clamp: 3;\">helps by soothing the soreness, aiding the skin heal and protecting the skin from further attack by irritants or infection. You can use Sudocrem Skin Protectant \u003Cstrong>Cream\u003C\u002Fstrong> at every \u003Cstrong>diaper\u003C\u002Fstrong> change\"\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>In reality, Sudocrem (or any cream) is not usually necessary to prevent or treat diaper rash and other local irritations. In most cases, it is usually sufficient to ‘air’ the area and change the diaper frequently, as well as cleaning and drying the area carefully, without irritating it.\u003C\u002Fp>\n\u003Cp>In any case, Sudocrem is produced by Teva, a highly corrupt Israeli company whose revenues end up financing genocide in Gaza and the apartheid regime throughout Palestine (including Israel). Sudocrem, therefore, seriously damages health in Gaza (and throughout Palestine).\u003C\u002Fp>\n\u003Cp>It is our ethical and moral duty to promote the boycott of Teva and its products and to do everything possible to ensure that our money is not used to promote Israel's genocidal and colonial oppression. More information about Teva, its fines for corruption and more at: \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\">\"Teva. An Israeli pharmaceutical giant whose profits finance genocide in Palestine\".\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FGzLojZzXYAAjGLs?format=png&name=900x900\" alt=\"\" width=\"627\" height=\"893\">\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>","9BOEFP5oE2c","sudocrem-for-babies-irritated-skin-it-seriously-damages-health-in-gaza-and-all-of-palestine","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1756106966\u002Fxvtyb6bmkjb36tkrdbhl.png",1756106971591,"meqsgvj80kuwi7kcu56",[15],"Sudocrem is made by Teva, an Israeli company that finances the genocide of Palestinians",{"timestamp":262,"imageUrl":263,"content":264,"id":265,"link":12,"videoUrl":266,"tags":267,"user":13,"type":7,"slug":268,"subtitle":269,"title":270},1757428470845,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1757428388\u002Fqgnbk6990nm7wff74is2.png","\u003Cdiv id=\"contentResult\">\n\u003Cdiv class=\"info-detail\">\u003Ca href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\">\u003Cstrong>Current Parent Company Name\u003C\u002Fstrong>: Teva Pharmaceutical Industries\u003C\u002Fa>\u003Cbr>\u003Cstrong>Ownership Structure\u003C\u002Fstrong>: publicly traded (ticker symbol TEVA)\u003Cbr>\u003Cstrong>Headquartered in\u003C\u002Fstrong>: Israel\u003Cbr>\u003Cstrong>Major Industry\u003C\u002Fstrong>: pharmaceuticals\u003Cbr>\u003Cstrong>Specific Industry\u003C\u002Fstrong>: pharmaceuticals\u003Cbr>\u003Cstrong>Penalty total since 2000\u003C\u002Fstrong>: \u003Cstrong>$10,695,276,796\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Number of records\u003C\u002Fstrong>: 98\u003C\u002Fdiv>\n\u003Ctable class=\"views-table\">\n\u003Cthead>\n\u003Ctr>\n\u003Cth>Top 5 Offense Groups (\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fpages\u002Foffense-groups\">Groups Defined\u003C\u002Fa>)\u003C\u002Fth>\n\u003Cth style=\"text-align: right;\">Penalty Total\u003C\u002Fth>\n\u003Cth style=\"text-align: center;\">Number of Records\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>healthcare-related offenses\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$5,866,079,633\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">15\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>competition-related offenses\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$3,509,706,732\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">28\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>government-contracting-related offenses\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$917,482,547\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">23\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>safety-related offenses\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$270,151,445\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">10\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>consumer-protection-related offenses\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$126,407,000\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">2\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Ctable class=\"views-table\">\n\u003Cthead>\n\u003Ctr>\n\u003Cth>Top 5 Primary Offense Types\u003C\u002Fth>\n\u003Cth style=\"text-align: right;\">Penalty Total\u003C\u002Fth>\n\u003Cth style=\"text-align: center;\">Number of Records\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$5,779,279,633\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">13\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$2,990,529,384\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">25\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$917,482,547\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">23\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Foreign Corrupt Practices Act\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$519,177,348\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">2\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>product safety violation\u003C\u002Ftd>\n\u003Ctd class=\" bg-lightGreen text-darkGreen\" style=\"text-align: right;\">$270,000,000\u003C\u002Ftd>\n\u003Ctd style=\"text-align: center;\">1\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cstrong>Notes\u003C\u002Fstrong>: Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the \u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fpages\u002Fupdate-log\">Update Log\u003C\u002Fa>, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.\u003Cbr>\u003Cbr>\u003Cstrong>Links\u003C\u002Fstrong>: For a summary of this company's regulatory penalties in more than 50 other countries, see its Violation Tracker Global summary page \u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtrackerglobal.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\" target=\"_blank\" rel=\"noopener\">here\u003C\u002Fa>.\u003Cbr>\u003Cbr>Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found \u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fsubsidytracker.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\" target=\"_blank\" rel=\"noopener\">here\u003C\u002Fa>.\u003Cbr>\u003Cbr>\n\u003Ch3>Individual Penalty Records:\u003C\u002Fh3>\n\u003Cp>Click on the company or penalty amount for more information on each case.\u003C\u002Fp>\n\u003Cdiv class=\"feed-icon\">\u003Cstrong>Download results as\u003C\u002Fstrong> \u003Ca class=\"button-download hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002F?parent=teva-pharmaceutical-industries&detail=csv_results\">CSV\u003C\u002Fa> or \u003Ca class=\"button-download hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002F?parent=teva-pharmaceutical-industries&detail=xml_results\">XML\u003C\u002Fa> or \u003Ca class=\"button-save hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fmember\u002Fsave-search?url=https%3A%2F%2Fviolationtracker.goodjobsfirst.org%2Fparent%2Fteva-pharmaceutical-industries&num_recs=98&desc=Current Parent Company Summary with Current Parent Company: teva-pharmaceutical-industries\">Save your search\u003C\u002Fa> (\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fplans\">Click here\u003C\u002Fa> for information on download subscriptions)\u003C\u002Fdiv>\n\u003Ctable class=\"views-table\">\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002F?parent=teva-pharmaceutical-industries&order=company&sort=\">Company\u003C\u002Fa>\u003C\u002Fth>\n\u003Cth>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002F?parent=teva-pharmaceutical-industries&order=primary_offense&sort=\">Primary Offense Type\u003C\u002Fa>\u003C\u002Fth>\n\u003Cth>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002F?parent=teva-pharmaceutical-industries&order=pen_year&sort=\">Year\u003C\u002Fa>\u003C\u002Fth>\n\u003Cth>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002F?parent=teva-pharmaceutical-industries&order=agency_code&sort=\">Agency\u003C\u002Fa>\u003C\u002Fth>\n\u003Cth style=\"text-align: right;\">\u003Ca class=\" hyperlink active\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002F?parent=teva-pharmaceutical-industries&order=penalty&sort=asc\">Penalty Amount \u003Cimg title=\"sort ascending\" src=\"https:\u002F\u002Fviolationtrackeruk.goodjobsfirst.org\u002Fresource\u002F\u002Farrow-asc.png\" alt=\"sort icon\" width=\"13\" height=\"13\">\u003C\u002Fa>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals\">Teva Pharmaceuticals\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals\">4,250,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc\">Cephalon, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2015\u003C\u002Ftd>\n\u003Ctd>FTC\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc\">1,200,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc\">Teva Pharmaceuticals USA Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2015\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc\">512,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-and-teva-ne\">Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2024\u003C\u002Ftd>\n\u003Ctd>DOJ_CIVIL\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-and-teva-ne\">450,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-1\">Cephalon Inc\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2008\u003C\u002Ftd>\n\u003Ctd>FDA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-1\">425,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-teva-pharmaceuticals-ltd\">Teva Pharmaceuticals, Ltd.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>NY-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-teva-pharmaceuticals-ltd\">313,343,793\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceutical-industries-ltd\">Teva Pharmaceutical Industries Ltd\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>Foreign Corrupt Practices Act\u003C\u002Ftd>\n\u003Ctd>2016\u003C\u002Ftd>\n\u003Ctd>DOJ_CRIMINAL\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceutical-industries-ltd\">283,177,348\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ffl-teva-pharmaceutical-industries\">Teva Pharmaceutical Industries\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>FL-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ffl-teva-pharmaceutical-industries\">278,826,499\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-3\">Teva Pharmaceuticals USA, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2023\u003C\u002Ftd>\n\u003Ctd>DOJ_ANTITRUST\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-3\">275,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-industries-ltd\">Teva Pharmaceuticals Industries Ltd.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>product safety violation\u003C\u002Ftd>\n\u003Ctd>2012\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-industries-ltd\">270,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceutical-industries-limited\">Teva Pharmaceutical Industries Limited\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>Foreign Corrupt Practices Act\u003C\u002Ftd>\n\u003Ctd>2016\u003C\u002Ftd>\n\u003Ctd>SEC\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceutical-industries-limited\">236,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ftx-teva-pharmaceutical-industries-ltd\">Teva Pharmaceutical Industries Ltd.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>TX-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ftx-teva-pharmaceutical-industries-ltd\">225,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-laboratories-inc\">Barr Laboratories Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2017\u003C\u002Ftd>\n\u003Ctd>private lawsuit-state\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-laboratories-inc\">225,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-inc\">Teva Pharmaceuticals Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2010\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-inc\">169,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon\">Cephalon\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>consumer protection violation\u003C\u002Ftd>\n\u003Ctd>2016\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon\">125,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-mid-atlantic-llc\">Actavis Mid-Atlantic LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2011\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-mid-atlantic-llc\">118,614,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-2\">Cephalon Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2008\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">\u003Cspan class=\"tooltip\">(*)\u003C\u002Fspan> $\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-2\">116,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fok-teva-pharmaceuticals\">Teva Pharmaceuticals\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>Controlled Substances Act violation\u003C\u002Ftd>\n\u003Ctd>2019\u003C\u002Ftd>\n\u003Ctd>OK-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fok-teva-pharmaceuticals\">85,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fwv-teva-pharmaceutical-industries\">Teva Pharmaceutical Industries\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>WV-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fwv-teva-pharmaceutical-industries\">83,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-pharmaceuticals-inc-1\">Watson Pharmaceuticals, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2012\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-pharmaceuticals-inc-1\">79,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-1\">Teva Pharmaceuticals USA Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2017\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-1\">73,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fky-teva-pharmaceuticals-inc-0\">Teva Pharmaceuticals, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2023\u003C\u002Ftd>\n\u003Ctd>KY-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fky-teva-pharmaceuticals-inc-0\">71,477,474\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-inc\">Actavis Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2018\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-inc\">71,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmd-teva\">Teva\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2024\u003C\u002Ftd>\n\u003Ctd>MD-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmd-teva\">70,281,867\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-pharmaceuticals\">Watson Pharmaceuticals\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2011\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-pharmaceuticals\">70,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fca-teva-pharmaceutical-industries-ltd\">Teva Pharmaceutical Industries Ltd.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2019\u003C\u002Ftd>\n\u003Ctd>CA-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fca-teva-pharmaceutical-industries-ltd\">69,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-andrx-corporation-0\">Andrx Corporation\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2003\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-andrx-corporation-0\">55,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-inc-0\">Teva Pharmaceuticals Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2019\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-inc-0\">54,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-laboratories\">Watson Laboratories\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2016\u003C\u002Ftd>\n\u003Ctd>private lawsuit-state\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-laboratories\">50,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-4\">Cephalon Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2020\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-4\">48,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-inc-0\">Actavis Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2018\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-inc-0\">41,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-andrx-corporation\">Andrx Corporation\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2003\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-andrx-corporation\">40,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fms-watson-inc\">Watson, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2018\u003C\u002Ftd>\n\u003Ctd>MS-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fms-watson-inc\">33,408,547\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ftx-actavis-mid-atlantic-llc-and-actavis-eli\">Actavis Mid-Atlantic, LLC and Actavis Elizabeth, LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2011\u003C\u002Ftd>\n\u003Ctd>TX-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ftx-actavis-mid-atlantic-llc-and-actavis-eli\">29,230,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-and-ivax-l\">Teva Pharmaceuticals USA Inc. and IVAX LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2014\u003C\u002Ftd>\n\u003Ctd>DOJ_CIVIL\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-and-ivax-l\">27,600,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fca-teva-parmaceuticals\">Teva Parmaceuticals\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>CA-SFCA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fca-teva-parmaceuticals\">27,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-0\">Teva Pharmaceuticals USA Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2018\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-0\">27,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-pharmaceuticals-inc-0\">Watson Pharmaceuticals, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2011\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-pharmaceuticals-inc-0\">27,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-2\">Teva Pharmaceuticals USA Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2015\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-2\">24,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fri-teva-pharmaceutical-industries\">Teva Pharmaceutical Industries\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>RI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fri-teva-pharmaceutical-industries\">21,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-elizabeth-llc-0\">Actavis Elizabeth LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2020\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-elizabeth-llc-0\">19,900,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fal-teva-pharmaceuticals-usa\">TEVA Pharmaceuticals USA\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2009\u003C\u002Ftd>\n\u003Ctd>AL-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fal-teva-pharmaceuticals-usa\">14,833,333\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-ivax-pharmaceuticals\">IVAX Pharmaceuticals\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2009\u003C\u002Ftd>\n\u003Ctd>DOJ_CIVIL\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-ivax-pharmaceuticals\">14,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-pharmaceuticals-inc\">Barr Pharmaceuticals Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2009\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-pharmaceuticals-inc\">13,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fil-teva-pharmaceuticals-usa-inc\">Teva Pharmaceuticals USA Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>kickbacks and bribery\u003C\u002Ftd>\n\u003Ctd>2014\u003C\u002Ftd>\n\u003Ctd>IL-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">\u003Cspan class=\"tooltip\">(*)\u003C\u002Fspan> $\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fil-teva-pharmaceuticals-usa-inc\">12,100,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fky-alpharma-uspd-inc-and-purepac-pharmaceut\">Alpharma USPD, Inc. and Purepac Pharmaceutical Co.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2011\u003C\u002Ftd>\n\u003Ctd>KY-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fky-alpharma-uspd-inc-and-purepac-pharmaceut\">10,200,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fky-teva-pharmaceuticals-usa-inc-ivax-corpor\">Teva Pharmaceuticals USA Inc., IVAX Corporation, IVAX Pharmaceuticals Inc., Sicor Inc., Barr Laboratories Inc. and Duramed Pharmaceuticals Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2010\u003C\u002Ftd>\n\u003Ctd>KY-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fky-teva-pharmaceuticals-usa-inc-ivax-corpor\">10,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-pharmaceuticals-inc\">Watson Pharmaceuticals, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2011\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-watson-pharmaceuticals-inc\">9,615,384\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceutical-industries\">Teva Pharmaceutical Industries\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceutical-industries\">8,200,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-0\">Cephalon Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2015\u003C\u002Ftd>\n\u003Ctd>DOJ_CIVIL\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-0\">7,500,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-3\">Cephalon, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2015\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">\u003Cspan class=\"tooltip\">(*)\u003C\u002Fspan> $\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-cephalon-inc-3\">7,500,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fma-teva-pharmaceutical-usa-inc\">Teva Pharmaceutical USA, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2009\u003C\u002Ftd>\n\u003Ctd>MA-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fma-teva-pharmaceutical-usa-inc\">7,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fhi-teva-pharmaceuticals-usa-inc-et-al\">Teva Pharmaceuticals USA, Inc. et al.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2010\u003C\u002Ftd>\n\u003Ctd>HI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fhi-teva-pharmaceuticals-usa-inc-et-al\">6,500,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fct-cephalon-inc\">Cephalon, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>off-label or unapproved promotion of medical products\u003C\u002Ftd>\n\u003Ctd>2008\u003C\u002Ftd>\n\u003Ctd>CT-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fct-cephalon-inc\">6,150,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-pharmaceuticals\">Barr Pharmaceuticals\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2008\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-pharmaceuticals\">5,900,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-ivax-pharmaceuticals-0\">IVAX Pharmaceuticals\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2009\u003C\u002Ftd>\n\u003Ctd>MULTI-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">\u003Cspan class=\"tooltip\">(*)\u003C\u002Fspan> $\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-ivax-pharmaceuticals-0\">5,400,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-pharmaceuticals-inc-0\">Barr Pharmaceuticals Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2007\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-pharmaceuticals-inc-0\">4,150,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fma-actavis-elizabeth-llc\">Actavis Elizabeth LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2010\u003C\u002Ftd>\n\u003Ctd>MA-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fma-actavis-elizabeth-llc\">3,600,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-4\">Teva Pharmaceuticals USA Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>wage and hour violation\u003C\u002Ftd>\n\u003Ctd>2024\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-teva-pharmaceuticals-usa-inc-4\">2,700,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-usa\">Teva Pharmaceuticals USA\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>environmental violation\u003C\u002Ftd>\n\u003Ctd>2013\u003C\u002Ftd>\n\u003Ctd>MO-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">\u003Cspan class=\"tooltip\">(*)\u003C\u002Fspan> $\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-usa\">2,402,793\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fma-watson-pharmaceuticals-inc\">Watson Pharmaceuticals, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2010\u003C\u002Ftd>\n\u003Ctd>MA-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fma-watson-pharmaceuticals-inc\">2,400,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-usa-inc\">Teva Pharmaceuticals USA Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2013\u003C\u002Ftd>\n\u003Ctd>EPA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-usa-inc\">2,250,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-usa-inc-1\">TEVA PHARMACEUTICALS USA INC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>environmental violation\u003C\u002Ftd>\n\u003Ctd>2013\u003C\u002Ftd>\n\u003Ctd>EPA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">\u003Cspan class=\"tooltip\">(*)\u003C\u002Fspan> $\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-usa-inc-1\">2,250,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-pharmaceuticals-inc-1\">Barr Pharmaceuticals Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2007\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-barr-pharmaceuticals-inc-1\">2,100,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fms-alpharma-uspd-inc\">Alpharma USPD, Inc.,\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2011\u003C\u002Ftd>\n\u003Ctd>MS-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fms-alpharma-uspd-inc\">2,010,667\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fma-barr-laboratories-inc-and-duramed-pharma\">Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2007\u003C\u002Ftd>\n\u003Ctd>MA-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fma-barr-laboratories-inc-and-duramed-pharma\">2,000,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fid-teva-pharmaceuticals-usa-inc-ivax-corp-i\">Teva Pharmaceuticals USA, Inc., Ivax Corp., Ivax Pharmaceuticals, Inc., and Barr Laboratories, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2010\u003C\u002Ftd>\n\u003Ctd>ID-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fid-teva-pharmaceuticals-usa-inc-ivax-corp-i\">1,900,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fwv-anda\">Anda\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>Controlled Substances Act violation\u003C\u002Ftd>\n\u003Ctd>2016\u003C\u002Ftd>\n\u003Ctd>WV-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fwv-anda\">1,800,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fid-watson-pharmaceuticals-inc-and-watson-ph\">Watson Pharmaceuticals Inc. and Watson Pharma Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2012\u003C\u002Ftd>\n\u003Ctd>ID-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fid-watson-pharmaceuticals-inc-and-watson-ph\">1,700,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fky-teva-pharmaceuticals-inc\">Teva Pharmaceuticals, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>consumer protection violation\u003C\u002Ftd>\n\u003Ctd>2023\u003C\u002Ftd>\n\u003Ctd>KY-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fky-teva-pharmaceuticals-inc\">1,407,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-elizabeth-llc\">Actavis Elizabeth LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2022\u003C\u002Ftd>\n\u003Ctd>private lawsuit-federal\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002F-actavis-elizabeth-llc\">1,100,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fid-alpharma-uspd-inc\">Alpharma USPD, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>False Claims Act and related\u003C\u002Ftd>\n\u003Ctd>2010\u003C\u002Ftd>\n\u003Ctd>ID-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fid-alpharma-uspd-inc\">600,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-teva-pharmaceuticals-usa-inc\">Teva Pharmaceuticals USA, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>price-fixing or anti-competitive practices\u003C\u002Ftd>\n\u003Ctd>2014\u003C\u002Ftd>\n\u003Ctd>NY-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-teva-pharmaceuticals-usa-inc\">150,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc\">ACTAVIS ELIZABETH LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2016\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc\">99,800\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-valmed-pharmaceutical-inc\">Valmed Pharmaceutical, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>wage and hour violation\u003C\u002Ftd>\n\u003Ctd>2004\u003C\u002Ftd>\n\u003Ctd>WHD\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-valmed-pharmaceutical-inc\">83,871\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-usa-inc-0\">Teva Pharmaceuticals USA Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>environmental violation\u003C\u002Ftd>\n\u003Ctd>2003\u003C\u002Ftd>\n\u003Ctd>MO-AG\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-usa-inc-0\">70,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-barr-laboratories-inc\">BARR LABORATORIES INC.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2006\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-barr-laboratories-inc\">65,250\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fpa-teva-pharmaceuticals-usa-inc\">Teva Pharmaceuticals USA, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>environmental violation\u003C\u002Ftd>\n\u003Ctd>2003\u003C\u002Ftd>\n\u003Ctd>EPA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fpa-teva-pharmaceuticals-usa-inc\">61,158\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc-2\">PLIVA INC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>water pollution violation\u003C\u002Ftd>\n\u003Ctd>2002\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc-2\">41,350\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc-1\">ACTAVIS ELIZABETH LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2005\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc-1\">31,360\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-watson-laboratories-inc\">Watson Laboratories, Inc.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>environmental violation\u003C\u002Ftd>\n\u003Ctd>2004\u003C\u002Ftd>\n\u003Ctd>EPA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fny-watson-laboratories-inc\">20,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc-3\">PLIVA, INC.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2003\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc-3\">19,775\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-inc\">TEVA PHARMACEUTICALS INC.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2002\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fmo-teva-pharmaceuticals-inc\">15,300\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ffl-ivax-pharmaceuticals-inc\">IVAX PHARMACEUTICALS, INC.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2002\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ffl-ivax-pharmaceuticals-inc\">15,120\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ffl-andrx-pharmaceuticals-inc\">ANDRX PHARMACEUTICALS, INC.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>hazardous waste violation\u003C\u002Ftd>\n\u003Ctd>2001\u003C\u002Ftd>\n\u003Ctd>FL-DEP\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Ffl-andrx-pharmaceuticals-inc\">15,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc-0\">PLIVA INC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>water pollution violation\u003C\u002Ftd>\n\u003Ctd>2007\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc-0\">15,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc-2\">ACTAVIS ELIZABETH LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2003\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc-2\">14,200\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc-3\">ACTAVIS ELIZABETH LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2003\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc-3\">14,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Foh-barr-laboratories-inc\">BARR LABORATORIES, INC.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2002\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Foh-barr-laboratories-inc\">14,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc-0\">ACTAVIS ELIZABETH LLC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2009\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-actavis-elizabeth-llc-0\">8,900\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc-1\">PLIVA INC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>water pollution violation\u003C\u002Ftd>\n\u003Ctd>2006\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc-1\">7,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Foh-duramed-pharmaceuticals-inc\">DURAMED PHARMACEUTICALS, INC.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2001\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Foh-duramed-pharmaceuticals-inc\">7,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-teva-pharmaceuticals-usa-inc\">TEVA PHARMACEUTICALS USA INC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2006\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-teva-pharmaceuticals-usa-inc\">6,200\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-ivax-pharmaceuticals-inc\">IVAX PHARMACEUTICALS INC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2007\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-ivax-pharmaceuticals-inc\">6,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc\">PLIVA INC\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>air pollution violation\u003C\u002Ftd>\n\u003Ctd>2008\u003C\u002Ftd>\n\u003Ctd>NJ-ENV\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-pliva-inc\">5,600\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fca-teva-sicor\">TEVA SICOR\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2005\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fca-teva-sicor\">5,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-teva-pharmaceutical\">TEVA PHARMACEUTICAL\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2000\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Fnj-teva-pharmaceutical\">5,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Foh-teva-pharmaceutical-usa-inc\">TEVA PHARMACEUTICAL USA, INC.\u003C\u002Fa>\u003C\u002Ftd>\n\u003Ctd>workplace safety or health violation\u003C\u002Ftd>\n\u003Ctd>2016\u003C\u002Ftd>\n\u003Ctd>OSHA\u003C\u002Ftd>\n\u003Ctd style=\"text-align: right;\">$\u003Ca class=\" hyperlink\" href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fviolation-tracker\u002Foh-teva-pharmaceutical-usa-inc\">5,000\u003C\u002Fa>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"mt-8\">\u003Cstrong>(*): Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting.\u003C\u002Fstrong>\u003C\u002Fdiv>","mfcmwkan19br1fqvheb","w2JcKARyoKU",[15],"teva-penalty-total-since-2000-10-695-276-796-casi-11-000-millones-de-dolares-en-multas-desde-2000","Number of records: 98. Multas: 98","Teva. Penalty total since 2000: $10,695,276,796. Casi 11.000 millones de dólares en multas desde 2000",{"imageUrl":272,"timestamp":273,"content":274,"id":275,"link":12,"videoUrl":276,"tags":277,"user":13,"type":7,"slug":278,"subtitle":279,"title":280},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1757579652\u002Fbstzkqz1dprzrdzqbdwc.jpg",1757580192358,"\u003Cp>ENGLISH\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Fmediant.nl\u002F\">\"Mediant\"\u003C\u002Fa> (mental health institution, Twente, Netherlands) boycotts Israeli products for  humanity, compassion, and the protection of mental well-being in Gaza \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.oost.nl\u002Fnieuws\u002F3561906\u002Fmediant-boycot-israelische-producten-uit-medeleven-met-gaza\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Bianca Lucas September 9, 9:19 PM • Sep 10, 5:03 PM \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"Mediant\" speaks out against war violence in Gaza and boycotts Israeli products.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Mental health care institution Mediant is taking a public stand against the violence in Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The organization is not just choosing words, but also action: Israeli products are being boycotted.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">At the same time, care remains unconditional and accessible to everyone.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The mental health care institution in Twente has shared a statement about the war in Gaza via LinkedIn and on its website.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Mediant says it stands for humanity, compassion, and the protection of mental well-being – values ​​that, according to the organization, are incompatible with remaining silent about the ongoing violence.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Suppliers included in the action In the statement, Mediant explicitly distances itself from \"the large-scale, systematic, and devastating violence\" that the institution claims is being perpetrated by the Israeli army in Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Mediant believes words alone are insufficient.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, the organization is also taking action: boycotting Israeli products.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Suppliers are included in this decision.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">'Silence and inaction are not an option' \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">At the same time, Mediant emphasizes that care always remains unconditional.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"Clients, regardless of their background or political views, should never be the victims of geopolitical choices.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The organization says it remains committed to safe, accessible, and respectful mental healthcare for everyone.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"Our voice is just one of many, and our action may be a drop in the bucket,\" Mediant writes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"But we believe that silence and inaction are not an option. Based on our social responsibility and ethical compass, we choose clarity, humanity, and solidarity.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">ESPAÑOL\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Fmediant.nl\u002F\">\"Mediant\"\u003C\u002Fa> boicotea productos israelíes por compasión, humanidad y protección de la salud mental en Gaza \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fwww.oost.nl\u002Fnieuws\u002F3561906\u002Fmediant-boycot-israelische-producten-uit-medeleven-met-gaza\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Bianca Lucas Mediant es experta en salud mental en Twente (Países Bajos) 9 de septiembre, 21:19 • Actualizado 10 sept, 17:03 • \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Mediant se pronuncia contra la violencia bélica en Gaza y boicotea productos israelíes.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Mediant, institución de salud mental, se posiciona públicamente contra la violencia en Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>La organización no solo habla, sino que también actúa: está boicoteando productos israelíes\u003C\u002Fstrong>.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Al mismo tiempo, la atención clínica a pacientes sigue siendo incondicional y accesible para todos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La institución de salud mental de Twente ha compartido un comunicado sobre la guerra en Gaza a través de LinkedIn y su sitio web.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Mediant afirma defender la humanidad, la compasión y la protección del bienestar mental; valores que, según la organización, son incompatibles con el silencio ante la violencia en curso.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Proveedores incluidos en la acción \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En la declaración, Mediant se distancia explícitamente de \"la violencia a gran escala, sistemática y devastadora\" que, según la organización, está perpetrando el ejército israelí en Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Mediant cree que las palabras por sí solas no son suficientes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Por lo tanto, la organización también está tomando medidas: boicoteando los productos israelíes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Los proveedores están incluidos en este boicot.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\"El silencio y la inacción no son una opción\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Al mismo tiempo, Mediant enfatiza que la atención siempre es incondicional.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"Los clientes, independientemente de su origen o ideología política, nunca deben ser víctimas de decisiones geopolíticas\".\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La organización afirma su compromiso con una atención de salud mental segura, accesible y respetuosa para todos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\"Nuestra voz es solo una entre muchas, y nuestra acción puede ser insignificante\", escribe Mediant.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"Pero creemos que el silencio y la inacción no son una opción. Basándonos en nuestra responsabilidad social y nuestra brújula ética, elegimos la claridad, la humanidad y la solidaridad\".\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Nederlands\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cp>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fmediant.nl\u002F\">\"Mediant\"\u003C\u002Fa> boycot Israëlische producten uit medeleven met Gaza\u003C\u002Fstrong>\u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.oost.nl\u002Fnieuws\u002F3561906\u002Fmediant-boycot-israelische-producten-uit-medeleven-met-gaza\">Bianca Lucas Mediant is dé expert in geestelijke gezondheidszorg in Twente (Netherlands)\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>9 september, 21:19 • Aangepast Gisteren, 17:03 • 2 minuten leestijd\u003Cbr>\u003Cstrong>Mediant spreekt zich uit tegen oorlogsgeweld in Gaza en boycot Israëlische producten.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Mediant neemt publiekelijk stelling tegen het geweld in Gaza. De organisatie kiest niet alleen voor woorden, maar ook voor actie: Israëlische producten worden geboycot. Tegelijk blijft de zorg onvoorwaardelijk en voor iedereen toegankelijk.\u003C\u002Fp>\n\u003Cp>\u003Cbr>De geestelijke gezondheidszorginstelling in Twente, heeft via LinkedIn en op hun website een statement gedeeld over de oorlog in Gaza.\u003C\u002Fp>\n\u003Cp>Mediant zegt te staan voor menselijkheid, compassie en het beschermen van psychisch welzijn – waarden die volgens de organisatie niet verenigbaar zijn met zwijgen over het voortdurende geweld.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Leveranciers in actie meegenomen\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>In de verklaring neemt Mediant expliciet afstand van \"het grootschalige, systematische en alles vernietigende geweld\" dat volgens de instelling door het Israëlische leger in Gaza wordt uitgeoefend.\u003Cbr>Woorden alleen vindt Mediant onvoldoende. Daarom kiest de instelling ook voor actie: het boycotten van Israëlische producten. Leveranciers worden daarin meegenomen.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>'Zwijgen en nietsdoen is geen optie'\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Tegelijkertijd benadrukt Mediant dat de zorg altijd onvoorwaardelijk blijft. \"Cliënten, ongeacht hun achtergrond of politieke opvattingen, mogen nooit de dupe worden van geopolitieke keuzes.\" De organisatie zegt zich te blijven inzetten voor veilige, toegankelijke en respectvolle geestelijke gezondheidszorg voor iedereen.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\"Onze stem is slechts één van velen, en onze actie misschien een druppel op een gloeiende plaat\", schrijft Mediant. \"Maar wij geloven dat zwijgen en niets doen geen optie is. Vanuit onze maatschappelijke verantwoordelijkheid en ethisch kompas kiezen wij voor helderheid, menselijkheid en solidariteit.\"\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"Mediant boicotea productos israelíes por compasión hacia Gaza\nBianca Lucas Mediant es experta en salud mental en Twente (Países Bajos)\n\n9 de septiembre, 21:19 • Actualizado ayer, 17:03 • Lectura de 2 minutos\nMediant se pronuncia contra la violencia bélica en Gaza y boicotea productos israelíes.\nMediant se pronuncia contra la violencia bélica en Gaza y boicotea productos israelíes. © Getty Images\nMediant, institución de salud mental, se posiciona públicamente contra la violencia en Gaza. La organización no solo habla, sino que también actúa: se están boicoteando productos israelíes. Al mismo tiempo, la atención sigue siendo incondicional y accesible para todos.\nLa institución de salud mental de Twente ha compartido un comunicado sobre la guerra en Gaza a través de LinkedIn y su sitio web. Mediant afirma defender la humanidad, la compasión y la protección del bienestar mental; valores que, según la organización, son incompatibles con el silencio ante la violencia en curso. Proveedores incluidos en la acción\nEn la declaración, Mediant se distancia explícitamente de "la violencia a gran escala, sistemática y devastadora" que, según la organización, está perpetrando el ejército israelí en Gaza.\nMediant cree que las palabras por sí solas no son suficientes. Por lo tanto, la organización también está tomando medidas: boicoteando los productos israelíes. Los proveedores están incluidos en este boicot.\n"El silencio y la inacción no son una opción"\nAl mismo tiempo, Mediant enfatiza que la atención siempre es incondicional. "Los clientes, independientemente de su origen o ideología política, nunca deben ser víctimas de decisiones geopolíticas". La organización afirma su compromiso con una atención de salud mental segura, accesible y respetuosa para todos.\n"Nuestra voz es solo una entre muchas, y nuestra acción puede ser insignificante", escribe Mediant. "Pero creemos que el silencio y la inacción no son una opción. Basándonos en nuestra responsabilidad social y nuestra brújula ética, elegimos la claridad, la humanidad y la solidaridad".\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"kGmWO\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"OwOEge\">\n\u003Cdiv class=\"cJ1Ndf\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cnav class=\"VlPnLc\" aria-labelledby=\"ucc-68\">\u003C\u002Fnav>\n\u003Cp> \u003C\u002Fp>\n\u003Cdiv class=\"ySES5\"> \u003C\u002Fdiv>\n\u003Ca class=\"mqNsCe\" href=\"https:\u002F\u002Ftranslate.google.es\u002Fsaved\" data-probe-id=\"saved_translations_footer_button\">\n\u003Cdiv class=\"ySES5\"> \u003C\u002Fdiv>\n\u003C\u002Fa>\n\u003Cp> \u003C\u002Fp>","mff4vedqz40g0bh69z","vb3wnFrBE1g",[15],"mediant-mental-health-institution-twente-netherlands-boycotts-israeli-products-boicott-teva-productos-israelies-mediant-boycot-israelische-producten-eng-esp-ned","'Silence and inaction are not an option' \"El silencio y la inacción no son una opción\" 'Zwijgen en nietsdoen is geen optie'","\"Mediant\" (mental health institution, Twente, Netherlands) boycotts Israeli products. Boicott Teva, productos israelíes. \"Mediant\" boycot Israëlische producten. ENG ESP NED ",{"subtitle":282,"id":283,"timestamp":284,"content":285,"tags":286,"user":13,"link":12,"slug":287,"type":7,"imageUrl":288,"title":289,"videoUrl":290},"Médicos de familia, neurólogos, sociedad civil, políticos...Family doctors, neurologists, civil society, politicians...","mfxsb3j9px3m80thrnm",1758708007399,"\u003Cdiv id=\"breadcrumbs\">\u003C\u002Fdiv>\n\u003Carticle id=\"post-6878\" class=\"post-6878 post type-post status-publish format-standard hentry category-sin-categoria\">\n\u003Cdiv class=\"entry-content\">\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Boicot al comercio de medicamentos con Israel. \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cstrong>Todos unidos: Consejería de Salud, Sociedad Asturiana de Medicina Familiar y Comunitaria, Neurología del Hospital Universitario Central de Asturias, Plataforma para la Defensa de la Salud y la Sanidad Pública de Asturias, Somos Asturias...\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>EL COMERCIO. 20\u002F09\u002F2025 \u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fwww.elcomercio.es\u002Fautor\u002Fmiriam-suarez-4664.html\">Miriam Suárez\u003C\u002Fa> y \u003Ca href=\"https:\u002F\u002Fwww.elcomercio.es\u002Fautor\u002Folga-esteban-221.html\">Olga Esteban\u003C\u002Fa>\u003C\u002Fp>\n\u003Cdiv class=\"v-mdl-ath__inf\">\n\u003Cp class=\"v-mdl-ath__p v-mdl-ath__p--3\">Gijón\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cp>\u003Cstrong>La Consejería de Salud\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>La Consejería de Salud del Principado de Asturias va a «analizar» los contratos que mantiene con la farmacéutica israelí \u003Ca href=\"https:\u002F\u002Fwww.elcomercio.es\u002Fasturias\u002Fprincipado-asturias-farmaceutica-israel-teva-pharma-20250918124837-nt.html\">Teva Pharma\u003C\u002Fa>, a la que ha pagado dos millones de euros desde el año pasado. Ese análisis, dice el Principado, debe tener en cuenta «la responsabilidad con la salud de las personas que necesitan estos productos». Pero, a juzgar por la opinión de los sanitarios asturianos existen alternativas a lo fármacos de la empresa israelí. Esto es, el Principado podría cambiar de \u003Ca href=\"https:\u002F\u002Fwww.elcomercio.es\u002Fpolitica\u002Fboicot-israel-cuestion-contratos-principado-asturias-farmaceutica-20250917205029-nt.html\">proveedor\u003C\u002Fa> sin poner en riesgo del abastecimiento de dichos productos. Es así porque Teva Pharma prové, principalmente, de genéricos.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>La Sociedad Asturiana de Medicina Familiar y Comunitaria\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Por eso, Rubén Villa, presidente de SAMFYC, la Sociedad Asturiana de Medicina Familiar y Comunitaria, es contundente en su opinión y se muestra convencido de que «se debe sancionar al Gobierno israelí con las medidas que tengamos a nuestro alcance». Por su experiencia, explica que los medicamentos de Teva también son suministrados por otras farmacéuticos.\u003C\u002Fp>\n\u003Cp>La firma israelí vende medicamentos tan comunes con el ácido acetilsalicílico (la popular aspirina), amilodipino (de prescripción habitual en casos de presión arterial alta) o amoxicilina-ácido clavulánico (un antibiótico de la familia de las penicilinas que puede usarse para tratar neumonías, otitis o infecciones de garganta). En cualquier caso, «no se trata de patentes ni principios activos que Telva lleve en exclusiva y hay otras empresas que los producen y comercializan», explica el doctor Villa. En cuanto a sus terapias más específicas, encaminadas a tratar la esclerosis múltiple, el párkinson o las migrañas, «entiendo que también hay alternativas terapéuticas en el mercado».\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Neurología, Hospital Universitario Central de Asturias\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>En el caso de la esclerosis, uno de sus máximos expertos en Asturias, el doctor Pedro Oliva, del HUCA, confirma que no habría problemas, ya que el dimetilfumarato 240, que se emplea para el tratamiento de adultos con formas recurrentes de esta enfermedad no tiene ya patente en vigor, por lo que se usan genéricos que son suministrados por otras farmacéuticas también. Es decir, la cancelación del contrato «no nos impactaría».\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Carlos Ponte, de la Plataforma para la Defensa de la Salud y la Sanidad Pública de Asturias\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Es la misma situación en la mayor parte de los productos de Teva, según explica Carlos Ponte, de la Plataforma para la Defensa de la Salud y la Sanidad Pública de Asturias. Ponte defiende que «los Gobiernos tienen que estar a la altura de las circunstancias» y defiende que «la opinión pública, de manera abrumadora, es contraria a mantener relaciones comerciales con Estados genocidas». De ahí que la Plataforma ya ha solicitado a la Consejería de Salud que rescinda el contrato y «se lo volveremos a reiterar» en la reunión que tienen la próxima semana. Ponte, como el resto de consultados, considera que no habría mayores problemas para encontrar otras farmacéuticas que suministraran los medicamos que ahora recibe el Principado a través de Teva. Carlos Ponte hace referencia a Navarra, donde «el Parlamento ha solicitado al Gobierno que no trabaje con Teva» y otras farmacéuticas israelíes.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>El Colegio de Farmacéuticos de Asturias\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Por su parte, Alfredo Menéndez Antolín, presidente del Colegio de Farmacéuticos de Asturias, entiende que cualquier decisión que se tome al respecto «es política» y «quiero pensar que, antes de adoptar cualquier medida al respecto, Salud tendrá estudiadas ya posibles alternativas». Menéndez Antolín señaló, asimismo, que «Teva funciona en España sobre todo para la venta de genéricos. No creo que hubiese problemas de suministro o para los pacientes, porque hay opciones o tratamientos sustitutivos. Aunque los medicamentos para enfermedades muy específicas son más difíciles de encontrar, aun así, no creo que vaya a peligrar la salud de nadie».\u003C\u002Fp>\n\u003Ch3 class=\"wp-block-heading\">Tomé, diputada de \"Somos Asturias\" pide «dejar de favorecer» a Teva\u003C\u002Fh3>\n\u003Cp>La diputada del Grupo Mixto y portavoz de Somos Asturias, Covadonga Tomé, ha exigido al Ejecutivo que rompa los contratos con la compañía, ha pedido a Salud que «deje de favorecer ya a una farmacéutica israelí pirata». Una empresa, apuntó, «que apoya y contribuye al genocidio de Palestina. Y que además ha tenido multas millonarias tanto en EEUU como en Europa, por sus prácticas abusivas«. Tomé hizo estas declaraciones tras conocer la réplica del Gobierno autonómico a su denuncia sobre el apoyo de la Consejería a la farmacéutica. »La cobertura de todos los tratamientos que necesitan los asturianos y las asturianas es prioritaria, por supuesto«, dejó claro la parlamentaria. Lo que no es «prioritario» es «seguir dando privilegios a esta empresa ni a ninguna otra que contribuya y apoye el genocidio de Palestina».\u003C\u002Fp>\n\u003Cp>«La Consejería se escuda en la normativa contractual, sin aclarar que hay instrumentos jurídicos de sobra, y antecedentes conocidos, para romper estos contratos», asegura. Tomé adelanta que «seguiremos revisando los contratos de la Administración asturiana para asegurarnos de que se cumple con el boicot a Israel».\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Boycott of Pharmaceutical Trade with the Israeli Governmen. Asturias (Spain)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"ryNqvb\">All united: Ministry of Health, Asturian Society of Family and Community Medicine, Neurology at the Central University Hospital of Asturias, Platform for the Defense of Health and Public Healthcare of Asturias, Somos Asturias...\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">September 20, 2025 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">EL COMERCIO. \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.elcomercio.es\u002Fautor\u002Fmiriam-suarez-4664.html\">Miriam Suárez\u003C\u002Fa> y \u003Ca href=\"https:\u002F\u002Fwww.elcomercio.es\u002Fautor\u002Folga-esteban-221.html\">Olga Esteban \u003C\u002Fa>\u003C\u002Fp>\n\u003Cdiv class=\"v-mdl-ath__inf\">\n\u003Cp class=\"v-mdl-ath__p v-mdl-ath__p--3\">Gijón\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>The Ministry of Health of of Asturias\u003C\u002Fstrong> will \"analyze\" the contracts it holds with the Israeli pharmaceutical company Teva Pharma, to which it has paid two million euros since last year.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This analysis, says the Principality, must take into account \"the responsibility for the health of the people who need these products.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">However, judging by the opinion of Asturian healthcare workers, there are alternatives to the Israeli company's drugs.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">That is, Asturias could change suppliers without jeopardizing the supply of these products.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This is because Teva Pharma primarily supplies generics.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, Rubén Villa, president of SAMFYC\u003Cstrong>, the Asturian Society of Family and Community Medicine\u003C\u002Fstrong>, is forceful in his opinion and is convinced that \"the Israeli government must be sanctioned with the measures at our disposal.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Based on his experience, he explains that Teva's medications are also supplied by other pharmaceutical companies.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Israeli firm sells common medications such as acetylsalicylic acid (the popular aspirin), amilodipine (commonly prescribed for high blood pressure), and amoxicillin-clavulanic acid (an antibiotic in the penicillin family that can be used to treat pneumonia, ear infections, or throat infections).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In any case, \"these are not patents or active ingredients that Telva exclusively holds, and there are other companies that produce and market them,\" explains Dr. Villa.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Regarding its more specific therapies, aimed at treating multiple sclerosis, Parkinson's, or migraines, \"I understand there are also therapeutic alternatives on the market.\"\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> In the case of multiple sclerosis, one of the top experts in Asturias, Dr. Pedro Oliva, neurologist of HUCA (\u003Cstrong>Hospital Central University Asturias\u003C\u002Fstrong>), confirms that there would be no problems, since dimethyl fumarate 240, which is used to treat adults with relapsing forms of the disease, is no longer patented, so generics supplied by other pharmaceutical companies are used.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In other words, the cancellation of the contract \"would not impact us.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The same situation applies to most Teva products, explains Carlos Ponte of \u003Cstrong>the Platform for the Defense of Health and Public Healthcare of Asturias\u003C\u002Fstrong>.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ponte argues that \"governments must rise to the occasion\" and maintains that \"public opinion, overwhelmingly, is against maintaining commercial relations with genocidal states.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, the Platform has already asked the Ministry of Health to terminate the contract, and \"we will reiterate this again\" at the meeting they are holding next week.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ponte, like the rest of those consulted, believes there would be no major problems finding other pharmaceutical companies to supply the medications the Principality currently receives through Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Carlos Ponte refers to Navarre, where \"Parliament has asked the Government not to work with Teva\" and other Israeli pharmaceutical companies.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For his part, Alfredo Menéndez Antolín, president of the\u003Cstrong> College of Pharmacists of Asturias,\u003C\u002Fstrong> believes that any decision made in this regard \"is political\" and \"I would like to believe that, before adopting any measure in this regard, the Health Department will have already studied possible alternatives.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Menéndez Antolín also noted that \"Teva operates in Spain primarily for the sale of generics. I don't think there would be supply problems or problems for patients, because there are alternative options or treatments. Although medications for very specific diseases are more difficult to find, I still don't think anyone's health will be endangered.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tomé Calls for Teva to \"Stop Favoring\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The MP for the Mixed Group and spokesperson for Somos Asturias, Covadonga Tomé, has demanded that the Executive terminate its contracts with the company and has asked the Health Department to \"stop favoring a pirate Israeli pharmaceutical company.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">A company, she noted, \"that supports and contributes to the genocide in Palestine. And that has also received multi-million-dollar fines both in the US and Europe for its abusive practices.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tomé made these statements after learning of the regional government's response to her complaint about the Ministry's support for the pharmaceutical company.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"Coverage for all the treatments that Asturians need is a priority, of course,\" the MP clarified.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">What is not a \"priority\" is \"continuing to grant privileges to this company or any other that contributes to and supports the genocide in Palestine.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">\"The Ministry is hiding behind contractual regulations, without clarifying that there are plenty of legal instruments, and known precedents, to break these contracts,\" he asserts. Tomé adds that \"we will continue to review the Asturian government's contracts to ensure they comply with the boycott of Israel.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Farticle>",[15],"asturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1758707298\u002Fjkiuxgtk8cq2hzzvgnx8.png","Asturias, España: todos unidos para evitar Teva. Asturias, Spain: all united to avoid Teva ESP ENG","0GOsbxfoDIY",{"id":292,"user":13,"tags":293,"videoUrl":294,"link":12,"timestamp":295,"imageUrl":296,"title":297,"content":298,"slug":299,"type":7,"subtitle":300},"mfzhlsxg0hht3pr3yyg5",[15],"3B5rvTkCd3s",1758810606689,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1758810170\u002Fec0ialng0boowkhemljm.jpg","Boicot (acción directa) a Teva. Dirigida contra sus 3 \"superventas\".  1\u002F omeprazol, 2\u002F atorvastatina, 3\u002F pantoprazol ","\u003Cp>\u003Cstrong>Boicot (acción directa) a Teva. Dirigida contra sus 3 \"superventas\": 1\u002F omeprazol, 2\u002F atorvastatina, 3\u002F pantoprazol \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Campaña selectiva, 3 productos, boicot a Teva, Tevagen, Davur, Belmac y Ratiopharm.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina\">Teva es una empresa israelí de medicamentos \"genéricos\" (sin patentes), una empresa corrupta y corruptura que financia directamente el apartheid y el genocidio en Palestina.\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-penalty-total-since-2000-10-695-276-796-casi-11-000-millones-de-dolares-en-multas-desde-2000\">La corrupción descubierta de Teva ha llevado a multas por casi 11.000 millones\u003C\u002Fa> de dólares desde 2000.\u003Ca href=\"https:\u002F\u002Fabcnews.go.com\u002FHealth\u002Fteva-pharmaceuticals-pay-york-523-million-settle-claims\u002Fstory?id=92593606\"> Y algunos casos ha conllevado una epidemia de muertes, como en el de los opiodes en Estados Unidos,\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>En 2024 las ventas estimadas de Teva al Sistema Nacional de Salud (no en hospitales) fueron de casi 600 millones de euros. Los 3 primeros productos: 1\u002F omeprazol, 2\u002F atorvastatina, 3\u002F pantoprazol, más de 120 millones (la tabla con cifras concretas, al final de esta página, abajo del todo).\u003C\u002Fp>\n\u003Cp>Evita el consumo de estos 3 medicamentos de Teva, Tevagen, Davue, Belmac y Ratiopharm. No es dejar de tomar los medicamentos recetados, es que no nos dispensen los que matan en Palestina, cambiar a otra compañía farmacéutica.\u003C\u002Fp>\n\u003Cp>Pide las alternativas y ten en cuenta que Teva puede ofrecer gran descuento a la farmacia si vende sus productos. Es una manipulación del mercado.  Las principales industrias de genéricos ya se han convertido en multinacionales y se comportan como tales y, o les obligamos a bajar los precios o acabaremos pagando los genéricos como si fueran medicamentos de patente (de hecho en muchos casos ya está sucediendo). \u003C\u002Fp>\n\u003Cp>De hecho,\u003Ca href=\"https:\u002F\u002Fnadaesgratis.es\u002Fadmin\u002Fla-curiosa-inactividad-de-la-mano-invisible-en-los-mercados-de-farmacos-sin-patente\"> los precios de los medicamentos genéricos en España son, en promedio, más del doble de los de Suecia, el país con los precios más bajos de Europa\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp>\u003Cimg src=\"https:\u002F\u002Fcdn.bsky.app\u002Fimg\u002Ffeed_fullsize\u002Fplain\u002Fdid:plc:sijrnjskilwxv3a4lmvqw2eg\u002Fbafkreifxrloizemyysn76r4ccn4uczf7jdtet6juajxk6opeiuenq4hmpu@jpeg\" alt=\"\">\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>","boicot-accion-directa-a-teva-dirigida-contra-sus-3-superventas-1-omeprazol-2-atorvastatina-3-pantoprazol","Campaña selectiva, 3 productos, boicot a Teva, Tevagen, Davur, Belmac y Ratiopharm",{"subtitle":302,"id":303,"link":12,"timestamp":304,"tags":305,"user":13,"type":7,"content":306,"slug":307,"videoUrl":308,"imageUrl":309,"title":310},"Éxito de Yala Nafarroa y el pueblo navarro. Success of Yala Nafarroa and the Navarrese people","mgj6upjcbidfu8vl45n",1760002335656,[15],"\u003Cp class=\"article-text\">\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"article-text\">\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fwww.eldiario.es\u002Fnavarra\u002Fservicio-navarro-salud-no-prorrogara-tres-contratos-farmacos-empresas-israelies_1_12667790.html\">El Servicio Navarro de Salud no prorrogará el contrato de tres fármacos suministrados por empresas israelíes\u003C\u002Fa>\u003C\u002Fstrong> y los sustituirá por otros de compañías que no tengan relación con el Gobierno de Bejamin Netanyahu.\u003C\u002Fp>\n\u003Cp class=\"article-text\">La medida ha sido anunciada por la consejera de Derechos Sociales, Mari Carmen Maeztu, quien ha señalado que responde al “compromiso adquirido por el Gobierno de Navarra de romper las relaciones con las empresas israelíes”.\u003C\u002Fp>\n\u003Cp class=\"article-text\">Ha explicado que se van a sustituir los fármacos suministrados por estas empresas que se emplean en el día a día, tanto en Atención Primaria como en Atención Hospitalaria“ y que la no renovación ”se realizará por supuesto con todas las garantías jurídicas y asistenciales“.\u003C\u002Fp>\n\u003Cp class=\"article-text\">Maeztu ha incidido en que “este mismo proceder se aplicará también a las colaboraciones en los ámbitos de la ciberseguridad y la tecnología cada vez que sea posible, cuando pueda procederse al recambio de los productos y al reemplazo de los servicios referidos sin perjuicio para la ciudadanía navarra”.\u003C\u002Fp>\n\u003Cp class=\"article-text\">La consejera ha manifestado que “el Gobierno de Navarra mantendrá este compromiso mientras perdure el genocidio de la población palestina, si bien, haciendo compatible su firmeza contra el Gobierno de Netanyahu con el respeto que debemos tener a las decisiones del tejido empresarial productivo navarro desde ese principio también de libertad de empresa”.\u003C\u002Fp>\n\u003Cp class=\"article-text\">\u003Cstrong>Nota informativa\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"article-text\">Navarra es una Comunidad Autónoma (hay 17 en España). Cada Comunidad Autónoma tiene competencias plenas sobre el sistema sanitario público (el Gobierno Central sólo da recomendaciones estratégicas). \u003Cbr>La Comunidad Autónoma de Navarra tiene unos 700.000 habitantes, y desde siempre (siglos) ha tenido legislación propia y gran autonomía.\u003Cbr>Su ejemplo es muy importante.\u003C\u002Fp>\n\u003Cp class=\"article-text\">\u003Cstrong>NOTA de Yala Nafarroa\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"css-175oi2r\">\n\u003Cdiv class=\"css-175oi2r r-1s2bzr4\">\n\u003Cdiv id=\"id__0rdswgcaqx3r\" class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Tras meses de trabajo coordinado de \u003C\u002Fspan>\n\u003Cdiv class=\"css-175oi2r r-xoduu5\">\u003Cspan class=\"r-18u37iz\">\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Fx.com\u002FYala_Nafarroa\">@Yala_Nafarroa\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cbr>\n\u003Cdiv class=\"css-175oi2r r-xoduu5\">\u003Cspan class=\"r-18u37iz\">\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Fx.com\u002FHW4PalestSpain\">@HW4PalestSpain\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">, \u003C\u002Fspan>\u003Cspan class=\"r-18u37iz\">\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Fx.com\u002Fhashtag\u002FNasaf?src=hashtag_click\">#Nasaf\u003C\u002Fa>\u003C\u002Fspan>\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> y Plataforma Navarra de Salud y gracias al respaldo de la sociedad navarra, comenzamos a tener frutos en la línea de las campañas de \u003C\u002Fspan>\n\u003Cdiv class=\"css-175oi2r r-xoduu5\">\u003Cspan class=\"r-18u37iz\">\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Fx.com\u002FBDSmovement\">@BDSmovement\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> (la Farmacéutica Israelí TEVA es desde septiembre de 2025 objetivo prioritario del BDS). \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Hemos estado haciendo incidencia en Gobierno de Navarra, segmento médico y de farmacias, personas usuarias... \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Agradecemos que las diferentes reuniones y peticiones con Consejería de Salud y con parlamentarios vayan teniendo los primeros efectos. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">En todo caso sostenemos la campaña de \u003C\u002Fspan>\u003Cspan class=\"r-18u37iz\">\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Fx.com\u002Fhashtag\u002FTEVAnoGracias?src=hashtag_click\">#TEVAnoGracias\u003C\u002Fa>\u003C\u002Fspan> \u003Cspan class=\"r-18u37iz\">\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Fx.com\u002Fhashtag\u002FstopTEVA?src=hashtag_click\">#stopTEVA\u003C\u002Fa>\u003C\u002Fspan>\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">, pero saludamos las primeras medidas adoptadas por el Gobierno de Navarra y Osasunbidea cancelando contratos de fármacos israelíes. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Ha habido un trabajo intenso con la campaña STOP TEVA que sostend\u003Cspan class=\"r-b88u0q\">remos en el tiempo, hasta \u003C\u002Fspan>que cesen todos los contrat\u003Cspan class=\"r-b88u0q\">os posibles con la misma. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">\u003Cspan class=\"r-b88u0q\">Agradecemos desde\u003C\u002Fspan> aquí a los más de 5000 firmantes de la campaña (más de 1000 en firmas físicas y el resto en campaña digital). \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Recordamos que en la marcha ciudadana \u003C\u002Fspan>\u003Cspan class=\"r-18u37iz\">\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Fx.com\u002Fhashtag\u002FIbaitikItsasora?src=hashtag_click\">#IbaitikItsasora\u003C\u002Fa>\u003C\u002Fspan>\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> TEVA fue uno de los objetivos trabajados. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">QUEREMOS RECOGER MÁS FIRMAS: \u003C\u002Fspan>\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Ft.co\u002FFxlgoCEwz3\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-qlhcfr r-19qo34d r-qvk6io r-orgf3d r-u8s1d\" aria-hidden=\"true\">https:\u002F\u002F\u003C\u002Fspan>stop-teva.yalanafarroa.com\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">INFÓRMATE DE MÁS DETALLES DE LA CAMPAÑA AQUÍ: \u003C\u002Fspan>\u003Ca class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1loqt21\" dir=\"ltr\" style=\"color: #1d9bf0;\" role=\"link\" href=\"https:\u002F\u002Ft.co\u002FUFkIUKux2S\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">\u003Cspan class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-qlhcfr r-19qo34d r-qvk6io r-orgf3d r-u8s1d\" aria-hidden=\"true\">http:\u002F\u002F\u003C\u002Fspan>yalanafarroa.com\u002Fstop-teva\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Ca href=\"https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDPwMAh0jFIG\u002F\">\u003Cstrong>Impacto internacional:\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\n\u003Cdiv class=\"html-div xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x9f619 xjbqb8w x78zum5 x15mokao x1ga7v0g x16uus16 xbiv7yw x1uhb9sk x1plvlek xryxfnj x1iyjqo2 x2lwn1j xeuugli x1q0g3np xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Cdiv class=\"html-div xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x9f619 xjbqb8w x78zum5 x15mokao x1ga7v0g x16uus16 xbiv7yw x1uhb9sk x1plvlek xryxfnj x1iyjqo2 x2lwn1j xeuugli xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Cdiv class=\"html-div xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x9f619 xjbqb8w x78zum5 x15mokao x1ga7v0g x16uus16 xbiv7yw x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Cdiv class=\"html-div xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x9f619 xjbqb8w x78zum5 x15mokao x1ga7v0g x16uus16 xbiv7yw x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s x1q0g3np xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\"> \u003C\u002Fdiv>\n\u003Cspan class=\"x193iq5w xeuugli x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi xpm28yp x8viiok x1o7cslx x126k92a\" style=\"line-height: 18px;\">🚨 BDS VICTORY! 🚨\u003Cbr>\u003Cbr>A local petition accruing over 𝟰𝟬𝟬𝟬 signatures has led the Government of Navarra in Spain to cancel drug contracts with the Israeli pharmaceutical company \u003Ca class=\"x1i10hfl xjbqb8w x1ejq31n x18oe1m7 x1sy0etr xstzfhl x972fbf x10w94by x1qhh985 x14e42zd x9f619 x1ypdohk xt0psk2 x3ct3a4 xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x16tdsg8 x1hl2dhg xggy1nq x1a2a7pz  _aa9_ _a6hd\" tabindex=\"0\" role=\"link\" href=\"https:\u002F\u002Fwww.instagram.com\u002Fexplore\u002Ftags\u002Fteva\u002F\">#teva\u003C\u002Fa>, a company that openly supports the genocidal Israeli military.\u003Cbr>\u003Cbr>\u003Ca class=\"x1i10hfl xjbqb8w x1ejq31n x18oe1m7 x1sy0etr xstzfhl x972fbf x10w94by x1qhh985 x14e42zd x9f619 x1ypdohk xt0psk2 x3ct3a4 xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x16tdsg8 x1hl2dhg xggy1nq x1a2a7pz  _aa9_ _a6hd\" tabindex=\"0\" role=\"link\" href=\"https:\u002F\u002Fwww.instagram.com\u002Fexplore\u002Ftags\u002Fboycottteva\u002F\">#boycottteva\u003C\u002Fa> \u003Ca class=\"x1i10hfl xjbqb8w x1ejq31n x18oe1m7 x1sy0etr xstzfhl x972fbf x10w94by x1qhh985 x14e42zd x9f619 x1ypdohk xt0psk2 x3ct3a4 xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x16tdsg8 x1hl2dhg xggy1nq x1a2a7pz  _aa9_ _a6hd\" tabindex=\"0\" role=\"link\" href=\"https:\u002F\u002Fwww.instagram.com\u002Fexplore\u002Ftags\u002Fboycottgenocide\u002F\">#boycottgenocide\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>The Navarre Health Service (Spain) will not extend the contract for three drugs supplied by Israeli companies\u003C\u002Fstrong> and will replace them with others from companies unrelated to Benjamin Netanyahu's government.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The measure was announced by the Minister of Social Rights, Mari Carmen Maeztu, who stated that it responds to \"the commitment made by the Government of Navarre to sever ties with Israeli companies.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">She explained that the drugs supplied by these companies that are used daily, both in Primary Care and Hospital Care, will be replaced, and that non-renewals \"will, of course, be carried out with all legal and healthcare guarantees.\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Maeztu emphasized that \u003Cstrong>\"this same approach will also be applied to collaborations in the areas of cybersecurity and technology whenever possible, when the products can be replaced and the services referred to can be replaced without harming the citizens of Navarre.\" \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The minister stated that \"the Government of Navarre will maintain this commitment as long as the genocide of the Palestinian population continues, while making its firmness against the Netanyahu government compatible with the respect we must have for the decisions of Navarre's productive business community, also based on this principle of freedom of enterprise.\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">NOTE, information:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">Navarra is actually an Autonomous Community (there are 17 in Spain). Each Autonomous Community has full jurisdiction over the public healthcare system (the Central Government only makes strategic recommendations). The Autonomous Community of Navarre has approximately 700,000 inhabitants and has always (for centuries) had its own legislation and significant autonomy. Its example is very important.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">NOTE by Yala Nafarroa \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">After months of coordinated work by @Yala_Nafarroa @HW4PalestSpain ,\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">#Nasaf and the Navarre Health Platform, and thanks to the support of Navarrese society, we are beginning to see results along the lines of the @BDSmovement campaigns (the Israeli pharmaceutical company TEVA has been a priority target of the BDS since September 2025).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We have been advocating with the Government of Navarre, the medical and pharmacy sectors, users... \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We are grateful that the various meetings and petitions with the Ministry of Health and with parliamentarians are having initial results.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In any case, we support the #TEVAnoGracias #stopTEVA campaign, but we welcome the initial measures adopted by the Government of Navarre and Osasunbidea canceling contracts for Israeli pharmaceuticals.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">There has been intense work on the STOP TEVA campaign, which we will continue over time, until all possible contracts with the company are terminated.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We would like to thank the more than 5,000 signatories of the campaign (more than 1,000 in physical signatures and the rest\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(digital campaign).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We remind you that TEVA was one of the objectives worked on during the #IbaitikItsasora citizen march.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">WE WANT TO COLLECT MORE SIGNATURES: https:\u002F\u002Fstop-teva.yalanafarroa.com \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">FIND OUT MORE DETAILS ABOUT THE CAMPAIGN HERE: http:\u002F\u002Fyalanafarroa.com\u002Fstop-teva\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\u003Ca href=\"https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDPwMAh0jFIG\u002F\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">NEWS\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-37j5jr r-1inkyih r-16dba41 r-bnwqim r-135wba7\" dir=\"auto\" lang=\"es\" style=\"color: #0f1419;\" data-testid=\"tweetText\">\n\u003Cdiv class=\"html-div xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x9f619 xjbqb8w x78zum5 x15mokao x1ga7v0g x16uus16 xbiv7yw x1uhb9sk x1plvlek xryxfnj x1iyjqo2 x2lwn1j xeuugli x1q0g3np xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Cdiv class=\"html-div xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x9f619 xjbqb8w x78zum5 x15mokao x1ga7v0g x16uus16 xbiv7yw x1uhb9sk x1plvlek xryxfnj x1iyjqo2 x2lwn1j xeuugli xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\n\u003Cdiv class=\"html-div xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x9f619 xjbqb8w x78zum5 x15mokao x1ga7v0g x16uus16 xbiv7yw x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cspan class=\"x193iq5w xeuugli x13faqbe x1vvkbs xt0psk2 x1i0vuye xvs91rp xo1l8bm x5n08af x10wh9bi xpm28yp x8viiok x1o7cslx x126k92a\" style=\"line-height: 18px;\">🚨 BDS VICTORY! 🚨\u003Cbr>\u003Cbr>A local petition accruing over 𝟰𝟬𝟬𝟬 signatures has led the Government of Navarra in Spain to cancel drug contracts with the Israeli pharmaceutical company \u003Ca class=\"x1i10hfl xjbqb8w x1ejq31n x18oe1m7 x1sy0etr xstzfhl x972fbf x10w94by x1qhh985 x14e42zd x9f619 x1ypdohk xt0psk2 x3ct3a4 xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x16tdsg8 x1hl2dhg xggy1nq x1a2a7pz  _aa9_ _a6hd\" tabindex=\"0\" role=\"link\" href=\"https:\u002F\u002Fwww.instagram.com\u002Fexplore\u002Ftags\u002Fteva\u002F\">#teva\u003C\u002Fa>, a company that openly supports the genocidal Israeli military.\u003Cbr>\u003Cbr>\u003Ca class=\"x1i10hfl xjbqb8w x1ejq31n x18oe1m7 x1sy0etr xstzfhl x972fbf x10w94by x1qhh985 x14e42zd x9f619 x1ypdohk xt0psk2 x3ct3a4 xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x16tdsg8 x1hl2dhg xggy1nq x1a2a7pz  _aa9_ _a6hd\" tabindex=\"0\" role=\"link\" href=\"https:\u002F\u002Fwww.instagram.com\u002Fexplore\u002Ftags\u002Fboycottteva\u002F\">#boycottteva\u003C\u002Fa> \u003Ca class=\"x1i10hfl xjbqb8w x1ejq31n x18oe1m7 x1sy0etr xstzfhl x972fbf x10w94by x1qhh985 x14e42zd x9f619 x1ypdohk xt0psk2 x3ct3a4 xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x16tdsg8 x1hl2dhg xggy1nq x1a2a7pz  _aa9_ _a6hd\" tabindex=\"0\" role=\"link\" href=\"https:\u002F\u002Fwww.instagram.com\u002Fexplore\u002Ftags\u002Fboycottgenocide\u002F\">#boycottgenocide\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"html-div xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x9f619 xjbqb8w x78zum5 x15mokao x1ga7v0g x16uus16 xbiv7yw x1uhb9sk x1plvlek xryxfnj x1c4vz4f x2lah0s xdt5ytf xqjyukv x1qjc9v5 x1oa3qoh x1nhvcw1\">\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FG3KCedpXsAA8swl?format=png&name=900x900\" alt=\"\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"css-175oi2r\">\n\u003Cdiv id=\"id__2714ppz0eie\" class=\"css-175oi2r r-9aw3ui r-1s2bzr4\" aria-labelledby=\"id__710hxmu6sbu id__u25jynflcka\">\n\u003Cdiv id=\"id__u25jynflcka\" class=\"css-175oi2r r-1ets6dv r-1phboty r-rs99b7 r-1udh08x r-1867qdf r-o7ynqc r-6416eg r-1ny4l3l\" aria-labelledby=\"id__gey38bbfzdf id__yyyq2nburj\" data-testid=\"card.wrapper\">\n\u003Cdiv id=\"id__gey38bbfzdf\" class=\"css-175oi2r r-1adg3ll r-2dkq44 r-1emcu8v\" data-testid=\"card.layoutLarge.media\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","el-servicio-navarro-de-salud-deja-de-comprar-medicamentos-de-teva-the-navarre-health-service-spain-stop-buying-israel-drugs-esp-eng","A7Xc05_yIV8","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1760002263\u002Fcdrmcycohit9oe2iibiq.jpg","El Servicio Navarro de Salud deja de comprar medicamentos de Teva. The Navarre Health Service (Spain) stop buying Israel drugs. ESP ENG",{"id":312,"videoUrl":313,"tags":314,"user":13,"link":12,"imageUrl":317,"content":318,"slug":319,"subtitle":320,"timestamp":321,"type":7,"title":322},"mgp6clt7ymsh6tplj7","lP-9v8iPYMw",[315,316,15],"Paz","Peace","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1760362910\u002Fzhh8ui3lbix6qjzw9jzd.jpg","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Nos alegra, claro, que dejen de caer bombas en Gaza. Nos alegra muchísimo el cese de la matanza y de la destrucción.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cem>PERO...\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cbr>No nos alegra que siga habiendo aviones, drones, bombas, tanques, francotiradores, soldados y pilotos bajo las órdenes sionistas de un ente colonialista y terrorista sin que se exijan reparaciones ni se planeen juicios. Sin ni siquiera plantear un revisión de la verdad que busque el perdón y la reconciliación. Exigiendo, por el contrario el desarme de la Resistencia palestina, su rendición ante un ejército que no ha sido capaz de derrotarla en dos años de dominio de cielo, mar y tierra.\u003C\u002Fp>\n\u003Cp>\u003Cbr>No nos alegra que se piense en la solución de los  \"dos estados\", cuando uno se basa en la expoliación y expulsión de la población autóctona del único que debiera existir. Sin ni siquiera plantear la autodeterminación palestina.\u003C\u002Fp>\n\u003Cp>\u003Cbr>No nos alegra que se promueva el \"borrón y cuenta nueva\", como si nada hubiera pasado, como si el legado de casi cien años de horror fuera inocente, como si la amplísima mayoría judía en Israel no deseara la expulsión de todos los palestinos de sus hogares y tierras. Sin ni siquiera plantear la \"curación\" de las causas del apartheid y del genocidio, el sionismo y el colonialismo, que bien se expresa con la aceptación de los hechos consumados en toda Palestina, incluyendo Cisjordania y Jerusalén (el muro, los checkpoints, la legislación discriminante, los abusos constantes, etc).\u003C\u002Fp>\n\u003Cp>\u003Cbr>No nos alegra que se siga hablando de \"Oriente Próximo\" en lugar de \"Asia Occidental\". Tampoco nos alegra que se pretenda ignorar la justicia que emana de la Corte Internacional de Justicia y que se haya incumplido sin consecuencias la obligación internacional de prevenir y sancionar el genocidio. Al \"lavar\" a Israel se pretende el lavado \"occidental\", como si nada hubiera pasado y no hubiera responsabilidades compartidas.\u003C\u002Fp>\n\u003Cp>\u003Cbr>No nos alegra la aceptación del sistema carcelario de Israel, que mantiene y tortura a miles de inocentes palestinos. Ni siquiera se piensa en la decencia y ética que exigen la amnistía general inmediata, la reparación en lo que se pueda y el pedir perdón (y el juicio de responsables y colaboradores, personal sanitario incluido).\u003C\u002Fp>\n\u003Cp>Nos alegra que no caigan bombas pero deseamos se mantengan e incrementen las sanciones internacionales contra Israel, en ciencia, comercio, deportes, investigación, etc, especialmente contra la multinacional farmacéutica Teva.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Ha pasado mucho y no nos alegra que se pretenda el olvido sin más.\u003Cbr>Sin ni siquiera pensar en reparar el profundo daño en sanidad, educación y periodismo, a la infancia y juventud, a las mujeres y a la ancianidad (y a bienes materiales imprescindibles para la vida, incluyendo los culturales e históricos).\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cbr>Si volviéramos a la Europa desvastada por la II Guerra Mundial, con millones de muertos, tampoco nos alegraríamos de llegar a la paz en 1945 manteniendo la Alemania nazi tal cual. Con Israel hay que hacer lo mismo que con la Alemania nazi: derrotar su ejército, ocupar su territorio, juzgar y condenar a sus responsables y cooperantes, y eliminar el sionismo. Como, además es una entidad colonizadora, hay que enviar a los ciudadanos israelíes a sus países de origen.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Después, la autodeterminación de Palestina, desde el río al mar.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">We are glad, of course, that the bombs have stopped falling on Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">We are extremely glad that the killing and destruction have stopped.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cem>BUT...\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We are not glad that there are still planes, drones, bombs, tanks, snipers, soldiers, and pilots under the Zionist command of a colonialist and terrorist entity, without demanding reparations or planning trials.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Without even considering a review of the truth that seeks forgiveness and reconciliation.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Instead, they are demanding the disarmament of the Palestinian Resistance and its surrender to an army that has been unable to defeat it in two years of dominating the sky, sea, and land.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We are not glad that a \"two-state\" solution is being considered, when one is based on the plundering and expulsion of the indigenous population from the only state that should exist.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Without even considering Palestinian self-determination.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We are not pleased that a \"clean slate\" is being promoted, as if nothing had happened, as if the legacy of almost 100 years of horror were innocent, as if the vast Jewish majority in Israel did not wish for the expulsion of all Palestinians from their homes and lands.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Without even considering the \"healing\" of the causes of apartheid and genocide, Zionism, and colonialism, which is clearly expressed in the acceptance of the fait accompli throughout Palestine, including the West Bank and Jerusalem (the wall, the checkpoints, discriminatory legislation, constant abuses, etc.).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We are not pleased that people continue to speak of the \"Middle East\" instead of \"West Asia.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Nor are we pleased that there is an attempt to ignore the justice emanating from the International Court of Justice and that the international obligation to prevent and punish genocide has been flouted without consequence.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">By \"washing\" Israel, they are attempting to wash the \"West,\" as if nothing had happened and there were no shared responsibilities.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We are not pleased with the acceptance of Israel's prison system, which detains and tortures thousands of innocent Palestinians.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">There is no thought even given to the decency and ethics required by an immediate general amnesty, reparations where possible, and apologies (and the trial of those responsible and collaborators, including healthcare workers).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We're glad no bombs are falling, but we hope international sanctions against Israel—in science, trade, sports, research, etc.—will continue and increase, especially against the pharmaceutical multinational Teva.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Much has happened, and we are not pleased with the attempt to simply forget.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Without even considering repairing the profound damage to healthcare, education, and journalism, to children and youth, to women, and to the elderly (and to material assets essential to life, including cultural and historical assets).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">If we were to return to the Europe devastated by World War II, with millions of dead, we would not be happy about reaching peace in 1945 while maintaining Nazi Germany as it was. We must do the same with Israel as with Nazi Germany: defeat its army, occupy its territory, try and condemn its perpetrators and collaborators, and eliminate Zionism.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Since it is also a colonizing entity, Israeli citizens must be sent back to their countries of origin.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Then, self-determination for Palestine, from the river to the sea.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\">\u003Cstrong>EDITORIAL, DIARIO RED, 12 de octubre 2025\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"kO6q6e\">\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.diario-red.com\u002Farticulo\u002Feditorial\u002Fplan-trump-gaza\u002F20251011204203056094.html\">\u003Cstrong> El 'plan Trump' para Gaza\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Mientras compartimos la alegría de los gazatíes, debemos ser conscientes de que la voluntad histórica del proyecto sionista de limpieza étnica de Palestina sigue vivo y más fuerte que nunca\u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"kO6q6e\">\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Millares de muertos después hay quien celebra el tercer alto el fuego —conocido como 'Plan Trump'— como si fuera el principio del fin del genocidio. Lamentamos no ser tan optimistas y, a continuación, explicamos por qué.\u003C\u002Fp>\n\u003Cp>Es evidente que, si todo ocurre como dicen, desde hoy morirán menos niños en Gaza y algo de ayuda humanitaria llegará y disminuirá seguramente el número de muertos por hambre o por enfermedades curables. Lean “Si esto es un hombre” de Primo Levi y sabrán que en los campos de concentración nazis era una alegría que la ración de comida aumentara o que el ritmo del crematorio disminuyera, pero el genocidio contra los judíos no se detuvo hasta la derrota militar de los nazis.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Mientras Israel no sea derrotado política y militarmente, el genocidio va a continuar de una u otra forma, porque el genocidio no es el resultado de la mente perversa de Netanyahu, sino un proyecto absolutamente racional, ejecutado con precisión por la poderosísima maquinaria administrativa y militar israelí, con el apoyo de EEUU. El proyecto de exterminio o expulsión de los palestinos de su tierra cuenta además con el consenso de la mayor parte de la sociedad israelí. Esto es así. Hay algo que todo el mundo tiene que saber e interiorizar: la solución final contra los palestinos no es el delirio de sádicos sin escrúpulos, sino el cálculo político de varias generaciones de dirigentes sionistas —muchos de ellos “progresistas” como Ben Gurion— con una enorme formación cultural, intelectual y técnica. Los genocidios no son la obra de malvados enloquecidos, sino el proyecto planificado de intelectuales refinados asistidos por un cuerpo funcionarial eficaz y por poderes mediáticos alineados. Los genocidios no son necesariamente la excepción en la modernidad. Basta haber leído a Zygmunt Bauman para saberlo.\u003C\u002Fp>\n\u003Cp>Mientras Israel no sea derrotado política y militarmente, el genocidio va a continuar de una u otra forma, porque el genocidio no es el resultado de la mente perversa de Netanyahu, sino un proyecto absolutamente racional.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Cuando los israelíes juzgaron y ejecutaron al funcionario alemán Eichmann y cuando Hannah Arendt describió aquel juicio explicando qué era la banalidad del mal, estaba anticipando una paradoja estremecedora: que algunos de los descendientes de los judíos europeos exterminados por otros europeos, llevarían a cabo una operación de exterminio igual de atroz, con la diferencia de que exterminar árabes no afecta tanto a las conciencias occidentales. Al menos mientras las imágenes de niños despedazados nos llegan cada día a nuestros teléfonos. Este detalle sobre el origen de los exterminadores no es menor.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>La clave que hace más horrible para nosotros —occidentales— el holocausto nazi respecto a los holocaustos del colonialismo, es que en aquella ocasión no se trataba de europeos exterminando indígenas, sino de europeos exterminando a otros europeos fueran estos judíos, gitanos, comunistas u homosexuales. ¿Saben por qué nuestras televisiones siempre entrevistan al portavoz de las fuerzas de defensa de Israel Roni Kaplan y nunca entrevistan a un portavoz de Hamas? Porque por mucho que los crímenes del ejército israelí superen con creces a los cometidos por Hamas, Kaplan es un uruguayo, un blanco occidental como nosotros, mientras que los portavoces de Hamas, que son la autoridad votada por los palestinos de Gaza, son árabes.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>¿Durará esta tregua de Trump? Con la primera tregua de 2023, Israel obtuvo 105 rehenes israelíes a cambio de 280 palestinos. Con la segunda, este mismo año, llegaron más intercambios pero poco más. ¿Respetará Israel mucho tiempo este acuerdo? Ojalá, pero cabe albergar dudas.\u003C\u002Fp>\n\u003Cp>Es lógico que la resistencia palestina acepte el plan de Trump. Su pueblo y sus combatientes necesitan más oxígeno que nadie, pero es poco probable que los jefes de las facciones armadas palestinas se crean que esto va a durar mucho. Porque el problema no es solo el ritmo del genocidio sionista; el problema es la ocupación, el apartheid y el no reconocimiento de una soberanía palestina real.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>El problema siempre ha sido Israel y su dirección de Estado sionista. Como dice Olga Rodríguez, “el plan Trump pide el desarme de Hamás pero no de la parte que comete el genocidio.” La periodista más valiente de su periódico recuerda además una contradicción tan dolorosa como clarificadora: “Hoy circulan imágenes del último alto el fuego cuando el conocido periodista Anas Al Sharif se quitó el casco en directo, celebrando el acuerdo. El genocidio siguió y él y miles más fueron asesinados por el Ejército israelí en los meses siguientes. Nuevamente, esto es solo el principio. El plan Trump no contempla el fin de la ocupación colonial ni del régimen de apartheid. Separa el destino de Gaza del de Cisjordania y Jerusalén Este. Tampoco incluye reconocimiento a la soberanía palestina.”\u003C\u002Fp>\n\u003Cp>El problema no es solo el ritmo del genocidio sionista; el problema es la ocupación, el apartheid y el no reconocimiento de una soberanía palestina real\u003C\u002Fp>\n\u003Cp>Con estos mimbres y siendo conscientes de que la voluntad histórica del proyecto sionista de limpieza étnica de Palestina sigue vivo y más fuerte que nunca, hoy toca compartir la alegría de los gazatíes ante el cese temporal de las bombas y la posibilidad de volver a lo que queda de sus casas, pero es también obligación de todas nosotras mantener todos los ojos en Gaza y también en Cisjordania, así como la tensión y la movilización en las calles. Muchos pretenderán convencernos de que esto se acabó, pero los mismos poderes que llevan masacrando a los palestinos desde hace más de 70 años no tienen ninguna intención de cejar en su empeño y solamente con el apoyo comprometido y contundente de miles de millones de personas decentes en todo el mundo los vamos a poder parar. Las bombas han dejado de caer momentáneamente, sí, pero aún queda todo por hacer para que algún día Palestina pueda ser libre desde el río hasta el mar.\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"en\" data-language-name=\"inglés\" data-text=\"We are glad, of course, that the bombs have stopped falling on Gaza. We are extremely glad that the killing and destruction have stopped.\nBUT...\nWe are not glad that there are still planes, drones, bombs, tanks, snipers, soldiers, and pilots under the Zionist command of a colonialist and terrorist entity, without demanding reparations or planning trials. Without even considering a review of the truth that seeks forgiveness and reconciliation. Instead, we are demanding the disarmament of the Palestinian Resistance and its surrender to an army that has been unable to defeat it in two years of dominating the sky, sea, and land.\nWe are not glad that a "two-state" solution is being considered, when one is based on the plundering and expulsion of the indigenous population from the only state that should exist. Without even considering Palestinian self-determination.\nWe are not pleased that a "clean slate" is being promoted, as if nothing had happened, as if the legacy of almost 100 years of horror were innocent, as if the vast Jewish majority in Israel did not wish for the expulsion of all Palestinians from their homes and lands. Without even considering the "healing" of the causes of apartheid and genocide, Zionism, and colonialism, which is clearly expressed in the acceptance of the fait accompli throughout Palestine, including the West Bank and Jerusalem (the wall, the checkpoints, discriminatory legislation, constant abuses, etc.).\nWe are not pleased that people continue to speak of the "Middle East" instead of "West Asia." Nor are we pleased that there is an attempt to ignore the justice emanating from the International Court of Justice and that the international obligation to prevent and punish genocide has been flouted without consequence. By "washing" Israel, they are attempting to wash the "West," as if nothing had happened and there were no shared responsibilities.\nWe are not pleased with the acceptance of Israel's prison system, which detains and tortures thousands of innocent Palestinians. There is no thought even given to the decency and ethics required by an immediate general amnesty, reparations where possible, and apologies (and the trial of those responsible and collaborators, including healthcare workers).\nMuch has happened, and we are not pleased with the attempt to simply forget.\nWithout even considering repairing the profound damage to healthcare, education, and journalism, to children and youth, to women, and to the elderly (and to material assets essential to life, including cultural and historical assets).\nWe must do the same with Israel as with Nazi Germany: defeat its army, occupy its territory, try and condemn its perpetrators and collaborators, and eliminate Zionism. Since it is also a colonizing entity, Israeli citizens must be sent back to their countries of origin.\nThen, self-determination for Palestine, from the river to the sea.\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp> \u003C\u002Fp>","nos-alegra-claro-que-dejen-de-caer-bombas-en-gaza-we-are-glad-of-course-that-the-bombs-have-stopped-falling-on-gaza-esp-eng","PERO...BUT...",1760363132245,"Nos alegra, claro, que dejen de caer bombas en Gaza...We are glad, of course, that the bombs have stopped falling on Gaza...ESP ENG",{"imageUrl":324,"slug":325,"type":7,"content":326,"videoUrl":12,"subtitle":327,"title":328,"timestamp":329,"id":330,"tags":331,"user":13,"link":12},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1760440173\u002Fdaz42erhdunlfmga7jsc.jpg","bima-webinar-teva-boycott-global-health-bds-for-palestine","\u003Ch3>Brief History of Teva\u003C\u002Fh3>\n\u003Cp>• Originally founded in pre-mandatory Palestine in 1935.\u003Cbr>• Has been the largest supplier of generic drugs to the US since 2000, is the 18th largest pharmaceutical company in the world, the largest manufacturer in Israel and the largest Israeli company trading on the NYSE.\u003Cbr>• Also produces proprietary medications (Deutetrabenazine), various monoclonal antibodies (latest is Fremanezumab) and biosimilar agents.\u003Cbr>• CEO since Jan 2023 = Richard Francis, a British pharmaceutical executive.\u003Cbr>• Production facility in Runcorn, Cheshire.\u003Cbr>    • UK commercial headquarters + legal\u002Fmarketing\u002Fsales in Castleford, Yorkshire.\u003Cbr>    • UK sales\u002Fmarketing in Harlow, Essex.\u003Cbr>    • R+D facility in Larne, Northern Ireland.\u003C\u002Fp>\n\u003Ch3>Teva and Boycott, Divestment and Sanctions\u003C\u002Fh3>\n\u003Cp>\u003Cimg style=\"float: right;\" src=\"data:image\u002Fpng;base64,iVBORw0KGgoAAAANSUhEUgAAATcAAACiCAMAAAATIHpEAAABBVBMVEX\u002F\u002F\u002F+lKTQAAACeABieAxvz6Ojw3d6iGSfMmJuiGynJiY+fDR\u002F8\u002FPzhxsjmysz19vakIy\u002FLzc2wsrO3ubmZnJ3asLPk5OS+wMAuNznp6uqprKydABOQk5SKjY6jHyyhFCOAhIUAEBNxdXUQICI7QkN6fX7Y2dkpMjQHGRrBeX9NU1RVXFzT1NVjaGnTo6bGx8eZAACyUlkdJyoACxBfZGW2X2TDgIT48PCnMjvUpqndubs2Pj+8a3GsQUmhpKXr1tevSVFFS02IAAA0Lyuhb3SNJS9yZWeTSE6MCxuwVl1GQj5hXltxAA5+DxxIJCmMXF6lhIgrFRqTfoFqNz0AICG5lpmhSE+gY6CwAAARm0lEQVR4nO2cC3uiSprHoTTtBRIQCQIKIireY8eYq8bEmTlztnd2Z3dmzuz3\u002FyhbVVysAorYJ+Z0+nnq38\u002FTGi2J\u002FFL13uoFQeDi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLieo+M\u002Fo\u002F+Bj+XlFb4GJjho778cd\u002FlZ5IFZPy43OMH+cb4kd\u002FmJ9JAww8Rt\u002Fn+R36Xn0mtEX5o7BUFPni7H\u002FttfiINmpa9Ht0AcGMummYQvmgrP\u002FZLFUo5vyD05eyeNfCeGghHHnN0+eJqcv38\u002FHq9rT++5GGYhoxsAKb60lAUY6nvgY\u002Ft224s\u002F54T+oN09lUiVJYq4nX9KY\u002FJF2qgVO6Kr\u002FWL4jN7mdTKFVcVVahat1y7fcoMsW8gTWUNOtbhNcsBDrRy4DNPN+GsJKaETvGh+iU98Es5M7AiVSaZcYcPfCu59AdcqXKRHuWt5ACsU4is2SYA8xOc3ccpyw2rVrpOnWKWGx7XvmUs2GpbzQ7vXmbGOSbI8QM66Jzg5D5QDG5wNrVvKVuXzw2Nq+cdd5s7PIebBey8z9urz2zdCrjBZVUi7RGLG4TxmnUmt5X8oVluI8bE8hbof+uz0ivgJort6mEgm5voium1etdlICa5WTr8T9+wvtmqgZZrcNKzPZ0KuYmlq2RgATdRTYE7bzMGUtyUzVQR2OZ\u002FuTfMtcV690ermJtYOo8HFnET1QfKI4o5LiHLDa7FG78gpzJ7rROf7An1BjdRjW1XITexdksc84qxSrP2LVjlOoVQun7qkz2h3uJWuYsGFnMTy4+HY7JHZfzCqqD0MZ+d+mRPKIqbWqm46VMtR6aL4gYj2PTAduJUz6UUeqkM8xA1j1tcQcqVPIYDPuKcTyGSm3p7Wd1KEm2cKpFPJbm5k4vHiUSvRncbH3JCIa2oVZjOnlev27W0P1UEqzAHBZ0V+KzgSG41HME+PVOxl\u002FocDiS5YZbyFb3E23HKRb+ahDJn9XaN4tYBw1afzS0AffvzFjCz3AShTi20UrhQM9zgSy45Nd1JdERyQUtXxO+6v\u002FtKrVOr079hJ+9KY3W60zy58rgJd+SMk8JQJIdbyleUQgv3RFBXr+nf9iWd168Ksvf54v2n92HK5SY\u002FEBOpG3rKPG7CIzkzo4GPBPRutnJEa10Qazifue6by02oVjKv5nITngnAkSUkP1tml5mwZiYzzYJu4bP6BKR8bi8EpFoYweVzo2IOCVvCu9rhlVJxVdgaCCsyJ5iTfkCbnuL8Pkr53O6Jcy\u002FkJpCeIfSWFLfi+Qa5NalIpHNYmsp485lLcPnc5IfDq24htypBKQzh6sQrUqa+S2tlCbPI+suKoljK1GxFHGcd4TNXyvO5kXar0L5RK1p8QK\u002Fk2EamdjCVGnmBvjDHoDfu9cBo0wPTTkMWhnCV9n4+bsR8K\u002FKnUFTIgszZI5lHdJn7Y6Gckb8AvaE2P\u002FgApQHThBnE1jllHCKfuADKsG+E2ZLCWILF7ZYcikI9ylUcsi+GfODnlCbns33g5eYS+1UfqucIxhg+jnwU\u002F7X6WMAQtOiZJezgg+nHjSbNDQCbJnrWAI3wpeHoXSTzuZExPztfwCINXAVlB2d0tlEYwVm9KSPY0ED+bDP9VhNqLhjAbjbtGdAgN9DEUgR7HD\u002FTR62m7YOwpOIAJwgc4AmIWxj5BOAjuF0e1hozP41ETq8aTrWINS4SaWuOlL7PfE8HuV1JZhwoG2F45\u002FRkyC1+1046wfQB+j\u002FA9FsABztN9NDohftA+9VHcLs+LL68nKrC2HcI06o7qh6iimwT57GrvQpIVhSlNDcDrs5WUo2yk7UdcoNvQSswiP46a\u002FhaY+wgd9MEdkFJ4QjlcjsnWOTV30huMrmXgOfmBV3hdFM56kEWe9dlvlhAJDlvpLkF8IE936BP7sBfE83cFhzbAMrIgy\u002Frjfe1UeRxO1OJKCSqcjC5CdTswt\u002Flma7gdSdCvjpEQTdVMfJHcDV5OUV00wuQEm5raK5aN8imaXPETUPPggM3yL8RJ2wG\u002FDs1gLwElt4XWifndqGSWX2cKTG5kZQqeE1epgq+UlXIlUnkWIEWP9NQ1LZHzs8ws58Z9AAUNGoGGDqOtxpBJq3exjTNEZyJ2hg\u002Fsw\u002FchjNhGXOzMDdFmE1vWqfmJl9sywSIUlIwY3IjbGG8qFMTTixnt5sFZMLIuDZ2rGFY4kzXcAausoGvqaPEQkGTZ+H72EVS6zRl34T9UJiDaDIH8AniZgAYHZ6Qm\u002Fq8fVUlct1Jh0iYyW1LfCCKWS7S+6flvHyrQU0n28EP0dpsYSKzrP0j7BuE54wVPJjpFxQYpyhxJ8UOjkPchGFwUm6QHD1RSneHgUdxK79Er9VEWrWcwkiL2q+yMMV5eLqyMweKLiwKuaEJugrjDCa3IXrLD9s5hf5QCLnh335KbpTUr2SRm8mN3IaRIm5ympv6kP2WrTX1I16Ug4TUsG8fwa2BYjKmP7V87EotsEa\u002FfY2QfTw36YGKWI\u002FiFs834SW9UqmN6VBLusA2hf7QGCQ\u002FDsHIHGf3ZVZxcSnyp0Mch5hI\u002FUCww2crA4bNptkDqzAEnPcBTIP76GjLhFvRFuTbYnJ7eKQHHjffkraIasqnkqYykjWmflzAqbFLIg\u002FFtubBOJuEafGGhLJTwoeGYNhYO0sIomeKMIcPzWS6yk3HaYa\u002FdBfhMgo6BY4Qi5u6TVmk47gdstGMiWunM1V5TLlLxM2ntmmMT7yhVdA3OKHIfS83OR2MJJlHMoLmtoezY00tzO9oyGeuuY\u002FqnyvwCzWJXKrfuU7hkd0UuLhCkKhHLkMFucI1Od9kVr13Bx3KLiqXDNAndHO8cRRB20+ns+l0Ct8e4NTKGI7Gex0edzFF2p+wUaewr6Z8e\u002Fjm3+VPsV7KqcN1UybOGxI\u002FaKgTziPPrOMxvnMHxhVOtBGGkv\u002FFWFvuVn1k03Zjz7Zh6gGQNWuBvbbUbwao+oTtXl6h4HequB+p9pwUM77Pn2I9pY\u002Fdpt5GNY\u002FkeeNmB5pyq3d412JuL2BukeeFhwhweUDBU1XuhTk84mYB\u002FHex4CsjLf9Iv18UN1eSavTicp9jA3Fc3EvnBdXUjEuvVPsmXKmKvejNYTo6mo4XiUHaMx1eituSAKwQ3LyDW\u002FlYbu7k5bx626YcYeXNekhOnpUo3ecrpYIbv4dnyXwQbsFY48ECOKFv8NndbyluVpilYpHciI7rj+UW1kPOJlTMGneqfk9ef9BtKhpRU\u002F7NA2tU7l4AVFqU+x6qaaOmXmM2Yn\u002FnFDdoGlfxtVwEN4UoGJudeQPqhM41r\u002F52Qc6St+rkOXUkgfGumG0cXJqd9cx3WsoagpvhuqyOKkWrcUEjeZob9JsAhGUBgptFWM9Bvz8ej0+5H5tb730hg\u002F0yux8JiwKT4XZPX8iQtnCLZC3tPd0XGl7DGu\u002FRQl0VNIdkuMGpagOctVHz7VDeGzWPgvEdyt9fIDubo6284+vktFI1JdrjEj5ziWYMPFvPtjZwrs0KzhRxi+odh1L7MvSqhH3bHMKcP8K+IZF9DmINm4Xj92VSojNVaqoKOjo15f5eDvY2nGDIg3qeMIeh6rKgq6azQRsrmHhSy43MGclNPzQ0\u002FVHcqCaPcIocsw\u002Fo5u4kkI7jgBav\u002Flnz\u002Fuq62253\u002FwQnizb8syIEf\u002FlFrHW73y7DTkw5VfCco9rTaIjabpAxVDbwZx2XinUMkuQmjzbojebij1unwhOxUMPmP+a+M2HAKleZ4wupxtX4ggj56zfoe\u002F\u002F6q9t13f\u002F4dvuAiiEL6z\u002F\u002F5vyXqz788tDtunfw\u002FS+vX2mLafRGvonLJEtgesPeCMIKNmDtTcOibmzUcL5gbMDCHwCYg4w2M6gpe7f2VNzIHCmkweK2Tfc5ZFUnfUMc4k3alW+vqqv+999xwDbdLYetZtC8\u002F5+\u002Fd\u002FbTxf\u002F+UpOk6+tK5mJDZTfUw+Vn6b4fLb+l43dCOydrYfQXdVQ3PV9Hz5oa1gmvv2Fwy758dF9NVvdUc2G88u7aFdX99R9h35Z80\u002FrbTIAOVVh2PANOvf0\u002FJ121m3+N5mfQe7ll+7hytM226UDJk66s\u002FRb9sB+smoEjLGTHx0WRpi+cfa1\u002F1qso2etUSr\u002FM6hsk5huz+eiKbJVOIt8XqXa3i\u002Ft7lZYHwMIYg9UO2\u002FBgBBO4ylE3P\u002FghOsIvhJQY3IjZlndVbvZoyaD7mit2\u002F3XYm5F3xghocTxn\u002FHbZFmtiJsJ3hljYsLUWoxn2BvIwrNtpYRlqPg2tWxD7gcBXhA78lDcc+oHthS9qw\u002FfMZgY3sjgUNg7mc6N6QRjmjY5VEm7Pz5fitvJXchyxE638ozuRLsVv6UOZUwfKQ3NyAYa2AzYKqnCGFn8YBn1+dHF+I97nQhWTneesxx3HCwyAoTOuTz9Wb\u002FcNRhYpn9trtg8\u002FR+SlIDiqebp63Ha3E\u002FfOfa3W6weLF3G7rFfrolvvTm6l7eMVtS9hJrXzTpggjGao4h5y82bhUfxwO5DiBtUMN4JQ6xeEW3AFwBHK50ZHDng\u002FMJcb1QkSR2\u002FZWUcaQexPr8sVdFsREf6r1UqHNCXiNinXaujyczSiUqasZrJ\u002FGu\u002FCz2GGSnPTboSwFJLmpoVVUXnsoJ6H991n480+rrj2k8eNbq2Mi0j123Sr4HO61ERVgr8mw63oRKnd1zaVMiTcmvGaHjgpbvsO6kISmNwEDSZgg3c2D+dxo\u002FuJ2Hn92YOaHYcSUoneCqOvf8Z\u002Fhcnh17YPtcxGvN1eJd6mm5lMR7Gg4DKNt6iHM5ob6iQMQbG4QWit916Mk+X2cktvGTP7oi\u002FpDatk86BaE11pcqh7UIm9G+3bP9bKNddVXVckcoxZYrwuJRgUq2qtLKZ2XQcAS47mloCbNiluGGgP2X4mtwD037u1RfUjbZ8e7x7K6X3P0F2nrtt9qj+krttNGhlwp7Rbfri7fDn7clEVqQpc4k7l8\u002Fpku63\u002F8+ZQld0d3Knv\u002F\u002FvXyf99q2buwJT0cTms+bZCvrazL+Im+O++IyR9nXi3UktTi7cEUteJdzPXiSdLM+owR\u002FdZkspSqlBOXdAQ\u002FPZbcxDf5sfwwaa\u002FCyxZMZqDEdoYbeVUMVL2zZ8j+yb0mwm3BmoR2YxQzxubmz4Q3qk37+cQ505v3Jegm3\u002FpUVp0SjFdKitjAcZDXfc2wGwI9gqAmxsAgw3dFJbDaTYRT7iF8dcQ7JBjHHjh8eCDP9Vs29Y2ThG3zvuCkCO4lWJvVszNfT0csogbfWHlVBHsjmA4q\u002F5qEbpAYeg5vmbsVgtBDuRONjRNuAkOjt90gDIOO2rqmieFpN2qkNtHz7dyMo2K77uiEsuvgFuFKmw6uteAvi0Q0D2kmmFS1IHLE6ybCIPSnO8zeZY59ZAQUJgvaJ3xBs+7KXC0IdoP1CJWqIm8AaKxMbekT66T0zl8Sm7l\u002FD7VDLYKOY3Y3FR6G3CoB6iTbz1C6VHEzYNTJm6uMVrpG8PB930sPOtaaxPmpzbeRrCn5hrNtORKTGcH01Is+GQRFtWTumXTex+1N7iViPJXATdVpVYfmxvd52B4ESELnVXYPG6Q3XzWfPZpC0lF9zGTyPpGwX3MnunMiskt1QFn7R2y0cVEAQl1nwLFnv583NT2ltn\u002FRo0rpauL1fx7v6npS9xaGtWdhm5GG5C7WDvN\u002Frx3dGDep\u002FGW7h1icHNL1y\u002FpQ+beoVHsPqQHGhs6zNhoyLtGkvXNYuj\u002FHPddiVlUSmL9mPuC1qTyNkMNnvLla7uSQlcpV7NLbqX7uqYtYzjaPuFm6Cv9s94xL9RZ6vay5fbD9ioHRuY+tKX2890T61K\u002FL9XntlRx8eUQKvo7VPNGBs3GbrhY3ETl2U5fCPCuaWu\u002F0j\u002FxJeJYyjmliy8sS3x\u002F7MBkfHVy\u002FQzz9tfJVfFdHeQOWGiavkd1WA\u002FMZmDG74d\u002FnBQbbRmELXDz4NP6UC4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4uLi4urtPq\u002FwGEBpsYlkJpqQAAAABJRU5ErkJggg==\" alt=\"BDS – Bojkott, desinvestering och ...\" width=\"50%\">\u003C\u002Fp>\n\u003Cp>BDS has designated Teva as a priority pressure target, requesting boycotts wherever possible.\u003C\u002Fp>\n\u003Cp>Has been involved with numerous legal challenges, such a s price-tixing, bribery of government officials and a $4.25 billion settlement due to its contribution to the US opioid epidemic, legal challenges from rival drug companies over patent infringement and surreptitious funding of disease-oriented NGOs to boost drug sales.\u003C\u002Fp>\n\u003Cp>In 2024 Teva was fined € 462 million by the European Commission due to abuse of patent procedures and using disease advocacy groups to slander generic companies creating a rival form of Glatiramer.\u003C\u002Fp>\n\u003Cp>In a 2006 interview, while Teva was engaged in 15 simultaneous patent challenges, Teva's CEO boasted of the agility of its legal department as what set it apart from other legal firms.\u003C\u002Fp>\n\u003Cp>\"Teva's legal department is big. We have many, many top notch lawyers that work for us around the country. Do you think that Pfizer puts us against the low-key lawyers?\"\u003C\u002Fp>\n\u003Ch3>How Teva profits from apartheid\u003C\u002Fh3>\n\u003Cp>There are 6 Palestinian pharma companies, Megapharm in Gaza (currently inactive). In the West Bank; Pharmacare, Al-Quds Pharmaceuticals, Birzeit Pharmaceutical Company, Beit-Jala Pharmaceutical Company, and Sama Pharmaceuticals account for 50% of all pharmaceutical sales in Palestine.\u003C\u002Fp>\n\u003Cp>The Paris Protocol, governing economic relations, dictates that Israel controls all Palestinian imports and exports through taxes and border control. This classifies Palestinian drugs as imports, and allows Israel to prevent the import of drugs from their Arab allies, as well as the large cheap generic producers in India, China and the former USSR. This creates a dependency on the Israeli pharmaceutical industry.\u003C\u002Fp>\n\u003Cp>Movement of Palestinian drugs is additionally restricted not just due to the usual 'security' concerns that the Israeli authorities use to starve the Palestinian economy, but quality concerns are also raised. On this basis, Palestinian pharma is completely blocked from Occupied East Jerusalem. Manufacturing Palestinian pharma is further constrained by Israel's control over the import of raw materials and equipment into the Palestinian occupied territories. Many Palestinians therefore find Israeli medicines more affordable\u003C\u002Fp>\n\u003Cp>A captive market for Israeli pharma is thereby formed by the barriers created to prevent the free operation of Palestinian competitors.\u003C\u002Fp>\n\u003Cp>Previously threatened with inclusion on the UN blacklist of companies operating in OPT, Teva was subsequently not included and media reports indicate that Teva's production facilities are within Israel's legal borders.\u003C\u002Fp>\n\u003Cp>However in HRWs landmark 2021 report A threshold crossed, the treatment of Palestinians is condemned as falling under the definition of apartheid, a crime against humanity under IHL. Therefore any government or corporation complicit in this would be in breach of IHL.\u003C\u002Fp>\n\u003Cp style=\"text-align: center;\">\"\u003Cem>In the occupied West Bank, Israel subjects Palestinians to draconian\u003C\u002Fem>\u003Cbr>\u003Cem>military law and enforces segregation, largely prohibiting Palestinians\u003C\u002Fem>\u003Cbr>\u003Cem>from entering settlements. In the besieged Gaza Strip, Israel imposes a\u003C\u002Fem>\u003Cbr>\u003Cem>generalized closure, sharply restricting the movement of people and\u003C\u002Fem>\u003Cbr>\u003Cem>goods-policies that Gaza's other neighbor, Egypt, often does little to\u003C\u002Fem>\u003Cbr>\u003Cem>alleviate... This level of discrimination amounts to systematic oppression.\u003C\u002Fem>\"\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">Foreign aid given to Palestinians, to a large extent, is absorbed by the Israeli economy, as the lockade of Gaza results in aid money being used to pay for the bare essentials , which Palestinian companies are disadvantaged from accessing, as well as the various arbitrary tariffs and taxes that Israel levies on Palestinian products.\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">The economist Shir Hever estimated in 2018 that 72% of aid money given to Palestine ends up in the Israeli economy.\u003C\u002Fp>\n\u003Cp style=\"text-align: center;\">\"I\u003Cem> believe that with globalization, there will be a\u003C\u002Fem>\u003Cbr>\u003Cem>time that unless you are able to compete on the\u003C\u002Fem>\u003Cbr>\u003Cem>international market, you will not be able to\u003C\u002Fem>\u003Cbr>\u003Cem>compete in your home market.\u003C\u002Fem>\"\u003C\u002Fp>\n\u003Cp style=\"text-align: center;\">Bassim Khoury. Former Palestinian Pharmaceutical Association, Palestinian Economic Minister,FormerChairmanon the CEO of Pharmacare Palestine.\u003C\u002Fp>\n\u003Ch3 style=\"text-align: left;\">Teva's response to 7th October 2023\u003C\u002Fh3>\n\u003Cp style=\"text-align: left;\">Statement from TEVA on Oct 10 - \"As an Israeli company we condemn this appalling assault and Teva stands with Israel in this time of great loss and challenge\".\u003Cbr>• CEO Richard Francis speaking on Oct 10 regarding the assault on Gaza - \"We currently don't expect a meaningful impact on our business and\u002For our financial and operational performance\".\u003Cbr>• Sales in Israel account for just 2% of global revenue, while production in Israel constitutes less than 8% of total global manufacturing in dollar terms.\u003Cbr>• This demonstrates that any support that Teva might then provide to the Israeli military cannot simply be due to a concern over a loss of income due to the Israeli\u002FPalestinian conflict.\u003C\u002Fp>\n\u003Cp>\u003Cimg style=\"float: right;\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Fglobes\u002Fimage\u002Fupload\u002Ft_desktop_article_content_header_800%2A392\u002Fv1647421416\u002Fdirect\u002F%D7%99%D7%95%D7%A1%D7%99_%D7%90%D7%95%D7%A4%D7%A7_6_EIZ_5830_wlxi7g.jpg\" alt=\"Teva targets sub-Saharan Africa - גלובס\" width=\"40%\">\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">• In April 2024 the local CEO of Teva Israel, Ukraine, Africa and Middle East Clusters, Yossi Ofek, said:\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">\"As the national pharmaceutical company of Israel, we have been harnessed - since the beginning of the war - for the benefit of Israel, the wounded and the families of the evacuees and the security forces. [...] we donated essential medicines, baby food compounds and computers, [...] we helped with harvesting and agriculture...\"\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">\u003Cimg style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"data:image\u002Fpng;base64,iVBORw0KGgoAAAANSUhEUgAAAuoAAARiCAYAAADyVNIpAAAMS2lDQ1BJQ0MgUHJvZmlsZQAASImVVwdYU8kWnltSIQQIREBK6E0QkRJASggtgPQiiEpIAoQSY0JQsaOLCq5dRLCiqyCKHRCxYVcWxe5aFgsqK+tiwa68CQF02Ve+N983d\u002F77z5l\u002Fzjl35t47ANDb+VJpDqoJQK4kTxYT7M8al5TMInUCCiAAOiACQ75ALuVERYUDWAbav5d3NwGibK85KLX+2f9fi5ZQJBcAgERBnCaUC3IhPggA3iSQyvIAIEohbz41T6rEqyHWkUEHIa5S4gwVblLiNBW+0mcTF8OF+AkAZHU+X5YBgEY35Fn5ggyoQ4fRAieJUCyB2A9in9zcyUKI50JsA23gnHSlPjvtB52Mv2mmDWry+RmDWBVLXyEHiOXSHP70\u002FzMd\u002F7vk5igG5rCGVT1TFhKjjBnm7Un25DAlVof4gyQtIhJibQBQXCzss1diZqYiJF5lj9oI5FyYM8CEeIw8J5bXz8cI+QFhEBtCnC7JiQjvtylMFwcpbWD+0DJxHi8OYj2Iq0TywNh+mxOyyTED895Ml3E5\u002FfxzvqzPB6X+N0V2PEelj2lninj9+phjQWZcIsRUiAPyxQkREGtAHCHPjg3rt0kpyORGDNjIFDHKWCwglokkwf4qfaw0XRYU02+\u002FM1c+EDt2IlPMi+jHV\u002FMy40JUucKeCPh9\u002FsNYsG6RhBM\u002FoCOSjwsfiEUoCghUxY6TRZL4WBWP60nz\u002FGNUY3E7aU5Uvz3uL8oJVvJmEMfJ82MHxubnwcWp0seLpHlRcSo\u002F8fIsfmiUyh98LwgHXBAAWEABaxqYDLKAuLWrvgveqXqCAB\u002FIQAYQAYd+ZmBEYl+PBF5jQQH4EyIRkA+O8+\u002FrFYF8yH8dwio58SCnujqA9P4+pUo2eApxLggDOfBe0ackGfQgATyBjPgfHvFhFcAYcmBV9v97foD9znAgE97PKAZmZNEHLImBxABiCDGIaIsb4D64Fx4Or36wOuNs3GMgju\u002F2hKeENsIjwg1CO+HOJHGhbIiXY0E71A\u002Fqz0\u002Faj\u002FnBraCmK+6Pe0N1qIwzcQPggLvAeTi4L5zZFbLcfr+VWWEN0f5bBD88oX47ihMFpQyj+FFsho7UsNNwHVRR5vrH\u002FKh8TRvMN3ewZ+j83B+yL4Rt2FBLbBF2ADuHncQuYE1YPWBhx7EGrAU7qsSDK+5J34obmC2mz59sqDN0zXx\u002FsspMyp1qnDqdvqj68kTT8pSbkTtZOl0mzsjMY3HgF0PE4kkEjiNYzk7OrgAovz+q19ub6L7vCsJs+c7N\u002Fx0A7+O9vb1HvnOhxwHY5w5fCYe\u002FczZs+GlRA+D8YYFClq\u002FicOWFAN8cdLj79IExMAc2MB5n4Aa8gB8IBKEgEsSBJDARep8J17kMTAUzwTxQBErAcrAGlINNYCuoArvBflAPmsBJcBZcAlfADXAXrp4O8AJ0g3fgM4IgJISGMBB9xASxROwRZ4SN+CCBSDgSgyQhqUgGIkEUyExkPlKCrETKkS1INbIPOYycRC4gbcgd5CHSibxGPqEYqo7qoEaoFToSZaMcNAyNQyegGegUtABdgC5Fy9BKdBdah55EL6E30Hb0BdqDAUwNY2KmmAPGxrhYJJaMpWMybDZWjJVilVgt1gif8zWsHevCPuJEnIGzcAe4gkPweFyAT8Fn40vwcrwKr8NP49fwh3g3\u002Fo1AIxgS7AmeBB5hHCGDMJVQRCglbCccIpyBe6mD8I5IJDKJ1kR3uBeTiFnEGcQlxA3EPcQTxDbiY2IPiUTSJ9mTvEmRJD4pj1REWkfaRTpOukrqIH0gq5FNyM7kIHIyWUIuJJeSd5KPka+Sn5E\u002FUzQplhRPSiRFSJlOWUbZRmmkXKZ0UD5TtajWVG9qHDWLOo9aRq2lnqHeo75RU1MzU\u002FNQi1YTq81VK1Pbq3Ze7aHaR3VtdTt1rnqKukJ9qfoO9RPqd9Tf0Gg0K5ofLZmWR1tKq6adoj2gfdBgaDhq8DSEGnM0KjTqNK5qvKRT6JZ0Dn0ivYBeSj9Av0zv0qRoWmlyNfmaszUrNA9r3tLs0WJojdKK1MrVWqK1U+uC1nNtkraVdqC2UHuB9lbtU9qPGRjDnMFlCBjzGdsYZxgdOkQdax2eTpZOic5unVadbl1tXRfdBN1puhW6R3XbmRjTislj5jCXMfczbzI\u002FDTMaxhkmGrZ4WO2wq8Pe6w3X89MT6RXr7dG7ofdJn6UfqJ+tv0K\u002FXv++AW5gZxBtMNVgo8EZg67hOsO9hguGFw\u002FfP\u002Fw3Q9TQzjDGcIbhVsMWwx4jY6NgI6nROqNTRl3GTGM\u002F4yzj1cbHjDtNGCY+JmKT1SbHTf5g6bI4rBxWGes0q9vU0DTEVGG6xbTV9LOZtVm8WaHZHrP75lRztnm6+WrzZvNuCxOLsRYzLWosfrOkWLItMy3XWp6zfG9lbZVotdCq3uq5tZ41z7rAusb6ng3Nxtdmik2lzXVboi3bNtt2g+0VO9TO1S7TrsLusj1q72Yvtt9g3zaCMMJjhGRE5YhbDuoOHId8hxqHh45Mx3DHQsd6x5cjLUYmj1wx8tzIb06uTjlO25zujtIeFTqqcFTjqNfOds4C5wrn66Npo4NGzxndMPqVi72LyGWjy21XhutY14Wuza5f3dzdZG61bp3uFu6p7uvdb7F12FHsJezzHgQPf485Hk0eHz3dPPM893v+5eXgle210+v5GOsxojHbxjz2NvPme2\u002Fxbvdh+aT6bPZp9zX15ftW+j7yM\u002FcT+m33e8ax5WRxdnFe+jv5y\u002FwP+b\u002FnenJncU8EYAHBAcUBrYHagfGB5YEPgsyCMoJqgrqDXYNnBJ8IIYSEhawIucUz4gl41bzuUPfQWaGnw9TDYsPKwx6F24XLwhvHomNDx64aey\u002FCMkISUR8JInmRqyLvR1lHTYk6Ek2MjoquiH4aMypmZsy5WEbspNidse\u002Fi\u002FOOWxd2Nt4lXxDcn0BNSEqoT3icGJK5MbB83ctyscZeSDJLESQ3JpOSE5O3JPeMDx68Z35HimlKUcnOC9YRpEy5MNJiYM\u002FHoJPok\u002FqQDqYTUxNSdqV\u002F4kfxKfk8aL219WreAK1greCH0E64Wdoq8RStFz9K901emP8\u002FwzliV0Znpm1ma2SXmisvFr7JCsjZlvc+OzN6R3ZuTmLMnl5ybmntYoi3JlpyebDx52uQ2qb20SNo+xXPKmindsjDZdjkinyBvyNOBP\u002FotChvFT4qH+T75FfkfpiZMPTBNa5pkWst0u+mLpz8rCCr4ZQY+QzCjeabpzHkzH87izNoyG5mdNrt5jvmcBXM65gbPrZpHnZc979dCp8KVhW\u002FnJ85vXGC0YO6Cxz8F\u002F1RTpFEkK7q10GvhpkX4IvGi1sWjF69b\u002FK1YWHyxxKmktOTLEsGSiz+P+rns596l6Utbl7kt27icuFyy\u002FOYK3xVVK7VWFqx8vGrsqrrVrNXFq9+umbTmQqlL6aa11LWKte1l4WUN6yzWLV\u002F3pTyz\u002FEaFf8We9YbrF69\u002Fv0G44epGv421m4w2lWz6tFm8+faW4C11lVaVpVuJW\u002FO3Pt2WsO3cL+xfqrcbbC\u002FZ\u002FnWHZEd7VUzV6Wr36uqdhjuX1aA1iprOXSm7ruwO2N1Q61C7ZQ9zT8lesFex9499qftu7g\u002Fb33yAfaD2oOXB9YcYh4rrkLrpdd31mfXtDUkNbYdDDzc3ejUeOuJ4ZEeTaVPFUd2jy45Rjy041nu84HjPCemJrpMZJx83T2q+e2rcqeuno0+3ngk7c\u002F5s0NlT5zjnjp\u002F3Pt90wfPC4Yvsi\u002FWX3C7Vtbi2HPrV9ddDrW6tdZfdLzdc8bjS2Dam7dhV36snrwVcO3udd\u002F3SjYgbbTfjb96+lXKr\u002Fbbw9vM7OXde\u002FZb\u002F2+e7c+8R7hXf17xf+sDwQeXvtr\u002FvaXdrP\u002Fow4GHLo9hHdx8LHr94In\u002FypWPBU9rT0mcmz6qfOz9v6gzqvPLH+D86XkhffO4q+lPrz\u002FUvbV4e\u002FMvvr5bucd0dr2Svel8veaP\u002FZsdbl7fNPVE9D97lvvv8vviD\u002Foeqj+yP5z4lfnr2eeoX0peyr7ZfG7+FfbvXm9vbK+XL+H2\u002FAhhQHm3SAXi9AwBaEgAMeG6kjledD\u002FsKojrT9iHwn7DqDNlX3ACohf\u002F00V3w7+YWAHu3AWAF9ekpAETRAIjzAOjo0YN14CzXd+5UFiI8G2yO\u002FpqWmwb+TVGdSX\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\u002F\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\u002FDTpEqCQKCgCAgCAgCgoAgIAgIAkLU5RkQBAQBQUAQEAQEAUFAEBAEwhABIeph2ClSJUFAEBAEBAFBQBAQBAQBQUCIujwDgoAgIAgIAoKAICAICAKCQBgiIEQ9DDtFqiQICAKCgCAgCAgCgoAgIAgIUZdnQBAQBAQBQUAQEAQEAUFAEAhDBNKHYZ2kSoJAikEgTZo0Adty+fJlxzjII23aNJQubVpKgz++NnJF2kv8d\u002FHiJbp06RIFyssoyE29jLhElznfq1dJPQuubC49kYWjHA9mZryI8QJWaJO7Rrmpr9u83GCH8tDfadOwHsXb0cHX26kslGGU420fw4FnKZjnCGV40zsVGOS9UOIZZNGpPrrxbJiBQH9In5gRkXNB4NohIET92mEtJaUyBEC2ihYuQBkzZrBt+fETpyg65pjtRxAfzezZstJNjWrR7c1voErlS1DuXDkoZ45sdPLUaTp6LIF27TlIs\u002F9bTjP+XkBx8Sds8zIqkZbJfvEiBSh9hsA\u002F\u002F3Pnzqty4uKOM103JPHEPS23p3SpIpyRwUCNPPVHkIODh2Lo9Jmz+giaUC6CiW5aqlC2BN1QtypVLF+SskVlodOnz9KxuATasHknzVu0ho7yuRvyUaRQPsqcOZOmJE\u002FQ2bPnaP\u002FBaFd52WZy5Qb6O0\u002FuHHRTw5pUpWJp1c+4FZdwgrbv3EeLlq2nvfsPJ6kslJE+XTqqW6sS1alZkZ\u002FR\u002FOoaGG\u002FetocWLl1Le\u002FYdUoOZQPXNmiUzFSqYN6Rk\u002FQT\u002FJg5HH7UUjYGFJch0Gagf0Wad2KWzi6\u002FLwynMyN8pPyOOXT52aROTzjENY4T\u002FcuTOTYWKl6AcuXKpKp3nd8DR6MO0b8d29dw55mHXCAkXBASBRCOQJqrYzVe\u002Fv4nORhIKAoKAFYGorJlp6azxVLBAXust7\u002FWIsd\u002FS2x+NpwsXLnrDjBMQ\u002FNrVK9AnH\u002FSmMiWLUNp0aVnL6tGEGnHw0cQfNMQxR+PpqZfeowVL1hLIo52A+C\u002F\u002FZwLlzZPTLopvOOePvEEUp89cQDP\u002FXUoHD8cQBhnBfLRBOIrxAGHFvxMUkfYtRH8FktDhuTdo5j9L9BEsoSijfNni1OO5dnRfy5spIw9GEMb\u002FewYaV7TGGOR8NuEnGsN\u002FR6LtB0rIHliVKlHYUpLnEtpnYNKl+7t0\u002FvwFbRw3gRhYFGbC+1znNvTYI\u002F+jrFky+ZFfYB3PhH3G3wtp0LCJTNiPKO23m\u002FyNOOn4GWpQpyq91e9pqlOjAs\u002FQeMiZcR9loB2fT\u002F6VhnwyhaJj44xb2mOnh++mwW+8QOnTp9PeDzYQeA4aOpE+4rINyZAxI1WpU4+isucwgnyOqPOmVSvoWEy0T7jnIg1lzRZF1eo35Dr6D0z379pJu7du9klXoEhRKle1uk9YYi5Qr93bttCJ+HiqVq+BNgu0d9PqlRSnqXv6DBmoYo3alCNPHu2wNv7YUdXuixd8nzs87zly56Wqdev5lIn6AKOta1fzDJzv+yZTlixUvEw5atXhcSrGR5RtHtog7YXz52nmj9\u002FSoll\u002FUVxsTFC\u002FfZ+KyIUgIAgEhYD\u002Fmyuo5BJZEBAE7BAA+QI5yOSgUQdxwofVKpkyZaAnO7Smns+3p7y5cypTCGscXBtpWUFKBfPnoclj3qAho6bScB4AQBuuE5iDZGAC61QvazpolQvxgKNh\u002FerUp1sH2rpjL435chr9PH0unWNihw95IAEeNauVV+Xi3I2kZ3wK5svjJqpqU5t7mtOAXp2VltgOW2SWMWd2euGpB+nOWxtRt5c\u002FouWrN9u2IQOTUDusYHKUgfvY6AdXFbVEgnb75hvr0HuvPUflShdTpNcuPwyuHr7\u002FNqpfpwr1em04zVu4mi5YSJcle3WJRyxL5szUt3sHat\u002F2TsqfNxcBH53g2XjmsfuY0Feh53p\u002FQJu37tZFU2HQqONZRRtCIXiWMAAxC4j6\u002F9o\u002FRgWLFjMHe8\u002Fx7E2f+hX9+f3X3jDjBO3OlScftX3yOcrE7bfKP79M8yPqJctXpIef7WaNGvQ16vXLV+Np1cJ5tvmBqI8b9JaWqGfOkpXuad+JipQqrS17345tHtKtIepVatf1KxNlLZr1J6dZ480Pz1meAgUVPmWrVKMsUVn5XaPvy3T8nN\u002F98KNUr1lzxnsSrVzwn2eg6OK37y1QTgQBQSBoBPRv6qCzkQSCgCAQKgRAlDo\u002Fcg8N7NtFESqY0LgRxMvO2kNok2+7uYFrrbWbvPFBB7GDhhqmGSBxoz7sQx+\u002F8yKVKFbQdiBhzjsd169Bncoc5K49SAtCXyB\u002FbnM22nNodFve1oSGD+qh6oNrO7JrZJCFzVmqVi6j2lG+TLGA8Y10oTyijg3YPGfYez2ocoVSarDhVG\u002Fcw\u002FNRic15hnMa1N8pvlFXDCaef\u002FIB\u002FmvLA7rctiTdG5\u002FLqF+7Ck34ZAAVL1rACPY75sgR5bGl97uTuIBTPNOx74AvUU\u002FDtvrpuD+h5dX9gchXrFmbMmqIuKoFY4YBsy4t1nxYJS0POnRxgw0DsUXfnExIYEJ7UZsn6p41e3ZrFdR1xkyZKGeevNp0qEu+wkUYF3+zOuBVsBgP+Kx4cX3iY2FS5BlU47eVr1Bheqzny0rjH8X1sCPpqBDagjYVKlaCOr7Ymxq3uJOfIz2pVw2QfwQBQSAkCPi\u002FpUKSrWQiCAgCiUWgNJu5vPjsw4520XZ587dU2bSPYnMZ2B67IXF2eTmFI9\u002FMmTLSow\u002FeReNHDqBcrKEOJCAG1SqX5ToFinn1PsrBwAAmP05StFB+NbCBhjeYNmN2ATbsE0cPZNv\u002F7EGldaqP23t5uW1fMhkuWbyQ2yTeeGVKFaVxw\u002FqpensDNSfA\u002FfZbbmBtekc1M+AWHwz8KvHgYUDvJ2wHYrD9dzuQ1FTNL+jkyTMUE3vMLzxQQMFixVlzbm9iFih9ct6HZj3hGLdJo3lGX2TLkUP73IFo25F41DdjpsxeO3Jz\u002FZFnrnz5zUHqnI3kKObwQVUNxMnEGvv2z79EZSpVYbM694QbaVG3Vh0fp5y52SyHr0UEAUEg+RAQop582ErOgkDQCMAuHSQb9sqJFXw4sdi0w0N3hcwkwa4uIGl1a1aioe++RFFZs9hFU+Gwsa9XCxr14EQNOLgcO4H2vF+PTgTimhgBWa\u002FAdu0tb2+iNPiJySMxadBPb\u002FV\u002Fmk2K3Jn26MpAvbs+8YDuljcsH5vLvPxiJ1vzHW9EzQlMWrCIuQgPhHSEDM9ZKOX4yVN06Ih1IWngErLnzEUlylUIHPE6xLjMXobij8Ze0WP7VyB3vgJ+mmxgDZMUaNztRM02acyB0vDvTGsmxIr06EMg6pdVec1atqIKNWpq+9WuTCMc9cuWI6fSxtutHTDiylEQEASShoAQ9aThJ6kFgZAhgA9vsya1qRYvIMV5UgRmKu3a3M6aL\u002FeassSWB7J+560NqVH9ao4mFXnYWw0WSQYrefPkcjSvqFiuJN1yUz3GzJ7Mw6PJiZOn6QwvsgVRsQrMSQb0ejxRZNaal5trEB300W3NGjBR8u9r2BNjQTAW7J7ltQZYLKwTPCe3NqvnSLbwHFRnExmdAItTp86oP7vFsLl5tuSTwb2UyY05D7QBMxihEnTL0WPxqs3B5gmTjFqNmgSb7JrER19i4aedgPBiUa9ZgC3MUpwEZju5NZrzLFmzsj2+\u002F6AZfX308CEeMFzmBaNl6Y627Th733KdytPdK1WhEhUvW153S8IEAUEgRAj4fyFClLFkIwgIAsEhAKIJO2u7hXlYuHiEXTkOG\u002FMN9X\u002F7U5r4zQx2N3hcWwg+9KXYnKIxL\u002F5MDOmPiz+u3CLCTR5ILsiGnaCsTGwGM6B3Z0ebVWXCwuQC8YORYkVYm2shMub0NaqWU+Yx5jDjHN4t\u002FmHXlS0f7km1mnagNp1eoU2axZGoU+GC+Zjw1w26fkZZwRxB0jvyjEfevEzSNHCsXrdN1bnOzZ2oTceXlUtJ3QAD9YYbR9i36wYqBVlb\u002F8JTbbX9Ak9DM\u002F9dQi3uf4Ea3NZZLULW9TPybVivmlqsbG0jzJ90cpGfFywMDe7vPC1evl47kNKVYQ4DDpVq1VGuBZNKPs35huIc\u002FRYfyxp1jEQ0AneI1t8oSDhMUpwE\u002FaIj6hkyZqL0fpr4y3Tm9Ck6kRCvzMgq82LTDA6L3M+fO0fRBw\u002FQkf376NzZs7bVwACpxg2N+PkSvxS2IMkNQSCJCMivK4kASnJBIFQI4GN9I\u002FvPtn60jfz3HzxCrdr3oZ27DyjinDFjekXg3mbzCR25B3mBNvW\u002FhavonAPRNvI3H0d\u002F8SONHPe9IhdlSxdl++8nqVnjWuqDrCOWMB+BK8mqTBpXr9uqNs4x54dzj\u002FcavW4glt0\u002FgsijzlZBOrTvHOm92Nxzx41+2l4jD\u002FiV79rnA16gGK0wizkaR6++M4amjnuTF8b6LsRD2a1bNqM\u002FZi9md5m+Lu+M\u002FEJ1xOLOpzrdqzZksuaJgVHnF95WnnVwD64wh4yaQqM\u002F6qvV+KMdjz3Skvq9NZrb6Ot2D15toBHXyUnWpHd7eYjXBzwGgA+0uoXQ32YBLlnZ1Sg80sCHu1mysatPq4CQzp67jGbxXzCCdBg4JFaw+LJizTq0bM5sfm4Tm0vgdBjMHD1ymKxuEa0pYfJy6oRnX4NjsTrXkZ4UeQsW8vvNY7OrIiVLW7P0ucZMDIg6+sc8CIC3mEyMhVmAR+wh1qbzCcg1Ft\u002FqFo7iPgj9b5Mn0uLZM+kSD3QrcdyHnn2BB0H+9ugouxx7i0nHM1IXLybvb8bcHjkXBFITAkLUU1NvS1vDFgF88OACESRJpxnFjpFTvv+Lduza79Vunz17nqb99i\u002F17PqI8g6jaxw8imRh84Rz50\u002FobtuGwUQEvsahdV21dit1eu5NGs1eXu6+vTGl05hqICO0oQV7m1m7cTtd0viFh2tBXdtAItZt2qE2+UEeVsmcOSP7X89PW7bvtd5S17Wql+ey9QOAHTyogS9wQ1OM9qzj+kXHxCm8reWVZA82WCCJGYXkFHiyqVyhtB9BQ5nzF69h8uzr+QSbEGEjoEwa3\u002FfQzt95S0MawAOQC+RL1O9u0UjNdujaMmf+Ch8PKzB92bJ9jx9RR1rgVKpkYUoz\u002FyopRFfpTF\u002FQn3\u002FMWqTcd+rKTa6wtKzVrVq3Pi2f+48PcQ11eSDow1\u002FtQwlxgRe9guhi1JBw1N70Bfb1Vu8z6VnbnaeAvbcdo00wm8HCTmjADYFPdCw0NQsIeAzbp0PgAadoKf0gAAO9WdO+pzm\u002F\u002F6xIOuKvWbqIcuXPT206P61IPsLMAhOdPPkL0KG9e8zBci4ICAIhQkD\u002FdQtR5pKNICAIuEMABBbeXqCZ1skFJlHrN+30Ek4jDkjoN9P+Ni79jiCdBfIFdm\u002Fol9AUgI98fMJxeu29sWonVNMtv9NqlcooP+DWGyB6GIjoZwsuK1\u002FdKEcnarEn26FbBUQR3mZgw45zncSyBt26+RNIOHZ01Ql80QOz5BZsgmVX5\u002FU8aDl7zlc7iRmBhBMntdUCttgdNEpTb3jZ0QmwxuDILDBT2bhllznI57wW+8CHLf9V4QWFmjLh\u002Fs+qeb+aJvnO1DNWgp8TO2BDUjSe0cu8R8FZZRICsxCnP8zMIAU2CAJh1wmIttVjTZ78vJA0g96syJxHVt4EyhovS9YoyuCnUecdfvd5iHRpNqnR+ZRHvpfYvG7DimV02TQDh\u002FN1Sxf7vXuMekBDX7ZyNeNSjoKAIBBiBPSsIMSFSHaCgCDgjABIBkwL7OxroVGP0ewSiQ\u002FrkhUbbDOHDXE+toNOqoBjwF59q41W28gfmmKYdVgF\u002FpYLM1G3Cgjjdp4lcNqyHuQe3k38JY0ahNjxMmjRsaOqdSHmedaqw5wEdtSw+4cmGWT+9OmzypbbbrDkX37iQ3KwycgpLg9mLtiYCpp+Q+uPnVKNc6ME4GTdCMi4hyPcV5rtxYEZPOzYeZRR2vNtHuJm5IMysZjTTooXLcj4+H4ystgsDsZaimst+A3BTWPWqGxqBiBZy9dzbn2R3Hcnj9vP0KDeOfP6ulOE\u002F3Q3LhOzZsumNOpGwcgrVz7NgJjrEI\u002FBAkuREqUYH99+NNLjOTsa7WvehLBYNvU5yyYxOLcKnjUsThURBASB5EHA\u002F4uaPOUEnWvtEvoXSdAZhSjByj32i+lCVIRkk4oRwAdWEVkbzTCCYQJiFRD4rWyuYCfYoCgb7zYYCjnJXlOOMFm3F17cxp5ddNvJp0+fVs0YWNOCRO\u002Fec5DzBTn1JwGIDyJQqgSbXTAIVp4A4pjGxnMF4sbE+hNPLDD9iXdUXbdxB5u4nGAyH8emMMcUqUf7Djm20dqCxF3PX7KGbr23q8ILi1hhFpSTNw+Cph02\u002FjpClJDgZL7E4ACgK4LBRrsHblcDDyPMfIT2XNeXxxgP3LvMfYE64A+DiTguG1ia+wjFYdMoqwD3eMe6WlOE7hobAN3e5iH6+asvAtqQh65U55yAIWza4W1FJ\u002Fjt52fzkU2mm\u002Flgt86D20ACop7OtNZCeYLJ6z8ghv340SMec6qs2Zz2C7jMuF30qym06nDtGMWmNlZBmfkKBb8PgDUfuRYEBAE9AmFL1Kd39ycl+iZcm9DCPc9cm4KklFSLwFWa5Q+BoZHGR91M4hSRYs0syKdWOL6d1lMb3yEQGuijcQmqfNTDKgjCYALE2ipYDIpNiaxyiRfcbdi8S3mzwblO4H8dZkGe2QZfsoOBih0BQl5ZNIMbaNG\u002FYo85Zhx15SZnGLT3MGWyirV\u002Ffe\u002F7Y+57\u002F+oVTKla3sbrCSwacCMGTDJgNmUW4LFi9SYaOOgz2r33EM907FM+zaHxh7YdWn9jkS36GgMkbBJllbNsLx3PhP96CPC78c67aca3k+l0Mi8IDqZ9586eUZ5fcrMtt\u002FW3A6ILzy9myVsQu\u002F36\u002F47McXAOe\u002FQoJt7Hoj0kHDMrOk8w57kPsUgUkiUqymdQpwKv\u002FIO65cyThxfBHvcj6zHsBQa+6nX1gqmOiCAgCCQPAmFL1Gdt1H+0kwcGyVUQuM4IMP9MOM4fUvBQDR+DlrpZ49q8oPRPRZjMtT11+gz98Ou\u002F5iDvOQj8\u002FoP2Hie8EV2exCectCXqyAIaVt2HHAMN2KhbBRra9Zt3KKIOLa5OQD6KFS7AXlrSK5\u002FiRhwQy0NswsIHrYCs2u2Yej1JurayVwKd6uVkwoR0Zlv8fHlzUT5lu695mLgskO6E4\u002F4272s3bCf8BRYmdDnZxETzsOI5xqDuegiIJtwTFi5RinZsXH89qqAtE4\u002Fo\u002Fp071I6hfkSd62z2mQ7ing0LTDk8kMA7DMxO9u309BnS5i\u002Fi67UHeZxnW3rDA83pk9zvNj8apC9ZvqJaGGp9Fk8kJBDIOuJY5VhMtPrdW022rPHkWhAQBIJHIGyJ+qPjrq5iD75ZkkIQiCwEoE2Gxw0nuYs9eNSvXYXgAcQQfEwPHo6lp3sMMoL8jtAgh0oyKd\u002FL9gQCmmLdxxquF3WkGeR8F5u+wP7aTqOOumdizXj27FF0jm3OzQQCZBMLXeF9xMprQHRAbmEGcr2IY6hwx0CtZHH9BjjAA4M1bOhkCIg6ZiLs5AIP4GDOkhRRO8ZaQecMz7FG3Wwik5QyEpMWJiPFmbzu3LzRlpAmJt8kpeE+2sdEvUq9+pyNb7\u002FgOc2RK7ci5uhLDHRzacxXdOUjbbHSV+3Dca3TqGPx6+mTnv4GqTb\u002Fhsz5pkubjhq1uINWzJtLZ89gFvnqKPjHL8bQtPGfaRUJMI3R\u002Fe7Necu5ICAIJA4B3zdG4vKQVIKAIJBEBEBs1qzfZvsBRfbw6jH6oz68sLIEf8yvkmV8dLE40O4vVB9QkAAsFsVRJ1wN282Rypcp7lNnIz1MKbbv3M+7UZ7k3THtN1bBAlU7e2i4j7QjHvDBnpkXPNpU2ahG2B9LMUnPnMnX77tRaQxC\u002Fp6z1Ico5cqRTYu3kQbPG3YkTawAz+zZorTPwsmTZ7guNqZYiS0wiHR4PstVq8lrJfR4BZFVyKKC7h7av0fZ\u002FusyzczmKPD+AgFRh8tGN4K2Fipewhs1Cy+kjWJPMFY5D6J+ymP6snc773PAz4xOoC0vU7kqte7UmV08+pqfYnbuwgVe+Hze\u002F8\u002FW9E5XiIQJAoJAUAgIUQ8KLoksCCQPAiCa8Kqy78ARW9IJzXBpXlT58TsvUolihWztj5OnhiBmWcmjRbUrAW4cT\u002FiZ5iA2dg\u002FV7S4Kre45\u002FvBD6w9PLHaEG5r8bNn0bhP\u002F+mexrY0+PJXkdzABsWtJuIXXrVVJ+cPX1evihUv0xeRfFYbG\u002Fdw8g6EzQTLuHzxkj7URx\u002FmYhuBzXjcAij9+QtUFJBLuHLFrLdYu4Ihrp3o5l+n+bpU6dXnhoz9hdZ9DiGPy7xt+xu0IcqbMWXhA6Vn0rYh6LndEHR1QiD3dGAJtuhVf\u002FKYSjh1jX+uegfChfXvpJO9QaidI3+jWO6h2k6Zav+l26SRcEBAEkgcBIerJg6vkKggEjQA+4v\u002FMW+5opgFb76a8Q+i4Yf3YNWEev49y0IUGkQDa9HKsGXcSDDTgNcQqZXgxKOxprQJPMrCXhmzdsc+eqLM2OTt7r9ERw8XLNyiPLda8cZ2DPal06dja1vuJLk24haHP77nzRh\u002F3i0YdMYuxY\u002Fd+WrRsnZcEYrYlH3uR0c97eFKaF5JiAIgZC6wByMgDIhyx+Ndu5gQ5oB8KsM95nb0yvMRgESv6vPfz7en78e\u002FyJjoj6dcpH9LAPl2oTs2KqhwroTTaFIojiG\u002FVOvVCkVXI8jjDGm1oo3WSIWNGypjZs0kRbMyhGTcLyLYuLfoImx5lyeoh+XkLFPLrE6SNi431Zget+O5t9rNQiIhFqg90eZYa3HxrRP92vI2WE0EgghHw\u002F3JGcGOk6oJAJCMAc4TpMxewezT9tLTRNnycb+AdR0HW9f7FjZihO4K4vdy9I+Vh94tOAg8ucO9mFhCyyhVK8aDCnzrGs405THZAJrbt3MtHc8qr5yCSediMRbd4cdPWXfTfwlVako903Z5qS3fwzp0gpJEm0EA\u002Fwm4W727RWFt1mJj8zK4mzesQgHfBAnm08Y3AM0ymISDltzStR4PfeJ5+mjSY\u002Fvx+KE357E16pvP9AZ4tex\u002F2mHX5bGg\u002FmjdjLL3yUie6+cY6akalUf1q1O3pB2nWTyPpx4mD6M5bG6oBgVGnUB6BQR3WCLtxcRjKcp3ywsZIhp24NV5G3qDI2ISoYJFifoMk7HC6a8smazJ1jZmqvOzOEe+FvOwm0bo2Afbj+68sNkUC7Ky6YbmvqZQu46js2ZmsP0Mt7m\u002FrNcvRxZMwQUAQSF4EIu\u002FLlbx4SO6CwHVDAGT1X9aox\u002FKmM3ZT5Ebl8FG+sWENmjz2DSpWxN\u002FlmxEvsUfkD28rWMSYlW28X36pI91\u002FT3Mt2TbKQP3nLFjhtygUJjNYCKoTLILEwkbIgYP25hioT5FCvJunhuyD6L\u002Fy5ihb7zYgbRM+GUA9WbuLnTQN8wvkGW6CwQzqCwIN3N565Ska8nZ3Jkr6df87dx+gsRN+8mkG0sPji5NAow5TlFEf9qGp496ixx\u002F5HzVpWJPq1qxEt918gyr3b9aCt2hWXztrA+hKl8IsiT+G2LgLJBxYA2PrHwZMNzWsRRNHv059unfQ+t13qrv5HlwOYjMePHtWyVe4iHZhpTVecNfon3RK4wwf5tY\u002FuD40CLc5X1TvPC+yNVwkmu\u002FhXJm+8I6ikBLsdcVKtk8eTyDYlmuFMc6RO6+a5siekwezlpkrYHPk4H6fpGuXLKRzarGoT7DfRWauU8t2HanlI9xPbEMfjr8Zv0pLgCCQwhDQv\u002F1TWCOlOYJAJCCADyp2q+z03JtKq5mfPXc4CUwiypUuTnN\u002F+5Se7TWYZs1d6jUjcUrn5l7ru5uqnVJBamHnXZfNFTIwabf7UGNB4xreqGcja9StHj9y8sJG3WZNaG9c3HGlUUed4KZRR7hwDwS9ehW2c9cQQ9zH4AYYfDHiVcICUqv2HqS0L5PCdm1uo01bdhPsqKf\u002FtYB+\u002FXOebZnI91oKZi16v9CeisGunvsedv0F2bwEfWAV4AQvQR2ffdPPHzrIs8fDjj+JNvI5c+YcDXmrGz3Q6hZl2mCFFaYrudj9IvDs99ZomsxuQa194\u002FG0418GBgqBBPmnS5eRenZ9RLmVHPrpN7brDOzzYg\u002F6PAu1bskianLH3X5a3xy581AB1k7HXdmR0z6f4O6ARA\u002F4ZJx2MA3t9eLZM+mbMSMtePGCb+V5xd8lJkpPxzM\u002Fma+Yr5QoW87PTGz\u002Frp3KfAX5W82N8JuA73Pgnot3OLX+RjDoP3LAl6gfZxv1r4Z9SJ179\u002FPDzYwG8kLdbmndhgc9BeiXiV+Qk9cYc1o5FwQEgdAgEPiNGppyJBdBQBBwicBy3nTm1z\u002FmuSLdIDxwxffFiP50y031mBDDw4k\u002FeXJZtDda7eoV6NEH76SH7mtBjRtUV9pXp3yxKc77wyexn3N\u002Ft6ogfDqPLdisaPe+Q15CE8s7X57lfHQC8lmmVFGtBhfxYecO85cW971AG7fsVHby1gEDFqTC+wzsvR9teyfVrFbej9Dryr5WYejLu3iTog4P3kV38xEzJVaSjjaBZC9ftYke6vwqwezHSqAxqAHmTo9Bsya12aTmDqXNtouH\u002FsaGRgN6d+bBDxanXn2ucK8Qm9c4PRNucMPMQY\u002Fn2lHFciWUXbubNN44l1Gfy7Tsv395e\u002FurrimN+xnZ7hvmL6EWaKyhXYa5ivUvA4cZ3lus5cLDkdKo83NvFZBsaMOhrS9auowfrvt2bFcEWTfTBnOwnHnyqnI9GvWr\u002FYRyzp45Tcd5MalZYEqzcdVy2rBiGQ92ApvaZciQkeo1bU4PP9vNtY93c3lyLggIAolHQIh64rGTlIJAsiAA0jto6ARavHy9HwnTFQgCBa31V2xK0IHJNQjftRSQB2x7P2\u002FRaj9tOuoB7a6WqLOnl8NHjnqrikWoJ056XMh5A6+cgBBicaLO9MWIC7K+Y9d+ur\u002Fjy\u002FTG4HG8i6q9ZwsjTaQdoUV\u002Fqf9Quo\u002FbuJ3barZNN9oCrHR4G\u002FdxhLbeOggw3zfOPYQ8L439+BUm9b6afWj7k0rUkR5uHj8d0pfr7FlMaZTt9njm1Enasna1X3RonivVrsMbIPm6GfSLeI0CQIiPRUezaZg\u002FUceoKl+hIuypJrvHrp6vzXJw727luUXn9hIYQqMOd5TGglRzWswo6Ag+TF9+\u002FGIsHeP71sGeOb1xjsFElbr16fEefZX7yKT2vZGvHAUBQcAZgWv7RXeui9wVBASBKwgc4k2MXuz3McEG2c1HFMmyZs1Mg17vSp3b35Nsi\u002FR0HYSdTwe8O5bi4nnbcQ0JgeZVRxzhe3nPvsPeLLGzZpzN1vMgBYULstaQzUPsBHFysC188xvr0m3NGlAuJj0pTbBQ8393NGEzoDJacyK0FzjAe0uoBAQNC05he25IFG8wZbWjNu4Fe8RAs2bV8tSQF5smRkBC1yxZoNUMYyMh7LQZLqTS46LRd7E12oz65eMFofCfDrzNgt\u002FUATZ9iT8WqzcP4rTw9gJNfpYrdu7m9HExsUzU\u002FctEvtGHDtCXH73HZjXYvVgzgDBnxOeoW4UatahD915sF2+\u002Fp4IlmVwKAoJAEhDwfSMkISNJKggIAqFDAFq3rTv2Uqeub9Eh1jrrNGLW0hRBY1OC\u002Fj0eUwsDzaYK1rihuobf9G4vD6GlKzbYZgmf7zqiBLv2PWz6YgjMZkD27QRmPcolIBMTq4DAV6lYmmazR5Eh73Snm9iFJRbCpjTBAs07b21EU8byOoYxb7KLztx+TQQ6WIjqJMqEhgdGs+YuowlTpysf\u002FrpBFvIA3MCyyQ01vJ5zsBmOzt0m4mNx74Ila9XMxo13P03vDvnSsV+RBrNAzdk7jBstP+L7CPPL\u002FTt30vF4\u002FxkUeH2pd9PNfnbdPumv4UXM4YPaAQUwhn15dh5YwPzFLNB8n+ZZg+NxcXSJZ6Gsgt8W7PEx46HTqKNMu\u002FcHtPw7N22kz99\u002Fm+KP8uyWZqBtLQ+YVq5dl9o\u002F30OZ\u002Fuh+29Y0ci0ICAKJR0CIeuKxk5SCQLIiAFMOmJQ8xotLN2\u002Fb48pmHR9N2BV\u002FPrw\u002F1alRyUuskqOiMNG5+6Ee9O\u002F8FV7PLbpyYH+s+5gbmxwZac6dg+mLv62xcR\u002FH0jB\u002FMQfwOUheA3ZXOXH0a1SBy8Iix0h0xWhplvYSOKK9MCdq3rQuffXpQOX60icyx7Fi5HOfLw5Hx1Lr9r3poSf6U49Xh1L7p16nI9G+dszWNE1uqOkl0heYjG\u002Fgxb8J7F4Tz6lB8kEIx0\u002F5je7r0Eftlrpq7Rb6YORk6v7Kx7z7rN6sySgHnmCwjiAxcpQ9v8QfjfFLCg1wifIVbO3G\u002FRIkc0Ds4UNass3DIdaKF6CobGz6YtKoA9dTJ3kTMfa\u002Ffp7dO9otjFWmL2zik9Xifx3NSTjGA\u002F0rnpV0zcPM1q6tW2jS8I9Ya3\u002FU25e6uEYYyDrMYP7XvpN2cGDEk6MgIAgkHQFfo8Ok5xeyHP7umSlkeRkZtfjIfotyI44cBYFwQgDEZ8HSNex1oSv9MGEQNahTJaCmGB\u002F6\u002FPlysQ\u002FrjtT+6dfp0tnzrj6+5nbDZSI8asAm3M7cJANPtcOveqDtw0sWL6y1LQcpP8peXwwJpFFHvEJsF61UvCbNH\u002FIf83FfKoVymKTqBIMCaPCBp1pkyulVGwPP9uuyS5YwzKJgoSg2DMJsCBbQoi+hzda1C\u002F0CcxHsVHvPI718CHOgCq5YvZnmL17jjYb1EBO+nk59uj3qDbOe1OPdUaHxPsOa+GM889H60T5q3cBLz7Zjl44NKIq1\u002FQd4x9NX3xnD3ovOeJNDw\u002F7HrEW0jTe0ql2jgjfcelKtSlk1AAk0WLOmwzUWaS6fN5eKly3vdxsLPkMpIM\u002FQRBuDE3PeeL7wnNlJzCEm6pf976N\u002Fc+cvQAV5l1GrV5dTJ9gzEs82IR2030VKlvLJHmmhUS9cvCR7aPHVxqOOJ+LjtHU1Z+JZXLqC3u\u002FxPHV7630qULSYz4DBHNc4x7PZrGVr2sObJy3nBb1ou4ggIAiEHoGwJepVi+g\u002FuKGHQHIUBMIbAf7WKm3kUy++R2++8iS1uqtpQLIOjTJ8YD\u002FxaCsa8+U0V9p4Mwq\u002FsdcZmEU0blBDuTQ03zPOwYlvZN\u002Fb\u002Fy1axR9pfxtYIx5sm3X+trfv5J1ITR93kGmY0qC9yFsnHp\u002FxvnfgNaSkjXkNYoKsLFy6lr79eRaBoO7df1iZYugWYvrmfG2vQGixEDZDhnTsgzwrlSxeiGqx951nH7+fShQrqCXr6Ocb6lVVricHDZ3o6WfGL9jxBzD6etpMeum5h9UupbqWFymUTxFpaMYR\u002FzS7El2\u002FaSd16f4ub0aVg+ApaNvO\u002FWqgYU0P4j7xm+mORB1tqVqpNGF322AFJHHFvDl0D2t44U4wOQXP+oyvJ\u002FHgwH\u002F2B7gc3LPbFn8879HsKrFEOf8BCwh6mUpVfPuZ8zN2NPXkvUvbNPxeajRoxCTfl6gDlxMakyBdJiDr8Udj6ZOB\u002Fanji72obNXqAck67OJvb\u002FMQe49ZSiePXx106\u002FKXMEFAEEgcAsn7RktcnVSqOm+K9jsJ8EnSFIjAnv2H6Ome79OuvYeo6xNtlMtEp2bCzzr8VP\u002Fx90LlIcQprvXe6vXbaAr7zsbGOG1b32I7MMDGNjBtgPmDVaDpww6ZObLr7aWxCNXqAQMk7TJrDq2bthh5Fyt6dXMnaJ1r16ioXEiazQWMuDieZ5d4S1dsZBOPV+kka\u002FChlWTuo4imOV64nMPrDXDDolrgs2jZOvrx13\u002FolykfKheGuGcVaNZfeLItffXNH7R7L9tAcxuPHkuwRgt4jQXM8MKDwZBOYANdhjc5wkDHKsd4ZuSfeSsUriCUVkHYP7yZl5OgaZXKl6I\u002FZy92imZ7DzbW2zeso\u002FLVa\u002FqSXdsUibsBO\u002FEFf\u002F1BCayp1ornAdPewvMXFxvLRN3\u002FNp7hKnXq+WjUgSQ2O7pwgWfFmHTv2qrfnRSmMzfcepufyRPS6Gz3\u002FUv3hKCfjkYfpk\u002FfGUjtnutGNRs2Ceg1p1DxEnTz\u002F+6l6Tx40fW9XVkSLggIAu4QCFsb9YPxrJkI8Z87SCSWIBCeCBg+tN8fNlF5WYlPOBnwwwh79RvqVVOmFMG0ypjCP3Aomn2S632bIz9shlSMPZHoBKSydAm2KdeQS8QHKc+ABXBsl2z8gfD507yruaM9xiJREJuOD91tqwFGKpDdJ198V81IwNQFGIY7mUD98Ic+wADoIBNobDp08tRVc5KriGD2weOOsX7tykoDCp6ItMEK0qAsO0E35uHNpHRi1NcJ2+iYOOc1CFwAvNokVgzzDac6JDbvq+nwdHr6BuVp\u002FxywR91gp24nVrMXfhB4syKP5ydP2sN0kQefOlG\u002FM8tvDX168kRwgzaUA5eXUz8ZSrOmfafMbnTlGWGwV2\u002FQvIXyAmOEyVEQEARCh0DYatRD10TJSRBIOQjgIwrC9tlXP\u002FPxNL3et4vaxdKODIMI39uyKX3\u002Fy2zC4s9gBVpWpIN7RV0Z8MRSnM0ytrEZi1UQv1yZYj4aQnMcbNBUpFB+H+JcqgTbmfvpBa+mwq6jmXjRHGy5Qe5rVuNdHG38xoOkrF67lQcErLl3IE9Xcw\u002FPM\u002FT5XN7M6eDhGLVhk66WwPrWZvV4o6z\u002FFJ6w8+Zk3Ge62Pow2FbHO3jdQapAu+Xqc\u002FaEYvYEXn3guUYnqGqOHFG6W67CYJICe+ngDX9cZR+SSNBwHzng\u002F1uxyxzDAmVKg85kOccLSuEBJlsO\u002FYBJRTL9A0xOnzhhCnF3imfu9KlT9NeP37IpUQZq2rKVrYcXPHvZc+WioqXKeDzHuCtCYgkCgoBLBISouwRKogkC4YQA7JmxrTuY2FBeTOjk1q4ha9ThXzyGzViCFSwahFYaGyrpJHOmDFShbAn694rZgzkO7NJBvHX26YhXp2ZF9WdOE+jcQ9Q9nkEy8iAEGlg7Lgpt9LzFqwMudg1UZjjcP8MLTP9ikxDsrKoTkKWGdavxc5BBmft43FyC3Nmh458LFg8nZiGnf076EJC\u002FxAwW9bn5hyL\u002F3WwaglmTtGmCHKX4Z5csIagjTF8wcLQz1\u002FIpmOMf2L3TO5gF0YeJT1T2HNqBs09avoDNudoN1XrD5TXs43+dPIEH22moeav72OOQnjJg59IyVaqpnU5dZi3RBAFBwCUCYWv64rL+Ek0QSLUIgIh+99Pf9OXU3x0xwOY0tzdv4BjH7ibK+O2v+Uo7q4sDslG5Qkkt6cDHvWK5kq4IhS5vXVjOnNm8m\u002FlkyZKJ8ubJZZu\u002F8tPO9vwpRbATqZNg8WnmzBmVt544XpQbbgKSeoJngZJTsMBz2ZzZYT2DcprdLcKLixsBZrFHDqk+RXwQfHhxcSuH92HBtkcb7zaNNd6F8+eU\u002FfmODettcYXJTtlKVa1J5VoQEARCgIAQ9RCAKFkIAqFAAFrRTLyRTGabP8M221zWaTYB6f\u002F2p7SGF38qt4Pmm1fOYRoCW\u002FLECBbOQVvuZE5Qg3eVTK8xP8nIrvwK5sfuhYkpWZ8mF4g654uFpNj8CD7F7QSkBu4CU4rs2oOFovatgSkQ\u002FKvDXeZ29r6SHHLKxk7eTVkwaYrKqjd7cZPeTRxonH+bMpEx0Ntxu8kjuePApAQ+0QMJSPrR6CN0SnlT8XQ8TFmUL3WnB8GU8R72j251B4lF5hkzZVa7mGInU\u002FNfpsxZlNccvIvMAs36Fx++Z2tGg\u002FhFSpY0J5FzQUAQCBEC+nmsEGUu2QgCgoB7BEA6f540WKudRi5ffTODvvp2hk+G+JjDDGYGe3bBzpzWXQ0RGTtIwjwlMQK7YmxagwFBVNbM2iywoREWeWIHVbNgYJE9G9scWz765jjBnmMzo9zsCnD3vsNs357P0bADXAb4pCbJnzcnk\u002FR9FHvUf5dOMw52i0LNcXTnh6N9+1gXxy4Mj4Ev\u002FfONia5KjLcacy7I43jcMYo+eNDP37g53vU8h0b93LnARB2jsriYGJ9nGM8zvLjgqXbC0mjfvt07lLcY4xpHuK8cMGocz0xlNAercyxUnTp6OK1b6u95B\u002F7cd23ZRFXr+c\u002FOgahnzqL37uRXiAQIAoJAUAgIUQ8KLoksCCQfAso9G5Nt+KTWyRzeAVQnMPHA7qAvPvswpSdfP8qIj4+okw27Lk8jDMQAG9zs3L2ffVyX0ZqZYHHnjbyrJBasmgX20iDwbgiFOZ3TOdoCO23s2Go3g2CkBzG0bgBz9R4TC565gNYdpAftVKSeLzA4gYtDPiSLoA3Kbp+PqKNaPIsjrrlEuJQM1DaniqEdR4\u002FFqzzSpUOO\u002FoK1BX7CUZ3sppEvdiJVdebBHwaWKncOwAwH3ERCW4t2wNe6biMs3azQ1XpcTpQP9avpccYbWTF++3Zup8IlQmt25VtO4q9AeM+d0XvwMefKTyEPOA6Yg9Qzip1G3Ql7Ttt11b7dSIM+zpQ5s3ZBKnZAhVYdfah+D0YiPsJc5+De3WpHUty3SoYQbyxlzV+uBYHUioAQ9dTa89LusETgLHtYwQdS9yGE2YDuA4r4O9h+2fph9WlgEkknPKdU5kFEOs0HGuSraWMNUedwLGLVtQVE1K6+KMKJMJYv61lQicWxTs3CTAJ2TrUK6lOoYF4a9u5LiqjDZzk8qsDdJfyYx7IP8hkzF6gBijVtKK6xg2eD2lUoH2u\u002FsbFRtmxZqFCBvMpsJTeb9rz06jCCtx2r6NpijXOGd6GFHIk5poiynWkQbPutgsGDnUcWxD3LeUNbD\u002FywQPnWpvWoQL7cakfS7Nmyes22Eo6foMeff1uRdXMZ6NO8eey9lfBjzM+xLzE1p3d7DvOXrWtWU50mvDEYDxbDTUB4E1jrD\u002F\u002FjTgI8YqMtayw4MEaRd6cn35PrGV4PEMeLSa2\u002FM1yrgYLOcwz3rdNOrvAg49nnwF8h4Nbu3qnNck8QEAT8ERCi7o+JhAgC1wcB\u002FoBGxx5ju+48TIb8q5CTXddh90b4A7eKk8YcNqqHjvgTP2sedtf4sG\u002FbsVftdEoak3AQ9Xq1KrPbxAyEgQYEZA6eYuyI33z2xjKdzXVgA28WLEBtUKcK3f+\u002Fm83BPufwzQ4BGVUL5TR1wn1oeYto\u002FHID26LsFrL5TXVVnRGXm3hF2LSAtcHN1m9NNjvv0uwJ54cJ76n6QZ9uiNHnbwz+XEvUq\u002FCunUYcI431ePCKTT5MXzBbYCeZWKOO\u002FsFOsIaASNt590GcLdv38ODlvOrbGlXKEnaExfoHUwtUVhhAwV7eKiDpTjbq8AiDmZJQyOa1q9iV4ZmwJOrol6NHDgdspnLlyItBzYLfYizbrTuOUDkB4p2yccuIQTLMZ\u002FIU8F+3gt9t3oKF8AM2F+s9T8+zZ555H2+QOkF58bEpZz2Ib+vkShC4vggIUb+++EvpgoAXAXDF\u002Fay5rlqxDJ\u002F5fygrsAeV9LyQ0krUQUirVS5r6wYRZBguFhMr+AhvZpLmIX7+mjTkC815btZew4YZ8UH6YLuOD79OFi5dR2Mn\u002FORnHoH4WDTpRNSNfEGo4T4yn\u002FL84l8KdtKsU6MCTbB4xcGup6VKFFKmGzrNPfohkI23f2nuQ6DBR7l22u78rKXetHW3T4bApVa18j5h1gv0MXzrQzArsHf\u002FESpbutiVAYFv7IysacausWaijvo4abyXrdqkNr\u002Fi7iV4lVFt4HZYBYMzDCjNgvrbuZY04m3ftY8HSSeNyyQdjzGZ3bRqJdW5sWmS8kmOxPh97N+5I2DWMEOBmYxZgH38UbZbNwfanJ9I4BknJLDIZV6QCjt+naCfipcpp\u002F3dZmCSXrQ0m7\u002Fx+8YqKOeIxUzHGkeuBQFBIHEI+L5NE5eHpBIEBIEQIICPHVzw6T6uyL565TJXyK9vYbALvqtFI1viB2K\u002Fcu1m30RBXKE+m7bsVjbPdsngjaWAycMLSF+dmpXsotMu3ur+Ai+ChftH8x8WxkazphxHOynBGyzBvhy23PDqAltenYBIVq9SjrAAlfmHVzCwac6bLelIOiIdiT7m2p848gW5gdcb2GgH+kNc2HkfjbPfLbJsqaJ+5Br+4mtWtyfq4GPLmUifZzwhsA\u002F\u002F9qdZfgMhdZP\u002FgRtHK3HOkyunWqBrxDEf8QysXLNZ9RXOYxw09pk4b6xnMAuehzb33GwO8jufv3hNyPysY1C5fN6\u002FaudQv4KSFMD6ZB7opecZA5iIBPpLz5sFoc\u002FNAvwO7\u002FfVlJvvG+cg6ieZqCP+VeENz9gLzKnjCZbwqzFwhjTxNrbswObIQf17BnUtV606FSlRimdLrg7K8VspX63GFReMvu1R5XGeuzZv9K2EXAkCgkBIEAhbjXqnxldfEiFpaRIzmbDA39wgiVlKckHABwF8XDdu3mmruc7ChPPzYf3otjbdlS01EkNzWYM1rW1b32JLPKPZFAHa0MQKeMLmbbsJi1btBGQY2tv1m6ApvKzqBXMYO9mybY8twYYLwNO8wQ804haOo7LDwATae9iVb+DyqrJJiJlUGGUiLQgjdkfdwLhe5JkFhMGuGjb1Vq2vkW4Nm7249z2dhgqz95kH72uhSKyRh90R7QZGcKcJG2+dNKhblab+OFORVjwTaG+zJrWVPbsuvifsMv23aBUPcDymR2jr2Ik\u002FUc+uj\u002FBCYv9UGOjczHn+weZH6FcMMNq0aq41WUH\u002FI7\u002FFyz1+tEHmjjJRxwBLZ3IFW\u002FeWtzdW9UEcxC9VvDC3oY5\u002FRa6EoJ1LVmzwDjRsI7q8gfwO7t6lbMFz5c3nMpW7aDD3GfDJONtBkDmXbevW0Lj33+ZBqadf1D2u25EDe83RtOfn2X85TFSsotq2ZzcTZ7b3Z2z1wuYtx9g0DJ1nERB1aPQv8WAOHmDMgr7CYtKn+w+kkQP7Uezhw6qISrXq0hO9+\u002FEAxd9TDNKjrtvWrzVnJeeCgCAQIgR8f6UhyjQU2Qxqo\u002Fm6hCLjROYhRD2RwEky1wjAdnTpyo22hBhayfLsZvGXKR\u002FQrDlLFZGrwkT0juY3EDb\u002FsZN\u002F\u002FlvOHhvsNdR26YxwfOzhNg9kvXb1Cop4GfeMIzRut7DN929\u002FzKOL5Nl1sWzposZtvyNs5jUcQsU7efoMnWF3kFigqDMBAnEtViS\u002F8hDy8\u002FS5ykwGRFMnWRmXr8e9pXzN\u002F\u002FrnPGX\u002FP6BXZypRtJC2Hcjj978WKM8vuvysYdDO16tVSf1Z7+muJ3w9nV7s9zEtYdJrR9QfuvdW2rf\u002FMA0f+60yc7q7RWPq99JjXnt6Xb6YgYA5EQg1BH0G8x3MpDSqX90vCQhZm1a30B+zFjGhXs2kvQ516dDKL54nL9ZOr97EpjQeu2rkjZmMs7woUvfcIe92bW5Xab758W9eNJuL+nbvQIV5Aa9OkB8IPQYCOA+VYCHl4X17KeREPW06RWbd1BP+yq0zN2gjdhc9x77UnRZugtzDlaOfMETYyKhs1eoaH0+e2IARC1ZtJpuYVK9T5NpK1JEa\u002FQf79ZeHfELHYo4oxUHBosW1g2GjbicSEpSnHeNajoKAIBA6BMKWqH88M\u002FHEInTwSE6CwLVDAB\u002FwTVt30R72EV6etcDWDzxqArJekzcYqs6L+fARhr2ocvVnU01opn\u002FnnUWtdu020R2D4U8dZetc\u002FqFezW+sq+oHqxW4ZbRzM+kxb9Hbz6ICcAcJEmgnKAt23NAMzpi1kBYuW0dNG9X2MxdBepAObPb0xYhXlekOX6o6Ig+d7GaTnKUrN4SUMFrLAZletIy109zfur7Dpld9unWg559sqwZt2djbj5NbQ0Pb7ZnN8C3tbx7Q1WcPM7r0sO3\u002F7sv3lJ9tPGt2mMCH\u002FitvjqJTp6\u002F6\u002Fo45Gkd\u002Fzl7M5izNtXnDf\u002F6oD\u002FrQiPd7qT7AQEr3PKO2eDZHj\u002F8xSesofFvtuTrHz\u002F7OTRupYs3autvXNQy\u002FdXhvKVyylHbAiPuwIz\u002FLO636y2U6tI9npDiOrfA9DAbszMJAwDeuWEa1mzS1zSIju3AswAQdgt+RnWBAsXDmDGWSYxdHwgUBQSDxCIQtUR\u002F8hxD1xHerpIxUBKBV7\u002FbyR+wVZJCtxxRocZlWuWoiTC2gaXX8qLvKiZSv9kcfvEtL6AxCDFvqHbsPEI460xLUA5pZuHizk1MnTyuNut19kD5jp1WQ1A9GTKYabItuNzBA3XQmGrr8QaAPWzZu0sVLUhhjsGTFelq5ejPV4sWuOpxArLFAN5AAzyO8gPeZnu9rTTGm\u002FjCTnnnsfh7YaNwx8nOUMa3zJwD4\u002FvPfMqUdx8DIEJwPGTWV7r6t8ZWZD+OO56ieUc470LwonvfNW\u002FfQRyOn0EXWqodS8Iwt+XcW3dH2YR7Q6gdmoSwvmLzQb9hhFL7emQX7JcX9QzwboBO+RXt3bPPbyMgcF+mjD+zH1Io52HuOjY1+nTyBzWdqUlSOHLZE3ImgIzOUs2Pjeprz+y8hecd4KygngoAg4EUgvN5e3mrJiSCQehFYwQTu33krvGYMiUECH9CD7Iv74S4D1OLFxORhTbNh0046zWYpdgJyVoM17tASw3uIToMK3gDvJNAm28lp1qjH84JLtEEn0Pzmzc32uVdkEWvUv2TPLieZ4CdWUNaefYeo31ujvS4mE5uXm3SnGEeYwMSzBxi7drrJB+4wB4+YRLv3HlIzBtY0GBS9\u002FOYn3jUN1vtO16gXvPgM\u002FfQbNXthjguCvXHLLpr227+ubPPNaY1z5A+\u002F9cPGfMPeexIcnwkjTTBH5B975BDt5EWOScE4mDLdxsUaCCz21D\u002FhIMCXaM82O1eVHteLMJ2xE2jS4+AdhjHQCcJjDh2k+X\u002F+7ulbm3i6tOawE\u002FFxTPi\u002FZBOd0HjrMect54KAIOBBQIi6PAmCQJghAHOVNwaPo2PsGQSEKFhBGhC4vgNHqgWXZk1osHmZ48MdInyXO0mDulWUb+0ivMASxN0qIBBe\u002F+fWm1euQSLUYlObpkPLBw2xoe07y8R+0NCJTCi\u002FZveBF2zJiU1xCmN4Yun28hDlzcSO3NilT0w4NNWr2Gf4+Cm\u002FqQWUwZaJ+HhO0G6r+0lzfRDvtz\u002FnK7t73U6h5rjmc6Q7wQOfduzbcAAAQABJREFU7q98zGY6mJEx3\u002FWc47n6YORk2s0DHKeFxv4pPZrYk7xo+GU2qfnu51mJes51+VrDsGBy6dx\u002FHLXP1jTX4hpEPOYwb2akA5YrACJ\u002F5MA+26rARzz+bIXzPRodbZe9SoYdXP\u002F47mtas2iBmo1x\u002FwxeVuT+BC90HfPOQNq1ZXPQvznbessNQUAQ8ENAiLofJBIgCFx\u002FBLBws81jr7C7xn1BfwQPHIqmp18aRD9Nn5NobacOAezcGcgsBK4FM7Kv9wK8aZNOow7msJNNY5w06iApW7j9TsQBCxTNAwFoqLH48vX3xirTG6e01rahPs\u002F1+kCZ9gRDZq35BHuNOr4z5Ev6ePRUtSuq2\u002FRIB\u002FOi3q+NoOGsjcbgxEngW7336yPom2l\u002FO7q9NOcBX\u002FZI8\u002Fe\u002FS8zBfue79hyg+zr0pTnzV\u002FrdcwrADMBr3FdTf\u002FgrpM+otUwMJqCZvnDB5HXFGuk6XGPck6BsyPWFwzTlAHut0QnSwnZdb7\u002FuGQQlxMXRmVPQcmtGWEam\u002FBydPXOGJo\u002F8mOb89rNnt1LjnsPxPCsBYN8+8vVXaOeWTWyy5Pz8OWQltwQBQcAFAs4Gii4ykCiCgCCgRwBaUyyKBIm0E\u002Fi91pFKaMWxeLN1+940\u002FL2edFOjmsp1nqFFtubH31xV1gL2Rd21z4dXNOn6jzQW70EL7VQvxLHWC4QPpLZOjYpsV2utAV9zccWKFlBbyWN3VV3+wESZvpjsna05gVzBrALpdYsgEd\u002FjEcY3JRY7YlHid7\u002FMpsfataSnO91LOXj3TQwczLihXSgDnmUWLFlLT\u002FccxB5SErQ23igBsxO6tviW7u4KdtjmXsFunNCK\u002F\u002FDLPzT6wz5UjRcJw57eusgUdYbf+AQeLI35chp9yn\u002FHj59iTbY7u+443hjqhb4f8eLbRfTegGeVz\u002FsMyv3l1Y40nte\u002FeJFo3zc+UYOyQIuQ8dxhAe5DnftT1yfaUFdeAAvb+gxsY28eqKH+nvzPK5v33q97Znvg7SWQgEz+8tV4ypwFXoB8BSQR3l3sBOXu3b6NJg3\u002FWG0WZo13kN0cWgU21xOHfmANTtQ1duuE5toq2HV0w8plXK+PfJ5NIx7MWk6xv3StcJuwEdK08Z8p+3JdnNOnTumCNWE8M8OeZaZNGEcLZ\u002F1JrTs+ofylwxsM7PqNpwO\u002Fl4sXL9ChPXvo289GMaZbFUEHviKCgCCQvAikiSp2s\u002FzSkhdjyT2VIgCSWbZUMSau9kvq4OP8MLsqtDNxAcGMypqZ4Fu7Yb1qaqfNooULeBdOYiHhzt0Hac2GbbSIF42uZh\u002FgMCnAh9VOQATh8xwE1k4O8YJKbDxk\u002FRDDpAXabDsB8dq+cx\u002Fl5Tj52E7dKsgPRP1YnHUjl6sx0WbsblmSfW+bteZXYxDbyp+lbVyOtX6Ig\u002FQgivnYMwx2MS1doghhQ6bMmdmFJZcPfOCDHaYn0BzDC40uH6M8bAykc0No3A\u002FmGMP9DdeGVoHdPQYfdXmTqDI8K4HFsvB1DoHJUeyxeMZ1v\u002FIHD9eWwNmpztb8jWssxM3PG1OhHGwcBf\u002FmkATeERQ7ma5mTODLP1gTImCOvPPmzak8AxXnAVvJ4oXYpaSnDbB1hxYdnml28KZeGHTYPfNGXY0j8sYf\u002F2MEXT3y1+sSFiYHIIxq0KBJD8JsxVGVF6LFp8gbZejEuV2cDmkd2mXXJlUWp3N6B+jqg\u002FywHwHcWeYrVJiyRGXjQWNGRdBPnzjBpjRH1N8F9pkebN668iRMEBAE3CEgRN0dThJLELjuCMA7CMh\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\u002FQelvYJAoKAICAICAKCgCAgCEQkAkLUI7LbpNKCgCAgCAgCgoAgIAgIAikdASHqKb2HpX2CgCAgCAgCgoAgIAgIAhGJgBD1iOw2qbQgIAgIAoKAICAICAKCQEpHQIh6Su9haZ8gIAgIAoKAICAICAKCQEQiIEQ9IrtNKi0ICAKCgCAgCAgCgoAgkNIREKKe0ntY2icICAKCgCAgCAgCgoAgEJEICFGPyG6TSgsCgoAgIAgIAoKAICAIpHQEhKin9B6W9gkCgoAgIAgIAoKAICAIRCQCQtQjstuk0oKAICAICAKCgCAgCAgCKR0BIeopvYelfYKAICAICAKCgCAgCAgCEYmAEPWI7DaptCAgCAgCgoAgIAgIAoJASkdAiHpK72FpnyAgCAgCgoAgIAgIAoJARCIgRD0iu00qLQgIAoKAICAICAKCgCCQ0hEQop7Se1jaJwgIAoKAICAICAKCgCAQkQgIUY\u002FIbpNKCwKCgCAgCAgCgoAgIAikdASEqKf0Hpb2CQKCgCAgCAgCgoAgIAhEJAJC1COy26TSgoAgIAgIAoKAICAICAIpHQEh6im9h6V9goAgIAgIAoKAICAICAIRiYAQ9YjstutT6ZOnTtH5CxeuT+FSqiCQihC4cPEinTp1OhW1WJoqCAgCgoAgoEMgvS5QwgQBILD\u002F0BFatGw1LV6+mo+raO3GrbR27s9UrEghAUgQEARCiMCRmKO0Zv1mWr1+Ey1Yuor\u002FVtLYj96ge+5oHsJSJCtBQBAQBASBSENAiHqk9Vgy1BeEfMv2XbR1x27aeuW4aesOOnAoOhlKkywFgdSJALTke\u002FYdoJ2799F2\u002FtuybSdt5r9NW3fS4ejY1AmKtFoQEAQEAUHAEYGwJOogjvMWLWcN7hY6eiyejsbxH47H4uj0mTOUPVs2ypE9G+XMkY1KFitC5cuUVH\u002FVKlegAvnyODbY6eauPftpxdoNlCF9eqpdowoVK1zQKXrY3bt8+bLSym3Ysp0K5s9LdWtWZYyyO9bz0JEYqtyopWOcpN6MdFyT2n5JLwgAga9\u002FnE7P9XkzRYBxvd7RKQI8aYQgYEHg9JmztGLNBtq9dz+VLVWC+UdlypghgyWWXKZWBMKCqMPu+ZcZs2nWf4to3uIVBGLnLIdtbxcvWpDq1apGN9SpSY+0aUm5cuawjWvcOHvuHPV7+2MaN+l7Yq6rJH36dNTtyUfptV7PUdq04W\u002FKv+\u002FgYXqm5+s0d+Fyo1mUO1cOGvJmX2pzz+3eMOtJpowZqVrlckqbfvbseevtJF2nBFyTBIAkFgRMCGTLlpUyZcpAof6dmYpIttPr\u002FY5OtoZJxoLAdUZg\u002FpKV9EyvgUzSD3hrUrlCGfpsyJtUo2pFb5icpF4E0rAW9go1vfYgxCccpy+m\u002FEiffvk1HTwcY1sBEE5otzNkzKBGnLFH423jmm9MGj2YWt0Z2Maz75sf0ejxX5uTes\u002FffPkFevHpjt7rcDzBlPqt9z9OK9ds9KteunRp6c9vx1GDOtX97pkDkAc0fi+88jZdvHjJfMvnfMP8X13bqEc6rj4NlwtBIAQI4Le1Y\u002Fdemvz9rzRs7FeOv7XJnw6+7jbq4fKODgH0koUgEHYI7N1\u002FkBre1Y6OHz\u002FpV7cihfLToj++dqVs9EssASkKgeuiUT9z9hy9+\u002FEY+mzSd3TypL9ng7Rp09CtTRvRYw\u002FfS7fe1JCyZs3iA\u002FqJk6fYrnMHjf3qO\u002Fr+lz\u002FpwoWLPveNi83bd\u002FKpM1GHSQ0GCnby\u002FohxSrMezlr16TPnakk62gRiMHjk5\u002FT9F0PtmqjC06dLR4+2vYd+\u002FH0m\u002FT1noWNcNzdTAq5u2ilxBIFgEMDAGaZ6A\u002Fs8rzRoP\u002Fw2M5jk1yxuOL2jr1mjpSBB4BojMGLcZC1JRzWwRmzCNz9T96c6XONaSXHhhsA1t+lYt2krNWvVgYaOmagl6Y3q16SVs3+kH8YPU9okK0kHgNmisirzFnhFWP3vNOr8yP1aXLFAMpCgPk5zChhImKekAuV3Pe6vY1t+J1nPbXQrFcqWchvVMV5KwNWxgXJTEEgiAjDRC0cJt3d0OGIkdRIEQoEA1uE5CX6LIoLANSXqo8dPpeb3dqKNW3b4IZ8mDVH\u002FHk\u002FT9KljqXTJYn737QKKFy1MQ995hV7t+YxfFHhUCCR58+QKFIXy5M4ZMM71jBCoDXlyua9\u002FlGX2IrHtClQn5BvuuCa27ZJOEHCDQKCF3m7yCHWccHxHh7qNkp8gEC4I5M3tzD+C+XaHS5ukHqFH4JoR9YGDR1LfN4fYLqQaNKAH9X2hC2FqODHS5\u002FknqMeznXySwt1gIKlYrjSVKFbYNlq9WoE9p9gmvkY3bm7SgDJksLdiatGskeuawONNKCQl4BoKHCQPQcAOAaffrF2a5AwP13d0crZZ8hYEricCt93c2LH425o533dMLDdTDAKJY8VBNv+Tz6fQkNETbFNhseazj7ezve\u002F2Buw+YWdtCMxWYtmlo5PANnvskDcoc6aMftGyZ4+iT95\u002FzS883AJAiuGdRidVKpall7s\u002FpbuVrGEpAddkBUgyFwTCCIFwfkeHEUxSFUEgpAh0fLA13XFLE22eHR5sRcEo2bSZSGCKQCDZifo3P82gfu98bAtWrWoVeWFVV9v7wd5465VuBIJtyN59B41T22Pj+rXpv98mUcvbmin\u002F4yWLF6G2re+gxbziGm6SIkGw4OTbz4dQ4wa1lFvGqpXK0kvPdKR\u002Fpn1JWTJnui5NSAm4XhfgpFBB4BoiEAnv6GsIhxQlCFwzBNKwze\u002FXY4cQeEtNdsWYK2d2ql+7Go0Y1J+VhAOuWT2koPBGIDR2DjZthOuhbq+8Y7tYE3bpHwzsE1I\u002F5bD5eu7xh+n94Z+rWu3mOtSqXtmmhleDoZWeOvbDqwEReHbnLTcR\u002FsJJUgKu4YSn1EUQCCUCkfSODmW7JS9BIFwQgLkvFG3i3SVceiT86pGsGvUBg4bzTqJnbVt9f8vb6Ia6NWzvJ\u002FbGw\u002Ffd7U2KD5GIICAICAKCgD8C8o72x0RCBAFBQBAIJwSSTaOO3bZ+\u002FO1vx7Y+buNW0TGRi5vYgvfGG+rQxUsXqUihAi5SSBRBQBAQBFIXAvKOTl39La0VBASByEQg2Yj6q+8Nc0QEnlZualjXMU5Sbk7\u002FekxSknvTYuMeLDTV+XP3Rgrzk30HDrneTfRaNSXUuJ4+fYbgN79okYKUL0\u002FuZG3G2XPnaNXaTY6zQTFHj6kNK+CXXrdQOVQVRLu37dpDsHUskC8vwfQrsZ6TQlUncz6ptV\u002FMGOAcO\u002F\u002FGHo2j6NijdP78BSrKOy1fb0kp72gDx3Pnz9ORmKMUzX8ZeRfrgvnzEtzbJfdmdejbVWs3UvUqFShTRn+nBEb99uw7QMd5s74yJYpRliyZjWBXR2wgvnPPPjYjvUylOX2o2wTslqxYS7P\u002FW6Swe7nbk9p67Tt4mGIY3wKMLf7gNCC5BTv5Xrp0WXlny5ghQ7IWhxl4bBJYqkRRbTnnL1wgeJPLkT2b2i1dGylEgZcuXaJDR2JCqmyMi0+gvcwHIIUL5k+WbyV+D7v27KcTJ05Svnx5KH\u002Fe3I6\u002FixDBlaKzSRaijh\u002FW8lXrHYF74J7bFblwjHQdbu4\u002FdIQW8mwAtE0Llq5UO6DO+Xmin537vMUr1EstMVVsw22vWrGcN+mYCd\u002FQ4ehY77XdCQhY\u002F5f8\u002FcWb4+NFvmnrTq7\u002FClq4dJU6xh8\u002FQQfXzTVHu+bnbnENpmIgPVgI98es\u002F2jR8tV07twFlTxbtqxUidccPMeehO7\u002F321J\u002FqjhI7Zs1Tqau3AZzVu0XH3Q0qVP54cpXoIffzqBpvzwu7c\u002F03O8iuVKERbWwjNPUn1nnzx1ikayF6VFy1bzB2MX7d1\u002FyGcNCHb1LVOqON17160EE7BQbWAl\u002FRIMAkTop3\u002FnL1W7\u002FM5i8rN7736ffkJu13NAFcnvaHNPYE+OadhNee5CWrFmgyJ05vtwgdmwbk3lKKDVXbeEhFxhoL589Xr1jZjP34HF\u002FO45eeoM7Vwx04+QgMC\u002FP+Jz9S05FpfgrRqcFPTu2jng+2nhslX04SfjafGKNZSQcEKlj8qamZ0clCW45e3brYtfmd5CHE5AAjfxPiNzFywlPJ\u002F4nhm7hLfhd6ZZ8P776ttfaNjYrxQBM+5lzJiemt94Az1wzx3UttUdSX7PGvniGzaH37U\u002F\u002FPon\u002FTNvMe3Z5yGWeLcVLVyAbmvWhHo+9xhhD5WkCgYeeKfj3f4fH7G54Tv9u9MLXR71yfqf+Ut43dtn6jtgfGfy5c2lFoB2ebSter58EiTiAjjjGV5whX+gzxvXr0XfjrN3xuGmGHCZb\u002Fk7+fMfswkKMrOULlmU7ru7BcHzXq6cOcy3XJ+jv6b++Dv9PnOOUpbt2L1PKSPMGRTIn4fuuvUmfk7upKaN6plvybkLBNIwyJddxAsqCn7QA94b7pjmm3FDVMc5RkrGmxipbtyyXT1Y0MQafwcPx\u002FiVOvcXf6L+4ajx9OYHo\u002FziugkYP+JdMr8MG9\u002FdjtZt3BYwKT46sVsWeuNt27mHsKmTUXccN\u002FOf8UI3IkZFZfEjlcY963HQsM\u002Fo3aFjrcHe6w3zf3XUzicVV29BDid4qX765df05z\u002Fz\u002FV4I1mTly5ak4e\u002F2pyYNaltvaa9BYDZs3k4bt+6gTUwCNm7drjQoZ8+e94lvxhQ\u002FIdQHuMVf+Zj6RL5yAS3NpFHvUw1e3R+sGC9D+Lo+dCTwoA75w6PS3F8nBVtUouOnxn6xgoXB2qgvptIofh6sv0Nr3EDXkz8drHZnDhQvMfcj4R3t1K6VTIAHMwGe\u002FvccvwGQXTrMbL3W+zk1gHerkU5gJQfKWrdxK2GXSBw3bduh3Q8ERN3YwAaE7\u002FXBI3gQ8bdj\u002FW5tegM7MRjiN+sGxUbP196n6TOdFSz4jU8YOSjgJoHHWbuJwf2SlWuUomEZDzSOHz+phQrfJnyjICDw3fu\u002FS1u3O+9JcstNN9Dnw972tl+bcYBA\u002FHY+m\u002FQ9Tfj6JybnzmvL8C3s9FBrev\u002F1XuRm749Tp07TGt4FFAM7fPc38fsd5zoFmZmo43vw0quDeMCwxLH23Z\u002FuQK\u002F37upqhgFa+Y38jfF+t1nhgvNtO\u002FbQmbPnfMq589YbE03UN3A7e7\u002F+gRqA+GSquShSKD+N\u002FuB1NfDS3LYNgoKs75sf0co1G23jmG9AcbVj2V+JHhSY80pN58miUf\u002F1z38CYoiNhK6nPNv7DZo1d1Giq9C0YT1qdWdzpY0wNBGBMsudKwf7TL1RjcLNcZ9o\u002FwB\u002FcObyqH6p9gOAuHDdZN0codFdD9vGN+d\u002FLc+TiqtTXaHVeI\u002FJMD44hkAzhXUIS1njrSNG+MC0eawbfT9+mFq3YKSzO97etgsdiT5qd9svHGZFT\u002Fcc6OpliOnAFm0605\u002FfjaPaLjwRGYVB+9Xm8e4+zys+VL2ee5ygJQSZwLT10DET2LziqsZk1brNauq0UIF8RlbJckyt\u002FWIFEzNjb3w4iqd8T\u002FncqsCDxQfvvYtKsAbwLx5c\u002FvnvfFuS5JMwGS8i4R2taz7MEqDZHDzycz\u002FtOVzqPnzv3UqRsHTVWvpg5BdKQ2rkAxLU7+2h9Ntf\u002F9KnHwy0NW8w4uM49qvvglLI4LeK5+BNfg6gZQ8ks+Yupkee7kU\u002F8PsJ5muQ737+g3owSXca9Bv54jd+4z2P0uI\u002Fv3GcLYBG\u002FOW3hhjJAh6h\u002FYdpFNK5kdn\u002FLaYbW7aniZ8MYveC1d0k8cYBQR\u002F+2SQaM\u002FFb7+8Cs6KYCdnPGm+Qaqs6EeZj4yb9oN5vE7jMQGR96rTpinB7C3VxMo4HDQMYAzf9OGzMV+pZQ\u002FsDCWZZbr2\u002Fc6BoSbr\u002FESsS3\u002Fl4DF24cFHlg0Hqc53b0a1NG7Eiaht9wsoEfI8MOXAomu7t+Dw93ekhwuaTbgayH3zyBb314WgjC3WEpcQzjz3Mpl2Z1KzTuK++pzUbtnjjoD7gXbAqEHGPQFr3Ud3FxAZDS1eudYyM6av8efM4xknumyC++fPlTnQxDepUp0mjB9O6\u002F37hqb\u002FAD13xogVp5ewfaexHb1C50iV8yn2ifRv1ov6PtZ85c2TzuVeMba5\u002FmTxK+Xm3bmrUqF4tgmY3nCSpuOracoC1Sx27vkytH+3qQ9J7dX1cfaCmTRhB25b8abs5xCm24273VE\u002FCByGQ1KtVjbK6tB\u002FFVGKju9q5IulGuSALb3zwiXHp6ojZG+ug8oOBvemVF59SJlR4DuDaa\u002F7vU5QPXnOmMNlJLknt\u002FWLgioHSo8\u002F2od4DP\u002FQj6Y+0aUn4XWPnZJgifTH8HdqyaDphI7LrJZHyjrbiA3Oie9o\u002FS4OGj\u002FMj6c93eYQ+H\u002Fq2UmZg8I6NZObx3hjQOFtlwZJV\u002FLt9mMZPnWa95XddunhRtuV1N9Ddf\u002FAItXr0ObUDtxtyZxT295yF9C2T8xNsv97lpQH0xIsDXJF0Iz004x+xeYyTFOI2uP3erVq\u002Fieq2aOOapBvlov13PvQUzfx3gREU8AjTxbotHlDmPYaGH9+8+b9Nph+\u002FHK7e799\u002FMcxvxsHI+Le\u002F5tCHPCALJMWLFHI1MEM+GKS0e6oX9RjwviuSbpT90\u002FRZbAa1xri0PebmdRP4TkK7HGqB+cwzvQbyN2aUl6RnypSBpoz5kPereV6tCwQZ\u002F2niCOWz3Vw+BkOffvkNjRo\u002F1RysPcdMyztDPvW5Bx6E9xu4UfXKFeixh++jWdPG02Pt7vWJtyQAP\u002FSJLBcKgZCbvmCasFmrjo7w1qpeieb+8pVjnGt1E2Trie79vfbNunJ1pi\u002FmeNDy3NuxK81ZsMwc7HNel2cQsPlQIGndoat3mg0kfPaPXzpuuoRpNPxgnHZ+NZtpBCo\u002FqaYvRv6hwBV5QVPc9okX1cvTyBvH6pXLq8GLeeQPEly58d0+WmVzmr7dngho44\u002F4eNlBc\u002F\u002FRqC\u002FNyW3PQQZuYO1PWbYNx3Tqd2xbadWqWhPP+GasK3McvPjvfOhJtcDJyAP9eWDtHK8GzgjHETaITVo+wpqoIyq49\u002FOdaUDPZ81RQnKe2vvFABGDvzsefFL1uxFmHKHBgnZKJ5hSx3vSSWuaXKYvkfaOBn74Tbbt\u002FKL33WjGFOYjP4wfrtUCQmtY\u002F\u002Fa2tjOP2JXa7M7XnK\u002F5\u002FJc\u002F\u002FmEC3d82H8TF7xKzqzg2YK0yBv0wOfmXZwKxbshJYHqQkReiGlpOvN9gIodFi6uZOGNw4SSwF1\u002F1zzRHs0SkX8vmH937vcu21s5ryBAXuNavVV0R3LVs8gNb7tXrN+OWo5QpVYyWzvzOUcuNBYdd+75FU3k9j1WgAMNstVlGjJtE\u002Fd8ZZg7ynmODw\u002FWsMHNjYw3tbseufWnHrn3e9NYTTGyAtGLzIXiPwwzBWf62wJY\u002FEBFv2qgu\u002FTbFl8Ba8zeu4XDgqR6vq3UsRpj1GIzpC8wjO3frTz\u002F8NtMnG2wo2ePZx3zCcAETPd0sCzZIXDBjCn\u002FPfBWKRgYYyMBc1\u002FjGGOH\u002F\u002FjyB6tSoYlx6j6hX2ydeUrOJCGxYryb9xbPKIu4RCLlG\u002FXC0v423tTpYiR8u0vrOW1gT2zhJ1cGisEGv9WTiZJ8NprusCzl0sWE\u002FZ8gLT7R3JOmIhym\u002F\u002Fj2eoTy5wwdT1CsUuK7nKTpoqMyLsJA3ZECvZ\u002F0+zJjee7RtK08Ezb+B7D2NJPAsAHJbqEBeI0h7hM35918MVXbg0HBjym\u002FYu\u002F1oCU9D40PrJKO+mOJ023vvE46HgaBZMBtlTJObw3GO5wC2osazaH6erHETey394kEOA8OHnuyhJelYpAUNlp2UKVk8WQZQduWZwyPtHY26v8Ab59nZCT\u002F7WDu\u002Fd4HRXvxGodmzE5BWkNdAAuJ4+836rd6NtPBw1JldDq\u002F\u002F71f6+atPVP8OZhvqBTOmqsWPRjzdEaYHIOnNGtdTJGn+9CnKZvh9\u002Fq788c1nhDVdTjN9WOA44ZufdFn7hEHTiTo5CTTav00ZTdMmjKR+Lz1Nj7T5H7336ktKMYKBZ6BF0CDB49hkyElgIqkj6VDiWUk68nn0gVYEzbBOoImHhteN1GDPPM\u002FzdzWQoB\u002FXzPlJaaJfeqYTvdz9SZr5\u002FeeMXU\u002FHpHMXLldrGRwjXbkJ72QD2a49VAIlm5Wkw4Soy6MPaIt4gBcA6\u002FoSe99gEGUnUERZSTriwguQTvCtGvPRQO\u002F3NDm+SbpyU1JYyIk6FhMGEoxUw0kCkSo3dYUXl7tbNLONCrI1bfrftvdxA2YKxkLBHGwC83yXwC8UpANZr1S+NE7DSpKKKxYVwWzFKjAPgq2dTpwWje5kzxtuBZr6SuXL2EaH1gF2obc39\u002F94F+Np1o\u002FffsU2LW5g8ZAbWbHGX\u002FMFDyLQxtgJPMy0+Z\u002FHHAueHUIt0i8eRLHYb+HS1Vp4uzIZCOSWM6kegLQFuwiMtHc01kDoSB2aCs8btzRt6NhqeJuwE5CSfm9\u002FbHfbJzzQIvDJn35AQ995xU9pAheGMFvUmeGYC2jHZlK\u002FTBpF1Sr5D\u002FLRBnjmcBIsRnQjVTX5m9PdUKeGrWcOzBJNmziSsEbGSWCeFJ9wXBsF3rp++PUv7T07M1Ks74KnGzvZFcS7vWqlcnbZqPBXuj+l+lGnoYcy5tYAz5vbdzsKC9QXjhU13cSizveYqFulHZvbYVZGJwXYdSLMxHSCGRx4xNHJCl6IrBN4QrITLLJ+mXGFYBbRzTvILq\u002FUGH5diLrVg8b1Bj5bVFRIqvBUx7aO+cAez0m+N728sKLd7gemyyNUbdDlndiwpNbJToN0V4umttOqhfLb25PCHMWJ4Frb6eQ7Py3PooCs2wns9OrXrmZ3W3k1wJSgk+CDZrgmM8dDMpBEp\u002FSwX4e2JBP7kw61pPZ+AZ4w\u002FZn03S9aaKH5e5S1kOEqbj6S4fKOhmlfn4Ef2EIJN6SBfHk3blDHcdAEk0U3GtmorM7rgYo6bK4HrWIgxUuuHNltZ8oAQHcm6nZaZdzf43IXbry3AhFt5GcnNzeuT+0fcH6+MQv604xZ2iwyZ8rEMyD66edWd9yiTYNAp0XxO9kloFuJyuLcjzBdcpLnn3jE6bbPAmbHiHwT72i792mgtMZ9fAfsBpswv3KSIoUK2t6GFYBO7Ag5PP3B1MtOOjzYikoWL8Ka9zyu1ovZ5ZMaw0NO1N2AGJcQeFGfm3xCFceJcAVTBvzawj7PTuBvF5te6ATeAuAPGIJFJs\u002FyyD0YSeqPPZiy3MZNKq74sMG9olmAzUtPdzIH+Zznt5l+MyIZNqDGtdMxqZtrYNrdTqDJw+YsTuLkomza77Oo\u002FTO9bV+M5cuUpM2LZtDCGV87FZGoe6m9X\u002FBh7PU6Bkp6+GCn6TTI06cKr9BweUfP+Ps\u002FdkG7yxYcPOeBBDMbTdjW2EnGTXI21UBa2JAnRWDu5CRYlOwkeJ+WKFbENorT+8KaKJCXFGt86zUWR8Mu3kns7PKzZ4uid\u002Fq96JcU2nSndyY2dLOTnSYPJnZxjPAMbNqYFHGqI\u002FKFa85gBB5SkiIYENmtOTDv16Irw27AhLhYy6ITu+cM39Zb7ntMuTPWpcMzN5sXl25d\u002FIfjbLUubWoPc\u002F6lJQIdpx+TkZ0b7xtG3GtyNAx6k1gYtCbw4GK36AUf9q9Zq46XnFWwKYHhwx323TCfiHhJIq6w4fv3pwnsdnAiexKYT5kzZ2Z7yZa203XAKx2brDgJ\u002FBPXc4oQwnvwNOAkB7ku2D3RTgoVzG93S4XD40Gt5vcpN42d+bmz7oqIqc3kkNTeL9iIBG7x7ARu5cJZIukd\u002FbONVtbA1+0uxNgF2+o5ycgDR9yDeaLOZtccLynncCPrJFhgGUhKMlG382l+JCY22dtg1A\u002Ffpw5tW9Pnk38wgvyOcKtoJ\u002FA8UoXNRUd+Ppm2834gdWpWVX7I7eIj3OndDg9U10qKFnZ+rx84fO3qgjZP+eE326bD3HM3KwfPsTvLc7xRFxZlnz13ns7zH3YoxYZSdoJ0OoEHoZ279WakGFRjoenj7e4nODKwevezXuvylzB\u002FBJKBqAcmB7rFgf5Vi8wQLHqBb1EsNNMJdvDSEfXvf\u002FnTG71rgKk1b8RUcALtCxZ2uvFcgg8t8HUSw6+sU5xQ3QtkunTJTiV7pQJFmKiXKFZIa\u002F5i1DE65phyBwc\u002FxLBh7cQL5wLZRhtpk3JMzf3yo8WrghVHJ62nNe71uHYzgAuHdzR2AJ0x+z9HiPLx9uRuxGlAjPSwm8V6kGB9gLsp24iTO5E7PxrpcXQi+3idXLrMgw1yVlaY80vK+R23NHEk6tiMz0kweMKfG4HdNzZrspMLbCJ1rQTvV5gg2ZmHXbrEHXGNBC494VXITjo829fuVsBweC7SCTyc2RF1xAcucPP41bc\u002FExRI3Z7s4KiQ0pUhYb4IhPwXXbSwvc2TUTRWuLvxgGLEj6QjFr1g23o72b5zr7JvNd+HJgXuDCF1alZRbr3M9+XcGQGYkUz67lfllvD190c6R46gu54Zmgdc1Rir8OHHu0bTVmqTFif7dVcZhiBSSu2XQJsF5bRZvBUCSEOSRaS8o7HzciA3p26Jum5hoBXMYE0WrOmvxbWTVvlalG8uI9Cg5uDhaHP0RJ1jd80X+7+n9qtYv2l7ovJIyYn+nrvQdsDgtt0wqYKnH\u002Fh2h0tOLGqeOvZDerKDfs1dF96g0c1kOfYSGPHZZP4mtVa7l2JQIZI4BEKuUa\u002FO7o\u002Fg19TYvMCuWvBwovOYYRc\u002FksLhDmmKxj+s0Yavp\u002F2uNgUwrmfztKsxcHnK5sdhxJXjVQRgQwcNOhbpGhpAbE5imBBdjRm5Z9BGzGb\u002FvU4++s2tg9egXq8N5q3H57BLrDeuiyYjJfcLXPDpXJOZ++B6eXMx18HpPFLe0YddeBCzmnvZtdsNUQ+0ZsQu79QaDk8eWBul88wFTPLmyZUoaLAgEZsHTf7hV6\u002F\u002FeJgkYRFiMLtGJ6rwCEu0Y9de2xpj4eYj97dUfv2z8gLabFFZCTOh+C1AoYjFy9h8Kdi1ZHCU0PeFLmrjMdvCTTegsBk9\u002Fmv6g2fHvhj2DtVlMyeR4BAIuUYdK\u002FCbNgxsBYwtnlOqYKU1Rqd2Al+nsBUz5Gve3hiSN09O1sbfbgTLUYMAFuNip876t7VVG8Zgig0kHS4\u002F4eP37x++0KSK3CB8oL4c+R5hZ9tgBFt6Y\u002FdF8\u002FbNwaQPNm5q6Rc39qcXLwW2NQ4W31DGj5R39OHo2IDNxi6rbgTEJJCcPH06UBS5b0HAupO2+XZBh8Wf5ng4h3efGbP+o8df6Efl6t+h\u002FHgbmzzBHSL8yrd0cH9szS+1XDt5cMKMLLx\u002FQdkD5SE29mp5WzO10V4VdnUJM6pgSbqBK\u002FKF6VMwAnOZ2x54giZ\u002F\u002F2swySQuIxByog5Um990Q0Bw7TavCJgwQiI88Wgb25qCWP45e566D+3B76z9hHR66N5rYl+sCougf2DGAXODOx7sQtVuak1v8vbIZk8QHdmVJXblg4\u002FfpK7oD0dYoLn6dfJoZRYVTP1iYuPUrrvQaCSHpMZ+iY61919vYGzM7hjX4XiMhHe0k6s3A9MYF\u002F2BuNAeBhK3C1MD5ZOa7md2cFFbvFjhgFBgEWj\u002Fd4dS+QZ30kNdeqgNe4z3FWZHsaHctAkjCMRSxB8BLCC2E3hhCeRJyC5toHAMAr4c8S49fP\u002FdgaL63McasR4D3ufvt\u002FP6BZ9EcpE8RB1eSwItaIMfYmy3npxi\u002FOCTswy7vB9sdSdh0yI7MRY9YhMk1BNukuAxRsQXge279qhV5O2f6eO3uQymXbHj2chBr\u002FptMuKbS+RfwbUbdsbr1fXxoDxTYEDz+vsjQg5Aau2XQAuEAXQkmFBEwjsaA9RAEnPUnUY9o4v9BNwssg1Un9R2P\u002FZYvG2TA+3k+v6IcVSjWWtlx2yYfhqZYYfWeb9PTrHmsUY7k3pMlzadYxar19t7p3JM6OJmVNasNJbNK8cPf4ecZlasWYHvdHnx\u002F+ydBbzUxhPHB3d31+Lu7u5OcSlQtHgpLsVLcafFoWhxd3d39wLF5dGi\u002F\u002F\u002F+ArmeJJu8d\u002FLujtnP571L1rL55i6ZzM7O9HWIuG1fj\u002Ff\u002FI+AWjTpW2Detpx+2WT38rD\u002F+VDdd\u002FgmvK\u002FnK1aU6LTrTqbMXXd6\u002FUYfwowz7ML20acc+wrTt7D9WKFVKFysgzBuMNRB6\u002FfljPhaTFa\u002FWlPQWEQ0VYa3rSRj7GxP4oUWEwwMiJDmmMM2m5Ws3m61qqt7XfF1kAbVUeIiX4O3JF+7ReiHJrdmaDWD2r4lZpQQG7lCtj8vbwruH8MrzUnjL0UpYbFhBBKbTSwjYNmT0NOEy0NFbS8L4cWjl3EkOrv30+vqa843WAZw4c97teGoK\u002F\u002Fendq4keKuTBeSyHgheIK5cv2mdxdsSAm4R1HE8RFEzCogArbK7polHCztm2ERt3LaXTp1331ulhK3iS1Sv\u002FL3wa9pv+ARLoALWpjuSGvjLJBHB7JVjwZccWWhw3UY+VIC1CyMn\u002Fk72\u002FpXTfZNSWZW\u002FaekMypnNeGEOXDjKbBkDi+Rrvi6wdTaaLURMBOs1KIHl66n63n6PzpYpnRL8TcZDL4CcfRuj2VWscckiWVdk3x\u002FvEz2SBGxD8D+9SKJnL16RunWEkwl3+rP3p2tn5MEJizjfvHHd2ovdB47Sr4psddcGY8wY0WiYUJwd37acalcpa8orzNkLV2z64B19Am4T1BFOuWWjOvpHFiXwXdtz8GhpnaAUIpzwmGlzlKZ4sy9bvFBQunG6Tfo0KSlfLv3gJ\u002FOWrFaOgYWCRtOETg\u002FGxzqAT3TVdl9r6IhY6u8asKFjp9PgX6fS6i+uO+055M+Vjbb\u002FOUsx\u002FzFaFOSqm+LXfl1gm2lk3w3lw9TZro8Ia3\u002F9nd339ns0PFQYhUDfuuuAKQxGmncIh1hky8k8AbhZ1kp45g74sb1WkZK3dvNOkvkaL5o\u002Ft25bLrAlUCB3NtsMuz14qPp1ymy73KDvwsPaQLFGbMJv8zU7gVXA7+MG0zbxXILXGVk6c+GyrJjLrAi4TVDHMQb2aC9utHKNH9wY7pA47Lcaq+nNrv1HWnyL4kZvFOzCdMdBqNjMhAkQgtSENIioGYRD+3STe\u002FcfkCw4kUybIztxTwbGkI3DTFkU4U4LCVoRvQTBEeY\u002FaxdOoUgRw+tVU9ZA6BYGooCvC1GNivpxElSUIyfOJCPhUK2r92kUEEuvXWDyvf0eXaNiKenpQBCBhtYoYWGdLFUrX1JWzGUaBDbt+OwQwb6opvBclj1zevtsy77RtXj05KmlrtkNeI35GlP2LBkUd9iycx8\u002FY54wM7klq2JT9unTJ93FnnDxiARriBcv9We7IXdBWE\u002F3TQqbvq13WOaxpiHfdqugHjZMGJo3ZSTFiS2PHteqcz+C3asrEsxJrLUs1SoY34A\u002FGvzIP4ovblBTtQqlFNeBeu1Dhw5FjetU1Ss2nS8TQD8J7bTZZORaDhpVs8kZrqGEPbYswSTmrgiBHNj0xOTiM\u002FSLG5Yzyeh7YxSUSLU\u002FPHTsNO3cf0Q6FAQf6diqsW4dhPx2ReLrQsr6AEz1yhJsd2Ei5EyCz3Z3J2+\u002FR8MTVuxY8kWlqgctGStEttRL2TKnM7fmwyCSsF7\u002Frsz\u002FH3ku6qXRuJdaRdNW6yKS8sgB3dRdzc\u002FQBvf2oLiUlS1qtR8Eorc6m2QzAkb3dftjyxRSRs9bzAJ1bt3EvkubfUQKLVmjmZiZ3WGTr7WDGBjFqzelYtWaaMpk6jNJCWako1VX+8Xi7NE\u002F\u002F6TuOny66pnk0LEfZrhVUAcvTK\u002FOmzyCIkf+\u002FCamxRD+civVby1syu9qFZvOGy2meMZOm2tT34ym5LWBDZeRfaPNAe12YJIA\u002F6V6CQtu9Gz59Npo5QdIzuHft2\u002FJ7M3jdYDcni0wvoad4YrvjdEDesiYaVoopHkHA7HQL+CNfiS1d+\u002FeS4+DQqMFbFjwLEvx4sa2FLf7caChq61KZYtZ6ltvJBVu0lKnSGqdFeRtvi6kBA7p372dIcM5i1ZR624DKKgCt8z1muHBA1HBm+\u002FREYRnp25tm0vPZtWGbYb3t12SF92hvTsLm1phr2GQ9AL7qM2MtLpG5W8N7gc4jtEYPoi1T55IR06cIXvNOLxwLZw6iozcXGbNpB9jBGNfunqjppAoOy+8GJv1Ihdg8Ix7a3Bvx5ohrDHTS2\u002FF8zYwSfrsNrEIukOLBpQiWSLpIaHYatjmR+rYayjtOXjM5lmCCLIIqte5z3DhvKEJnTh9Qenrn38dFQXWssroKXPo+Gn5YtVCeXNoKirxcytRyNiNt\u002FSkvqJCtwvqYFkgd3batnwWJU+q\u002F2WCvRv8ZG8W3lCCkmATOmCkrQYL9uFmPKk8f\u002FFSekjZFI+04ZfCZvVq6FYzYxqj29iq4JnkHKAIMuOTGN09e67vbgvlgWHhLNccWeRmUwuWraXBo6cowTIwNiyamTzzD2zqJvhj7zVkjOIJCPZ2MsEdayj0Em7URg9e2Q0Y\u002FRoJcBCg1HTn3kOCSZcsRRLR57QSFiq7cprxa78uYNxE+O7PmzOLFm6bPJj2lajRlNZv3W3z24G534x5S23q2u8sWbnR5oFqX+7KfW++R7dp9i3BK5ZeOnn2knRNAGbeoCnUSugbwoSZZHQPNVJMGN0PzPi8Nh6DvnLBzDmizvnL1wj+zfUS7rMQ6qwTooYu+X2MqQW5OQ3u69AA12vV1SZYG+7Tew4dsz6kw3bTDj2VoEl7Dx3XtaFGIyPORosvDcsDMRMGZZBMo27meYvovMP7dnXgoZUxS3iZq1ivNSXJWly4xqxGybKXpLT5KlC1xh2UBb6YKcBC3rkTh1Pm9GkcurB+JmHcLbv0M1ysGkl4wLNPJYvkFy8Xie2zeV+HgEcEdRwbCyt3rpxDhfPl1BkKCc8UT6hW807Uqmt\u002F6Y3CuoOT4gYMAf\u002FHgb9aZyvb9WtWdMjTyjCaOsVD1pmkt6gU04TFXfBWiTfi0wb+Us2cAzxV6Nkdque\u002FZed+ddPw01muP\u002F3QwtC2euSEmZQ0WwnKW7YupchZ2mFGxX6QmEqc+NtCKly5EbUUJlcz5moLS7CTNPJBa8QcWidZOnD0pKyYUiW31YIvXrFB+W3ALZpW2n3wqEM23DgiMp0r09d+XcASLz4Lp\u002F1CKZMbP2zgXvTbll2Vh2KmwpUpQaYiVLVhO0IsCVmCCUDmIlWpRtMfxP1tlPSlUtaP2TJvvUdD2z1j9CCpvSuUNHrmk\u002FDXrWVCgN8GPFWYTTsN1lKdNVgcd\u002F7SVemhTgo3wjJvQTiHY6fOSftQtaHSSgaF0EznK\u002FctLV210aEmzAGbd+pjI0TD5\u002Fm+dQupSP5cDvW1MnIIu2os3pUlxH8oVLEBZS1WjdIXqEhlarWgq9dvy5ooGnUETarw7ffUe8g43e\u002FD5p1yZaDRfd\u002Fovn7u4lXTirGN2+VjwYLLO\u002FfuS88bhfCAZsTUuhMo7zAjouV1b9TAH3VfjO2fSVeu3aJydVvqymuIt4F1JNYJ2v+powZYZ\u002FG2AYFQA0QyqOOyYkxj1q1eXjH1OH3uIr0O0H77h4eKybP+sDyYQgk7rHAiYEW4cGEJb6Ao37H3EI0TiyS6D\u002FhFfJEfOowRC+smj+yntHEoFBnQTEDL0mPQrw6BdOzrnxOLlf4W5jmxY8WgGNGiiuiXcvtp+\u002FbYR5s1m3baFLUXU1ayFxebyho7MBnClG6HnwaTUbjtXcKtEuzho4kIfdGFizlrDStc94Fna\u002FGCBJeWsoSHCUyBYkSPRgj+At\u002Fe1smVXBHi+LlYsHLkxFnrQzhsQ7uNCIV4w69RqRQhUMptEze3SJEiUHWxWA3eU9R09\u002F5DZXEzpgj1vBqodbGIDRHzYKJizfOe0EZNEN9NLRtOtS0+Twu3obDXjPPle2U\u002F\u002FY6p8LlLVlk3Ub77cJGF42IaUm2DB3jbHwcJLf1\u002F0675c2cVbhx\u002FFW5Sw9j04ezO135dVH7QFJUrUZi27N5P9gFb1DrWn3g4YpYG31cEQytdND9dFg86WYL51HVhEnj05DlKkyo55cup70VK1o\u002FZMm+6R1uPGeOqU7WcEFTP0q27joILfvv7Dh8X99NcpNrRoj3WLE2bs8S6K2W7Ye3KyvMBNvqyhFkv\u002FM4Hj56qaGtldSGIp02dghInim\u002FjQQbPrH1Cy4sInHCVqpdwX4X5J16Y4AZU\u002FW1DOMZLSO9h4+jQ0dN6zZX8w0I5ANtgrKFQF\u002F5pNRg1aZZ0RhBmebBpXrB8jViIeFtooV\u002FRvKVrqIvwf370y\u002F0YQfp6dmylBJyDh57ApAJ5stOcxSuFH\u002FX30mYw2cAzBevcOgqFA7TlZhJm0yuVKUoxxXMKCdcR12fSzIX02\u002Fylmi9uar9w+RkhQjhhAZDYhiFeovYfOanIHLK1TvguQphPnDCe8iyCxts6wQwVQvKf67ZQvxHjhUba0cTEuv7G7XsUcyIwxvNbL1UuW1y4M34hzFG0Z4\u002F02qn5kFEG\u002FdSe2jT9Vs1y+IwSObJ4ts23+e5AwbpszSahtEiiWDCoMgHkiqbte9o8R3Ed1\u002F8xTWHj0Dln6BIIIb404vHh+YSb0ox5Swh2TmYechghhG\u002FY6JkZcfP6NWjskJ6aJwY\u002Fx+XrttIsM8rEzenyoY3KzdCornU5bnxp8paz+AXH9NK5vWsIQk9QErRECBgRlISV2Ic3f354wUVkux4\u002FB6UbRduNQAeqGyZ3cMUNFuNbtmazdIzw7PProB5UpVxx5cFaumZz8VKnfQOEH+zvGtairm2b2thTNm73E61cv016HK3Cgnmz04ZF05Ui2PphGjGwqWr5EspaDut2eDBkERpVvRcGPIzhngth7Y+ePGvz8ClXspASNS66eLF0R\u002Fqar4s9TwhiP4gXu6WrNtkXae5Dkzv65x6EFy7M6shSrJjRFAE9XeqUBOESi4Y9lYLzHq13jvhNjJs+Tzw3ZpOWrTFid8DjBAQ0KGLstXn4zQzt3Ynq16ykdwhLPrSZ0Oqaed5YGokNCGjn961VshClFvd92eJD67bqdpH8OYUnp6nKLoL2IR5IYNOogd2pVeM6ms3iZyhsaO+u2fBLZsZ0qWhEv26mtehafcHpQ6uu\u002FYSS5blWsSWvdtWyNLJ\u002FN0XoxWz7oj\u002FXW8rsN7JkSEN9u7Wxccl8TgjoBcrXC\u002FR1RN\u002FwpqXOFJQSzxSjWTD78cAWe78IUJcxbWpLUeUGbYSCzXH201JBstGyUS3lOSepopjZtesxiJ48lZuxWveBl0PMWpmJJdCk\u002FU+0Yp32cxLPVryEIR0Rz6RXrwIsh8mUPjVN\u002FWWAqWNYGvGGQsBWHepBKFhkiSl52M9uET9Y\u002FGi37T7gcGO1HpKe4KXWgbCWVQTJyJU1IzUSNqR6SeYhRa+Nmo8bblC8geALDDd6qqs9TFMFVUjHWJw5B+sAOtbb6jma\u002FbRn4cyY7PtSxwBN2kwRohiLbjv3Ha5oJNUyfOKFB54hBvzYTixa+SyUZkr3DS2aMVpZyGf9oMaMQqPaVehHYVJjbWun9idbIKTW0fqEBkVN1ttqnplPrXbQ9h3btkzRCC5YvpYwzWid8IK7dvMuSxZYVBdehrqIFxAwcGf6mq+LPVeE0v597GD6vnFdwgv01l37NYUCmLoN7PED1axU2r4L5aUXD3M8KLOKv8wZ0lJ6EdjKyLuMQ0cuzAjOe7TeaeA30b1dc+U3P2bqHKH13WYzo4pIl\u002FsPO5qUQZnwfZM61FysF0LUaDPpo\u002FhdB1ZIR7\u002FW90E8KwIrpCt9iAWLanLFfUnty5lPfBcxq9FAvOTgOetsKiVmlA5tWkztxYzwhq17HLpLlSIJjRC219YmHROH96GQQvrF2g\u002FrhLgavTt\u002Fr9z\u002F1JkItRwmQ0G5jmj\u002F0eo6BOVZiePam10ZrW1Sx631qfWcsK+HZ+WBDYuEtcAohavMaQFM9\u002FBMxOy+vebfvl91f\u002FaEYcJL0kaCvft+ofS0Zotjbd9zSK2qfGItD5RiiGdjf21sKvKOLoFg06jrjQgLWXYLcw5oEZ88e678wawB2++FNgXTPzC5iBk9uqLJTZksMaVMloQypf\u002FGJd5T9Mblinz4Mh36xVNJi0a1qeCXN09X9P019IFFPIgyi3UJJ4QJDqZ44doSJgFaCVrfJcKDAGwGYUbS8ftGyndFq64v5OH7c\u002Fj4aTFjcFX5PWBRVIK4cRQ7adgOQshLnCCex0\u002Fla78u9sCxvgFrOWAmhulfvNQUF5Eaa4mIfdZBdeByc+O2PYrGDvcC2bS2\u002FTGCc9\u002Fb7tGw5d8rPFk8fPSYoMF++vyF8pyIEyum4u2oWMHcDus9gpOfNxxbplHHrCQ08bsPHBEucB8qplpVhZ95zNIZmQoF9dxgCnJchLs\u002FeeaiUNY9pJJF8lGdauVtfi\u002FWfcPUb6tQ7F0WtuyIgooZEigqONkSwGwfFKFYPwHzWMxeIApvssQJqVihPE6b0qFPPJMwe4VtKI+iCbM+mMHgmYTZe+vZBNvR8Z5ZAl4nqJsdONdjAkyACTABJsAEAk9AJqhjxmfWhKGB75RbMAEm4BYC\u002FArqFqzcKRNgAkyACTABJsAEmAATcI4AC+rO8ePWTIAJMAEmwASYABNgAkzALQRYUHcLVu6UCTABJsAEmAATYAJMgAk4R4AFdef4cWsmwASYABNgAkyACTABJtbYXbIAAEAASURBVOAWAiyouwUrd8oEmAATYAJMgAkwASbABJwjwIK6c\u002Fy4NRNgAkyACTABnyIgi3P4PwqWGIg+xY8HywQ8SYAFdU\u002FS5mMxASbABJgAEwhmAv++fas7glev3+iWcQETYAKeJ8CCuueZ8xGZABNgAkyACQQLgVevA2yiSdoPAsEFOTEBJuA9BFhQ955rwSNhAkyACTABJuBWAqs3bpf2f+I0IoRekNbhQibABDxHgCOTeo41H4kJMAEmwASYgEcJwB79zPnLdOPOPdp78BjNXrSC3r59Lx1D2LChqVqFUlQwTw5KnjQRpUudghLEiyNtw4VMgAm4hwAL6u7hyr0yASbABJgAEwh2Av\u002F88y\u002FFy1DYqXHUrV6eZowe5FQf3JgJMIGgEQgdtGbcigkwASbABJgAE\u002FB2AiFChqRsmdM5NczkSRI61Z4bMwEmEHQCrFEPOjtuyQSYABNgAkyACTABJsAE3EaAF5O6DS13zASYABNgAkyACTABJsAEgk6ABfWgs+OWTIAJMAEmwASYABNgAkzAbQRYUHcbWu7YHwi8fPXaH06Dz8GHCLwOeEMfP37yoRHzUJkAE2ACTMBdBHgxqbvIcr8+RyDgzRs6c+EKnTp7kQ4fP0O7Dxyl6hVL0cj+3XzuXHjAvkEArvNu3r5Hp85fUnxX7xHu804IH9bXj26m6NGi+sZJ8CiZABNgAkzAbQRYUHcbWu7YWwn89eBvuiGEo+s379CV67fo4tXrdPHKDbp99y\u002F69Ol\u002F3jpsHpcPE4CLvOu379KNW3fpmvjeXbp6Q3znrtOlazfp1asAHz4zHjoTYAJMgAm4kwAL6u6k6+a+oY07fe4Snb98jeLFiUU5s2akaFGjuPmovt39rTt\u002FUeYiVX37JHj0mgTevX9Pu\u002FYdod0Hj9K+Q8dp2cxxFDNGNM26ns7s1Hc4\u002FbF8nacPy8djAkyACTABHyfgckG9epMOtG33QaexrJgznkoWye90P\u002F7awd37D6l11\u002F7CPOOY5RRjRI9Kowf1oJqVy1jyeMOWQOgwoSlKlEisxbTF4hd7C5atpY69hlrOZdnazdSqUW3LfnBuxBBmLCFDhuAZm+C8CHxsryQwespsGjByktNj69KmCQ34sb1DP32Hj6dx0+Y55Ac2I0QIosiRI1FU\u002FEWJTFG+fKZOkZSyZkxLWTOlo7QigmuY0K4Rq5p16EXL124J7DCDXD9bprS0e838ILfnhu4j4JpvlPvGxz1rEPjw8SM1aN2dTpy+YFP67PlLatG5LyVJlIDy5MhsU8Y7nwkkih+X7p3eSTB\u002F2bBtDw0dO40ePX7GePyAwKw\u002F\u002FrQ5i0V\u002FrvMaQX143y7Uv3s7OnvhMo2bPo9Wb9xhM1beYQJMwLsJiAlsRcEDU7V79\u002F+2DHbrrgOW7XDhwlD2zBmoYe3KVKtSGYoYMYKlzNs3Xr\u002F5x9uH+NWOz+UBj+4JAeiiMMWAHeaiFevp6MlzpuDiC96kbjXKnT0z4Q01Y7pvKHy4sKbafm2V8JBv2OZH3dMuU7ygmPYfq1vOBf8R+H3BcurcZ\u002Fh\u002FGXZbrZvW5cWkdky8cfekWIBZpEpjh6Gd2LGcUiVP6pAfnBnvP3ygLML8yvphbz+e2ye38WJSeyi875cEXrx8RecuXaWrN27Tjj2H6M91WwhCsZlUsXRRKluioPIbzyRkBswq26enz14IJwGXlfVIS1dvpANHTtlX0dyPED4cFSmQixIniE\u002Fx48Wmt2\u002Ff0ZOnz+nh4yd06Ngpsf1Cs52aGTVqZPq2Wnlq1bgOpUmVXM02\u002FYlF5hj3dbGuZcnKDYqjA6PGYcOGpkJ5c1KsGNEpZKjPTv1gIvvu3XsKEIL4Xw8eKpzfvn3v0FXsWNHFInbPafAdBsAZugRcLqjbH6nf8Ak0dtpc+2ybfQjkR7YspWQcptiGi97O0DHTaPj43\u002FSKKVGCuHRhv3P2sLB7P3j0FDWvX0P3OP5QABv\u002FQpUa6p5KcArqX8s10IUfiIJOvYfRzIW2GnU07\u002FHDd9S7c+tA9OSZqt+26krrt+zWPRgL6rpoAlWAWcYFy9dQ4zpVFXOFQDXmysFCYMvO\u002FVSzWUfDY88cN5hqVSlrWM++Qv8RE2jMVLlMkiJZItr25yyKHTOGfXNlH8IvvIMtXbOJfp+\u002FnN6IxeJ6CUrIwT070vdN6upVMcz\u002F9OkTwYRnwowF0ro9O7aknp1aSevAu9kvE2fSxN8XCAH+g6VuGGEW+uTyf7MDlgLeCHYCn1+53DiMts3rUagvb3Z6h6lcrjgL6XpwNPJjxYyukftfVszoQV9AhxvC+BnzqGiVRtRj0Kj\u002FOvXTLW9cfPu1XQNnv1p48CwRmjKttGjFBqGdM6me0+rATXne+L1z06kGW7cQ+PKWrUO9Bo9VvOwE20D4wIEiULpYAWHrnVzaJnHCeFSjUmlpHb3CNs2MZRLM7usJ6eg3hDBYz5Y5PQ3p1YlO715FTetV0zuc0MS\u002Fp+4DRlG9Vt0IL45BSSFDhqQfWjai0KFDSZubUXZGihhRseU\u002FtGkxxYn934vI+\u002Fcf6NXrAGn\u002FXBg8BNwuqMePG5tSJEssPbsCubNLy7nQlkCxgnkIb796qVTRoC3ChXvCivVbU5+h45Wbi17\u002F\u002FpSPxaXelL7Ga+As\u002F2VrNtPr1280u4GXn4NimtrbkqsWnHnbeXnDeN6IKX6Ys0Er++DvJ94wJB5DIAkYyQR5c2QRi7ODJr6YkUkSJYhnesRxY8ek8UN70\u002FTRA6Xmuuu27BLmeY3Ed\u002FKx6b6tK8KzW6Z0qa2zHLZDhZIL8tYNYBI4om9X6yzFtMcmg3e8gkDQvumBHLqRhlfLriyQh\u002FiqqmNleb9ubTXPOUPaVPRTR\u002FnUl1bDeUtWU77y9YRbuxNaxZznAQJ8DYIGedYfK6QNF\u002F25XlrOhf5DAIHKClSsT1h7wsl3CRi5VXVWZjCSSSJHihhoeN9Wr0DLZo2Tar2hOKjzXSfCy2RQktFsemD7hOlQobw5LM2ePHtu2eYN7yHgEUE9bJgw0jMOF5YXjUoBaRR2bNWIlvw+mgrkyaYsoMmYLhV1bt2YdqyYTVgEYzY9evKUYC\u002FbrsfPulpJs31xvaAR4GsQNG5ohTUGx0+dl3awYv1WevvunbQOF\u002Fo2ASzQHTRqMpWt00IEMrvr2yfDoycjmSGskzKDUf9G5rp6l6hI\u002FlzCrKSdXrGSf\u002FLsJcU7m7SSTqGz563VbaM6VSzZeBZx8j4CHhHUjb70RuXeh807RlSuRGHauHgG3TqxjQ5sWEQDe3SgCBHCB2pwPQePkS5qC1RnXDlIBPgaBAmb0mj2Irk2HZWev3hFG7fvDfpBuKXXE1i4fC2NmjSLPn785PVj5QEaE1A9lujVdFZmcLa93riQD1tyeF6TpbWbd9GaTYF30Ro6EKYtsuNbl1UuW9xissOuiq3JeM+2RwR17zldHok9gf998r6FdvZj9Pd9vgZBu8KYPl68SnsRqX2PbP5iT8S\u002F9j\u002Fxfcy\u002FLqiPn03fLsaepqCg+Ve4fAzuBDOf8cN606IZv1KlMsWCezh8fA0CLKhrQOEsJsAEvJ8AovYh+AgSzL5kafPOfQR\u002FypyYABNgAu4mgCilJYvkkx7m9t37NG3OYmkdTxXCvr5CqSKafug9NQY+jj4BvxPU4YoNQQKev9B3gwR3brBtldXRR+b9JXf\u002FeuDVg4Q9KbybHDt1jhDUwVP2w\u002FhuwD3W5Ws3RSCus8oYPokor19jgonAw0dPlN8KggUhUiuuiy+lmV8ikUaKGJ5+7PAdIQS2XoLrseXrNusVuzUfWrO79x8SOJ+9eIVevnrt1uPZdx4c1xrnCTev33XsYz8cyz5+iycEEyyw8wbNomVgHtjANQEj3KvhjtWdiZ+J7qSr33eHFg30C7+ULFrhXLwTwwNwBb8gENrXzwI3IQSG2XvwGO0+cJT2HT6haM52r54r\u002FJz+F6XsgxDI4FVjknDyf+X6LUvkM\u002FgdzS78ofYSQQLSfZNSF8feQ8dp+56DuuWygpqVy1DGtKktVfAWDSHJKMGOzihYC87\u002F4pUb4ryPi4hrJ5XPF0IQuH92t273eDDOWbxSKcfDQi99+PBRWaBlXw47+O7tmttnS\u002Fexmny5cKO3WERYg4BuPVWNgBAlCuejFg1qEXzouirhYXjo+ClCiOetuw+I8O1XCOdkndxpq2h9HPvt4LgGWCi0bPUmweKg8O5z3CFIh3ANTOnTpCJE+6si7BahFfLWhJfxY1+iHlcSY4Vv4BoiZDcWauklmL+0bFhbr9hl+XC\u002F9vk7t5927T+iGcHQ3d87T19rCJy4924T90hEl1Tvb3HjxHTgCv\u002FmoybPdIgQmSNrBqopfGMjOJEZP\u002FPv3r+n0VNmK1EXTwnFiyzBC8yGbXscqrRu+i3BvZ4n0j\u002F\u002FvhV2ydsJkaXxvXjx8vMLG6JJJkuSiOrXqKgExQmKxxHr8XvqmWh9TN52JFBQeFOBYwdcd7107uI1RR75JmUyvSqczwTIpwR1PHzOnL9MFy5fp4tXryufF65ct0x\u002F611PCNhd+4+kazfuOFSBwIS\u002FLWJqHL5Qa1ct51AHGfDFjMVKQUkZRWhja0EdQvLZC1cNu4KvdGtBHSGWL129oWiEoRXG3yXx9\u002FLLDV\u002FtMFKkCOqmwyc0Vw1ad6fTgqNRgqCrd87VypckMzcXaGmnzl5Ew8bN0PUqg4AQG7buUf4a161Kw\u002Ft2IWceVngp+2P5OkUYuHHrnvQ0cY6eTp6+BtCWIzrwnEUrpQ8N8c5H5y9dU\u002F4Qua5h7co0ol9XihI5kqcRGR5vtpVLxvo1Kyn1IeQhErJeOnLirAjHfYdSJkuiV8WpfPw+f5k0Uwn3bfS9MioP6kA8ca3x+8KM1OHjpwlM8Xn\u002FobFvaNxnO\u002FcdrrzEaJ0fvPfgb\u002FrcpbRgykjKklF\u002FhgTtewz81bQbxoXifqCVEieM7\u002Fboy9du3hYKooUiKNcmh3s1xoTokFeu3aKBv0wWsxDzqW\u002FXNtSiYS2t4TrkBecz0WEwnGFDAN7s8uTILF7Kjtrk2+\u002FAK9WP7b+zz3b7\u002FouXr8SL407lOPXES6K7lQduPyE\u002FPoBPCeo\u002FiuhesEs1m\u002F4RYX37DBtHM+YtM2wS8OZf+q5TX3omvrytGjlq3Yrky0VVRARVaIwCAsz5QIWv17IlClFWuwfOd0JzvH7rbjEDcEQ3sBDa2GuX85f\u002FVre+4Ql+qTB49BRTQrqsP\u002Fi4lUVtU9vCrAWuHyH8qSlfrqzURAjjCePHpSViIeCCZWvVIuVz7uJVirZpzsRhlCNLBpsyMzuYVYGrSQgF1il6tCgEN1TZM6UXWvbTtHbzTrp3\u002F2\u002FrKh7b9uQ1gPauXY9BFu2depJ5c2ahZvWqU+7smRWNzoTf5jv40J+\u002FdI24Fodp0sj+VKxAbrVpsH\u002Fid60uIk0YPw4VFS7RkJIkSqA8GOFLWy9Bq96r8\u002Fd6xUHKx3h++nk0zV2yysHrSLGCuZUFWiFChqC14qG4R8z82c\u002FqBOmgGo08da3xey5Tq4XGCLSzINhDUB02drrDLI5WC\u002Fx2S9VsTqMG\u002Faho17XqbNqx17SQrtVezUuTKrm66fJPvLgNGzed\u002FhTPLPXFLEG82MpMFUwv\u002F3rwyOGYMAfq0neE4PSP4j3EoYJdRnA+E+2GwrsaBAqLe5ORoH7i9AWNlu7PwsxW2x8HKQeCkiOwHuPcP0I+gkrApwT1DCIq1y4h3D5+YuyUH+Ywrbr2V8xC1JM18zl0zDRlCtJeo4s34\u002FlCywMTju79fyFEQ5SlJIni0Z41C0grcMN3DWoS\u002Fi6K2YDStb6zEaIQGnnyL9qCUf5c2eiI0GSZfVHQGh8WjWROn8ZSNGPeUqER0xZsEK54ihiLfUqdIqnhohPMQNQTQvqTp\u002F8t4CtZJK9YWT6aVL\u002F5xQvlVbS1U2fbLqjBgxpaf4Q4jholsv3hNfdh5wlt5nChuVcfimrF7FnS07xJwylp4oRKFoI8jOzfTRHoIYx6OnnqGvQeOpYmzFjgcHoQ0tcsmGJxyYWZkfIlC1OHnkMIL0rW6c69h1S1YVtq1bgODe7V0XLtrOt4ehsv6+osUt1q5W0iFNYSZmZ632eM848V66mnMHNDCHBXJMxwNW73kzK7Z90fZsN+\u002FukHatu8niUbZje4L5Ws0cyp37ClQ6sNT17rKMJLRIpkichotgrDCwh4Q0UrNxJrIfRN7KxOw7KJWaf2PQYr60j6dGljyVc3smfOQDPGfBYykIcXdJg26qWeHVtSyuS2Mym4t1gHe9FrG9h8mDqMEveicdPnKtpytX3xQnlo0fRfLQIRXlww06iVEB06m1AqwC+3LAXnM1E2Li77TMB6Jl2PyYNHxrNRem2dyd8pzK84+QYBnxLUYReNv5UbttH3XfpLp\u002FHbdB+o2KEnTZyAYCuWNUNauvfgoTLVA02vXoJniInCjv2nH1pqVokVI7p4QPxMmHKUvSnHjRNbU0i37hQ28dAa79h7WMmGycryWeOFnXBK62qW7dXzJysL\u002FoaMnipsM+dY8gOzkUmY4eBPTZt37NMVbDAVBkEosAmL5qo1am+jPcMLy4IpvzgIekN6d6KlqzfaCPQ4HrTdivAxTH8xmjou2GTipWzJSkdXfbmyZaSNS2Y4BNCAoDb655\u002Fo3KWr5GmNhieuwZAxUzWFdIShXixelsKHsw0yBh5jh\u002FSkQ+IF69LVmypa5RMmMdPmLFGu56QRfW3KgmNn1pdFpDi2avaijqNahVKKdtt6DYRahk+8BO4XazkK5slunR2kbXzPK9RvrWnSNVe8GMLW3z5lEGsA8PLbuO1P9kVB3vf0tU6RLDGd2rlSsUPvP2IC6ZmV4IQwUwkhPVP61FSsYB7KkCa1soBy\u002F5EThHU\u002FRrMLY6bOJUzLI9y5dYJdufW96Y2Y1ZAJ6qWK5ldmj6z7cMf234+fUs2mP5C9zTxslaGAsdZa4oXxxNkLtHHbXs2hDB07zVBQ94ZnoubgOVMhoKWos0fzdzAI6libtkSsF+PkGwRC+sYwbUcJ++jypQrbZtrtRRJan2F9OisPlGmjBiiarSG9OtGhjYuoTjVtO3S1iymzFqmbmp8QYIcL212ZUg4PcTPu4C4IDZuaOnzXQFdIV+uECS3s1oWPVjM3ALWNJz9hI1u3ZRcbIR3Hb9moFkWM6Gg7j\u002FOpVbms5hDnLFpFZt76+w4frymk4zpNFddeLwodhFWtGQPNwfhQJmYJRoz\u002FXXPE39aooPvdQTCNPsI+Vi9BEDITYEivvSvy8YCBXTRStszpKG3qFDbdxo8bWwjhOWzy7Hf++FPbXtm+nmz\u002Fxq27VLN5R00hvXbVsppCutof7l9Vy5dQd536DM5rjZe+MYN7EszK9BIWSuIFcO\u002FaBTS0d2dl3cNPQrsNpcPKuRMpVsxoek2VfHjr6TtsvLSOtxRicWvpWs0dhHSMr4W4\u002FyUS5n72CQvo9dL+wyfFbOsrvWKb\u002FOB+JtoMhncsBGJGl3+\u002FUVFdeG1p5OINKLLw3YQ8ApOr4eNnUO3mnb46T0suxurR7nxSUAehDFZeVLSILfltDLX7rr7DAgloNMYITWrsWNG1mil5sBOExlyWMKVVoZSjxkxtA\u002FMLLBKRJSzIevD3Z+8vUaNGpvYm3DmhPwi36b6xFVBkx\u002FFkGWze7BeW4YWmZaM6usOQTe8uNQhos0iYMoyfPl+zb0RcM7JBNeNdQrNzL82EaVavIWN0R1dHZ7G02qCU8P0Lsw29hMWannYvaD0WLIhVUz1hxqWV4GVJlvC7lHlikLVFGR56tb\u002FrRHpR\u002FLq2bWbUhSmvJkadeMO1hqY4lTCF00vRo0VVFmuGDOn4qMHvfvfqecLjyWeTNL0+EMURHmW8PW0S0W\u002F1zIH0lBEF88pndmSzv\u002FY8gvuZaD8e3iddpYg1m1AhQ1nvOrXdsnM\u002Fipoit81ftJR5KHaaApQ8RykqVKkhDR0zPdjWZzl1cl9xY8e7p4\u002FAiBTBUTtrPfTIGtpbtRxeLOACTJbsFyNq1W3V2HHRqXU9uCKUJWs7dyywNGuPjT4jR\u002FI+TxxYnLJduGazT7ANl7lAS5Qgnn0Tyz5mJvQSBEaYx+il5mIdwNeWBoycKOIDaGvh0qZObrM+QYsN3Bzmy5lVq0jJQ9+TZ\u002F6hW+7OAgjXeDFDwvqJmjozMdBWo1wvIUjS2iCE71b7m\u002FjbAuFx6Za6a\u002FOZP3dWYd6RyibPXTvecq2jmVxHosUBC4D7SWZx1DbW5k5qnrd9RhRKIK2E9UpwAayV8HuTeem6fvuuVjPNPG94JmoO7CvO1JvNtUYST8wCcmICMgI+K6iHCRtGdl6GZcmTJpLWMSOow+YyZfLEuv3A3heBfbQSFj+uWLdFKYJQ0Ub48w1M0nsoBKYPV9eFhx2tlFEsApalkBIbIrjf1AuGgoVYelpNaIXz5sgiO6zflT1++oxki2PNuNMEFKOIer8tWCbWfwjDdQ8n\u002FF5U39NYiKz38od1JEUNvNQsDKL5y\u002F2Hj+iXidpmRcBROF9Oj1DxpmsdWszwOZMwA2I0Q3hJxIrw9oTvZPWKJR2G2bVtc4c864w4sfT9uAdGo+4Nz0Tr8+JtMmW6BE9AnJiAjIBzd1hZz15elkT4z5Wlvx4au+7DAjx4b+k9RFtAhSyzSGjVtXykYipXNRGpWq4EwZ+vLydEGIR\u002Fe60EUx24o4TJwLt37xRPCIhG+l7sB7z5RynTaoc8LDb7SywCtvd9DeFdDdqk1RbuLTEt\u002FzUl+MS193hjff6xY8Ww3tXdNhI2\u002F370lE6dvShsxLW1hLodO1kwy8p3up7Zi3oIeH\u002FZJgI76aUdew+J398jShAvjl4Vzfz5y9YoCyQ1C0VmvpzZ9Ipcmu9P1xpmMT3E4v1mHXrpMkLMCCg3tExodBt5uABjmzluqHjRXUNYBwH7cihzmtStJh2JbPYHa348lVzxTPTUWH3lOHqzm9bjx7oaVyV4QrJeZI1+oVRBPBN4i7sjApNt3L5HxNRYQfDoxck3CHy1grqRmYme1wj7y9qwVhX6edQUXa0vbthagjoiRKoJtvS+nlZv3K57Cqs2bCf8BSVhsVmKpI6zFghQ9fr1G90uk31xxahbwQ8LVglvSLJkxvc92mORoFHaLgRdTwrqcGt46NhpZViRI0eULtZEpUplilHH3kNt3ONZnxN+3zBN6\u002FR9Y+tsw211FkyvIrxMeSL527UuIyIShxS+5vXuuzB7un33PhnNhHqCvewYWMAOs0oj00q1D5gLyhYTGnnFUftxxaernomuGIu\u002F9PHsxUvDU4kfN3DKAsMO7SpAoQgTnLDRwyhulbNkSKPcH4tVaawrt9h1wbvBTOCrFdRdxR1BjWqIYAF6LsoQDRV+neGHXU0IALLqi2CLsNm5smVSi3z2ExpzZxIe0lh4FitmdILpQhyh\u002FYX7Svjvxo3GPq02sDE2eujY9+cP+5jVkCUwNZNwHYySGdMwoz4CU24difSNmIVJkbO0YXN4DJElvEQHRlCHpxejiMKe+t7527XGuiH83q2Do9lfO8xyerugbj9mrX1oODGjM0ms9YCgzsl\u002FCSDolVHKlTWjURWXl2MdTd3q5YVmfZXL++YOXU+ABXUXMEW4Zz1BHd0vWrHORlDfLqbkVdeNWlFQXTAkj3eB0Ox6qX7NipRaBNXBAl+4aMQCqujCy00M4boKrt1iRIsmvGBEDtS09pXr2ov51DH4mzcX9bz0PmFKBG9FshQ2rK3vdL26EJqgGZSZ0cBftKeS9SJSHBNaV\u002FjNdjbBVAuLlc3ODBh95zAeT3zv\u002FPVaw\u002FxPJqibnRFy9nvhrvZ3hdkBTCEXCPMpKHCQ4O3rI8wShL95Tv5H4MiJM9KTihQxvOHsoLQDJwoL5M7OgroT\u002FDzZlAV1F9CGRhw20fZBLtSuEUkRftfVFeCq5wqYddSoJHclp\u002FbhzZ\u002FPxfTe27fvdYcIO01E43Rlum9gu\u002Fnx00dXHs7r+3pkQnCGOz8zCTMYEDjVl0mtNghx7qkEMw8ztp5BGQ8WlZoV1M2sW\u002Fnkge+dv15rvKzLkhmTLFn74CiDnTpmTxev2CACPB1TgvBhHLBLb16\u002FhhIlF9Gpr1431rwGx\u002Fj5mM4RQCRxWaoggqJpxReRtXFVGZ7LauTk0BKXvK46HvcTdAIsqAednU3L7xrWpB96DrXJU3eg6YSPXfj1fvU6gNZt2aUUYZGRfYRItY0vfcpsLHEeeIFxtaD+6MkzKSIj7bK0sQ8WvhTfK6P02ICZdXvMdMgEdU9qN61d85UWtsw\u002F\u002FdDCeqjSbUQZXrFO33YfUXERHRcLno2S0XcO7fG9w4yRO5O\u002FXusI4bXdG4IlNM+emK1w1XXDTM246fNo7ZadDkqMvDmz0IRhvRVTH1cdj\u002FvxPgL3hDLpqsHMr1FcC3eeFRbSD+\u002FbxZ2H4L5dRMD46eSiA\u002Fl7N3WqlKM+IoLey5evNU8V9rAQ1NVgK7DJhscYf0ihRERLWYKHEFcn2ALLBElPmma4+tyC0h\u002Fs+o3Sk6fmNOroR5390eszjgjh7ol0UbjnPHDklOVQeLnNnf2\u002F9R6WAp2N70TkR5mg\u002FuTpC9q8Y5+p6Wcz\u002FsLxvXO3Byd\u002Fvday72eZogV0rrB3ZQe8eUNtug+ileu1Xw6hwfy55w+mXgy968x4NIElMG\u002FxKssMilZbrLcoUTifVhHnMQEbAiFt9ngnyAQwfVW\u002FRkXd9puEMADTA3VRHDSDCPbhDym2WAAqS6cvXCYsoHVlMnJpBdtAuHP7WhI03LArlyX43jabjCJ3Btatodnj2tezdskIrWrZEgXtq0j3C+XNQQnjy70qLFy+VtqHWmgmMAliJ7g7+eu1\u002Fvvx5yjNWvwqlimmle1VeXCBV7Z2S10hHS5DocE0M3vjVSfGgwk0AazvkbkPhn+EicP78Hch0GS\u002FzgbyJ\u002FvXySTIZ92sXg3dtvBAgfDrR0+eU+r4izYdJ4MpaVl0PcwyzJi7RJdNUAqMBEWYIOitGQjK8by9DYT0rJnSSYd5Syf4llajf4U7PFkqZhBQSNbWbBl85avrOdCmorDnDGdyQax6DPi2rlWlrLqr+blpx17p7IzaKKEJn+twW+nu5I\u002FXGsz0ZsFghlW2eOBe0Nx9DbT6n7XwTzp9\u002FrJWkZJXvmRh3TIu8C8CS1ZtoHv39X3gN69fk4rkz+VfJ81n4zYCLKi7EG36NCkpXy798OvzlqxWjoaQ0mWKef+DBy8X0BIZJSw+lIWdR\u002FuhY6dTYDS6Rsc0ip75+ZjTjLrx+nKz1wAnUtJgGvX6zbsEF4NGCTMRz1680K2WKEFcw5cC3caBKMAiUuu1BtXKO0Z9NNNdnarlpdXevfsgfKqvl9ZBIRadwh2rLMGM5vjp87IqLinzt2sNDeTfj7Q16t3bN6fIkZyz+w9wgZcgowsniyWBtkU88HJrNEYuN0dAz5+\u002FmdaYOe81ZIxuVTz\u002FYf7EiQmYJeARQV3m5g0DNSo3ezLeUK9ZveqGw2jybfVAuSI07NBNFXCzunvvganesYJclhD6HTMKgUkQKqFV1UrVKpQS\u002FtW1Sv7L27R9H23fox+d8r+a+lvweRycKTDXoFoFY0EW2mOjhGiIEF71UhURSdcTaebC5ZbDIMgRQrQHJSHAR9rUyaVNp4kZHyNTKZgsYJ2JLOHr0mPQr7IqpsqMBAV\u002Fu9a7Dx4lLXOrpInjK7EUTEGTVLodiNkkSTfSopt37knLHz0JvEtTM4oS6UF9tPCTeHGTJWdlBiNTTHjrCWrq3v8XwtoXrRQ7VnRa\u002FNuYIL94Gn0fjGJHaI2J87yfgEcEdYSOlyWjcq22\u002F3PS\u002FvijQfugCmgQIDFVq5fglsts1Dq9PpD\u002FQaLpNrrJWfdrpKm6afIB1\u002FTbaoSbkCzNX7qG6n\u002FfTbjaeymrRvATPXzcDMpTtg71GDhKs27iBPFMCW49B49R+tPsxESmK\u002Fx1Gx3GVdcgc\u002Fo0VMbARMCMoI5w7XoJfn87t26iV+yy\u002FHOXrtosIkXkSmc8JNWuWk46Nsw2bBbRbo1Sw9qVjaooEVQx9e1MevOv3K+2P11rcFq6aqMDrjDCZdxvYwebMneKYqBx90SALqNF9WckZjEOJ\u002F8lQ7bA1r6Ntz4T7cdpZt9IJnhvIFMYHeOtjgJIbWfWla1aX\u002F3sM2wcLVuzWd21+YwbJyat\u002F2MaZUr3jU1+YHaMxv3vW7nJYmCOxXW9h4BHBHWjMLrW09tm0bwO0A8fjz7evpO\u002FHGhpb6yPHdQvfITw4aSuCCuUKkJGCyGtx6G3HSCiM+oljN3si4ZRpD+tB6jWcWGnPuDH9lpFNnlrN++ighXrE7zgIICMqsWEcA77TpgH5S1bVzGVgW\u002F2fyQ3nmF9uij+iG0OYLeDoDZl67SkO\u002Ffu25WY25UtcDPXg3EtV10DHKl35++lTPYeOk5Gmr1d+4\u002FoDrpjq8Yu+f7qHuBLwaiJM22qIDiHM8mMfTDc6RklmHjVNrB5Rx\u002Fw\u002FDFl1h9G3emWm\u002FGV7i\u002FXGr99rUjDowb+aGhSpwI0+g3B25aRFlXtK6if2QzWiIyaPIuMBFD7Yx87ddaU+SHaeesz0f6czOwbyQRG5UbHMHK1KlNWaPWN5xiE9PHT52sVU4J4sWnDoulOu+Q0enEL6guG5qA502sIuF1Qh49tI7vYA0dPBhrIy1fabhDVjowCsiAMuSz944RNo2xRqRnTGNm41DLZyw+m3+Gv3UxKkSyxtBo8YmzbfcCmDkwjtATfhrUqU\u002FYs6W3qau3cufeQvu86gHKWrEWJsxan7CVqUPwMhalQxQbUrsfPBO0mUuF8OZWV8Vp9IA9rAjq0aKBXbMk\u002Ffuo8FarUkOBB5O79h5Z83IwHjJxo2dfa2LXviPJCoVXmqjxXXoPswo66b9c2ukPDy0+n3sN0y\u002FGCt2bzTs3y3NkzUScPaNPXbNpBCBJmnVKnSGq9G+htaLFgPiNL+w6doJliQaBRGtyro6GtOqagewwaTY3a9qB9h09YBDQIangZNTLJ+n3BcstLrN54fOFav3oVQIePy6Mzdh\u002Fwi41bW2jSR\u002FTrQoG5Vxr9hhBQaPi46TZMcY\u002FEi7yrUo4s8lDwV67dUr4P6lod\u002FNagsJAFb3vw9xNq0Lq7MkuzcfseWrZ6k+5wvfmZqDtonYKDBt6TDh0\u002FZXMtdbrRzEYUbSNTKCiozJq\u002FnL14hUrWbK4ppMM8s56IzL1n7QL6RkTndiY9+PsxYaZRljaKeC2c\u002FI9AaHef0uSZC4WZhtw13yrhc7ZP59aULElC08PZsmu\u002FtC48fshsWo1C+x44ekrav6xQXVR60K4P2FvKxiTr07rs\u002FsNHdFqcnyyt37pbqtlX26ZLnULd1PyErWz1Jj8oQjMiAx49dY5u3r5HDWpVoim\u002F9LdpAw8bowZ0J0TaM7KxVRu+fv2G8Gef0qRKRgumjjT0592\u002Fezu6euM2rdm0074Lm31oYDr2+hyQCu76MKNiRisDG\u002FkCFepRzqwZKV3qz4uFXR28yZXXACfd6fvGhGl2vSlYsII3Fa3zQAAgrSiJ0Fgu\u002Fm20U+YnNhdEZwcPaLys2adtYq2BMz6HIRwZvZzjmL2HjqWkwm1qqaL57Ydg2YfHoSXCzrRKw7aadtWWimJj1Ybtyh9m2mAaBsWFzP5fbTtX+GDeue8w5ciSgZImTkDtmtcXWjlHN5Pefq3xOytbp4XynezZqZXD73n8jHnCZe1K9bSVc507abhy3pZMExvwLR8ndgx69FjfBenICTMJM3qZ0n9Dl67coDPCbSx83p\u002Fd83mRv4nDSKvgxQLPu\u002FsPH+vW27B1D6XNV4FSJU9CELzMRNzduG0v4Q8Jmtmaws0jFvDbJ29+JtqPVba\u002FZed+On\u002FpmqyKUBQ9FPERtiospBXtCmHbPnrKHKl\u002FczQJePOv8oI0YVgf0noJxAv3tt0HxT12kzIOLRkns\u002FiejRr0I+XPlc1uFIHfxUsdZuiMbPOPCa9yUKyVLKJ\u002F\u002Fwr80blFcBMINUAkVw4C0biOHD9NW3cdIGhK\u002Fly71bB7TEli4RhW\u002FUNTDDusmOLGC3tu64QANxAUew8ZS3sOHrcuctjGDx2Cf5KE8WweDtA6YBp0+ITflOM4NPyScfevh8pDNWH8uBQjRjTho9p2LHrt1HxoheyFx\u002FZC+wstcVATHvIwS+jw02BlbLJ+dh04qvCDSUp04akCQrRWih0rBl29edvwxnj77n06f\u002Fma5cHyj7Ch\u002Fb5JXYcuEwnb8SIFcolxHqaXQpsWlJQ1Y1ohCI0mM36r8cCqWLqY8tCFwG4mvRIvBnA\u002FiKBTdatXoLMXrkib4eZ4RyyqPSGiDcKkytXR5Fx9DcAECz5fB+hrM3eL7wfsnCEwqGmt0KS37NLP4WGQK1tGWjZzrDB5cRQU1bZB\u002FQTbE2fOK\u002Fbhv06eTX2GjtNcQAytLMx2Xr56pVyDuOKl0f7+YD8GLLzac\u002FAYLVy2VhH+AwLks2hoD0344pUbFDMsaFxDid+N1vcwsbivwNRhg9ByvjMws0O\u002FeJDj94Dz\u002FUa8hGKGQOa+DW2wAPuiECgPHTtN8MGtJah7w7VeIrSP127ewZA1E4SMA0dO0rQ5iwXXS2K27w1hrURvca2tfdhXLluM\u002Fpw9nlIkTazZj1FmNOFnf8O2PdJqMHk4d\u002FGqcv8Uw1LMRRrWrkIIoOZsChcuLKVMloSW69goq\u002F3DTOKxCD4GJQAWOpcrWYhOnZUrXtAW9yuEnC8tPIapvth96Zmonr\u002F9JzTX8JS0Q7yYjp06lwaOmmRfRXMfL8Ewl8R9Dt+pqJEjE16IrRNY47l1WMgkUF61\u002F+ln2rH3sHUV3e1b4pmHqMhrxQwfXoJ2imfa3CWraPyM+dRfzMQuEPcVyBnWSinck0oVLUB9xKzmiH7dlBdP3QMYFOBFDgpFvLh0F2u1zMhS6BL3r8OiHcxjXwh5B\u002Fb8MYUMo\u002FVyZzAELvYSAiHETVTcrlyXqjfpoLxpOtvjijnjbd4Kp89bSt36jQx0t\u002FA5\u002FOjSfgotBG1odxJkLGzzwzLTIb7kN48bv3BY94WbcJq85SyCLcZxbu8aEXwlrnU109sjxIvFkNHTTNe3rpjumxR0ePMS6yybbfgvzlmypiIY2BRo7EBr1aZZPWrZsJY0pDduvh17DzV9c8GhwKhLm6b0U8eWlgeRxhA0s\u002FA1ho3xz79OUYQtzUpWmZj1mDSiLyUQ1yN9fv1AVWiCBZSYtkwjZh\u002FKioek0cJEq8OY3nTHNcDB8VLaV0TMxYuWVoLWJ5UQGhEB9NLVGzaaprBhQysvY1h7oAoGWn04k4cp6EyFqwa6i1XzJhrOTuEhDnMqZ1K4cGHo0UX92TtMozdt35NOmhC08BD\u002FoWVD8f1uRd36jyRozfUSFKZ4GUiTKrmwa02laKQxoyVLwXWtazXvpER3lY1NVhY\u002Fbizq1q65095dcA8oU7uF8mIjOx7KcF0b1KxMHVs10tSYGrWXlY+ZOocGj54qvQ\u002Fh+N3bf6fc796JZ0XRqo3F7++mbreVyhRVhL8MaVJZ6vjaM9EycLuN0VNmCxNEc8K5XVOb3S5tmjisk4LNdoocpW3quXonYoTwlEUol2pULKVo+OPEiumSQzTr0MvBBDCoHd89vcMlL6NBPT63c46A201fnBvef60\u002FCE1XUBI0WJZ3EXEjt377NdtfUBYhwUNFPRGpdMqsRcph4I0jqEI6OpB5eTE6D6PxxxXh4PesmU99h49Xpum1+sPsxA+tGlLDWlUctBZa9aHJnz1hGJUW2oVfJs202J1r1YVAWK5EYcWbCExMgpKgLYAZQM1KpZWpzQXL1mhqZmGn\u002FEOLhtSlbVNlpgUzQNYJ5wnbX9x4swiNc4Z0qSmREObdrY1wxzXAeVUXXoiwgHmGeNFdvGKDQxCoM2I2AX\u002FWCZpJfHc7Cp44d3cmo0Xf7jy2K\u002FqGBnXnqrnK9PeoyTOFtlZ7yj5Pjsw0elAP5Xtlf1xoAbNlTie0q+I7p\u002FylUV4MEe04MMnbr7X1uUBQxfcSwjKm6fGS7mzCbxQa+VHifjNZmAlgPYZ9ihIlErVoUJPaClMioxcf+7Zm9+EVqYRwJdqic19N4btYwdyEhbJ4CUMKLa7zijkTqIl44Tty4qySp\u002F4rXigP9evWVjG9U\u002FPUT197Jqrj9qVPfC+jRI4khFz8RVa28WzDtcuK36p4TqROkcwl319f4sJj9SwBl2vUPTt87z4avJoMHfNZC96iUW0qmMc5zxWeOFuYdxwT5kWfF9zcV6bb4TGjaIE8Tt2MMP0I2zlM98PECZ4ekghbYGj7q5Yrabg4L7DnjsXAuw4cof2HT9K9Bw+VFx0s9mpSt6pwnxnV0h1sl6FxRpS4wuIPbh+DO7nrGuC8sJh2q5jGvfvXA8WeFx5gwoYNQ9ACwWwJplnZMqV36loHN7\u002FgPD5+85iqxkJleAyCh6fqFUs7mLzBDARrJPCdwyLdsGHCuHzYnrrWMo06ZuBWz5+saNyxtgUazqJCUK1duazN79DVJ4\u002FF7jDvui5iMVwXZjnhxcsQhN4KpYoG2Yd1YMcIBckFcd\u002FD7\u002Fmk+HsnlE2wLy+uE3MCCqV1W3Yp5g64dk3qVuPolYGFzvWZgB8SYEHdDy8qnxITYAJMwFMEZII6fEdfPbzJU0Ph4zABJsAE\u002FI6A8\u002FONfoeET4gJMAEmwASYABNgAkyACQQ\u002FARbUg\u002F8a8AiYABNgAkyACTABJsAEmIADARbUHZBwBhNgAkyACTABJsAEmAATCH4CLKgH\u002FzXgETABJsAEmAATYAJMgAkwAQcCLKg7IOEMJsAEmAATYAJMgAkwASYQ\u002FARYUA\u002F+a8AjYAJMgAn4LAFLnAqNM5CVaVTnLCbABJgAE7AjwIK6HRDeZQJMgAkwAfME\u002FhURn\u002FXSaxHanRMTYAJMgAkEnQAL6kFnxy2ZABNgAl89gZevXusy+EcI8Qg+xokJMAEmwASCRoAF9aBx41ZMgAkwga+eAKKNnrlwWcrh94XLpeVcyASYABNgAvoEODKpPhsuYQJMgAkwATsCEM4vX7tJp4WAPmXWH\u002FTo8TO7Go67RfLnpIqli1LypIkpVfIklCZVcsdKnMMEmAATYAIOBFhQd0DCGUyACTABJqBHoFi1JnT81Hm9YsP8RAni0oX96wzrcQUmwASYABMgCs0QmAATYAJMgAmYJZA2dQr69OmT2eoO9eLEiumQxxlMgAkwASagTYA16tpcOJcJMAEmwASYABNgAkyACQQrAV5MGqz4+eBMgAkwASbABJgAE2ACTECbAAvq2lw4lwkwASbABJgAE2ACTIAJBCsBFtSDFT8f3IjA8xcvjapwORNgAkyACTABJsAE\u002FJIALyb1y8vqmyeFcOMXr9ygg8dOff47elIsWvsfndm9yjdPiEfNBJgAE2ACTIAJMAEnCLCg7gQ8bho0Ah8+fiTVF\u002FOV67cIf\u002FDLfOHyNXrx0jbKYbIkCYN2EG7FBJgAE2ACTIAJMAEfJ8CCuo9fQF8c\u002Fsp1W6l5xz5uGzo086fPXaLzQvCPFycW5cyakaJFjeK243HHTIAJMAEmwASYABNwBwGXC+p9h4+ncdPmOT3WMGFCU\u002Fjw4Shi+PAUI3pUSpEsMaVMloQqly1GBXJnd7p\u002F7iD4CMSOHVNcz0R0685fimmLK0dy9\u002F5Dat21P+0+cMzSLb4\u002Fowf1oJqVy1jyeIMJMAEmwASYABNgAt5OwOV+1F0lqMvApUmVjJrWq071alSkWDGiy6pymRcTePnqNQ0ePZWmzl6sO0qYvpi1UYdJTckazejE6QsO\u002FYUKFZI2LfmN8uTI7FDGGUyACTABJsAEmAAT8EYCLhfUnz57QWcuXFbsjpeu3kgHjpwydd7fCOEbJgoxo0ejG7fv0vlL1xSNq6xx+HBhadGMX6lE4XyyalzmxQTevntHqXOXdbBNV4ccGEF99cYd1LDNj2pTh88yxQvSspljHfI5gwkwASbABJgAE2AC3kjA5e4ZY8aIRkUL5KYWDWspGszOrRsbnnfd6uXpyOYlNP3XgTS8bxdaPGO0okX9fezPFDeOfrjpf9++owatu9ORE2cMj+GtFZ49f0kTf19A0C67Kq3bsot27D3kqu7c2k+4sGEpWWLXLBg9K14QZencxSuyYi5jAkyACTABJsAEmIBXEXC5oG5\u002Fdm2a1SOYHchS7cplKWRIxzq1q5ajw5uWUML4cXSbB7z5l2o17yQ8hlzXreOtBVt27qe8ZetQr8Fj6dLVG04P89XrAGrdbQDVa9WNxs+Y73R\u002FnuogYsQILjlUrJhyMyjM1nBiAkyACTABJsAEmICvEHCUjl088vhxYysLQWXdxhGLC\u002FUSNPSjBuqbM6AdtNL9RozX68Lr8t+8+Yc69xlONZt1pAd\u002FP3HJ+HYfOEr5ytWlhcvXuaQ\u002FT3YSJrRr1jQXK5iHsAhZL5Uqml+viPOZABNgAkyACTABJuB1BNwuqOOMjTSZMuEK7SuVKUbFC+XBpm7atvsgPXryVLfcWwoOHz9DBSrWp98XLHfJkGD+03PwGKrcoA3duffQJX36aidpU6egft3aag4\u002FQ9pU9FPHVpplnMkEmAATYAJMgAkwAW8k4BFBPWyYME6fe94cWaR9fPjwkc6JBajemt5\u002F+ECDRk2msnVa0PWbd10yzFNnL1KRyg1p0u8LSbgO5yQIdGzViJb8PpoK5MmmuPXMmC4VYZ3EjhWzKYJw98mJCTABJsAEmAATYAK+QkDfTsCFZ2Bko27mUGm\u002FSWlY7S\u002FhQ9tb08Lla2nUpFkuHV7dll3orwePXNqnP3RWrkRhwh8nJsAEmAATYAJMgAn4MgGPaNRdASjdNykMuwkdOpRhneCq8OmT61Xenz59Cq7T4eMyASbABJgAE2ACTIAJuJmAzwjqCAtvlBLEi2tUhcuZABNgAkyACTABJsAEmIBPEPAZQf3ytZtSoFGiRKJcImCSq9LHj5\u002ForPC7ffevByLMPWuurblev3WHrt64Te\u002Fev7fO9vptXEtXJpz\u002FXWFudeLMBbE+4io9fvrMI98VBIk6dOy09FQwltPnLxMWG3NiAkyACTABJsAEfJOAR2zUXYHmyvVb0m4a1KxEESKEl9YxKvzn37e0ZtN2QoTLXfuPWKJlhg0bmpIlSUT1a1Sk75vUpciRIhp1pZRDkBs9ZTa9e\u002FeeTp27JG0DLzAbtu1xqNO66bcU18p9JcaFP6RXAW8c6qsZ127eURavqvvqZ3ph6w\u002F\u002F9IFJmM3YJdw\u002FLl+zSQmkdPvuZ4E3ZMgQlChBXCpdtCB1bduUkiRKEJhu3VoXY7545QbtO3xcRMc9qXy+EEGl7p\u002Fd7dRx4a9\u002FxbottHX3ATp++rwQzG1neuDBKF\u002FOrFSxdFGqUr4EJU4Qz6njoTG+R0dPniW44Nx78BjBc1AoYeZlfy7PX7ykMVPnKC46Hz767PYT5mBpUyenArmzKx5xokWN4vR4uAMmwASYABNgAkzAMwRCCIHGVtJww3HhOnDX\u002FqO6Pe\u002FfsJAypftGtxwa7ZI1m9Oxk+c06+TNmYXWLJhC4cOF1Sw3yrx287biOWXJ6k308qU8QmiM6FGpb9c2SuRVo37hK91ZN4xjh\u002FSk5vVrKIeCFrto1cb06lWA0aF1y+PHjUWXDm6gECFC6NZRCyD4zZi\u002FjOYsWkm3795XszU\u002FIaA2qVuVRvTvRoH1i16xXmvaIwRQrZQsSUIlSq1WmZoHLggYhVkX9e+S2La\u002FlpEiRXAQbtU+jD6hNR854Xdav3WXaQ87+D72696W2oqgX1oBvbSOidmK88J70YUr1+mieCm4cOUa4SX17Vvb2Qvrc8FPeOrsRTR07HTLy6VW38mTJqL5k0dQloxptYo5jwkwASbABJgAE\u002FAyAj6hUZ\u002F4+wJdIT1FskS0aMavQRLSIeANGzed\u002Fly7hWDqgpQgXmzKmikdnRYacC2PKgiu1KXvCHrzzz\u002F0Q8tGupdz0469Tgvp6DxNquSWY3zXqY9TQrran5GQDgEdkU2nzV1iOV7kyBEVTfE9YepxUQiR9q93799\u002FoN\u002FmLxcBnB7TnEnDAy2sW04yCBv5y3\u002FrIMgGoRvNJvhejBg\u002Fg0ZO\u002FN1Be167aln6tloFSpwwPh05eYZ+mTiTbt35y9IPzE4QdXbt5p009ZcBBEHZKJWp3YL+fmQ+HgDMeb7vOkD3Rcf6eDdv36NS4oV309LfKHvm9NZFvM0EmAATYAJMgAl4IQGvFtShKVy1cTsN\u002FnWqJrqqwrRgWJ\u002FOFCuGPHS8fWOYuIyaNJPGTZ8rzFI+WIoRVGnR9F8tJjTDhIZy2LgZlnLrjT5Dx1O2TOmpSP5c1tmW7eyZM9CMMYMs+zBbmLdktWXffqNnx5aUMnkSm+yoUSJTobw5LHkDurejvx\u002F\u002FJ8R16z9SV4MK\u002F+Gdvm9iaatuFMidTd3U\u002FFy8cgP1GjKGHj1+ZilPnDAerVs41RJhdsvO\u002FdSgdXdN++e1m3fRKCGw9uzkueBC+XNlE4LyWQoI+McyZldsBLx5Q7Wbd6a9h447dNe+RX0a2ruzJT99mpRUtVwJJfDUybO2Zk77D58kvEwM7dOFmtWrbmmjtZErWybaufeweBH8V6vYJg+\u002FjfY9ftb9DthU\u002FrKDl4eBv0yilXMnahVzHhNgAkyACTABJuBFBLzO9OXDx490\u002F8HfdPTUOUXgO3PhigOu3Nkz0eBeHQkCWmATBN2aTX9wsBlHMJzjO\u002F6kRPFtPcfUadGZNm7bq3kYBNXZuFhbkLdvMOuPFdSx11D7bMv+tj9nUu7smS37ZjbS5C0nNNifbZHt65csko9WzJlgn627D+7thND3x\u002FJ1DnXmTxlJVcoVt8mf8Nt86j1knE2euoOFvef2rKbo0aKqWdJPZ01f0DkCSg0ZPVWsCZijeyxrcxHdSl8KYBdeu3knYZN\u002F2KFqySJ5afms8ZrmLNBa5y5TW1fDP330QPq2egWHPq0zcGy8JP46ebZ1tu52tkxpKa+wi08lXvRgQ79UrCV4\u002FVp\u002F\u002FQI62rB4OhXMk123Ty5gAkyACTABJsAEgp+AV2jUW3XpR2HDhqWHwmwCphOqGYo1nrIlClLZ4oWoTLEClDRxQusi09sQgErXak43bt1zaNOiUS0HIR2VWjSopSuoQ1P64uUr8ocFem26D6TFKzY4cMmWOZ2DkI5KDWtVURar2ttOoww29NBCVypTDLseSbCL792lNc0W9vRPn71w+pgdeg7RFNLRcZum+jbnMG9p+m11mjZnieYY8LKWMV1qypw+jWY5MhHJF+sgFixbo\u002Fsihno41qgB3alM8YLYtaTu7ZtT3RZdSOslV600eeZCFtRVGPzJBJgAE2ACTMBLCXiFe8azF67S8VPn6d79vzWFdLCDFxOYN2zauY9OioV90KAGNm3avldTSEc\u002FtSqX1eyuYF651hEaVF9Pj548FR5dNmueRq3KZTTzsag2fZpUmmXIvHnH81wgrJsJjKU76C8FO\u002FYd1pxZQHHsWNGphJitkKXyJfWjosLsqtfgMbLmShkWn6aTROPFDNChTYsdhHQ0hs38mME9pccwcncqbcyFTIAJMAEmwASYgEcIeIVGHa7sYJbwlxDU74jFcX8J0xcsTrROV6\u002FfJvypphkRhSvGJt9Woy5tmlK8OLGsq+puo41WSpIonu7iukgRIypj07N\u002Fvn77rrL4VKtfX8kLHy6cMOPQ9gJTpWwJ3dOIHze2btmNW3d1y9xZEDlSJKe6xwvgjwN+0e2jWvmSFDqUPAJugTw5lMXNej7M4QEJMw7W6w+0DhgxYgStbCUvZKiQBGFdL+XJkVmYUmWiIyfOalaBFx+sATFaWKzZmDOZABNgAkyACTABjxDwCo167y7f029jfqb1i6YprvgeXdwnXAiuF4vvOukK4VhsN2XWIspSpCr1HjpWCTZjRKx4obxUvWJJh2pd2zZ3yLPOiBMrpvWuzbY\u002FaNSjRI5EQ3p1sjkv7ECbLvNUEje2\u002FgvSjWCaadB7GXM4OZ3WatriAABAAElEQVSMDVv3CFePN3VKib5JmUy3TC2AW8aCVouA1Xzrz9\u002FmL7Xe1dyGCYwzSXbtoNm3XpjszHG4LRNgAkyACTABJuAeAl4hqNufGqb9E8SLQ+2\u002Fa0BnxKLEkf27UtSoke2rKfsQOCbMWEAlazSjJ8+ea9ZRM9HvzHFDaeKIPkKQyk6Z0qcmeO9oUreaWkXzE0Fj9BK0\u002F\u002F6QEMhp3R9TqXypwsIlZDL6tkYF+lks2JWlUIKnXvJVLqs2bNM7JSU\u002FdswY0nK1sHC+nOqm5ue23Qd1zbw0GwQhM4kwgZElLNrmxASYABNgAkyACXgvAa8wfZHhgXYS0TkTxo9HDdv8qFsVC0TrteomAh9NpnBiYapeCiVMBhrXqar86dWxzocrQjXKo3W+uv3hw0d10+c\u002FIVwaCZjqScLG+fCJ0+quw+eHIKwhcOjEwxlv372jDdv3SI8aO5Y5Qd3IHOuFCKx1\u002FPS5QHv6kQ7OrhDuPWXpk70zfFllLmMCTIAJMAEmwAQ8TkBfJerxocgPCPeALRrWlFY6ePSU1AWitLFVIWx3t+85SDWbdVT+nIkEatWtX2yev3yNOvUeJvyC16NzF6\u002F5xTmpJ4EAWEZuDc0K6mZcU1oHR1LHwJ9MgAkwASbABJgAE1AJeL1GXR0oPhEwZpnwTvL8xSvrbJvtRSvWU99ubTVdLdpU1NhBlMdFIuAP3OJdu3FHqQGTm49COxzwxjgAjUaXfpH16nUArVy\u002FjRYsX0NwSYmEmYm4cWIGKoqmt8OAe1CjJJutsW5rRlBnG3FrYrzNBJgAE2ACTIAJ2BPwGY06Bg4zGJn\u002FadT59Ol\u002FtG7LLmyaSvCDPnfJKkLQnYyFKtOgXyYrQjrs0ls1rk2ndq6gBHZBkEx17OOV4P1kw7Y91KxDL0qdu6wSDEkV0hFMad\u002F6hVSxVFEfP0vb4ctMnNSaRusg1HpwX2mUAv5xbSRVo+NxORNgAkyACTABJuBbBHxKow60GdKmoj0Hj0kp3777l7QchfDFPm76PFq7ZadDFMm8ObPQhGG9pX6sDQ\u002FgoxWwCHSSCIazYNlah8BBCeLFFlz6aPru9tHTtRk2Zg6M0uMnz4yqKOXRo0YxrGd2YaphR1yBCTABJsAEmAAT8EsCPiiopza8ENCS66WAN2+oTfdBiimHVp22zevRzz1\u002FIATP+drSiAm\u002F0S8Tf6d372x92IND0QK5aOb4ISRzVenrvGLFiG54Co+fyj0LqR2EDWvsWjFubH23n2o\u002F\u002FMkEmAATYAJMgAl8vQR8ThoNZ0IASpQgnuYVhTlH2dot6fT5y5rl8Bs+vG8XzTJ\u002Fz+zabwTNmLdM8zQTxo9DK+dOUuzSNSv4SWZcE4GzHj81p1H\u002FV7gNNUpwQcqJCTABJsAEmAATYAJ6BHzKRh0ncfHKDb1zseSnSJrYsm29MWvhn7pCOurJQr9b9+Nv22cvXqHfFyzXPa0yxQv6vZCOk8+WKR3JfOajjhmzKtSDf39Zih4tCmXJmFZWhcuYABNgAkyACTCBr5yAzwnqF67IXQKGCEGUM2tGzcu6euN2zXw1s0iB3Oqmxz8DRKRVV6Y3gViouHbzTmURrt7xi+YPPi56Y3JHPiK05sqWSdr11l0HpOVqoZHmHS8\u002FoUPpB9JS++FPJsAEmAATYAJM4Osl4BFB\u002FePHT1LCZhbxqR1cuHxd3dT8LF+qCKVOkVSz7Oade5r5auajJ0\u002FVTdOfMKdxRTKrqTV7rNt375utSjdvey8X0yfhooo1KpaS9nTv\u002Ft+EGQijZMS0WvmSRl1wORNgAkyACTABJvCVE\u002FCIoP7u\u002FXsp5kePzdn9Lhc+1GUCKLTpXVo31T1WKAMN5hkd23XdDkXBE5OLC6NEiijrhoIS\u002FCay0ADrpfsPH5ERd7VtaIOFs3o2\u002FWp7rc8nz15oZWvmffykH931f\u002F+Tv+TZdyiLiPrJ4IURfTWpW41ix5IvKt20fa\u002F9YR32EblVL2XLnI4qljZ2bfnpU+DO3f54Hw3aI7AXJybABJgAE2ACTMB7CXhEUH\u002F6XC60IdCQUYL\u002F6u4Df5FWG9ijA+XJkVm3DmyQZWnU5FmmhVu1n2OnzpIZrXrypInUJpqfK9ZvpQ8f9QVWrUbJk+j3CX\u002FyeLExk7JmkttKL129kRC1MzDp5cvXZDT7ofYXEKDvT\u002Fy1pExtb\u002F0Z8Ea\u002Fr3\u002FfviUj4TRChPDUrW1z6y4dtldt2GbYz679RxzaqRlDe3emEHirNEjwUKSX3r2Tv\u002FyindGC1n\u002FfvtPrnvOZABNgAkyACTABLyDgdkH9nvDLfePWXemp\u002FvHnOmn58xcvqWXnfvT4ib5rPAQn6vR9Y2k\u002FObJklJZfuXaLGrXtQap9MYQ6jO2+OAe99ODvJ9SgdXc6dOw0bdy+h5at3qRZNUUy7QWuauWr12\u002FT8HHTha34f1pUmATJhN2UBn3+\u002FOsUG7MWnM\u002FFK9fJ3tQopwGXt2\u002FfU71WXW0W4h48dor2HJL7s2\u002FaoacSNGnvoeM04bf56qk6fD57of8ih7FaM3FobJfxTHxX9BIUyPbnrlW3TbNvqXSxAlpFSt7Js5do6uxFuuV48Twh\u002FPRrJfRdKG8OrSKHvBfiZUcvvX\u002F\u002FwfAFUfbSgn7\u002FcfG6CL2xcj4TYAJMgAkwASYQNAIhhPDmtvlvdN1z8BiaPPMPw9EN+qkD\u002FdCyIYUMafvugCijnfsMIwjEWily5Ig0sl83ali7slaxTd7LV68pd+nadP+hPFR8mDChKVXyJOKYj+n5C32f7Dadf9lBUKCLB9ZrakxT5S5DRmY+COiUKf03dEl4tzlz4TIlThifzu5ZrXUo+m3+MurSd4RmmZoZIXw4KlE4n7J74OhJJYjR1FH9qX7NSmoV5bNW8060ecc+mzytnRTJEgk\u002F6+8JttqBTce3L3dYP3D63CUqVKmhtKtV8yZS8UJ5pXVQCHOf9AUqShfGTh89kL6tXsGwr6fCdKdc3Za6XobAFdFZtdZDdOg5mOYsWuVwDJi7LJg60uE77lBRZGC9RLr8FQkCuV7asXK27sJptClZoxkdOXFWrzl1b9+c+nZto1vOBUyACTABJsAEmEDwEgg1QCRXDuHazdt0+Php2rR9nxCwhxMEbTNpx97DtHrTDoIwefDoKaGxXCyE\u002FNE0d\u002FFq0jJ\u002FgBu9msLv+fzJI6hw\u002FlxmDkHhwoWllMmSGJqEQIOLwDYwDciSIQ2VK1mITgktqlEKGTIEVRDCWOliBTUDJkWLGlnRMMv6eSQiX567eJUQzh6vUK8D3oiXkCoUNUpkh2YZ0qamZWs2SV8mPnz4SFeu31L+VJeBCFpk74qyQJ7sNGfxSkUIdziQVQZeXKCVjhM7BnVs2YigLTeT8uXKSpXKFKWY0aMpZiPXbt4hmPv80HMIGWl+9xw8SpEiRiR4ZYkmIn6Cs3UCK5iadPhpsMLNusx+e9eBo4oLRvQTPXpUXaEZJjB1qpYjmDbd0liYC677Dh+nwvlyUayY\u002F9m09xs+gabNWWJ\u002FWOVFcvLIfhQ2jDwQ0t37D2nHvsPUsddQ+uvBI4d+rDOwqDVDmlQUL25sm\u002FPALNaEGfNoqc7sjtrH6fOXBIvQIohVDIoRLarmy6Valz+ZABNgAkyACTABzxNwuUY9Td5yutpvZ08PZr3QOJctXohaNKpNiXUCGxkdZ8zUOTR49FSptjJcuDBC4\u002FgddWnTlN4Jgb1o1cZ06epN3a4hhPYR2kkITnoJMwxlardQzGT06qj5OH6DmpWpY6tGJDOb2bb7AFVv8oPaTPoJdp1bN1FecLRcA8L1YKuuchMjHKB21bI0sn83QiTPVl3706I\u002F1+seFy86fbu1Ua6ZWsmojVpP6zNZkoR0Zvd\u002F2mpEUx0yeppWVcO8dN+koMObHYVq64ZYkDtu+jwaPWU2adnShw0bWnHpiBcQmLvYzzTEjBGNhvbu5DCDYX0Mdbtxu590I+aqdbQ+C+bNThsWTVeKtu85SNUad9CqJs2rWr4EzRMvvZyYABNgAkyACTAB7yEQ2nuGQgSTk9hCOxk3dizheSMGIVIkwqzjDyYgsO11RQh7CKslhClFi859NYXvYgVz06iBP1KaVMkVPKEjRqAVcyZQk\u002FY9HUwJihfKQ\u002F26tZWaIKiMsYDwz9njadSkmTR51h8E22\u002F7FCVKJGrRoCa1bV6f4pmIlFmySH5a98dU6iVMjE4JMxKtBG12lzZNFGFZtoixVNH8dGjTYmovNNMbtu5x6CpViiQ0om9Xgg9wNU0c3odCivNauNx2ncE3qZJR787fU\u002FUKpRw0tR+FNjqoyd6ri\u002F1+YPo1s3gXGvDu7Zor3mDwgrd64za6c++h5TDv3n2g\u002FYdPWvbVDbxQfN+kDjWvV4Miiu+PmSQzc5G1h3ZfTdbbap6Zz6C2M9M312ECTIAJMAEmwASCRsDlGvWgDSN4WkFQu3D5mqIJPSm0oe+EPTDMaYoXzKM5IGjEYcpz5MQZgokCXPkVMWl2Y9\u002FhnXv3abcww7guFtpeF2Yg4YXNM4T+CqWKUmQDV472fWEf5jrbdh+kS9duKP39\u002FVjYOAuNcZVyJRXzHa02sjz4AT9+5jydPHNRaIkfUski+ahOtfK6QXqOnTpHW4V2\u002F7KYdSgm+MEGPlQo2\u002FUGsuP5UhncVe49eEyY2TwmcIZXI5jl4CUSNut40UuVPKkvnRKPlQkwASbABJgAE\u002FBCAl+1oO6F14OHxASYABNgAkyACTABJsAEFAL+qfLki8sEmAATYAJMgAkwASbABHycAAvqPn4BefhMgAkwASbABJgAE2AC\u002FkmABXX\u002FvK58VkyACTABJsAEmAATYAI+ToAFdR+\u002FgDx8JsAEmAATYAJMgAkwAf8kwIK6f15XPismwASYABNgAkyACTABHyfAgrqPX0AePhNgAkyACTABJsAEmIB\u002FEmBB3T+vK58VE2ACTIAJMAEmwASYgI8TYEHdxy8gD58JMAEmwASYABNgAkzAPwmwoO6f15XPigkwASbABJgAE2ACTMDHCbCg7uMXkIfPBJgAE2ACTIAJMAEm4J8EWFD3z+vKZ8UEmAATYAJMgAkwASbg4wRYUPfxC8jDZwJMgAkwASbABJgAE\u002FBPAiyo++d15bNiAkyACTABJsAEmAAT8HECLKj7+AXk4TMBJsAEmAATYAJMgAn4JwEW1P3zuvJZMQEmwASYABNgAkyACfg4ARbUffwC8vCZABNgAkyACTABJsAE\u002FJMAC+r+eV35rJgAE2ACTIAJMAEmwAR8nAAL6j5+AXn4TIAJMAEmwASYABNgAv5JgAV1\u002F7yufFZMgAkwASbABJgAE2ACPk6ABXUfv4A8fCbABJgAE2ACTIAJMAH\u002FJMCCun9eVz4rJsAEmAATYAJMgAkwAR8nwIK6j19AHj4TYAJMgAkwASbABJiAfxJgQd0\u002FryufFRNgAkyACTABJsAEmICPE2BB3ccvIA+fCTABJsAEmAATYAJMwD8JsKDun9eVz4oJMAEmwASYABNgAkzAxwmwoO7jF5CHzwSYABNgAkyACTABJuCfBFhQ98\u002FrymfFBJgAE2ACTIAJMAEm4OMEWFD38QvIw2cCTIAJMAEmwASYABPwTwIsqPvndeWzYgJMgAkwASbABJgAE\u002FBxAiyo+\u002FgF5OEzASbABJgAE2ACTIAJ+CcBFtT987ryWTEBJsAEmAATYAJMgAn4OAEW1H38AvLwmQATYAJMgAkwASbABPyTAAvq\u002Fnld+ayYABNgAkyACTABJsAEfJwAC+o+fgF5+EyACTABJsAEmAATYAL+SYAFdf+8rnxWTIAJMAEmwASYABNgAj5OgAV1H7+APHwmwASYABNgAkyACTAB\u002FyTAgrp\u002FXlc+KybABJgAE2ACTIAJMAEfJ8CCuo9fQB4+E2ACTIAJMAEmwASYgH8SYEHdP68rnxUTYAJMgAkwASbABJiAjxNgQd3HLyAPnwkwASbABJgAE2ACTMA\u002FCbCg7p\u002FXlc+KCTABJsAEmAATYAJMwMcJsKDu4xeQh88EmAATYAJMgAkwASbgnwRYUPfP68pnxQSYABNgAkyACTABJuDjBFhQ9\u002FELyMNnAkyACTABJsAEmAAT8E8CLKj753Xls2ICTIAJMAEmwASYABPwcQIsqPv4BeThMwEmwASYABNgAkyACfgnARbU\u002FfO68lkxASbABJgAE2ACTIAJ+DgBFtR9\u002FALy8JkAE2ACTIAJMAEmwAT8k0Bobz+tDx8+0KtXryggIIDevHlD\u002F\u002F77L717946Q\u002F+nTJ2X4IUOGpNChQ1PYsGEpfPjwFDFiRIoUKRJFiRJFyff2c+TxMQEmwASYABNgAkyACTABewIh\u002FieSfWZw7799+5aePHlCT58+pZcvXzo1nKhRo1LMmDEpVqxYFC5cOKf64sZMgAkwASbABJgAE2ACTMBTBLxKUH\u002F27Bk9fPhQEdDdAQACe7x48ShGjBju6J77ZAJMgAkwASbABJgAE2ACLiPgFYI6BPR79+45rT03SwVa9kSJErHAbhYY12MCTIAJMAEmwASYABPwOIFgFdRh4nLr1i16\u002FPixx08cB4wdOzYlS5aMTWKChT4flAkwASbABJgAE2ACTEBGINgEdZi43Lhxw7IgVDZId5ZhIWqKFCkUkxh3Hof7ZgJMgAkwASbABJgAE2ACgSEQLIL69evX6cGDB4EZp9vrxo8fn1KmTOn24\u002FABmAATYAJMgAkwASbABJiAGQIeFdThUvHy5cv0\u002FPlzM2PzeJ3o0aNTmjRp2KWjx8nzAZkAE2ACTIAJMAEmwATsCXhMUH\u002F\u002F\u002Fj1duHCBXr9+bT8Gr9qPHDkypU+fnsKECeNV4+LBMAEmwASYABNgAkyACXxdBDwSmRSadF8Q0nHp8SKBsWLMnJgAE2ACTIAJMAEmwASYQHAR8IigDnMXb9ekW18AjBVj5sQEmAATYAJMgAkwASbABIKLgNsFdSwc9VabdBl0jBlj58QEmAATYAJMgAkwASbABIKDgFsFdbhg9DbvLoGBjLHjHDgxASbABJgAE2ACTIAJMAFPE3CboI5gRvCT7usJ54Bz4cQEmAATYAJMgAkwASbABDxJwG2COiKOfvr0yZPn4pZj4RxwLpyYABNgAkyACTABJsAEmIAnCbhFUH\u002F27Bk9fvzYk+fh1mPhXHBOnJgAE2ACTIAJMAEmwASYgKcIhHbHge7du+fybv\u002F3v\u002F9RqFChKLT4Cx8hAkWKFInChg2rHOfdu3f05s0b+ueff+jjx4\u002FKn6sHgHOKESOGq7vl\u002FpgAE2ACTIAJMAEmwASYgCYBlwvq0Dy\u002FfPlS82BBzQwVMiRFiRpVEZQhLIcLF07pKkSIEAQBXk2wJYe3lqdPn9KrV69cKrDjnP7P3nnASVF7cfz5lyK9dxCkgyBNpCggVUCQ3qRILyK9ShMElCYoIkoTKYIISFOqSFNAkC5FOoggvQhW9P755Zhhdm92b2939rg9fvl87nYmk2SSb3ZnXl5eXtA2CusGbX6SAAmQAAmQAAmQAAkEk4DjgrrTXlIee+wxyZAhgxaQIaBDOLcG6znSpk+fXpInT66F6gsXLsiff\u002F5pTR7QMdpGQT0ghMxMAiRAAiRAAiRAAiTgIwFHBXVotKHNdiokTJhQnnjiCUmqtOlWgTyy8g2BHfnhteXOnTtRyu+pfLQNbTQ0+p7SMZ4ESIAESIAESIAESIAEAiXg6GLSq1evBlofMz+E4WzZskVZSDcKgGAPAR+CvpOCtZNtNOrKTxIgARIgARIgARIgARJwJ+CooO6UNh2LRrNmzapNWKKiSXdvnCGsoyyU6URwqo1O1IVlkAAJkAAJkAAJkAAJxF4Cjgnqd+\u002FedWwRKWzSU6ZM6Qh1COupU6XStutOFIhFpWgrAwmQAAmQAAmQAAmQAAkEk4Bjgjq8rDgRYFeeNm1aR2zKjfo8orzGpEuXTrt0NOIC+XSqrYHUgXlJgARIgARIgARIgARiNwHHBHUs2Aw0aO136tTapjwQkxe7esDnempVthPBibY6UQ+WQQIkQAIkQAIkQAIkEHsJOCaoY8OhQAMWfSZJksRRbbpRJwj+KNuJhaVOtNWoFz9JgARIgARIgARIgARIwI6AY+4ZnfBXDreKCdSuo8EIENRRNv7gYjGQ4ERbA7n\u002Ff\u002F\u002F9F6Xs\u002F1OmP54CyvrlwkW5cu2G5MiWRZImSewpqRlvvb+1bGs8ePsyK2KXxy7OvLnNgS\u002FpsTGWdXMsX+tnczszyr1M84LNga\u002F3+0vtsvvTsVNq1924kit7NrUI2nPf4TbudbD2h001xBdWdvkYRwIkQAIkQAIkEP0EHBPU\u002F1YCRiABggwEdZioBCvEiRNH3wP3sgptUb1foG2N6v2s6WfOXyLdBrxljYr0eMo7Q6VJ3Rdd0h386bgMG\u002FuBbPx2h\u002Fz51\u002F2+y5AuteTPk0O6tm8h5Z99xiUPTqbNXSi9Bo\u002FR8f\u002F73yNy48QOfXz3338lX6kX5eLlcBedKZInlWM7Vku8uHH1dbt\u002F\u002FYePl8kfzzcvzZsyVqpXKiuV67eRnXt+1PEJEzwmO9d9LlkyZTDTWQ869Rkmny76UkepbpUv530kZUoWsybRff1Uudpy5ufzZnzRQvll49JZ5rk\u002FBy27vC5LvlrvU9a6NSrJJ++\u002FbZv21m+3ZeSEKbJp6045euK0Wqz8r073WPx4kjd3ds2kZ6eWtiwXLl8tbbsPMcutUaWczJsyzjy3HjRq11NWfb3FjJo0epC0aFjLPI\u002FuA72nsLGzMAZ2bhVwuW65ht9vVIPPv3ebekT1Xk6mx8AqkIG0t7rYDR7dB37W\u002FHbprddxbB0Iul+zO3cfWEYlv3teu7q7p3Gvg\u002Fv97NpoV661HLs81uvGsfu9jHj3T7vyvNXBLr17mVE9\u002F\u002Fff\u002F+TYydM62xNZM0t8P97LqPPJMz\u002FLP\u002F\u002FclZzZs0ochzyvRdYWJ+p++eo1uaqUV3lyPuGTwsm9TkZf+9o3f\u002F\u002Fzj\u002Fx0\u002FJQkT5pEMmdM79c93evA89hDwDFBPVBPKHj1QlAPZsCPBvfAJx4i\u002FoZA2+rvfZ3K9+miFdK533D1Uo3I4MLFK4K\u002F9Zu\u002FFwiXbw3sIRnTp4301ngIYzDw7pTZOu31G7dk3cat8mLlcrZ58TBdvGKteS1N6hTyQoXnBC\u002FWD0YPljI1m6mZj3\u002Fk9z\u002F+lF5vjJHPp08w0xoHW3fukXmLw4V0xLVsXCeCkI74Tdt+cBHSEbd73yE5dPSE5M+dA6cPLHy1bpP0HDxKM3evBAZQew8c0X9ffLlOJo0aLM8ULeiSrGGtalr4XqyuI3y5dpN8vmyVIN4aEGcV0iHQP0ghHXXr9e4K+e338EFirbL5pcZz+axVdrluvRBHzTKkS5VYMqZOKpnSJJUyhdWmaIk8Pzs27john67Zay3C43GSRPFlfLcaHq9H1wUnBtKR1RW\u002FuRM77\u002F8GkT5H8Spy5eoN26yY3cGsW4F8uaS7GsgXLujaX4EqEY4cOynPVGlke2+7SAzgIUgZwW7g\u002FNm0d\u002FRA10hj\u002FcRvr0n73tYosRvo2pXrkkmdZM6YTnPp+1obebpwAffLLgqOCBfdIvzpFwjTBfLmkp4dX4nQL27FezzFbN47H8yUdZu3yaEjx+WPP8NnnqGQQV8P6NZeqpR\u002F1mN+48KCpatk5vwvZP+ho3L7drhJbLx4cfSztnfnNvJS1fJGUsc+naj7zVu\u002FaeUV3hfHTpzRdYPCqVTxwtKlbTN59pkikdb3wsXL8uLLHeX4ybM6bc9Or8jQvq\u002FZ5oNwPnbSDFm9\u002Fls5fOyE\u002FP13uDe5xIkTSslihWRYv9ekYL7ctnkZ+XAR8D6vHgUWxggyCllcksIzS1wv2leXxAGcQKsOQT2QEGhbA7k3qo4Hp\u002FXPvTzrNRxb2wvhtMegUS5CepZM6aRwgTwCDa41fLl2o6kht8Z7Om7e8CWXS58tWelybj3ZtHWHS9kQ8uOqvkHImyu79O3S1kyOB9ny1RvMcxxAg99z8Gg14AqPzpg+jQx\u002FvatLGuNkzoJlxqHL52wP8S6JfDyJGzeOpEqZzONfksSJIpQE4RmCAgZGRkB\u002F5cmZTbJmyWhE6c8jyhymSoM28v2u\u002FS7xOJkwor8aTKUx4\u002FsMHSe\u002FXrpfJmY5EGeEdGlSyfujBhmnIfd5Vw3yfrl0S3YeOidLNx2SQR+tlW9+OC7\u002FGV+GkGuRa4UxkH62+sv6BW6d7UIqYxBdq1lngQB5\u002FtdLrpmDeIbB9VElwHzx5ddSoW4reX\u002F63CDezZmiZy1Y6rEgb9c8ZvJw4dz5i7q\u002FKtVrLfO\u002F+MpDquBEo18gGC5duV7K12kp702dE+Ub4b1QvvYrMmridNm196AppKMgKHSg2Kjfurv0GjLaY9m37\u002Fwu7XoOkXY9hsjWHXtNIR0ZIITu\u002FfEnadapr5o9\u002FMhjGf5ccKLuELCrNmon0+cuNoV01AUKp5XrNkvtFp0jvIPc64pnrlVId79uPcdMA2aOR0+cIfsO\u002FmQK6UiDwc3Xm7ZJmRrNZMO331uz8fghJeCYoO4Ev8imKZ26h1VwdaLM6CwDWmOYm1j\u002FKpYtaVah8vOlXa4hXeM61c3ry9TD3Hj5Q+hf\u002FflUOfjtl7J5xVy5cHCLfLNkppR8upBO\u002F9agnlLETWtmFmRzkEtNb5YqHp4Xl1d\u002Fs0WgpbALnymtizU0b+Aq5PdQmqGn8t\u002FXJvR7c5zcsSxY\u002FmDGPDn00wmziPHD+9va19+4eUtWrLkv5LdqUsfMs2DpSoFWw4lQWmldTu362uPf+2+7CsbuwjM0TiMGdJXzBzYpU5+FcmDzMjmzZ710atVYDbTCa4gXZqe+w8z+M+qdPFlS+XDcUDMdXi7dBr5lXNYae8QZYfKYIZIqRXLjNDQ+FQNwMFhYK\u002F2HmnmZv3afvL\u002FgO7k3brNejnCcOGE88fiXwHWwGiFzkCOcHkh7GzymTJ7Ma2tgdmbNHyfOo2Z6mGcNGfW+7PvxiBmHvnFXEpgX7x24X\u002Ff2LE6aNLHL\u002Fa11wbEvm9it3fCdy6DVqA8EM8z4RTXgdwrzQOuflQt+o32GjROYs3kL7m2xnke1X6zrWCC0Dx0zSfYcOOzt9i7X8Fyt2bST\u002FHj4uEv845nTqz1IXJ8T0+YsUqaGK1zSGSctuwyQBUvuP9fR10\u002FmzSEwM0zwWHydDMqgpvVqGlkC\u002FnSi7ngHVGvcXg4euf8+gVb78cz3zS0xu9uicz\u002FZqMwT7UJUhHQMaKo0aCt79t\u002FvI3DBbCmUNEZ\u002F5s6RTZ5zM+O0uzfjYj8Bx0xfIGQHqmkOxBwlOrsqOgYUwWrPj0eOmUVDsC5d\u002FP50Hh4QmLZd8\u002Fk02fjdDin\u002FXAkzra8HMKfYtnOfTo6H29JV6+WVRrVdsv+hzFmswnP4A+oJlzQwpYEJDDREEAp+uXBJhr\u002FzkYwa3FPOqcWvo96baqavV6Oyx+ntz5etNgVbTE+\u002FPaiHLFyxRmstrl67KSu\u002FVtqSahXNsqLroO+wsVpbY9xv4Yx3I\u002FDGtOvoIb0kxxOPS+8hY3RSaM5GT5wmb\u002FTpbGTVn1hP0LFlY\u002Flw5mf6HGYu0OxhjcCKNRvNtO2a1xcM5kIt1Cpz3zQGGvULV27JiV+uybLNB+X2PfOZH09elA1Ks17h6ZwemwdhckJ35wQFjzfy84L7QHrVgqnmbxRC2J4Dh2TAyHdl+w\u002F7JLKBNAQlDB79DT3UtH0\u002Fy8zW1es3ZM7ny7WAjjJRn4nT5sqM90boW0CJgD9rqPNKF2VGt11H4Xu3eOZ71stejz+fPt5su9eEXi6ijhAse73ayiXVp8pkDteiGko9XVhWfPqhS7ZLV65pTfOyVd\u002Fo+Fu3bivt8REpW+ppl3TGidP9Antq9MvQMR\u002FoW6Bdk6Z\u002FavaLcV9Pn4nU3iXTxr+pNeaJEiZQz8ieUrXic5I6ZQr9Tsd6oeav9lUDnvD1R1gT1LS+629og3pfYFBkBKwT+njiSMHsHQJmQMd\u002F+Ik+zvZ4Jv3pxD8n6r5o+Ro5efqcWZ03+3eR19o21Tb1+5W2+6XmneXa9Zt6ZmGcMlV5vnRxMy0OoHSpocxdDHMZl4s2JxM+miWXLl8zr3Rs2UgpabqZa5Bwr97K3POVxrXNWWYzMQ8eSgKOadRhUhJIgJD+r\u002FoxBzXcu0egA4JA2xrUNkZSOOwYjYBp7K4DRsoPe390GWRBy+WPkI5y61SvJNBGGMHO\u002FAUmNXfu\u002FGEkkRaNapnH1oNCBfJK13bNzKgpsxYIHpz9lMbqzu9\u002F6viUKZLJmKGudqZmBnVgNW9pWKuqJFQvolpVK5hJrNfNyCAfYEBrfalhLYA33m2b1lM2onnNWmGmwi4M69dFmQ3dH\u002FD0VZx6Dw0X8JE+V46sMuL1bnZZQyoONupZ0iWX54tmlzfbVZFMaZOa9V\u002F0zY9y+cYd8zzUDnwdSC+bM0naN28Qrc3DLEz3Di2kyFP3bdMPHD4arXXw9WbWZ9Dsz5e5rEnC89\u002F6u7em9bV8a7q0qVNqG2Zr3O9\u002F3H++WeODcZwmVUrBYnPrM8L6PfLlnhXKlJRZk96WbavmS7MGNbWQjnxQSpUo9pS0Vs8gI+zefyjCIGfI2xONy5I9W2ZZqr6fhpCOC1C8wH4ff06HQOtuNeGqXrms\u002Fo4bC1+fejKPNi006rx52y61ZuiwcSoYpEFIx7sUASaLSZJENHM0MiA9BlFGaFLvRRnzRm9TSEc83mkY5JRzGxAYefj58BFwTFAP1FsLHp7R4U0F9whUUA+0rQ\u002Fya1axbCmX238yf6lUqNNKcpWoKm26DxK81DCi9zdAEK5fs4qZfeuOPXLu\u002FK\u002FmOQ4WKC23ERIlfEygEfcU+qsFTBAwEaApgucSq4YYGna8qOwCpuWxoMkIjWpX14eNLKZA32zZLr84YOcLby3wxuPpb82Gb41qKE8I58yBBiLr1bjPy0xkOcDL0prmp+OnBYun3AOmT6dPGK48J4UPmm8qzR5mDRAwPY9rCZQ5Q2wKWPzZrGpRZRMT3qp\u002F1OzLwROu37dQam+wB9JOsMiQLo1ZjNUczYyMAQdFlclejiey6JqcOvOLbNm+y6zVZrVY8PTZX\u002FR5zuyPS5EC9wceZqIoHmz7Ya+ZA+tVCj15f2BtXgjygbVfIjO9satKzRfKa48jdtes74QECeKb5hlI+9vtO9rO2siHWRisN8LzGiY4mLU8dvJMBOHeSO\u002FEp791x7PfavLS4KWqEapTrWJZtat5AjN+7ab7JlPgfO1G+DMWM7ZfzftQEnl5xu7a52r\u002FP6hHB10uFu7CrAbvI8wYM5CAlUBganBLSfCmcvu2d7s8S\u002FIIhxCe4Z8cWnVfbA8jFOBDBBab4R5hUfRD7l50sL3TuN\u002FPyXOYmYwf3k9P1SocZrh85bosXLZG\u002F8HMolGdalr7mky5i4pqgPkLBgAIuAe8ABhTz5imxcPICHVerCyYvvQUIHzCBKZqw3Z66hEmMEaoVK6Ui\u002F29EW98YtBhhEJKM5JPuTpEKKumZWFjioV5sCnF1Higmh6UBa8XnkIGtdjzhfLP6cv7D\u002F3kkgyLZyMLVk05TIGOHD0pmHFwD9AA9X61tbz17lSXS1oTGoX1Bi6ZY\u002FhJzsypJEOqJMocJnw9xNmLNzzWGN\u002FHOat2e7yePmUSqVzi\u002FqyTx4RBuoCB9NvvTTNLx+8If\u002FAE8rwyb4KWrUbl57XWzUzk4QDfbW+uXDEAfq1NUw+57aOhTVzzzf1BZ\u002F48Oe0TOhCLRZFWm2drkZj1e3fk69Yol2Ncx3PojdGTdDyeBYYpilWbjjRRsVWHwNln6FiXe0F7DYUEAsxaXu\u002FeXj1f7g9mXBKrk2D0CwRAa79YveG43z+q51jfskyZMBqhWKECxqH+PH7qrMs51jUNHjVRPw9hBmQEaNqH9+8qEKqjK0RW9zM\u002Fhw\u002FYjPrAqYJ7wDsIPLGgFsEY5OE4pzJLXDbnA+Uid7ByiztW2bVnRLTHYLi8RALMOCROlEgat++lFo9udVlQWq7008q0rQe9vngk+XBdcExQT+hF2PIVKYRobEbkRFl290TZf6opSYt8apcs0rhg1S\u002FSGzuUoG2z+voB8OEn87V2Gn5urQGLTWd9tkwvFFs6+wOfhAJrfti5Qyg+rIRJBKugDjeDhp9wXPNk9oJrRoCrqvYtGspHnywworSGY+JbA8xz9wO0AfbpRrAuqIWGuoEyg5k4da6+PHfhCunTubVaqHhPLWtkCtKndYCEW\u002FhyX3cv455mhWBWs2lbxAVP69XgaIDS3hhTukFq2gMrFq4a7wvq3meENu855bGeebKmeaCCutMDaW+Dx7KlinkV1PFbPaT2WzDCKTUTBM8d1tDIzQ2o9Vqgx1Z3ou5l4afqTVBH+pfr1VDrWj7Uz5vlyn78xtA+uhhjfQw030gTFUH9\u002FK+XZcqsz92ro89hsrBwxgQpXqSg7XVrpJP9gnUrBw4fsxYvDV56weXc3xPYlmMRpeGZCtx7vdrSpbjjavBiDf3efEd5K9lhjdLHsANv2rGvfDTuDc09QgKHI3ypu3VvDdwedvl2wRrvngezYFtXztNmQnZ5rXHWQU38+HGV96SWcuLUz9Yk+njT1h+kcr02snHZLO0FLUICRjxUBBwT1BOpkWGgAUL0H+ovWIIwyv5DDQYCDU60NdA6BJofdof4wwr0bTv3yjfKDRReYGfPXTCLxksZduHQEEU1QFP1+ogJOhtcC8IMBRpgq7cXaPQghPsShqrFk\u002FDNiwWqCJ3UwklsDOEpLF+9XnmcCdfmYJFsfbcXV6Pa1UxBHRoSTI0bGjdPZXqLxyZR3jjltfh7tnqzQZnwHw3NjLdwWKUxAsxY8qn72QUsVPru+3DtnvU6PAy8rbTsg3t1skbHmmOXwbf7SCjEWhnsgbSvODDQNgbbdnmwR4L778ou3YOKg8ayqtqbAXsLGAN3PXN7b4O3ahXLCOzLnQowD2nasY\u002FMmTxGP1udKte9nMj65YUKzzoiCMOsqVXXgWojth\u002FMKrR+uZ5gQa01uHvOgpCeKUNaPfuDna4xg2rYcCMfXDxiTY63WQdr+f4c+1p3X8u26nDslCS+Opj4++\u002Fw9xfue\u002Fbcr\u002Fr2BfLllOdKFJObyoxmvfJhbyw0xR4i0NR\u002F+9WnvlaT6WIpAccE9SRJom4i4c70n7t35caNG5IiRQqfRqfu+b2dY5Oi69evK+2Kq\u002FbYWx5P15xoq6eyozs+caKE2gsIPDLAIwo2EWr+aj+BKQwCtLPeBFBP9W1ct7q8MeZ9czoPAjoWbcFHrxHcXTIa8XafsH3HIl5DUE+ezPv3zTq9janLV\u002Fu+GaFYCPCG5wfr1HiEhD5EpEmVwmWRqrcs2DQGtvnGglhs\u002FFSjyvMes0BL\u002FsVX68zrcNtlt1MgzBKsJi+lnymsFylt\u002FC5cw\u002F7O5JkCcyH3F61ZcAgfnLt0X4uOhaYeg9IIdqpT0uPlxAnje7wWnRecGEhDuJg9ebTHalu1hB4T2VyAK0GYV8F1aDDDwJ4dAtYmwgsNBHWEWZ8tVbOp94d07t6ofGmL3YAcMw0wn8PaEXhGqduqq+zftNSjC9Rg9QuEY3h+gjmTL7N03toL2+1GbXq4rPGp+cLztgv33c098Oyf+NZAl3054LO+S\u002F+R+pZ47m1VyiFva5O81S2ya4HU\u002Fcq162Jn7nn5avj7EPcOxGtNVotpDBQuI5W3l06tmphNwiCgQ++h8tkX4XuQYI0VFqA6OaA0b8aDkCHgmKAOISpp0qRy69atgBp\u002F9epVSZMmjVo5nSTgh41REXz5f1fagWvX7rtEMq5F9RNtDGWvL2gv7AdrVikfYZdLXIO7RtjJGg8K68Y5uO5rgIeI6pXK6U04kAcusOCX2Qh4SGGTo2AEQ0NulI0XQ2TT2yvUhko3h\u002F1m+5A2ynHqE9qXSuVKK7vPcHdu2FW0hXLFBReLdmHGvMUuPndfsNkdEC4v2\u002FQYrLfrRhlY\u002FDRl3DB5VHEuWbWx+l3e1rax2IwEnh3sNmCyu3coxB1UbhkvXbtvC\u002Ft4es+CupJdpWjeTKHQLF3HQAbSENasHo6i2uiXlUeKxpbfKMymMPOTPm3qqBblV3q4+LO6j\u002FWnEDzLIMBibYvVPAQL\u002F6z7T\u002FhatqcBOUzr8j9bQ5vZ\u002FPbbHe1VBntB2AUn+6Wb8tqFxbII6ZVdPLxkBSqkY2HsK537m+4YUTY8U01\u002Fd4St6dzjmTIgiRlav1zXRUjHBShlMMNq7FS6\u002F+CRoAjqUa27+8ZyEIxzZHOd3cTCfTgLMIJ7HiPel88sFlZY2O\u002FuzhR9h9li4\u002F2LMuHpDAoWhoeXwP+cbHrKlIFPI\u002F6jNh84c+aMEir+c6RqENJRFspE2YEGJ9oYaB0CyT9P+Q9+b8oceaFhWxkx\u002FkOlBTrl4gUHq\u002FThy9kIT+WPuLjGuBbZJ8xfjABfs+8rn8tGwFbUVvddRrwTn3MWLteLWKNSFlbdL1SDiegKcMllnRVo0LqbYBMnY9tu1AMeBQaMnGD6UEccPFnAE457wEvQ6scX3nDwQsmcIZ2MUb7YjQDTpl7KR29sCVdv\u002Fi6frr5v6hM3zv+kQHbPJlGh0G4MpHfsPmBbVWMgbVz0dyBt5Pf2iW3p4TPa+HuuRNFoE9K91Ssq1zBrBneD7qGZ8gPuq7mCe16789RqRi2Z2qDJCEfUczVYwdov1u3pMVuJZ5+\u002FAe\u002FKidPmyItNOppCOvgN6fOqzJz4lq2QjnvBBBGDISNgzY97gOcvKBOMkCql58G0kSYqn\u002F7WPVP6tC4ubaFQcg9rvvnOHGDgWiU1+PM3YA0KZlQQMKBbbtmMLzxWXAYFiHOalXEffoYOAUcF9VSpUgXccowooZWHYK3NVNTDI5CAH\u002FBZVdZvv\u002F0WSDFmXifaaBYWzQd6I4V7Hgtg8jHm\u002FY+leOWGkqVwBaneuIPkVi4ay73UwkVYDETrXaFMCfUQT2e20tgRFRFWId5M4MAB2mXdOQ\u002FeXrD7qqc\u002Fq3bE6iXGgap4LQL2mdjMyAjYYhvCdsYCZaVUtcZSpEJdyVKovPK5O88cdMCjBHYVNXb5M\u002FLC\u002FdnH874wTgU2qtZpfSyYq1GlnHkd2hpo8UM1wAXj6QvXZc33R2XotHUuftPrli8oaVIEvl7mQbGJzoH0g2pjdN8X2lz8doyA4+YNXzJOA\u002F6Ee0KsDTFcoaLA9Pc2+gm48EgKwL4VTxd+0kyFXUk97QZtJrI5wLsBrm8HvTVRzwogSdo0KWX53MnKzKmVVy09hPkubZuZpULYte4TAY30sLGTTTNDJCxSML+ZHgfYKXb0+9O1K8eoKukCqTvkDWvd4foX67IgNyBAk95j8Nv6GP+eLVFEihW6z9u84OMBzBYx02yEUWrzuhOnzxqnevMkY2MoRMLV7pN5c5rXefBwEnDM9AX44sePL9A4B2pigh\u002FPpUuXJK7aVTF9+vT605\u002FugaD\u002F66+\u002FykVVlhMBbUMbQzXAK8GCaePltf7DzelStAVmEd9+H9Fl3autmwgWXPkboLFqWr+G2klzhksR0KRDox6MgMU48MxgBLyQvU2fN1FT1qMmTtfJ9x44oqbHj0abSywMgmB7D3eYmHFAwEDD6tdXR6p\u002FWHg7adSgCPblyIf+NAL6eNKowcap+fme8pCzfdc+uXL1ho7rMehtKfl0IYFGKRTCss2H1C6kh7xW9cnsypyheOi+1OwG0hhMJ1Wa2qfy5Zbjp86Ymk4DhLeBNNwAZlADP08BNuoHNi\u002FzdPmBx9dp0UX+p4RAT2Hz8jmC3ZUjC7ChLv\u002FcM2qh3vc6KRYyWk0QIstvvQ7TilzPVLVGyfWbN821OMaF8moDIU\u002FB6X7BrpZVG4bPsuH3PXLCFL2Jjqf728XXUrtv7lMmFtaARY3QrtuFbavny5MW15wtleneuMkf6+cLFkHWb91db3yURWnbDyrPQcZzB2Vh7Yz7MxkuCrHgHWGs2sCuwyuN9LEv\u002FwKte8PaVfUgwXCk0GfoOPVOmKb354AjBCNAE45BS6Chp9rxd+XXm7QCBh5foCwDy4Rq3dI+5cAB\u002FIzQtV1zl82QjHh+PlwEPD8F\u002FeSQLt19DaqfRehsGFVfOH9ezp07F+WNkOAnHRsbIe95VUZUR+ie6u1U2zyVHx3xsPvcvuoz6d+1rVppXlSwTb01QNtUtFB+WTr7fYH5RKChWf2XzKk+oywIF8FyE2jVisP9Wj3L5kvG\u002Fa2fWPhkDdiKOzoDbIh3rvtcuZ9sILmVMA7tlBGgTSmYL5f069pGvvtqXgQhHemwSNb6EoTLOjuTImwK9d7I++4sb9z8TTr0HGJqjox7huJnAuXmrHHlQtK10bPGvkeh2AztBhUD6SeyutrQGwNpYwt3o3G+DKSxA7Cnv+jcPdOoc1Q+YQbmqe6Ij8pzvUWj2uatsTW7vwEzXxgcW\u002F8QZw1QDsBcyFvw1q6o9guEXnjgMcL0uYvk0NETxqlPn9dv3vIpnadEUDis+myqy3cX7hjhMcb6fML+Fdh4zfqcQz8fVL7ojQB3vlEJgdYdC\u002FNXL5iqn7\u002FGfTE7YhXS8S6ZoWz03TcMNNJH5RPuO+d+OEY7FEA+uCvGIGnbzn0uQjre1XCpy0ACjmrUgRMeW5xYVIqy4AcVGnGYrTz++OOSLFkyr1NwyIMpK5jOnFbmLnDHGJWHOfJ7CmgT2hYTw5JZ70epWljEYn0AnFcr\u002FLFbJgQ8mILEUzMZnkK7Zg0Ef74GlHfz5E5fk3tNd+HHzV6v4yIegFEJ2bNmkVun\u002FKvfrEmj1LbbUbmbfdrkyZLKuGF99UW8tA6rl2y8eHH1JhvY4c9bWDzzPW+XXa5hoxF\u002F2+pS0AM+iaMGM+nVBkcZ0yQV+E8vUzibJE10f6HyA65eQLc3BtIwpcAsF7SR2LTFCBhIF1YbygxRbjaxdTqDbwQgyKZOFW4XbRVqfcsdeSp4wsmXK4c2qfE2yxF5Sf6lGNbvNcHuxxD68NfnjbHy1fyP\u002FCvMz1zYFGjj0tnSf8R45SJ2t4ur3yRJEilzvFoyoHsHtclPQpc7wJQPC2+xdgrmkVZbf5eEQTyBnf3ahTP0mqAt23+Qn3+5qO8G71zPFH1KsGEcZmKcCngWr100Q2\u002FItXv\u002FIZfdwGHv3+e1NmqhaW1H11E4VXeWE\u002F0EHlGCbZjTt4UbxMOHDztWLEwooM3Oli2bT4L66dOn5eLFi44J6WhIvnz5Yqyg7hhoFkQCJBDjCERlIB3jKs8KPbQE4OoQNt4wPcKi9sjCkpVfK28zr8vIgd1c7MYjyxeM6z\u002F\u002FckGuXLshBfPnDtrsr7Xe8FT26+UrkifHExFmua3pePxwEgiKoA6UR48elStXrvhFFWMHCOfx1JQUbMKxgDNt2rQ6DvbrkYV\u002FlSYeNu6wlcdupzCDCWQ8kjp1asmdO3dkt+V1EiABEiABEiCBKBLAJk51W3ZRGvW\u002FZMuKuV43s4ti0UxOAiFPwPu8egDNy5o1qxaUo2J68qjy04tdP+FDHZ+GoI5PLZ77IKSjyigHi1Cx+BOC+j9KUMdOZTChuX0b\u002FqR9d\u002F2IAQPawkACJEACJEACJOA8ASyuxM6cX837iEK683hZYogTCJpGHVxgfnLihG+LWrDJEcxbHnvsMS1oQ0D2RXvuC39o0yGcQ9MOwf2isnu\u002FojZW8kXLniNHDl0vX+7DNCRAAiRAAiRAAlEncPnqNe1pJeo5mYMEYjeBoArqQHfy5Em9INQOIwTxxIkTmwtF7dIEIw4COjTr8NUOLTuEeLtBAbTy2bNnD0YVWCYJkAAJkAAJkAAJkAAJeCUQdEEddz906JDcuBHuv9moDcxToEXPlCmTNnGxE5SNtMH6\u002FEvZw8F9o93C0+TJk0v+\u002FPmDdWuWSwIkQAIkQAIkQAIkQAJeCdx32uw1WWAXsRATmnMjwN4cAnrmzJkFPkwfhJCOumChKuqAulgD6srFo1YiPCYBEiABEiABEiABEohuAtEiqMdRvqDh3hACMMxOMmTMKBkyZNCadCWlR3ebXe6H3U8hqBvCOuqIuqLODCRAAiRAAiRAAiRAAiTwoAhEi+mL0bi7d+\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\u002F++58cO3lal\u002FdE1swSP168gMoOCwsT\u002FBnhkUceEfx5C\u002F\u002F995\u002FL5f\u002F9L+KYyFquXZmRXbfewHo\u002Fu3tZ09odW\u002FO7X\u002FelPGtd3fO7n9u11T2Ne3m+5EEZdu3wNa97HXhOAiRAAiRAAiRAAg+SQKwR1P\u002F6+29554OZsm7zNjl05Lj88edfmuv\u002F\u002FveIFC6YTwZ0ay9Vyj\u002FrF+scxavIlas3zLzx4sWRn7avklQpkptx1oP+w8fL5I\u002FnW6Nk9JCe0qlVE5c4a7kDe3aQfl3aeryeOWM62bpyniRPltQljXGSImcJNZgIPxs\u002FvJ+0bVbfuBTp57S5C6XX4DEe0yVPlkTy5c4ulcqVlm7tm0u8uHEjpG3Z5XVZ8tX6CPF2EXVrVJJP3n\u002Fb7pKOg5D+VLnacubn82aaooXyy8als8xzuwNv7UibJqXky5VdtSOHlCtdXF6sXM6uCMaRAAmQAAmQAAmQQIwhEFHNG2Oq5ntFDh09IeVrvyKjJk6XXXsPmkI6SvjvvzDZve+Q1G\u002FdXXoNGe17oV5S\u002Fv33XZn\u002FxVe2KTBg+GzJSttrgUSeO39Rug18K5Ai\u002FM574+Zvsm3nPhk+7kMpXa2JXLh42e+yfMm4adsPLkI68qAP0c\u002F+hkuXr8mmrT\u002FIR58skCbte0ut5p3l+Kmz\u002FhbHfCRAAiRAAiRAAiQQdAIhL6jf+f13qdm0k\u002Fx4+LgLrMczp5fUqVw13tPmLJJPF61wSefvyewFy2yzfrl2k1y7ftP2WqCR0FjPXehM\u002Fb3VJVXKZGL8JU6c0CXp0RNnpMfgUS5x7idx48Yx8xvlWD+TJE7knsXlfI4Htp6Yu2S2nGA2BX92Vkobvt0hJas2ku927LHk4CEJkAAJkAAJkAAJxBwCIS+oJ0qYUKaNf1PixHlUkiVNLJPHDJGTu9bKj1tWyPEda2TdohmSPm0qk\u002Fini740jwM5OHLslOzYfSBCEXM+txfgIyT0M6LPsLFy8szPfuaOPBsE21O7vjb\u002Fftm\u002FUVZ+NkUKF8hjZl65brNXbXTp4oXN\u002FNayjOP33x5kluV+cOPmLVmxqbR7GwAAQABJREFUZoMZ3apJHfN4wdKV8vc\u002F\u002F5jn3g7Qjhsndui\u002Fmyd3ytHvV8nS2e9L7eoVzWyYGenQ6w25fed3M44HJEACJEACJEACJBBTCIS8oA6QFcqUlFmT3pZtq+ZLswY1JXXKFJovFkGWKPaUtG5az+S9e\u002F8hwWJTf4NVwzxrwVKXYs6eOy8bvv1ex1nTuSQK8OTOnT+kdbdB8s\u002FduwGW5Ft2LMR8rkRRGdCjg0uGH48cczl36uTzZavlz7\u002F+1sXBLv\u002FtQT3EYHn12k1Z+fVmv26VPm1q\u002FT2Z\u002FcEogQ2\u002FEc6euyADR75rnPKTBEiABEiABEiABGIMgVghqINmzRfKS+aM6W3BWk1REiSIL48+6n+z675YWZtT4EZffLnWRRs7Z+Fyc0Fn\u002FZpVbOvib2ThgnnNrLDXHjn+I\u002FM8Og4ypE3jcptbv912OXfqxGre0rBWVUmYMIHUqlrBLN563YyM4gEW2lYsW8LMtWLtfQ2+GckDEiABEiABEiABEnjABGKN1xdPHK\u002FfuCXLVt33RlKsUAFPSX2Kz5IpvdbMfr1pm9z5\u002FU9ZrIT1VxrV1m4BrfbjiPtkvqvG3acbeEgELyUF8uYybdTfnTJbCZulpEzJYjqH4fHFQ\u002FaAov\u002F440+ZMMXV40qeHE94LPPoidPSbYDnha\u002FVK5eVF8o\u002FFyH\u002Fvh+PyP5DR834RrWr6+NGdaqrtQXhJkvfbNkuv\u002Fx6STKlT2um8+egheqf9ZvDZz\u002Fg0ee8KjNjgGX6Uw\u002FmIQESIAESIAESIAFPBGK1oH7333+lRed+ykvJFd1+LCrs9WpLTyx8jn+lcW2BoI4w67OlWlBfv1kJkBcu6bgn8+aQYoWe1MdO\u002Fhs7tLda\u002FLhbTp35RXuzad9ziDb38eSy0Z97w0vOK6\u002F1N7PCDGWz8sICkxsj5Hgii8BdoqcA3jPnL\u002FF0WTKkT2MrqM+22PcXejKPdgmJQsqqwUiGdKl1P6J+WBDc97U2Hsv35ULenNldkh04fJSCugsRnpAACZAACZAACTxoAv7bgDzomkdyf3iDeblDb+2Sz0ja+uV6Uurpwsap35\u002FVK5WVNKnD7eB\u002FUO4g4TbQaq\u002FesvH9BZB+38QmIxbOznh3hF44i8sYGHT1orm2KcKnKHiXMf5Wfb3FRUhPlPAxeW\u002FkAIkbx9kxHgYEsE83QmOlRTcC1ho0UGYwRsDMBXytBxLUFlYu2QMtz6UwnpAACZAACZAACZCAAwSclbYcqJATRcA0olGbHi5mFDVfeF7GKI20EwFC6sv1ash7U+bo4rDR0qr1W\u002FTxY\u002FHjSaPa1Zy4jW0ZTxcuIP26tlU26lP09aUr14tVE22byaHIl6qW1\u002FcumC+31xLz58khr3dv7zFN3pwRzWaWr14vN2+F271jDUH9l15wyQ+mE6fO1XGnz\u002F4iW7bvkrKlnnZJE5WTg4ddF8MWzH\u002Ffq01UymFaEiABEiABEiABEggWgVgnqG\u002F7Ya+80rm\u002F\u002FHrpqskMO2FOhyb60UfNuEAPWjSsZQrqC5evMYurqYRZJ01RzIItB71fba3sq7fL9h\u002F26dh+w8ZZrgZ2CPOgZXMn60K2K5ZvTZhqFti84UsSmZCOxGlSpXBZAGoW4OXAukgUg51X+74ZITUEeMNjDwYn\u002Fgrq0J5PnbPQLB8+3gO1eTcL4wEJkAAJkAAJkAAJOEQg1gjqEL7enz5Xho75QO7e\u002FVfjgWA3sGdH6dWppdr0RkmgDoZc2bNK6WcKy9Yde11KxSLSYAe0a\u002FqEN6VU9Zflt9\u002Fu6EWtTt0TnJ4vXVwXB9twLMQ9eCR8R9B+b74jzz\u002F7jMSPF8+p2+lyDA25USgW6a7buNU4tf1csXqD3Bz2m\u002FKdn8T2uqdIfE\u002FGfvCxfL9rv5kEHoMYSIAESIAESIAESCCmEYgVNupwv9ioXU8Z9NZEU0hPmyalLFea4d6vtnJcSDc60V0oz54ts+mFxUgTrM\u002FHM2eU8W\u002Fe9wcejPvANvzNfl3Nok+ePqcGQ5+a504dWN1a+lrmH3\u002F+JdaZjMjynbtwUZsn1Xmli4x4575rS+xgO3JA98iy8zoJkAAJkAAJkAAJRDuBWKFRr9W8s+w7+JMLvEuXr8mLTTq6xBkn21bPlyfz5DRO\u002Ff6sXb2S9FFmJ7fu2VbDHMZpzb23ysFue+2G76IksHorz+5a5edLKy16cdn43U59+R2ljW5S90WvpiLffr9bMhQoa1ecjntJ+UWfMm6oPoYpC7y4GAHeXka\u002F0cs4jfDZoddQOfPzeR0P8xf4RLcL8A6T9InwmQG764iLFy+OfDRumCRJnMhTEsaTAAmQAAmQAAmQwAMjECs06tfVtvMPIiR4LL40uueNJE6cR6Vp\u002FZrRXo0JI\u002FpLlkzpgnrf4f27qgFI+C1gljIokp08IXzDnaOnv7\u002F++sus7\u002FrN25QP88vmOezgSxcv4vGvicUbzN4DRwRuFf0JFcqUUK4tP9O7rvqTn3lIgARIgARIgARIINgEYoWgHmxI3so3zF+wgU+6NKm8JQ3KtaRJEsvU8cPN3VKDcZNCBfK6uEdc\u002FOU67XXFiXtZPdbEjRtH6kWyo2vjuvfdNuL+cz5f7lM10qdNpWcGOrZsJJ9Ne0eWzp4kWGfAQAIkQAIkQAIkQAIxlcAjanGdq0NpP2u6Z88enbNIkSJ+lsBsJEACJEACJEACJEACJEACBgFq1A0S\u002FCQBEiABEiABEiABEiCBGESAgnoM6gxWhQRIgARIgARIgARIgAQMAhTUDRL8JAESIAESIAESIAESIIEYRICCegzqDFaFBEiABEiABEiABEiABAwCFNQNEvwkARIgARIgARIgARIggRhEgIJ6DOoMVoUESIAESIAESIAESIAEDAIU1A0S\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\u002FCZAACZAACZAACZAACQSBAAX1IEBlkSRAAiRAAiRAAiRAAiQQKAEK6oESZH4SIAESIAESIAESIAESCAIBCupBgMoiSYAESIAESIAESIAESCBQAhTUAyXI\u002FCRAAiRAAiRAAiRAAiQQBAIU1IMAlUWSAAmQAAmQAAmQAAmQQKAEKKgHSpD5SYAESIAESIAESIAESCAIBCioBwEqiyQBEiABEiABEiABEiCBQAlQUA+UIPOTAAmQAAmQAAmQAAmQQBAIUFAPAlQWSQIkQAIkQAIkQAIkQAKBEqCgHihB5icBEiABEiABEiABEiCBIBCgoB4EqCySBEiABEiABEiABEiABAIlQEE9UILMTwIkQAIkQAIkQAIkQAJBIBDH6TIHDhwoZ86ckbp16+o\u002FX8qfPXu2rF27VvLlyyfIzxBzCGzftU+++363HDh8VPYd\u002FEkuXbkmWTKml5xPPC6NaleTapXKSpxHH7Wt8C+\u002FXpJP5n8hFcuWkpLFCtmm8TcysrInfzxftu7cI03r15RqFctEuM0XX62TMz+flw4tGkrChAkiXGdEzCBw4+Ytea3\u002FCF2ZuR+OcaRS\u002F\u002F77n3y1bpPs\u002FfGw7D90VPYfPCJ3\u002F\u002F1XMqvvdaEn80iLhrWkeJGCjtyLhQROILLfeuB3CG4Jv\u002F\u002F+h7Tv9Ya+yYAeHSR\u002F7hzBvWEUS\u002F\u002Fzr79l6uwFki5Nav1Mj2L2B5L843lfyDdbtkvdGpWl7ouVH0gdouOm3Qe+LVeuXde36tulrTyVP7ejt+0zdKxcuHhZBvboKPlyZ3e0bBbmHAHHBfWNGzfKjz\u002F+qIVuX6uJ9CtWrJBr1675moXpgkzg2vWb0vfNcfL50tUR7nTopxOCv+WrN0ienNlkyexJkjlDugjpho+bLPMWfyUzPl0sx3eskf\u002F9z7kJnMjK3rXvoK5fiWJPqXq5CuoQ0Ft1GSBhYSKJlJDeXgnrDDGTAIQIfM+cCgd\u002FOi6d+w2X3fsORSjyytUbsvfAEZn12TKpVa2CTH93uMSPFy9COkZEL4HIfuvRW5uo3+2fu3fN73C75g1EYpigvnjFGhn01kTdsIJKELQbSPyw90f1vAyTQgXySry4caMOweEc+348opk+mSen3yX\u002FdPyU3PrttmTPlkVSpUjudznBygjmGJAYIVnSJPLB6MHGqSOf69Vg5\u002FjJs9LhlUaOlBfMQmJ6fwWz7c5JTsGsJcuOVgJrNnwrxas00EL6I4+I1Hmxoowd2lvWLZoh+zctlRWfTpaOLRtJ4sQJ5afjp6VK\u002FTbq81SEOhYpmE+Qv9CTeR0V0nGjQMpOmyaVZEyfVuLHjyv5A3jQR2gwI2I0gbEffCxlazbXQnqihI9Ju+b15cOxQ2Tb6vnyw9cLZd6UsVK7ekX1XX1Elq36Ruq17Cq37\u002Fweo9v0MFQukN\u002F6w8An0DbmUwOHx+LHkzSpU9gqXFD+Cw3bScW6reXS5auB3i7G5O\u002F35ju6TWs3fBdj6mStiCGkZ8+WWUcvXrFWDyysaR6m45jeX8HsC8c16sGsLMsOPgFom1u+9rrc+f1PJcymkcljhkiFMiVdbpzt8UxSrnRxaf2yMm9Swsy58xelWuP2snXlfEmfNrWZFqP0WtUqusSZFwM8CKTsBI\u002FFl31qwHH79u+SMkWyAGvC7KFAYMnKr2X4uA91VZ8pWlCmjh8m2bNmcal67hzZpEaV52XpqvXSrsdg2bxtlzRo012+mveR4wNNlxvzxCuBQH7rXgvmRU2g6FP55aftq5QJ4GOcQYoh34mbt36TL75cp2szbmhf6TNsrJw49bN8tmQlZ4BjSB9FZzWoUY9O2jH8Xpja7NzvTS2kp0+bSr5bOS+CkG5tQt5c2eXrxR9Lk3ovyhczJ9oK5FbB3ZrXieNAysb0LYV0J3oh5pcBG89eQ0brilYqV0rWfD49gpBubUVtNbhcMmuSHojOnPgWhXQrnAd0HMhv\u002FQFVOaRumyJ5UgrpMajHFixdJb\u002F\u002F8adkyZROvYNLSPMGL+nazVRrvhgePgIhp1E\u002FduyYrFy5Uvbu3Ss4zpkzpxQuXFiqVasmefLk8diDV69elUmTJilzh\u002FjSv39\u002FpU29LZ988omsX79eLl68KNmzZ5cOHTpImTLh9sx\u002F\u002FfWXLFiwQL788kv5+eef5fHHH5d69epJw4aR2zND4EW+7du3y65du\u002FSLvkiRIlKiRAmpWbOmMgdR9iAxMHzy2VKtRUTVRr\u002FR2ye7PZiQTBk31LY1u\u002FcfkhVrYMf+hDSuU91Mg6nGbT\u002FslVzZs8rL9WqY8XYHG779XtXpB73Qr03TemYST2WbCSI5GP\u002FhJ\u002FLb7TtaO5EhXRrb1LAtXaIWne5V9pA\u002FHj4mV6\u002FdkCyZM0jp4oUFdUmUMKFtvqvXb8ik6Z\u002FqF1\u002F\u002Fbu30QsVlK9drTe3J0z9L0qSJBbaV3Tu+4nGq2Sj4y7UbZYX6O3HqbLiNqFrsCDvRl16oIHi5BhL8bR\u002Fu6c4PC3c\u002FXfSlwAYcAYuN2zdvKNBeRxZ+\u002FuWCfKZeTHvU9wULB0sUfUrKlCwmL1YuF1lWn673G\u002FaOwP48YYLH5L2Rr8ujj0aun3iuRFHBX2Th2MkzsvLrzcq2\u002FbDgOGf2x6VwgXx6ATO+996ClWHa1Klk2er1guntk2d+1gv7sFCumVoMbaztwOK5uQtXyNETp3Xflyn1tHRr39yjgGUtH4Lu+s3bZdO2nXpxeIrkyZT5WF61GK+KrU2ye70vX72mzYHwO9h\u002F6CdRyzskq\u002Fot1FTfwzraXMieqRO\u002Fhaj81nfuOSBfb9omu9R3CXUurMzuijyVTxq89ILH36vRVqyHwOJ3PJtOnj6nB\u002FIw20N+\u002FN58+d4YZUXlMxBGqPOY96frZ0NbZf+eST2PPQUsmB713lTBYupmDWpKjmyP66Tu9zfyn7twUWbMXaRP\u002F1V5Ed6dMluSJE6k2XRp20zH2f0LpB+M8jAL9u32XbJH\u002FbbSpE4Z\u002FkyoVE6eyJrZSOLX58gJH8ndu\u002F\u002FKcfVMRcB98JtC6KGeyUmTJNbH7v+2qLpsVr+fPWody6UrV9XCzjzqt65+Q2oxq9NKH0Mgb96glv794z05YvxHcvDICfl+134JX3vlXsOI538oYX\u002FOwuXyg1qzdeToCcmrzJzKlCgmL1UtL7B59zVcv3FL4IABC\u002FDhVCJNqpT6+VGm5NN6dt1bOYvVzMCPyhlFlfLPSqmnC6vF+z\u002FJ2k1bZYt6r\u002F+p5Cw8LyuXKy1QotgFf\u002FvLrqyQjVNCpaOhdOnSYUmTJg0bMWKEz+X26dNH51HCttc8U6ZMCUuTJo1Oi3tY\u002F1KnTh02efLksP\u002F++8+2DCXU6\u002FQZMmQI27lzZ1jevHld8qOsFClShO3Zsyfs1q1bYVWqVIlwHWnGjh1rW74RqYT+MOXxxsybLl26MNTNqGuDBg3C1KJZI3mM+qzd4rWwJNmeDqvxckdH6qVs7HR5ynzApbzvduzW8enyPRempvhcrrmflKzaSKdVLwiXS57KNhK17jpQ55s4bY4R5fKZ65kX9HUlHLrEGyeHj54Ie+7FpjoNmCR94mnzGOfZilYMU3b5RnKXTyWw6bTpnywT9uulK2FVG7VzyYv8+Euf\u002F7kwtSjXJa9x8tfff4e91OxVM1+aPKXDshQqb57nLP5C2Kr1m43kUf4MpH24mcFPvTTClLbarJfRNnyC2ZzPl3utm\u002FK+4tIua\u002F4m7XuFqYGNWbbXgjxcVC\u002FkMHzPUO6oidM8pPIvesqsBWHoF2udjePUeUqFTf54nsfnEe5oMFz9zZawKg3a2JZjlNF32Djb6\u002FiOeApG+eijtj0G2+ZH\u002FafO+dxTEToeffREsUpmfvffQrlaLcKUZxPbMpz4LUT2W8eN8XsZ+Na75u80eY5nwjIWLGfWuWjFemE\u002FHjlmW0dEnj77S1j+Z1800+O3Zu1btPHIsZMe83u7oDwXmeVu\u002FG5HhKSBMsLzGt+7N8dNjlC2NUKZdOl0WYtUDPvjz7\u002FMS9b7m5HqYMfu\u002FWa9je+18VmwbC1rUvM40H5AQXgnNO3Yx\u002FbeGQqUDft609awrq+P1NffmjDFvLevB\u002FhtGu1w\u002F\u002Fz5\u002FK8RisF3u8vrIzzmyV2iaphdv0YoyMcI\u002FF5Rr2TZi4cpJYaZq1G7njpeeRAy47wd4Pv6TJWGtvXG7wHf+SIV6urrShnmsShcy1uqum05qOerfd8Mu3Pnd4\u002F5re9iPDPRLnfuOEefqlmECOVEtb8iFBALIuzVIDFw2DFkyBBRAr1A092pUydZtWqVnD59WlavXi2vvvqq\u002FPPPP1pTPmjQIK+1R364joQryFmzZsnJkydl3bp1kjt3bqVp+Fdr1WvUqKHLgwb+p59+0prxsmXL6nLHjRsnf\u002Fzxh+09bty4oTXyX3\u002F9tVSqVEm2bNki586dk\u002FPnzwu84VSsWFHWrFmjr6EeUQ1wjQib8Pqtuwu0IPjDMeJwLdAATRnC888+E2hRXvOXLl5EnsybQ0\u002FtwebOU4DmABoELHQypv48pXUyHp4AKqkFsuDRqVVjWbVgqpz\u002FcZPs2bBYRg7sprWmV6\u002FdlCYdeosaGHq89d9\u002F\u002FyNlajRV39m\u002F5Z3hfWXvxi\u002Fk5K61MnPiSEmVMpk2MRr09nu2+Ue885Fs+HaH1khj8e7ZfRvk7N5vdBlY2Hv7zh1RLymv97ctWEU61T6U37rbAO3qcFCvjrJx2Sw5t3+D5lW4QB7tVQftU0KBbVWghW\u002FcrpfcuPmb1lp+Nu0dObZjtWxZMUeG9u2stfP1lY14IOH4qTP6e4Yyyj9bIpCiXPIOGfW+9H5jrNII\u002Fa2\u002FI6s\u002Fnypn9qyXNQunyautmwj6vt+b48VT\u002F1oL69RnmMDLEr4jh7d9Jbu\u002FWaxs5cNnE4aNnSwtu7yutNnrZfjrXfW1Q1u\u002FlM5tXtZF4Dvy3Y491uIiHLfrOVhr0Qf37iQbln4iJ35YI4s+fldrKFH\u002FXoPHaNvXCBlVBLSI6COke3tQD\u002Fn2y7ly6ch32uStZyelfVSzQ\u002FCgAw9R3kIgvwVv5RrXXu7QRyZOnStYP7N09vvyy\u002F6Nck79ZsCyS7umcuzEGalQu6Uo4cXI4vLZsusA+fmXi9K84Uu6jad3fy2\u002FqN882ouF82jjzPlLXPI4feIvo3Zq5gph9oJlglkyT2HmvHCzCWjT8UyNLOR8IqvAJSr+jNmEd9WMFM4nDO9nmz3QfkChzTr11R5d4sR5VAb0aC+bl8\u002FW39lZH7yt15A0bNtTNm7dYXt\u002FXyJhzoY2FMgX7jEG\u002FWu00937C57vNZu9qmZalkqiRAlk1OCeyiT0U\u002F0cX\u002FjxBK0lvnDxiqgBs55Z8+X+kaX5eN5inQRrw+Ay1ghwG4uw9Kuv1TPzlhFt+wkbdywAPnz0pF4kDG8xeH8d2LxM0Idp1QxFhbot1Uzjddv8RiQcS9Rs2kl+uXBJa7zRZjw\u002Ftq6aJ6OH9NQOJZQyRqq\u002F3DHSd9F0NTsz6K331POyiTItnCj4jeF5acyU4\u002FfV+42ILnij0l9GvWPdp9ODDUOjXrJkybB27dr59FesWDGtcfakUT98+LDWdkMrvWjRItsqL168WJeRPHnyMOXuMUKaY\u002Fc06iije\u002FfuETRdc+bMMbXejRo1CvvzT9eRnTJhMa8fPHgwQvmIQLkov3Xr1mFK6I+QBnG4hjTvvfdehOu+RKz55tuwFDlLhD1f+xU9it2gNDSpcpfU2l9lyuFLEbZplC9Vc5QLDZ8TwZsmTP1o9f0w4vcUoDnASLuDjQbBW9kozzqKtyvf0DZ60qhj5L9u41a7rFrLkTbvs7pu0Ey7B0NDhbq36zkk7O9\u002F\u002FnFPEjZv8Zc6PzR3dqGY0nggvxos2F0OU1O1fmv4UGAg7UN+gx9mHfDdcQ\u002FQ1kCriTYoH\u002Fzul\u002FXvD99hXMdMjlXDZyRWtuVh0GQiDf78CQuXrdZ5oQUO5PdhvTf6HL9B1GnR8jXWS+bxohVr9XUw8KTJNRiWVxyu37hp5sUB+BntLly+jotmDdeVQBaW6anndRr0pV0wysdv7JcLFyMkQRnG7yRf6Rdt+wCZlLeFsBOnz0bIjwhlNqDrAI27XXDitxDZb91gDS0htNd2wXje1G\u002FdLcJlzHqB9eOFK9g+t5Fh\u002FeZtHmcNIhToFuGrRh118Od5gX7MU7KabgP6wy5gZgq\u002FAfydOnPOJYnRR5gB9BRS5iqpy7dqeN3TBtoPKA\u002FvN3CA1hXvNrugBiTms8UfjbpRZq3mnfW98Cz2FJQJik6DWQhl1hchGd7pPQeP0mmefK6GrUY4QiYvEXgOGO8WzIBYA\u002FoZM6ng88GMedZLEY6VgkCnw+\u002FabpYAM42v9R+u06A8O406nsmYOcF1tNFOpsGMMGaXkWbanIUR6oEI4xmD55Ua+NummTL7c10G+t3ufYFMvvSXbeGxIDJoGvVDhw5pG2\u002FYeUf2p4RorwMgZUajtd2wQ4eduF2AlhzXMQIePny4XRIdl1DZFU+YMCGCnXjlypXNPLgOW3ZrgI25MmHRUbBpdw9oA2zeEyVKJG+\u002F\u002FbZpV2pNB1vTkSNHSoIECQSaeTUYsF726Rh2XpNGDVIanoPSvHN\u002FbUc75Z03tfZXmQqIEgp9Ksc90WGLpilPDu+2te55\u002FTlvXKeaJEmSSI\u002F4YRPqHmATt+Teqnfte9g9QZDP4Vvdk80ctByFlX0vgjELYVcduACc+s4wiRsn4lIQ2BcjQJsMDbenAC88dgH2\u002FZHZQNvlM+KcaB\u002FKeu+tAbaLiLNmyagWQmXQt7Nrw7dqE61dew9qTd0YtR7CTsMH7dacD0YZVfbr0\u002FheYy1F4kT2awqiWjBsRWHjWr1yWalXs4pt9nrKvrxapTLaHnj4O+HeZmwTqshxw\u002FpK8mSu6w3AL1eOrDrLgG7tXTRriMQmY+XvzXwpQVOn8\u002FQP2jS03z2gjJEDuwu8IMFz01Jlq2sXoEV095BjpKtaoYxA84k1AOfV+gJPwYnfgqeyB46coC+9pdriye4WHqowy7Pmm+8E9tN24Xc1U3pFrUOxC9BuJlBrHIIZ\u002FGWEfmyl2ofwsdqzwi5AW4l9IyqVK61nHezSBBrnRD\u002FABh6hvlpT8LzyLGYXMOthXfNkl8aJOMgSw8Z+oIvq07m17VoOvNNHvN5N0qZJKWfP\u002FeqRv6\u002F1wQwzZiDhKrO62kzQGtDPLyvHDQiGDbv1unGszI\u002Fko08+06f9ura1XQeFGZL33x4keM54CrM+WyJKYaDWy6TSbTTWyljTY5OkXq+20lF4zmEdhKfQq1NLj+t+2jWrr3+fynJZPpwZXndP5TyM8UET1GHmMXr0aJ\u002F+lBbeK\u002FsffvhBX2\u002Ffvr3XdG3bttXXjfR2iT0t5FS25GZyuzSIU\u002FbxOo0aoJlpjQNl964HCWhL2rQRX4pGuvTp00vRokXl5s2bcvz4cSM6Sp9YWDKsXxdRGl+9eUvdFyupaahesmnrD9K+55BIp6DsbpbB4lbx18veX\u002Fx2+aMah4WYL9cNf+hgSsw9zP\u002FiKz3djoVcxQo96X45Ws4xfYhpvcGjJso7k2eKmmnQJgq4ORbjIdy+84f+tP3nZdEwph6NoDQlxqH5iRcqQptug+T1ERP0AjdvZjZmxigcBNw+da\u002F\u002F+dBGu\u002FYZAnTJpwvpRcWeqh03blxPl3yKT58ufHANzy9YROdEwEYkCO2xeY2X0K5Z+HUjvaeknhimUwtMEeyeR4g3PKHYPY9w3Qh4wXsKKKPy8+HfNU9mIciLBa5Kcy8DlFAMIQAmMRAIMMAyBNg7agdOj8GH7wny2n1XPJapLmAh8vlfL2uzBCxI8xTAsFrFcMEHm6FZAwQR7Pj411\u002F\u002FyPO1Wsg49VtXWmZrkug5DoBRy8Z1JG7cOOodsNNcJGlUGsqbuYuW69P2Lbx\u002FZ408Uf10oh9wz8PHTuhbG2YenuoRHZsunf75F+VA4KZWJrS2ODJwrxO+\u002F03vOUWI7Lfuntf93DCvaqLejXYKnhaNws1fsH+JJ5M3LITGdxkD6MicNeA74ynsvPecw8DI+I3bpW3zcj2lmHxEoFyDswRPAfXxFPD7xC7iCN6eQ57yx\u002FZ4z70UYMuVOYt07NjRp1JgJ75161bbtBBoL1y4oK958+qCBHnz5tXpLl++rHc5TZnyvjCkLwTxnzKH0aWfPXtWOnfu7PVORnughS9QoIDXtJ4udu\u002FQQqBJm\u002FzxfG1vNrx\u002FV30+\u002FsNZ6jyVQEsZlZArezatWcNoHp4dShYrFJXsfqVtq0bRU2Z9ruwRv9H29lb7QMNOzxB2\u002FLpBAJngfaOncumHhw8CtI5gA08r0EQEGqzC1yPySITihvZ9TU6dPServt4iappT\u002F8GuvazSxMMDRS3lacObABahQLeIYLcPtzPaaHxaq3D8niAE7zDBDE\u002FlC\u002FcEhRcX7NUDmYVAPTG4gWCIkEe5J\u002FUW8uYKn5m6dPmaHuA57RnC272jci2H2pkRwfCC4Z4XA1V8BzGLgGD8FvLnySEz3hvhnjzK59bvh91vwVuBPx4JV3ZAqOny+khvSXX\u002FI4Hh4cOaGJtd1WrxmvZV\u002FaZaF4A\u002FbDRTrlRxaaRm\u002F7Cu5kGGyBhhsPHSC+UFHjbw7HxrYA+zuivUzr6Y8YD21Ntgxszgx4ET\u002FYBnLQRjhGA\u002FF3xpIuy7ER5X3o3wnfcW4KoYwVBAeEvr6Rpmlo17ehqowFPPsyWKqDUne3Q\u002FP\u002FtMxO+lMchEve2EfU\u002F3d48\u002Fcq\u002F9kT0zIcRj9hQzp2g\u002F9qPwJxheiDw9h\u002FwpM7bkCZqg7hQgLNA0grI\u002FNw5tP5Xttxl\u002F\u002Ffp1iU5BXXly0ffGAlcMFCILqNulS56niiPLj+twsfThzPlqOvdbGdijo15og6nDdZu2ilqprjawSOBLMToNpsLy582pzRHgjjA6Ah4AZUsV0y4h4XYOruYQYBZxVC3+glDsybQgmPWDxq1D7zfUgsC7amvlhtJTTdnBhSMGRt\u002Fv3i\u002F9h7+jBPjwF0qw6gFN5YJp42X7rn3K7eEK2fjdTv0gXPLVeuUycr1kGT1RLQicKJh6jGqICe27fm8xlCdThai2yVN6LBiDtgdTqvheR\u002FbS8VSOEQ9TJSMkVwspvQWrm7frSuEQUwV1o552Jlh4vrw3ZY52bTn6jV7SpM6Lys1hAq1hh5vVqmrBGp41DypcUwvqEbCDrPJOE2k10AfG4Nua+PHMGWXnuoVaabBELdbDjAE0k\u002FiDlhPPqflT39GuCa35YtIx3DNCUJ+3+CsZ0ruzaU6mbPx1NbFoz858wYk2ONEP1gWSyaPgOtCJ+tuVYXxPfHlGGb+hQN4LhjYdLl7xW\u002FSknS9euKAW1O0UXGjHjVvhyiVf6m3XbiMOzyyEZJE853SaJOHPwkDabzDEbxmzhNbBqa7IQ\u002FwvxgvqWbJk0Tbd8LRy4sQJeeqppzx2FzTzCPHixZNs2bLp4+j6Z2jzq1evrm3Vg31f5RpQmrTvrQXIL2a9r7R8F6Vh2x6SOlUKWfLJ+1ES0o26wn817IYXLF0p0NhHh1ajnbIFxw6QsLnr2q6Z\u002FnFavRNEpskw6u7k5wxl5wkhHXbGY4f2MYuGmUCtqhW0nd0LDdrqwURkZgdmZj8PMLNhzG5A2wK\u002F7p8uXqE9VLz4cgc5uGWF12lJu9vGhPbluLcrKGwggxlgYlUgby61luCojJ00Q+ooM7FAps2zZEqvhVZsRoKdAp9Sfu09BWMaOH78uJItS2ZPyR54\u002FKl7fWBotKwVmnzPXhS27IZ3BlxH2k6tlHbvmaLaewTMioL9W7DWyzjOp\u002FxCI2BQf2LnWiPar0\u002FMUMEnNv5gZgaFAYT2z9TzEM+o1t0GysIZ7\u002FpVdnRkgnYVsxxqgZ9ebwA7bmhXMejAdxAmDMEKTvQD9qiAKcY\u002F\u002F9yVU8rsBHtNPMiQJ2c2ffuTZ85FWg2YhiH4qwjAoADeXBCOnzwrFeq00sfe\u002FmGWEEqcru3CFVxGWmM9SaDP1txqrRo8IeE5F1k4qWZ\u002FEfxtP\u002FJiBhnhicczUUjXJO7\u002F+9\u002F9w5h5BA2AYfKyYcMGr5WEC0QEuFp81Itdpk7k8D\u002FDhAUmPGp1tMOluxYHzW69Vl31wo1FM99TG57ElTqvdNGmGYvUiwQuyvwJfV9roxfF4AHQfeBbPhWBl7PyiOC3\u002FS82tcmYPo3WXClftGox13W98QvMNds2re9THZxOhA1WEGBeYhdgopNTLeZEiM5RP7TnA3p0kO++mqd3rMN09nal4Y9qiAntw2JYBNQlqnbJUW3vGOXOEt8nzNJgEyBfArQ6djageB7lvvcCV14pvBa1UdkLI+TOnk3buXpN\u002FIAu4ver\u002FGXru7sPzOEy0lgIXNvDbwEDFWPhfXT+Fgxc+ZTJAWZMLl+5LlBeOBXQzzAzmzCiv6yaP0UX+82W75Vr3qg7AHCqTr6UA3NCBAzGEQxtOja2spoW6osO\u002FnOiHzBQMt5dcM37oIMx+Lh167Z+TnmrD2Y8EYw83tLaXTPWZOE5BZOryP6SJ0uii8Emhe4DZOPZCuHfMIOxu2dkcRj0IUT2nMMM7e3bv+u0+B74G7b\u002FsE9nNd6t\u002FpYTG\u002FPFeEEd0Js3Dx8xKpeG8ttv96eerR2C+IkTJ+ooI731erCPS5UqJZkzZ9a7nML\u002FurcQiCCP3TTrt+qmzTDmfTRWsj+eWRq06aFGvr8qDxmjlTeSfN5u7fUapoUnDO+v00CD1LH3UD2l7CkTBKyOygd0nVe6itqYSO8q6Smtp3g8nFs2qaMv4+WC3S2hza5YtlTAO9B5umdk8cYUnNrEIbKkQbvubfEjPIQ8UyR8Zumc6veohpjQvlJqd1fMlsDbCBbsegrYmTDQAPviDq800sWMnfSxTJrxaYSXm\u002FUeFy9flWqN2uu\u002Fl5WvfPdFqIZm8t0ps\u002FTutta8xjF+p+9Nna1PjfTGtej+xC6AnsIXSot35NgpLezCs4k1wPbUWAD2IH8L1jq5H6OONZVtNsJA5aPZW3DvR2ta9LmngGcqvHpA0+stnaf80RnfpG517dsagi4Gwcr1oL49vGo4ETwxdKofKt77Do7\u002FcKZHD2YYRO896Jx5pqc2wUtUnRfDlTXD35nsER9Yw7EDBozGolKPiT1cMLy4VChTQvZuWBLp39Txw3RJ0L5j525rwHoFw0f82+9OtV5yOcZaDW\u002F7r2BBK0xiYeLmbeA0YvyHutyaLzwfwXuV9YZwduHJK92587+aC54jW0fhqb+s94ptxyEhqLdq1Uovurx6Vb1AlQvGn3\u002F+2aUfsKkQTE5wHRsZKf\u002FtLtej4wRuH8ePH69vBXeSM2fOtL3tJ598Ilho++uvURewIBhjMwjlZ1Q+GjtULSopKi1ee11vxjHxrYEe3QnaVsRDJF56LZvU1ldh61iyamNZsWaDXuxpzYKXAAYM81UaaAGwGt3b9tXWvO7HhscCbMVuuJUKlncC93vbnRvbM0+ds9BW2wtN6\u002FfKdjxYAf1cT7GFaQu28XYPEBa2fB8uwMIrTlTDg24f6gt3gcamPQOUVxssbrUGMMB3Qe2oaY32+3iYWpwLzx4QtgaMeFdv4gH7f6uGFK7F8B2sVK+13iYb7kOxOYex2Ytx89ZN6knBfLn0wjcI9PB4YQ146VRv3EFfh1bK2JDGmiY6j7F5FjZocrclX7V+i3QdMFJXBR4X3Nc7YCBlmPZMUotJ7QJ+Iw9aiMfCeWy8BIFC7ZLr0qdGnbG5VvEqDeSbLduNKPPz7LnzUqxSfekxaJTt5lwQhLAgGOY13tzZmQU+wAOrN61X1LsBWlW4kn26sH9OC4ymGO49dx8In22080AVaD\u002FgXnAniL6Eq8OGSgFl2Ikb9YA5B9ZF7Nl\u002F2Ijy+9No0557bUJB7u0aqRblJlSDwfWbv5c23QdF+H7ArEjtGKrr0KpJXfP3EpVK4X0CLy4ILVUZvoTK5Z6VTBnS6qSGkG\u002FNN3JAd32qfNvrTdfchVvM9lVWm\u002FphtsBTgMmgMUODNsKjkDVgEzQ8n8EGzwpsiOYt4PfZQG3Q6D7YhdZf7aWhPdXAJe0rjcPlD\u002FeyfOkv9zyx5TxOKDQEZiwzZsyQZs2ayYEDB7SgC7\u002FmEMrVZkiyZ88e1cl\u002FSY4cOeTjjz+OdrMXg+ELL7wgr7\u002F+unZJqTY\u002F0sK62vhJYGd\u002F5MgRgQtH7HQKV5CnTp0SuGqMSsD0Uv9u7dQOhd200AEPFL1ebSmDe3aUQgXCPd5EpTxPaSH0lyv9jPQZOkY9MC9I0459ddLHM6dXPlVT6zjjxwaN2+QxQwLyawvbb4zGv\u002FhS7QaodkDDavUqzz\u002FrqXpBj+\u002FZsaW2TcXLoHytV+S1tk2VTW4WbUMHzcIy5aUmsfKXDw8F7tOOTlQOi6oSKV\u002F7sJEtWr6uFCv8pNKgF1SLEZNre9PvlJB+5\u002Fc\u002F9YAKD9OohgfdPqO+WKSLaVWsi2jVdaCMUTbkcMWJ79bWHbu1JhveK\u002FoPDx8AG\u002Fn8+YTG75uln8g4pVF\u002F58NPtM1xlfpttRAOu0p4R4BdrPHiglZq8ScT9e\u002FM\u002FX4Q3OHtpKkaNMP2vVjF+npn1Xy5cmj3cvje4CWW44ks8rHahdZd0HcvL9jnbw3qLqMnTpfJM+dJqacLK2EzkxJ0DonaiEl9fzFdn10tPnzVthrj1BqNqo3aqUHTAu0nHVq21ClT6LxrN36nngXntV0xzOWC8VuwrZRbJBZ6Txv\u002Fpp4BnDZnkXajiucX2oWZxn1K+4pp9XjKRPC4ch\u002FnPnMArSIWBmNGT20YpHcDfkat18E+FzBpMEzFsCPwgzDvcWtupKcQrqbOXmiaLTnhOQvP50nT52l3wBC49hw4LLPVHge5c2Qz6xNoP6AgmOfgO6c241GDqu+lYLlaUlwNMjJlSKdd1GKHWSzsrVujkn5fmDf34wBKKTgxgHkQnjmYBatVraLA574RMqv7TlXfrVf7vSkLl63RmnN8N\u002FDO2r3\u002FoF4PgIXqcHGK3ZT9CYagjVkbd9\u002FpnsrDMwWeYd5+b5p8uXajXL56TdKkSmkmL\u002F9cCb2mBN9p7NgLRcgzRQsqT2HKhee2nXrgiR17sQAbC6Y9BTwXTqvnIvYfUBsO6d9UsUIFFK8rymTugB5IJU6cULBXAxZkewvYsXmT2lE2d4mqStGRW4oWyq89MGHXXzwvsWgVsocnb2a+9Je3+4fytZAQ1AE4b968snnzZhk4cKAsWbJEtm\u002Ffrv9wDd5gGjdurDcawoZDDzL0799fqlSpIn369JHdu3fLvn33Na+oZ4sWLQQa92TJwv1wR6Wu0OjgRWsErOq2nhvxTnxiIeXzzxbX29RjxI9pMmg58IeART94qLzWpqkYGtpA7ttW+ZyGoI4QTO8EvtQRnFfMnay3RccDqn3PN3Q2PBzxkt+yYq70GDxKvwiD8eLGA\u002Fer+R+J2ulN4MUHrrjwZwTUr1\u002FXdnqreiMuKp8Pun1GXTG1vHbhdL2pyAzlSx+LZfEHzjA3gIYmmxIqnRDUcU8sIoWN\u002F0vVKmjBFcIGBqJYfGcEvCywCA8eiKzbdxvXjU+4Y9uyfI42t\u002FhCLfDdtnOf\u002FsN12I82ViYIqD80nA86PKcWfFZaNEMJPyO03T2moBHgWQiuB8cM6e1xQTI0sYtmTpR+w8bpbd2XK1d\u002FCNAywmQNwlr2p6tobVgwfgv6Zj78q1axjOxY+7lSLozVmnUIYEaAtu95tTkUNL52i93Qxu\u002FXLNCzDguXr5HV67\u002FVf0b+3ErLBy8q8LIVCgHfzTIli+lBPb6L2Dwo0NCswUvKycAqvRYA5olYnIoFlFZBHfcIpB+MOuL3h356te8wOXjkhNLYhs+CYBOgji0b6U26eg8ZYyT3+xPCbCG1xmLfwZ\u002F0dxsF2c08oN+xWVa3gW+r5\u002FBu\u002Ff0ybpo5Yzrp3Ppl\u002FSz25\u002FuPdSDLVq3XxTVTs1pRcafYXM1ij35\u002FujYVxfe9R8dXjGrpT6yvwD4VA996VyvA4C0MAQqEAd076AEJZtW8hSSJE+kF1JjdfH\u002F6XN0f6BMEPD9gqvPuiNfNtQXeysIMwNqFM5Qb1RGyRg32oORAgMkQvq8fjXvD3CTPrhxf+8sub6jHPaK0IEqnEnoBbhDhhzxXrlySLVu2GNkAaGSg8YerSAw0Mmb0PuKMkY24VymMeNXW6cqm7arWbkCAcmqnx5jc7l\u002FUbos\u002FKd+wsAvPr7wQ4OEU3QGuuiDAQuPzRNZMWnMRlQe6t\u002FrGhPahfphyxvQvNtt6WmnV8YKIjoBZKbww7ipTG\u002FgCxmyOP15hMCWPKVws5DIWxEVH\u002Fb3dA5qrXy9dlc3LZ5trV2D+go1MsB4FC988aa\u002Fcy0X\u002FnFDaaLX9vDb\u002FQDux4DImBtQVvpjRJ9nVTFj2rJmjVFcs1oc\u002FaLBB\u002FoxKY++PEBYT2QRSJzx\u002F4OIUfAso06\u002FIFqcG2g+oK2YX9ypBGpt\u002FuZtmBdIWIy\u002FM3fapNkFgzpMzW6RaYaTHhjyXlAa+oDKls2qxjTJj4ifM8bDYGr95w4TEn3pi7dQB9byEdzlfnx\u002FYtA8D4JEDu0mXts30bQ3usFkvlD+Pz17qjHy+9pc\u002FbYyJeUJWUI+JMFknEiABEogpBOwE9ZhSN9aDBEjg4SBgJ6g\u002FHC13rpUxUyXiXPtYEgmQAAmQAAmQAAmQAAmEJAEK6iHZbaw0CZAACZAACZAACZBAbCdAQT229zDbRwIkQAIkQAIkQAIkEJIEaKMekt3GSpMACZCAdwJYTInFV1kypVe7F0f\u002FImjvteNVEiCBh4EAFmdjk6rUKZN73RDpYWDhbxspqPtLjvlIgARIgARIgARIgARIIIgEaPoSRLgsmgRIgARIgARIgARIgAT8JUBB3V9yzEcCJEACJEACJEACJEACQSRAQT2IcFk0CZAACZAACZAACZAACfhLgIK6v+SYjwRIgARIgARIgARIgASCSICCehDhsmgSIAESIAESIAESIAES8JcABXV\u002FyTEfCZAACZAACZAACZAACQSRAAX1IMJl0SRAAiRAAiRAAiRAAiTgLwEK6v6SYz4SIAESIAESIAESIAESCCIBCupBhMuiSYAESIAESIAESIAESMBfAhTU\u002FSXHfCRAAiRAAiRAAiRAAiQQRAIU1IMIl0WTAAmQAAmQAAmQAAmQgL8EKKj7S475SIAESIAESIAESIAESCCIBCioBxEuiyYBEiABEiABEiABEiABfwlQUPeXHPORAAmQAAmQAAmQAAmQQBAJUFAPIlwWTQIkQAIkQAIkQAIkQAL+EqCg7i855iMBEiABEiABEiABEiCBIBKIE8SyY2zRv\u002F\u002F+h7Tv9Yau34AeHSR\u002F7hwudbVed7mgThImTKDTF8yXSwrkyy3p0qRyT+LxfMDICXL23AWP190vtGxcRyqVK+Ue7fV8176DMuGjWV7TpE6ZQvLkzKbKLi25smf1mjY2XZz88XzZunOPNK1fU6pVLBOhaV98tU7O\u002FHxeOrRoqPs5QgJGkAAJkAAJkAAJkEA0EngoBfV\u002F7t6V5as3aMztmjcQcRPUrdcj64tihZ+UD0YPjiDs2+Xb9N1OOXD4mN0l27iypYvbxnuLvHDxstk2b+lwLW7cifJam5dlWL8ukSX1+\u002FpPx0\u002FJrd9uS\u002FZsWSRViuS25dy+87scPnpC4seLJ089mcc2jRORGMSg30sUe0oV5yqoQ0Bv1WXA\u002F9l7EwDNjrLcv2Z679nXTCb7CgkJIPB3wQ3woqh\u002FRb0qf7wiKote8XqvICJXuSLiCgqKCnhREFH0ilxxQXFDNpUlkEBCQkgmy6yZfaZ7pvee\u002F\u002FN73lPf93VP98yQ9IR87Vvd5zvn1PLWW0\u002FVqfNUnffUKadOlbJKg7EXiqynSwQSgUQgEUgEEoFE4IuJwH9Iov6FAP6jz\u002F8e8fjLW0lOnhwvt33urvKZz36u3P75HeWmm28rX\u002FMt31t+4kU\u002FWF7yIz9Q+nrPDukzvu6ryjf9p69pyVzs4Muf+LjFgs7J\u002Fzd+8X+WFSvmRp2ZmS077ttZ3vWX7yt7Hzio2fe3l4u2bysvZMByHtzLXvVr5Z8\u002F9NHy5l97ZXn2d3zzgjncdsdd5enf+bxy2SXby2c++J4F45xvz616MrJ929Zy8PCRcv2jrj7f2aX8RCARSAQSgUQgEUgEzorA2VnlWUUs7wjf8NSvKl+7yMz27n37y4+89OfK+z\u002F8sfKLr\u002Fvdsk\u002FE9\u002FW\u002F8PKzAvI4zRpj1nK+3XOf9cyycuXCryG87L893+T49jt3lFf\u002F2hvPG1E\u002F32VcKvlDgwPllg\u002F8RRkdPVk2bli3VGJTTiKQCCQCiUAikAgkAg8agYVZ3IMW9x8r4UWagf2Lt\u002F9W+ekX\u002F5AL\u002FtZ3vlgXyvUAAEAASURBVLt86N9v6goQ1q5ZXX7yR59nXY8eG5Ht\u002FJ6u0Pt8Ktnf15ck\u002FXwCnLITgUQgEUgEEoFE4AtC4LzNqL\u002F\u002Fwx8t\u002F\u002Fbxm22Tfe\u002FOXWXb1s3lMY++pvzwc59VLpapxWLuz\u002F\u002F6H8qtt99Zvv6pX1m+4kmPt5nG2975F+XjN3+mHDs+Uq649OLyLd\u002Fw1PKsb\u002FtGmXXMs+tYTOh59EcHCO8\u002F\u002FMu\u002Flo998jPlR3\u002Fq58u\u002F\u002F92fFmZoH+kOU5PqTo6N18PT9gcOHS7v+dt\u002FVr18vnxaJj8y4y6XXXyh6uFp5du\u002F6esWnLX\u002Fhde9qUxPz5S77rnf8v7ve\u002F+x3Hn3vT7+8R9+bmGg8OGPfrL80wf\u002FrfBkAnfk2PHyc6\u002F5bR9\u002FyY3Xl299xlN9PP\u002Fnwbat+XLmn\u002F\u002F6G99WRkZP2D79wgu2zA9unR85erzw4unNt95ebrntc2XLpo3lS258dPnqL3\u002FSok9fauJua99V79wnAolAIpAIJAKJwMOPwJIT9aMiWy9+xa+Ud\u002F3V37dKA5++7Y67Rco+Wt741j8pb37tK8t3fus3tMI7D977Dx8ofyb7acwP7tpxf3nJ\u002F\u002FqVMj4x2Ypy6+13lb9637+UD\u002Fzrx8sbX\u002FOzLf8v5gFk\u002Fdd+7ifL13zrc8o99+2WKcxHz8kG\u002FYupM3nfeke82Do8NFiuuuLSBdV57z9+0IOPg4eOOpy65IVLbPPf\u002Fdf\u002FWN7wluvL377zzWVIMjrd69\u002F89jIxMdXy+rt\u002F+nBhwz3ve7\u002FTRP1jn\u002Fx0+bXfeZv9+Dl+fLR1\u002Fpzv\u002FtbTiPpDbVutjBY5eNPb\u002FqTs23+oPPMZTyuLEXWemLzwxf+r7N4bg4sqioHar77h9wt6v+Znf2LRVWO6sX3XMuY+EUgEEoFEIBFIBB5eBJacqH\u002FPD73UM6UsK\u002FhDz\u002F1uzTReX3p6Voqkfai8891\u002FUz74bzeVF73s58uXPPa6ctXlC5NDIHjzH\u002Fxp2X\u002FgcPnB\u002F\u002FKfy9Ml60mPv0EvPx4QGfo9DwL+6F1\u002FXZ4vwvfExz3m4UVskdwed8OjyyUXXejlF5l1PpeXRRcR9bB4f37HfeWXXv+7zuvHXvC9C74ECyn9\u002F17wkrJ69XD5pZ\u002F5cc0YP7E86poryi23fq689x8\u002FUN7yR39ePnnLZ8tPvuq15Q2\u002F9DNz9H7rb\u002F5imZ09VX75N39XM\u002FF3lR\u002F+\u002FmeVr\u002FqyJzpOXf2FJyNXX3FZuXPHveVVr\u002FmdsmXzhvK6nw8bf2bs57ulalvz5Z7r+fve\u002F+HyrOe\u002F2OWq7fsJj72+PHDgUPnQv32i\u002FPyvv6n84f\u002F5S79s\u002FM\u002FvfuuCTxpqXt3WvqveuU8EEoFEIBFIBBKBhw+BJSfqP\u002FOSH7YJyH9\u002F4XPmmKawdvV3y1zlqc98rswn7iz\u002FrFnnMxH10RNj5S\u002F\u002F6HdK58on69auKb\u002F7uleVm2+7w7PtH\u002F\u002FUZx4xRJ0qe\u002FQ1V5qoYyJyJvf3mn09fOTYmaI47Mde8ByvhHLWiItE+Imf\u002FdU5dUA0Vn255\u002F5dXk+cGe8fePa3l5\u002F8secvKAFi\u002FiM\u002F+GyZgnxXufKyS1pxvvQJNxa2x994Xfm+H\u002Fmp8jd6CjKfqP+\u002FX\u002F8Ux\u002F\u002F9P\u002F5z7e\u002FSgO2602bIWcOd7aM3fdpxh4eGTovjgOZnqdpWp8xzPeapzktf+VqT9Bc85zvLa1750hYRx\u002FTlBpl1PeUrv6x807Nf6MHL7\u002F\u002Fxuz2QXEx+N7bvxcqS\u002FolAIpAIJAKJQCJwfhBYcqL+5P\u002FnSwrbQo6lC1maEKL+adn2nslhx9xJ0mvc3p4e265jFnOv1r5+JLmrZT7y9+\u002F\u002FSLlDyzaeyX3q07cXtrO5Z33bNz0kov6Wd0CSF3cQzle85L8WMF3M\u002FfIrXrxYUHnG07669Pb2FMxi9sjOnOUNz6dbqrb1YHT8gz\u002F5v+Xe+3f7A1evfvl\u002Fb5H0TlnXXXull+j8n69+ffl5raTz\u002FRoELYZtN7bvzrLmcSKQCCQCiUAikAicfwSWnKijMrO2zLLyUujM7KzXpX6iTAQuv\u002FSismFdLH13QjPmZ3IrVy7+oujWzRuddFofLnokuf0ygcDx4uyZHDPVX\u002FuVZ\u002F+Y0UXbLziTmLOGsRrN\u002FBduZ1UffNznXz7ysfK\u002F\u002F\u002FBdBXOOd7\u002FtDXPWip8vmHXXscG+TyvDXCrzHl4KZkZ9cKDftukjIyfKCX3t9eFwS9G2HoyeH7\u002F5VifDBn2+PX6nvOd9z38uP\u002FOLv1F44XTHvTsXxbUb23dnOfM4EUgEEoFEIBFIBM4\u002FAktO1HlB8ft\u002F9OVa4eM+aw+Zm5ic9Awkq6MM66uPD9VV8ln3D1XeUqX\u002FrL6uibvx+jN\u002FXfPJX\u002Fr41tKIS5X3QnJeqo8wLbaO+omTJ8sP\u002FNhP+wXP73vRT5WP\u002FM0f+12C+XJe8cu\u002FWX779\u002F7YK7gQxmo2Y+MTGnxdVX7vN149P\u002Fp5PX842tZiBbhD683jHnX1FYtFsT8knncVGAzxQazOj2WdMWFHYG3Xdd8RlIeJQCKQCCQCiUAi8B8IgSUl6iyf+OwX\u002FoRJytc++Unll2Q2cf21V3m2lWXsfvF1by6f+sxnlyW82JzzgibuxuuuecSXcdXwcPmtX35FedSXf2P57Ofu9suhvNzZ6d741neW33jzHxZWhfmVn31Jefa3f3NZpYEWM+yY+Dzju19QTj5MM+lf7LZ15Fi8U7Bu7epOiBY8XqelJ3FHjp79PYQFBaRnIpAIJAKJQCKQCCQCQmBJP3jEUn7MJGLi8n\u002Fe8jq\u002FYMeM7prVq7TixxP8cug3ft3XGPhTrPG3jNwrX\u002FNbZWpqugwM9Lms3VA0TIgubVZXufnWO05T+Xe0lCbuF376f5QXfO93ldWrhm1Kw0vA\u002F\u002FUHnl3+5o\u002Ff1JqFP9\u002F1+cVuW9deFTPpd9+z8zSc5nvs0Mu6uLPNvs9Pl+eJQCKQCCQCiUAikAh0IrCkRP2Tn47Z8q9\u002FypMXtOPlxbq6nOJyeqz\u002Fb5+4ufzBn\u002FyFcX3Zj71A5Hd7J8aP6OODh2N99B4NqDodTwgYdOG+TR81Wsg99jGP0sAkPux0vuvzi922MPXBvV+2\u002FWdyN91yWxkdPeko12kVoHSJQCKQCCQCiUAikAg8WATmsrMHK6VJx9cmcaMngqg03st2xywy5iHP\u002FN4X+SNAjxNx\u002FR8\u002F9H1dU94\u002F10epeBEU95h55jrYWrOiC+7EEtQnL4Gezc3Oziwa5Yvdtp79Hd\u002FspweY\u002FNTlJBdS9tW\u002F\u002FkZ7f8s3PKWsX7d2oSjplwgkAolAIpAIJAKJwDkhsKRE\u002Fcue8Fhn+tda8eV+rRAy3+3a+0D50\u002Ff87XzvR\u002FQ5gw5W8KgbZWCllNf89u+Xr\u002F+u55eXverX\u002FeXUG667uvz+b\u002F7CosvxfTEKeURfia161\u002F2hI0e9NOavvOEt\u002FvAUemGq9PSv+Yo5KvLSKDPmuN\u002FSy6QLud\u002F9wz87K4mvSzZ2vpvAyjOdbvu2LT7dteeBcuDQYR\u002FPj\u002FPFblusk84HtnDPesGL\u002FWVcnzQ\u002FrLP+\u002FB9\u002Fhb++C3Z8ICpdIpAIJAKJQCKQCCQCDwWBJX2Z9Okyefnmp3+tl2Z82nf8QPnxH3puecLjrvfHfW6+9Xabh2zdvMn6nm+b5ocCSmdaXo49k8Mm\u002FaVazYZ1sVkn\u002FpHkrnjC08+qzvp1a8qbXvuzC67G81p91OcZz3pBedPb\u002FtTrpDOrvHnjhsLqK3\u002F\u002FLx\u002FxYKyvr7fw4aTF6pMXVN\u002FxZ39V+AAQX\u002FAcGT1RnvmNX1d+8Hu+o6Ubq6Q8\u002FoZHlZv1xdOnftv368NBX6qvn95R\u002FuU9b2\u002FZwD8S2tb\u002F+okf0dr9u8v7\u002Fvkj5ZnPeVFh3fQnPu4GleugP\u002FLFYIivuP72r7yiq8yfWhWRB4lAIpAIJAKJQCLwiEJgSZkldsr\u002FW18O5WMvb3nHu8rLX\u002F26VmEhNe9442sKXxPlg0fn26a5lfESH7ACynWyV77h0Vf7ZVk+JX+mL6wucfZLIg4yybKBX\u002FolN5af\u002FG\u002FPM\u002FleSPCTHn9Deddbf7O87OdeW\u002F7y797vjXhgwMd83v7bv1yufNLXm6gvVp9P\u002FaovK5gEseoPMnDIne9e9Lz\u002Fohn+V\u002FnLrm\u002F\u002F0\u002FdoLfpNZe\u002F+A+XiC2Mt+UdC2+Kl6D\u002F7vddr4PIn5Q1veUe57Y67vVEWliF92ld\u002FWXn9q1\u002FuJxTzy5fniUAikAgkAolAIpAIfKEIrNBM6HlZfuWozC5YV3x6eqY89vpr0173C62ZR1B8zFDu1sd77rlvl7+Ues2Vly26PvtCak\u002FPzHiGnBdUH3X15YvONu994ICI711qK2vKYx519YIvJCP\u002FkdK2Dh4+Uj6jQefmTRs0u37VI8rsaaF6SL9EIBFIBBKBRCAR6C4EzhtR7y4YUttEIBFIBBKBRCARSAQSgUTgkYXAkr5M+sgqWmqTCCQCiUAikAgkAolAIpAIdC8CSdS7t+5S80QgEUgEEoFEIBFIBBKBZYxAEvVlXLlZtEQgEUgEEoFEIBFIBBKB7kUgiXr31l1qnggkAolAIpAIJAKJQCKwjBFIor6MKzeLlggkAolAIpAIJAKJQCLQvQgkUe\u002FeukvNE4FEIBFIBBKBRCARSASWMQJJ1Jdx5WbREoFEIBFIBBKBRCARSAS6F4Ek6t1bd6l5IpAIJAKJQCKQCCQCicAyRiCJ+jKu3CxaIpAIJAKJQCKQCCQCiUD3IpBEvXvrLjVPBBKBRCARSAQSgUQgEVjGCCRRX8aVm0VLBBKBRCARSAQSgUQgEeheBJKod2\u002FdpeaJQCKQCCQCiUAikAgkAssYgSTqy7hys2iJQCKQCCQCiUAikAgkAt2LQBL17q271DwRSAQSgUQgEUgEEoFEYBkjkER9GVduFi0RSAQSgUQgEUgEEoFEoHsRSKLevXWXmicCiUAikAgkAolAIpAILGMEkqgv48rNoiUCiUAikAgkAolAIpAIdC8CSdS7t+5S80QgEUgEEoFEIBFIBBKBZYxAEvVlXLlZtEQgEUgEEoFEIBFIBBKB7kUgiXr31l1qnggkAolAIpAIJAKJQCKwjBFIor6MKzeLlggkAolAIpAIJAKJQCLQvQgkUe\u002FeukvNE4FEIBFIBBKBRCARSASWMQJJ1Jdx5WbREoFEIBFIBBKBRCARSAS6F4Ek6t1bd6l5IpAIJAKJQCKQCCQCicAyRiCJ+jKu3CxaIpAIJAKJQCKQCCQCiUD3IpBEvXvrLjVPBBKBRCARSAQSgUQgEVjGCCRRX8aVm0VLBBKBRCARSAQSgUQgEeheBJKod2\u002FdpeaJQCKQCCQCiUAikAgkAssYgSTqy7hys2iJQCKQCCQCiUAikAgkAt2LQBL17q271DwRSAQSgUQgEUgEEoFEYBkjkER9GVduFi0RSAQSgUQgEUgEEoFEoHsRSKLevXWXmicCiUAikAgkAolAIpAILGMEkqgv48rNoiUCiUAikAgkAolAIpAIdC8CSdS7t+5S80QgEUgEEoFEIBFIBBKBZYxAEvVlXLlZtEQgEUgEEoFEIBFIBBKB7kUgiXr31l1qnggkAolAIpAIJAKJQCKwjBFIor6MKzeLlggkAolAIpAIJAKJQCLQvQgkUe\u002FeukvNE4FEIBFIBBKBRCARSASWMQJJ1Jdx5WbREoFEIBFIBBKBRCARSAS6F4Ek6t1bd6l5IpAIJAKJQCKQCCQCicAyRiCJ+jKu3CxaIpAIJAKJQCKQCCQCiUD3IpBEvXvrLjVPBBKBRCARSAQSgUQgEVjGCCRRX8aVm0VLBBKBRCARSAQSgUQgEeheBJKod2\u002FdpeaJQCKQCCQCiUAikAgkAssYgSTqy7hys2iJQCKQCCQCiUAikAgkAt2LQBL17q271DwRSAQSgUQgEUgEEoFEYBkjkER9GVduFi0RSAQSgUQgEUgEEoFEoHsRSKLevXWXmicCiUAikAgkAolAIpAILGMEkqgv48rNoiUCiUAikAgkAolAIpAIdC8CSdS7t+5S80QgEUgEEoFEIBFIBBKBZYxAEvVlXLlZtEQgEUgEEoFEIBFIBBKB7kUgiXr31l1qnggkAolAIpAIJAKJQCKwjBFIor6MKzeLlggkAolAIpAIJAKJQCLQvQgkUe\u002FeukvNE4FEIBFIBBKBRCARSASWMQJJ1Jdx5WbREoFEIBFIBBKBRCARSAS6F4Ek6t1bd6l5IpAIJAKJQCKQCCQCicAyRiCJ+jKu3CxaIpAIJAKJQCKQCCQCiUD3IpBEvXvrLjVPBBKBRCARSAQSgUQgEVjGCCRRX8aVm0VLBBKBRCARSAQSgUQgEeheBJKod2\u002FdpeaJQCKQCCQCiUAikAgkAssYgSTqy7hys2iJQCKQCCQCiUAikAgkAt2LQBL17q271DwRSAQSgUQgEUgEEoFEYBkjkER9GVduFi0RSAQSgUQgEUgEEoFEoHsRSKLevXWXmicCiUAikAgkAolAIpAILGMEkqgv48rNoiUCiUAikAgkAolAIpAIdC8CSdS7t+5S80QgEUgEEoFEIBFIBBKBZYxAEvVlXLlZtEQgEUgEEoFEIBFIBBKB7kUgiXr31l1qnggkAolAIpAIJAKJQCKwjBFIor6MKzeLlggkAolAIpAIJAKJQCLQvQgkUe\u002FeukvNE4FEIBFIBBKBRCARSASWMQJJ1Jdx5WbREoFEIBFIBBKBRCARSAS6F4Ek6t1bd6l5IpAIJAKJQCKQCCQCicAyRiCJ+jKu3CxaIpAIJAKJQCKQCCQCiUD3IpBEvXvrLjVPBBKBRCARSAQSgUQgEVjGCCRRX8aVm0VLBBKBRCARSAQSgUQgEeheBJKod2\u002FdpeaJQCKQCCQCiUAikAgkAssYgSTqy7hys2iJQCKQCCQCiUAikAgkAt2LQBL17q271DwRSAQSgUQgEUgEEoFEYBkjkER9GVduFi0RSAQSgUQgEUgEEoFEoHsRSKLevXWXmicCiUAikAgkAolAIpAILGMEkqgv48rNoiUCiUAikAgkAolAIpAIdC8CSdS7t+5S80QgEUgEEoFEIBFIBBKBZYxAEvVlXLlZtEQgEUgEEoFEIBFIBBKB7kUgiXr31l1qnggkAolAIpAIJAKJQCKwjBFIor6MKzeLlggkAolAIpAIJAKJQCLQvQgkUe\u002FeukvNE4FEIBFIBBKBRCARSASWMQJJ1Jdx5WbREoFEIBFIBBKBRCARSAS6F4Ek6t1bd6l5IpAIJAKJQCKQCCQCicAyRiCJ+jKu3CxaIpAIJAKJQCKQCCQCiUD3ItD7cKh+7NDe8vlb\u002F70c3LOjDPTMlPvuvbvs2\u002FdAOXL0aFmxYmW58sory9jYWJmemS39AwNlQFs5daqsW7+2XHHFZaWnt6d8+tO3lLvvursMKuymT3yqXLR9e3nmtz6z7Nm1p\u002FzNX7237Nm9rzz72d9VnvLUp5S9+\u002FaVD33oA2XfA3vLlVdcWrZt21xWakhyYnSkXHbpJeWaq68u9957b7n9s3eUqcnJMjQ4VFYIiFPKk7wGBgfKWuW9du3aIgXLho0bytp168qefXvLjh33lvvv31Wmp6dRsZw8MVYu2LatPPrR15XNmzaXkeMj5Y7b71D89eWSSy4ro6Oj5ZM3f0o6XFCmZ6fLoUMHy9TURFGxS29PT5kYHy8jx46VtatXlRsec33ZumlTOfCAsDl8pMxMT5aJqZPSqZQN6zdoWy\u002Fdhkp\u002F\u002F2DpHRgsU7OnysTktFTsLf19\u002FWVYYauGV5Xx8THpeXc5Pnq8bNi0sew9cKjsfeBgOXTwUDk5eqIM9PWVTZs2lAu2binbL9xWNm\u002FcKL2PW\u002Ffp6akyODQoPFaUI0eOlAMHD5bREydKT19vWbVmdVm7Zk1Zs3aNdOgvp5S\u002FcdBeMPm4t7e3rBAu1OfJk2PCfWVZv2F92bJ5c+nr7yuHDh9W2Y6WWYG3RrImJiaVx6HSp0KC0aWXXFKGlP8xtY1DB\u002FeXWbWJNauGtZ8px48fK+Mq7+zKHslS+aemnAd5bhJuq1evLrPS5eTJk9alR\u002FGkmfxmrQdthzgDg4Oq7BXWkfoh\u002FqhwOXnipPUaHB4qq1etLoPCc6XqaKV069U2OKRzyTwpPI4cPVYOqiwjSjMxMeFtRrqqwZSVVK4A0VHpFdYcneJPukWcUtCtR3r39q7UXtvKFaUPjJVHKbNqWyq32oTLL9y5Lqhj8p+ZkZzpWZd1hfI5RTmV5ymVk\u002FoDK+QPDPSXAWGOPsOSCw4npO+49KXeZnROvDWr16i9rlWY2obS9PcPGC90JQ1lAeNe6Ud+09MzZUrbpK4dsKOu8adNDAvfnt4+p4l4Uy4z1zlY9KkM7LkASLNC+ffrHD81G8tWSOlTfsRdIfy5NleoHXG9jel6oV0Rf0DXwKDqkjZGWeg\u002FuIY5J77Ex17HPZLDRn2SJ+Fc5+RJG6GuadfDq1Y53swM+JyS\u002FyrFCAcWyK979D8XR5ozuXORg4z5cuanm39+pjwXC6NsnXLmH68QJgImkqvN1pLpcgostQdjty+1kV61BepyRm1yfHzCbZR23jfQ63aKvy465Uk913kjpKpt0D7UmbBfqbxW6nhW9TKt6x751L8C1fZ1jbNXGvTAhQRLUX3SopQNbUTpZnVt0Um5f6AoTXEiv0YAQuTwm497hCztL\u002FngOvPqPFZA4HvGtgQGcvN0pv9ZIfxqHkQ5k6MfqfUa8Rq5NZECwRBVjHnTNtF3js6K38pTxUMPXPXjOu08d3pJdBGRpfinmgqNMPKbm0f0p\u002FhGnUfi9nH48yu\u002Flp4+c9TqF5IjDgHVnz2aq1UrsKkj5cb9K8KalJFF6Id4ubkyaH+Nno5bj3WCLOIrfHZW18M5Ou6z1HVo1U7k\u002Fq992hxFPGPvhG29nbfV4Cgc5bNebpdNuY1FhDtmc15xIMTH9SKMqC4bssCxtheColVR9lnf07g+nW+Tjp1xbnDjHClunzownpZLe402izS87O2fSFPTOg04N+23gicv6275jQCOEVTL14jTvXSgbFq3uly8ZWO58uKtZcOa9j2CJOfD9bxS7nwIRub46OHymY+8u\u002FzFH\u002FxqufPWT5R77rq9HDywvxwTKaQDp+AQt6MiZQcPHSqf\u002F\u002Fzd5bZbP1vuvPPzZe\u002FevSK1IpjaP7B\u002Fv8j0YHnM9deLzG0zYd2wYaMbNUTmqiuvKqsF1r333lc+c+ut5UKR+Cc\u002F+StEMEfLRz78r7q5nyz\u002F6eueJmK6tfzd+\u002F6+fPa22w3+9ou2i+Bt9o15WAR3q8IZJEypM4esmnSqM4FQcwO\u002F4IJtIiE9zmfnzj3KXwRQhAPyhOMimBQJuveee8t+lRMiMybSPDU1WTaK7K\u002Fs0c1GN43Bwf6ySuRzJReZrgEGBBds2exyQagGRHi4gZG2r0\u002FkQp0sZAaiODwsAjk07JvTyGgQTHDkMuQGNjJyXHge8X56ZsqkZbXkQ2Q3iZBvWL9O+a1WYxu0zH5umspvSLKRAUGBYEEUKWuf8oVgc\u002FMlH\u002FQCHxovfpAf\u002FCCr4BE4hD4OFzbo74uQG4DScaGBM0SdPenBikEL+8nJKePITbVXeEEAexqyNTQ87MEKOk8p3nENjCCLyEd\u002F5Nd6IQ64UUfkyUVKXnGz1iBDZa0XIR0+53QM1Du6t3QRrjPqQBUUF646AzrDfrVJ6gSMahsgkmUJQ\u002FJxeeVH2yBNJYyQXpNfMNbGMbpClMGL8jKoAHsIej+kW8SEjWsHhNGXgQ56mlS784ny06PRvsiTPfLostAHHayz9rgo1ikTVwgwxAb5im0sowyQm5BXy9QOj4EQeplQu1\u002FXD2ScP6dTWp3rR94iZb5udE6Y8jMu8kdP4rMpadNRR7sCf\u002FKmHpFNHVE+XO1oSYcsl5uyN1vF3QSeNNLDeesYwkY8Bk60GTbrKgXcdpRnq8xqRzpp6Wg9rcGD\u002FzlXGcTr3MgRvXDV3ycP4Qd5nfrMPxZq0WCkS70f1z31VYMlhJrXgHK6TOr6wfm6kj\u002FXEgMsyCONj2RuD6q33uZaoD7IO+qPciOB27wGuTohXuiGHvJ1BPbEqzvqTycBkYJUjzQU7bnGnATl0cEn7T0ycNU\u002Fzs7f79LkUwvf7Bt1XRMq3znn0bSpdmnnysOfaz\u002Fc3LCaB\u002Ft6TJ2gQ3Utf3nU47qvcbx3w2qn47qrYkJFrsvOFHHS+VtD58aT\u002FooU1w6xQ47LND+iBaA97VEnjTqkss46d9laanaW1IlbZaT1Rjkjsn9ru2vyQRfiLLaFxCq3ybvDs5WukVfPae++H1TZbv\u002FkQ8SqfN2HQNI2R961z2uKJpx4TdyI0z5vBHTIqTKrDIKixhxpPv6S28a6nbYmiZT6bQYfyHCslu6W2vqx+Jrd6eIc70zpEQ4\u002FOq4J2l37D5dP37WzHB05UTaKuA\u002FpHn2+3Hkj6nd\u002F5oPl7o\u002F9eTm4976yZ8+e8oBm0McnNZOsgkK83IDUWJjNWy\u002FyuFHEGxJC5w0RZNZsZGSkHNWs7mHNLo+MjJYT8jtw4KBnwC+77DKRuD6Tum3bLizrNYMNyfzkp24pt956WxlaNaRZ7keJgPZrdvkekfAt5YYbb\u002FDxTTfdopvFrGbXLy+XX36FOu1ey4EAr169VrPUE55hXq9Z9M2bt3j2cOfOXb6w16xZ6xsNhOLiSy4uGzRbDFE6rsEHs6LrlEZUwuVk5nyS2XP5rNFAAnK2ccMGPylYo1lSblzgsUrkk40GCzm7RLP+hHm2cuKEys2srWa6dXPbvGWLN2aFx0XSjomoMvCZ0c2QjoebGBdlEG4RXg0SmA1mILJag40hjQbrDZO8qQcuYAYjvsjsSR31Kc2wCSIdGH8QGAYY6L5KstAHYgnJR2\u002Fy6RNZo36ZreSYMkFYmf2mgdONQZqYwSSdB2y6eUL0md0eHxs3OYQsMhNXdUUOhHZI5fAMtwglsw9TUzxRiIEM5Ya8gwM6MIMOTszgccOXCDvCkY0elcwjAwIIkcOPMEgwbQHdkAuWzEYHMVZZFBdyR148BRjWTDyYoDPOM3ciz+GEoPJFBRPnSk7ZSw74U2YI\u002F7QGE8RlUAKm5IN\u002Fj449IBBJZdYcPcY9uKHMMRPqOnQ+kGewhtCSXpWtzAmHjHsAI7lVNwVYBwYqdVAlVuNgy2zaCh6elZCwmAGKARDyIc4MGCSilY765tRb9ZdfEDDlr3wjlD0b8mNmpYluP8dT3CqbqBBssDHXcpnlB45uNyLfLndgV4+JH7OLzNDHoIX2RN7kFzP5GnAor6p7KCAtpZfLIY+W\u002FjpGzpmcZSFvke1MaWvY\u002FLTVv3NPnIfqKEunnPnHRsVVFeVp1Qt5Nxt9Kw5UfA1oT9\u002FHdUIb4bodOTHia5cKXanZdNo1YmOQS38xqXjTSPCm4a\u002Fw57qgD2l09MCvtiHyV1TXmrX0\u002FHzVd4XriOtPadGsqqvGw191neWtfg\u002FHfmnybcoxrx0EBvqd579ouU5rz218ahrjKHm15XfKbh0rnGP+qmuFycNhZ9SJdMqj0Ye8XIM6aPm1wgipjgjR\u002FojXOUtL9Ejbjk0qp268GpFVmPaUg76yXQ55ONy\u002F+nEZO4I7Esch8TuyjOSRwL+NPEfheIEtsCMGbbhB1VHRrybhOM4rMXffTP+sMvheonD7cU5cSYxfZEd6lI78CMVXTsGOF9Ei3PlGmhoz8o8zktmhYBw0chuZ9hP6yCSXGo\u002FonDq80amG2Y80hFqpiOc0\u002FmlSaVfTNPvT69ZRW1Xj\u002FGqaCGpkOKStE3GaeAePjZRbPn+fnoYPlq0bZYVxHtx5Ieqf+8T7yh0f+6sgXiI2G0ROIR2QMMjZKj3Sh7hRoZg7MFsNwVmveGtElCk\u002FcSEijJQm9Mh09x6Zndx9TzkuM5H9+w9q9rghf9oz48jM7HqZh1wi04ljinPvffd6ADA0PFhuv\u002F1z5eTYyXLjY28sT3jCE\u002FSonhlYkTml2eJZ9EGTMS7oAYHNrOvhw4f8qJZjCCT5ow\u002FEFL2ZSb3wwgtdNjjQxMS4CBpmBCKSuqYHBvQ4XyYNM7rZcM6Nitl2yoYpycmTJ0S2REi0ycsN9ZjMKZB90UUXeTDC4+GVksHM6fjYhOSs9Ow7M\u002FArGKSIAEMmMVmYEF40WkxT1opIM3vPDZG0yMSMwIRVx+QHoYFQBkGPPGqnxs2VvIhP2jADmDXBWy3ZDK4qyUYOOHJOHXIz9gywyCDyeNwN3mCHLPAFu0EGZY0uECdu0BBiSD0yMeMZEvEdaHRQ1CDEakfMyJq0qqNhxnmtTBYwDWKwQ3nItxJXytHr+O3ZOgYHPDFB1wGZeYANTw\u002FqEwR0g6zTObtTV18AYaZzYzYQXDvJJDjS\u002FoY00BvW5gGMBiq1rVAe5NCW2DimPJQfkk5ZiIN8HIMyBjXIgcBggoFZB+YuDGK5dqj7SbV94kGM0BU9nBf6KR\u002FyAI8YlKhTlmznafIOhrGRDuJOmayjZHMcfSdYxmblJAVsTejl73ja47h9MMiYgeDLi3ZU5dWyU8+4mA2HIIcM\u002FGMLbFHWNxrjE0RO2jste5dVenPjqY6yIddYUkbfiCoxbzp7Issfh9q0D9K5jJSgQ4br3zFrOGmirMRjq66eL7SvcR7KvlMucjrzrnIX8qth57qPtjm3XDVt6AD6CgczonVsIBPoRN0zkKN98\u002FSGeuK6AXSuM\u002FKhrlRjPkamr1WF9eopousQkzDFqQNNw238G\u002FKlCRZ1hNbFZadeFYl2Y11RTvGZbJO2TTF8QkhsxPVsaaRpIj3su6WoO5eIgrlk7SJQwqg7B7YDFjmqbbwdfHo69QgKln+TX9W\u002F5rPYvi1TSV2h7b1riB\u002FVGTo0h05inVp+7f5ojq6qaEVpnA74b2S1fB2hxovIjZeiRJ5O2CRolcNlNZJR5kZ3ojUQaF\u002FxaBJ37IhDPk2OUTbya3lGCJGIu9CGuPCPfgoV2Nzede9A1yDgcS1x7Ik7riFdfw6jv5O\u002FzxsBtR6QbvnyZ+\u002Fcmjx8Gj6NN\u002FlFHGL7r56TPgKdLGSRuHXUhDdlNhpcoe1wDo09BwymSduR3ilbfjpT3bfjkCbyq3rIx16KGJg3mqF3lev8O\u002FIgDWGxd4LmuPFzsEJVZ2R3z54DnjzavmVDRF7C3yUn6jd98C\u002FLe9\u002F5Os+orhah40bObOtmmXZAHuqjesxaIJiQJUgrx2vXrhO5ETkRHJDE1auZaV7VECpmSDEJmTWJh6zAB5glxlSEaqBTZ+b8oosvtA02s9l79u42YR6Qucmx40fL9u3bypVXXWnSCQHnsSyVSVocs9jMjp9QGDbd2PS6srjpK5x82YJgYV8LScMOWbNBIjiQ2lPa0B+Cir045Ap3QnbQ5Ll37z7Zfx\u002FzLC2kbFY2xzSgQ4eOaJChmXkRN0jCOj0l6JdsLjDiTU2J5CkexGxCM7y6DwahlB+yx9FVoKDT6tWYyTBjHWYOzJBLjHWkYdmkRQSVstFXcNOE1GMDjM4MKkzypZnJt4hon\u002FAP84a4cOJi141W+mCuEsQ+CBIy6yACDCHgyIFQ2\u002FYbAmoyKVthyeb6gHRC1pHHzZx6hWTSETF7CvGFVOsWb71pW9Q7ZaR8lXhDCE7Kbpp6oj5wzCzHFkSgkgfCyJv65wkAxN3lJW8RDPyx2V6tARgDTEh8mK1gVx3EGB3ocGkD5IHemDDx9IGnAIMi7cipnSPtjTyJT9nIF0JNuHyMJe0c4k9bABdswr0xQBWWJsQqP10E8khrfVTJ4EK5kU\u002F+mE85\u002FyZebbv4sYEfxDdckCDqoDqIOXWFIy66k69vgjTClou0MSuvgYl17tBXZYo6AydmWBuzJGFXZZGWukYvbijoajJOplV\u002FBhZqC8gIzKSAwrhmOK9lbWkGENUpHv5sXFeoH08IIgL60U8hL+RQ3mjv7HHz95Hy\u002FP7WPOfnUnXDf7E489Oc6dztuCnnfJnOy576cRuIvZsA59QjXi2cwDgGRWBK\u002F0gcRVB70jWuOuZas7mV6py09G20d+JQ79O6ltk88FZ9eYCna0wHun+zRV9AfJxSxW8zUx61LS\u002FytYvrlMOIqfZF305+zRbxHt7fitlDy1UlMgz+aYv6AsvmOmqn1tE8efJpatphnbjV43PZz29rc7LkpDUSjBBq0G2Mdub6tE+ral3DhEX01m\u002F1iSYQodFcolz4xFHTeggEM\u002F58yE\u002FTRpAqT6dxIsL4j31z4rzn16mvk0a\u002FWg6Ut0btH6dd9IdstOlS0F7Xg7Yg3hxz7+UaafpBXT8c04fWMKfhOiKdZOBa10g9Jwx\u002F8nC5fGY\u002Faj7SEB7XXtR1+DpNFeyY+kFe4zcnSGJ1x2hikYccEfzfsUcL+zdxHK19XHVyQsIaTZ1vldnsaQPRDiKryAsJnfIIi\u002FPq2zqT\u002F1w\u002FBIfDH3OY1cMDZeuGpZ1ZX1Kivm\u002FXjvLW1\u002Fyob6J0xDhmUiFpmIRgX47ZxBoRd\u002Fx5bM9MLOTskF5aNIAGMh7bAxakBNKBGQNpMcegkZ2QXdDuXbttooItN7OPF2y9QC24lHUb1pTL9BLpmGzU77v\u002FPtmHr1P+a8sB2bqD\u002FwXM4ksO+UJwIQeQHPLDj5cFsZfmps1AgCcCqzVTjYMAcpFN6aU9bOsnZRqxSoQY0wf0nJhQuGbRsUOf0sugkEVeyuRCgQwxQzrB7LIuHso7dnJc+DCrvtLHIyrXSfmNiNCj1zG9QAl+3LxM2ETUjh8\u002FUY7qccuUbn6QPOLxIuTI0eN+CZNHxAxILti21aSdvGhe9SkERKjOgPPin00FRErBmvJ7wCEZKMjNlNlnTGcYRHHOAAmiGPI0s2s7aZFi6egnBOQnLCF3hBGXixqCjhwceTFIAhOwozMhPvWB2RNlrjMAJk+qC8gjGGDOwoCBDSLALDfxGfBwTv1QhiCF4edH69KJl9OoC2Z7sen3I3a1VS6ySlgpI50fDnnM2vOOBAOFIKoqn9qZB1Tah34xE0y5YxabQVzzwqNwo\u002F16pl37\u002Fn4RfMnFUS8cUyfkBU6Y83D9DA7oxVLJYzZdRVdnoj\u002FdvNg7T5XBHb7kMECoM+fUP8QIUyyXSeVx5y1ZdcY5niAE0ZW35RCHUiOT3NzpK7B2yODCYAydcMRD\u002F3pjADPiOn7VkXqzPCUgf5URHRgQuT1xTZAG\u002FwYDSLgHUjUf5wVWKmdD0pFBGnxDXemMfOff6Kc7IyWpjrqJklE6RVd6BnWQw0gXbYm2Q1zycnmIq\u002FO6VXnsyan6L7Z3vI70C8UjzpkcaXAtLHU8X44jPMQf12mTF6JqvvOPjaNUAvuKctUNTN2mVUd+qgLxlnPfobbME0WeULofVH3xtIp+iLahimjagq5jyTdRV7\u002Fqa9kYEic25jdogehiZ3Ieh8yihx8HXDdxK4422oRppxajMka7r76dZa5+53u\u002FNHkKMOqkExPKSH3W7VwKUq\u002FXVlylX8i5PtoB5HOmzTq0o8eRVW7Lpy3VqnNhKIv0cdvSnntdPbefpUSaVjritPLpOCabFg7o2pwrPq513lkO5R99mvb649\u002FOcjgNP+\u002FJtTO8FRVPylFJaTtaI6GJqbOm\u002F1oYR18emiVXPF0Dvj8qvvtUn4df3E90DEnXNRjhyA4traIL28q2dVC9Q2PFJ02TroGJkrg8vlYtrAM\u002FJDXXYROrA5JGapMJZ7V2Ih+uxdMQcV6EE0ia013k3yR2cCsmabQ1MRQWuc6X4XDyIEazb8XhvIZFhDhfKJ7C79XM+rWXbdP9e+ls1us0Wkunh3Lw8X96p3HA3IFZSIgXe2bPd+\u002FeK1OU9Sa9rABCxwtZ3KgXHLGxvv+++23esVVkG\u002FtmeBKkSjTIhKNHrXNGL0dOa9WPadsNj+nF1IMy+RjTdrL0CrRTIs99w5pZHeqTzfoa2YKv1guo10oQxGZas5z95QGtBDMscxheDN2yZaNnHLmAsCfnhrF2rWbweYFT+UOYMKvwjK88ZIjjWXAwOqFBAKvLeLb0ysv9suh6rRSjOTqRfGZzJ5THFg9QWOWEToWnA702s+BRMC8rTpdjM8dNMsfGJoXVkC6sfskeL6Mjsut\u002F4IAaGIOctaVfF1xvz6BJ24hWcxkX2V91dEQ29JtNDHtkCoMJCivIxKx8j14e3eSLlJn40emTJro0YAgkK91AdIekFyN9Bk5ciIR79gr8lTsEkM4DxwXfB86KOCl9GSBBaiA5kNNJERuwcrzmmNVEMCOBOELKIfdcNXS4s7qBky+kDBnYvdMmGCjxNOLkSVY6YdUI6kODKFn3cBMaknkUM3Fr1mjVDslh1RGeyDCrz0VGnRCfwRTlIV\u002Fa0pTaDc6DMpWF8rKhL3EiHv4xKCC3SkzJh0EX7dYdrs5VAgtQcuUCTkFEtZNTuOIM6onILFiI7M8MY7oypcGQBqkyVYpB0Yzyj86kkkWSQ9RtDy+8glyr09XfSurI\u002Fb0OlAeOsrLyD3KoLwEmPxEj\u002FcTAIsygKKw7IdUVOhLOi3gur2yAwYp\u002F0s7qp0WekekbggKUJ\u002FEiZ8VtbgaUFZ17FcCqNAycOKeeycxlE1C0e\u002FoEBj7UIWEmYS4JujBg4kkFJLrJhWyVI6QP1GmPxCNP0lZ\u002FlOJYS4AojhIpnL015lzObXklAAZJR79o3+SFPK44tW+1S0zuZqUiAzLrhP6NHGSRvzyA7Lw759WRi\u002FPs0IWg+XE6oi\u002FpIfmAFi6OdVb9tGfCwm0SvHRODXDOezSYFO7USl233\u002FE5D1wxo+OJKy+W22xPZn2rdM7g2DOF6qNWqD0gn7qdhJ2rXbnO1A5w3CbQJ+zQqXd7+4fr0u0b1h\u002F\u002FTR2qDLSvimFTjw8Xhm0Nu\u002FDIjc9wCmqutTOXoWJKNL\u002F4q7psOVdc6yzqTuGRZq7gSBVhbncdclphVRQy6nGznyPNJ3HtsmJQde2jzkT0S7Riylxj6Aw\u002FNb4VDotQFwB5jW7uf3SMl9N6j2zk1T+dOcnZsERC+3qqMsmjtSlG3E+CtHOdSLTxNCKorT\u002FriRrVNfpVPdxvU4bOqFxodiir\u002F6aMeM05diJylUMgO8WtqX3e+Lc9owyOPOenprKClrdCfX7IqBHJgw2lIl4rFV76IxRd2u2KGIEnbdK1Ia9aX46uH4e1ytnk4ZTOLeTyq\u002F8aDckfv21HefqX34iYJXFLRtQPPbCzHNp1m25ofTYTgLBx04OEccP77G13GKiLtNLKFVdc7hnqi3W8TuTdJhMC84g6cUYhG3o22G+NTF8gzThmIwFxRsSFWWxkqguW\u002FfFKvW3bJ3I3Um66aVcZXiMSriVzxk5uEFHdoJnlrZoFP+GZ5isuv0Tkd79MT\u002FaIJGBuoJcf+zA1QKZWJhBxGNBybJBzmjcmG+g\u002Fcny0HD5yyDPAkKb1G9b5xj0mM5mjRw43ZH9Gs+\u002FDGoisVd69JlnU3EUXXahByh6VIEa2U8oLyjU8qNVbtAqlDB9sbgPhxVQFswlMgbw84d4DIkLiHbNaAURPAPqUd08v5AY7ZT0NEKEfHByzmcXQoGyjt2jG12QizA4YWUOIaF6zks+MNMurmSBr5hxduJD7VFfcLCnrlIiyiSvkTESUGWdIC2YXkmpZcYND9yBZJp9qndiUgykz6xB32gI3YEw4uHmTjnBmUmnMvDfgZTkln1lyZp3X6UYNrsT3EnzCA1lcYAz8mIU7euSoZ\u002Fl5SoO9Pk891uol32oLT12SZnYWkxpKr3cebNKDXD2FUDmHtfyiZ2VdonY5UIwZ1jo7j709JBWTIHDAQdpoP7Yd1+zhSh4+NDf9mp87BMliOTkuYNRgwMF7CzZH0TEyGHiCI2VFHwgkRL6MQ+gxb9LLwAozUZTudMLRRTQvi0oOS1sin\u002FcSuJaYWWdWnfr38o9qRJgxzepFvNpdoqdNTBRHYFkmRAhCNUsbojOU4pXkMNChHNRLkFxm+RlEk0cQfwi6KBk8yjhXk5Ig\u002FFxRzPLwNEdtWfXKS5xgDeakRD7VQTsV13bbZFab9kheNvdRO55aqUGlIlof4oI9SQFBHTXl4OapM0TrmFAdk4AbK2n1R1uouinA4eDLzD5xqW\u002FK0tcHMVQqbTEoirgh9eH5te5NVi4nZZWrenFMec63A8rY9OsD9q49n3PkNiRdpqkH6elBvLB8QBMbd3zuc+VuvWt07Nio2zR9BG2WwRsDdQb2vAezCuKu47WsUqVJF8JpizZLUh5BQBoMpFPrSOq06t1HUVd+8UwBhLVbhirXPto1Dn07sa7+uT8HBIwvCLcdWHZiSijNptNxbv+mHdVw2lKtH46QpX+OmjqqMfFr5EaEyIPjRif4W6frPEW\u002Fuc6J2l5K7HJIGDpFeQhu8q\u002FJO9SpMjvbEv0YSRzN\u002FWltm1VO9E3tjBc60jUlb+TXvojj1qaw+mSScAWEEPWToQslAL9GdhPc7JDsABNrHVb\u002FiB5nrocmObvOMrbk6mBu2kiAX2fWrqIaUWG+NsEmolcf7xFIXsZWEWqyzrju7BsP56Uf+v92nEjXOgc7SQ\u002FkO\u002FMlS4Upv1ZcebXw5FCbB57EmBOplDvv21uedP2VZYMmfpfCLRlRH9n\u002FeZMZHrVcdvnleukzlglkZo1CsCQgM2wQvwMHmCkuZeuWrSZmFPiaq68yiWZVkh5NG\u002FaJ0KzWyi2yQvfsHHKZKV2lmzyzrqNaEWZIROfwocNlk0xTWP5wUsswjmp2fuv0JsfDtGFWs\u002FCAzTFL\u002FW3RuuI7ZTJzVMtCcuHwgh57NtZUP64Zz\u002F4+zBRiZtg265rBfmD\u002FAZtkbNi43oTaK9XoacCuXbu0hvsezZCelOnNZr1geoHJY6\u002FI5knNukMiL7n4IpGuMFk5JpOV6Wkam0i0llpkxniFSDgDG8+GqsTccHn5FmICuRoXaZueHNGLlVpdRGS4T\u002FqtWSPiLxLTsxI7atlEK\u002F6wBjlDWl\u002F8xAnNuGvGe2QE+3qNP5QOQgIpxLa9R2WGzDJAmVUnBEm\u002FQC\u002FGCk6Tt3p9e5UFzdRrGl031WiwJjcrMGXhBsxqORpYyFwFImuyKv3DUauqelU02Pb0aLUZxe\u002FnxqyMbGctrBmgMLOMdLCgnUxOrpf+Y56FhtANMaKRw4yGNsRa9Ky7TBtjSU2eypD2lIg5N\u002FKJ2XHFi1k9SCu6Tk1R1yxfOWpcN2\u002FREw6vlc5KQ4Q15jMoLNDQGT3rAJF6oO3iMIHBjIf5XQYOEDrrRmco0mgSwUwGL\u002FRKX+S7s7DsIPqWL4IyPRVElUf\u002F6CkRZUi6mPTqHNIK5pj3rFD24MTKFxxhe0477R2UfMFNxxwz1zr2gCBILnFZXx057mSlE8SX\u002FMKMSERd6cEAP\u002FT1TLXiMGCZOaXBhAgspNxlUe7MuAShjptN2IuDjkiuCHmEk7NE0xRIW4m62jA3EzL1n3oh6tUDJJVzWvH99ED9QOy5QaKg\u002FhWuxmN9Iegm6ZRb8qy7ojk2eZJGrnbu7NHC9aPyhH+UCU19rhjxFEmTAuSl9kldgR19EHngOvf1mPQtx3ETt+V3hoMqY7EoVXZnvNCknaIzrO3bPkKGy3gGvZCxqJymfFxjkqQ+IVZ10qEHwuBGG8Sfa+KwniRiQog83s25Z8eOcs89kPTjGlivoyZCOT3tnB6bLkdOjpSDeuLJy8gsfcq3LNarX9+gpWWZ0KEv5akk\u002FdWg+oW4tzSYs\u002FNG7Td1rj2DV9oe1yF1TzuCtCkLOR1QXuJz2uE6MajYdwSfdrhY\u002FJqWNnQ2hx7oU9PU+Mi2fp3tqwZ27l0cS+n0\u002FQKPA4kqZQ4uc05qjA7xCqdd4Coe1l16131H7PCzB2kaeRw25YxdtNm5FUQb7ZREEvcQgR\u002FSSAxujkcdh16kchY1ub1Dng\u002F5mSebqPSrDtex86pxnEEtNTFPd7Xs3isYXRg4hsVAxI+ySmijb5VSs2mdc1\u002FRzYQSLUTUiUc+pIui6LcpE\u002F7qwBWGvuEfRw06CqZsvj4soBXTIpymKoL8ULrDp+OwqaDT4lTFmqgx8QQWBDR6oG+jH0cVN47DhdaO0+hZQ7xHr6h4lAzd5+1b8Rv\u002F1vmZDsircVaR49YB2pNtYE9Jdux+oDxx7ZVNioe2WzKi3js74oo7qBcwx2RjzI0NW2PMLpgpueaaq33DY4ZsTI\u002F9Idgsr8gLpDz+fNKTnigb8n3q0EdM+iByoi0iI7oZqCM\u002FprXBD8j2gRlnbNFZ4eOqKy8T8dNLl35suro89rHXyW57qmwSYeaDPpinjMtmnJdSpybXyK5ddt8QH5F2iLUuP+vJi3\u002F9fTIrkf+YH3dLZw0IvDqNCA4k+JJLL5W8E579YblEXk5l9ndCL8lyM2KWd0zh3AFYspHmQSPkUe+F24Ooj4\u002FvdKODRGKLzbKQzB5DMrbJFAfbTmaFaVwQI1bDgcRi435Ug4UeXWS81IgpzKB04l7DrPpKmT0My2ymb7VWzlkfK7mMiqTv2\u002FuAZ6NYe31Yq8Yc1ywWTyRYDo1ZrFO9+uiPyjsqXPoHjhgbrhc+wMPN2MRUHtgTMzhiZpdZLW6QEH10Q3fIqYlSQ764UZOGOqQ8mIxgajOwikFY3DTdRhTOUwhu8DF7iW2\u002FPiagujt5QqRbeTFb3z+L+YvKJZ2xZz8lG34GHLEkJrMUfJimfgAJG\u002Fd4eZVZaDozTCx4UsNgiA9JHRaetIONm0W+VFbSYvgnL9cPZkS0U9oegzs6CgYCvKRLmUgrimi9Icuzs3zgJVbOIQxGGWQdnBlI6TLTBU3awEogq876ZkTUe0V6ZtTpQgLBBh2EY68GYwwCGKzR2dFmLJuOxRsDC2kxI4KvP2bHIdpjsyfdYfS77HQO1A+EOzbynz7FqjI8TcFUJl7oI\u002F2sbGp61SZX6CkTrtYzOqA\u002FXZG7IalPd69Kd17Id6hvIkqr9qXSOD5IUT++jZJfQ1gCJwg2+Dp14Cr9nEQysU8m3rTKQt6VlJ+S6Qoz5jyt4KlGDBIaDCWMOueGZDn6QXUw882AIIV7wNHEc\u002FaoMM\u002FVspIWPejTQl+FkFbOsprjqBcDFWH+XZqfhYiec3JbaOd5ttzQsdPVclS\u002F+efVnz0paxm5Npkpx5SNa5MhLK2ByY7Dzcv4u3bpKavePUJ3rm8maBiYb5O5Hm2CvojBGf1aD7MEgpTVjMYn1Y412TB64piffvbq+uVDWnw7g8mdTZs2ux+sT7Z4wRvi3q+njSZUYKImOcOeEbI0p4WihweQas7ULf0gLlqID\u002F0zH4P5mLVjxlFtA2eKN1\u002FmfBn1nFZVMa5+7El\u002FJvk1bsSrZ\u002FP3UffzmsD8SK227YCOyE1qedP+XYWttAvpdrYyO9zyo2wut1tZI1ZhNsHQaeQNDhFG\u002FVU\u002FfLjmF9JB0ez8RKWmcMKO0jgOrbe2BO07hUsC92Mnb\u002Fxb4Wpf7WNFhIC35ETei\u002F2Szmk78uLcJWsXlNxbIuKJHz7Nn4LAsW5EJLaxkLDgq8Rt0lAO9PPTVQ7jnFCuaavS6OVrxcfE1+aUjc46XshZ7cg0ZNVIBFQB1U977jsxi+VSN\u002FkQsXHkX1WUAOvR3CNqlPa+U884VgJnS9mMDAC3xEcYp3h3OhCL0LYvauActfmpxw6jHvwXkfbsP1KeeJ2TPOSfJSPq9951qzrQTSKOY2Xnzl2eVebGygXEeuS8RMiN37PE8oeo7rj7bhGnw16OkBlqPlpUNFsLcTvZ2PAyqwtJhCDu2ztaDmgJQ+zZH3vjDSbr22QHjvx9eqy6RaR5+0VXag11lkjUjJjygwjzwuWFW7eJNOtLklp3vE9EbEBECP3GRfqOaaZ2YnBC8TBPYcZTBEs3Doj6dpGzNSLGkE9equQF0h07dnjVFsjupZdcan0PHTygwcch5XFMNxiWf5QpDOm3X6ia5cXAPn25dL1vFjSYSd2MWLrx1KxIk7aJ8VHb8K9bO2yb\u002FfFxDRxEvCCkmOAcGjvkJRiZmYLA8aVUGgnre5\u002FQh48mRbindbxGTyHQlZdSpyB3igQRHdBMOzPI8SVT1q9fbfOjUaVlcHVIH2jCPISXDPlCI6SWuoKcsNFDrtINmZlkSCgrwzALykwypiwQcUw2PKOruBBdkzPlj440YM9u65x\u002FLt62AABAAElEQVT6hdxB4Gn2kDdmqbGZJgzTI7BjAMTLtnzEyYMFlYPZNNZSBwPIJzdr9Ga98yCWehlW5VZ2khwEd0amQ9SpBzmapQN34vIuwcQ4eDG4wSQnzFwoH8SZ+kUKZIL2RP33SGfw4Cu3EGoVWGVhdpGbvkxZRD6oN+sgwk6bYnYHYgh5ps6Qb7kYm6sXOiUZ5FcHO30Dmi0X\u002FibqvmYwnwmcYlYX4qg6kTRkUr88qcCUCMzQlYFF30kRZsuFtLo2nDe4+NpUm4llO+PFXOrD5ZZM6ps\u002F6pjjyLchy4QIX+LafEbYeQCgdrxCs+Ce8VEZXc6md6Mf4JwbChiBh0mVbnTg63xUoshHY3P5mRyrP3D7c2kDJ+qWaxoX4oWqy0d\u002FE0\u002FHCImbPKUA9XDu6Om0sa0Bd0ETN7nQ1yS\u002FSpVMHHqADWk5pr1UPGq4I+oHWTh+27na6xHxE9qFKgsdn01nyC5lrwM\u002F3ifhmuT65Hraed995dO3fNr9A6SdwT59Cekwy4N09wn3GfUJTMCsUDtWjZUeVQl9DwPfgd4BEXa988JADMxn9E6HVux6QBMvB\u002FbstiyqZtPmTV7Slw\u002FZbdX3LtZplp6noTFwi6Eigz0G+0wy8JVbJmNUib4+oGZxAz9zqWudLlaBFUfHk2LeN+2ANLSbh9VJIXQ6PVv7fkGqdF49FCkIb4ignKfncXbxkW5hTCK\u002FJqxT3ZpREzSfRDnXJr53oWxLmXmnbX+OCMSpL66H4WHP9uE5HC2ajwIoQuTUKFrlnZYIFFBLv9pqGk516ciLvrzxd5wqqO6JJITAyngFWn7K0HgRhhRCWnvHpY4jvoRUAVVw7MnTwud6L3QWWjb5K8Jcm++FUpBr6OXsidLo4+I0+VYNQ0IovrhKTcFqdq1iRU72pkhkKCH2FX7ykJMf8Tucg\u002FghJtGa49A8IvN7WIt+LJVbslVf3vLrL\u002FfM+YEDB60bjymxT6aD5EaMLTJv+3ODxVSBznufPoJ0n0g3L1sePXZERHaD\u002FImvzlslxYaX2W6bdYgkQT7oaHl0yqP8fVrmkI79hsdcL\u002FtxrbW+e5e+dKolDkXmMXPgMSlVzk0F8gSp5MNKPHbFphlyBmnAzAIzFdZCB2BuKlT6sGZ7t2i5R2ZF8aM8zIraBlo3a5bfw0aajZsMN3nKBWE9LnLJS6sbZM+Ow\u002F7cZVE5GFBAhrHJZkaXlWLIn1EuL81OimwxYw+x5GkEuqBXmG7wouWY7jU0VV5wlD6a2SYNS0pCgJENyTRh1DlmIrzESl2QjvpYLWy2tEyPTpkM8yXXiclYiQci76UQlbEvAJWNGyBmNLxAyGw6gx4GEZTbBN64RUMnLfiSFsIEgbLphI65ziGybJBKr0CickPS2SD9dU106oz3EXCQAQ86NOvOQIrVQcJ+XfXLYEJ4oB9hlN+20yRUnsitM+TUJfrw0jL1Rf4QRxMF1WvEi9k2Dy5V56QnLpvrQvlBACBudKihexBXd7DShX\u002F0q+EQcfJmBpHOAMcePGIPcZRutCXtFc0Vz54nSTx98KpJXjlJ9rxqH5Akv6QsvWkXbhvSzcQZkq\u002Frhacj7CvhdW7oLH2oJzBjYEVbwg\u002FbcfQhPgRaxZA+1YwGnbjp6LqiLvmTgrRFrjN5eVMsIsa\u002F4oOBy+S43HDkp7zcHpUPOMpXOMbgwuhYmAWF0EaGCb7C0I10RAs0Q67LINn4Kol2kb\u002FrxcfSF9W8oZfqSPVr7I079UM4dUBfoLI5H5VSx7Us6OqbGn6oOS8fvHAOi8Pz+osuX4gzHkpQcUH\u002FszmwB5OKAW2EVAcPHCi7d+7Su0i3qV\u002FeqzbOYFHtivjoxSYMqXc9yCtDemrTryqyZYrajua69aI0pJ2nOmH6yPtDfYrQqz6CjVY2K+I\u002Frn7qpPrXI3pv6LBm7Hm36bgmUJi9PygTRfox+oBhXR\u002FKsExpQMCL9tbZdaQBQ9PGmQDyhXqGgpPuTNsc3BS3nnemOYP404Lm1yNycPP9T0vYlK3V4iJZS\u002FeI33ielniR0Fb0OGhUaYrI3bVJVwM6zqvejZf1mH\u002FciiPxQtnB1Q\u002FZc5q0Tmp+Vc7cvYWEDH5DXEeUKn9eILgR3T8RvfM4BM0VtpAeVf\u002FOjGtZIkdi1FiS5\u002F\u002F2nrjky8Z10tp0vXHdca\u002FUrq1njY9MjkN1HzfCGx\u002FhZr6gS1A+7rPYs8mj4lz3eBh3T2U34UhyBEtulMBzIRea+Lf5iV34uwAUUgK9a+JUSWSDq7XdOm8ag8\u002F1E\u002Fu4D7VjR9oIjDgkC1nKSMdGqlEldCENvvJs\u002FGMnHx9EWP2NaHHWeVzThLR4Iv2kx1zVKPTQdktG1D\u002F8t+\u002FQh4jUSWomd7Vmbpl95MYPGT+s9cFjpYsJ+Q9pFvoSb3wcxuRNaIzpBcpVMlFhlgRCTDwIcJ2Jb63qoUa7gReMFAbR3bVzt8j5Ic\u002FWQuIg3ru1qsDO+3eZTELuaeBxQ5E5iUxGTLaUJ2SO2XqJtA0lJhPWRzdtVjTpVWe\u002F7cJtNp1gkHFcdvF7ZU6C6QvEtJJRdOWiopZZOz7IE\u002FmI3HgWJ+xcPcspQgTBHBY+fK0Usg8BPyrTHs\u002FCqlXxMik60Qgg18zgEZc0zKSCqzsAlYsbDWSHK4sZLAYwvEDKi5b9IvueldUNEltvVlOgvMzCuuwiqmuUP6ZBDHi4jCH6HiBpZh47eeqRmWbIjBVSOcHYX47VwIAVfvBHR2TjuPghMZBLzE64sTNoYKUTBiSQSfT040RdOV7Nx2QtZrq5msATSLnAuCCpQxPoZrCBPp6hl2xIFBtEC9MZCDhlID6XUxBUbLrDD\u002FLMTRzSS1xqLp70MEDUTVztAlk8CWAmlfQQcT9iZ\u002FZaZUJWiyRKUdoNplzWUSSgknKXQzmYyqmO3Gnop+oMGSQvOs+QpzhuSnRAQSLAIV5AVb0x6yj9Y8PmH79oI7QJ8gN7sKkb5Y38GLAoTLrzFMSDHu15AoMOOMg35aW+GJTyVArzEvSOGwl0iYFWzDITz2Eg7XJQZ+HAnhPC7dgbKw0chRFtpubHjQQd0A2sKUedsQdL9PbWDGLqAMoDCfLwX+gYN7VKKINUGhvJr2Vw40Jn5cPdz\u002FUEBjrHCxcvCsWgpJIkdKybZRGRNFW2TxsByFDhI8\u002FI60Efk89ZXNXxLNEc7HLrqO7PJU2T0Df9eJolLIQhT0Vv\u002FtSn9KTzPpNl2iR9IOYoIMFAkU6BvGi\u002F\u002FdoGtTHDzlM0\u002FTtcNmDEVhravTY\u002FcdRAQGk1nxHpdG0OkF7XN+l4Yjqqla5452jXzp3l3h136wmhzG3Uhvi4Gi+00uzoF+h36JM8C+Y2rTw8G6YIZ3BnqzOSdmJfMZ2zb10EZ8ioCeqUhVeVU1OeUR+D2YoZbc9CJIc\u002FN81zbIuNmHb+TtyS4eB6seikHS+OO88bUaEP10tHOsLQza7xJxzI5sBGWBOtHoSceXpVUa3IeLTLPv9YuUTe+vVRk2nnMf10p2un6PRtjpVdZ\u002Fnax6FD1TmK2var8TxBoEDOW5vqNfxrHk1fRbnsRaY1jAN6xHAujk7cR+qEc+5H3nOMH3++JppUugnFUd23xRs\u002F36SauE0+7V0o0grVaZXVjqOjlr741pMaF43k+NFm\u002Fay7jhp97e9jrvHIgSQUzMm0dyEtAp+qSOQFtuGrcyrD\u002F7FHjI78G3UQUWoc\u002FDqP4zxSRCqCV5QnPeZKS3moP0tG1Acm9pQjXldcywaqk4aYM+Maq2WETSwEE8JNI8EunWUaL730En+dlJckgXejZtW5Me\u002FauavceeddXqKQmyC27NhsY5\u002FOjDyzuyxNCFGAdF5wgWwXRfIvkSkKtuO8bIqNOgSF2XZIC0SS\u002FPlyKZ02ZA4C7C+IanaXm8awCCov2E2JENd1vvkCJDPHvIh4v24Ge\u002Fbs00Bgp2ykRzzjfeE2vYipQQPklZpnoLJlqx7LakABSSJf9DSZRbYINfGY8WXg4PU2dUNZp5lwyCOB05o5YrCA\u002FqzH3qcbD\u002FbZbKzRzl1qUmSXJfwg79hPQ9Ah7ie0Ag4vUQ2JgNeXqVYIL8rLTDVPCiROTwYg2awVrycDwgE9aH9BEEUOFZ8nARB28JYqbvcmlEoZhAVSCLminJjYxKxzEC4RVnVwrC7DE4YDMq\u002FZt2ePTZCwWaX8rEaCGZRXbFGZIfDo5YEVyqitQMogzJxCkj1QkT\u002F548CTGX7imBTIDyLIaigQfJdHF20lWOwh6F59pCHc43qagowg9RKg+glyGzbi5GPiKOAoK1jGzC1UBVfJeodZhGRUHRkAWZ4ILm0BAswAC1kQZXSkHulyuCfwpIV22atZRToByCvdCuk8O056EaBT2pDDLHg1QQL7QdUDT2N4MsJgFz\u002FqiTploMpAkwEmg010pE9jMAe2xlKDFLCIvi5MU+jI622BslAOrwak49aNTLr6mMqSTHeqLnsdiMQgDizBzHJUb8iigo2X0vnxruqOARB+xA8shYKU8my6sERBBny1MyWOn27oegfbKtMyGln0J\u002FhTNsoTnSx+1CM3AvaNa2aVQm57wBC6KIlkOX2NX5NJiMuOfmDxMDjyO5sLnJoWO08vws4mg5RkQ73hMLXavWtXufnmm\u002F3uD19mpk9jRp327BfShSnXYbR1tVP1VVOstSp\u002FVCCMKmGw1MsMOm1d5yb3uiI8244MiLzIuy4ChbHKlpZzVZ\u002FlrxdLqSldv17aVYsKnJAZ2CGtyMXWo7bPCjLMtPPFY64fNg\u002FOUCDgoDgLunOpv4pbjTt\u002Ff\u002FaaaWddZVWfKqueL7pXWWrc1l6RW228SUhxF9vmyEaePfQb\u002F62Uhk0\u002FlIu8Wvl1HJO0hi20JxxX0\u002Fo4PPiVCy07wxU5gghtjr2Ln7a+NZb8CXKw09Tjuf5g7jrquIY666HVvzVy59enkbJqPqq5d+iIv\u002F6sTy1XlMHlwN\u002F6RZw5\u002FZXD8G\u002FE1j2njSIVi4gRfRsXqsulvbruOG7SVBMmisv9o8aLMjfpG\u002FExlq2ZoqeOfTofhci9CfRJJ4aha8gJf+4nyEC5KEqnHj4m1GH8tPV0fJ+TTUeYjnXWchy3dVDeDmzK0JQj8CdJg3ELaPs0uKN3pIs65LSeOwhprfp1KfXDyi9L4ZbMRh1CzhrovCS4XquwUBhmUJnZOLD\u002FgMitHoeKgMeNjUeavf4AEmvn8uietCfHRkRMWB97bblWLwbNnlpZ7rrrbn3856Ts0EdM4CAb1157jb4uerXIvNZeV+fc0zOsNc33y3RmowjIcLn44os0Ey55mm1hhRDWTmc2G9tnagoyyE1jWi+eQhAxPRnU2uur12wRKRXZ1I1mpfI\u002FLmJ+n\u002FLA3lu3Es1Sr5fcC7XfUO6WXkdkYrNjx70mGcwiYUuNeUufSZKWFBtgNlfLDCoMO3DyhDxBKDFXQRdmqxksYCJDtUO2GHhgi+6ZTPiD7mLMYK3sOSWSje2ytmm9yNkrsiXCeVwryUCEmetcLWLNYOSAZpWG9HIpKyesWbve9pk8ETiqFylZUYe4ttEeG1W9BGGErPf0Xii89cEnEcEePaMWffSMlhun9IO80Yn45VARPvbc9HC8JMwAjKcEEi9cMBNqlncU8aM9HNFLt7wEyE2YmXxMDmxyBNlSWU2A5YcAbvTMdFNHDPrACj142ZPOAzw5B1\u002FIGXlNTDAbzEzwlMkogwEGMSadkqcE1hXCW8mXOwvpgz2t60Z7k1498TEhU2YQE550MIjwkxTlyZMRCDI28qSTcP2p42s6FMpAe+WDVjOeLaTYouIm5ZAUEU7OpQukmzzU5L1O+koRRMxReLkTEmOnFViI57ILL2bVe3VN0QmDLYNd2gPYUl5mD21eJWzWnFqjeooBD11ZaxZdaemosS3n+qQMtDV0YcAcL1EJIZ0zqIIgQ5qVTPqrHanAdKSUnw3cGFLwH90wnSvag73iO68YGCDHZF96oS96IBjzLxM75c+sttMjUkBwDGaEU7dk5D5FYb65KY\u002F6lI5ciVfrnLbCMXpRLudnPSkDmClYuIM3calHsOxpyDp+iq640R6Qjx\u002F5dt5gnA+Bcp3H4XP+fr+QvObHnX++mJZCRIXSoE79qYrudkKboO3whIanTnwzAAI\u002FqxWN4hoNfGlTDKq1iJCJPLKoO\u002Foi8l+hdU5jRSPVr8Iwe+HaxTFIJB+u2xUm7DoXIfeL4lpRalJtaUDXyzpNdEyqfg4fOlB27dutF9h1rn5+u5bJ9QBO14LeNpC+8R4H\u002FRt28A\u002FVzceP9oBfmyQ81BzOpS1FY14oX9qtK0x6na20tPJWLCq5JtCh5XQUpTOvzuOOKHMOiVNdJ0bV3\u002Fk2+aFHR\u002FTQv1Gm5hVVFwmQXG2g\u002FTRsXr3WNOTvYvm6jv7J1y8BHWnm1F3FgDiLOPSlc3b\u002F0sSZI6MjXZSrjYWP5hQWHdvhVALkGpVRsRWiY1Sr9uek4TprOcKbOParx\u002FJ0d1sDEVK3kBiZ2I\u002FcVKqmH8TrjC6iK1\u002FFZGscuFQ82EcrcwbOm6O4d+qqVDhxSO5N+Ttm4xG7Dr+aSd3XhPV8kf1cjF3KwLLB3jko4zlVIVmuY\u002FKgPvQD\u002FtHmFsnoIXovGVG\u002F6RM3uSPdL1tFZr6vveYakaZJmaUcLlPr1TWqVUBouPkz2weZGhUh5IuaoMBN98LtF+vOWmRjftwVtVbEeHBoVbwAqjSbNm3xDZYvc7KSyVoR5quuvsYmIay60qcXJiG4rKm+Qct5Xagvc65bJxtekVtmkVndBLIFQZ+YHFO2s5pZZRZRM9y6wPoHmCmFTA+VzRo4nNCLjPfce79JNm1\u002FtQYQV111lVcfePSjH60Z\u002Fzv9YitknZc54QRXXnmFdGYJyWHNHO\u002F3zOj42FERqQnN5kgH66eXP4XNoG48DFjGRNoxs8CJF\u002FgCdTikXx9pwhSDGxxkDDORU7rTTWuWnZdm1+jjP8yEH5VtPivmrFQ50J8XJkd0PrhKphoqI1gd0+zSrvs1uMHMiGUwpe+sTF74sBCkiwuBi3dYYfzNcNHrHLx87RNfB1xAzEbhICm2CRchZSaWcBo\u002F\u002FtQxZJuozOJirjSlpwSQXV7U5WbPjRICjo7c1JmVZ6BSZ+m9LCFZabPtvwj7apWZawSiR\u002FzeXjZ98VX5kyc3e4if61UveJI\u002FxCxIcpC3KW76ja7o6xn4XnDlXQZm1qMcEFoIMzKQGQMBno6E+Qh21pTNZRFYxDk1xQyicFEcv8SmFyLRlY4cchgDCcUzgiGXDiFmhnUEafTMIVgzYwveQUSxAdC8rswAwrYcUjwpnSfUNjSekeNpTHxxlXcvJkSehjygCoyIQSdImb0kpdoS1yTLQ06p\u002FLX+KB8DIID3MoUql46sf9jmoyfl5ImAVpwRXpSLJy+mz9LZlaZf4kUlcNws5afVbsCV\u002FBjMgotTaG1G3qmIQYN88Edf5UNZGdjhkOOnRSoHxFwRnAfEPP4iDvWGo7xszqPZd5J45CmF0jaqKo5nXOVDUOgZg1TWmLcsJXLZSNlxTN3Tluu+xlG0B+1CPf8uKgOdzuaM5bx455Jujlylp63S3\u002FEUxk\u002Fd1FcxGUL7Hx\u002FXO0masOE6tNkVnRrYKh1tidNhnhwCuk6Ip1br61PQejDqNqc2VAfhXAOiFt6obgapU6RV3z2tNsLgskfthr6IK21W8cf1EurI6DEtbnCf+nJm0zWBIMdAkEEs+Z9L3ZwtDuWaj+HZ0liRpf5RfaBHbSVcB3adO4W3IiyWP3IghU1El42qWiSh86Quz+I6MZp\u002F3IkX6pr0SP\u002FIO9pODJwVWMujsniwTb7z9HMUyuqgtm6ha\u002Fg6sOOnpnFslafqeA5FmyOljVx4R57IQ\u002FXQqSPBvEPC2\u002FoSGPnjFzUQRy0YmrITU47Ipylc80QBhesag4+RjXNT\u002FJqsnRS\u002FdjrHk3j2cax7ndKfrThVnjX3SdM+dRx\u002F6kslBkcw7cB7rmk6CvKoMQhoXKTVSdsrQqqMGtSkabUvt4nI0b\u002F6qSJaeiBJ6SK8+oZ4B+nHAyPJIm09ZhSFXufDLRlRZ0UVljBk5YnP3XGnZ8kffd11ntXEbGXTps1aR5c1dLXkllZo4aJjBg4cucHbvlkdKGtPQ\u002FaZHaXT5vPpRzVjPDY+6VVltm\u002FfXka03m4\u002FMzcieFNqLYOr1pRLRES5YU9PjeuFon1aOUWruyicpQxBnI4f0s2MI+uoY\u002FrCMoB8kAg5PKKFpPFkYHbFcaXVjUcbj3F5+XNc+TPziy09tvWQs8suvcxf\u002F6yPf3m5lVlrbPKpsinNpNKRPPDAQZmW6MVaZumPY6Ot2XQVnBlozELQDd35qAf1DOE8oA8zYU6z\u002FVLNBA3qpUzhMiTSzufnT+qmc1g27dOaVR8eZpnIi8uBYX0Bdv9Bm8lont7LVJ6Qrmsn10nepNYh5gVaBj3HtO65XsYV9n0ixzQsbq7Y0x8W2R\u002FRbDxPNYakb58wZhaKP+7K6hZ9E2VmFcIKeWFjFg1MmLHlhUxwXKlBEIQT58GZcF8hHfolhyUzGTgxI81qLWDpWXjHVV444cAlAtnlSQhEOgYqYTbChQdBJC2mQBxzDQo6uZhhJw5ty4QMkZLJTR59BhTZL02ylyeDg1OnsKnVUwClAR9McpilHhIpgFTiwIqejrIx4OADVMzqIYO6pt2Sjwc+WpiEY+pOWZrEcm7b95W0\u002Fbis6TN7tVwjBaZz8uy7wmw6oHMTRupBeXjGF8oqvdGFAQdEncS0aQYnlJkXcHlyAT6YI2CORRnRCzJNep5W2IxIfvqmj2+OyDT5VhzPnKOj9IMf48+M\u002FpSukXG1KRyzqD2a9RcyzhfCRDthht7k2bHix90Y5ZMMO5dfhSaqPLiHgAkknXp3GdW+IMbUIYMedFipJUJYDQmHP0\u002Ftmm7VspBBu6TZntKKP5BKcqDskROx5ScMvCEIJbQxMMJFEOHyRU\u002FLpIzIiXB0oSzUGTc+4qBzJemuL53jb0GW\u002FGB\u002FFpYhVU5zxFzISUN5Uwsd2swXwPliAhTgpxcixLQz2hcfT8NxPVAXfOsBASwbunIF1wXfMFBdqXIh3ZwzK445is3BdKzEChfubLRxUW1M\u002FehLMIOhDvzEyf0KT5p0PSr9Ok3inFAf6tWqdI1SqxPq\u002FyHuw+pLh4Y3liO6ho9oNS4+IDe0VcuwWtdoN3z\u002FwS9u835Oi5Q4SsfPfIACnE5f2lK0sUgW9X36cYfQB3W4aLV0Suusv04l58fpPF\u002FoWGkpV2dZ2tHiGnCzdmNpZ0T7n5sGrS2slZw4uLlxGxmtQlKbRIqfRgonLRf5NAnoPOTchzSiasTTy9HEVTzIKIPAJqOaxOe+XhRkdZEZyTrizDs8hzhVBDpF2doySN7yVETyrxi39p3pGmFxXTdy8IvIjUfdOUedhJJVD0fVSafqxtWFJlZoVaXM3XemqiHys\u002FAIqxgSau9GtziWX0tElJW821skapqLMyB6a8DWUc7aFuZg4RTNT1MU0ldnHXRS\u002FeacK1MnQZ+aoNmHyh2\u002FKIguFuTW1si0x7zUD+50yWzUb\u002FnIe0SSxsu1j3qUCMC0bLl32cYbsllfDj2m9XUfEAnnZUyI\u002FaQ6e+ywudFyU52QLTkElK+HEodLlRsuN+Ujx46aaPNS51GRzY3YpxOmjn6lbg4nxdDGIZ+6wTPLvG69PoKjGZRJkeUJreV+RGR\u002FQGRyBaRCNwQIzqhmffjgzyqZa0CSIeMsLyla4nhHNbN\u002F6MBhE2pWMEAX1n9nVYN7duywHTz28JD9bbKRxx6YOBDk45rNNnGSfuP6wiQDC2bZsQ2G\u002FNcZbEgtL2RSvZiRQHxodKMi9Lt371ZDnrWtOySLGx43OWblWWWBZRmZ\u002FWaJSj76BIHkpVTdJjWrLxME3RQx83F7Vjn7GgKELAYGzGSSPzbokHONknSu2TDhgO0xS52t0iBotZ5eoF\u002FMmEIYdSxSjt0+N0lMQVaL2DOjho06BAXZ1C\u002F5c4lic+0XyZQ3g6WYhdPsuQghs7GqCM8Skw\u002FmHtQHN33qkw3ZmMVwzKVDHjiwgqRDliFIMbMbL6pWPLkhgB1EGl0ZWEBSwYCNPHGsqxwzeBB95oXxiziOp2gQBsrErDK4+nYif2Z6TQSVV5iVoAuaSrpJCMSaQRHPEGiCMYvtWXTF4g7DdUDdUFaTPaXjr0+DAdFR5S15RJWelXTSacUjUZVRusVTAsiN6sBh6KByMNBQvbFBtiQALYQJA2Xe45BJgdo9GJEXZJ6BZX0SAM58HIw2QBkgpuDmmy44KJwZTUg2mBHmjBXWehqgHPHjGomNWfoY\u002FNikQRgwA8vAmWX8GBwxmGLFGf004iJPBrc2m2jK4g5fZTKe1KmPnUxlEYr0MZIQs\u002FfSH2kQbG1WytBE23aZ5ItyLj+yfDMHNpXb5\u002FhFHGR4NSg95QIfahg9yJO4YNMoX7MyPoSBlFWRjCYLclYaZ6\u002F00qlmhD7gq\u002FLRHls4o4bi489GGsJ1gsIWRG0pQRyzQz\u002FJigkTJgtEmOVvXZ0ULFGEumJQHk+qXOtN\u002FZIX1wJLle7adb+S6+kYM9rOljJrk0MNysgTHNoN5JsZbatHkOLV2TOSoJPL4DbItRADTEmSGHBV+5efGglIe3JnhcwCT81q8KitX\u002FIHFYf2OKtvDZwYlVnmBdvLpZddQWxDMqnVrRho9OgJKv1ZA5P2AsGOfXOzBgj5O45+KA5yqDtM1LRz9Ua6KE89rm2lni+6d3aRX8QREKFCk6RpR3NyCp0axRyPJLjQtb23rAia8+v6RibXAeAb+yqlEUQKN06Fz3GgIEca7eI49jX\u002FdvQOmSRxQPVrpY7ovpirOlyptAcF+dqLKEjAL0I79GpdRIQ0TgcgG3XBMfVJWOBHPJ\u002F61xnJI3y8V\u002F0HTugUciNYcfhv4tawJlfvnKevu5DbNJfOKB3HTZ5VcxSjTuQcQjmcH3g7kAj+dyTHjfhNspa39Zdn3C\u002Fa2NR+0xEl3P0n+2arGTs3sDW+9J9ki1ZcDc0WwsI\u002F1FAkFFaUKo+T1rH87WjbbIre0lEBnLNrfhxuHxLh2ThHIBvVLH2Tt3YZav1EmZTG+pDWgvVbZSEh5BBaXaQnpHE1uvb1kBCnjuKFHB0\u002F8bora6qHtF8yon7\u002FbR9oZsHjJTNustiPHxKxpUPHbh0SAXnl8WSvZjF4wSdm+fjwzpgeU46KPMs0RR06j1SZDYSwsW425jSkg0CyxrpJtuBYKXvlCZEM\u002FCHuuFWaaVm\u002FcZPMWjTLKyRn1AiOa\u002FZkUHI2aGYff2YS+dgPs3SrRESZFeRLnbYnlhjCp0XwR0SYDx446K9vstQYM63HNVDYK5t7NmaoeRnz0ssu0c1gqwkItuqUHX1NaqQTRJhy0SB5uY8BDOYSEEzILeTMDUn6xo2Z2VmZcsjsxC8UumRqUmqUYHicF2IxG1IHW1eQ4YVZPgLES73c+CA8EFvI9HENOrD1Js9N+tofq8Iw+8kTEBo2mHIB9ct8iCcJg4Ms\u002FccKNmskX7br3Bx1W8R5VlU4xBMREWxItTYTE9U1Dd83dwi4Lmz8IdM8rq43RYgEZWfjOgMbDwREHmyXLZ3AikBwCQKom69k0bbCTjyItcupckH+KCMDCEhB2Lsz+AhbeWY\u002FKSvlJC6XGcTBxIC2ZBIUMr1iimQOaHPZ1dlCyJDhDaLuy5GOIdKCjTtr6c37BZBf7YwaBJjBQWyQH5FGlW1WpidBghh8hN0sdVaJWCVj4kpOA1Yug3TFUQpv8ieM9sxLouDKMdcR9dOvwRGzkJSdLz+CiUklCgoTBink5fXFEdzkE2SYemPWUfWkMtGmOWZmk\u002FZUByYS5IGX6wryIzFc+5Bv\u002FISScfcstLAIrKiDIMyUmf7AX0uVXAYzbDwGdweuTONPaqqwJqVKw81F6thFJ02doA1tJ64nsOWaoN6pR\u002FzZOx1x5RE3qZDX6rIpN7kqP8vUT23D6EJZGLSxgSdlCRKMHPQgI0reSCQf\u002FTXKGkd0wMdYE17jEKDNO8Qoltur8uDadV5Ia9K4bNSn\u002FsEHV\u002FFiTwEqlg7UuQrmOMigPpGJiwEJe+TLA3nGjcGArjVdX5iQgDHvuuzXe0C8COpBkbAmrnFWOPUaIkyrTdSHMHVr2ki0g8grtFZs68Z1Kv3sSb66NtXfc\u002F0z4TKjpx\u002FMntNsV\u002FIRLA0merUfUtsZUn\u002Fbo6dUU7KTH9NXmjds2louvuQytVVWGsIGnv4xBuT1o0hWMkoPAj4CNl8XOg+f2HNs3qI96oXekeRB\u002FTbZVWnz5VEP4Zyz8bGf64c6io04TYxz2zdyQ1Yk9vVUs0OKyZmzDBX824qgs6pthx+HndtpaWrcGokIcVyl4VPbrUNrEk4aZ\u002FXlX8sf+87zkIG\u002FmolyIDKJabltzfGJAAIjrH3uwA7\u002Fdjrk8Yee9ZprxW7ViWLouFWuqkKN2LG3\u002Fo1MvOM8IviYtE5Pb4CGIYzjxkPXS83JvpEYDe3NvtO\u002FCW7SB94hK64LjgOpkKpfJSf3kMKvPby3VoriuJGgI1yHuJZ+9VTYkEY\u002FDqrpHTd+EGXdFCHybQW28wJvh+pXkeoxXk5DuANCQuDZ6UeKCAuhIaPxcVj7mPxDLjV7mr888Fsqoq5piaVxmGvwOXfWOKfDZ2UWbrLcULiBQS43b9li0sgKG5DQNSLftmGWCpD4fXrpdFQz6XTI\u002Ff1j5cTguEkts9Dr1ogQ9PR75ZWDIv+fvOmWcvU1V5fLLrvU4LN2uD5pVw7L\u002FGNkrdZR1\u002F1miJcahRaztwOSwU0Kog4pXLs+Bg7cUHh5kllqZvV8o9JMe69m7nkSwMula6fWeIUXZsp5WXKzVpdhdRbWgL\u002Frbl4qPSJiPlauv+46mf9cpPJrybLm65fH9CSAdddx2G1CdFgfndleKhJSDjHjho+dOyu5YObBijYDmi0\u002FMiJzFA0WsNuPWehhmbqsc7kHBvbrKUasZ479N+Yj6\u002FXy6H5hMKYnAys3hy0mNzXIOnb8vOy6ebPWsZcJDQMOMCFPzHCY6R+WicSQbNz7NJvOYIKbFBcQN9swEWJmVesSK\u002F3MdH+Z6cU0I1aQMVFQmaKj0KUlfwg1N1IuCh5Oz4ownhgNe\u002FL4qqRuvrqxMtCyjblmjSc1QOqfChIfZDtsmXmyQhzkgwUEFKKIbAYNMXCIGVpMUEiLErQxk2thXC9OLnrP8ElNymjbarXb3lDWHQblkWiTBWZwIR4QSQYd6BuzABASSYM8KbdKLGKgEsSc9qwoTm\u002F\u002FhnzgN6MZwFkNxtCrX6Y31H01TQlCGKZEdFM44qGUfuc4\u002FCEhbNQbOg0IE\u002FSCPPXr+wQQWwZZtEc2vgyp0isN1xaDA3UHECwNCoyX0kL4IfsVZ\u002Fy5IUF2yBOZbGDT0rFqhp7NRhxAWKEPDRkrCq\u002FNbQU5wh2iSt9RZUK6iYajvnxtKi43kCh\u002F\u002FBp\u002F9G7iGiPi64ZEuqqDY1d55G0p+g1VWukjxyZXYYBcZRvxGa\u002FIgwGXOhLvwcQ6KAaDOo6NkdISBiFFQNXDksnfOrNvdFR6Z0T0RicTcoVjooH+tLIYbDTaK6KJMLiQXq7uBRSNuxHpi9Bh5vLSzcSCLJ2MekEP4lHGUCXqTTJ0Dimm7zwxqm9VaKKA2XOWWpxUfx6DMT39UP70aaeoS8uS7trXbwdwfYCl65sCyURqlvbDpoxJO6s2EmWMwbtgjnat\u002FAJf4So5mBZSVvI0trQd+dOf9qktn5pR21QYM\u002FisAsZSjmv0AvuEZm8YOCLLVy2FRYZ\u002Fm5\u002Fwap3MCdNJZ3DncaeIL+gYIejhbZ4uCsIONtpPIxUQ8W\u002F2je+D2rX0J3tJMBxzClzFRlvizHGq9wL7hcORPldw5N1qsSGJKLRdNbr6AmNHQBwSxdrSBymuMgxZkUPNiT1tDRc5q222lFMox6QlYiOPoyrMUtGlFe7QeeE6dXgTtshO6LVDFj5UDAXEfztu51FcrPJROTjWP6ICrhBacSFZu1ycdbhG39g1J3OC5Xead2dsclF+HQV3qM5rMveJ9byJV+M4qyZ5K54CieaoVUiHTosdRvlr2wyUIzuuGVLpR\u002F2Lbcl1hmh4D0eNWng4ms99qB90McbIrnHbx1x70ZaQpeSRxPXhavKPgx7yz5IR9d2794ioi4iLSK3XS6CYU\u002FiT6Sospgbc6HGQVMjOzKyIlkjFuGZAIV\u002FcNLhRTE5AHliyTy8jFc1WM6OrGW\u002FsrJnJg9TxMiFmHzt37hbZorMuWtZxY5C1sRNlk8gq5huQFsjr9TdcLzvn9fp0\u002FGHJ0KNXETxeVIUYsK43NxqWE8PeGHtzZplX6gbCY\u002FILLrhAq8hsL\u002FtkjgPRhbCxSgsDBGamb+v\u002FbNkj2\u002FRPfOITXhqMmXXs4iHyfMWUR8MrVjBrjekDZi56GqBBAZ1H3JSC+HJDxGabWuYmxfKBq9auKuv0NdN77rvHJjdx0+\u002F1F0yxCadJYiYULUq2+iJo65X3ahFtz3yKqHET52kGAxWINvbcY1otYWRUa7eLqDO76plX6cZX\u002FBhE9ah+Bpm5VlrMmKbHgqTSqqm7oVOD9KFukB6EyJ+VczwrLjnoD\u002FaYuPBpcG7iNGJ\u002FmVAyeXTdy6CFO7DcSoiijKS5+YIPNtc69MXFBcZXC4l7UmEMdqijSBsXiGXoxosjz\u002FHxfq98Q5tBD7CHIMR7D6p\u002Ft8WwX4dfuvwqLzd4z4IqTy7AmsepU2FypAorgxp4eGZP+kxqtg49IZAmay47ikd+s36pNda8j5neuKnEBQ4ZVnqlYRlQ2gKA2txDZalx7CfdaB9SSf7CQ\u002Fihgxu+PEnKnCXhJlbWQMdKR3kYWFQcuMZIQFzwPqVZSKlfZtTemVWnTbnzkZ+JHKCimu2NWdZSdr46x8W7CrEsJvqyrdQsJ+ZaEu98KvHmlITEwU+ZWz5txdhoGUqXS2WTh8NaHauURe\u002FQXcHcmC1NP8pIIQ4zbZPe0NkARzdoRXValY98fM2BmWJYjvystwltUzBk0sApBHl7r2PJwIEP9Uadu96RR3phXeuZRJBstQzXjUzlTQ4rdsih7KRnj6Pu2KyPMIjcgowq1LiQh4uPUvpHY5dfvxAWjnH+VaDERDrFjJAI\u002Ff+Zu7Ofza4sTehfzJPHiLAdntJ2TtVVWVQXDX2FQOoL+s\u002FiqoVaiCsagQRI9CShFhcgIaCaW+CyW11qqrIqMyvt9GxHeJ5iDp7fs85+3\u002FcLO7Oz0r6o833nPefsYe21156evc7a+7SMt\u002Fh1Cb17AbDqzI5q\u002FBeYlxwebkd7\u002Fk62WH3jjTfan9hl6k6ULs4z+qQ0KHWInH1x1wDYfOVZn+eNZVJqnvFWPlBefAZg2+1Lm0o30HAzudUHaePxQ6H1Rn2aPEZqkTUioZm6Qu7ath2uLqRP+DJ9rr3Wn3nm6hYneUkbXm9HJmJoyWfzur+i+pBTg0tuuY\u002FDt\u002FutjEswPyPwEiRPdWJdv10qD8U+loHJaetQ3Uee6sMy\u002FRJ7NLLHIj5EdB5\u002FY4jNc9XX0l3y5FdW8pMCGS7mt+GGfIV\u002FLP6SWa6HaZPdsWN55irKROO4hdvo7OWwRUhdFmJR3\u002FujvoVx+9BxLPWHeUnY+m\u002FRH+Z10ttxllSWC7e0se1x7kOkdErxIF+HedwzN0muOHHf8t0Q41lyldEWrc5xaB1wxc8u7AGtOHIeksIjMG4rfF3q0ZD13xFb2VzX+DaPIu0IbOWRMII5Kl7k4jBJbrF4LNknTeHrL9J2yNNh\u002FDqXFv7Hb\u002Fqr7T4UUJ9j8raeOB+fZG7BfsfLd2b68v\u002F+yT8LEP4odtUB7DEBsZ85EGdbRqDi6QBemruaYcQ0RMdukPL8GW1HNO7KjKbjsYBc4J5QVNwHGfCYMwBOtn+7du1aASM\u002FO1sw9\u002FBJe+Yg6dkLWNG+8cGNuN+q5h149gwMA46uNMjAGRCHRyCJpsy+692JIPzQRAI5FgDip5OM8FPAmkHKokiTEFpmAN9e6gC+AudO0812HQ2HNwl2dAGCfRSEOwBpYLOg1vOAl9GQnpF+6JAHDTJ\u002Fz9JjVuQrrOzar1y50v3jVRR7CdPAA+s06E8GqPMH4oE2kyPbVpq4qFCPZ2JjZxl5p5U2eLGLNsDW1jz8jtZXXd8q+VbZlQFZ2ymF5rb226Gx8s8khpkTgDF1esrULiPV1AbIk7324BRx3LP4NO7ATs2aclU\u002F0JUWbSTzJGk7KpfIBthzDPiZV\u002FE01GNL+0XDKzvh8WPSUA0cU5GEK5+lsAGMyiDa\u002Fi5u3m83tzdhwVeAQ\u002FiTxoB7BAIWUhenzkwd2shWrgVVycOE2YAaIJn0gL0R1nQEA8yH5+aT1j2yqTB0FhFK442Amyag4+S3wONMKEwOkl5kCZjTorN5l95oORM+PAwfG7hL\u002FtjHO\u002FCyJhPAkkl2J9rxLziLWwFqykXeuQ3\u002FUy4SRjuJ5g7gWnSnXhfYJ\u002F\u002FK2k9BF5p1EE1+tvySV+53R8Ls\u002FBtm\u002FA7DT2ryOGsJyBE4XXIv4N7RHNmhz0mYKTd8B6R3QknG44f3ardbhuJWzLmCkcPz0Erew6u661QHXNUdZ93jJox812QnjLuSyeRx8i7\u002FU77DpDSb8CTkd5iotMkxb5XQaHmnbMLrlM\u002FwuOhXHgnTJPGSpIWw+9S7774ToJ7do9InW5cEvOtTLgYQK9WykGSlUdkrp00mw456ga+poyY92nM5iEfjawI9psQ4Lnmqx60PrbfGDLwlXOg4O0Dm8UHSPR1TvgcJ95VJe9r488+\u002FUKrTZ29v2BAvCGvKsCHOufaQh\u002F1DnCbY\u002FrqF+9aXlMsunUm5iU15x0s9+oa0Rfttj8bfAq9466qilNTK+C6j0p6yrCwSfx\u002FnMOVdxHF86PG447T\u002FujXRyUSj+JEez+1+J5e4l8tdnvPkPj\u002FLSbs5PBbP3HZeuUnt47ILOhOQcTmexmGoLfiOEL+hUacyvSN57KYyjEuzdHAVSLnMSc5z35Du\u002FcVRvD0nnsbl0NX9TK75bbLhmGPyt7mPU8nt+G+Y5GUj21w1U7mbLCKyv23Aw3Lc+016nsU9cC+pRayh9mVSnpL4\u002FOfanFcecy\u002FAMEdG7qdstz6njiKPrCbMFm6LObG5zSGMc\u002FVah3Vl+JgYy73lgP5GfJ7RGl7nLr\u002FJoph\u002F5\u002Fdf4fStj+9Mo\u002F5EtMtvZTeVjwOW7Zt+9erTAcm3+5VQXw9lvvK97ArTL43eye4o2ZUlfXe1HbTewFSBVwYEe40boD9jaxwAoINidwtQ65J98c5e6u+9P1pu+6X3VXQqBNAnGAAgPHfa\u002FSsxuzn92mtNg4zZINPWMyMBgN+PZtr2hhZ+EjEAR5PzQfY\u002Fv3H9g9C8X1MYWmk7Hrz33rsd4NRj2nPgz4Br4Ho9WyByt0PNsyYVyQ8w3kWMAZcmHezvgWcDhsIe4JfX5OHLBAItbyRufXmr20E+8\u002FS1aol9tAPQZ2LktMWljxj58I3BsItbs9f7RzdiMpMFtBadskcH2G3rOGmNCQmNKHv0UwHSGfqSbVrnTCTCqzcWJkX9DHjKhqnMgyy8IlPA2bVfyQz\u002FwAsbXV83vXt39inWWRp8RxuWASZhADhacQNtGBlwHdoG1AV8mW0Ao8qcm7wCLwtY1a6drGn6w4eJGFk7TXSYu5AfGkujzg34QUPeTAq9sTDBUV8GlIz99AAjdW74UxfwIgF8fPUg23qGDt4CEdIeM5lJfk5mC8aw0HwBfurzfOF0dqaZiYqdUqbzStUigsoOrzWtiS9azW+00lo68Mx8SFspkM6NazsWmU6gDkyRNYKpufHXeaJtgjSdSsFfeEb7XkyLpggGQCVkOxa0gHZtA3gLoU22dmga2\u002FSuBzCpYdKUdEwGlUMHB7ykXswRDt2mh0kq5bl5D+\u002FygudEa13wGrJgNELBHz5O5TXK2pWn2RzpNk3lNXkLoYZOWs3+lBW\u002F2kpXDgN0Wxepn\u002Fo\u002FMpHHmZhxzEkOZJDfEe2UlXzOGVqRIVcTMzLtkfIWHdCUR3U+w2VoZGIXm2nlhX00FmBFRxtfJ1ruF03hyl\u002FiSK8JSCRHJz+hyV\u002FdmXBTf\u002Fk3VMpuuxO76ZM51zW5aVnFjasw+JW+KZUFvPj1ZoGm2rav4tm3H7jvHv7Jt37nVPoG\u002FYt1Nt0JxkQwcYSbNMk0KfuPKLyYqFlMUm3eJvHWITLER4sq4eVNvILz1q1pxyZYUlGZTievSu6eviRx1bemyC88nUtxfJ7+7K3Xf5U+8eOjR9MfTnvUjhx+JZLfcajr5lm3OifIOjyvoIrlWLwV6K97JW8VD8Ec5L+uvfPDrWVWr\u002F5UhvvHf8fd0BRoxVvXXxdx8cF\u002FY6mxf134nfsS0M7BDUf1LVd53Y7ebY+tK9x3mZ5AE0Zt3eJvcSsSgTd6ou0pcz54cpuzLq7bzbo20YPw4y0g+ouPvcQmH0Oz6Qrj5tcdewHuQjT4RnvneHhTwuMg2C5obnrf63JN4M3xIBtLNPXbx0HzobyM00Zi\u002FIR3R44T1\u002F1WV\u002FkdJHR438ArDro5NgoiDa1xzu8I7Wviad5XiW+C2NxWo6s5JQol0Z+hGmZ1gyZkaxKGAwFXe21+Gle8ydOuvvM8IDdE51c+VzjZ3\u002FFdgstvUT+M+bvdf2dA\u002FeNodmlAmYoAMf\u002FmT\u002F+0r1I\u002F\u002FPDjfJHyg4CmO0d\u002F5z\u002F46uhytLvAaQelDMrPPH21mmV7gd8KsLc9Iu01c4AL58fGmPb1kZjK2BKOLfX7771dAVo89DjzkJwWowJh7Lw\u002FuHE9i53swZ7dRbL7yaVovh+L9lq3fCuaHwDq1s0sQA0ope3GM57eevPNANR81Cbg43R2EbBwFNhbWmZ7oV\u002FOhAQwNxEwQVj2vtIGItm1u\u002F8gW4LxkxdAFt0nn3yi4Jy9pAGRaQxg\u002FkVey0rjiy98XfRCJyoGGF9HvRX3RzK6nQ\u002F4ZJJC22wyoKKwle\u002FAGhrkxSzEYGmtwEsvfZq3G+8EyMbUJm8wPv7oQmzdP07NnY8KGX7PBlgD17TzX4QngIsZkAmAvNI0P5a9422v6eNE56Ldl67yBV6ZJF2MDT97dRWaGZIFZv2yYJ7lqYA+QNnExMCt3AFlfkAGUKg6O+1Ug+4CKCciO0BQmtXommjkVbaJXBtgaCkfGt1ZC3CrdYm\u002Fs2lmoFe23uZIk22tcrPtIhlLX1kqs3mdPoO3RqgBKjv3fYuxgGTyxk\u002FZtbFq+G3RGug0Wtdkt1p6ciMgZdVJSp7uB62sSYwtAeWxJOKHD9uFkpWjJl\u002FhXz4Czab3SfjG2aRHziaXwNQAenwAkMM\u002FANWgIYneHWC9k+BQZJ8ekMNMoMA+jMvbAkkLQLYcko68KrsTJpThoxON0Cy4DL86QWGBIYC5J2HEjamVjFZuuRst8XSQ8kBLPbKMAIWkNZ3bXV5WnhYN3sB+4VmuQKC6xr8TIKC6e9knZNzQk4Z47bDdeK4fz\u002FHjmoLI48gVsEWPPOR75K84Eid+DwLKU7ARMwAOqKok8pQ8QL\u002Fx2QF1tFIfZoIyoN7bK3UU3RWusaSVNPI79Sdk+WufJk5dOJzy6xFW+pZAHhpHsmKmLm5unu+mbdnu1ERYfvjvy8yuS7M2obRIKnHw6+ufD8In7bkw5HMp7dbHhryp9O2F2\u002Feyi1WuJkxoth7n6qh7ykfYRB66rRupHxX98E3zz2HJgWzlQvyWrfgJQirql7UlfS+X9jpAPRP9uNyx\u002FiO0LqYPuhWzSJr\u002FR\u002FOWs3w1hVAIzcNjDeLH3LaHZgOfTfkwxOTv0OV3useLRFw3vrTJprj45EV0TcAv\u002F7\u002FGkeCTD\u002FG+Kf5QRpG817G\u002F3\u002Fsvv4evrasPOz70PLXywHGf1I6tQydMTxzpz7n3z7OHXLb5eAnLp7LeHX0Wbu82t56nH1o+ve7Cbf5Nd1GL2wq8nFwn6KFL70d+e45XgH0ftCe252mxOn5+D\u002FOz7ndsJvFFZV2ls7uvjDZB1X3uJ\u002F4Bb3HQ01fijbz5be6lWfeNct0R3KffVFN\u002FdiaM8d6lzL3Uxw29va9QBy0sj4D22ImvMppxSKxlprhxyGnfpsNe3fszeToM536fjS0whxXo8B7h7djH2+LEPVmfJovXUl1EVqzf\u002FfqdAfWf\u002F+KXBYk6QVrzt95+N59szqvRACB7of\u002F8F6\u002F2\u002Fu\u002F+3f+wYJtWOf1rAFUWL0az+UU0xcB6dN0B0V8UqFzIqnxatZp8BKR03\u002FFHLoT2O7NYM4KxswpN6pOPXwrQzOLLD+5lD\u002FIPapNoYSVN8FcxBbEzwafRpjBPoI0Hkt\u002FJ9oefBGy89NJLRz945ZXu3kLaN66\u002FFxAzWmV8DvA5kde9b+e17\u002FsB9k9VSw3IMF8BcroHeT6odC4aanvGk8G72S9+LSq1r\u002FUT+QjTM7ZxDNAX\u002FsPwcC8DM7BpMNOQq+kHNGPLD3jZ7eZueGL77+DGDxBlVmOrSItCDZpjepE3Ahk8fZkVgGKOdNc2idmO7Hbc7YoChFkka8tEfh\u002FeuF5+aKJbATMg+yjSTZU09857d282zdk3OxrQgiqLFbNDTyYQdr7xBgU4M5kA+uXLdprkZIefx7re4GIHfJpTr9GBdjL31kN+ak4Q2gvAFETE35UW8q6PCYUtXywEXKtZjdxMSJgddZIXusoFrwXrya+wCVYZvfvue0cnIpfJbL4UG16+ysetksxmdrPtRJOyGcDKztUkgulS9klXDsmnuultwGrVADAex2Z3triUJx\u002Fm8Xc6i4zZ2SpDZb32iNbZDr0AjoAvYeftEjB9v3k7c4Z5gB12lFBCJH7vpB9AuLogE4G7zBuAobRudRPtbOYeGUiTzLz9MSGOhj9hT2Z3jLOxEUdTevdOsN0FsEdjK72CreZ7tN8AZSKknmc\u002F\u002FGjXTZa8abIF6Al1Y6vPgN5oL1XLcJkTy8P\u002FPi\u002FNfwFJwhDwOgVxvx0GNSc5h6nS4b34QzylEIiW\u002FITeg0xGOpglPLpL9oSHRm1vE6c8Jfya3OQmVKeet8LlCe9d+2HSQ\u002F4bgEK4aWCkJWEQ2R9Th004ZzIjDeHUceXFzE57cI42Pr6lNXLvBC8xOjlIePTQv5XyuXVzbxLlzZH2oA\u002FpRCplSM54c9KKy1bN9KI4+Mh3E\u002FJmU12bvEhjZOQNqL339TPoyTczw08+\u002FajrelQpE7vbafPVtOvMm8bkXJ+JB27yJQ8OYS0cXeW\u002F6pkJsUW3ysehLzNxKTwnp+S4lMndmb\u002FMb3OkzzQZlHz+BNpp1LdJKaDOnPKzKB9MNJzaRY\u002FQmqnjPM7v8fKrW8ujxZ4sJZH5l2KOzbP33+KnGRR\u002F8hrWmleF1jxzcOyQaNLdAZjx+nf+lm8\u002F4n499M4p5XZ4SH9\u002FHN7vXX\u002F7u0V7Xb8h5pZEL\u002FnBTuXRKH44pMT1KZ4O+OWyf0w7Sx+wZChwww+FuG9pc+dxeHzNYfNMONEeDs53R47neuCxHQ879XlzPNRSL+rDwqTkd7Vl5OqaAHPdEvhaotP+l++67mu42BgolXq7W+fKROXbICusq76rUeZn8eLp8H6rOwC7SfEeuE89V50d2+Uhbja\u002FeO7BesnXQ\u002FpTN1eOEhAhHuuoE8fIom74yFMTHvnpYXYiOGgbfFesIReXjTSKDx8HqT7s9a2evzOg\u002FkVA0lcnbsX05fMAgnPZ4cV2WBdrR332jbcyIOQT9wEItOI3Yk7Cdt2izA5Q6cTZqX\u002FysV1XbKU3n3+nxaU1ok1+Iru0AH8A9v37AbdZEGkbQtpzGstnrtGKnz66\u002FEQ+lR5QfCMa7XfyYaA7+QLpX\u002F38L9JYbwW8f9L0TABOX36iX8n0pdJ3334rnffN9l3PRBt9KSD2q0wcBtBEvikZ9qcWuL799vvRvL+bjyBdyd7hl45+9KMfHf3kJz\u002FKF0l\u002FePTmG28WLJ4PWKeJpjWi8aK1sqe4CYWBCYAEcNiSA0s01AZxIMnASev7RLTvJj2Xs0AX0BnTggxgAcb27jWAPp+dboB2YB1dDYAcaewtqryatxW0Tf3S6LtqEwAAQABJREFUZtJnK+5V9ZeZtNzLx5KYExkMgeWPslAW7ng8fD\u002FJll2Dyt8sBA6gD5+3N0AuHyZfyoO5EG2z4ZEJ06XEwautL9nQ91PiARb484VMbzd8gMeOEUCvtE3AABbg+2TC2BbTolZAag3wtR9vg\u002Fd6Pm8A8jYEkPRlUhMf17U1pY9OeXsBJJNTtYPhkdxN+tAkI\u002FUFaAKwAU2dubygi18NUpLunWRfDXDy6Dk\u002FCaMjTJcV\u002Fu8FXJic1HwlaShPZknygaYOxRoB\u002FFQLnbpR2uFBRyiM0yRIg1cnur1o6BQYK5GEVS41C0kYNEd7vPGQtAAvB4CVb18ln2NeBaSbCJw\u002FxyQj+TzhS7fZHSYysa+1rUD1ViFxdCJ5wYu3TyZ0p4KK8Co9b2+YOuFl8hJwlc6N1r4AEf8h0kEFI8mMe3InJ+Ddc3knl9Ad2q4je4COf7XVaDh0ru0d0RqQzgFNp6NyEShplkbc6k+gmShVfqnoix9Bk43K1MDTOCZTwkgQXehV\u002FlL+8qDeA7YprV5DTAZLszwmKWXkDz3xfAXZdwqUbO8TZkC6SQ2agOn0A\u002FK0DuH7Fz4qT7KV39SNauAfzMfTpKh+q19dc6HcItvKs5mUBTTy1ixtUx\u002FjmxDe9Kmv5E9EJruyY7JNiWKXK23VBNibqJtRotzJpD9zz8pGnde\u002FiISvkbl8A8\u002FeoKGawC491KGEzTO28OftZWp\u002F+DU5jP9WH+7cyRuR8BuyCa\u002FsQsCZuGTRSWAeq0hpAluZNVDKJ7TO52Nxt1JXvDn88qsHRx\u002FEZFHcK\u002Fr59A9hIGnMYAz3O9W7SSiX+s3jyoJU4nxwHHs4cP\u002FtbpulpOm6ZaMRsbF4mdrEmaMrIZSTupXlLfLcC9OADXucXz5Dh7vwZNIYveeG9hx7epvDb3GZ3AwFpbs\u002FtnxyWOztPXt36NyY+cHNjIFkv9HLpW0ofpxWOvWNwxbqobKS1yQzgcrCClcKkam2vguSu7XmoZF2gXc3i9gxWt8ks8N8rSyvrMzzYapDduVi5dl1pXwYt27bz\u002F5+y+aOw8Ob+B3Qkv7X6MZBatx3frv7uC\u002FHRp4HeVx3+xokQNwjlIL0VbcQIO5KLgEid0913u4bz0+O0p4gc183bXel6npwSK+PuW4F0vxMslvOJoRR1VvuXUZ3N4c0t8R3foJLg\u002FschzI5jLn8f9frd7aY9J\u002F8t\u002F+wHT7Tj49iOmHXlaeffiaLSl+KicZTBdq2Z\u002FTRH3bQBkIAy0Hb8cy1p9PhfxUQf70AD5ACZGtekoEAoGcTzRbysccfDb3HAjjOxN3XOc8fPXX1yXTY0TgGlFzNF0cBQjRojYD0e1kgei1pPHstPATEnkvHTYPDJAZYvH499u4B\u002FjSnV6MRPxVQA6Qa2A3MysKONRahemXMpOeTTEoAbWDFRIIWHUgy2Dlsgwgw0kb94Ac\u002FyC4xl2O\u002F\u002Fka3mPS1zaciD+Yea8CWRwCIdtkCUNolg4jBxJsJYJLbAGPOA\u002FrVRhplhwr5ZfIDqD8RW8yapQQIPAhdAze5zOezRytHCycs2WobbFCZ\u002FNzMoKxcvvfiC0fPPGVLyzvd5x59mjZ27+gBxV+knFRKbQFQA+Qru8gXwJQvrY\u002F2nbZ5qvcASEB2dpoYoLriog0MAegzsbFrTV63B4DQ3gMkDvzQjhmUyVlZkpOt2D7Jmwb1p5PB8KAcgV8AvXbk4VXZOdmBA6zSV0e5kS8tsTI1cbBYGF\u002F4cUi3E4jkHtgywVRONSnIFUBfdAhIx4hvk4pOGjopODCfSV6ASvUH\u002F8CoAw08yBfgo06aBMiX\u002FAPfeB3AClBuIC5l5t6hO8E7fvFtsTB5KidlZhCk+QfKPDvW4KBs0cEDgEh+Bf+dq4z8hVVHgERAa+pyNPPAV8LryloX1MU8uDcmkru3FpOWffzHDEfZD4ibyYv8yavTYREsf7QKnjfe8C5PhzsozTac3lqEVuSv78FQskIwlecqn6Wh8yxNcRz4Q2cHpmUox3TSiPQhFzx6zE\u002FiiLcFbfj+1H0mFzV\u002FSj1B1yH8AuGjXacJRzxHyqAT+ly52KnKlayBZSZxJsY039rkl95o5hlt4e6nfL784rOYwX2Y7yrkbV6emdox\u002F9MnorfWdygfyhWKkBtZc+RDat7G3c9HnXx1tm+DUheBZfVc\u002FTDYVWY1FQJ5p960Ppb3kYQwA8pTH1Ne+jRSWnXGVT6Frtw3+bhf9SC34Tda+9BSkEx58KxdONQfpphAvLrNvE2be\u002FW1V7uD16X0bY\u002FEpE8Ybyzx2Lc98hD+1eEQ7r\u002F7kbTHrUxNQBKv5YuZcivlOVY9XXVWuMNjufeK\u002FlbGx9xbalusg7R2aT5Ec9HHKzqtN1vVWby6cio\u002FW\u002FxjvIVNsptKLOSOwD6veFmJHVz37EzaEf0cDTwxZLO8JQ0TuWljD1\u002FVo03ioknPmTKqWWDulRd38Xc8brRHlsN3ZXEQZmTXqFOWJZ9EmsaAxElrc0s5ey6d\u002Fh7PUostQaW26uaxMkyA9dyYOr3dIXPDS36Pu5YffcGWd9y630LldouiBwrN5cE\u002F91PK3Lc4jbC5N+yiNRH9TpDtORch+ucendKaazyOH1OwCneXXzKrYJafGAf3rQcqibIWb\u002FM\u002FFi+udY8fXvxujO6vE1Hs8rj8l9w78Ud\u002Fq1Molv1FOPEWLw0TnuZZnNTNxNWPSF\u002FcRRdjnte15ombnJEW79\u002F\u002FWy\u002Fn7tsf3xlQ\u002F8f\u002FzX+e3UOeaKf76WdfBPjmi57R3FzIx3IsSrSt29PPXCtYBRgASyYbgJQOFGh\u002FOVseXou9OLD0VV5TAsNMT5iNXL9+\u002FehnP\u002FtZ9i7\u002FVWzSHz36wz\u002F8SbdItLC04DOg\u002FYPrN6Idfzdg\u002Flw03d+PmcnV+J09euH5a7VVpyX3qt+rUrvEWGj5WTTCBjSDoo4DLxZ5PpU3AgaxsQmPNjnA69qz17JA9NmAEds+5vPViff66+92P3X8GSgAD52IgVN+PvwwZjjJ44svvFC6bPnfzyJYJjFoOAGzL2I2w85eocs\u002FTSYZnckA+n4GSzbvdrXxdVcDr8H1kcgMeDLBEBYAvBzeDbatQqmYBbqZXKiagCze9FsAVL8UGrAGuNvakcYbXR2iBbR2lHEvLJBL8w80oo9HlbSgOHwvG2\u002FhyYCpi7301QlgfL7syqSGXT+tM5MZZksBrUnXvcFf3vgDpCZdQKGBWx3AxyOhBWCQm8mCeMIrC5pe4QFmJj\u002FACvloWNVSZ0AHDPBuAa23HdoVAIaOr6t65W\u002FARks8k5gByrcL1NUTYYUj465D2NIwUfMmRXjxva2ZRj2NXf3it0B6m2\u002FcgNsxsRlNs\u002FySQxcTJ98FIJErQE62eCYP\u002FoDnyDaDVtqVDkV+yIQW1KRr5BkwmPDKEbgaMDv75AP+JhDeuLgm202\u002FIDIyc12TnIJc\u002FuEHj84BjyazANyAfLyxD556uIGlhg3AShmQITCtTA0AMwGZARrYmkmK5+k0dXyONVi56ghnp5WljaX9HwBP7vgRTlwdrn6n2tcODGkEJTqU23H3Zwbcds7STtgQajsoiAcgN5r4kQ6Z9Nw6+OU+MSUzhKcu8B2+CkZDiwzJuHkL\u002FSQmSMNtUcsqnva0hs\u002FJ5iqjqevqmVNYbza80QPemf\u002FdzUSZfPFGFgCzN3\u002FKoWWfeLKMV8\u002FaoC1dtVNgnmaaRnylgUZlhbctw7iMRMr65Elm4pJ0tD9nZZDfqUcz6VTPO9HNhEO70g7UXfxTYBScJQ7C5CW5ngE\u002Fk+JWdttk1CQL0FG\u002FtTkToE+zHshXr9W9a88+d3Qx\u002FZ2vnOJQ34VfR6\u002FNUB8zqZw8SLFl3nwn7+QcJiLpuk\u002FokZ97YR2Lbh\u002Fys9w9r\u002Ftdfrh9izMES3PRaJYmWxjd0ZZ2GOvzum8uUwEavD+oqK8NMcHGd++wUZh8CC9Pc65AixfurcfrKuw6I+MVz3V\u002FzEPpb+47mSXgahMocV9+w3QiHCe2J5u748mgxfGYa0O139jcxze\u002FbiIXsbaYX4+K3na0rWhfke\u002Fi8\u002FCKkj7BQdxL5OrW\u002FPduu0+Ajc3NtQ7K6bCsPCw6G5mEy1HH8fF7WD\u002F7nADajoCl6dr7iYPEjoF5+J1+W1aV4wGfh5SImdwPZZ\u002F7LesjR5xwe+gUR9uf+ibOFqvui3thENgn2vq0gibPm7AaoM792dpN7j0e0tDzeub+Nw6o\u002F\u002Ff\u002F6B+kA8zXRT\u002F7svt2P559yi0gvRGN9s9+9ldHf\u002F7nf1GwDbTa0vDFaGqfe\u002F65dKDnarLwi1\u002F8ouDQAO4Lct976eXSOeO1fEARLa69w3XWXtu+F\u002Ftv4NbgYU\u002Fz57LTiQHm3exp\u002Ftab76Ry3Q1QfvHoj\u002F\u002F4jwLUnzt6+603jn4eoH86r\u002FFpZQ2Ob8VG\u002FS\u002F\u002F8ufZB\u002F3tduIGJe4Kl1YVCHXojA0Ynpma\u002FOAH36\u002FbpexXfiXaezwzOfFhIqUDrBgUDIzyC1QCkEx1PsxevmgZKICf7qkexoFaEwFvJPBgALuYtHxtlWZYOFpWGmMNhz0\u002Fmo4Cy9AEboBQ+6Y3zYBCvGUMjqx8sfST5CEmPqlF8mRwludqVoHL5E+D1aG0w1DJwxteLOi1ePRsJl3KgdYfSJKmBr1kJN\u002FyX+13aA5gmM6Z5u2zz1Zesm4g6X0VMGuAHrCQxV8G5uZlwGrp016lwShfPJvUebMibwAeTa4DCJZvAFxa1UxHC2jA75l07HQDRBqUvc0A3ro4VsFFLgCCBc3qGaAiH+7xCtSYpKwTcG76oYvFHQgPHw7xaPLaiONvckK21SIn3SYZMHE62u0FYOQUKFE3aOY\u002FTbnZK1\u002F5T91MeSRv+CGrllfKEi\u002FK3omW8gDIHfK+6o5+B5\u002FCiO8jXgC8iWE4zqljHuCn3GfgwFUOIsrFglDu0m4ew494ZElbDxS3yOKKr9PRkuskSy9uyk39IX\u002FCwd8Cj4DxlDkwqZ4OiFydcKInqdG+um09roB1r\u002FmrzMNbrg7xyld40q5b9+PmOhlyzZEstuuNe2km\u002FOrgVz7lubHCo+jcSy\u002FPK+zGRXlchIVzdADAY57xR3YF6EB67uc0QO7lO4xtgwI6\u002FuNPBg601Adu2jLe+SlTH7TyBdEQHr4DhLQzE2OTc3VRO1H\u002FXSuzLV9oy+MsDk8dTd3XF6gjzBOVDf8ZlPwmPG1hzrKZCqBfmDziNeHJNHRctUP1wSmcEM6JM\u002F2JfmTKqVnqvTq9ytwkdMmsMq1IwkP7raSV9qvs8WaigX\u002FtWfvyJtAH8c5mbLkbnkcTr+ynLEUiV\u002FyfCM\u002FlL3wufuS9ZS+gBB46VriHnHePh\u002F6H97sA3\u002FLmGEuVS9hcV569H4dVP3dJ7iLPjfIUYa67ULsbslhCmHv9PZdEJLNcd\u002FLKzfipW9rYhP2m66JLPhN\u002FUlFG4zb8rdTX08Tb2KvjhN9cehFma1V5HvpDfVHJ00aoaQvTcIe0VryS+BpPh+m5V2\u002FROJ7e8VDKQhtwtE5X7uTYf0\u002FHIqznnWuYXeU58RFqSezcFwGciLcPz2coqvfuVpnP\u002FcaEYD32slouf93ryHjSbNwkuMtLHJpC8rTKYkefG\u002F9ep07lYVcGdc9z+2V94hZ2uxH0WPztod7zM3XW\u002FaJFNouPvduBf\u002Fu\u002FeZYiDv\u002F4b5pG\u002FZ\u002F\u002FD\u002F9lFg5+lY4t2\u002FYFXH8Wrfo7WXj5cfbztsjQJ+qB1LdjT\u002F1eFvOxJ7ayn2bPIGO7xuvv3wi4sr96toMDAEPrVDSINI5sf+1G0sWpGYCYz3h+Ox\u002Ff8AEOgvvhD35QE5qz2UYQiGVqYb\u002FwT\u002FLa9oknHj96\u002FrlrAXIXas9uX3Xj3a2YNgAOADjAez328\u002FilCQaGPv7ko14B\u002FI\u002FyyhgofOX7r9Ss5PNMFGjGDT5Phr4r+3t5A0IA9V\u002F+8pft7K\u002FFhv7ZTCbsoKJhGKBpezvAZvAAXGwX6QurtPg9kif5PB9zFZ2agUNjB2yAdxpvAxf7fKY0ajhwCnTZdhJovZj8GmTxQutukDwTIAsAaYToDUicPe6BpMojcQFiZWkg9xVAHyupvX0AHlMQ9q1oGvwfSXj23xoPzb1BFAAHfGl\u002FgU4fRfImg0ZLXsjS9pcW1npWhvLmq6OPRjPtYL+uysufhbUaWM104iqsNMiz4C8gdbT9WdsQcKizUYbKaerOreQV6PBl0Wijc0VDngBjaSlP6wQWP+i2rMKrLR1HCz8ApCAyJhjoLHCMZzJYNr5AMY03PpdZzgDgPYhRDsoFMCkISdkAXcpcHshZ\u002FSdru\u002FFoA7Tmq0MHQKVB\u002Fsx38AOQzNdbx4THJEF7cJCX\u002FOFJvh06NPbLBSrhRVkUMCb9dQWK2oEnfkGX0TVHaevEEq88oRV3oJvZC\u002FAONktT2rTeygm\u002FeFA\u002F+LUuFpwZwHNGDjsAnGdl3xRzo056WnlZ9U15ko12hYaJ4siVJjixy9jIG78lGjfO6FX+TXs6\u002FUV\u002FDVx4Il\u002FhHIegYaQx8u1wg2jyi8ZKQRxupbfJU94B5YJU17gXgIrX0\u002FPcq4v8eyaPwk38mZj0bURlMJMfRYTfTqpTh8ln2nvqWvLpaJ5T14SzDoPsZrjENxYmPTbx2qy1CMNPvSM1ck1ZhEensikITz\u002FePCUPstF7\u002FuGZGVknpFt+UVIeeNB2vLHyFlb7U4b1b7kAO3kOTyaazHnkST126qekY8yUr75xSblT6JDVpWjQ9dM+9vZIbNSfzJvTsxfyPYukSy7eljqXzISdiVOSLBeu8tMMzbXMbZ7bpXXtuNOxp0N\u002F9+pOr+5\u002Fzal+\u002FnUPbJbj7XoYf+rluKz7Bmtx+ll++1gTbs\u002Fj8gnLu0NuPOsFet3lRz8jn+t6EEnYUGic3ifxRt7a\u002FRZvyW1MFCbGyKuRy4NoKE1Jrfs6huTEqf8WbpxwvR1DoA+rLLQVzstrfz+OpYsAtlFKgBV2keXnJEPYZtrVXOu2tWfBHKuetQzzM9GXb0khlpAS3m5zbf9R9zpPHd2ilWadSXr5bze5iMZ90vY8odZzfeokl5PuPvbvcBcSk8Ikvr9Hy9OvSSV8NWyuE4LMxdnzNI\u002FzvPIhROluCa3Jq3hN7YDGunXdqOyS2Lkp581\u002F1S1jltPxx7\u002F3Uq\u002Ff9uc7M335r\u002F6L\u002Fywd5YPsUZudOwL2Pv8iC462xWtjfuD1Y\u002FZCT2VkpmBHlPfeey8DdXYNSOs1mL6QjyQ9Gfvw9LUBvB9lQehHrTiXL1+JGcu1ANAzRz\u002F9879o560DJxiDhy+G2l3EYsYClAA2tuHoMhm5cT0fOgpwY4NrESsgC9AaUGiKdd5oeyPwXuwx389JQ+4LnmwzmejY6lFn\u002F2W2+Hr\u002F\u002FfcCHMWxLSLQZD\u002FybM0YN2kCVCqDrQ4NrABzB6CAKUBcpWGu8sYbb1UWJgkmI2jxM1CpNICdAY0QAE7PQCWTDgvBPrhxo4PVk09ejj28bS6zkDYg2QEMGXhMADppidzDXD\u002F64RW0vM92l1lkG36BJuf5aMvJ1WLROwlzi4Y5aX\u002F0URafxRSJ3OSPvD8LAAbEgS7p164+QMZgbqCeD+pEq5tOqa+w7TyTiYd8FsAmn0DoB5nAMenxkSb5lA+0ku2uV7D1YtkP3+Rp7QLPKf8x8xj6JgcjQ\u002FUAHbIfLW0mhRn4a44TkxnlQ6tnH3o76nTiEjdgHRB2KEt1tiA8MlHngNIB3N6wTD5rqx5Za5xAk1PzFY9sAG6ghNxs\u002FTm00\u002FGHfhejNnQ6gzz3VV1kSDMurvS9ZcE7eWhLwG0nsSlPcsRX+U8RA6xkKLDJijoK6ADtaACxTL1s5Qm41OxmkyuZmMigh3cquL6BSJraWU1nkjfhTmbiCsQYbHZAM\u002FSsqdB1aucAmfrsT31zqtdot\u002F2GL\u002FWZXITTBpt2+AHGdKKNj0ZOhwt61baSH+AHqCXf+CiAFDtl4QTU5IlcUSid9KHqDpmVZnyUV+PETb4K4uNpQreAsfIxMVaeSzuPzuqoF60CxWF00sN\u002FPKfrzo1nsslZ2lVKjKwmrc2\u002F4XLvmnMdZFvwmLyrB+KQgXqpjCRWkBr5SpVc5i1VJkORrXPxn4CVBZ6B9B7JU4TR+lgQ3zBIqZ8hnrD7vIgx5WB3DWmtt2DhOkEnpHu8ziL0mLKZbEoz4ckY\u002F90uNGkVJJfHJtVJDP+pZ5vMwqvdXO5Hu0+BYGtYyh305UW+8G74BbxtH2kb3CnbKEBSn5\u002FONy6evvb80bkAdVzOREO5JH4caNJn8qnvHHls2ZHpHi19YflXPnM9LC8BPfNfx9fu0eD\u002Fm050FoHfcK3c4y8b674Z3OLs3PL88P0i23T6g+eE2hKefGy8xudr+dgS6g5D9a\u002FoIp\u002FteiyL6tE6pSyRwzORCpCPy1aa\u002FeMnWmWWi78lP+49hGio47zGVcqCT0xktrDjyGMXZ4D6+E8SK6wwQ2H4KrnG5Xp44K9uO2GGh96T78h4nlN2jbh324U7JJj7FsuubMZzaHGc9LckHop5yFtK4YCG27YF1+W+eC+VlZNDGg+R\u002F+s8IrMSEq9pJu+5XSmM02JmLy+BW26bV+mEVuOuyKGivzw8GmLFOfCQs105bu5TL+ahflv9WPfzmMRy0\u002FE7QSXN\u002FW\u002F\u002F+KWNyre7fGdA\u002FV\u002F+b\u002F80MvL6W4foi3U0NxZ7jqYD18oC+GD60i9\u002FZoA540M6ESK\u002F\u002F+\u002FPf3b0s5+\u002FWhONeLUD\u002FyDaVtpQmkKLLy3ofCFmMzSbFkrRcgLITGi6p3cAGjeapTvpjIF3IOP969dremKAoO0HZnxC+t2YFXwQAJpupDbKOgamBm+8\u002Fmbyka3LsniqWqQMDE8++XgXsRocvB14PItaf\u002FSjH3ZvdXnohCMDQvrsAI7YmGfgtEf71atXCq5oaz9NXgw6+DcZ4GYQBeQMcNICHPEHFH6UdGwnaLJBM+zk52utAM4n+agR4KVhqWQFhwWn83qZu7cBpyNnkwmTAOVSoJy3GUwzgFWA3FoCwMbe7TfDk6\u002F5fRIeb2RScP36R0mbLb8K79X6DP6qH7MkNumAoPRrcpECXVslCnMxgJNN\u002FcVHrFeIzWvCAqMGZfUGAAUelTXbbhMCEwGTEnIBLoDKDrQJT9bidfAPLzT1fWOTtyvWC4gPUAG5JjLeaFhfYNtGE4UCHfEDLgzoNQUICNN2gcWuT8jECn\u002F1T50SV91ykIOPLXn7ohyYOOF1gXj5ASw05gUyklzlaxIh\u002F94mnUpaYy6wAa7IHniVt4KkpI8XsiJffFbGcV+TMeV55lRMqRLXJNhWpyZQOosFetQ3C0Xxo\u002F5Y72CySNbVRqfeqYciyb\u002F6Iax67Wg5Kfe0Je7CjfwHYAoHIPkQkrdg\u002FCvjxCFToMFR8JT4ANCUO43obPUIUNV8Q7qJMMBstLONnh\u002FUlLkJzEx08BEeQhtf+FwgXujKEGCDFJS3Qghvjsnf3HNs2AIDvIXnDUSODAbI7wDuUCg\u002FpTUCaZ4aPgTwNL+oS1cLLRvDS\u002FKhHh2C9oL31Pe6YwKdnImafgVwQZMzyttf8z9hm7X+NOgMuAXPA9K94eBDDuSImhIGlvWN7knTH\u002FlobwX2aW+9J2PM7BjJbQ60pv\u002Fa6kPdlDtKw2\u002FvpRuXU6mL+lpxOgnES\u002FyWjPYTROU\u002Fk98xT5Ga9EOjRRqwnjbMTQ94H5LGd+oSLbkNAyr70DBemAwyxQLUbRN57mLerJ6Y70Pot9QdE7vZUlVaUhq+yltoq7stSfctE2ni4TcfbTdbkK\u002Fdk6ls\u002FYZzWuJvDiM+TuaMrMm0z5XClG2cln\u002F9+pxcujZ9PxOmAd1vdLi3XkQG65i8TJwVXWrrI1mCyp4+W9iVd5O+hkezp+e9W7e+tbBX5INj0di513tP+6HQzcJya5zWkS1\u002F0o3n0Nrzdri3Pr89UD8MO\u002FeNi4Y\u002FCR3we3C7o7F4mXBKwjGuqy9T50bkW7n0QdhISNAVze3BfR7bd7hOwN556M38lsljEVf5LlJrfBRpuc194iZT8jwcl+zv\u002FCOf6+jd9rO\u002Fj2\u002Fzu4VMZqfvE2sft0\u002FLj0B2zOFXVuPGX8DSc7M\u002FWk5bvrhOfRj\u002FkmqAcd\u002FlfQu\u002F\u002FCsRbvmj9JHQH\u002F34e0PkW\u002F5+Z0D9X\u002FzTf1QQyGSE9vvJ2FwDC7TTn39OYxnmtdgMKrSqdhCg5WaaYQAA3n\u002F049+rzSDTCFpc2tZlSsJc43LswZ\u002FKdoU\u002F+vEPj1544fkAjQ+7kJMpje0YaZlpci8GOOqgCPT73385\u002FDxdgFV7+GhVfOzm0ZiGPBZebUv4SUwdHs+uLT\u002F84Y+PLmeHGlsOfhh6tOdABLtun81mX23LyKtPXQ6gzDaRycuVK5c7UQAq5Ak4d29CAlSZqKBHkws0AkcAEY3xs\u002FlyKdtJ9pLs7i0mZR9NK04mgAvbZGmZ\u002FAC+NGYqAkACLAOHwC2NNGBLxvO11bMdBE0A0DobcMy+3EB1IYseldFzzz1fN9pxAA\u002FIop2qRtkglwHrtnylLIDHo3zEZTThAB8wY+hgyhDNZFoAYBOPDOTRqicPM7EYG2hA0ZuDS\u002Fk4FcBZwJOB0VoGH2gq0A8YlRcTAxM0oNcWkhbI2q6ybwdMBDSGtAONDx0DqwM4X9vOWQ8AkJITMyeTPDJ3mCxZ7AnIo9nFrmSDNtOLyFA9ArCX3b5Bf7aKMyEbTTaNrK0klZG3AuoSOcq7DgF\u002FQAYQY3cJtE02TJaqOd5Aui+9Sk94YIT8O1HbABue2bFbG8D8p1r+xK39fwSBH1svmhx05w\u002FlBXSFJjnhHQB0b5IgbXkzUWSmZQ95Wvov8wYpTLRdmtRVronkuiZheCQ3tLUNz+TmVBZn0M+kWj3Dl1M7bN4KDAesExC3XpO\u002FVaeBQjxoQ0DcascFielDWs\u002FKw7ZQUNzQlw55KJOpmy2BLf1BCpJbCfY2Tws8JlLjKXuH\u002FLXs1Okc0sClo9qmENu6fZ7jzs2ZfK604DfePRt\u002F+BKggzKQnbPAPGnO1ZuBtC1hQGfENhpi63dW+MYtDeZW1gIM7948tcxxFkcDB+31rdt5I5N+RF1B40TkDZxGUGWSKWCBcdOefDRPOMFH4lig2vJJHSrYH+edLLEuffVa\u002FycsvpuHMpN6El5NDjppTjl3gpW2MXVrFnNrR\u002FLjwIM6YhzpB60INOuQmHP5YNi02yh9AGd1IfWRiZwqcyd96r20B\u002FVYvWa7Dqh\u002FGNPB23fzBvS2t59jfiV\u002FIdw0Ja4EKHykb4Ix+djXlYL2hJsyzs1vOKYObaRF2I62jzyme1Xav\u002FYE0KTfq\u002FtvOPc0ht\u002FFc8HdCi8fuRe2NPLce+6hP6zxHAYVu2PLfe6mvSmPdeyyszlldIjsZwxu+0wAZSFcT1Qedsvz+LsipF+f9jjPW2po+EuY5gsfgjvWdTEfh\u002FKP9oTYflcc15Xe8tpClgfe4V3sJDY+wgvrZ8769HbCbCLb\u002FIV17P3apsLYalt4nLYs3CZp\u002Fp524UpCgB5NQzw8ILAdcxc3\u002FHzjIXz\u002Fx3dLB42RJ3KoIIDn\u002FMlwTtee9ftG4n9txx3nvVl5R2Z4aNp5wsc65m797t35t2wW+7s4cdh4R6n3qZDFISIgwX9HwA2nuhy7Tv7rWfcVZ8kFlYn24OiPfvS90vm2P98ZUP8\u002F\u002Ftd\u002FErvtbEUYoAf8AOpMH25nYDCw+LAOs4Lb2SZxzBPuB7iO+QhAp148c+25SOZkgaEOXmdLiznmIvdrKvOLX\u002FxVB4Fns\u002FDyyQBt2urvZdEo2\u002FPahgcEsj18J4tK33jjjYASr\u002FCPogl\u002F4uj3\u002F+D3OyAAVIARAHj+fGxls+\u002F55ctXo6l\u002FsTbkBoMnoi1\u002FOh82sqXj1Wz96BvlbMLZZhtMpGsCAACaeLzxRjTwAbz27gaMgDcFBzy8Hr9+aAgICS80ywATEPpYzDCezJ7ubNrtCMMcSPrX8lrWxIQ9qN1YRjOUhYAbQGPXS54GTyCFDTONtMEXqALm5B3w+SomJ90DPADC4Hc6+9xfi728EzA0GaJNAgINSoAik4maX8Tt8bxJeCQLSS+FZhdyZqJTwJfyEU8HDPgZ\u002FJf22CSCVkw51lwnk65PMtGxdaQwPoZlQqZcnn\u002F++QJ2fAOMpRNaDjyoTxrUaK4\u002Fb\u002Fl7S9DdhLLbzwDs2GUHIHrjYkIwMvDBo9FA63jIRgsCCmjAgboVTlkAwmRpsmBRcj8WFV5NTgAKOw69k4XH+gCTrkuXHh2+Ug6fVvs\u002FIF35mWSRIXMiwBwN6eIDcCGDmQSy9x8N+tiZ29Vlwsg\u002FfsRdwB4gKSCNPGiU+atnlRlAlDzKZ8shaehE1FdXP9JQ\u002Fx4L\u002F2dTr0z8TA69kdAm7JlemUce4smrq\u002FImZ3kDmqvxTD2RdnfuSdnxp9z0lkDeAcCVZxMH6dCemqAX9JX21CHsJdulB+jKAzno9PrmILQK4oWL3wKa4gFLeMJLyzl1ukCXX9wGTK3OM2HQ8JebdRWOLBNhaCSNAkw8oc8vB76cwCw+yVTcdUjfiTjeeWkf5WNdE3iFafgC+8lvNVmhb9DGHToNsyWA36afsi5g30A7YKwsy3PiS3u0OsOz+lDgHNkIo92j24EqskvwDtLafmUinSS\u002FJgWdNCWeD7TdSd\u002FTtzAB\u002FKPl3mSHSE70lY+2zNSrJk8rrchRvWUWZSFz16vkXjthk07OaM5E07oF\u002FQu6OULDfeUdEHgvbzul5cuxJrLMGEO8QdUVdfVe2i2gbg\u002F56V+yWD0TTFr1W+Ht40++zIYHn+ajbzdqSsic0PaVn+etlEmvdo+mttFF1OVDQeZGWuWNHCOsbzjC8nZMXdg9bXnaclbZm86kVH7t3yqjguumH2oPXXexw0\u002FbWK7dNk7C0sw\u002FlkqjKR3cx59f62oJV+RC131+hsy0lQmbAMePJkMxQC7qxpTZtAEMbzTiV5Z63e4PwgLpKfGNky2J0u5PiPS\u002FbB0TvySSweZzZXYlupE5dtnooNa61bD7EMglF\u002FkNsXmoC977nIuM7OJy5PfwkcrQtuya+qR8du1\u002FexYFy+r68L+FGddJZxdmhRXh+FHe4lRavOKwuw9zu\u002FstnZVeqYT3OIuyO0sCmZJKXjnsiHj4puPfGaCRSrN3W\u002FhetvswMe3\u002FUL6T1tQnPG787FiYsFxXHpofXG\u002F0xlRtxox9uYXAjlZzOPnkjDa\u002F5b9dj7sP\u002FYkpwt9AoP5\u002F\u002F8m\u002F6Edx3o\u002Ft+acBnGlvAT7not19JPuSP55t\u002F2Krm7p+Mnvw6uTtJiDTNJAdQKKZ7CvQdKK23zPoGBsBryeiEdWx2teXjfnrr78ZIJzdY6IZZtbwYgD2K6+83J1kVHzbL1rcCeB4ZQUs0NpazElLb+tHXxj9KCYveGm1TUcOcFsw6jPT1wLSf\u002FSjH9ZcwkJGA4nDR0AeeQS4ZobzeADmlYC2J5IXGmaLHh\u002FLFpRXqvX5IhpL+7h\u002FcOPD8Goy8OTRFwGqip3GkXZH528w5PdEAPEnWbz6xuuvZzC+k51srnXy8+ILmUDE3toBFF3NBMNe4ni3f\u002FAyF4hE2wFUvikApg7O+w8SLl9aNfgDZJ9E20yLD+zP5+Ptr34xQJ8JTcAd288MUMFsR+ezMNfnws8HeJ0JWLJ3\u002FYWarmTBV8xpzme7NpqT2uMHhClDkwEA3WBpxx6v25nW2F\u002F\u002F3fduZDJiMGSTHtOi29lq8tJjkWUWiwYo2x7Sji7AqIoODNl7\u002Fctt4DTg3s+2f54ByEupA9X8Jqzypj2\u002FcvVqJ1Bkavce9WyA8Zii1C67IN2e8ucjm9TJTCiVi+7BmyAad2ci11bVBO3dfCzlet60xKlvgNS\u002FcwG+XpObSHW7S+UaPpSTBbYmmiZM6qAOR36qZQSqIiPg1aSB3OTZJM\u002FAdtqpwaQ+2+FnTdCWyRg\u002Fb2xmu7zRlgoLsPUMfdckWBrqBABEFtLpGc2iCcWy4wbGgWJ+NJ5kN+YyM1jiXXx7sGtXA\u002FYAUSYG2w4d6EceYX+k2RHUxMME0PcQYmIVvvGmzZg4iK\u002FtoIm2Nlzb8PAbIiO75FfaBv8Bc+LrT9R6VSUll1O6Jo\u002FqRgPEDfxpvsk27lwKaCObAu6EAcYbJ\u002Fd47EQng2cihI66mHhJUP0AYGfADd0kmKjlge+EEGodm1va1PjHHU8hQn4D\u002FJXb8OTZgd+VpwRPXLlMPHECTg307gvoBTDQp8zrvpV509FeCuJTL8TPn0X8TvdMNmw92DPPA0Yjg5ZX3uykflICAN3q7YOkkcIZIYwgIvPhjVLhThQxt6MYGFO+qYP6N4oOWVhAG71ZYB4zvtCR38nGaOABY+HbbiLgSYPT8OwZP+RGo94JR8INK8lp+rE0sD63fFJO8nYzvJGxepJAUQrlOf3JiQfJY96gfvZJ3owFrF\u002FPOqTreRvso22+l\u002FHue7m\u002F8XG282XWGXNIPKcuaTtTRcJviIa71l0TlGbBZDUTCH0hM0MMqWdTfqkTybQ3hOqTssCTvMm3urXAnDo492pi\u002FCvLyCcponFSe1LHyFl9595TRlNH+zu1qC6S2\u002F60vda3PM+\u002FEGFlotbtQctv47HNYV9vGic8ayZk0jYZ3r8G0BOmBTIRylGJe+5x4B83IB0Pi4\u002FmR5CEJaOpE5OnjcA3XITOUSJzFSM5ycFv6p77uvJQFjmbniz7K+9Cb4c2s275OXZJjd9QaArjL0bo9k+b2NIZz7h6dizCGw\u002FzXC7qpxo16oTe3YvmFLLMhK\u002F+bbzv7hsPkaHjRrx1DI0t30MhXhutXLWdySrZud\u002FndDjYqPFbJ+L4cYpd98Rced5SaLBj91t4HuVSWkj5RSZ\u002Fu0TW\u002Ffg3rVTKgvKGO3BHZRMiHoZe4pf1od0E8iyNSct9juZhrr333JMbWtuZ9vDv\u002FfB7Ynzr4zvTqP8\u002F\u002F+f\u002FlAEynWdAzsfMALJ\u002FuK+Hng2Qe+LxRwKo8wn5aPKAPIOAzrIdXjpbgBdA+Dxb0X2axZsWcNJIA8y0Gu14IggACqj\u002F8AP7iTP5+OzojTffqinDlWi4\u002F9bv\u002FzigL\u002FbvGUyuRdttT3b7mBsUvve973XR6a9eez2d5mwfyAzFTjPMVUwCXo\u002FG9O18pdQOKUmuHQ3NDs2tfdWvXo0G\u002FelrAeOXA2IAMFvMXQw4tB3iowNwAjyAzfMBOo9Ha+lNgo6Zuc2FALfPTBQy+H2YtGmYaYlVJNs8dleafLzpRgaJt9\u002FMV04jg8tPXjm6kpM2yOtZh0mIxZtrm8LHMzm4HNMQ6apIwmlMtqEE7FTwAUb5MFLkKd8fZ3EoU5FHwvejmXwYNA1Op9Ihnw1Cv3uHFsqe8wFmqXBnMyCpjHdp5zMYL7\u002Fz5wC7aNRp4gIggDzhAC2LUQ1QZ8P7uUwETgWE3bp1L28+bDXJptwkxgepDE4Z9ALY5rPlkWtA4wKiXm\u002Ffy2BKO64enc5kz4JSeerr\u002FuQVuNJh0OoycaKFL\u002FAMczU9ia86pmBpB8\u002FlLcrZ8GOiYmJhIoFv2m9vFrzpALi96TChUkY0cfp727oxbTobegYLoNl+\u002FiaV3v6Y9Jhs1HY\u002FdV7epnNWFLkruJiOGWBcwN1kh5mUtRHyrPzORn4DrJNw4gKQgJo6BUSfzcTJoD4DvSBAinMAOzBn0mubvpkAWJCbSWnaRCgmf97sWEg8C1KVBS0inpvHTFCFJyMmE\u002FzJrOYSGWvwbyFfxx3yD89kxaG85BoRqYEtQ7T6litp1xQob3fAiHtZiN7FhHlSlnhA27HMXsgQz4C6Nq0DJf92knGvX+uRzpnMpZvfyFvelb+4lbk+SFkANfHzhgaj+iZp19xBCvmCq7cEQ0tPtO63uPGZhXOrg06AhkZOxsGNA+CEVtzIobJTPuFPHW3ZptwmT+E\u002F4SZh9tjJU1HLNsBjhGf+m+88NV6d46iOJQ0gueWQgAOcpL+5hy8ArHuEAx4541N\u002F8mV+ZR1GTe7Cp3RSukdnky8fRjOpNIHU5rQ963koO\u002FTZ7W8iUmWnrrZOJMzKN95MHu9FQUPjLu+TTiYDybc63Ulj4vqoERramfIjVrL19raLVdNv1CY9fOxs0lOO8inPIihPIF3d6oTCfU6TygsX88Xk9GNnfJkQLyl\u002F\u002FeEX2cXs83yN2lhDuUDJcD3A\u002FXrGt+vZTYy55Y2ML198lW9b3M+Eg4zDNw2\u002FNB\u002FkyuRN3kM5+Zy2IA9tn\u002FosHnG37qnKK\u002FVFfYT+W3NCNWG8WUBTGaB2Mo6UFgD6ycjyVO71ySGWACaFgq\u002Fw2zX1R9z6Sbdc5an3HodPATjJz6obGN3dp1z3z7n3HJ7lc3eGhvqI5zkTZh1x4oaT33wu1oabPakNLHLYeO+FoEKzZjy5rVsbbBNsvXLXo8QSJoHc9qcRRCTLydbEjL8yXA+5NmiujVuJkhb3\u002FCHR++kvcrs7kNhi79z2oeOUdruSQajhQ2ziJW+524dYIR+6hikT1x7N58Qus57xh8HtOLjdeZRi6aD10Bke5g3S1OcSbBIHlCpY8klY6axr78d9S34fRrD+jc8WcwXr9dCtdMVJ2Uwi5eQgfELXa\u002FyFx0+PFpKyGp65tr5uhBpWeM873j1tPnVGf+eScCmZbULbdBPmD3\u002FwvUnvW\u002F5+d0D9\u002F\u002FoX1Vqz2dY56+SBXPny2r4dbzoommSduFesNcNI5+pVOxEzHbEwEoBc2pLaU6YTJxBCvZ2dNobWqZom\u002FOwvfnb06qu\u002FrP04MPfU01f7tVGDMG39X\u002F3y1aT3IGY112pDTAvK78e\u002F93sBuo+14wbIDBbv0ZrYaUZNTkVn6mKrvkcS7oXnX4zW+0pA+hM109ABC+MVr3x20Em+qvHK9X4GkUsxF2EO9NxzLzQ\u002FACpACCj6oBDzCrLxRoBdOQD0+GO+qnqpZi3s0rPiaSviDITV0twrYAXKmS\u002FQ4NMcszlnBw\u002FMko9FtBbqmhTcyoBkgCRDA7D72nRGHzPa5ZOVOaBoNxuLcqcCp+J1kEy4M9E8Z1C1+JWJjjzTZNOC12Y6WiNl5s0D0wfyZNIBsDvwBDgzuyigDaitljWTIp8kt6jRBImG+FLqgwXC3ZIxQFkdoqlz9XErANJg5zSYA42a27J5reYqz7Ryo7WcfJigtQ5FBg73NGLVKAdgygcenQXbAexMc3xYySJSHQLgbmJEvhIFmqVBTiZTs9PMyGTMai4UkO00tEkXHUB48U9ewPvaHpINfZhrPTDhcGj4FUDcC8STuDQBY7srJXppKmMdTjuduBWUtbzDX\u002FIF2GOcJhn4Yf4CGCg7mmjlZts7h\u002FLFVyfIkRkQRlOKFXHIb8DmTAbRpVFTFgWH8cd4B+\u002FJwOQ55WAgqRlP0ujkIP2FdMkJmLoX4LKAlrpTAJSU5Y8c1GPHAEEySJjIw7EDqJVZHHKtX+KWZ+2UHHNytxhX3tUX9Vp++QFceJcNP6PRNPLnzGCen\u002FTNFXL9PTuarPJNei1n6ee+g2d5UDeVAbAOqA9YJUu8bxQqe3w4xva+t1sySbuPeBj3yib3o2XOzfz3ajhRX1a5Tf4HlE8GNxoueMhp4u0crW\u002FqStrauZTXmjyacKnjriYE+nN5cQDxfWuYvnV23FKXmCxFvilroEc\u002FNPUTOJ63cZgtUE38vu0Jz\u002FoEEwITVxOWxglf+nuZN8mSRiet4Q8NYSLq1o+po2NnjjfikjY5dQKQMj6ROhfknolI1hdFM3Ehc\u002Fr0YrvzxJ0ob+6mP76dN8BfZAvXD2Ma9+4bR9ffevXo+rtvVzl1M+PW6dSZ8+kDvX0kV+3HoZybN+0jjLWM1InUu3BqepR8C+LJfc7wciJ2+KmZOTNBPpkz9ye9Lcgb1wwyCT5tb+qXCbuSTr19kDZ23+QuZ5\u002FjXqFHZOHpsN62rrceK\u002FfxMwkQptfw0\u002Fuwh0X8zTRCvabVH3d+4z81OLHE\u002FLVnC0gh\u002FaYz8dcfqutvl5I6vtVzea+0XXOTIh6\u002FPLQdcSTzJBlCk24u85AwuZtfYSaQq3azeNy7H0QvMZGbOoI9htaimfD88RLfh8\u002Fh4ZDElpfQ3lOd+\u002F3zltDDFyLFkyys4\u002FB+c6tTwWWCNngou\u002FLocy8lsznt7hdZ15HJXBt3HHfuQxOFodeb3nPbckPO\u002FeNR7hts0t0\u002F13H9CLdLMHSQctmTnJAHySy\u002FRWJx1HLeaJXTxcNK4+C5\u002FJWx4Xii4WUYOOT2bxxQ\u002F5f\u002Fyz9u3nWuwBgTBAtEaVt0iuyUddI9kjMgAEilrQQWNSSdOzvFtIwWmcF5hOLT1na+uNiB1OtxcaWlZGy79cGHN7qnukGeJvbD2KH\u002F4q9+mQnD7dh6X20ZGuyuxqb84wAh5ik+MHQlfrZnNFlg28xkAc\u002FSMNC4Byh0uLW\u002Fz5dWr2TB6ZdZgOesnXjy1zzk2kWAARvp5\u002FKRIaYkR\u002F14EwAHDKkYriYkwto+EMCmTf7SPvRR3z2eycBTTz1z9FQ0+DVZCF0VDBihLR478Xz8KY7kCgCQD1rywR94NwGh3bJoEAAjyxnA2HQGsOmX44xHwB8Ifi57zT+6gWhgiOb1TgA6vkygLPK0S0w1q5ENeV0qWI99eWQPOFug1gahcoc3miQLVoFx5W63HLb\u002FvjDLlIaG64svP0\u002F85CUldTYTDHTl1SB8O+7eeJjIIQxEd\u002Fca9Sd59LYCCDf5s\u002FA1RDLQZXjr4Jh7POGjgMhAmFRSnuqc+MAqcK5Ocaudbq61W9\u002FkCowAkRpltcaoGPhyKocBHQbYAaBomTQBCd6a0EwWGIQX5h6tV9qAQT08OIB+b6SkwWTGREw4PKGLB886FcCowC5+zTB+yDtPJi7C1YwmwAAI1Va0C7yjN29YAiRDVzmrx+pEwWVG35kAzKJg5lLMVmrOkDKuKUOSxaf6hA8HkF6+4rbkIdDIZOpc+W\u002Fg+cELE6C9NjWVMXTlpSAqfCujTihTrxboV4\u002F4K1f014mqvC0TjqaC0RwkhT9DZXmPs3qiXfEzEZ726+0DAB9ZF3rIZ0LkbNyEFR9I2ag2VEEKt5yr4wc69d\u002F45MYTKXVmQPrIagF2bVIo6RRMhl\u002FPysWBD38NET+Nt27cU6cbJ\u002Fmv\u002FPMs6PAyE4dSmegJP2kL1PyEqjrDFMOCTVOupp3fM3EHlM9HJt6ySRen7aMTrsqKtGNp2aVI29UGWqeUU8KoJzMOUBZIM7IhxPCjzFo2hONs2gGE8W+6rQP6ldHEW+vUt4URLk20Xa3UCQxrR53ohYpynImf9RdTl7QP5a5N9G1HzALv5RsP929HUQCon04eQupMTAbP5rx0JhP0gOSL6TIvpaleOJ2+4WRAfMxlTt2\u002FnTfBn1XB8yWzmLSjauOzZsVbYX2GelrTNu1X+wtfyr\u002FjXHhJgMr\u002FVNKgWbdIluy93SxIj4b8dNxOBJw7T7qPHIQZgK7tkzH5hNZ9k4RkgJLHc\u002FqoAnagXbop9wHhuc+zsplndS33yqZuWxrSIcuD8xS5756lvPnLVu5zSdeYGCrWdm5UUe4p\u002F+v+m64hMVETXjv02z\u002F1pn+rhobeZCXXw3vZ46GuTrvBCqJzdYsXvg6\u002F+G2Q+lWu6qgIjZerUCXQu94PjUmjSfJyg5ijCfSnPO3abMI0\u002FHhN2APajV8Sez4Pg06E47+LNzJayR\u002FeCz1cReqCrGDrfj0fJ\u002Fu1p13cjd+mm\u002Fv+HbgNP9Iav5W+IPKSy5y9KadlyuOOucblMGHnbvvl18DL1fNGdRdvSW1dJ4JgE3Z\u002FRaWxtSn9NxoTcLsXYIsvZP\u002FneSvoxcjfPI36\u002F\u002F4\u002F\u002F3f90uf12PcZnGgeXXcasnSeqyPWQbL1Bua7R3RBWQBfgH0HrAzcwJMBdHV0ADy\u002FpaEwANj68JWXX+wuLI8+djEA+omasfio0lvZps8CP8D8ydh0A8cA46uv\u002FurorwLgzZItJgWgAQzA6IUX5mupBh9x+ZkcAOh2huHG9EbDYqNoIMcncOy+mtUUYDWXGVgAZyCNVpYphLB2NzHYMHFw0BAZvOxwwhzFh5\u002FI5Jlnnm3+aVRnkAbWMmgF\u002FJkIPRrepAkAWvyIhjyqWEAn4E5+BkALOA3cBq1VgU0+2GfT+BlkgUcA\u002FemnrjSdApbErdyq5bSXu73AN5vS0Foawdbq\u002FBSMRjgGIVojZWQXEFpPJgX2hP\u002F00487YSMD2qDTGWTdW2zLRANYz6jRvOF\u002FwBiNlLzZtSQ7xiTtgtuk0QlI0h7gE4CVOCuM8taK2MhzV27KGvAjB7If0xk8TEdCIwg0qqvyRW4JWn\u002F76isnml9h0Dgd22yHekqjTyZTRzXuke281RizJV8lBTpbDtIMD8ql8shz205AjrZBWynf6pByJI8Cn4SXDi2k\u002FHcwSlp4dWhfyhMwN1lQH701aIbyaziRKXUFYFLG6AEY0lDHLMydOh1wFSDf+kMOid82nfKcAZBs1C3lna+dhp\u002FZP314SZTmFd0BbjNRiHPlJK6JGptpQ1Ht\u002FUMH6EJPnDkzYc5zuBYzbmzZlc+AUm4c8Kke4aH1UELxw3fDJDp5q1euI\u002FsxO5FP5c9NmmyLp72IikLKK7\u002Fckt0BSXFb9ws0CYnP4bXRtvtpf6Uy7MazXJXvMqlc8qdMlb38SFo7bc43PlrmuXft2fwKC+zFLefKf\u002FlNnkoo\u002Fujg2ZXMXYFzbmPSkklKwtfkJOn2XvkBt5EbnL5s0En2bjTb1pG417b6Ni\u002Fyc2jj8jFtWzjmi+zdacMTIOcqQ8DbfcOGnrVKyglQLwgP7\u002FoHb9f4nQygPhHNc1hvXSY3aa222LqQZ5PQttf4a5Pkk\u002F8mjq66q+9mHnY6xKy98dbAOpEzOWsWFQB9L+nejeLjQfJLBhejZHj0ku1mfSsh+vfk7bPs3nX9\u002FfeP3rVNbEwJmW8C6V98QVki77NWQ3vrJCdynv5S29dfK3eSTHnkWRjlh1\u002F9Wct2mdSkDz+h\u002FxEvQDY1N9fcx18p3xdPfl2T27km773PsyqRfDxIHrv+IuEIs6IBjNW57Wz9cx9+3eeGNOuvEKed1GXnDlwLldD5DZupq+5\u002F21OcOUPXZGN7zmW7005U6ynP1P65z5W8KtfUmdzllKucZSSXw7zy6iEfbrZ85KFALfIVZPK4vzYKgo0vzSGk9IavlerenUtlnsjCDGfLH8UyIJEhu8hz5tZrb8srfr9+CjQ0J\u002FjBPQdHnA7jcXj4uawMgQROnINzH5bMhqjr3Luiv563e+ly93fox3kiTBKH91uyoiLalLbrpBrn1N9Jt6FW0EljKMZtkwHaTV+wPR915oI\u002F9Fvv9Yl1OJ5G3cRHwc\u002FiS8lvhzA5viuN+qCMjfa3udgFhQah+0lHc7o63\u002FOxSWdKsbSxtGc6Uzm0jSLtL7tlYKQLy9LxPJ\u002FFk6+88nIF9uprr0ZbETvyAMSbD3xZMh8ZCmA8un8zgynN92iOrz370tFP\u002FvD3uiBSJ0kbDrBJyILGJ7L9on22H4spyu2AdR2hD\u002FgYlEcDfbn+72QxrF1hLsRs5fRpts7s6vOhpnSsANfbb7\u002FbxUVPRiP\u002FSDWe2VUlmvVPs4Xil9EKPxEt8XPPPQNrHr0f0xbg30LW99N522YRcHrxxedjM\u002F9C3dg5apK3ssBVJ37\u002FXj6uFPvp2sAHSF\u002FOwPdl4tCMj2Y2YCo84wno13H3oz0ZjJj6qLQGn2pko7k2iZC+wZHMVaUC0VxptgOFa7v\u002F1ptvRcv9VLS4F5NWvtaadJn6MAcB9BXZmTMxCQiR25fCa0CNV9hs7nVQFy\u002FE5jOBdOT5CSBO2UT+ythk4\u002FzFJ8PTxQD1bEP5lf3RY9cZoInXAk6vxAuA1YMx3VFvTDpolg2mN2\u002FafYfZw93Qu5h8RJuVOsfEBhBcIJ0GfTrB0fQlQk1XHok5jZ5OOuoRzZHy7+v4DLImL4C7CZbtLMnKnuT8AYZzqVM+enXz5mhD7yTdm9FSSZt2slvdJYzGWg1jylM6mNGUdQAGFQM3cCyMj74YVACXAt6ks0wETF4cS9vtrcaFC+E56eEVKDoZmTd+\u002FNDHp\u002FpRG\u002FLE1V1w7+QicrgbwHH6hHYT4I6f\u002FNXUJ3k24QNYbBNqDYB0AFb+Jqxte+HZZMWCQQAbYEZf+cib9HIpUDSxzhSr8qgjfjea5H4vGqVAVuYAAEAASURBVESAknFUSBzdi+ZQOzN8nQiPrUueCj65ASwBK6U7GnCgTKdaYBpN58g3fUzC0ehJ50FQ1cmUE5jA5lwbUWboC4dGQXpk2AlF+JRv6XUiFB6UaX\u002FiRma49DwLZ5XtyFo+m38h0gmg4W94SYQ1AOABZGkYbySSt+Qd\u002Fw51xPOAuMjgVGjF+FY6wgJAwJV7cdjlzoQesMvEuHIf+SKpjoRgTx+rUkdoq7vveDICRD1Inbx\u002FMu0gWti+aUi4kw8yUUo6ZIQITe6se5n8xTEckEPC5tRvYGv4N3GVD2fymLizGNhteI6bL4tqX1XCkGx41DakYUHoufQFt9LPBx03vjqnnZyNTblJXYK2jGbdk\u002FizENkYM2noA7S38JLyTfSWP7Cp7E7l+wPkkNrUMNY3nQhfs0A\u002FMg1IowNnA553f+FfySee+JHxidA8dzJ9Rfpobx6bRgD9l7e\u002FOLrzUdbjZAvh92Iak4SOLkQRcjoT4LPpk596+pmjZ559rv0j5YF+6U7SuB+TFS3GAncK8dTCpJmUlI+6i9WUPtDdsm\u002F5J7oyjksBN7f4K3Jnj6LDPCWv6mLJGKS2owBwu0e6tda19\u002FHY7hukbivuBJiWz7cx1exhyjXHqtfryq1ZcPObjpA\u002FPKTKaaUeqSTffvMXR+49k7exqU\u002F4zV3eHft0N653DmisNrYFjKxEaJpJQHs+zMPipG7KqCn4nbS471w3\u002F1z2vG68TZjEabQtbmltKRwW0JbK5v2Nl4MsDc0ytlLJw0HZP0wAz7v4D3seex4+Of06uUx29vmZWtkYzUXf8FSm2MTXhFjuQmLdc7MQ\u002F95vDPY+Hnx3ZdCAW8wk3Rq5hec6x0E5N+4+L\u002FxX8Ka9xRiZCdcEhUod85hnEXZ1x\u002F3mtuJ+y+t3BtTZLssA+2MAGpCr4JIB4L2ATueZv2otA7bY\u002FtqGENi6c+e9Li4ErgExn4J+4YXnCl5fffW1aOs\u002FijnIxaPvv\u002FJy0snCoIAJWzBef\u002F\u002FddI63o4F+Mp1eFsYFSNGgPhHTD1rB99+\u002FcfROtjwE5vphn1ztX\u002F7sc893sAKgLa6kpQaWmL9czFdVX3319fStN6JhfioLNS+n47xbbXe3Ags4AV59DIjGBBg4He2OQeaz5CXJRbty++ijgPCXX\u002FpezD4CgPK68vEsqqVtEl7FBowVML5qmx+wXdAfMw8faPrxj34Ys55Pjh47\u002FVhkcr5yAt7I1b7pHwf4m8AA\u002FwA7AM5sgzxpxNlsmoSQBf4BMIPi5\u002FdjZ5lBxbGAE9AIoOPfYtHaa5\u002FPtoxxU34+YPXlV74omi39QksZWoTLNMeuJGy4C+Qy0H0VngAMddfgPY3Yx63OdMtLGjNhvSbuxC75ty3gnc+ZuHxW+sAyW3DACZAHPC9cyNqH5PFkQAvtKgB5LoOeQXhAjRzNomMNzEBtVwdA18TF+gS7B1lQG7TX8gLgCvQSvsA57hcv+cjQfPxpFnd+Xt5pqk0agDh5hx0WIFffvTGh8T5\u002FjvY6SQBaOeW\u002FGsF0+gXhAZrKA5ggKx+XYnLAzvbUyXPdaYNcyFn+z2bBpfwCqV75Bzq3jZEnGnaY+Cplk++2JNNAVkBT0pR\u002FHYZyYB505m4+9JK0qi1IGLw5gCvyUTftxX\u002FzvUwKI6Opp9GymkylbWjX5LIm4bTggFhBrZE5nT8zm9G+eSZm4GWAkjoxb8qApExuyi\u002FwNNv5qQ8TNjyHd4D6XmR2MvH79sUkKFkamtIeYJusDPhyo4dJIO2hoF5FgGLzf2rrSMljtDCCCwvQ7supIC31tjRSH3YHmSKX8isIDJ20\u002FPwk3dApZEhawuCzgk\u002FCNZ1LWEz4m\u002FDiJlBk1gkJrd2Wn1VvgIYG2cryfu2WZ4ARp2NtihCgE26SlF5oR27RPXciwodMsNC8S7b3kS3wkno1BPI2IvUDfzWbip80aI+xsr4joOID5mdiy928JTbQTF7aOxv\u002FvulKZAtATboks2w4+3YnabDT1yfdi6JGnVInTqSukSAZu6oP1q5Y3I5P\u002FOrvvC3CHJnPm9Zc5SIAt+VDHjnxZFojxxY9383ksKZUqUvqNR68fbmTxcw3swOV7Sd9xKwmQOFdP3XmbPqfhG+fk\u002F6vsg8f6r+8fhEFzs3EP5N2Sil0NgqWe5lQ+9L1zZjTfPJBPhQXwX\u002F4wcksPM0i\u002FdB88aWX289ezSYF52NOadyryZrrg3Npb1FcaDvhXbs7mTVCyc3UuwL65D28k0l+54g8wlXOOOdsXRNkc9m7b3Wh7ltc9wLkp21jc2594brzXnF3qTbkSku4HvFuS5C+gmiDiE+u\u002FuZYgbfHhy6V81CJjziLiQnYxc\u002F6oE0e95P\u002F1uRcUziplOLgN\u002FE8H0suz\u002F4FEaIZTIDyOvT91nv\u002F2Dv5WWcDlA434Sd3vW7PpdM4vZtwjTP0czvpJIy++evHMcaPZ+PrgY\u002F7b1mSPfyhJL1dOXluukOoYbawG1fj8bXfvXJmvFDe7hr\u002F4JmzDkS59DqUPWKkl\u002FWbh7ps7qW4MfU1sM5zy9gqj0pf+B4t+VJuP7dc96wtl4apgDYXl+Er141eqYXpHfnDsHVc6cZj4+sgyLe6\u002Fc6A+lfRorNxvvrU1QCiaGUBAn9huIsPN8BnMNJp62ztg\u002F5MPmAEXANTzD0AYTuz\u002FNmf\u002FbQmID\u002F4wY+6aPTmrX9VAf3q9Tc7sKeHbXrAOaBAG\u002F3mm28e\u002Fd7f+nF25Xii2w+eO2fQOXH09ltvd9\u002Fu77\u002Fy\u002FaOf\u002FvlflJ+P87l6Gmpp\u002F8FPfr9mMAZIgOVUNOkfZetAoJGWkaYacGKWYvHPzbyW\u002FU\u002F\u002F\u002Ft+v4P\u002Fsz\u002F4si0LfCS\u002FZGSYLWc+ePZk3ANlpJkDHFo\u002FPvXDt6LVXX81e6q93W8RlQ37lSmzj89pUBcoQkg4\u002FHXiqxsW4mVz86Z\u002F+mwD+d47++I\u002F+sOBItTFoWDwK0DEjefed9wvygVpmEsxhALHPPv90Br1QBL5pY3LbCnchr2lPR4vk66xs4h\u002Fc+7LgypaG6CsHi7QeiWadaczY\u002FClHZgFjemHgoIUiP5p+\u002FIx5Rey4M7D2zUDSZDdOy2ywpLEsSIzUTOZM0OTcFzJNUgy8189f7+TLtpHs6j\u002FmF0AMjKpTbMaZHH0Wba\u002FXwJ1Uxf3iqUuRYwbduAlv8hJ4kMEtNv3hA5AVJ58sDfh\u002FvLL6MvStbZi91x89elwdTH6Us92HWi7J4xcBrmR9+haTkDHDsKjudvxSGYJespNO8sZ+Xro0zAbdDryZvC0AYpzQeBWFeibvAEOBQmQGpChDIPGrnJ0ICJx\u002Fky35A37I4uSpaPxSR5nQkDUtHvMA9LU3IA2YZQ5lQpWkCqDYxwojfXRaN5I2sCH8Whj4VMyfnsjOQgZs7t6G2T1JGXgzZcLyIG8cTKhDLrwDEzS5NH+JE565SzhTlaals7uX9GdQMJlIgIRz0O7Os4m8dR7JZyYGA6YDPFPv+ANKzZs8Jo4D\u002FQI2gCWncHgBzmmIJSFNeZ44dWm5zF3qaUgBmPjFC9ZnMpA44vORIR7YblrpsMkxHbftJUskYfIUf1eHOAGzzevQH9jAv0NKfoeodAGPkc9M8O6dSt7CO77VE3XJBEweF+gdOhNP+9KGVz4rK2Al\u002F6pqpBhRSS8OocdsZOOy8pFWEkh5ZeKbF3BTLuQRueBXGfID1ANyq0UPXby5b2l0YuM5cbT9uGuXIdf40jZZ9vXamn8kml1W7jSfiZP80TCrR0ROg87U5YGFkR3ZI6d7JlGJmACSCztT50IDeJWNFFGvgI\u002FJs+dO6FOfybDrnMLH3UQG8E6ey2Q6YU6eTluMDMjQaaH3pfS5QCN+TTYBfIoJ\u002FR4eP0\u002F70J9qn3dvRQkSe3fblbLnPxfwTso1xUrge7f1UbFpf+eN1M+bR2++lh3C0n9fvXotGx68kD4tioD0C1\u002FevHP0afon9UO708erT9JXrtKdDwqRe1IIb4DMyRNpk0K2nIXvU4PEeYRSAW01DyFHL6mXuaLfBOqB+xziCLM9kof7ib0ct3DCxrOuuVdvesYVnXHfkeL6jYfipkhaxxaz8aetmDwqExMaPUdChKE5E5lM4oZHdbj+5W3jGiN51s80v5vf5jzJ1m3CcZCPuW73DVwydZ8f+d27Lb5XvF0Y\u002FPrbBR6+Dgjlltukyb39kJvfcKwwi9cVdLmv5\u002FIV0std+KkOpKYBrZDfdOWpjR7yfHh\u002FGBm9hE7B9C1HHhoyP5s4MTEPy6Phy+E+8RWGS+4XcFd+J9EOscnT8bTxKOru8Lx7mJvy0f5l2EBn0Rei\u002FD8Up488tuSOpxr3Y4l+U+Tf3u072\u002FXlf\u002Fyv\u002F0GBigGRhvrNmFK4FoAEYAHTSsXgrsMkiLHtPhWt+PV+VRQI9pl6YAvQYTIBXNCcGpw+T2cIJNLA3dwWctI80PbRsH8ck5WPsw85+fhCKvv056I5vxJb9HfeeS9a8l\u002Fl4zovFAwCVb\u002F4xS8Dht+vtN56662jf\u002FWv\u002F3V5ZvKhg6Cxni+GMrMxuJzO\u002FuvvHf3lX\u002F786M9\u002F+tNOSv72H\u002F1R9jXPV1i97oyZxKdJ\u002F6033zh67bVXA94+i0b9hX7V9Abb\u002FfD1ZPZK18EbfK5ff78gxsebAHAgFyCzc87VgCWLJmmk7LbhQ0hvx6SH5lbHzY5Y5Vraoy62jfsADrai8+oeyPzVrzJJyIRDRQaSHwtYddhT\u002FrNPv9gBROCQBhlv6BuoaJeqWZRWqjdNu60LgeZqcwMO8ExT+l7eTkAETIJqX526AMyz6ye\u002FugF+AeY08Wyi8WRfeG9XDFDPXXu2e6A\u002F+ght+umGBdzJxyQQHWn5WIoPXAH03kgA7hoK+dDqGtjUH2AewKMpZtIkX9978YWA2GyRmQmVRZI0yU0\u002F4EF8mlgH2sBYFzJG42+ANrEzyZzBcjSKKlzBd67yoL7is3XGZCXuBU\u002FpTDrYh1eHtqENqOtaO4Cgflebl3tA3tsKmnOFrd04dUxdGJp8AerqB1qnA1BNPJQ9YSif0X5bIJtdmAKIymtoAXW0mZ1sxc89Xpp+6KLlXt7lYy2yBtTUMWWuncnXuUxgvGkBEpW1OumYTlwnDWx6YzAfftKWHcqerD0VFIUWP3lSnmsQkN+W+5YG2eNNXPJQZt7SoOeorMNcO+08r2uBZXivpi7+ncQk9cnLlBE5Sld5AuvAqnjc8Qbk5T+xklbS23JSeTfxprd\u002FNCT4GI80tI3RmBlUnGlTw3LoAiRoA14wRrhGP89AX+tl+Gket3wWmoRPdZQcTBbxPMfIFpvKSz6mXgXolraBeMqp3IZm31oknIlITUxCV14L2OW7fG2TxYQjp\u002FVmaEDsTMrId4C7OminF+Ytm2lJaCJ6IkBeOeF9+eFHfQXc8dJFrRsta1m0D\u002FwIV1O+5G2toRntcrySD\u002FVPuuqurWy9BTK5FJUMulA966JM6NQB9SOkO7mfuh4lhTjaefoEb2PV0lkcOfkmY3wzEdPOVrtFv0Be2+mE0ZqXrzLh\u002FyQfrstGC1HoXArddCdHn2e9zjtvZeeYKGQ+15cxn4ySxfXNN944+sXPf9aP9n2ct9XKdtqzCjNKm5Um3luNAlhPB2ww3ZFXrl+vp5H\u002FVunEa5hc3SpPV+Xirt7c1cNcI9wm1DBbWNjGs3KRVtPLs5oV\u002FcFc3fc5Ez3ls+4TnvR\u002F3QkPnGSDPylE\u002Fk1pgHhc04RSft7uKkFUcwjiUtCVcnU\u002FLgkT\u002FhaNCowHt+Q3ed6emsc+PPSzkZ42mHjrqFjyo+7hybF8pdlngbaj4XYhxrG++Vn8rbCL+91z8+VpT2\u002Fnt900iztH+VsPW5w+K6sc231vD+55iPfrT+13wixehvdJ6\u002FB+kkFsS26Xjps+rEiHT02c76\u002FP6URr39wxKePHVpa78US\u002FHbfS2DJT3h7KGLfW+CTYK9IHrLXui5PjkB\u002Fl2zJO+S6SwqyoP\u002Fn+ix6\u002F9fGdadR\u002FP3uYL9ABROkYdXpPZn9voOmJADF27EA40wxg6vF0ogYkHRsN3qV8+OZuXhn2NX\u002Fc2cICS4C4xiQc7Z4FT74ISvN7M\u002FbOOjA6HxrRN994p9r8m7H5to\u002F1H\u002FzBT45uZgeV12LK8lEWa7JBN6gANC+\u002F8lIHYABCO2KH64MWr772WhamXjn6j\u002F+T\u002F6il8uYbb+brnTcKqPD8xutvZv\u002F2t4\u002F+2T\u002F759mZJdrH2Iqf3T4MdDlAHBj3oSAfL\u002FqTf\u002FknBW4A16nYGLLZN6haqPpYbMSla1eTp2JH\u002Fnhk9XbMeWyDaOtIfl5FA352hgEeaLDZ2s\u002FkJR92ShyA1sBkUkHutnuUxo0b1xM+e57nz5Z\u002Fvranw2ezbgtIO8MAxPq4W5E1jZB0fOXVlo7vZwJF21ozmMjG2wIV+kLi2iUG8NA9miTg6+loyQESn+juoBL+x4aZhixfIgxANxlg3nM9bw00pmezIPhiXv3a\u002FvHK5acK5jp4h3+HwVA8e+Z7tXw5ExivmmmWaITtLGRSdj5glxmJSYCvnirjpV0EIoX7LJMQ+beI2LZz3nSY3OFV3u2V\u002F\u002FLLL7XO+VAVuZkkAMrs6wFgwF+loK22ViLJtJ7PRGtAknproldgF3k4TK68YbB\u002FvPx0QV1Bb8B\u002F9jG3lWbBScKfDYg4kXSYObWtpEwdyhhP5EPe6oM6ov62s0p56C2U0SOP+kLrxU5iTGjuxHSpnVH8EiWj8eykdCJyIUu0TJ7upMNTt+7fUV7WmgA8gDv+ZlAjV4dFdvwNcu0YA4zOxw6j4ClgAXPS1NbD9mj4I2e8kiX5GLSYAlifcj\u002FAhsblwr3s4pNdNYBA+dXuHfK8Jg4Anc5wlXHzlJwZuKMm7QK5BogbGkyrAFb8iCscEMAkTT2eHZ7Y4iR6eMQXgFppJXwnFJ6bn6ScfI5dOFFOt0wWQzvpZ8ReQMMe28C6NNiCh0jSnokV+Fj5p30YgzuIkzP\u002FxKl8wpO6AzxLo7wlLPk5OjEK3YsBl\u002FhTP\u002FWZXZSYcOQdYok3oJ4GcgB9lh6GTwC4IDjyAJITsDTQVub3Y5dtsAO+z53KhCy7irTNpI2SS3lOFOWu3RX46BsSVz9kckeOgCXS+gxlLi4wq+\u002FXh\u002FK0bqXbN8ZPHTmXOGEitEwQZwcY9LTz+1mToGI9iEmLN3Z41ReqbxaCJpN9s0neFy6YcGY9VCakD\u002FK64MG9LO7OAtATKRv7j4Npqime793NYtWWyzwDiAAmGYSZyUvqk3Ueqwzwvp7Vn5ORWde0pM88n11jHs2WMUxbjG0PTkQhEFl9GRbO5\u002F7L9CWfvvernBlX8hbT+puT4e128nUrY8Gn188cvf9G3FJ\u002F7FBmcwLKAryYhPhC9uUod5rn5MXbjmSjaaQ4WpfISd3Bp7aKb5MK98yFTI7JWXtSF1qmpNv6RJTKeeqBsrRwVr2a9jR+Cd402n7SJ53O21vRjUEUA8LLvzqx2pi+0lgkPe0dhtCXq1+3IiPlaqtjeRrlFHOpKHjy51k7SaINIzHtHE\u002FizwfB5CFvmbT\u002FxFl9qDq6+O0kU\u002F7wHz7Uo1yahmcPBYDxn7rOX2gOfqYduptDHzx304OkzsRBfd8itK1PtAnY3x0ZRNFYDrm6zdm+hnvS3zgYmvuHPM8xWUw+he25fIZ+f+VjS0eYfZoTZsX47a\u002FiOTAs6ZFlJFs3ye0Zl4eES\u002FqH2mvx1mFsscC7\u002FVDlt3wSbeuPUWmqJYWWGhqXplWfg3zt4x+7K5+J1eBDb3jnNjTmTSqy89zyUKu2yVMVHMaTHENmC3csod\u002Ft4TsD6j7Ao5C9pn\u002FuOSYss7sGkK6R6cRpPn\u002F5y1cDkF7r9olPx1Tk+Wq8gdCjgLGYQKTjcd5M4zaY2PpK4ysgTcEwiwEoCA\u002FYPtOGaf9uGsAAjBSmj+gwC\u002FnpT3929Nprv8oXRn9cLTUbZaITl4nLArueAUidtI5eBQBqdYA0rTSWQJ4O5gc\u002F+P7R3\u002Ft7f+\u002Fo3\u002F7bfxtzljfCg8WHFxM\u002FbwKiQb\u002F51Zns4x5N7tXLR3+Yxa1MBm5cv5G4d9qpAjzshe16o7OykwpzE9tJ6kR0Zo9s2uT3AtpV4A6k4YsMqnWPnHUuBjQmRrdv2QYsg0M6LRpdWlKacSAP0JW\u002Fx+wZnwHqnZjpeNvxXOz0X3n5lfL+WUDwVjXb0QLAOlB8oXkpZXr5ytNJM1r4gDd24ve317JPdMGptQDvF3zab+D+tjhYZwmgPhptuEpdU4x0ujT5PtXNtMi+9TTKV6\u002F4gFPC5RDPtoXSdg+k1CTF4Bw6aKlX8mwQMImirRdePgxCFmPJu\u002FjKLYVamXGjXX\u002FyySf7ESx00EPfYt9Tpy53YvLYY3dT99K5ZvBQZoAkoNK9pZVJ6M2CzRn4CibjhgeDUbqL8DZfg1WutD40\u002FCav6p2mXFve1AvtQ7bUTSDkzu1MXg3qqQsGrlnMGvARN0eBuslK6JKTty4jpwxUuccDUBo2OwFgsjPlO52\u002FTk8dr5Y1\u002FODVIG7hLDDsg0\u002FalrcHXXicNsWMBIPKwo32rV51wI1LAXTqZQFA8n86BvP8fWimA7V6mD\u002Fti9mA9GquEzeDz31mHhEC\u002FjupjXmWckMDmODpfoDwDLLNU+Lod8gvl17xl6BNo8MD0JYOlWa+YTwmJFraPO3bg8haJGXgEGXR3bnFfdIIL\u002FEvF+VJePwPj\u002FhEf53KA6AA3onRKJ3UmkgBQ9MyoMYtcU9Z75L4J0\u002FOhIH7KR1k3EzmDHoFyBrkBrrlpdlM4AKN+qGCZuJpB\u002FxyVX8MKlIRoprP\u002FJRjGYxrec9tB5\u002Fa3Ze5pJwy2OREBsJV+smTOhdxJs6ALuXHLhw9E1fy1GaVPc2vvC4tf9NOyHvqTspbumPfDjjjN3KJDAHJxb92MR\u002FfSviYRzFjyU3rv3Ymd0wK1alTWfBp+8NEz1U9RC9gOmB\u002F6kCkkQzdzxoPedBe7fYlv9qhA0\u002Fkn1DmgpnMykPk6j7tQf5W\u002FttfJFMms2mdhvOUefq1xFafzwa85x3t0bkT+bZExi7bynpjfCKbJNzLGqIHAeoWj98PUM8U5ejel7GNT9u59dn5o0+uvx0QDxCc6HqrxzKpv5u3mLfT1izEz9Y8baf9ym\u002FCKNmIT4Oo7DwoldvJi\u002FpQ2UdGbdvhzTa2rQYJkwxO3FSuk11rgFbcLARXTs3z1CP56oQ3BD+P7JgEMju6H76Zcd1J+iZFeCEvO8OdT79qAqL\u002FOnEvJoXhxloVsrTLUOZmEaJJcUwtvY3XP+aKr5p05romICGZggvx1C3NMfA8EjfxDq\u002FKDt85ge6wikTHhLrnsfW6YeKVa2turnloc+B2ePRxvPbOcRSqpx\u002F8745pYx61HU3AIci8Lcg9wdf9IOLh7daHHbLS+4Mw5FE6pR5iB37y0EfpOP5\u002F6u5sS68jSdNzAAEEZpAgOA+ZlazKrl5V6tU6qAvUXegudKx7aA1L6rWqpe4s5kAmJwzEHEAEEND7mP87EGRlpqQu9kFt4I89+WBubm7+ubm57+0skcl7R9R6+\u002F\u002Fpr7wWb0q7ZM\u002FStmUxue5IGb2xI5p0zrsiDlh3Fqmwi5M7Enq4ezN5vSkfsrfh0C7sdpJQmW20bY\u002F\u002F1Fmpt5LPebs5G\u002Fgnz3bJn9bjKtfZCD\u002Ff9c8G1DU07iNcSmwvCAj52M+Tq0+GWu4KrKtqQUfyJLAENHkA5F\u002FJqgoYXDy4MqPvly0sBG51QPbVFg\u002FoY5W3uNAuFgDs5QOfkE+JpAgupPxsE8Zi+Sj\u002F6weB5PPn\u002Fre9h32unruG7RxvtTBUR6DzJFXoZYkG3hw3swIANqz1X1WeP\u002FzhywBl1ugGDBSRTsLWef\u002FwD\u002F+w96tf\u002FSohMD1+bu9ebixfffn7UeQ1+aZc39n72Kr+LNEGCAMqA1cvWrB0oTKymNTtdM7ikDI+KX8dBSvfKNgEWRxfWtVRAFC+2Krzs\u002FCVf\u002F\u002FVLOPAHvA9H2pKkIQlmM4GEIA8wK1DvFiHcHy8dnVRX8B4Oc5A6OZBO6vEYzw\u002FfL6zpAb61Rlla2CQWWKsPdI3WNK5yOet6tkXW+\u002FeyYJffgYKTwO+gKTyXL3GcsaildtINFy65KuhV\u002FYeXP1hLNbca2x\u002F+eLScuuRpoPi3Cx0OhHWleNmBux2M+UPxJpdUN8s1SzL6rT\u002F08nPoKsbz8dHtDLj1f\u002FyH\u002F7D3t\u002F\u002F3b+dnV0++OiDAQKAugGZARsgDRQAnYtuIHmB4cPD1UnoFAY0VNdkFGzTSeGXfLXpcdGKF+oRUdrAAvwLrM5OLANmSrOORFkBAQPU1xcXiOH7\u002F3zAx7Jo4gn5PwkduAaOzmeVE+ckei2OpXLU0bjIFN+ZDKDDoIEM+ZoheR6wDvwU\u002FtFDoJq1apVNPbwKLCqH914skESFSmf5waNh3CNKjzyxwGtfQPrhYQOj6nbkoVhmN+gHSnfFYf2SlkXCyoJP3H12szLRqeNZO2rUUSOi+lU\u002FnSa8XV1cU97rF507fiq7CL3q74qrIJ5qA8PD0ppyqUe6QWBxiqszrVYm\u002FErDK4zo19PpFHtvizv\u002FFlDr6pQW9RY8qx1wnQAKd1FLRjj1JTnpocy\u002FUi4PaUpwZK0ZJ7MMfPdZl+2I4tefocFZIZUDP6f+UY3o0hZWexxZ7X7K4o\u002F8ymOAf3FnK0L59\u002FNX2aU5QbtX78Ku3wojcEGS39VexSNjBqpkZOQsWULTzEQBlC2Y3GRqk0MFlwN9Sm9oc+RCXc7z0jAgPslHHX10\u002FYVLyZv2WthZa6EMycPlK2YjbIPLvS69XdrYeS4fbrnstT\u002F6zGCF6HxIyHsBpo6ql8je8ZF+r\u002F7UBz5UfjvfVNj+qw+LPitXccxgkCe02I5XOU5eVe7KO31OeZ3rWr2bWblQ33GpQcP5HWg\u002FaHW1OurLSpMfN\u002FxLrUexLud1Gyacb6H5heK9Oi7N+q1zzbhciie+isxi\u002Ff2dezOr6GvZvoJ9kJvifu8MElfbIms4t3ihv1H\u002F2hIDj0qWlzKwzpNhOkldk1PGCc9GPtPl+KU90q2zpqB49ArQ+SwddVj9SNOx3CrX7DdDhuOdMAKdSaakfyEaGIKs8ZLP7frs6xlx6GEH\u002FktPfa8H+khuUh5HW+cZdEWHY7Wv6O3e8\u002F5XenXs2Sq7fFabFCc+F3Z+EpDO3O+uPfvRIc5Kf8KJ35OR6wm33nnmkGPZTRh\u002Fho65K9yEiKXpnwm5Pdg9304Vcx0SmgO92\u002FXKe93SWT3fvXLyRLKTdPHnVTdD9RDWzZYumVshVzY\u002F+buS3YWQ4BZvkvjnz4FwGU7QjYZJEx0rtdMs8LxHZ9+op58e2zNv8HJCnIkrM9Zub97UyU9T+ddx\u002F7MBdb7POi3uEt+0haGGzyUCuNbh82m2EE2YTz75eATy26ywf\u002FjDV2Npt7iS1ePVyaNcVO7XWO8Pc6\u002Fk06ehYjTQMvuHB3yBZ\u002F6BgB9r6rm2djPFLK9bATnbJBIeNHyff\u002Ffvs6w\u002F+fxXe3\u002F\u002F938\u002FLh9ccHQk0+EklDoUI\u002FWjo\u002FvRHricz6oH8AKH3B\u002FkDwz+\u002Fve\u002F39G1rI7jh5hEjOU4AGJryK++\u002FCqFu6y9pnXfD8Si8Yd89uUDqNqi40oLYQ8uXxugeRSAB2IAWB27DpWv91FTtaZ\u002FgTODCR8N0nlJj7WVRfjTTz8t7uXKk295QFFjBq6vXlv+4uieQVHPP\u002Fzwg8nHe00BqGapHetGAxQWqLt3v6+janHhhSvTsADhFwFDW4vJ19QkMHpSHTzNCnT9xluB9VtZ1E9m+0UWjIsX42UfBHmWC9JeLkezS0Otj0LFq7cbyHD\u002FOQSQo9uAST46CUBZx2OxJ4BHQVvUNQC+hmeLx+W2Y7vFOoeUGwDAwqazVo\u002FKZwvLmUrt\u002FKJ3OrT7ydUXX\u002Fw2frbgtJZt4LbkZ4ELHQVeUzX+sfqagjfQsQ7hRfySHzB50gDxVbMUsSoygOA6myx03vuhF\u002Fj3lcHIrN4AK2JZuN5dTI65GOEBfqsj4MKCUsCAbiJ3s9NKZx0KX2xWJdeOowGZS37FHSBW+mMxr45Y69UtpYYvOt7jtquTF1AwlqwYATTz3SUP2ihZouAWTWvgN0AmOsaKXhg+796fexXwKH1A5XIDXf7W0mCNV4cPk\u002FsnlTFGlIe6WW5xM6MVH9T5GjysXoiLA975KY\u002Ft9eLe8AYIdey3s850znNHkvG1v\u002F2czxfOrWOdF\u002F\u002FOxecF3vF2AQR1JQxe61BifZF61okMrLOU3M1pwgq\u002F\u002FcpxF05ChSnBeVb9ZAotOcYGYdCfPsMjvdGAC\u002FW2yjXJTz0u0CEtcmpgr7xD6Mvi+zfWyVVeaaJTOgBopA04W52ZZ8JXXi+GQDl11e1YsshTNwZlEhJPfvKGgOhgz4QHyBfwkdZKY+SquPTbDFQr2wLuK98tPNlRh9v6FHIzA158Uu7eLytvYFTeZThSoT0NT9GxyqY8aOVygr8WsKJ\u002FZCcrrLiJUOEB8SX73FoMaO3yUipZbQPxaBr+l3ZtRj0NvwzcqiCDIwfa0BgOHxp6MCD8JPl\u002F1awDI8XoPvoi\u002FbPf\u002FfFxBNZmr6RbtRODLzyd+ivtcsqyzsCSnPU73g2o5qui0XEh2m3bSLcaXFxIl9g2+LXwDFTJwNMWv9uw4Yvff7l3\u002F+GTXOeuppP74KCFqRm\u002FzkeL\u002FpghTD\u002FtexkzmK6oI3d0SEw9rHz61LUt5tK36otln8HiIN6QAfVKAkeUO7OOL6bg0dIt99r6+E4z29N3Vj5ufPdzJ6S\u002F5hsrxbnF9RKdu36MAca3RP7pN1\u002FEsuO9T+qrbrWlbrUysryMJq1zQQsDUrrZAvZzBlrRRP9UICIxdA6JbshWJPZ\u002F3i0Zxs\u002FK4b1jifK8n4cC7Y4JI9ybR9urOXs\u002Fr6YJr0Bb0O0sIFmnW5arxMp4x8ldOpUTrX\u002FpmLx2eQyNPyZstdGV9o+SmUJs1GhDU4MF8exPhf9R7D97M7qj6OoIP6fNrjsFrj526f8oi7N5erFenj4dPmkhPz7Q7JDXP3\u002Fbi7MR5vrsg4n6r\u002FbPzwbULXh6vy9pmoqkNO5kXb3bCB9DTTWxJr6fK8mvfvWrvV\u002F+8pfTQClsjZfw8nn7oa0In+QjbuEjQKpiHj5klTDFf2EWHb7dQkig70UN9fm5tkYsbR3t0hpZ48r\u002FaoBjtiUMJPMv\u002FmO7vgBoFnnaB5ty4FrDB5RbxkcffTSDCLu6PHrU9H\u002FgmPXg4jsptvZRv7yz8t+9ey\u002Ffaq4s98dH\u002Fv32wrXXN4v\u002FtYD9Jx99kk\u002F5cXndmYGGfdo\u002F\u002FfSTlPde1vyrLYi8FWBkNb4+vvr7WVLsMHN0\u002FGSAaSo4kLq2F+QCwdKhixhgFB91QMCWRZvcWvhm386nHNi0IFVnyEprjcDjlDewxTcbL3SgPrgxfp7Vhc4U\u002Fwckv8o\u002FvXgWXrHCP3l6ZVx\u002F1AFFYieCt5rxYNU2uLGLis71oEFFScxHbmxFZqvEt6Jxle\u002FZuLjMAsZU5HE+zwAmhcqiMgONi8uHUYfrpx7RzH+bBYYM3ctiToZYYceNiuXseG2tZmYDiBVv+aYvkE0\u002FaLULsNCedTTRzoKDhzoslnig2+BA2gWppCw\u002Fzxe4j0cU68XSn0GGANG+PgqUr24yCLxQrMD5K51wimoAZ89Y8Q2AWNjN9vDP9W4W0lYX+AcYs3TpcAZ840FEbK42eKLD0ilRgkC1cAaPAAFwwfKonSxAzbJF0S8rUS8nn7GW9XTSrfyXLlWOym6KeYBdaSsHdyw0A85AtkEGuZm6Vt7iUpIGMuQTKFouNHX0scfgakB6tAF5ZAtd0lgAsHT315oDfFEPS\u002FlWtsq9WeaTkLiNFwC09o3PBj7LMlpR5sCfTXl3oYamDtWDe\u002FR6IMwa2BjgdF9aPZoyW09h0CSPJTPkRSnJ5DyZezL4OjCGHvksmQVYhS8tHVJJsG5pM+Uuo8IHyHf3eKy+pIsAQB2tAIa2uPHCM\u002FRqKw45aLf9LV51AHiW9mS4\u002FVWgyUnuK60txNBOtgqxrImlG91S50omJqKGb12ifh4VgnvBkFtAu4z4x4I6NPbOseguVnw1KHWP98Aqfg1IL44yop9xw6CXkQSPlHPzmwea0XIcCH7VgIRVWpud4pUXucPzbSbIc8CH3JIfHy1C29b2xTXY0\u002FZm0Jc8cqW8aL\u002Fy+G+3CCD7KP3k2FfHMUr72pWudwbQ0RhtjAa+zGo3GyAFSFePMD1jC96cqw\u002FqsqnS\u002FnTvpVqZjycpD56Xx8gc1xhpZT7fv7DCmcWSuTLuNxsQheW\u002F9KcvqL6e9lfeuU0++O7r2eO9lrj36Pv7e88e9w2EZOzZ5XtjUbcWQN522vFNCzs6vWpWeumv+Lnxq7JwTbUZQ8OldHs6NkCs7siDdUos9fok+kG9GvBqO4wW3FXxWvkZXb796qu93\u002F3mi7GQe053mbl2ni9JV7ZHd3wN2+xqH3ir77FGiDX9q9\u002F832N4eX7\u002F+\u002FT7cqFbA42MWJWH7mDY++CDD0dX80HnHjULg4euaOvMR33kF7PJZD\u002F\u002FyNDL6htPyRd5XbNnS77XX3K12ie5WDI+oimpHx\u002FV\u002FxzJofTPHtVu\u002FCdJcJC81ttYOHXswZKz8ujR0kMrzHqyXa\u002Fg1XoPFl0bTW9CrKuzz7frrW3vQkwaW7wfU7x7Og\u002F\u002F5JtdgKiuEKeW7J7+qPQKhR\u002Fx13HW6u9+8UE5vF9h8G7xSoi\u002FcAi+MW27RMs8Wy\u002FOXv+FlP7VvPrZgLqRMwuwRXVP330aWLsyO6rYtooCYFnVoDVUllRuEMDCJ\u002FlKa4QD0FJAXBDWLhJvj2ADbeIAxADn5tfKyrkW1SwlTiCvBahZTa\u002FW8AeoRwtwcpS\u002FOPDNt\u002Fqbr\u002F+499XJVwGIV7Mw55NPPmtbrI+m4b8FSAdEjf4nfC4Z\u002FLcJFT9qVmvWBf7qD9u+8ZuvvxvrxDvvvN1OIp+05\u002Fo7e7\u002F+m1\u002FvfZfFwj7nQPWLttmywLUitFg0q3PK49qNbChtd\u002Fjkqe38asCBdY4wdLr95rMjj\u002Fj5CiAQaYqXQgXs\u002FOwAc69Bw60s7PiOx7\u002F4xS+G93lvj8WCvzEwajccPsdmI\u002FCsfjK6WryUK4+4x\u002FUoY1mN1iePb+XLns92Ug5I2zGGpfpGShUdF5oJoGwtwNQRW3x7s1kSg7BnpaX9mDm5mYX9RqDt8dXHawBS25Eny7HOmeLWnIBOMmBxECV2pUGCgcYsCIQqdJhZrMdC3mCIvqXImthtMIS3hyNLgKSfxXSsLQNi4zNwp2MFbF1b0GwHoJvNtnyZmxI\u002FeZ3+LP6UeOUG3rl\u002F2C+d2xIAoFxrG8Q64tI6bos1+ViMBjxeuLB2bdmmvskrYBBJcyyQCczafQUfGgjq1Cq\u002FgZHpfL9XTZPP4IA1zv1Y\u002FSyaXfvSL+Wj7w\u002FIRId8BsQnPfjip+PEW5Z+dffiRcCg+PLTzkyVaxOXcj0gU\u002FhNUaJxXIfELd01YNKhsWbrmEu7q+mo45nOWpqsbCxdDulNvNoZUKqT9I7rlzw2q6XBzuEBFyMuOwl9Ct1hUE1GT6Ldh2QW0Fudm11olG8AbOnqZB3azNLa1Hw1FZ3qi885nkp5zZotS67QgJFBwKUr3CtWOPSRlUVJKYwL0UpZ53H6nFx2yH8GOYBMwcVUjBUSfULppAE5qQMKdBXqxEcX+oFh8YRdh3c6sJOdG9OkL1CH6Xyp+Sn6dMBFcDfb9fWM5dlhVmYRtUu951JRd0N7ZVgheyjT3uLZcDL+eAT8bPU27akI+ClfP8+AIu3AoGS\u002FPQ6nahpMXOq5QZoBHLmnbyaseintre7xJHyf\u002FASmkz3046+2cB5grI5KqnyjJXkEtAwKyAuQrm2q02mrCam2p99QxjKcs2vWXuVJkiY+w0PaaLaGPDbQ7h+JsWvKzBpE0wzqcDq+A+b45S93mi5wPXq0UWuNsqDLp1T29tNPgUFxBpjnzuLDUfvR66c8Bl8WOdo7nqvJAaPAXlviAvbkqrwwCg8PalNjVC\u002FicjNpHJDbx+HDe3utbkoH1\u002Fd1fhXfXwTmXzVT9yJDi20vGYdkaBOA5z\u002Fc23v47Y3RX0qsrQ9vovtZi\u002Fwft84qDbd3Pn2rfS\u002FrOd2w1o4ByurQtx1WHawv0XLH1L\u002FT88\u002Fqw+5888e9hw0igHYDcm35oNkCX5Z9\u002FSwZqf5sovD8h7sjCw8YiHIfZRx6cue7oel+BiS6QL1Yi0OXMBLhzC9\u002F9XmzAufno1HW05xLp6FrBhadybC6Pp4NJ964810K5J9a4Y2jqsPl0hOv1QvZLi65inXzrD+7axXy02O1oKqvulrKQbT59acqX+mVmAH2Co26jjd\u002F3M0h\u002FO5quzg9ezWD+0n99PHKQ4a7Y9Mx23lRc5pwoZTn7P0W8+wZjWcSPftqd71A+i6M0yTZn8oq+SmlZ2eSGX6c3gshl4m44p++2zJR+1vSk+Kb5OQj2HburksPzoRZ9\u002F7+az5+NqA+YCmGA5J8lm9k+f4oH23uHt+3BeL3LaikmLkWAEZcEixo1Miw1TaJOneN7fKlvorYtYZD6RI4nboFazoN7g0DzErDVObzfKovNBV4JWV1PWV0LRoul678jlrdD7x\u002F0gLXJymBH7L2ew4gGkDYKcQuIbdu2f\u002F9esAvt5kWbT7LYv1dO8R8\u002F31fRQ1YjNJKYepsb7\u002Fz7swEWPwzbhkpnbtAYortSru6XAx4v2y6nmLRkT3JSi+fa1xDAtdv37q9906zD3YWeZHiYeEXFmjyhdMfAthpnNkJ4XW+lk8bGFCmLMrCAUMWUBJ6itY2mEAzcTZ4sXPLtmPIAPasFID3rQYUdgJh2eJzf+\u002Fu\u002FfjHvSNwGx22LHzwoO3DCmOLSFZggwBl3zpGoJyF\u002F0Vgk1IE4s9XD9x2gHhK0JdVr11bg7EBbnUULOQOna3OiRLVKfuwjq0BdcaX4l02kLF+HzToevnqrcIVt\u002FKqf52Ezpyl9smLZj\u002FK79q1R9UbsAust7C3+gdIF9i0mDNLcp043hjkXdoNdn7ZwMY0sLoVVssmF+qAzAEXXHxY4Z7X+binJkwZD82Vp2rOUmWbtzVNTDbF3cCke2DGWR6AATqFHyVankDH+OP2HA066WUBDKyiubKwwiuHL65ezF92ZkKiSVx0SU+6ZG3A1HB6pS2sDwbxU52ZmRLS6cp\u002FZFqbK\u002FyArtGiOFU5S5PMHJ3zgSQhljIlB4DUALSuZz\u002FqwpLP4wafz5oRmzxLl0Vu9tdvQCMtH3bS0Rrs4MmLBsLD+woOlKEB2FLnXBUODtagTnEMENCrjgAXNC0+7wBz\u002FPFs+w0Yj76x2gLDQJp6llazDgP+ul4DHAM6gHkp+pLpeKPsdd1b+cu0u0XrVs+pqfIVZsV3tV+nzF9XxXU5QBQocPToTRoTLbqjdfLt\u002FmTnM50qXPGnrCXSQT+Oe8bsLrDA9KANNBaehTBBkwFq+rfAAWDkQPNcleZ0kMqsTLvfgGPIcscLRZhySkvvu5JevBJHotGkic2MS2DFh5FmNoS1mLWzOvMzIB83ikDg+dw2yAFWG+ABtDMoTP4vVs9TL\u002FRO\u002F0Y2yonVdL5yOiOBSElWtDc6Bk9TEcMf4NKuKkumDYDwCS\u002FwuLZXGzrP77wfwP0Kf+O5RIZblYuMKZt+yC5jUz\u002FJ8\u002FBaZh18z1Uu2SLLZhWPisc4f2QGIp7zTbfhAHk2CEgiK6u0CzSCUQnjty+wWo8krJletEyQys\u002FdpUa8dxCdW1tkjKCHAN\u002F95y2CPzlsx6W4WRu0IPVl8fdbu1JltJUx18cA7mEGhcM7e4f3s35XptXmpijltwbS+PnqpHZZfdJ46m1kxkLS+L1+ZkUA3uq3OgLQzdwaOGljDCjPW091OVoOmr270izxQWsJrqYHnj3Ttlf\u002FbcDy+JkP3IULXjxs5NGHAau75pizgdQf5Dr5sv4dt7WnE319ZbEbzL0Md981o2oAfz2sQaeVzOgXRrhtgPikwcfDdJL6p8\u002FNQDPC6CvIaIJfOWLbjg1kuYdzd\u002FqstyX9zw6yuUKKr27I2Ip99jzplP9IohenCZ9e\u002FLO0\u002F9yDlV8tt6jK9OZ4c+2dYzuvDN+8371dZBRoS4dsbderFP9v9O3el7SBDR5gwFkr+8rrz\u002F0Vf\u002Fv9JEy0zIyVEMrpXpAz9TMl+hEPCkEPJ8tqZt5PsmK+uZtH\u002F8r+\u002FGxAfRuVv+zrh5ebrgKe4tooq+kEa0V8rO+3yweXBu4mwAXuj3UrAAiIXr0a+J1RranEVEUdDx82ljajc9ZOFcHaCWA+fNaXFGuMl\u002FJZNV2vPlTT7FaRAh0Lbp3Crbfzhatxo+Vy1v61VePd2SaQJeS77wKzpWmLwI\u002FyjWMF4CtOaR4+A559edXC19uT1kGLu0zhcaXhK2rLwa\u002FasrGeKGv7D+Oacvtdrha29rsx03R2SLnXh5YolFuB\u002FaMUCsBtuvBKvFig7Mk8e1B+tnq07y73BwMg2yaasbCrDn4AU\u002Fz64vIAczRKg68mK\u002FpHhWPFtv86ixYgzcIwHUg9q7CHDWQoZ0BKmYFEsxpmCYB\u002FwIr11jPbbQ2Aqz489xVTvv4WIFk8DKRzJaEEWa5vBNjP7S3LPSvezG5UZoOk8d2mGPrXqXpieWvmoDozNa1uKf9bJ28NfToBikSHSFmTkdkeMWYC12PdjzemdJV9QGl0kUvW6QHhdSID8qvJy2Zosqybdh2rcjKl81JW9wC5QycCCBgg+KDX\u002Fvm39s4\u002FZrlZ4Ptc77m+oG3AX4pEZ+NeR0bGj+ORmZqDA4OFBepHb1Ru4ARIwlfvfOxnPrB0lAtRfFYvgIyBzXSS0WhKXJxnDTK0B6BG22GhN00f06e+tR\u002Fq00DlfPxSzwa5Az6qI3lqDwPSpn4u7j19tQafBl5of3FBnSy\u002FY0B5A+hl0bFr38Wl4LcfHgaVWjBop5sGzsntLKSt\u002FQLrK701ha4Op2yVQad\u002F6RJffWChuotmg3P5Tt7J12vgptTRAcnssHePSBJlvPjexfBhdE+8kyf+oHvcSKQVDyfKxO2y+y7TOYwEElgpzpXnPZPDdu9G+AkVrfQSOZ7OIqRj15bQevlFKbIDTeufFKJfgg6yUvm3jlIRx71FmJX60OQ9QAzoBaECiq2xGUuwZ4sysiAc2sjo6NLuT0GZLHf1WIGnzAYogB1ZT4B6HX+re7KzOm4Ad9UPUKm+ZKBNk82qqmcAT8R1PTLdGZBeWzIGFg8akO\u002FX7tM\u002FA\u002F6KS04w8KQFk+L5KqhyKLWPsq1FyXREZYk2dWhwH2TrSRzMxUO+8iMvRZ02vPoiPAQkA5fxPc7FQwBZWbgf0QmVJTkA1O1iMjnFH1tU0m8SxIsijK6k1woez6KZPE19GzBGe4MIsnwY\u002F44D\u002F+2GWn7LRa7VotMfNSSYumsLpZJWDrKiIMrbx9UyYjEemIGa2RdUV0Z6yUegpuqiRXt+Hc8u5C5zHJjdD5ifz4Ie4YF1ddE2pmjev7qX91C5PNl7cpzOfKnNZah52dqjCrL0lQKpZ2A4vUvA4pN+YGYIKyuxeN36L3Hwc1+bzHUJV\u002FH\u002Fab\u002FD4hmYk7NpA8nm1WYVDMgOcunZD7SfP9+swGuDtdY\u002FZYhRsfsvn82HobgTnTvqA3R0wPXV5g3YXqeHxqqfDi\u002Fjdonp6671AccZ5\u002F745W\u002FTc8\u002F3buUycz3jYC0to9thxrCs8vVDDIJP+sr4D\u002FfrcyvEjWvX9z7\u002F\u002FFd7v8r11uwqfWNR\u002FggYgFd55kS4HGducF+IN0eM9X6J4tRjsSeMcKc\u002FFyquJ7OAf96I69n8cXF6qId1nF6sxHZpx94\u002FEWuL8ybmSrkaKsIpCafBlo5YVvXeStRR5lv4EYg3xKz3P\u002F07JJZ+fFgzfSVx5noLvgH3Cb7LY71DG57Lf7To5C\u002FvlTSOIkuojh2dE3698LQ8V7i5OftHIhNx6Yazr\u002F61Xf9sQP3rb78eJvvypRG2ES0QZ8cHH5rhqzyLSNIDrL3Apz3R7ZNOAVr4Z2qSRRFg1BELc\u002FTManeqOz0U0BjZ6c\u002FLFMHR0bPiP+hZcXadq\u002F26X\u002FZrbensQ1uCe1dbFDlf5Cyfa1efDXA+lzLVgJ\u002Fk0\u002Fe8DuRVi37u3PGhpu\u002F37geef\u002FHpx9FzvHez\u002FW9f3gwsvVj+epfbF9foHui\u002FDhhW1udNNR5yh+mjFocNHF5UPh2mBYzcOG7c7OM7hXsvK7WFdSwxLwOlADVw+vU3D8Zt4\u002F0+6APUXMnf\u002FessDUcpI1syLteIXHiy0l+5cm7AOp4RbkCTmC5\u002F4naweZCf4tNHI6B89YFL7LNuwLTivRb7aowA7c2A8NUUIb7eSnFxw+Dbrn6eV46Zoo1+5Xn4Q9bgLGEGLldZvl\u002FmGlP9AfAPmwG4UjpXooX11xS3NQcHeJdSHqDbmc\u002FgSUDtOOVq0DWgolKYstehswZO56DzLyy\u002F8qstttVQWcnJwYsD1pjLDVBWx0UgvB8r7\u002FSitcw6YZbeK1dbLBvIdlyo3nQSwKsGT3EDCmOlq8PWabESAah7V0dNDN22POMvO36t8fNS\u002FIzQSddAy8BiFoxFA8U\u002FILiyrBmhpUCAYwB6gEv1ptNF9wDneQ7Q65wMXPvybR2R96xEV6\u002FeqM5b0xCffbQI+EDnGkSanVodH0A2rkzATnxSx\u002Fx1HSywLFR4BAiNH3DtxVZu++0kYVALcEX0KD0d4vnkVT90ofxglQELxadBDRRcDu\u002FrpFenvjp3g6ILbZWHrwMSk59zY8Fm8cQfcrvqkjqeOkg2gB3WQVbCAZjJ9H5ABFnT8efes7JX3w1apNMDIBHALrfRyWtau1fIG0AVqKoz5pNKtsgcx2y746id4Yf4aOjnKMmSnr+dq6sprBer\u002FNM7F2e5KCywK0cUAIA6jticPJRH9+UWRseP9Jd\u002FvVQ\u002F27tFh7Tn7aKgWyn2x\u002F9+\u002FSsO8lmp9+0CI026JD0FLwxm6NmUTPrl3+1Kt\u002FKgaUonzd5vU\u002FUR2nMgNit3PMJvdT6ZdVr5Vh+7eMpXytUdV4bkbWRyWSgHJNe20Iu+c8nq5eTs7WbpLnTPHStOB9gB4TV4xI+pQ0LgWe1R3V8gN971G5mYgU4pV3fL\u002FabykzN1h\u002FZmf14nu2twFh8wK3kkk7ZaHJksZDEyLlQXvcYPQH47yIABwRxYFC8MBFjCw4jTRn3J1OBmWe5rdwnpYem\u002FKJ1j\u002FKs9cVGwg84VswpZqG0KQJ8C2WRrdoyJB4We9gRQP2SAiAVYg6faHINUCUWDAU7udMU3M4j0ITsgnzgPzRb8F7H7eFRcOossXO5DS8fHgfroPKm+bP1owCWM9LR\u002FetLAfX+2VU0WIkRcPEyip87Uwbl++5X9Yhs\u002F4Nq5+GgBLImYhfTRLZwBGb2AlleV3aGt26zA8aqtGNUr3W+Nlz6PwY4epge5Uqm+c7UZ20Uq8PkMIlezzAPrz9uS+Mn3T\u002FeOHv+w9+x+X5x+u29jFP9BLqdm8Z8y4JUvd54nT7i9tm2zneVaL\u002FRhfvrcH8t+ZEDd+nF7GX0QfdOWe1rPMvR67+mogCn4LkwysQ410jNprgdzjW6\u002FeVtZ8XTez59dnAm\u002Fxdoi784\u002FPRVM23I4n8YqbRm6N1ia48xJeZY+Ec6Llcrp8564Pv07wXYJTGJSfnMo565Upyl5RA5i4i4Pqa1UV9gVQsyhtESGfYU\u002FfbOLupXMG\u002FI9RdrIcV8ZLMye1Ks3snT22NLbnm+l\u002FWmYoUvgn8Q\u002FG+7PXU+Ou3hb7nTlluefi\u002Fdf8\u002FxnA+rffvdtjXoBDqCK7yzLIl\u002FoO\u002FlTa7SfBn59Op5VGCjctmKi8D\u002FKT5yC3SzFQM9YSyiXFD+gggGrsTearwH7SA9QeT1wy0o2YC6lZvsm1hgAkXWEVYJlTmXZt\u002FU4IDTTmbW9FzXk85RTH\u002FF42Ir5R48CqdG83\u002FT7Wzfyhr68v\u002FfurfZFv2Sf+BRnH2W6eu2tvQc1\u002Fvt9MY51SSVxwTnq89E6nEvRw0JiCvju3Tt1Esd7\u002F9d\u002F+scZxf\u002Fy009bmf+gBan54VUeyvzZD+2M8fB+1\u002FneffZp+6\u002F\u002FXaD3wt6jwLWKxx+83Czv\u002FJ1GAABAAElEQVQcwORm\u002FbV\u002FO7cSawKA05fHrKw6Gh3FUnqUEsu\u002FLTH5t3MZeZlVW32pi8uX2lO+OpPn08dNPWs9KdrXleli065PGjDcv9PsRmWyW8tBNM8X9rL2HjZzYlDGj96ONZQtgGivdPVlFwH14DiyEKp0Kfvn+UICqmjo\u002F96FZh0GsNd5LDCJN1nVr2T1qOxcIpTpdfV67gb3Kh+VavAUb1+OLzb+2wrQrjjn+jBSHwHJV578kR0fmiqDvYd1FBq9nU9ePGdhJkssZxY\u002FNgjgHgOkFlb3D7gAPCyMdl84iKZLWa9fx9vXyY6pfAOQ4zpj4HzqpjBAWsGju0FoU66uyaDyrgHnAurk+STZw0PlFR9A9xwYx1N7\u002FvtKrgEvIKGefZpcegcHq12wvtudQpkuBOQulQZALV1dzUHX4zqiEw3cWzxscKzNRMDUEV9fO\u002FvYYedc7Y\u002FcvS6PjW7l1IaIBx4ukFsnPbimd7UP7c4CX213WajNeOQmVRwNJdEZmTZlLRGDVW13qWofOXsWwFizS+Qi2DH1c5K2ppTlqyOgT9wkbnMPSgjtmXAzSGggRRZfGVC1FgNNyvW6dmZhKKKUSf3j6+wVL81JR6sucUToFAozaaK0ymRUQMMG1gGzYNzqA5MDhKlXuzslvjLqnEV1yrRKWyLl1KAovg34LG1EAW8rXLxRJNEl4j95i6aDLM79j7cNPns+YUobGBNua\u002FvaLBrf1EeJdUwZd1fDx9qXzk+dOgasxp8B6YgYquKsMN3pi\u002FGMLGkrZdM5nZ3MzHv1sBusqc9rtdVL6aFZ40EGK+PT0d8ZSZI7\u002FCSH5HUMHPFKJsqhzWg\u002F6LQ\u002FP1qkA6Db5pAlGDhZeiNgV762Bp1Os7AD1LvnYqdKT9Jpr9sDPY+MGRDsx9MeL\u002FBN13ZvtlHejDUJUe0l9xH0AM5YRAbKu6xy22i2MpD9nLyVUhT3GqBl1e6Xtf4kH3Xf+rD+CoNevCDDlbm88G4s0cU8qv2+zLJMR5hFJFDAslla\u002FOZKZnZ1ZqMjYwYw5TUWevJcWtY2qB9GEv2ojz31Ob\u002FAbe1ZO4rH5VrY\u002Fqbso2KMMedat3Le7mn0cvprZjTIcf9me8\u002FkyID3JMv8\u002Fvn4UF79r4w+FthH5foZ8D\u002FNqk0vW49lcDEzIcU1uKqahq+2P0a79i9t7ZyLqv5jwkT3vhmQ0jgf72b2oTZQ6L1rjSIvXjTzltHv4Z29R8nRccYii4KfZKSyvTB8cLHZhisNQpLKvafl\u002FTyj3Isn90uvNEsfXWNcQVc0KKkfaaimq5rOuQ\u002FJ83xprVkuPFbqnnZC0Vz3d86jJ7qM\u002F1r5ertrM+nlMpqQS58UZmRpC0kO5rXou5dnzpPevJlA5HsdMoueFWnKtHsxNHg+bjmFX+1b2EXbFk5kqa0kRJj\u002Fu+TRtzsK55p8LYv8RsOZ8ILOY4F2qUoPjRPR63Xd3xW0KFsePz1TwXPsshpuznUyLFZyBCNIaZJfxO3SW6kxXnmwpb1j1i7hP3U6DfmnXq5nfyLIVif4+3MePxtQt3iS3AAXsy1jo9dhTtRSTq9bZW\u002FEDgRRNNxGABCrye\u002Ff+zowddhuML+YPdVZPS3YlJ6PDmlMwOUsgMzixkVAOhp4TgzzARVTciMdRZodEeo0TNHNUUdYXY4l8u22Efw+1xsdF2WMJru9vDgyCjed19Ta0\u002F0BtAcX34\u002FWAGTK5EIKjaX\u002FrbeyjjfIyOAzi3ket0\u002FvfABIQ09AfMzlSgrW7gf2eDWA4eoDaLKO\u002F+3f\u002FtuA28W9b7Nsp4kCyu13e\u002FDxlFfHD9TaI\u002FzXf\u002FNvUs7tnpN\u002F+Tft\u002Ff3dnfaWrUxW718v\u002F\u002FTX5Ps4C7ZZC76RV5rae7sdYAAuu8Kg67gpz9miMJ6\u002FFy8t9rxfmkA7UESeCLmZDY1ZB8C6zdfbAiGAUd3y779YHQCA3Ez4UlpQpA75BKpH1l3A4fXrtYcxJS0PLjeaiKn6EFP56Qztd2wgkZW8QQM\u002FfD7ygCrgosOeD1o1sDoImAKZMzUfvQAoup5HE8Bp8fD1wPPz\u002FaPxu7dX\u002FaWdr7r0FhiuU6oOlt+5DoKFdnUiLGa0hQ7xQnsUC48HeAEw6XQNyLjsAGkLvASWBuT2PibOx1GEq8wnO2sReseKHq+yw094nZMpd\u002FnxX11+oNwyFpgyfWyNgQDk3GCWrALNOs5XxcE7HzxBp47Njkg68L29G5OfDoi8ATgD5hsoqB95c00y0+XQqXKZUf\u002FqZwMH5Oy4NIQf63z3Y1mOPxTr1pnGmGkvntlr2oDgYnydwVpxpacto5OLkDJV7MrKNWZ1lurSLJJ80L25HMgbOD1fu1MPwN6kWzyywJJrYDN1VJuXF+DkUEfScqsOpLWOZLCHAI\u002FwiVvv4lWDBnThwSrbAkeVfng\u002FLh7oKS66B6gXb2YmeqLzW5zZdTqERorO0Tb8rW2NhRdR661X07G4l+aqhf4uYkbOJswuwuQhTvdAz5RL3gXSZgyCfFhmXEGqW3WmjcmE24\u002FwW\u002Fm8Aw7DIh2dy5allGwNLV0r78rLu8IPACxCciAuHbD3Or\u002Fn4pK3svFq1RvZ6xmZnTTiF3mZAUSGE+t5DIrJrTZjoG+R9fNDcpi8SHRoUHfaLstuclC6Q1dpGWzLL8aOrK98VltVx+pNWGtfyIPy46F1KSz7e9dygzTgSedPB1uZyJbDmWwNik5fPc6AM4OD0jOruIwmS67UrxmzbdbMwAB\u002FlGt96XXp7CutNyLH20JXec7iRbJaGvQJ3W1gK4z2v5Xph\u002FkmSF8czjVmXMJ6h0UDftGLL\u002FQ3+gOs4\u002FpXGaXJqENv1\u002FIW0C4vLnPLgEJ+0k21AWD\u002FsD5QnjNISDcbhOnX\u002FLrtHK9dFHZ41L0w8+HB2oaBjTLzU\u002Fdl1amDnktzgX8+7cuQRrdpUWvWtfqILrTSW+rLDATDTiGKvEC9\u002FuJibq6XmiE1INk\u002Fn7GEqGRU8gVTsxe+BLtmYNe6r3GNbdOGw\u002FTytdwPbXmpPOp21UHUBSJPr0eTqUPAmvxG\u002F7yvEFMSZ0fxYl4pdaWEHYBpYrFkdD3a\u002Fo4eELhjgf3ObnZR57k\u002FDmX3chIXYOkH6cfx0zjerFa6S7j7iahSJwEPdscuM3FWxisZdfDmWNcTZgvWjftJznVBFNP5NCGXPz3It4hiF3mL4zxPd9nioLS3oMjxahdsF3id1t9dxNNHhZSXeCLtXs\u002Fl7n5dC\u002FOmtG+CdnWGX+v5m7en2fz04kwQlyj+KWU\u002FjfJfe\u002F+zAXVAT8MFrjQmHEM0gME9wzON706LSu8GFAEGPoYUCQX3w3d3xk3j\u002FQ\u002Fem4Y\u002FO0OkUDffY0qLYv\u002FjV3\u002FcO1djE0fl8oXn4iFv\u002FbEf0DSjZo2+jj41EzhpO0Y0FAkIBH5Y9d9tR5i79x6mtHzQaDVwNf0wF5B3j\u002FqaZz59gKUV6q+fl3hhnqaELuWO8NZNe55T0iwVq4Pr9Sico5St1ffApx1TgODf\u002F\u002F63AcD9FpK+W3g+423LmK\u002Ffe++9F4h\u002FKwUNWLfzTQuDdAbvtAXVvcD65QY9Fy5W3hTYizqnSzkist7aBuzcWNZyX6GcI48VgHK5fuPtAUkGCecr7\u002FXqxXaOV1vkeSnQ9jDrrA8UzW4sh4+GN40WoqHZhjoTZUKDLftMiz569vXsNGN2Ao70XIf+MpBOQHXA4tltBwgw7Wgh62FgOrJT4HUOPXsZkGd5YQEGhv0Oq1tgjhX+xQU+zAuETN230JafswHVdL5AfvWpE7SX\u002FsP23GcZfj+ejjtI4Z7XQd27d3dkhAVVp8StRkdpEGlXAr765JGCHatdskFRK5OBw9HRWhgtXyCdvyNQZ4A4HXiyB9ToJZY\u002Ftc5MJ59iTwYWKAMqora8Z5Ff18AKfqwvKtb8ejdbwSWXXFfkN3vaV1\u002Foe1JnNp\u002FMpmDKawBaz7kW4Rk59ow\u002FvwGZTo4\u002FvLZhy0AdwnSo8cGwVppmEdTZpT4wpUzqS0ePp7Zw07lKYwZTyZlGtVw3cL6YPdJZkHnT0s464dNpawUsDR04cAQUO7otcn+4olSPFXwAgYGYjhVt6BqQkbzYK1p5AHLx0AUoWLBtfYT6Uhd+yiifTXaADp3lNgiRjqzXWT3TA1nyItVz+kl6DnUmnq4RGFC\u002F6gif17tVj1NuafaT3hwriXXtb2nqGshZgfptr9zvAnvcu3l1Jj5yBjx0IY9JQ51OXtEg3V4AyeTLFzdpuwieQdjrrKPkX12Ru5PKKxaaxoovg2hQRzNDsCsfSlZZUVQendyfT8esgZvZmfierKJKufC1QOmo6qG25SAPnqtXABS\u002Fxq2h+pK12VM6WdovjxroVQYA6uhFpSjscC75MpoAfOk89YRWY91pY\u002FROITdXM4OnXk366KFTyQa3l0JNOnQ5QEnu1sxOBSx9taQseD5tJjqnH6uceE5Xr0WUuk259Lp\u002F46JZm9J+pnx0szf4UTnEZTCw3mQGnLmhaHNiA+rHtXtriKSlLiQNsKpbz9AD3A5Pup6sO7usFhYfCkdP4eW0idyGRn5rR5W6MNpJ6dUufO1UWfQ1qs0MmBlHBqmjLP0GCWZh9HtjiVUG9VAeU8\u002FVEYu4IsTakaUqv\u002FD6VQNmOkG9FR65BRyQHh\u002FpTwavadOlOC6b0aGe6Pclywwx8bK4uCTu8KN0hidLxEeuZvAVPWamR4+3wl+bvVi\u002Fn4hmF0pfROOlpp2e5N5qQuN8i1m5r+IrCXcso2IZTo7xfgA6sF5kZaidCO\u002FGP\u002FGcpz11doyFuTJrMOpe+ceKXGjhV9uboOvPpOdyF9+l+LvU59L1uvB20pucT+N6XfolIf+53sWRkkPqkli5dL09dJ7nxYvm9aJnW8DtUrquJ8wK63Iqt9NfOhavZNKVLEp7kp8Eu8enjq04yjDXwg5xUnB9hqiJ8eM\u002F4kxK\u002FZkYc7\u002F4\u002Fyej7iKstHc0SVI8RK7UJpMlJ0PQ3K\u002FQi6IZcJ2pn12An\u002F1E4\u002FwsB8C3f74dMPgx13p1ghqbQrIA27qRJZ2FzT7pdnlh5VNzQPm9ew9SVv+498unbZfYF0Qt+DQFz\u002FI+Pu8pQUrSoXE+bSU38ZEnUPGy6TjK0PTeqxbEUQZAGbcDlkt+v8+fr4\u002Fr+AqmzoPF\u002FfbtFnwOULgUIGpUX8P0aWlTgpSnD7VojqZj7U9+P+swXfpZu4Zcyh\u002F\u002F1tu2nlsuBvyuKRzWGh37+ENHI4shYPog\u002F\u002FH\u002F+H\u002F+H3t\u002F9au\u002F2vusBS3PDs\u002Ftff3V7\u002FOVvxtQfyda3o3uXEkC48+aPsTDK+1E81luIRogEO0zyhfLA0\u002FtOHL5arsBxEd85rd62HaQhO3d0iLoD9pxBtC9YheWeKFdXG1nG\u002FkAR999+11uFd\u002FOjgM+qsGa6mcHg3stTn27AQRgr07vtAMOMM1C7qurN1ttLz0uD8CwTvft\u002FOx7NPV7P7BMsfJ\u002F14k8aHDyMgXJCo\u002F\u002FOloWNeCerEgX75629gDvNTguVDo\u002FHbXO08DusHcHdaLq+EEE8Pun0O3GY7eapw3KbHNpkKIn0uz4QfoZSL5oTQIwvoDu6oAoVNpMJ6UsOsWlWoHfJCB6PZ+Fp70xPTw+4dUFzWL7ToMXYXVm6CSvZoOAPp34Bh51KjosQNi\u002Fes2R4cMWVimrsCdX4o+OqbzIgfzxbIHVOKNc5XUcv3S6wL00yQEl48xlR3jp6RDVlc54rO+lbeA74YoCQCDlWrMl1njMzkrztd8AdLyYjhRPdJrD7aW81fV8lTPAtF95F1AOLPWC\u002FHG9wIvXFxdQKnh58petzNUjkANc+LQW6786nRmqeDOCXDp4DegpvxmhGbg1eATa8HqVYfEd3TMQr8zkUhoGITNQ6o4MiYMPsW\u002FqSzqeCzuDofLR3uZDLs0UDGgPfOADoD6dYfLsemgUr\u002FBTaE+6Vg14sx3Teexu5nl\u002F1E0ZTh1H2epsxRIfcR1Tts5o5uKB9WShP5OHdlnD67F0LEoOtBf+sAWFwNJY\u002FZVz5KJoU4bAZeUZmnrnPHVVGOAOfZO\u002Fiw6n4YfyTr5a246m6NSxzZPi0wGvcz1bkhsPo3XcXarnlXBJ5D7h8\u002FVlu47Kq20YZKwBRxSRT\u002FU79AF81SOhUiZ10Flb2wCc+otrGNZ7tDXga6BCbmZA3UPGHjpPHT9vceS0vxZlzkeGJF0YhhztxkJNX0B9PTsQWQtUe62NAMHSHvhrQLRrW8roKPt4rO1ydXszsHj2TPtnZPHthPTYgP\u002FKQdYK97J1HQwMBg76Lek4tB1l85zuMbjRbxrQC6Pu0EOXvazvmz4jXXChtmhmhcGFCwreaP9Ll+bXPvVinRcXSG2PkY37pK8Yqw8DEEaTMineMLU0BtAlQ9KqpJWVfgMjijN1wzVPe9oZIAo4g\u002FnYY4CFL8qDbn0iPbtmOFjyyQ\u002FpXTqv2s8dZg0irvZxQPEKPjrDLmrWbOmzuQrSZWRBfZlFJpOXcpNCy0GGIQtkDYW4uJxULoa8\u002FYxcR9qSnKvzNTOGU0lzzNX2tIY56x8865+ib2dyf8oeoUcnSEPM3iWzxFYM8e0y1NVcO61DeP+wmU7pmEhFrB5WhO16C7mCrdxXsHUt3PZOOutaGX507MJsAH3Kg1YRzsYv0hQdHb1b13PpTb+\u002FdKw8V\u002Fm3dHbhZVP0RdYK9+Z+S3M93+4m\u002F6HjzRNXk8YQtp5Pnf3ovufyciqwenYI8qMiSGhercBDd8+0hY0\u002Fk45gu8hbmlOYSfW\u002FzZ+fDaiPxZtiwoho1fkSOhZYyk1BdLS+LDo7ttS4dOqzi0fA6tnTwHeg+NXr3w9oA3o0PomZnreLyLvvvpeFNp\u002FsQBZwJk2Nd+2oAdRf23s7AArgPMhafbcvo1H8FH4teHUEKRBbLuqwbrRjihX2\u002FOtuHK9dZOxgEjRIofdBhrG8HmXpN1VX801ZzmKaQjzNF47FwVdGfTXQ4lC+4izHQA8wmo7NpadFL7l1XM2aSw4OD5\u002FmaoP2T9rVpT3n89V+0pc28exmvDmXpV6nzOLA7\u002FWDfPp9WpkCfpBP\u002FJOs1AD1LFoq1klghP80Hr3z7u3SbVFSgBdY1SlcyafeIONOu+3c7YcWdfR+Vvz3Pviocq7tFm1HeSlFZ2rVAlQWZC4vrOkAirPFqGZE7M9uqvqXv\u002FxVA4zyjA7bSspbh3ot4M2l50U++xYRV5wpzwfvv9d0eDSn0NUfGQEIdMpmRoA0oIhPOeXdywG7M11eHbJIsRCeizbW4wvl9fJ2WzU2+6HxSU8aBi6a1uOs0Zg+VrjKoDO7nEkF2GOlO3eOy007NbD016EZTBhwAuSOUpzyLFcunZiZhgYSpWt7S65JputZ8wxopgMvjWfVEVpvNkC5ncwOwK6TGsBdp6g96EAOAy8ANPn1o2BMm8tD2NnBRjnrlKVh4AcQULpALZcysiINnTjeCzeWsvi0DXDIujTxedppgwGghMwBzGPFir8kXxk4sZilMmDb2hdfUQvD3PvJd5RX\u002FZx4+zrKQMTL\u002FPwHSJa+f2iX5wTC0+pXu37+PLqjSV3jPyunbV3t2KN8OmG0KI8pelupmkUzO2UANPvHF44OWHQnF5WPS8K5dpggY5uCXZbYaEZ7ZZIuuSOXC8QnZ9WJ+HgF6ItL\u002FswkDKPKRXa7m5Gr7VpYweeY6+5LZ7+40tM+14HedUXOp8PQBkp4rFW7UCtdmRUYGVPMxf8qLv4WR7xCVIz5lVF3WSRb5GeNzgxu4pd1C6NPlLuFeFv5RiZL2zs\u002Fehod2r1MZyA4V6td4ef6dd+1r2xa8ImGdayrGUzsQBOwIh9uN1NLBTFbwpq97lcnOGC3OgYMezl6ehYYMrLoU5JNsi0HeYe0usZIP\u002FyJ3jmrz96Q5cKvGa7eVCf6hM2q7XrNKPQqfgLL84GlrtfCRToqkJuuwr+SG72izemgCza8om\u002Fs0MRNk24ZV8vy0h5nIXz0ayuzy1W68GmGAhsQMFoBpNqsXagiYNIjg9oRY4JjDXC4D5qdXLsx3XyrPmLkl6yns5JV9TaDl+LglfIaWC\u002FXR\u002FJL1xU+wvEKT6d9p9+0\u002F2dtXDByxECVLDAkqDP5j\u002FwWF73azwzgsLS8DK7MqHJ1eflyGei0r4JNevzULQ7fZgXRdq1+0S5o9KOPDepX8MdPourZ9aP6nqogA1Lf5Git2Ftv+0aLrXeBdTqOXBmsVdfVg74GH15YD5NByEDF7DUXq1rzXhvPFJaxYxktxFHO0Xq1nQHn06Z2MhVvErRiAvKdCRipcy7IyK8nE3weDK+8Wz\u002FP\u002FCYigSkvOynFnBVpZNaf0zQm6i68uHO\u002FzpPW5KpXWvIu7i7YChvJQuODw99d7NN7F02MrZdz0pJWqNHnP4qxS08mpTlp766ls1qkqz99CD969E+\u002FXk9Ld+gs3R3Zq0w9\u002FGn66BwazxZ6UhG4d3gtsY4Je+Z+PROsNxt\u002FInAFUbYibulOcltdK8U6hh7BhJ58fsqT3rwJvkX7Wc5bD\u002FIvTuzaNXtOZ6mo4elQKUJEs5ACMw5+b2\u002FXGQPh9iz3JUxC9U\u002F\u002F9NvA8\u002F2UpKmwvraWxZ2ScfCnpSD+za9\u002Fvferzz+fabrf\u002FOY366M7xR1\u002F6TomDdYuHL\u002F93Ze5RFgUmjtLo26s9DEJjdY+tTdr9BgNLFGiFA\u002FlrmOgSFRYXWJKLVeMQARF\u002FPKlT94H6FMugJ6FmRaoWVR5ta0oTZNZVDULaCrE\u002FusAlK9Rsn6ctDtKSnZ2OYleQOxBC4P+0z\u002F+YwOLPvCTsrGKn581MMTSa2sydB02A\u002FA4oH+9RVi2P7x2\u002FdPxJae0LRqbzqtyS3sGNg1+MP1xsw0W8Brc8DO3ENF2VRTqD4H9Sj1A7+0GKuK9\u002F\u002F77e9+U3tMWR3IpAKjfrm5sXwj0PQKEU9Ys3yw8MWkGDQRXh2BbS4rVRz\u002Fu9NGKDz\u002F6cPbQl858nCnLOlo\u002FzK3pndIF6vHfbInz\u002FfwvgVB52P7yypXbcy9vP6A1MRpZMcvia3bKwrVmzeSsejR4wBszB8DgKbCvUc3evvH2Wrv1GIjcaIbB4tGnlclON+LpEFl4xxIVPWM175m96W2DaTB06WVW4+gxKBt3nLYTnLIkE6xSqxPhltWi4qxwh9EY4cmmRXOBtmTMNPSA+unolgvOspSxHrUdZzJBZpRNevLHd3EMIQDhkpzO6Hr1\u002F+JFi1HrbGbHI5137+kLYAsoIecGWw6g3GI61uzxUU12WNh9MOU4ftjDH7jWngAT7dPALswyZYrkWZ9BMY5OQoh34QPWSGdhJr\u002FyHBktzFKw0dC1drS52hgUHeqsD5uiblBytdkn9CYWE0dZdNzWMNiOkpxQ\u002Fm\u002F7ymyggIUKrYzn5Me1n4H5uGWVH6DO6rdz1Bg9hRc9LlgApDArT3F3A\u002Fu61dmxAhCasDrapdCBF+wE8lIVXeBF153nupcG9OoO\u002FctaV1w9ZKRtQSdsUQZoei4nvPSvtPB+BgG9WXkW2IBJ2x9QvizNQDsAYiEgCtWXGadxdZF\u002FaW3uAyd4IxN\u002FAbfKS79ufLMGxtuS2P3ZgDqQb53IKhP+Agx4gn\u002FjllEULDCDqX7RjgcAnbKgYcrTYEop6V20jFtB+dpLPCEoTDq08NIZugrmGYssnivBQW2NvscXA+zZXjEh0AehRTgyB2DSH4wnBneeWYj9+hKQXRsrLNlGb+Izi45noNwslXoB1C\u002FVN1xMT2jnBnEDYHMk09dZC6St0gmMK8oZsSNHsztLtwai6gWtM4AjY\u002FUdNe+pN\u002FWjze1fXt2xuqQDpCnO0\u002FJgIEGPdkcPadvLaOUL2xaMXknf2AGsbZAL7\u002FsXR+10whAzxqSE\u002FaiyHI\u002F7jk0RMjwEehuajB7AW1sca1P6LXVmsELX7DhZ\u002FkSCXOLVGvSNu00yKV26Bo\u002FoGPVzkgHM4MvAzM5hEpj04xMeCVuSY1CSnmd+s56is9kAbn9k1I+7nP7XbNg8K7+XL9MfpY3v+MC9Z9xeCm8gNPvJk5jC7vdudGvh6b+LuZQyZpDkCjllg9xmAA2ge7Z7h9Bu1x90btdzXvcZ6Xvftdt+1nS8OUpAGWe+axfg9KWIJDPZxeSV07wVch2epwek26VgQ8Z6vNr4PPOngJ4XaPda1Ikz596fSKRj0zOn12L03\u002FOzxyTp2dB39s1fuN7S2OKciX8237M0riCT25mEdyF6PDMUEXiWvpW8MAhfJ5Hp0Tl2p7nGkzKZRwXXpFyvHEqXfCcDp3G9K85KYgWe+13ZxJs6291PHv8N\u002FvxsQJ1CXSPsgELFnq2aAiQU7PMAgA5QZ2inFIs3KbVb7SBicac9TVm1xwqcsgHgLGZ06Jj\u002Fy3\u002F+Ly2AvL\u002F393\u002F393uffPLxgCpuDRSVBigtiorifPrDo2ngdicxtSZfAA6Ivnr1oDxvjgJiZaeQMFrD5\u002FfKyqgh2DHAVlcs2QO86lhs73TpcuUyUu+5bRotTAQa5+MZFEGN3gIaiu2V7SOb4kXX+Dw3eGEl1iEYuNzL2s+ya\u002FEp3+rHD7O09xXU27ffn08pW1z7xRe\u002FGTePD9rXnfWUzzqwTIHy8TeYAdKlTzlfiCfKw0VH57E631wdso7aN5yawFcdDbn6vgWtrEkU3VoMetjHqfJbj+eUPjeS69dtW1gnUt2xLFNw4uqwAKi7d+8MaNo65B9+sDAXnFyLo3Q0QDIrv60rnwbEyURJDG+ANv7sFqI+bntLDRDP0O7QaY2LSvmxHmkUrK4Ag3QRwzVKh0zZCzv7\u002FXY9lmj5Jxd+\u002FF8BcXV\u002FUKeo476c3On4uEWhgTXceovpgOMjS64yG3y+886tZK0POkXzzXznfVRry3\u002F53GdRrnN9qWNPtmyPZkYFSCCDY+muI9RBXb1qwS5+BrD6zaBuLIhrtyL8nj3fWzew8cQzfKWYKAt1PXyIPlP8HkyH1SClYp+C2omX8hk\u002F3uIMuIkPs6Cu9MgkK7VO+UFAnT8sa1cPazfVlc66BMfvtN5odrrR4dS2WCT81kAha\u002F8ApGiEfpI48byjEOdJ7cTZzMcAt24uxHPyQIamnsbruAcdSmmHprUoOGtY9WgwoSwj19XF0j2p1uTKobzDvzr62dUlml43OMHHJVcLQCLK4JxVkW8tHsiPfE84nTgQGK\u002FpEQAF80+yJM9iwngwsixCJZh\u002FI9tGMyx+AcR+sxYumpZEL77MoKLLAbqVZesMpLQ4teiVJr20OqbqQPr9kELmk6a2jk3f4HHlsRd5hVKK6rW\u002F6bGpO8mqE2XrpM77361yCV3c0lgyIg\u002FxgLRVNjRtgH4MGrs6HYBbEDRZN0GGRt5avCfOAp1ZwOWn7sv8fALjOV7js4FM\u002FyvPasfCAY54bxBQ4iNz5M4oUDsmO3YCOooOeuHEICU+qgrhAPbho\u002FqKphnolp9vMCivYr1o1vEwPW3rXJZuoFZbfWVHqlA0rkze5cEgsX+e1Z9\u002Ft7ptcWL6Z7YTrezkw28G3PqwfnT7uVxstFEGggH8tU35+8eYgC5AFkFTr8peuQ1gxaN7hePSRE61c\u002F0cwKn\u002Fo2\u002FO76cvq3P67kV6jNHEbPLL6v7y5TZsuLLqc+nuvgdxXb9jMB6Hpg0selzrW6gSh\u002Fdmb+RprRXBAbTlpc7IDi7PrEQ8cKM+B6jPV8LrX33pOrBrVo0c62cMYMiXfouuYShQz\u002FQSmcYTffpRrjw+HkjnMrSpW30euhi8uNc8ziCnL5S5eL7hwuj2\u002FJlBCJ5mlb\u002FebOdBoLw4VV0zxQx5j3OJafZam9\u002FJzXT+CuFHfkROVp0m02nBngkyqa\u002Frbj1LqlIpcJAHjvi6q2vxbXJBV54e8QwfpvU5i9isxpkEJLjyWCI7+mINVXvVOzM8KJH5DDiGOFnvMuqkdh0j952Hhqmu8tyFGzq2OIVRF4u2iSnWaZqez9Mz4efBT\u002F7IdQ08XLhe8c7mRTd5iY71XCLFFH5dLXq7WWE8fJPOkLIr4ylvd2GltCWy0TzPyusUrM+D3R\u002FpbPzcHm10db9yPX2xe\u002FCjp7uXP\u002F\u002FpZwPqAPU00hqUTggI4reLuSyXa3qftT0tUNlYYfk4m3JlRS9YijKFXSN2v7\u002F\u002FoqnwwNC5vkAWePzii9+OArDTwLXcMz7\u002F\u002FPP2PP9q7+s\u002Ffl3H\u002FWDvk08\u002FGcD1+ef2HU8ppGBYSe98\u002F918GZWC\u002F\u002FTTDweAGP2nXaazoPzKOiWn800pBXxZuSkj03RLhdUEWpzzajpoC2T5hbNw6lCAEFtLpZhvZ6UIOIx\u002FYB3As2ePAn5NiypPNB0fP21v8fYvb+pT50IJywPwtwD2yz982YLTL\u002Fc+\u002Feyz2fmDxePhY7u6PNj7tn3qAepl7TToaR\u002F4BiX2RzfNiqmmXClJym78vrv\u002F6ss\u002F9AXN6iJAeqvZDJZ54ODpk0fx5buxVAJib9VRsdxa\u002FIn\u002Fd7PI6+zeaqqVW4ovel5oEfB3338\u002FefjCmwY1fApwGqToCHSwXHQoYQDYAlaK+Ms6j6+rr2+zqL+XH7t30nV+\u002F\u002F0PUq4+HJVPfS4xQLLFkeNLXR6ALUCQRp08DNLIht1xKHgdu7imdtN01U3gLX6fC3g\u002FKi3uFQA62QFObSHH9KtTpihMYaMfz27UsbzbwlTWdZZ+X9U1o+AA8A0iHQYyl6o\u002FZwMY4GSs8a2VAEpmoVxtYCxMU\u002Femom0X2u48dcQ6KxZ3A7tWJ0846Rpo6NCWdaxBZoDhUTNMQL41HvIhN8OvaMdzHfNsR1fHxa1sQGrg324H2qV75dto0dbwa+sgtAVtwBd97x225WgdslkoVs0BgHUBFT3WFqpn4gMlBZp6YSgeSBc96kMbJmM6O1Zd2\u002FRRjNPJSzMZ8cETAyxp6kCfa5Nk2ICqzqqnU6\u002FkHOCRnDzNcgFHZkHQgU+eT\u002F3XFoEd5VXWc+faxWnIMNBYCnU+wR2dLIEDFnu\u002FpviBOX7t0gJkk7nkZcpc5vzd5aNuZ5u2Ci3F6SSdRWJ964cGe1YCXICPxbPrvWKs2ZSkdtLDY2k69D+RM+m6F2el7wUavO3oNIYG4KXZvON45KM9KAIwX+dbLSygHi7pPjqG\u002F8tCHcoqb0BGWqvtYI8w0qYHgUT8WeAR76vrkaMGdZ29kwCrN7pf5m6gvDML9Go3oOyddIDJmVWITm2uoje4yAIdfdoeIC1uF\u002F3U2wQZ+XM9XJhwLLxmDsidWUEWdO4fhahOHSPVE1ZZcGQB9TWgWNvFboN6hpPnh8141eZnoX3t2ABgDA3Ror5n549duVZ9VNbk+bg8p62SebxRrOICi9yzzLqmvmeWqtfJozCLLwbtW5sDQi1sZ8VHK1mX78zmjT5fA1Jfyyb7BjoMJJWutFunQTdWH9PPpjtmFrjByHxfgYz27YgXL9C79I\u002F1Uu\u002FcfjveNQjNZx5\u002FI7tfOqK01ZVBqHsyZocqMsVwpC7JjTzVp+vpj8p\u002F9Ki+MLq0HXrO16Xl81b8oMvJlQznq6qVQTm4AaHf4EOZhdOmGUU0o7U7F9lPl7Dy72RypCImGPCTRcYlsx\u002FPnjaYeXFmhiFZedYHDa9c6CNSGcTsjqZ\u002FsRHB9YyEl6N1tavagX8yxVxtwW\u002F0Rnzc2rvHu9edCrJ70PVKRzvEBTT70YTdk8X0sw+2rTjktWuplafySTlpFXWFmVQ8PXskQ6U5xyDT9XbyEvH0kPfuBh0ud2c5n77zXBJbWPcdK8YuZ+\u002FO5LVF\u002FkmUifejP7v8JpUCK+LKasWsRidfLHQow\u002FBmbubVCr8i9U6Y0pjwW6SJuvuzK2d3w9ddOiuR04hnI3S9+LTRcPpy6I2eibw9FXY9UYIdBevlELaF+\u002FnP+\u002F9Dx8+R7P\u002F8P\u002F2PKSMdQAqphufnWBYIvrim3VLuHUCDcBQCi7BOFGg74EaSDHJ30WjtykLpGY2zvPrIkB1jNMoBR6XBqmDhI2DFEjo7NKQk7rcQ8k4WY4tW7955XDopqBo\u002FH2xxVgeylBcw494xSjLl+yJa7Vdt9EoxA8BAECViL23WNzt3TAOuxuw\u002FfYklmNarMoFsHYn9vsW1lRj\u002FfBbtTz7+dBZj3r797vjree8AiviQc42xQNBCHzz9IJcRoFSn9LzpWryhUADz+ZpfUgNsAJkWBvF5v92XRd9\u002Fb1mvlQnv+XLbltH+85Tk7EMfL8Y1p0EAUERRA6wUpo5M4wGmr+\u002FWDFDgtjtbvFhAVB3ZH99Z3bA02U6TQpQOtxHPvvrqjwtURiurtMOWm2SFRVr5dX5844Fr9xqS9wZ9BhLouZdF1SBCs9TpctEAXsd3ufy2vcD5Btu2U+NXxyz3yifNmQItD+d5X2cESAMB5E09kjmWbu5V6Cta5TOI3G+QaX3DWtcgX+UZ61g0jwtNnS+waHYAqJ6wgGmH\u002FOZfZQAc52t\u002F0Qmkmup1UATAywxCRiVQEoVN5pUXbdOpRy+erTYDXIHMy5qOh8otvwXStbuVLss1Ogcg9F7aw8PSBgZmFihATFWRwV6vMJXJwJKLBD5Mh03mO+SjToBPgF0c8qKzXgNMoHCBwJm6jhj5znXlEB5Y1FdaTD37\u002FVceAxTypq4F2upraI42\u002FMCwBYx3wCmayPO4O5SPNmMgNTRqoqUjPWWbcogfkCAPzixKA6DE6d8qD2vnApYDDKO1BKN3db5uQRU6iHxyccJThoOlGwMFDUDiTmWuLvBMen5qDQMowB0fPB9myL868QM4pRXuK7NmAnKpOmn631AJLMd78ZRXkviPv3gzQKmQZGjy2OWNJ1vb036HBxN+uVFtuhGQ808dgh\u002FqlS7Em8UPun3xU5ossX6RMTRMnvilgv1643rqpJfomvbcQK+HBak8yj3pR39pDU+kGI9WfGn4ue\u002FoAr3ahLKgiwzgG5lXt\u002FKQDgC6toS9MOtJyChAqk2MrJUPvi2almFG2vqyZ7VTX8E0C8ywo94AV+3dDLFvV4x7y27nr1nkG1DTDl2TPzMu8vdDj8G9vtH16Pbh3Rr82qSBDtm2l8UL6VhjRcbUGboNYGdWqr6JwWg\u002FizR8rFzAuj7CBgqsztoD4LHp\u002Fa3NvpEHg6A1Q6JcdLBDOtht4KHOtjphMJpyRRv3QboSLXSJMxrJuDPdNH7olVWZzY7qL6Zfih8GfPpRBjTuLHaZUd\u002FLWFHlV890IB7T1+p49QPWr9DF6W7W+Pgwg7TqpiY5vDBQ0Ke7J0hlM3Kr\u002Frwbg08DYPuym7W50IDDJg7caGyLKwwrfIUvjPB0zhq0SJJke8c4pw68W\u002FK62mgcK8\u002FaZ\u002F15KaQRtCfPep+8+YjZQeW2ZSZPAO9mga423yBbfaqjNUjSZzMsmhVda5m0QfWiLn70Q1dHUeOkP6jdHWevt2d489M0uicn86MPph0WwXn3o2+2\u002FD2bIM7S2j0Qb11Hw+76NK2NpM6rbS86\u002FXW\u002FjklV1El3Lno1ZevPm3C7fCbS5LiLvmjZyrceSuxM+JXFLn038i7eRujK3JOJPo+79J7M4cHf\u002FdWn8+5f+mchxH9pKsV\u002FK8VEQJLQGhl3CjtrWIwSaE2heKfxDicqGEZSRoDTu1lY38uf+aiO58uvvxz\u002Fc4qBUgO+WVwAvgFbpUv5sjJq\u002FO+3N7i4FqwA\u002Fazoj7NCa\u002FD8iGfKtYYOzH9\u002F595YiIFeK\u002FD5KD4zVfggd5mUio7nSoOBWljKM\u002F+49pQtqwFhrAQPHrSgp1Zy+b1blWl93t1zfY7GqCN8moXmQRZwyklHAbwBGfzYWdKB9Q8\u002F\u002FHgUOmAmzKsrBiX9Asjyp3CvtcqdlYHk8ffzdbk1RbcAIR91ZaXQ+OLP1OI0cAOKBhNmNmrgVxr8HGeluhJ9wDxQ\u002FjBQbqEiKzqryX3NNh6rH\u002FXFl3rVn49BnW+Ac3vqwrQl0C5f\u002FKWg1evx8frYzjtZ69Wphoqe+fAFJZbgsoAD2hQ0xfwgIA+Q85VUTh3bWNGzkOgA7AykTvnW237x5c3KUqe0NRIgk97CHwMKHbPde2axVl+SBSZ9yQ4gYrXTKfloyPf5erLKsOKTL\u002FWjgU3n1sX5G6uBrQ6qrShbLGtANfJbGurVseRxya8EdLIUpc4M4DcwOT7ui7zVL1m+0eyRBcbkBG\u002FRG+k1h91Ubzwh11xspuPTPrpm\u002FbeA2EDJwHXxm8tTMxYNOg0YxspbPQo\u002FFrFkHZ8MKv1cTydfx+ZQVs\u002F6Hw0Gy9Ga\u002FF8aQJMca7+l\u002F7wAOkhlIhf+7ccv09CzwDm+ro4rEBXt5B9Ul3B\u002F64i6q4wkcRYZlteUOflYYQMKKTOdrDjkHrBLbJMZtOVHnAwAS3hncbQ2hOa1F7yBjo6SxZy7QG2ps3qQJn7N4lL8rh7oJWVgHVd+LgUzgNGx+Q1IRvn6TYmlnVWRxXoAfHkP4C3fKaMCdb1O0VPstQC12Okzbg18u8+xcguHN\u002F2UgV91ASa74U8pEglpDb+7KOgc6n2AlGeexNsFvg3aS6O05xfjyNEMSgpD3taswqqfmT1qDY08dPDqDbMLOrwDwsjf0CdQFM0goUznWe\u002FQgQh0TIcUbdyTADVAdkBa6Sivtmw2BU+0BQUCvsOsQ68cHKOnd53bAKu25jRVrrMjC20b1PRJ99URg4W62QaQ6Fn8wrdJbgAmI4q08IVRQhjt1sBZ+\u002FHVXUk7SCyDkfaDLz5YN25TZLq2tQZ0tdHCvq5f09bMZgmPLw58Rxfgq8+zDeLIWfwZlpUZXtKPha7qzTYwYK0BpHfyVq8GETOjIcfSJ58GXUuClT3d1cCfdVt9aTv0+xjDKhdjivUb+\u002FsszkPdzLpt+kA7o8fJJ59u9GwDMtzY6n8DgPKewU95eE8e6TU00JXeOfDRO7Po+Ik+s5hP0kmVYtwWSbB+4F7urHa60Z6UmXzgnfU8ymzLSOvDAHB5jIycq\u002F33T3tWRzipTvVns8C0b2io52ogGasvqWjHDWSP6utPzifbfcDoeQbCO8mGukPHh+1gdjX9UrLlb29\u002FM7Jm++Irb4DDeFT6Aiy+VM\u002FJ1dTjfHk4uYsQLn7qiX4cHiaLLPjixNHKob0oWrxOU8zajZ5Pe5J21vbz\u002FOhTgez7ozuSj6n70q9Yoz9Im3ZrsfroksKy3APu03YF7CibHx3yncPpJ+\u002FOBtyCkdkfHz9+sL1XH\u002FT8HAXZZH3uPd+i\u002FYnr0wWgwozVXqwtsXW57s5Grt6FnzhvzuNas0Xd8uz1HD1fencjB797s4WXWIU4dX2ZW38KEkM6KWVpKG1HBIyrkue7sPN+ezdh3fw8x88G1AFdX\u002FGkoKbfqDFQ2BqXRkTh2iJxCQvrXe4YPeeOcNV0Xw36Zn7YNPh7t98bRQRAsIpbTCNdI2jghG8vi\u002FnXX3\u002FTc9tV9eXHmKmRs7T7eppOfmg5ySc7YKYjZ63jejMj+9hNIDXqmfKNn7bAApQtrDuowT\u002FKl00\u002Fej2AaCqTH\u002FPjJ20vOG4ZrOspwnZZ0JCM7OXH393Kc75z337z\u002FYDMv\u002F3bvw2cpawCnTebbjtIEdivWieq09CwWUKe5M+s0bKgv5s13KeQKYrxta8hKqOOSpnx70bK5XGAdgYkCQvXmKePTQ3vZVX3ZVMDpj6jHJC\u002Flk+1Aco7TaHO4CBtQPjG0hvvWY0MitDEJUN5KU7CDQBRgumGOY9\u002FfM90XqzNQN23udFYTEhJ21EGuH6U9d5e7GYafHmWRH\u002Fdx5sAHoMOlnZTl+rEVwr5HN\u002FK7cQ2fxcOvpsFVAPI8bc8niUPWg5FCmyOYp9OL4UYn85fCByk1A9aqJwxZWTqSgvHpItXd6Pjd7\u002F7Yu\u002Fbr7+ujtrismcGDxS9DlJTtLBxa3BkRudFdilwZb2cbJwC6dJYPNHp2fve9DVfydx4Sg19BiSP44My2oJTByst7+xskmoeebtwlSxwaVkL1nRBOu4jsyiVfQZi0ePDYTpxP8pKGbSJD5I\u002FAwB1KPyid7nkLB\u002FdAEr1Ckwo09Tdrt3oZI9225f6iJW2ww8YqDNNP5871+FE08lJs0bVu7a2gSjdfBM5\u002FSp96SsT2VLPBoBk2qwRMDrWlt5rkye5D+jIAWa6gKz5Z5BsAGlnCrK3yTe5JC\u002FHx3akWTMA0kbvAPZAx3RgyYt2qJ0YdL56VXuJr+uz7Syp1VtxfJhLnfN1XftM1361M9RXHnU5lmt59M\u002FU+oBb8tu9MqLTmdJeYBFSjCP9P8n97VWL6VjWuMuIM5UmeZFGw1dizPPMI+ngo\u002FR7NiC5smpX7iuMXnr4TDkt1w901R7lUZrSAwLmK6W54ABb47qjk0nfDQCV1E6+uYFtQJl8km\u002FASXYj+8n\u002FAEw0oRJ99Hvhomrqjjy1z6ASVD9TknRj8cp7BnHpD3Kn3shmHJ+0SmriKLdw54WR8dSPfBYd8h2Xi14et\u002F0jmaZzy6J8ejtZAvFLR1bUvZct6KfP9E3qHA9ZJv3aynziyl2dzsxuFL2oDa21RCSRbOiSyqef+NJDJ0AM6JGj4W88LMLI+vCqa3KpKIs3O96V5mkdx+MSEHB4Lr09X+GsftWBuH7Dm94F37vRTzVYrq\u002FUpjYXJHEMHAyc0Xexj\u002F4wIuknoirdXJvqHcDp\u002FdGzdNMYqA6nP9PWtAEyAfSpf7KC9m3GF5\u002FozTEgRHPdYulbwEpH6SOA5wYQ5XmltOSvb1QnbY0waa9B3PoGhhlecaq+0ll6wNdbyQn9fhiNr18vd06skjZ+kCvxAFn31m+Z\u002FTab9LwyMhBeqO4N7kCKEx+Qom8ylp0\u002F6IuqxX2W1f5V2wD7QvbzJw97zmX18t4HH32SIa1vhET3y1y44vje4XGGreRgFqlmMMMbXx2fj8KV7ql+w6t+Bh6wg\u002FV4+iVr0fQ\u002F1zqbZdcWDSVSpFO3ScTidzydgWVgfX2PoDqozBGWO2Kz8skcnNQtKerfkg9tdDUaslbfYtC0ezntonBk7P\u002FfgbN\u002F4dDAHAXTUk6P3b0nE2IuVlsanSdKF5u\u002FOp3\u002F5tgR\u002FeYB0V1u+7tnG9h2O6meiT507Oja5XhKmy2EsUB2zpNTF\u002FPPTVc7UldpNhon4Io079+kWBnOPPfSQf92vd2uh\u002F\u002Fyvz8bUGeRo7z5hZpWonSAv+mIE87pIFJcOESwxkc3YDJgRKMLELQEZwDe1iAt1AQuZ8eOsUIafS8rBFBjAeryfW8EHncoZMJ8tUUit3L9kA5\u002F1lGAwYf33n2n532589VaWLgBdADGrjUsBFwdAIKbfYH0WqvCn6cspOOLi+eAtD6W8EMK7krvLNKZFeg691q0jsMivBtZdOV1O2vstXYX+eUv\u002F2rvt7\u002F93bjtVOAYUKuvsfK\u002FsxXXAquBB8o2kMWKoLKBoXFxSLlqwGvv2AUW7NaCN6ZAATOLj54G0ljpj5pu9WEhcQA3X0EFfj\u002F++KO9zz79dCzpeGJhFRBhn3NpfR2ABYwJMjcjnQWri4avP2FZ9QNEHToB9YDvwCgL+FhZeq5zMS1LSQGTQNOlgK4FNd8E1vmRv99++To59etsz\u002FqrzThcDXjePnl3wIMO1PQlSx8r6nQCo\u002FBM81louixaXDAOAnF2hdHkDBoUBLvlZfcbbk\u002F46rmdcCzAVd9+ZEFZPTMDQrGSaYNEHZvpbLvoAPXTcSaHLPws8kA3OTt+wmIYn3pmMAHY\u002F5AV34JU06VeXm8P+wGQ07Fm6eHiBARPhx9Yj\u002F4BBBE6U+61HXUFEBjMSXOUeanZ9WYsyOXHwn11ZIulOFntH9mi2GoVcx66K4uz2SM\u002FeUn\u002FxaU1exMEKt\u002FkWYdT2Lo5mKn80QiENeBu\u002F3\u002F0XogX0tA+bAEKAJKTjb66n9JYyhDw920C7V2qLInA03nAoGc6GD95WMBaDzWd2sZfFadz1qGbfdlvsRhdQC72+5rsWJ1qf+cybWmTU9beOwyE6QrKhzxpL9PRAyOVi0wMII0XG2AFJNVl4jrnkScdNOnCkOh0WDRLpFiM8cRApdR6EQ1Z1F9mHbzQqPFcezoDJNPReD9hyGfpCe5Raa+Og+x2Wxri4CcwIE+gpz9dR0lngwcy9DL584GoKkPESWs+PlPQODkDQAvdpoIkXocizW33B3T54cMqR+mUnzCeSbEHlT0Kh2\u002FVdfV03P1YztNpBl8GfT54NNscFgPoU+fkjD1aOyfjqwyrLCUx8g2Ul3ivdufut0HxxodF45pdIFNkJwrlNP+wBq3CscJOdZRmtbErRzyLX71tnQRdbwF4fsvpL7pkjBK1+5elrR0YuLLoSl16dN38Kqf2QV4u9uMiMbIe7WMp771B7sxsVMA1+Im3ZCg+TQ2hK\u002FrJvUEu3sxRHZ8OAEtbHWzgeXM7MbjdBloTPz7rP57nisMo0BB9rOpVTvTmflJ\u002FgM\u002Fyo+vsoDQGhPoK1vKxIne2uLPMRmcB5eIYnLhg\u002FZ7+tufn6a\u002FuL13KfaeyPms9jD5IOkAznR\u002Fltc\u002FcOErTejR8pgfNNupn1LM41nFx47ueH7n2vcCsthSP54ujrPPVYP3A0fN4FT0DlpP91Q7qq\u002FpOg12rnjxqtveQW1CD+YD6\u002FpV4lzy+rpxxOF7WHlrobD\u002F148ctno83D1qL9KK2ce2tdzL01Pe\u002F3fdMaq82kKiozUhLo3KkQ+CZ51nYHz9+0KyvmXP8Oz\u002Fl5fqpXT9px50vv\u002Fpq7w9ffjWyYvb24wYAH7z3UUZJfSGdWRuIIm1t2vCLNSsxxsb69oNmQk6y6NtSdTa1qB4Mxi9WgIvW8FQOsuc4nxySLwbIkRUpE7CRWnnMpezeHCOAE6hnWwCv480u7pvAf+ZK+xtJ7v2W1Fx2s\u002F7vkqbVCrnLH0g\u002FjVcRTq3YWzbSmrArXEsD17GLr23T744tqDvBJqybfpPHLsAWZ9v\u002FHFOkvsuoc0fpDo0eS0A6wvR\u002FLtdd1+7ehF13PRpw3\u002Fm\u002FwfGzAXUAjZIYoEfRBNbsqEEJrA5eowtw9M6n2zHuwv4CQSwsmLbPIpzgC8dKbvvGj9vq7913bw+A\u002FfIPf5gFpHbm0GA++eSjabSmxOXBXeL3bc\u002FIIsIlhmCXYVsFfjANm+WMcF\u002FKbWUUQBzWwbPC68gBNp2\u002FxvJWe7ZeCfzceXV\u002FtjS8+LzPQOffp44sLmRVPErpvP++RZptM9mLp02vWfxpAY8G89ef\u002F\u002FXeZy0MvdkiTiDy8u\u002F\u002FMPkfp4BOsn7p9vknmvICIj\u002F\u002F\u002FPO97+5cK\u002F2HLSxtkWxfD7XN5f55YL6tAbNSA\u002Fi+POrMFeX2u1nCnxzu\u002Fe63X2QN4oPZ9pb5cFPCdrgx1Ump2+v3d1\u002FkB5i7iZ1z3r1tQefac54PLcDOPcMAwIp4e7U7nOxwAB8YWPCxx2vg1HksmY1S8NEUp0VEXFl0ejdu2M3HFlg6utXp2QtfHdiH\u002FG5Tnxarypvi3dx5yBJaAOGhIXn4+o\u002FfjNWdtUJHcBMdxbENJ99GaV5oILUAG0tOdRnRrMxmAOzsYJbgF31oylqF3\u002F7utwPWdT4+gAW86azJ3o3rbVkYb8mqDyetTsXuMmufd1YTcm0golM+f375urNoma2YgWH1b+GpMshDh+V842aDucD69evJa3XxsDx1iKeDHKA7vsbcAdp8MtWPXXOATDTNDjPDszq9BjcGcEDzgKHakk7SAcgNcKpDq6amY0cvITY4XQBgue1crQ2BY2MxrFOK3EKBpayKtRlgojJrq\u002FoHvK+xDMjAe3bP2equDwQJ4xgFHL2KI4xZlNkNZj2IokBD9TkWoPiFHsCfi8P++aUj1OfLl5cCFu1ylFyRjZvJNcDy5GkDpBbiAj7cphbQX6DveR0zgIlm1lCDl4NoUQ+RM+2cixL5BVyALu\u002FMAA3wGYsgfvjp4EujM0sbZY63A\u002F6UsxSDST2PCwBwcWaKtHZ+3Bdu93x4pR5k31aQ4k\u002FHEz9KCHBwVPT5I77LcZGZFz0ukA59GDnUL\u002FlQB9qNBbt0HTepk9o6q9tql1m9qyPWpP35KA11GACS7sqlvwu4kQs6eenn9VZ+nse2KdMYXhAcHxCs\u002FeMDt4uJW10uIElqits7QEpY5dNuRg7cDBMkXDoTbhenR2swsOrEVpTapPIDRAa5y80s+U3q1k4wBkkVSdxO2sGlvl79qvNsiVp+YJN4YwAAQABJREFUDENjmFGm9BWZNjNqgPmgdkhH6IPIi8GhPKWl7aEZH8fyPgaj9DemlC5ZR75BEQMVN0QDfoOIl8kgIPo6newbHA48kzaCXaPDrOwUoPQ8I18L2O8GfpPPGkDRqwYKBg3yxzvb\u002FGrPaHye\u002FqHzrHthGDF4epTF2MweI8utc28Xj0XaoIp+8BViPuNmfgLY6WwDBvyYtV8Z3pTPYHwBbYxOl2cEwAI6DT10kH5XWPmoCWXQT+CjmdsZEJWuNq+8M3sVzQbNFWXvqDp6ecyvvHqu7uzUJCwjn3ahfn0MkIrApGmD+tF0wYvyOmywYFb5ZWUiA1wcX76k1ZKFgLi+41z0XI0+O\u002FC86P2TJ\u002Ff2njWz96L2+aL95L\u002FNQHUzl5t3bn8Q76rX3tnk4mb9waVcKY9etGPM3e\u002F6Qvof9r75+o8zc072GXboXXnoe7\u002F59vvdlpq58jxpgX4usRb\u002FXu2L4Qw50xbiwRhJkpHDZEb\u002FQd+\u002Fk0cBA5f1S2bfL9dGWOFPMkScVG4zB+PamVySQ3J9UtwZANK9PcfzkSlnjOuJv+t62FeaE2oTvfV2BTp9Nw\u002F\u002F5B9xq8eO051d5k5O69Ci16EGhPNHK1sh5j0aCPwEnQAFWu\u002FF9didOJvm8vxsGKG8Pxv2Td4r6Aqxpd\u002FbRcwunWJGx+RKriY1eWzHer\u002FdzXky24V17ZDGdj23b8ox7\u002F8Ff1aP+i9IYIuqIQOoY\u002F1LeAb86SQpuRQTYRp\u002Fxd5pYBTYNkXPnQAIPWxkfi9wSiFz0UjyarQsg4Ae94a1Wn41QH7dWb3zcR5lWfrv5+suDCXDNeBZZ+\u002FsMqLzfNLIncICwoWRP4G3NSOXg7EcxexpSPoiC0I7H0err5ldvRoI6YE+5ss\u002F\u002FnHv62\u002Fv7H32+Pne3\u002Fx1FoPr7SUeSP\u002Fm69+1leTXo0j\u002F+3\u002F\u002F71vU2QeBKs\u002F1m42k8xf\u002F4ovf5Sf9fe4t7+d7nlUkJSe\u002FD3IX8XGjmw1Ovvzyy72vSv\u002Fb0jf4OWi67tY77wXKW3x6oyqr0QIT0r3S9fvvfzhADkDX4O2HbloTiPvlX\u002F2ixasfjdvIo3aIuXeXK9HjvccfPpy9zn18gqLVubDWmhEAQYAiSufSZYqKa0j+wlngbU1W91SHWedSpehYDgJW05Cq11HOdQLcfy7GX4pap3CSLJDhG7ng+NAU671t9gYYpJBZgSx0YnHR4VxLHih3+VDk99vZB6BbYJF7Tgq9jl\u002F+Bgbq89XrB6OQ97JGvN1gzIdfTJZa4c9FiBzZR98OD3\u002F9N79ur\u002FkWG3\u002F77ZTd9p8jD\u002FEVADdgMaMDvL26e3fA+rd9xVW+LCdmIMh8Re4IyCbDrF6Hz1O46In3wB+ZB\u002Fp19kter5d\u002FO+90b8ETYbqbGxf3jvUskFD5tRmzKROXAug3nRCrVO8MFAAWcVjk13qMBTIMclmRdYzqQ8cLHBy3M4d6Anb8gB9AXtpmkSwM7GH81NHV\u002FKowYNIPoDjI+oie9bGYGkFpvdab1Vnu164vJotrj\u002FjS0WCLr360\u002FVl81bOC1QEHfOPzfs\u002FpgglTmQ3YdLCNVCCVAbXj7lDbvXC8A1qjCevktc+u53P1qQWuAAbaxczqliVTeqbeC0gH6OgA3jWQq\u002F1UfiAGyNwAhbzRoF5Hf+0Ag7ZGDpVBF2i3EhLvCD5VICB9AfVKNmVHG3eD46xyXDUu9jto\u002Flz+1k5cCDjE9uiLt6WlDtDu7PkAk57gDR5l1OuZvITyfAfiejfp9IesypdS13mqd9tl6uBKYdLU3gDHGQgke1JT\u002FllAt7tW1zMo6fm4PtU26U+zWda+AFJ4hTYLbrkwOdQzK68y4pF2iyaDBnI+1tzaN2DFUr3KGp0KgNbScD2LVrsZ63N5m9kayzRqva9+ANNgeHkDnd4bUCw6ZgCqLqv7V2SzPuRl\u002FAdkJLEWb5PVAGk66nUDdW0WKAJ6ydws8Iz22FZfwp0EoOwc\u002FcqChtmdqDwNZlabXS4bG1C3YBCPHPIy0HHe5N3z8dePVyXqdurCXvcz2OvZzGQFIiedkhqeR4dkN\u002F4pv2P4EH10Kd0zeVWA5+li3+RgySUTeLCKwaprRhb\u002FHvUzc\u002FjO6AZrO+h7+TG0XL1ioKENGaybNTTjao94swbKT28D5j7Q1P7yFxqsFGP4pczJydBVHcyAvPZXwKEFEFc3rNNPnxisLz5VbcNbgzF6hRwdNRue6\u002FnUP5Zp8+iZGTrvqm+zJLPfegSM\u002FFV3jE0z4OtLFGOYu5DRq4H0o8M+vNeA5eKFyvPs9d63v\u002FvPeyfx6r33P0mn2Aigwc07bQjx9nt7z1qj9v1339Q\u002F\u002F37vu2++rp+\u002FNzpZ9T1OZvCKsUp\u002FhA+VYgHuw0d79777au9RfdT5yz7YVj0kx9qwtsC4o+x01vX6x9t9wXw+ohg\u002Fuay+ZXea+iS690YY4jpdR3\u002FH3xnAxoDX5U8GtXX1jrEDRincdALaaBh\u002FvU0b9HcdrqTlGD1UWPRpa3\u002F2KMykL9ifDfSTF8U5TXPLcMu5RDzSP62LdTcpdDl3u4xWMp44li5er1acVcpd4ELM0\u002F7A5p6i+8dFcy\u002FULqayFWBLE89OrwVz34Mt3fVS3N27rrYY8+hn+POzAXVKDIgCEjROwGRAQmcWCoLlfqxDCQ+fNi4BlAErxJXiP+1M2Ai+6bqjoz4RH3AHMJ+ztmc5JdTSWFPYtoxiqRTWPtfv7P27f\u002FffDcPutb3gafqlZfeVX3\u002F8YYtQH7SI5c5YrY3RLmfRZSm1aM5UHusz5elrbQft63vzZj5tr\u002Fu6ZI39QmB+v8726o22yatMf\u002Fjqu71v\u002F9f\u002Ffe+L332z916uNqZA91uwwvWGReWbb76twf3HgMne3q32JAfQ79z9vsZ92NTYH7Jqv7N3M0BoIZayAXcWbv7is7\u002FK7\u002Fhm9D8vje9SwEbpfY3z2lENeblUzOfa4+fRkT2oz+99\u002FMln5Xstn\u002F5vh9+PG5AAdvf6Gulnn308fuO3W+zJFebe3ft7v\u002FnNF1nt\u002F5g7zMcNGj5M8OpIsqj4aBFriQ9SEbyxiPQOSJuOs7plASaoZkwAVyKrk+CrblHOlcr0TvVKkVdZo8gvN5A5OH85vj8e2fjkk0\u002FGsk+Gf0gxDSBOLqazT6mqzzXoC7dVJ7aV1ImOZYdvd40J6DCwMNi6T06acrQr0LPex7IGPh81m\u002FHWyN79wLYddewzDJSaHTGAo5jUi4VNymVG4OmBbdDwNGVd2gYXLNoGfj6mxUqHOUcpTw2YVdMFcDdAtrgUqGfkGagA\u002Fs0SbFPL+GLnFIMgNCirH35bQDmDkp7PtHvpGRyYAWEt26aN8U67shWlL+oungBd5ZkV93J7xQMHAL1Zh5fPtVEgg5\u002FumjrXySrMKOipMINsriKB\u002FaaOJ83K4mMj51mnzjUACqwBweP\u002FDSCVwoWA8MWsQDVjqGRkZwbv3aonvODTrMNwTRHOYLN7nQLgh+esbBsvTPMWobyWv7r3jhnglYN6lJbkhVvlKMxES3H2TOenWPvcQjrkJd+CZOU2k7eeewfcnCTH6FXuC5X3Ve0YQHWoXyp4Muy9OtYxjtW4uAPWSx\u002F41huq+wGZkx5a6ZeARWkAeetz4kulo1VHMvQM\u002FYoUuDBXMSQWq3uFeZ2cvA4Ec+Ege\u002FhzHnAtzQKUD7BbHcdLdUHW1nZ6AJNBcalG07LuL1mlm+U38lEcciM1GHwMIw04TgDA6p7rCrAhvHa\u002F9Hq8ih8s6mY48Qqr+PGy\u002FiJjwFb06ivszIFOgNThb7dDN9pn9rNnwNXBwdIF+I0uaetrZsC0mCOJ5GaVYVx8Voqlh8aVDkBNti\u002FHK+fhwS5\u002FdQWsz2CNLEaM8mmPrwPK2hS58BwNwg0g6lmX0w6n0v8f5u5s2e7syO\u002F7Bg6Ag4N5LNRcZHFqqVtuKyw5wg7ZfjW9gF\u002FBt47wjZ\u002FAF75whC4c4bAl0WySRbJmFArzjDMA\u002Fn5ynV1Fslu2ZNZF76qDvfd\u002F\u002F\u002F9ryJUr85e5cuWqPUt3tSkxR4+5h5DjOa9O9Q5\u002FVR7WwY\u002F++r+\u002FjA581Gdz58QuudCKiHGv732YebvGiMMG1eKYnuFkQNfVBmNe+4c22uzPT4C\u002FMUp+alNzGD8D1saYzLVx3n14hN5RPqBcC1aZfbBfScabMQaSJdt5AQDRoU9P2KS6QovEsJsvPO9A\u002FWCDGmNOTev7R9vwNl3OQDo6MEeTJ9HA+PNqCyvd6WTR\u002FfQ0GSFcFL0mTCa+V645tVsM+QpX8mxZcEoIwXM+c7S+n+3vXDTd7bfDDJjDFyWriG\u002FOlUTgVKuBLx99vfnD\u002FW8233z6m2RuB921wvA03X70JOxQuMvtAeh3p+yLWRJXwgcMV\u002FwDb7w5yLiJ4c6nN87nBDvbSeleB4H1B\u002FfvFlJFxun5Gk8wc\u002F5vQMicV98WWnNHlrRWKBqPK4XPXsqxY0\u002FbhUtX2rt2K8PhxvAbOYkfefInnKxSsYrQPx\u002FwzQBO75VvrKey\u002Fl1tWA98B0rd1yVluvP\u002F9aWKbpiuzPt6oiJ6qdv797\u002F7vr3Xgyv8pfftje7t7\u002Fgxjx6\u002FXPmzq39yo99W3f+hEhS06ln3rXZsn\u002Fmjds2N3dtPs6p33OCRu8qongXo3eiljNW2+a2PxzXMrz\u002FkPz8YUMcshCe6E3iTDirAZHT2EuzeebsnVr3OYSbCi5B3L6bM99GEyeJsUmL85eFM6FQokHilJW8MJ0zA79c6tl1oCQAHUF0tpEEsnAOFgDChDE49vR3YJTxv3boxgPnrb76qOctrQdE8fdYkaTKzyjGpE9XOZUUD6W+XUYayF+7yuNzjJxO+l6rn4180eS79fvPv\u002Ft1vN5\u002F84dPNr\u002F7vX23O1Ya\u002F\u002Ficfb\u002F6b\u002F+qfbz788P1SQ96ekJNHPUuli\u002Fv+V\u002F\u002Ftf11\u002Fy+\u002F+7bd507O6Kb4AMpD7+edfJjT3Nz\u002F++OPN++99lKfXkiAwfH7CW07cfVhbeKZqn3jc6P0qoXkn4E3AJfIL+XlnczqAKff6t23w5AFj1BCCwgZuFnpCSD598smkS2TkMK4++OCjAZFCPQD13QQMRXa6GDkvgJxHGp1PZjg9a+MrwT6etX5fMY8JvZ4xBnvXWlaufxPTmJDeO5cQTWgDB5b4CCibIIEtYURAmPHe6axnINWS9MRAVp+VhEt5sK92D6X\u002FLED+otNX9WuWCjNurrRR836rCN9koD2LhrzlvLZAirhyv1OaYnkJScD1dHVrw9s77wSoAgTF8jMM77eJ10YgvExxAeo88tKJWaVAM3QCVG2atQnZhMWTngFUABnedIre9eVRpgBTktXNK41W6Kd9o9h6jkDhkcOXF1ox8uzkfu9d+80zNLPpzW+Eu\u002FE6Ey+YYwP2a5\u002FyeI6Wx+n7usgVih7w8NJOL3y\u002FsockcpI2DLMzLckTWtOG5oYoBp57c\u002Fj0bNZKcFUe7\u002F4AlxTrzO9oPsJfQX0G4PCfeTSbSJvDlm8X6LL\u002FA3Tt3vriHjQAQF8Ua2qDrv7hXQbbi8ZPqBJ+seKC1vhQHeYvIEzJfyeYa6tmkE1egKE\u002F4SDOciAHjJ37+3++r\u002F40fj0oXRpjaJt6zpjpC\u002FqiF\u002FXHLHG9zk8\u002FGOnKtNETUDdHMyuq3HJ27YuoshEVVlsZwFP1zj+1qzp9BKjEbL+pjAFc0WzamXI+jKcOW4J\u002Fc1h87Cb61AXzkpgl54AWMb3GlAeVEtGibb\u002FtDXjV33iWx\u002FioT5WPBknlqlnjASzGbKO0rFDag3AUeBOXTl7qM2DuZQ4DgJMmtLKcD8EzjXbj5KgsY2VcT2awzOqqgdm+EL+Xt\u002FHAl2ln+7Mx5ezBt57Aj+bHiYwv4Ubo4jfT3fPk4OrHutcmV\u002FJRHxxWJQzGyE1axZ4GctCMEUymkHVWWWeeVBeDAAF93\u002FLVGDbVgtdOtMp65szyJuNf\u002FGE1YeRdnbC\u002FwTWGxoDyNgsGxStyGaHDmbrv3nle+OU6ZwFQJ0PGIKqN6LlbO2rNPE8e+n3mQOOh\u002F3h9QF9x6XgA0bD5QeCUbDlqBXTmWWNddZWtzVFEStR0Zo2c8taqQXqy+alcXmJpU58UeqpQdRhTTgS\u002FK8dq1oTAJiftAeC44JWmS\u002FAdmrvXeKKl0Jb5Q2LzAZ\u002FXP84y9H7Ny9V9xtNPs9H8FOC9+jRCqbFkHAtnaaJGI\u002FK0NMXJ6HuPnm+eBvT14dyc09JKY22RqGI\u002Fp82JYuB3ouHOoZS3ebrjjKfpoaPDvN870nDe39z+5Onmzu9vDH9zGNbzCZs6X79gGODNyo0Ma4enLkRbqzg5SWpHPRxa1vDNBfH2\u002FWc2mgf6ak5y1BkmNDp4Hvg+6FR1SSJymr182cFV985u7nTv6dJEfvHW+5vzN96buYWeVn5\u002FEl7gcDNPhn7RBm8NkebdcEVHcsnlKhsRdXxHVc9rfjr+\u002FP\u002F19v29jY3ytoX0oPH9Y0D7977XiO9uV9Dxy8fV7u2V9e7auu34KQX2+u7R4+\u002FfXeyH7RNz7bi2P7lWUbX6uN2NSGWYn9PuZPIf1zC6sSuLfOuZ6ZNadLwvWrY+rxr9O3Pv+69\u002F0aelpf+iItbDNttRqJjFCZuvjxwL\u002F3QJvxiOYCMkgC9CCyUoO4pbp01SE8iHq4W9uP7pHz6b7x9+9P7mr\u002F7qFxNu8CiQSGhdCSx\u002F+OFHAZeLszRpCZuwvV0ss52dBMR+cWH7ecbDHJuH9+5s\u002Fs3\u002Fdm8UBIqbKDNhEl5zCEQhJ0IvEFc6xBtZ0VezZC+0GZQy+vr215OVxYBKY3c2QfOjD99rw+iNhNfB5svPP998FdC2k\u002F1uwPmdUj598MGPJ7ZW2wAMc+WDd98fZni7UJdHgUEKb09sdT9OtpoExTd5xcUxE1avW55zoqfjj8PmxckFPBNGln2Bo86125RsZ\u002FOrX\u002F+qzaHPq7fwmcJsZPFweubNm9czAp4XOnJ3vOt+E2f+wQfvDcglDAFnByLt5bF1bPrEPCaAed8ZEBTBkyfi8ADrYvn7O+w3BofxBFheFY8pTvPRo7LMPH8Y\u002FcVMtwk04f4sofnyeSFHxerzKl+srt\u002F\u002F\u002Fveb3\u002F3m15t\u002F+jd\u002Fvbl1bDyob3l7hEa1YaeNQTun2qBUfL4VEZsj9zvpj5f5MCUgxtgprMAoI01qxottNPy63PkPUzh3vv4igP2wUKfLs4H2kvzwN67Hp6c3X+QZ0W9gwx6Cn\u002F98rxChdzPqbm\u002FuBdiTu3lAHgxY5i2mzKUgZSyip4OZ0PjodQI+gewU0leFjLzpcBEAlCdlhYocDbCkSOVetgQLIFG45svZwPTV\u002FpOZxngKCWNI+JM1ZH9fisrGoXAmoUlWP6TVFAdp34F5NR6UFJXMJieqX3rSx4+FHVwcHiCQxLULpbEiNcA\u002FpWplSlsHrMbXK64\u002FhV2ZE0caqDGfba69kEISg6od+22oPgokzf6J+gLYEmwMrK0IVib+HU9u3enuaEogAk+BwpHswFX1zx6GrgOh\u002FXa6EAQgwF6JN3n7zl8ICEVPMbSUqo1YNv3udc2qjsonxWQGijk9qQ5rE8WHktqxG5gCig\u002FG23TsVezuCa0ZJVb7Kgetmmbd25ONu1hRqw\u002Fu00fASdOFJAA3BPTIkX70+6wY+oyG3Ssn8kGAyWvJm5T1bgZCNDyVwX1K\u002FHr\u002FTew+elX4iWjgrwJqRx5FYLTGgWbj+TQnXzb2bVQ9nWG7I9tW\u002FQVI37zJwG1eEKXASf9Ouzw3qUq1xwbmaEUgbYG89g3\u002Fjee8OR1vjmHe+OzkYDjcl56v+VK7QGNjuEBlba3dQp+AMMfUb15Zgev5nmVcnXmTzOidUY1GQEwMED1GvXWFPMZz0TS6w6Hb33izyCjzDy8OCE0GcOwcCmsxUd1dX4bX5kngqX7P+OOHqFBbxmBsTMRx6ytZI7TyQid1UtCMd1mfkoDJuuQEoHWsJ6JUvBQgyzjnqZ0NqZUvHnu7umQh5UV9ECr5qvLy6dTZwHc0eZN8wDt4clZ0xFQiRv0b8I+nGhtziH4725iSE3jxqDk9sqp7J8vKANiAb+13rxU27xOWkgHI8YJ+0gsv42JxqUQFs78Lv9Mfs6qTwRWPzWGDtfVFmVBOvQgUJ6eAaXQXmtkATb9eBNJfBIBP4K3KMSetZJivQvCejz7I+fbSPFplkL+Tojg+cfiZ8SKr6nk804p443G6\u002FRsO7zpdOWcq2wZKK9q83GgudA3PCW2hE\u002FGwdTGOq+Hynp2UxN1nPPYbN\u002Fe8yGP+vJh18vZs4S2nCnlRBgPHfi7jz5DWL3NvpzG\u002FViKJW2+9M+D3XiuxXxYO8+rZg6EHPrbxNc2Wsay\u002FK4QX\u002F+Lr4fvwAXrQ21YS1qpIefLz9lsp0n\u002F0FV40wLp+0UORp9CW+ClZcxToP9u95wqTe\u002FnyUVEFnHTd\u002F\u002FWXm1PnCp1MB1p9uX7zrc3lwpLeupF+3L04ceyrvhmyylebuRFH4DdixT++aIpXH79zoG6\u002F9yAeGjHdvetRM+CPnqvN398zJa3C3F\u002F\u002FFezfqacPvnli\u002Fvpd9XPX3OvL3HT8Nk8e3\u002FBdEUpb1\u002F74fXvpuzp8OH7efb1We44\u002Fr7f173RQ+e5fLfTDfO8SnpiSklcDCtZTQxdVTB+OO+INPbzW5\u002Fn4g\u002FzzgwF1sb4mpM16FDhL+70m8u1OFf0qjzav+fMEx8T+Eej7BE0nX14S1tBx5fXaEqOQmDuBYkLiSmEpvJmsxq+L1\u002F7si6\u002FHogfOHxYb\u002FsknX86BRr\u002F59W97JgFTb37y46ub\u002F+5f\u002FYvN3\u002F7nf7v52Y8+2Fwpm4u85oQZBbZCL3Y2n332+Qi6W29dn7AVG0JtKLUhyz2\u002F\u002Fvb+KJmbeXNtTMVWQise9duLYvrefTch070Ww3\u002F6o1ubf\u002FG3vyisop30WcIELnl0\u002F\u002F7TyWwC0J4+vV9Yy5XNp7\u002F9rK4etHH0w831+idUZXlM5EV\u002FESi53Hunhnai6hdffLX55DefJHjylL+VRf\u002FWW6WSKovI\u002FTsT5iP7BQH0zrVLm\u002F2ffDTx708LI3kdMJC+EvD96qsLm5\u002F+7OOZ0A8f8LzvjwdXW6w6ACIUgiXFBy3tSSF5+ODeZDixQYanQIzjN9\u002Fe3fzhU\u002FnXV9YXHs4f\u002FfgnjdPO5pe\u002F\u002FL82X375WcLtamMlfV4x8I\u002FuNR55fqPVg\u002FuPE0qbjJ+bpWl8dwD7uzfbYV+dh9HsRXVKyWnzKY8WpcS7ZSWB1+D5s5Tn6zyI7S2VH\u002FjkTkZPwHFOh20irSwfgGdKME\u002Fvbrv6OwC2kcmAePZwc6eVkAd3d4eP3oqG77z3\u002Fub9Dz\u002FevEqBvmpsxhCKVy\u002FV33cSfPfzyt\u002F79t7mq8++6DTb98djNGA0Zb9X\u002F\u002FbOp0QDSLe\u002F\u002FCbD5H4T8ajxuTn7KmR\u002F0X70mZzzGU\u002FphP4YpaXtavwABJ5xKwXDd+d2M+7ujmEgNOdcdbwuNdjTlMOjR8sTbR\u002FH2b1CaDKmGGBiqQGkCdcAnRKsk1s84dHMyoB5Ev8WF5\u002FXmRBmCBIfA5LJ6ei20zydePN+EZbyOOA\u002FwLw6KniAy8kTB41XRkVjOWA3r9QA+yQRhSCbRLfOc8ACMKQeqxm8vJQXQTdgmWFSP\u002FTf6sl4\u002F2fTKFVr\u002FjfLut\u002FrZJlSdsuqZI41qv3x6gE7PHMZp\u002FHhoNHkho2wvJ68yUJXgLABTzXsKHDZA5vX+KW5crp3wOlZYOOg+iYOteeBjpUKsNrqG5CRCbF5lVIesNI9jFSGxUmb\u002F7rHEjcFbVwnDCCwDFiY+xP+UNvDZxnWyYpigF8Uyvb68FntLjvEEbCe1\u002FlEoVsAiXyiKQNg1eZQ2XAYC7zAgP6bckEz0i2z+\u002FwqALLffggyb\u002FPGCdDaBmgEnJpPMgLJwEF2ArdD67yIjAdz9lSgZRng6zwKjg3GsNMTGQjCDY4Yf\u002FrduB3W780L50QEkpPR+k35kU0TT993SmqW+wPkjAT8YCzwLMA4c6C+cdRYTaQjGUFjrGWM7AeAjQFQ7Tk01m6pW73rixA4c7HqpjzAR\u002FjDtINSjWZkNW5HfBvP8fypgwzOHA30ytr3Uhu6Zaf6eFKzTHrKGK8Uv1cunxvD1uqw05r1betIehP\u002FHERLY74HfDWPzCcJA7T\u002FUQDtRX05J5a4MEihYg6wsbJADzpQDsBXtpU5z0o5vFYA44Hoah7NymKy5FmykEOkJsQiQNf0bujIicTY2ms8yXEGLcfDo0L0nFrNgSCXOq+2A\u002FQahg5ijd8znp7XppeFZCj42o0SHiRfZBB6ub8MIit6NtxeSIbwlD8t\u002FI\u002Fx9SbZFns0v+O7jGZ60QGB2n268MsZ64zIGYto8yQZKLWuVSmG2wLdhcYoJxpKKXmicgHvg8aqddeejZfjjSvRyuoZI4rMuLx3cd45s6RSvtAeNeBZ+A06MqxqyfCH+XB28ipaGCpZwrmMxcKJTsfXQqKwOtp5kVHAsgME8d7lwPpbN0tl3MrVtStyudtM2wpxzr+jDNHNUeEm8ZJxkYs9DD1teBKvAOdPrPj2rg8SCpAd+Z7UUi\u002Fjz\u002FqkPituDF6riuhxFo36uyE7XW2BHfZzcp3diU8LH2U07Z2tn43rswyFU6871O7J3c2zxzmXTiWHonfUHBl0mNFNHDNQzuPD+noU7nqV\u002FHhdGNEYvtGM8X3YnBYWt4zonuszbz\u002FepWfSQjM24zRoajJcJ3ymfjfsvYDcP\u002Fo3+s4P\u002Fbiu67lLeNv9mLnf6vsKLTF3Xe\u002FavPvk6\u002Fff12\u002Frx+09yrECh\u002Ffm9uNnvv88T1XMcaFzl3+q38tlH7dWTPfNL9HFGPnZo55\u002F00qj1yqri93jhn6ZMnDS7CWau37Yf5ZW\u002FAHKJDxttgP0eE3lC2fh+9NRQmSWQ2NI3q+TgbSzTSTWKcpgFrG5u8UuUho8qrznXgCZyQx8Pnr0NGa9P5PjQRsMKTcehA8\u002Fut5kOplX9GZlHW5+\u002FatfDZPxVJ4PgFsivXHj6uZvb\u002F7NnGzp88S6xigr5pDCqbIG3UBRRMCiTZ2yc1zO4y6u+mwbIC0PAnM2JTqg4ItP\u002F7D5t7UV415JSJro4vvOBjSFovCm8oDaMPqzn\u002Fw0r2zxyp2Uev\u002FB3c3d6lIf0C0s4qt2kjt6+e2ee7eYeptirFYIORAnbVn9YhP2aaD6zu2vhpkoWHlwZcEB+IT+CI\u002FYbwf9N3mHecp\u002F8rOPi33\u002FCKErkxfkcIycOwHw8y1dHmRQsdIdTMFQ4fW5ef3GeOhvXL\u002Fe6sLlTni9s\u002Fni8682D1u1AAB5nNAREKB8gbaLF6W6XECTuhRPezKwD7w+eVQ4SUBhMs988P7mo8KDCPrf\u002FubXTeKAcisYN0tlxWsEDCiXgsNAFJz48Kbl5vLVjugm1OIdHmh9cSgQb\u002FHtwo3E4AMKl4rpOxvIsGRrsw4aWtW510rGxWL\u002FpG2Uw\u002F\u002FqlWtDFxuGX8a\u002FJijwz3P+bX32bqleCMKrR3lI8ui8Ks++DT67u41zSpYyGcWacCZgtR3PU0oAOdDKC7xfOBKlJUWZmHk8a1OxOgHCo5ZgeVtCXP1WbxuvyUQSAMPreIDwdc1+ANlQnj59mKhwX9mK4j9GAJAG5GoLkD3CJcVgmXUncKGQuVZVAw7jd20EENCIMqEwKEAerWeTzajnK8t8EzY0fK1PzSGHwqT9Gl+gNVUR\u002F4NMOymYqq0fGH2BL8YlJSVecxRD88Z\u002FsYB\u002FB4iN3OjCjtz4\u002FSdmEw\u002FYd8GYG1CezMAbFCZvBxBLWZvP8hBPadGPMlgbwgNY8ch47gM4L\u002FBFtD6jnGOgTjSfqRzx8QSv+82F3eokqyZUS\u002FnVq64R1t66P0Y3RIuuhDfVFD3xPw96DQkDZyyVCYY8Ooif9ivL3hZtVCZPfaVEl4CKP+bCrETECy2dP8vZ8aLsUi8yxA77HltWfs\u002F0tzbQBRhbMTrYD\u002FxXtmYxkmbzbu2VdnO8Z9U1m\u002Fb6\u002FWUZrfCfeskw7WDMyKSB\u002F6xgzTWDqH\u002F9AVTuQQNAyZ85QvYBE0ICPDMv\u002Fap\u002FlCkPIjkr\u002FGRWHcapwTCIV5vL895YAFDAN\u002Fpq03ZfwawGVQbes5JXi7tXs9BUu4\u002FDq2qf+v1pE2VqTwhPLZ423mQEIwGYXcMXT5Zz354SObNV72\u002Faiofj6cm4ET\u002FgNbLHit25c50HsVumpdqJd6xEaDOgYxVCRp7YqGsL\u002FACwZ3fXCjBjF+1lvAIeh3+bH\u002Fqr3b5H7pE9CG9O000TxtT1oXsEAIBnrmbMjme3fq4kACsc6UmrU9pxiRGerFgg3Ib93WR+RmtjacZOGEdjdZgRgSYyZWnL2YvkgPlj7tmA2ZhlZNP76pPuwYoKo5WxjD74cPYRxENktPEZo8zEqmz8Qo7oo7m1fmOMtyH1ZSMGLOpP9ZOtE67XNXNEGM\u002FrZ5VZOXRR1O25eKz6rRySMbzlQsfIMXrkXDhCSJOxlZ7Rs1t+5xA6Wd9mv8+hPWOP2yzavqbHDyJ+jpVkPVD9plXOcY5Ei6by0MTqv7AfIZGypTm3RMYctLBBGc9NqFedRlPjimZofdC8NS7GlbHDeHaIHTmzTmMtZLbPzdbhwzMB7PLrDc+WKr8EHDnjfv+rVh\u002FvzSrYy2ggjaVTVc+2cnfzxq3NO7cKlbkc\u002FXIi4OHDVkN39vLal1yAwTXnKsR7xpkRS0dwOnIYjGyvT8326E6imwiNQe90m69eDe36zWcXXTh+N9999G4+Muy\u002Fkw3zrBu8XF+f1r9TElb5ey88s+o8\u002FslN6vD23efumc\u002FHsvpPSvHD969V059U3o++r\u002Fl3XHJ1+r7u\u002Fv7p7z99V+pxW77\u002F5S\u002F79IMBdUDsQWD1mzv3JwzhrbcDCHnPKHneA4qXYDSBDJLJ6OQx3hbW6okzPGOWHKXr2wkg3cuLey9QZFkuqzTrnuK6ciUQktfAphFKlMKXbs+pmJb3d7MqAWyzUCYXS7EMA95lYREmCTDj8Jk5ZCigwZplca80ZwmZ6hdPbtQf5iH\u002F7Se\u002FmyHzrAnIW3Ht2sO8qG8lYIq\u002Fq4+EpAkGbP3m158U6\u002Fxo8zd\u002F8zfFRl+e3eEPA6mn86wJPXnz5mptfNqGzr8r68jXbXrslMy8asq5f5cn\u002FIsE4KnNv\u002FyX\u002F+UAgF9ldAhBuVnecV5fIR6WEtEEKBcqcK2+Xa5PloS\u002F+fZ3YSIaPOs6YfH7QogA8v3KIKz+s3\u002F2N5t\u002F+k\u002F+qrZcbaXi9lj+jBsK60rglqEA1BI+z0t\u002F9\u002FhUxlH0Nn6MArnACcdtSrybGSCE2bO81zbAis0FqIXY8CZcvUpAtZmx8h6WV9ym2ZMpFv2xWYay4YGwix5ItHFmNl\u002FmAZt0Z3mdnvfHSwg0n\u002F12NyPp0niwPcsjgZ8IcvHeVgqMC4\u002FP2mC2+gKEmmQAzLPSOlI8ez1\u002Fkhey\u002FtsfgF4XM0r2nJhaXVZi7j8J+EdLQNNEFXu4d07WF17R+Dj6n4l3+7FbmlIJS4YGjwpjglgb4J5Cxutn4xHgPF0WTQI7TWpgE39SbgR3GiblZAVKzGwbiAv\u002F4U0G4mfDb3PrUm2k4PbbwCQbgRhtB2xcL5SIIfP66HngJ68OsBcw8UdBrFMwVZHAIXxrd1A3RSszgwwEwiII+rx09Xvlg173LU9+IKb2AxcMO7wJvE8mjmhbsdE2HoiWJx060zV1Az0AHKVqDPSRshzANVI3IOjVjWTAbqcIeje2vI+LJ4XXADyA4AJs5ikwqjy\u002FGVcKd6c5BTTibX3tgQEWA+S7b0BQj7neP\u002FPu+VEm9RudAMy1lCxsyXK6HM3mQv2ozgkBYQxotiLqwvQ\u002FY+7IXzSgAK0GCHuQG\u002Fqg8QK2vNDjlI2ub5KVtVNfAfzZsJu8wwtWWZ4FGHjQ1z4aAI2DAuisjOYtWpBzPLPGjTrRT4oXGCEngafxhGtgL7LYfpW9s8CXeqNrPD6pY2vHZDupTa8zdoF15Z3N48y43tlp5Ss2QTsyTwgSHlaH1ZstvVdN\u002FVsbkBr4dg1oGy\u002FY0L7f+h2dxmDohu04KEsffPeyYuURQFWI13j8un6yFQXXhqH6jh7Gy\u002FidiI+Ua+6hBRozYBfgXbw4YDQeBkYmacDwbIZSz+1rq7HrnQ6wN2JiratH6AaDw2\u002FKxq\u002FArfuArckm1gTv64BWBh0ZNGFElWnMZ9Nm4JOhpedr7I1V\u002FJaOc6\u002F3OrdoG\u002F9pAxkMxAKn7o2j4xX8JRyx8e23rWxEa31EZ33nKDDP0YiMuVsu8bPJEycg81zbBzRe3sb0Zf3ZE8pUf6wS8qCTbYzlKoj48Xd0wuvaCVSfxrv9bEiEpAgV5fyYLEs9iwWBUu3TB\u002FQzVgfpDkDfsXOvCns0n\u002FRzjCrmQNNut5AxdMJPY\u002FD3nDkq5S+eterCubX6uj+Op9dHbcZPhx0dJY+BrR4298hbjquXPTfjODR\u002FNSmZa+4Adoaa+\u002FDiwhMr6YXy8ZB2+GdrAJPn5oo2mxt+N2\u002Ft7xgDtnAW4+NvxiIdg+ZeTl4eR0h16htugS1m30Z9xkc7YRzpa8+RQ2EG3vQv793e3E+H3smB6FRVBsNeCSHeffeD9ru1en\u002Ft5ujtC+cLDy0c9uK5MuGlC\u002FTpqEEyHvjyUOrs5MlOS9Jv2kx\u002FGJ6gc5ol7YUxt2uRsUKneNcLGDZ+83netXt9nzeirq+yfC1He\u002FOFnOyiFfvjO78vw5XtxSn1+3\u002FQfFuXMTyudujUPz1W3TVIm5ThzWBv5ccqaa76YX31yTPfffvH9+GHA+oBBEs3L19l4RXq8tkXMp4ECmIyu8rFbn34kcwkNnCZKFnRAWneU4KJcONtFb4wXpyWZ1m+T5++mlR+129cC3wUQ07QNRPECpuMo3garZkYTeIBHsWraYtQFsLEppK7ZT95kDfSRjTx7TztLG+AUEy6eDb3yb5C4F+\u002Fnje23xkBsm3cuVNowsPi3eoLL8LTcpfv768QnUnp1Qx6EDjn7XuYp99S1yeffDIZZmaSK\u002FPaxVYF7mx++e8L40gwn6t9gBxQt5uH5f333m9F4IPAs82vnd6WVc9zdLuYaxP4xz\u002F60cRG\u002F7pyeYrff\u002F\u002F9zVuldFzAdp0QeqUls93irG183Gkiv5UR8E05XX\u002F1q09aunyahX25Jb1blfXj8fRKK\u002FhQLLAJG6cC1saMEDUhsDIhcj9BLmTHRtG3SwcJhFN4vEQ3b7yVcLy8+STD41Uxjgf1B8B4U9whGovFvnFjbfCxskDI38tbwZi40kbQOcn0nMOGAsZ5d9CO8AQShSIBHq5ZMuY5f27vASGfkLzUUighZpOP+xlgVm7WqkwhNMVUy4ajTqFFJmdD0fg9rn0pSQovkD0ApclK7OLV8xlUV08yqPJYZzzs50FPf0SDAJzQhxZoKQ3eCBvzKCnEIqwtKVKeeO\u002Fli2Kt27cAxOAThhbwKK3gPgEd0B2QUB+BITzXYmVFWUWwSpABki6UUxfYJYDntNN49VKhUwwWKUAfZwjev\u002FdsxtpGwvMJaeURspN5pPZoE8EMtODhAUXoEUEAjKWMmn8pFQIQ6CK8xpPV+9B5lnktnzKM9D0QUQN3EtzilIHGqDDPTAhHIJSi4a1X3wKNNhQusEU5CrNYYnLxG9qcELNaSQvYm5+1k2ItppvyGwCmkP5nFCxx7wlKsG\u002FNm5On2yBc3cAWnxCZwwjXX\u002FcwQGpo\u002F1cv79Ao3Z7vfp9fj1Hj3miizJZ\u002FvXxe3r9+04T5a3ySXd1ZE4A2SnluH6DiHpk0xijJk0V3HeWSO2gZfT8pfDIFOfWk\u002FAawywVdO9fnZFMraDaIm1fAH9lGftocKaNNza1hQqB4Eylgqy7ANc\u002F1cox4RwOQDghAB4YtQHdqgDfHhzKioz43roe9KyOmHk8bsGWDuTYYB3T0DsQNCKkhwg8UUSHzv39mfLqoj57pptrYeNTWmprCRoN+00ZdcZ\u002FxMMlwR48ASa+bx8tjHA9Uj37TAcZksr30nD6OR77P7gEGlascBwsBR+S0drgPWPXrGJQUdvfwzI+3ONoAkmwpq2aKOVX4RMSb+1\u002FGQ6+Lk54GKkPjK23md7\u002Fx6lq5QC9AHB+gq\u002F6RNsAgwPPqpfAHxS6DBX+Zr8bSGAH+2iRsbOiiHcatv9kzEm8JzQGED5P9wL+wDA40slKbyB0bzK2+ArYPbJjvP3QVWnJWKEny6emb9GBPaKsxRV\u002FgXxuAYPNeO8Sj21xPZp6oHXTIAq71H41bYY2ayaeAc84P9ZOl5DBdQ2cPHZJFXvNspJzxq3I8apX5QvxHH1jB8NcAjf7Bc1ujhJy22khfool+Llpm6M94C73tHJDCnHZzsDAk9M942Ttx8rQxqQ21w\u002F2PcihZYW0QRoeNrosWxgIvaZtxRD\u002F8YTM\u002FObITCKc\u002Fdw8z+ioLz9ANnGTmsjYdZHiuVaqlWzk6hM\u002Fov+scWSP3apvn8RY57neSTC539JO68VKrwZJqpBY253Ns7j+8m14opMiFnn8TiP\u002Fq+ePN7YxrwJ2+vfbue5trj95rRTbjpfHmILQ3g+PldWM4ERGtbqs7rB65FUQXWImI7+tnQ9Df6r\u002F50rf+jt\u002F8dvxxBOR86R9xIevBysH\u002F\u002FSnf5XmiD3\u002F2misN1FQx9yz+WN\u002FX50by+JfKM397yBXV+qQMPOW12ro++03B6775+R\u002FtPzv\u002FutcP0br\u002F6X\u002F472N4B7zYRCe7h9islbMaIxOCQB4gQmETnoSKQ4oe98czzLIHMDEquhLIJs2LhNihuKomDaDH8ypVHi84zzehRuj6XSgB3ia4gQ\u002FAfrxxCWZlTlxcQgb4BUAdNAQsbyfeGs8l4NHFhOFFkAaQUAeqXznivD7JV35vYsFL26ddAXXZT5T5s5\u002F\u002FZNoGWO61vMg76wAiG1Z5BkdhNtvEytp06eQygJcA1RaeUhlFTHZx8QSpZ6Qb9Kcz4hsJMnTGbC8SnGL+0Fq8stzihAbhe6sY6l\u002F84qebv\u002F6nfzWHHW091Tb1mcCyvDAOKC0TF7hTH48b4XGQe0SYhfEgpHlkHDbE44z+eB5gEkdqnOXFfxWt5HOnFCcGtv7jDROJgsYXPDjaSggtj90CrNpnw6YNhdoERBK+PHfqt9+AkPYcRTTeoa6P8o0BFnjgBWII8gCmFOIPdBSr\u002F6iybazq4tCZh2pyO8c7h\u002FGOTA2WLC\u002FUl4uFcfHO23W\u002Fd+5idMn4rH1WEY7K3Sskg5GHFlthqz5tGZBY+2kBQpriRVMglqK0YVVZFIFnvYB67SZiCFwBEICkzzxmdwu\u002F+vSzzwo1azUkOlA2vD7bUJXZpMobTnHGYxTLhATgrZSGcrXPPOzj8BJRqZx1\u002FoCMNlLoAdeJPO2KF\u002FDYLJGTkp7rN8Yg2uHBATpdVgfPlj7hZy90GOUz3xYgUXbFVgzamGvLaHDR\u002FPWnngXw1\u002FPipfGB5zRhQOEx3fDr1hjAM5S2axP6Eo8Mb3evOSpEz2mKrqGP\u002F5Q3fz2jvehEyZqPBLqypo7jG+cZdSYXANjlRKgMZEUbf80NbUqiTBlVVi3rb\u002FVb2cCXTEgrTMx7AfDRhTxLZuW0APwn\u002FrZ5KNbY5m0yhYPByKAtHsBf+jPAol+Ms9+XglrE1yegwbj6festdI85MnyU7J0VmNpuXvrbvozz9K06eV3NfyEhVjIsmdf46vSmb9rtL\u002F6OHwY0V3eaetqqvWil3jG4jMc8h7rHr8p2DS\u002Fpl5\u002F118qduv0pQz3K0DfGpfmkPrxIRmgTI1rBwOZ4ByvbBZ\u002FXOGn293znV\u002FOA3qKPFoeM2EjWaivezqmUfKIT9ANotPoHVHIqCUnjVTY+Unii05b2+oGn8D5acFrN\u002FE8G6JdrnB3kpOxSeGDopH\u002FKqq+8tT4rR7\u002FoKDp0hWDg8w5z6n7GwjqFOgdXPABkz0pfY0iOoA1eILdlTEMHc42hYVVKHeZsFY2eMT7qG16v7+Q5GijjbHV5ThiQJATOnVA3WYHOaL4NQyKfXRvDJXoA5ZPBpYkkpeeFnFQcfObzw2Sm\u002FpADHGhoj5ZovbzSbwaH0Nkz1sqofw68242W\u002FiYZA56Ln2alonu2BuF4mPFM\u002FDIrib1v55QkEjPG0YGBMfw1sqPumGWYAZdFn5EV+tkl46N9WwNty5dbmYxH\u002FbnuucEiPWhuWk3y3KwAVW8M1LjaK\u002Fd0pIgVeobQtc4msYflZHVdDYdd6e9iK25syqPqFir3MgfX80C7NJG3C7F9eLc01TnMPv\u002F9J5s\u002FfPKbOcRJ6mqhRefDKQ7pGhBdm4B1hggdZI8QHRlu\u002FzOQ3X3VR8NwdoxZEW2B\u002FyP9mr9j6Vc\u002FBrd3vxdZu33Np++\u002Frl\u002F\u002F\u002FsXj2\u002FvBb5Xd\u002F9\u002FdO+XNteOxOP48d\u002Fj8R\u002FW5ZqBGRq8v\u002FbueW4V\u002Fd3Guz6D+8aXvPht\u002Ff+ulOT\u002F78O3t17\u002FoneT5QV54VB5qgFYqvJWSbO2ovlvKO2EPBhtwvJIVaOI9K5uFiYeJd2OK3RTSQZkzEGcme5YuMA7IzMSIYUfgJ6At89799tu8TI9HiM5pjU144QGdKN5xxE3IwKIJwGhwhLyxAYAJ3S++dGDB\u002FRF68plPhoMmBiA5cXpZ0zyihDPQucIpWOmn83h\u002F28QBahPwrSRQIPpPsDJWJjd2guDtTkS9dp0H+3oe7V\u002FlCX2QoJIS0BH1xVnXjme8yAGHL9soK9REOMk777wT8C+Pe0LO6aiu8RZ8\u002FsUXpR28OyDOJtt3ylIixGMMm9opHOGtwkluFpLDM\u002F7LX\u002F5yDB91iUkUj4264tgJewQhxITSfPTjjxedu6Y\u002FDAhKEV09ezIhQGjwDt8p7n2AV5ORIH+SoKC4CdcLgX5ZdIyPCf3okY1GKYFT9SfBcTnrn4AGbrVj623l2UfERE3Lrk\u002FGyGCEaANL3yyUBuxigkl4DEX48KF9C\u002FdHYE9Gl8bOuNg\u002FIH2hnPQUCWNBn3iSTp64OnsOXua5v1eY1kOGVjz0wYc\u002FmhPhrE7sJqgoYZu2TtnQWhuev2RAvkzZZhjGZ7wwrPelNBNNEZaSHsMyRULoEvRWfWzGouRsmrViQ8HsVsal6DogOppTnOJvCRB0RhehG1YD8MUokmbrrtzoHSYiXv9uQvWLL7+IN69tPnhPtp8MwcKSrA4shRP9oseA9UabUp7Qm8aUcUop6Ju20r8ylDAi7RVRH2XIsKWct2BnlnC7X7z+Kdk8GktpDvESQ46rR311bGgzQLc5uAQY0ALQAFd5F5vzvJG8wl7aYJx5BgdUMzL6r0sDUk62KW68sPEsEHHYRldeHXSf8rtxFGT3U\u002Fyph5phLPPM5QQAH2e5t4p4xk7ttPzPKGXwqRrNm0M8Se5FgwHg81nTNNA413\u002FBnb5W9dQV0PIaZT31A+jGASmsICxjZIF+oWFoVFn1UXjSm6Pmb9GnO815Kg4Aq5rJCsOotadFlo6zZXhYSt\u002FyzvLsk5FCqYBprcCDE2N6nMZugFFzC4+qU90DvIx7fWXU+sML5vV29WNkXNfcAzQARGgZt44BYsWFfNVnSm5AY7S0UqAcPLhotipGIgcpReC8yIyoykIgZfamjm1bh06uqzs6VmH3VKbPWkDg6kn3TOYwI6gdfR+g3a\u002F93P+Lx\u002FHvlNNlrZ2fK9t8eFPfB+TXl\u002F1Wbrp12j3gqGv0hQ2\u002FAlPGo82OUkb\u002F470TspU0RqttOVmK+W8a9dsaZyFKVox51I2NkzO9Jkyo8V7hoBku5I25UV8RRB3uQcvpbqslQBu6onndW7w4P642oRFjWtsBW3zvYbqGjNQOzynTNSuN2m2D+kHx10I9j2b1sPGJpnTgfks+ZugCosC5EM4cFo0XXjEVujS8geIMVx7rUyvOoStW9TjKWqXMs46fD74B\u002FJu\u002Fs9EaMF6gefZlaGD6Rpx18XMj01EMb6A\u002FcK0tQ4fqwGP4V\u002FIDc5Nsc68xsQprXnNAzAFUjZcxS2zMO\u002Fl9mKE8K5bHPCa0Y1J5hgGGZ+sPp5l6yEK0w6\u002FaYDzMiQHXvqPDGMLxo5vqvf4vw1IvlqxfMjcDNxrSJd71S7s5od483gJ1K0crD72xyG5pzDK+0iWv0mnwjL5f5RxrPt1qlfXRMd6iN5yeXrNaiQSYa99BuvNBoaAB9Kf3Oj+kfs3JvOnLE7BGnnSRDB+WiGNnp+wNzY8Guk7FczbDZmBXYp2PgKt7Q5ctb\u002FRD1\u002FU4+kYrXOq3+T15NejcsPaxSTf39akXOnnak31WhX9chf5d9zbf15jr1\u002FapdUff5p65e90+93vuT19K\u002Fq5y7fvuy5\u002Fe94\u002FlW6Pww7wuNHF5TmVkARJZ8\u002FHI5jAgyhso7\u002FZvP\u002Fl9TNVO7qw\u002FR8cLe3ESF7AXfwYkxYGxx1A7hm7SOYb9SlS1mRS4EzPNw+F3HswHDwLqCUAhKgDlywbXkeOytdjsSflgfAIQWDIhlGtcPGsZ7uuLtzMeSr1Xm1je0j8BLaO0Y\u002FDThbvsnQcaxQ86BOlSbcm4yAttmcgSo5WBJ2L36rc0dufbWf86L9nbtzpR9PrVYsVuDQD69LNPUw55qK\u002FtV18hOJWxE\u002Fi\u002Ff+9hwPXeGBQ88rwyP\u002F35z1pSQ403hY5cK2PK2wPMeQ7mYJ7ApphNYHC8NoEPhgJvgtSAFCEgR4cBglIZvqpcnq1r0cYBUTyL3965M8KFkbLb2C1hX2xfew6cZCqrxpUMDiDRCz2NEM\u002FP66dbQHY0aQN38jaLg7Pb\u002FuKFK5v96ytmUiMYcuac7Ag2VD7KI7+bkLpx\u002Fca0X0YgudcJmGTjGBb7bex5UTt4wtHEJiJgcXkqF49YMTkEwuu7cX5R\u002F9BIzCIjj0G2kzC7WciPdJX470J89flnb+agpDvl1QfICLLrGTkD1uNZQvd1Ke9edlDQ8+dlr0kAEtz4jMI7RSClwG0gO9otLr32MSKet0mUAgBcAJNLvB3R6uWJVjnyhBDINifbeOxwqJcpETJs\u002FhIa+Ml4UQzmjrG0Z4EysQSpXVZwjMOTjgf\u002F4vMvGtODzUcflOWocRUKIYUhBUyRrCXw5V0WskS4E5yMF6taOIyRxWgbIAy8VAc6H7a51b3GZnklqezAbTRHYxv0zN1Z\u002FcIX9UN57gI4ATLG9dyj+RRlGW3gM+Bn0hJ2JwE7IK3n3lSIlR5p1JYXPDDUf5Qd5dzHxlkb62fl1cVpk0ajuXe\u002Fjce0uWPeb1\u002FqYICw22XTOIj\u002F0QAoPYpHDpubxswmz6PmOsOziTxlvI4vZ6OsJmhw\u002FOI\u002Fylu5kWzu89mqRsV1H1DFEAq4xDw9MuNnbgLesuoMgIgmy8VUZxr7CT+qXnGiB6VGBFil0Lt82mFqMrlUZ03oIeTocwXX5wERGUCHB1E\u002F2gAc3wPmafJqQ2UzDDUaWNXmKae+cVqcGmORoZd2ru3aDxDzBlPSC\u002FQCHUBK41NjGApvepanEP155rzIL8+Tp7NKEx2el3JQfWP4db+2m7voivcBTXtKTgbWBq81D2ZlrPEZEF+\u002Fec3VoyA0Vt58r74BVV2ZcZqR6b7e13wovj65oD3AHJpp6drsaB4sIMzjbBMmw\u002FrCBWWi6TD4amefzQHcrn9WwWTU4UE2Lv7oFKdsi9G22mvuo4fW4OEI1\u002FqJfvQ9+s34aefwtT7GC\u002FOHz8Rrty+lslz3jHc6TvgMMr5otVe4y\u002FrdGKDr2j\u002FFIQXMaqsxJ8eEXXjRl49znDGsTyfnhVbiA3KSrDXJVlu01Vzk+R8GnzAMTpU31Yv+DI4zbYS3ioBHxTnjGzKEgTyCrnavFdE6oSP96acxlHll37iTdYXA2YRvJdV4MZpq\u002FswHoF1Z5gLaq5uMUg5Q24\u002F9vH5HOw0lf8a5Yg43PnOdpdFLOdOA4aUFlOvGGq\u002FKwavuxJvKNScn1SPaR3wjDphux0tDzT30JlN4oQfQ9+xwQGQ1DjI+kZ+DUdRT+XQd3qRjlWq12964F\u002FWLvtC\u002F0+0HOzimk9NlL0QbWZdgg8fHYbj7OSKOGqvX5mYl6bDN66fJi0JoDtsvI1Rqwhbjw8OH8fS9bzrgqdCfDMw3YZO8VT2WgRcf4dfXjKP4ZKfxmbFbRJs+6f\u002FQwCAdfx61Nb+aO2Zad6yfj5\u002FXMM\u002F5d708o4nb6\u002FMLPplL3ftHN9MN358+880AAEAASURBVH+Nsj1MvgIb84RC58N6HJ94fhW3Pq9f\u002FvH++4OFvvzv\u002F+v\u002F3GDuBITeGkD21Ve3xzqflIblVbdkQghMHFmMZqkQ8TE1wo1wbxJZXppNimk5AtvvBNqcapewANYxu0mF\u002FgQv4bZV3ISrWHGTycZHIIkSWXG6eVWPl94AWvG0vA6EIqt0bc7aLj8u5TXKpbAHEwmoB8Z50iky\u002FTXYfvNSpwkDGJ0r1dXFjqu3y5zXT0wpOfD5Z5\u002FPRNwrNMHkPsiTQJh6Rjy1dEy8KK9Kici7wNjg2eUlIGTF5VGw6MhDS8ESpECb+kc5J1BcZwARxgSiHeSXWs5ivR92L6D58cfi1K9X1sPNJ7\u002F73aRB44ExiQgQoGel00wIJ4bwOuVLSFFe4qPVo+1CVF61GVPe+WtXy3LSpObFolxtqBV+Y8C0k8JfGYFkyVn7DBRuWuERZQI6+qqcWWqnPPuPgPI8rxODZJRW340vILeWalfsLAUmpAqdAYTl1VjK\u002Fd1i993rT194+4swqQZLfOsvl2995dEClGUrKg6yTD3PSrF41GEzVoHWYSj4V8o\u002FK0RCamRNiUcSjkKE8CcPlP0Q+M3YAQqzxN048EwNmPJUdBgAncLR\u002FoppzMoXnkGXlI0+CBXYjH8utLog9EtdDMtFi4RhAoqHTApD9VhxMT6UGAU7S8I9s+UZHi7GoTH3Wh79FUJhrvGa8rRXc4qg+xpTIMmqBv4wlyn1mG8UoTAIysn8nWX+FJRrA+7q4HiGGivGEV7Cs9NR\u002F\u002Fa7MZjJ0jt+GAXZ9QHqPYdI40WtXPeT6HhWGfP8PEN5plA1epU49ZureC8m6x0gQ29GFbr1f\u002F0lc3zXd+CNIciLrd3m0gDW6E1mjfxSRQ+Pd61r6E8ekRH6rEcLWEeXmj+KOwQAuEX6rsUr\u002FZ1pg2iXel4Z2p6nr3l72IpUrZl+NnyVzdhopS8DbsBx7R0PYG0C5HhKF0BAK8PS07VrwIV21if90C\u002FXpoyq5fWcsLwaqY36yVCaVzRedOF9TOaaj8oxH0feHPe5fpOlk1EmgTfjWxneV8YU\u002FBc4NvY9T94I5VE2Oe0+4Tx4Fd8ZG3Nm5gIeavwAaQPnPnTF02SGzgLswwPGsc\u002FTBy7y7lev13gjybk+kyPqXjxQX7uIv5XLOTB7aY7rBforJl7j7XXw3tP2LT1cYH2uGxvjXh+TyeQXj67zF6w4kusVMZ+B3NFZ+lv\u002FgMdKn\u002FZpgz74ro1zve\u002FkBblovIzheMyjk82bo0sa48ethNpsrp3GzhjrC+fE9VLycpQxsr3QTXihMD8JDZQZ6yZr9iZDGecQsIi30Hq7eqJRDFtAec2TwF1lkrVWavSTcW7jNKltD5hwFtfxnZBMBoIyjKc60AtPkSPbe\u002FX+YAzBElIc6wOywl9dGt7xjHLxOyOI\u002Fh8gXV+MEdqMsdb3nXhYeskzzZ+1sjNkmPG00k8udlt0XTrwfLrSKqw5NUZB7WEEcf4YKWF\u002FZLHfXB8eRZwGeWsgGkc0wYcjD2sTOpIdXvqND4zytm\u002FKMW5es0KfHFE+Gf4oR+WLbGUAXKgrGsIhcKlG0QFRY5yF086uURkvtLu\u002FpMiE\u002Fsi4Jz3ymZqbpN9ci08lJziq72dr05WckcZqObtWZjXPTtrQxhU22K3eObyt68z87X9o8v1fAqtfhyZo00tbfTIX5mUwPb29MPTzS9f91P3z2v5+\u002FNXbmiHrwipOOb6vZ9c191XItpx1e\u002F+SF774Z\u002Fvnu9e2PdsS1tU\u002FbdD22vb9T8vw5D+60BcAEOBZnp8s8cIU7rWpcpbeE5oEL2EKdJlA3xQjThnYFGpCyFby+GFCJnCL+LwANs7ZFBNfz7MLMPEOXEwI2ihayr+sTAMMDArTIFy\u002F\u002FfZuISL3Nw6+AdQBj4mviqkBdZP31tvne+ZKwDuves\u002FgFeAH0wMhhGPNHg+q5fKJpzvNu7S8Kg4PIaTUPUtXMTfmPTp6NIJHiAbgf7946MdtArOCwLNAKAGHhLiXOG+DTxBZmnT4BMFKYPFmEx6X8r5KA\u002FbLTz+rfDGQpQXLYCC4ZVxR7xJ2pzd37xxODnT04b14u\u002Fzrb5qQdwMBFDhvxeOHZdS583WrFWtD6sc\u002F+XByqNukKP+2NlwvJaMj6E\u002FI0ayF\u002FWO1wHLuKJHauABH3rvGlALx++eff1k95wr3qd6kPqU2WSgCIs9KK3fneH8BwUoIGQuKipCXo128vjAYIAcfyG7BA0\u002F5STVpDwNQuQOQxDdeBCHhKnaRkGcUoC8DgiA3nnej5bf9+Y3xIm6ZUHu3MCODbInQ5iix6\u002FLk77VJ9XxeNHmYzWbpvK50MMrm8FIpu+5vnpSv\u002FkSCTDYEYyJUSBjXd6kNT66ct3ieArHKwouOrgQ7Bfn73\u002F+hugNrAS59B8LFoorzt1oENJ4qU8GKj11Gw+vlXowNo02rFsAaY9CJq+bMEjwJ8ng9mDsKglJg6M2SevRiDBpDWVoGrKJh3xmCQIo9A4yN8cxFF\u002FzlPvQC1L3wKK+PeyandL9N5c1tkwlv8KjtdBonBuIhp7hfibFuzI2nMUI79TGIefu3ICzO6XPkSamu8JhlMJCnW\u002FCnPmDDGHdxeJO8SQ1Om9EZCFtG2qINZWkOU+7n4z\u002Ft5xXVf3Mf\u002F42cqr9AtrCtqS8eQjMA81SrLPYpbJWsOaq\u002FlIFNhxSvvNWzYhAtZr6YREtfVX519R3gHoDiy8h4Cpw61PsMVuC4\u002F8w934Efud+P5tROjoLlneQIaASrBw0AP55yvAtkRY+em7HvmuuasjyLPIMOVMnT2VziIEEzCnrAa2Oj7aufC7ySMxoLeJJ\u002Fy1O6QDXeMd\u002Fd7zM6UOCT5rGyeAqf937yVbzrFMfq2q42oB5AiB+0eZima8AoMIIIZ4aP15h7bkBJtPTyHDmgHONnpUYftuBHv\u002FWl\u002F9fv0\u002F5kaYY0GW6MEQY\u002FHeX1w\u002FNe5p7yGGHoNLog2aSNvO3m6Xifm4PCxPTbqKHPbIquTAaClUwMAGTnkpz5oP\u002FjaIoXObJW5p1lKJDf5sQYf5XYbJjxXMZl5feMOYhvZ8wqC\u002FYjgzmSdMd1htBRqyvko8\u002FjIR5DEA8Ug16bxQ5XxejGkV\u002FpNuWvlYZo1n1b8LjmQDwQTegSumhCFOOF2HnajG+NpfAwaU5PJaMYpRXU9RpWeRxypiK9bD4yXKQdZuSRW862kM1K\u002F6smmSXJg+ftRyoe\u002FdihZV6cSm6Zf+iB9wB1q8fkjLBVchHPu0dXhxfo+L7oo\u002FGNK6OlObY2Rxs\u002FvD5OvilPiGpe7OQcHtHsMVJ6x1Nj1HfdaiXjA8+imTr0abdy4RljbH71yOhvMnDqTzYaBDw7vNw7fhunTuOmT+reLTe6ndevW2HaL4SKziDDbO5\u002F2Wrz0\u002FjsHBwTzetcOrBV3PSaP+OsHXsxwdmiGc60QsdoEaqrjYh00NC+yhn1+3\u002F3f252c7qlQfPIp2PKEHfp2s1C88Jd9YMxcPPK9c27nYsCh2ydQPql\u002FWSpl\u002FFDch32jh4MB2Gjo69aNcXD67Wds2SZe7+7PPTyde787n6\u002Fk7rbf31fr+\u002FurRCGAb71cvf6z7XjK97d9GevkReu9dOSmn92w599JbW3jZ62\u002F\u002F0i\u002F+yJ\u002F\u002FivpO4P8uLVNWD3yq5i+eX9996rc0Dvva7beAhMibGMiWJkFvULu79jsOIwluAL7PAWx0t5IS436Vf4hs0tI0hrKWV+q1zbhPTdQB\u002FvuZANcfGALkDtgAyesAHnSYPm3EwuAmFlgLk3AhV4WadWxpAJskRJgxfjxElSQppwjvHVp9NnOlCp+GTg8qB+8IJS6kYbuLjYd0uL4gN5mM5kqhLi0jACzMmCEVB2aNtsybsqnGHzeqXJGmBTnTJDyO7gfoJWGT\u002F7+c9aynqw+c3flVUl+kzmnOoDuLb5we2qJ3R5OS1XzgTcEdNYZpQObyhx\u002FYS8HCTs3rp1ffOgeXTn29uN0eHmZ7\u002F4RSe\u002F\u002FmTz73\u002F5q67dK+772xq7YjN5wUwuY3KQYEAnwIDgUD8wox8DJovVvNvzJiEani8eX3gTwA4YG09\u002Fwm0eZxQAhrKmMJBkdzlMiDHwTAtAgueT4DNuFKqxWaCRELXxySEltbR+E9IE3tYDqD0LuL6ZWPjf\u002Fe538eCT4vrf2fzk44+rt8xBefNtmFme3\u002FgzniSEZFqR5vCgZWTx\u002FerYLy5QPtvzhTI97sCJ+8X3FfBXm3kVW0mxbJwA5ulkGBpzwk87KFceEsKMoSjUhyC\u002F35g+yVAb\u002Fim2nLCn9I3veM1814\u002F4MCJMn8WtO3Rip7hRAMweBQdFHVYfYGYuCPOhqA7qA8WrXvSyOkEoTix8Y6pehrPfnVEwB5L0nZCdg1V6x5cGf8V2M1IJYYq1+M+AnXAOrM3rC2TOylj84DGgTWYjgMO48LpRbsaXAAesCPUR8rXrTN+rcebtCn1ZypdBAVD22LwPWKjMUbLTvOV5HQObsk7BaqeQlt7KHb4k5ijAaDepG2ubtvd\u002FNTaf+yMnxjuHBv0uPaPfu6uqhdos0EyBr9CWaBrAoLi91OI5429jMtp6RglAAF1AmK+wl9pZ4VZlBvzW\u002FwFu+H7qnKemTehdE4qFbY7UJ7ze0M1v5KJQNrRomg1Il0sZQDbmPN5jsMZTc0\u002F1NKAjT42tNvRl2ul+9wxY6PTPAR\u002F93BDNmFvVHE+5ZyrfXLRSx2BDW\u002FPUC89Ktau8UcJVabx546rI6IcG0GEZNQC9Eod36o\u002Fr+myc9dUF5ZCr4dCuGZ8uN5a6o73AD10CqNEN+rHKUbKXdw8d16k9\u002FaH51thTrmdcY1Rol1AyoNwcdl0fURDPbo1pc8685nn126wwNK5poKHrou9q68j8wJF2v4p+jC\u002FtDZ43L9F8jcUYhA3yAX7Q8jqMp\u002Ftn2ki2vOY36LuTPRk0L5NbPOtvAnGojNfQUF8Yb8o\u002Fy2Pds\u002FrEOaKck\u002F3hIzJL\u002FWS8Mx4OnDYdzdFWn\u002Fz5XQNmJbH+mcNktT4MSI2G7nlZ8gdgV1iqlMBk01aPIBIv\u002FunXXaOfk29k+ZQxcz0DsnJfJn+D5sNz6rESsDW8Rp80DxESH+MTc7GdWAPQl1MpWnV9zcEq7V6f8Qm8i8fmr\u002F6bPPivS+MAmrMtIrxTaLdZWeAJe\u002FCE9jovAq1dG6AcfWEP\u002FDH8jEbxos9jnDUWVtt5ucX8G9SRHbVv5FI01Lahb+O9lSkcU\u002FarmUt47FShb6+EtXUCMUNG0+EtIaT2kb1qPu5yjsR\u002FUh8+zTn2uPBj9pETxaussbcKRteEr+qvUJhcVc2nk5sLgXerh4+++LT+hCfCI0\u002FTIzuFAF4s2YU49mf19UR66N13PqreM4Xl3ijFYxvfGzs8d1Dyj3rSeC8ZG9mHtuSfealSOpc4GAGLITw547hkyJYOrotVh+e2r+8\u002FdWW+\u002FMmV7W3TFl\u002FIxe9ebt3+fXfx+NqA9W7uf\u002FPm+MN6\u002F+N7j69sa1X8d5\u002Frw7y6sP24Lvxl\u002F0IAP8hrJpKNOE1qAuwo6myPlTcZxgN+LDBMAqDSDnibDh8+SvE36RymIhbdBkSaaUBxzxAoug9YW5Yz0A7ckM7vURsFb+RVBny3XlibOUxkwEB8GwFg86V2sFDlaEdEYFw2lKuWBANIs0yfkKFoAUYhB48K27n34KvNy1Ibzka9wLk0Vtrhd4CV5SuO+FbxzZfz4Nvg+Ou\u002F++VYtwANL64NllISUeSAFxBxLo+1XdsHTbLFwIn2rgPAIxwT4rw0szu\u002F9gIR4s2Acu0Tpyzzi8kslOVinmKHFcwG2\u002Fq8czmFEB0IKF7o\u002FQnD2Gw+Kk3mBx2mdLvDdyhxqwrSK4qll75SrvNV5tqAZDNkaKuxMc+X5Q8wvHwB6CxgwiN8sdj0g8CbJeHb5Yd\u002F\u002F\u002F23A8NOlrNMvbzFTqDD1QDbLGn3fiEAaWIAz64zNswTfZ9l8n7HHxctzSU4J2TgGOCg24D6BANx40FCeiz2pBgBR5Eae0BdeXOKaJtmCFJx89ILVnXPNzbkRCsKLwpvedrpqm8SQngV4pM\u002FXThJRxj1x2vigBbKK5AZ\u002FXlW8Q7hzIDxTphTJJY+bdwizAloOdPFd198yUjMGx5fic0XevD0yaO8m\u002FYKABWU+hrDiVfvmU3pIYFsoREnMrzQ48ljIWKrTqBigE1tBi4Yj4DFQStCDr8C7pHKPOXNpyjssfDd\u002FgsCc+K3e3YURjznxMtm1ew9AWh43HbjfxuY0XarsMRHBh\u002FmGoBtGXUMquqIxGNEnAokYAKrX5FuAaXq5CnDBxMKFL8pV\u002F3G0GdgnVG03xwdGvebco7Sutulf7TmIVLXyea\u002FjqqDocA4Al\u002FOKLv2m0+W5YHP8doCfs05tEvN5IGKI6p7672ctqVYgRsrYONxqw3GST3oNoZr5S9FmxKucnWvEheoqNjj1\u002FfKCaiZviCfT+iAoymPfrN\u002Fwv4Mh4rheeUDLRMy0b1AlhLIIoDDZmXKztw2H2jF2RDXPXgRgWZukBONISD9tHtnz0L92IabjTHXeAN+HAeRLMVen\u002FtvCyxG5lcHGlotNd7q0iZt1UbzpCemTvTkjR5QDTx0hsbQqw74DT3138tc0ZbZoBctx1HQdX3dCYiM3KxcfK4PPTjzLQHgcV+bI90NFPRlGRfApRFe5eCtCbHrfUJlos\u002FQqN\u002F9RsavEITmXiAYff0+wAJB1N\u002F32Y9RHeab39Trz\u002FP6YzwYk3SAyjVxGUPxVPykrunXzONjL3DX0EQ\u002FAGVzmxyqGbOJcYzqfuPVdsaHPT5nOujG2C4nSrSrTmPlT8iH8p4+bo9Qq3oRd86NQOMFrPSPTmvDoeyEfSbrec+1n0OOvMEPwDGP8NmzyYJkCtmnn+4v+X5zRLy+xAlLL5EzL3K6GQOGg8wqcn7jk9nAXOfJcnQASo3Q6eYwelk5tMqs7pP1A52EpcAV9DuajzMvuut7hKqF3pbcUKY9RePtN77JKbyDvyb2euZaPJUxyrs\u002FoXxoljNmjGFjl26iLxms9IW5zbHGMfgkh8jJWV04mLbj\u002F6UL6Dtjj0e3IU7pquruYnxDdpmPzY1o++ZN\u002FK5znWzhHg6emdPdJ\u002FzxYsZgMQJ1jJyS+lgmuMI3zyaTWwmyx09Ypv1xR20O3i+E9nWZyXjQzweq91rJOlW\u002FDjKuT3S41xv6KP260wbS5dyLJvECT710zCeSN4et3juR9U36rpvzzmdsBOr3M+bU+\u002FLDD5fxkuPLarhsVWQe+uBbcmHJIBn0nOjanI8H6V3pUtdcJ1F0vL\u002FjuePZGURvQ5P19bvLfZjrLvynvFQxdfV8z5KxpO1cnXq2lTESuuyeeeup49\u002FnueMfJnKgz\u002F+pzfhPafIPBtS\u002F\u002FOqr8aLb\u002FCkG7W6bI4Wf2ABncvOkmzQvLKk30CY4UIAK48WKApQf65S1\u002FzBgDIhTziaUWD85PwmLlSJRbuFno4QpBpPHshJvLWHAk\u002FTpZ19MPOLNTs9chxN1THb1iC2jZCeerUnCmzhKpwls5Ch7KRgvXEygR\u002F3zLQHtnLJc1UDVFsAbSBcjrS+W500ucXyUhWOXCRAHm7hXPwFNfeFBtlzo9ExZTHhXHSbkNwIMsM+mr+88Vbzn0hy+nPzbP\u002FvpT6qPILBZdG0ctayP0Qmzmfx9\u002FraQn1cJDzwlxGCyD+QFE1vKWj7sZMQzTUYxiBQrg2qn+4TnvPPOW4UlFSZyJ896mzCfRvcbAfjTCf+m1TDq8qoBIzFy7eap4b3lDZZ+co2RUz3LDlMsgNh4E4OX3US+9fY7KekyyLRJlNdboYRFEiSarbg7SgNvUHSWL\u002FcS1DfaMNytKRfyYnnVZomyz8JvKNBJ05jwxEOEPdpca7Xlb\u002F6Zw6eujncCSLCRdRRqhclHa1MwwfJMjvbG0ebnJ89Lt\u002Fk04P+8tlf2lUtlB2r57+yZViguFH\u002Fe8duvbMgpX\u002FdkR6nN+qGvFDUw6VwBHq8BC10bgK0L8RFgfzHeOTxM0cS7gBlPFjByq+w9NlDpJyO4YYpOeaBSrKfU07P6R4ExAk8laIFx\u002FaaiKC8GIf4ldI2RumevQ0YCAQRArPYk3OONexlo9lVpO088UEEBAylnGGuVq22e22mT13jBpo6lhCLfGNCeAwZkMKnBA7w5Yc90KM1u48mjL0WijDs851cymswXCstyNaA9AKROr5UrhoHxRQRzlOED9FRhSmeUgo5GQeIST2OUMdxd77NrgKZ7tLvmzWmq5zO6j47Mz0BOfNP0HVrMKlBQYb\u002FybcQCSvA1ei1wWEmNIbmhHfh1AFj3zTysnqWcgWkepuUZ3cq6eSbF\u002FSrFqowBY\u002FobnbagSb\u002FUufpE+S3v5lF1uR\u002FP40srIXrPc2r8yRh0ATAYzejN4DN18Kbx2dapPp8p0zFWXOgedZ7MeER38ltf\u002FD4eW2cJoEl3jtESj\u002FCQjnysbmCGLH5+auWD5g3TFl5VfDvgKCPfC3gjQ9EX3eavvqGZuaufeGHGkFFNPjSOyhMyaf7PXKqNcrEP+O05dPNizExN9Yv8e53DAF3r9TyH191T0XNteDCDCC15\u002FcjzMQ4q08qfduzXNq81ztUxPND4ALXVC+Qi43iIk+eumzNHQhVq\u002FwCj6Kd\u002F2rZtK1lOZjBgPK9dO4MU1iqHUJIxLptXB30GyACgRW\u002FGuP1RNtozkHht1ziqQ3n0GpldwRPuea8VaQe0WYE7m87Cz0vuMgoCetFoC9S9K2RGfcrCg1Yv8KuVQ4DPykDFp0v2hOUFCicbV\u002FONsUbv0bkvOl13+KMV9VNnyIpllNubWGltdEw2RgeyatpUO+jPtTm1vRnxsjkolBOt8ObzdKXy8fY4TKIRvuGtN5cB9ERkhkpzjD3XfyOTq3EMSTKlclaWp0Uv42I+0b\u002F62o+N9ZvlFY8HZCPDC7zkxoGxxHEmhEw6Ss4x5z+M\u002FI6XnL1irAz6yGeYoPL6Z\u002FAIGajOcWDUlrMTAsqpZ1zhnVbL98rgczp5HEC3r2rvHKcncG++RMt0xEGZXWwSfd2q2JxYXMcvlNzi8qX2OlXmQdftTxJFKTML51nTbHDMOLi6Fks39s35nGznotnryj\u002FfIUscXR3GvXkYTe7f\u002FnTz6w60e3j\u002FdhgnR18O0xvtUeTENMc4SYUVPw3HwWVSHL\u002F9zvuj\u002Fx0QmHQ5diSSVdU3tCDvjA+yNErIUzvnQm9\u002F8jq+7t7\u002F2Jf5rizP+DiDMQ\u002F7MhdWhccfv7t2\u002FJv2eHr7rO\u002FjTNn+Pu\u002Fb36fgH+SfHwyo3wkcAn57exea5KxEcWI2OzbhgNoAPEFt9zvFoKPjUWlC+by8FFn8CQ3H7qLTVpBhaqCY1c0SZwgQMs9jFqDVAN\u002FpqHdC\u002F3HLRDZf8vTdL0Ye2LxzJy93m\u002FykhuJN\u002FdGPSsVXfPqdsp389pNPNl992amOgSGgR4wzprl\u002Fv3SCuw+nToDo6rUbo+CJVgLapDLalOccPlK7gaH75SgFbMRPh7lmgqMHy1xcHi\u002F+AJVoM3HAAWox6xSC9itrrRy06bPvhLd6HORzOUDzVLgQcz6iEZAO4rHBlrC416mmBOzLYukIGEwmVl5g4k7eDfH89++uE0p5Vmy2tZmUMfW8ctX17jvvNlZ5wROYUkY+uL82PgKzp5vkxgp41E5\u002FPPizaavxfvCgrDVZzBf783pUOsqDLPqb8QWhpUyeLSkO3wmsy3rCcCMElUPBYfzxaETf8dAkuAg6Ro3ldIr7BcOiovZ7P7TM2z2WF0GR4RnM02dCD0CT49vBUO++916nwf52cpc\u002FaXDQP2k9gO7tgDG+O\u002FMkz3uHy7w5DFSUCYiAd++LNvFYGjwXf4tfH+\u002F6yQubnYysk8IcGk\u002FeXis9Oil8xTLpy4Ts03hwCx5fRSf9XQCBIrAkbTNdArFnrBgwpp4LpSmeO5kZTwKjKc3qP924rvSfy6s5YDlPyena4XwBqzmEetpihLKYcrRxDZ22wMQyJdDJWAHEbrSngHEqNIkH52XXKZ792vWm509HQ56vN\u002F2+nzLCM2cCBMCLMcG\u002Fp\u002FcycOIjKwf69aL11hNtkJYCERAbvu7+AanxKw8+4Ce8SBsN24CWmIA88MwRD2bLquYAGpl7PPXTH8wyL170wHdlmMdW5TASY3aWWCtZPQvYV\u002FbxXANceOWW0bOXsq9NLU\u002Fzks3hH2henZaQ0R9IRLMBhs13DR5lUuNcAzjQgnyjNCekKvnAo8lY1p8BzNULhL2qHQelMpzQn54DPvQNLZRl8AE8bQAyAQsgfoBlcnAAHznQc15zb\u002F0Exn0GNvWVIlEHo9ocUQY5i96uk5\u002F6AQADSMYd4MFb5s7p14VKVA4wIiRBjmy\u002FLVnd6uOb5kF8cXavflaOcQVIhs6VOQBROwNwVp6cqMww9MI36EqOAaHfeSE1Lrou+kbq+rAUovETcmMDn54KgTs2KHq+B6Y+RlNPD78PyBpWUejx77XXdffwlG5pZazIdPJzPMnRc0sfzp0BfhuhjdEmOS\u002FbCv4BYNDVSOi3PuEDoXBWdpUFI8sgRQ9ySpmL6D3GQeOAnkXVHfPQMZ82Z9HePWixeKwy83Q6PGgdfiYbFv5g0KwVIfMA3xhkPEW2cPqo76i6zHH7ahjKxuNM8+BN\u002FIVMi5\u002FW3PLZH1DH283bfqT96cplUDQGPbeeZIxliAUgTxZ+cTqds\u002FTpytn+qFA\u002FySVsEMWJ41Xv8xjlXVGevyTyyL2KTS\u002FUoEo3tOOUicb0GX1h3AdMa9PQh+xdOpd+XoY0fm8u1XYrMFbztU\u002FYlGeH72sDw9\u002FTc+Bi42YM7SmTVc1hQHTfciqts1SejJxrXHsIJkBH42ze2XMzfFs55vLgncg5fN49x0\u002FUb4ZT874+r5WJte9uwpTiPyFk9lMxwCQpsNJ9kDHyOnl58qTDGp3EXv9aWX3d\u002FXVysI85PQ65aIJnOdA4c4yFPPIn8HatjpJjFE3Io3GO3vPqMwffQby0I549Q+BUZVgdn9PQ68OuSIPwxP6drzZ3OjX5Ybr5QcbJ41tvz2o\u002F48KerQft5XpQ1AOn69lW3B9+WBroj3+6ufXu+4Op5rTwaAeMczCM\u002FD9uBy5ZXLht2HH7\u002Fv+8KWIVNvPuHy5iW8\u002F2Hectzp6JtC2ga15Nx2OZ9P39q9y++219+UH+\u002FcGA+nimYgwWu1CSpwGXb4vttgEDQ56LUXjnJrbuWJABYJZatwDCZouJSw7cU7yU2iiWnidzCE\u002FC9fWblcmCgLSxlFHg8BcC6WpeV5svH3SSJkFkyY4Q40UVVmAT3wcfvD9UBnCBZkqFIhQ+AmCfbKPYvtjj+vP4CeARCCleS\u002FspfAbITKxR8ryUDIuMhTzRLEifCRWTHWiWDYWSnPj0ACdhCfyL0\u002F42A2MJnARHjGrJTRuADAYKZqC8HHLEC\u002FnyntPXUn4JH6CdlQ4EnmgruNSVsoBcy0vPMFL\u002F3BvAI4T102qEWPB9v+V9IXyuXb8+3gJhPpZObQaVlg5wf9r9+rBzKgu8cowZwfPksc2pCQDCorZSjI\u002Fb8Pqs5fMXAdTrGRYUr2tOG\u002F2w1IG33ntncr\u002Fy8unTlctovZQrHhALaA8C2lg6BALr\u002FncAA00c7vD0xZnuzTjJYOPlA3BGWUbX4Y9ozQs2oC2hNbw0\u002FFS+2XKra69NoGNMdgy5A5DEW0tXuRv\u002FCtd4XVkXAsAz49A3gYyPCaCTO5a2rRKVdeVUIVLn26QVfxnPAf89dTqeuNiYSaUlT+2beAn4ccgRwSxESjsYGw780genluIRQOdMXpDZC5ChA+g0XAkxnjWsm3Jr\u002FCl6RltOlBRJwKHNrnuvCj1qHB81DvgbIMCrs4IU\u002F1gpYOgIndKOp41NxWyu3bjZqXWlN00pAOa8yKfrKw+hEzpPVs65zj8429jvnMXjLbk2zlaM8AmhZCzmMKHmnUxC5sKzynv68umAlIvxdxO8PuSdjD5owAtmrvC6ooH4WcYO4MS755RVTDB8UkPNHXQDnvTfnxsAN0pSOcKBtI8iSoXPHKroVXfzfDyyPWP1Cr+cBLL6GcjYy2M1y9kZGGRX3Y3W2pzhUEwtxQqQUSFTTuWpy8mMLTPUFMqfx9c4re8DLLvvdHJtQHL3Gk\u002FL7wySaaB+BEb1q6cqcb37LOwFEMD\u002FQNMYOBWAJkKpBkg1TkDc9iTWOfq7NgNUb9r8ag\u002FI8xQsUAR888rpg3kECJo\u002FaIG\u002FnZUw4xI9GNjoTcYwjubAnoDOofkZ8LNPx5icKXzlpP7XJo6ZidttPgPiDe\u002FIAnLuVLx4Mr6zIomvzUH9Jx8H8Oh33\u002F3G0+dzlypWSEMhOujbf02rAZvi8wcQJ4ss2S+eWPzivmXwKH+BMtyyjK1AYfRSnnCB19HVs68F8\u002Fbq4zyLxsCDP4CeIPBZn53NYXXWPPLdSsHpE9EGcIwf3Ye25FqldN\u002F3mwxnDiTfgEmnEz9KRmgXMM2gHYNPnfUPwDO3zPmdvNbkD\u002FDGUcVTCRii+xoHbRfCs4CoMWWMaitPrznmJGXjMu2rDvwkDIbptNvYoid62b+gTM6K3Kubg66TqSdrD5laUdW1XV1pvNCyMuj4qp2\u002FCDxzmTxmHIyBHXcLedHHCm+UFjCmW6z2vmleApTmHE8+udsTQ8Phi5EHcUv1KZcO1+ZZta7vYuXJFzyLTlwA+Mh\u002F+rPSQOMhRvkypHus+6qjuqz8vsqxNvs70h90\u002FuGbdNMFfc5xUFmemxTUfR4HT\u002FLx1Ol0ZXPEeFuRHGBM70SM4Y\u002FqPtxZ48lwOyRLbEpP1qMCmWfFwaoqoxgd6f1J7Rk9AHBx6fuFrBD640Wvna8L\u002FROSOuPRMxFueAZvD08WT67dI1MbD06D2fRerUC6ULbh82P5rCB4Yb\u002F7XhU+E8d3qTkZh+x07XR17nX9vQC836zsvHqQ0ViSiv27d5r\u002FZ5ON+uIQwGeDU0Q5PD91tlTLDzZ3v\u002F5q86Of\u002FtXmJz\u002F\u002FJ21QLbNQ80D7ZoWjsY0UMxfNR2NWk\u002F\u002FiFw7yvxf9ufSGenz3w3HFbugill\u002FVHj9khLrg\u002Fn\u002Fo5bftE\u002F\u002FQ73\u002FptR8MqN+6Vd7yQicIY4B7hFVChkBYk34tryC9yUABYGTAZsBt1y7mYeXNYVGapISAF4VICfPoqcOkA2YxIcHy+NtAScJGFhfKzCQi9IGIWG4mNGWjbcD7r371dwPsWY2Ep4OJtJdSu1BM3e4ZcdUxW20xqOqgDJ1CagISfmI\u002Fxd5ZfptwFYNYXYDkxB9niT7pmHpgExB7+licV5s0zj1uPAGJPL15pOv2DP5suowjLROJoSdsTNIeH\u002FBsE6E5iOFv3271YLg38B2thAS86Qgysd2MCEqAIiS8\u002Fcn3\u002FjoFcy7wffKG1E3dk5ACiC+0iTFpWV8u11eKWvhN4UsZALzs2yPvLVXZhIeDCZllsdusuE4rJYiMtXg\u002FYJ2gvd4kZMRYaZD15FRA5UxhMDpMYTCOCAihJl7GyAuN3c+Lrh\u002FADOtcbNteBt\u002FllA7vztPAsXj8UWKVx+gY4FWZlBVB7Y\u002FQZqz5jQIT\u002F40vLMuejwb70dTm0IM2jMpcJA8w4fUysAbUSDd58UJKo6d40A6eU6rxXiFKZ\u002FMcORTpwuWWH1M+pxowHnIy70m0EfaCx5YHMkXNWxevWXqkqBg7NrXKWDObhlL6o+TLq30uXgROAHb9YQQDtZ7jfSPEGLpWIl63LEnBv\u002Fveu5snF54UuvRt9Hk6yvFc3iBAzJxCD6CPYtNG6bccVOTwjBu33q1EoUCdKVBsPhBBqQMIVxvLa60q+czgs7TOoziKnJDtP+OELSlPexwep\u002FzF2\u002FvDEw8aLys\u002F9hpQQjIWmeuEnP0T6lMe3thuPByA1Pw\u002FTJiai0enwAnhKzappmC6l2ww57eeYOEyVoxO1N857ro+CRc6U657yko56uWhxUfmC744mfKzEds48xBHqhSN+G7SGf0ZCXknJ\u002FSs3wGL5p45zPPEMOWRG8+j0ameWjzyTqYWL2CM95XA17fcSDOW9rhM\u002F2qLvpxQdm1ibA9Y7X60UYr5tO3reiberr\u002FGg7dW36UgxGc7tbeCSyvayljPTR\u002Fik2mDUdP4moFHlWVFAaBiTKMz\u002FuIw0GC8w0QJ9de2+Mg4NGVJM78rY4HJ2tAzeHdkaMqdbETGdVR5DoLaCIBMRqhq0jfUAsTwJl6wkb2maX7Awtj3e\u002FQz7kfRC8AFDLXTf3ihR6YfQMp6GQdAhlcaPSu7mwCPMQ4qd8t3rgOirteUkUfoKRQBADtxMgM1XnfwGYOU7LIaZE472XOl0S1uOnmD9vQcmQMYqR+QrJnTHmOB7xhus4JlDhv7rpvH+Kxbh1\u002Fxt+eFcp06XZxwbfBde7W9plZofcL3ZckaUNac8TtjhOwx39BIvYC559EacR24Zb7KHHL95rXojjZWQhrP2uwAtaNoTl4bC7RVjs5wuDAO0R7djHMdiev7i96rCqBf3HnGYT\u002FDB28q+9RO5c2YkR1SEjLskmP13b4oY+RME\u002Ft3tAk3GFb90F\u002Fjin23ANcYzV1VYtVR5fiPs8rmV6uOxsN1c2\u002FAe+1ZdEqG9Rv5Z\u002FVCGKtEDXSD++gaGyjJBeB\u002FzW1d1Ub1SSu9Dsejz4wZPaYs4+5MhjHY698YFzkCrU6kgGbujgNMm5JHgL2xGb0Zj6MZnIG0+624Pm+l9eyr+vK8Mjoo7WwbQPXP3KMnyPrTZ3IeFZKZu32NX\u002F16lRGqDcJharLi5qV8TlDXRCKcaiUkW2XlbI+v3cgQeJmTh1xqkmx2AupWi9BsX4hMOmQMl1etttKh9Xm3GPeasrlwJR17WIRBZyc8bN\u002FXp60OSCSizr\u002F+5\u002F\u002FF5mK0ofu1G92WXFx8ZryHAMdt\u002FSHejDcu2r58Hc4dOe\u002FqcPHxHXFbN6DRPHb80PreRffObz5\u002F39S5d12a63\u002FpPzv\u002FutdfWojn\u002F83\u002F8j\u002F274ptNelt8uTxxeSLMJh6We9AmMl4s7ALgJtiM4FmCS6gwzO+hFUKJQFBAGBaQlTsF6FAmRHugKMlwEmF1XVLgbNZtNbYyGISPywEhnAR+iJfLFDES6Hsm4XCXCt22WftHCu\u002Fpbf8a33vxLa8fk4KZQQsJi+3edcIFRMRgBSGI2OIZSrGgd+ArgHbeR1Z6O4FfmVFEY6jXWK3nTi4l+f20qWV45zw2QoQ3vLnCQoePmEvlzJkKApKwsahptUIb94vnpXbt78pnOfu5ne\u002F+3QEr5ANoAqooyD5JCaurwnN6BFXRuBZmlKeiX4rsPb++x9MPnwe5qt5UWXGAdSceDobMTNGlqctZZKmpJSsVqDhhUCYCTdCNOGhvpXvvLCJbgZwAXDjS9iLY7MplvCyvwGP4B\u002F7BijIAbXdZyWEx9qGOsvmL6LxfqCPklteiGLhKkdZ+JCBgE\u002F0fUBIPMTKdz9wL2Um0GszIc+RfNXPOzxIKI4NuFYbHj5IOOfx2C0+fy8jRyzn87zR4til7ZsMMXm5CbVZCapOhyUxGADSh1YTogsxgE8pbsZlM2HiHoF1HrQ5rS\u002FaA4+E11o2L8NA\u002FDFepdpOGOgX658XkxdHWTOn8rrzkps3aK3vFDTJO+EXlYmO5pF78Cjv2niPmnvqM4ekqDxVHOH1wmBuxfPXAutA+\u002Fl4+EorEXuWXBOq58syc6HDuqTqepESfBaYTfcOmBbzKjuSjaayEVxubgkB4nXXlzHam7cT99n48PaZV4xHBuCIzIwAvK3PxnC8ol1ZSnd5F2cVq9\u002FcA3QYW+8N2AA5wHWJ4r6nNGRhIWP8UYLaUmMqv7cKmbCl6ITGeMYYAiiA+Hgoh4YrzIExx3hfS\u002F4LhIy3mGdsQA7wv1ZQyB2x+ub0jH900AbjxrDVXnJsAVW9b8xqhRCM5UETk73CX6adyQ2yz7h6Vid5xdaqCYcCcKb8BfKBbLSYDFHJAqyInvgELwz47n6KdYydeHCW8HtfIGStQGyB3TZLjIoBQwRkVFkFwaID1rtm3LSPzDbPV87+ZeD7DmADj0AkYDnGZ3MREJ9X\u002FdpuyNa2qWv6q97ASDQjw8gcccXfjW3tQsPpqIJ6Bt0AQfQEnLb9cm2Aeb+7x3j4ffpaHcu5s1IxukY\u002FMJ7oGJvuG8FouFZ3OEnQjSFg5QwtkUC\u002FzGt14XXtZJyoT91eI6fiN3y2+L2wjvhk9Ft9WXpJPPhaaTX\u002FGZOMJSFDgC\u002F+MibAvDYNOI+26OPAOk4JGzGdoWGukYNWdMh8KyDKcgidFeoxKJKxw0s97zUHffW+9GSgrz4NYO058n4L1ufmY\u002FofBubIFvNMe+gC99KrgJH4bvWirbbgC\u002FQ3b8lmQJ0BzOljpXnNaf20+pUn2ByNyHStE7sdGPgo+c8RIQuKl5hxzjn3XxrnYJvna9PLwQBW7ciHJU\u002FXitU6IXTCUqMRPWa+2Fw\u002Fujc9aePoODyMQTKV00w79EtfzG2vxVPxWLwAgA4Yrn9ogifMUQYzXYgu6M34w9\u002FKmzFtXOcaZooyQhJfNjZ4jxFNdk6e+vrLeXGiMz+EYhJlL+MN0QCANH4hm6WVnhNKc9yt1SAGOudK5SYfjAse4g5ZjqYVEVHTJjrhRGN2pracnkP1kn2J6hWG5awcG20zWmKZ3WLoT1fHbvfJ+nO+PzytLjJ1EidU5176hXPPyi\u002FZwQgzJv686Kxh7fn2D\u002F+zOOIf+m2VMb\u002F8+U3K\u002F6M\u002FUsNq2dRdG\u002Fz2p21RlkKO371NG917\u002FNk7Ch5f9\u002F6T999y8S9+0Yg\u002FyItQ+c1viv8N3EiBJ+bXhsGvvr4TsJS6bS2vYkAndPGiP3nS0mnfKW9Kj7CzDKK\u002FABxAb5IQyJgMY1uaR1QAZwREnhUZSxDFpPq68BNKgafqeeW5V+y8kBDxZq9end28VwgGoU1RXcIoKdcXz5eC4HVxsA1ASPDuf\u002FZqhNfHP\u002FlRp4u+1+dLk9+cECc81u7wJmszAwC8++3dmYR71ceCd58sLTZ3PshgEIJjOW\u002Fnatk+egZIJpSePVseNYwJIGvHp599tbn31d08+Y8HpMtc89FHH9Wfm5vPPv9i82WHSuES3z\u002F55Hcj9DD7w8q8nwcNW1XcLHnb8LoNVXEq6W6bUD79w2flPf+iFYV30hYph2gvhdRbxZkBIx9+9KNoe73+3m2iy8Iixz0BcXxYDxo82R1jxSZOgomH3UoDkCOLRNpvbeTNSn9aLJtjqi9c+HD4gcFEuFE08uZSVEJQXp8PiCdwH96LlikPO8UZHAN+KwOviHUFvgCR13u1LgDLc2JSK8cGVDH4QJcQEB4vgtjSse+I47CSZymi6xlhjCZZbJ4VCvM6oeqwIyFCMg6JR9\u002Fpz5K9l\u002F5TBjtnyvpDWcarwJ9+U3SyuajvSfy3U53BxIy5aJhQvTYZhs7WhuLg8WBemt3a5GRdz+JXoMofAS9LkU04lHNqq9qtWLV0mTdj73RgO5BiHrzZEWPNaOkAou4l+N5qY8+zs1YdnoyyAmDOowFBPiQrNv3tePr6W5vb8W1yfeIIr90MpF+\u002FgZCbEyklB2tUZW1xEq7x6zCl9CA62pvCGLGByOrRgK54cHu4zbni+S9evNIcuF6Zb3UeQIZt4V53SgFq5eJmRoHwHfOaYpIn\u002FExtEwOPn4TcTLgE5R4viaPn7eqOnktdEeT9tzwyQkooyjqC8eODBEdyCBDmZRJq1JxODpAVvETkC\u002FDECOBFtuR8vnqdGHv1SmchRC9e9QeFR+3vG5OAac8VrD9jRe6Mgq0vPgNp5q62e+ETc0nfBpz3u7h0hhMAPq8E3orVXMCO9xEjU8KzOZq8qI34fgyvyiAjGW3T174AUEeW6xtYp4OiyXifey7p2t3+UpLKrP+MIjIKwB9gX31CCNChR+sLx0Vt7Ts+HTqd11fhaqsstGbgHPas7ElofbrNgWTkGKRdzx8Y3QLqGZIe40kn7w7jXwb3HBPe9WX0RMPqflOIHWCLhvQDD\u002FqJdASQDPT1eDxcv7r5qP6i4+iQ7jfWC\u002FAu8K5c88jvnu+JocPoi+GdRRPjYYzwhbYrhyFBX8mUtBNtOF7sVdAuOkbbX2fwoJ86rWLgL3NAn+3lAcg4cYQIkj0cVPbaMIwBSHTdu+S30zNPPadt7scH45hozLQDj7vfeAJMQjgudhbGqxeBrWl\u002FGbR67mzeaPcZR2OtnPGo10Zgk\u002Fd3nCLNH0BzL8OdI2e\u002FTCHOZJAZ5NVL0C76R2t8a1y0AR+acwC1tMn7J3MEVZewo3EORF1yDv2EiExKxeqf1ZP0h3lYtRN6aQPqy1n1Y9QsY43Ba2W7qoZfyLats2WNWe1qTMdYi4fw5ujqjA9pQq0w2OcDjHt\u002F1n6j\u002FXTa5RxIaK9dzvNAf+XNqjLZFZ4AYhlY0heqY\u002FgVHyQ3yFb9ouOB9jOtUpOj9DWDxLs+4LM1P+INMiZHToQ0waNBfYlWTdsoO5NsOklnG5OuDCZAI9c4osh6wBntPeN8ADJfxpTn\u002FWal6TIHSvKfE2wO6wucmyoAMX1sDu\u002FtlQ76fHKwcvCqTacV2v3kTAZ0NJoVvHjrdPSosJFjnIzaC8gL6Tk0HuGQvXOFCZ7PSDWb0uNRIdqSW7L23Q8TlN45I8RJ7ytcq3lZ6Mu1NrSeac\u002FVk\u002FZqPL771ebX\u002F\u002Fb\u002FmJO8N69+vLmazkFrRrm\u002FWS0K6JOpi2boRkMe00\u002Fd21d0+A+9an7PxMMGdF7ryvGX3oxFJfe2LTsqVycd5K7u9\u002Fn44wzo\u002FNCVbZHHP2rfn1zyzA\u002Fw+sGAOos4vmzQ1+Evly5dmcNkbEz87LMvZhPJOaClgXbcOqAsJRyvumwc9\u002FIysxB5ng0QgUCxEjin89C9Lv6R5\u002FT+g1IJBsAokueFibxz60cNbvcS5lHoQsrnecKJd4Sljfg8GQQAi56glvHDSW3vZlBg+m\u002FbVDpgo\u002FaZDMDzw8cOAZE15PXmq+LfbYp4pw2JOvl1MVbq0\u002Fa3AsnbVQETS50manw+Zb9KKIh1++CDdwMl1zZfJlj12\u002FIp8CnPNIPhZAKPUuKVBxJNUBtxCRbK+Td\u002F9+s2AR1sPvjow2FmnpG3Ko+nW9ommMThSb\u002F\u002Fw6cJkDKCBKbOXygHcAJ9Uk41aXiJGUyUKxDwdR74LwqjcRjCgNz6btf25ct\u002FGI\u002Fbtbyoxuad4\u002FRLDnEBkGwa\u002FerLL0Y5XwnIMyDkkP+6zD\u002FANyPJMeeuybizVwqnw3aiEy77B3m+Wwq7ev3meNZvBRTFen\u002F95Zebr774avNuecqvOPQqY+IeQNzf6ZOtNgSajh4cDuBlxAEDb3fYwuU8u3uFnrw6R7Gje9636Hhqx2Yt7C3kIaBLqPYfD81773+YsmkXfV71wxSU1QTg4WwC8cyVljZTQMDp2QwtKx68BK\u002F2M0D2Lo\u002FRBSSYxEeFCsnsQ3FThInlURoE9Kl4aS+6uI6HhG7cD6x\u002Fe\u002FfReFBsSLW0erfsP48y4G60T+DWrbfql424R\u002FHk7X5b+xcODh7mlb6cYLw0fXj2vEOy4i\u002F1bYX8bnOEEniWgaM8XtZLCfAb0flKc9HqyqQQSwnsdh3Ue5CSfFz\u002FL7ef4Ee\u002FeD9Bvdn89Kc\u002FTwif29xtReOb0nd+8cWXs0F1Qk2ak3jWPgLeEYLbBlaAncF7PUELRDyuDTx2gIXTa\u002F3mdMYbzZf3Pmrcr761uX7r\u002FYCKjcqlgUsZnCqz0hbImr9APIXSNIidhAwFyJIZVnIolGdl3NH37V8+qO4LuCYDYu15H6GZl8T4UFrmJcXfhRGdDHQyAyjsx+TNmmsHAfIdeYHj90utyl3IqL1wvtSujx3sQZG3ovW0Z8zznmv9PiMvXu0\u002FwHnS4eE8yj5ePBmAEJqHLzYn4uWuuxeQGe9b5exSThVl3gON5NWljIW96Cwn\u002FgByTyWvJqPHlM+zHCNULpACMHoOAOZzE35iFYvBqS97GbRi+IFzPCbumDJ9GW2BdKlWj5LjjHVZiMjgiRU2n5MvqvLsLkMv5S\u002FDCGBA+EitCrCQMWTuyvKVWdmDPH5hpl4yWchWZBWRkg\u002F4PHs0qm1kZnSotJ4X4mAuGfzS0hVeNjmfe57cQ59J81ofgoINZ0ZWugAo6enmkLMqhPQxXFq1ip+NyfNk8YA+ICQm4bGvgP7HDzN6Hh+ZywFA9ho\u002FYB8oBxaES+7W9jf3o1M0f1PGoN3kD8OYnOY5pgOFOxZuXfPfjCPjya543f2Z408LS8CTPJ1CCU4V3w9IkPdnkk+cKmQt4MNI0T\u002FX1urB8toyFs8WCnTzSqu4yalJIFA3zgDDAS2ykCMCdgL69ZD8NW+NpTai7Qp1qM3l5b6cs8JY7VXemQ7TAr67NbpGY2PR+Fg34TCxissp8Lp5xTih47YnZwuHmNNR4y8hGWN4mheN22QmqY+no+O9QiDEY5O\u002F6Myg3Tt7uWw+1V3DOcqe3M8bHo9eToZwZDBCrOqMAVcZRxnuDua7kJwGOAHeqxk+aMPwutRZHkfNicsX4v8MA3J+9QMUW5\u002FRWHkM3aP4hWl7qbagh\u002FllHgghAZjx7zff3ot\u002FuE0ynv4f1u4ry7JjSfN7ZKjUWkDjQlxR1d3F1bVWcyBcfOJsOAUOggPgHMinrtWLrGJ13boCN4EEkEAqpJYh+P+Zx7lN8rXyJA4i4py9fbubm\u002FjM3Nw8HpmDnxqHOSWnaI3PzKfoNucoaqeTkvP6Yj8Rx8z+kBfZmu1nBQCaL8+xgo62v1QRjQ4VXJJSMiCz7gK+o\u002FuTPxH6p+miU8ftW6u6DOxgLPhWkPNVgYc3BcDowcNo+K4CCcNDfcJ5pQvHQejZnssZESgxstGd6TWy7rCudxw+zND4k6py1euv8o71aQ5hA\u002FjTE9Kj8JY5Z2PoljPSseqXFDH4Dt\u002FbzrJdwOLVvf2tP4UnHn33l60vvv711seffb51Lrt5KlrvkIETHSYFk77koKGzFYoePfpOmqo5sCLj2Rymkd1kFv7hVHqhIWyweZP5v75ysFjUCX7Usm\u002F83hP76cqeRnDm1V99SGb93wUTcECMuadLe9b7fO38z73eR4P\u002F2\u002F\u002F6vwyjUVZPx0vO2PIMIxqADVQzSgRFxGKYvwEiGqCqFJ2hSSlAWAqPggW8RLlULBHNE0UFNEUvROCpDgqTAInGXiyFRIRd9JiyB5KQ2VublpoIAKPpuQOw6pfJB2JFH5WWTA5LAflkUj30WxqGJSvl0PwNfEzpqdqYZaz6TLmLEng2ICyiTMEOYMlweNYstXY\u002FBqJIMJRIJCDEk\u002FZmLQCCMXoZwYkqjDKRy\u002FcuZ2AdgmA50rIZYIVhfin6KmqP7trVT\u002Fcyrucqz0RJY+RJ\u002Fen5yl3a+PvhRx+mLMtTjr4Axf2iqw9L6RnhqA0KXtSbl2tORGNEM3+xE703ZaaG\u002FETSGTVKOVqpEDF1a5vT5+XrvylFg1O1aL+iU6dEf8uhNjcPitw7OKgMgpSk3PBSLppL4MxhDjY2zrJygA04EgEBxikWEVgHalm9iazjZMkVZQBmeZU8Rcvl\u002FIhYrH7MUnXjm+XJxm9+0G5OGQy4MWSinfrM2K+Dl3IIm3+pHWgC6HEMATMK3\u002FxNxD3epdylLXEo0J+RAEAnClXboAnlbq50nIBTpvLR8dCs6jTeNYcrXQE3zyZPvK2teHoi2ik2hvNVsibvtEZP2mtpN1p4jxGvX+8o2lYErn\u002FwydbNQPOZ85fbI3K9OTrs4Kt\u002F3frP\u002F\u002FBftv7lX\u002F6wdbtVl7ut3DhY7FFycS\u002FH7qe7P+dY\u002Fbj1U5+LqD9syfmXHO0HpV05bfV2zuKPP96tEtODufb7HDAHaZkb9dg\u002F+viTras3bswqEYeGApTL7208K+rIWDe3w0tSPZqXDDN+75KUPcV9It\u002FRgdEVxadvOCmUNZ4gYxN5R6uusYwsl1gAYOQt+ejj0TmimcDELN\u002F2rJUWtcCwDV9kmb6iu8z1RuFvfppL8zKRKXOK53qq9kVgNwaDrnGNv\u002FGb+\u002FAj3U4HjkPR2DfL\u002FRoCXNADb669NSsCacx1ZfQXEETf4VX6QD\u002F7Nt5ezrneTK5u\u002FLLAcg4sOiXhAPJBAABAAElEQVTLK+Wq67qWU0OG0EjqhmcAjfbiSDk6UyoYHkZfKQDoayyib24UVWTE6Hq8DPDREXT0AH06kr7f2L0xkN0XTbwm\u002FbCmyMQCP1ZOloy4hx7FB3UtgmU06x96sjuPC+TYMG9Fzws4APRE3RnyAd31Tn+1PUAc4eelrfX8AQR9NukweDB9iafocg4ROad37S\u002FxGRpo2yZ4zpL7zOsG8NPxABg7KLXP7xwL+pZ+MgdK4wH2m7exalOfgEjzZ6N0F0QrDtHJfNYXm7Dtt1HlySqQa9gJ49ykCA2fmc\u002Fa3Th+5sP+CIxnbpXiVf98V8pCNumvK8aNHy8DqJP2Ep+Ya3rMmO2PcK35Hhr2jCDO9HmcsProczIxzmjjnf1VtUGH0v+z4psNF1jjqIvyP23Vwf6iiD+gkq7D35NKkuwYB\u002FmjMwD5CQ7dvD7AnpOJ76ReCKY5WwA9DXZ0cN\u002FhcfeTG\u002FqWnnEFXrdqL0XQ\u002FNbzgg0iyZyJldZH56Kp1XQOoZW6SWsRzW\u002F+R\u002Fc0XqsWEyiIHmMfIgR+lfrjGnyFBlYq1GSXMvl4ygeTB+DfKnb6MdzCGUFXTjXZrtv9lV6K3\u002F0cOex6EHP4JJ0wdqn2jdPVxtKf0WbhBPKDfznf+jBpPV02urKfNmyvqlXdk16kC+gXjOR6AB9G8zIOesd8LrwV4O7vNQY0yj7j5bCLA7WO0vlvkoPDqhjJNLD5VLU4gVOpOejtoCY6Wz\u002FZ1XlGepDsjgxHQ2Ptq5619LM+Lr3c9TPnWMh3PjfDvU5+aANNyNP6EJ08L17uHu\u002FVls\u002FQxayfXIoOJ+34CF3003V+fv1JK9Pv4fXeIup6K9\u002FbSW4\u002FlX6iVqpScQTCizKgmAjExQSE4BA4BKL4zrdJlCHkkcnNRstZUoyJle1BGkzuM8D\u002FqBANcPVzwGEvI3q5SKSlyas3ro2yYhjVTtcH4Jtg89gxD9oSKKeUzjJTbdoUc1xUARNcLRXiYsDqWikrIuSPqyDzur5f7Rmfljaj3CBBWEp4u3SXjrafmuAxaMqA8uPhuRdjMK6ejyEoE99fu57gxYwmFPjVlonVt\u002FFIu+d80bwbKR001A4nQL8tZw4QjI6UMfZSu\u002F0\u002F\u002FPu\u002FHWX38P4q0WdDEMCsrJMImmcbP2GhlEQ4b9389aTaYEyVBwgehwhj6rdUHkALfW52IuyvPq96S5Ffhp4BoGxPFbVU49zGT1H4o+ZSrvfLnJs73UswGG8HRX1cu\u002FutsiinKX\u002Fu40\u002FkqbbMm9d9pXKID4sk3y\u002Fy\u002FO7gwoB1S5K8apCjjPpxoI5bcbAi8ahUjGevbBaVWpBiz0BTGJNGUnT3VE4dYcebQEAiNJENhtEcnC0lY3snmjKW0cmKSDNQysNyErUlhaWLVATbeqmSSbzHiNsTcenqrRQmoxbf1ro5tzmTvFPAnitiMc4NgNPv+MPJs5bDRQhEXhh1NP8p0CvC9FGbm9Wa9xJZodSJCqdLSganSV649DEA4txRm4Qpkww9JUIxvqh+u+\u002FdY\u002FPjBzljp7v3aXR7m7G9EF0vXWkDeBtl7YH4vhKl8jztt5DChqcn4ti4F11ExnJK4hsO7ShIHWyYG9Czvd245MxGXzTaja7F\u002FkfO79\u002F\u002FOefanomUM94LEHDArIpcv349wH+xCP5PRdiLDMcvQZfGnCFjfJqbVGQ5j6eiT2MKECDIYZEZTtJhkSKH5kyaDMPbtfMuqvb2LeXKcNZS7aKN6iv6zfiQOUpdO\u002FLmjUUqzlrRshxMd2UAkgVAhn4YYJWcDKCqnaWYOVw9oz4PWfp9Xs0Lms0D67PIIzHXD0qdXACRO0XE9qpNT84HnPXdAJyuI2ezkW+oQgYY7+7FFP00Nv9wOD0D9JPXAau1v\u002FRsMtB9Gwdnv8pJdAHdMsv98VhNzdhEAEX8lgGrH9F0HJWcam3qOyNWa7OaIu1ljFnXGds4O\u002FlcUzUkwz7jjfb4ltNQp0dm8NEALaCDvPTfnogygNWz9to4zDH3Ni60n4hwP7thXRu9Uvv16XT8roLS8\u002Fis6HU8P\u002FMaKHCwToOZ+e+BJmzk3Gd1t7f\u002Fz+P\u002F+vn0rc1wE6HrejJKHrztsZkDyuIV9gNNG94AQWCTzOE\u002FuhlwFQwBelR80renT9fqx9iGxop\u002FlNc7n\u002F70YlsGGHWy9Ll0mE75Hn8dnWxKXiDCxV2d\u002Fk0RDX0mettEWrEWQMKj+uZN7mKxrnMte5Lj3vNRQd68oIK9C6GnJi\u002FgLnh0MmaA1jkDqoVJT90\u002FswIinLCz\u002Fb2cAbJmBJzE7D5ePkwv9dkCPOi3NoIfpq8FMC602ncCK2fcdKTIN3543Zj3AoHaMw\u002FzxjN6PPyyxiaoot\u002FoqJ8cJfRGA0UayFGsteYyeVxORTa6+RunNrpy4ubVhXDGBLiayxU4O8ohuzK6\u002FOy50pIqvNCCUwD17QSrFohzd4A60nkubILVduJ5wSh9K6xdv1cK8ATq4ms6QOrOu7fZgWi59rdVICE9YUxTBrMxGTtn4PUr0WrpStm2MNVRcwK0D40GE9ExW9n67Gd2uOlLRhU3qDP1b9L96osIN\u002F0KT2xW6PQRHayYWKXnoJg7\u002FMfGmdLho+5zsulBupVezLjWdLo0uo0D0c8JcvQMfOYe\u002FbcqQ2twnAdn9JyDCjhEtYJLR1sPf5Ze+XAU7pWbH4wM2LB6tj1R7GzmrUeN1kyWF4jezCF5M\u002Fde9JbhTtDCzEcfq+BeGzzat8Tf\u002F\u002FvnYv3EJ2vAM1\u002Fzl+98hgza6s\u002F0LpnDg6N5++kKUXUuzEkLPnHbe3mtkb2XpuxMtjGuw3HKxbOpTwTNsjihBSQtr2Jiy7Sb0mgUCU+0uU1wlEh07H1C2iSKmIuATrSi4VN6JkaVCwqCVpBr5iAEk7HJ5doof0txGIwnTNEzwpZeAISXLwCAll7rJ4JSgiZglFXGwhLT65ac1R2XHqFsHjAqtUYpSuX9bLrB6ACxyhb6JuqlFNYmYsYLNl1WAXAGBiUAhPD4SKWVk804lHtjYhDQSMQIsJavDvRhkjEAEcpzAPU5Ejgh4YECMInRRLUf3LvfuNdGTlFCtWtftgR2eHgrkP3B9E\u002Fe+ZNA4I2A9cp9\u002F3yA2kTU6gMFRQEC4rPZM1oBWvcCU2CU6I0a7ASfZwzYAPpo8sknnw\u002FYevjgfpFWkdS+j04iCDb7XCzVIiYoYtLSXaD1TEq\u002F2S8lpVSklsN\u002FeXh\u002F6173PSm\u002F0HHN6HnxZDPt3plSBy5WM74ylXd\u002Fup8T9ST65IilEEVe8MuZ5l08a4cByaHYiafMBwWPlxh+QFtkUE33w+p\u002FH+TRv6z\u002FeNGJlLNXIsG3miAaxmFYFXXKk0bTVi8OWrrbO6M8YcahOaUgRAKkhDCYDKH55Fgmw0NTqUSut9ryMlBOoY9xHfoWEWy5GrhXMnOzMVU0hqLDo2QAj4rScHzlTIrOXXhThZyTCA9nQLTEgWBKbu7sPRuaXym95FxOzrmck70U8XY5g\u002FeLht++\u002Ff3WH4DzHCTOJUABQI7RbmYm8tX8Mn5kBbAZxYSf6xe59aKo8aAfo+Bxvmsao6oJ39+5MzL9U6ljnKkvSuP69a+\u002FKiXs+vCaWv2PWwZ9nkP0tJ8cH1EwOY49KLlXbeNlBr4oJke\u002F55pPzziM3spImvfpYb8zCNOvOot+6\u002FelRk0IuaScgVqRG9cYA15lSJUda\u002FRbe8mufQeMEqPssLAeGY2WPI+en9YZtPrhutpFpBURZfjXvdOH\u002FkcnilTXyOglBtjyNP3ByB31PLqB4fOZ9KBx\u002FnowXjIK\u002Fd+88J7r8fZ24AgNxsBEHnpvbuh5Iv7jGFiNbCyAJ0fNce0At03peAuvcQjCBDk2onEiWMtJcR2wjvZ4Hc\u002FjSTKgTf3VP8DwbUAZ6JhTquuHlaKjylyiD943CHoNLdBT6o3oMuA4ueLtBbDqsBwndFxR0VmZ7N6pCBKzca7sZTl\u002FrvKjyQPAsf+652Qa6HlEA8CMixEmR8PPQ8gaOqErerpGH9DJvVZe9ROvGwvdyMlZNEiXkOEuMG7t0t3a43TiMquvZFIKCvvz09279XGl6fgceKWntT+rF\u002FHBBHs8r7br9rzQx3sisM0HwH3c9\u002FSqFdhT5RM4csC8SX0gP+P05IjGbuNQ2OOR2hp7tFZmSpXy3OSF7Z2Ib6PhqK2+LUDfY7d2u85hN\u002Ftni9KX4jSy8NfrljPD9grcTC600e\u002FiYTK25AcPc7574tbZVvVs0ldEgi3XX3pj0iaSwXfNA+fAfAzwDzCRSzID0JO1kZGAMAfONeZWv7Q3J7ji3X5nU42TbMw8dT851faS9wJp\u002FV73hoeHgfFC91i5Nq8Dvuu3oNrCL\u002FFFFxrbuVJaz7dqbV5npST8Yl6M6VifNVg03EoI3tFvc+tz\u002FaUfdvE60B4gB9DtZ1pgeUXg2fSXLwsEJQ9ssFU2kWbV1ES63cvWWLW+2h44qwHS+4YXG79UDvoIfa00jI5qwAA7\u002Fl18lgwmp7IUjJ2tMp9oO050NPdyD4AeZ\u002FX2jGg3ILoRBXodpATE1rt4MJmt7+v+gk3p2joy8ve6SjAqYjmI6riUw5etur+J2ewTJBfNwFQjO30uGSrP\u002FnT8Nit5+l3rKq2Nk9BfTfPM39KFvmeNjEz3WH8vf2vX93jRp8txNQa\u002Fb17jDM73S+e6x2dzF0bxd5ev1k5a9Pc8aD1l09a\u002F9ed7A+qqdPBU5QfyUoEr5QVFrW3GWgC1UooZ7BGOGOcoZqEYXr0MzMQYlikx7ZwihpFiChGcdTAIQVqKS6Rgt6VTz5kDJ6QodC1lotrM67y0tUwEBKtwcKESQefn2ZbngVWpJsvzXV61yMJeB7gwSKI+BIzWs1v53Gcfz5IaxSDP+EmHGolGY3YbT+Q6Y1bpGZafbWKZvtXPhj+\u002FHxLOOoj5375N2FPmC4TU9xiSgSM4RNrL9+i5DjxYOWqiNbNE7oIYHVgX3XtXJBkgtizJEHi+1QOpKL\u002F8AnS8C9gC8lv1u5SDHJfnATwpMKtm8st5jr8XkM2opcSkxqAT4MhwSTeyyfHncvYtNXJ4Pi5SC9z+t0oCiW5K\u002F6M+t6Ihqvs8gK9OrxxpfRYNvlQk9+Ll0l2i54VSSOT\u002F77dSQcnY5AYIiy7I4Xt1EBhvN\u002FsHH+W4lHe\u002Fu5\u002FzF8h8Ue34Z6JogctnbQIlGg6GQnv5qJNqU\u002F4ifOmgC5pojHDz8PJ5kQ1Ru0pbHadIjhqjDWtLYXVD1wIfeEDUmzLGR8Ym\u002FYUDKr1ku2itiP\u002FmyPa3jW8dxqHGfLnzeCDnRDkqNJvc42REf0bhF\u002FHhZG1vl6eYgpQi5HAu0XWgQG76piwcY4z3z6SwLjJu9Vb1CSsXmP+dSAinov4A+uRBSVFA7GEpAaeLBF24fG3yJp9Gtx++vb31zV++2\u002FrLt3cm3QnIIxPyS8mhw4tWSoSoCwWdUq2PnAA8iydc76frnUJraZ5SPMoIMzzkEqBhwPGC1RwnktJuzj7g\u002FHz22Uoxu9p+j0utyD3oc8\u002FlyPTgBV7Y3jeB6BwcPM7Y1eg8C0\u002FRDRO5Nmjv6hUzEH5d8lXkcIwSZ20Zf\u002F3kcoj64PMLlzImgU18543eM\u002F7m21Ha9sxIp1rR6mUA0AT48Pxpr74AOHTbfB5X0nHSruS9+8zzlhwn732HNuRu2qhvO53gamzdGj1Figw+veQjY+6Zgqgbx2kujOc3NeeND6gYw9l10qGM3VzQc9n5kUOAjmUTbRMVtuxuPo7TuSJPA6p6NAFKLYb0Gmul4XrUOK9kaS3J58zof82Z1930App7WcnSl9Gn9VyBAZFafV\u002F9bxz98wJc8Ad+smLHhpC76Qd6nLzwkzH7yGOs4gjuAJpW9MibztC1nGW\u002FAyyuBfBFz6RsmEHX9M20h0banQBhjVvJkQ7AhuB\u002FtOeU2E\u002FEQQAK9dX8Sgfs1uFVY9a2+RQgmChy41B9hU62xG+TeLcPHbUPWDuaXVvnTrVamd3Bz8+erSDWRIkXmaJhFKs\u002FVqBbwpko9\u002FPu7ySbHNgFZsklMDg54l0GNhkYoPs6GaZrLuxKLV0OF\u002FBKb+i7ClhWUEw0ui6dWYpp+k4Jx8MAH36WeqhkrxWXkS1ucv03P8aB3v03wNDqLF4WCJqKSNENbfejqXum6kf2bkA6+iRzUjG1QNYXP61yi+ZhKuc0b3j3VPytpjhZHzvaPHr+VKCKTlI38POab9FzK8ZJfhNAb7HreORgzj\u002FQP+NeDrTP8SUZtfKkKtZepZDx\u002FSv7MaKrU9MBdav6aocLdkjZYefeNMZxsnWua\u002FWXA+gZ5pf+Eexio\u002FEDnoErZk\u002FP9WxdtN1cuwsBtrdKYFAuvbsFRTkRxmY19kHBsVsFPrQD2O\u002FHI329ddjvsxoWH05gKWBv7H1a+\u002FomjYke5Ai3GtHYBKLodJ+j19D0pI\u002FSDms0W5JskK0ZmwmIX+IPUnXKCcZ4oGclPetdW1KR7P8T7HzW6tLIr5muxLAhktHXTw62frxdMYcXT1tl\u002F3ns1q2PqkbXnjYbY9He6s5fI+Tx6gRttNNcL6ctvYsy5nCGCGTrkM\u002F8nF+7w6\u002F6Gy917bq0n\u002F1t\u002FiNQV\u002FTTmP3t+u4ljv5Cr3mOv+eDecpfr+3jf\u002FPrvQF1EXA5xoQPIOUJmgyRAYZddJbSoqBEPBgTkThRAcoYIxy2acXys8HyuuT1UpByD4EG5MQsJgGzrfrSPaOJRxqAxGmOj395MKDc8xhF0V8K3IRNpDiFKfojGglwUXomH7g12QcJsglrLnrOWnqWDkMIf3mg3nXlJ4v46YdlOoJyudx4HecgOKzG5sXXbzuBL1r4foHwtdT08mU59u3UpxiNnWHf31\u002FCCwzLS5Ya5DUKItDg2h7XCr9laPekYHue\u002FsopvFROt1yxt4GZ69dX3qTlyP39G9F+f8odag8NlOeTpkQBcQaAP0rDM7RtDvXBjn2fWZmgyJ80jleVJnxYxNt3oqI25Iq8ijAA9i9SFhOVS3mKCCvvd6NIPiUijeM5Q5dilI6hbN+DDsWaerJJKBChLKD8b1F8gEw+p5\u002FSNZ53oFOuV4ouRR1vKZlpteBFS5DvDp4OT5H0ye9Omb3KKwcw8ABDAbg12bMaY0zyOgdIxCfoQsDxAufHM\u002FGPyjwUpc8BtNlLUKMqN6Sl6vMC+JtyX4CGKCjPfx8YyBGwosBpAHLfve0zjBV3GafVDHPOkbkwDpQNli\u002FL9f62PhVNaEOuzbDkY3gITzeGqSpkPMnKs+NSYOLZ4\u002Fjf24ZY9Z0tj4s4qKgykYftDF7O6JOcmj\u002F9+XZR9G8mNemXQDxekIPPYESKniEiuJZw9Xa\u002FI8F9gfY2txnCGLT4eylLBmdFz9YmTSaIDJkPxoJa61XbZMQGSY0wXH\u002F+y1+qZvT51t\u002F+u78t5edWEZSPZr4e53w+L1fToVCiq\u002FhMCohqTrPyUX+AuOlLdBHBNf\u002FLIe73\u002FuZYMXYL3C1gpRsDslZ3Zhx6q\u002Fyd\u002FRJkQYQTKOO8crZEdDky9NapAPdf84l7vue5Bz1GgQMqY5YyHs3hOPBDi2jgfkRwn77G0Yhirq2c+O64iPOAiBpr2l0d3xWRzPBtdz\u002F+xK8Ay8xBfatrc884RVr1XQCArRnvv0b0f+jVXHDEvfF0HRyHmMwDFnSyOUPZqXJSA9pLtYzeGX3d93vx0xwXHs8xVnq6nhsf1k9W2qfm\u002Frhn4Ys5GdKze+Yuh6B\u002FdLr7Dpyq2U\u002F8Qe+hJccJbUTxyYD+A8XoYy6kWT1t1ehFB9PVieF7exRUy6GTrDItfl1wnK7h2NHvA1DISH0hU15DV7RFuGiGt8yviKB5mL0ffXpcqhU6AOFA9Znu1x\u002FP5WDjRXp\u002F8f4CUvNZ10lJ4LTTL+bQM6ymWO0Yx6z7ZpNfNKAb8MB2Gxu1NZ3CXYJCUTe1GGhxqFonGdfly87CiF\u002FJBwcpRZSgBgLpr1aKj+i3dKNgBnrhAeBd1Ns82Nx90Mb57TZhTtqLGYweK4jQRvX6g1\u002FOtjpnFaOv5v7lZC7eGdsM4NUmEOzZnoXenF9yJXXxNTDYaigdu4JS5adnm62kf\u002F\u002F991t3C6op8yqdFq3p8DU\u002F5EzKlsjvKgSAXnDGhq+7dOn8rhvdnR7cyanBV8biJ1lhe+vm8BP9OryxPphnuY5sC2hpR1RXHxSXeNieHc8TnHTy57kzl7beFlVXFvoy3SEVE6BMriegFu8thuIck1m6IDAdL1iFwS\u002FHR61KnapoQUHOK62o6wqdrF76PrlMRuhD\u002FA8Od0vjjra1JYjGjlxvb5fouoAdUN9tcw09CI95jn5wlM0fR2Ei\u002F+lW\u002FDwHjeGJfscX+E8\u002Fmu2h28hQPHUYzjlV5J+\u002F6FqNeZa2ScsCvvF4\u002FR\u002F5Ti4iYvyY7U027SEA4G2EXlW\u002FrNQ1X6mkVzkizx7cncpv3xdQunTt1tbXv3tRgKqUnuyk0ReCj47sS60Yx3QhqegZMAa+w3PjzBlA4\u002FVyLfotrN5n\u002Fc7hkpY0X3ZPnZzP6YGxZ74bRdrnveb57tOOf\u002F3UYJp5fdfP9\u002Fl6b0BdLeiJ+KUcMDRwYjc3z1QE17IfghHi8SpTJqLrAAImVSWgkSbEPCwA0uYPCimQH3MBOdT+Xt7rKNUIaMOJezAyR2GWYONBmzsoTMxBwT+49zAn4tH0g0JQdUUbaqyKwNuFLXoz9akDVgdNspzAUdYZl8npixEBeQIp5\u002Funn35JeexUhrJa0+dbosqQGrOlYNUjnI56IWGbCFW9FDFROk2f5IAdHZanmJCLFhAePzkuC6BavlqHM\u002FnOKG2QFXkhgLvlhrWXf+hMQQLTSkA6phc99AWwwDby6aXQAOfSbzyTQvI3Jwhg9VwA0+cU62z+Daju7q3IqmVFfChSAKAzwiKOKn4Q+o+qTU94rFTc7TtKycm0c9hPc2RTzoXyzHb3O3W0sVOqDNJxpatuXr85\u002FPCw+Xl7qTr5qsgUaVfKabe0krNF0NGO8Xb89utXAfsUp8ObzqckrpfXLkJlE+qs1mRk9gJSBdKzqq3S5BTJTzvVM7c6Cp0zICf+dBGQnQRLucjj3ip5bKfU9mia2lc9RSoNOuJj0RSgBjDh+KGfdC4RQoof7zEajLUIO2VKyU+ptHjtOFqPsUvhc0bt2XAgFAfQWDiQdBgQ+vPPbdQsPcQqxdWAuusoF5Mg53JFt5OG2sTPIqc2qaGLFIoxWqK\u002FfXetyJ9UnnPl49tN\u002FyhQ8y\u002F\u002F+qfZMHovueAAkx1j5djoM15k9PDqirYs\u002FmWgEocxCj73N+POiOofY4G+gBkFNroqOZ24TXyl\u002F4AWfgOgbfqTG18OU6lOj6b60G9\u002F+5utz3L+brbJ9Xxg4O4P3ye\u002Fd6eywIVAm1Kk9+vjihjWn\u002FgI3wJBBwcBDx2M8zMPI7\u002FTDUakXrhObuYGlC2DvWQScJm0g8ZNngQavNES79EjNdAQFiBbm8rTDf2tXeNdzsA8Xhd6DjCaEYv\u002FRImc8kepoyvQrC33MSp0zTgB8ZLv9RgBfe5vzqZ+Y+sBxejddyq6HOU4cZKYDMBBFHVSdzhu7A2L1PUcjrfxufnabHptuCe8t3J69TMK9Yxkpv7NMwIbajdr7HxycyVZN1bpB3V\u002F+MXcc0roaYb\u002FzRt9T97q9xj\u002FaDCORd+TE5HAcXrjA3zkNaApBx7vDf\u002F0fGCT7JkDVxkXm+H5lsfpebrdnqiLVbry9h1dKYBDF4rYuRkIGLPa8+hN+nBSeqr5PPPQYKwEGTMNO5HrVjLGAYxvumruH5noGm0hgHnZbnxWgqveOfwtsAFsGZsIqTb0m\u002F6d6PVFemONy\u002FySOdVSvAA3evXgpN+eYS5mBaJHur5O+m\u002FmEW+qeW2c0tnoF+DcfA3rN3fut5lXlFmAR2oQUFETtROo7tlowDE4KAUBvq8j0yd9RlOOBdt1qoOKVOQ4aFlngXxAMTCGd2J4Nh7IN\u002Ffm9Iz2VWGp36Ly2iD7eGx0YnZYlHtkuEi11eHvvv1u60EBhI8+\u002Fax7yaTcf6vS8XR92SlIIsWEztdvKyfDT\u002FWVPA0PRFPBGKBwVlSamw2vjXMdBQ6tctWvkb2oQbbQwnv0bH3vZjeO3ND9ghVPSg+8892dmXspoNfT0yLqeP1CYF05aJF06S\u002Fv7KVpshRnEAzZOPXaND8LByy7\u002FLb70MHq0LkCbOOc5ribqOMjK+zpo+yCVX+BmDNTiEFZ5YJqjRVu0l28xWHEo6ebzLX\u002Fhe1Di+QqOcQfxs3206ccvdHP\u002FVz7S5Ld7CHa6QD5nXKOjeMoXXZ45FlhhhOeFtyxUrhI5r7lTJOnwRjxqTn3LCuVbABZONpbzhPHyyFbZ+Mf82O\u002F16MOinwbAr8UvQUeP6wq3HlYkV1rHoDjnQKVTVs2dunTHjJz5rnGuGRwOSVkxhj1kVrsv3nNz\u002FprpGyKX\u002FR\u002FJmjamQekS5fMnNzWZe48eUenpHTdOw1srvq3\u002FySO7+V188aNWbLntZl80RmUMCypAnYy+xwAtbkO+AbKHTH\u002FtmVlzCuKhWkoHspcHi8gxCiKH8grDkLEjKsUlna096jNno8D33KybhZNJqQbUMpDH2VQVN5nlKdKFXbHYwxR6L36JSqDgSkEk+tUQw4EhW+pTh6bJS5RXDWxHz6IUct3w3SUnu9Ffx8XNY4ViiSf37pRPrKJFrG2iQgIooApsJcpJkpuY3hOn8a4MVzfeeuXlCECw0O\u002FkpfM0LyLVm\u002FbhIkXAQkCQHnpp4gJR4JwvSi1A10fV\u002F+ZScF02qXE5aajJaVjTvSdQ4XDCLjxAB9zcmdRTB70mht17benPKZNHuoAK21JGaMr8Coib0yW\u002Fswl4+SAKGBzryojThYF3F+U4mFj1JUOVDI\u002FSgEeHqmSkxAmzE+er\u002FKVIpxX23go0iNaoNylGrnbgZOzefTXWskQaXhbpN\u002FGlOMB54HhF1XCOXg+imnKqVFg0Zey37PE2ZhsQN2JdvsJmFy\u002FvQz7QUKvz1ZnGFjKH184vAv\u002F3H9yf+tJBuDDNntSkqe1Fy\u002FXhQBOCjI+NjkABvA+y6zJhFrgPXZWcH5pgzPH9ELRAU4NAyhyyBGcvPYMK+Mhx58y3h2eBPzqT9F1yoaz6eRYoIFB4dDpH1Bj5cfqwX75\u002FMD66Z5ztrSXZy\u002Ffbv3hT99s\u002FcN\u002F+T8rmfpjyir57C1vFW8qySfSQ\u002FEAftqjnM25v\u002FVpY9CX0u6z4dllZOps7blOC0t5ARdTSi8Fh1cn1zi6SgsCGBhtjs39gPo\u002F\u002Fdffj1zYJPrbr79qhaHa8o1ROdUX1c8HhK4kV\u002FhMidDRiIBVfHRIqVK+GfXZRDl\u002F0hkc7hRoNEY\u002Fb9HcAb0nBoEM4EFGSH3qLhjdC\u002FTSKaL5ZzMKFDxjq7Y+HqG\u002FyfMmn5eMoePigWWA3bsXQHIg1XpGHdPXXmQMCNE\u002FckcHqiupP9oh1yKmwK\u002Fvh77pE3w84FCN5poC+uf72pnnRc8gQvctMLlIwzj1HrqULlL\u002FY8bhJTJhXgQZ6LNI1P3JRn3DX1bYGH0rmOaAbj\u002FX9ZtNfMZAh4wBrp+zmdPS\u002FDsRvLX6x6ED5KWTHJTqCCCLRO6csSfA2OkwJ0OvQMwGPEkxOD727MV\u002F9JdrGVOAhYw50M5qhGocvpugTuOkl9DJvWwvUABE4hN88K6IHD7uggFYY5hxVd\u002F7fTawxQtrBXjRHC2xh0Y4J3NtRO0x0wa9eFSIcYIblZW1kVXqxRqHPSZdWH\u002FG3HezfvF+0RUvzavnC1YJiABBG9DIPqy5NO\u002F0ed81RvPkd+2YK\u002FpXkIuTYj+VdEI2Qd+6uDlf9nk32dvfX6tFnFPtj1w3h2hmjEDa2jBPZnp+A6V\u002FZh8OHkk\u002FcXDlTQOYeOdtzzasOX2WjUp30E\u002FQABlbaQdWOXtm4zMWvIl\u002FXKNtTuXom+ZrpZs1Tv3r2iFZDwL22chxwOqH+vtTMhRdu5YuPQwrlNc4fKc993ah\u002F2as5MBzfYc38Mw4JvWLfNb1edlALPUNbnmbjRG0un\u002F\u002F\u002FrShUsmrcsdfB9Y3lWv0eTfeR1d4UjtSNd6iU\u002FJa02teYyayMc5sYwdg0yL1j66Nh5szpYbxsfG\u002Fe3O2vXNOTddGtMlh8vPFTkGpctrxl7Ql908b\u002Fa28NfqinDYGl6VnfNakrXfXD2Wjg0Dn8BVd0\u002FzjAzzrFdeftI03FkhvcWnmly2boMPMcXM9401G5n734vOl3zje4zCc2Bj9kM6zypU23uzQcfb8TWnFb7IHHL+HP3639cd\u002FPj\u002FFPewN22lc7CE8yLldgZW1T8bQ8Jo0HMJ5Lr1C1OmzcTa6wMgazPTrrz99ZtxZ8+Gzk2vwZUy+ro8WbMF81M+adDvxSyK6y38+eI+vpOT9vKQ56DBBpkzP9pMH5CWCblmGoa7GyURxeV4TLY4oqrJ4M3BAIjJRUiZzL2+L4cWADBmhoHAodwy\u002F0854lLEJDxOoQ+tvkUZAHkj0NxAtD9MLMKI8eJ\u002FemIvgrLzBFFrCChwDYATNUtzz+n8ukDm590WvlU8CxubY3NI3wiPTJ5FJoO5hxsOJW6LslDYjTflOBJ0CiVgU6hj\u002FFIX+TFQgmhESkc5XRQwcIGUTruVSSkBEneIHur0oGkZKOxeKmAKXu8BFisYx8t\u002FduZPiKwKVUhQBnt35jXccoxQ1Y3Oro9w5D8PUQ7szRXrPFo2\u002FOYpU1EIurZx0bXgxkHKM0Z3n+6AoCAMtlQiPnm6DKPBgDvGFZVKVAs62+rApqYholKRxSQMZxynlK+\u002FRkuHzlkePW8o9U53ivaLg5y80Z83Ju1dFkgPVjMox4G+1pmdxYijQB\u002Fd\u002FSnE+GZ45W3TDisL5nCyHIBHmF4Hcs\u002FHNbgpOCpGxM5i78c5emy1F1XfKceb921S6Kty8mHzvX35ps1BpPCvqMv5zKTytWNQPESvKyXgBH7whL187F7aXoseTHBiAyuciIfhoUr+6F8C+Ht3xiVQPRmPmt7Ha1CN\u002FWA14DiGwTtlZDuT85HHE6t45esBkSupqUWkbci01\u002F\u002FFPt7f+8Z\u002F+ec41UFkJT5A18zTADxFSNYyFVQz9pNjx5QI8KaX6oU\u002FKVsrp9xoDGH+QfeOnwCbSTOH5vD5RhwOiyGw0ZvSBF03sV2efkbXx9dtv71QWTv3yC1uffVKd\u002FJzdp0+utqm7g8yKoMrxxSs2IevuRBm1X0NJdb3pw\u002FGa+ixGBFZzD9bn0YPjg7bKvOoXwDcgst8BvLf1z4KsdhtG87wivpP602enAreTtx6NVnpBbaSCps34lg6bSE7tiQzjN6VnfbYqnkTvnuE1z67NgxwNz8I3xrFkmuOwIrt0B51FxsfZrM21itF89LnvATTGlB7ZRos+9xZNbzTzPOl++9Kf6pt7AG78Y87JoY26NkqLjDHrrUFFQ1HTdEzj0kt6YwHktVRPzwKEDLoVxlcda\u002F66Jjk0jSgadFfydVybnot3BijUL3ot6g1t9BWv+d7Y\u002FC04sJMzQn+aD\u002FoeDTgwCEbHJdSj432kasq01\u002FiBtzVOoLOLiUVvTkU\u002Fhi8Zd3oYiPX2WrJ2AqRqH5++emXcxiOyjJ+XvhDAMWeeud0cAp0TITRv+Kprub2KH3Bk8Ahq6w+ZN9f6+FcZ6W+dNE50ZuwncJMMiTAa8zy7Pln9lc52tpx0zs35CwJBFQwgy82FlJ\u002FLl1r561Aac9CH9S+gF10FyNjjOtnHjac+XUwvkQd9PHwHzPVf\u002FQFsSJA+GROedoIxZ1V3jVeqEfK5ZlKeCqYJ\u002FGgXeEMh4xod102z6tMm01ndas7NO1mQKsGuo4kcbeOTYqiH+BzQjXjTzgYncFLcb57IywS+4m02HV9zIg7jbfX33eOFX2eADRKvLaDOMbZCtOZR9aZYdPS4PomQ04FsOL5Fm41eM5frcL+uSx4O3qn53j6kHMcG1rUo4U3uo0fjNI\u002FsDgzkp\u002F74\u002F9ienmPvG71kY7mfAnFkY9cqxgQ21\u002F47dkQFFj\u002FnTJXwzKvXeAEmKGBYHziAA9xPeKiven4B0H6h5Y5npXnRS5CUIyedhj2MHMOv6Djd7F7DmYBNNDc+dkQw6ah7\u002FW3fhEp9a5NzMu7emedsRj9hpJfhAgETmJBenLTlMAKHT7odLOD3rF1BueYi5+hxqTD\u002F2tj\u002F+Iffp08EQNI9JynLE0St4IT027VnImqTl\u002FrI\u002Fn348cfzubHjTHpgrktWqAe0Qo8muf42rn720QST\u002FI13ZQCQy1qd\u002F+hxezjILzkdcF4bZhrvTMP9eB+v9wbUG+swCgE9zpASeCPlGXuZLMaB0Vcbm2D5XQ6uQ1WUAbQDeDZMJvjjJcVgS5GdRENiRkoOuKJsEI0RwcA2s4qKPy137OMPlB28OQadJywtRM7xAOAMrXQUDDgpAidGQfUYQH02VA5waZKaCCDMJNpopWKJiPWFQPPnX\u002F5qgIzcLmBU1Jwgnw1ImHCRQnXGjbkzTiKFz7quvydvtj6bYONZOeFF5imEBB1deORoqX713Z860bPvjHkAYXSgdEUwMDShB0blSv75m29SRG1sKcIN3NvM++Llow6GqBa3qjUxMqbWH87LL9HtWqsElME4R4w3Bq9flPlEPBo\u002Fo2P1YgMeRVtFH7RHiagUoqY6PgBOCMxEeesfRWap\u002FVWrGs+Kpl0NPO1muAHB51V2kf6xABTDaO7rX4rkVFGCMQwJss2vDl7YLUfvcsDc6XlLEDK0Cd3pLz6rj8db3zR+EetfWvUALix\u002FXyh\u002F356Hq41fviPDena3lYfUVPKX0iG4cjiBOOBqlSoja\u002FLWOAfHLfPlk3R989Wy8qOHyhfGIxlgFXVs+mX4x3BFF6sxnkkJPCmPHl9drV18uVJZEJnwx\u002FNdR33gS0aEYjGnNq8CK\u002FL75Q5TaDscmeSD4zObduIny8ki+17A2Onac3re8Fpz0w1bd0un+ad\u002F\u002Fpet2wFhYMQY\u002FZy85fqAZ\u002FEAWZoIbnOGn8mt71Jn89PvPmfgNqtn5NDO\u002FT7uMzqO8mZgKP9WlOrjtAE01ne\u002FA4nMFgCKR89Fv1qIxk+nj9dSulIsrreh6larF\u002Fd+vptsP2zMGaX6OKCoCfAMMgRweZY5Q8tYVo\u002FrV7\u002FMp2htDL17piv103jn+2mjHuEHnMHQjxJfoJeuQFvP96I\u002FlCDV9wENfbDdvLkHzf7\u002FL5\u002FhDzceBtwGRPd8fQfM0WTuq+MDvNNBvnO9fmsRrxgn48PwmRPj26yGeaaUtHUCMydITnjRqeYCEJp0k5xJwGA2y+YMS1XaOP2Y1XMALpFvf6Pi9LXfAHG09zkn5XHzTj\u002FPxvj4Fs+jvWCCvHAAy\u002FXaXPrCwVFrnjnrzsZAO7bCeNAAaDJ+fdjQhHNL\u002F+Az109\u002F0KV+bBc4kO4iwkgmXtuvEj178rQjnMnITnv6G839jdYCL2TAXA+oji+sKOn\u002F8IYcXLQOsADl3TJyw3ahrecDLKjGedNfczT9bx61YW58vr5bKx8AGYnyIifbOa4AzIv4ognPLlW5Kl5zyaQa1pb7zbV+0w1+Dn90vX0y6DfOVoBGZHg7kG7F1H6po\u002FTVkm3O8dLHY0\u002FSN2R9P9B\u002FPruziQKOoxT9ya1nhaVGTuliKRkpo\u002F5mt2yqXfzDFkT2AHwAE7\u002F1j6ywbfh7\u002FyDnqzbnIKRGCRfgjJfZVHSSOpkBqhRsDkC8b3XRxk3tTtWsaG\u002Fe8ZR5cM+szueczasPgXRAk06R1rjr73Tjm5wswFdQSZ\u002FPdQ\u002Fgqp2r2YPBEfVx8V36Ihk+DLS7hm1np0wGneOciTelsArYfdh+Gg6q81v8ZAtUdeEUyA8XyRdYmU3d0XGcmPiGPVxOTWARJ0SvHjbOztijQPJ244aFYqjps8UzOES7LybNM515Tqln6UhSwdhN+zE4Qh0kVEDTHKORqDysQI8Yo2dZ5etH8pkOjXeGr+LrmRefAbLR2JwJlu0nf\u002FpmbLNJNJ6BX4Dxfhk5Oais50ZO8D1ec5Di6JeuabCNncOlcIi9cuXgB7jhorFttblknO1adle+\u002FfOcwp1SkreqwvXyaXMS\u002FZ8VeDJuFaqs7F1uHp3EDZ\u002FUdLRqmE2wDc8cmA8++jj9VDCrfijGoPyxe2bsjeNd8k2nvcI\u002F3WyPoeAg+UeD5QTKnlhZBWP7oiUZRHcpVkt+AHlSjMx14j293htQv9shKKp8jOdRB4E1CmyjWAHeaxevNvAFiii7c+cux+wfBDIvbd0rheK770R\u002Fy19s0O7HKJSVpVlEFlnxnYklQOPVRRERfErK9Q8qN+fYeQbteoQkEIwx5aFe842AkggHgInxnYgKoIsUy6N3jDjweq9lLeDt0xhU3XBgVHRcFNBkf5yHRnEQYlFc4BD40Ac5YaK3vpcSdO\u002F+g1Hg14oOEgTzJ+JJsRiPt\u002FsoscdScDJg\u002Fqbs1FJ3op0o\u002FePHIrm13\u002FUUt5Ph5E9jB4z0pPvkzXFOMA+6irycLgWC1+24dikHY2Ciic2glKDa2SIwhBht5f6hJ7orhaeCCGEzl+Z3GdZyMOVXRzd\u002FA6KblQOgy7O9acNNWc6Xjg1+DthWeqnIACPyKIAv1xT4FEk\u002FXf\u002FqaqDm3NBdm7+U2vSz+uqlx+wEAD64cbnSfp9unS9qIY3TRhTG6uYHH6Y4yl+vT09KqTK3NqCqcPLuoHr7+z+sGuXVg9\u002FfmXI8YxQo76l0EM0ZCKfWjqMRTS5VP1e9X6W3LmX8Hj+u6ktpNiLUe48X4PnlF3sErgw9gYpxwJiUxjTAO4W7yQs11+jDoOOFoWcAKFYZo\u002FksRYCn8JvNtmOQ44Od3aW8VppLfblcatKVlVo0+aDNC6Dvdysrp232yliJ09jE+4c\u002F\u002FnnL4UXmlm7l8uODuSIxI0v6YN4Z1jHsZLi5AGwd1T6AseeMwUwGjqbCywK\u002FjF5DGvCtTdF\u002FJbq8PAew8WL4\u002F2oYNN5Le5Oj2p\u002F4Xvm6P+fwmgdGBv1\u002F9eWXW7e\u002FqXRnDpu0NAZZugv6iQqScaBzKdYVmVNdYQNuGDI6R\u002FuUCsMlrYrCpQemq\u002FWHDDB2+yd6w7ULHJHGgFVygN+Pz3V0d7JBhhlegQCvidI2HmBBxMWGURUSJtIegQA0wFBUeMr\u002FdR2DOpUgAMlogCpAzjgZ0zE6czn2+GgAev3EZ\u002FrDifBabS4wy9BZNXAf+kh1m1z15kjJvkulQm1dXAbFGIBswOORFbyMq\u002FsnitzzkMzmRbpnwHr8KqruJeJ39uytGbdIHH5\u002F3ffmGEMMPU\u002F4AP1Rke7ajj9EATEYevvMtei09HpXRnDtSAuQRrHbaoCfrjNnvjeCIFrzuQAQQ49fj+orA9uPk\u002Fkz7z1\u002Fouerf3Ona\u002FWh56OfyPr2OFS6lkMSMNG3JYcLnG6A8hqP9htqrQvWzJwGUIzJdfjTvwmE1J651u7IUvdxdNgmQOige2YVpTEunkN3vFILtbMAD0BaVBdv91AOvLRAINBYW5gaXkaaRVe8FL37ggxq1zMB9NdHpQo2tqNyzgVt3jQfUgIvlgdNTqxGvQG+0hXaA5rPnKnvBtybrlm541YhOVKtDEfD5XwV7Eif4098KpIv8KMwBN5it+gn+kgA7U3FDZw+6wTMOf+jfkB2aGq8+otuHBh9M8cvXgSoyG\u002FjQndOgbbJj5RF89OFRdTT\u002F82j6mAja12HBhwi52TACNpHa\u002FM4DkbtAWVs1TiZyRjdAsSjIT0vL508ANSNPhpJV1nBHsE237WsHhiO3nVqSmU2BqsP+oEjrYAcsT\u002FNg\u002FkjP8eAsv7NhKZNS7F1DzHST2M3SOMtGS\u002F76f7+buyTQlM\u002F0YCOhFmqiN\u002F1QP4Jr8QLFy+s1YO4r3kDxutXz91upRkd4CefHVbZxUsqFfk\u002FCtscvluOoTFGlHnO6Iz6Q2d5NhpR+eg5vE6f9McC0eYreW8Y0kcBYybJjb7vsTM\u002FNp4fr6SMyU6QSrTPGQl8O9H9UUHMx+a0fWjPcka3D3PG4gfReu1bnRYA\u002FCE7fucvV2dM5OtGNdp\u002F9zd\u002Fu\u002FXZ578aHc7WWw24d\u002FeHrT99c7tTuR9vXbl+a+tv\u002Ft3ftUfi81kZv1flGad7oxVndYISdZT9mDc92xDM0ZLdJTOG9T5e7w2oY2ITI29ZWgRAy6CJ9lGeW1Vao1AIz+vXjmUPUGSMTTYQb3A8VqCRQGMSM+ZzaS9Tu7xJwpyAgIkyCZgTuFpCGmNWz5wyeFQ6ylou5WGu5VSRH+0RQMJPic5hKpQgJR6RLa377E1LLMD8x598vPX111\u002FNZ3fb9KayDYEn6EDNGIa6uqm7PctMEWI2y4wx2i\u002FS\u002FGTrVmD\u002Fq6+\u002FLAJXVHkirCmBQGTyMwq4Jsyw\u002FzXsaBEDiEjziI2NoAJ5ekqRYOrFIDtTOeXO93f7vuWsPv\u002FoI1Va1uoDh+fDNnliXNF6Ck2uNxraSEqZU9ZvE3bKA3iknKRVcDzQ4FbO1LWUkkg8xbtxvihIinP6Vd9naT0FybjykI1F5NZPArLXoUbnzlFkAYWiWZfKLxftMRee+bxNumcCmK\u002Fqw+mA+sU2oOIRxtOhIRT4m0DybjzzuM2TZ2IrVQyOA4yOYLbUeKsDdOSjXSo16UJAXnTRs20cftTmpG9u3926\u002Fd298uzVNs6BI119H2IfIWMs7t1X\u002FSOnMP79qCo0X3715TgrV65caP4uNX6RVCscK2rxunZEEDke0rImkn4yT5SbTUYiCOYXjQENfGhuXA8gAD7KEaJD5Mq5akWlfqH\u002FJ59+NnwuekuezLt8yUs1CWR5hrHY3Dsbmrsmpm91JwVUYz\u002F8+HOHGP15HEZgxXvADlDTs2dZPt7BU3haNGQirSnhZQAXuNDn4b\u002F6xSAz\u002Fv\u002FfVx3vGspbKotn9xefICb3y\u002Fod\u002F67oQz993N+AsyAUI\u002FwyUGnPwh\u002F+8Ie+Pdr6m99+PUuXz5Ltuz982\u002F4DR2O3QuZRvS29y\u002FknM\u002FrIIG0MvKhgj40+KiDFmxmcxH1oju8PO9RmNng1\u002F7MXJcOd+DsUYvhugFT01cdFM6MCBJyEeHn4fyp9kNGuY+QAqoN03aT2vGzFpH8eygEiX0wZIA9sWWkigwZCrH3nH+BJ7pvcvmvGGlv\u002FzfUM2zLs5j2D2z9AEFA+SveaG\u002F0FGsgiQ2le6UEySzZnJuvTgL6MlNzbzz79JPAhYicokB4t2okmvhPEsAEaeIgayah64nRmOqDVLbr07t2qQUU8PA4wLD4QWVs6xrysEp3kW\u002FQP\u002F3I4VlQe7RaiiY71m46q8wPeJvGkzzgeqkUMIGxMZHtWl+onvb2ZdzqDA3Xcz8VlnIGV0gI4nooOeGdWluK92Qje9567FxgZZ6pnW5o33+wVvkU77dB5dDMwiqbm1ry51jjwP7obwipGgPbNeX3Go+aLLOkEHpt62FX26IEzbuAaBVxLfsw3npFuZsz4eu1v4YrT5aU74rs+R1gpnTpDfieayqbs+i5aJwcAYc3kaJX+1\u002FwuQF1fkg+AEr96XsQ1+unjHETElnavKmVs3IBhE1kfyC76rdWomb34uT7UxkGb3KW2KT2Lr61QO6CO\u002FRadrnDw9GNAeo4i3pVjIRIO\u002FJElqzPnsuECVZ0PttqhC0TN4+FNmg1Z8Tuw+S79CkST9SkJWAAeyEJ\u002FwRBBE\u002FPCjrNlAlw+9zx7EwTUPN9U6itECeuQf7oZn0V2+H0q1gDt7scJA1D7zrWn6rtUWEEokduV9kWu8Uk8ZW45Ad3pjBj9Mzc+d0+DqQ9LjtAG\u002F5Fx+4peF1mm908X6FN0Ak\u002FREWi8+5jNCYuFoaTM2izMgcQDSoxqYxz8+JdM0RHsiYH2yOa0ee16vD57HEqTmZSUaMwGSVE9ypmboAFZsJIW73C+JvhWX9Fen7DJBGWaqzf12\u002Fv8+aXr+rqxLnkjT0vvNs6ei5ffmQB0z8buZRul5bx5XUrys4J0jeNMZwic7bNZPaisJOdnJx1KW798UhbFk0fDE067\u002FemH7zpc6ceJqgu4fvb55616Pyst9J+2\u002FvVPrch3aNqvvvpNgbdr2d6KGoQ18f7BwcI2KqrhFbJGz1klxDd0qYIM5g7N3ufrvQH1\u002F\u002Fgf\u002F34m\u002Faef7qaMbGozYUBBEc+IA7xjShMAnBtUsxcx7gfI2q2fsH7xxa9G+UuFMaEAuFqbSymKGq2dwJSWyZuJj1ibvGlK4GYRc7u8GRHMgfEoEJHiH374YQwFRhpD0M8x1rW3+WnpE+D827\u002F53YDrTz\u002F9NINc+kv9uVpEXCRfBP77O3fmuHT52doCAi5fLt0joQRynwSqbt1sM2n8RRi8CIjl50sXd6od\u002FenWD53aySukuBgBiogzsU6JyzDX7uujBDCwK3fN5hs0I5wvT6mc0NhyVkTGHaRzpRriyh7yEAeUdL+IsM2njzoYiJMgPQWgQwNjYoQdyGF+JsrfZ56L9owEWjOuY5RSQANC6u9myZ+yIqQA42effTb9cxrsw96UB4Bv06SDsCxlBgHjj5RvClgUx1HzQDEKmSOAFnjZ3y8S3vf6Z6Pq559\u002FsvVFb5uPH3bKpc2qWZTmqBM3eeX1W9lMeFit3zIcm3sHb61ykWeKSpytEsXzl7+0MVFt91cjfOfbWS9awMily+qDiggLrEbqmbvLrRwYhxQdyoxW5nwBNItv1DuuklDXj+KO9ygpSuzs+aLCOR3MveViSl\u002FkG38Pnct9VLnDki+ggTbo0OBHmStv+atf\u002FWqUIp\u002FnoDVQfLTbRhogQXuUOzpdrP3X7+6X5nJ\u002FViY+u3y9JcI3W\u002F\u002F6hz+WXlbllJYfGClpKgDNij6KsrSpMMO7NpdSzos35sS8kdPwYs\u002Fy+fCyyYpfqcH\u002F9wu\u002FLCDfWKMRANFHLv5vl3WfceIZcjkKrXYBd9eLJDFEgNO3330bX72d0qO\u002F+93XU7rzXhVgpKBdCjhmAk6MwJon\u002FOy1AWT0jbHiDWOdKiQ90xwxijbd4u8Zzsl9Q5PmmCE4DphuB4RHSdY\u002FIBsIRXNyqP2bLbfSaWQLeCIfQ6PhpQXWz7Wp0DPoRZvERXVFxv2tJe2gB2Khx0Qik22vjdHyPM+ZywLk3T5\u002Fc9rMCzLTXfPs\u002FgBex1nvc3NtL8RuJ31akTksgjob9PWj+Z0odrLiZGErQ6pTPU2nkB1zRfbPJicMuL\u002FtRTk8sMeowEcjszcET\u002F\u002Fxj\u002F86tGHg6EyrdIwWwDxBjehDz1h94DjTXVZQ8c21Oam2zehtfNyAYPMJ1HieMdCtK8VsReLNH0AmYMOxWfy8cqmHhwM2Q\u002Fh4gMyaa68gb3tuImD\u002F2YwW\u002FJ\u002FLNt+bK6+JiGdGON5+Z5gPD9tz07Pmu2jp52HBhpnL2mdvziQrXqPn0ovmij1avNU10cR9HBTzhV9xP1oCd7MS0+cOshnwEu\u002Fqv43v7l0OQ0A5\u002FTLyXz8uWYGK5njECjPnoF+by+VYSKVAJ8BLwEb6nfEav3k0V5xzIExgjIyAGiL1w2vJ5KxaVUP89CFAK9fdHqechvQXvheh9kyOCluFj\u002FEM3bqi+9G\u002F\u002FmuPjrMHCYhlr5RlVfjhzavT45hJf8GHxZfin6pxdfYIAGz+4QdyCExHxuhWX+tfglW\u002F\u002FVw0QlsOlLxu+lE6KLtmzwiei\u002FwzJjJgboxfJSO8Yw44T7CANvEA4K5KGDmZctPRT179BszCJE4ExadsCPo0oUMDwFXlL3puVgKxZPSNzJPz7Q99YtO9m5xspIBD9iDZQlff0zERsd8LopjbaMleOlzSaa83b0nPM5aAZSsJs+LeWAB1jrIywmZ2t5QT4NJcDd\u002FVT7KtH2zXPC9JAeJ7SvdG00irXxw\u002Fr52q0QyPxyPa2a\u002FKE54yF9KLdsM5ZAbWwyecB3po65SIt8CIVeUyI+IVOtDfEzhMDozPZ8bBTkh\u002FecnBaT7P9DxzfC69dDkHldNzpGpb475wluWPaaQgdd1BOva1NJkw6PkA9jmOW3ry6aN7U6Dg+9t\u002F2vr9P6uY97z9fN933kh4rNs5sn\u002F8r\u002F84B1x+UuT9wxutrF9YZ2jIFMBzynsL+qoad1S5J07mcbpgVrJnX8KQ6b38770BddFPaSMOaMGUeNd8QwAAQABJREFUlA\u002FBPX+06r9KNyHMmO7tU6ddOhjgeUrix0lH+OKLLzJ6eUYxD4EyYQAacIRxRRptOJV3PUu1KRj+5+TMNWm8XAddYDqnhALLBHUTZcNQQLaDdEZYAyyYiDFC7BUdyvvKkOBWFVMsXTkdjJDTLtoDaq9Xk53xAbSfPVXd5O1EBSg7JeUoRMJPeQO0X371xRjAUboxIzD+65u\u002F3vryy69K+bm\u002F9Zfb3259e\u002FtOv6vNHkhO6U5KSXQk9DxXuWSUhfz+M0V80JdgAQ+T5nPjxoB0TpGDFtQ3vxhoB9ilbex0GqV7nuRhc4rk5hmX1QsCQsn4CUBKM1rL0kvpeq6qJE5nXGlI8jvPj8MC3DuRdEBX8yvvjKHVb9Iu4mdMAIdIfGq9j61qvKk03w8DIvVHVMemVdHwm13P46esH7eb3nIoEK0KjbzSe\u002Feai4RXDWWAW+xJHy9VQWZOg2ue3toNnwJ43Pz8fF8qUyedPsngZzg5BknzKGLLuO4xn6frv5Ub0cNR+ClBRsHY5OzZxCiXFKiyeVppT5uqjMVpck5StXyouoUjmPHktTaGop2THykstJHSIr3F3D0r8k+x4Fv9GuOTsuRgSWGpC50e+mjkSmlG+XXmm1K2CgL44QNRpqgyKwsUzfmuZbju339UZPrPkzZ1qtQBOpZjyLiCLIyV9xiQ6Mm4joGrb+TD2M2Nfo9Rbgxradq9DAZAoJGlaIEY827\u002F5izX1\u002Fi6ZsSqtiljcplRTa7Xsxt9t80hKhnVgxzLl6eK5qZsAfcfW8kiQ9dv3IouV0uB+WaiIVJgjB2feE0\u002F+jnGDujwnO2VHqR9NO4p06ZxkXVzYj7prKZ\u002F3iMHfY4nAFs0iaSlXUWx\u002FqZ\u002FAEc8vcnbJbMrumv5PWd\u002Fi8HMqHle48R3Pmc85sjuxjUpBH3vefancPqspOAP+ZN79WvqGw8YWqCEzgPUvJSjNObRK7WLDxlMMugS\u002FXxbtA2fAR4HrwNdGRDR192zyWiOSAXBh+cmyvliVdlypsStW9fSx9fil\u002FRLtMDfThftaQVPus\u002FGuyZP2trDVhlV9brXKoiXKJMN2PaHONxo6NX40Iw+pkMAGcCPHNLL9Dv9tOQt\u002Fuk5A9TT20CUvz17Po9\u002F3zTvQPw49TmtgkLuwk+Ahjkz14CvqPo4M13jNdeifzRCSW\u002FgAg94mau1EszxW3Pse\u002FPdf\u002FNyzUG5tsbmvZy3FT3FE\u002FgLXwHx5pVeWHKQPMx3epuj1LwBUN3QkxpfPKNjI2vxvz6iCx5xB\u002FACjPsCiHPWAf4615ztp8MBbJvedNPz9JvdZQfoD3S4caO83eyqNn2\u002FVmvIYivU0dW+nAl2Jd82YtJJ6KB6k9Sjvbq412ZQOgcv42s05fC5DpiiM\u002FDRbEqcPq9I9vXSLz0PgDRPV3IYDMfYyLvnlpjRm+PVu2fN5vZ4BE04FWgw\u002FFBu\u002F5kz6fzp4wJv6Gg+8JdIPt262zjwGmxBb8+JrF23nBnBPCsgywnyuzFYTb1U6h0dhyfPN5YXL50o25km6fZZ8WwONlXZTpdDfZqNzgnAg\u002FY7AZuzDyj5QRNpnfjRvgPpuV5OR8UfwK+5Od3eKRsx6R4Vg+AmgbLhz65lW8bhD3y+TLablNpe1bMAxKV+A8pSH7PXuRzDe2yDebLyEEeM3jym17ORU4Ci\u002FtIRwy+eE+1K0u0681AgKUexjk1Unk7AK9v6ED3MkTQT9+Afp78e1fbpbOm5eNJY6Cx2Cy3J2QTDGj9HiONjftDldc\u002FBRnh87Afe6HdtC4pahdk7s3ACGb+enqQ7XoQnX4c\u002FX9e26wXfyJJ67BwWKXqA\u002FDvOU30XJVfe2Yr7ndvtj4y\u002FjpOn881jUrH1+unDrf\u002FrP\u002F8fWz\u002F\u002F+N3W3\u002F77\u002F7D169\u002F8buujT4qu1\u002F6F1IRnHFRy9DhbtZ\u002FNEs0vqhPemWmNn+ieCPOeXu8NqIuQGCzhZCgodgIB+Hz00a2YrQ11pQoAY4S9XP4iJXbD2\u002FCQUWtQd6siQhnyskVeRK4t6U8uWITm3QHDlmVfJIwUFMADRF26fL5NkdcmOijSglAMp4jNzlMRdYKxcucJOqMBNBAsysT3m5rS7nv9zYroEqC\u002F\u002F\u002Fu\u002Fn6jw7b\u002FcDvDd7\u002FqTjUq1aAmkZkegY60EV\u002F3cK8MYon\u002F6+vnnn\u002FYcaScrOsFBkdP1QdHg3\u002Fz2t3nBHxSN\u002Frzc3J8mnxgdeeNPyklfTBe4C2yrk\u002Fsy4Xj71pMaS0rNasQAjZ47NW5TDpar3X94+Djlsio7nGuD5selcYhWPg0cAr2EYVVqeTk05vRgfqCsB\u002F+VxVT4UA88rTzzpS3OypUrT6vS8V1CJ1q3u\u002FWnP\u002F15cvc\u002FaK+CqNpEJhrz1EOtnN4DOeMp6K+++mrScVTkAQY5UTb6yM+31Mzh8nMBuTbGNNYfvn+7dU9EpX5zVp6X+iKa9jgeedgqQTOQEjg9AOHzX30xQipa\u002F3PR5WS8+S79JdD+qiXYS1fOlo97tTFUrYWDAojEbyK0IjY36jugQblwAESa1ai3dAl8na7u+bXAhn0I936Su5ZnXaQAPz158kv0eD151dcClq4XodpOp4q6iiqQD1GkbhglIv2HcyBiNA5t8vHZp59WT\u002F7K1qP4xzgBdG8pTBS1z446jS89G50zbs0NYLNX9P5a+XVXmx915+\u002Fc+bE+2fMAuJa2dLLczJil\u002FpBteImhMvemnVIEDvCKlBLyyMDMSXBRepRQzz9OQW0i4ifQIF4UDQJCIQxxQuAiwNBTCAoAgSYePQ8bA5AxjhZHLc2fShdMicj6g3\u002Fw6u3bt1ue\u002FGTr119\u002FOWlAP3z33dDRIU+WODkZaP+29zgWAcT9CENKAO13u1YqmgDXJdv6ry8M6hiEBg1ckjXOuTQm9BjQUhtnk62JgqaD8LnbndyHTlZSXGdlCZ08BojUH5s4z3TKpEHTZ+QToNspBcx84W\u002FAHdAQYRTkdeKsPSY2PmPcqeff0jKwok2qf+WpA5RWQ4KvjYk+U7WFDAAkAxK1XV\u002F0cznLAIHoGCCw0umsLNRAf9so1XMOlbHtZOPGQ5dZ0Zil+oyd312OL\u002FBrv86zzS9jz+GWc4weK4oGwJpoPBBfpFbsmXFiNXqOnm\u002FcA\u002FRLe5tTktPDdMIER3oY\u002FvG8s0VC1U\u002F2+6QapXP0mbO+E1gxDnpEhI4jAHBkAaJXhrQHs0X4CV1MPIcHH8zqVQMBqjjX+Eff6WB9N9fAyDiWjcH8AyljW\u002FqcXXONsXiNPsumcRa1JQBkfxC6e\u002FlsZKbfSYO5I4sIK+UEXdDVS7tD8Pl9yQ4e3bQ7Obx7wKJ0oByvnuVgNQ4NegsUaGIc+x4\u002Fe6jiebxulQTvT8Q4ueeoRbQJXrjrHBBXX97ttLrXazYJxrPodgjwRGsBJNH50Qe15aA7fP6wfUf2laxoKLBYL7oXeAfOXS\u002FVAC8p9CBAYRVg8tM9N37qv+FT7INGADK9GkG6P51aeNecmDc02epUywbcG33Wd+yWNCmFC9wDXFsRfd3hWAC5YJiIv0j6jmpImK3X6L7oszZJrwpR5k8frNqjk1VuDjDAx3m4fLF03vQhW\u002FI2OaFn8PC70jKfhXPYj8I8MxdOkjZec2AOPd+eCvOBvycAUj\u002FQydi98JPnAOL2ZOHbp53q2ezP5krBHLQ9O\u002FqjoFUFFKT67BVdsGrccGfzu30FdLGIt\u002FbsO+jP2qnv4YvNqk+qO\u002FpnZxoLXueQ5PFGI7SOD+obvTA4qgbIhUt8zQ75fLOPZWxNnw8\u002F1vDwQ\u002FOhDSe6XioTQfriq6q57TRXB1Ud+qu8RA98JMuATn9ajX96lOOj6AKbpTLQ2+jxrEpg7OdkFeSQWaFZHMuOd+5MfVTgQxW\u002Fl2EnKz09qIEWrOktHGNFT4DvKOZ8+jA81vvBz99vffunf9n6D3\u002F3303bVh05fLBqI54UyPNWAvG3ldiZschlB\u002FB7er03oO7odqW9GDqC81pNawKFIDEkQP4osDbAPAEBVq4kzBTi06LfUiUoIN4VJeu6X3hQGZ+JePedSaAIRYFFBAFfgI2AXg7UAK0irsAFQ3MmJ0GEj4Bhiqkkk1BQ8JT6CGsGR71fk6ccInBGub7pntvffFdZuEezQVPay09tmJX7zhj++te\u002FDtC1OfXaDRI1k4ZZKU0vqR6ERc31yZlXrjEhGeM0SmcdwnSr\u002FPFPP\u002FkkMP\u002F5KGzAU1nFO6X\u002FeN7DnscISpu4f\u002F\u002FhAEMRTTn6H310M+ByKeDq5LYiDQkdhrxzp1PdAv0MzSzNB572PzzT7x\u002FMnPDQgUZRb3NFqKTEiLIYG1pR3AR0Y3h2u95xwQCPKPIAnOZkquLEsK5Xn10OP6Vy\u002FfqNUTocIHNMAfncXAPQlNFnn3+29Zs8VfNq4+eH5ZfzjikhQGKAZ2N6\u002Fao66zlxjIANb9KGyBhlyTFkA62gKJHF27\u002FQnJp\u002FlQwYMOlTt6w4dO3LHJdzOT3nzyVgRRavBC6coAfwcYoJPRBCAYyKDNw+DeAfHv+0dbplMcYJeLe7XP2K3UdO47XM2TJ8zqmx7Oy0ShOdlqHsOVdKX6ruK756Vj+N71K8qo8UyUQMGc\u002FoO0AksMEI7AdGOKJy70UhtFdXx1DIy9vvVKcLF5cy4MQCfDvN6dkL5X1WCeP2tymY776vb+ridwhZERirPxQ6bWJujzIu+AR4swlanrPvJoex\u002FqIDfphoWZ\u002FjccbDZ6Ph68\u002FwQn9RwZ4z6wPJvk8mnabP+2IuB+INYmBHbTAQIkgT+XRdkbpuqm+iuDZRH7Yk+V1pZh9vfVWlpQ\u002FbvX813gKQX+cgMYx23AOL6LiMNlxQ3+M5hgj48XDjFb08ZKx6FIc9eOSp80z9ohP2Ov3X+BhsemivZxit8eE5Bha4ADxsNJvo0FEpcNGGgwJ8ux6QMG8ANdlwUJpVg9N9v5+cWVofoOy5zQnDSPmP4z38t4ClMdGNDJ4oIbmkp4Z6aOf36I1mUrfeoUNjVG3C3Lqf833coE+VBsJZIydoBtTNHEyP\u002FW15WqSYs5ENy4ChcUNpzCJGGaP+6SfdzAkl1\u002FaSOPiM7nEjoEKGJ\u002FI2fGus3TntrMguXShyiZ+mdO5L\u002FGN5PwcsMGjWvAUQdrY5soHL\u002Fp40qSZtAwg8o8FN0GHSDc433uwOnp0DzZoTVaTM7chb86r\u002FEwzoeQAjm3P6NGBtyV3ueXKwOKOf5iWadw9nWmCJvEzKBzoj1Mkc+TnyER3xoHMG8J33Zh7Nm3lB8pnH5m7mvTzbAZ\u002F4Uv96pp9eNdvfix\u002Fxgpvp6gmu0AXjnMTjk+YTHRtrTBAtRfXj+cANB2elLXBo8Vx7f7LbwPqcbNqj0Ph8PC5a2MQPINLXkRdjm07H39HWAXJ+SnM1DulqThxmw9gh8jAR8Lpr7Cv3+dSci\u002FDDjz\u002FkmL0IpF1s9eaD4RnzY4IBvul+\u002FR\u002F5CCDipwWB4taTfuJx8olCoxujC\u002Fkax6er9UFZRWmWbD55xxPSILYlufcfOugXeaafyQIarf76W8qb9JOKRuSUcUTtRzNmOjoCjBycKRIr8LFJYTT320VY9UVEGa+xu1Zq7BGjqyc40zN36IKeY1YBafbe6cT9r8MX0wvNiYAgB7xGqw7kgKJ1EB+g\u002FqrV2icFQNHlTLbrw+PK+yar28PH6cDk59wEL+Lr2o8hsosCGemK+mFO6Q66kdaOhPMcNECj\u002Flv8Ur9G9s1nwavd+HV0qvlIbk63ak\u002FX+sxcsl1wlrFbiR6b2rWcvFkNi6\u002Fevg6jlVKSGu450q44aWxMM5H+WlF1K3TS8pK5+i7Yx7w40bTZGR0lDUXlPnLJrn5YUNJP2APd8cn1MMAE4c6GBxuTCoFzMGPXDO1jPEFfGNZp0sZovp4H1u90kOKzhyutW6qtFU\u002F76KSOWeXlmKLzTnqHDJMjP\u002F\u002Fuyy960r\u002F9tVDlv72dUa6UB8A2wlWbDK2DbfwkBMDbmTMvJrosb5kQU2oPzq4a3Azh8vRTLhdTbt2H0CrC7EdAL4ZS9RYv6TMmn8clCgVE6cMoFsqs2bC8vdNJnmvzjCUXZRM7cCbBPL19elJfKBjMdbHDVChiEQi5VOn7MWr\u002F9f\u002F+\u002FShFhsUGzBtNOGME1N1oKc84GD8g05thlnclRYVyWBF06TGXJiIsXUSknUEXYRMdnShpDM0I2I38yaftNtZWQGByue\u002FcCbiXYy8SUb8oV+knGEbdbYYmUs7f6Phh8+C5PreRjlLHOJS8+eD8MLCWogAcNdGNifGjzPQLyBiAEJM7ZfRUfwMEGF85RlHnOT45IfrlzeOe92QqtMzGrO7RR\u002Fmom13zaGtSvvnzn7Z+\u002FP77aJz3m\u002FLBA5wGpTpd73OfUWacsgc5O9\u002F8+S\u002Fl2T8K6D5pdMddGw\u002FU32ddQyFfu3Jp5gwItgTPsRLV\u002F91vf9ecOq1v5XQqdymP7GUlK2e1qh5NNKqxnAUcogmNZ05WxLNNOW36fVHlnQjYZtcO1WrF4Gz8ezkj9zaHlJLAc6Po6rdo7ESW6q\u002FUm3PnH219\u002FqsvW+a9MQbt5xwxNOT5z5HQpfcQbHOJ3hSk+0WAKKhZ0ow3tosa6ZdnzXJ4GyEpLIDPtQxIKm++V2NWhOvnn+7PSsJRxu7Zs9LOUjz4pluin75mAGmtVDS6i0bhQXwRoWcONsbQStJEf+rDRMW7bynS1Wd8Z94OAuP6Z663U+ZToqzv8O08T8PzbfePMejvOmHsQ39jTIbwaVw4TiUgwVTvJXNSRgC8sr09YviafhGFGXAW73GY0UYZTxtIR86SiZmn+JuBBrD0RJ90l6mdqFY84LO+ro3a7L6pDuGDrBiZQh99IMtKwz7M+AJVDvRyxD2HZqLm9ePN66fNgcpQReMi\u002FJnGde5IffsV+dYOwybSpv8AwICAmWcTnAGPP9ZKBFAUffQr4zoA8IQG5ofuITf6CSzMgTTR1T+GZ9GBUQbWjA\u002Fwjx6NSfrb6L+ey5Airu\u002FxhhQH5wRciGc5iXTLvfheX0TxjGGqTDVuBhNNOGnS6Dh9+JttmL4bV+M094Iq6CQaD1SZDwZ+Inv6Ea3kSe\u002FXv7WPJCehZ+ITc2X+zRHDjhYA4xjKnhnWry6+VLvGPnIVkHN9\u002F9MXfD12pXudRD2OUD+BMzrLdeZxOfgrzWWvCLYJIScT6Ut\u002FDRiJThOtR7X1kC5btkj0dBnvdEt9Htntmcbvn88aRONsrs1VvCmiR8\u002F5vP\u002F1Tq7TAXjc9+4Fujii5j2hmPFzTjXpfwvsrHumjfqFZngBj5ShMO2Ye3ZSxazzrRbik3lOz7b\u002FAP3Nvef1zYx96YfaaX5Ei9FdcMILzYx3gjM5tVTNGodVoHcTlLMSazPqwwcPR5bGmRYkiC+UX1YSF43DbNN11UemAgla9Yp8Q2+R1aG3z3uT73Gc64+qW1ZSbKJka0VUUdU95oCs4Rk8Pk5PwS+01deJNPcc3wPFKqy5zxyPHY1n6RwpTV7GRYl4Dlro4LuDAjfZDfoD+IYFAHvAHVg9yB6ytzOY7jHni3fM3gx72tacz73nEK5+wjGzF6HyqxsnZoI1fb5pY\u002FRWQvD2bQGt6KnvZE179Mfo9f4AzOlx4zJuugYtzedaWVz6cvrU9cMb3cRmw0lkB1\u002FZSLvSN1fAgRPQ03JfDGDxsTb8jv4CEw5k3CsafZAcjczVL3zGFqAHmRQQ2CuVVTBAK\u002FunC972TP2jJwVZ0eBs9q8Q14l80elhiOydrIFJWep7q+DjoDQH9BT9beywnTz+BjLRdStIEKdg2No3mAPystX7e8qIwxytVlS+UdBL3\u002FaztwIkL+orWyyQR0b+p\u002F\u002FhfzTif\u002FOLGLyX14sXT8ebNnk6KCLjBNDvWqYG6qQ52Gwo5eJ0wMm88ZjkcBGCez8\u002FCECUZpDxMtlSELQ1CiUCYGhRp8sdMT9pJIRGJAHhYxqEBqyAJpGuW7dujOEgaBiGA8AYYMpHAT+fYXYCxpC0GvtXBiLoS7DybC9aUmUQV1meBeZ3hsFUsZG3CRSamFWJBsiPXXqfGsa1POMQghReXEoXq0aitCBly\u002FGwi7nBDWPZILTbctUwTgBb30RNrgXifvc3vxsDKq2I0bp8pYMVGpMxivwbj2iGpZkrN50EGj3G+MesVUv59tsnW7\u002F\u002F\u002Fe+rNf6XOVCmx6c0LFO9KVL90aSUmLf7D0oXqc2p9NLKx3GCdGQFo77RY\u002FLOGHSRNhsptk9liOvztdKPAO3Dlqe+a5OGSBewADyMhHUP4ObwmHfV+73747dV9PjdHB4lF9lJo87a2Mtgm2PzurzkTiGNDvJdd8x1So8HnyjXPqJmdFKAF4qQ32jcFKsDFPYDF59\u002F+fXWRx9\u002FPlH8O9\u002FdmeVzmyefPonORY0YfIpL3iHhwxeiQqJPgBRnQ\u002FThqP7JIxYZnehX4r5bStflS9dbXdkp3en61o8\u002F\u002FDgOGPqI9FPSHXXZc\u002Fbj77ujTK60CiNyfj8DZR\u002FEm8D21M9POToaWwqIf4w\u002F\u002FrfSAGBfv179+HLwmcodTJQhsAnVJj5RhnPJVwQbgA+IS9dQLcCbUgN6Cd1uaRc2xJkPm6D2olEtjnK3dKcNStIFlB\u002Fy6u8Ag2jFeOpj2ncUnGtHqXbtOFfxhBNfvWYkMX1NzjMWOO75+tFYE+Cektrs+zn8xFzUnjq98jO3R8ZbSUv+nqVQn0dPqyD3ot2nbe45atn01bNktUgInTN9i9fwnDQxlcVm+RffADnHOYCjRwA9kZ0AawYDWNqJF4DR6Vf3A4MD\u002FqLt2+TNSoO2jEmNeqtX8jsvXDmz9fPDx1t3Wv3y99WclLdVHSCDFLnlX6UtG3S8C6hFm+gDKFP40hEYBbxLh6iGhHIOdOqLZEw0M5rVz1fNYaPoxMPaic7mVVAECDYGq1TapaukiFlO5tgD9ORnZKXMUwCC3ptp7Bnk09xt7zytnOz1CWKI9om4rpOQq2QQPfbqB4MPoEpnE2G3DO1ejqW5VMlhqnk03leNj5ML0DCy+CDO6e9628PN2fSpDy1Td\u002FuAuoN+J4f2Mz2z+pjuQgt0QCPROWlCIGfdGkeUvItyNohIDRw0p9mZPuxv4Ko9NoE2ehkPcKrYn9fogFl7KUMoIouOc0ZBc8+J2Smff1ah6gOwtokUX9zvxN9W5xwONo5VbdKb5pu+mPJw3cMpIVI9bgGtOk+HA97SdOj4tMkAOFVddtKR9Nthc\u002Fu25zc70z9AGoWWhsiOFCw4394wutgcn4l+gCKbqb\u002F4+fQZwY6VYmqezMGA0ToE1MaVIyvK5B0eSptp7D3OPid2Af\u002FSRfSkCKV9B+sZ2c1WIKy4CAgAfuhipZAzOKlR9d35F2bd\u002FWwa8Gjc7Lv0CwCdtgBePWtAczqXblDCFz0Bz0nL6vdxWKPzpNk0lyLcxkpP67fIsvQG88SG4DEOMBnhiHKe8BV6LWciZyMZFEXdbAQ1VwJ77Ajdxv4D+RdK0TibnEpzW\u002FZJJJnDJs0oenfNAPUmeiNbdN1Odk0wSB\u002FT2j1bieRVKUQ7nFzPYducJA0\u002FeCb5oy\u002FwJznDRNvRFs1u3bw+dngOB6qfF846BHKt1F0IXB4WQDpIj2YpJ8W4YTd0Oif6xx9Sbmq9tpODdMb0s8\u002FO5fTBWcMrfT96xc9kA\u002FA1T4Nt+ubC+QIW4Zc3b6SsLocHTxFKdkP\u002FBSDod7Qx\u002F2TA6hmn5bD0Jamc7FusMr1BuFwZ0zT8SZfpBVJMsCC5OEoeBWCOjs9F7wKHzavrZFgIEJATadVswFH6+PLVG\u002FM9r08lK7qLMzX4a1ZHpXCVVhddV4AJqaN74+DQH4QHnHHAvhxls3fdG06iG3Yb\u002F+VLyjhni6xmxo9H8dfLNwXv8PF7er03oP62pYHmJOEVpd0LCFXirygTYMOrcRjRgzMPi4TeDNhen8mWQmFiLwdaKR2bO3hwPsMo+9tFCKXCYNDePHWRcxFshuFsRLRRDzNtInunMzTuxyiWtGxyJaSE0iSIGkqRMVkEwCYwXiTvciqE9Pnysu1IzkuunZnQrmFMHQ4kqk4xj1OS4aJcRKj12TNEBMa7TYDOdTIcgAVEPyni3ECmz6Ns64DlaEqFQFq+vHJlbb6izDD205bLMfWKcubBBQDGo69fk4teP0S\u002FLP1xUBy+Q1AYcKkY+sGblCpg6f12G1d5oCrliCiIpoiEiT47zOlURsT8oRPQ0n+9LeGJpK\u002Fd55h6at7W\u002Fuuedzbgfanlq\u002FOdMHnnjjKDLX3mQJlroOnHH34awfmwPOOvvv58Dri6X273kw6wefWilIBH90b5nAK4oyHPnyNiWVZ1AisXmeYB7RwwNboZeo7CdqkSL+sX0GMzqWoTVi5e5VRMFL2x89BFq0cQG\u002FMvD3\u002Fe+v3TnydSpByno8cdLlSTCfnRtCPCgo4UzBhTjkPEcNKonFV5ta+iI0dJH69cKbXmfOkm39we\u002FhPF396OL+KhJxkO8wlojBGtTZtdRKdepVxPx9PXb96ceXDqn9ULeyEYGdGyc83Hu5yLBz+LNIpSW55jmPq98XByloLLoAXmdt7uzZKePFBgaYBLfED7ObDpWCS+p08upM\u002F6J2WDzLhmosnNg5+EZD72CPyNSPjLF36fS9bv5HA+qw0vJfAY2aOA6wI\u002Ffe2+rpsSg41d17U\u002FID45YOgYTbJutQzN7B354cd7W9+2efu3X38VXXKq4sH941bRUusAqeudZLjRFQy4tKtth2bt2dgNnDIiggOBGZsGevKMvUEwQmmePumz+E\u002FpyURyAYCuPEp+dVTUhFEzHjn7z9pQfPd+mykzNufOBbdetEzewW2M0PlzEQdYaROzTZ21GD9ZHgasUuqdMLvqOFsqjt\u002FjJYYbsPVCE1El+uFlY5kc477abW+CuugNe4IeZEOw4zCjxKD2lCLQAcB01kE5xhxCm9cm9SX9mokMTAaEM9oDTJOPhjKA7uzpTtJtilY60eILcE6KwzvAKD0ClIh425B+MZ44nY5+nj5+U3u76awjS9LRx6b6g8Z\u002F0OcDDs11jdOPDrOyIke3vnyR89D8IDBdzDE+05vc4jkgAPATqcI9onjkiE46yBgzym\u002FiJVwJGAAD83vy2kyN44DfBYDmVOeeOfMef\u002FZffRXBw5sLoAsQAIo+2ThrPhtD3Q3mY1OPHbH2pRXQF\u002Fqazhdh1Hf65rjxTFnDQRr1L0f5VPN0\u002FDZAYi6ioxMx9Rs4HCCUQ8qeGbtnAYx490x7g860ooF\u002FVcDgqL3q+6N0NkfSKhJZA753SrsYAEiH1xeOGdnyote1J3ik8gpaspECK9J5PE8RBKuZ5nlWW85Ek+Yx1m6Y\u002FQ+1+gEoLackIB\u002F45iD6SXexjxMoq49vVMaIduTZHq7f\u002FuY380wbm0VW0Zaue1FN7BdFLh0Sh25zYFMTyoaxuWRT3+11E6SgX9lGKQh0o8\u002FZcc+y8oZfYpN4MKe4a+k0\u002FESHna6CDQfFCtFeYPpM542Yg8nhD3xrd3RB319r5dzGQ47zCqKdAN3RBc1p\u002FaIX8BJ\u002FHJjeSdf4XB+GvtH9\u002FLHoq4CAZ6avhvfiv76jUzhdHOfCNtMG\u002FXnqTfMi0JIM16XhFXv\u002FAG9YZ6f8+I9uXe3zFQ13Hgm84bvwZCcF0zz+BfhL4SH7O6V+0jPobq9REzU0A0x3dtAp\u002FRS937EftbNkMZ5tvgc8NyjzQZLYNvPMCZuVhR4k8OLgJScLz+oQfu7zZUPgJO9WrBoQthzHhNwlsWyEHvsL9fCgcZBJuulCfGH12HhdyT4c5BzLhGDLBVIEcNk+zgsevVgkFj4C4pczLhhqDtI38SmHayQn3SYwRQ\u002F5m2xs9nXBG\u002FvxVMTIPqBttFTet9z6t1XSoiMvNT\u002F6EUGTDz\u002Ffz+u9AXV1jzEwJXrpEsW8XUqGFJXSE\u002FJiGE6pHMA7b26WbptYjAl8E26bTRHGZM4rophQn4laPD9oE2bEt1y6ifBJnQCmMAsmQWC\u002FUzKvEqyoPW0QHMCUNw1Ui\u002Fz6e2fHqXfLMA6Yj0ExzYq8iEAGqhoXxSkCJw1Ff\u002FSXJ0\u002F5iVjspoxGOAdgrCgtMEXBT5Quh2L7OU5t8ghB129eL2pXfVNg8XKOhZ3vb49x5mImYNsGt1Ptcp+24lZjsGn2bZuH4pBRMJdL3Tls+U7bAD56UAZKd0kTAn4\u002FuCWvXi66ZWaRjpRHyhKof9WpoZyRm3nrlCcaICBlduGCvrRqEt3k4U0Zoq7hmDiNTXk1RkZKh9z6qYCTUfFT\u002FrbI\u002FkenPtm6WcrKT+Wou47ylHLzOvpFmeZ4OW7qv4p2Kb345VdfFtnuBNv6RIAnHaLNde8aN+NvpUbtVLQS4ROJouB3GncQIDo9W2CoPnJArly6tvXVrz7unuOt7779yygL9MKvqrqo6sMRFPF5\u002FqJ74zu8ysjfKOUFCHgcD+Bnp6pKozIn19v8txyeVdZu+LPPn76u5n4\u002FbZSRuvO0cTMActqMSRWRFynV\u002FcCO6NhuPOP9c47MgwB+HQwQVRmheaIwGFBzsmrMV8+1yL02pCX1oEBAMpUCOmo+X2aw7ISnQHajFalaSoQCafZT9BwTBsL4j4YOKfRRmGYkiuNXr3JfQSH3GZvXgPDmH\u002FBgkLxF6anXvnT3XDNgKzlhD7p95HUiIKUlMIpANoBJqb7pOhvAzCXV6X2YfDzIcfnhzvdbv6mEq03R8gXPNe2WO\u002FUGGMGnA8ZOdMbz+Nlm1BnByTjIKMX\u002FNqAEKHbnGBkBArysysE06PrGKVeRDDGexiHNiIEjH85TcIjUd70BCVUL3sTLDhWbVI2eZZVtA7zpDZrmtPEWNRXJ0ndOJ4N4qgOI8JKI1oCBrhPte\u002F4uWYk2awWAk7UcHLrPsxi1d1UfeNHq3m4AndEcPmmFSPQbDd+JyHWn1b2jjMsRhyL5tip58WJGL5pzZnxGhs7kfJdg1JgXHTgygJEVPwYST8uZVQlnHfJFTx7Mvh0bbQca0H2NYRy+aEmP0blWq07fBMJWpQjRTcEDenvl4i4HFZu5Zid5tBrKOUOP0X3RGw\u002FRv+TT2GLAcSSBDUBltzzfAYqcgAFU6CsgUv+bG2PiGI\u002FTinf7bvE+FvBvvYADc4LvrWwsEJPD5sCvLhlgF00A43aujh5cddqX48AJe5f+sdDEVlmtOU6eWn8YoAY4rGh+81SLvh8wH1\u002Fo38v4xkrFbkC9Ce17DmOrAe\u002FSl\u002FXpTJsF635jW3Jkzo5byTsaOQaaGm9PO2gVc0Vql2PbFx0kZw\u002FV061PP\u002F00WvbsEJFxi24DavjQ0r+2AVxzAtxMIKMryQQZtBfNSahsqHvQFr2AIT\u002FxvrnAD+SOjnWtvVJ0Kd05exH6jN15aV4PpP4VBW+8kyfenBs7TGDe6RsV4sinOXRgIGzAofNT5NtqhTKHeJvck39j8MZrKsCZP7YEQMMXnEkOhQCZvptjfUOXg53GsPm8fgCxuA8LzipNv9BFK4U33da1ghvkxff7BXDOzF6IxYPUzALrXdf39AzwrIpMXULhE6zQ3NQ2+8d5WzKwDh2DRdhB5QfJ+8vki00TzJxU\u002FNrRn7EB8RYeJocwjSi+MXp7Pv4gT+igcIW58TImep1scZTQB2ifalDNLdl509yaF3Qbx6N7zLc5M5KxCQbsr+7XBn1nhYs+Ht1XnyboWhvk9GzBWs8cByEazwFr4SQO6+oPvR0espm4Z6gKKHgrX\u002FxMMiO4xnnbOGiesTZAnwRtopPUrrKjhw9m1T5bz44o1amf5kQfVCqy6ow+6IuG4zQPbsk+1AOrJvAI+i291Ifv4fXegDrwIQprU9\u002FPP\u002F80pRVv3LhRVPTKbFR0Yihj5nuRdMqIYsY0c8pXUUnXEnKKkDLwNonyuYEc0XkAkwAC934HboFpQJci0CbwL0K8FGqABYEzrsNAEdDGSceym0DCS1idMogxCLhJFfXRnnswhD4rx6fMn88m0huzYCoC7359sjQ3yjimGm83r3KAX4JiCZ0hdP+F02tzoWs2S5NPnNKZcKioAjzbyUx5iHDohh3SaAIsK+v3JDAuqq6vLyv8f3xwcQzaXkB1Ss8F5ikKqRCcjUt53m\u002Ff3ZjnicCNoUsxWxqMHxOclP+rZ9FjHW4yyiphi7dLpSiqYH56ltUIYJ0GZWR\u002FeagE0lpRADiAW5tu0d9+gkkl6fvHbd4489O52VBqLhnAaylafWMEBgzV6lSAqeLN3Zw\u002FOZBffPnVRBrxwnff\u002FtAG1gBCdGe4r5abLtpG+TMWT57+MieLiSpJORGdBdwP2zD8Oh6hhDkV\u002F\u002F1\u002F+k8ZmL1ShZ7OcplnMrSMjn4vJy4lEi\u002Fg672XVhVKwYnfrqV8bKJ91nzYaQ5kbACniD6e4ohYgcDv6twDgZzHncYzkd748aOPP9y6eP3G1sNWm\u002FCFXM8xgj3j6o0UUON9GEBVPvJawJ4Ct9xm3s4eRoNQkuVnRls6z+kMpWiD+XbIzH68l7qIzilPBj5wkI5Zr+hAkUx0KWXtubtCQQFmwT98PTq1OWJo0GR94LuUu9k\u002F+Wh4J15gVEYBz2+4Y73cO863m7rY797GJx2E8RSxqTcBhfggxZ9ZmxzOU9XmHaAZXz1NbgGGD3OY\u002Fvd\u002F\u002FIetW6V+qXQhcunFKNAfkwYQuLh6qgOvoqt50y\u002FAgAKlrOmIcczrByOtIo4BkX0gw\u002Fwbt5JldvgbzKYNDgdj+LhlVnst7reHxutlTpQ5chrxzfZbkD0ydKOAhWO\u002FLZ9KG\u002FI8fdV2T5x\u002Fe80BGjDaIJyfdKoo40S9er5xvcrhttnSHpvtDg8DLF0\u002FeaXHa9O8NIEpv9nYAIzT5VDW8owPrWOfMbYM8U619qQ0THQtWpozPaKXbEysq30XoG4cHPFNjWagARAQ5Re5FD3HQ6p4WH52P3DkhdZS\u002FOiq11VdWkGG0hyiMd5wnbYZv3GW+lzuuO\u002FI0hjkxrxbtSs0IJPz\u002FPTbgIbmUxQe4M2fmfnWt92DBS71Ac2xH34\u002FPOEBYHM7YojK4QV8MUCt6\u002FCnMetPgxsenTZEw3v+4n\u002F8svS8FaIpAwgsN7fyzYdfalt08VT6z01K3M7nIt5Sc\u002FpQRSYrD29alZ7Ur5ytAUL1zamhnHA11fmQz+I7\u002FPym5wF+IupSZBp613TabnSAHA9ygukNK634B7+qDMLmKeTw4Ycf1pczs6HzaXpHjm2dHDrV8MxZw86eBKDTswCctEj8s1Ifldgs7al5xjt0uD6bH2lrdLlno6kXfjdu9B19EOHcv5FPcot\u002FZh76SfaAM3yk\u002FwP8eg5u97eV9v+HuTv7rivJ7vwOECBIgvOcHDIrh5JUUpVa1Z5W+80v\u002FVe77Ye212qvXpbUpZasKtWczInzTAIkAfr72UGU\u002FS4+9GXeBHDvOXEiduzht3fs2IH38a6fUkNs9pyCCjmQClVY+dan2fuR7fX8VZ1p8VZdyZ55Zr803+Yabxn\u002F\u002FN5n5nnAXimlIsicTX1cuKAv66dr6H8v3\u002Ftt+MZYfVZ7DWP6qe\u002F6gX\u002Fpmf6IX3p+L2PlkKCx9l3HCZk+109yrxypVT3fy0DQTpet\u002FvQT\u002FTmz7InAqLnB5\u002FongHPqoDRcbQQ89dyeYQ3ESrU1kj92AV\u002FDJTCbOaOHBHk4UfTzpGt136x0JIdjL2rPvE26S80e8frIVNf6HE+M83SC3k0W68s42z1jM51mpcGckTUbYq0wegHJHDErkrARung2m+pzRSL0fwX7cpa24oGcF6lEeEc6FJyoD1JypMWgE7yo74JDdOoEbKKvQIz+4P1deqXr4IPd5G02mAr0muuh\u002FQc9\u002FOH3wSLRS2DlY70+GlAHyGz6xAB3vv5m0h3+4s8Pi84C6061LN0k8HKkgJQSA\u002FgAcAwpMvmzn\u002F10IpojrAS7ycOIGEzO50xwzMzDR8AFipdyxWIml+dOeUhpYSASkybmyMsXaXLYjfSFtaHTBFISN29dL6+9TZm1IZ\u002FyxE71ObtuNiykBCyZmCB91d4Plf3b3l5pKYC+9oAy3q2cdcaNoCgZ2fyNwhIV8oc2KDtKgnGydE+xAbfy+uX13b59O1rFoBl4xgoTAujG5P4jhhIJP57Sf5njsV8aypNHALlcQqkbyrtVTz6FYMND5KwfeaoUnqWz1B5mUmJsaNX1Tvt6+eLJREfQEHjQxhjtNq5QYipGiLhwfuRfWrmwsx4dT7Wsd\u002FXyhY1n+pnFmHr05bifTnAoL4C4X0YZ6ZcNw9TZ1MCvg0uol2HFH3fufD3OE+dFTv6zZ4\u002Fm+TxbMV70kQYw0azmx\u002FG\u002Fd6sd7pChm7du52FfHPAtt3Znu\u002FKGKRqbch3rzJG8cfPWlJiUX\u002F7tN9\u002FOGMyLuVrpL5T58qwZf0rFUhr9Zt4jwTgm+IxSBODNF\u002FBRDGQUJMM0EaR42nJ1UzlG6rvvv984UwnFk2dVLDoVD+1t7HWEe9PrzlF6tz79PBl5WJnGNu5FPzfrl9zQJ5WCPFYKKKBOkTnDQDTBDn+Rgd0UnRQbDpj3bFaKZgyH8J7l8rcBBHwATKh+MyCc0sQsPavZ7rkMFxC+DMgodJq8F17E1Oua6ALw9tF8uy6Z8bjOpT5igNHkyCD5ad6Zq814CFxk4AcY1r+0a05ozk\u002F8oI9SLjiEvm8aJyL9Hh+leBkw46OUz53ogIscOM\u002FU\u002FgC\u002F2iED5sMSuQjV0MM1H\u002Fqon36nU3wHoOgz3YD\u002F+zAHg4MurQGYXtEy8y\u002FyKiLNobVs32jj39PVfb\u002Feb5XojIdU5pEuMCAnmlqm1daJVlJErkDKMWAZBzJ17nxAOwOGbwYA7TNiKyIpOm3J2WrLzEszBsjZyDl5rd2zGUie9KgozIF7Ud748xcqdADqgeIX8Up0YsSMwQufyw7i6DLSnN6tY9GqvhkjvXgQjzPmZ+LfcHrOu0geRxK\u002FZLwbm9xk9xsXB3C\u002FcQPq9+9XICC9vvaILJ4eeRua95RIR\u002FcEJQZ8CKwIDuAjYJvMi\u002FDH+vWxOYjfm5UB3sDMcJp5io+AFDwmvcaKKidAUGWc08bSxDbf8XzXzyZXM4AHzHc0M08NiA8bXZccDD\u002F1RMBuQP0Hmg3ze7pbjcU\u002F9\u002FSMmq0fK5dZfsSW5XIf9oyt9KeldaVaJ4CVDhkHswHuHi8IsStqvFKUcuna12SlwvPrWwhe1J4dMY40zNAIPwgacdKdN\u002FF9+8AA9U\u002FbO6GSlNVpKYJW8M6cS2dXC1+08aA9DA\u002Fu062r8MPJk63yZq+AtLE99dgcsqXA9my221wBDvaMDR6Z67p30cfYzYO5BpoGXLqi784XSTeOifgml8CRdMT90vcWuFSNRYQyBjMpvdnW4ad+0vsAJPssqhunjn7ES3TA0DReETW1arRWixZQJ9um2HM4m7PaWF\u002Fm1Q\u002F9NM8i0fKozcfMKRmpMtTorO5zv64B3u55k55mA+gQf+MPF3CGyIRHjCOcfCOD1d1xhrvn6Fo00T98a0V59gbEH\u002FQQ8AoLwUAc8nHom0Or0GhPJs0t3iKrRzpFf9DySLdu0mkFe0YPo\u002FHMWl2qT2SFDhgnvD6QKCld5J6DaB6NifOCbvrlu3F0SgbgKOAZ81pz2Zd4gA6IVqLVVk+7reBZUf\u002FGzeYOrbXbHXjXG7+Nc+NTvCTtte+dT+AU0Oel2Xb72GB2efb81O7hgfN7CuZlC70fsHORG87R972uNQfjvMQrKsMpd40WCDC83k82Fw3XKkK8EJ0a6NBm9EL9m1WI2kJfY3x\u002Fsj4a9Ad6+u1f+\u002FpoQN3kYUK1waW\u002F2M0tii66AxAB7IyBwRFwBhIYQijMZUzfBpbedN3VqphQohM5+GCIMCfP0rVUG5AOZL6o7q8Jfp4in0hYzPwyhnL40ixfWAJpEjAnAXLz5KVnGH1GCAiFiMAoxr5neDHhRARyOY+Vz0XhrWipSJF89nWcO0YC4JWawlgY7vr16ogXUQMoeGtOa12lKxlbDL1KNB2NyaqA8Svdp5zjr375y4mq\u002F+hHnw7zqGFK+B4DufVV2xda4rlcCssYL+UNYjZl1R7cK8IbsL5c1JhR1zcH48xu58bGwAECs2zec2tu40njpXjNDaMPG3EA3laj+U0Wx3wyLMdPyPG38feHwLw8d\u002Fl9K6XoeOPciqYE82TpNdfLJedRi3K5H\u002FCwjAkwX2uOXzRWaVCeR0gYSMPgkUfSaH1mjD4H5M7XX6cc1srLzZvXq55xv\u002FlAk5c5Rx0ylCBdi+ZnA+VvWv6\u002FG73lK1sWFcl70eoDj1kKEMC3Xw6t01mBtc+\u002FuDrlMTlVD1otwZt4Tz7iLMNHVxtm8NgsOzZ3r3tTwJcunR9lyQgxBKIZeAmfK1WnMg1HEI3PZJBij42DjJ8lSpGg7777buPVH7\u002Ff+Mlf\u002F9uNv\u002Fqrn86zpZAx7m+KELys3u\u002FtTz8PCJ3PiehArOiONyltjsCzgDqwimCiC69zWhgjqUhnz+cgluKwJZE0wsqJFvUz\u002F5gtrp6+Lj7H60fA1Hf9q9N4dUU8GCCRs6KBFFEMQjGTJWM3XxMV6bPN+MTfXqO0a6ur5rNl5Cl1UYyUd\u002Fd6+ZuBcps3ucRHeMKyNeUnreRJTr1onSVJS71W4gB195LJvbdPc3aqa93f0r6ssJAx6SH0DBCx1zjM3URmP\u002FxulcI95pii9vN4wFg+ovsmsp6+Wv1vXPWSvrDx8t2Pv+ze98mt6hWiOFVhSj7J5tGJySJhp9N1Vxrn8eelsfQs6V2ALVo5o+B8wNFqzoDa+Hn2hAR2pUTs7ko12B2dgG4ctCZ5qGV1xdzvxS\u002Fu0TsbKwG2MaLARc\u002FbDSRIn3leTf2HObNPq0ZkpS7ib2wmi+Zc2pt5topl5ekwXkszNh\u002FJfnQw\u002F6OT0yl0C51ozCK0St7hdQe40RGA88mmHr8QAFE4hhbt6emRM7ycDEqZAJzNOd7E0\u002FgAf3DkX71ckbJVYs9nOcJ9bl6kH0pHGkJ2zwAR81jf0Op95yeYH+0aG5AvMq0\u002F+qUyiAtFx4AbPAKgc87xoTnXGZTViucAxfO5v42x+\u002FHMkbyQpT6YL2e8PWca6ef8WoPoMhHRvookPukYdCuhRZnTEWSCbOEzAG8ncG0PgrexDdgQHJLaFf+ezh6cPd35JfHF4WarE9HYHop6WnqSkn5vKndcecB+5in23fuN7+89mKCGaltIBMzTpVIkVdpgv\u002FXBihB5e5suxGvshJVw+tDK08mKCXCQ0R4feaHHyEsN0yX+Rk\u002FXoI\u002FoJYdE+15+jqxFDPZgdEJtmUPfvTkeT\u002FZT69riiOJxbXsOZ0Gdci8lnjm4vjPfAkZS8vzEQ\u002FuDolY\u002Fra4ctp9keJP+6v7pd1+bK7\u002FjfyCM7u3HPN94j4Dn6k983XjokZnzccv1xnO83Zg+jvac4QHxySM+pEt3ijB7Ntq+jbbEFi05Nyeq8T73hAMSocZWekXAfG3kbD6788iRt1Hbnpw5PTXZhEdgJekydJ6Amt\u002FJBMrjXasQ5oU8obt5QS33LQxk3qQUr7Qc18MTJsf3uwKb6S74hx1gm0Yf9bty2eiDcBzTiDDyz5Hh5JE31Jn5r13X4ivgHQXIIp48Wr2zD8A+GHJvhW42rLIPVaEo26sxlqqC9zkarXa\u002Fze7hZWDdeBxiZU61Td8Iylp5WXak\u002FjV\u002FQ6fG+voDj+MD+k4KGboIik0KsL73Jeww7dU+psGXbzrp29g+1uujAXWKg1EEygEk1Vcmv7JorUEBL2vXfQq9pVGgE1gEas2Uibh\u002F\u002F8EocBFewEvemqglDpZH5xoMRklb0uU9mWBM5ntCQuH7zGQTPow30dra8DyReYDbZEhnEamZyEBGk4CtiPVKdZmoUm2JXgEFmE0fpMAQgAOl50xMzDWRjLw8u9HfFplluL\u002F66ssRbpGfx4EMyoSS0sYCrkV9O0GUAuM1EsrdrpGfrIa7k9r+4i9+3HPzgmMq0XqCzaDw+EQeRE9t6ASYzzcuTCdq5Ih7hnqWa9rkdrLrEPpYVgqdRAnljivHBVSIXqti8yaFVlO9Y\u002FhoiPhqC0\u002F+W8ZCXrxoOmN6fFvEcuWN2tiCySfSHaMybBOdizZOUASO8YHlVn2UDiKtwyrMxfM\u002FnvmcJfPaATalNZ2qb5QYB+RxaTPaE0V4Vd7vfn2QEiXlaQng+XLIOzyhlRuKldGxynFpJMUmo1YFWn52aApQZLwUixw8tL98+Uo\u002FWyqPXyhRfLF4jhLruS+dfFqlg\u002FrlZc4XAGBiiyxED8cV4wf8LFfQKbXeFIMNog7LsGRnWZZi0\u002F+96Png3sONJ588GeV6s1rylMLZ3bMb94\u002FdG8N6NiBkA\u002Fbsr2iOph5yhwPh4eDHGAwR3MNy91+WRqNv6P+2Y5WtvExEOMOmzCNDkClZmyXrlygUReieiaDU9+UsMTgU9wLrfleR4lhvvOsa4wTo\u002FJtruybkR38TlUWfvj\u002FWc\u002Ft\u002F3\u002FVzbmOUlpFFb32iOtHd28Yg9+PBOjbyJ3fdaoy0oQocDJAC8kS7Bny1WRMvcDilIrnOOQpARpsBNnarELDAxSqNpvNH+YQOhgI4DlLq6l5PpDVZnAhzfzNs40iqG23sjdMSrVzz28mvlJcnzojISTx18urGjXTXjU+uDh+KJjq4DTgHcsfhid7G+ybQI\u002FSyZYN6vC4vX+qCqKvrRJ3el84id9jhMyoJXYiAgPDkdDc3HArR7u3KBk4lkZ4jstXwZu6O1\u002F+J1HecHoPyqJSyJ8\u002Fa6wPMd5+ILH1kmZlzbGP6GmtGKzBFr78pL5dBpp9MsZUfA5iofsaLjnEwF5CuSpE5Njd0JjABIDHKeNGX5MlmdPNL36K3ClWje6PL0j0r1QIdGvqA4xVpXiARg5zN6OIrlSMEJDzXpkIbAgfkAyYMPuMeQHJo0mxMr0EOmaCPHF0yYH5ssmOzyCtu3QqAejj97HnD831O3j3LZ67F\u002F1Ka8DLwo4Se5\u002FsO3bbIXryFd+gHPzUw9imCitZZISM7r9t0uZcdQZPT6XNzbvPu3FIbVsKONT5RzCfp\u002FXsFdgDIsxfbq5PtWFUpokm0HR6K5zYD7gIPnDr8qF9Wf61W4k1AXboi\u002FqD7lbplXzmafrKv7Msqz2vgKwprrxmH2FwLatAhAOxagTyizwy1viQ30Weq6EQl9LEqMPLfd3hi7S9pRmtngCy6Akie7TM0jZ5mYKXioFs0jwc5ewJ5Q++ucT06b7ZPYftDQOlIrvV\u002F+tP3RoM\u002FBhBG53luc8PpEoElp154P7J9eJvXeMR4P7zrxrxgD5\u002FPazU+87A2upZi2jPgEGMd3jH\u002Fzbff9YFs4wtvfx90Hf5ig71Wip5r0YstineT5YYyevx4Y40gyZPv0tn1xQr42Ix4DKYw6Clb2U+FBrbqA972xovsfh+NDUsdNUaR8Oagf8dzKAQTYBk0VBnNKjIgD+foCyIB2trDc7NvKR7kXKHopDwNv9mT1th6CH3KaRAVX6uE+ppti56wgPkgO+RZeosqPFmq5p0zQuZ3BkBzxAQNnoYXHPZoAzFrIwWGHNuDhg\u002FwBvk3F9KLHbYFHyz7veyPOcFfbCDb+LoUMYHHCYD099KHUrjSmekpmLAGpn\u002Fm0erix3p9NKBO4DGon8Dy1apYUHpSXo4IHL0ChZeKtl6byUIobwaWsDv8AEh3tDxQ96M2jsmlYwhM7gD88rgBMAAesXlIls94RwhLsZjwfh1G0o5Ddng3ALpNf5\u002Fc+GSEgGOBa4E134+nHwPOMjAGj\u002FiiN4i+1\u002FdLIRWBr5Sje0fwEwreu+8AGG2hAYP1t\u002F\u002F33298\u002FvntcIJSkVYPbLa1fLii9gyiQ3oe9\u002Fkoovr9xZc\u002FGkH59pvvanNFAeV4YxbPs4ELLe4VDVFTnKcIllHWFwPcxjcb79qwia7ngLDaNSbL2IRwHKiiK5yp\u002Fd3XQ7\u002Fz9W+vpfq9dlWI0BACAo2mBNUfTJKc8MN3NwYciYxLs5EvD0Qxvg4bet5zlUESKTyVM2HeMfJmmq9fh6FvNQdvAtuckqno0L3Tr8ZK2N6mnIF+fUbXKWUYEEKTCzmCe31HgAd8FCH8vgOe9gN4NrvxeOWsWZ9jYRAAAEAASURBVNVx4BPHQAUMS++LN0qfiA+Nj4LRQTXNRSRtBGF0OBCPSzkhbBw9KxqMI6XEszZfL1Kkb98u4Ux1TpQBT6IrXqVMOZsiIMCwKIfUFzxiPi+0SfTY8ZyGHL9f\u002FN0vJmXqsx\u002F9aHLMVQqSWywyIPKpf1arXlQ5aJYlgfT6Tzlwwo6loJmdOaAmwG7zsWjDKPv4DEi3cRCPOwhnnNDGwEAa\u002F6TzND6ZK6bbvKOPZ\u002FTHjIXi5SSnM9fnfWUlocmthf51nWsYGUErP7Uh1zfi1U5\u002F9CvDq92JuPeLe8cMdZ02rD7pF5muuxMxlTMIUJqPkynpOSCna8kUBax2+xal3AZSKWtOudyvfjDwRz6nKgZj24MySSNDInj645NlHDNa9UR30Y3R9p0++R3\u002FHw3eipNKMOb4TA7BufSRiPLzVngYRg4EgAoI0ofPcx4MGh\u002FaQ8DRRTvgVY69KKLxykWusz2vntR3PDcpKvWEg7kTT5yuutAYlNonG2gpgn1gw29k3toujz06ubemNTcGU57y89JeVEjBC9Ki0Hpvf9UTBuakf3T58MnklDZujqM2DnIGGGfPw88MLD6aFdT0nUPrODVnck7px1mRSk7pnLflhNIr6Iqe9KW5EVkFGsi+AIAXUMhA4v0jJ24OlypkxlmdaH7P300WbYZ+kvzgDZwk9QuwRB80pmPNItskXcBqDNAxq699v1aoVA4rMNB3y6HIMTIX8dU4qHih343beJfhXsYcrYBP8+AZ5sypmZsVKfdcTof5FQUnJysSi9txIXYKBCSb4+j2gEMnHHa406wyFFTieHDYlNU7tHm1knuCKS\u002FSkz847bnVFTrZpkHlOwHbkb9kDb3fdB+m1xelhUMak5IwgDpa3b59c+PWrZujg+X0ooe0TAEktsQGewfHzUbmaOl79D2aw6ZyfgegBpg0Bukl6OKNJq41Tn00r4vDOPv+XnuTxtYGIoe2wPlquGuimfkcXl4pa8C4v42VPd3qcKpJsyjy3BejL\u002FFpDy4Hu3mJFgI0gjzmaWy9zulPdqlZqs85i8mm547s4Jvmzgs9FyZYfx\u002FpON8tPRE\u002F1S69hmeAS2M2p\u002Fo4ed3phKcFUZQQZbdgFliFbfAyH56DXmjgxVZ54WMpa557PIfzeBvC6R3BmffpPYUV9JkTwCnfzqFj1hYfxHZ4osEKREmPsiJEts3FGmu8\u002FEafF38vHl8BK\u002F2phd592e\u002Fs5VE9emkxnMNzrSJq61nYzWeCWWg3+r2\u002FPXv4+0M\u002FhgeiFxlcQJ1O4FD0d3reqg+8oI\u002FGrGOCcX6aNjrroEAMGnMKp2LPB6zUR9OGyi8\u002FhJGUij2R7TwRn8juwM9WAYdXa0ubctwnt90+kp5nLsbZ77vho55K\u002Ftdr2YNJPeIUNTZ72PD0mfCOtGLP4WxwYj\u002FW6+MB9SIqX3zxxXSYIHthUsKBqXgdlvp03uB9J0fU4TQi4wCN6AsvkbAgjJzt54EkYISxvXX71oBsZQZNNpCm\u002FVGqMRrlDEARlK130EbLyikZRmGemSK7X6R7PyPLWZB6g6FMOOFBcIpD25aveUyMAtAlArHAlo2LVUnpcx48AKV9Y14pMc\u002FHQDEwwPpvf\u002FfHycP\u002F8yLj165XrnDr0qTpcDZEAhnqpy3R6LsKKZfKxf7v\u002F7ufF5G7VkRX9MtJnj9MHXDLjgy6fks7AdJF1NVeBnYJPiYTgXN6FgUPfLqPsPMcjWnlfo5OG7rwhA8PUxjRayIno7QoHKDdBiFRt7zl5BVYcA2aUHiukZMfFUcwLUlRouZgnKiihaLJ5y5W0SQF05Djhf1Z2fj5z\u002F9m4xf\u002F5RdjZNH9pAoZAWXRzZigeVmKbjlMa+nuRJVb7HmQg4j+UnD+\u002Fu\u002F\u002Fodrwf6i+diApQ8R4K9EIvKyNdW26je8uZNgBg7rXXK865RQRxXI+HgD6gAsg0SoL8IBvXvU3wTbW+XtA4KowoB8UvJrANusCAa5dUWG5jTa7PN744quv5tCj3\u002F7+D1VauJ+j0OmtV65kKGwMrgZ+c\u002FA8o2tOP\u002F30s423rw6ncg+H9GIb9A4PK30WIHybM\u002FaqFBdpMA8f3N+gIhpY4z0zzxZFVi5OxMNnJ6KpeTU\u002F5oSiY6zweBzQTwYdYFzRC0CtP9wy91Bks8Gxn+7BC76ZZWctREz\u002F0FH7lC9enn\u002Fa6rfW4nt3X22QN2DUM82D5xyBYm34+3hKd5ODVj7iAMHkdgzsB+N5BCDNU01O84wkfpjyav0O+VPo0qMePwrIN\u002F9WpIBD3TIWBtQL73kwh5RBMJ\u002FejC651q83+\u002Frc2LpvDCgdlgOlX0rM\u002FdVf\u002FsWcKDyGr\u002F5arfIgPLjVGwi\u002F0DyJ\u002FjEUIpgAhE2YZHrqLPdMLzxmzwAjLuJFzw2\u002FtvwvVe9C\u002FC+SpRSrlboX8RgjbfmbjNurgO+Hto2V\u002FN3vuiePA+RjQFYOf2h9DCHwIKdUpZgL55z7sJ4NJJpnOlDVEfqEDBgD4ExXv6\u002FtWTFM\u002F1tNRBtyhGZ45U2RNOMZsNZk0Zvm\u002Fk1zrC362vd0AprgFzIqvQvt3zb+iVqmVwCY6UtjOz6VM9K5zR3nQP+tVrkHrelifGgOze9++vYZHuxZ7MnwKh4UlOAsNaatZEVgAE8jnv7jG\u002Fy2orkBheSF44EvJ7hS\u002Fy3HAyVD78bnO0CDTAHpVl7OxZvs4NAvOzhlNPu5HfBeEeNkMi\u002F5fSCcrpbmsRe4q3cjJ3K9t+MTpVnNw4y7vsn9BVKVi7TvS9pbIjYOFzta1+u\u002Fzbyl0KRbybvqYKpaff7Z7dHlKnE5n+D9wcXGns1OdygDPFHC5tLcrYj8cnqsHgDInLE5tGtoFciuP108YyTTZEPQBTEHxOKr+BMt8YcAGqKxlWzvixdpjWiPH7yWFtH\u002FBXzNr3ttoufEccg9b+Bb95hn94oKUzsDvBv\u002FpKQ0x8MH+Ky+4w1teU352vqzrq99fBPNvPQTr3BQ\u002FtQjfEHvdZ288PnX30t\u002FrE2xaEbHLAdM6kRz1rxKkSVn5MCm8z8FGWtd\u002F8yT+Uf70T0wU39Lk6PPqHOlN\u002FE1HTGrMV0rimyvUsQaPDUOZz3jKPbp8Dza2wsDL\u002FmMc0u3zF6W5gGfoDWcI2qMljTy8JHvooX7VDSaMod9b6bMM9l\u002FnA5AAzwBf3BgtREp3DVzJXCBzvDcyRNSlFvBMoO1SXeu9DN6pufWVh+PLKOne8iW3HT4ydz4zP4ckXybp7m\u002FAlf6JcoOD7Dp8JvNxk3Z8C3MyR5IO3Yg3s67AgrxCH41r3SNuRsHFR2iiWfhFX3irMB9M66eyvkB1NkHutf8WgH8WK+PBtQfFdW8dk2kUKpJKRUBDIyBMBgCE5506EQKUYQT88tblyMkV\u002Fd8XpklfsrxSVEpVUGcdmmOEUQ1gcstY\u002FPyP+voeUBKeoJJF5UnfGqFm\u002FRJN2gS1bnEKECUpV3RGLmIQDnuwczu\u002F\u002FKrL2fS5bWLhuo04+s+hudSaQeU4CzdNYEmgbCpmuAn4Cjyz9HQFzW7Meut2zdqKqCXQrFpFkiQ8kH5S73wGYGUCiHaP5HAGIrTwmBowzHwTmUUKSbk9+49S2k83Lh180rg4M8qVfdJiqjT4YDH\u002Fe+HTqeqB\u002FvJzUBsz31w\u002F0HP02eGgxJMyBq3ZSgAmzCIhj+4c7\u002FnOWH1VVGWG9PPieTnyZ\u002FqgIHT53ICAtqElYAA\u002F8+6jxDPISkpbe2INltitmFuJq\u002FvVcQZY\u002Fq6vOGM84DhaHH29Pny1a+Os4YeDryaclxNOuMPSIk+WuL2TJHk9+9tDqS8DtuwXJnHrnOsvJNcbYxCoz2AouUwoMsmIEr2PCCbkUOHBXxKH4iHgBoCC9jz3hlhm3ltRJJXLJ1IZN5JegAMB+5hTgpBxj9SbKhCedAEU7RfpPxCOeJAq43LUlzQ21HDN29m7OqHOZc64LyBEyXIaW8zI\u002Fv4\u002Ft3oEkBKPhwmdZDD+erFs+jAQYxvmwsHgTy8T7kBu1KDlI1qeTxZAaB8RolfjyeloSWCM7ZZgu85Y8j6DG+PIakd8ogX5tp4pGmbd5fV96P\u002FJV3Ng3saTnOZfPeVVSf9Ny9o6PljCGt\u002FGcNltDnqqd+Rkb6q\u002FfUQjpi+HxMVr31pXs8CoeTFSg9zcCG5wVccERuJVMkQ3X9wvw3d3fO+9LBTRXLJjlWe84Hi7374bpziOcCr6wE4yptzv5aejU30iSMWsBujUp960RtveuMHwJNzjIcdoDH5kd3nZEf8xKCSw09v3577EIxjqM3HBRU2kwm0oTe8lEEVkVcrHG8C6etUv85Q8IyukYrBmDh1lz7bb3wA2qYcY+lp8ZBIlkOWOIWCGnul\u002F3iO0mVAtpFwvGzCVfniyeOcwecZxoz3qeGvwEvf4\u002F3zHVZGXoBwqw9WWMypsoKqFwHIdDfZ1de612dSFnbapHh30hYZqHHUey5jhvcZYEEFq6Vo4iTCiUA1H9KTGFztLVAiMMDYor8xpivaSLmMuLG1v6h52MnAH1U0eXfQBtHamDTI5sFrAFI8OOw1FGGDcnZ6C2bgqzH8jZeNAjDnLIooph\u002FekaVElA9ORVFpz0Yf+o7NAGiWgMTT+L3Ppez5fBl6oDbews\u002FRG7AUbSMzE82PtsC4tvTzoHrT5V0NiLDhlm1Q0hY4kA886U+lHjqYbWgfX55NNsiHN90kPcIqinnvkY3VwYEFENIBUhd75AAh9oDduX3j+vCHVYeXrdTtJJ+yazyAnpYrLdWSbiA3ViOAUvQFANn0vfSvFxkGzl27nJH0SdcB9UvONdvcJvho5XpV3gTrXr+ziiqa3vXxGTuLKHQMfWI8QGTmcK4zOVYOzRnZ1Be09veRPHKGh7bx8lYnkKMxoO2n57DL80k\u002F8TodZs4nsNgYYAT9oAfcJ62MjWIX2KI6uPgkZ9t8HvXX88mK9mYsGu2h5vDUbmNsnvEhm6Bt\u002FGQvE930riWH\u002Fcqsju7sGT5jI4BmBRus6jo3QL8ATIGJcWKaK0BRAPL9K0HRRcvhw7rqQDjg\u002FGjzO\u002F06dI1ug2WSU\u002FLjWRPc6ae\u002FyTOdCHzTBeZ2BS9WdFt6i5UIKZ0PCkr6ib+Nl02lGwRm8T4dzbGXauLZ2uR0bhV8AOrxG3sKP6Gt6D9997RUPQ6mfslKANTVTT8KCLlnv\u002FMoMAudOc5IuO10PG6TvlV2lWJe\u002F+Z37bkoBfHdD4PP9EdglFMym9jjE6Wuzd8wgmmrJ2gw81cb5sEbxpH2ZY7NNb7GAs\u002F6PZeyz8M5ySPZ\u002FVivjwbUf\u002F5vfz5K3HHvvBCDfRtDmDCE2OvUJoNk+Cwz+MxyEmallL4vVePzz78Y0PXFxS9mwkaIgfwIIQqCAJQ\u002F5qRsefSY0QtTe9Ys7\u002FT7mTMrIgDQT\u002F7dS3l\u002F26UPXB\u002FnACh2JPHlhGSEsn6IlFtyJMQHPQvIsITxVCpDKTeYGoNRPBQED5+D4M25ANbk6FMShPtxS5OYjCH54fvvJj3jwYP7cw3DfvXq5UlTIVhdPiAPPVxjJcFqwM\u002F++qf9xPS1k2G7f+9BzLvSTG5V3o8ivt\u002FmSV7xy\u002FqX9k\u002FgisK2i3+rZbBnAVVOxu\u002F\u002FcGf6cuWK1KPyZ2tvz8EkPfdcYJWToR6v+uinA4oTAWgeeapSMN6VSnFQ+bBZ9ahdIMHLisLJ8msdQLAX46IZoPZ672VlB8shD1hczyAwcp5FSKWmSHlhNEVaLgbC0BxPYH7RIfMJ+hECGwndr+wZwyH\u002FXgrK03Jtf1+EmhK5dfvTjU8\u002F+9HG519W+SRjRkCd\u002FilqA6RQJCd3rgfizldO8uGkKVCSaMM7Hk8954OiYHA4CF6UC4cS6OJgAuKUJEflfm2KUOIJvMWZslGPspqVi9pVkeL0GRFvpQJFhhkDJ9Mx+Jaeb7UqcnJWTO4\u002FSHbKK7ezXZRsRaRSTtVLfvpYWlWOabxvadpm4TPNE+PPoN2P1wZoBTr3OzAFqOTgAOv4+umzHM1oTzGN\u002FuimcQYy7Mu4\u002F\u002F+XXDN80YaCoqxGwvofWcOfQNSxWYZf3y3D12ddyQh7aXuiPtHS\u002FFgleZ\u002Fy1FdAcQx6ytJz3DKRG7LVZ1ZVTmynvPtigAFFmIKmA\u002FDMiydtiGwOb7dp+Wq8PDzR5kgAkNG2GY5iv7V1q\u002Fl4OI6ZcU+\u002F+n7G1h+ABqPL2GjfnL592z6K5k1wwHuCDY25jmVU62W8OSsABhIhKWMgYgBYdBmlXVvGGLfXH+VGH4\u002FRMDabnSl\u002FgNXvJ3bKmWwOmX58PqtfPY\u002FRURmmpkZuvvvm26mFfvZCBvqs+uiL5ybnNRmUu3ou51Bk63\u002F93\u002F736de\u002F+dnPJvgBZIkoOVyJkdbnU4Fn\u002FZMfW7earxUxYqzlax5FrkW5RKuRQHUQvGAJf\u002FNYejX9QE5c43Nzjs5y2PGU+TpalZSGN8C1z0506MtUqUrW6KCDDPCSKzK3wFS\u002FjBMR44zxJJcrMrpA205GfgBW33M4zaNVBweF7SbvANfokPD0QYfosDsIiT84BjvRDC85Wdp4vTgpwK6pmz0L8Yf5BFqkWg1Qb3zGSl8cvdHMqcYTNU4P4J8Bc+m03NqZ2yfx4TuEzuahC57nlBy0ZyhS1cnmOzoCgvTX+7MB3z4fZykaCQhsH1dhxUpJrXb9buABGD\u002FbWE7UL\u002FnHVmeMwUoOiCt44LGrfG5j7LkOXXrj5KKuWJHZ1R9tqoFvHxJnbZylbsbJANtywN3HSV92cNnfBabJ1chGNwiyoBv6aYf+JKcTAEl\u002Fmh\u002F8YAUshu6a5dyzA+aTPsV3UsbYHEGcsVnN8eNHBdN6sWWu9ZqgSUEzGMO8AlI7PUMEV8ljqSNknHOPF44cCmk0r+PnF523IVBHNsYRi56eh4f05X1YgT4AwIxrpULShesda41+ECjxEgxyDeKxFxzum7duDchUyAAGonfoZHadPAC0MBGaCpqQyWkgugL6Fy9VNCObCmMNoK3toXw\u002FYSSHor2qb9LjbLiEPeiWrZwJwR1gWLAEjTlr2pa7zZKzFwMuGyMaWJGd6DYs1+tP8z18gGfXaiGd9h7fRiuOA+wjvcTf5h6dzZ+fR7rSQUBo6nls\u002Fvp+zaN7BDLZvoOcFnKC7w4O2\u002FNYH80BvMbxQHsrZ9KlAWy0mKpn8cqFZOjiFXLau6E+fCyivlKc6Yl5xRvKfApYkjM6iyySmVkZrR9+Wtmc4Iw+ua4iDcZtbvGUn+hDZ8NNeB0\u002FNL0f7fXRgDpvU+8mUpgikuoitxdDAdQYmLAfRb739gC3SGuQTerj10XRMybXr9+Y6DqlJzpG8DBWNw8zak\u002FkFii3MRRRRI5NmudMPd\u002Fa4y1RBoCza4BlyxqYA+BmwCkO+eSYSNRG1J2gKN9F4ZhQ93EYRG5Xnp7JOqjdlgvrH4Zeymopb0YbY2G2J7WtPVFZuccqfXimzzAiQVV2EJNZgQDMgX+MI+3FpDtUxe59AmCMngfYUka7KTh5h5hdNOfh\u002FcpvzYaHh+P16ZelHxUeVPtgpCz\u002FALjyZnm3TvJyOtiAiBSFdJMnVYaw9EQNyKl+86b60EWo3xZNfBbgAxR5pByBrFufi3B0eVE\u002FVQtYOodt2Mzxev9B4KzNqAGnqV1aFQbOz\u002FXAr01Mv\u002Fx\u002F\u002FnmUurr35kaqwqriUHO1s6I\u002FKe+a78+EKC+23fOE54svvmyV5WqO3uP4LXrnfW\u002FvVEHjUptVd882R9cS7ncb39z548Y\u002F\u002FcMvNv7LL+7Ocu+15s7L\u002FN6tzCZ6YESGgQLFj5bfh34Za84cfptVlHiNEuXQReTmRt8abwTQt27q+5RQtMFXrj1VvWsRzom+RwtKWw4\u002FoIMG19t42HpizUlz6BTOb\u002F84ckIZ2VRtiRTvSnOgfG8EvtcejZ6fnFFRY8hSYubxcasKqkFcvnIjIHut78500p+zC8BeQDXl2u+WbWOpPgF0KNb+iMixQJ959cvRq1\u002FnnmmD8uyL+d\u002F60cfzi2VEGJYTRIYHsPS7k0\u002FnUJe5v4u7ZuZZuz3XPZowD+RBOoGOHLQR2UZD1Y0YMn0gQzaCf\u002FPtNyt6nhySfacsvkvmziZLZ5I5YFRaE54yNvMBgAHcHsaBPzJKfs4mptETK\u002FJN+R6nU\u002FB6vzt1maKeSkrNnX4uQBZd+13bFDu+PVEp08mJTjYHPNQXdGdY9vZE4ZOJPuNo2\u002FApCKEtQQibo8yT\u002FEq6ioMntetlOuHmpzc2bn1aTvG0t6J6u0XcrSDdvHU7I3l+4+uCHhxYjiQ+U\u002FHomsDAtVv1z1IyuVS5QGnTHKD4RtT1eoGDVy+VYuUYBUD6OTowWoum76a\u002F5KWjJbDiuqkYkSzSISdOrqg7Wtkcxomn6+gdKRWAHD0GqJoDMjbgID439sWXyxjSV\u002FTs\u002FwfylvGTk0r2x7nKOfGscWrr74C19OXrZNTK5endy82Z5y3AJXLuejxGFuhgoE10lt4Feu0j0U\u002FO1Jpzy93LAJvHnU6zBNhFycmKlSt2RjUrbdKL61TX5KnniVa7lK5VsciqrhMoOEKezzkAquUWS3GTQ4w5T5dvfbp8ZDLBGZvSd0VjJwqZTiEwUqcAMY4p+u4H+jm565ThtToldUh6pYpa\u002FeK\u002FkbcEa+id0A6v6STgPHPVeGfloLbMj3mZuZjNrCOlw+u1OLR0Lb4lL38KZKVDvfAKm23c9Kf2zB37BQga4HJcAEj9qw+1Ayx7Evv8bO\u002FJ4Ak2y2tWXWq3hP7m\u002FsMm1ujew2afFJlXaq8JGAcL5hgHoBECtPAAx1r7dX2eAVjTIQJAR44UR\u002F7NPkmUSirNAc8smbDa4YWeZJ6copNns\u002F\u002FOarFnhe64lg6+klN17jwAXIprMoEO7KggSl0YvT97vQoIouVRtBw4hQE4EfptTxtdaDxSHAV7OFVvWlV\u002FUgqt\u002FUxs4hmOfCsweBpQxwBMOtaZdsIJ1PesBjQIeGeB3fBW\u002FZEaRQ7MnzLKIwvpSOMZWxcdJg3E911P\u002Fs\u002FVF1kR5JE+W3rXfEp3Wjzk2WR9dB37UN88Z8lac9nvU4Wr8S3ncK0wwELH4he2ma52P55MS25sVjRP363wzWZjk9J\u002FOJqDDZPM\u002FNX261b1j3Vas0tghmOlEQmanUy3A+Orsgu6CLbk6Dh4ajAd4B29NT3vlZa7xtOz4lf0cHjjoqM4zn+DEfUHRQMBUcBYOgtQe78lUcoLUZWHw8ArykEpY4K1bAwIAcoE+c6db5rgdp8nrJhHxGbqgicoifF4njxQDLSWStbGM4pZlPvuD\u002FenjR96tlwlgiAq2uPoohg7z682b968OcJPwEyKvFiAl6KQ8oGBJ8KQItdvSoIiMkkEU84eY+VzESsAfVIH+p4xTmYnmqk6A6VMGatIYmIpgEcZUYqKUtBHbb7tBEICeqV0EKDdYTy7RcgBOsBLO4z\u002FlaKIDPwoxu6\u002FHPCU4vAspWYjqc2KcuiM+8KlKykHSzwAmty++l1779qAtUp9iRoWUUmAM0cDQF+XduAoeukBDMOwfD95rner884YSUUSCQbC3xWRAHIIjooSFAeCEwDpQferaw6kqeKypTpFSkL0jcElxKPk2kBFYRn\u002FCHW8Yf6N2TUTGehv84530Ot4im+lHEkRulN6yh83fv\u002F1Nxs3bt3b+OLLPxuQapXjKDUJYP+h3G4HAHGyGBWRMFFgzzG5jKcSjhQpg6+GOafrk1Zi8OTDDg2xXC9d4FSg6ETCzBBNxZH61LTXv4jZ3OJ9itsSIEM7AD9F5nlyfp8GvA7f35+l66vtX7gaYH+YHP3qV7\u002Fa+OabP3Z9tLWcmRLWn\u002F39UstKhTE\u002Fp8rVjxrDw124cSlAL4qC8VT2sPJ05tw6QRdNN489jHYx59izxom\u002Fo7EE71Gk0cJn5mD+96dffEDyRvdN+\u002FPbzK9P8VUXf3i7kiwPLujnpLv0NQUM7BFCz13RVw5y\u002FYhO8wTC1W\u002F4CEgfsBDNT0dD9HO6pkopDIeUKdHQp7UlahtjDXB8nQG14nTqcZsu00NAFQOMb2apvjZGbmp3ggA9cSJojZ9ifZMyHiDbc8j\u002FLJ9HU8ZnN3mK1D3X5si1asEYHOv3I31mCBws183pqo05SDFKHn3xdDG2Gdt+Kx6A5wDWjBYjwygAi+SFYyv3VJR99OHoGOkVQIy84SKoeDh9tl01Bpu4t1tN++nP\u002FjqjkaHoOiDjbqf\u002FijCeO9sx4xkmB6w4tdNmb5F5QE5Q4W26wfkCDXyAKJpzXlU0UsaQbDDUUmu0L3qFvwH9AWo9w+9oAMSTKTxnyOYU31uR8BndpOSfCCt6i3YBzIw0WuJ3\u002FE8fW9VjqNG6bkxfxmHIMJMpfGXuPBeNAbmJyvVMn0u9GXvRWPSDscdnL+k5K2rNEF13KtAn8OG5dLiIvbk7Fo3IqrlgCziY6HmigdH7Ozqln41Xjqoa\u002F2\u002FflzPcuMbGdT05wedens85a1Azj+ghd3yvjb6v+13UV03zZ0VZ0ZvtqCvZpyLn0YsNUJ7Ppk3Amh7gFHDi37Vh39kIeN0pu8YtFQXfDW3qH7mykZgc+AyQNbf+7nEzH7N6VF\u002Fbn+z\u002FM7bR0\u002F1lTtg\u002FNHQdu2u+jp5Dltff8Vb\u002FyOcEWD7IyTynPkxgY1pBndWutgcIRksrTBwdq6KbUlKb10mRzfbR\u002F0306NtxVnoGB2mNN9rWoLllf721i+76eDQPh4Fw18+mv67HixyIifaza\u002FUBrfCDe1+\u002FjmeSMQCcfnUdoEz3zapkwZZxbKONldWjnG0VWADZCfSMw7I2lsM1eIT9dbjhyFr3eh4dQz\u002FhwSfZfsHCxbv1cxD3otdBsst5IG9AvbKvO8YbPdHg8NDqQvLUvNr\u002F0HDnbTwAJeEESE30m1bXOAB0smfDYXQpnALjsKUwEvnEL1Jfjpx6z2PPBaTII9pNhLr+G4\u002F52q+6FvrTea4fHotf6Z9DTmh9gQ9DvfM73jlyCvCHQCp9bM4aRe8lSyLs+FhgA7YRVH3WORF7raI8LaPgSYFK36k537BqexUB4NSYJ7r0Yme07ATKM0zpYPHH+jC+GbletN35oGvgEzxEbwlIRw6TMTwMC4weaIB+fqwXjfVRXheLDCPYVDwJbAAHRoDQKnDIJ280A+JdB+xRMRSt\u002FE\u002FKwnVrySig2SAJu\u002FxmqQdyg0UlEAnIEr1SmYPXJr9bFBrzWUpFWMvg9++36zfGxSQY5FIb8exmJ3wikltbu\u002FNcioOA6t\u002FkZXf\u002FMETL+8tolEvVNUcGndDrp+eJDpgiiv2wXCnMB3hLPQEUAD0KyXgYGwLIiLxurEA75sF3DLT2CesPgeEFVmLqSli9K1dZfWjAgUGhUBiMR6WA3IsxLmbwLjX+a9XuBjzRRd8A40lJeW15mtDLryqSEE0ojQeP7jTkOwMUlHoE5m\u002FuXEvYUzQtrxEwYNZ4nHX0sOd9+\u002F3doQWLCcRvBibetRQ0R1w3X4eBVKktBDmbY2CNG7O3SSwAcr60D3P+uz8Eqov6iW6bZ7XfMfzkYQdSPFsUG62Xwa+9eIl8Pm3vQh9PlGaWwQLCF+IJkfE\u002Ffv1taSR327D5cOPP\u002FvzPR7HvK0PZfH\u002F26a3At1rCLTvW\u002FyuXO4wrJ5GyeZRC0mfPQ\u002FulGE5MGtJsOmwwjITvOUTm6UarESdENptXQ3Wf5S99O4hfxiA0DoZWpNySIGUmCvfJjRtVxDkz6VGPAgE36h8n12dPk5X70X8crwf3BzxJDZDvynCpHW8PwzLYefKeHX+JCNhsKKrx6Omq5IHWou3mUV6v0n+MvyCL3NrpeT\u002Ft3dBfG4XwvMkQIZpXnxsfBQlUfNBL85nvybF7XEWqKXqydNhztlLAvvPMde36OUr4g1HoymnTPYi3HQ9xskUKGV+53MeKnl7MOZIOIHp9MXocdCiKaDvZOgy0DTAuvGKPgXr0h3fpm3IbOdMfDMyMzXiMtX\u002FmjMON33xHvvSDPhLF+tCx+Mcph3SAaM4C9RwcgGgA0Ic2jcv4j2S+RpunpT\u002Fe9fshEP\u002FhOZ7NqfFM45jAQGOZvMv0CSMJJAPkNpmfDITLNQYOzAeAsRWI9Tcj4zAlRv10471dGphDjvCuoIDgxvZx5fesduZU10fPPdvm0QE07YMgJ\u002FKdAVtlYjkjHO2GNvPuPhF6BtXvO3s5UPVvjHZzQo5OpV\u002FwzURRe\u002FbQtLHNIVA9D7DERwf1G0BgEFNO3VvkFXCNJ+gDTgsnywQcU3959Gtz1uf9b942gqKhoJA3up5pnmKbGds4gV0zerB+PX++9LQ8+8g+AK5bBvjsFFHDcyK0dP3k8dZPXDJR2ObZX305NogdWsGG5rZGpEo2mfHh4icRRToXX6HzFFHoew7fifSg8e69o4ty8gIUxQebf7WdOQw5MZ\u002Fc2LhY6pYULism5OdlQP5FAERQ4FmrIU52lc6wEwpTAYSIvc6+sHXAUpqMyKU3RLqBC32UjrAi5Z61AF4gRr\u002Fxcj+li6I7ezROcDSie\u002FGcuTGmBZb6xFRwqptXsoJW5MG8uGYi7B8AGDsyctd1aIM3VjvaWEAN7cfRry94hV7nFLlujnfvM6sPky\u002Ff40fr1OfR29GcfuKoYVobiO1Depptcb\u002FxiKzq02Grlzal4hE2hDOPHq4TiFlTnQ0KnLJDbIY5BMSlpUqHhTNOn2kw9eKIVxfAFcQLEfY5e\u002Fs2WrhnAgW1TSbxOcdY2tVUC6HnkjlzR7aATfJgNQdmQGhO9ckT6f1+cuZn9b7x4mWOK\u002FsqzQNv4YONTacYS4eKt8lg9j1OjdZWfJdsoZv5nFM2oy3NjddGh32QLfzmbbX5KDI9ctf37B160kHHaneCH7UJc9GTcIh5dCq7cRn3u\u002FaYTNAm0gmcksFVrWzZX7wklQ9\u002F4AfyQ6+OXiBrZHECTPQw4B4N6sfwQH2is161X8dZAS+LoMu4cMibaPnWdsGedI96883OyNThoT1n78KR4Zz4W7pUBBj6Hzn8SwfEQ\u002FEIm2TWvdABDx72GVlhZ7Y6EXn2PKxLPsr\u002FPxpQB56BVJsX7xa1dCLnUhhLsIFSL5MVRf8k7AhjIignm6bUhwOuKQveKyJb8hc1lpNGmLQrUuEgEe3dv88RKJctgXMS5dWr1\u002Fu8zY4ZLZVX5IQxugNOy1sWjTbBJke\u002FEBhDmAyMBbjz+niRomMEjlBSYssbb2kyYEshAQl2HQPuixHfjyMBMItY2fTVcCePi5EZw1R7ABug5bmesRuAxQT686p8RAyvPOFERxI2y7fHTgLNechdL1IpzcBmxIeBORFGlWwwq74S3h1CFAPtNiYbSNXT5uA4QIPxeh6wfRA9nObJs0w+80hFgVpi6ztCNLmXORN7L3MKiia\u002FLP9ZGcjTgaaTzZf+i+Ru1yYFe6nowfEi+KIYo+xGsa8UFqkf7rkUOFY15k4R8LMpQaWzHKbB2Bk3gkmVclQwJRJDpCAJZwagJbxGNSsr9hngByVA0dkBU6nfGc\u002F3bVAWicE3NgaXADoGTeWNd9HCvgj9QycDx3NSFjhBz1shsPmM8TPHr96+ygH4uvaLcPVv8TWQtsAJgz1LnhRGUUHL\u002FsAAg0hR4ike\u002FVYK+m1KgYI9n2N19VqbuaLP84zu64z1qwCZaOUXX\u002F14rvnj73+\u002F8f13qyY\u002FgA6sowEAZ5OgVZQxLI3nWfx\u002FPP6\u002FUjnKyZH37JQlA+vvuj1jZbQpbCfSLX7OGNTmAhLBkq6jIL27Y3i\u002F\u002F0Wq5cAAkxpDNsrca+bIZyk3YNmtQO2RUXeNfpIVTQ7gSR1QyKMuu16\u002FtEOpi0pu56ydjI51s01pAe746\u002Frlq81dstZYL7Svon3PAZnkMLnlKErz4sxbMQO07t+\u002FP3rBPNm4ZvVr5Lx+6IsosIGIGJl7UU5ggh5hkID1caajI1pS7FYN6Tk6y09RLCCR42yME3FtPEu3rAoCjKhx4VEPnJWMWlv10t0jP15FAqDQHLRqEj\u002FiX84VHgUQbKLajr7n9s\u002FngLRknh5E7DHKtedeRvpFTiGnUh8tp18v7eVxwRNgSP+kvRgP52D20\u002FSZ1Rql3\u002FCstEG0klYlmr+iy6otFF1PPukY8z\u002FR\u002F2gN7HGmReA7Qm2CMSfeluPatT4H5BzYQ1aJMyOmrvh+mzT1uektIJFeCyjjIXzhWnpRn\u002FHpsa0VgJkx9Gz34UPgXGfQfnRBjozIuNQicup7+l2bAy6SR8YUaDtZtDFyZnhVDFpnQohKz2pPvDF9i54TaX9nNTDA2DPpcXagmVtyUwecMTAwp\u002F4rYoAnjmikPaky70QOzW30suwuTfx48s5m2YB+thNe9VmlJvqPLlpVxYoY9jyg3ub4KRwwKz7xZc96FRB98fzJbOx82n4INmKV8ixFR1UZ8lhvpECQ89cBRPN8eNBKa+CFI6mvnDlvdoxc4tP3nR0w8k1GGwe6HdlIvISuZMrLPC2+F5SS9pOmjvYixmtOs7lkb2Sm1eTm2OsIkKl1z+bozLEOrtmsX9JGVTuZtLTurVPxXT+ih2dN+l7zgSePnrn0UX83Dg4BHiSn+HOtdgd66\u002FOsJMcfdPXiteWAzvj7nP13jfNF2IMeMXoBDdhYeAIvTMpqthzAHXAdb5L5M\u002FYQlOYyMhYfA8dnG58ymOhhXgRM0JFECfqhrf6TKXpgKrzUDh3dlDSPOVqNf\u002FRY9FVqdVbPk9kzZ5YO5ABPTnU30Af4WN84l1YjR4fHi6Nvo8PMkefXP7TyWrzX2RP9TYbIspdx92fXtdGzgJLr5cSfPUPWyAU+ScgjFpwyEXgT2kCP5h2fkGOjQQe62FyytcYI+Buf7yba32ezcfOD4+v5eEf75v1Fq3H0JVpwaszLs3TlYbyvbK\u002F0WbqVjPfovs9hSHbZpwN246AKMli4KBD7QR4ctGcTvnnXDzbhjT16DVCwZq0gLjvv+1ld4RzHSxwHdNHnj\u002FVqyj\u002FOiyDx2pfQdmBMIIoHNkojQDHLBU0EQDv57D3W5EiTATgQfjy9hJWRRBgKyaEzlmUJD\u002FAtN5x3a3KXB7o1BtnSEGLdvv3ZAHWKThRK7vPep7eLXCqx+CQmXQwqP3U\u002FhTXGJCHWHiVh4jHy3sFaguJpD1iNsTCp6wiWcVDGXsaMyQeMDMNRWJZdLQu3Gasov1rIqbRRvAAOISGkjD2JJYcAPyngGcehTXYgr7q6LuEBjuFxbUK2OUtFRVJiqr3Xm1NdglLiqU6edcxkaZrnjUnljw8zxkSpuMbUMlbOgaUq3jKmfVaOG0YHAnZvqHojh+70KLfH39yd\u002FHfRYY7Q9Q7mMU+ibpa7jX9o0bjOBKJEMszvLPH2hT7xdC3Py8v+4ssv5jMMzfiLhLmeB2tegC\u002FKKn97aMTYmivzJupM6M2FFZXnRaRF90+eOlPljVuzaee3v\u002F+6DbSVbKyKytUcvN1SRZQ3vHi+NJD6gw9EGp\u002FHp+jNKVL2jpIxz99\u002F+82KXEcXUR050XjcOQAi8Wfj2bciCPGluWSMRcsOD3L6Ulhogj4UCDXMQbK5Vc4c43ilz4H1YyIRnfj6MtCyWf7\u002FxQuB+EtXN36SQ0OxaPve99\u002FPBlplDYfP6vvL7ejQUrjB6NerQBTQz9E9BXTUl6MT58awRr+t+kDJrRfl2W8x4fA8vo+vy08YfsObLCYj2lfzO+Po12mjS5fTqpn+fbjO7xQXvqZwxzjMfes5S74CLFrqczwtYkZ3HIGug3jwsM+AN7X5TyVHDA8t+\u002Ft\u002F+U38+nhOfv3265cBrcC8I9YDPk+KWlm5wUs3mk8GyAqf\u002FgMmqjjpDx6SFgCcA4YThXNRYyA\u002FY8Tjc5ucABcBA8DWapt26KYxJM15WmvGupy2dANw078BhfHoPLt++NyKVY8cR8T3q41Mb23vxcva9ibv+HvyUqV3xNuqRNzPUX7+qg3FocuTp8pHL\u002FqNj6eaVToLSOBwf\u002F3tt6P3\u002FvIvfzIrksbjGgcz0T30BNkydqkmdPWzHHNl+zx\u002FgGW68FjHwtPLxjMR0Drvb\u002Fyk7z4nu+aekXU6NL4\u002F0+Zp+yKO75QeFG\u002FiseUkMNZAXHLe812Px0QK2QnPXiXd0p\u002F1s6Dn8BKQARAxrli0W2tvzRtwY7WMnNARcuIB6wFh0ZGTsPjbk+LZ5gHw64sZB51xOt1Az9P\u002Fo1vnuQuMT75sbVipEpCYDWNonRwDHMYCsMsYqskeAgiln\u002FsV+KNX6lzOQYGMooqx3Tilp6qyc\u002FmGg9\u002Fs1bnaPFVyM7mlL0QfVduhD1+m618Cz9kadgQQOl2g43ZBCTLuwLTvv71TBayvN96nz7YCFoICwZEpCSmSauTLAYqO\u002Fc4BJaf0p82EZEtfybNKG+hF\u002FtkE8jB82tz7ueY\u002F2gTg8TCbp32Azn30HLr4vSaG3\u002Fxufsi4GP8CMca3ZGB46eianuFaPOX55nFSmTbj2a7R\u002F6Z12vbMBeoCoH13WPqGpy4HI95ujgaUJlBsoJ5yeBr49NszPHsCNKM7l13Qls+NzaqmVfEBs+mExd9tmsyJRr+Ro9qd62ta88aNZwVIpHgJGtBt9hGwCVavreALvkivXEE0e8ji4XgQLxqplxQ4smDVz\u002FvgndQ93yhe0OcwSHZB4I2NVzUm89PzrZqglD0GotbeBOKDnq99fR7H4E80iA+aE+NCA7S3OovG9Mc4w\u002FEDXhnHMfq+SzfqKvr4CRe5ziqTIIrx0PHkFAjeb4zkgx7qkm6pT\u002FE4Xl98AqSv1QN6iC3hZLHz9CT9fdTmxnvoYMm0YhpWHv0E1J+2z+59NMjAjo4ah7QVcJH1g8Mc1Q9zZbUD388hbnWFLWhdPzLh5ZUCNLqluWfrfcuJEWjFP+Zz9sAk50f2y9yfqJ0j56Zb\u002FtUvUvxRXiKU+\u002FttHkppinBa3hHNfvlyec0IjoWHuTMUfhet8jeATWhFtnZ31wEhImBSXoD1lZ8FSK9lW0tTTwLeBHnybyMYQ\u002Fq6TScA8bfVHRd9vFjtbhtOMf6kFfQceUWkCTPxjBB7OKyfiI9hXryunFkMJxftfkxpPPLLCekohO7lmZs0QHj7rOhEiqF7fe7lmTxoOfYU7E5j2z7VUn7tMXoMjmdjWqsGImYmWMTuDOAor1kFkKzVflU\u002FOCmU5qmiIHK60A34Ba4ARArF3xPZrS87O4Hx5oBnP\u002FmP9YGy9p5Dd7qWMqZIbt68NRtUv\u002F+uUpBPHuQ4rXJfFIeo\u002F16pJoSAslMiT5rTxQwMpXhwKD2AsqucYQqIIQbmRRFEyI8iF5j8SYYZ\u002FdCFgZAKcql5ftfYKFGA+WRGU5oUkMJoEXAGeNJgYv6XLzvFM2B+IZBLSIBqzsKxTom1IdK9lJY69FZcfuggpO+++aY2Njtxr\u002Fzwd+XzB7xFG0UoGcHTtXFuq5z7+qT2OyP8+NGDUnOKTqVQ1RkGCIF1SkqqFV4ByDfz2PEupSJXcuM9A4bOi79FPY2dQreBmSLhQL2Ivy40ju0coZelDw2gSJke3wn4k6EM9+eNW93mkwHVx6XCLOWdwm8e1Le3EYbSEt3wvP36LfpjqZyCPX5CGkOnAjcu8\u002Fw259Oqh41H6EZB4Q2RG8uUolP90Uz0np+kdP0JwLvGeCgufPshgXXmCO86WINceQ9vDzhlKJYBZRDHMdVmskLZ68+A+67xr5szLUVMMipnov2V9p6cTMGqNHLv2+82\u002FvY\u002F\u002F+ccruMbX9z6H+q7NJEc6ioyWPLVV28yAVBIB+NMkxV8DGB7BCBBHdE\u002Fnt6whn764vqDY4s22hJhH1odJmvNKxCgjdVV0a0MUW8yvfGm+3u25+mDawcoNM6aHsMoujXXNl4RxKGnsfcWkdIf\u002FAQ82zRvH8lUfUqOzfGj9N6pu1WAuHwhR6\u002FNh8nH6JyiQeoo34nXf\u002FXrX097Z+Pzf\u002Fc\u002F\u002FY\u002FjCOmAlTd6k+FjzOhRDvGDPlfH\u002F3Lt6QcZ9h6Hq3kd3ZyMWfETtKBb8fscflWPyZ2gAn1vQ9fZ0v7s4QCggRCG+HRAl3yoNuJeB3KJKktfKa499JF2hdb020FphGQG2IklujaeDUQCG\u002FgQD5orP9mAiVq6sP4wkOaXbBifeV7OzaqkRD7ZCwaWDXGdcZOL99kHRt1bXzjA0hjG6e06aVeMu7n403u0V49u7vR9QHFyggeVYNyPTw\u002FbE7Df\u002FBxLj5zL0b9xs4Pw2uwunclhUA9zMl\u002FcezBBqeelIalGJWAhJYF8s2ucoinLmd68kg6+kKMWBE2GOhCtAMJV6TKVff36d7+bMsNkbXur1aXBZz27v+lMvHkUvUSbiDR2gk7eis9e1xerWuZ\u002FOY4RkzD0GhnocwAvktX3+L1r8Tz5idOHLq5HB1NypA\u002FcT0843Ri98dUA5fqFltOXrjGn\u002FgZk6Qlt68AcHNV37NJEaxuLa5OckSnAfPrRc7t97vEcbQ3Aaz7oQp8BVbNi3jjgD7wA+BNjIFJqZJcM9lCOlx5gmwUV4RD2HU+iaY8bfsJTs9G8z+e79Ij5P9HzjVNFNc76AoMIhEbrJz4\u002FcoLgEnoAMFeFh3wDkmRWCUEroqrYcF7Z5Z0CbpuVTla8weq49q2IsXMbVVhCt52er\u002Fwn\u002Fl2OzJoXfTZr6ANfINzQIb4Y2kaDoeGQszmIXgPes4OppirQVH42GkxaU3R4HZ+y2+sevBk+KbBgpRXvoRd7SHd7lrxzhNaHhpyOsJK2Itb0hOvUTZ+AavzvBcibm\u002F4bupJTdJdyS6egm2dkTvNhOFzRP57VT3RF8uX448H+6GV17+1Bm+vjAXbIZv0T8GIMoZAD3tQHPOsO1Ze0SX\u002FMWPvcxm3jE5z0+VEgax7wr\u002FzfRwPqsU0DtYSa4g18qPtqKeJph7moxkCw5NWaksb3ISfcLtyqqgRYkF2kHEOLXhxrHhfAWZHzU7sXAyDtnI+xjkAwwlEu6mWKWExEoKUMEWKbHm1+ZOAtbSHcAM+WPUUiMOjRi+KaSFoCAvC1yt5Y8g5F0spx2mzzweaxvY0TonCYqnGK3Fm6BqImkppCNcknTiwvHvDai8EA50uV0pOqMhGf+mtF4UVCZbzGrtQcxrNB80zCZQn4bHWHRXNeVeYQEz+pvNC9J\u002Fdb5nxVzeabA4CfZRj3E2A5\u002FmcDM5jIhjvRF0Dq1Ute31KmcuEt656qBOOxNms8qcSd8RG6naL20kPeFOlOTDN6q+ykCDBQSBAAcUCHQWQYrViM8WzMlsRt5uV5772zrGrzXQZolqujX7Q\u002Ff7pDiiort5eiOShiJOJu\u002Fi5dvjoOBgeKYrY0fLJonOU8XvR7\u002FRZ1DpQ6eVEk9Ls2DL+J\u002FlMlIeVCcS4PtxKGzzqIqaV9JRH\u002F7PPbGxfPnNr47W9\u002Fu\u002FEoMPIwx+dYNMWFqkFY+t\u002FrwIXnLzpVN0l4\u002FuJJDsjZDhy6kYK0J0DUbHnxoiLnUyCUDeXzKkfiOMciAHjYeEWJXMtQ4xFK4VCaTsLrVNv9eGaz5+10LeOXKUmhpHT7CexTgG8zzg+t8jQXh2+BsK2NP\u002F\u002FJTwI+5zf+2OqAKkoUgRrYcjSlegC0UocOKitINt6nVLwjVv0\u002FnGidqB2g\u002FrQlv+lnvB33NqcpOs\u002FvlzGgRSgie7cydB8M7pGQfPgpkunabhveoOA1NCC+FAKgzJsTSJP319KofqTIKbfjzSXQ3pP6EMcF0MhgdBWJUXLyZE2dil4ct9YnO20veYnm9379YuPKz\u002F5i4116w6a9WYKkVaLFrrnp\u002Fre1Q8lQ+CsVZzoTHy9FTzaBM4OYKAgZiXbop3a6zxYNVESxHA3g4L9SD+IVxpYDvoC7640bAO1nakX0iXHluKITvsYzA26inegrZ1UfaKEWQQYgTb3fDIyo5qNWEh8UKLAB1PwAumfPnswQvyj6rcZ2pU9fOxGwpd\u002FkWI5o05Y+rZJVe0nI7NdtsP6bv\u002F6bnNorPaVoc+cWnDv3rL+vB\u002FgD1cmicxOcpHq8kn1Xr+QURfOZ3vbnqDb1vJScl5yhZNuGOCtxVtREigEYQPJJVYbCDRPBsimUwST\u002F8t2lZjSdk\u002FNONlT72tpKL6Y3Ae1n1e8G9PAdoMfgmp\u002F+N2PYOS4yunSredmkZ21KC95rj4Pm2u1y9Dma2gQetUGvc9Y5UufS7bs58Iy2ih0cCzZpM158V0H82aMx\u002FYgnAljHtkRLrVLYNJwNalVDtF0ASkSeXCsf6iTSYfJkfwHW5jlZMx6pLcpISlfZ7hm76elrnS58uwPNnJjMGXhsBeTrOxVA+C6HKScqnWgjP30473QH4DFOVf0xJnMBcLJjAiF4w+min3\u002F2WZvebydfOxvffnMnvdoqSrTYyonbTO+phDJzGJ8CK3iEEyBVT3rAgLkY1gFdQC+n0jg2gRk3NN4ENOAXiE2HRcx0ENC\u002FdF4fTCSSaE\u002FVpp5peiJNt3PO6JoVkcT\u002FADbdPcC8tgD65Ywt3WMjK51Kn44NOEVmOQ9AJSBNb3WRFxmKZuws+dFfmy53lRzuJ8DMds3KxtywQKcN1zv0VnxF39NY7KQDBLUhreig+Xj2dAXgBGysuoqK+4k+RSi6JlrVRhBngCmASYeQrXf6GEgesEhOoteqpBJPNI+BofrGiVgrQ1ZuBHQeFbV\u002FXNEH4xE5J+dsmwolqjzZVxG3ZidbhXn3cEoQPmjVTeAFkIfB8O7b0tBgKQDfgVj6OSmQjcWETFqNeW9O0dbraE79zUFk4wfE9vfu+wKyJzqrRXWZcAcnwj6gKcv6JlvdrJMzLVkZfJ3csCeyJ041h9pGHzJ3Jp09xrf5YVfMK1zVRIwOl\u002Fcu8Hc8fsT79Kj74Sb614q\u002F8yOsJNTkPBdt57potplyBf7lq6uK5FAxZZ6HfxvzZrLRn5Gh79jptifsNRdnTlsZVIQj\u002FRpeWxUDOUjJ5tOc+ZfZpvoO383p5LVlTCLxMMKkydXXj\u002FXC+R\u002FlBfjI1TJBlPD2TkRKATx7UR3jluIcpjMbitLaBAHoG9AT8SmMBQJbRkh5MqiWm7779ttZ8mXwPvvRZ7XRCZyBRNHVa23GO\u002FLALeVJmZioYR6VKKpolNmWFjAGPQaj6HnPBEKUjpLAHIwqZt1MwQGyZ6tHfDHmdPiRCbehRNsMsr+V2Tos4kWJUCzvUuoiQ5b9GA8TJrK7n1BIvxGFOvW2yHuCwIA5mOdYhuNtDsyLIt1Pcyg4MNsZv1Mp1929+he9VkRmHR7wvJ3LP3zzQwClPNDoey6AfSzlagnnTAroXPnp6KiqCWPFKRHhtLFOxOZEkZvdloRP1+5B0Z3tDPF+jg+hUDdXXWf05CjRepbcXmcQgX5VS+xc3z3tKPtFN9eiBYECukXPJk2gtsbpwf31wVKx2q41PHObDsqAZOjqWzwdQ8cXPQs9nme0XwQ0OA6cL7vK1d6evvS50kr53M3RqkNOQFuBrQsZj9q34XA2cyVMBylt\u002FHixDSJffHazY+fbhCp94F4gv\u002F5cz2CqloEXrZzs5RBtB1YAdVV3zhd9\u002F+Krz1NuRekDyBwizzFmKz+i64cp8bOt2Ihcxl0bjxJozsUs5fdsRtwpqfvNy5tAq42nJ1Kik17SfEOuh\u002FX1RGDheMr8AM\u002FlvB0CAj6PWLcr63nl2s0i\u002F\u002FHZ+3vRrNSOePiEMFk8xwGLytWcLYeyezYPSmWaFYlodbyN1pduTEqP+X\u002F\u002FXv3hDEbzSQFTnpQvxe0n8A6c4CPKkOGcV89kj7zGLCZHyxlZy6dvAzbaQx\u002F0FGH1F0UNOCdZc69G6jJWmLmiHN9HA5F1hp0M7ESf3ZBsB0+m9KQ2RfuU8vHouNvNWzm419MHm\u002FqbrtHfAUzdfSIeKrW1A1T6rudyzukMkUFjNDd9PPfpkmg0vvGaaKDx1kdyrvcD1JoLDvNWfcKvU2mmuAKKjP7oWgEKIO0oAmV1TMoNejikg6FoMP0VoHFfsoFOHFi52vr6vuh6RSg2XiRvdMoTQYYA8Jkz0rHkjopSNa738d6+zWyP2zDdXCdLlnOlQTFqZPXsmfPJSCtv4ZXvvv1hdKYSpi+fFzDZ7qyHa0UGA+8Htfn65ZMAWiAjB\u002FHKlQsD1OkvjumT+NnBUy\u002FiyfNEARsPAABAAElEQVRFye25oQcY9Nk81k\u002FgWKWnYz33XKtA0orUf2fAvBlCm98AEcYOz5OhY5UsFf16laOAdl04hhiwQF1pjYAVh1TON7AjUjV5rsnvZsAH\u002F1hF6ub6s6JwadEx4CJp5ggvAxpWEXbqF\u002FDpM9O+nOn0nKgwOWgehwG67rAVlAW8gc0mRv\u002Fqt1VLUfqJQDb+SWdKbmxmXkA03mm+VMNqlPUvfmyl5XKrlLdvf7nx5ZdfzQqtVdTvv7+z8fWdr+cMhSfVBt\u002FLkRbs0O9x7gDOdLf3Vm1YcRhHpJza560Gvo6P8G3d3bj\u002F3YON7\u002F7w\u002FcZf\u002FPmfbXz5+ecbf\u002FaT85X0\u002FM0cZASoi7q\u002FiSGm2gtadi+nGJzidNqkCuBZ7REksTozIDna4mu205I\u002FfW11gbyS2JUKlBPQZ+QpIg2PvzHP3UNPpBqmj0D1nMhae3gIr7KJBAvt6Ry8Mb83R2QGfd1nJcHq8IeGpu3ZyKj9HqBoQskfc71NpPAAm7wVmD1VCsZ2fOsaIA2AxmdG3+BqqxsbjevRiexvc276JwhiVU+hAiCM7bCqqgTs5DLX3y6rj817fTk43f619Dxn1TPQTr\u002FpGfyLnyc9K9kwttn4Wj9mT0Vywv5qS4WhB61+PXgYjmlezJMqJlZSbaR832fOS1FFTUWih0W2p9pXjrI9aO\u002FTCYIXHHm8vQfcR8\u002FQaJ+tsS\u002F9JeIMSOuDnHK2vvkdGyC4J5REP+OJdKjxv3QIUTRI55w8t73xID49HThNo2VnK9G8V0C1+yeLokcCt3QijDepTLWHZv1\u002FggECAnQtrZsS6Fn1p3+RM7oVJGkO4pB0MDlbzvLY4HTN8apcTEXBaMLubKfLrJ7uVir2dXID220KiKCbMQ1QX\u002FKpB7PXL11gRWUCrwVkzjZ\u002FQLp0vN3TcuGbj+Zz+DO9\u002FDJZkaY8AYT6vZfMjlMbbg2wpPdWipS5\u002F1ivjwbUMSPwizA2vdihzuBgd0sYOo1hRjj6lPIUMeRB+Y5wjsDFAD4TEbZT+l7LgVsZGYrWTmg1pH0vouMnMOstEoER3nQohKVZQJXgSHHwpgxEunwmKqLeO4DFsSh2Hn+0kSBDNBtDmjQ8Y1Oal4lfIJ1CKQrRszC2iHg\u002Fpg1KH+M7eUxflVt6VSSK8qKUKDrAaJZ9ooPNqjbKYBYMqWwiRlBKDdB6\u002FSpvNacE0FDb9VbVatRRfp6XzTE5ldKxvEUB+N6S3Ci0aHLmXEhieH7R+ahv6OVFGSiN5nORRExv86fnc2ooS4r8eiUDl6DLJ10gBwCw8e3e3eUhU1b6b2MnmnNu0Ng8L4UkVad+JKjpiJRYCipgd7yIgHJjlOZUPqiNbULXtVMPNbqOwin15yAjKFIIqBNolXt2irTiGXPwsgNNumpojQ\u002FozgPjeVAfi2Jxzm52OBSh\u002FyH66qP5vNhy8aVWEYzHPohHDx5MLXrjcOIeYGeDrkjAs0C+TclOf8NnNvk+rrLK6wR\u002Fu5rtHLCd5uVR7bxywE08ZPx2mtfN9U5p6tswTbzQAFL+LUtGi6lRjZdTpjtVuTjW0v9eNL\u002F\u002FzaLHYRH+nVZ7zEdwJcCVg5Niel+k2ZxRCXari9Y8bqWlKzZ2zxVJPx2vxxvGgFfIoz4sMK4yBYdLRKwUhxQ7ecAHQIl5m39+Nh94mKwCB+vFCJjr2K3P8fLBe6tSXed6vardJry+pQMwSs8QxZsXL9PdfvR5V0207lS0O1WUCxh\u002FE1+9yXmda7pUVY4dUbLoRKFbhRCNJ6MU5GxKNcA6DEzNxnEKvmtmxaOGGHGABy9zhhZoWEbSuClgRnl0VkwrsmmU2qfLRml3zeiQHOagTf1Y9fet7OiLNsjp0D1ZcnqoYABjaQ4WiIkm0Up1G7S\u002FH3\u002FZM6H7nHmgGGACyvbfdGpyRpjj3CAngKEdm2hfx\u002F\u002FHjj1rHFWtiNnsoaAPVMe483XpbOkMelRU8\u002Fw5pyB3Em+G6FwR+mvXb87Gw7evy2lONi1T44fYMrlazqmxowUQiTe0dyrdvs44EMWnuwCUVvZKebFKZ77oOrr28G18Fz0EYIAEvMfPVEOZwd8OdJMX+nHp6tJnAkJWGBdQD2jXljmR6vQmPhCRBSrxLd6jezk0wIY+km+dELVGT1FHq7eTn943dCH+sMJEn5MDc790V\u002FJRG+ZvlSG0ksdZA2qsjCy7hZ0Jtgj3TpHCrWhwrPG9zP4JuogCP25FVxrQj38cgP7qx9H+\u002FFQj++Uvf7nxm9\u002F8ZvZX0VlbrXKyFWjt2eaRnKE7B3QCL3jYuHuGfnhtFlzA6wJD9No3d+5svP6f\u002F93Gz3\u002F+b2bl9Q+FCN\u002FkxId1G09R+tcOsMtu1g4azUpJ\u002FZ8JG563kmGOFj3ojLHL6BvNjN2LbsDPIq2CQQ5aOpe9Atg5UNwUe0\u002FMi2ccOUjknfowR1vpM89Fc1Ixfej\u002FgOOk\u002FTAY9XvJYaCrcU8+vb7glxoaRyka0e0Cgd77yfQc2pXcFkQNzBZkQ8PeNdA5HHQbPGLFNF5J9pLE2gp3bKYbkr1npXSudJSTGzfaS3D2XHIZ\u002FXWI\u002FZRjjh\u002Fq\u002FHyu98ZBt8FAbLd5HNubPkBvc3hcX7tv5jMbgq+cGbDf8ovTT0WP2eSH91sBzh4J0O1kWwQKleZMhIdv2U39sVo0wL554Px55rG+qyMbW9kFh2QpioAuptk95M8cS8mdqL+5qB26SnovatgnMQHQ2rLyZ59M7Dnz6FwWq0jHr9afvpemyrHmmFtpH5yzoWy2vuHo9PRgorWabpM6WqGJVX06bYB9c0iu8Yt5T+Drtzz\u002FNd\u002FdksMeX9b\u002F2OuDPiJ\u002F9NOyaX6fIhT1eetVZ488S+bTHYcFYel\u002FTvbwWW1pT\u002F\u002FQZFJawwrny2S4XLEMAZa6073AP7x0fgJ2g+Wyu0sfrO+moWSBM0EWjY2uPMJbPfBf\u002FfpoQH0YJ8ER4fuuAzd+6OTJxy3B1u9heJQ3GT5QiuflyzzHhmbpaT7ru1lCUWowAAU0f\u002FbZp2McHf4DtL\u002F+bcfA3n8weZoYggAryygyf\u002FTSnsM7ZgJiQCAeYJqc2p5tqQkz+hwhKTxADqOK4BA4E+vlOhvKsBogSqFSbiZCZP9E3qflD++JFDVRhN+zj6UUXwYiLLEyVowZMMKQU3Ij6HGCMdgFTjk9eni\u002FZdA\u002FjoACzpfbBAlQHxkwp5k+SMhFd9VVP5thPJ4zQTGgkT45ifJyddaVj7LEa1ysLrAryrdbRN0hCG\u002Fz\u002FAB0YxsBy2DW1XmWCDlFaA7WJpVWIjI42gRw7lX6jpL+pHKQDmxiXIEw4zyikznd3qqmfs4EpURQ0UYJTnywdstz7DKIgXDpQyKBr18HhAIN66j25c1z6qbEY4aQImRgGQ9RJ1E69KGIzMsyttG139GFAyRCb4PZtetXumYZQArwaZF0p7TebBwUgs0qD+7dnYgIxWNOpCVRYDbGjPGozcPaUH1j+91uEfB3G3dbvr7RCs+VckRVdvj1r4qEpGgtSVPYXpwPERarMYAQyCwFws70oNrGy4CJtCflSE9ttwQaUH\u002FSaaOP730XrSmUFE\u002F\u002F4I+J3hWJPZ6zsl2k5F1KaOOwDTApXs94\u002FLB5DqRzNCnSZnWeKRo5jnQyOpGz6Oc7Y6cgfde09QYBGUj\u002F93eS2meU4dFn7iPT67+4aG6QdrLy4NOx9Gz\u002F46QzTOut9OJxn6X8JifbRemN9xNZ7vIeYhXDisHkshqnh0TXgiIbp53MeelcUd4cqRS+NIGd5vh8AKj6QdO\u002FXInhg9DP6AbRKsbvKHKED61+qQoFqKs2ZZWOLDJOK+0gYaB46x9AICrkNfLUT\u002FzsbYgMzsEHw616E2dH+xOxj7ZTvaU+0je78RKHCj9kWiLo2qB4Nz77l9\u002F8dnSgyKaIzeWrn0SLnSLWNq4FGhuDyLVotmCAzZjFOXvH64ELp9rSv6K+p+uHA+SeJLd37+aAFuwQRBB5d7Lp+cD61cvnN27fvLpx4+qljdMtYx+UCnNCGgA9Fo\u002Fu7r6e6l30B33JuFupfFVE6crVnpzOsGIkmieIwphJ6TidjgUKlX1cp692XeAQUCer+N8cAyyij3gLeMRC21tONdTPnIaeKZgTR5jKvser0S46pgDi+\u002Fq6LRq4gDeDKpov0ACADx\u002F7u3\u002Fmz9\u002F+cbhGrzcPeOGoHvQAn9qk411LlzDIAD59wkGnFwfANef66xo2B3\u002FjYyk5rQOl6tfqFD7\u002F8quvNn7yk7+MPhfHLv7d3\u002F3dxj\u002F84h+KljrbILDVMzneHZc6zyWnUoCACjqt\u002F3p+469fxwRGOgSM\u002FNLBxkwfsi8A0+PHbzf+03\u002F6v5qv4xs\u002F\u002FelfBuCfbvzhD7+dedVHOlrUmD30XLxW67N3YR1xj98XmDFm7WtLYIl86G8XzDPZQ\u002FsSBJeUULVpX1DAya\u002F2XuB3vGrmpAHW\u002FXQeuiwwe6wVIn3ynHHgGnfTM\u002FgArzhpc5zb2sGPez1PI+yNuVi0sSrcfA1\u002FLD7YzB6rsqPv20SYA9tzRo9lQ4QEOHWNfp6LQziNJwL0fAd28Y2c5QCm1QanWeNtMo2vvIB0fSf\u002F5kmgz88tMmo+6yPnxNg5K3P6prnsjlk16Nqo0rVRv2caJ+eMLeCUSq10sJEov76RA7x\u002FWAoVGSL\u002F5lyaDP6VHvV6ADCwK\u002FhpvGhZFLm2R6NjItH4eqVrbDnb6hoYyv63CczVn0m3iQ5s9TgkPXNAd00IYL3J1kzpzORYf\u002FEePhwdWuBLFT5tWml3UBy7C\u002Fe9KUVlViWiyejBnk9nwY+bxlbHFnhO\u002FtL5aLfVPguvod58Tx+t4Km+N5ru4bg0N42LjRpniO6oT+z6zFF7BOhzvDkH8M3F0aPPpKqw1ednhbxSyOnBKZ8ZnfEZfYSmnmtfIl3ob4EB9PS3\u002FWGcEHhS4O6\u002FSaD+X\u002F\u002FrP5Und2uivJZi7tz5NuXdRrbACm8FBTHLDKpJwSAD4LYwS95bTPe8pd579x8USXlYNPdaEc+LA8SfVK3FEfAqwABOmIHmIiiUBQIPEK\u002F9K5c7MbT8ZMpeyoLyOhTLiiA01d3ndkTVIysBPOSliOQgUcwZvBQ44VrsscA7QUoTj6BRLiIm0lpsOIwNhxmOd1oa5Xxqt4l82rJi4F\u002FflM0iBJaQGb2dGPjd04TEc5rYEzvyWYtWlYJCmSrBRyAeZsgcQW5DI\u002FBog9yjwzbpFm1VUUFFCkprluO678JBjkvXAV7y8QbgpRxfRFtRJZu4vOXOUUgAihKJPHbKkpJWHWfASrRCN3mpKkJg3Hulp9i4SgkAlxeK5juVbynxjGb3678DOxzksjxiXvqim1rPnAb9kiKFITA8J+nCRfMWj+hffVHnW+SagRoByTGhjIAA3ituIsgaMYf4YbscF32bHNK+IyyEH83l8rvnSQ7k9sWd6LE3zuT1G9cHaN+t\u002FvyTcgKvp4ScCHoj4P1tZR5F2y9U7m7STFibnuPodcJtD8N837xcu3Z548bmrYnMvwwEKhuFxkdObB0dXuBgbNVJ9Y8tZdrLsfW8tgJKJ1tme+Ud8FEP37ypRuO0ObnqltQt7cpvPwy87eaEyH1U\u002Fs4JDVst4584WYQ1BUqefv\u002FPv9v4xT\u002F9OmP9dcq0iEvAV8k\u002FYAAwGeAdzf3ziq0TrUxYQsIZoqS8AJeZLFf20XofydNS0GRLTf0kIQthEtzpmhWNXUaZYaZAczpSpEwIw9VTewbTtZwtNNt+i\u002F9yqKPzfmlOll\u002FPtonyXIDgzt1vM94M1KoQhH8o42BUBiAD3NiAMHKKN4EHQxyDMENqRSx5ADwGPNYPQJ4+EbUFtil7fMbg+Bz9VJTh+GsMSfA6pcygezFqNrC7h4EUrf0hHqKHxrlPlqRGyJkkY\u002FTJs\u002FTNL\u002F\u002Fldxv\u002F9Z\u002F+ee6RS22T4c0bFxt\u002FgYWi8W9fSkdpOTbHF9AWSXRgBwNOdrcyVNLZnjz6YVLROAyMOZWFD\u002FdziBndvU4ZtpH5cTrlURuUgelz6bBLZztAKj2FH0TA+iXZvrDx1ZdfJQeiUgGnxv8op\u002FTx68czbyofqaPujAe0Rkd6109HogOEdBrQlA2O9xcwoZtscBMp03+gs4uH1+gSQIyMvEiGJq+3+bJSAjDSge7ZzzBudfgXeD\u002FR59qeEzm7LpbpJTIN5CzAuPh4zak2Ri80gXhmeJtY55DgYS8GHtjC8+bYp3geb+GpbPv0d5UVtWKDHwJ88aqKN8\u002FSy3tFJW\u002FcvLXxVz\u002F7WXN2bgJM\u002F\u002FiP\u002F7jxX\u002F7+Fx1o9k1jiy9zajQ8Tt+7tXLE6C\u002FHgp5cssVWeZmfeXfPpIw1Z\u002FpMzwpCvY23HlbY4T\u002F+H\u002F9ntHLKtdOrz2ZfbeQH7IFnss2xWCuSVojuFlhTrWc2zUZnsrDoyl4AkQBRgKSfZEYfBItUI6Jn9jrtEa3wGLB+WspXfUEX4\u002FH5nBUSsGmw8dNylnfafE+nzTN6pnkiQ\u002Fapmc9ZeccvzQfwzoHZK5jzprEag8Pr3h8UVInuVqb0S9ni7VYoSG\u002Fn6bTnveBPju+r7IaVK3aRvsADQNz79p6wC\u002FTdsU6enXrggc8V6Fnpn1JiyTRbXWdHTvGO3\u002FE8fTEVg2qnKUub0Xm+rl1zBgz204ttsupAv8whO61+0sdoZEWUbUZ\u002FfE5vKUBB3ukTjMge+p0cH6ufUknX3qO+7xmCYPi3oTZf9ODCJoetXI2+qw\u002F0b10eQG5+OGw2pm5usS05r8mz4Bi953fzb3WfbL5OF78qbY5OOX+lVa\u002F0B10DnKM\u002FfMChJ2fy\u002F+Ezc8OZEMhCaw7IfhFvqXt0lDFt2\u002F0Zr630nhX191z3oiM9wZ6irQBLN8248SRZIgMTJGm85EfAlW1Bde1w4vGM00WHv9NiY+uEq\u002FEgmYooHEJpv69K8bHP0LRZ1cIv7hfAxKfS7eCKsXvR0Cq8rA16w8rIke2s9X\u002F1Sxc\u002Fyuvv\u002FvYfpzb2v\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\u002F5sUw7d3qmufY4q\u002FOCj44fLlnNZLVyNipyQ25yL2ltWf9hyRI4rrZADvwsU27BRNv\u002Ffw+cY\u002F\u002F\u002FOvNv7jf\u002FrbjX\u002F+9R8mX+9YlQHkp5\u002FKwXzfSZbkrodEE4pLZLjPSWX\u002FkQNKDE\u002FrR1e4tBe+n14PvUc2amDAS\u002FecKDLIQBhPQZSZdIbDBjR5pk1rkdsMwxgTMKsPeszaKb+Wp1PRo2hF1E8C9X0PPB9vNehS1XxOF1Hfeny3sVZ3OtozPrpKl2y1\u002F0Jb4+QFlCjqMXjJhOgHnrZHY7PSg6IkujpL3vG1pVGbD\u002FER\u002FgZ0XqSsOcFoYJmfrAHGRy+f4amjMxDIgYgLAKZfjounX2bDVxEsU85JRZ85dbT+\u002FHD\u002FUSfrftOzNzY+uXm7laqbIx9ndqWQZIy653GlU0Xfz03KXis57Y\u002FgwB\u002FbTN+1d+T41on0w5U5\u002F2CnOZZ+8s23348hFPUmQ2geipm0Fik1z+L979uY\u002FUk69Gy0eG+zdTQGKsz\u002FmeTybODN2OlCwQPO1jfffhcYrEJJTjuH0PXkB1Dh5EuBSEzjp1Yp41+HJ9XcABU6RhTdnALxotXS2t5FG0CGvVBy0F4A6YN0pRVLq0MiayomRdYxwm+yL\u002Fkwa\u002F6HB+VbC1pkxOszoGW+6UF8S\u002FfiF3OI52eVpT4sgA8MSE\u002Fqb7LY\u002FfPs+qvKE35Y7eDfgItJ6cUGWR3p6iSkvjTBHDEpfKcC7H\u002F5s5\u002FOCcmKGvzqV\u002F+y8ctf\u002Fmrs1FE6JcexB\u002FYG9pazAmx4\u002Frz6ORHYrvlTxD8aDSjpM4CEfjMugaX3rWgBRoop\u002FIf\u002F8L9v\u002FPt\u002F\u002F79sfP7FFxt\u002F+N2vN54+uj8laid4RkdHG8BHYEq9fc+nv042VsCPrZBmYNxspdUktGGrOS\u002F0a5zS6sqV5toKQzau7zlRp+q+zYxzgnfXGhOAQ+cbrvZrepxw93brgEu6lC6j58++6SDE7M+RThe4EtgyT1F6dIkUF7r2fYfMOHRGegh5Z4c32xwfWSuj24plwZnvvr83\u002FbtU0ONqfGllD8AcoYzP6L7uSkQC5cl0MC7+ktrR6l3OKPvMWRwQbF7qBX6lf6Wk6BM+l8rVbb36w\u002F9rK3M\u002FPMce+kNBB5tdjbfJHpyiqsucetpPtg8NOLV+zsbpFMTomtHTaJjD02fAuMZhLs771nH3YqH0YKk89MzOHp1o\u002FkT\u002FV5+mYEPOi8DXcbLUfJ2ouAL9JziCB83bHL5UG+fST+fKSZdqut9cOBhReqoU4qlc1zWDsxqr8bJxRyvIJp2esJpPB9CTL189naCC9LSRhyiBfp4\u002F3N\u002FzbfAUcMXjs6G18U4AtbgIWnDk+mV0NB4VlAH+OXSwnrcAabNSmwIJjatn2N8mmOPUYRuN7TNyzstEyM1twULYUVCMTM+8puvwKv1Ch9AP49z1TDw5BQqO9ER9W9H+Hv0RXjTYR3tJdzlz9vej1IEd0bslkA00YqiyEV+b\u002FwwBD3ktwQOLiOfnwQhzOaoRHTFGSfT5eGX9zYAgwALBlQoKTAF5ylJZyubhi1ZQ7qLFUmN44hQLhSciLYJvc5VIAiPKqPb4pQT6KapgwyklbymcIqPEZnNNfce4lL6\u002FbXYjfECCRowRaPH9vdIo5I+riOIIeu0AXtp9kaHVpmWSt88SkgSTYZvl42tXYkx9fNjm0LsxMaEm\u002FByc6piXruGAI3mnf+zQoKdFgSlMJxJiVgrSs3h143wkIEP\u002FlAO6ERifM8By3gFMy1Eizp\u002FcuDYMx4tf8c0iAbUuOn6uqPrLQKP70NZYzKcqHUQLPdGCwTW32sTohM1LiTTRDqBLVF0Ex9xwyGwYe\u002FKkzVTlLTPknkfIfPdyu5WAlLp0GPR9U7lKimsUdgLiOeZplu3iOXiEZyytRtRc6gEnTuSBsnUokOit0xsZI8ZEnhwlR\u002Fk9uN8G6O5zMJNVnctXrg2\u002F\u002FOY3UhNE849t3Lz96caZBPtx7ZpPc0mRyIk+Hy\u002F2gOb+QmlMDzdCQzNXT59LLQCsMwfN5WY8w8no4nEMKF3ltX64d38A\u002FhdffLFx67PPNy421ycC4e8B3YzL8ZPl3Z9bRlIVAErmoM1mb4pmty7SATefViFof+O3v7\u002FTCbBfNzZOaTnqRWeb+PoafURNo4F\u002FlKgoD9AhSmcsFPQA+XjFfKN1bD2KaSZTr\u002Ft8rRb4rjGpY7ymegzeisynzMh8c8K0dcsYlPeFuubU0niFsZqNZSnAqaIRD4i7MDyTj9j9oiaXSgu69cWPZvnfBqMb7VW48OrCRHrBJmU1CaF0kZHnaLsiKkWky5MeGa6d+WxkNdDaOL0pYy\u002FK1pIshYwedBBQRI7xvP4v+iDlioQWR2klo2hPb6BCH\u002FxzP910+9NP+9wpnqVf9DkAYDXGOvtT1Zz+X9bu41vPK8vv+4uLdJFzIkASYKpiBak6u+V2y6s1tqceeui1PPTUEw3sgf8GL\u002F8BWpYnkrwk28sDqdVWp+oKXVVdJEESRCBI5BwvAH8\u002F+8Etad54yRf33jc8zzn77PDb4ezThrG11uaHP6qO+YMPZwO6TZo2St3qvctfX1vdzinUYvRZNG45MypPhleUNj3e+zQA1iboI8cmmtkQG7fTcOsiFEDh3KnTlcEQvWwIPcmHTft3Cox8szqaXB\u002FKSSeXNvh6riVvOztkje4Atre3n4O+0r\u002F9dqD9dpGzx23Cdi2RwciRrgK0oltAiSM\u002F\u002Ffx7QwkMffkysLAA4MBT6XJRekECMgygibTTDzKewIrPorufdL+xkxkb16Xnta\u002FEJ3gRv9HlO1sv9HU9ssnw+06Xa51lOZbSRq8twCwjPrwc\u002F3Yt9sUa+x59Nrana27yzzPylh4dQ9xndJDQ6UXEeMozklOHj519773V2bPnGquSvyerLzqJ+UL6WuCKM2fOgkbuzZFNxLofcGWBXi9THPOb+zYBwICjODITIHzWDmRzfJXzubW1EgwD+IBiGUIHtb377j9qj85bS+R4spVLlsM9Rq7jSDIacbpWtcXJCgCr\u002FMLeIrK9lEE6DZMNWaLM48xlcxx2aM+U+QDSU5oVHz1+HThjX\u002FAk53H37mxCn+PQse1+nwOqGgC7SS83kHiOQ8z+L7I4mYX4zD4F3wP2Zl0bp5KKB9XhQ6DqsfEcPmAzyfGreI7+uFvgSHntq9Z0wFby4GyBdd\u002FJ3gS35un6Np763ET+o8ta931VOYzabTwx9rRr0+WT4UfL0WNF6fssPkM37\u002FXnrBH7PdnEXps1ts69xznkVLKfQKlAlrIUtg9PzT4Ln0sv0v8CPv2yevlIiZ3sqaxq\u002FJnOeKbLz7Zsag6RAIT7jC1O1iNl9+dB0AGL3LivIIJxtmTRawG+aOD7Xse\u002Fgq5rZU10SbqfHROE4+QLGgoERPrWITzTuigfAdgBXVlDXVPYF6XEgrGcD9eT5UBfOAIOM4cu05yiHdvUE15RbQGQw3DsEjlBB3IzTkZyLtoPwNMV+\u002Fb3meaoM1xuxmrjQQ5\u002FazF92K0J2iXfHtYjqQsDRMdK1qa0sWVZSmk5fLJ7y\u002F2fZ7Os5QSZug796dHlBjfgf2Wp9AI+hiXe1OONAfWDBwhx9Zgp3cuXr+QZFnmtb\u002FiTx+oaqwUtIru2Vno6HiFYlCShnlRGzA6YUw4iqkcyCAA2YRMxQBAMRzEQbH9TdCIdGNriiOiIji9A\u002FUqC8WxqqAFa95GKcQ1puROBZkDVtQg8waOgMTRGIGgWY1IYI4wUIi81L6prrG+0Sagd2YDknqI8lMiLQCFDLIQ2RqXFwwxLxGhpWThRmZhR2yx0Ykj0i3daJqWiu4T30EY\u002FehvnKGSRDwaf0jEHYwXC92UwgUnRY0d76y5y+vTpAX02imjtROBsKgM+\u002FL6nFm0Mvp6uy9gYPAwnU\u002FAgYBmdu8cAF\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\u002FPT9zw+QRPjkIlSPjBgrtcAxjFgjQEPbmlcPksmyDg6AcPbtgbQM0LDm82R3DMiHoyqDZY2FYtKi2Ipe9me3tleD8rnL9v3Edg8Umefk6ffDSBva0Ny4Lev79tXB4I6qRw8cjw+qJQiUHynzi0PM1hOL8ajjDQDSZa\u002FzalHR8brxStZHI7Bwpd0ABDcyFrjXm18DNdGxlKJ1f3Tp1ZvCRC0P+RV3hYAsLWNilMja67pFiDxUOVp++qIJLN5\u002FcaNOcTraSVbm0b9xIkj8XZgJbrq+by19Zy0fbqSvrx\u002Fnz5\u002FlCx1vkRz0i8c6KY7us0AXDwpB+ie2mXiGfPQ0\u002FxgPDMgDS8FOvG+yJ3SHKWA9IGOUmwRthw584vrpHt0VnoeMBoCW5\u002FWnEOFH3CKqGO3mrXctAn0LqOLV1x085rs1dim1nZ39kLdvfVFu7ffOtMG0o8GxN+\u002FfzvAfGl14UL7j6rnl0anLwbYtnbm7TqtpsBfsgOEmDceoqubkzHjqf4fCex3P61pE5j5mLfMo3K9U5Xz2et1sfueP\u002F\u002F56tzZ0yi6unLxQrq0jmSBU5la4BBvqzfWBWtAkushWTaHI5PgjgMq2o5WdFNbYpIBQDj7EkBS+uWn\u002FVPGvgCxutMM8LTnqPVLLwvGsbs2v5K1+\u002Fe1HtVlo6xq701msuBXdx0dAPA9bXz0CUArYj51z6+dsGfZG3zC+fJdDvla6ecls931IuPj1o7jZpOhczPsDbB2MEfEXR3MxmgDO5H4bmyOIqsc2wSsj2SXcj7xzyLbi\u002F4g79ZodMmswFKKOd10ui8dYb50xtN0O5uUlh76cFotJkfE+tM1bLZSIbTCrngNeKWbONv2p2CB0ZnzmaQ5XSLCT\u002FfijSVKny4b0Gr\u002FRxeKRnj3KfbqOfu0+jxd7x6benlsWLTsMgNcXZNDI+BquPq09\u002FbYR+BZAAEOQ5dpFdq1p\u002FtOawmws6mcbbTuRtmsZLL5CBzBLINhcvR2xbP05OixZFhwBm3pV86HcdFrdKzBoYmIuX05AnQ7O1SS3RWI8\u002F7+9oK81Z4xGWZZ52+u3SoY0jkz9CK6CT32cwHcyrzMjy7JmUmvIiU+Q3a8z2m0QdcYJivcTw4E2zTy3+cX25\u002FWMr7RPTkZvf+mHobyRh6E6OPvfDy1vgDtrt3fjnA\u002FLHW86bWJkxEiwsFbVo+FyfUqlsbWk3xz0QiE8gueGMWsNtQCXr50eRjrnaJUFheBeFoWMXol9LurFT72Gky+msM8vC5lBXxevnL5N+Af4R1HfvN6u6tTKI1sUTgxn3SI6JiUjO\u002FqQOAAAYDd\u002FUQEABQReqmf7Y+LpBUlH2Pdd0WFj2f4CKE2k2rJRelFzI2HAE8kr\u002Fnvz8s0bqk9tZ06rDzuer5rju4nCrNl9wIUrj24Pt8ltCIdZ8++O4bA4QMyGMceLz16bR6VSlPnezSlffwYT9dmJzMNEGGoDJVIApCO0ZW6cBTMnULEkLrNyBgcrQvM3uZl3dSbjVJISagnpUFE4R\u002Fer042J+bbvG2GmDJUw7+jcQLs0msi8xhetxN0V5OHHttThnrZPnoksmNN9ZbtUI+U5b0ETpkPYQOojH2iSilxdOX0EGxtsdbWAv+7ltrikozxEDrJABQNSHnYB3G4khZUmFKbHCWbRfXpp5SVHVE8sjJffvHF6tNPP1v99m\u002F\u002F9urse+9PvTjAzQBKwx+vVEl5ljpNh9FwEk4cPxEAqC5UvXi1je\u002FX2\u002FjM2Q8D+Z0gmBFlzDKT0XGJBknr3WvN7+UAUOov1mxGqcVX\u002FtOvzl+c2krvXyl1K4oBZL3z9pnVD7\u002F\u002FvdX7RZgPVT+\u002FNzodr5xHdGPfoePTP\u002FleY9mSwdlJmcbri2KmSIooFeIGfvAiI2c9KU6fIXseQCqj9Z+m9wbg+9LrRyIwcjA\u002Fo7W61DkIqitzakfrNd6l7rBrp8myRf3d9YsO47WXL+iC3ot3n8X0A5YCsYZhM1iXLSK\u002FdbU\u002FWcNHl85\u002F0iFWV4oiV56Uo2ohgVe88aA2apm0QEfRlTqb2PSLNwFqsonPJq0bUzBw7o\u002F3jZNR2xEt8dfampZiS\u002F37KOGgo58MhxNjyQfe5eSRLx2EhiyNBd3Geel3uo9MMmjbW1MtF2VARumn77YUNd8oP6\u002F3941bd1frOWKnOieB4blw8crq3bI+P\u002Frd31sdaJ4XLnyRE3e1+udO4k1+nQC8E6CIUM\u002FiqW9rzars71Yyz5kFTHY0l+tF5Z8lT0DkcycaA8\u002FRVEtPwPxSBupUrRmPVVK0Fkh\u002FWc2ujVnru8mf+ncQr4WIjgAjnSxIMOc9FCyRpZJNsnl1Oky0VsZ4v44Lj6PNyFbXAUqAcjQDTNDIODlhL1ofhhow2JWDbU3x2rP2YcgOilTjRY7J5p6AhzmhMgC6HjnhkREWHBBYmChjk7QvAAAD\u002FkVFMd6k4wMXE8HNIJMDMgUQ07k+63cAA8\u002FQ05wMssnOTPQvyykw87wuKvQTk6xNKKBC4dAvnkpegJK\u002F+Iu\u002FLJp+sTkv0dyJEkYzts39nrQ+W9N\u002FdBreGLnxb+N5OfyUroo2bKuA1WQn0nfe9x26T\u002FQ76Z7OaOirZEKW+6c\u002F+9nq5HHZkEpG43cZxInE93MjPmPDDtfpQvmkEj1OLx7meDy3FnH27OWa+0S\u002F7sUe2XDXknVvoEd5jFrr9hYkF0nzACC6hMy4L2dSwARQZxvGIctZxlfkEui3frIsorG70kfKqKwNXjFv9pDjRFcotxhk1Ah9fzbx9RNNjf9x93qQc\u002Fs4PQNjHD12pADN4xzT68nuvWxxm\u002Ffj34pyRsepixcgMF\u002FfZ\u002FtmHwBM3f1FqdGbziDXdGYHpkbnJfKM5zg9PoR\u002FAEEOxsvGTW6mu0kEs05aIrObAlMcFqAeIJSNcGaLiOyUbCiyt\u002F+ke7B5WBgYHOCdXNAl1sb9yIe+8TbKsl34dIByzvi0Mo6HW8KhJbVqDsZK5szX98k2Z41cWTvBLZ8hW6LOzwrEiIK\u002FTGfJ6l0tq08\u002FnAobKE3c1vh3ToCxAExf1czBdcgIO6Qf\u002FPXsL6A9e5Yah4d5kf+ZV5\u002FBzx7khWNijPilV5JDJXPxMFnv95c1Xrh\u002FL\u002F0OOwS0zzaGw0cL4oTZTnQfQU\u002F7yLYUnPSZV1UWyGijkwCmOWmT+zy9qH+98QoSamUKs8y+lPh7oUfOUfNfgs2L\u002FOEJfOt9\u002FGnMwPrwwszi7\u002F\u002FP1n\u002Fa4+9\u002FmdXqT\u002F\u002Fvf776J\u002F\u002FkT1Yff\u002Fe7HeH+1uqjDz+Y9n6tf5MSTQMQCABhk9YCBGuaX82pI+UJnzQEMN68Z8IMpsUZo9drFAQg8W491Y8eVZu+pLgGoBHaVttppqdK8+11gA9BDYi7P0ak+LXYU2up5ON2GzdFxtV6Xrt+vYin\u002FuvSudXsBYy8tzS7X6L\u002FlAuvfXOTkYi+Lh2EyKLsCuiJOnhQFgAQpSTawDgNw0YIyh6TGp9IH6VDkUgLoYP7Sxd6EHDK2dht0qXsROaAhAEARSN0uQFEAfPLl78eBYN5tHqjzB4GDkTPKG7rIUoGZAOuBHwiIF1ThEekg7CIgmmvRXkaq\u002FFRRObAKeNEzdxaI2tKmRqrcXKIXNv6UC6+Y56Ur9eB98NtkLQmly9dypm6MUqrq\u002FQZGzKWXeM2zBLETSGmyBheikJ5ErqMM\u002FWaD3ZkJMeQphDcGwigYDYzB6JHwJdU7T\u002F4hz8cR0pNchSJ94DWIkGN0yY2PBh6HAFcFIQXHNwS+ElpMD54RCnBAX33Dx8dJaV1lXICEf+Dh45MWYPew\u002FsPHi0yf6q9A+0zaHwOiJD9eOfc+6sjJ09XzrFn9aheYg\u002FaxPI8EN2P1ZdfXVn98tefr37xd+dX5ytj+fr67dXdohoPq+m9XknDV5eurs5\u002FcXEA3Z2isPrGviwi+7x7X\u002Fn2+uqLgIGNqhFiQIXo5cOiVdZiIzBmfrS+\u002FQDWe9Yu3qB411P4DB+esSkQnZQbWWNdgSZFHhDyvUVRLTX61lr6z8+hYWuKH5Q44RsZFZHebj48gy+nvIXlaKHJ8vMUr1KZ9GZC3z\u002Fx3XpRmo\u002F\u002FwQ9Xp945UwnBl6s71fAfjIbAxGZ0hCF8IFqYsgVeyKknftuU2QHbgTVGiQHgqFGuQLsBMygTwerWxkL34G3gQ9cjf9NbeI9hAeQ8yC3ecw0G0PXxoJ\u002F490G8B8w4TOZlP0XVHxfue5nR6MUiPw+mlMWJu6feOjPglTHTkpHBEz1nMx1UdL2SOnRk4AE2tdx0ENm1FoCn+Z6JVjsymrcLKjiSnhG2xiJqO3YCEbWgVffPUe1zJwssALX2sAD2No\u002FTUYybtYwtunJ06TpAinVEB5FbgQZ0pgsAEGPy95zi22fQ1HvKBtGVIRPJGvAVTURj0dZraOZ3hhhw5NgB8zpckB1OrHUaHR4fzBjRobGKAqrXHqAdEKWzBRaMnDEVRfb35h4aQGb4IL1N\u002F9CB9J+x0l10HptjzPNsfIJLaOl1AFQpDCdIS01R\u002F+MnTq0+\u002FOg7ncdxIAfx8erf\u002F\u002Fs\u002FW\u002F1lQB2I5chOVqbv6mpDl2CQcRS6Ll2M1vPPa3pv6ujJ\u002FPbZyXY21oU3lXXZsM7GtY8q+qCbv8kbuZPGFzhyqJ1IIbm3lmTH6d30MLlY+H6zRKEyleQfPQ2GjHg2zdGnMrhskPmbg88JOOALDjPnHliUnWKD2Qo8Op+be23Nkam7W2vJznO6J4PeGrLHHOvU8TCc9VAnfj8n3PVF0L0PfHGCgAsdiGxq3MOGBlCtuHKJcU4TnHsBczYY\u002F+M1meyTBfTsCdsfXUSaR1CjLz5gWxenghwsZ7Sgg\u002FlbewND\u002F4lmR0zf8jc+HRmBY\u002Fwd\u002F7DBNyqBvJpOfpTu9ll2aTZoF0yRwWVLpv1qtNGWFRcI+sz80hf2dHXB1ijgOOsls9daJTuceg4hOpgb+ZjAQPS2JsrIjFDr1aVUBzjvOq0R3DKbu+NLjsVvQGb38Tt5NG\u002Fy6v54F23w2sGcO40Z8ALZwD\u002F0Pv57TaEB\u002FIA\u002FORbd\u002Fvrq9QkcmJdmEvgDHR5GA7Iy5TDWrfeHzrEfDnQ\u002F5YN4FQ\u002FAWUuHlk5fjU+U\u002F3J+l0BpmXhR\u002FXQavocFndEyB4A9goPCNnRSayM7hifw8aauplPpdu\u002FjeSPwGXzn\u002FniYo6AqAj40X6+7lsDuQv+lu+B\u002F89\u002F+d33\u002F7\u002F+I+m\u002Fm8cEH70fIjFdGXRvBs2ffmdQozwNTT4TGKYNRlXH35K1MyiuFTvl88\u002FW3Kcqlv\u002FGh6pxE2dWgj4KIAQjMoXOHRvAvXbw0YJ3AUTJaktm45GEMlCkjou6aAFKAz9soITqNuOoOMQDmsCgUsojFgMQEywluBM01KBNGx6IfCmg59l47vonoxpwW2RgABhFu9axSPwAOhe+6ogTSUZQaASPgDDvQpA4diHq7KKmIu8dmaU3rP+M1TuPZW9p5Ef7l9EOGj4DyOHUqYdwJjbQ0Zpp7NVPzXzIB0vyxWtcR6d7W3Ajvq+bAwBqnWl+RZfWAsgXTQSJGfVKXCGl8AMTacSaGlq2RqDaAYt7SrqdPvzVCq2vJcphSp5BVAyuj8iKg4zp7lW\u002F03TvtF7jTxlmRPqetQWjmuDWwYdxTHpWgihby8JURjEFrfJFkFMer1hX\u002FASjTsirFQDkAb3P4REZ7AFt0Ag66XMDr1sx3icQUTQ6cvHqhVraT54rIalX3KsAqjfv1lUtTInDs+MmcweOTXTlSJP1FtJct0euaAj5w8MiABMJ8Jy\u002F\u002FWX3GHXiyp0jmniKxhys\u002Fsfv+Thu7HgeEHhYxVNZw5fqd1fmvvlnpzsIAUpCLscgxjKYv6+hi3Nsr81G7R4ndq+PM02tlL\u002FruT37+y9qjlfGIru+eO5eh6rOt7YnWgWLj5IlmK2fo4kM3gJwMoKWNR8dqX0nRcCwBr02lKNPDyeLwcHQOdHgLvmbI1P9ruak\u002F\u002FtGjh6JnxqX7PS1CPPfp+j5L0XOuGJxI1ltKWlKGLcQc5JJxj3HHgOio87JQ+pp2adFr1rS5mJPNSwwbI2LzL97gFKt\u002FtTn3acZNat\u002FYWYsB8THJAKJe8DrARqGPAxrP2NeBEAyG+XmIktM7Nj9PwMD4e7reyHr0F2UFLhibAW1dkyF1X6Bss76XA7lVqU88PVG2xlOSfCI123akH5Id4OJuPHQtg77ls\u002FPLmmV8zPN4J4EekDXZJ9pfN5ecF2B6F+e58dnYJZsloimDs971fY8s7avV564i498E7gvfp1OPFRip81TffSoy3zrIPOyvRn1nEcXdoqLVZD6vZNGGKiD9ydOcjuRKdJPx0s86Qva7SJfMWJFeRqqfdA+Qrl\u002F0Yrwy3r0WucaAHTpcXXD8bv3RVW0zHtTWjA4HoEXu0NamPmB31rIP0WU6FuneQSdrOalUzdrS067jusDJK2tljcoWoLbymImOxYsDYvvMYLOut6X1m4BE+3+AIFE1DzoIs3JMGGPrbp2BBmPa0dOarlW7zNnaHm\u002FicQemCZ6Q4a8L\u002Fvz0pz+b77IxGA0P4RE0wTvj1LZm7mcOjbY3+tysY9\u002FoRXTngHFqzctrfg5o7ycZM6YBGfGhB5o47Ih9AxbxBHv6rCjz85yZvjxgGsAZmqUHjHl\u002FtpeO9bpuLhvxLl1hDHSs65IhzisAM5v7mosJsdGutX17OmIZ5LzOds1\u002FjQGYFKgbexiYZEfZLzptMoqN11iVe4h2eo3tQnulIVvbs4RmbKYGEfQDm7Qe\u002F64HeNGBY0DvcY6dlN4XWm\u002FtmSs5C\u002FDtqzRRW2T9+qdsJv32KrqJfhvrjCVa97VZF\u002FuH8MuyQPCEdTIj80519d0nlbco66Bb6EtzYPvpFPs5nBr6qrJIr7kAm4uuZMf6DR80dvu4ptzidRBikwfxipJVUNHaD0+gUw9jNm+6HB+Nzu1v4Bl957AjY04WY61Iu7ynZG1H10VjwSdzQne61WTtGRvd3XUA1S1byoT1XQ79fK7v2oN2r7LUHdvvjQ7lECyd4Cr\u002FiBesg\u002FWYzfPJlmzB\u002FspRBbBi6NEX2tEC9MPT0RzrKHFZSuoW2kzpSp8B4um2HYNDciCzE7FycusUd8D\u002FSU5ZrU\u002FLDu5vjem0c2+fzC5Va\u002F746gSvRk4KaImW72w+IkPE0rqnuaJfNLMu0QffyKY87iwTEXt2GJ3x8bZsJZlYSpjih97zQEfr9KYebwyoA+Rffn4+ZlsWlvDYwAdwMqT794s6lqotTYqYShC08RE1xXCYlbBtFBXU6UR6SuTqTEDjzNtnBgjqq0ORKh0QAQcqKSqge8cBhlU62oYRrQgrf0g5Y1KK0UKqEScklItoCRDp\u002FjxvmwbViiv\u002FuNO4RWd8T\u002FRwIlgxh3TvB++\u002FP6UbohgvA1+EYklJLZEDRoNXz2BRLoAr4DUR8JSOzRo8WF0MjLebjGAD4lJCFCCBM\u002FcxKAkzIQQ4ASUcrBuJyJKyFsYDoKM40M\u002FGVQZMtEkGAuCaY5Ib1xI1zFA1F+AS3RlXNFHLT7FSWrIKAP\u002F2HW0w7bU9lYU0qKUvfLQaBow2FBKja+0moxDYMFZ0I2AUFBoAZL06igjNlb2IfG6sV1Nf9sPJrw8e5BFXq00ZJSNj\u002FBcDsHivDnPZPpshm5M17T+RAqVCxgFUVbwyxo1Hu7Pn0LyIEkdqb84TBxJPPA6gfHP1cveg5DJkz1OmCdhkK+o7zJA9fiT64zRXnS\u002FKVoiUFz24fu2bqQ9\u002FK0PMKN+PjnpViwRQPHszAA5+cRqlXsondx2YOsm7D9sn8aB1ie8vXyoK\u002FsX51bWrVypn+Wb1TU6VI59dQ4rSWlKwa4FUm2enhtCLhD+6Arf+ZFgmbZc+wIO3uvaFyqwufH15nAIOC4C3rU1mezuhFVBgGMiQJ51iXRagLoslC7HIIr6mtMYgbDs5To4IqigCg2Jt8Z4Hgy5iRYGqXzY2QJWS1s3jZb\u002Fj0WfV4Uf+HIglUjcKMathLPkQqxfNXSePLeutCZ8+B2fLOqVelKKNx4ygrJsDSdYDRcanJAJf7yJ38br9LXh6Q5qzezIQjBaQhqYTIel7dADedfwz\u002Fse\u002FndU0oIZ8vKiufoxcr3NegJNINU6feuXJ7vU5vG8Tr2wNenDU8xTnvstmIntaks\u002FmuB5NBQC2BQg3iqQ\u002FuVfmrLZ5Tj1Uv8vBELW\u002FdOnK6A\u002FgUM0xoDVRmvQXoGU+Snyyh3OiLQMESL9fsEQ6f\u002FRgcgGQLEemV1oQze\u002FeuT96Y+9e0dHKdfZX1iBa3viEFLf03JZRW+98gI1AuqxJln0MmDQ8XnMgTOI9hpIukj0xf7QR3bOOwDfHfWrguzY6L5vR4t3k+NmzIlHp1SNH6EHGeInk2SBWvrDPO1wmfTblauqimUqA01g4RdRgzkP0sEdk1oJjGGhx8qS+0sDE6KKug4dj9LFDotijM+ILTga9No5EawmcWms2TNAB3btN1wmU9z1gch7NewGSDHvzLW2+2tI445Ft6SFnS4ho4nn1\u002F1evXkWeAYujq13Xn10n2D3y52+ySbYmI9U8wUC2AH+TEePE0z5DyPw3QL2fI899jrwBY7JkouevcszZFB3CyMIBJy4GTl8EBgVidKHyXbS1DjPnxiHIRC84ZXm9uQEusjiuxaGazHT8ii7GrYSUnmdD6KKNeIfTpJ0unUv+OEPWyGFQ+FiARHbdg+6gf22EdZCWIJYyCglB4HbH7gXMiso\u002Fjd7s5fBV1xdNt2eHzTQ3a49OkSX+T+asZWOQuebobK0F43rz5kzaS\u002FGqOSkfG5r60RyMx9NGYU9OPDYa\u002Fou\u002FBLLQv6nP\u002FIFDPO2esANQuehOe8yaW3\u002FbLyTjiT7oZH8BfCBrOdHs4QbDiHcDqUoROZGYF01kNCNq4BKQXJ6CE7ImbkxO2BEgFM1fvFjuM\u002FcLc9EbxkS\u002FwWCi0nSc9VN6+GyCqvFc15\u002FsqfsZZ\u002FZWec\u002FkAjKZ+EXWCs8MsO9vATRZQ6BcO1ZzWviK07KUJeJ943a439b45lU8hQ4bdSqyvw5uIFfD16bd31X9mH66iBPEluPtPtO6bYumdA65PFBm6OCWfX2lde9Lfj5OtxJx7aVPHKsP\u002FvNT41TcvpMtv9uesMp0n72qM13lh8b8nG6JzlmkyLxkmR4+bEHndSW5BUWjH2CuLFjgVnCkr3a\u002FbEZ2Dm2fq4d6Lbv98kYebwyoAx8WgWdGyS0EtYGgDX0ZT1G4nUXUbQ7EVFKMT59en0WkBBbgmpLsCF7AyjWAZG3qRF4mYtZCUTaEEFEASt\u002FTt1gEnkK7Uxszkb6pwwMSIyyFh1nVmIuA3Sp6S9lgQLXnmwZWxBV4ZfwBMIoLExNy9W5byi4BlAyJxcL45jJRdM4CJd\u002F9gE0OihIbB+q45+GU96IIlxSqMQINQDdwJOJB+cxY+vwAg8bd5abcA0CjbBkfjErBKXfhmPiuebr\u002FmTNnSikemRaXgLwLGOfUIT\u002FRJacsRZsibfKiGB\u002FmRKiR13\u002F++JzCubs02p1ZF2OgUDkWDWMMhFpsNJooTUqVhzl1oq3Xsz2L4Iiw+TzaSTthdNF96T4Ayaav69duzDw+\u002FOCj1btvHwig3M5R+bboVcIsSsIodpHZ7d0GUIcW8e6BVgqA8\u002FcyMHY3gIhPpnd1r62lbEryZcBbn8cUyrbxqg+Vpjtqs1z8c7frPHpUiU9GmKLcUlRT79ztRZ\u002FWqgnUSeXBveiZcnoZTYEdabS1Nj4Bq1LKSiaAKOtzr7KFO9H6QZFlUU8dYU4Ued8RyL8dwL94+erqs8+\u002F7OeVOSzqxvVr9VrXI\u002F1OCjwejVY2nlIYhZGRK1CLb0dbjcJKTafGE\u002F9o+LLxj6KOD4YDM8o+if9teFRj\u002F6BoE+V\u002Ft5Sf8U7kJJ4lB7NpqjXkpsRhwyP92udSVPEu+cKH\u002FsYDNmAfPXq0jkCnVqfPfBS9H05npVu36+M+4Pjg6vTqZDQvQ8SgGUt8SvGmhTuePiUXr93lsMarT0Z+i3xUk68VH0O8r0OHOBZOGX1euxXE3AAAQABJREFUNP1RUcrnRY31tj7e9fZWPyvKBMhznnbFDyIq+F7keoEtSpOK0rZmeqw7nh5YwHNkeIxSNBJBp9z1vQV0yKJIuLnaaL2QZHFERdQpXw80pyPck11n0NBLBJG+2VaLOMBdJMhjQFefpcs4jjvTa1vzBsYohwCB1xvpItkvmzMZMvpt06At+mfpksTYySjRV2Ty4f1b8U7jj0eBrUPp2HfbqyI7Jlq+vYgTvfJW+uDjH3xv9TsB+y+++HI6GuFhYELUa0vj0fP\u002FYdf6Jr7ceFEP+K6pX7vDx5S\u002FkGM6oKm2ls0h+eYw4SvjpfMmSxU9xvmPl+03wkOAXW+v7jztHjkjdBQdogzBetAVAigi04AJkIxt0JiO8xlcOvsq+p1tQFfRrlOnT8+a2BzIiE6GpveAl5etCb03QPT1fSYtndwqd+FEjh7rPkCNmuUd8x1R6XRZ89IjHi+rO5+xxt\u002F4hg4iG2wcRgB4tuR8+aysrvWhp3WzuV5ACR3QgPP6skAU\u002FTWgtW+4jjfJ8RyF3jXHvrl27y\u002F6ju4TcGpeni3EwluBm7676ILsQr8PDeIBY\u002FHP2LN4R+bBc9f6ieF1GYYBp30M77NR6GxOzsCYNW097T+wPqHXCSQ8Sq6mzKYBL85vfJxuV2IEBE+3NZ+fh3XaluNyKF1ZP6p0gQwwOozT1dzN3JgBW9e4X2SWXdp40SbM+uQ74GeJmJftiAa6rnBondGCtyYynO5eywEcHVqkdqKagTWf3yOCHh\u002FQRaLErwrEzTa55skOPcVPrtNItBXeJjDSvDmosgMvXhY46KyXpYQmYJfc4A3gGO2VkC7lYoDhUtYFKFuj5bFkGaa+W5C6tZepGuyQTQdwXXsYQOzWGlq85Gs6jqT1rQWaz3vRWJc1p3gru3ze2sIN3nfa95IBk91tCtEVr3mQYc\u002FplpK1ILvjjMVm0y0tu0mPsdERMJ7FhwUNearRQsZVxt198B5nQiChC7Y+7C3bZT70ba8\u002FWXjRNfwtaIFPOVLLXigZ7UpmkkV0wzt0AUxGARj7nE3Q2Pt1nCdz4gzDBspf74V96Atri5\u002F27LE3AVYpG9d1OKswgvNGHKD37pnj6bw6ad15UKbrZiWj7fd50NzKos8BZRwkxGKDIltuVbala3Rt43lUJldwbzKB2b1dnMLuMZigNZ9sRZ8dDNhg8f6beryxK12+VIQyAopMMTQWjEEUubEQDlnYsXNJBxJw7RRnA1kMY\u002FMQhXLnyZ1hRqBcDS9DwzAyiAtw4E0tHp\u002FaRwqGUAFJCCyyPq2iSsMDb8oyAHKCM8rR+CIeARTZdS0R6FF6LTZwISo3yqPruaeIMAb1fekNSlxrRcxL+Yg6uM7MVdo4hiNQuSirmxs3o0OKPOWtbn6URWMBmhmc+R7lH\u002FNRlJtRfMyKqY1rR6UOFDegfrBaUNfwuvIUCmzflqWHqbEC\u002FtPRJoWDbt90YtzUZadIJ8Iew+4rmnbiWLWBjVVN+52HdTzJq2TElpr7gzFac+r+FJ01EE1osP1tN7l63l5LyVEQotYUL7oyOrt2Zby3psyiMebm0KAxoWKgKTAtsjY2AmwpTX2aI1jUfjmgzz4G3qk0mdKU59Vt76hrybYdiV88ZVzj0SppSkjWM4RL+U8Ks7Ep1aFoRDCME80IlLWd8o\u002FobvPN44cvV1+30QrfnWqfhFNWAXKlGRSEWsJn397os\u002FfbnNnpq4HDLSnCJyn7a7XU23blm+kuwvg8YXzbpMsR3dbpgo87DvrzC1+vrler\u002FrNf\u002FGp1qZKuz7+8WI3itWi27KXYWaSL8tje3Bpu5JUlsOYpzq65KNmEPUPQH42fAmVwUpaUbHRYZGF5n9J8WQSlpR+FRy5EFh9Xkz5RjuaJz0Rd8NbQnJKz1qNNlppgS9Grc38g1N\u002FaVTrb4Ep9uc+eO1tm4q32ibwXvyylBxcvXulzrwLyJ6NRCtI9ek6WLBndOTQV\u002Fc75LgtyP4P8PCD+qLr6hynNjRwcXghDoSPHS2OP5ynIh73mQKA9revxujW9yIAcnYil6GxjzcCQSWDBPHASvlVKYkPpZlZnAXgZ1vTQgLc+I\u002FILFAzYbK4AtqAB2o9RRJcuKMWOb0Vg7SPh+HM8Rf\u002FIHcWM\u002FzlBkxbtS35ag1fpA3T0fWMEdNfqYb9RKRMnW23l\u002FTIy9NRmW0hMIHJIn87ZD4GTxw9rwVrHlQOVjx1Pfh\u002FdDwB2eFHLlxMTbY4dncF+04ZSe1AAOmUjwNuBMoFKMWQz75y08fl+HRuudF+9syN8PPY4g3n+woUCHYdyMo9OUGNrWQvBYuuwUYQpBhyr+aoTJbe1PuSdLjV\u002FfGXjMkcR0+AxtkB2A8hXk8rp1m5OdmA9vWrs9MRExSxm\u002FM1Z29t18OA4e32IozQR9NYUHa0XoVELzgFSvmefiyARugEwj7vXjJuD3VqzQ\u002Fp7r3WI1uZ96HRR1iWwU111fGmsjP+TdLQsJn0zTkobEodWzY3+XfRfB0mlG518uSX5H61f8IT9YnOuJi9ffv7F8JgyK7Ri8xxnT3Y9XAu\u002FYbRX8bb5ke8l6umKhouXFqDVX31+Cfb4rgd7MRtOEyK8yb5O+edru+VW7ACgfqiAGVJPqUNr\u002Fpys9h28vZQ+5Pg2d8BnHFeOYO+hIbmOk7uj7ib2MgCPgB56aIFXDrI18nkPasZa21eEpt+WJV82Ei97x5RqkjOgVcS4j4zufZpu0AFl+46yHOncnWjemm4vow5sLxsoHTaoW0s\u002FC+QJCDr7gszgy+GRoZWBLIGfPXUBidnn6TqCfeOQte5cG2UwW5JvQaFpr9d63AtH0O+v0g14mI0WPZdRN3n6mQ2ZCDL6RB7RcM6ueeFv5wQMUPeeQECORYMqq9Y441M0oD\u002FQb\u002Fiin+YwMtRHYalIvPBB9xDdno27vfjyvsYO6ZXkRPAI798pcISe1pDMK3tZS+8Bo+R0e\u002Fffmo3FFwv4xoO8CHoPD3av\u002FluAfTzI9kyYqDfwWH8LInF4OTiuOfLffM1\u002Fo3\u002FwJpBOPw6f9Lc9bxxdOkDghnMNp+F\u002F+GPf3uQ02i2Pha5TAhQfbbaphHlgLRvXYQqdvsgKDGLjubEprxUY1qximhske6YgmLvf6edtADt6uO5L3fNidvxO0fXZCxc9zZSq44iM0xJdYS48Hzu0Ts09xvYcpyTdbF8d3bAt2reKzR8GrGQ16rypxyZV\u002Ft7X4014UrTrdaAwNYbKIillUbOFmRhjJSZSo9uOSZEl7P2H2BT7xtqyEUukDnilLAAzRh9DM2h3H98bIeCBORSIk0BYAcJ3zr2zOnLicBHATijNuDsc5tb1IlYtKqawiSDK9zND3+\u002FuQdEs5TCLIdaPXPrrm8oSMARhngh6dNch4uuvL0\u002F0WbcPHqbXePgUO8XN8XBvtcx2XgNRGNT8ZyNa6WmKBG0ssJ+7Go96fYKtpIcAmzvlIwMAUAAC46U1tnFSAnucBeABHTdpZTFFQWzSrVffODKUu3SkmuLr13bUjmspzyFgkXVAN2VHONV2jwEtRTiMS5GkjHTeeVG5yqYDw1jdKZ3OQTj+8tiwpej+OAcpD4JgDwEaGw8nRvnCOBtFEnRyuVKU2eah\u002FY3n7XdORycnpGo3WXlKwDY1UM3nydLcGZe+v6VocuKOueZQp3faWEy5WVuRSeMFxNWVinTJWHhKd4tuMaA20BFMpQCM9T7zOqoH7HrZn2PRduek8RyQ8TBe23rrwUR0KetMx+oVRbjl2kTHdgdm9tdC79CRE6PQRdU\u002F+fTC6u8+Pb\u002F61a8\u002FXX156cpEx5+mOCdyUjkLGifVUw+pjk70L0vQnADylEr3GOPcbGYF0jKcRJHY9OAotgXIpJRQPb6iGEVXKMnIkeJMZfS6PyhripdzSc6ep3goxzH0Fr\u002FHvN9nGYfhs77vLXwgYnBb2U+A3WblH\u002F3oR6vf\u002Fq3fXn34+9+ZbM7f\u002FPhvVuc\u002F\u002F3xqMPd3LL2QFcBhHDuaD+VLsXEJtDw7HlhsKKudbyfbtcN7cLtj7uvlfbsIpBrR+zYx5uwoa5BEvFUEzZgdBBSJ2vhY2dhuWZ3A2Fy1+8Wz\u002F7HEJh2SzhgHrfvSJejJcBoT2pn1lBTE12hl\u002FsZIx1DAQJ6\u002FgSAAG88f2nFoyrQWvUYZd52eC6DhBC0O9oDX5s\u002F4oqE6yG47euTZqwBhexQ2ytyo8RWlodOeFG02suUUz8baF33PBWQd7t6+GUjnSFbqlwMi7Xr\u002FhVr915HngJPN8Y5ztxEUYLVu1lM\u002F7ekL3Zqb84EDTi093H0fJGeB0\u002FjqaUaV7HKknnfPncmEPQ90+r2i34+TL9wvgviiCJT5oKH5AxgeZMt3Y6yyPvFxrytz27W9zdM5CowqIHXi5MnV\u002Fq5vbnTw0FNksTH4+gQqsh1D315nPhcdzXkDEGKern3gcDp\u002F\u002Ffjc0\u002F1EZOlaoJHjQceaDx4WYaOHtm6QLZm2sjPpKIf3TAS+6wLI83vj5yh6LEGTBaTTd8YBRMkkyoKwG6LpLzt4SlbAQWrq55UBXLz41eqz8+dHnwOJwMLCh5zlhYL0\u002F1J3Hs2itTmzE\u002FPsvXEaXwMF\u002FITHEGlKLxqHuQzRyHTrs3TTEtkEmMyB\u002FAeOuh\u002FHUuSaswc4m+8AjPifXQTStlSKZl\u002FXskF1AWM4k\u002F0CEB2+xk6xteOoRW\u002FyMRHNbLoMJecHXeh5602ObZa0Lk4DFjhAX3u5BqDGo9ZVVnNXss1OsLl6028PS5CeKZNozZSsiKoa9wDJxkZ+M9iNmT1dsIRMpXW\u002Fly5KNMZGAdACMZF56ACLOOdjDuZrOayDoKDWk4I1ot16mt8oMKPcxqmmTWpob30GFPYS2u6pPl5mGv0nKNgYPV4ko66jrHGj78tjWkNlL9ZunIrGYeyvxX210ziSU7K7Ft+qLHM4j7WcIET05ADR39vu2cC56Co2VrmQ9sGLY8yhDesksxzFjbITxma8xuH7A0b7KRC09A7vXtEw5bfa2uf7rXF177IAfvpMfzQOMrHoPxhIQGSjDAhenECSa3TPbWGUbtjLXb9xy8a5Jh6wCRWuwQP26jhcqoE3y9a073I6EGX0QC\u002FCPpx6QH09vhPMQzd6jmxqE6sEm63Eq3uiEVuaApmHoIV9JTvK8sOT6C1j9PmFy6snt+LP1sdri2ha57k9UjQvzl5\u002Fty50zH36sH6XAkBKBAW8tjfm9coe4Tlr2+3e2OONAXVAzsPgCBZij+A0AUxns8CtToBUQ0dxAHGYmmfrGwRae6gHMSYBIwgm7MEQAPGUHADrda892KgTQ1EhyodiQTQO8+P69OrDLjquNEbrLmBaquxl159SmsCbexIGoI1xtUijWBobh8M9LCTGpHwxOOGWetPSavGuF2ZR0w3Ui9oC0TYxnMwgUWoMBoDu+0oItIQaQBSY2GizIWDg3nhbdFhdIxqog9q67fgABlEr1xapU+YheyCirVepMctAoClaMpgWArNjWO0qKVDlHk9ryTbtqUpvAtizmaKfvNt9T+vL3XinU8Nr2lCCjJOIvuujvyg6IQXCRSApbYYYPdDZ3gRKmhNAiIyZIjd\u002FTK\u002FukYGWzva3z6hlvNOYnj6XQpMGTjtFd8pkoqH4CFP1kKqzQ95moMOHj+WI3FtdvHSlw30uBUIOVP7zdmUux7tfQDdALAtAcERBOYyyHA87vnjr1gBPyg0L3r6ToT2sO8uxnIIDqx2l5Z5VFrBxvc5Ala\u002FcfnIrcNihMhniwyffXR1pg58DfrjfYfC6u9xeffHlVwFWh5pcmjrj65VtUZzq8fwUzZX2nI27zfmZjUHxK6VHETsOuz+G76yj+fYWKkSSJVJAZ3hjDD5Zo2zRtu9jIqBxKckAaijwZQMY\u002FvE5hoFRnIfvW4B+emVLzgIDD8y3dL3QXdWQFxuYjk0BgQfVVf\u002FNX\u002F+8aOyT1R\u002F+4T9a\u002Fegf\u002Fmj1X\u002F9X700P7\u002FtFfXcHJp8W2ZBFIyvKXl4k+7NB2SXjx1etu8j43rIJB3bvXz065OjplOvtopLNf2dO1c5HWcsMw6PKkHR3uHTpcnKacg58MPjbRHsZ6wZK3oyfHCXhowsetc5zIl+0n83gUuDdm14BAlzLRlRGhu5iBMgL3jL\u002FMUK9h6fV39MPjCPdM4alz5NBjjlg4WFNfI4MozEnGu85zGazLKFPzfqSD20FZdcABOAG1FJvS5NqWVqBcevfmOKVe3cD4VfTT2XYnmeQlOioS5d2Jxb2+zxrrtZ\u002FMn\u002FRyfyu1g7Ucjt8a0vyIGW\u002FTx17fO\u002Fgovs5AXhC5wh0uBugWrt2I\u002F4+vjr73gdzyNTNIqFfR\u002F+nlQPiNydBTkp4eC4ejRbam9E71hHoYwjRCXsBsMpx1l+ydFtGNx9KX9lrIOtDxqfuP0Fi8NBhDHU\u002F\u002Fa+NGt2B1u6Btr53rwzdWtFPmmJHa6M+HO2fAGxu3HriOw4gZ41NwCezfo3DZ10HAZU8TDYlOSErC1BSYlB98muA3ldHnqz3AMF4iKVLAtNbGefmbMDAPX16s8CBE4TdwBzNHY94zN\u002Fu1VwG2Jg3evaa59Ch75BZnxmw0t82yeJ51yTnxmnd6ApXVvrkCZRuOHOhBz1PFy5lCFxf7Qh9pwgsHdF16AlAHe2nLW+bRADwadkbDcmJrio7kzundpKlkbdnyY4bN2zfEzVdout0Nyd2GS+AqIvMsWNH0vfATXTvfQEm1yFXU\u002FoQ79gQ\u002F2JXgScdtnJw8Kc5KVugK59WksV5lKFFK1FWNOBYCzLgQfZT1JZt6S4T1d+zp\u002FNKAopaC7ovTPLUvph+NwcnbQqNrMeXsrMCKwIsSvY0BsBPE+BrfY3HOgBu1lXkd2fj9br7GxdejSy93+der\u002FuyRmGQdIOo++bnfBZf0Uv0\u002FYDRdAGgPvzRHgw84NoutdA1xyY59plGMPtQtmwPmJctfxHPWstZmL7gd4AeCF+GvLznHcPdGk1cFz\u002FJJnh3dGFrMxkcTlzvb+4pMJ+RQ+sXjafqoHEs4yMViy1Co+2t38y7+Voj9hxfu4bGBQO+YZd0nc3iHNouVevLJRovY4oGrjWn4vrb56Lr8GC0k2VxFw4K+\u002F6krIz9Xg+3BeCrGVcu9Gqjw9\u002F6zGzer0TqrZpeWG\u002FlmLc1GvFuYzJPY4zcyxqjYtcUrPWQUVFixJ6jF+vJrjTI6EhPAe7Ym7Z5M483BtQRjIHhIXmarcH2f9448FCktlovXr2nXsSU+a5dDE5R4YRcz82bN7f1XLpxqEG38EAoYIy5KU4R5OnxGlMTcO3BgFdRk8cB0c8\u002F\u002F2IEFig+VbpcOQhvV6QXC1L4QLxrE46dlVW8WOcYLBEdC8KYUSxvv12UF7BMEShbEMEH1DG9FDIBoZBEDK4VAWY8pKAoasr4nXffbb6L5zgGqTEDMa4NvBNIQEPkxAK7FkYTUdaXG10d5qQefTPyP+Cq+9rY99mn54chbHI9Eh0oKorZ9dXgcowYqTWp7+pWnz3TNlLaOeMiwpFywpwUKVqeqPOHg5ZcQ1REWyz0spDoIhICiEs5nj59ulM71feWzu5vIACTM6qplZn\u002FAOPoal6LEImqF9WpB7RTUE+ffiuFWr1hjH83p+P+w+ra93eiLPCfI\u002FAgAZqjkLsmoDQ36CZTRtM1p0e7yEtAmGJRBzs79HMsRM0YXcKIfsdPnJyomw4zW9rMt2NnSiKw+LQa+Fu367+9LSMUP4oy6j29pb9PnTm3OlmEXUu99erPT739bid\u002Fnp7v3rp1b\u002FXF+a9WP\u002F35L1Y\u002F\u002F9tfVd5yYY7uFoWxRg5aYmzIAGOAv4DxbRnN8EU8nAPaL2sBV\u002FWp5rkZffUlxpfRH6MefwC307mlaw+w7H1lDq+6ru9Ze5GvdEWKC9gG7xn0BSCMPNId83dKpuv09lxf2ltU3wEaDGOqtA+m+vosZ83m2PXAzPYO99Em7a\u002F\u002F4qel9a+szn96cfUnf\u002FInq+98+IOMW4CtzYYPHt0bHueQjCOR4RPd254B0cnnXusN\u002FGxpzmmG1R4lDfHjRtmS6\u002FE8eT5+bMfqxp0bq0c3llapv\u002FjlL+fgluNF9G6UIdux51RaFEBbalCNdluKEY+qg3wc33viaXJCdmfzWnxqPngWMOPMoPWioM0V\u002Fy7g33ppZwlUAGaCAgwQeQV0yAgjswQK6I7FNJqbCBPeA9QZGNE\u002FMChz+Js1JvPWQHnIk20Lf4huK2PQ\u002FQr9lBzMgT51+Ll5U5YtQ\u002FCkaE48IzM54KVriKbLDOlIxWjKws16xwyMmP0UW6rbvX27blAB\u002FWOVegHHntb2ScZ2e46BjiqPnlwLlO1pP8I76YNTqxNvnckYdyZFpWIvKreZfRx9Hggi6\u002FYK4FHGl550wMxGgAu9N0ozT2aCsxr\u002FkH2g3QY98xadGlr1fQEHxg0VyQz6xZ4TIHBdjt8rzndvcsK+DQi\u002FSoasjegsfU+HftPmTVncAT9d\u002F9ucFWBdK91nz9Lt6UN6Y6KSamnjczyB1h5b4xl2YVPfAnT0F77AM3SggAWecY2nBVvMIRXUoxG3HpwvvAdQqOH1u3Fb767e2uRc++xrY26eHjOaXgOCBqD7GW0Ad\u002Fs3fE4dLtmmYwSwgLaGMuuNTh5+DpCczxt3ct212OaHDyuNaa3oC1cEQvxN3yuZeVEAoUsPjwFm5r7YwAXMGaXMClpsL9ghCzQR9PguDdUcF4BuEZdIfDqp31+0PvsD4TIrN7LxMiMCdfhIhPXZdry4nHxK9oLPPNNFNrsXUDSyZI7RgpM7Oq5IrjVB641oQS5nTtmtx+ma59FaRu5F+m13wRZBJzIh0o3DBFFasbEbT552BsH9B7PhEaintx+1\u002FkA8Z+b58yX7gC7r\u002FU0XCOZxYJS4Lhl7GCPb2v0HF7GPAHX3ZJPw\u002F+7psFS3qR6i+nM6OPq3DtbbvHwOjecU3uZKD3EE1NIbuQg1\u002FhP0Mh9yZt0mExk9PGAigbFhCwYFo7Q++Gg6t+Tws5tO3aT3o\u002FLcs8tV3RAY7j5oG7mbK16TzU42+8DIY4Ech5JZ3ziz+7M37EoYYORXWVV6vzEPLsDHgWhAeE6qz7ZOV6y+MzLXGtKxLrdRK8Upa5Tli0fMZfee9ge2vtYYbWE642t5JyBCw8raP2jj7va1auD7nUTsyi7s3N5rjT8NPGt+MJ2BElfruvfVN+G60WfwHNmPfq45QYLG5gY+3TjpKNlb\u002FDQn0TfnKTcsI0QnCMKY34ZNcG\u002Fo8caAetwf4KAAWsCUowkhLIZ6lmBiAoyEANLodsUD4EvpRv3IA8YTRSIwMbiuJHNSl+9FfO2U9hGEhHu9ThAUkciYxVJ\u002F6HAPTCKaztu2kfKrgNO5NlidO3d2ai4PHsqoJnAUj7FgrgFBEXctht0WoT0oPgInEsfwI75ovLIENdW6eiy1dlrDLZ\u002FZsYMRbbNm45Da1eOzL87mTt79tdqjMabA94Oizur2jhwpul5XDhsVKU2penW1HJHLl6\u002FUEjADU5QZp8k2qLdG26S4yFc1WjkA97uWHfgOGlHaoh+tyJE6QVF0NJpIDZWcgNnotL7zSOtQpKmx3GgtRKR9\u002Fn5M\u002F3XOhog60MGhivwJmHZXSxqdsIpUcKxEJsg+YGpzh\u002FIV89E9hBNDkDE3ofI0ANEJdbmcM8daH2heDP3GY4Yohq8ecEc71\u002FftPzTR8duyFJWamMueWs\u002Fxup8X5RCNUzYgEin6dqZr2RDLAdQGcWcKwOFZalvxIeWxew+lqotG6x\u002Ff3GiOPHSgYXvRlo2Mzu07j2tlV3eW2gwePn5g9d4H3x1wvt5mx93x4PbA9+XqtX\u002Fy85+sfvxXf7P62c9+UYnLJ5UXBOLST8CGjA2eRTcCi9EI\u002F5YEHGADskZx9inOy6vWTQRMtGhrNXC0YqYz0JvAA9Z9x3qIhlASE8jvEwA4XlZ7aPMeZfI8p0P0oUuXZoyf+0xTNYR5Ws8+1tv94xnN0YPiJUevkoN59JZrD0joXrqo6MrjOodrwwiYfP3NpdW\u002F\u002FFdfr\u002F7uk1+sfuu3fmul64hWf0+fKzcQn8igm29j2DwcZ1\u002Fg8nBg+0Vy8iqgzjBsPbLWNY+sDp48OuVOh+pLz8m5XFecC5cvrr65fKn+8k9WFwNg9rrcju9PNGYgNfzRNRozg5TxowOU1+xtoIyrja+AOudry52c\u002FkrSjhyW1TqQ\u002Fkk\u002FNUfgTvkJcMCgqF03UQaA04qed\u002FsuHXDjhgOnqr3tM8NrOdt7Wu\u002FnyQWD2u0zJNKfy7XoN4eoMFIMWlOu9KVrtyiuCwDt3lutfGNwYueLFheIE0XfaM5rPte11ir1qU9Nx4jjsW1ziih5U9e+2SXLGjJEAKpORHQc3seYNhjvr+RhnPb4hezcrBXkvWRRy1m89aDffVdW4JPPzhetW057fv\u002FcucD6W6NrH95u\u002FO2FsOF6KdWQzWFc0y85WoIB9ofIdixHi4uEBeiSi52YPl7gUG2UdZmMXzz\u002FMhqkdbuC2vT4G\u002F+jVePgzPSVoR\u002FdIwgC9N4tIMOx31eryQMn2wifE76UImYfqk\u002FdJyuZPnvWuj6otE724kZ9rLWYlOVZHehurZNEvIOLlDqik8VlvNkv68MO0X1TcpD9Yb+AhslW9RXRxInc1Ulq\u002F\u002FZjOQBKegC69ghkJ7TTW69b1eMyeLJT9FfTW2Ty9S0XJ3FundBFip5BnvmVLCqxANx8UflBLLpEdqMnGnLmybNxA2XAnrVXpkCnpDmaFjBVlLF1e\u002FJEjXw8GAAdB7\u002FvPO51Dhz6PyvY4Zqjtx1ik103f6NiNwAwgJNTCVjvzmY5cAvtRNSbVjRbevAXoug7dJW9aEvG4X511brENLPhN+MWhLBvRUcgmU92bi2btENnjXhHoO1wnT0clre7Me2ofO5IXeRmrt3XGskw05NNbuaPBrOmM570fD2FXlTOQTdPNi2wRS4nCt56k3eY48WrMoKpbUG0BznI9iVZFsGt6cjTXxxGkext3U+wYaOfylvYerSe5g3xHj3ob5F4bX\u002FJ465kZFc035Uco9WWhLpqtTYwds0CN07unrVrbLNurSd+I5uqUGTUpj58S\u002FumGneXT14W\u002FjF\u002FOmiyya2mphHsBPun3Ma60smp0VnTwTau22cECDdpN3r5JfsRrybfyOpsDZjIY3DFizZkZ7e6ZB9Lx6eP8QmsZ803I+FrkxkUjBSwKjgQLhhnJLvbh7MDOQLxkkOI8rAadXIV\u002Fc2ZAyiw6SdHGp13pavs0UKPBwVgXFeg7nnK9UELN6VYrcqLyiqf50RrEvGkyHpknQoLXYe2PQu37QG0+5nMctacoM0ZsyYcPbZ3m+BZYF2tu9bd2p2y4Wi6WZPuG8LUdPE4MzAjPutab+qxINM3cDUDxcQYRdspD5OZyF\u002FGgzcMZOwIQFlIgFUkSrpswEbLQ5B5iEcy2n7yIAkgUEZJUHQmL8JMEChX6klEdus9SqmV6B5KMhDteinbv\u002F35L+dkSZutzr13bowwJcLQAq02HxouxcBgM8auwREAnkcJ9oHHjRkjMnRLerlTOHNAvg3YAgOU2lJiUXQF80QH0Sk1dwD57TYWiiZ18To93Byl4Ej6I0fbyNipXsc7epsSOrhnKWsRAdYp5ubt6xmSp\u002F289ZsIvGiO5v3721z2nY8\u002FWn0aUNRh4BGgHADSro2Ac3yAQr1jt6RM797pNRETUpeA7QP+M9h3Ku2QKn4YnW9Wt\u002F1QOjCFc7uTEkXFRA2tGSa0F\u002FpOc3ny5GotMm9P+kgt2GxE6roO0Hj7zJkBPrfu2Ay6dNuQorNB49trN6aUgbNzrEzH5aJdSkOOyLD0kxH0tCHGGEVd1I6jzaRvu96OakLX+r7IofowmQHCc6isAdCxq7pGNYZrCdn6+p6EUAcB5VIJdNmTI811X9GKZ0VLgb5dAfDd9T\u002FfKFL1IEO0ff\u002Fx1fe+906nib5fFLCNamUQbl2+ONdR9vPn\u002F+HPV\u002F\u002Fu3\u002F671VcXvoxnKDdKDDAXpV1EiiJifCguYxO9GIPX74wka8wokhQK1OdExxYtkXINMIumjLHxYrR1Zd\u002FErz6I\u002F7cUDd2q\u002FCYdB95zCPpS\u002F1O8vZbiMxbGdXmS0UjbPSc66Vp9PvEKWAFGy+f8HKPnVh4pTg\u002Fy\u002FFSbxbohHDqiu8VajsqvOnzp\u002FOp3f\u002Ff3Vn\u002FwB7+fw3Q0OevsgOTAycRqybc+0pGpHuFXAqzdh4NNyeunvy8naW8O8LkPzq1+7w9+r4hneziq9dfR53bPSxcvzAbu0++dXR06frTNvNf7vnrD1quSEDiPo7q+nhMZWAZCFyKVSdGKcP1IYL0jrQOv9+P1VGx8lfObU0med7QRsBUoquXAoNdgI9rayCnbIVLLQAFtMmUWAXDSQQhAn9MNe8180exY+utpwAK9RcVmQykjr4woXlRWB4iT61cZ0l0Bj50Pt+UEqHlu4z2eaV22JsOvkuXntQvd3lx39d09OZ\u002FKB9555514\u002FVCR8xx\u002FGb7oKQNpjPb\u002FbOnzD9OLxqN2VbcqoHEzKKDf\u002FDzTUfatcNbo49lPkmzZfP6zn\u002F\u002FtON5KEZx3sCNd\u002FfxJYH9LGbr+fvzIZt0yURmv0Svxx6TGG38cnJ7Bf4tBe5VtmJM7m\u002FurgMaLnDmfiYGHloIc9lcwxIw+YIH+xqU7h5Zn9M90WmittwUa6M+z331\u002FnAhO2Ved2qqkQV\u002Fk\u002FUfbNHY3Hm+hZVWdcPs4vtgez13N0b76zddt8K\u002FtaKUVUwphfNGQA8pp42xtgo4GOTKiLGkixzEAGzznBQARycqWAaI746mi+o\u002FKDhb8EDh4nkOxeln0Pj56VX18C55eSj6bJwDNZlJMjP0Y\u002FN4HkjibQPiL9mx1t+R1PjY2boIw2S+lIqMK4pN5P\u002Fq4nP0G7B+ndjJ20REQA9onmFRQjO6kv6yXEoAHlUWuVSfsXtvbR8MGvkoW9PTmZDfc4Q88gq\u002FpVC9O69\u002Fsu1Old6S\u002FGnnrBbQrlyEvADtAjJ5lTNIFG9nBpjOBoKezaVRbWAEgWavKM7M9HIDnffdhDheePZJN35KjIRvJFnBSOcjdaLJz6p2B4GV8UaUbWMNdzXt749RhiUO18Ww5EE1WnBNINiazHV\u002FSGfQpkPakYNGTnMkHfUfuYwRyaAKUCaDk0FAiFQ8An1OSAask16iorMXPyaok+\u002FT\u002FgXSC143T2myPZzx24nONCJobXUzvgzKCUDAQ2UbnRS+QGg6NwIJ9Zn2mRSc11sWcdDoxyjiuvzmVcZauOF2UjeEIrDcO8uXzdMS2BITNcB1PbWSB7SkBKd6Gd5yiurdAjO+sKeGsyxXMs5l9EpQgK1Ni2tjpUjhkIx32IsziPY4VTNBMu2fcxmMIIE+gtHso9XNPNouMTZlsZVgwQl\u002FPua71a842h10ARoe+FEnzyt70++02hlrnl2uVae1Oq7dEdejstRzUh\u002FfmcKtH8F92YN99Dtmr+Q4HGoZbgmHkPfluDhs5auVChtecGDuR9oIpTPX2svI7Z62idN8nY+ztZBCiKfq9qceCKt7A1UQup01gS2AziugcJgX4gF0p6gF8Dd5GHAyzOxCl04KFBoBebJSCbQetCTJCIla+Y9F4STyxIwFuTA+YSndqu6fd3QIIlZE4gEatWd0hjh0exSqC+9lnX8wR7u+8c2ZOTQXKqUoOBGO9NcKGugaQ2iighALjMVwYmFL096S2WkUg32Yi6TYRKIDWmHl9gKPvx4KrP\u002Fv3fzab7A4URfzuxx82JxtuirLFjDxCUXZRknzwbr+\u002F61PiOpvsXJ09d65uF3uqea6t2o1bU6MOKHFsHCoAENjJzGn5\u002FNPzKbl79XmvG0eG9dLFS5Oqt6H1aIadkePIiEIxNvHURO7PvPN2VNiy+vWvz49SOFyUAjhEDuUnlNimwQLKrOmjlOvS87ssQuM8Xhq9y0X3NofW6cB6ARMnEmw8YZ6UEyOgDGnprrI2JUo3A\u002F1odu6996YzjnHZXCo6ebUNhpSIMSyRhVo6Ncf19SV9qdxGNGecqa5OqQEq2hzysB105DQ0O8bVwuEXNJAl2RXdAN090Wpb4OdmIGdrpTDHT51ZHTp6snrX3UUVvyxqfG1qXmWLvvrqq9Vf\u002F9WP64EeQM+Y26S5f181180LzXxGpGnZULSIFmMLqM+zezOoVCGQ7mlHvjQyIefY+mlx\u002FBzvvu+i+2iO\u002F0ROKTq0GcUamFGPas1invmuSNE4axkJ9B8l7r4+9Pr6U18XMNhMt3KKrePmP\u002FO7v3u4tBv4vmixyJqIEzngQN2Ofj\u002F5yV8n2w9Wv\u002FM7v7v64EPnDezv86UnHy\u002FzdR+\u002FMebLZqrAbZ\u002FX9eTZswvD13jt9InTA2DuJOOySGfPvTvZl2NHdIrq3s+\u002F0ybVHKGuJzW5o0gV4ySSqwxCTbm0s4lwBA4eOFRm6\u002FTq2TElIXfLQN2uPOLabJY8evTY6CuKugVcIo50VmvFYGj9J0sitc0Js1Gc\u002FNILiMJp9\u002F7tsnjKZMitw4NELW1gf9RrIvQz9+5BDhhIkSNgyU9rDUQ\u002FCZAzyj7PoNNzNgiL5Bjfu2c\u002FmFIxNKIL6UC16ZO9yviRO5lEugKfL8A2w9p\u002FAIy9OjahHmnOTEicNcafvpIRA46UzwmSHIxuSn1++tOfDPD67nc+mnmKRgtipGaT\u002FWQvfSVayloqzQAP7JdoKNFGDX1gsr+973t+dZYAA1w4LR6P7DkVIo50cA1lApoyCjKYAENOdmsJvDDOd\u002FrukwIQJ0+fXv3OH\u002F1nNRZ4OCfwKjvT+YWsHM8mnK6jiCDIK61dT2xbHa1GH7BmK2xS1wZ2Rzr7lG5ObFAR5addlyOGtnQS\u002FqZ72CN6hZ2y1miLlqNHm4UM3u7sGfswm9pGjlrjiKA29psrV1Ynjp5K1q0zupOBkagCJMQKSIo3uidecL8BKimLAbeBXmWFA+i7NxtA1+gZ7zIivQMkm8dEdOfqy96rmUe2WITWwTCc4COdkizQsx24aePh7ZwKrQDRl05Kdcw4xlnyhxG3NtbAmtIlfleu8aQe2FNGBLgHvNS829RbSHFoCLTg3SlfbG2MXdBmMujNs\u002F+7XrqwOdCh+v1bcwfM2OvyYuvLxWb2OnmxJ0tE+WkO47Ouo3UsOREYeBlvs89qrI3x2Y54urV82jqQUxu255C+QLq2xPTiQ+1rs3OCafZtiITaUyM7pf6cjHTBAc2c7ukqhJ2jk3Uz9mWPW\u002FuzHpCFJdux8Syd9NrGc6wcRGZPFbkeHewSqJ0tx08yxmQAUJRldU824+WMwUc36R+PxLswx\u002FBf6wB7zCFo2T9BSCu2aTHIHDC9u+vDZK5jbinQkXejmHv23blntGS\u002FOE4CLKO3zLe1WXR\u002FANzYuu7Mp7ViNzwnM9F4Xr1aypUAXXzM2QZwzRUv0UuuK2PGudu+tfKd7ovHR6f3O93ifvR4yzl6FS8p8+GAeZCV4cccFXPYdBhE1n1vyk1fVEXRvR+pTMh2+I6N3g+fXmpNwql7Oj0428nx3LYtLNfaD8AeXnWfeLoByDbAEA5F5HQ0\u002FJF15YmwoTXEv0vnpCFl\u002F1iJN\u002FN4Y0Bd+YO0EUUGJOl1\u002FLRa6M1NG1ohERIGbvu+0pwtHmLu6nWGAbAjgPcSnKVeCxjIey7izThaYnXbi5FaWqbZzCXaxYu9GIi6cfN6AleULPDGGIqIY4z33js7CpdB07kEoMPkQKeFFrUV7abkCDoPXs3i9PzsGlJq3megF6DcBpMAI0OuNh7jeRgbKaGwGQxGU3RBPdPRDKCna+grCwTb4EVmjPvKlcurry48qzXakSLS78T0q+ligjb\u002F8Ee\u002FNUz+Zcbopz\u002F72dTCiyjoGiG6oIzo7QA3Q3Dp0pUE88Y4H2+\u002F\u002FU5GpOhYEX9jVI5zqDF8WxnOF198MVkNLbK+9\u002F2PB+B8W2rYxlDgUgSiSTS+RcnNgUuBZ\u002FRxHTX+lIsI9sna9QGtuqr8xZ\u002F\u002Fxcrpmh9+CHifGrozAO4vsuKkSVkGwAGo1\u002FVFf+5Jqb1WAMAfAbFeHDSOnawKo8movHhxN6+6cqlosKtyB54w8DFgBOhobZ0SOF1sor152HiXLCV0jrwuElvJz9GcmItXv11duvBVZS6nVh9\u002F970U0s7Vj3\u002F8k9WF6Lj\u002F0NE2M1beVNTtcbz7d7\u002F6u7Izn07d26HA2KEyGqK4E0lvfjYUAeqM4\u002FSfbRYU\u002FWSWUrrwGSBtbgyipygJBb2pvKcONt7z07c9lBHMlZqH\u002F+YKjETKaYxcb78sAjSX758p\u002F+jn1H3Ho\u002Fh8iVIA8b0fb\u002FqMP0TOR2lmHAYc9NqMofsvY0Azymr5HId4Ub4LwCTvOh4AgMDMr3\u002F9yQL6mtMPfvD9obXoJQecE21M9MLQpXtQcgPSWpwlmvlw9ctf\u002FHSlm47Na7\u002F4+Verf\u002F2v\u002F9XI1B\u002F8\u002Fu+t\u002FuS\u002F\u002FMer737349UXn\u002F5dwLh6xeiu\u002F\u002F9z0a8HdwKLjevh2myYllEj3+fOvrf6+OPvN849yc71+HDJ5KnP5hAOn7QO6ljvBVw4ImSfgRWAUAK2rYPKyC4+ZpQixwBqNb\u002FOHQDob95cTu51MNpkNlpC9MZvz+NjOsT3goFds0hj4HBKXOqiIpoPbJB37SPpDTQD1LECQycoIHvnUCQgA5C0X+Tm9RtYataSDpp66+GfjFcyF9RvILFQPIN7dq4vx40Da64HdDF0QOb1BiwjqQWnTNmFL79c\u002FeRv\u002FiZgvmX1\u002Fe99PPfkIGjvtt7G1qFRV3XAyJOyILfSi\u002FvKTjlBNdWRsWw9MpCAfYPJoaykkR5xutSwYFHZHC0RQ3IzklHWb0pR+st4ReYYQvscZAnWotPBotX3ioj9+vyF1S\u002F\u002F7tdlHNvPE02mjrlM2uH9Ryqn0v2rDOazq61tWyjL2pzKkdIf\u002Fd7D5hCPThu76CoqKlVvwdBV+dqUETUJtcXbe1802muvSqkjp+eIUfrnSZabbOBJ4Ihtun796zlH47Y64Ob+vOdg6hwTsiBbQx\u002FgEaDORjr8uiM9om4bH3qfIzyy0\u002FqJ5M6Wtu6xxglq7dCIA2jdg2pTLoX\u002FdPUBOrrT0KxmQ6u7t8oO7r5Te9W3V2\u002F949Ory1cuTSCILnqR17A3e7LQfG49thHvyYCx5cAX+7CvMqqna82ndScjDWTW2++cWhm3YHnjsgHbZmX0SVH1OZ3MNltoAle40veKr8yaTDlgr8ks7F7TMcyJudZD9mWx6xx9c9TNi1wCjcqaRPAFksjK3vhXF6kn0dE11TPfTe\u002FviJ7KIeAMATvO8s6dZeq7D0xCpu6VfUkkktn4OqfM59ba48HBGl1Nh8YLwKn149yZ3970oIYMXp9N63BDDgCbtmy2LdvUhRedmy6NtoSXrgUi55TmxjrANprTtZx3jkdUHln1N36d7mrplYY53+Vwz944oMLnmzv9iHZKVSdr1RqOzukeADx+HjnNvsJbjWLWF0Z6HC3tlenq2alsUiOQAcLzU44086xsqtpvcmstW8y570IXsrIE0F7GD+a3GfzET3QPW0Sn+ryTXbWaBMTJMV4TeBlbEb\u002F7nN8naGv+zR0ddwbqx94WvFkwWHxKfvoMHnmW3FlX3W\u002FIDzx3\u002FVZZ+B33VkeOl9HcJyjcoYvN9eFLNe8FCXJ6XQtORYs0XDIUDeLTtfiQ6G7a7iVQOFKD7P\u002FxGS3e1OONAXUGHxHv1hf5xnWdT2y0IVTUSqLYImFUAA9zmLxNP0795CU\u002Fengq4lBaenFLqT6tDeKVwOr1SkNOpHDVpBWxjqGlnSnua0VHtEp8kLBaYA+Muqd0t9aEABzlLRU8gD\u002FBtTEICLYIU9oSAxICYJ1Sc5IbxsQAGP9598Isfpfy8bqnzVoUs3m5D4ZktNWf81gx5Mff\u002Fc7qH\u002Fzgh83vXnMuuhzw\u002FOLzz8YIyASceutMIPV0G+eqzz24p7GX4h7joaXlt7WdvDIgHt2+\u002F4Mf1GXjD1d\u002F\u002FMd\u002FPF1hLl++FMjteelSIPJBzfxPj0B+24YvY\u002Fvwgw86LvzgzF90XSTgdJ+RjuXcNOzGEShIKMxHycKf\u002F\u002FlfBp7rDx74IsRobR0AsFHEeYh2SI\u002FH2XwBlq+6NiD+3ntn56AlIB5gv10WYzrFFFU\u002FWDmMPuX76gjypJ6yjiwmoARSNuOdnAybSt1Ha0onoao3laEglCKT1mTWrHkYl0gVYAckMVLm6t4VMkVHyrq+1K0twZkOM625jjdOM5Xular86OPvrY61OfRO9cslVadby68++TwAoDVYR7oX6T0SCHT41Z\u002F+6Z+ufvbTn01t87laQgIx6yl3IGPx9DOa3S9VOvyERpSsFDRaU4B+EudNkC4iY4DGiH\u002FIjzlyBier8ZrfdlY7b84iXF53FV\u002FarOWdjVOAumv1X2+OghpAXZ2hsgTfEWUHhsjPXL9Xrf1EIlKyFJv7ABp+zmdcM9nmEPgsI+EOnA\u002FGglyIRtibwbl7UDbr0sWLq3\u002Fzb\u002F6vGcPv\u002Ft7vtLZncgzPt76Px+jqEz9RfveOz8imDX5OjXyUXCsTcCKfTZNr6YNjybJyrU8++WR1o1T4mVL1f\u002FSHv19Kfnc11tcrkaHwy8plXB0jfvLk6eEzDp4yrS+\u002F+DLjJBq6s30fVwd4K73iID4vQvJQ2j\u002FFrI5bFH+ckebHMXzvvQ8mCkuvbDo1aEDu0ckmIvSmsziuTwPf37Y5yWtKnXZ2jZZt1t56awlYHmDKYUSenybzDv64Hx8DvYeq4adnHleqouRjZ7yta9PH36sDy9E24iUfDBYZNYZNXWOvzPVqzsntBBOin\u002F7vnJKntRGz9nTmbPBtbeegtQYmyqzM7kg6aE4k9p3moozsYHK51lhut\u002FHPBrazldvsTZf+bXLwqIAKx3v3Lvt5cloKbuzek1OTfAvYcHj91BhADfvhnBcAaUuZg9nsGx1w\u002FGZkOYKNjuQQAOI7m6NgCv5CV1HWR\u002F2+O4N6uFJB8v0\u002F\u002F0\u002F\u002Fy+rzi1dKf+fEB4ToXOCWQf4qAP+Djz5afdQepZ0yt811TlaNec+lG2UC1Gs7T+PuU6fqLo4Q+dMJytr7fQlULADDIt7hEMT3MqP7950YAPOysd4qC\u002FvgQbXzZSGMAY8IHo1DFYFethnXuk7EjQHP4I9uGHHuvXRrb3cLgETUcSkXbalaT3IbQGmt1M0\u002FZauSs0dlC\u002FAt\u002FbZ7txroQP6+gkndOzLW2rBMcUB\u002FT\u002FTzPJyckbGvL31b2d\u002Fz1fe\u002F\u002F73KkLasrn99a3X6ndOtaZmbyujUIuPfLtE4logs\u002FbQxG54X0K6MjG6mB0TVHzxn915MwIWNtxdIOYzIOMCLFzy3t1bru4uS99kU0aJ7KJTWxx2Bep9HB2Vhs1k+\u002FhGplxUQnBEkof85VtMtyXsRajZzkrn0EZBHXwLqT5NRusx\u002FL9+Ofo1baRfbodEDOyELxkETyNmoLOtum65FZmV\u002FD5TV3vaoLHZ0wWMDLFtzcuaBH4C2XZWFHMmu29AtoDWOcLaZvvU9j7F78R6eIZN0NNDqZyTuyW0B5NMB8Tv+Qx7X8AHrgC\u002FZVsEzhyByOGzI5Jx4TmlKcxcA4fTTKwJVY+u3c1jS592zWxlRemxxQPEfPqTnYRnrq7kAfDMB1mjLRsEoe9Ozc9ZNw5oe\u002FH2Zg+O7HDnBiWVey5g3KvvCkw68lL1w\u002F5vbbwXWYQsLnsroA56jJ5N99h0YJ3fowFkaepln32d\u002F4Ej6Z6HTsol5vUwKx3Z5cv5r1ViGkF7wWo1x4sFsXbw5ey2az7Z4u6vkcBWwrZx1Wz377amhM2dtuj99tK2xzsFYrjPfM68GP2uz0HN+R1sL+oYebwyoG8\u002Fi8SSQMQKGelktz64IwlPDFBvPO9yjxTQvD3VPIriUvNKQs2fPzO\u002FKYKZOLaWiHp13NX3YU1IABMY7Vq2q9NnUBEUwBongPSxSwnvDrN11PFljseFK6z6bHTkPNpN4zGbQ14KN4TGG+nnlFxZC+l4pD0alJAFxxkNrQcpoMw2z2VnC\u002FERDlvpBE91SWzUtuvCbMTWHXa\u002Fq7V7tefdSX7qvuR+s5EREQEoYvdzvgw8\u002FiI4vVxcuXBiA8cmvP2nD3gcTqX7n7benbkq6+IvPz09HDMqMQBKCn2dMr536dnUqMKK2\u002FlbR\u002FQcPP1vdf6tUfIZIBI1HrsYV03\u002FnOx+tfvjDH5Y+vt382k2fInkQ0DF+gIAixXvqf3VcoUwYK2CdAQFkOCbv1uXG\u002FdBOWzbpp+ul4q2niKZ2X+6rplBZjM4VSlj8PrX3o5wYmoBFylh7TfWxA1TjA7S5V6ssIEk0XSRX9A0IU1dHsToRVMbDQVjWVERmbcthdiHhKYtS6Ea6+ttaL27LmB08fHT1yedfrf7qxz+tZv5agKguQYePdT098Dcqmzq\u002F+vSTT5vT9tU7b58pSnY8AyhSqkdxDl80B1YpYUYGbTl\u002FBNWGK48hIY7std6dde0D8So58TpFBSSnwGegyQvwXMTFWnhvQHyGeaLhpuJanvG6G1Mo1h7oWCLoQDVlkQlMAVI6Y2S6x4C83vI56w\u002FwARWU7BgChqE5AqcDYvqMMXhQmFPC0XwpdJ9zG59jpJSafN3eg3\u002FxL\u002F5lTtu11R\u002F\u002FF3+0ev+9DwLrn48cWg912xQ5x8z4n64vG8EAWScJPstY4pVdlSDhjytlPkR3nfx4+9bbq+989GFg\u002FQ9WX33xaUdf6\u002FyklInReG0kApFqge8cvDN7VT4rE8JYOp34YJsN6Zh7d25276WsYHfAXeQWIHraxj86wKJszcHcX+bLBunrNig2Pvsw6BLRGnw\u002FXa2irV7+Nn\u002Ff73RkMmDckWiirJFxHERj2pbzurVx7o93vyrCDBRsJEfPciJnA1bzUe5Bz4nOc3IZMA6HTezA6rFKACc40pwZZ2siOKH8RyeNOGFAJGONbwfoBcIHmMRPnOBTbcDkDNANt9s343o7kitgTj3th++9tzpx+MicpqskBog27w+\u002F8906\u002Fnza5swr3U9pT8AhWUUjm96fB\u002FaOdPaBkpLtO75e3bz2dZsV04mdHMgpYMSftvbDu\u002FH+ZDeTs00HBD2NG3TjzIxT0rh078Bfe9KXP\u002F75L1d\u002F9md\u002Fsbp51yFF6Zvojf85SropXWyNNlrHc6ffTk+0OZ7hf+ok5QfDKztyxKcz0jYNAZQmFYum7kY2F7kClvfvqySBTo0XrK9o3Bx419jQyVweRzf6Tfeo6VzV58iK8gT7F55Xf2yT92yWbMPkbBju++wJ\u002FU5+lLjIIM1aBsTpTyV87IVa6Je9BpzZf7O7PR17qs\u002FfmWwktgNorP+D+2W1k0EgT6nDbOJuHLrSrBdO37mzfUD9\u002Fdlnn61+8eNflu5YKzBzafWzv\u002Frb9kYdKitxM9q2z6m9J88nIl6EPblY35+dazyvwpq50KOnr35zdWQ+smQvtOzN7rXG9PWm\u002Fdpa68ZizcQIVSeKTpeJtgPS2oMCWJzwxS0I9DRHoFOXopGvMk10hIPbBCJmQ2SyppzqZXbW6d9XLy\u002FdzQTDBGsOdq4F+2m0z4D0Prst4M9eHcieA73KcwTG8B7bzTknrC\u002FLbjkU8P5u24zXsrWnV2cql73dfquYsXHlxLVOPitAqMzsTjrBNfclz5xKNpjDrKRRVFu03bqizzimyeOiNPvx+jf2jv6KJVqnmkAkD3iK3liPxwQV2Uc87tTt9eyWFoSy9jDHkaM5aMmIMiD2ZGsZ7t05FsZjbOy1n\u002FSjMxro+nFk6H26PfqwZ9bBvhIu9BI4SoaTg83Pci6V5tmM3+X6DCc9PEEHxQdsgPGTZaWnAn3mNleOFhwHWQfzsElUpppj61qyWA5yasqz9q7tc9Osog2+ExiduXQ1hOl\u002FV3YPpSn4jg632X6i3F1gHJ++IwMvc4KnXpWx0o3NJabGvTHM+ve+ixLJ+V5\u002F4VdryN7vzMGCHzzp6adlCm072XQwtrTfJjeme5Bt4zODN\u002FN4Y0AdE4z3fWx7GyN5LgyEiGbKM\u002FAFqABVopkMmCisjRzqrM8W9RBRNeH7RWoALMynF\u002FnR3ob2mp0AAEAASURBVAd6GURgzne\u002FuXpvroe4rj8RuTw1ZSj7835tcNLRBOgG4DhsFIIaI3XvjDQP25gp1AVULXVQ0nbu0VASDOkuu5ml56ufTyB5zxNNa36iwcboATgSJpHdW0WRGNQlU1A9VOl0n7URQ8pQZwzHfwO8F744P7TQSUP5iue+QIc0kKjF+xnLdwPlvGvRmi8\u002Fr2SlNPtbbYSS0vpu4PhMv\u002F\u002Fkxz8eQ07SCc4yr6Udl2g65YdWWmPpSy39rOUl+jCY94rqnT17rnaUX6y+rB+4jT2i34y8952sRohH4aQwrC0nSkpNfevFi5enjthGDyBFP3U1fgyZFCADB6irqZ8e8AE8ESBrAsx9UxQSeJAixC+ie5wvx6YfCYA4Op0Hf6x0dis340+lTH28ExjH8UgRisqLcLsOpZG09Gze96uFb01trGV0vgn4rWfAj3Tq6Cfnv1z9f7IJvXagvw\u002F23NsG060BgB\u002F\u002FzU+m3AhvvXfu3HyfUefsiKhvq9MFZQEg61NNgU8rs5Qb0D0gOvoNE2KU1oBZMi50Be5FjzwowwHDCYvvMbiMucdEhALR3vcc58kbLt28lvrXJTqDR7W7pJS8CaT53eeAD7I5Y+7+FCHZaDDD466zXD+T0ljHkDY3it0FfN5mO1Eo4J88e82DPDnljTMsC\u002FTF55+v\u002Fm2bbhnTP\u002Fqj\u002F3x1+tRbY2g53eSJvJincYmM0R9OB3zRur\u002FIqbVBVO35syJbopz0BMfwUuVS\u002F+x\u002F\u002Fz8qzzgVj8g+XUOAqXl8UFR5nJSugd+UVNDITx5dLO0fGC0Nai2P6RhR7e+z6sK7aXymhCpDm7HY0kFnau6\u002FCYzcB4x7jeFFDwTHn4\u002FjIc7KUle56BfruhjDAEM8qczM3JaM1LJOaq9tEN1aJxCnAzudNuJOxwPGx0ZwDswYtr7rnnQQ51naXpQcbRfDmPGKHgAHXafUjRHdU4cYvA9YogX5R1sg5wUjGh+JlNmvc6oOVX\u002F113+dzF9I72Xse+9uuuyTX\u002F2qWt0nydvR1cki+sDHt9FjS8bnUFm527cOBWzLdAW6dmbgGSc6Q\u002Fp\u002FT0ZcfTiQ887Z91e\u002FrEPS1UtfjSPNuQZwONR4S807frUpXHmIExJf1m8df+Jxsqo8QA2z38mWI+6\u002FOP\u002F5dHY6crCocbzEUANdW5PJ9bJcNirLkhKBqT1P56kPlkXkVLMnghT4fvRYumzKF+KbbvYbZ5Uuk4XaGOe08sHWlR4Bbm7omrP93mpX\u002FC5AcejQW2VH+xl\u002F3bsnUil71Xi717R5S1cI8OCTARYNjjZw1sOAmfSAzIDzKmgIKXhyu7P3p5UdXRxdAP3b9wJBZQLYCFkLG\u002FcfJFf6rDtVdb2fshIH45UT8eG502VT2+i61rUf1\u002Fbu6ePyOlsKYNT35uuL367Of\u002FJlwKpuSqfLEiTTz5MNNH9Rpk6rSQ4yEAi0cfiPFtzgHOBPAQXlU4AouxCnx3tlL9MTNvmiFbrvyfkThOAs2msAmCk\u002F4pDaR0QPzjM+dRAcWZuac\u002FaY7MUbSiQsKtkjl6n12S+gWYNx7N13M8ywdDJiB5WnwEscjydtaMf7ovEi9TZHyvLqVESGRGdftvH3xHHlrPTm9tW777y7Ovf++zlgNb+Irr2aTSsLHe\u002FaT4ZGu4DL\u002FgaUATgZYJFZusDTYVzkXlBDZza08mBH0MZjCZAswRj8ttYuyMkKdEd0gvvwArvtsa2w8Gy+TU89qWMaO4KXPUXO7WFTymPjaNOf8XWBrmsvRZhotdSA0xN0yVyzNZChmbKkgiTswNKNJwehz7mO6wooslUy+XhU6RFd7r70HV3BBi\u002F2jQz7braGjQlEj9NnnK39rpwJ6wNgywyxKWypbAZegh\u002FI6m\u002FsV7ThkG1em96hLyc41vzGnpCqaKss6pVGBl1TMJijB9PRleyI8cRJ6SW6f8frbOar1Z21HLhowoEwZ0EIQk8\u002Fpn66nky5DDZ70L366dnyjM6hx43rTT62\u002FtMeb+KC\u002F+Kf\u002Fa+jREXJGQU1y4y4Vkr7As8AkkV55+3Tq48+ej8BODPA9VmMe68I1I0bdXKIMBZFhJZAY3zKl8GZDT4xjsXTD\u002FdMkU3pSSDQdx1xDhgzqKL0x6s\u002FPlHEyIlwFlKtlZS7KIfouoXCiBZ9AR+LQpnNVoBhURvMaKWMg+HweYslaqBbDKbgLPg+L1u7QWlqEWOtz2xejBembMemNjWJaDPt1zJKDBRBV0+lN\u002FTFr2pF18mChPdAUbwjRbOOZRSBB6CDQ0JJMHRSsO4L2MhGALBHm7doH+MK1JyqRIDyUZ+3P2NyrLFJF3118eJEKQ43T3W8f\u002FmXPx5PFuNe7f5q1aUg0Xd3UQhzAKiVo2iTRUGKiqrrQm9GhuJSZ66khyLwGLoCNa3pbHLqQt6zPq6NvJSViIansY2yiyYEE\u002FNb9+lJm4JyvcNA1tFjA1w4A+SBYiMy5km5TSlHn93kwxcbgZwyJE9EZfokPpuNJLv3r\u002F7DX\u002F716t\u002F8P\u002F9vrQCvFYVQ167uvXVLIV++fDUA\u002F+eBmCsZhjradG83pHSWmr8UanOneD0pS2PBUyIvnoAxUEoJcXoYut\u002F83t9AA9C7AN+Jt8w8rcU4k10PsPZEG0ZyuR8jsAncY1Ljip5ABG25GUEnLyKUfi4pTEopBZ5iogSN1eu6IFGgDKPXl3tyRJYIO1oCTtZkMzIf8w4PM0b40tO17CWRYiQLDKLuEsqx8DNguHSFaJyt3SaYIV\u002FmQ+EnqAHqoiwzd2229McXAas\u002Ffffi6Nk4CGCdaI8Fh0YpE+X6tFpY3YX0Zt+fTOJJx5qjy502bl+5dHl+AoUUuCwXADJ19n0eDczLuKeUqN9l15RJCCzQb5xsnaZ8hlFBD\u002FNe1qe1aj39LRq5pFYZIDzad9NXZCH2jB9LsWdobWxT\u002F4s\u002FBhg2LuDch2TJ6FEbtUX0RY\u002FG0bIWvT\u002Fr2\u002FcYXEaIjCw6JqPUvZY2eUpIKjuItvQUWhPqI+kWZYWcMIB\u002FX\u002FQEKGz2vPjVhUrrLs7fdKGsFieOjCo7cXjazqzWybpVKd0jV9aHwVSKdL\u002FyM1mKQwG6vjYRV04nHYoGsl\u002FWHz8ZC5kiS\u002FgeMKdX\u002Fe2edPaUb\u002FWe79D5F7+6svrFLz9rPIGP1\u002F9xRDhmAEDL1PrvmpJAqWoAit6ibyPscn0f6jEBg+hCl3mSDWtJ+ftJn+A\u002F9oD+p4tFBulp67+zv0+dPtPeoncDtLuX9UxvXa0s8\u002F69sok5V+ZkbQYcNA900k615EPgmWzTo8oEj5ZhzcELJIqo7y9o4HA1Px1lf6OzGy5faY\u002FRhcvtR7q6utnmaCU9Ai67W6MWv0yBNoMOkCsoU026U20Fv\u002FDa867RMCLjlrGPsgqflG2SpaE\u002F6dEd2WxdOHTgkGnDGzb+ierPJsboj2fw32bZBN6i2\u002FE93dPXcz7TD9HB3KdrSHQla+wf2dlV1HoTJwB3or\u002F+xgsvxnEjg7gVYBchTqayOz63t7Xd35g1PxDEYQNlvoFaemrJFEbzaE0fcNoA5dmAna0RdAMOpzOOuQ4wZ+sF5gK5BRXZUtffy4lPJy760fiyNdls2ISY0jF0Jhke8B2vmbPP0Q1A5fB08uk7eHtqqKOhx2KngFtO0KLT8Zbr0fXex2fkWTnIZGLieZFm2eqWafAO3TgZyWhFZ+iKo0adnrM+o9cbDxmkQzzwJP1JBseudH\u002F0g8FgJnTsreYSjboOWWH7rLVN7jpGeY\u002FuHzDdetFjrtHL8zsdRZ8Zg9IXGMK17NlQQTCyhljpgpl39\u002FTT9wcAN0aX87fPeqIp\u002FjN+b7IVuBqdfWd4qN838RkbInquPbSzYZYyOM4BZ60zc1pv42OD3Ju+fFYWzD3IAV6RpeLk7Yq2U+oXfTlpnBf8YVxLQCuCNZbIvPrv\u002F4f\u002Fsd\u002F\u002F\u002Fo83BtT\u002Fz3\u002F+vw3Ym9RKk0rCmnRKqAXht4iYeIo6ElLdEO7evT3gWuTUIl8PrJ4\u002F\u002F8XUrluIJWoZcWICzDXeX0TE5BSRn8AjUO79bjQMIhqvV7tILyakxIAm3wGmdHUBACkVxkr01f2MA6jHRC4GPC6pGQLj0JylR7nvYNhJRfV5TLn5pNgAaYpAJBNTSFMZB6ZaDmviidflofGITk6dXe\u002FxwkXjv63TiKi\u002Fzy8GKwPEgDQP0TEP1ze++3W4YMwpKf3PGRLChR6cCXV32o8BCiJ8NngCHObJWdGv\u002FWog1fwBIBvzKAQRRezmxNEzRfTfqS7bSatn3uZofbg6d\u002FbsAHVj9MTcomX2EYj4GY9IuIyDsdiQp3ZdilR0aFeCoVPGF0XyjJczYl1skAW2lShoqTnRw3hDdwuHTTHeaDJp+ugBBIvGTKeVAJIxG8sAqFgCEGMonwas\u002Fn\u002FW7vPJzmy77\u002FtBI2cMgAFmAEwAJt3IS1KXlEtUmZJll0t\u002FiV\u002F6tf8tl0OpJKeSZFnk5Y1zJ0fknGMD6Pb3sx40qfecM9Po7tPPeZ69117ht8JeW4SWoKHtZpta92cQ\u002F7d\u002F828non7k2OuNS7StOsMM49XW4D\u002F+x\u002F80HSIyqUNXa\u002F4ao9DYbMhBs0VxLM8Xrdjq3rAFvm10kT6zGcd3hm1AcMpsAex2my9CTtG654CX5uk6POrVr\u002FTU8mqS5ulaL+\u002FjvwHQc99FuU8JQQaQ\u002FLgXhenncRz63dgpJ4rV3NzUPawXGUBrY8L7wLgxePmca\u002FwK2HPiPJ8RAUwnKt3YGC0KzL05axxp91GjyKC43jMWA5Iy5+i4a4bcoSlAg41\u002FeBWwUJO\u002F9fu2ZOvataurv\u002F7rv169e+5cssj4BWy7B8McgwxQEO3h4CpBGAPTeIj3GEp6JD00B4P1HADO34zRuAE7joRomyg6AhmVHsZ0hc4f+Nl60S\u002FoSM7xl\u002Fr4LSdonNLoar0TFUObtXPNRMkDuPiZszt1l83Fc9GDXlzqXZdTiAGmiZD3d+uw0I7hWgwWmir3Et00WvexTgACI4b\u002FenuuIWuif9YGfwK6ygwepVMepluA0TOn36w2\u002Fa3Va3g+uZTpunHzevSoLraI4tFK12QGnMKpm4puUID63TJ0OpPoOiUKrRzwdo4SAIAOOJecAs5oLlK+BWroA2uAX43dFx60BqPX0teylH\u002F85ItsgjXDq3GOmyKwz\u002FeEY43tg3Na8haVSyezRGwPGUCbefVZdBzj3NiWUkqlQgtgAV7oNw6SKJnnaG5AV9Kj872fHWt\u002F\u002F86D1ce\u002F\u002FXj16cd\u002FVCXRJsTKQeIvPec5Mk0pOQlQdI8B6mS997R93F3HqYMHHOpXRjgwfbs9Phtdu68Sl6cB6Avtrfjq2\u002FOV5l0bcP4k20bXqMs2VnxHb+qutugN8swpAajrL90+HI6ezKXoM110LNt5ILn4\u002FsL56T5jIWQfZJpE\u002FgUVNIEQeOLAxWRTooXnfdGxeHP26HQ\u002FNoqsWyMlVPZXAOai4NaWTpmv7r2rKLYoJtDuoEPyhBeWa5Y1BwAtk3Wjp2ajZrZlwFE0A+45l4A7rIDPZMs48JPtanxKSHwpi2Bvp4Vp8mzN2Sv3mM5F1sb4AuwTaS9ApVRGwMH4zMNz6IRYZmykw5Q4jeRivuI78oqX8CyA7TneY7O2aOjz+Bl\u002FowEdRWeipWs5hmwwvUev0vM24P99zbobxBuyV+Rtf5uk2Wbr43NDr+RpSmZ6PtrTZ5xQQHTLZm9hFkTesiUcm2k9SZ82L\u002FMgLxx8+nOClGjevehQ+IM+OlilwtiEPrD1DCBXwJXMkDZrK8tBbqytgBmnyPhm3t1PhJ4uc6+FfuyOUcwoZ47zc+M0X\u002Fc2XoviebqR0Qc+O3rB3KOv5+MDB1KOKkdC10Vz4+Ew+LwvOlTnwEjQOJYMAV3IUSPHsJtD6DwLz8595nnJ9azZDGfm9T\u002F8j\u002F+T4f6jXwvq+0ffZmnNZ8IOJcCEQHWzQL8BYs\u002FXpbkBG+UTTTAB4JWJzGJiC75ezRUgDQgrIUHoAc9dz6DcyBhgZsx\u002Fq\u002FIPtZun3nxjDPF4shHNhpUrpa5F3ET0RNxEQjHIyRNvDMA9VUpWaQzFa1GAZdeLmhAabYmAZyl6BgbgJlS+MJQx+RzhEjX3eQoAcGY4Ke8PArP3Mw7XO+FSfaYDXChTrYFiramjRK\u002F4YISEkjnZfHanaNWGr7f56E5jOla93VKuIIUXo8dye3v2zqLJjIf2hspszr4bkG6+h+IsYOWbb77t+Y8ylO65d\u002FXlV7WnPP\u002F96uzZdycC8aP9HcbR+hxKwAAJIANd0R+Yt3AiZ5yT6YBRxJVQMFyEkkcJRFPMgLAXpem11LQtpUOEydw8Q2Ty0qXLM5aDGQzKAW2jwAiKSPvDUqaEGMAAfjgf1tbGLMDsShuQH2V0dgWAlfMAktsTwFTUAHZGw1xsfpy2h6V2lZbpVbs+PY0X4+Le331\u002FYfXJp19MtuFwddX368QhJd9H64xzIyfmcmvhvoDEEi0efo4nOEfG7ffYaA692CHlPopxAexNrytghyVi2I+jgLYUWtPssylJf28eaO\u002F7RhtAKdMWYfm7G\u002Fmt65cf3ZjHvgBydYN+9\u002FdRav1AQS6\u002FL+9Za\u002FefdZ5nZNibA8dyxtO9jMeazLP7vox9ccRc5x0gYOsaz\u002FLzoqhESw6M8xrMiQ4O2+LcllErisJ5vl3pya9\u002F8+vVnzz\u002F+dT54xPtSc1\u002FAGXPd3IpetEfSGBssOWO3tPTefWslY7+5NTG5us5b29VdnCqaCYla\u002FPo9QDJg3s3V\u002FeflcpfqytRB+LYOPRm4zqePCjh0Ffcs0WcAWRRZM86mq55rcj\u002Fgdp2zebYZP7588NTvkMx44NDnVC7pbP05nYf5Qe6CHHWOGnAiVrR0Wl1xwDMfPbwQXqPAy7auFmd+ImuraykMwmuJu8vqn+k42ZNrEFjA6Tpyfffe7\u002Fv9IgyJOtfiUF6wDorEWPgW\u002FUp6QD4J5uQ3NGzdBVghdaMoRIaBp3xxDs26u3fW9lFND5XRxD116Ltb50509kMOoF0IFa0WBUF7eyQ+V3nDO3tbl4tynvxYnrxRR1fKk2L1k+an0YBF2tNqGXs6TZtc\u002F5vXL8yLQKfBnLmNOGZI2DIocCTrXvj8jVAob8TMCBKhHY9J+RZ0eYTBR1O1uHr2eUbAZCAan\u002FrqmgTT5dB03f5ELBVXTzAqrzBiczmut4cycfwbp8xGyJEFykD4CiM45osoymgwmHm7JAJY2W4gThZ0RRj5UyBWZ9r5PfS+5\u002F++u+id6UgrecbBSvuPSylXvSxqTQPAGNxcqdLUXx3KBt16EBR80oeL6Xjvjt\u002FcTrbnIxun3\u002FSqbyVSE63HGMp67dDdjjeBSJFTeO2nh8dK5rd17j2dWDcnlO1zW2+AOLLUAebti+duTu5u\u002F3swer\u002F\u002Fd3flJ08VhvDyhAOBOwDqZywh+0le9HYnx9pbtFT2Q\u002FQ52eAb5zUbKPILjm1F4neVc4qmETHxGiF52TfOEIivTm22S292bc1PjRU9oKeeJ0umyBC97HkS8Zref8ZXfCKd\u002FE3J87vj3MqHj1KjuJnQSd8bV+E7IA9Cy+zi\u002Fcn4+AsAS1+46uxC9Gr51sEffvZZY4tXUDHKT3iAJEV95UBG+e88YvAAnfTIeZxUeV0kE2jeAhtsMMEFuI5gbclgzOPWngOn\u002FZMOpOc64ADQE\u002FUvOctmzg57q+CFX3HV6LreFI2dOcAz9phP77ZPRdACrvQp3Sw8ho0wsshrXEy8J2Mifpq+h3NJ4LcZ8yZrG298EkXzj22t6ZsN4C+FZ1ns2xqN09YB73IHfyANpyWxd6QLXei31uzfgXuZTbN3+dH\u002FOKThjN6jE4ztuGPPuMEcY7T0IWz3Dx2VZJKx9I3dPR6NLJOnvv39rcbo7P9Y4KXAjnKzTio+2oYwn7IjHG80Mo6ToalOQjmgSWJw+yXUtPf8JKlbGFyR7e+qPxFJH1PLU9tXqaDQ4ZzD7oZjdmIH+r1gwH1aJqgtUmpKAaPdjmxbalNB14xI0GeyfWdgZgFjHAWWR2nmrC1CvKBatFABkpdtnTVjZs3inJem0VE5JttBBQJU\u002F96osiAxaAg1jB\u002FfbaPddqhAzH2ZnyOtTkQo3AGrhQpZewwlefrjQ1AAN5LOUD1jpda\u002FH43DtF2XyLhFPidq5XNJICMoEUfL7V7aZc4RqIFAmb27UwxtNJvnjnVprUnq+ulqNTbLjVjbbrZ2zhjIp46AEzx66jgEA4AVF2uiAqGJGCbHQqgx+yhPW2GjZYUowjl3dKa50tTX\u002FubX63eP3d2HBcbJ945V5Qxxv708y+i3e2igo7PXaKDb1QSZFMkEHwqUK4XrbZijBLhlqHghdqQiQOVI2nVtKcaXuD8SevHA8Xoe8\u002FUWSfh002Fw0LhAQZenm\u002FtCKPo\u002FqnTp4fGnCROj2i7Lh3Xb0T\u002FFPmRw5ypnI1qXNF8hDnhwz+cB+k8B2R0uxHKBx1eoXZ+X7Raq30exa\u002FG07o5NYyxADBxGm94s6OmRRUpAtGfr77+ZJ79o1oz2pC2vUMf9G+10fVK9eoEbQJgPZChGTq0BgR3SafDjSKhDEBPiVaAGpoZO2A8P\u002Fc8Y+idUdae34+9Gnef32C8+u56mw03ai+Hl3wBaiIWyx36RHNiQLwWpQZk9OX57uXvcy+P9hDj8L1n9mJYn7vu7+\u002FvPin1GljPvfubZ7rHPMW1vnrPi\u002FPsfqOU4\u002Fvl1bPbJW\u002FddwZYfHLjZZ0X1qvlTLGhD\u002FqTQZmVz7\u002F4fBT2yROl9NsLILtlPOjx6IXoY3RHi7QlxVsvwGjUmmWIvecIaoewyMr8qj0EOhWdzvnWYem1+lW3W3v1sk2N92\u002Fn1GV8r98q5Z\u002FxunWzzcUBdK0+DwS2jxYQGNAbzfDuUmIFwFaj2mOBuxcdtnHkyMFkujlGA7xIjva0QVCnm9FFlbkZL9rv5Mjuj3cDDKKnL+NNKeSWJ\u002F7sq\u002FnsScft6d67yt4cbhwnTwZav+xQpyJ+L8oqAS1obGz4l0wBVG9Xgy4CdfHi+elQM6emtp4h2b7KaCQb6Gi5BUNSYUPTBQCJCOUEuV\u002F0RvPn6Rx6Do3pFmt07Mibq7Nn351slj0wAhOcUqcG8uU4vTsrYeQE78zgzWbc5J\u002FB0\u002FVFLfKevd0voO5Yc1Fccm7\u002FyXsf\u002FqjTLwu6pCv2yl7JrjZOh7cA6Wi+RDWdRVG3qedFPpuMTZETqY0hgdzNDPTedOyZTrIVvFEnn6ZMNzkIhaPNYNaBJB452H4gLS6VTehtLRMpMs++LKU4gXE6oi\u002F8t2SQon8ygVYilPS5r5GjZMHYGPbEbsCOMi17HXbFd\u002Fvp\u002Ft6\u002FcOF843qR0xfI6cSVnfHKugh7a5lFTxoXvT8OUjoL3ZzCfOPmvQHpft7H6QkI3G9dX8RLu9pIGqHmXAeRbhKNHzlX2wKGOxrvHHinpCCdkrYrOh5cVm\u002FuxOPkbz07AjBtS14fbtROucPLnrfH4PG2nNAWeDOn52l6j1PlGS3zOEgvek4EmXXAE7LJA+6iE7AoMn9oe4cSpf9Gc0QTBxs9Sq441PZj+TnNMjofRhBA0qZYKSv5kfFWPmVT4hLN5fSGG9LVyjg2ckRuhgOUv7wWTxkfmzzBs3hwcQTUdHcgV+OQXVC6ubOgF3wAkOskQ5+SR5sdte6jR0Ws2bBxXA+m35IN6z1f0dkhhkub1toTv2pIwXleX3cQ3+JQyFbJCstKsaPr6YPJ4CR3E+iLwZcgSMC0e8dKsUjOznaR66jW73QMwOm5AKSMQx8aXmOz9qcvdwfundatDImTQs\u002FgKzJCxtkmanNsSPPTuY5DCTMYa7fu73FP32EmMudN+n9LP0ymINqi\u002FXz1WWNkP\u002FzNvHwMJ8tWAMrj\u002FI4tbCJd7TnubaOqz6o75+ShM13pCybEL+OYNKSkYvTfBG58tq\u002FJtvU3vI5POIN0pD105sOR2yZ4gOfTu9YQDUXa1+qLj0aTUWxsHCOft+dJkBJ+o4OUNsq+s+OTDUrRsV29EZ3TAT1\u002Fw87RrplMVWPP6CX\u002F8GYBQzNubNYQ725vj8HQFYl+gNcPBtRFrnmIvC8RbARmDLwQGDgGoKLrgFOMSMAwLpD8ZJs0OCaa1e\u002FnFrrPMjgMlrTTyUohCKZ2i0sayi7rPKK4clmIarYPZPg+PBXoagFjKMxnA6nF45VJjalXBrYxh3vzxFuGxlHtpbrnBHqARYIFfACI48V3PYEDFnh8mM4czc\u002FiL8pgqQ\u002F0N56X0pHvv7\u002FeptELw3D7izDu7BCHJ3sqTYlp9gfWpYqkwK0yZjt9uiiWXdUp6acxd2ZyIk1rMQCDemTv0Sk3MAdzEWn51d\u002F+KiV2K8Dy5uq9984NKD7aTvAr12+ubhTVJxCRfjYfAXpSfluCSXGJessqAFVTnrO7k1IbA5GTLbjb+Gzm9bJhDYP7ojw4G+hjk5BSn5ZxaIJpl76lbQQO7E8pU4b0rbeK4qdA0e36jRuleZW13OvzjwMkJ\u002Fq8KOZiFJYNPx0JnmLXweZJ2QYetVNqpdinRWFrPPWQ0YeADlhpDBspKaUNon7Sz4z+AHZ9jFOqon3ma8CiuKIo1sKJq7IyUstaNFEo5n6zKDv3bi3jssZw4NE2dk1UHGF65sIbFGX3RPAxyIR4UTrkYhi7v6Ct9zkVnr+8lu+ULAVDMYp8kAay4nRLUSkvMjIvhG6sPP45prx7zX+9\u002FV\u002FKk6gj5wONvKYnLIHsPu49wLDvjIU5jdZ59YwB7t1X7sJac1JH6fezZ4wB6m94oqF0jxRcfCUaxUCKxpIjgO56dPz0009G4Z89e270Bvpu1XgCxeZsCMZhiNpg7o0mNlBtq6vU3TYU0jWXi44DFZ99\u002FmXy\u002FiJn9YPGliI+Wlq\u002FSP6jgPmk1jPWj2pFd7+NV6L9z9tMd6R6YpuHjU0fc4EBgIl3Jtpj3MCclTJuukCEEA3RCHhTHwsIa2s2x1D3Wal5PCXaM1GjeETtrPFOtiDD5pCf3opeSXcR9SNHOK9Ft5qz9RglP8uEFh1E5LyC0tuiwgyHUrCOcxp9xJFnKDnWovZKvF4mW2inxGiJ6uVE7GOUMyaNHZ8zhuOMpvvW2lgIWO0q0HKkoIPDpZTCKHFAc5uzAAGbPdGDjIYe53cyunNn3V4CTupAlR6J2ooSPnl0b3WhQAJ+cd6Cko7vvv4qIGRzl0h64CFZVK+Khgxw1IkG9HIBnGxDAh1QK\u002FKYfI6RjrZoQtddqtymxya7Sh+KSgNRrxwIncHwvGPGx0GPYtYDXbbVBWVo3WyaRF8LX+M1azSdc\u002Fqs5aAj8LjgBYmzSVIUdcBPc3Tgkyi+YxAP7Ko0Lifuajzy+GGtGjtEZbOA62uv1yq3OurNjQB+WSF6Y1Nj8\u002FQEWblSEOrqtYIaleQ9b76OOT8Yb621lsiRS5OeL5jVAAV0DlY7vY\u002FtSBdof7kzmeEIy+44DfXJU6A00BC4\u002FfvIZXOYfVFNShnDm\u002FtPdIJrNDt+sDkvhwlta8Pl4zKLVgF\u002Fu46tA4bWy4qpIfc+O7wtWirbiUCr9Ta1buSJHm1d+0DhyABQpzXv2Kklc3jgYFHegDFby4YJqLAz2m6u9zm8v39fmazj5Eu5TTzXM7UP1dZ4Rz9PcKSxL4fZLLqRPsVb7BBbI0tovbanL5whsit7AzRH8cEZa07DHJ1eaWv2Ci\u002FQS\u002FSb+n16e3unUW6L\u002F9gIa7Q9WRXIoLoXnfsKWPY7HALIkjv3QkeZDqdjss9A8vYDZRZzGmTGrTU9Swf7\u002FrR1Gme4tTSuYTBM1hcM47uxDWBtnrKT23rW0+u3JqoNNNM7Y3fMK94R4W5RxsGewEzXcGKsG12FT+beHkN3d3\u002FzpnOWYFPgNjp67uyx6jMw1lLyF\u002FDPKWJj3YedsTbkbOt3+qWPzj3pGDybOAweom98ln3z88yvccg+kjsYkG4yLvdxXzICvylhoyvmELX0bI+esduwzK4nUkRlXmz27EnMAV1b41jQ1znM8dnMtQHCWgIO\u002FdvfBYzZRvOq21F4tRx8Y+Y0oVOP6x42fhs0lWHMnrgjXp95psucnLqlj3fRXT\u002FQ6wcD6u9Ux+gFjKvhm00CCaNFsmqiVTYujnJL+TBarvXSy\u002FZWUV9ADVhi\u002FCbFm1Aji8MMTqZ0KQwL6X4WmSElTJS3OlJMhYhSIoUNx8hIDXtPJJhQvXfu3Bz4c\u002F361fnMgYMUiSgMEJAi6b5KCaSx3JsS4AQYv+eLQgO9vFkRVn\u002FjAEgFDXBlzFKqDDzgerPNPF9\u002F811zv91n24DaWA7ur3VR3uBslIk5RVPjlO5TdCPhttkVwN9TRuCINmdFeRlY0QrRn10dsgPgH9hWW8dKjdR8M3C6bFxpI6jNTS8ylqdPn1795Oc\u002FX73\u002F\u002Fger77\u002F9djaqEhIgHV0wLmYn7G8VYZfG0gkBLZ0IefSoyES17UXD7hyutKce+ZSLOTvt9VbrwwBKq1PohGABtUp3omMCtoATB0Tda+f8g8Zbd5u3Tk9pE2VFWYuo3ChDcuXKzQxN3X6KGnDA8ABeON7zOEQ2IwP7onFaIe2YzIMoeHwUcADaByy0HmogCbeIhP0QlL26uh09j5KSrlVLbE1mjWe8WrytGkMbrwI96q0nYtN9N3KYgJYgdb2lA1eBdfOlQNW1toCtEeUU2OjL7y8TfsqADBBkQk2xYWoi7ucBy6MJeqOXdcTjPuMuXgNeaIZeFJhn8t77Nvfx8YnQpLzmU97oL3PbVzeZ58VnlI3XALXmRwFTyNZCOcZEYeKRAd74cu41QyZ2veafMdLeGN7tXddPRD4oj2eUBciOmb9MjeHPEdgNmizZPP3td9+OkbPJlBGZ+\u002Fc8G3e3lVocx6PPLk4A2lK0AGbdZcomkbsf1wv\u002F7Lvvrf6v\u002F\u002FP\u002FWf3v\u002F+bfrv7iz+8VKDiWo7sv\u002Fj+xOnjsjYngbNaL\u002FlBxg4NHT8RbO2uZ2hkNgf0duysB65nbim4ffC291dq9DOHsZXiL7FsHz7FxipGUWl660VgDJVUp52ResTHFbTOrNcI727dnkJrU8FK8otxqDF5zwgtPnrRXp6gmML049kpkbF7i+ASyM4g7W2ctYk+UfTido6ozhzIX7RStGcMsGii4gMjDf8nCtoC3ceATcohX1cOq6UbryWiNfk5VpnMAT9z5onvdvX2ztVo2ydkM+FwELDqI0IomSa0\u002FrWe49abnFwcm0B84eFFfepGzXbUOlDHQfej2rQ6eSlYd8Pbm6bcn8v+g8YuQymBlY4tY2msjUd8j+kfWEI2GHysRaiJDG3qXLKqpt4Hw5Mnj8S0n2wa3dHz6YV\u002FlOfs79O7o0UPxyd3VpcsXJwLOwYwiE7g5EqAHTHZaq\u002FhqvpLfAVDpAutORvCynzmRggFs25S9RFNBHUCI7YYbtpcx3V8kbnctDm8EzNZvN9Z0zJNajZ482sbadNr6XvoqfRAvvtB9pc\u002Ff6qTc67cepLOXzaQ9eAD6nrIBuh9t5Aisd6CXDW9bB\u002FsIim20Nuvxpc5DVNBGvPskOk4Qio5Iv4sgb8pIRVQHp3Hye2d1s02uj9cf1+d\u002Fd+VNbw7dRNl3dYjV7XhmWzZ0PT3A8ZLR2IgmrUyT7L49ez1+o3PYSDyuh\u002Fbzft8WWAFc55TmAOTuQ5XDVqoTIdOfj3LU7s4964NTZixntr0M7KRgHVorsRCk0gTiTPx+pPF9+9VXw+\u002FPy8BwpPGJ8w7IyRJtTfYwTuskQq00TtYAeHciKCgmY1uNRPJON1Wi0nXA9Gzsxm+9J5Pp4LgHHaT1LIdeScNsvI9BBYe2HQjS9R7ZWQIQ6broPHzS88gi22rz9ePkAk0EC9efxeAFpsgmXSPY4kXvspe+vBZ5ZbPSfSO35Ljro3XxYZ8YXLEe7tAG1N6Bv9e79C\u002F57F923ee3NYadL4s8p19kK9Z9CYDJ5nVo19gYvNa1iVoylc7qFmi5fXtBud7fKkeiMyYA1nh6xIzduhPWtFB+NX1gHbIxo4vS4YA1OWpdtzIfaEQOFwC\u002F3ItTwG67nYzAIqci071fCRY7bk74Q6DgZQECZ+5Yf8EDNHftUpjWVAjjWM8l4u6Z4wB0D58R\u002FH1C92Sj5tyGrh09l16biHrrK1sqU+HAK\u002FaX7pzrW8NInc5cxiyg+CJ9ZJ2iWvSKhjnnFELv9t4P8\u002FrBgLoSiq1FoVxFp9V\u002FISQjYRGcRDWpxJjDBEWBCIh0hd7LooEAlIulJzEsZSC6RiHM4vZZXg+FCTB6zUav7i8qjGDffuvQmjY5tDDG8vDR\u002FTno5\u002F33z0XEDscJ\u002FDlVkmco2uZ58U7fYjIDjVNt2gLaGQbvIbkvinnzsVqnRbljYM94njFXo+6FDjtSEgRMlPvqlVvNtahcJdxOf6PEMLPUsMM6ukFL3P17gAjzleq3Gf9DRdFOnLrVyVmB9hSUCIE6a98nlRZDAclnqymV8nz\u002F3DudDPmZ6RRxu9PfnBy6HJ+uzMZGSGMF1hhn30fZNhdrpKaf86H2HWPLEHAQCIievUdecxracigR4K3zjDVS7uS+o6CbBMFYojiiUJy2pa5PWlNdKkP+oDpzG3cOV6Lw5pvPqz+\u002FtbocnW6W+l3PMCstuptjoG0khXQ440d4ZESe7+1Z3VdUZn9g8LnyisAVQ\u002FokpaRDhl37+mUb05YDhy7SdFvdCyihEx2eYr0oin1t6LK+1lGXAA6RNQSaRHl99v790vGJYPI6zomavB2VR8y64+toSXkPbaMbRwbvou+A9Z5lnYej+i5FP1rSv\u002FgmRrBREh9LJe7IeHh\u002FS7lTkmMcyEkv9DcvX91u1mtRGgsvL383hwXw+tvUJjYmCshrK3K88L9r\u002Fwvj0Y3nfn0O4MML85x+F7Fb7v9KbmYsjUdoI\u002F5hwATcKF4AMa7o9+2tee29kjfO3meff9qGxTOVYJ2eqDMQL5plaBT\u002F9sbCOZ11aG1a6OFZUSPGB13faaOzsf3+97\u002FrnvemnESb07\u002Fa888G2DAUB17r5NpIfSv52rNdRPLU6uad+mo7iCNjxuEoEDuATDR3f6cn6+lrbfA5p06pmbMb9PIG2I0hsg+vGKs5PiyC\u002FLQyiP2VvwggMFzfX\u002Fh+QBLHk2OKj\u002FDb4\u002Fp8M\u002FjArC4y9BGjZE7kk14DihZQHdCL9xlZm7RvBX7XA8XrRe19lh4SjPCd0VLbiffx+PBSBHci8DwbaGnkyg84QzfSlVpiOkyGQWLIOAKPRu8utazuK6Kmg9K2jKXDoQBCmYKIPFHShh64EYGUkWypnMFaNHK9Nbx141rBilo2nnmnPQVnV18VMX18P3DWSNRNJ5TNJdlM1vAy5tLr\u002FEjPFc2np\u002FR8dxw8yIK\u002FjlfCd7oM3tWr9hoUfa9E5GE0BR0O5qgR0s0M+v30h3089AjAzTG0QRN9RM4EcNbSUZ67yEJ6EYPi78aDfv6GB8kIOZ7yupEFv4uMpjMe5qoEjNFE0IOcxV3ReAFb7Ir2dwINCsSeFBC4Hdh\u002FEGC+lz48+rqyhsD56lZrCBg319b49Wrxd+88O+tOlvDjrRvXlw2y0SPWD6DipQ7Iar1b\u002FaGPCfi52QyEw4t0iizh4\u002FTbndtPVl9\u002F8e3qWRvnlGJxRG26PvNWB9NF19ksHX8N\u002FfuszMkegDaetE7PyXs8r3e\u002FUp0XrfWR49XHV6KzGVB50XN27Ghtc6J0+dlRqcBmBy09zkF1bsDGZg5memn2ggTWZdXokwMZSmD9UYcgftjeq+PtQwM6b7VHKU0wjpIxmTjg+6w1hSsehzmMhe1RurK3++ybji21rHTYXVnVKa9tTGuU14CpbHCZOPwzeKD7OElcsE7mXuOA6fryCuDjC8+ie6b0JJ5Yb\u002F28hyacVjhEQA9o0xxiNsz2d+C5S1rTJaqMr+gmsmVdyKT5s6Wc5kJNw2sbtWJ8np4aWoUzHqczPE9ASDaczbLnRCmca16WBRAoEeWfoE73phOe5OyRYYB+0dvkCAgOBva94fW3eKm1RlcvwS+BFnznb\u002FT\u002FXN9vE4HvTWMX6R6719gnyx1fKjuR3VjLUdyyE2yCccqOuW6aAySXA9QDwNPGdAINiy6Q2Uo9z9iWLMCSkej2vRduyWAKtApwcCS86N0du8jwYt8m05JsmJF9ZOx3A0pm4sMwZDOPB40hPCpw0LrtyGHbVj2Ncm6lVHQwCnC2XhQYENwE4m063bEDrokfo5\u002FyafQzvsluz4j+8f\u002F8YEAdcGVYFrARuGihGSE1vAg2mw5iHFEiRKIQRaqeFlFSj3yiyPHJk2\u002FGFIHBiMZgI4YI0o0bdeloUSkh1KYA1UdjcswvAup5nnH0mMi7MpdHIzA+QLFJ2WnxdT2DAWzauMgojTnpOZOmTtkZ\u002F+7AJGVsl7g5bWyU+noV\u002Fef5A\u002FCUPIHCtFOv3ueMQxs69WL7ElRRof0ZR4t8715GpEWVMdj7NI8W8OOZpeiwE6BBWHjXaPS8sa49yuhePD+R4\u002FGwU5J60ar3njKS7k+xcjwwqazD2uqj6uErJ9GCMvpeTuGKhqjjp3QA8TG4vYcOPrdlnA8dOjpddPRZR3sRZIzXcs04rePBFChB8N4A2MatVm9KSHr6CG204JBQmBspevO3QS9fLOauHqyv2agamD4GcFeaJGVtY+69OwHzPgOYchaAe0rxxLNjo5CkPa0zIPSGdHhGUaeCxQihZLWXgQhgiZlCVmuqM4k2fdbrSd6wWkLZiHvRR2RAlJYz9KjNo4z6gNUBhRlafEYx9WXelKQU82QTcmZsWMkaD8Be5m8U8T1FFT975stqtgF2yo2CngwJQE\u002F8u+ciNyIoTaF\u002FKEb87bvXjCea9IG5xj3mKf2+fF\u002F+MG97y6sbbwF035vARCLte6CcZEcoSPxM2U\u002FEpwdQ2AzZOGnG0ZfnUdL41HgXUD8\u002F9CBj8a\u002FUqzs3+9Gk3ceA+ryoXqzdPSjSHbUK7XyEFKINu19\u002F+\u002FU4vmfOvJ0i1WowQNimJzzP4GyKdHW\u002FidSk+Dn2B4q4iWA7ifdqZUoyMMonvvzy8\u002FgtEJ8DfvrsO\u002FHN8wDO8dVrbQ7t3MjVV99fmU1RWgo+zcEqy1\u002F3izZsB7CePuk03QD3y557t+if9m9OVnSID11wK\u002FCqU4qSEPOzrgINZu46hhF9AGc0PhwABdQ4\u002FcaJFkdqXwosKid7UkTvQMdXAzNq7mXGdkZcxh4NvWSS6CDG3XrRg\u002FQfmXpZbZXMUUOLz3Iuygig\u002FrZtldxkXPH0RKIaL\u002F7i1MtEqcenH8m+7jqcgi4ePfJmG9p1cgFCRPqBvJ2Nx5imTV9OhYM\u002FHCr0NJ6SfdN32\u002Filn9VKbzQuR7I\u002FCjRzOtea3\u002F30uFNlX3\u002Fj7YIHx9s4f3p1IXDx8GEdp+IZEobf8XKsUgRZJKvSoGRcSpo+6qEByrJ8jeVODvz+AJHDyr6\u002FeLPMpc3AS8bxXtFifPY0p+InP\u002F1gdSjHZm8gVBZH4ORWek2uFj0OV354BEAtazHlgOiOZ311jZf7ijQnBSMnzyqNGLmOvkDC9l2Bk4z6y040XC8CuCf+O+B+6Rs93UX4JyIfLURo19ML9xrDtYISd0TA01MyoGqPd6WDyMD+5noiGXn99fhj+3vpJS1s762u1z7X6br2ZpHJaT3aZDfpqHjxKXlu7ee04uZCB29GSLwaZbPJ3GUZifaBFfCIc6fU5dqlu7OmWu6ePt1+oGi8L51Mxyk\u002FURZVILN9Azklm9nn+NJzdgFEPXt\u002FWayTOWGn3z038nI3vUq3PgrwPC24sRaQYRPatVqUvaBb4+KU0jXLno+lJAPP2df0IBv06z98vPrd7369+uWf\u002Fem0Ht6T3n9e+Q\u002F67FyLl0cWisrHR+Y5e6wyqqPT+j516vHh9sLE1ov9n3apyabXrtZts8gyB4FdXEqacqH67N5sHGeRfAPa27Zpt7uUjj3rWsEcgUY00L1J1JpcvnwRLonebKpyzaFftIIVBBYBSryAzQb8tYZYjX6mU+Gf0dVdQD63DnDjJNLHA3j7Gx3KMV9VMsxeGr+2h8CybLbAgZ\u002FBSw+YAGifH9xFp7See3Y3jv62txIl+orKVl89NpdT2zM5FkrSZKPpLwEN+t+1JkFC6GnYYGybD\u002FQufW0dJrsTjQVX8SvHQoBD0wzXrTUWFRDLiajp+O7rfvgiyRs6+Qn\u002FwlyeQ++73ufNkwxaf3jSe0rU7NeYTG7DeekZ2QGfEEjY2qxv06j5WKOt7GRDnHkIntCRyorQWvDENT15aALv+F2LzNBb1+QUZat29Z51mrKbsN0P9frBgPrNALBDMyzI2bPvrs6cObPaEYAEWi0aodwVY+1+wZgBCpW8JCCALyL4Ygy2gDymYAwZSCUzQIRDkU5UC7\u002F1\u002FhA+Ao1nFMFtXLJI+raf3Hg9Bblv6q7vdAKhU+mkHC2mE\u002Fxul97lRTFkgC5gbrOpv0t5Sa2qAx2w2jOMEyAf8Nm4GE9Rb8yzALGlBITwiGz43KHuIXpz6o1Tpdq\u002FLYKhxpAT8yKhSuhjYMrGwRSiwdsS0t2ln3RZGQMXzSaVHOh4XLSIAErn2bijpIQy2KqdJeTH2xxnzscDoLfquPCwQxqAFLusrYE5Mvj7m4fIoEgSsA6oiTbptqOLjvlcziBcv3Uz2jhESqYiABVzUiIi5Eeb15QuGX+KEyhgSAimtQNYKKXH\u002FW69pkY+gyf1ZuPtWrSj7G10NTbRPs8Ja6Woi7YXlXujaLcIrDrzu0VfCcwo5K53jPbaGEQRSY5fYt1aNtCuA\u002FaeT1aFgrZ5RRcLm5dEyh8+qkVk\u002FRmOV96j3ZlIKKCndOl6JUo2u1JoFKpOIzx3nYDMy0mkAAWwjjcZ7yV1ScJffcXb1mMBHv3cvUj3yyJvrtkCvROd7t4xRe+lhH2u6zabexf2+WIq0RGI9rvPoSVlrbTKtWjnBYh5DYCmTrrGtf7uZ0rbeBgeDhDDgUZ4daIW3U\u002F0szuMkgRLXD\u002Fg3L3Nrdc8r7ktz5m35h9j83JvBgafee7y9nJ9zD5gdEcbrW0YcxqvdPyli1cGrMtO0BvdZeRwqaGPtyjppvk8+pHNzSqdZKMaRmUad1aff\u002F5Z49LNx+mVLyaTIoL229\u002F+dvWzn\u002F9JfPaiMpvz40jr7MOQ7s3R27mnDeKZsn2BZZu7H9wDAKJVWY6HlUzI+nFy9wYWtRmktPASY3atrJfovawTWXRI1om6SnH+yKmLZetaonGqb+bA+4xzI8jbtWqrlb+dfOP56vU3y4gFjum\u002FJz1zwHXGhyy\u002FSB\u002FRNTom+fyzNl4yytaJ7HPYRZVsdJu9Iq0ZogPraG8trEOmrt\u002FjgdZ\u002FNtNV50+nxV7jJNEHMmqyBeQZN010vAvwPSfBRtad29s8V\u002FRbiQJj9SCgbv8J+fb89YCUzadJTF\u002F4IRBZLbqDje6lh263D0at+pm338np6bTk+1rRPiqqntySg55Hl4zhbthGvhnv7g2EcLaVt9xLP3x78cLqZlHc+0Xmr16\u002F1T1s\u002FrfvpQh5JYO7Amib6ZvLlQKePVtHrNMd+PPGmxPhvH795jhcz3rutOYMZNGNapXJEaeAEabflqAEnkAReiZQ3hc5kDEG8mLiOao+NJMuKuLYuh1rP8GlnNDn2Z19AZOr6ZUjb7zePI5UinNr9X290G\u002FdywGLt5\u002FEy4CUVozE2Ya3H3344eqf\u002FuVf9nu8cvn86vqVyzm1F8oedF5I9eATmW++6nPZLPxPx+XhNs7oniwkdc1DAKGxJ9t0jINa6CwlAC1UGzLZmJwaUe6AxvrzB21qfpajkQMjMhzd9+Z0uBa\u002FPAgUP23cdLtxsm\u002FvvFsTg1NncsCOjs68kkN0t4zukyLYQNhEVXNknfSM\u002F2YcjY2+ZdfJbWRIX5VRqqb48IFq3Q92MnQuzBeff776T7\u002F629Xp6PnOmVPTHWczGVJK4ZRVYJx+BpQ4ynWSz9azlUk2O94XZ39r78mO9n1xoBKznEH6TFY++vU72rPPyi+cGwAXkDHle3DJlMnGgwDgs3jI3pgkbfSkcjRA1Vqw\u002FfQ2cGtc1oW+fA5g0u\u002F9TFuSS3p8AYk9vPf9jX7Ch3gMr9F\u002FAmbGJlOgA5b7cjTptpcvk7muhaHoDpHhqZVvYcmu+wiqTdQ7ibJfa86yaAx0DDsDPNP1dJ4vMskJYRvpMht3OSJkE7hdItiv9HvPGDsReB77PDKy2B4THYDbXM1tazz\u002FYNMW29cdXtGDjC3OOtoOr0RX4NpamMOLnL\u002F5InfNTYDAFwllvFz7LLmZOUdHNs9n8TDdpJ1zLIHhmpcglTkvmc3t1aRl9RqDEl8MEQ2bs+zFHPrYegmeWDf02dhULsMxa53CBs97rvXqg\u002FEU2v0wrx8MqJuY3c6EWRRc6m5LwWO2qFIKdH3q0RgM7ZKkQQAkTGkxb95oV3xC6Ge1j4zBmwFHKTeg8uzZd6fumjf7+9\u002F9vt3k1am9tgCnwwlKqzoKYm9A9623T48wOJhDGcS1QLzOMRjtv\u002F1X\u002F3KEyzHn1wO0DNTZc++OME+\u002F77s3hhk5GRjK+DD\u002Fsz7rNeNtofK1PbJFFe1qw1PP9SXtpQ3j\u002FdKZmynuM2femg2lN287sriIRN6dDiO0w9RxdZN42N1msaXdMLxaO5ZeJmFXz0av+DRQn4f4JIaui8GLZ4HSDAojf+\u002FOjdjjtdW5c++l2C9NX+ON6uVsVpNVGAPfg2zKdVCSk0mfpEwcsmSejNVszGGoGxNHBSDF\u002FG+eejvlsLTZE0Wzk989AeHXUugOh2ioo5R1GhA9AWAp6RGEPE8KgSF16qcovFZgIv8YWxT0YP1gHfpx6NCL1uRkxupH\u002FW2Vsv60KFIH1QTWgYxtrcuzhOR+EZuD6tk7oMhGQjRT765MpiUbXrKbm7g4vZCQP63\u002F8q2eebzjtPXg37bt01FusxG4e+rVLtqJeRi6US7WBcApja5ObeqkUx4TIe9vvGdpedcTYOAIPyyKs\u002FGmwCjmUcizzjIoC60pDenYssLzLJ\u002FblvGkcDmBHCSDoSwos1EuXRMOqg4zB7j7kCeKcgHmaA+kLzIHoKu121L+ZsXIWW8yO\u002FNzTbw1rwZqtO458+8+L14p2S3D4W++5tV8xlHpu3un0uJ5CpSiRHlfi5wwZLPWGQUOnSccL5qNx67Wy\u002F\u002Frb74uu6KlHlCp3jtHKKd2Z5t1unTo6MRJUco7gVaOmfX67LNP0w82jRXhSn\u002FYsK0HMpnVxvWLL76qLeTvhg42K5MnQP\u002FHH33Y\u002FStPa1\u002FEyxdkqOxXXTEyN52+Ga823sfr92btgUAHGPVWtGtfSvRjlAE134GCE7UzPFrE3LrfC0zZc4MiSl52PqgEpPHYG8LIHm2z5sFA1P6iuSJrruEU2u9gfbaA47aexaDTeRcuXBigrqaXfA4AeeWsm6uI4ZKxWcozhmdiGSDOWhjr9p0Zq1ZEenfWMH3AGbcxE1jnuBX5wGnNt+h1grS1cZKx25Gz\u002FDgnBu8DapvxpRS2DJmNjU4C1AUlkxU92ywYfdkC3a5ssjv\u002F\u002FXfJaOcrVK9+6vSZ5DHAc\u002FNi6yuDEuhpfbenr2wylXnb6H0OtsPZbDy83ab2C4HVi+lzAP1omdgz75xrjOnLdKvzFHYG+g8eCrDvK9jyMHm296mxC0S88\u002F4HOQt3Vt99992UdjwvuGBd7kVfDr4gxjjHARPyCrQJYpAzL3S3frt2OAhOwCYeEIyq5SZZE2U9Gl8eTn\u002Ftyhm8VVeuAuir29mCtcPKH56vLrcf5\u002FL1DtHa1tpH4xedpM0RcELiubNnVz\u002F72c\u002FnYMC78fb\u002F8e\u002F+TdmYC+m5ggwBBPXZzwMQACYcIEqu3IMcv+xBO9K72ug5MIk+eFEEnXy+2KH+f7GzdIEDwXZFY3xBxT9L5+zOCXLOiQ28dwpaXegQQf2zj8erx3Lg9B0\u002FsLufo+W7755dnT5zpsP8TkS\u002FFzlAd1ZffPNdNJOlEeWs6cEhZQDAW2MT4W1dB2ilv0SX9+8tYwx0l\u002F18VvZjPV0tEwo80S42B\u002F\u002FpL\u002F989ekf\u002F7j6Y4BdhPMXP\u002Fnx6mj2Zi0Z2ZNGKKFGAABAAElEQVTcaA08QL1MxVbEleP4IMd1+Ald8aqNremRbW3WFSVloyLLgC263bN2lGVn4m0u3x8uYaNmA2vPetwpvGglWiorMl+7cg6T2+PHj3dt3dCSgSthCg6aswwEpGSo9uXsGItgWz8Mn1ibfuye5D2+7z+yRjdthnsQQAmqzNYCVrM77LK17b1RiK0oHoQdVDSMTPcXz2KDpv5+xryUqwjybWt92OwlCBRg7X5j26JBk\u002FPp+Eg5ELBPb6ObuuvsFPzBbjU2ekaQxcPZJQ4Ii+MzvozJHNiZCdo0DmM1R+MzfjZL2ZEsj+tnPZLhKWmkV5oDXhU4QBd6derP6bN0Z7eY586J4Nazm5BdY8wtGqDM0d5VEMZhRXCLGVpTPGENZpN0c52AFd3VfA\u002FEHzL1u\u002FdWydH1bLrN3\u002FTYZDabUx+Nt\u002FsbR2mD41qGpsAr0L65O\u002F2Lnh72A71+MKD+0Qc\u002FCgC+kdLQT\u002FblpKNv19MYwzAEUmrKDa7W9g6Yx9iUgLIXXvmuwxE0o5M1rm4UkKgOPaUJTIlkE2gpGe0ULTMD7D5TT5QROFJEClExjyNu1YmJ8HIE3nrr9CzSZUfEJzwU8+tHjgcGj3fN3Um1XU3AePiMmdTwwmnRukXHWKJo0jSM347SxxhuDiBICVHcQM38H7cRAtHhe4FCtfLHjh1enT37VhGGz18xaso1wwLAWdC17jHKhhB2XxE5UR20A9DDWTMOx\u002FlORC\u002FlZKwU5668uIOl5HSaAErv3Uxcqs9998yp1cOA9jdffRkYqD1aNN6W0VNru9n8RSMAdYrVFwYEmJ4A5ymI49FdBN0BAU+K\u002FGmFtCtweyggbAFuRv+7zU0ZzbPqKG\u002Ffu91aHWtNc5gSGONcL7VvfmiBRoRjDgBCz5QNo6xUgrDOJg5gK2Y\u002FdfrY6sMPPprjm9XkA2OiiXrkcwB0nKBMlKjYEFQgp\u002F0POh0UIYxeh8uoEGietBIphsOGPMKupmyUbYK4PUNOURkHJaALwM0bt2a+CwBm2ETTlG65D8sYiOq+WoRZA\u002FceQ9h4XkY3oIXCGAXc8xZP3nuUGqHv5\u002FjUGCg\u002FcxFNA9aAMy+fNy7OA+MjcoJ2slJSfZQnpUnxRY1u9sop6ndjWYAZtamigYEUrViiQhSnlCQZpai8zME9pzbR\u002Fbp27j0\u002FNhdzc73n9R6wsiUXPgPQkA\u002FH0isLGXXfP13aa7mXnxiTSQk+x797WovKjqLvsTIbDrC5A1R\u002F9vnqxz86l37opMTa8zm0TE2gNLRyOHqhx8x6v3HqVMYv5dvvf\u002FanvxjZ\u002Fs3f\u002FXZA19tni\u002FK9dSb+vbv6Q7XrH\u002F\u002F+91NGceH8+Rnvz37202kFakPjby58t3qro9P\u002F7Bc\u002FocWHN3VZWc\u002FJ31mpxUHRxWi4q\u002FWwMfJBOuNZkcwpnYuGuhFUDZIyT0ayYkdy1GUppn4xwHQkUCqy+bD7kbXdB3d3gNg7lTqki3r\u002FaSBpbQdgocQnHonekToD3lqiYIRU3nUz0Kf\u002F+BxD3hoIJNx7eX8i2qI7m8nvjr4PoGgVBDtEgvDcHAjV34AV603\u002FioDjSwfJHC9YIaMBcO8JlE05XzyIXzbjPfynReY6Y8UYt+6A3f5k23uzDo2WgdPKUQ0xnYbPgfQj1ZurC79ZZvFutD7YZs\u002FXy44+e3qu8Wasq+3PhRymUYu6u8jn9hq23ypq\u002FuBuJ2w+erm6Vr3v199+33zSufuPrP7ir366+uhHP0m37Ctb8iDbcD59XrS52hmH2Oys7eBrL46OA3TrTk79oddXH\u002F7o5yNnb575cjaY32j\u002FwOVvv6mURhvZwGrtcfEew03fMu4TvAiwkwvOLZ4GyumFbeldTucT+vNxmZiypnvXDq9OHDq52h74e3wFOO2E0dPvrPTMunn97urizToRZUN29hy13GttdD795uvx35+sfvlP\u002Fmx1I133t3\u002F7N6O7b95Q1rWr7E0njKab2UD2aFRFfM8O2RBPV+wL6O\u002FqfjuiOyd263AwJZjLXqFKvdL\u002FS9lepQJltTj03WLkG49Mf\u002F02lXLI6EAZnvMOWSpIcu69c6s\u002F\u002FbNfrH7605\u002F183vxolPBb6c3a02599DqdPTVkUPkdVpmzl4TJVrpnuFLJFz0kOfcut0+i2yWzNPz6qfn5\u002FQ9W+T1MNk\u002FXJnUz\u002F\u002FkFzVD+Gb6yx8O9J6MRnuSx\u002FsFipT+ePnM8Gj3Rx86il6lJwHBRV\u002FRgwI4zbO56wZk7PTuoQJasAFZluWW4aZvbTYUq92xuzKgngPD0FkHuhZe4WAfTX\u002F5LsPqIDybjNF1AY0iuun4xrOzWvMEok2\u002FS5aUnp4Xneo5yevo+dYO2J3uNvEWKLwVUcejvbHoh8ZBV8yrMU9Ja3oauCVISsroEVkLNmt0fL9zPvdmb8gq3h5nrbXvkZOheViWyn0FH8iCkzu11abP6Xd0mbGH1dgFL8Dd2nIGdxRc2tDRqN+BXJlpNoL9QJPh3+a4O50ieEiPkSvYbSNdr5sanZESiXY5fQVJ9hTg25mTtQSh5omtaWPpx4lut6bGtLNxkAkvG6fZVRvLn+r21bkeIu\u002F2YrCrnOoHlWXJ7HM2Zch0MlLCcqCg5MHGpoXn0xxpmG4CXD0DP7O89KExwzJz0N6QPW6J\u002Fd0jcv5grx8MqF8rIvbhhx+O13HhwsWmobXT4WFsQplktJhNFjGatC4ADsYQ6cRqNqNYGwsjIo15gOZ7dWaYVFKLt1UaYzPV7YkQL5GOH\u002F\u002FooxakI3UjrPql5ymQ9bxdkYUzp08NeBFxAsxF0S+XRnS9qJta1euloaVkpfkwkZIAQidF5sAW5TSAplpkDCeiZQHn4J3mcfxYKc2Y3kISOBkAB3dgYcpAFOXQkcBWu9Xu3k0xVJ\u002FeGsfAQFvlKGVlXu5p3D33SQw1dY3tVt\u002Ffhqg5vKBUfDzXRp5EpTmJSky6MBqtG0sMvT2aKQPQG\u002FqzP\u002FxhaPzFJ59Vt1hqtTFcv3Z59dGHH63+\u002FBc\u002Fi86iLe38L0Wpw4yXA6YYaeU8+1JuTwMaJ9ozcPINkbPqCjPKwCPh2BtofedcvZYzLlejpRrXt985M6BUmQ3FpPxIVEEJ0WvV+FKYjxsrzbFLxCxD8LT1d9DQyUqDEOQPf\u002Fik9bk6JQHffPd9NH6aM5GSKMKgN7xIgBrbW\u002FXFtiboJ5JzuT7aogf4QtcKp8na7GfTluN\u002FKQpKz8ZUXQzefvfd1aHW\u002FYvvLqSACaAMz97KYG6szl+40BgJf+uR8NuMKyX+RmlrdaKHAm2yEUv0tvFQDNFvyaqkjDhzNFprwgDN5rukYQv4U7oU2gh739FFpNDfKVjC7cvvgKDUre+U6+jo1hyPjtJNqXDmcBGFsShBJF4cL4prMQBFrhoXR2yiAhnNUbqe2RfgRrHT+Q1pXozXYmDi0+jOeXPfubTncYA5NxQc8CD6456pr5FhqdQlAtK9yXxjjiTxD2XeRrqMmRSr5zlE4migZntOyI1quZVcvPfeu313HHvOWBEL8vU0ekqdy4rsq1RKVEWXBq1NlXC9EzD\u002F9I+fBWo4kG2syzCertf2p5Uk\u002FMnPfhz\u002FVlqSA0l5Pw4Y\u002Fvt\u002F\u002F3\u002FPvK5fuzIncDq592c\u002F\u002Fah6453V1sbrdU7Z0WEwOwKZytF6+NBddB1f662M3\u002FbHQ1VarJ49rBSj+exMyYvMvjyyrfR4afB49kglD+pvb9+1uUwkvc2GRfBFyGxuRkfZNjwtg2CtAXV1x6LW61Kq1X4\u002FqGzrWXKknnpXf3ucc2rdGFwZJXTOFPYd2G\u002F9o+XOxveykp4XAZ8NznO8ZIz+hiYHi6RzQoA568cA9cl4N1DVmHQD2h6Y3qz0aHvy+zwAMGV\u002FXa9eeEfODiAAEBiXCPy0PWP5uw9D+6w1fpbBey3deP1iwYN07\u002FFqmt9861w0qfd0O32X\u002FufxWjQVdFjuuWv11RffrD77+sLqSn3w72cT3mrz\u002FI9\u002F8k6IY9\u002FqQYDrYKB+I77afySDnhO0lLBEwB5PT3DY7btJLaTztZ3d3\u002FkSn0fbteqqTyV37XUoeqwE0UZ\u002FdBQE4lQBETbxbtTJgQypZ3UIzLM6uah9bdAFAACseMs14fmr6aSNzX2rn\u002F\u002FVX9XlpW5CBY3087+ao\u002FHVV79bnb9+b\u002FWLv\u002Fyr1T\u002F9q38Zr7Wp+uGD1Ynjh+oLf2T1q\u002F\u002F8H1e\u002F\u002FfVvKiP9JrvXnol0wlo66HhngRw9dmLGhDmstywkGqGysSoBPZRckAWyzll5\u002F4MPVj\u002F92c\u002FSn+23eKVDnBB7pfk6+OvypUuri+k8ztZGhwfZ5wEUbcazNueyaeh39MSR1bvv\u002F3j1sz\u002F9p1NieeFSrXw55jv2rt44dRQZplyCXdRb32bkrTbIdA6Ahaftw7CJmfOrReeB6NPoC2JVJ55O2Pak+UQrjtLDaB9xKh09ufr5zwPrfe6Pn34eP+1Z\u002Fat\u002F8V9P6ey19hxYh2mnF8+rFRctnxpoD+wL\u002F\u002FIB6V6gThceAF1bYJ3IZJKO7NQKc5EzmR8bpkXWRWLpumFln48e+IOjy8bQJWRN5p6dOdbG310731vdfK3N2DHc6Pquhx\u002FskzOKpwOwdRaSxVgClK5DazqcfuT8AcFLKcpSe70z\u002FlJrLdCyLV359JEAWutMP7TeDhhjxzhL+Ma48T+7bQ1kGdhAWa9DOee6F9HYaDFZ1\u002FjjKV0UL7EQdBzbJBJvnrAP+jW8\u002Fl\u002F0i\u002Ft6lpJSf6PzdybjXuixXkDyeWsP6G5lJ+i6XXR\u002FDmEqY3Fu4ln7Ujxv05vZ7QjQKLJP\u002FbcvXclWOa8A3\u002FnPKPA4+yGbYSwq31VlrJehybLER8lpmRtlz5sF2dibPUXYBd52PikjE49tf6IyId7pvhvRXUcdPHqgLNaTdJZMPn6FX\u002FHQ85iBzs2Y1ZHPfVuv+OVF2O1Fe9E45pwE8\u002F+hXj8YUP\u002Fdb38\u002FdZITjQgU81gG4Pb9wPqBiXbeCBjy2m0GfOfdgF5RnExKwOtmyuJSDG5JGIdS2H0BBQsTBAb6XXqSoHz5xVcZTsc374\u002FxHGJ0NWLpl14P94AfECDyJF1KQaltBOLu1U\u002F7449DxT2DQnnZZhKAQi0eqCL6qnQFuCfg0tcY24lynACOgvSoMamDA5Aw+OOizdKumPlgnjbv\u002FXkMwmMV9b596\u002F4Iss0oDx7YrFj7wwAoRfUi40uP+EreZiMVA00gtQHcv99BJQxqxjWFubUregQ7Wk4kPAO02bh5izrrmNvZc+\u002FNoUY3A+KER23blKA0zqO1NMsaT5RmPPLkwqEkR48fGyBEeT3SxSBh4snvnoOOtDVcvEr1foC9l4jZ+fPftUn3VrTZEXC\u002FMptyumUKf08GSJ35kkIHQqb9XfN7VikMgUuGR4HYZCsCdKcoOeXBsbIWR+oQYgyUjYjrrEN03Wxd7Ki\u002FVRr5zp2lfv2nP\u002FlodebU6UlHPX1MUCNo6zMnWraeNjQeqWewetXfffpZ0blvU\u002FZ10XnlUF68eLFSnIxjisLJp9ouUXxAotSoyKOymqz17HEQhRMFOVRWiCKhGICVBWCnaIxgUHvrkzDjUXPDWxwe\u002F3mpm\u002FOXLuhP\u002Fu4SmZzl8xxD859ISYpmwHV0X2rUU3g+aqo9yx0pIzfxXfQI6BjVNs\u002FvL42R4+e9JZLhZ1GXNr01FgpGtF1Uypw4LAwBJ9oaAwHKorwm+xNPTZQ\u002FgWWMNinb6pJFwsmKUi6vjTaOU+bGObee99AF79u4NaMfB5IhlFLmyDC+s+O\u002F4WhhSh7XU6yvHQ2otn632m\u002FyXWt5NCM5dO6+PTZA5uTcfUXo36+8SzvI7\u002FtcXYvqPGGt8d5HH\u002F0oMPPeyPWFSxcDgafnYCH3PR843FH9p83Jx18\u002FPiD08NHKxopgkrWJbne\u002FvQE1oBjQoMB3Va+4FoDRO1mG6XEblEW8OXPoaa0EIZ69SFbisQe16dMZCjgBDqb1XvdbIlfJSMADeE1LFAG6V8ndtnTncm7Fl998VTbrzpR8mTQZ0n8aH+3a1Tr2H2sYN0yUCg9yrEXEgUlgY9LD6QcvgEqQQm3qRCF7T2S8u6TD23+SQRq+YKTScwzwAsKsHcYlbzba5xznFFmP\u002FV0LVO6vj7us181rF6vjriuGfSmvnVidCwDi3EvffzVZuv1tUERjvHL+wuXV7z\u002F+YnXpxt3qvt9e\u002FTJw+2d\u002F\u002Fqdl3U7W0vdam4c\u002FXX36yb8rcHN7Nu+98ebJAV4GDORw7AVvlCGdKlr+sD0KTkf+m7\u002F523hjbfWnP\u002FvJ6tyHHybDgenkmbiq37WHgqOqZp\u002F+tCYYBkXJIV51UBnZfdpcQ\u002F3pkUrwJqMcwCmLoj\u002FUk4z2vub6xlvvrq48+Tibs2f181\u002F+xeov\u002F9l\u002FFRh6vvp9QRXBg5vX9q3+7m9u55h25kN8gic9l+w76O+Tz76YzNPx9ClgeSCdg\u002FYji43bdeuBlYc2wsdrHKj3338\u002FW3a6+V6szPDm6BwAhA0zH4frkRM8db+AWCp3AO6t2+mbyod0F3v3nXeTkY8qx\u002FlZG3N\u002F2v6CN7ou21S24\u002FKVi6tvK3e51j4AzrFoPbrJwJFTmzNtypvSOBouepFj3cj2FgDzRQ\u002Fsrw2l7ltvtnZvnnpreBPwuptef3jv0erKtZud4Csb8tPpCHOp7i+\u002F\u002Ft0fVh+9dy4nfTkThay82JHdbRKwA70E0OJhgS38zq4mbtGXPKljr3NHX0DVWkEwciYA86x9FjZFp81Wm7OBNOnpg2RKoGB3RCPv+ACwRkMZNNkpemtwiLLSMIMxLEGSiNtrIv0jTcQluWzcbAQduHSNCkj389T2N87Jjo3+7M1eHLOpmn11PZUuU7nYBrJdVi9ZWzZP1lXt0FLG4ZR0f7N21Ky5cAw2O1siSc9mdd+A+tp25R\u002FKWpYsnDMUYB1y4UqWwt+0SUyDtNaNkU4JJJsrOsMJsnNNruhFZYJ9kRObPp1wi3ai2GwaXhkb1TMA+s10hU5fO2sgMHLX9RSm7PzGpg5X6S7rkN3VlcvcH5dxR0u051QYA73DDsOJ+P1JeADv6Tiz5cjTL65jo5aAw8Iv8Aa7vyNaLPbbnOhA6LQxluK0GmPH+sF8trIjSl\u002FQ0x6S7eHZH+r1gwF1hpuXPgAuoomEW1aMZiFHQef9AtsWW63mo0dtvGyBRLmvFJk1YWlT1wIHCK08xvU2nlIEgCgP+ac\u002Fe2\u002FSs5TY5599OUz31plTGdOlLaJ08dNnlcwwLBH5ZPWjgPOzD5a6cxFDX9pAKb1R\u002FzeRYDWjPRdgORTol3qfVoRzsFAGrPFhiGOBCDt+lYSIRBNO7aDmVNGMqjnwlhkH5Rn3UjgOLHm50RHNGQuR0iUtpwQkAKv+OcYOPw8jbKULgxrRbxFk6RWAm8c8dM2zE2QXDdM9BiOJLOsmsTvg+P4HH6321hFDPbfMxd02Af3qNx8Xobg1YORg83O\u002FGzeuT19qnjCnBgPaEwAsYkobroDDPdaCIHq\u002FxRUxuHTp+urjP3wxipnCEqXXN1qd8hs5Yu+dOxdgupmCyItOUE69caKa\u002FdPDvzZoEmqt3rbveBpNX+vaX3hEzyhtbSNrXm06pBraN7pnKcvGIsrFSEnPb2RIpagpQJHLJw8yVnvaC1C7LdFMHvrxQM3r1eACFk7Hu9uaffbF16tvMjLW5siRpQ5Vx54wTnxHAW8b50U5j3Uk8LFIymXpB6yPNyO0\u002F2B1m3nbeBU4AcTU0bsOKKIQl7q95KD1gmWs+whyc\u002FB3L8picI5f55pFidN1nAGG1T1pCKDYFzC9UV0qXmdsBsx3v6lBDIQUv2o+y4bRpdd7NIoGXp47T25MlKWhLd1rlqghZTxpxuYwctn9KaPpGtE9KTBG0Mv70q6i6njTCbYcYMZDtH4cxa4fw5hscIQoS3xG0RuJ8SxOzo5kvZNhc75noyTQ334MRkUN9oP+hu6c6JO15wNqAACGYsDsK9oBverkT2bgdTP6+ONPW\u002FNPcvTuJ6u1Mn3\u002FnZ66vT7sH6z+\u002FM\u002F\u002FbGh269b1ymR+M2DpTKeA\u002FqTymPu3rva3yu5Knz94XOS+iDY+Vp+t3vnJw7sBPCeeBlLSUfsS4CQkqc2pyYgzmg4fUpogo4ZfdAZ51ngZz9tFDO\u002Fef1I0rJrlxrZRiHXzZU5m9HeQTb+MYVUvv6\u002F7vMiA6CLDeRnjEC2t2\u002Fb+JrIok2ctlD8shhDg6OfoOzxpHfs8HpmuLt1vcZIWHnue3FiT9bIYQIFIoC98DQRZh7i2712TjtYxCe3JJD7dWYcsvGwjlggZGdjeuPZ2L+P03uPSzTr17Nx9aHV2rYh+oFNm7dscuzvpyZeVpPWhKW\u002F8\u002FKtvJ2vwk5\u002F8ePVX\u002F+K\u002FW\u002F2Tv\u002FjLNiF3rsOdm7PJ8k765uL58xPsAWBfBrxuRWsZIBFE+ll5HX37MNvzv\u002FzP\u002F2tBhSurP3z86\u002FR+JYGl9T88+25O3utRqXJGUez0m7JLJ7PqlIWXxnlq7iLqnGy0kTFNwovW1fWq35\u002FYN1Qw4GgnHXMqHlRmt\u002FdoDl41+afee291qzW73kbDY21M\u002FuDHZ1fXGnuJyjoPPVhdLCMNHLJBJ9NVZ989Owe8CVp99dXXOSRfFgG\u002FOo4MTS+TwkaOTUwPK1FqaYsMJoPJ5VuVVuFhpRr\u002F\u002Fj\u002F8h9mEiv54AC+yh6\u002FnfOIR+8DYYZvoOWVHXqs\u002F\u002FalTqw8+\u002FGD1i1\u002F8SQD9JzMWiulyNv7TMrWfFehgey+cvzAZ6cfNtaX++xdIswXsFl3h0736J7U3kXXAiX4i+wNuW9fXs6v2J3GMj792ssDbanX18qUcla\u002FKmJ2uLv7d7O\u002F+yfgKspjLSxHwngcMjn2K\u002F5RoOIFZFHjRscBTVwHO0Y29X3RP9jMayFjOGhtkDq61gA9kKjiu7Ks1B8wp4Vfac2RQKYzoN5vEnrnXluxYP5iFPW8gAyIFt0b\u002F9ixAceq4G6fabDaVbRdUYy\u002FYCkDTutHhbDKdKkAnALMc0rQ4zO45n2ss5v28+XLk0Nz6AunGo06v0TSnrst42A9iTF7KguGZCbw01wWEyyI0N7RpvOyB5085pzk0TvMfHuyZnidouRauEaSxLpyEbdlQG+\u002FHccmhpUM4UZx7GEfb5iIBlRgH1OGhnq\u002FBgTHeL4tq7I+TayeQ70lvhaCmpS4bPu004wuOlIg93CLYZi9BQ+6Z3kPr9rYViNy2rU3R6QZjEHh82bhfNiZ0ViKrNSc9YHzKrqduXqbJzax+18Mc7G6D730AHmf4ue\u002F9bZpbIOoP8PrBgLqjegEVdaQUt37gABsG2KqFIiCExUJdTviu5RljYqlz7z0Yr14kzkaZUoqB7n171QguoAcAOn78aJE00VxdFQJKbfDClLotnHnrzMKYqU9pbMDgQQB7jEsCxGM8d\u002Fa9xvfKy8Xofe2MGVYdRIEPI2\u002F3K\u002Frk2S28hfWl\u002FGZHqRpzsbAEZm\u002FMYLOfWrA54KEFBgYZy4cByo2iCgyQyDDv70glH0C6DgXmvbERGI4hp+9wmEff2d3NFQCyUUz0WVTI85+q96vd2a5dRd1iPgp9vMEYiQ64U0SDkgW0tUPD+CKk++skcLWOFyL2BPtBkei7AdjIm\u002FItlRqDiSpI9yj2Pbh+aObtMJGDXbPeB9VFGwtNPIAyKlFOvNSHAePLl6+vvusZxkzJPEtwnLimfdzh9gI8KfpJAe0t2koA3npbWVQdNxr36+0tAL6cEqrH9JkzpyblBoRKOx5sPlpeZYEnXXc\u002FZ02NLGEE0PHAa4euD1B4vWiTqNbjxqUv8b6M7OHq07YHHEMy007uy+8vdoT9F6uvvvymetFb8VaR\u002FKJAyfGMPTwc7fL4S73rMOR0S8pZKl7k6VkRVNEnzoWuJTYFSuOTzucBOuAJHThNPHs0o3CN2a9QtW\u002Fpr+X3fnbNgOKE3n8U7mx2io\u002FJ1Pyt9+cAJZ\u002Ftw9Zh2lS5r6WZZ8VD3WsAGCWYrFGmFNwolubRref+YyhwfGs+pRINiq42V0oWeJtrDa97Us4zlmTb\u002FAB+kdhnu\u002F0usseJKlpaecKe3uNELdGjJcOwdOxRfqOXsUALRS67GeF7tnsYh84iAJYNv2TYBkA8xXhw8m30tenzfvJIzxiHddKhgZx7T3SEMwDwvwysAyKiJI5Sx+fS+05SPhGgsvmQc2+Oh9uAKFLKEbh69dLqaWvvlM6KN0beHhbtFJnU2eRgB7HsT6YPVkNrs+P2nUXEM7TTLzr6ibw4FfXOc2Vah9ILS4pclD3pTSa0oNXKL6PTl9r27a2V7NxTzkC6xJ4IrWb395kT6NC4HjXfl2vpl+YGMI4DDZimd2kvUS0ZkbXqs\u002FEE2rXK3YvTkF6pDAaYWKJcXRsIVVfLmBLx9dbZguAxehi3MuGcqLXuB6K4Lx06B574THodiFf2MrzRwjLceJRD6lMAg3IZX\u002Fv39fmuv3TxQry2bEyUPXnr7XcDy0W5qle+WTT1q2+qOS8S\u002FuGPPlz987\u002F+V6sPqi93eNmvf\u002FN3BQd+VzbtcjKZc929ne7LUXmUEX4S\u002F+iSY4\u002FUevtfZO6UjehWcaOD7mzMPBaAVrLySaVST7v+TOUVMcvQkGNJ92jfpn3lAhj6U7Qk3wDey2g\u002F4MR7wMaO9ESnTe9LaPa\u002FVrajE7L31\u002F7u3E9yciLgtSLdTiB\u002F6713lozM3poMvN3JoEf+ec7jw3E8lXMBZqJ5dNnxYzJKa2Uc3l\u002F99E9+Xu369QGNnJDblZZcvHhpADtdRMfsMo7mqM3je33mcIGOL74E8Nt43X31rgbEHqBRNlfZCydJxxIlkw6j0yb31NtvR\u002FMfVf\u002F\u002F0cgJ\u002FfN9evOLL75Y\u002FfGPH3eq8KcD0D1Ty05OWeIzay\u002Fry0HfE22dlkoHAeT0CU+CnNkojilF3QFqsu88gPOd3v3tl+cny\u002FNGHXpO52icOtNBfIfaS5WSu55uaXopuUpdOuMiQ9ccK6vMgX8R\u002F9vEjFfdT9kGnl94lDPL1hZ9zQZaZTw7Qb3mQFfh3YlKt35sq31obJ61ftKeGmDSnjLHTXfb0aEzlnh7nAHPLTji56cCH\u002FRyX9YPjplhwxLdDyZaZJd8dM9e5HTseb+z93gLLQUFleDS12NbRj8vn3GN53jGZEkEP7qXL\u002FrD\u002FXSmogsBbvegLwBqmGtnz4GJdpU92R7tGtwEGOmlpbStYEu08BJ9do9Z6MZK\u002FukH+trz1da\u002FaCP+zINMuCbb7CXgsjiIy1kwo3PSZehHd+7bXxAvm\u002F14Pce6ZysxmY4+\u002FV1QcHtOu3vJ6HH0rWUabrUrOm\u002FvNOBlM2r2qutVCJB3+svYh0cnaLPItnHBQdScrAXtBrtZB+su4CbIhH7uocri7t1k5mHBhn1setR1b0zQpwW5TMRv6BCJh05s0Zbzgwb\u002F2NeyCv\u002FYu\u002FR5Am9w\u002F1BbFeCOqLsovAynNJpSGIbZ5DA08IuRAAlEohAwH29kQHpMKrJrw6gomC4wFDzBkurzvk4LPGGG2PNu3ryecjnWBo\u002FDGbM8pKeLQgUUDxwEDjIcjQEYl1qzcUd0yQZU3jmQAyQdLbrLm\u002FqH0pBaOM4Ytfervi0joByCgrPBkceK+QEDqUyAAbiw4LqEAL5d0mKrO6xkv2sZYfXs+N9z1EoDtzS7TiD+vnhq6OLvKaIM+a7dMU1jZVAwmCixWrWpJQNKY+6vv\u002Fm+LEWdbqqXvNBmIOmi118\u002FOvWF6sfVBN64Wbu3AMOTIjrrWZFnbd57VO2utCowxBmRsuZsqPmjLEeJNF4750VkfpxCvy71WYSTIDEyQLYuHvoo3wvIOxb7aRFJ0YkLF6\u002Fm6OzLCHw4a6yf\u002FaEjB2ux92lrdy0QfHuyKIeqSd+941i0qHwoGulK8VoRM4JsExTALtKBjsoUbj67NfWre8rsgCb7msOJU6dLrRd9i8++\u002FPVvpxbvm\u002FPfrz755NPJXnA0UidFz+pJXIoaKEkPNs+Erf\u002FUtC0t9vysDjHg93L3rD9e1U1oSd8uNYUA4IDT7vFKjvt8yiq6pU+7B\u002FBL4YoQ94T4zOIDwaNler7\u002FtFPbHh\u002FYZDdOW0CueHm3wRvu8eq6ec6imgE0hmHAWRNgiObe3Z\u002FMMQz+69Pdo1fKxbWU2yD9niA6TZH52xjYUTw+EWXicZGYjTb7UprkdEkdtueAckt5iqpdr\u002F52o\u002F7kazmwy+c4PXVoKIXsYTpAbGuc5MQ8toAPBUfZ+yI\u002FgL\u002FaQG07ybENywtQv58uSX7ieYpUX3\u002F8rHTqYZsO8QZ+sQAcqitl6vbvbXNfvPrRR++XVZIqf7J6771zc3aDSJk9KlLtou8nTrTpOjqJFn4WMKHRXz9+bGrYjeVE+ym0btQ29XGK3kbA7fWGbi9d1Q8d2NK6hlvalJTBznGRddt3EK2WiLQIDHoBLodEhdSI7894R9dbRdUfFm1+kUxyasc5bl3oDzr0dnsz6Eyf35e+EsCwLBNF73m4IoKOHrTKourWd1v8A0CrSQVIlogcXZ2xpAvTqcp2NnLY\u002FcxRA2oEVh4ks4szIOLIgYvpfCmu9moek9mZ+QnU0OXB7fiDvqRT0RM\u002FApgtWoaw6Hrr\u002FKBsxI1rlyovcUBMgZY2wYuIX7qQ7ooW127V27vPKwN56+1TBSOuV7LyqzZa\u002Ft10j1EqCQwq9WHYZ6ObMfVspzfKcOggw95s9vzn6QuA7s32Kr311qn461Z9ydtjUyRNwOZE2Tl7DWaKNEBz14udbeIUK12avtgvml9yhT7k5UVZhD3tKToQML57t3bCZUk2d5eFTPdvT9c9id\u002F+9re\u002FTvctIPRRuvfhk+pgW38bGM+cOt7G+TOhEray1Lyv5EkrUq\u002FXs3H7Yvp3ipJzwoBse4vezXbdKCD2KFvIPliR62UqAFBO7vcXzheU+DxZKUiSzbQ25MxGbrJLb8qEAC54QokfOdoTPzeB1d1blZ1c\u002FmTq5b\u002F48ovVd999UyexK8ODFBqexE979wT0+jxbN5m0dI1zQvBvb3fvvg8jUjb0SzopurkGXclx\u002FyYzleFkx25ee7B60Hka57+\u002FVOvSN9qP8JOJsMdq2ZOnlcPcKsDTPjYBpOyQSLagDz50J7wFQwiU4EOACS8uvJe97VlzUB2A1rPJBSdOlFjAsMGtdqSvOGqJRzqrenVr2X3Rryf1fXFCRo\u002F2M11qDdgM9xzQ1oB1anPQU1i4Tn\u002FJWmOkj9FObTkb7mV8y74gG0lFbr2XnIyN9x65VqrbmPH9q\u002FfX2v8muLJ81vjMrblma\u002FAnBxnABta98LKSVrwwEe3GpCZd1h3cVAnwDwDTZ+hscs1OBT77XbZ7ibRrFw3QLg7Ajq6De2T74DSYhOzDbZucIViucU8G78lS+eA0VGB99sekK9kxdIy9ulfBDjJrfOkOJUsCHhF0+qRrwjH\u002FNVd2lv21Jw\u002F+mWh4391PCVZDnGfr5AM\u002FCjRuW8vOpMPRyHjNazLXOTNsFzmxv05m\u002Fvad7GlnJehcxOng+LJdeM5iob\u002F1YmcX2mxlcobs\u002F+h\u002FmtUP83q7DT5KBzAsxQ5EH39dXVDKvd\u002FVHEpnIcq9DgZidBEPSJG+47kSBkKNyaUx51Ci3gOSLDBv50FCDBh++NEH07VETbhUkxrF69dvjCCIgjqAYw8idj8MqM7q6dNbpe2+qGXSm0PgG9W+ffP1dwOyT1amobWaji8izEpmMAbFAywZP+\u002F2URvI1EkPIMJNjXUUanNh7O8U4cEwLKS+miJfFlRXmiedvEcBM5rD+PPxmGLowL6INGUA2jSi3k4Kc9ox9XcpoUQ1OvX3GHctIYw\u002FRylgugbZc+ornZGwSfdRmziuXL1RerU67gy8zVxobff2rjz\u002Fhwn7jordnhYdBFwe3n4Q6NzTHPaWGqrtYveyWY8z8lY9jw9tHitlX8o1cKsXujaLBw8erZzn5OqXv\u002Fwn\u002Fb47Q3SxdV88eUKmhvxaXQGeBLoAlpeVPZxvFlKsah3V6XPYnBJ7vPrir7++tTr\u002FXZtb4yGR96MJif0DhEXve2kzwEz3lwMi59FbGkvN8uPW12mw2xqHDaDHKnfZHZi5Fq\u002F9\u002Fo9\u002FXH17\u002FuKUBwAn2mPuLEoBOFMAwP6eIlyETdnLbHTOoZPt0BKMwqOQRDjwJqUwijSeFKkGcClf6yh6RHExEBzHMRSsVTzo\u002FRhjvkZhxz\u002FJdfJBLfSX7r1Evvu9P\u002FjZRzlso2jjKQYW2E0kZgyjmFN2FL2fKUZrAGjjO4Zxs6PJXz22331OJICSWSIyoxWTkjFSPWOiEfGThxjXOItdyyC4b+80N4oLLpRlET1jAL16MwW5rSwVWcaaai919jHXuaZ\u002FGFGbsHzeeJptvFDUpLZzIvNSxZSoDcU6D623AQx4F8m53Zo+etSatIaHc\u002FTUvEp5cqyNXaREGY5Wq1qPHjt6cvQRJ\u002F5KkXIlVxuVlwA5J4uq29zt1F7t1NSOO7hMlkW3A1FfhuNOEVot25x2axOnUpRZt+QUXQ5WC79rjw3mOb0Zu81kVEs6Gba792+N8kZvRnR30e7dO0Xvq9PNgh+odVx+y+rSkcuT5dGVqdULeMIM6MNwiQofm43VESujt6Rh1aRHoCKA6YrGsZ4uBObQFd\u002Fi6e2Vl9BRUvzALI2I1kD6\u002FNb87hfxvZV82qjH2Z7oY3pOgMP6OrxFtwQBgtFJ3WfWPX1CN+9YX7KeDNemYENrDKQ4PI4NwNvkjKO9GW\u002FYKH+vSOWdW1eicSVsb7YZPf3KEbqXDnu5+W0b2wJzRU5ftF7XAvQ3Z+M4ff2w8SiJs1G87OureSrvEV1Xg\u002F+y77ujx2QzC16oExcttpkxsV7dL9Byq+wIGVXayKHbE8sfjQeUPQAlzWhoRr\u002FiUW05AQOGGI8JSpnXzvhvM8dUxPeb7y6na1er93K8tDm8cv3K2AFdYR6KIOcJvLxvY1\u002F8FLh\u002F+CAg\u002F+jw6sDhyi9L5gPkonj4\u002FOFmjl9y4NmkjkwkThP04ti8e\u002FZs7\u002FvLIt6u0x5QUwER9y9\u002F8+VkkIB088QXeHUrMMYu+6R1Ud7z8lZOq9aV319bHfrdFwOsHpYVEtC5XzZJhprMCmpNq84+z3lTxsauATnjyDUOmYjpkvWKXlMm0ejHOY\u002Ff6P39ATfBnecRzNx2J1ebsi0FdZKu1rm9JBcujQ7Q4cnp507B3le2Qsmm0qK1+IPd7DHjLLQc2c3kKc7eXoQ34rVG6Zb4ZDZJdh0AtjdbAngvGSiOap1rmgt5EFzkRLmPPQccNgCXbnmlwcbuTpYA8XvGgLa+z6bePA52Am5Y8IwyDMEMTSk4QrJ7RYNdg2eTw\u002FVnBSj6nR1xCjjc4UWGAVWgHv7ZlXxuPOUM+GuToW7nJ0B+cRx1MTMOemv0dXbO+sMNiefowtljYdxdMwEvZSCtgZaodA6nRUDJ2sqGvkRY+qLx4iHrac38B\u002FDvZvfQuZ+XA9qWqL22uRzHtdarx8VnrxyL1vpxuKMJznPI0dCse0xQKd3hfsat9fFE2qOnjaBd0KTTa3SaNduuE1YnE2cr\u002FE1Wk8MJUNNH5k2ml71+Ret9JiUwUtV8zOOlzexRMvYe2qHJ0oPf\u002FJXPLOOcRzdWvEBHe\u002Fl5AerGwlVcnBvz+aFePxhQf+\u002F9Wqpd7mTHlPt4ew3YglMKwK0UyRToRzwRAIzmd4tIwBFmgEaE83IPCoaXz+vHhNNZosmLtInUUFZKSiyIWvMFrCiH2ZPXX8Q1QQcSbObatsZo36gG9ZPVv\u002F7X\u002F\u002F0oQ88jrJsbiweIKSgv0cwZd4b+WZtmRsFRSAkbQ6VlpM4PmN6GkZcbAfd+Mfc7dXVQS3vocJtYG7s6umcJ1t5CbnuzBKJ9hF40V63pS0KLwTPqxrqegnva7wSTIiAks94xA0baDFxjgEUoUnhdT+ClNYksULOr02FOn3599aMfH1q9efp+0erPO7nv9nSp0FXDoRd7S4FvbrSTOXIDbebeA1JK0StQtNR0LU7TrQCODapPGi\u002FADShSJocPO92z0\u002FOOH1n99CcfNC\u002FRBzX8OUoJrtTsUiO2WW1mp\u002FBlyLRPogSvX7\u002FeHD37aYdL7F39+MP3Az+bq++++242e12v+8uF1obxVtt\u002F9uy52Vy4t6JO3veBHKed8cfO1uFlN3qtGvY9PVe7uB0pREr5ywvfr77pEK7Pv\u002Fx6oumvB97xDY\u002FaPNOWCSDnKOBeXaK1cbrrnjYAckbQG9\u002F5Mg7KlgIEGK0BIEL7UHZdOjxr3dwTUPL+GK7U\u002F1wwvL3wN2JTXBTfRJ76bk19uVzkddKN3aO7zcf9I5rNiE\u002FZSzcAlva1Fgf2HxpQJSPkCRQ0QOZ+87PvjW14pwtAcOZwovo9q6HMmA2RMTY2MH\u002FmF8CkmF90NKF74RV\u002FZxDMw7godVmuuVPrmB4d5cW2oQOguYCOPtG17kOpi8A4GGRvxl\u002FXCuVyskqUn2O973e4zYPKmF4ErJe08bIPAcmVdh2p\u002FtcyNNHWqMh2x5c\u002FKIuznDTcXphqG69fvzlybt\u002FMzcC5GuX\u002F\u002FJ\u002F\u002FvwHp77\u002F\u002Fo+Grt99+d4IDt9uw\u002FOtf\u002F7Z13lj9xS9\u002FWZvQD\u002Fr5+er7b79enQ\u002F8nKj0Tos4zrZNxBvxckwV7+yrhrwsVP21lV9o37itEhVBhLs32gCafdF9xWZRG25tquqd7p2uiZcOB9BOtFfmyoGOhk\u002FfWT1yhA\u002F295xdAYs3yxDZDEifOplSd6N9gZXOQx5AIWK1J5rYJL8+wYIhS7TGD61nhjbOGeBBeTE1ggEtyNDpfs7IekCVw8Zwknl6Gd\u002FvTU\u002FNorfc1lNWZLMTHzkIIsei9yLOLesAJg8UZRWpVJZyIDm1Ie+JWuaigBvTNcXmw4erS0ZV5Pqdd9+f0sZHD0+tvvy68x9ixidPKou7+G2guBOLG8v6k06Z3h5nBtCALI4EHTyg6UUlFLJerVdxiEpQOrk0cH6o0gmBhWPHjo9uvlnzgoedlXH\u002FQRvthdBbl6d97kEdhvY0p30FWNKOQxfeEiA1GxGTA04KxaWWfz0aMPocRoff\u002FPq3HwdyL88mWfWpN9K5X3z9ZaBwbyUcb46sO+XzWevHydhWuy8dyh6W2d174P5q9\u002F66y2xe7bnWKz3S\u002FekRembK0dKHYxfpv\u002FjFF4BsrSYwEBgVKdYd6ZPPPl19+dVXQzOfpzfQU6aLfQI+R9f0Xo\u002FrlR6MbrJX18tmrK19PzyOZ+gfGbGDbf70XXZYJpHTh+d0S2PH3cPBOEvQIh1Az0Qz+kI22N89jT593hkgdMhkKwLnE6QKoI8znhNk7lmkyk7aaFuLyrvJLsf6ncpybCzdn\u002FOlpHJ\u002FTnZGsSVZslSeAUj2bu\u002FRI97pXo1L1humB\u002FB0+GEzYQ9lN0+2x0PJ2LSljF6i4kMvfJyMsJHgf2+\u002FoiP91y+9nPw6P\u002FUs62DNZFzMHe3paBhFxBWgAxgN0Odda1yiucYqg6uKgN0cOjX\u002FJVCpJKpGGMZiU37rkqfd\u002FXL6s1si7c4cEGicsgzZhuaIXzgF01WpsfXjlI7IBo+T0nvs+UTZXwHieZ99bIGePy\u002F7Eq\u002FYX+PlXhOEaE39fdY2+7nYm2VO6P6itCIeWyoNyCd6LjRlf\u002FtAjkH6P0dI3TknkH3aXVBhgHQkMjdZ5Kf9TQaWblHtMHuRIjhMyXmZbES0Lew2\u002FKMUZmcb+tFTMIU9Zhe3d5otehsze4Wvra3nWZf+NDLKiZRt2rb2LB1oL5D9CcqJBG0FoJLd\u002FsMjzvWwDotdXd5DJ9Ri23+oF0v7g7xsuhGNwrEiegARBeC98RhT\u002FqJSvFlMi0DSP9PJpN+BcdGPhwFNkWleJGBOEblXmnkIj2l1crHTHOPrwSxt4RqR1LWU+JM6lly\u002FeaXPpxCKykjJq0X99NMv6w6Rgi5iox7wtYz86p26LgQigXCGlwcpoq6GlJfdGs8i7N1Wi7HmgCEpEcBNGY2OIzbD6j4zgh1jiIBOxCDFa7wv1lv0DC7grovAoSJTur+o5d7RJsqWO0ZJgWLebBAPUESacaDARmFjqwbDS7fjGbN4nxClGoehRSHuVoKytv3p1HvafAOEant24u6hKU\u002Fx\u002FPc\u002FfG8M\u002FoDQ9Ke5H61vNKZ3PZCO7gwBI209HHBEiWNcXWB2HRc9ibO7N8gHd3iOyMWJ10+XtchR+OiD5r1WRD8noWjSg9roMficnS8\u002F\u002F7Lo4ZVOH633espfr\u002Fl3Tp\u002FKcLmulnw9ayOFTkHyeNXUXq2zzMsX1wP6B+r6cGpqMV+rLeXhFPfDolf3GuPNAMztHItb3ePq1etjQJ+0niRHTeQy5yK3lRi8DHATJQ7TeuvAKTwdOLK55upkZxgQ6T7p+hRCa\u002FSsyIO6V9FF9Kbg8DeZpDAABoqBkK6lAChGD28KraCn+fJv37uGMnc\u002Fv1IdgJl1fpFimtrf7n36zOlkiqj6LBA8F6dIRLJLPwdC1oqaqD29efOGhRgDhFe3FNHUiSZnFLdxGh8FRJkaHKXl7u7vZVx+nGhu1\u002Fm+\u002FK0r8R2kvAx6xgvIi2CjF6XKMBuzQ1VcSzkuRsznKcgirNESb+06tjcwVZlT951I+Rw3vpGM6JqQ\u002FNIHRVXRWeRcSZaSMfWCeENUeUeAVyQFbz6ui0psE+9Q9juLMl6pVOB2kdsOzSrzJoIKsJM\u002F0d9bZX0AegDPOtI9V3MUHxYdP1G52KEybc8e1QWp7BPSu4cSlNEBgSdjck7BsaOvj8zsPZSu2ukcgfhus7r1h9cbb2NJvkVzAaUp1wAYkjO9mh\u002F3M6B+PB12rbECEAf31fs\u002FQGRzoX0W2ocdjj+Ppmt1THl8\u002F2GAY\u002FfqaXS6fPHCbKSOJbtfRic9YXnQGgB7EjGUlXCKtHZbang5+S7KICdfQDn5tXkcb9F3eIAOGJDxim8EJegm+sez6N6dfTcPfCUaPXqq+Wo9uVFkcw5HaivHk\u002FQHY+uQn43AtwzXjUpByCWwd6AsnU22otW48kUA\u002Fv6Dm\u002F2kE0t7bArS6M6yWVeI5zmODKosBqO+ke4WIACEDqYXnJ0gMzdBjzZ5Hq7rzMNa2r0I\u002FAM1z8p2PkwPHy3QsH2tsrqyZ+1gWO0K4NtA\u002FhyAi+\u002FZKzwRu01WjmOymX7eqF3lWvZMqdbXX327+uPHf2hvUpk98thntLm0Af7WzebTHCcSGTjHQ7u3F2AIUGz0tdaztPq9UX\u002F1K5WzyAyba5NE\u002FsYWb8cPInwilOwUfa0GfTIrrQdbKft3\u002FvvzowO++frraN1+kJgALekB\u002FGfNyLL7Aupkyia+3Tk+1liAItHsuvR6AFh5ipJKwS+bhdlHG\u002FwBdtFM9e1Hyn6jsUzGC2cCBLZGNTR+wQb2+UVOFL3o2UB6JDCC4S+OH\u002FpyGq0d+8NZVM6yFn8r7XocoLNxlU64XUnUuTOnVifJSzZqeyVDhH2t+ywHrSX4aNaY0NwcOQQ7duQwxG\u002FuLUCHvrJML3uPYz5R5PjwaXbk2SNnkySb5pxeIR\u002Fu6T8ZIrQkQzOL7qO0lO7YAu9b8zdntj+piAfi\u002FZ7jOhUH46T4ezfZCsrNHg+y656Nm3ji7ZlLP7MP\u002FuZrQH\u002F2VOnY7tbDacz4hg1XbsLRByDJf3fruUp0F5u3PLPZ9Kzdye7O9Cy9LnJNXxsjIMqBmOfE8\u002FrL05HaV45z0WdFyDkHMoWCirIFgDj6LHvIygwln55NT7oxPvO9x83YnFWANtYKTXyPAeNPv9sDqDwnLNB7AP2LAfd01Nym67fHn7JQ6bF0IhlcG55fOgyhlSCoMUzJUWNd9rjRjd07fvBczpHgMJoJ9Cnd0S2Kjcfvmmkocx7yt2ocsLYyGGrvoZ\u002FgR7bfeppLz\u002FmhXj\u002FYnYAKEyZ8CMcAIey2bcvRuoyj+k0MQrGLDGFqwJ2CVjOFSJjrVt1hAF8eNLDx5psZqiY+iicjrdxCeppycl8AAGMCmk6la1kGpIsua2ivkwLj7tAIgkNxjLB2vTrro+3+xwwcBZ6mcpX1G9WgZgQwopS6zxEWRnY2KfW+VKq0CIX1oEggMKJFHAPBcZmIeuDl+PE6hxRtc8iRU97effftUUYiY5EKzw5dfEez53U\u002FeF4f542Yg0HMKowio1iV9DTBUV5AOu9XGnZVmpQl8btDL85fOD\u002F1Zq8FzI+XMj9ayp5RPBntzp47N4bYhjz9hQm2bjVAllKStoOmSFq\u002FHAglNGqlebH3qynVYhGzHzygfktvdfVheZ0vpP1vRafAU47JwQDH4YP2D+RopewuFalWN7qn35U1Objqk4\u002Fvrf6bf\u002FnP5uCKzQyyWsGTZSvuZ4zXSEB0P1jZi+40Dahd\u002FCndaPS8dc8lG17ZiIcedN9rldN8f\u002FHS6pvuq70kZ0cEjvKhWCmomzdLdUcD0c61BE6kzzz1mdcdYX8no9qUTDilPAF2NdOUMGHdXspe2U3kiGc7zrxINiVqPQg3PrCGY7B6fsSIXxYj5DunZULNy2rPZyg+aWdvAdAiocpe1PlNhCFZcR4Bp4lSdQ8KgbIAuidjkYK6f5scxAvRhtIAmNQKAxe93Xt9rvcX5643epFHsgN4ueGaqEnXLNy4GJ0BCSlLkVFG1zPMF12H73oO2SL7ysuYHXzKMEzkou+u33oB17NPpPtNSUxgSAu9fUXCGUp9vQ8cXBwYxnsOUOu5Ayj6u81h\u002FlPyxpn48ssvm+P\u002Fz9p9PVt6Zvd9351O5xyADsiDASZyhsNhEElRUpWr7AtXkZZdvpAvbP9xLvtCtksu2aIkUhLTME4ABjk00DnnHP39rLd7rHv3Bnafc3Z43yes8FvxQZMpiQwtUS33l2LHwy9FigyYU3DrFLKusLSiTDUv5qyoXS\u002F+yxmBd\u002FOqvlsB3WuleunN\u002Ftd\u002F\u002FdfR+M7Vb\u002Fz6D4bGD1a3si2gcsPx6F3ncV7hK5crBCx6h1bUdezff3B15PCxFJWoWfnQh\u002FcO+Fyfd0ZqhoNUrJ210RcZb1OI2+r1u3dv7fA6GG0tGfS0Nd9fwev2AKeWZafPXlx9fuLM6rUU0RtvvhEYLLK0TdpM3szWDK0f\u002F+Lz8j0zYAKloBjaRI\u002FAt5NUH0bLxqAj1HjaWqPxjrdeiwHH+4dOosXGJGoI0DB+yD+ycArq+t2DIqXo1rX3aJV89DMzLJpDV9FKbJw50jh6r8+P94sqqzh+69BbBmbrfvHsyVmHdRu2ro5\u002FfWZavjoAh+y5G3BPqESvrXmyZp08oRlAADp6BETi5qF5J2Lua888nazKoym9bX379aiUmYcZCLu3r2XAF9UNjCpEjPAacWl9pXk8vLNu0l8mrN+Y1eVsdNBKAJ7ndEPrzpP+MENha92EtsSXp09eqDj982mGoDDt\u002Ft0bqxPHPy3qV3Sv9VjLoeHwLPql1UzO8ejGu8lCe8+je\u002F7k2WT2qUkJVQOFPjwmctbYhqdadrIMENJEgfEDvGOw8Ri3DzrDcBIBUvQq3hapkjoHqPg7Dlz+bj6MXEYt8GTv6Ft5\u002FwMM+2nfHdTjPIGtFctuiU63liYIuANlnE5+Jx84bOZ7XdddyBvyBQ2iFbRGNjWS7sPZlDxvbIw0csfYFDbS4w8etMbJtTp1jszxuZulJ1wrZYmT5VY8uyujZW88v7UbODlyXZ8nh6Q1MJSAOwYO+uDwGrCYDOX8ke5DtXIkrKtIkEyBQeAC3tdNrRcDRJE6h4vvkhfPn8ZqneESND3r3Gs8uE1vWes+T1YbOyAqykc\u002Fw0dbn5Ze1s4tY2JQxCPRBuPffi5Yp9dbt+U+eDM91HubivhI9+NJBwal1Trv5dZttLQYA4CnvbB\u002Fhj657V3L\u002FVyPHlRIqitam9PrGdPpGs0rKI1xorZ2W+GzdCQDHz\u002Ffx28tA\u002F0yE1gmO38v3u1oozmgdSBbe2uyybytNxkCK3JG3Y1GOWhFURgH6go8GC3GvhhDja1705\u002F3YJ32UstIeo0Bwbjb1vuMKhTYLUrRdY94Lr26raJ\u002FeztrEJ6ybvaLbkF3nECyBERkdCsz5sni6F6PHlUP1PqSI+sC\u002F5N5wKDBhzzpxNisr\u002FV7thxoILmmZgb+e1GPFwbUdVNQiMD7YrIeilQMHwBHnBh0BFWHcwAAQABJREFULOoUBwFK0Zo8YiZYMDPhs2v34kklsITCF486TxeQUCg4IaV7ifcoZBtBeAGANmbXnrzl+4Q5pckAsP3fPTDB7q6tEGd3XgkFVDsSMpQxwMlbsOS7svQQvBBIubFSYNpQ8IPlCFzxEBM8FDMv2IPDFbkAe91DpxKnE7on79S+ioW2b9udwrgcMWxKkS8HVzhZk3eJWEuutCY2njdwATGAjJBlS7cI0T6A0Xi6hukD6IDX8jkgqrXp\u002FjyZcvv0rX\u002FzzTdWu8vnxLjC8\u002FoFF7Puflp07ckr83KzSkD3PiYyBy0QhbG10LxZvvqDCufkhQpDjyJPaT4MjAtbJy0ac8Jx5dCJun\u002FkpTx\u002F5sTq+pWLk5awdevOin+KpCRctGakJHgLeTKupkAxwv3ud7OUoSPlrR9s3568Xk1CXqmbAZ1UTMWg3TsOPFj+6qGAvKrv7XmTHAMhmnE8L9IZhVWlLTjEAj0BGGMtJwgIJdbxnQA4658X2cEgOuSw8nmw5D2\u002F8loKtLFdIUAC6lu28RYmOAOS9oHxIHd5imwDR5ibclKYHNvPXvRPn1lO2xuvdJ8YYN0q81ISJpFw1wBsFuUInPJ4U5TyBHUV0o3mYHUT+tvrnUzgEm4EM6HmmviAgr3SPk\u002FUIn7zvvUlKP1cvOoJ\u002FAhsUcSLUDEGQN0YXdu4GQmuvaSapVDiRwXgFP4o8gQ15YqnNxS5YpQtQr5uCvYqepXfP50AmosOEwBbMaDuzdhdAD5aM\u002F4oftZ0LQEppOggIwCJwDTe8QQ1ricVtjlIYgyNrsHL\u002FiBt4W8GacPpoW6inN+iZ9BheCXeq+Vh+47ez5493VCrFQkM37kD2CRjmvvtW9dnP68GABRWo8fXXntj8tP\u002F\u002FM\u002F+Y0D7QPRdt5grl1a\u002F\u002Fv3vrA4cOZiXKcUS\u002FbsfYMi41z7s4uWLK92PPt3xZWPIsZBC+d733u0aFWfX3YRiCTUTLtEBJZ7se1TUIJABKHMYbCI\u002Fyru\u002F21q+dKz2egGKDz\u002F9LBo\u002FVU5ndNy8t3Z4Eu\u002F7o\u002FGM57g4+srq7WTUuXjgVp7\u002FJyndbck1IGI6tbTWOtI87R4bqvmgiBIV0ak9a0\u002FJ3WiOfOTwMBY0yHgnb8Z73lrLJwYc8S7A6DkAbNnYgCx6iMOjEfvr2hQsI0aUj2EHuGnbtiVltrN8060pTwDA3G5cu1T7wfsVL57JALrYPgvx5zC5lce3pbPW66KDOdAuVXD7GfCx+4t8cybGrlKa6haUDsDLU+ezblfjWYDYqvXev1t60qXpHLKl3HWK\u002FV5AWrRP6gN6Mu6EYjxRRCdguJYc4CkH0G8lH7a0BwerdbqbLL505bOiLFeHdoAnlD0NBSrSF13eEf\u002FwoKKXna09R86S96qH+a2ivF\u002F3\u002FDJ5e3NA6u7SqQb8PeOXfjSWZW0B9gG5\u002FZSfPwXn7Z8HAKfF7aQcNQn6i7y6v0Xe\u002FtKOMPg2fGifOMs0DsCnxol\u002FGbtPHueJj1dEydDpZilbFYxu3R5o2cGQztmSoUwuoH1pXHRhBNaeZdBED8OSBuWXxjdOCldLZjDUHThIvsQF\u002FRSd9dmFL+hi+8DB9jh6f3BfrVcyp2t1pXRytU636q+\u002F9aPVqxmzxw7uXq0LYD5J1uvdv770JfL0bkYducVJMyIuuiSD0bMOXdPuONqETQY8DhZpRNH4gMKtwFx\u002F99nKukb+wi9qTR4VwRtnSDRmXz0Gn\u002FTTmo1M7XcyCiCcSHVj5EDyvr99f8BmMsd+e8BDxkOvA8uMIdjIwxj7ytDIAPXWiJwcL3a8oc\u002F4jnS9CC2DgUceHcMhxPbi5e3a3QNtiBRMylr3ipDaA6m51aD0cyJ9jQNf2ULjUtPip3F7f5p+BJCttQgUucI5NA6rvvV0Jzpo37oe2TE4Y\u002FSyfPKcHDlDRq91bzeZ312\u002F9Zw6IDrLzbu+a6\u002Fq8PI4OTZza8icRtZWRIoscuYMM1Bt4dTWNE468ElrWDX5gHn60fifsczIKWv0JEwjomj+m+IJRoxUS40vGIxqNy7lDLtfBAy2KIOs7yx0LgpizRYis46mk9HZ+F\u002FU44UBdYWkCAFAQFBAOsLlZbMQIjbeNwWgR14hQIhZRxn0WcADmOAFZsnylgtZHy\u002FPmOB\u002F9ZVjAxwQGSFDsbgmwCt\u002FSF\u002Fl7YXl1giWlAyFfe\u002FuAtKwuAOWWEcKbhD3vU65ki\u002F62qtHu2dtG3g7+q5DQAYopFAB9UWZ8VY7yMkplYfa7DxmbSwvtWsfKxUDgyFald+8to8iDlYmYH9jOkVQPBj0SYBT28bSShIsUxAFJPGm5ukFroAyfT51hWCZbeq+sdysrc4WctyBKikwQ+VxIuIjhChExY\u002FaIg0YaZ0VxmzfGXCLoHmIHeddZLMWhnm+93TQUUAJN\u002FPkCkU50QtQv1A7szNnTjXPxeAhkM3N4UMYXg6ohxxPuYMX80zeYLSJRiQgN20EgDoKuhDpjqIlUnqsB88+0CQqwWPoKO3rRUCO5D1\u002FOYDypEOSvj59dnWq9BVK\u002FECerC083gfrh9+1bmRQfFU++yeffNrBGx0ck5Cm0KQCAJr3aoM5h8pEh2iH4KPktO570v0Alc0xodQLe2hcpOAAjz5vTSkFCl7ocqrOY1LX2ay4JMeDyM\u002FjJ7rmZDIkkAkBTOt330GbQtVTiEpgtKdCbq65KKvSUPKq8Vjylk8ayJbSr3g2ovE3Xn93XifoHvH8URCRW1swgkEPdUW0QsEiTOYtArCk6SxCTtje39KljGe6HaDTronvyMH5t\u002FFqE4fGrdvtjBrK5P5EEBiS0ZkP90DnPHkU+xLOrMNKYGYOiEqRU44U84R8fSdASVEu4I2SAw5TwglaRqXcy\u002FGczqlzDCFRkKUjkjE\u002FzvOp24zTQa2NlLbPP\u002F8qnnc+woHWSheg8sD72zHROhB1TFJrVVF1dAIciPocjOccWnXn9obV5fa927fHKenW8AZ+aI2FOIHWPRnvZMn2PIZfHP9idbsc2d\u002F40fdLQzqS7NBR5kpAcP2kbB3u9NNGPPUhX3zx9ep07UqvdnAWXrh47sTqt3\u002F7RxXCHYoHklctx6aACgq7l8eH8e8USMpbgeX20oA2lwP8NEM6dbv6oBSxjz78ZIrB9evmUTyfd\u002F3QvvJ0M7qvl299v7V87ZvfXF3JI\u002FzXf\u002F2Xo6R2FEHr5ej0WXSl\u002FeDJFSLe7YC3AArHCiBhXyh+r8+hJK2xMyFEm\u002FCU\u002FRqvZ58bGRcPAfduMOC8PVI0u45i6nd0oq+7yJDvToSyn2hAe7V2dFIJAPotyaN93Xd3mu9+9EwhPihNxNhHL8Sba9GqOow9eairxFxdfHQth0J7Vss09BoZNy4OoQrJ8y7uk0PdHnGAOIFRSiSZqLbp3l1pMhXm1it856NAZjLyTFbdnVIq9kwUtIhq3ao2blq6Xt2KJu8mh7fnAd3SOBTYb+t00ze++XbH2+9dffalQ9MCwoEwvDdpQNH0jtYK+CVPPBmqwCma0RYSTUvN++qrk9MhS1rSoaKtS+pDgrkFGAnUGk7aCx4GXFqv53\u002FjQa+5\u002FjxaYE4IMppBNBHX1g8AkZb2PELsb\u002Ft+IKeHAmUeSrqW3t6RXn1UdJRTRpoBQCbNT+ehtis54rTLjKBk55JGkBFGp6Tz2O0LPaHpaK\u002F9Rj\u002F2cYy3+JpsJF4TgSMD\u002FO59Pd5FxhhnwLsIwDgFmgvgR1\u002FfLqUNUGRIOmX3VPrhy9Zvf12fpG8Q4Q8T7NOqsWtJH3xS\u002FRjgqp6FrHqcTqY\u002FFaoDjmiczrRedLWcewS8dH9b9Ol0RopmJ7Xr2VqPowW9dw2FhvgXrdO3A\u002Fz8TMBMxMkV8UrXBSiNf2i7e47Rle71OucBhwdQyhm0AMpGySnSQlmrbjd6Fz+OQYT4W2h6iYEmQ2Et+nZdFOTtR627z+IpOoryk3YlCpOFY3Au8ewzgfBojYG7RHGkVSVLS5YA\u002FK0FzDaGZLSJPnjr4aLZr4YIn4ls0Mnu+XxNGUYwCYAPSGsTzbAdHknW8aSPQWeePeicwYf+gHMG6ySx4yVrOQW35Nu83d\u002FJVW1\u002FRRIZDgPKGyM8p4CfEYp3GlI4IKfcloyV1mCKjIvgwFMMW3oY71qHbdGNqJq1F6nniV+AeVLMehjbs71djGYkbu85QrgSX8zjhQH1kydPTR9zBHdVoWALQkCa\u002FJWLF6YNI8J4ftIbQiVIJG3uSkDqoY2YeItZcYiZIEBBvLw21ibvyZPqcwoM5adjDoejACSKBW08zyCmPHjgpRTPrgFZgNbOHZdS3HV1CPyfq8pfX2wnTRKcQPve0h7Wct3IS1tCdgG7CNthN2NptumUGk+CtoUMhRsd0KETCiZ3+umurqeN35cp93t5ove3BsIkFy8WLs9o0FLKEctyAAH25TTWQpAx2hg07SsCxWQ83GubKiRLmGCaIf4EDI8iy1G\u002FUQwp7w1T8Eaat+Kz\u002FQl9\u002Fb2ti1xv3iWKZX\u002FGys5CtrcDO3criLqbgopcy9M81Dyr5t+9b7UjYSnsrDvG\u002FlqD7WleJ77M83x6Kd5SECVScLd9Esq3B9cqtFM4ty9FuWMMKLnJjA35ctsCKkdby7VCrY8ClXXG6frXrqa0u4ZeuASPvb+bANnaOHgTN9cJYdehK6tr7f1aioGKP3U+YDJtJy93Kt7xIgenxuhbulowcwvHV7x7e\u002FYF2Gydnyk7DDZtu\u002FLoJTIHNGjzSKkw\u002FIAY9IpRAWyAXN434elEtK0pKC36CEP0dPzLc63h0r1oiejsGKU2301woQndgtAygIN2JjcOFye0Zu+ih8Rne5chWF7PxrqB6AikIPL2bWFjPHF7+IPUpQh44+wrelJHsS4vnw45d7vP5LYmPsaDlsBqQaKn6DZF+rDvb0q4POlzQMWALiAiAUhY8qau37Bj+Nb8GKmMaeshpYTA9rrPAnKMiwPRDWUnXUi4eq7leu0V8ETZSJfAs9bWT2NacsutaXyU93dyhsuxnEJWQC4eBn4jrfYpwRnAEWLXdk6thGJtxzq\u002FvvmVaF7ho3atG8tjFfo\u002F1+d2rA7ux4uNPw+cLhQ8dS1F8sWcIYXWI0EsOkQRMlD1lr761pvTCo880ON\u002FWzLllTdeHdBOXmnjeKvuTsAV9fug\u002FVFc\u002FdrRDmupLeyd9oXRcuLrU3n8z+YpLvp092xG96oWo9tL78q4DUia85bkzZYMlXY6b20GdukFx\u002FYfrUPIk9Vf\u002Fc1PV++\u002F\u002F+EYQeTNWkbE3QzQE8dPBOoONsZXp5iaEaIry3d+9MNSwC6uPv7wl9HO3dUenVGSB+I+W\u002Ff0e4qK0uIEWRc4cAowY4zC2dzhQ3q8CzcDCjxJjHe7RSma53gTvYKsek6EqJ9697d8trXlYaC1xu2rvQeo7seDCsfsudMHHeT0qIikPVBoqeNO\u002FfBWp89fntaXTo\u002Fl7HDPAXitpZMJn+Zh3Sz\u002FO7qQoqeYUDpWXB19lAIQQD+Y3NMR5sGd6xlCdys6bPzlhSvi3V7KhsJ1BvPjUvcG4Earwvt4YWOeXQXMZ851vsKaeqXAXT93tv8K3hwR7lTjw68cC+QezpiKjjqBVphdJAdAGM9jMmhDc1O0by0smT75EwrPGDx18uupgQHU5VxvDPzuL4qyu\u002FSFASuItC\u002FiJYe7AA2e0jkm\u002Fa2fwMr8DZBFxx506o5akdKrZA0e9Jq0A4a38wkW\u002FZehk9wAqt1HxE6hMv2ilSMPsT7014umigTsaF3JTk4mhkG5IAOIY9KRYW1rOibAEx09bD\u002FIqC7cvFuP3gMih+39\u002Fgz0PI\u002FG0Vd43vWbbtdOnzC+zCkMCfTwTHoCyo\u002F6Pj3zNN3CI\u002FvTn703Z3F84\u002FWXK8jtLIV0683bPJ\u002FLeQ2cIgp\u002FN7f3LV4gvbav0c6tImDjm6E\u002FrVXyWFHsHJrVXKStWX+6F5\u002FHphmLUk0WUBubtK3L\u002FKQPWW\u002F7jLaWh3WXYlMP9h6cNQMS53uB2VmTwH3ef44iTr\u002FnjqVJE5k9fLaPLQUsJKpxPTq7UkaAzj6i\u002FBwe46BJtj330s9J3I3Nf3TfhvSDPUERa83zUZHgEnGWveg+6\u002Fou+TdRxtbVOD0XkCzCUL52+ELKIJWysbkw1GNLU24\u002FFsPd5xgL0hNFrs1pDIbW0ecsDbrtFpEOeZCzgnMpGuCQcT80Y20YxOSJ19e332u9t8GaNAdP9EVWwZTupbZhS\u002FxDRqHj54YU\u002Fb8x\u002FuUERtdRYp9hyCT7W1N8tXFj+9eeT9St7zJqtwTiGSP8l9aQbBRxszeLXOrf7o+\u002F0LDBGrP7W6cWNIyUc\u002FMFPV4YUH\u002F\u002Flx9kjaccs9Ip5Fsxi4k7jIGQsFMIaQB3IIjnAaABeoEcBSs+y8s0IfMIy0IePnq4qT7N+1DLqMKaDkChWBCABXxIgLcoQItWbEeOHZkFlhIjP1XR4ZIvWoeEgD5wfrDODRZb8c3WcjqF8YRsEIXcNVbTcswwq1Bbx0K+iKcx+QyCZKELYQ6obm5yg2\u002FnEZ72Zs1r546OlX+iM82uiEl+XyHRKPR2jHYvb4V1wNwE38YKeeSo6fjSZBJKAeB+qpxeikrlm5JiI8miZYTvv15JaK7Lgr6dp4hnEIhDlE6lYzTI0yL8PbdWhAmoEqjx7jAoBXq1bgfCuU5bZWxsTnmur7vMkxTOzt3NZVeEXhX1tk0Py8esXVZjdy+M7URaoIBRwWO1f\u002F+BuffBTt+jvE6fPhcxB+gOdgpeQo\u002FHY1cA6PKli3mjvlh98NnnFWRtnve3F\u002Frf0J49TXHKZT+YQbEh4fuk3sCnnYj32RerazGRz49wa6+s6ZbmnKzPK6Y4rLXtM\u002FaNAYGneY8tlohEpGKJE0QZDbwKBMM8W8zGqVOQgllAlDIhaKclZfPzN+XOMLqTYXH7bqG7vrZzZzQU2NAxBrjjISZYKX+h2IV+FmUw3x9aYo3zHKkkT8h2zciun7z7vDs7A5D+prQyKvrdUfaiHPKx0RM+AC4fBmy2QYE90Cjl1qRn3a3BFOqg75Sh+gefedQ1B5wkOKewsL2+W7GkiJg6ES3idmzHr7fb447y3lD6UestxYZiU8RGoKqw35lnF49LTXBN99TelNBNzKbwouf2gVDjHTNv3rqHAczdecMAcGPW2YUnfTHQF8VD0EpDW9+JnosnozkmCHl+7ShPjnzzvfs6Ur05XrxwpbHVd\u002F\u002Foy+3Hnujs0urGRrUpyZPeH8HdT2PVceVxXlz8jE4eR0TSD7Sj21dxs\u002Fac+lL\u002F\u002Fu\u002F+Tt7W7auTp0+1Jp023D4Dn9r\u002F9X8Ks5zI+E++MxrZnaH60kuHV9\u002F\u002F1jfbn2ojOpL902j3s08\u002FWp073Smah4oavbQY9Y\u002FXxRMd6MEQlV7xEG3Es598enz1k5\u002F8ZPb4m9\u002F4RsWvFZha29bpXMbET5s94\u002Fb11x2gsyPQ2uFqycbf+t3fbY73V5999EHjKJ0lw7IXxqmgvoUytL4MJD\u002FHUx5DWBtAcryXvSddpaEMfVOklDEZ4v6K+6yXxwAhiolizSTg2LCXwPN01ehaPO2iL1LQKPi1ogXmeLd0EzndO3eX9tR6Xi296FZ1MEGr5i2tIz6It\u002FWVv3D+Srcs2plXfWuydd36y9FDXmvKvLHIldYrf3+Fv+tK3bjptNiiLKHrAVqHDr0cHzh5kPd2S2cu6MyzhOPJB4aQdDsg4C4DNSPgTvS5pdS9HaUtvrw\u002FeZ5cfeOtt0d+ftFhTCIGjFnees8tGY4DoJvj5En3Ez9YR3RH+GiW8NVXx0vFOt9aimTkHEkuMwYT+7PGHEUDcPq+e0wruby2+N1ZG08ziF0TU5EnA8a6D6Pmaes6QCRZxuPOiMYjasWAEs4u39Ec4OsTJ\u002Fp5d\u002FWbv\u002Fnbq9\u002F7vd9rLEUxe811Od4+\u002FuSjwPDljIl7S4QpPhOB5iTgLALA9fGmx+w577En0EfG+qdfh0Z4+cnqMQ5a424x7xmjzlMMLnU0SeaRD8t36TiOM\u002FJDSlugqbHHYr0ev3b9rxvn+x9+1L6n816qcsn1uv6szzgGrBHZl2EDdZUWhke9P+mjyVoe9edyeeRwe3U7Watj2wDUUl8YvY\u002FSi5w0Bk8fb7beRpv8UCthUAMAAd3obMmLXyK6vROtA4qR5DOa1RlG04QH969noN7K+Mzp0\u002FtkG7A5aYPtvyiHOjcpgncvXc\u002FJeH7q5MjZMWRbZPp3cuwHSEZ37b91w7eMnqkv6r4tQod1tQbxK6eR8div51kQ1sVaSObxfbzVbRqLvWN89kJP3xve7xpSn4b2mg9aHOdM7xtfpDL3h\u002F10l9lUGhYDhw6R3gT4igIlXVo7jsfu2Rjtczs3P2GuGKlMgAYS+NeOdZwHvWYssjOmkDz5aS\u002Fca8m959Ve8M\u002FG0uzMEVb0QAMMMU40T06ANOHCr9Gi9R9d2pz1budU2J2MmSyKroOeGPIiZfTOpBk1To41hOCnWrUX9XhhQJ3iFhoAqHjfLJZe6bojWPQjeSIQt5QIYTbKnyVkU4SaJ78pgTIdEZrdhscbBvgjUqAQYLKgGP1SaRezOTHYePl6HwgYUJRwBXa0ZxSW4XU\u002FlMfAdSgjYRinm377W+92\u002FzsByZMRodwvoGOp8t2xMwsq7+KePYA1b2Le33KfcREmQqADvh4rkI1o+9vGnrh6IoVydjxu21qPTYEtqT8ky+E805cLW8tlvJ\u002F3fjm1LaEXsQrhIIp7HQLwOIEfX0WMC+BCkDw2WhTNQTDdR\u002FiYAFw8XsI9iD\u002FizlIeYdSaxh1j\u002FMgXNufxZPaak9l47ze0NutjsEYw3mKFtk48bOFXh9YOxFQVj+ZR4fWXvyUv8bVXj+QNKy\u002F4RKkwpciw5CkU117SlgioBGXXVzQ4fU5T\u002FphCiJwFav8cQHS7eWwI0KxPOWwu\u002FWXP4SOzv9szfnSuOfFlyuzcxYrozq1OnDo1ABEL6H++vvVixcqvk0bAw38r2tML+lZ0NVZva9imjqILm47AJRjtIeNmLc\u002Fao0AmQHL7jmhH4b1RJIGRhNKmQmUsa9fYm7cL0LieIcLTZA4UsEjLth21CCx0T5ACCXI2R7C0I+Nlac0ZfoxXKVljfXefOZGWxzJhwaBxsuzNwK6UJkWJ737r2+370+ZdSLq1YugAAfKVRHGm+DE6cmjL7fZpVxY\u002FICUMySCVesBrTnEQTowlPOJ3c5HH\u002FCQeW3Xa7vi\u002F+9zu6ioIafy2eHiMh6ERTzUGHgbeWPmGrnHpopSbDm4pJUnU66X2kADmgZ+80Oa5IZD+HOgBhqPkWw9g2\u002FoA6Vq93bpZMXZ0RsjxxMPOQOTi7S3PN5Dgveutv+LPhjlzS\u002F9F\u002F3UiCuhsiv55\u002FdC7ouBUyXzfnnMIWAvXtEY6Zzy471wA+Zw6nDwT\u002FutrMRuIO1tOu3G83vkQr752rGPqv159dPJEawyYL573d956PdCJRAKUyZbNHcQBjDysmPDU8U7QjY4eP6l16P4jq9\u002F+jR+ufufHv5a8ObH6+LOPVyeSkxsuUqZdIFo+UNresdfejD\u002FVh9ye1nrnSuk6euy19id6NPb4nLK8F\u002F98ePm95MXt8QC+8fabq+un6z7VwU2Hjx5bfee731udabxoV7RqrZ\u002FbAmkMoS4zclA6g7MjpL\u002FsjX555Mk2nmnPGCc5utCtdbeW5Bhe99+EqKNt6w0k2CcP3xUC5qGiqHWDSRz0vmstaQs8l7yTVxsXxU5fnM4Rc6411+VFjrHrkiMORLmTR\u002FRyoFvE5uWjybnS23aJrOaNXr++\u002Fe6eL8UfR4p0SHW5XtoRIxA41m7TtTQNmK4YyVe8oZCeR9ZhXHhjf44FvHi396\u002FcyBO\u002Ft+hvPP3ysTeilb3xwMPk0fnS7i4HtB51PsWFvLRrycKvRx7ib729zceD53ucMGPwtGKtG6fGhb53pXQlqST7SzvkPEkwtsfAYsueR3nWun2KmtItrV3RtgIMswt2om3oAYD2PUgomQBmjA6s+B\u002FEASDsg32ZyMcAxQX4OPeBQ4yR9I233179\u002Fj\u002F+x6sf\u002F\u002Fg3G9OmnCyvzedP1\u002FWILP7FL34Wj19u\u002Fo\u002Fj1TybI3sNIE9shiw9ZJ+aXuNE73gAfzf2nqML+pDPmYtxL48M8daa3rd2OkDNfFuLx8klOCCYOdFhtWY37sifj6Z6H1+ZuzoK+eOffvHl6q03X5loyf30pjMcOKweF9G2XjzMHDPkJ8OAwbUuWbFhUylB6Xe57dbOGEVOdQe7HX6QEjQOtdbrYZ2B0Kk18lnrMM44Oqyx4HuAl+wnpp127iRzaY1APL2sjSfjzOcYE+pnpCzykN9M53EuySYgq+Ab3mLX05iiJZrUtIlyNma8pOZs8RSTbQswxotBZQPoUD\u002FOGEB9oR2yWSRiUqP63brbEq8tKR\u002FhiLYHHW+Idzh2NoYf0iLTAjkqTH43v2jbNpq3cQCtG0UaWifj5wwYOdLnfAbQHRnbNeG4h\u002FY7uROpzDoYhK5l6BGO5LnelvNS\u002Fcrku+OLrpVKGPk1erUBAONSomQMSOtanAucSDnufD75ZeYwpvlNSk4C0Jjo4cUoWHSySMlaUT01hPREk2md8tbbuzCGtENpdSJ5d3LKeG9LcmyacLSWqcfRjzrhWSPrQG+\u002FqMcLA+rf+c63h5B\u002F+tOfBUavDdB9re4mFo3Adowx4hN+AEwp\u002FDv9jiEIMNbk3rxYUhAwg43eEvjwoFwRO++hax3\u002F8viAccpW4ap7AABSF2aRW2feeLnDJ0+eDMTx9NbGsYUDQnam9J1auHiWtpSHXZi0z7qvjZ\u002F2UHmQeW\u002FeiNEcfCJMTBpRaIAZIKITyIPSLISg5I5eTilIxteOaNeeNjFCQ8jy5XfsWBStPFhhFKGw8T4kvYD23E59NWVK0Ee4j1mPI9nWx8h5NANMqHTydAuzy7EjVIB+B0TslL9dxGG3CvA8TgQmIwFQB\u002FRxlj7OSYxhTkyn3dLTCCuWLQTNw3wnZXSqzyLq+7WoO9kc9R+NkR3kdPtawkxxa\u002F3aA4t6kfO+Arh3yuvEeITko6cB5hTbjtbt5SNHG0+9mVur8xcurU6UV3i51KN38jb+s+jD4RIvHTu62t\u002FnGCBf1LXlvfc\u002FWP3ylx9m9JVawoJuDdHNnGLangC1DxNWaGHayuUBlzfPq0PIjacwIZdEbW4Bp+hnwpP9LseZAWdsX3z+VeA4D3zfFwnYu\u002F9ga9m+NhHdXcbgbJ0ZH+41vYDbqsldC2BuKx97eyF0wIOnyv1Y7dL+eIko50Uogjbtaes0wKZrxdutY+NNURvjxSIMAPtaqS\u002Fbo+k9e\u002FZHM7vy0B\u002FsNMa\u002FjbYrWrt8oUOhPo1eMiS3FZ4uTxqo3FZc9l5Ahldx00aFc888AvEMRQ4UCCPjI+Pw4PUgwAizp5uKENU+LXKZtRqQnpEyQj+hJtSMt5wuLEXNib7C6Js3U2btwRTwNuf2ibLR3hTpAuiAWks292YMPymUI0qAn+WY78o4sF9A1YS8G5e1fgKctH54+0CpIvv2U1bSpsrFj4+v11\u002FdfBxuxmh076kF6J6u56RkBc4cBpMetM4x3CCMgrh6etdZ5nqFhanYMWju8uYn3BVj+757yHnGq\u002FcDzwqdXyk6tyfvdYs6XtmLRReO1Yb05YxwMuZe0Y7UQPehGDgLijxlbO0NVN7Psy5quKciR8B\u002FT92hnj5TPmcuXFz91d+9t7r+p38deLyx+t53f9BiLntzKbk5NR4BbkV05mOc65ovb\u002F+Jr4536FPGE+OocD9e0bXm1QDXjcsXR3Ydrh5kLbly906nuiaTHB4GNDAu0SSZR0FJL7APizd3kRNtwYCw\u002Fh15pC7F3i4eSi3ZACCRmsUAIkNT76v7taUENB62rgPkWhnXAnCmm8zUG9RaMi\u002F3lbrx6L7jDArySSqEFIhIYWSCKJdUBSlFNzJk1zLsGvYocWldDs7R255s9jclK+K0eWOF7LduTCvfY8cyKLvng0f1bc8AuppBDzQBL6Ke+wLynACPK5rfUZ3MkVcrwo\u002F3rpdq9Mf\u002F\u002Fv9a\u002Fe3f\u002FN3oqP\u002FhX\u002FyLOSlV9PfWrSeTxkJ\u002Fmbc1oscyhWcsOzcpGk2HRXd0w8WLF2eODGh85Dtk8HTVaF8e1UXI4sqjjj0CTYFxi+DZ+pETfrc\u002F+HryuIGY1ksEIome3gu0ocE+DUw8IGjQPW9l9xVV2VMK5JFjjzJeXlr90R\u002F+89Xv\u002Fu7vJX8utwdnR7YBtkdfqRvagT9YvV5KCc\u002F65WgJ\u002FwI0PPwALB2i9gmYMnf7PWk3bc6j+AcwasRDL5MSEhh7Tk9+4nMGDafXrdaZI4D+vp9BxmO\u002FSa51dxHxpB+B3QfJZV5v+t71Ffqdq\u002F2lCAGaAGg5RiZXv88BbAA63p\u002F6rcbo3gD7Wp1s1sen69K1E3lo\u002Fz18XvSX\u002FJGqyQFC\u002F0oL8ho0Sy6hyz3dVGaA8dgT+2XUxkEOGDODhSNgE8O364vIki\u002FXMhSnhXDYAZbgyORkYJjd55zLeHku6+6lh\u002FbsSe8l83iayeQNGTnSb32PvrH+PMiiUPOYNe6eyU1ZCpwrsW\u002FXVCOYgdJc0IXvSjvlqASqZ979\u002FSvd0cWAW91v7DV9whGHf3jxPYxh6qj8EQ1zCNFDHpsqHB+DrPH4\u002FK10tT1XrIlmh867\u002FkR8MrS3h5cA9e15wd0vrTmfa1nGCQUn9MI07XD4FufNpTIl5JpvGPmynKPCKLBP+Iyc87AGAFaqtw1qjdtDBpO0lY21FR0d0X2sDVlHruEfumxX8oUz6\u002FqN5awGBgnDQnTV+qFl6W8TyUguPvfeu+\u002F\u002F38cLA+rf+\u002F73Aq95lU+cCGCdGWDL8pGnjikIc8zjuG5edoDqcHnmW14vDBohU7q3C4VuK3yIUCzQeM0DTYQCwjrfd11PON4GAA+YexRCi8Wrp4JfeBaAdx3EwkK+cD6ruM\u002FwGhE6J0981THSr8xpZ\u002FlS2qyO+k6QY7TL5VDroOBAJSkABJtc6mTiCHv50Fs2ZxWmNO6V\u002FiAt58TXJyMG880jHANeL\u002FSamTgGyVj+vcdQk4sYbcYQS0EFMN1+z1ilNPD2CVuxcgk9kYfb3WcKmgIl8rcbZIqmMZZLqV0ioHD4SMo\u002FAwITTXi4tYlyYgaswEPZ9WLITnOK4TIeMEbMID0GAANMCU6dcBSGamfmp\u002FD0FD8FAiLzmR8j61Y51FJ6AF4hSyDcqWa8FQ4emlPO2sP1jJj2S1eVy1VNX6\u002Fo8FD7\u002Fp3v\u002F2B1pW4wn37+2epCyu1c80wirv7kT\u002F5DR7d\u002FNrSkfdnBQAZa6Sa91vHcpTfpb6yDC0a091iQoBAF4X3AZJPChNGA0wQ\u002FoSBsN9Z6Ao5XWF\u002F2W7dUg5fjHUgXvj5b\u002FrsoyobSEQj8pX3TAri21ppMEezSFo0hWQpBBo5ezdNzl\u002FK0tz37zZDDx10\u002FeklujaKgN3V54fUHzM+Ucy+E++Zbb67eePPt0rJergPEyQDp1Qomy8HPsHmp2gvCledF8e6Pf\u002FzD6GpHh\u002Fb8JIPmF127DhoBSGMQ5pxcw+b9mOCIpp7mcdvYk2Dx\u002FiiTxjbCvXsTSJT+RGYAhWjV53jmGdUDxhLoGMDvaAk\u002FyGOevNfWy4zxG5pnyAFyWnOqz3jUuo7AG6hhPNFgY8G\u002FQJLvAZr28Xm+o\u002FUCaKwtI2pfqQfWBN8fPPhyRZN\u002FP8W8FCSPepzet3nFyu\u002FP64Eu9pcOY66E6FpFRgxLPZwpDWCHx5jC4G0BbsyVoPb35s2dzRCAff3Vo9Fb9JBAFpH76ONPVi+X+vLKkcMpFEpuUcLGuiVB3swzHqNJUfb4Cn\u002FfuHo6A1EKwqHA8e6iWRvzqJ+PL0qtqPXmb739\u002FdX3f\u002Fx49S\u002F\u002F5f+5+vn7XzTHr1Y\u002F+sGvr77\u002F3e9OqtnUgaRE71VkKeK2O57bXvSG5+ty9UCXklX7ihLu3HW4vuUPMmj3r9755jurzz9mhLcmrfWT9uNAHvSD0c3OaEgHk7170UI0Eb3ySiFS9OvBu7Xk1KaUk8EMTIbwpmjjAV7q\u002FUWuN9\u002F2kQNkIpNtImMBOGljZz98f\u002FHs4YnFgSDNZnt7v66g1dqdaKz1sYdSDe5TxEMrC+iaS7U\u002FigBvdX6G9WMY7+hJJj9JzqiZEWHYkrKd3PeutykPmQ4zt29fHHku2iDF5mQ8pSdyVsQYfOtyFp3PWLqaYaWby+HSBq\u002F12h\u002F\u002F6V+sfhKdXeOhb0\u002F\u002Fmz\u002F6w9UPfvjD6PDS6uTXX8XPpUgUCZJGJYeW\u002FL6WLJNmtX6DHPde70mufPKJw4fujPw8VAE0jxt9paaEZnlcNAbvoF\u002Fr1bb1v3\u002FMcNkUtDyb1dos3mvrtDxQf1\u002FPO6xuYgGLJL\u002FGAXON+HCpacqIar04iU6cPLn687\u002F8i9bmwhTlnz51ZnWocy1u3LoYkC+F8djR4ZMtdT\u002FRtedykYBHGeFLakJ3CawxjOjDpZZgiZrEFM0BoMy7bfye6KK5AUrkqqeot9oWnmtrxDvs86PHGyMdyHHSIJpxxmCEQB5vzxF14MCB1YV0wd3buqOYZ9cnf\u002Fo+vlYbsTVdSk7Rg9aHE2VqG6Kj3uhvaYEZFI13R\u002Fu0vbRLtGv95f8zBMgXxvnt0kPVgjCazYWjDFhlKCxysogenmG4dF9PAN+16RMF1dfpq8ZI9g9gLQ1K1NY+8fiTIdLfOB3sVSBhxijS2mWG\u002FkVs0QH55X4oA8gHOhc+9XP5nc541L0dgMUxMvRgzL3OAJh7YvguTo7Rm\u002FK+0djiJeddbh1a94ki91FGnLUhS8lV9GvNNkhnK43QeNz\u002FOchVayICxmBda62ut472gKMT\u002FO6lptk9e7quCzzuO4v4sAZLpALtwHK81eQy+mE4drfGOJwya8pN4PyCcaT2GfOw1pxb5JuxmQ86hFvUntgfQN1hYPATx6TPRlWDGa0r5x66k9rqjJbr7QlMAZyvFwFq7URKmGLOeIB3e6XxvZhHK\u002FFiHpsLQ0l1cDjH3pjo888\u002FLyxfr\u002FMWiXIFpBAxK+2VV4414UKyKRotFq\u002FkreWh2F4eGAtRaszFBKfNsECUPIV6Lg+SgjceJekydnUss94HzIAyT4DU\u002FXg+t\u002FRETJcKObI2hbIv93nX\u002FOKLLycUua+x6M2u6wECftgmbUyoAg9CKjZEpfy0LhsFVU5lniJpLCdPnl59\u002FuWXq7OnrwQSU355t1jSwEpkGJFkrUUYwDThAmwIb\u002FP+IXRFPRhqgMwIPp4t5V+LYaMDzpUsRsWoWsBd+eJ01j3gKGy4dfVqrR6d1sbbzLARzuXpXdvs2HRCqxByzAawYzoWO68Kq288DK1Jb\u002FVYogWbI9RDh\u002FbnzSgM2L5cy7uT\u002Fklw5I3KK9i0Aved+FfY9nbdDnb2c1NRh4eNXZjvdPlzDgu6HfA3zhsJIoz\u002Fzrvvrn7\u002Fn\u002FxB1vPGWa9\u002F\u002Fcf\u002FZvUPP\u002F\u002F56jvf++7qH\u002F3+746i\u002FFf\u002F+l+3PkVjAvqKBglqHm90pI+r3H1yBAvEWSRCDBijYJbmZg53A\u002FMjZBKUTyvOfBIzb+hzGwnxHpMvnWrUbUHI2ZHwBKcDtM6kwEWDXAujoTMFisOA3W9n6TKHDtU7OZAB5DpkYmtK2pqit+d5mhP6HaGQAGwOvDUMKvu8qcIx+6ZTwJ08nATGO99+d\u002FUbv\u002FGbXXPd6uOPP139h\u002F\u002F4J6VPlS7x279bKPpon0nRf\u002FzxCJBf\u002F\u002FFvTP71p5982JjPjbAGegFTh7MQmgOCAjHGOQZyr3v\u002FcQLNnJ4LNkpD2pZ185iwZus5nul4E3D1pIQnbNrnx2vUddSLAOxybd3TCaHmeeN2+ZZ5+fWGBiwXcKwAJ2CeoJPXp2iWIUAoasUogsV7JGdQTrUIkZx3hgMZsCeFBgTpyUvZHD12bPX9X3swMoR3FqCcdJdqGnZHj5c3B6y6xrWreT0DX\u002FaXrLAXWrbxTLuuAvF7AXIhXqlxe6qRsAY6xahdYQCdzfuqAFNEjcwiI3hXGCgbnmaglbsutQvdoTFGLQXKSKEsbmZQ79DmMyDweLppCNlvywDN+DpfGk88ve7KzWTmS6Ws\u002FKDI45U52OVbb7+7+qf\u002F5B+vfv7Tn5bb\u002FmlnBJwZYM5TrNWYAmIG\u002FaNn9QnfefebpXN0YM6pk3MQ2JEjR+ZAn246RrL57Nv10vAWB8CDh\u002FUmb1\u002FxCnrVjhT9ik6gN+kSFDneIv8Yf5Si79iD8c72Pi8Y8M1olter08Eo1L63GK8ZiQEQaw1g0AfWlzOFrI8zo6X9tbA8sjp7oRar8R9IgbaAoKiyeefFi5bX5WBQuBrbNiYRmcBWdHOzeV+6tDHPWn3u1\u002FY+o2byl7FZis\u002FL3TfeO1Px5rkLneLa729+4+jqo8Dz1ZwHq7KktkWvm7ZUSL0vEB1N\u002Fvlf\u002Fe3qP\u002F35X7cWq\u002Fqh71wdPXxs9Ws\u002F\u002FMHqvffeW33wwS9KtXht9Vp0ePH8mQzGDrRqfzfmyWx52v9ywemp6OB6Tiltch3YwzDdl1yzb2ppAKYpZG2tAdBNFRgPL8YbeFp6B7pdvJPP6pS6wYCNwJl1b0nns5Mr2\u002Fe8Nu8nn7C2NRjI8XSR82Nkl\u002FZhb8jAv\u002FyLvxjDFo8ncNO7ZxuHqPUn89S8gd7SJccp0hcuaJ5QY4fmS3Y87nuMR4vuVFJzou+GD9q3wckixh6NjTEHOKED9UscbXeLSgPoe\u002FYCyavRAQsQU6ciXWpjTRAOrfZmREWUq9dff331jW+8VdH0h6uvv\u002Fw8R0jdypIVFy5dLM0LgCPDFE6LoARKo3eLgYal8UlllSaBb1GJSNKO5PjOHHUcdg9axwRlPIaf6yTU4VK3pF5Fj4yFXs44LMKaPLoT3Tx3LpjltuicvPBUr4aXbocdLqeXH+Q5d54Bh6bUVnfnhBJdIZtgmRvJKwbCTcWu1qqx30t3LBHhqCEFLBpqiBOhjA94zOkpclAmAU\u002F3hvjLGnJyoi0HJYkM42tAlRGAv9caL6MD4XoPzdkLhjCjgF67X9R0vO+zibPV87e5wRf4Gk6DhdUwkCNjqPTdRfY+o93mayw3asFqSxpC9NOWAsb9RLtTeM6weJCeAntrzSvX2\u002Fx50hl09tBaKdYULYXzNNCAZzgIRdnRmX2B\u002FxhDik0Z8GNEdDv8gr3spX0Dqul0Bol9HxKwFr1nP9CO3x3wJep6rYguzGbMXWLWXLqfFsCbHnJuLAZBb72QxwsD6sfefH2EFascaH7pyLE5BEiHDyf5SS0xJaDr66+Ox3yERcURATq\u002FO0lO2IV1P3nnMfxzAmj1IhpeyzwkTftIHlmLT9gJa9ggvbW12lKhLa+acUDYYYqbeTkAMCt6KaHpOwTEWNQtNu\u002FqtQTqtHxMie6qyl0Rqu\u002F6nrQdUQCAjTcOkJFWo53a937wnQ7l2ZEyPd69l+r\u002Fr0+ey+uXxyvvtXDZ7\u002FyjH5dScibGSRnESEKHcot5NTArAp9juAuTbcr6jFZ6Ncu8vqDbd21e5fdPqF1ZffDhl6vzl07mBVIoW6eA\u002FfsTIrsa543ys5f12hlIV0wnB1M3CUpmW8V+woVENmAbvSZctY7kCVqqsO\u002FEDDwZFIkuJ71aAU0ewbzeDwNeuyui21lhp7STszc69TUg9CDh8ijP4I28666+O7BGIAHqF532GFPuydD45jvfnC49Xxz\u002FcvVXf\u002FsPk3fOw\u002Fid7363dTq4+slf\u002FmSiMJvbf54N1jhOxoCbA4T2QdrT1TrL3Iu2FMLITxcCBySsF7DIW+bI6QES7T3BJYTpuOk2ovVHJ9tnvJcvSH0qgpKwlnfvkCWhv7a4fcPQmNN+tTkt2J69m\u002FM27Wn\u002FAS0pSBW9upO96\u002FMb8ohheswucoOJk1e91vVLBzJGoEMxp1MKjfHll45ORx0hxb\u002F6yd9OeJyB6\u002FHmW6+0BA7SSZl3ouJ3vvPG6s0332jsWvD9ed71igtbHwKU8mW+UFAErXtSTk+ja0B9vOh9Inma9c9bg776z99JpDFM+p4WoIs3SAQsKdplH+Y19DtA5+evvH0ZoJTytDzUZYOSjvci78B2\u002F7QOdwKm471rznOt66JeN5bruWbg+FwRDIr4YYXTm+qg8XhA\u002FKJsKJI5DyFp7jyEdXk8pM0AykDPEpqVlqPwU+5qY26NpyhpvCMOTslLW1rWjfU3U8RLJx8dHRgMj\u002FLc3Jx0rsLF1QUAFdPai7JJpjjc40EF4U4MPlaHFQrjQTT9i\u002Fd+UZpL3te+8Fs\u002F+tHq7fZFz33eTAYNA0Q0ysFIR2rdaGzSG24lCza0X4+i57MVh16syLShpYx4i4s2BiQVlbnH559+0vWphgcp\u002FeRjT945rSG35FFeH809qvXctSvnVp9++F48cW9kkojc5x+eX71ZkanCY7B6+\u002FYKxDMcyNrzyT8KPLjRekYnzYljhKd0iu2jr3GqtMboWREa4GUDfR692Ws0QzkztChsB6eJdAL9ZJyRoyX8zxHCI0+Oo7tVRj8A8oCR0qVf6iRjnaiWTkcBKXn6OTEexDQAxp3Gdi86BB624enoRfcw+cmPi\u002FSlnicN7Gz1QQcO7Cxid7hC0moNMhzWShO8mYPB3E+dOdk+SQ9by\u002FD9PL1wq5x2B0ZtWd2KvvYdOJKDYm313i8+6CCtz2fujF35\u002FL\u002F\u002FB\u002F9o9c47b69+8bOfzaFCrx07mnzKEO4\u002Fj0d18WKAyo2WZqBQfXf0e\u002Fbk6dVXX32dbtlWZ6YOyGv8DCUuYHvi8+ijSWDh4UnrTHd5WC9t7RZgtgCHYMSACfuC3nwZPYiYiRqOB3Su1\u002FeSqXPR1nLqBgKIuhRpvqDHvjMY\u002Fu3\u002F\u002FW8msuzQHGdmrKtWST2D\u002Fb1SWugH733c7j9J\u002FjOKizhxPjWHre39+pQX+cww9xrgO1Qb7dwo118HNIBS7j4DDs8qvD+876WRtfLNdUK7WFvOM9UkOTtiR+8zcvE50EgO8LouqRZLs4nf+q3f7DTeE8nhLVP\u002FcTTn0pWwxZ701L79B1bX8v5\u002F9XWRLDKtJ36WRrFdPUx8ITo7qTbRjjoIJah5olaPSyV9KnqM+O1T3\u002FFgvN3g\u002FS+yYm+eRLhB4XROXus+xxnIGQLISS070JroZgTscpKdOnNxdb01ygc749BAQ3c0UWB6ThTvYYbQ1WSGh9qCxclWFLhC+s2lWG6I90eet8BaOUut3b23LmRdhzG9Y13dedL9IhVB66GNB+kxjkdOhyigvWXModPqfnbtaf861PBeOfLj9W\u002F8\u002FT2R6fTuOMG619PHDm9jOAPs6FU0sjzJ3kMjcINCS61vW5nk0BIh+RWIRRf1QPcgmxvqLO2WIvr0z2Ci9pljRj3cWq+R9TeTg7oIoScZBXAlGegxhg1jtTsqDof\u002FnqaPENWOdItomwHiGwciXa5QHR9wGvi5Phr3HTpNijV93Uq1FmUQtOfaU7rH4lAq5ar9kaYtLU5U+9Ll8EJ7zGBgbMA\u002F8MWGDMVt7Ql9Tz++qMdChS\u002Fgav\u002FL\u002F\u002Fq\u002FrX77d35n9eqxVwutPpmQrXQIyvvVciaB06+OO9QhAZ6S1DGFwJcvCGgo2NPD+F5CGtCxMAjYEdSUBG\u002FqFMm10AQKSw1xToEdQdbCjrfuXuGMwis3W0A5iy8d2L86lpcfsGd9YTIEx0uwU9upBKe\u002FAXFhS31ll7QU\u002FXYLZwf4X3vttTEweMN51trnPCZZnCkcYcBvf+9b5fS90pzPTd7zWqkqeFxBGyJEzL\u002F4xfurj1afrl7uAJXd3Xeor5l5T8iPwkPE4ZsIgIchj1RCaHOnpiGoHbvrYnHk7YqePlr99KfvZxR0+mceSsV4D8ur3Jo3KPIbRcrilrKztfnz7Gzp2ZXjjjzio327SYJrXUT\u002FtPXl+VH8qtgSU1wp93Z9gnpTg3mawryXR3NzDMNzAdjqtKPg83bC9GkgFGDfVj717db8paNHVzv27i\u002FHs7zv1vhQB1Io\u002Fv2Pf\u002Fbnq89qK7elcPfeBBnDTLHxqdPaZN4YS3s8TDGYsPCjlIFDWgAFTDRWdMJVWNNhCAtwXJhujiRvXjr1PA\u002F\u002FNczVhhglH+ozgc\u002FjoD95yqlQtrY3DCuMGvW0buWLR29TtR53o0E6EOhSNDqt3w427rw0PHlrCc3xrrRec9pl4xwrupDv89ZyFC7tO96hdmA6WOS8AGgo0EN1JeFh\u002F\u002FizTws9f5xXes\u002Fq1wutHzl6OINg89AcEHvz+sU6M\u002Fx46i1++f77CQF5rZtWl\u002FJu6XizLb6hT4RpgZAxXtpJQs1\u002FHBZ4yHCmaAelhAPQiV+WNm+NEz8VxiNgx+ve+36fUGT8Jn2G8tSvfL1QZ3wsorC1ImhzunM3EBctzHHLjV+YUFhWvjbjj9fc3yPAuy7AzLD3t5WiOCkQ47APPM8ibmfOnpk1d9S74suf\u002FvTnrUE0t72UtguX46G6pbSXuxOiF85XaB7dKHJ9\u002FKgjn9vvph5wjp6b67atpZ70kxAGUuXJC9s2rdaHsSCMH4BNSTwOYPCSAgjnisidOXlyjDodnrYEHpLizbd0uJ37V7eeXEu+nVrtQx+dD8Ax4XRMxcfC2QyWtZQ4ekuwdLjWq6sjr6VArt+rBeMnq3\u002F\u002F7\u002F5svP+uvTu+1u70b\u002F\u002Fmr9qHfM7N+dVXXk5elqoBEN8p6tN1RDDUtdy\u002FfaN+6hdH1tyPx4\u002FEc1JBAG7eQspKNJMxeyvQiralYQAXAwaiXeFkofrnNQNk73hZkU6PhZZnKYfHyF\u002FXAxYfJgfWdQ12xdPuh6x8HqBGv74lLcVntwdQGBP3yJ\u002F2Jb\u002FeGCk32q+bCtrxbGs1fvvk0a06ZN0K7DEQNtirgOHiAeXtK4qbYnyacu\u002Fiea+vjz5hYMvJL8cvcNX3b\u002Fd3yvze\u002FStFfMqDT7aiON5SRfq6rmyvJsRpw6dPno2+flZ6zJm+Hq239gfj+3sd7vY43t5VGgRnwfEvvgyobhpnkflOMd2sFDpObyU7ROnOl5oEgPhe5NJS5KWNdoBDsgprGov9BHIX3oA3ukCfff5Yfo3Y5mGh+yUhR+Y3odayFQMOAmZLmsBy3QS9q8bD0lIUJ0qt7NXk+vTdbo63S0W4UlTgTnLkyJGX8uaq+ehiPEjkV8W82h3yImtf7LGxNbyV3hExw4tT2B\u002F\u002FTv\u002FtFmTpCiNS5XTPDm072BkGA\u002FQDau2VIt7vf\u002F+H7Yk5bVy9\u002F8uPVv+Ar5sLB5JiTzxqjpwt6Im3kxHCeQYcHj12pBTIq9V8vLJ6o98vZIhdbx6iTOanBalFJy+nA0fzt8b0y2PGRWPQiWjbjvY5p9qTjJTH8116BzANJLZW5JRI8KN0Bq96ijS+j34xlr9al\u002FHiMuyTV5wkt\u002FrOzYz5l+NFX+GEVI9xN\u002F7ctCHAW4GsE2\u002FXihJNjUH3s9bLmKXz1M2q1qAKKkXDGOdraD+8keIa41hRdJChr\u002FluvNTfnAfSnUQtHgDT5ASnZfsFYM89el\u002FEL6JrTNV\u002FRM+81RtLIXIAlhaVsA95AKyvOmRscFNOD+vPSFfI+TQ5a08YbsD5lvSiFBOOUGnExqCOzt4tBhejKXCcoND9zYnUdJb3yRJOrIkUxnOwiFauG9yvPRRtbnFMZ8bCs64b2N3uAfnAWZaiF6OZhR7HUZdg\u002F8\u002FH2OVGt8iLd8\u002F5r7mLSohy25cQavfJiMan1rMNFBEnL\u002FfslQrFAEs3ZdyQxw5o4qwgo6bWIXptSPN9Q3oRj5nbi7jQewHRLz7\u002FcnX0yNHVG6+\u002F0clw9eMOIN66qSfpnRF2b7315jCM4huLtLsJv\u002F32N7K8617Ra7w6PJk2fgmhPV5d6nM2knKVugLAA3882zwR8qsnV6rvuCZlLw3H922UkIhUG1aQEKkc+t0BoiOBd4DgQoJUL23ARNqLULfWXkI4QLQ2g07D5AngpRYR0CbvzbfyogVGWPE3Aq2AnzzROYSk46mFyhRifvrZl6PsL17KCCi03i3HOiS4hbyWsFnKtLkI36vkBtIZLwQ7kPSwHGvepG9+882IaWNFP+dK01AIKSWkvPjdWeeBSVa5oqubCYv9eRUcA46HHRsO3Oq64sCCbhbNJ5giLAW22FeOldzrzXHC5fbrQV50ObiMh82BeBMR2HYAAEAASURBVINRmLMzK7xS8NXVhLkUh6dZprv21R3hyLGsSgpw\u002FerAy8eKSuyZPf37n\u002F189d4v3x\u002FwtHNPB3pExJQSw0nhFRBuDQA0FjM7mLJSyCn1aOgghu2lngnH5kKJTR5iDOR3EZUx3BKQM6eYBqesWxcgiS4ozp2FTYEygB+425I3fQDGZgIjedb+MvSkPmBaXUSAmwHpAc7lmGaFqLyZxhKYjGb69oyXJ3FCgc1n0kRwamvR8OZhnXVJ2BwY0InDe4yGC1+fXJ386sSvAPSVi5fnMKnJCW6+E3pMwNujieo0RxGHmwHAUOh0z7gf6FrLk9THU26JHrduZE8TOlKwCG5j\u002FdV4Z8zGHj2ElihaHjPfAeKss7kAWQTpALZocXgrnpi1Nb9owvoTyFJQ7jbOPY93zzXniGXzB4hTBlqhAepTqB269T0h9OmC1B7Z\u002Fw0bdXaxnynPwLffyQXRFL\u002Ffzdu1P9A0ueopc\u002FUQ9tL+Sos5eODQyAIgVKvWJ49Lg4hw8NYUi6cgNmzYP3MSEeMoYCQDzxO9SaFN4VFr7LCyDckA+3bzVrwc2JLWoVPKziNF3QLT034wvjtfdCxI0OFhgbiUI885T5V+zca\u002FFXCMh3YnHxxQde\u002Fek9W+Ul8c8HPq6y9X7\u002F38\u002FdJdTqWMo6\u002FWoTrSocHbudsb+ihqqphMUjAOIMj5pDDRn7aDFy9KI9hUytRLk8YDzP7wh3WZOXkyQLAumVa73BT+y62f7gVkpTQXtD\u002FevTxiHCGUkfVCd3ht4aPl5+LBTYD1J1qQ4oOOpQVyYHjaU+CfoUV+uib+bjP6n+c3sNMa3EmmbdyY9yl5h5a\u002F+PyTKczUrWX63cfCADcvlnUH3ghPaQsOp2IYHK6QF+gVimaYOPjrbgbjV8nlMVCaNyDmAKz9OWwU1cv9Jc+slfoacvteqRc3RXZ73h+G7UCk1mh\u002FtQicIUDOL3\u002Fxs4ywclQzBgF3qSPWbykwzFvbvo2MipfUVfCaK8y\u002F3prYU+u5FD+Wsti6WD+yjXwCCtdHm5YbveINa+XnPMi+5bf51\u002F4sAN2f9qbl9dn57mII9\u002FUZzxxE5PX+c206Fki2BzqWAe8cD4xrXZwe3NcyU0opHq0lZpcPs\u002FWZgFD35ZU2dn3tgTmnK5Mh5vswMM9va0Tu0XYt4Ly5Owlcbj660F7wYpHzV195o+9pG7yzrmjVq0XTl4s0TZ0TnRM4owc1bIDTXHgtx4Z0jq+TmRyAZ06djOcfzV5u7u976aTLRa+lcErPa2rRCqdLOqIB4W\u002FF3RoIAJdoU5OFhxlhKY+M8ozO+G+cGKKf0YTIi2LOe7XsZFhYzUTf8KG9IHdDHgM+1a3ducOgTg8XaRbR4UzbVVTponSJwB3gvqEvae+6OX1DtntYY05MfMc45wTZVbol3b45J1kfr5NLhlPX2rkrwzZap8OmZWffGTnfnmyr5Wc7OGvbnaorQT0LWJ7oTYvpFbqQITt6JdqQriO1D8gWcfDYxKprf5\u002FrD68t8kfaTCmd8Toi4YyCp0Qk3WPkQ3SvgNbf41gQ5Rz9T+8sr8Noz51xTqJ9Ks89jNMnes6t+7lgMzKL3IOTjF\u002F6HMxGX8xhd9GlN+jARZ+Xutl6+uzuB8m81lydgowDKXtdPX5IXzc+hgMjROQFeuhGY6QwqKcGIG87fud4FqXh2LhcEwU1fds2LIbNo9Zh0bE5FdontPaiHi8MqH\u002Fn3W9Nsae+oFeqIG8VZ8F4lG4FfB84cjvikwt+6KWDw+A8XwTwjlIqEOflyxcSJgGNNtfq+nntLu+n\u002FGkn7SUoImY8C1rIhWpbxvLDWDYcoRM6A4x6TRjoSp5wBDjAuPdPnz4d8No9jMxjDjCyul3Xxt24kRBKyCMioQ2tGb1HCdlo+ain8\u002FLpJAPcyrc722mE028bI+fdEO49dSIFH1ha2u8pgnFkc172mFMo5\u002FGTwHCKbI7rTukKDSI6FjbwFKwYsXc1T9PXJ67klbmWdzqPUGJhbzmDTjfdVxeJ3YXGxvJtvOu2BzQbYxcfYrEPjxPKxj8SpbXEREKkk4+fMmRxAr6Y4yljCXjv\u002FemvnSIlSDY2Jr2vtVVaFzA6llBcF+j8+pQOCoW+9udNP3wshXioDgqHpovA+6Vz\u002FN1Pf5HFXli5SIXe5HLQeEkxOMUF1ALrlIjUJsxIgOiFrsjIZwgGYAqNYDrFHyz0vjLrRNENOO6n98fqT2D18fZzPtTaJpgSupS2I+S35j2Q57opoeBzBK572AMP4UuCnkdNKpTe6At4ti8JS\u002FTSd3x3AEzjJqzcGzgVXjQY9wV85cVi4q3bEkIMnQpD9WK+Xg7znACYYFAAJZrB+0MZ6O\u002F\u002FOOl8Pfr92d\u002F\u002FQ3m8L4+i0z3iRq+NUGl9tAa05+hlwJWFcXNr1lgpx2WtcMsyNuNa11gfl1OHz4RU8ad98HAd6wEMAiFoBrjxGgHnY\u002FYgsRztlaKU53nnkyJFeYAZl4TbPLv2kwxngG7oefZhOSnxfEWQsV4PXhrDdU+eTvfJW20dkge8F4w2fIiHRNEo8wFvfZuRxqN\u002F8GCtNEuJMF5jQ2OuY8z2xf4AXcY+eertmS5AHAoMMtExAN698JODbkR7jEO3i5dyEBw7diQZkyer62vBdjdg\u002FunxL1aHo+\u002FDrxxZXbtYl5b4ZH+0c+Ly+fY\u002F+g58uv4UWCUfHjeGa4VOj584v\u002Fqrv\u002Fib1Refftn8UwjRiHs5bMxeMArthtZ16IKConjwiXRBxpS0vYV\u002FnoxTgVHzyUcfDv2+euzo0JDuH7cz6h8GNMgeIXlrBFBbjOeeb2DSDclCfOj5fJ+9jk7MTWoHJTTFbNHJpEM1TuNqk7tuBmRyzbkaz+U1fW8f0Oyt5iM1QerZ9pcq+gz8mbOwty47QvyP6hozfNl1RS8YE0LSPO6zKF2HfNqqsLb7isTqzgOIarmHh\u002FAy+tTL\u002FuHjyyOr9fyX9wyg79i+p445B1YffvzZ6kzR333Jrx\u002F+8Hurd7\u002F73RwwV0rFOJPMaFzJ0C8vXSw16czqraKr\u002F+yf\u002FkEAaufQyif1xjdQfDJ81E8pnTdy5lwoBTAyGfq1tgCEcT1sD3kr6S9AmSzhkQZmJh\u002F92dqjHetvUYev\u002FdqDbgh99hsZ07MF8blxZPSX73Fe2BeOCx8j4\u002F1OvKnfcA1\u002Fa1EsHeTXfu275flXqN\u002F63czJlNZKr+XZjdbVZog+3M\u002FbPAdP1XbQRR\u002FGm\u002FZzDLAYGIgX6ZTjq9PH6BO0xOOMtpPrviklS3T7zKnT6cO9zW3p0rQ\u002Fh8+l2tFKbQTIpRLINbZfxqrgXQSSg+rjjz9Z\u002FVf\u002F5X\u002FRd9dPK9NXjtSg4J23Wsenq89b80cZDWhpU4Bwa3SGpm9Hd1KStN5dCkF5UUciRtfoLflTxGBHfN+2REvOOym\u002FPOPhYfyp6xCPuj2FN0b6xctTXJkMe5LxOc0sGrfCUykvB9KNItsaPGzefKnvlZaSTkIH0xmH\u002FmUExU\u002FWz94BmXNoUZulm5mDszYmP6Sy6oiyMcwhCk5nXw4bPBHWaxzOYBiZTJhGF2rGtCImJ1o+VNTYl5oTuMb3OR\u002FpW7zJ8Yjn4ByOCY6qdYPHlvaVk6LSHjw3IhniHjQi\u002Feu56Bc6fcl46KVZL+Oa7IdWjfGF\u002FvztiTbpcMSZ076fjRehzpWXtYYVyW86CObimX9+T46iJZr8XD9ZBzyDJxY6H\u002F2FB\u002Fsb5pPe4zV0SXesOuqHbFO4T0+7twd9pCjmkTM3GhOHD\u002Fm9RFO6dp9nwNKxT+4tmMp6ko\u002FW\u002FEU9XhhQd9iMVmyOiZeD6Yh5XgcnYra14\u002FG4mwKflIUWCJjhQeUh0aN2cs7LAWORISxLZVGXE8LqalGzE4\u002FJTUXQLRigde\u002FeYrUMwG+D5bvZIDlto6BbXMDGRh48cGBSXihvXnEKB0NJe+huKQ6CJqLr\u002FjaLAne\u002F2bguuisFh1lslgdvCgvxV4wVf9zMoj916lzMtSHwfnE8sTs77XNtc0KQKZ3ljdgmJy3jZcKPPDzNicJyLSwlhI2R9UYHcHR\u002FuXZVlfyt3i+qcGh3BTWvrHYmZG9nCBFolNm+PdtSMnXPkVvZ2BkVjwOAmJTiQljrKIohpABua6BFmNSiKxUn8s7i84MBVaHKWxktjJOCQpYoL2CjY2EXOttZuPhYaQM7ip689sY36gV9OOCzrSjC56v\u002F54\u002F\u002F7epnv3hvBMPBl4\u002F4age\u002FVCfQb+Y4xkLr8MD+N0aMhfHRBA+dbhkMCdTep0cfjfc3ulmACUUXwzevhSFsOqpptbr+KL1uCtAIbW+Rq1oKj9xMShJwGzrxlWdMuaQEOATLCZjlorXfBDkAgpYoMYzP6z7huK4fqw6gGYDe2s6YyBxjI3wSTMJ0BOm27Xl4Ep5XKnL8+utTedzOdZ1oWo53cwUsrbl7EUwMSEpPC0ZjEokyRp0mFMbw\u002FBO2a32f8ljm0T17z2Pm1w3GO2RMzWWm+\u002Fy9PqAN4ih03vc+O57llAFQSNhYS0LWA3AjLAfMu02vAyie+EsEp0+MsKMYu13r4zOErbBlsiD+bHrtM4UVmIr38ByB6HPG7m\u002FrOhGIlKYxP3yYIAxcuffuojU7Aur4iEect96a6ZUNHF4sSma9CGSvo5JlzBRKXrOEs4NnRJFEjCi9tbqg8NwKZaI\u002F6WlGgT61gNzWGo\u002FH2T617lOc21rgK11ttEkNtXTkNLAbrURfewMe58\u002FmtQsUu79uB5u28fJvDpx\u002FtfqHX3w06XIUgf94kK2bIktAHT34nrmQhZQ7PqcI0J\u002F9EBWgfEUhFb7jIfnbQJJDdESCTnz11Rh79wMhYaPWfinAImfHYCYTogWgmrFi454bne6Dl7pc46uDVmDNwVjkyKS\u002FtAaM3CWkTZ0oGL2XcbsYA94jT12TJ3mK5zJWFd3hGR673dX6KFbkebxVj2L7IJUA3QIvuijwkJNRW5rP9jzWB\u002FOQO\u002F2TPNHreUtpAg+LGKCr281Pqodicuu3sUia8L5op5MpL5xnJGjhVjTg+Jm6cdxdHXv9jdUPfv1Hqx\u002F\u002F1o\u002FL+92dEf356l\u002F9q\u002F9jSaMI7K1Fk3dLMeJ0GtD5oDqlZCV+RJ9SAv1HrvmbgXe33t8HDjrJWBSxV+MHwFwRHLlrbCLIfgIvlrmNnr9HjvS7ffHwbx9rGZ85JfrD38v7y2d8jtwnr1sA34g2nr3ne+2DlJSJbPVT9yk8ZsvfeOOV6mDeio464yPac3Fe8Q19huFxLf3zyScfTfqdDmzduP1cIhP3M1Y5QfDB6ND0K8M9bmuNpVbcmmgLLyqwx2P75ltvlhZ0LufO0ei5qGo88lK1BSfpzviRwF8M62iqe5EHaJAudq9PP\u002F189Qd\u002F8PsZzq+sPvvkwwHrrx57ubTKA\u002FW+P1ZUeYk4PnlYbUvj4cBTC\u002FK4lE6PMYy6ruJDa+Qz9C9DeK05O2xQusO90qZ0GLsd+Bbl5UjbkBHSVBoiUMfRY73IUVfGecbevDktc8jsLRUOb2khumQFFCFKti6F540tfaI9agNxgebfnPsVNhGZv3OzaCKvfGl1j5J3DFOyhh62Mr5Fljmj5vl5ELAAngS282\u002F32eigJ5kxhk+DnVqK+My4Nz1LaWJAMXilMMmvfxzdauogo4FcY4wC8qY6hyeSScnxLfHY1hwL5oJ2RjYxzqJFDo1u3n1EdBhtjMb2IH1A3jyxfv0c4+dXpJxO6DUedPdWY0Lvj3PN2kXndzLuNeYgxzgHRna1JmToFJX2eXIKoDfX3hn6odPRkTVKuI7uon8ePMrw6LPW07rBlKMze0HKnWwD0csHef6tO4COnxmiDtoydGMkn83Xer+oxwsD6t94880JEVHuFoeCtBCIzYlzctwwMS8kAa\u002FNkcJEnuWNgVGFoUJpkzPaBllsnwMGMLF+lcAsoUYpsW4sNi\u002FFCLwWn9CMZGdRbRoPTOsZeK54pJQXBEZosl55zhQ08haMpdQGAD44pCvOHAhXQF2qDOXpfsC5UNEwbJvHgmRHborBt8esGuOnfxIkx\u002FM01xR\u002Fm6ttnMLJPeWsOoL+6eQ67kkoJBhiYMoQOGhqCbEYMQsccGPN51voNR6NAElMdS1Pz6NH8j0bb32gFYm0Cq0dwstSzFBSyEmZ7QtoXrnaYLr+umfeCYRubTEcYIDQ+ursjb7Lly9dnIN71l6q84v5Rax3UrysaEZFsrvv81J0kEt9ePcfCdAFznWW0QHg73\u002F+3urf\u002Ffs\u002FXX340ccJv7ySgSpWMgGibZLUm3VyM+JNHrkNOxbQzosppDmCDEO29xS5RRG+xWxm2oJEEwtg69dZM0wxwvI5Y7hPewHESMGQ9rKlMSpIpBB5RwkSAsBXMLC1582832DnwKs8gpTuhI57n5GDzgzBWPzqNb+jd+sTCfaIhY05SbR4mghgdwh49ZroCq++PEZpRMKa+p8Lp\u002FF8ziEllHfXvhNABwbsLYBmb9C7EduzddE3gcFwlDvPAG1K8\u002F4IGbRhreelWa1JsRnFZCJN\u002FnkkYVkLOcBLnvh4CLuXTjUePof+CXw86YnHeEQcUEPIum5qoPk\u002FB995XVsTRvk8m1dL1e\u002FCiJQKg3c5XXRLIAs\u002FUOTWFqC2\u002FkDDGOvNbdsmaWHlvcYjPOE6xGzf7qCQBag\u002F96afbyMoXQDbmAnyMZyaM7AJ2JM7dmXHDvMQgVu6ozhd1z2t5YRQkwcUo\u002FoF3kNFvLxdvmuN0LAWmFcznu59cWf17huvrfYmK+6Uk6315LUOi2nIzWmhDyDg\u002FLkbq1\u002F8\u002FMPVp58cb+wp3ACEELs8Z5FD0Rt8d72zHqyFUzMdpKFtGMUxoKh5oGEAHrAhbxmUFG0Dr2XjuQDhzdVv\u002FfhHjbP1bM0BIgcASUWcCFxzwGOuY62FvqfLz\u002FBF+93AGbr2GE2TW9Yfvf8K5Pfd9XJ10FK\u002Fe5DPDB6fGyPD5+NpoFtBpQiqU1avNL9zZ05l2JVa2NxEQsscCBzbL\u002FIGUAfaWmvk27ymI1TRCh06pChyLFCiQMWG5DlDAk+iIy1LGYgMZXM\u002FkLy6nodTxNOJul9WM3OxtMvf+Ee\u002Ft\u002Fqv\u002F\u002FCfr959953oatENV5KFioH3cFakm3bHX9szfG4UAfvssy8GBCmKHOCZnlsMmsBF68OZ4oh38oA+NH78NWC9NaITRdHs2eQNx4rjXU+22l\u002FAyHfm4Wfr0FY1\u002FWdyu2ug595obxc+nM\u002F2secRFrqzKw39JwoXMNMezBZ1PfcGSh8+lHqwFM0fOVok9OLZ8bAbN8\u002FvxhwxPJhqZs51INWpvks2e58zYZwRyRl0Iqc3luh6PLXL6dBSElYVObZAeSwVTEo32zZOkOOlr+ANYH570Y3XX3+jbnEZle0RYGaOkzLUvEV\u002FOA02F72THgoAP09\u002FOXvmZHUs51affXG8TjyHcyClW9EC+Zmj6W659OvWLUa7lIcNycSd8T0ROPsQ8AZUgXn0ulZ+8qOiT+uLtq6t21wucilO1b7YW4cEbqA\u002FkmXA4Thv7EPJb5lprTeZTCoPXE\u002Fe3x69ppPakcN1XYKJktci9loF6wwjdWucCiN7M+oY+31fTvudW4oWpRRJAYpukj2bORPbyF8Zst0zblndr\u002FGAvHt7\u002F3DjUvRKjpGF1tEawkBSvcBR46dXPNAnfUYeoT3j2riekalWYAGkjA9yMxIYRx91R1+j3YY0IJ3hTbaQS8ZIvjhw7bncGKffOCy7RmMaR0\u002FrKod\u002F8tvjZfpODRanFRkqbXfBjOG+rinFhuG+GB8NonuTT+huolbReQMYGcKZg6ekrYye7jOwhu9aE+suzQhNVtHnUl0jrNLamGdXGR7zGTJDNOjh6FT6qdeSK\u002Ffa461qCZuDHvjm7suMjBf1eGFA\u002Fdvvfmt1NmaRk4cYbiaoL9duS69ZVgiC2JGwA4wBxbMpvBMnziRAntRu7pWKLMsZL\u002FwErACPFCeFYuG0ThOq6IsxloNEyglvCQF4xGyTCA6eTgpEQYZKX9Xi7kuY+Z7+7nIwKU0FEzxke+qasq+exICSzbPZ2odRNqQIMGvTFBUQyhTahHPjc+EOgFr+uDDTuarWnzy9n7fg9cD2rvLgA9UxjaLJb7z5+uRUUtwORFIcsn1r7cQyQIBnnnihfcLvUK2ogHVE6ohzhQ0O1THPq9cccCDVximoecBvb1\u002Ftb00Bc+tBuFl\u002FgqRpj+BZvGMJ7VaTQpEmwTsHUE3Lopjpbp6Dxx24oXtEsbTWTeV2QjnlnCHdONB+v7TOUljkpd8LLJwtR\u002FjJuqVg7mfvfbT627\u002F\u002Faf15T+WBLAe\u002F8StSMScgzvgeFx60J\u002FefFGaqg8oCpFjpOgQUZh4FlJijh8ZLAQRjmkUp9Y3WnSBbAHK\u002FDFP4MWCi73WHoSvztg\u002Fb86gLdQJ0ACNh6voExRBYf0y0ofXYlrdPmhTlL7xMgKGXSHYYE4BiNQ9wd8\u002FeeA7Wl\u002FsbwALWGQuKRne2N\u002FKNpfwA7F47cuTo\u002FNzqYIe8JTsSFAQDXgFo8M2JE18FRq633xVI55VyAqvOQQQOeiRoeJ\u002FHSOnKxtlWzjooijGuDf1cHw09B9IMUeClf4YvgDA0bZ5+Whf75R7jLWjj8Q\u002F+GoEPmPa5Ucq97j2PEU59J\u002FLqWs+EqNcbz+PcT49at0Vwt3554NCe+fo6PsJTOmygEQ9KfXmfUdZnbcfcqxVs3uhYKoq0NqAQyNMBAnCgfNEHpYu+3Nd+tUQzP\u002FszhkbXAfysh1Nnrxbx8VmGk3GQPdZeGh0DaluKQ7Sw7Z+xSI3Cd6IQjxr\u002F45QW43BLe5kzd3hatOnyxQur\u002FR1Dv3lbB6ddv7365YefrD4PVIgiPoyn5Mpa30VhLwab0yMpAgRKJol2oHugXs6\u002FuhxGh9cYFgD2wQMH8+Lvq9Dxi\u002FKNL\u002Fe5WsoGAnjVjx17NaARP2QQUaT20PXtn332UwTRz3kvGbrs+ZL2hC91OVhSX3i3RIDsIRowzlnelriUiHieV5vzAXCcNI8IiyxEWxtyzJABDNHLpQrdrA3sg5wPvF4M6clDrYBt6ktculQF++ApDeBBXrSL56W5JKPG4ZIzo7MQ0JGweUw+tIqn0ClwsW3b85aiq2qJHgf0agMZs\u002Fze7\u002F\u002Fe6g\u002F\u002Fu\u002F9+9es\u002F+mGfK\u002Fc5njt\u002F7vTqww\u002Ffn2tvSTfwjqNPch7toTneVWcqMO5nDeIrjiRzl6YkPW8tAGiNgLZZ1\u002FbQA9AAuv2FPu0xfpsCzNaJHLHeizzxfqsaMzgox\u002FXm+30eDzxlsUfrfWR4cAxQ1\u002FBCDgLi1O9kweJ\u002F7WV71rqKfBh\u002F386wXIplL126sDqRgUe2RP3R5K46sbzU785qAJxqn2qfWmeA+VBnGhw98koyTPtG4+T0WZuTW0VeDh7aVy553a2KmNwr6sTZQB9eu3kuB08RkAwrTq5dvb85XjxQHvul0mU35JxhBC9GjVqjpVPTprVqB\u002Fbvmda0H370QXLx+jQrkMN9uvqyvTnDjlb\u002FIZov5ez+7UOr86e+aHeSGzHlhtJ2FAdu3SJypctN8+eZBtbb49Ht8SS9uP\u002Fglgy0PaUxOUchw6R50wvruxdaRS8KvMn5kXNdl5FFBon2IMe1uoZJH9mV7GCkqnF53JqjUWMab3pgkaEzj\u002FZm7tH6a\u002Ff8pPMjniTzJ+2yNd8Ja8S3N6Iv3bUeZGg1hBGkPO6AORoBTlPoXYvnvjE0HvpP5O8+I0TUYPQYIPpMF0Y3qIl84FRlVJAfdA5+JU+e62LeeqTrc1iO3JRGdSdcY+1hNTqFzrCmeFflPX05JN8\u002F40HvfuPE6PM87HMYZPLMdUUHGZOcqyK8ZB0cp2vP5sdLd6VxVPQ6XgHmFwdkhkj8hU82VQfjhhxOeMzekK2Mad\u002FhiMVbZNQ4Jfr5pC436M5YvTcprn2Wc5ejLYjeOjXG1vZutUwaAEjVYkg+gS16l5Nyo3V4QY8XBtT\u002F\u002FD\u002F9WYRbAUXh3cX9v1gtGNRmOZETEUwOaouvKOr2vrsVhslBX1JaWHALgFy85hQ+AtAei\u002FD2HoKzIQoCEIAUlikm2OQ+wMkSSnQzAgpBsZZYWlczDvRrV0iDyQg4BxMJczMgKF6bRyEhHkrFke5A+\u002FnSFMbb2NjdF5B2Xw5HxSmvvPLaFAn+\u002FGfv5024UUX60dUrx94Yi\u002FOzTz8ZT\u002Fz1gLiKdflz926l5CIEVrUcaJ4jx1Jr0cYQ0SZxVx5XYV9Wsj7pvAQ7atn4+msvFy142CFLvA+BlATjZqH7xk0AG\u002FfFrsVLML2KxwtOEC1eFD1nKVLdSZa+p4yflFHUsKMTLyn0B4VAo8NWqPB4\u002Fz2OAPfurnVWHvLpSVz4WG\u002Fn63mb9uw7kBK7v\u002Fp3f\u002FKn\u002Fe17woyMijrkNCACkFIUMoV\u002FFzDFupf2pK9tVn5rjLkAR8pwYZ6F6HnhfScy6XqLoqGEfKZ\u002F5hnbN58+0L5R9hNWzxOpiFglOzqTlwfUEkS8AL5qv\u002F0cL1yvqzs4eOiAN+Z1AgZQWgAEAL0IvLmZ7zcutGXsrjVfwqiNZ8Bg67avLjjq1qbFYH9LgSFA3TNV3qB5EAHiUk8SxE6S5F1WPMmTxQC9eKFuNdENj5TxjsHQfQk764tPJi++q3Xr5dHnfLb\u002FU+jMNH4Zf8z0ZgqGPM9eNgeHzRiLOfsggAGwLcZKezDr0ux6fQAzKe+TLtIDz86pku7Va61Ob1ob4+va\u002FY6HedDlRF6\u002Fwdu6pDgBiPZfFAMvA5LuQWZs2QJsAzl661fwtv7O6nvf+16Ta58agmsBrIsR5T68xADJMr7FAAS8I\u002FIteecDBVMfE8AQ7bmknWjKT698CsKauTe+lFuuD7bxSB\u002FgQW8y42G3vvZAt5R1KTXdXQAfXr0L5eBrE5bTJR0VLdeP+IOPvly9\u002F8HHzVtP+CWUzFMHpAP86FJeNNnCuH0OHvCN3TM\u002FzgH0PeCv+Vh6XnYRt6NHj41X\u002FovPPx8g\u002FPf\u002F8LM6Cf1ahzQdXO1pbnsDW5S55wD1fkoFAr68RplNpKR9nM+0nU5O1qFBOs7OOl3x+MnrpPyeG3r4apGPm+caZKATiEXJrBEZReEyQvGG1Ix1TwNRORsoxXuBboaLblJ6Oyua58ESTZHDvC0d4DReKQKAz50UrdQBDo+R+31fq79mkEwVpQzYWqvWBm9IIVTYKyVJmoMzHr4d\u002FfyP\u002F\u002FP\u002F1DkG3y0N4+yMxWFGn3z84eqrr44nO+pMlddfxAqgvRqAFAVDU853eHTaXnc9c9nSXlHcjXd6s0cEA6SSa2ubOjCv8Qz3taeTTtY64w5GUk64hZ7IuOHH5SeaBUTwdWzTOizeOr+LpGaz9V4GUMCMLEETAISIMbDHYWFf0Qz52yiT67ymZI5rBFiLRIzOCFTjma0VpTupE0Bavy5dUGcShxc5YXNvRsubb74+kaoLdbTRsODb3\u002F52z+93rQ69SyegyaNHjza2JtJTpE8bPien3u7ciB3pWGeaSPt7ki68mv59qTa1V29Uy6bbTJEjrQ+ll5ETd4tMLTycgRad3ChKTU+TEV988dnqyy8\u002FbZyr1WuvHGl\u002Frq9OpJNapqLC+8ZAPXzkYDK0iNfFi6u7AW6FlbqWbew+ZOzjp3m44zUdntB1o259Wq\u002FWaGunRG\u002FrQDspl+\u002Fsem1y8gd0xv8Ao57g1pUA0l1qwGB\u002F4ycntvIMi\u002FpIC9mW7taVyvWfBnq1V3wU8EXL5CtZw8nougoq7d0UlIZzpCiZ49B2BgN9SD4\u002FjJ\u002Ft+83OM0HjvNmKaHeWpjctGrue1xaDEVCVd64oXWoeQltA88jZbkCPkTkA8\u002FYciA7yIpOkxkrVeRT\u002FAq\u002FmgJfRH5lgtJ6KwMkv1yU7eOM31rZ4iqfj+\u002FV58r1uPFqOetgrMpUOYICsX1\u002FXN5\u002FtDREAshBTAN3maI05vLb0ec4K9GY8HCQ0nM\u002FiCevCAcpw9hlrS\u002FeQUZpr+Jt33GfQ+uZ414jWDQ3EKX0GQB+nYPxnvd3DOOy3miJrIh0P\u002Fz1kxLQg7itarmONSMKLerwwoP7hBx\u002FGVKUvJGxZYi8X5lE4ylt4rv62epHvdDhI\u002F+nUogXdy4ePrD745SfT75Rgf+ftbyQElqOVKSOL5Zo2AqATegFcWFeOcvUzKuozjvblkRDaC9T1eRaTUDCQb1FZe66BIXjSKaTLFb26vlCza8l7oqTnezzCKfG13RX+JVAu5yWxIZu7v44gly4vRgFK43HbGRJ7o97FKsTfe+\u002FDIVrXOXigg2AA4AQi6\u002FlpOXKbN5WKEbOjVYwwrRRbM0L5asoEQVFwOrg8SlkBtA\u002FuHx7Bs5Zw2d06Pnl0oKjFtQDc5Q5tuppBQDHoCJG13R6cOHm607P0hq9Xa95+z+2t2VpzTVK0DogRwcV4CUVpCC3NhPUAeRXlmwIPcq8i7\u002FJACw2Vk64t1QeffF4nlw+oqNXRV1\u002Fts3dW\u002F+kvfjJghxd9cvBbE\u002Fuwrvvw1qvQ1rfX3Fi9Y52W+2dPxysYoxDSfcS3ZmyEhvC3vzGAhx+E1nwmRlpugsWwadTVnABC13GwEIMHo4qS2PMBw+3xCMqYfcRfrxMwinr3t1\u002FTWaN7+CwlQYGNNe7TXuvp+l4zH4Jh+dmoKFWja9xDvyl5RtGWrTsrqI0WMh66aLSa4Ci0zFMib5LgoJRu5EG\u002Fl3eL8CBsjRsAXY4sB04IP5GelAHQQxlk2PEejvLuvhQOb8YYCq0Hmh\u002FQnGI2duMySII5\u002FdL3Gn\u002FzTEU0cp6g1r2\u002Fl7qJxZMOvFkLr3ugVfO3D13Qv7Mm1npRrMvf7dxcn1ed8B3PaPxnTNJMpCZNtKU90ULPuMcLm9Af\u002Fn42JgpSJES7L52XeBfHE9yNtc2T+kA2mN84BtoXD9f7z8c8tNZctEMla3iDr9caUNcYc+dVsQrkD2eAzwM+EzaOzgEQET6H8GhvqoXo0+jZyZ+wia4hZ5J1h\u002FP27yzqdDnP9tYM3Nvl2B\u002F\u002F8vPVT0t5Ubh4r72fDhIBYNej1Mdj1Vx4r8yNbDPvUYrRJ6++dmqMRmk\u002FnBfAHANdOtVLgYuTJ07VHertWR+5pie\u002F\u002FnoMESdvPn1UFDElDcShAYekiMzIWRe58ZhIUXtrP9GP96UE4OnZ4\u002Fgsis8IkK8bsEuhS+dbwGFKMGDKuJBisDNZ4DPScZ62hrxX5oJ2tfdj3OzOAyoqeunqxdWWCxUiXU9Oh67l9166xLGRd7fxMhZ2d6bEjoBkW5ws1debUs+L1drIawdypORtLUXK70AqauX5Qg0cNLyP5NvL6Z8\u002F+m\u002F\u002FqMPijq6+\u002FOLjUhU\u002FGVmkKPVM6Tiut6Ue+Bfbqz0deKOQUBeffclighu\u002F3n+4LpmcgRZIZXyQCWQ1fQB89cExfsfz3ZvWYngLL42cSmc1dsWkPgsE+emBvv3lmiIRdoQh629pYXhXmJ2zZ16j95I97eA4SbpwNBtIH\u002Flafm28hb\u002FW7WSAKd7UNrEGC+mHm7evjsea3JAe5Mb2FahXdO1gu\u002Fulj5DZaEHHtAMH9s+BRT+phehHn3yaTtve3Bl7nYBbQ4F3v\u002FNO3vHaltbd5Xog\u002FM7tGzlz1nJCHFp981vfWr359jc6ifd\u002Fr2biZI6tW\u002F08P4WkOsA9KLJr7LlrovVaYiY7ASzAGJgvjzN+YaC4n\u002FM7REA3jEf9zJnTq5\u002F9vLSJaO3Y0SOd7vtOaVKlVMVvd4vS3083Poh2gUd8tyn+I8uAwCd53HWGkXKqu5xUEqAOP+7pIMON8Z3UXM4\u002FAE3HIeOytmSl1Qc6yQ453vbz+JfHBxPdiZ7xCeywlpx6WhvcBwkM3vWopL2jj9WjBIyTWfAMuca5ZI6wAz7QJUdqRsMKNzilFC2VQ59cfNz6P4qXGKqbyPmIn1zpf1J4ZK\u002F9fvSklr+31RPwWHPI9Oj+xkuePE5WuRfdO+mYzYkcdT+RljEm+izZKMrE2ShPXRRBKi+jnBZEt+tjODQP7FMdcM9aTphE5vzt9Zl\u002Fsg0WIBsex+uo\u002F4HxPHsNYB9A356jAzLIf\u002FgFL+Kn0Xle6n5kvgiV90b\u002F9bLfybFxxDQ3eBGvzrzzvMNa0g858sg++sD1W5I+y9gXvUw\u002F5Dz1kz4ii68nF+5n+K9v3Z46Ybie8VuaoPqxF\u002FV4YUD9W+98c4o2bTRF6Xmh1Jfxgjdn4J3Q9wSsgZBjx15bvfWNN\u002FO8XJ1N0lLtQEBJ6oEHZSKNw9OCycGWDuJ9SkZ\u002FWjlGQA1rm8DmK8BYjyIalbp375Y2ENiZIrGEqM8C+XKWAHcFejrTABdC5fIatYm60kYcLAVF0RFPOAPE5lGgQqHChrxeDWt1KeK\u002FnEeOkAPytFF0fPWWzTuGWHUSUBT4oDDf+kBkPDA5lpjN+pw+dXo8NBhgY4SukFHB3OR6ZiTcD8BdudzR9jevZuFreVbYJwLbW5u\u002F7YHzKyk0hw496DQvIOFi4GBLhoaOFDc+L2JQTu++1mx7c9uUkNhayG93BWeAiP7GTyN+QoLXkJWKPB3usHlnVm4Cb\u002Ff+gxFlHV46nOZv\u002FubvEojnJrWFN+bjTz+f+xm7EOaibLLA2x\u002FWrPAj7zowxmNrL3n8MQ0PFOBJUNprSoDFzCDqpWHEAZtJGh5ZwlSf4PHaet+T0orZCbb5u3\u002FGwu36AxpTimfqiXzy5Kn22Jhintbd\u002FSgxNQWKq9bysi6KK+Gd8l9AauArAQX8CXVa836d+\u002Fuu8RCwHj7XEEbQPQftPFznz19ZOQFwUpjkGpdjSdHO2gwjFx0q8qFdJxokkIASBZGvvf5qv+9ZnS031Lqp03CTOVmP8M4Adf\u002Fnp6dqvzngeRnSCNlHWfnP14aiN2+A2feSg11vESYMFfyDbzc0TnvB+0kBEnTmt6TaEGDtZV\u002FmjaCevNc\u002F\u002FZbodO+e7uMXfy9KCEhPAEb85iHl7cSGU7P\u002FQIOUDUW\u002FaGQ88injtm4emwMWaCWrZIQmHr54\u002FVIpCJfHy3f86y\u002F7biA03rD27muv5r5t2BLG\u002F\u002F+U6ICqPsVokgvrGPOF\u002FihcgHQxDNE0pYlmnGXgutaHMaZw1jwNyNoNSOk1Xpbj0Zr1+PGPfvT\u002FMnenX3Ze2X3fLwoozPNEEAMJcGw2u6WW1C2pJdtLlle8Ei\u002FZTl47f6SSt15ZGZzEsqS21IO6OYDgABAg5nkGCvl+9sNqJa\u002FFF7lkoapuPfd5ztlnD789nH1Wf\u002FvXfxdoOFQ99KXV\u002F\u002FGf\u002F+vqclHHnc1Tven9HLI9ZVc2W4GOUYynGCQ8CEgIDJApuoBTwWBgmx0ZiYm0NgalaOrule\u002Fcu\u002FubyhHqrNUXp2\u002F394DjDpILfF6\u002FXplehsjamsfeLcu+G47P1W+ujG6crEHrah0Wp0epE0dvMXRKyETXRxaa40Z6SgnEZB6iG52qbIlMM4T05uWvv14MfA6Fsy3U+qMTMAtk7Xheh4+iqO+8973OYDhWvXEHpt3sBOZA2TOlcl0POG9s1HYuh29x9mSRHG4Xf2e2G13gqPX51siuB4KeuDY6rsU7T\u002FNIHXZ05WqtNKPHv\u002F13\u002F8Pq9\u002F7g99vPc231y5\u002F\u002F7ew9IHsOTWKfjqSD0WW6AtHFX14Z3thfKdPOPdfmiebHydleHTfdZ4PyrewAJ1DUXnbgwOE92Ysc6WwEgKX2Fl19oePLcdZFjxf9QWrIE30zICyZ4XDgT\u002FLKvqK9r8idfIrGBi5aT+vgGo7ug4CxDbXs6VvZ2LNnz81BQNuLEgOMmydx\u002F\u002Fo3v6zm\u002Fjerv\u002F\u002F7n3V69DtFu6+XOT2a3aoFbM6rMdBdSvfsz7hdK1IO8dl0E331+ReX2nj7WWPkEBWMKrN7NfuTdlydfXI2h2ABk3jeDkzHr4tQe\u002F6\u002F\u002F+\u002F\u002F\u002Feov\u002F6f\u002FefU3P\u002Fub0QdkSLbxtROH459oFA9tdOMph+vnHR00R+\u002FIEmvsIOCmg5uMx6WvL7X2QHN6Au9Fn3\u002F4zcern\u002F3d3+WMnVydrpXnnmh06cKF1f0CdG\u002FmqG0\u002FfXro6XTRpwEukJE21A7Zz7qVPe1LJufVbXoiZz56KHOYAwSTR\u002FvXdhzNjqXXW6rVRvIleq5PudOVyblgmk47AioA\u002F6Hwh\u002F0OotE2JgKodMoS0V\u002FKGoHCp7XI5ITLqD+NZpF79aJ7A990j4i1Voz2YDnRVKta5cLAv43kG2WlXEif0IGydloUNt1xMjf3j6gz5\u002FhNycvo+x5E50TXF08FInMC6MB4V6nfyxf3J6C4N5vlOQD8\u002Fc6DANI5MIC753LmNcWoSKjyy4JE8fBE2Rs\u002FnbpghGwwmX1l3QLn4apQVnNdHIyNxg3we\u002F6CBZbsLvs5Nqjv9DyeIAfKlJUyyupvDTC7hgwrL+REr7bkUPQ8L6B9bHu8YiN0q9EzauXYaeUcEPjOOnf7eCwaJVtLeYx9gzrCyeLWDSkbwpnd2JoNjYEmy9Isnjbu7+r1nQH1o0eByzaN9CJY07GiSd+7x7PQZ3lXnvhrq2NFmkQYHYb0i1\u002F+IoBycPUva3flmOUrCd2NIj9q\u002FEbRB9ooJD+jFuXFYN1K2AFLiwm0Tgo3Rec75hStJKiAwxLBADLUwSbIgHC7+p8\u002F25VnlicaMxmP+wIqNvwwwjzuKYFpcXhqwL0F541RkBS6tCjAaVe4yMOV+psfqsxBBOZ4qea1UrZT7tE9AS8mhaeqfv96TozOBcDQzZvLQUrmuS+gf\u002FAgj7Bjkw8ThF3VAL4+yuibjOmVjrnnTOjvfvrUsZg4A7TjdkblQTX418pOXC7C3omWCdC5tTPDjDa\u002FPazu8EGHdjg0RAnNA2nIsh2EUGpfDfw3rUFmYnXu7bdK3R8uIh+YqP97yK17Xm5n\u002FcVpu\u002FiKRkpJ3SoSebm6QEzM4BImRoUTxLAMyIt2UnX2Buh0g6kJD2MEEFmryZY0hn9Mo6MUUe8VrZcffPNLf\u002Fv2j8MWvbd57eZ3ztvBvhyqJL114+aNlGxO3a6lDg4gYowpiOm60F3tWZhDtzJCIo6iGIT2\u002F\u002FXwfqTAAbP+zWACsF7mA9gkpl3SNX6OlxzgoDRLS7BI05xTQq1rLDWfMV4641lt0J52UJdI1bUiIlcyOviRlw4MzyaiaAxoq8Xe2kEvwDf6UTRb4zPPnDH3ntpg9B\u002FQ3WeMj1IGjDgXeBb9RWspHvMEhhb6u\u002F8C6IEC0WJzUjLysgvzM+d6tB\u002FwECCigN0PaKJss8QzNrSZWGN\u002Fn5KT5krZuhZocf3Ugvc74O6jxgOTv2yvhzlONLVx+1zDHuMsgnXl8pUBSYczfGpWJ9Xf9T5j3OiCXr43i+ZkTZf08hKFyuh3LaDF0LuOA8AJ9CwGRYZlag1FgfpyDZZAT8YN3TjsCx1T+vGM\u002Fum7K7V6Hg3uZBjeeOe9StSurf6qQ8pu3isqFMC+NvXRReYLOuhak5WKHtK6ZFFZn6yhsSQf9FLjdLAH\u002Fp9Vb3wirjZfMd5qg\u002FXulrK3vh9\u002F9EmHtL0xOs9c7J8B6h06JX2rFMz90WGitS0mYDBp7\u002FQRmo+T0\u002FwmStVEzXk6hHSf374wcC\u002F0ne\u002FdB0\u002Fgr00nlg5YnJ10QPPb+Tz92Xzo440iXk5E1stZZufcO++vXjuTAf77X62+vNhmTKYzULFjOwcJGO3elbg8YRSjE921lL5kxsyhQXTn4TWb9SaD6S79fKSyjUvtIbqTzv43\u002F\u002Fbfr\u002F75n\u002F2LAMvjjqH\u002F1ep2YF0kT0AkH3kCQvgITZQryOJcDdwdPuSQvIOr73\u002F4g+ElGy83chaUSCSFE3yi73fnjOzZGw+0FrJcsiDr69mxxqzMaUv6eOhrvNFzc88MXTQyFTEAO3xBxWyuK90hgkv2Imqfs7YyvHXgSn8fLHAzGzGfKnvcHhg9sfrgg+91uFbdwep4szwHSGr\u002Fy8UvVy+\u002FeFn3qQsTKRc8+OLLi\u002FPcndtrn1wJwgLklJrVrnHLrmzOyQkekDe8cOp05Z21q7z41ZXV+U+\u002FnO\u002Fq9x1UtvFRh\u002F7UwedsfPha7ZjJkhIagRt2UvmLfQH\u002F\u002FJ\u002F9STYw+SZ33P6CD\u002FYwiPqTBRFVAJHs6rYjs6hUjb05cqSGB9FSEA4LAqMwwOCB7kemZGs+++pyf96yOt2GzifpM2uZqE7WgA56UHnrgzIm9Nt69raPRuPFYbZH63GZhYc5PoIlSoHW1pRs5pkUBHkeiHYPvLNRvbLPGSsdJRt0qZO7L3\u002FdWS3ZH6BV2847OW17Ze+zxbH12Ek6ZDar9lkOEJliJ2KIoY37AqfDS80RfQQROV0HoteB\u002FZ003u+cFeDey\u002F6wcZrZqmi8qzEpbbyXTVRuSicIlGEozgKZ5PwoeZGh9Du54GzTc661jnSCwOsA88ZNX70MTymzWQJqResbBx0KE6SqkoPWMqeEDCzy32onl2xmjEGJzVxb9OgpoNs69pyxYY3Dd+sKPNMv6DJfJurnXrMxNQFmj6wBWfJ9KiiaIzkZ29PPnGxiZG8PvPAyedOGlZ6nM0fGaJTuMXxXRkR5kxPJd6JRGWwOObupVfLLgqJaKRdU79W8uoEGHt\u002FV6zsD6r\u002F6h1+lyIrwZnhEvIHqRZBKs+RJqrf91T\u002F8ZrXzwuejAETQKIKbgahDAdt38\u002Fp50JcuXirlmQcaIYF7BInEwyzS05hQOgxjAelHMtSTkvkWXIm4M8q8X2OgzLfEpAAxD5ZX6cAUzwbMpPAAdeCfc3Gjnql3bt2d1oZHj3bASQcxKJ\u002FQjYUHRoEDT1Jg9yZt+3QisZSTSDFoMo5K0RiMwBDuCxA\u002FrM2SdBhA3FBXTzKUgLmo3clTJ1fn3nqr9oX17g2I\u002F\u002FKXvx7hAfZFoHxNiURMzyGYjVDpiQ8\u002FrOtKY1uvlObU6Rh5x2cdS95BCI\u002FOF+m4Wnr9WSejHUkIns8YHNLCaD4KtD9Oidp8B5zgyksBn8NHjk6LrK1FDC5dvV06+m4KLAWTQb3WEc+3bnXAUYyrDOVa6zZRPoLQGvHavUQXp11RzyHoHCrCCair3+S5oqMIKSDlFEJGwlHvqw4oclLbGBT36ouwERY\u002FN8y+A1jLHxm7eS+Fs3z3BxHGXa2bOm\u002F81cavFBNay4ZIveMLPzukx659tXX4QO\u002F0icClQOZJI\u002F+NvzlRm9bec4Bi98tUzvMA02WAfl0GB8gvgD7ja9Rdb4O0DgcMjTS4K7V9S\u002F+0RLW0az3u3Lw+yk3q9nHj5vQsm6pdJ53aEwJmIv5+58jKIM2O8\u002FhjW9FChm3zBWCh82atsJ8XQ8YY5FA0DjRGy1F0rdvWIgMUmnFLf1JcjMfmdRSR+85ni2R6H6lEEc3bXNPmM4RNQALkuicngIzgey+K1By0H9Uqcl8g0oa1rYGfZeMs49ecm7ixU6oMub7k2rvt3H2m+6L6kg1QbmZ+Xp7pw4sTwoCrJ+SkLPRTCiGjtln+tjgz6JND7z7pDVG17W1s3BNQYXjcb4IHA6o8xLyUkeQENYpn8ZW+8lfTMWvnL3Sg24eVfVT+V9\u002F0J83vZUYocSpzVoeJ5MY6mpsIk+CCVdnR3EVe6Zmpj+672vwu6X2fa2zRkQyxccpI6NPNuvHz5z9rjJ1rUFBEhs\u002FhY7J9j+\u002FfSlfIyC3dHAA2TrYv68HJxuscvmW94gAP6GV9h549CyjNxA+QtX50MV2g3IXu29pnZJxijAGSPmevDx5kGDGxjioTKc+Y3VOKkG46+vqZ1a74RumLvS6yHR68p3KNw0eaR9FZugzAx0bZ9JEdMgQsGSNQjh8Ya61ztzXfe0VqN52xn\u002FzRj1d\u002F8e\u002F+YnXwyKHVf\u002FyP\u002F0v9uNO12RM8rFSIvUjKW4PdZR0PlWnbUzeRj2obeCU6ph9fPxXdA2Zd52yQK5cvZrfix\u002FQKZ3NakLaK9gxMfX1jm+4zASv8bzzsk\u002FVBI\u002FrsRfQQwRYYco1JO0MCYNlaiY9syVL6t9Rnq9E2WeBFVNN3+kzU0EmoAhQfnv3+6v33350SU+siE4PHOH02BN\u002Fq5FtgWdZbeaS\u002FX\u002FnmRnpkVx2DPguAfjHjYYeVRx47VuezPVurAb+RfO5cnTsXHeLRHWUDX6tEaNGJGwWgbjWnsgl1J5t9Iq2HNVEitPBV00ueRVvPf\u002FLpgL0BbPEdR\u002FFeWaHNlrFAuMO56BANFXbsw3P14a+USvmEMpHDNYNQ1kom8R7dD0QClOY7mfTme\u002FPuwzIFB8oOH11d+erilNpo0XhC5qkS06vX4sd4yMFE6vSrKWqgrU\u002F2S9CFbUejKW3ovso5icb27TZ1xqvTFrQe8P3HpmpTfPPm\u002FbILBdHupXO2BZ57xp2yXEpT9oZdli8Z7sUOGz+cwdlnAznlz+Ip8kUv0MfKOnUx2hod0mKt\u002Fa5p0byvpgmAujIvhzhy7jCJDLlg2Nb+tq1rn7xQiumwwmQup0QG35g39\u002FbRnejnS2eVJyaJP7NZFm7Kfpqfw+AEAD1PMHEcjmj1JJsFYO+aQAC7kOzn6CQZE80ntIla4+bM5Jyki7c0p6d92cDrSzlMrDA2Z6Rh1n8B68+eyXAupa2bewomyxSfkuFxdsjQOMCNLx2g5Gv7Dk0\u002Fwinsbvw3QaieY05jE6O3U7thTk0N8OKWulm54mmlWLOnqL\u002Fv1rEqWXe+gHXjDAp43r+34CKO9GInUyvf6s5u8U9+fWdAXdRSDZt0z\u002FnPAoylv5zoqVb93FvnZmGulMJ\u002FGEMjBOL8zg9\u002FMNHnC599UfrtEzSbjSqUCdAwnVkCLITQATGa82NavbAZVxsQAMN7LToPjBdIQYsIEVCbegbwR1h\u002Fk36kNAi+9wEghgZBebQ8r\u002Fk9xuY9q2FnTAip\u002FswMHCXJGVD77p53EzwnrB4\u002FcaLF38gJqNtNoPZSgNtz8MJrgUCRVacwOqENo44gNC6GkEFxgmqzHiUlKvHlF1\u002FmODwIPLbJNcVrTlKO6vs94+OPL\u002FT3Jxng6gX7OnT4WAdJvbb66Z\u002F+yeqNt86u\u002FuZv\u002F3a8bxs\u002FH6boFyPLwCg7eZbi7DCd5nm3udlEJ02z\u002F8jxjoXuNMgbN0Z5VaCeB762uvCldUuwA7aUFkVp576JqDvlYUsbjyffnKXxKG7KmFAxIL54pK4dEEtaEmIRzDHe\u002FTZgOqA3AO3bvzfwcS4I\u002FG9f6OrvPWdo\u002FNvv7plz1DPxEKG0Sda67K7DDFXHEDpYhVK0Dq6x4Ykzhi85RBjRZxptP37787ffvT9\u002F6\u002FcXKRdjJqz9MM82TjyWDh0efqu10A6OMwJ4iAiJaAA2s0GlspsXAZPnlUVd\u002FLLoVhG5d999b5TordsdeR6A1bJvE5SjKdqKrK8FJoE1pVrG6ZS0vs08JpoUzZHNRmnKYxk3uizzHgekmjrAARg3b0p9U9FMFPlbwO2z3geIuqz\u002FAeCUXvztby+TZ\u002FchfxGgcSxKkEMCRHhpJ+mTrgec3EPUUunR0xT4tgDtGJwiFfvqeGAfxfMMi4yLeUmrr2mdlsE8WMrZ5vA33tRRQqmcmnYRHMqeHP3jOpnnZrQYXayRyP29nGd83IgGUHICGBDABz2s0W0Odu9Zg4OyaukJ9Md3sVJGSXSreffdM8za0fNODLyenJ7tjfe+\u002F+HqX\u002F7r\u002F2b1f\u002F5f\u002F7n62Z\u002FHKksPamlVtbaydzIIW7q3SB\u002F+QcYFLLc2RaI4EdPXumeJohqDwAJwyCGlz2yyOpEeQvtLl74ORH49eurB\u002FXcni6jESFkYWQbKyRmdbSM3PWcxGTCACj39DGwhPr0oIwPoO\u002Fq80TW+CNBAN8vZnBHgVGgG0bpaAy\u002FRfyD9znYdjDgYMgIB7tYUDZQThE7m\u002FIdrN+6sLlQqdrOsA8fv+Gu725R\u002FtNZ2RwI2Ipjp6jXRyCKHjV0wwPrMXhZEa6weK\u002F0sKLE9ntjR71fK1B4\u002FeXr1H\u002F7H\u002F7B6+713V\u002F\u002FpP\u002F3fq79NRz6+f6ca6LoDNV73QgPRQ6WBeOyr+nrbo4Q8TsBUTw2UffXVxTHY7733Xvry\u002FuryxatTejSR4eaDzk5BjYwDzm2MxR3POslZ5JY+xF\u002FddmrURe0WvuK8ygqTtwBJz\u002FQz4HmwMR11SnZjVa7JWdjdfPHDo8cLKL1eoOn9772\u002F+qM\u002F+skcLLg4e4HM6Ize5jZjXq9QAABAAElEQVR98NNdgmfE2Trq+X\u002F61JutS2N\u002FVpvPB9m9dJE9MjZjvvnmucbwavXRx7K3TueuLjw+oVPxwpGjB7r\u002FmZFBB\u002FQ5s8JGyi8+\u002F3wcIK1TRWoPVlaw\u002F0AlXfGR8ie2TWZZ+eedB9XKZ6t06VqPdq\u002FSxTLB+EiAZTMTNHsrkl+gjh2Wbbl\u002FP8cmGZw9bul2c7JZ9Ggda7QFfvIwWWmsRwoKnjh9cnXl8zpqxZNHjyx2gpOb6ijQsYB0LSu3phtTryPjTwDe1nBbY4I5bNy2C1j2EtZw3fOyKwAvmj8tm3q70qfH6YE1OmVn7ZVzGB6VxXkQ3ZQvPgo\u002FPH4SiAwzZTRH59jXQV\u002FvKaCnDPRhDq5A155sv1Ny2U9nDPjb88pdnEoax8SrqgXaFxLGuXHduMryx19s8uPG\u002FbKSD4WKkyXP3rPL2+N1TpIlHH3Z73gS3mIHXyWndBtQuv5MtoMNjUhWfWSNrY2v+1nLXBmsQkmta1lFOmBNdj2HJv7I\u002Fa\u002FmfNkz0aPDPAso12FL69lIFF3hPiIcrzZnFlidOjvDrgiUGPdGZm3T7i46ZNnkyXbZN8B5YC\u002FpT+9xmMnW2C7PaQbANlsws0mG7BPcL1qeLjA12Qg6kbOns89DhySGIZa9ON2kF\u002F7XOWjv3vRR2b6n2XHktEaLXVium4v\u002Fif98Z0D9zQ5MUKMnGs7TVl8pqgmIfXa+GtK8jv0Jqb\u002FZQATs8eYZltNnTg6Q\u002FarUG801UeQYVi3rRF0yYjw\u002Fiz+HdbRgiElZE0gRh2dRiIFlgHiW+3u+eiWbOADq1+rkoaOHezD8wPdS8iKlHIFbWN6Ur0mDFmUC9nQKAJhbywF3auuk\u002FJTxyBhYdmUUohMMptSTTSyeo98uDxqIFbn79a8\u002FihkXoMLrlgnAKJwWRoEzcPTosdXbb7\u002Fd3HdW33wtY1V7v1KabEhDnI4IWlWqibp67WYdJD5NoXTIydGjMdfLic4PPR++29+vRp+tKXG1WkVusrkvAupqoJOcNtHJdETbmPatd95f3WqeN+5facNp9e0pgOvV03IKHrdbWzTh\u002Fv32HJCyiG\u002F8vHV1ixQEp2oifDE34SXshHSidSJHTXQBcjaSZIAeL6BwE+CIslMWDs\u002FQvYEAEkantI53a8HHKBDk5SfffXkN+F9+mmiBTWC8W\u002FwI2DFmozRSsgPG+puNY5QMxUjBW0tf1sMY3RyYXsDKAs7whHF5cfAokQHqvbUAWeM0vriqSZj\u002FlBgUEWUgH1VyJHIHvJrXrrpFAGoiwZTK6+feWL1XdulSdfX2Vjwuomvqxo5+nEIKSKTdBkI\u002FH0xWKLfNbjecZe+PY5khPJVhorgYafLDKJET96Vslo1QnJgFSEtXkqtp8UiZDQ2ASjWgDkkBJH11TQYGoJtXm2zQHBkB2aFVNFr+Hi3jHaTDHwwCvpm0JCyYMle+sbfIkEgi8uMxeuPQocXBUtOL\u002FTg8+I2BBKD3v\u002F\u002Fe0I78b2wsm\u002F0GeLYKAPkytgVSWNfhq+Zgr4mMig5OSzRdlofTYmNn\u002FFuWAxh6WmnSRmMe5RufDDCMVmis5MZ88TuCztHpyZqSB1mrzy7UPeTw49Uf\u002FvQPM9LPV198danLkvdK\u002FpS1OGmTEyd9vNVGstZR+pgOsmGVc7y+PQIlx2tAHgJ0DcMlS3ikiCI9+XmOPVnCFwZkfSnTxwEdG\u002Fneefut1ZnXj49s3cgRH4jV0F0LXNoToyuUTckDwFoo91iMtvpVqexARbrVBmBzRlFr65qH6bjnRUO9JzW8KSM6uXAoOJgkg0wAbE7d3VPafktO2qua7TuM6F7ZwvMBKLyPlq9XCnbyRC3tjlUzul3UufIC0cX+FtFaj9Yq\u002FgpzjhNIPsZxb96CBdL+jyu93N8m+K1lA89Fg+99\u002F\u002FudGP3V6ue\u002F+Hm6jF7kDNaXuXuxAexT2+1nroDqR7\u002FpUKpKF9ikKaOLdoJCwOrhDrL53d\u002F94eqLz75effrRl8l6IDPdvB6dtka\u002FfdHsdpkDm6bpMQ7Ko56B7AJOdIB9JdLk+NUheXQA4KnLipKm0VnRWinN4fYK6UEvE2LTvMyclr7LfplFn\u002Fy3\u002F92\u002FWr3z7tsjV7c6v4RThpbjeAb6BYyA8+J\u002FjZcuuD+lgctppWurr774uufapBtoaR5qfdWtP6z8ZfuOPv\u002FwehH09hVEJwEOusC8n259EQ8FPB\u002FrhqbsVOQ7YBr\u002F3bmVXPXMjRddb7GCjGz3\u002FfSX9TuRzbvZM2zq3p3M65GvzljnF+VkOrIoeeCYrdVmU8nB2P3sLqB\u002FOnsMZ6BHktqX65PX7Jxo6vNk8cChIxMdlx1+7eTpNlXn8IcDZDPQh\u002FwBheQCyH2Y7K7lROv6kmJqjZbotkBXw5rs6EIfTj1nJz2ebOjKhWaxVHY3YNr3BLl7N+vWmE4Errd0IvS2ssdb1goMZZ\u002FpoRn\u002FlquDBTg2AxobDznfVzR89\u002F7D1cK3xy\u002F9rUqBjvKMHds79T1diq+UTykPU5Z7XwabburZDwPrr8oc3E\u002FGHvR+A54ItwzvbGZuErHh8BJchHYvgNa550JTto5Tj7aJzXyeXOtsdTB53lkgha3rT72W+7knx1KmKY8hfu7zOTGAOqdGKZFONVvrV0+vTVDHmpDrxkQu6AzrKAPQr92\u002FsUVgOmaz0QMZZreUr2x0b06g7IBuQ9MGl6wbTBNiw3YGsNntsd\u002Fdn80fGxBfm58LlT3S+3CV+epGZbFVSTxbE9xQdpYOzkl99LDS3\u002Fj3UR8F1MkHTPNdvb4zoP5lyk+d3Kkzr0eAVdHBNkje+1UCv6Tanb4ouskDZixtaLqecP7lX\u002F7l1FsjlNpxCpZxxSATNY9IlJUoKYUkckS5Ah6ECxO336H3AIKiIRkMBwJg8kPaHrZYAIHenj6DGYAD0SELCbwwlJupffdgqHGtyMZi6IsaxeDT8qhFxMh3U8DHqnmzKIynOi6L63qG3DHd+qbqscmQKbcgTMZsLhyFy9VMMiycmof9HmtUZ67O\u002FdDM83ogk\u002FA2kAxbfeRTruipfOZA9ZI7MnTrKS2RSEAdg4m465t86vTrCfGDgPTt1del4PD+68cPr44UST9YZG33bHS9n1JMMeZwSI29jPkeVnt34+Gt2YF\u002FvcwAw6EXMeAwtOoZlDPaUE5Lfe5SB43mdssDp7zYTaEWMQPgJi1F+Jo\u002FAdRiizJcAG5GNrIT9IkkjaymcsnWGJZFyDC+99CaRpgf5\u002Fs\u002F\u002FmKZ0YLwzsaOLnUlIKvcwTqgu8MdDh2qD30OHB4BdidymJBVZDy\u002FbwJxfDHgM17h+aMBwECZNNThvWEbv3cNpeH5aBSLLH8XVyjV5wS3tcojrKXTfBceVZKwt8jVWTPrRMvL8c1Sl87Jk8JbT1FQUIsMiGQsUU3O0\u002FSTTgHJ1Nxo3dxECRqHz9oBWkAtIPYofgNyGW0OMzngZDme2wsN1upKYB6UZHYuGSFfi1NLVoH2ht7L4nSdH3uoMVlIn0Mvf9iUJ7Q0fs6hOcyGnRTrHLLRfVwHHN7rkJKbN3NwMv5799ZiMzBKiSp52dYmbfN6vXMXyOH1G9dHDukeER+gVXTk5UtReAo+AxaAo3PG6eJ0zDiiWc\u002FadJjpA69Z58Yu2iwCZvOr6K+ov4Nv5sS+9Ic642Y5uu5Z93yVjmLm0UD0VEs10f3zn11YrX319eqf\u002FYs\u002FX\u002F3wd34QQPyHWrDeTGaVtxQ0SG88e1y7sZnbop+WUodkvRNMZ1NUa2ONOREWg\u002FwwAkoN3zx7tjGtr660V+RADr1ILf608b6Lm0cGpeulok8VQNAV5UHgbDaKRRM8LwWtjBAtZFGWrGPR3\u002FTWtm0MEqBeqjfesu7K19DSepEb0Slg3+ZJa3K5\u002FTt09uzH6LOih9bG2usAI3Itfb97ryidjGIdJQLqdrkp8en\u002FDKnSxAPpMo5Rf2p\u002FzYs6j4gxKPV53L2UB80L87XW1s4zGFb3sB5+vtczj5fZ\u002FdN\u002F9s9Gl\u002F6Xv\u002F7r1Rc5Nvj4WeMW+ZblYNCN2zzd61rNDbTTvd\u002FegqPHjsaXRYr7+ukf\u002F+H0f79962rXycgp1zoQTZf0Ot0DIEvNj60a2i026Gn2yZ4Tek5kmO4wdjqCflQ3vC3d0KACWQDDkuHSuYwjbY8B2k9ACXitBtumUZvRRdydVfLNN22e\u002F\u002FqLnlHQKyAr+MPG7OuZhw8vm5dFTJ89f9QhRtvKDnzdOpaxSfdf\u002Fvqb1psuKGOcPhKFdLKo0pCNjQcB1y3tvyqQU032rl1LOZkxKkXZXxbs6VOR4GWPjGVZyqpkD57Meo1Td7\u002FodTpQyYBOIUDp\u002FiKyd7bfGZ6ZZhDZBg7J80qdJmgQjTR1YF\u002FRG9jqrZ7ZOSh93ss+Nw4QWd8Vb9gfMZmS6L89wP+qgN96a6tm\u002FkEO1Y1kxv4s5x6UTI4e6euYjQODPmwvnefFMdLS0B4r3UFIP+dtOQOjdqJtlOWgTNT2W76j56ygz9qwKgPbb3WIao2TYxtJU3HznlPLH+dEwAW37z2qjv7O2CV4CXbZuq0A244Ov8uePAykA8ixzGrrHrzLMUkn9De2D\u002F7g7NuDZ6\u002FM8zK6T4v2Z+6KsheoiOnIvM9NhLprlbE4o4EmZ7fXa8Ix+wDp5Gg6Qan04pb0NscSX8vE49s90RQd7Sl4kHwoMcbLNq7SvWwPe7etObCHOwpOCY5weDfP2NksTbb2wDo9A6+x39YZziAT+F82gZ41JjwGiwTx5z3jgq98dsdaOtiYkmulZDq6DG7pbwJjS+Y12WuOdJyA65OnbEX3amJb4zU2XFlgj5hxsJdKFEX3g+xliPYNHx87dmj1pM89rWsV\u002FTn19c3vu3p9Z0BdekRpyoEUrt3n3\u002F\u002Fwg8DloTEIBAjji\u002FBJX2EgdbAEDmMS7K1bd7c7+0yeUF5phJYqnWhv6SdRDkqV18yLfRDgX2oOl3pwhAHApDfUUjFM6mR5Na\u002FyehhsClaEhEE+ltJlXNaLyu0szYcxMe14fj2HMKlVVFM8gDLGno4mWKFnUeYXL11Kgd1fvXHm9GxsEfmSWp4oo3EkdEcDz5SdzTKUuF7ob7Rb3nO0e8QcavAZFzSasplqqik3wONRCv3O3cDBzm967vFokLLpWGobZJy0SdkfPXY4QLPe96LCATEeuzEeOVKE6l6bVaPB7VtPiuTdKEJ+b\u002FXakT2rt988udoTwD+wr97sZRseRa\u002FzndL3IAV0K69bnbsNkOrupZII30YHIGHOEeTGh\u002F5AoBpCAoO+GN88ZTGsKyYnSMAsIQNydkYLkT+\u002FA3MucA3BQ7vFCwWBlujrKAVWt1ssV\u002F3jvwR487X8vLwx65hkWTsKiQFieA2DoAMdNgmRo+PV8dqrAASZG6MAgPiPAWSIGUaDxEdAkKd0Vf90Vb97zd++HZBncXAoDJEAde9LWl00MiXXGjnWXCR7e7SglPD14dLPxvF5UUU9mymVzVppjo7b69PN0cBbutTgH+VUAIz9FxThz3\u002F+9\u002FHS7eE3\u002FG7j4wDjwBsnFW+RGUpWaltmxCE6O3bYtGcjl+gteizAdXFKmAXODmemv\u002FQ869W3eX\u002FoEujC0yjSLPu3r7mOkVzu5VnKTdBnz+59yX5GYisnVzQRQM\u002FJ6HOL0ryfM7rWXA\u002FPXByqsmePOW+dQ8EuXboYrT5vfZ6XxTozkQ6Oqg2A164tG3LNw8Nt7LWW6GMsnCDAFA\u002FbY2GOxm5+Y+wD8fhBGnXKGeLVpzmfD9GmG7wK+Lq1z027wwF80sRS+umW9Nh6QATr2tgtuv56WThg+csLX7eB8cF0Ytqe7MogiNKEJSJXvCZL0TMYiDgyg6ETTW\u002F3Dz6SFn5SFE70\u002FfZNG8AzGc1H9gVvKE8RELh06as+86oTN99dfe\u002F994o8nuxuG6uDz\u002Fenw0Q7H4wuXsoG6RO0ybg2Jy+bNwFHNBnnLGPb7caQ4fGG4tHDK\u002FhMzWaXjx1ASwaP4UTj2TvQB9x7zjYoRY\u002FXgLsddVA4EJi8VlDBhi9fyriUZjx7LksqglnXl9ZkuvL0DJ1jGEO6BBiwBvTNo3hdicoaJzinjXH23k9+78erDz78cA6D+uijj0fHkmLO+6vuQYexN+YFWCiL1OMdKQ7XuUVZlbKM8+fPz34q9PWiq83dulsv2bsJKGWHRIfZBQcGadOrdPGbGiZoLCDAw67Z07AlOllb4kLm8ZtyIcRV046OSi2+VZfL9z7geRyCI7sr58hx1fDgTuVyZMdBPmyyjJC1YLP2Zp+099WaVjRTdwuBLV1JdqzvrfxEg4SyHzmlHBfATYtigORJ\u002FPu8k7BfBi5v94yTp9pk+0jZEXspYKNUTemFEq0O5\u002FMperBnKTHDsynP5iaIoe1gct2mVEBstG2Exrvact7pzAu8sa3xT5ev1pd84NmtNuR3LblGdwcs7i3bIDv9JD2ov73o9JIhCyA2Pp1Rpl95m+73Z6\u002F2tNdBpzNO40b6CK5QrjUR70b+sHmtzd6AbzOf0UKwAy5ZMiHpETyXHmwIjSWnNt58Fo+S924UOCyw11joEA0cFHIkWZEqgDy0qRJAuLvPymA10GxC9q9nKXd89LQNsukGjia5VE7ktFcy\u002FzD8AxTvb75zuBB5yFbBA+wdB\u002FfA7X2rWwUWdNJ52po9bmBawiYZ8UDOdfxMH7JRbBc91lBnzazV9jrIyQABvAB3Q+6rIBTd17qOnsS3LSu5kd19Ed0fVkGgEwydQlY3Xz5HxjxnT3sNrAP+fxRv0EmDnwLv46TFH2wiOZxThePdTdDORkyTj8YzdroxeY7OTmSKfjI2WHAwY+vkOvpfUNCGX\u002FtH3Ht0WfPn9OEvmT\u002FjNM9d2ZH1HQtonyxXezEG54Rxn8ZTT5\u002FmHOT8OHNGEPXgwT2rO2HWm5UjIWVEbY04D9\u002FN6zsD6qLhjKz0ownv3ZOnXOeQ10+2UfLcWyOgDIMadXXeonnnL1xIqZSqjkMwnZT8+v5KY\u002FKSLZzFl1KlaERkeMjA9qR1YsLnzxLmGGm8sdIdjMxEbbrGz4AERuSBTQuiNB0mnVrOIixq6He1MWZqqFMChGozA\u002FCyaIe2bS9bVIqBkrW4hFVk+WZHcTu0wYKcCOzt2Kl\u002FblGiBH6zZdZrtXekHK9fq5NNwAkPYAJRMmkVp36dOXMmmhUxLzqm240IDuPzxhsdXFLk8HrvHYipbThlxAHkSBxDBxxSDBGm9zkit1NWReASLuO1yfbFsxMZCK0V9TP+rOhdB0zcfrj6+d3PSjs+WL3zfunwcyn31uv8ha9WxQ+rS4vpKd8UhN723bovqiUhT0gImmdsKWXlOcqI0FetHrBnjr5sYFrLyZKtGAMT8zKCWkCKAFJ03XSYf36ILl5oYd0ABF0CfN5raOd7X8uV3u3Vdb99zR951Oik5GSJ\u002FL9KOEdwe+ZTQpyC8gVYOClO+pQBYTBis+EZYBoPGbMvf\u002FNaRtMP\u002FUrQvZbo8eL5e5MiW56xpPIYzO0ASN\u002F3llZ2DTlBS47QLrW9gQqlUxcvft3piF\u002F1t9RX918Mt+5J94em77\u002F\u002FvdXv\u002Ff7vV7N7IuUj2lSEK9Au4UgxkI2v6p099cuBBmNB092c1m4ofT8bhjJsDtqybteuXy+93QmzfX4t5bSAvUU1UFLGabyMI2WIP93Tz+hEuW0ZpR8xZrHJ4gKK14Yfo1HXDGCg1IuMmdeBA2UyGI14pZl2jdpK9ZO6PdlstwAGcsgJ2dnGPg6giDOHX7nSlW+WfSjG4G8iHKKNan7VTgOKE2WRIekpjLuXeyuJI6\u002FzXvPAN9ZtnP6+O05+skCBPY6\u002FObivr4la4Ypuurmxl2zb1Dt0YWxaV1xjA9hnHczyB7\u002F3Jx3Mcmb10eHzq68rI3tQqdmeQOzQtBuhTypmgOpaQA3wBJhEkL0vOjSRpfog04NOOP4yegEa9t\u002FMASnpKYEQZSxAhRK93\u002F2dH46zM2sff+8tSifS+uBBOu1eAGHAjM27Ac2+rLNxM\u002FxKeNrxPd\u002FVSvdDNCIPy5qKlDKmHEgSNBu5Kw8cnWqt0qtS1kr7zBMd6V3OstvpB3\u002FkxMnV1nj\u002FUoe96UkM4NzVMrfgztED7Q9IdmbDYXxID0XQjGH6IfoMf9FH\u002FWf9nMzpxOQd8adSJTylLe2Pfu\u002F3R6b+9w7mu5Hull1iX8bwf7ueZLC7RuuCTo3BSbUiwL2VbFSW1rycBv1Xf\u002FVXAwZ1ejBn9eNAh43HwIH7qDXeLdhyPRpkQ\u002FYVcZfNul45I\u002F4lPw0ogJd96t5JVaRdbBa0ZzOgTYUcgI1kRscetfIi47P5sAzbPCv52XTYrbvyOmUi+HhKFq8vLSTJxpHApMz2dO9pAZWHPt73uHHp479r9ctPPhkHRWSYcyW7JdILSCnR2LtnLSe\u002FUoVAC1vECZzoaeOkHwSnAPUdO2prvONewLPNnz3n2rX2rxVcQmu8gyeM7UJZjbfOvRlvHlmdPXduGhmc\u002F+zzuhZ9OrbXuon0boJ0zgYbvDN67toJzFXWmYyTS0Ey5VT4d+rJGzvZZlZ8+fuu7pWUr+6WHZeNPnLi9dWDnA7nIWwrU9BlY4\u002FU5OvX7wRMOMUeMuUzqcwCTQWr4jMtEjmZuytXk01gj+m+AbDRQbns\u002Fakhj0YFG154RnxFr6MnQP80PsXLC+ZItyaH6zlHFQ3NnB8X\u002FX65UZQ3GVf3Tc7w56MH0TbCWn9BpDRctwEK0z\u002FJgg5Hd+8WrAiPmatnK2NECO2BOcL0g\u002FWltxPp0eFd1NyS4\u002FiRfhMUgK3YwQm29SRgdYB692Tj6T\u002F2AAbQyUvVwauNgkeNtb\u002FM+y\u002FTf68q24NdjJcOk4nzYKU6EygoiMTRdI\u002FJJA9Qr2tevI9nIlulSnCGE8w7BCtajiPQnMh5DDjZaUFaJYvGuXSdKzvUs9bXOwOg7\u002FhDYPjRwzRJc0B\u002FgVTPmMxBOlhQbLf79p3VcAaM92AWuj+xXRVnHj376JGy386qKSgDI04ArM80Ef9\u002FZ6\u002FFGn8Ht3sgLdXktjeZBzygduo\u002FzsNQM+QEMzVBFk47Rpu\u002FGFqnw6m1AgSuXe8QkFoYbcvjtCny5KlTUxJzMMJLN9xKcVPghFAqaVuK3fHJD1NozyM4IzBAOqOi1lF9ligLb4kEPkw5AJKHYzzgX+pfhJgwi85sHVc4o9siqOHWXmhbxu9JzgFlqi7TQmMADPe8ncDAoMglQ6duDqCQAtX5hkDKGNhBvntfY+0\u002F6dwx6l2PCe7kOT95emHuK1owUZOoxHnRD12E\u002FFBp\u002F9cDZUoaHoz3udTCvcrjfxkt1Ksx8M+L7h8IWBw9Vi1eHEJ4Tx7tZNMA0MF9x1ZPHj3vYI9qSfPgJyIX0H61Y1816c9XX359IyZdwMuLV0vf8\u002FEGo0ssl3xHlO5J4Cd6pEQimlKcDlUaD7e\u002FTeQtAdue8mLsgWyODcCBbsl\u002FEYIEpTVac7R91yQnIyQMnpvOe37qb4RD712fXQDXyFXvGRXgtPzuk5TQeNjdwzhE9V0lym\u002FMxtjdU\u002FApl\u002FjN\u002FN58863hxaVFYwI7Ry0D6kqtOB3LczwIJXpE98qTnrkskQglLsYygLoLOIbacGnN5jAiveZF7Cfb0BrPvJIRL4pEzS8jwnmTjv\u002Fo\u002FGcp16UNWI\u002FJsRGp4QDuq9XaB6Xv\u002F3SioxzO6WhEaTSzW9XOisT\u002F+je\u002F6YCxG\u002FGgLguLkh1j31RERsgIet6PV\u002FGgv70WUDqQU+2wEE6NuMvTChtdxxGwDtuKmFHwDLJoh5Syl1K1RXG3RsIrKc0pCYpixp8Jn4hwV84aUORAppaBwITuTPhd7S1Q2Bky0bjPVDqyNYMnAoLPHN28fSdglLG1HqxL1\u002FobZw1YVaI1jrvyjQSZUrWGAGd6PZkNwBUAGPLHQ+ayVSqi+VLa7rkJcsy7\u002F7u2713nZ1f6Bw\u002FXGnieMV2C2oA3axlvRJrGuHTpePQ4+qFVJSx3bzxbfXPpq9U7Z8+sPq5t3jdfXpqOR+v1aJZpYoABTdFzMFgbNfoS38z3BoDO6pZtAseTjLKxPyvbZR27PPjUvXI6v24tj7Yv56d\u002F8sc5\u002FSdb6+ZrLn2CI9Igo1UOZPyHZjs60CxsNmBqAHXzpJNsVn3xrbEkABNli774fNahMT0ukqbUTScbR5zrOb+9NcbTe\u002Fr77D1IFy5OjC5RlSTGT3db+z3VxjeAWsNeW\u002F3644\u002Fax\u002FPr1c2r10tbF2xI\u002Fx7K+O1sruMItEYt5fjmW4sM0w0Aiqi4g4Pu98yHZRrsuVnfXrQ41iA\u002FZ98604ma7xYxvrz61S9+kW4PXKFVG7jVTA\u002FQSjlxhOhZpTAOm3ueDKy17wLNWuHpIe39v\u002F2bn00W9Qcffr9gyvGZ+74CI0frfmIT8fbWVMZrNirHU5yOx8nboWzDupKoxqu2ttL8ZCw91vcpk+lJdO2YIrLbZAXW\u002Ff4kWyn7ZbPgHI4Vb4Od2vwpnXsOBAHo3Uy0dK2DcYBYjtSr6uOnTPS+SL12ogHC1sYGzdeOnSgK+myi2Hs6kv7l8+Soskg8RB5tWldPHkRNFwTEi0YfP65+Oie2tVBDTl7JxqsiltplxgbJdjqtCLs1x7OCeDcCxbqFcLDxz\u002Fbk6GnjvdReKgGTN+IF+7HYi1\u002F\u002Fw0eV8FwbJ4hTw8bpYMRRceLsnKYbP\u002Fb4ylGcPYGHaysYv4ioOzTOKba7o3cSGA5JNyfHL1rP6bzV2PHgPoGsggLdJOxSxrfx3X1QBDu9s3vXkdHh9gvs23d4gn34v9tEG53UOKBl0eNPvKN0Bv3vFv2+3dkmDrTTgtH1sCSHnUsJZJN5my99x18v57Mi9jmfrSyQbM\u002FCq6LhT3Qtyi7rJuWU16dd4+RL5RyDGwDXbNaWwGK3nqz18aO16rx\u002FvMh8mYNrHM5kpY34asFtvIZnXrWeSc\u002FYaM5QGmbGJ8OH4wnbbIhOtmzcVarqOlZxsozdR4aWXmAfrZvGCTrVwOlb0q0vs\u002FOyAk+e5bjkhL\u002FMOXCDF86USdfBi+jILk97x8ZFrVlzAJoensBJNFZRILP16PFyFgk73\u002F\u002FJDppaFwzZzfuf7tdpTsZZiRL+VB7ENsEJAnccAj9PWXLPYif6deTCXgAZvCY8ZVSPK4EC2O1pQJ\u002F2jTaH2nomX047hjM3D3Rz+BS7Q69+Vy8r8p28ngSMRCaPFhnWkxLzIRYvkgctBadkA8DYX5\u002Fwd955b3XurXOrC59\u002FFkC43LWBg\u002FVq5L5ylPONIny3VufefqvTzTr6untO+rfF2LFL7V+il2BiUkzrvkCHTUqMEUMjnQRC+QLUdqbgbIbZUw0fAmIEiyUqM17hKEyMukRppKGUu0wdZIsiNWYhpCE5DqJtvo9X2eoCNTa5vXq19M12Uym\u002F23dv9bxt9Zs9FWDr1MvmAlAAOperR3eohFZJOGmAZtc+q9PFlYzVgRSQ0hKbi6S1HaqkvlFNmEMFOEZrKSM9wu+oISya8urp6Vp26RKTAogW0z2g48sP7s\u002FgBaAfPinNl9E80LHNq537V9+0AeJ2NZhNkdUoFZgHHkOHfYaWyUFKF7BNBhI6B5OklvqyOTJHIQMtUjJC0k2Ivsj7EjFyj+Yl4tCN0pXdK2MQrcbIe9Pd+t0DF3BvIIjhswQnwUpAZq2i6Rg2n+pZxrz55Q08R9KSpREoShPtCSDQ6qYT+Ump4cNjOTWiqiJIwDpFsygk4\u002FLiDBhrzwfkGicD44uSoKANYMbYWPGGCIAonPpTdXhHjh9JLvZ375yT6DCAHrjtswzL9oDj9tYzzTftwUZdpqx2VCa2r5IAh2ucqEXomdNvVMLw\u002FurD738QD9WSrLVWAmbD2IXPLnSc9mf97mCve+1XODbRCQ4lQ71ElppT9OOkMCicwi3J555ow2nenVP4vEjEze5nL4nN2+riE7RRwhFmZA4N0RwtWqJojQbRvl\u002FQ32Y\u002Fv3gO0LF5jUgHR3kiErMOrUufoISXMQYOMqkt3xg7LRRFXij6yDpOMIO5\u002F8CykflZY7U2SmmUyYlaHig4QLYH9MaD5BO4BRgnKgb1eGr6gcPlGZun2FpKPMCJXTYPey6njxzRN301ONxvkyL+L6bTvTkOSzSGndgixdrcra82eGsvMjbDL9Vw37y+euvse6szHWv+D7uT8zo65DYtfNS8F97uefHq9p3mIUqZIU039vi5p8DHQkP805tTGyv6D4TU+SVZ3lKwQ2r5D\u002F\u002Fwx6vf+d0fZpgB+w7bCYxP7Wh8zsE0xq2l3M3doSrmp1RrHHPzq\u002FRlR5FL4IHjymHD1zbDcsDJAJlZb4GUqIlwiQqKYnMczIP+t29gdB69HJFe9flHRVRzGxPybdW0f7P6r7\u002F45eqv\u002Fvq\u002FrL7M2dzVPoQPAtdnA767tnfdM6c1i3z17MYQxSzjgJ9EajY000GPi7hZYpva1gObjox\u002F0fq98eY7jWPH6le\u002F\u002FIfZtPjGmTcCtrXUq+PLpM2TC0YY74kOimY\u002F7LO91WNa1H4AOF8kM05wvZEePn78RAc0fX917MSZuutcWh1ro+6bj8+WFb0ZwKt2uXT4N80L\u002F5E3mz5fL4LLgeak\u002FnZvVPJHdpLMsQnWgq4BkjadUqPAG0nUrJEAjYN41uI70XU0eFY0PS3VdQ06YOw7cEuXAyTqrh8\u002FAvyiUWuzs1Y4dPqBAmdHK7l7Gi\u002Fuab\u002FSrl0H04vtF9hi3elxZwosoLzHT9RQH3VlM+SInWFzlxngKaWnAZf4REcPYx7bHu2UbtxOP62xqwEu3W\u002Fup8dudIiSMpf9gfSz584N\u002Fyhx07nIRlwOB\u002Fl+vlt5WKC7z3FWtQ4UxaSLRGJfdYYKMKfu3ZHuj9uLIVOwrcP6ntUt6EmBBjrYBtfnTx+uTrQZ+L0z7dsIdD++8U1145Xj5vg4LGs2LXc9R4Je2r+7zYLpy105KNvW7XWq1WjZR\u002FthBIEePipyG0+b+8tQnDp2oH4CA9Gim4xdZDNkyNabh1NPgWZySB6VCnFqgGi6FCAkk74LIHAc9+zNGeaIpavGOe86upU0vVSq1tzV42v1e\u002FK1nMVswp0OQ3wcphAVX3R0OqX1ZVPxQFNMBy1ryYlgA9nMRjBfdDndthxaFG\u002F2mmhzc+AAsvU9eXSVC\u002FHty+7n+9L5iO0cEowzxFHayAZbC3sJ5oCo+EhZz3zNU9kUwYh0SdeNXG8JO+bkyfLoJw8+jG3udxuPjQK\u002FytLKDrMNbIix4lPOlEAVUO3vS3CGjCxfaDBzo7fi7Rd9PuJONoNMPg\u002FvWCOljw0tXFK8Jt38OBvGQfUcmQKdesjEZD\u002Fnjv\u002F0f6CX7+QVHZqQQ1v07j2QYVWjxWjwLBYgq0xCyzkgw2anUwnJm2+cjXhOCGyTTRPUlkkv2Lsp0d989OvVsVvHVq+fOhWDdsjPkVp05SFRAoCrjh5P8yoxCjCizncTpItcWwgeHmO0LwanNAFrO4K1EhsD3s9d1P+EJK7lkcX0FsZPgBXABWTrtsJA2TQpyra3He6u2zRsOF46ieH2WcpL7bnNb6dPn54oC+YH+nW3UMsvqq7kh7AyGkDgbC4dkBFwjHYi5JjA3B\u002FOM3IIElw05NGiMQOiA4v+7sdSPIRLWQPv7kl1njzWo+1OttnLhiOR+kdt0NJ553lAVRQZaDFywNPs9etuemMkibg5zQabwCjDNiVFMfMC1mLy5sCoS+1S4gy7Lz8zeABMy5LAL8DXnN0fSJ\u002FX5vd50vIe2i6RwNaktVlrDUWrN1\u002FdApk9ehm7PxQpWEAioMUDFvUBSFKI8+yNDG096jk0BhTYGePI1EVfAk35e\u002FkuAuZzE9H8dr0n6kuhxgeeBUhI9\u002FuU0qE9gfMjR6utbj+E+b+q\u002F+tSRxfQiEbG66REHSIoii5ZnTt3LllZb4PXN22QOjp11\u002FuLNJ88ebrfD8fD1c3F+1J\u002F1u3ixS87aOST1S+KEmolis9kYXZmvEY5kQFwsu\u002F4Qi03QBM5UlYiCP2QtlHPKvZ9OPkCmu9\u002Fu6mOsgbWrSEaT7THZxo8uRpHJfpYKa30YrqeIdPAALX2816GOnpy1j3bGnBSKVPlAsbAYKDv4lSJhOeuNC4ndu6YCGROVIbZhm2ncMpaiZpJz89pe\u002FHipFWtW5bH+qkxViqg9SfjZ3059iL40vXPK1ugR8hOA194iOLvOsZ2g0NqkZCoeQGtXsbZ\u002FwsvRzPAbsBIcxtDMLSW4nZP\u002FI0jgN4OJMoJZpxOF1U\u002F+cap1cX2hYhGiwYySui3mUnanlyjC8dL7SygNsq628licEjW02sAMvCivzpAeKNN7gfqcvKnP\u002F3jyb6IwN7tFNeRoT4TF7bUi1yYK940J7XOeN2BRJ5rzJu19wDBzAcJ0KJnASt0FWcPqFRKMLTofjIXE7Et+rcJ0rto7ut5vjj5Wjmi7zdtnP74N79eXfn6UuUYu1c\u002F+N73Vz\u002F64O3VzuTy1rUvxvAx1urNixlMxG7kNd3IMWi5W1uAtLGkZzgHLdrIpI35P\u002FzhD6cU7Je\u002F\u002FFXDl11ZH+DspML9B5fN\u002FdZpDHjfdXSR6V3sB\u002F5gB5bAkKggfjh5spLOs+cm4hscb75LSzrgFnjD10pR0I2Bd14I\u002FSCa7KCrh1e\u002F7f3NoWkNRSplbJenYR0\u002FkS3Aqblnh8jP\u002FfjhQbzJqRYskr21J8HcBQO6tOctvBgBBrxM54p09vOd32527N66qlBx2ysJUK4k88fWaEpw4sSR1q2MuFKaNo2SY4CYo+RUV8ENmRhjJOs2AKPVyxbHpleZSUEdc0dvf5cREXlEk50yA\u002Ftea37VY0fPZwXarrSx034uNH3v\u002Ffc65O\u002F02M7zn11os+tXOUMF87KtylHIvHuzi5tZP47Jol+y8XiiyVmLKQ9dax8OMHeH7ah8Ivyxq\u002FIdGWd2fSf7V1DtaSUl2vIpZTpwMNq3Hk+bI9u1f1edtdLbO6JLBiwdhY+Sw2yAjZ2CU+S9QY2sCfDNYWnpGqgujR\u002FNcVJ8aax0TN9fJAtRLxlsvNGQriJXXjYtiipzlLZE992tgbIW7S1DkekDGQzOVaeg5xSQK8ibPaH\u002FlRgfTadfv934yiTkdjWOAGg0YO8Nx7M4OfTOZFrSRZNNJz+zpkonowCA1\u002FTYOd\u002FpcMHSsTN9F+CAoYwBQLUGZMC86BPvz34geKX9CZvBUjX2ukRNwLN70r3WYCOnBAD2uIYx8syG72p\u002F0r7079Zkip7ZEmC3J8WctxYJxJfrnKd0LXmg1xaQvmAG4yXnSwAumjdu4N3v9DeMgowmOa02u4dB+FxGfOYiWJLS7bpFhhx+9aSAApzgPeP0zP9fAvWdAQHG1XqePn0ipVRd5mdfpvCKWrQA+wMRWsthTkrw5z\u002F\u002FRenZy\u002FWMfqcNmW9UV\u002FvV6tG9h9OtRPRZx5Nvrl7t2rurHTc76j7hoow2U8wMPeX28GGelK3TAYcx9LtT0r2kMzCK1nfF1CMgMCV1U1Sgz4oKMTC+pPRExuLlhCwF0yJYNJt15jjaFkmU1LPxjEWwGxvYwUxKYBZmRIMWOEajSAAcykx6Xg0+Rax1nkgqBXwkpagtmvp1n1fHzFiq2WNE9OtFUwtus4yMwdPH+weE8PakzYAZEfeXL4+NswM46o0MlCgzwMSpl9WJU2eLkp6Zca0FXtIvEz11JLQ6z1Hym6AlukGcCwBHzUZLcJs9mvBUASfKkTCby2Z02TzUKlIYW7elMMrviqyNYkW8FDvDwyh4DwBJXTR+9+pznu2y7rn5XM+24cszFlDc3\u002FvYKI2u9PNIc9\u002Fn\u002Fe4pWurzm\u002FccYU3AuCCMpVNAOTmUvRfF0qda5xRd60fpj3D2Cbzjua63cck6ehmj8aMJILqNUsBvjdchJ\u002Fuqy93RZ\u002Fy9m4yx5zR2IkzP7b4ZWBFJG6IYh3ffeWd16vVTk2Gyv0MU\u002FbC2YpHlXvW0n57\u002FeDJAlIuNbgCOiDrwydgCG6LhQKu6VY6d\u002FR54ZAHkAGvKrTGYU0sx60dWpM2lfZ1uaBMxgIh21ggdrKvIEToh8sIbvne\u002FWYNko3sOvc113vvWyekaNGU4NyO5lBkFuVlCM6AxPgaIFgCwKD0RipfVZHMgrLfaZq0ZbWhT93ymvRyzsa+54EdOmajLkQyUThYMBfkjv0PHdM9syu7aVfW0s8m3z\u002FhvcdIWp2FZX\u002FwWb\u002FTMl8kgJT4AsXH4vjlOP1sTdMHH3l\u002F4afkdJ6uvl1W8VzTvWJHidz54d+T+fi1SgSt6hxMi02MTs8hSEtEXOWp0k9WKEfo\u002FbuyLA1s0M932PL0miynKeCBH7Xvvvrv64z\u002F8o4ng3g987ARsRN4zbMumM+tkDuo4ySbj3Y27rw4JkxJurvidnhXQQHu8Q6r6ceRBpsGGuu10aDKOWAM4AkVoxWiKHtuQO0AuPWvMMiMv0tfbAx4Dvh5Eg+585tTrq2Px\u002FU9+9Hur14p2Xr14IbCylHTsCiCRafxDTY0tbfb0t3tMK7z0zla6PR3IqQTYz507N52Uvvjii9osXp5gCX2i7W43DORo+cb5Ujsb4M3wCwDZ42EjJ75YDG8lkwWS0MEauf+17BMAeuHChSkbu36jTaLxr83JgiT2QQAnd++WDW2vEZDJcQCg5lCa7JkMBhujjZz1oALJGjrOSsccaGcc2h+LFNuQzvEW0JnOLNH6URFeAIwsDIAFGnyqe48rublws44LiI140e1htuzABC125SRx9vEuGeJAAqCt\u002FNDGwUgCFHRH5Jq5kg30xKtTQhizAytzUFrX2a9lHouefJlNv9Yzl3r1zUMCOamyXzdyZg4l0\u002Fv3Hcw2HpkSWH3jXztxfPbdnP\u002F00wJS98ZpQCc8hlfZ5SXr2fqnV2aj5OifBew+flL3suTnSXNxnay6w8DgEdnsJ4E6PdXvtu6Pc34OTnOBqNZasrsi2vvTiUpugthjKxfZX\u002FrhK8t14u2WIvoCGEvrymQZGI8e9iC0qKObyB1+I4sNf17kCX2sOfBpbl7wDMDv\u002FAbrKotxsn0Syo8e5pA\u002FCR\u002FQd3qY70p3voqHXiYD5FSA0QZu+n8aPsQFur88TjbNWTlvj5z1XZp5JL+rIvXdz5jHPkRDANj6TaYyWcdG3hOd38UWtO7msdSwL9hoHIeeTabgEBjJs2ZM0RFPbsvWkCMBWIFPZXPuw+7K9gq0kDE6hX4i51uTx+4yoH5HxmtLheJ65LPqDWpsCSecw8HeCeywO2hnPmNz+ju+AarxrffYzu4Qfdg3Dhgc1y2zV2zeUu6DvnRPf\u002FD1LU10aOKgivALPsCNdKYvuuC7eqH0d\u002FLS9B3zXgk8AK5SVwimjlb0j1f+Wqk\u002FbcAYxOvV1H52\u002FsJElU+dPpUSrNd4IGNrSuxQ\u002FULP7Hq9CN\u002FBmA7XpqQSZKDdM\u002FSUPQVotegi1tcqlbF5Yw5G6TO7S09ZIApn3QEpBKbbDHl5QgjYSvC6xyhalRYPA2EKYBdLUp7PiryttlRbFachPs9PJJAQUPLrKR1mkyeoVyiGBGIxGWEE8Pxdxxveslp8KUBg\u002FVCgSMTPZh6LKnI1Y2rsT\u002FcW\u002Fbvfhp4M1QJeFuHB3IQG6phDPhj00ru6l5j\u002FlJ3wrnuuL+N+ngdyqDZnxyojcpLdtbq63Mg5uHnr+kQYjNCaoA9SUByLISeWo+6jhsiJSMCSUpqNZThnId1cT4pFWAjAgJeUBhrqGTvRtnmAZ3BiCD+hAfZMJ3PQg333VNfMgPzy7Q\u002Fdefnst3SeNFlK3uc5EQZu7P5xL48bhdoPlCAFSWjV\u002FHO01GGid1fN9UttumjuItQAqvkQTJub0fjYtxvhOCvq\u002F3QpwLfq8ETHl\u002FrYFGzKR+mU6D\u002FaNtG5F\u002F4QdXJbtecMj1MCHbhknfdnRBi8\u002FdWt27Q1x1L3IceV\u002F6aoo\u002FIWTgflQTZef\u002F1kNchvDM1kZkQDJxITnzJyNnnTcwyyLhrPp4tGBidaoBHUA\u002Fj0S06vWs\u002FapOLL5gLgAnIT5el5nKuhLRnx1cfQznvzvnVNdvzNvZfT7HoEDdxreJGn3GfI5hLpjwf6jBW05JQovh1e+9Yx9x7ZArxEao1NpFbphxQ6hTq80X1tqvzgg\u002FentZm1\u002F\u002FzCF5VTXOz+5AFAWYB0JByj8Erkr+f5Gl6ZqSzj5UxhD58RJEB3L\u002FPzPDzu\u002FUVH9cEIuQBV\u002FO6eXdUYaJNuEgGer65dvhQoOtQmujOr60URP3n62Thfs6EqcGTz3J2MsBK0iWgHDcw5l2a6ziz8armiYffFzy+LPulsYpy\u002F\u002Fwc\u002FXv3kxz8tknZsNqZb50NHjrb2teJ8fLe1WGo\u002F8WELki5j\u002FBp6hp2zoMwAQBFFk\u002Fmj89DX4jBCAPVi5HyKY2UUSZ\u002Fpd401iuXnd4Z5+KT7Ac96i1vbPrTa0bXS9CK2SgTeeevN1QfvvdPm0ZyvePrFozvxeCWBOfHaN040nSy5ec\u002F1Mhf9rZ+me0Vtt6aX1ccz5iKWNnB+74Pvz7WffHp+nOnTZ86MjHBEZZ9kYkW6yZOMLLshkARM7jW3xmwdAJgBNGMntmS7Ph3nUYb1buWNdwp4oN3Zs2cHjH\u002F96PLoFmVlDv\u002FbLNGyX2uJgtfxouiy5w0vRVvlGegosjo0bp4cIM8mIo5hB8TU57M\u002FgDo5AlYBnFGEAHo0idWLAC+6bcrY4iEOAVnnCBgPHpDK3xENdqcP2QdBIe8BTrvjB7ThCBmHyL3njXM+GTOyK5q6yNVkNdIZAhMcEJtqfU7k\u002F1CRYPPi0Do0ip5S\u002F95MxymgEGUrrpRNvFu5ix77Mny72\u002FwqqDIlijk+n3z8cWPSLEI\u002FfvfnDIhs0uHpAb9zFPpONpXFPgHmGzs7q\u002FRUp7QDzVeHkS+++KrSrWQnHc45e6KTTbR1T2tDh63l5O7YH09Ff+0ZtT2ermHxhdI94xZV317Jlrr3\u002FTlq6KQs93G0eMoJa5VfVhY3pWzR01khorit0qx53IyjmwcZyhlKTnRPORRIl\u002F2WGdsbLQ5WUoVmgnj3o+EB+8FGb8IgbtHajz6rbK219DlZqtgmsShDkPiojXca8GCUaGNcNpA6QHLqxHsC+Z\u002FARXLxKvwwgbZugTcW3mnvSZmVxXl3PV0QyO07W6lbmSoJWMhGZuPi8MNMvqMvHLWZ\u002FYqFxFqT556BP6MdO4ZHyYS\u002Fb11nj7Kp0Y4exAOjc6K10sT1nj2RfuPoPaoGHlJuq059uV6QQgZ2KbmEufA8GRNkFeG3F4utWxzmRefY30V2BI6MWRaTk2pvouCbs2oE09hMG8nNc9PuRbZ\u002F8us7BOq1+Svi8E3G52r11Qfr6LAWY4jKANFSW4grGnn4yOG6Vrw+hCAortetQrub2LnF0Q98z3iQPB7GT72bjg5ffnkxZtgSYDqx+t577w9QunChTXgffVKK7GLPapdXzI7oFtEppoTCCVKYdrytFBDCiyI\u002FbffaRow7BnWRlT5nEQIEHbIxtVxxC+\u002FMJjjel8iCTUeYkRHdnhKgWNWWASMAz3QuSIBFabZtzdPCeAk+5iWsNtrwODE3Y4EujBqF+7LvfiY4auEYEYzBSGI8L4ZdKQZAQ6gpLdEb0VSCjlG8Rhhj8vWU4t6coD3R8X4G4sb5IhtlKXi2NqUQNPdX7uK+5kH59VavxpISBEYpYY6P+dIQoIvLGHHX2gAj0rYY9CJV0b5RxLQZEM9YbOwI36DVrvQ5NJ99BT2bQPSGv\u002FghJder9wisP\u002Fk+f+Vld19\u002Ft95AvgsmqtnPi6As96cUAW89ewF1bcrG4PT5HtVn4oWiVV5T2tR4KBnKXmT22LHjUytOsG1SEaFV4uPwiLtlgqw3xTZtwVpzDhWloeyDEsDHm3RDa7Sl4K8XlePM6oQxbdUag7EoQ7p581rX1J4zXrT\u002F4cjRWnBmbCiWfUVRFhCdvDRpddM6GzlhUI9sZVE2ZR9IZpSJaAe5KxkQ5Vu6L8WH8SOaWxQbqq27iCLjCghrAQqEMkKbDrMIwwCHb5UyxYxXEZ4iXBRea+Ze0chr0prRwN9HB0SbcTjjU0AQv+IfoNLfx6mLr5fN1YvOwONL5HGJkI+T3JxEFpUCzSa+QK6jyg+dO9pBND8aev+vq\u002F+t7N2vJusgcgeMcg5n\u002FdMzy74EPIuTG+MwW3waWSYyCAwyHM17o8g+2m8C0AE8\u002F5\u002F3F+Yep7DPLAa3te9mzwOkO9df6\u002FCXa+mS+63lidWPfvTD0QtfVAIzvAa0NW8194yxDh10nawavn\u002FS2nGaGAqlOY\u002Fjk7V03fMGzYCeqb3tn\u002F\u002F5vyor80YBgVuVD94dgERHPX+Rcew7J3\u002FAefS0\u002Fk2y+xf9bp4TiBhg3jh6jyGdpX2Wke3+W9Tro1LP25TFbhPfLxk2az+lUhzRBow\u002F8a7nz8a43sMXL\u002FAJwGc9Slcfyx4cK4pJdrb1ty1t3Hr+zDHxdYWpbtpZFNaMzODXfkyu4rfWS0mDnwH09XSqSlXdNDjMJ06ebC\u002FUuxMcuXDh89Fp1sbGRrx15IgSRoBscVwFaczbGF2HPvhxy8uFH2Qs6F3yIqMFMO5KHulomSzR6PfefbdWibXgzBbJsgEkDD+dBKDKclrMkd3uLeKItwfwRFf0jPXi0+bZ10T4kseGNe8BI7sCZzYx2qvEHtAbHBh6xf6FyQpHq40CAbLDMhoO41FWSueStYmK9hztCbenu2QKXytae7ugQcMbutBZysyUS06JS3p\u002FshrRhh1lA0Q+OTV0L95qSvEyG64m2npVzhMC41Afb3Mzer786lL2vmYOvadbhiiow7\u002Fwvfc5PJeffr3ae205pZPt1FL2\u002Fe+91+dfrC5dvDjXKQPc1R4etESfRe42sz6tX7QhzruqL9++o\u002FLVgL9Ai\u002FXQPeRuXdA2ksut1W\u002FvKWtlX9Bads6asRXmprSWgXvVZy29+ncAn9P2LEYc29y8R++3N0T2UiBmT51PnK\u002FwmBPVunJ8nj2hE8vW9t5Satrout8ECZIsHZ4m05osxnGj64\u002FnVBxKp9mUul2pTVFtQc2njc1+NbZI96dnsm49Z7KUhLRFhCmMS6nfNjovDODgJI4xnQ1wv4rHtXZdbD1qLTI2ckAnx1doSy7ZN3xDT683V0ECNmN0RfKs\u002FGX0a\u002FTo8pkX+cLRfvdMIH3HLs6Islh\u002FW4D5q8bi77FUekqUu1Lmxg60a9Ix+jfarW1VQsWOGI\u002FPLt\u002FpRPYef\u002FSRufc0P+g9ek0WyzjxKf7ijLNPE5RtDlurjthZUHex37BBN48WZGB7z3BQ1vzcPh+BDLwv06Jsu5+mzNs5EiZqL+OuHNXJpM8M\u002F+n\u002FfGdAnVFbDHbR6yilPlQv4b2l1Y4loLeK4n700cez2Mo9tBuU9lDiYlOllKzNLPp\u002F7wtcEHrN8PXTpThtRlJnzavsAQGYIoeBk13VtX344QeTuqNYb1y73sLqKqG7B2BZj+YYbOOVHsxF8\u002FuPl\u002F08gG4T4YuXdr8HHMaoMB6S9hjLIuke0EJgiO69KHCCWvpI66UU1+z2VZ\u002FZeJcOCryravH1BM67FlEFznXkYAj2V5s+pwA2H8IxCm6YfFHam8yBlq9acOmtibblpVPgWqzx4peNedIyWm4pw7HZNeWQ0Hke+k20obKgfQF4ESY1uVJFFLuOBDZmDZgc8N\u002FcmyjBA2r7v\u002FEh3ZKNeNo8eLmElHD0fwY1SjVOBOrPo9DU7w14Y3FGYaB99+0L\u002FaSO3AMwUbIk20AkaANCHhPNtd7yGhrNZ5fPk5+RIdqjrwHsXTffEWhe5rAoQKl5c+AQKQc5XstMjpYMUKp91lW7SfTCM14AhxKAG2U\u002FKAotLn2ectDGkFM5Tld1sToMicSgud3nagqNxfq5zwh0Cgm4s4EGMKRQ1WHfSSaudMAIw8tTB0hE04FBToTazcuXL66+\u002FOLiRM6\u002F\u002F8GH8UJjjAai3tKXWjGKDgAqL6sbdsw3avgfnSYC0vqSTwcqRcUUbBHpXXrdx0fxj7VYDk05GIgsM9X7ImmUKQMOtJMJBspaj7K24PHtNp0Eoo3lQGc\u002FDI8AOdGO8lyup0ClJ3Mq4+uJWkQjYNY1HNT1bVLTXqbYVQAAQABJREFUlDhFD1xm0DL6IlrqQXv0KGwOzr4iS2pvJzLv+c3dzwN4oiGDue1F5q55W4Pht9jLenZVg12MiZtuVJLBuQdiJsuAgvGvL\u002FLhns+KWltXNPE+AuNN68UAWDO8vNTIA3nG7Z2+GjuDr7TIJsIb176JBntXb799dhxjWZLPKxMku8CZk2sdTLQjx6pRJVJam1WvWUZEqnVXeskfOF137gaI4uNjR4+u\u002Fs1f\u002FEVg5nvtV7DhcSlpAxbx7O4OjlImsRGd8XGE6XNFBFv7fhjDNk5LfLr+rQzO\u002FBC9a+lBYN18gEjAEC3JAcd86nUb2xJwWIwzeuF7kSdRTvdbMhB9JjqKgK+10c8Gtimdi85P0m++RI9F7GyWfNZBR0vnrcplyjLpidwkSqmnk\u002FvP5tT9lcqs6mR17WayGJA5ceDI6tzZt6fm+mc\u002F+7vKKmrD1zxuF4VUKibIAgyMTieT1qqv+d780UQJo+ALAz22LZovTucw0ujbAbe3bzamJ+MUfPjhD2aOy9kFpd8DBQAJGbhx43r0WKKwk53ofmTqVfNXviiDht\u002FwrPCiEiFBIM9fQEYgFG+nLzjdPJYHD5tvDgN+GAcmeXk1PLvoP5+VgfLF8UobztzwOTvNPj2oPMqb9i5du3alZy4AydrJXitr4AxbuwYyILelSjfUXz5nAdAW4adfOR33c0QvX\u002Fk6Xi9bUumjzc3kXp37sUpaZP60aQbKyalx4FOvcVyix732XDlLAqAy9xMFHbR6Zm\u002FR8LPPPoumi8MBQE7Za3NCZ9w3TnY8xrFl92Ty7QUQGGHfcP+r1ux549hS5ubgmTL4BUJeBtz3lAVhc9VK0xsxyWzedZ8ePZHb51jAfRqrNreOn6dDZnN23+ldnYi21m2pmHRr1kbuAwXnwg5A+hz215pNtqZ1JkMhwOZqz0X6I1orewHSdwWwlxapovvKYbJllcHsjGfUr7M\u002F9qwp6RWwY\u002FtGz7XmE4hpnLqtrO0MY7VvJPc3nSiqXEQ72gLuzj\u002Fpx+hCrRsH\u002FlnGt6ljYYAl4GVvxO7WsxKc1nroH62fx3dz3wCwfU54DC8D5\u002F0YDwDnPTM9zaHHE55D97uvF55bgkQ5cN2Trlpbu9P39vIVFFPhoJyXrhqbRHX3Ofz9orXg+G9ZS7bjE0HVlz1rOZhKty\u002FYDgvXLXD4WdCJk4xHo0M22Nj8zjFAQ\u002FxGDl9l5zeSSXOmPh8XVGbv6PnHjX0pGawlKLr0mRTab+dkXv\u002FU13cG1O8FXEchJyWMiY1NlJRyAKctHmwz3MNf\u002FboatXo2F9F4nME6dfr0EGIEPCLrXKA2jdGhOEQ4eYxOZvzmxrVZNAZOa7nbt6sru3gxom3pPmdm4Y+1QfBerZEeVlpi0+PeVy1O4MnpfFvu5vGXQiVsUm6zo7gOKM+e1T5R9DDi+nK\u002FjRhuGDYFhFks7hzfTQkkUK3PpDlEAEZZ9XlRo\u002FVSX3b7S\u002F2I\u002FtnUxRFxg6udQsrDev+99yfyMtHU69djKgpaeU4GNMbQOUfUF2gFWIBEBgMQoNA68SjwAkgDmTFJAobWykiU1wDs+rdSrO5LgTP3BJpDcrt+6zoTzOlazQ9DNohhSgzajccYzweTrskEdP8nlNbC5U0HmO7aeaGUPyzGzucY5MXo8dzdcgH4+WJzW9PwAqAYcy9GVHuvAf69544LEFqEgQI2f0LCcLiOcE25Ut+X8fbN31tDvy+OY89prDxlKVTlK6Ih22vftkTNmi8wUdRB1B\u002FgvnXrXhmgq5OCXU6+OzrRnpcvi3Bn5B2U4f53cwjv9YVH0WP3trIs8QGnz0A5VIR5lEoGCy0pYNMHhu91sMc9PcW31Oe+94Fk48Cb93JEpS5FjC9d+rIx3SiKXieYHD11v1p\u002FAnaidGPco591pBgpGFkdqWfKx7KCjL4zYJzbnTmXejPbzLVRr95CK3M9GnNA7aUAwgBlxthriZam1JNL2Sj896rzCxgrhEf2ibo0lzGYydE4OK0dujJ6HBlZtsXxyQjOSnOEReFyqJIvHQNE7ijtReF133jFegELIiITaezP69FcJIfxs4\u002FlaqcyOo5cXfu9e09XH3\u002F8aWn25QCvdHDPCKDEIwwKI4aHUMfL3zjO\u002Fj7ZGPzVf373vjkZAxq9YrGXac8UGEd\u002F44x4G00YjpZygC9A\u002F7TIq8iY0w4vXfpi0vvnzr1RFvLqOGzOUFDOtkMUtOdtS7a3Fznfng5bIzyiZpzBHr3R80UuZdCO1lnox3\u002F4k9WPfv8PAl6ba6\u002F0gOTjpeU49O3REy86n2CRjUVWhwY9VzDC+1Fhft7ca0P3CEKMfoiJGl6v7szxZGT7jc4D5vHX4rxHFrTues6gdR3HpbG3ukPLLXXVUfcJ\u002FI8+S1424hGOgvKDDQEIhrEzsJRNAPbUjlpsLXqfVJffjQdMvnbiVHNfrS5fA1xFy4+v3nr7naHRV6LbOTocVAYVr03ZS0Z107kE9Kw\u002FGhh3\u002F89LEIReRQs6Wl21QIULOPbTQq6xcGidlgvYXv\u002Fii+bd2SDpcs\u002FFN0DlzaLVIn7ooDZF0Om3WZcWdWf9uxenNx4ZHUYOODkoxIHTYcIJi8iP12zSJlc5eIAlsBtIRF+PcG82gHO\u002F6Es8Gx37o6\u002FJFnQdet6+4xCjkyNXPWr0HT4fOjVdtoue5Diolbevij49e\u002FbsyBF64BNybtM6e+AAnMVRCyD1HpKKoh89GhbIGbt6\u002FVpz0iPePoTkKl5Rxw+872ptyO2tnCBrQ7\u002Fa\u002FO\u002FAwK7EfnP4FH2wtdNzd0Ujk15Ko0RR8WJOQx1PtMcUGLn96vasP0dTRvxF+uJmjsn+6P7h+2+PI3CvLOZkglIWNmjLZOsA8jQAH+prnPFyAqAUh12ZQFvjs7F7Q7eXmFDUfL2\u002F6YkeDJ1MmEg9nLFlyhmThfSbjMDwkMYWrRGgrrMLHr2XLtjSZzZqA\u002F1yLRvdz61YY0unJ9frx470rP3jlNi3ICPB7nBo8YL3OMP4W\u002FtO3VV2wT6B8o1sjLaemmpM8DN9TEd47kZ8vhF9lG1uD9SL0NMjXkprrZOgkswuHYm\u002F2R82Aj8Nnlg54XfR7eOYt\u002FDsUh+d4Ao+GpvbuKa8LxoL1MJa9KYx00F+t9DsOXAO08mcymJM+U33s5kemCdjPsvpmC5FfVeyIyOpCYh74SMvzj\u002FZXPQRbFQQovXmUEMkglQy2YKhnFabqNe2qPaY0cz40IkDht\u002FjupEPQQoNH4Yu8TR98l29lpF\u002FB3e729GpjmJfPIsAR0o7+s1CUhLKXZzMKaJhESj4bzowSMpCylBq62i7sHm+BBfRpVaAlSjTAiybCFwvbb6jtDyv7Te\u002F+XT1i5\u002F\u002FXV6t1Ol6YzjYgQAdGftQTemTwHILkgxjoBvXb6dMtpXiOxLhGetGYrHTKzYRPquAa3u7d3cFarUMCjfisFkgBojgE2Ivc5A60Tgf42BETCkyS5lR9hZWhEBdIvOkj+90vim649CXry5eHAYzf\u002FM1LyU+PFhAgnGgfH3m+XPRqsVxMBb95Eegq7V0ja4fhI3TI2WHWXimC8DvcJ+MFOX07GktIQN3lKL1AdZ0TmCEZsy957MTNSQwfUkhTtlGimTxgqNJkfN5oU\u002FXq4ucmvluOmAn5l0AwHIZIVWCNETxLeL4+2LM+wwgUhs5Do\u002F5bb6\u002FGZ1VE599HWF3wphyAHwF1LreDTf\u002F80T39h\u002FDZN1E0XV6sSH3m6u3ciLz2PvY8FJ0V24ieiMSad8DGh3vRMEzbXQ+fuy1xv4ifr2agaGElkNe7lTyoiUcbnAf9dEMBKUwJ0UGopYyF2UQgYzG\u002F0KRYD88C0wA5xSeji7oDPADnpysO7cftyn7VBsCj9WF4djq4ldfrz755KN+XjolMejGciNQqnvMEwAn2ukm1K3iAd1bOiio+4tkUVjALIW33qYn0TWi5Yj47YHtrTtaCzyXTDAazjtw2Med2nfWU23uczQnWg3fAI3HgKmo+QJeg2QzB2nuOesg\u002FuckkBd9jqcOOB5bSlbIdDqg+QM05IQhxhNoJzo5kaxveWSMeNevFcbyGbKM59eK1HFWREilsgGa6TEeT17++labby+2jg\u002FHKfK3MYqNKXZPMcez6YUGbSi\u002F\u002FSITeM+X1\u002Fw7vLS8N85WvKCGUZu1BQAtgFfkHT3cd6MykRdlAizGg+iEZjdv1wGqteZ86dgDUv3wB78foDzbgUhfNOcMcky+Lx213lqtpQcZ1gOlVw9lTJ8VYHgY\u002F9iU+iKeX0+onL75ox\u002F8YPXnf\u002FZnyX+HP2XoARoBEs64Lh1qd+fglpx5IQgOGGM7keL4iEzLWAKTm2UUnoHO9JI1c\u002F0Au+bj8BVGSJu1pbyjqFV8DwhzEsfBjq70oi+0dCgJQzb6O8bTWtD7U57QnKNkgCKAtg9fqrdNh6UPdhWY2dYcX6RfXgX2jX1OdIz2wPp6WcsjRzvx9cyblfqQty\u002Fjue2B5mTn5Kk53Ojipa\u002Fj\u002FZcT7VLCiJ84neTlGeAbzzHiZHz2+fTd8jPc0wQgWnLc6fsDZbL6IVoojxS0ETBh0Ct368upklfr\u002F00PnCwCrBPXODjx0hK8Cog2f8GipVxxkScYQmtDNdaAiTpcARl6qWVZaMUx6lkvq7mNoZiUgEo8h9bNj3MdNBn6syFsqjS9Dl3WKYovujqeGhvTWgLzZGOc354NwHAYlbvNSccNbOQznWJdU6jEYmgFoJEDQQRnMDwpUzsbpgusqeEGRLtl1yDZsglTm0wRzqPhgUvZPwErOoXupKfJsuDX4WrJvQAm6+B9e4HOnDk950ngXVnh5YTvdIdxJWMzxujhd2vKHlvvGzkFDrhi7\u002FAiedwogLeRM7G7zd1spdrix5XDoBXH0S0nsNBa3gmoy3A+bT3MGfjbEh31P2dr1tJ7hbJaKITq6QH3DGLf+72SF73sQ\u002FLNKJr0s3E5gGlP2RFnzGwLEKpPv\u002Fus1pF1Y7t\u002FN6eutd54Wva3s1hkWzj5IuNkz9w0k1C60hRGruhbNOAczcFwzUN7xMWpqP664IzsBxkF3AH73c3tWV8Rqey9jbWtUzylH73gFtxAb1o\u002FW75lviZLQ9aTbWfSeKYAqtJY7Yndf73ryRPaL46Pz+Lj6BX9d+Kl5HfhKf72EmWH88jL6NGYR8TbgWmwoOeSoR434yCjSnV7RG2pm6v3k6s0taXrBSdsZmjdE05b9jDY3+jesAv7SJ4myNTNRO6Va8++ww7glOUYm\u002FCtrE8AK1kcW7eU3xvQYFclp+r90WETK85Q\u002Fon\u002FfGdA\u002FXBg9Oq1Di0KuNiUA8DYaPewZv2UrYiDlBijQFBPnzlZ5PhwButSX19NFFlngosXEej5bBY9WxszEQ0eD8GxAATzZD1rRU2ULPz0pz8uam0zT90NIr6Twwiimvg7RdREC44dzzgmOIx5PFBEudNRS\u002FPNxtYU7pO8v3gsxksA8qKePxO9zsPLWFlQitzvFn0iHhEdAJ5oQMrJuERd1J6p0deea0+A6VlM5LjsU6dOzuYuhpkxE6UVraDMs4ajqERINz1soEWkbL6PIaFsdLiRqtmSsTiw2vZgbVKHshYAHgPjJbW+pJkTvNLtopd7Yh6Rgd08xAwUoyzVtV4qjCCJgPTnUQB9G4VJgDgZTvp7XqTAoVKAx3pMaw25LwwUxUVpqIPk1U9rp+6x1FhmfklPN3V\u002FkYhR9QTKm\u002F1CKEWogHjPlP1Ab8qGgpY221b3mLVOxns1SmB0yqzjlDlMJF9dJm96MbhAs\u002FVCG2UlIjg\u002F\u002FOEP4rED087wjTdPd8+e3dgpIY7Ng3ru6sRw+XJ7Kfrs0bI6p0\u002FXRi9jK1SM7wAXm9Bch9745lj9lDmh1sdLKdKDe\u002FY+PJl1xcupqI5Kls43RgouY9vX6SJSe99\u002FJyX4uAzR7ak7BUBv3b4ej+xtve+v3nn77daQ0iytX8kEg\u002FLGG2\u002FmUNyYtmXGsa1o51r0szFPylxN\u002FcG6xeDH25XXrOegjGJKLnpz6GuPxPOUi6iDcSmDAvDYmTu3v+7+t5LD+ndnDKzho0DAnT6\u002FqxN99XUH+j\u002F59JMUdKUJPYdxOxRf4hlRJes9QCy6+JsIiOjJ7gyyri34j6O5AEHOeQYynvfZJdMy7DH8ga4DirspuXk8m17XclrebF2uzhhFPb755sr8\u002FfWcGYCGbhF1VmKnfSm+slFt\u002FwH7TPRtj\u002Fe7juFb\u002FjPmxYGNUiMHvRFvxe8ZkpGR+NVc+vDMb+o0u4ZhNBcAiHwsyjyeiA4ihCmlWr3leIvIFT1VegXgfHbh09b96Opsmyk\u002F\u002F+x896zcojXcEs32F3E9nuwe6YtjETZd3erMhPsBuPspLE7L6bfPrv71n\u002F1ZUXhtO9sAmYO1LWdv0s2luEVbGVCbGpto9dac0yVCZs6MCbDWIo9uWyK6OfnNAZBdHLEMcOMBpIB09bb08bbnAf8+j37WeBznriHTIm1k0P20sOOIagOqXCcWSz6SvYzvjkC1DAp52JaOdtIjELt1676RofzKQHrjU45BktJfO9faAJpe4gTvrn3pT\u002F7oT8sqnOiwpE+KwO9Znazs5Z13301m9iQzH68cJObQMfsrRP43Nq5\u002Fu\u002Fmek3d\u002FgDMQYMybmZ+mMSDFegJrsmiAK+dHkGV\u002F3UkAGfxBP9jDYgPvtbqa2CC+BByAbtxbsUF6GG\u002FJBAkWsV2is4nYPJ+MoS\u002FaDPiPdhNBLICEvnQIeqIt\u002FtLq8+59GbWlwQI+E3B5VFtkz1Y2IQNhP8BDuio+39F6Sc3vLoKLf62NgNmLorZsrFI\u002FwZzbZbzNyUbhCeTE1zKXc1J4MmsfCEXx+YXP0hPfNKayBWW8gTCHGb5+8mi8sARhlFw+qmzAXrGX1fq\u002F0KEtd+JQwSmHHDklVsT3SFlkc+QgCJQI+p06dWr1zVaZzbsTRLEGSkgFGd5\u002FvxKvdPJf\u002Fef\u002FMvYPv4+NNrHmPEGP+NT6CazsbV4PA18Xv7iZ7AXWusxBO++9fa4uSWfTA0Dmk3T50dX5AiLO7jjVXoM7nU7L+SArnDooRJSV\u002FZv\u002FkjuvJ2VWH+QIqCqADdA2tbo6UFtWZWfWdUtYQwACwE0iWqO6iHU4liyD+7Ol63UEW09IdyTvG\u002FHDtoB+LJOcpFtaY47Z44KQm5ko\u002FMiORe7K4DpDIzrK9I9+6\u002FMywGSVc+i7\u002FUvGLqKeOhj+fB5fOCPA4YnKg5CwR7VK6Yrkm5MOU+geM8A9DGOOAlvms+hPjmiloNkJGAUGnPs0BhvVZcS2NHZ2HVAnFoKBgLnr0d9G3ceNkd0Q4bZ3z3dlLeRrOvUVSBOY02yBjp16\u002FbEx2dnGPbSPGEu9vBXqDI7G+bR1IWPWh7NC3uk2wYnFiWxdevZc3xyAdbgG39OXOsXt2UdmtRitlbjsSVjFwYAwHV2m9EjVAhl9NfKN17+b13cG1G3ifFF9kFSddjWA9Jzu1sTuRqglPc+7YfQogZRbKdvXO+KawR7AmNKgFHXBkLK+\u002FPXXRUaO51GmXCm5FlXE+EqR+NsZ3FOnTi+17gncjYwaZ6COq3mjdkYf6+ubDEi9eG\u002FeGaDCC6aMn+bh3t2w0z9hzRHQ9mg8oRiJMrgTaCIcR44cSiksEVJCvHh5HQ7T8+6UTlsiKRnhnkSIzdFx8JQxZfub33yc0rkVIy4AHZDE8AwshvJstPD9NTvuW2S\u002FA3uAkPvG5wMwB2QkiIAcwd7ZqWma\u002FAMPwAanYZP53EN6Z8BzNL1ZhJZy2F4nHh7oTnNKCUvt+JqIemPC6DuGoXmdgEoClURhSk7Hy+rtRL23VlaAozGxMfoFyCawfgbH\u002Feg3\u002F8673Y9HPb9kBObHLnIdQY008zOQJoq0VuulrR3UJAJHoAn4jp1dt140OgGddFf7DFxP4cyHJaO6oZSwJ1gHhkmKVsRGOYloCN5jZHd24BOFfv26ciydg7QkXI6j5kSKRjNeDkARTWPEAXUGl+F9++3Tq9eK3DEGk\u002FINZPlZbbXU2MtOrBTJp4Rmk2300mWkPw6\u002F2aypDOfrS5eaw4sM\u002FaGur5Y0YgDIgDZZ+MEPvl\u002F06esidYD67oDHFxk29Z8ySEdqLVbEOoMuIsSkL9GAxjK0U\u002F+tDlWtrB63OW0xVbokule\u002F2uaie3dF5q91gm1RkZ4JIDzN0abUjYXxFlW1soymLAAHRus\u002FcrBkvrZPhMtcZUHQwXerP\u002FwYvUUuRMusESeMAqR8bRryO5l5mZGS9v8tf8xPy\u002FJOpqaBU4QTRY\u002FnOcUbG9tX96NpbN+FoqW1NAsIWD8OPDBCdvGa2w2vMhz9Iko8ZTcsac8lUMsG2f7avYzP+MmGFz0E7E7Ev8\u002F725xOOtdklLrO+DyMsfZlYBsxP5AKYE1kR+lCfP6wGmMbgH\u002F4ux\u002F2weer8x993OEr9T1vA6ea9n0yjPHlrsC9LNK+Stu4yUD5sdbre2+dq8tkm+Ny6iB5Ncy+CJshz5o3B2VdeJCDTN4WGizygi5kBtDBT4wXpxQIkFK2XkO8PtdU5vcl3Z2x7z+0sM4jA61hD+9e6nc36cEYLuctDD26Dyfw8UNygd5lBwLsSg1Gt5VyV9u7NUD0pODJ3ZwTJTvL5rhKbIouOgPibtHY\u002FYeOl+Kvk9PJM5W+bF396tfnp\u002FzHfgylExcufD6f2xwPRxIv08n4omHPa9MhGd5M+c3BOek\u002FykWHEi+AhY4z9qFHP7MBotBv1nmJXNwugq5dnhZ4n356fmjKiE+QaJ4lMrrQBZ1e4gmR9HQZGcBAw5lo3s8WMZYbmi+lKq1B9KKbAXb8ygF6ZL9JXWPmEJ6cskMBXbqPPOsuY6IvNrIJ2RiAhT2JK4Z\u002FF7CXQ911fta2UAZ1MmI9Cx\u002FNQPrXOvpih5VyCSZwrI4dO9xfCREnTcZ2Iay6XvJgM6OJKIHZlA92T2taJ5gDUwIFU7LS+PA3GzXjTJcI2F1LT98M2Mt0vtbXj3\u002F8k7FrP\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\u002FUEBMAAaC9evBzY\u002FaTF2dNu+nOdMHc6ZlBiU+lKC3+7+jUpJUewn3jtSAST3tlW+6UDLXApiBjsyuWrAe8MYmmzw4e1eewQh0dtsExoHae7vi2DsgVoz+tsXGoiu3XpJ3XubYroc0+edGxtz\u002F1\u002FWLuzbruuK7HvB33fEiTRkmCnpqSSVGVXlRw3yUvylkePfM+8ZIwaI8OxnTzY5bJV6kiJEjuAIIiG6HvgIv\u002FfXLiS8xwc8uDee87ea681+27NNUhi7JROpgAZTZQH4T5CPwJDFNLHzzOMvi7l+k1pUL1zT+WpxzsTZUUYoocis1KjnBetKBHA3Ta3UBqiBnrZOtZYtxuMZ5PZixciVwQP4VVk8P7+5khR2hjkhDReYUJ\u002F5\u002FFhrJcZ1fdbB6X1dOurzR3HEReNmn6g5GovzEYoWt94yBGZNTG6zHmiecNIZK2aQFGdiLEvvfsqYmdA9Ut\u002FYL559af7tz9Z1y\u002Fj3zOX4bUMedcj9VDYON3XPztjALxmrYvRRdi7Lgbd6f4UnDSx55oDQcQrNgHPPdB9oren62bAOIJLDpGNMGBO4ejVfzMcUAzeaE+tKQ+eU+Qz4xNAaJjgU0Kje8DxE6eaj3T\u002Fig5iVJEkhhtHgOJA64wDqUuG4IP2D6CP2d0frWg5OryhRKG5ixIyXEDD\u002FDiNOsL89Kc\u002F2fzT1q+Ldn23+fbw1Qz1UxPB5vUHnGqmK3tJQcMjYcPxFCFh6OOt\u002FfuLAOZEwsHUl2dcAdRsQj54ZOalvIahdCBj0NkGDJJR4s1LRAYM0dHQXjAUWQcjTo4ImDQ2PFEansOwoDgGFzk2UvHbipQRJ+Ud+ww+CFEOhazaRE4YecFg\u002FkMYfusnuqREHkbHNqOdPGHNi0YI\u002F3EWu0aG6lhRT4a6iBghPKO4P9pB55SQMeEXPYKHYAAhvG1kLppdBo37rYUSYexur5HhTun5fHt+FAE6bKRRCv06UeNnOYbolOpgUN8P\u002F48zeH70k+8lG9+sDOadzY1LX22+++rLzf3OmXgiwtYm+1A8JUQ74z9BEI78mXfObd5791y8sjJtc3BZJXKelXrq317mEQ78tELKneEQeBecX8HYGob\u002Fk2FkGZr103q6ZH6OodhYz+MdUXgQZRzgye3XgpvvV30rfkJHDA1448AxWkxyIll9Pmn8CGF3ypjw3cqhQGsPZGXrJHavCOLqoCDAkQIuECQAcvVqJWyPklU7\u002Fl0wTPZnnIusaumnN7js2CcffxKdtam\u002FtZDVDGZ119Y6wZVwBo8CGQIo1isogJasxZwZk\u002FA5Dm4y0dqVrYiwk+XKAWST3nrz1PCr8dRw37uXoXFQVD0+WOTQGBkMOWDqaPu1Nyhy2sizfudshaMe19\u002Foad1PVjJOyBOlaWDwYDayF9XsXtfbzH7y1Bvx4qkOWntj1mvfixKlyRyRY4Pb6AWfhiP6yt4j63+6JXK8IyP85PCHIAbkT4Cp6xl0jwty+dxJjOjd3PGRWmeZWQ4eo0WUnf4Yp1touXFnDT1\u002FS7CiddJvggDbJYd0ngxn1DmyRBaQYz9Zjz5fgZRO58wRunTp8hwi+LOf\u002FdUYjL\u002F85S+7bxljo7eat7XhfZleBvexZMLxYwfHyThdb3aBiSPZCc9zLB49dpJ48mtzIMf55PDatfbT2Uj4LF19NIeZUTfra937k1cCYZNxhLd4wCrRBnreNtLRAkTTC7t6VqyzeZTNsm2Ez+Zusq57RJp3FTY\u002FfrQDCbN58MDj9I96fjCnHzxqjPqezRA1H2eqoE28ZRbsBwa3a9GvZw+m0GFjhqB5vr0qePNg8DyZrASfp8kV9\u002FhJ\u002F+B5tIIntg6yc\u002FDy0rOCFozYcaDjhWVIy34ne3r2PLQf5O3L7kMvO3YKfBpvBWzHkA9PIzfRi2eTPc1Laacg7lRVxMMi4Zxh0XryHE+TITJGd7sWnGZzf8+cbH+8br3oCQS0whaUESxYsjtjesYoiNA95qLaYNec2bD2dzDWrQdVCoyyN\u002Fe9JBuyEfFV87UW+ksgig0J7hOQaMzX9XpthnpwHQVy5\u002Fb9AZiUqA0hPK\u002Fl1UmPY3zIXekBAsvC3jx1cpT2b6sBFpGweUPK\u002F50839\u002F\u002F\u002FvelE69PF5kPPnx\u002FoheMr+OleK5UZiKlzasXxXBYi5Ty3bt5fx0d\u002FG73i9Ts3HE1xS462aayGPLenby2Iu3RWX8rBShaEnKk9E7WdUbaaGdMRWGL+gE64wdiML6o6qqlWqlDjIEYCXcOxv37sUVe6\u002Fc+qi\u002FwqbqMRMSMRFFAAlGkDzaV3jx9WgQgBhTJpzgeVL6A+Ccd1ud+IopJ8xbJF5ETyYxu5rMTGficIjBggI+XHfEwRDEEBsWMapbVt0q6UUAYg0AjbOxQJ3AI\u002F\u002FEuGw\u002FlIvA5CKqE39OUxtOYo2XO4Soi3iMwGis2HHpkgNA78WP\u002FNETX+9u3Y5p0rV3rDCOso2Sdg4HY+39d5+JensPoEmnucmcE9TwDN6\u002FGsbLM4saTvlq4NIDb11UYT8T55NCbPsei6WfPnRl42qCMdkTTGSUML4zMqWKo2wx8\u002FfrayOSZIlPGezNlrJRJ33PGkEiWKMC2YYZJCS60Q7AqP5ooXopCpIMgwg+iotvGCyEL54xhdf6EzONHYLLul3J+u64HH374qP0Yv5mDVt45\u002F268cGxohuG\u002Fq6jR9evL0RDd++jDD8fpRRfWRumJJE5NMDw1v8lSAFjGAMftVtEq\u002FAIGDh4hfNQ937xxfcqD0CzDSw3rb37zm81Pf\u002FaTyWp9UecZjgnBjucZAIS7tTK08Q+HHVxGQIavoR1ziOZkJ3z\u002FTIemrkefYbzfgkHPZAjJqrSModsxaPqMY3BwyiQW4skVc+QE6zgl6vdF94Cn5xpX3230RsHptMHImM8jOPOdiHn3oBVjwe0YNRRLb+OM4msscxqD3ay7lhxA2fA2a++zvtnsLcKys\u002FpSRK3EQ07c8FFA8qcNsN9e2Rz7+kQO5enNOx9e2Lx74a3N\u002Fp\u002F\u002FbHPti882t766tLlftuNFSuh5Trqe0Peb++FOJzx37nRzeFEw4qvNsQy0p40\u002FGctZq3R6T495RJdmk2tKZjkTHJEmMJzLATL3Ur\u002FB6f79lJF59z96H8M+jvrT+lJW\u002FdH1C1azzp4xMjL8jsMVfaNtdDCGTELgZXXVYDeRv+AmsiswowsGBclIETWnDJ9VIvH0+eO2RtQYoJIJfIaOlFI+rmzxWdmj7zooStnVwUoML13+ZvNZbX7ff\u002F\u002FDjI5k+Eknax7cXPn444Ih14u2n+7nt+kYxtaTIsZHRibC1xiGzUe2gxwlm\u002FDjtozEq95eC68ci6WYXQduxtWb+nYbMr\u002FLaRXgEYW1L0RJFkgnilu\u002Fn8lUbwZdOLCpMOCE22A6hvkKPICvwNOgAiIbhRxENWpnbRaf8sVk1vF4TuSRrtWMQXkjeQLeTn00AfLL\u002FAWkZF\u002FHSEfD\u002FbdNwx7AqUAHzl0An4MvGltEM1owpvU+imZld5TkxdpLNqZDGUneDRsMo5lmiz4EKPyHJuwhEWXfWYce+8DggqEuAEEOnEq+WrR6++cnn+V4CADkaIWDMRyDi3K\u002FS5cuzVwvvntxataNYZ\u002FW0Gv0NkZh40yGvOYAghQ2+sm0mSMZsZU+hRMZh5dtbD6wD262NqcLxLxdFlZ51lYX6HZCUEwXmGjUPA8lTwVi4BYrWSc9a7xIObi03uaxPueE5WBkByQJk2fhgX5OH8gi4ZGBe7DhUMEju8P3z54sZ3F4o7U\u002FT3Y4oVtgDIDxjU2jfqKV0a2NPU5nk4Fnch8tKYGbQFKfoV00CpZwczAaloWC33HsXlS7Hj\u002FIri1ZvfS2QKz3CxHz1n8qemPPCIxESTMPch4e4EuWTVciBjU4GZ9MZc\u002FsigY4G+iPXgFLcECnXnhgO2Cwd1\u002F8RB61TrKGQa3\u002Ff\u002F1CNvuf6A5VWVqlOYJmKhLs83rQM9g4xncfWJDZdApZTgbpDMN49\u002F3YisYHn2APVuQO+6JZjS1UVGRom+36oo6B5Cqbj0GvvGrJ1cWraOB1vV6boU6oziaUIl178uynjVYRgF27nkxk9+RJfSxbdgQtPXDwwIoWf33pq1EkvKTDAe1M0U+eEYJnLHz00YcJiLyVUtxKW7TXu5Px4GAEjAmpEOFo5S+qX0sUjmDdVVpfKQHiEYF4UO3elaLr0X8CVQlDkc0I6MCBoiMJfCUHUhgQfLSTv07W7mv3nuqSEvzSLYTWbCLMmCb0KO8dKZnnMR0lhtgJJAwxXmcE97Qa5vffuxgDSEE+q9PD5REQyjAw+\u002FvvvTfPMw8nLRKQogpqwRCCaCtDGvOqgxpOjHDs9CeEGVSiw6L9IqcUBObhWeurPaelBZEX4YGAPjS1y8c6hriNOi8\u002FH+PrQAwm9SbN5L7ZVNZaZk0ZqwRNdBwMMyYTBDzQ5EnrTCC1oXQrg33IkVQmOAYM7u8XmsUHXv0cGLHB+n0xTvCK8NXbjVE2imKGmVsSRbNmjLQdEfWRFLFRCThMsrv7OEpTatFPjIjGtAUlSChhTtbJk8e6S3rteTCrewuPu7HhhgDhub\u002Fz7juzudnGX579zuhDNIPQYOTrwS6y5Flown3wsoxLAlq0bfU6n9aiGVKzeQlMra9xGGhodu5rRgS+qNVEepsLXLANPJ+gI5TfasOcU+bOna9u85tr1Tb\u002FcRQyODKmn7xw8qH6wARQRuGHH7w36xWR0k4ST+l4RFgtw2iVE026Mfrw+bvvvhuPFRmJF6Uo0ZK1mqtTGGGGQY5HlARdzwg6d+HsZCyUwMCr9ROCI+CiHQphDlxJKfuc4EdTSwi6Lic5gYkfKIBlJC3S8SU8u8a\u002FDOwF8zV30X7KwMnCPmd2wOfjnNK9OcGH25hNOaDlKWVojWrA\u002FT1pzK0EfjAZ47u5q7HFg5So6KTP0R4hqYWeuSwq3p4VB8LMlqEr+jn15b7uReng3aikPTIZTuHRMeTkBJ4jx2WAHGr2qBNLnz1vI3gt7b76\u002FI+btzrk5Nz33t2cOF3NeXLp29LwD5JxNsm\u002FVQj0aEGJN5KFD4oG3r91NeM25yTcxMIZHDbMxrs9Z0zMJjmOTlF\u002FeIYHsyarliG6AhDozXpGgWWIcFzRV1MdnI0T051BapQtOYiv0C2Fuyv8jIMGL9Gw91Jc6x7KuFuHd\u002FAweUOZ6Zuse4Ox4GBXbTVly0SKpeptIJvN\u002FtEpBwv8yOwf\u002FfjHm7\u002F40Y9zLh7Gl+erOz+zeffuw5HX8PZtgR+0S4YyThmP5gkG1g2\u002FjCEv0TnGzRgJr\u002FDnGvQFKMPffQ4+6IcBgTeH3tNrX3zxh82vf\u002F1PUwZwqmycji7nz51MBt8Z2tR9LHKY38FldHgySknB8Ag49N\u002Fs12kez3NG4Md75EZzdD\u002F6I4s4kk7mPVpwiXGu1NG8GHmzluaO\u002FpRIqDN+\u002FES9uX7ojMfewRWv+Nuo5GiPD9GczGVw468n+Le3dQsi0N\u002Fm37STDWRW\u002FFapn8PE9lbS04DN3bMXEPGfm0W3X1bOlA82ONVOUBbqWFHt2\u002FG++mr14LOXJpkFfyKqDifSBU1m09hqkum1VdZWC8ej9vYcL5uRXdD9eouPTuD89WjPFZzg1L99+siU18ApmfhG2TgZCsGw5\u002FEgo15N+N3mw6g+c+HCnFj6uNKiB3gjOjrYEfbkohLSpwX\u002FwApiyDU6QcChm4fHyGKygR4EJ7+CI33gXAslqOSrF4OZ8YsP0CA403\u002F6\u002FSvffVwt9NgWfa4tJBzic3aRcg9wngh5zyHDjecajvFufN7nSkbo0SNzMFP71Bp7lU3VRete0Wr8G2LNsamPnl2looxjpYzmsEpyXkRXWgQrEWGYIyN61C+cdfjBM9t8IpjEQCenwULJV4iKh2Q2jb8MaQa3OcMRW8O8R+YHk2ddi2c5on5CMLlGB3N+D+4\u002F0pwZ50oK28fSWIKHxl7yz7VL3\u002FfBzHtKLsE8fiDHcAP5yN4B\u002F5GPdHzPcuaMaoZp59s9Dpp0j\u002FE5OuSZctWZU3BmT76u12sz1NUpITJlEpBq8osJVqpDZOHwRKnVgFVeEoBFG9WCacnFGA5Eo2BsMhE1HwUYI9jYBzFff\u002F3NAM7mLEYqpXqjiOhsdOp7xGpsx9aLuhBU8Kl0RGeVKHqMlG\u002FawW\u002F3\u002F5Nq+h6VOt21K+ZOkCIg3T7u3qlc5F6OQQzH2L7wzu4pP3ijVomisDaMigQVHA5\u002FzAPoTQhTKu387rExxdPNL\u002F7pt5uf\u002FdXPOgr+wjxf+0hlDhTFUhKMqoTddyJENsTeylg82Ho7ej4BwkMnIKQvEYp\u002FeOkMf8wgyoGQMISICnj53KWiVdaoBKJbZpZ6PCNAGxUZXHqAi\u002FATMgT2Tp5wQDTmIsB4KVzCqfjcS9ql\u002F1Op3TPyJ4HVR43f7f1cBmj2SkQ+Imr9GxImCtlfOjkQYBPxwKA5A3am7yySsTNBQAn0oyvnUfMzmqfdZyzznLnGTIwI4\u002FiJeXYWFVHjbCe8Aw4uZng6GOT+fV1LRG335uBdGYYiAOZAi54HBuanw4NIOXhKuU2brT1LOFAG58+fn5IpPVjBqCEGR2N4NQewAa99dX8YZ8n6Wtuu5kZ52TSqA8ocLpSTg6lHyPQ8AGQoxTaDP8L8cYBQE65Ty6MHHYrUhrm3M85kTm5VTvZ1nRbOnT0fzVRnHh\u002FZ3MIA\u002FfjjX+eMHZus1NH2Xygxu35dmYvabSVWq6sQZYA\u002FCC+86JRTvEKB2xBH8ErxqwllLNy84Rm1GYv+HteN4PPPPy+SsHfzgx\u002F8YPOf\u002F\u002FN\u002FGtoLUyNcHcQDpqLWHBHCd\u002Fs72OVMYRR85HtlMffrorNKqJbA3MY1w97veOZ5ABqcx3wTRWpQ3zFe4FTmZcruegYaJ7hFb8ZADc6yMcaxyXKIt+uGH2d2wYKxHj\u002FsKQrOabZxbMph4g3jMPysaykwso5RSXFuy5uldNYcmVXRa\u002FNioHsvxxYT4ZXopbfWbzdqE\u002FfGm3W9auOZNPrNh7c3e7WPfX6\u002F0zo7+OV7722qxk6Zd09dexhPanuf1B1oV7T0+EGHt1SDrGPVrjIte8oo2jOkjEIkasAdr1Gs5gamKG1g1+\u002Fo0LqtYxzh5kVhgRWjpB9Lob6iVffvykk3rk1knFk8gVXR8XaqHrw41EMD\u002FdTJBH7AjSOhvhw88fi8zap7nGEhJS9LyRDXvYehAn9KKI+mGBkxyj+M4xp7Scho2VW1zLo0KXOxNtFc4w7+rLuHkZV4fZWDVOOdccAY8cIb1rNjx5\u002Flgyi4l3GskXxWn74j5+96WZHb8czBgkk2iXI43qz8RNnGRN3wHPgYN3g9a81wrxXlkmE5kdE05T4lfDknq5XmkMo8l8G5q420nO8J9iTT9PDmkMLx7M0hW63zFZ7A3gutMWA829rXWhmPrwxDvBgPgdXOuqUJqnmbz0RAjYceGou8F+wIpMMbsXCylFxjEHVf1yznbdGYKYwxlkyTuVO2hmboSzL5eLp\u002FW19Nu9qeRX6SQffLRIsIcwo58143k33oVHCL3HirrLXryaY5lDD6eJkT9DJH\u002FGj4v3+gk1DLAuoMh6dvp8Nlbs4+ebN5FEhsjOePo8EJ4mRTFN2XZXay897up8m+a6O6ANehDOunBQIeZ9S\u002FDB\u002Fbzrhx6D1yYU\u002FGrM5aq\u002FYaLTUCuTTyPp7pb\u002FJ9jzLFShaHNoMhvdC\u002Fs7\u002FpWTiUYeGoJimi++RPuB1+jY58Lvo\u002FB6LBDbOyMbow3Lf2fsXPSg91ILE5UiCkCeYAL6cCPS\u002Fj8mmy\u002FcbQKkN5fyUcvkOX3TA4Xc5b+qLn4F3BFVlLpcKep7wS7Bn\u002F9Jq1MtbZgavEcVUfyGRwAFft\u002FQoUaK83MrXR8RZdYf79UTB02TfoFX69wBzMHg88bEzP2M+m2tu8HOpls3sEMj3iwcv8jNU\u002FS0fsXnxOlvjee9E1XugttEImdceCYXKg\u002F5SVxrV9+wpX4QeO8dvwtTm2bs+ixzjMr+v12gx1k2LoQKLfGQU8YbVrjzpyV53fVmk0SCPkCJAjCTWt6ezqdXiJMgcG0v59RQhSsjaP2AEurWBjJ4PiVhGKzW2nP4l6d28CSkmJl8jJ3ryqR49fTHnKmpPjbDN0MpDeOFUUX5Soned374qyV9NEuYdkikdEmhAiEBkuu3bdioBvZ0TfrZTggzn5T9QMP03bqJjSOhioCEvESET6ccYoxaLDxOXLX09kSscbBMFTR4x+J2x4goS9mv05SKdn80IZ3tOwPyLEABwIUQYni+oyIsKOeJW02GjBmGJ4IhiMcLt0nyNtnx45uDlJmOcARH6N3Sls\u002FX62Tbz3MFbXYlyRJYIAwRLmlB56dxS0Mo6XeZIvSWQr7aKdMRDF2ePC2xJEhNG0S3RJ72i+dfbueifkibokjWIcxhMjFk1H7AScZ\u002Fc5HI9R4771tD\u002F\u002FO+OlPILbMKs5xYQNMRfzZI25uzImJSoOIyGIwJqDgk4Y7SPww6PNaKI2XmhXbaIx4HZowbz72x4J+yLQpOyF6DR4qTOfbEVztohlUKa0omF8IIJFyXmJ1j1LiJkqOhnnInxS3iYfRYxh8LwWhJTc7p5F0KH9W7e\u002FTZExhLZSFm+OM\u002FHi+c2JcjvC+HD4xW\u002FSfjb+Xr369eZXv\u002FzFZGbm6OloQFmVCL+aUAYWgTr4Cn5Sheau\u002Fk8faOnpyTIkGEXG1PieqSyDUlBCAOdSyFc7nfH3v\u002F+0zkt\u002FFz2dKaJfliKDzf4CwlYkjxEM117bEXGwIdwQB8NAlxqp0xt766yTwTXGdLSwLkEFLl1CdAzy4NbXg4MhElA1Vp+js+Vorj0nFA7DE80ZA52JYL7IiDWWlDoanKhmczbUGPfdQxntb26yHaLM5m1Orvf8pchEq2Rk8HSA6cUh3sFRcb0LYwZRMCeJbhUt5ii5ctyR5tRkNo8zSG7keB0Kl4xtZS7X6wrjwDMRSycBHjkQnssO7tpR1DT8kaP7gu1eDkmPed61L5MvtXDIiKAsc6mrB1a3vTOag2N1xGAx2c2A53c8smNHnSwop67ZLlEin2aWTdF1aN7ayUeAkqkUQWfoPgj2aqh9PrjtJ94xJhogF9E9GYbmGRqMceOOY5BBsCdaDIt9Fo8UndVBRCkEI59MREe6esmWwc3XX18ZuB\u002FJMdG+dW+8oESMMfbVl9X5V0bJyBONHUdt8Lbw5BnGQAOi7d7kKUU9tIaeWj9DgYELhqEemf3phRaUgyxZEF8V7GEIfX25vUDJaxvqwI\u002FcmPuiAbbPrLnrGK\u002FkQBCb7xnaYDPNBIIpWOG1MfSCjIyADCpD\u002FWDGFLlsbsoqwWhkKp4LTpxL64AvOEXDMiSE8vAHGdp\u002FHsxIsraJNkY3z6IRbT1DX\u002Fc2n57xDMAyPhe9rD1mnLG9ZZ9FhZ\u002FX5YrOsLEUXAWsOBwDy+SjNa4WfO4V1VQCIZNXu8YM5WMFlu4mn5X5cTpsLCVrBa8EsxhmeFkAzzyD4ujLRw86ifnw6pBmncpy6BiZGqVF6tkFAb+99vnQ0NBSxpQs6\u002F3k87cFON4q2w+eMec46gIxu3qmbPOulOCZC+erU+9QpOyZg9FBXc43L+K\u002FtT5wXDKEkQ6m7A7Ac\u002FYK3M11ze1xZbeDk2RDHNg6ujOHbHDQJwxBRqKWmuCMptHQQxv7i6onmaZksS9nHIdV6ZaWakvW4qMlb\u002FGj54CTDlna9KpZnxK+eA4tyuKjPbzCKWHM03mCHfj+QEFVfNnk5nr3yKj5G09rXU0ekvECJjKwospkg8zERNKDI1mCFsF9T\u002FB50TwFZxpt3mjPa9FkAY9wB4b48E\u002FRdOvkXPRz0VPOPt5qUkZij6GtLXTauThsqkaYeZryYCU9NrDvL3xifDoZj1uTslTrmTaaSH3+2\u002F4JBusTwQvybUs1QThmF3kCp9N\u002FHJCZOznXnF\u002FX67UZ6pj08OGivRmBhALkMB5EFhiy0kX+plwYyOrejmYUQOxWxCpywqBzvRPJbtehw+mmEPhWGwBPZigxtjEr4SvyRzESSurFAHkhd0W0MDIEMWpv37u9+dWvfpVgg7VaFh6OADu9an8HLGEkgCYU1fxhMqcQzqafFNit505R+zKjO688IXI8QaEFJWGDIJRuMIyZWuPwF4lTd\u002Fpdc+epe5kvpSECrrwA0yBkhEj+SZcRVkpe9iUwCOIpYQkmmPfpoUpaghejkuK36c6pnvFXzJdAqR5z2iG1FEzm5NNHpeXu3qkfa6lgbaic5KjNmY2wR4PJe+893Fy9fnPzzbV1IBP8HWqzyChtkJuxEF0PCZZew5iT\u002FonYnztcQbQlYRTiGB0DSheifT\u002F6wGfwqs\u002F62jgVpFo3prOWZaB3QUQ\u002Fwrw16ybDqCPgCIcxaBrPnHpMPxNCvTkIygkYBFQNAUIx6UXPUB8FksFD6Ckj4jCKMLvfRkQOkHuVReiYMv3M+45zqE3YOkF2pfEoSIrpTnQpKuC+knUT3RapWB602sdXkcVh2NbY0hjH6IsTdayNz4drG9fXm4dF2KVqOYs7Mr58z2DwbMqOknHg1eVLV7q\u002F7j1FerRVfLMymK03NtPzXZvGXW1Utd\u002FhdodZKe0QBbt0+avNl19+XoeDd2YPiE3aE52K1rQx9Ux0RGiiX22lOAbgiBd1fuCQcBApPNEkGSY8de163Wdy4E7Fk59\u002F8fnm8oXL0dN79S3\u002FdFL\u002FhC8F8P8x0gmuaNMaV7Qm3kM3wZsw58C6Hr8z8vF1GI4uQrh3\u002F8Mj\u002FAbSkRsEJqeSPkE7XtuGJD62vwLNjqPQ\u002FWjKvQzl5QxQPutzz97PYKXgX8ku8zIXfEvRjLHX2tDZensm45cBylhnXP05Q\u002FUyw8bzHUCSWK+DScq9NexFFM0EHWLica7D+d2iwPfr4xwGN49qmacXtejWrRTe\u002FbuP61jxqLR1Pc0bd29KYC+66edT8rQNpwFj8zKa2tLvOV6\u002F\u002FzAFX63B3vCthacgAzitGkxzWDDVd5wjOw65OXUV\u002FhweRefhYlelO2MIzO8ZEv30sga0fz\u002FZ9KxNreQFQ2vVSHNKGeneC37aTk6kPoTuKf0\u002FmyP7LiBJJHR\u002Fq2\u002FdEE5+vvfeu2UwlaEpo1l7OeCRfHYwHh69kEzdTocLYFiZDCVeFNAhN81nG2+Yj2NmXZPlyokdeRzumkhrWusaAzmLZOiubxgHZDedNesO3pzx3bWOfRa+ZGnsWblai0ZlaPb8PCxju78j0yly8zKWdpXkOuMCPjxnSqCCo2cYnwEuk8FpHznaNTKtdASD5Nat+wM7QRdOJDpEn3Qip4ixZ45wCCd+xy\u002F4w+94n65AimgcPHw+xm5lCnv2CbqteaNtLEhmbOPRXq85YyF5c\u002Fz46nVvv8TSW8v5sLYVYQ0+UfU4ZsnMiQLjbrySDCCnZbwZi2Sy6OzUHMcvShS3tk5Ge0vvKY2Bd7jFN2QxR8Xv8CvABnbm8Ty+AxP6V1nVruSBklv8zCC0frbGVieTnu+sigPpRicIN+1o+cXm66LoeOenP\u002F7xHI60I7w8TffjD04PZ9P6rANs8QQYjn7vWuv3nqxxfDScFbzjpp6NntKd6Urz5rShUQ7EHFQUPgR57hQ0uvrtrWymymzo7zKYe2vpqOXy0tV\u002FjnDTr2QvnFv3jmSjUiFOI6eADeFtIvS28mQ8vVdNKwqKxvzHYJe5Jz\u002FZOBPoaG27ZTFbx1xn4l2LNl7G92w8+iEA1G\u002FdWNFyONJ7Hs1svZqv\u002FTLTkSU4KKMBh\u002F4fQ5zMHt4O1\u002FjEXBCo38kRz1tyKZ4I9l6+cwjSo85deNjeQHhXBsamQtdNd2S8Off\u002FvGQzXpTlnvH71\u002FpkKNkoDdja\u002FRwwDTwZMOxStgiZQTf1S1kbuqjvmopSta0yaeS9ReEzeH1dr9dmqB8tZas2PRKsR2oKvznarCAFwiMWlaTsHDNroYQAw0GUD6PaCDq7hlPY1zKUCDuAvvDuhXZAFzHR7rEIqFTmibeP1SnmzKS+7hW1JvQQAyJ9VmRrT1GkR3ZyF20m7I8WmfnNbz6O6VdaAoMSgFKo0k2Qvw7rWRGPQN9\u002F4SIEUuhSrJevXJ0SGy0lp0VRCEEM+nnu3FMKtijqk4yeZG\u002FlKh3mVB9qyDpz\u002FnyeeZHKSYdGFBH\u002F3owyik3EACy0KxrvNm9X\u002Fuxu9fN6l6vJP3KkdHZ18jtTpo0+9z2oZysDa+aXUUvBYlqGLcVhU8hH3\u002FteRumxhOmtsg4JgTryHK+ezVHz+4PxDy6e39zotNTbN+sx2ljI\u002FnZ9eQ\u002FUvmpHLfu0FwIFJjhpQqWknuuljgibSbS6uygffBJYGGcJfwzRnb1t7sccxolt0f7QBeZMcrdmymsRNTgQ4H7aAY\u002FRZwNRUYUlQBrHWL0Z94wDytp\u002FsjE+W959gj9lzfCjtJxWqb\u002F4dzcd3238Sqwa+26H+GyBYbOi6I7U+USZA0dS9udxcNSvf\u002FBjI2AGBAP6SREKZSzD+HVJeJRihkcCxtgUgTAAAEAASURBVNwmIkZwNzcRRHgh1JculW6nVJtzNMios+\u002FBnoN9tQUDV58T0D4ndKTxHf7hZFsbvG7vuRV+i6glFI+\u002FqFtLdHTz5rX6SJ+qi0ElKT2vSTTXe5vfffLbIrv1hH9DVLJyrgd3e06CvnGXwm0zbOu5Xd92uBt3J9yIMpqzDMvd+OtmRo+1nTt3pq4kH0XDu3Nmvu3QijaUZdxfrp5fOcyJerfrSKL2n3LaJZWv1KF6Y\u002FCwNorBRl1tXCOLcEJgRlvBikJdr2iCII14xiEK\u002FJ7vhnHcCFRGcYJ9Z7w0EfJ4bYyQrlK+QhGjN\u002FibDEXPRZOchafBZ9fgIUMFDcW0L5uT0oNlRKH26g1rmadNpcjYrp3ary6nbgzPgg4CD\u002FDLeYJX65tNauoxm19FDvELPrFZcs1PUOJpis3aKTf0a3GPMxYePgwm2QmUwuMybC4SsLH2l+2xeVB9+vPmuq954uWVVUuxatvR5mM8sdc10efu5vw0+fsseaLuFExs5JZqDyCttc9fwSyyC1fNJ1jNs\u002Fob\u002Fy0jLzoVPaLo+owDhn5kQVxLzs+Joa0Dr5HlIsyMpeWAho\u002FuFRlUokJw6O5CfpBF28p0ZE3fo8FG7N8235VBeO\u002Fi+7P\u002FSOtAXT8Y9oxqjQl07vjgw4ubn\u002Fz0Z8GLg9dBXRmNziS4fuPbMUSUoWgjaGMxeOrM4F6GIMNKv2UbfMFAGpu8oqXXpvfuiB\u002FgHd09zNFniMe2fUb+KnHsEJ2ydM\u002FaW9AI4T26TQ4P7SczAnVjlbXqfnKSk2jxLxkEnt9ybVqkY0Q2p4wnvMlWcPyAbBnQOfzxPEOBA02mHWgzJ52r9eFW80m6jMEfombOC5dLfq7oXs5RtGCeAk2zuBAoWu1uf4ODQ3yeVxaKtjlNMq6xg9t6foZbn4MdeXjn7oLpoeaC\u002F8jUZ62bMbwzmdZUghd9ax0D2uEFhuSLrerOg8PeaFJN\u002F4G7tVC8XYlGxqXgx942dyr7m17u6WLGuMwzO2FqiIPP\u002FXu3mpYNnns3Fy+e63nkd+WCZZUOlCWib2W29qUTwPlUnaqOJU91qrofLunGa7VvJifOn30rWl7dXe7cqbSl9RzKnpBhPZlzcK99YNcKjDzPrmAE4y\u002F6YjIx0at9KOjX+q15RZqdfJ6c4PSzj4LhjniSbHuSY0fOM4iVAKmBfl423v27yjQkdOoCV0CtZ965w5YKr3RCev3cWydmXBkMB4QZQ\u002F20BxjHa3ftjY0RSUZvBSKCG31CV6G35bDjx77LBiH3W3K3BFGwLor\u002Fovv3FIiQ4TJ\u002FvB2Z9ZhoArFwztE81IbL\u002FeGsPFN0HEX1Xoa1DEq2VzDyGZnuc3piLMZgQdfThz5HZ+iH40Ke+Pt5gcHdzwRyBJdE2FcgwXj0vEoB9z8NzrPhs3mzj\u002FALnLxorjZAmxdZJrrfYpp313UN2WZM9h59gr4TUTFDtJt85VQF\u002FTHOY7iuoa9HY671T\u002FfAZdumOJYt3Biv67Uw+hpGO9PpXstY5HVbQICJAJzCRbEFoamplAZ0GMOUbSRsIELbookERriI+FERIm3MDuxvA2r33a4mDRHM4RgB7Ns206llgxjChUJ4MDWMGZQZzwxbRs\u002F1G9cGye998OHm9Jmz\u002Fb57Itu8d560SKId3zYSTA\u002FflADCRyTqAymE8JqiE3l5uvmm7jN3M8jV7RI0SgXOX1jRCPXeLzsZ78jRiL3\u002FHmSwDJE2wJ3KXvbEiMZ7VMSLY0FBiTB4AEL3Fr3UTu7A\u002FptFgrSXO7Y5XWcHTDhzzagiyJUiUDRehJfIH8PL0fKElOceyzl5s3IY7ci+Cw7okuGXyqm9YRGEN09sfv7XP2uPwL3Nb37\u002F5ebg0ROb62UBHtVtgdFoUxOdjjnV4q1arAiPUE\u002FpA+zyLoNX1zjQgJmFoNWgYvQeOXhvOtA\u002FSif+Qfv9sd5D7AmSgVpfDry7hkIQkUJH2y9CxF+zmaZfnAbXvyP0KDQMODAPd6KiogGcQcfKa2d34cKZ8fIdrOBk0Eiz5dRXXvq2wydepLxsRNTuSus8tadOf0PDT4rsONBCCQolTpGOUCuzAf7gsaKuMgIZ6d1HOM+rRaFfuCJkCAWK32pEUB7HBxTNCJiEJCXE4NfJQGT7rZTEtQx1NMgIAYPTp8+kuKvTjZ4e3K8X9\u002FFDmwvRCqPAYUVaf8rs3Aj3TmPFD\u002Fq7yyo8f8YpyWHMOH6QIr76zeXg9HBz4ez5aLqMUcqDk8HJZYCqe+c4q9M\u002F3YFHBDwBeaUSm3PnL5RputXhR3+sVv377cd4Z9riUf6MdJEpByvhKUpTXeZSVFYfDWWwT+1x85ZBGAXOeGLoUjADwKggBAeaQETp92k\u002FlQjs3XMiuGcIZRhCCLiKBvkPT4lUMVI4Y+asc8PLFJ6oy4jZGIORnt6NZgn\u002FnMBwpIUr54WhMPw5UV5RyxzBolrTcSSjT8RWq1elZTbpJn6GHjmOE4XhwGawo42hgeakPtc8lzO35MfznJl7Zf70MrbO3Zik+T6p9G6c+HhBG0edXRzecZRyPeiQmAUkTgvlu5uhnrF0qLkcPJDD1dpsrH3aPOaQlGga\u002FB2+MkYgWoxvBs7NeWRSE5hMVxAKE0OvaM8zdjztmtbC8EHzaNzGVsb3g+iVjOGAyJpO7\u002FDB5RqDIyFbM63o8knUz77gkJgPlzm+2pYplCo+EDE\u002Fe+7c5uRnn2aov9IDezOGoq3798oGbqoxPpyjvcvZGRk88dHdr24VUb8+eHqcAU23MCTXAWdtqky36Ibi+ehmIqLNIPU7zo4IgxahTbeMBciQb8oPFk3SvzZO7ktXUO7jnEUzgkgHMmTICHuk8NC+Pauv9JQJNhQHiZHOQM8GHDp4JBIfz5G5Sg0FbY8dzBBobA4euuXYoB9Bgdmk3nzoWUfFP+XUljncGqOm+7p4jJR+zv2twBgCFbKV4JEL0Kdop7VF45FMn4cPtNk8Hjtc72DXRob4Al68lCA49G7KuvoMLa\u002FTPptncyI3m2ZZ6+rm0XzXyPoae3TAjG88xhpjDx1yANOnBbScdCkirUxxf73EHWwlk21fFf0pEzpnJIS\u002FVUrZ88tC2Vv0wQfvln1\u002Fo9K\u002Fq5W0XG\u002F8jMHkIzqHby0zz154p\u002FLRo5svL1\u002FJWL\u002FTHp9KRp8+2Fwps3ykbPkbOXrP0gEaVgh0BarNH\u002F\u002F4+eb737uYbVHJWeu4me3AUN8PztH\u002Fi+hJ5BpHLLqKPrtvNztIQALyWifHeHCAnjhDyX5zfE6PFbBQ3hanNJ+cjMYdB7h70MuubJOAWxlcP8rScDLoqd1at2agPymjw07Z2TOXhRmNJowOJcPvhsv85JG1+5ILHBAH3JGXaApu0ceyp17pqv7uw1ZEFjSH5Mec2zKfyJS1dkZFsta5OYx865msSsa6O8dh73OlZ+ypxMc8b3R2axGFZvd7zOz5iQNlpegbDi3ZzdZBa+sFftFs\u002FI\u002Fv0AO5NM6jS5oPR54+nsBQz5bBJE\u002FRJL3Ml2Fr9Gn2dlUcESXjfTraNacoe+6dIGCPEjLAh1sB0GbiOCQ4NGB6wLS6ZOQjnSPrI\u002FtMX1gPuf26Xq\u002FNUJfeZ1CC+hgsQUYtMGHN+79\u002FH0B5ZHkvrVCaYwR\u002FwNuurdapxTHMhAyhJ52p3IUwsDlQX2QvBswf\u002FvCHGV8P9sCW4X2nNmdXQ+qezcUPPig91kaRBBCjRa34T378k9olPqkc4MvGOTqHKX3++WdTwwVZCGs7veJvyGc0LAJGZKmspNnLrdVicerzIoibjW+9rvM6XpRBbb4X7+y3H3\u002Fc7v8zKZx1mIPLpMtEwzgMIvGi4BPhiZml8g+90amJ\u002FW7uWiVFbiP0CSh9wEVYtW8i\u002FBh\u002FDD8wVAJz6Gx9ZzP4EbAoi97aIhQ2Nd26fS\u002FiUq+dd5tHqL3bP\u002F+bn20uJ6QeZPQg5nF6YmyGougiJnyWRxkdpoQxZ9cEcMRIeTGgKFmpI3sNOAxPnjL0+773GEYZIQS+MRZcAAd8YoOE1CiIADObQhB6KT5eLeHmdLw4JfzA8ivlTqEFcw4WRSuVRdWjKUILwxAkaodvFjkRiTt37u2E+YnBu41mpDeHSVRr1ZguQUV5mM88q99ftCFJhBv+ZScetqlz4Hy4lGE4lKacfQ\u002FN15zgDU7MFqNScmMI9dPL9wQfZciZmShCP73QHSSs+fQdw6i\u002FR2i9ElxS49\u002FmMDpiXDu\u002FA6Vy50yCuiCd3Xl2uh+8U7mL7zxLicqKLJhfeGktdzMIOQWi5s+LQInMMTYYNyITBCWh9uTJ8YGhdYkcXbt+bYwffHH27LkMlei\u002FKJN5a1uqjer7H7w\u002Fyud616LBvhy6Mof9eDu+ImS3un7AzJBsHpwq8sP3Uq+bJ9EV+L2iI\u002FQgwkKANujAyxz7v\u002FHBaMEVJ4\u002Fyw6\u002FdO\u002FCOjj1LVGXKbUKFTeL7SnUzap0WiorJpjm2PdrH3\u002FjU916TRYokCeC9D4qy3WveOdsMdS3mlCQwJsBYpk2WC23iI7LBnIYoGmtoIp4eGve3RRD5jobv3IMe4aKBa4+cNbTAcOWzFMW0Wa2M6tSJakVPbm7duDmO\u002FERk4Y1WDk5Hms+OHMqdwf1ha3mS0SO6LYtIZqSihtaX4wg2lDmljQd78CuYJDBmDfhiolbhR+kB\u002FuRcHShbB3bwgD639yZwlmPOkaNGG7wEB0MDB74iUxmP+3KUlV9xdtyHpvWQjisH5wI8DHeIBOMjOw4k03JEK8NynsaFdy5mJFUO2djbB\u002FyYL11hbsa822Zlyn3S+dGLKB8aNS+OE7yM3OonOsK3jGdw4GB7Hcp4xfMMAZvmEDdDZ859CHb4jWy3RwlabcRXC7tt6II1uvXlpPqTUeZEFoC57\u002FdVkolu8Rk5JVNzuAzKlEYkE9b6Coglj41hwzb6gXfZIXzjee7Hd1Nq9OqZ6BGOlpzrgY0Pp2QWAmBQkbVwA8Vey+gwj2D0Sj5avyHdJzDzpDaCDHWb6YZOorF9OYiBdXTaRCSTNf72qBR1\u002FzgkqzKb+F9kU3mhzMf16Bl9wQ39iL\u002FImKfJpesFDJwPoYUih3A2oqb7yHR73t56+61k\u002Fdnps\u002F7xbz8Z\u002FXz44LHWkANVlF5bS\u002FCBZ+VJ4OX5z6qxt6drXzTmWWBG5jvZU9Dg+rVObc0x4zjeKFDooMCTp46NY63cZlPGbYFQJnUFcrZbO3Pw6GDxyunIFI2T\u002FwxE8h19Wa\u002Fa+B09Hw52pEefxht0mf15J9+gU2XUdW5pnORLGGmc8Ak24WDRZXDtfqUxh7IHnleOfO\u002Fgk8oiwfOVM88JaI7oEJ14Dw\u002FEB+DC2UJrkwUYedD44YIOmKhz95FvglWIYEpaW0b+W78HP\u002F9FV+SJf9CKVdJnZKGP6TiVCROwoNtewZv9IZuy6K+gZkAjV+CCk+hFH9Khgj\u002FWICByYCvHrTHGWc4Wnc9DyNhHruk+nxnL2zw8a3RE\u002FEU+yCjCxzgm3TsBmp452fqeNdH9xpk1kBlh4E\u002FjDVH3FM8YnkMDyfPX9Hpthrrd5wQS4Q8qEPqyqIfUDo+79beGPWNQj\u002FJqYQPsvSnlXowaG09Fat4K0DaV8qwPFLU+d+7cEPWXX30VM2vd1IFF1RRjapvtvGwEJJTuFRkM1NXzdWx6Uel9+y6nQI9NysdmvH\u002Fx83\u002FRNXdLc52r7vbk5je\u002F\u002FnUbjy6lmNcGV4amWjnz5+UjBgSubi68DAGLoBH+iPdaDExhS0tuE5mox82OYVYmoyTAEdYffHBx1mGurts27lZkbUWOLmRg6WbjwAnjIiKdbigpwkcUlQE20cHgJ1oS1WQ8JuxifsS+ouvL8OLk3KrEQ42aen8RJTDe1a7+W6XzTpx6VonMe5v\u002F+dn\u002FtPnf\u002F4\u002F\u002Fs7EYuq05AnuUkXH3bsZOva0PjAG+FAAhtCtpu7PvXyaUlZ3oC0vgaTMXasYoT33NOLFTH5ShSOGiDUJ82GYYDJP1aYJmjNYMcuNvKxoZGoY6OPzpOs9OkWFKhkcQGCdBJAiNqaWWEmekf\u002FnF5xPtPZmg06qRYp7DhprJElLNsrVORLyBKKGJsA1sG7jPBsYZeJQlp0mt477mvG1ktbieuxh2hEN\u002Fj9Jtznq8EyrD2HjYfyY8\u002F3Rn66Yotw3xbu1vTuKKcBBphAOBP0KzDjRbRSHulbl5\u002FORbK9+8FT3oGX271Ojnn3+Z4fLddKdxnDk6Qc8MR2UaMiXo\u002FHmGKeWzc5e+8cc2f\u002FXPflJUSrlK7b6KYKB3PCaitS\u002FD8eHD\u002FfHtzc1nn9Wrv4PAtIPTKvLMmXMJxjY\u002Fds831RFfz+HjTFO49++3iS+FSohPO8hmOwZBa8Lj20YaPoBn\u002FM8Amzrph0tITilCuBgaK4IBdEvoBxl\u002FDMDAdBv+sjArhTqp1EKW2\u002FW9DRMugZfBAdfSv5xvxnR4in7BqjjfzG32HaQo0RS+8hZNHzmWM0iIK+mZmurGEE0SDTpSVJDjwxjM9O+BGTfBEv3YjL1Sr8sQfNk1FuVa6\u002FId2hlKeUULuAW\u002FkDc2PJm8jaTuPZb8OpI8pKA5MDuDI7l5r8DIvmTc3vZCcGJ3yQ6BUWMM9w3P4anm0fz6rZ8eyGAoa9cUkKbsDP6wdt+DGXnFxgKzPonnU+AZGXiY0TgBjIIqjFXiydznJMLm\u002FrCxwdWT1GSrmScs8Dg6WBvXl\u002FI1FvpR\u002FiAjNPt3og904zYGCl5VBmKDOKfRPo0bZV\u002FJd\u002FNkGJCN7kVj1mZ+or1oQacOPN8ke49Uah2t8ZU8GqM1HUbWWLuyERkueoZi5\u002FQqt0GHdMG+8CzboAnAjNk34ICP0Rmnzz4pyp1DpHkC2hgnrmvgxzwEPMCbse4nQ0FQR2nYvdaEIuDFOOZvj8SekEKvBJlBnjHBkPyyVvg3NrxxDKyTnBm6s+bWN7zVxdMqs3uN5T5r4sSsIZZxB1qe\u002F9\u002FzW3+1Jmtde3Xs96BLzL\u002FL59ngaEKeLQCgHJWesh7rdggSXcWWIKuARHejl9EU3WBspYn7GEOt7WUBPQY7vDobg+69cOFCDRSOT0Dr0YNrA1eG5+2cJ4Y3eevld3LiQHXocejgkOwj27eDdOZNP9Dnz8uanSp7JMNzo1JY9AHmoug2dJNJc8r30NDSWQxMhrzN\u002FDLPL6LR\u002FWrCu5jTPThoLmwTZyTIsIL\u002F4+D\u002FJNpDN7J1e\u002Fc5gZkMuDW0ePJYhniZPfy7eJFzZ0NlMY7GOJTju6+U+NH2Rxw7FIw7qIpN86h0zT7rix\u002FQ6H+P062AjS4acn6iIVIMDTJ4\u002FQQP9+ARpcVdMPjdpmk8Qn+7iDNjPFlZNtmSyUrwqgoIXoKTsoDr1XMKLLK3ls1Vo4z4dRyInqVMRgDHc5S1aqUsqKuCQmBjtRBFb4IyyaL0m2ejP7y6eMyC53\u002FLWOvpNzQuaCXLMNK2dc71yfeh00wYusGGWTpMxnUi6NGf7z0H5w2cGh8djMHfc1\u002FXa1HsaxiN0SySSwjwbikMxgGEHCzqJFrCi5rTHSNCgtMbkFrXIOBGnvTtOqzM6WqnTibMF4Kku97OIHn\u002Fgw\u002FaWHd5OgG8d7FNRvV2tmnzVJsjz5\u002FXpu77pbOqT8xY0W0FSkQH9VBFNP\u002F0y19mtB9ZRm+R+HEAIkaE\u002FrtPPm3+dQnImJkoaXPfnpv5TfnOIGzVT4ukERRhZwwhQudeNd4iKaLbFK5OIrPhqfp8BjjmR+BLuItYqm9+NK2RCEXfczw+++zzjK6vpmf8z\u002F\u002Fu70bwE9KEPrg+L3uA+GxAxQQIe0VbVqRrjIjW69AI6\u002F82A0oqcHeMoJ+9gx9E1u8\u002FuLM5nVPwr\u002F\u002FV31T28t3mF7\u002F67eZavWiHiSJKZTQOQHmRQjoYw1eEN90ACO4dPR+xlgsfwZEJktIUWaGwFzc71U3qD973xFC6GugTvVgFVL0WsUvXoQS1tI9jSJ49gbmoY9GHKLng0ZOiH4zm+btxGXKP+1tHoTc6AEqnk1sdPnL16uVgt3cOzkrXThkIRid4n7TRrsGHRqXLRuhT7jHiUkprfhh2PhtFttL+Y1g24NAHYyZJYVyKdQkyzL8U7fYaI\u002FMRIPCvnAtzz+q7b3XbEdlK8Ce8PZMAbpARBAxdhsxmhwiDVoardpMz9yBFd7bayovvVsubgcI4Yax\u002FU9SH8kIzp+KlCxfOZVifGYEzCjlhyhASnZsoBIMiaUP4Fa+ZuckceC5jnrKQUlZ6Y+4EN+fUIREO9TL3u\u002FHZl198tfngo4vzHEr1KYdgwNK6gxPDAXxFmdyzjJO+W6Jz8LCNdwJdJAz9gPW84jeG0ouMnBGMwelPSqQxzG0rBTewLAL1eGrmCfjGSKguGDeW8ZrfGDeRK1amLP3NAPP1\u002FmSBqBFeUyokcmktakFlbob9W4tn4mOKl7F+9HlR5hSyfS8DqybOgAmxY0DO76bQZ6P8Wj3DDa2PkqQ85u0TF7YpMVxOrXDDMGCk37+r5MjXD1JosmzncvS1JJQJuBvv780w3J0zsjsjxR6XKddKcTGuxsGIxDzPP\u002FNj5rMUsj0naum3lAbK\u002FjR3RtZsyKvkiiKa4EA\u002FfQc\u002FlFkDz3zxSNQ0hkZTHrxvR3gp8j1d37S6L5hmYMAzgw68VtkTJbuCN7t3OsFSqVIjBWMlb8p4pt46on1kw2HOpxKyK1e+zmH8djK5DPMeM7IRTTFcxzCHC3jLyDW3hdRFgWNoBg\u002FyZ0r4WjsHbTapVeo0Rni3jDGQUccQIH\u002FsFeFQW8OfIm\u002FxOVnaUMlaJTgZFMn4bTjAeBNpDtbcv+RHq5Q5ILfJcc4qh\u002FtEAQgGCseEE6JWxXqeP0\u002F+BE9GbvUYfReZ9Q+cuI4cGRrzqJ634LvwxQHxme99DhfgRYYsh3HxHX4ll+HXevCDOmo4dx0n5Xn8MbXS8dhA0pgWHhlMJr01beU4y1iNsVO5jrGUjFjTvpE16zRnzRR8LoJLHzsj5UG61PVOz5xuWoy25nonHibjlBo+ad030nMyRgJ5nFtzlJEX6LBG2dWj6Tzw0mrZ37va22NOePhptfLgDKaz7uAoiDD83e\u002FHO2BLgKJtG5u72SuMal2HxpkJ1ozJO2VxBBl3Vd6CHhjrcC9IwFl71s1\u002F3kgcvloH50E2xrXoUnTfqbxP2+RyIFuDkajzS7Mqsr9z9gHurwSE46scTvCDwzun16JqsI+HdYU6HsxE58GUDIRzaxum71owgntG58gbFNmER+9F2yaPRshq81y6svHCm3vdxwZxqBtYzTjx25TL9hOvoMdpPhGcvbYDi3icsb5gVBAnHpL5ntr\u002FYCEQgHcEHO8WoDJ9gTfPAy94DWDNVXArORaOW\u002FjM3XPx\u002FZTQNk\u002FfocnRwcGcDPP91OrHx9bmM\u002FqEU7G97pHN3b90fDeCWbiknwRZHIqlln9kZPdOkLoa\u002Fpd1+Hpdr9dmqI9X3GQdCvPo4fGIwgErS8lBKOUS9SRwD0RoBH3wtagAQig9f34rg6BTyIqI\u002F\u002FJXvxnj4P0PPpj7\u002FvEffzG7n0+3uc+BR5\u002F+4Y8ZIt8MQ73bATUM1i+++CJGrpPM0XU4wq9+\u002Fduuubr5xS++GFj9m\u002F\u002Fxr4f4Ll26lCOxeoa+997Fzb\u002F6l\u002F9qeqQz5j\u002F+7VchLkLImBdFEj0VqWUYSD\u002FpxKE0xcmkEIz5GDE6jBC+YACNDPS3iuqKpl9r0933vvfhPPPb0nY\u002F+P73+\u002FzQHBZjM6uj6im1b65cGaIzp5\u002F85Kd0Z2UrtaIKRj1m4EQwYxj1zJ6H6O4+rN91hgXjczpg9Lke2gQQhS1Ktdlxudo\u002F9byEVgK35yrH2V\u002FZxMPqmHftPLT53\u002F7t\u002F1o09MjmP\u002Fzf\u002F6lDHoo6JTj3naqTSCcA3qlk5kHHYR86pP6\u002FOlzPb6yJlAYHBDpCqGjv8zbBdphgzzHvhFU9S9du87WpUhrVGhDzGE0JE+vzEnka4y3CJ8gYVzYlohM7uynjrUo2tuqywCEQoXi2U1Rf28v9HXt\u002Ftprps+GtMo6b1yfCdvpMJ9017vXrdXIptchRsxdgBFXG9NS0ZahP1LDrhpl7Xr8umCcopC3BmgLDrK4dZg3b\u002Fl7dNFqXmqBuxNjD3P1FWY7gajzGJYHkmlGErbML\u002FhTBZtjOqXPR3VKe1SIW9XG6KqfybrxxQ81yAhnsCbjvEmCijGiaw6pWc9KWzdeGPwaZ2sz71bF\u002F843yDL3iZR3enppQGw3R8r34VRSKkmCkTfSUQdfRb2pxz0xteqcv5hgTkr7nCMqYmcvJk28O7r7+5ss+L2rVmJxUG2CVvoEDPuWIUmbLCOo5PcP8U\u002FvdXwQwkIApYQoGs5aeh14YwWqT93Rgh2uSlmu+abox1hk9PQdfehG66Cm0AXNjKnlJ8Uz8Y5WnTMQ4GqOg8Neqq2aki\u002FhxWhjxFBnc9rPHMjwYiZSGqPl65jJY8tHDT9eirYwXa3DnMr1R+AzTOK8E\u002F3y7xkZjT1tnPsB8yoFj7CsPQ3OhZe6faFj3i7o9TUk9wx+9laEcPSHNzkFzUuU6alst6O4MrT1FpynbpWgzCOseA\u002F7gzhmf9WdgeAj8zn4T9cvBkDyizNdmZJ23Do7D76fPIQ68gAnuGXPl7xtHqUV82wDkxDIKwEeJkNZtq10cJU5eTcS8e9x\u002F+FBR5DpT3L8fP3SvWnLwsMcJTp7OBtz7s7H5UbxNtn2ToS5QhB7M41D0JsgyShxsWXct0JrXTxu6bU4VwUwmdR9Dd8knBktua7JVxng7Wmc94CZIkuUerlLUjU2XQRyaxfPgN059sEOvezOsBHRGziUHEm\u002FDSwxbp0bCL7iPsYBuWqO3II+MMeNl5prT5tWQ8VPRyp41RkbGARiNswFerQX9DdW9GmvdlxEVHMDHhLcNqS6e6zn40ve7yrh5oQu68OkE1lpyBrOxwc+6n9QO+RF63lGEsyHB2BrAheOLrjGfuYiUO3NFSdGU7qWL7rUhdPHaMqwE\u002FRigIunHj5adS16LlivnOFFmQR0wnMoU0vlkJN1r\u002Fp73XfhnWPuMzN56ufQjuSViDj\u002FaGYtM6Cb0RAkRmKZfjmeoC2Tt3VuXr75zv\u002FKb\u002FekIPftluC8U8DjexnkIowr0wpch0sdbcHEMv\u002FBJRw\u002FPIIo2WG6X\u002Fu4uGDIR3IGtQJfyrrLyrc\u002F195v3vfvf9dw6plRWxo7Yt6\u002FNzwXFdgSPA9FNVXtNf+EF3ezi6BUBft469mfYb0V7j4Mb2XysgMrOouu3k9fKZNAdZxgNozeZ35UtJGeWc9PUoHfwbH5LBoRDdJS7AL+cVC+07dO5vvG2ZffQfM\u002FvlvkM\u002FBnAM154EtBsoD89w7M5uXs6aNIYcDV4bYChh2jCYwRuwNjv8E124Mn5rs8nO5t9gt6MOfNrjs5pwRtkg0mh\u002F\u002Fm+a9w8srrv0e+SYSsbjsa9xigv+JMUmzHoa9fNOoMFu3z1XU+GWOfc9Xr+abWv50WAfPXV5QzPVe4Ba3cjFIpPOkpqliEhbc6AF+1QhhCsg9nydiBRuQml9OWXlzMsrs0Rwu+8c342sgGuvqci7J988rsiiac33\u002F\u002FB9yLqexMtl4b\u002F4Q9+uLlYtP1HP\u002FpRz7+XkPv7zb\u002F\u002F9\u002F9t8+uM\u002Fw8+fG\u002Fzb\u002F71vxxn4lJlNP\u002FwD\u002F95HAcGLuZ8++08zwT21JyJiDZnxAVBSka2y24oE0IB8TalQawadFFLG+7UE56pr7R1XP321CgfmQB9uxnUH37w0RjlOobs2nVvBDxByOgh7E+fPtF8jlb+0ubVYCiKSmjos06w8N4RE4Pobk6DiIvDffSL3W7rN7WSY6Tb2BohZ8xWq1JktAh0hAovjKaGasNTtexH92\u002F+h7\u002F92UTA\u002FuG\u002F\u002FLJNt9V2pkRFMHQwICjvVucmUrD\u002FUd5sRvveP0UcF5E39bAebDKk8c2SzwkvBlbrA8v9NnWltEUTKZVtJujPPh9eG2byHEI98T+wJggoSuURNvTYtIKmOAbZxRNJP5GDosPDjZuVhWTQnz59tixLp94VXb9btFnpC8McYxMy8EORYtZRZuaUwJ05IcxeUm5T0tXkGEwHlRO8ugfTm\u002FMIKOEJi4ggGBGrltqsE2Jo5JWD4sAnwpHyggfPktExBvjE9w3TWH0gTWnTs4NfLl58ZwyRh48\u002FzljXU9\u002FeDQLXxr2E8z5dlNDSi669GC2eLV1+NEW2SkuuXLk00cZPPvlkUorKvs6ePTtR9nPnOsgpPN+uheisoVnD0fMeQJgz+MENH6BRm0zfqkZUNIPhjmZFE22yphQfPb63OVmt6I9\u002F9Bc57A82n376+4E\u002Fg4IwHBi1UJHVVceHlzLVW7vsmw1kj\u002FL2CMBtHMHP406m01HjxUTvGNdoDL5eRYjgok+XgcNYXJ1ktC7c2xp87vHzoPDCIOMI2uAHJ6L8eo\u002FjrXESUwiUyhiZZDsayBkzJw83vy6d8dCzLIrP4ZSC72mWOtfNg+d79GHta55zQUOY1raigH1Gurny\u002FSby3phqokX9J6IZP92p5ai6XJurvyv7xWHcXeei452qbDO62ltlh9PbPuU60bo20q56e2v0fqWsgqG5Kt2h6Cwk0A6dGpchaKMpx88GZgpVqzyRPA7jtBJsHhSmQ73u34PTfm\u002FOlKnBrQ8stYM8evRk6+gxvcBLIIdSdu0YNK8iVuYHEPhppZ6Da3BhsL9Zjb4a\u002FGfVs7sM7zoAj6HWynrXMjcjR2SVjDc2GYI\u002FB69d\u002FyjDhlzGayJvHIgxdEepw1002To5JBxFkfOpz28d0\u002F8\u002F+mB8M\u002F6sDx2TD6K8sjle4ErGeFs\u002FI1I3GpFz9zIYI+toAM4Xzbi\u002FS0dGOHjHOr7++vLoOtFi+ohxZUzPpDvRZWTXqhupZwbCGQ\u002F8vKzLyzOIq+fRGPjiLbzRjb2CWp8tPXLI1VOSAV5ejHYOAxpkiHozGM3hRV1GBCi6pZ\u002FRTJNgFMHvrKsv4GhwHb6fZQ9Mudn2o1uw+TBY4UznKpv7OYei5D7bl+yhT9AZB0O7ZOulz\u002FAcPvayFCV54Hi7Di5P4hvBAbYCXcQZePigSH34PJYuM1+69Gp6A334Hkw8R2b52DsXxnG42j6cNwoongwH9wuG3S8qD4KyE2C2p\u002FexncfSO\u002FFZ\u002F6E7tpG59ohoX1a2YFe617wHHslUMj90LAcxuauWnq4\u002FfOT46OADB4+MM7nzaKWrLwUswHw5hZNhanzrIyvgSnDEGQxgcOjYyc3BLPtnHXm\u002Fm\u002FwqM6ixgLXBG9zQReY7cgne+mxbNoDDrAPM+5ye4qSSr\u002F05cBr6mRVFWuGbTpsxWzQaMRZ5g97tQdvR2gRsrBtPwm23zzUDi55J1+\u002FaXTvN7mE30VGeP5nceAwdLjiwnVY51\u002FD43nRHwMSH5JP5cj7NEZ63a9H9PSTfmDijP2cF7h0H29xf8Ze1jHPQtYxwNsHQYH+b29gR3b2V02pc4+H11\u002FV6bYb6X\u002F+zv54Tw5wadqWTP2FQvamNIGeK3lmoVDvArBprka6EZ58DBqBSEurDbXI8f6EDVPIA\u002FU1Aihh+8cWllOvW5uc\u002F\u002F5sxAH5d1Fx3C8e6i2qvzXWduFmv6\u002F\u002F63\u002F7r5vPPvijgcXDzb\u002F\u002Ft\u002FxIRP5sDMi5d+jJkOTBpf4b5DwP2k8ppvh4CkYaB6LV5JuO8KC0kI2ZKBEGJJrz5J2fj8WwyuVrkHgE4BQ2KGFc3iugSZh999GGG1fUhUELrH\u002F\u002FLfwvJLzbvv\u002Ff+MKxuGlJw5nP+\u002FPlRbH\u002F\u002F93+fontQOvvk5qPv\u002F2AErINmPv30D1Of5\u002FPz58+WcjsydMCxME+GGRh\u002F\u002FNvfjtBW0\u002F5WB4BwoY8meJ7r9cuQbQPWpUuXpgxJX\u002FcTeelXvqnUJuPtX7a5FFH88le\u002Fa9PidwOPU2UNDqSIblWWpK7z\u002Fr083VLqBw5Xb0eohmckrsxF1O5ICn3VAotS6ooQI4nM9fx7t6WvGEeRcoSMP7dLG+CWJz0b+vodsTj23qYTbTCt+3AdWp68qPNOBt1sYG5tFLjSKpmbK19fGiV14mQncKbIHiTsRdIpxfuVJtlrQFjsd6pahsyU8SQgGaRocU5tQwN9RrgQpBwzil8UZ1toTGQypR7lLsbE7K0HyxP06BzDUlJ4QaSEsbN792Jkn0vrbXvl6AfD63ahLaAsztN+ioR\u002F9vkf44nzmx\u002F88KPN8aLhly5dmXImtZz3tOqc9lEvK\u002Fe612ErH2\u002F+6z9+0jgU1Y7Ne++\u002Fs\u002FnhD3+QYf3G5sMPP9z8zd\u002F882C3Ur16+ytF++67Xw0Pnm6jsmzQoRxNwOccbkeVGMRPMtBEyI8+PTLwFOmfevScSXgrvjeRqgePDkxLyDFuUoqi\u002FGBOkVBAlBoIEfRjvIB7PAZeh+Kh2\u002FWI3npR9CR+s46Ba8YMnLiPscgIZdD17RjrcOdlPIYGAa6PuDIzLSTB32dhomvCK3wNasJDa6OI4GLbeBJpZ8hPKhctNBGKxny81999kcWz1rIUUY8ZY0E0yNzmnrmvq\u002FqJpmaM6MmLApclelmnkRmzAaanr8X23XwfrWhXubM5i1juaf5qXtXqXnzn4nS00rVnR1EzXR1szkz6BifwS6HisWir2zO6KBgGzZofGLKtwJ6ymSDETIyyBny4yhQxz4wg6yGvKUYnR\u002FrJOCJnD9Z1qod2Tc8pCGMjugwOI3aM3wyIicjFNxWkjsyaoEPjbRtzPajxPXMZEBQzfMpCOrL8XsGKhafdm3ffu9gw8T\u002FnuUXeabPo9Qx1cJmNbs3ZnhX4wWtKmhhI5DxgrIO9oslk+ziGnJGiq2hkykeCF1yIlgocPEq+gBuqAy+lTmMYJHtlRyluMohjTU+sjYjR1YiyZZQxYEau9OHj2ddQkwWk0LODXN+h3x2dtcAgrRwjeUXOCXbRVfaGnMpBoVsFJew7gtfJIATHCRBwOBoD\u002FqAQb4Lvf2+ozz39g1\u002F+bNx2cf\u002FjVbyJTscwC17KWH3gOQysrbIxXu63Hwj\u002Frfe6ZqzIV\u002FdPIKJ7l7MVvhqLrGdYyw6S3Y6Uhx9ZoEZIdlXq8SiZLZodbOFcBJaNQFauzFfZwpucpL2TdTQ\u002FeJ\u002FMVLCT0aAjbxZ0kkX11j5W0EmmGV0o5XujdtJ700fo+VG6WCSfjic3lFiSHYzEphw8d04JyckCcrqyXI3eGMRTPpi9QIav7EY0FHzBisM2sAzDu3UUav4jC4Lf1KTHFwIsI19bo4OMyFuwBRtwAxsdfnYX6NHGmLHPjkIzmRPJAxnnaCv+UZrn\u002FSJ6eZ5u2HpxIIgWdKhk1Amne2ojqRtK6Bl8dvu80DTjcmdznJ+tlawew7k50HmD49ZFXiMu9OA+Dq4RlYQMEfX7OAH+mo+Wg4z2p3Vvc8CzMlmTgXhFh2QTB8VzIuuuqRtQZZdsL7QvYr1kSU52gc5tAxydonHVGWxG8yJ3zI1cReMzzf7xmc3f83N9ONcEnFlrX\u002FV3xnrPxP\u002FmaWz86HP2hiUNT8FdojTw9E8gmVn3a\u002FetgEefv4bXazPUHShEAf7wh99\u002FJbzbeVyEDVMpOxBlkfoWkUOkJ+uMQujfylhgRI+R0t+EH2MAE2FOXtPdO1sTqX7\u002FPa2VDm\u002Fef\u002F+9GUfEThQZeHjJOrr8x\u002F\u002F4\u002F0y9poj620X9BvEhX8Tv3XfOTfcYyP3tb349wo9QOpIReOHC2REgN67fHMPTwU0QidhEAHj+HALGSTTR56WdGtd8pUltWFJS4IAlnzOsRV5+VV38z\u002F\u002FF306nGSUzhIdaMoaAw2pEzB0cM5mIjHXMxljSv3r1zU1IJGwYRJ5NCIna23QjWkUp3QyGH39cpPX6tWDz\u002FhhGjFM1yxyM\u002FSmOn\u002Fzlj5vrOuqafeMELQuxEexOnTvePNGJlK3lZH3b\u002F+anf1GU4dDmP\u002F3DL+qu8+XmXuUxh45kbBXZURt7h4J+mEFd9NRO9NW3laerZVaefjib0xkjap0JpgY8RsYsIiQTWQ1nTxPOBDYm0\u002FpJ\u002FZ5pHatF1rvvvLv54P0Pg8ubfbY1LTq\u002F68CfBw9bUxsaRZRvfZdAD6\u002FSoQ867EB7O5ECderHWs+Tp7Uyqx0hAxH+GAUigY8KX3EwJqr+SmmPAOg5mM+ccDVhtJQYBcDIXoYlAeK6ZXQsYYYXx\u002FjrXiIG36ITwtb6vNE9AWsjLtxxVI0z13p2z9M6TbZJJJzC8jvm16PaRs0f\u002FODDcf606VTXay7POLMj3Gw0vRcdrE43DxL66OP\u002F+nf\u002FDsJTeEV7cuYcIOakVXQk5TxCsed\u002F+umnRdnP9F2tVlvrnxV8DlWC\u002Fng0\u002Fvz56d61SL12tbkmDHOiYvHAlQAORlNWs08W6dnmH\u002F\u002Fxv5UVu1JWq4NacpxAZXvfietTQY2VwN1aKX3wIODADbzIEy90iTAIzFX7T4AThH0ctLND+tk\u002F4WyM3eDCIfvm6qJ\u002F63sSDaxIZnOOFt3HmHInXiaD4IHSJ4vcQ+gzGIxvJuiQHoqMw5vHrUivKNko3\u002F523zNRa\u002FPpPfNsHaMwqLJBdoZi31nnirr0i\u002FW2ILW2jTz\u002FDV+gweb3srR2EnHGiVUGr9+2R4fseeutMxlu0Uc8qouKw9nulmXBix7oqO8jRyoZyLh7kAEtM\u002Fewsxq0e7SG5YCi71rj9r01MPbtP5hsSrQgw8Dws1bKW4bKqZGMEnRIKQq2eGsfqE+1DIB60pFjrXfJBLyknlmUOgOpiB9QMcZWXXbGRnO2n2ZXzkmSdrPzASe5CH7G+hNlaBN4ODqy3SnEFPvt9tbcLJDwsOCObKKDbXS6Ii\u002FHyQjfYyQPPF51pYr2FpZS8j1qBWjQ2IoGTmeO3RlwyWiGvoDIgZ6nLa9Jwyl5LeOJbuk2\u002FId+JsI2xgd5sni\u002Fm4KfNqTOeGDY18EjRR\u002FFhydRzmWcMQbIp7hi8Euu3GoP0duVfTJaZCpuJbPV5gvwgN0yuNNFQytDXT0D\u002FHpFc3Qt4m3KfY5+l9w1f3IHzl\u002F0XLyGlsfRLWNLPsG5LBoZyBnhnDGaV8Sc3LYG2RQMGZ1EoGPAeaYX2u5ewSQ0hqfGSALD7tN9Sf3xnj3eGfHxqv1Gz7If6F4G\u002Fe2i2nFL9709ayEbDD8R6eaEt9ehdScmQ\u002FJ1mz1xrb0b07npyrfzua5wIvbqyp++ijrLAnAO0diO9mUwyOhuOFXfjkb+8Ic\u002Flgl\u002Ff7MvXfptevtEga+T6abdn\u002F1xc+kP3wz84QbetqPN8LhO611y5WmGsuARHMlKyQq1gPiCHsDnwXLgHY3k+O5NTzEKdbu5\u002F6ADIHMwdgTbE8eyBU6dGudYCdFWxu7OAmRD5+m\u002Fg9XGHKj044VWqq2BSEG\u002FWwXZtG\u002FcUXMHa\u002FQeJ6r1Daaaz9B0gQP6cn5HLH2uph9d04lowL14fyisaxi+aCigDc3Qp3DOvppgWGOgpXW+BXlJhleWYpzu4fz7aR74H01pn9qvpObIarqbEwM37Br0h17QqrnKnqBRf8uE03\u002FuR+OqIUae9vvQZmOiIXP07CW3Rfgt13fRRN\u002F5vRtmXsZFE9bke3AQ2DBXYyNIa\u002FTaHmP+eA3\u002FvDZD\u002FZ0OJvrd7z4tmnx7c7q090ppLeBBMuDaEACBFDLgTJP\u002FAL1tQCHW6dEdYGzmIez0Z9e1xa53hCEC\u002FR\u002F\u002F\u002FX8YgXLhwrlBBuPj7Z7pue++247s2hreuHkt4\u002FtCht67EyG8dGlFkPfGKD\u002F7u7\u002FefPDBO5tPPv6kGvI84hhhTum8agNeGycnhQ\u002FgNgNpv3Z4EDQp2YgLcdy+VXQ6JCm\u002FQcC8vYn837g+9cSn3\u002F5xwocnf3fu\u002Ff3vfh8TY7A3N5\u002F+\u002FrMEbUwXYs9UfqBzx5E2tCAoCN82pFY0L+TH2AiKcS6y8t13N7pftxmM82zzzddfb\u002F7pn35ZFuLcwEz9seiA+YsK6HIgGmR8JTXnzp4fAeBAqquT\u002FSj6eiFGTDFn9dUl4unmTK2n\u002FvXP\u002F2pz8fzpza9\u002F87vNpWrzXrx0ItrB8HG2Xq9FM3I8rl2vHjmhoAfu85ecsIRyuMVsK2LcZxlko+RT\u002FodiJoZz3JfZ0bH1rftmsFB3f+7syc2H3\u002FteuKx+vhpbtYEff\u002FLrzdUr36R0M7hTyA4a2Z8gElE\u002F0+EVmI7h7nmM3FMZ6Q49IfzQEgXF6MWIjAip7qVEMZyyl4y7ruFcjcEX\u002FBezrWgOrx1zooODBw+P4bIMxtZYBkEkgSAHa4K5AOTgsH\u002FmM4oEvVA24O9vBjD+mGzEPem9UvQpbzLBs7YNJsJMX3\u002FG1NVv2iQXbXEqjx7rcLCMHAp1IgVBWC2urkoH6tSiJMB60bUonLmJenHetus5v2mPh25EBJ5ac7Qs0vjmqbUxW3bHfhB1z+h7ImzB6cjTDIX4156AHt+9d3sOR6hrgi+nk6N9LT4Fj9PhCD3YJH6v7MY4Md3IYDx2LKclGE6Xh55PMOo0wvg\u002FWCTIfYO35qVfMQPFetSon6rEjgA1b6UZHHIGBCDme2SYy2zdjLZuNAYFNObQ4PhhJTQNF2xfGdavhCsjivNFWYJZ6Bha6DEelQ0i4sQE94dsC6MzIAx9r0gw\u002FC2DDz2u8VECXBpz3v2YKFUfwnmWZ9Hw6KfPqYRMpyULohPr9xLZcSKlKN3QZ3CyEfjrr68k486WNNMfOaWTEjl0JGdjP4WUgxdMOEcONZsTbDMmxthurXfuoB81u0Ulu8\u002FTwZPRDfaMDBE\u002FpLyn+ZnK48J3+IdS5Azde3hvjB4wU4pHvsMD5WWfjGwiQIKLjhhoCW8fLaXPUD\u002FavggG+HhAAZmxOzgVpa08BE\u002Frk61BwKWvvun3+3PS8uNKo+4\u002FvtUm9QOb7\u002F\u002FwRxnnB8qMftJzO0OCEdY8GWBkBlpVviBz5+VaegR\u002F0EPKA55V707ngNfLov1zguNslF+0QGfNoTwZmQAiGm9\u002FjLnOIXbxM\u002FrlWBtjRaUdvJesC89kDHmDBxkYNkziZTyHv7WmPdJ8GeWcZE6Gkz+d3u17QS60Jps09fgCXsHVcxa+kmHNhYHg+smGBHOlEGA\u002FQQR0138r+LDqxcfACCbk53ZG00bpZYQsw34rWodPnTYYPHiQEybgBb7jEIRbPDaveASeyTq1xeh1+GLmIXhR9rkGCwiDLAUPxrmgF3Ywy+11KZ2DU+MxlAS37AvzvYPi7LGSGb2XfnsU3OlYBvubyS6loxyccWTAP0f1VJ+jX\u002FJYFFyZKtlvo7gI6suehU0Z\u002FmP4dS09TEZ9kn3z\u002FY8+yHB+uPnD559tfvqXP9r85V\u002F9ZHjgqy+\u002Fih7DPYM4fiMvOHTTjS7H0tkUw+Dx2KN0rHMT7NVj3IOaskVlONYYhzRG16V7rGGzowBVcCRn8dndh4c2dzovgXw1Z5kmttSLAmfobM4Z6Zn6vmuVah9DJxhONg6P0r9b8cLQCtg3Jn6hT+gq9Mf5pFu39ZZrwWG+694X+3yXjOlecqYvx2GfCHxIRHfos2+GdhZdorNWu5DcLTmkOWSN3HVolqzrjr6frGt05E+0B\u002F970uO7+h3t4UEBBtkmWQt6DC0Lvghs7s9OYj+YxLYeafDhd58N3ZtjnwkcCuQakyNCv\u002Fnec7fXAKcmw8nC52gDD7NZyTuyUrcd+OPc7djVfszW97per81Q\u002F4u\u002F+GGG+u8zQv9YGcXVVxHzUgYRPmbFbJAlAg44N25oM9QR2SFKW61ZYMTMoJfGgSjGL+PU0bSMyru1FNQZBkGpjaVcMADEQdqTrnPk9A\u002F\u002F4vvzHLWFmNDGQoYOIL956vjmj5\u002F+LkZ+c\u002FPTn\u002F5ooiQ2211O4R0\u002FcTSF0EakkMRjJtCGYJqvcUQRpHT37\u002FPd85k3ZkTMxr6vzCLlZT4ffvjhjMGgVDdJUajJvdJzvqs8yCmYb1SuozxAp4Zvv6WiV7kQb1rt6aRuwjUBLdL3op+EpGdL\u002FSVGcwbuVBrx2Sg4sBQRu3zp0ihNa1zHvovygZPWUzbJHSg62ka\u002FlMG1nJPP\u002FliJUClHm5bUsu0+2YmozfutYHX29MmMr8ObX\u002FzyD5svL11PYLTxKkLcnbJ7660cjJjELnebgB\u002FV+3pXESgRE2\u002Fzgf8xcpJ\u002FNn0uJfNkcyhB7dTHvXsfb967eGZz8f2LGV9vjbD99tqVFFUtLsO1bIysykojFWFIADk2+1SROlHmJUhEYtt0VcRXaczUkmZAOPmNYkNwcEpBgBkhNBGZ7vEiJFY0fBlBGJTxp+wDE8OHdDZjFNObywicuX8GZ7q9eq2\u002FRxD0yRhaPdvfBNFSmJh+vUY4pqzg1zxFWAmHiTw0KOdUWY5MjA4cDjG6l3Gs9IOgM5I1NaMRmAyKdYDQikp4JjqCC9fjJ4puGd7ueTXHxtlWYOhc9gdtWuuLvQmd1s2BdQMlxsFRpqM0CRhWZBVc1nPRmTKWcchz1BnpUpIM9N1lWRx0xND9U4apdXrW8FJrIDPmKOgE70Rpix6qL\u002FU8+0HCWDwHv4wQ0d6ErghJ84TfrTZ+ae\u002FFQQmdvSqfSD5w+NGNqPKclhlsbVAFc6Ul25FGkF1r3I7iL0gDeJfNm\u002FD2HmcpBfSSpd1A5JzXwjnsrHv964XejBHkoXy+hYeCY\u002F2RK5PyG8XW30NHfcboYch4pT+7U6T33uabourvzd6Xw9Pp5eDBY5uDRc\u002F3Ol04fDMA7qacjT0R2\u002FajBPyBkezOVidQzsnClRrhFbzmBYb4gDJ+mgFgozRcMeYoQ87UpL9bARrnAHpZD0NRxvRoiuxupQT6798oAuw6JTKcP5v34UTdu0COEqUFS\u002FRby7tkOyf1QPjWIOCddy5ubiYLPv9jQY42uNscXzJv896H73eC8LnBgQCNjB1HYLJTABWcRNXxso11ghEMEM\u002FwE3bQl+\u002FwGWMd\u002F4AVvBpCWQvnBkzwkJNMyeAXL+i3+LKxBostXkSasyFjyrD1BObA0EpIp8QZn+iXUURvke+ey+9nBOBZJYw2dh+PV8mq2xmcdI96rZl3MOaA2Fs1Mr5nM44ER9ZL4KDfokW0hp76sejJBTkjz\u002FsC3W2\u002F4Gfkk7l0M5nkJzzjecYS48S8VzSdXsmxCVZgPDp+VsugEanHe0okgkBwIxvcB45o70nlk0p4rONR7+G37p\u002FSJ0Yo2ZJMkO0a4zJeN+GD7XPC13Th1lYBrj6jf0VRb7Q\u002F4a1gL7N9JF5Hv8pI0eeXX9VIIsfxcPzBMQRjBheYcjqD0tAivDt40DrROcPfHoGbZXRvpndO1HThPj1btvBUWfS\u002F+MsfzennqgNuldl51POmnDNcLuevfSJdf\u002FRYZ83UOQ08dArZ1fgqBBw8xwBnE3177bt5pjk8yXi230tG5n4ZMn3fBSwe9PnX39RxJn1+MjvlBx\u002FtmzatSmJk80bGlrE6FP\u002FsTQ8LhDIktzLQH9RN5nkw3Z3dohwOvSEM8mXkVr9vO3zkFP09ZTDhDwXRe3Pd0BN9vyLv7CS8gYbIiMnMdI1g5OijoIuWRq41Ur8M2Y2Rv34d+qAv\u002FqzXmpe5vaJHuJ859Bw8gU+80eU8O7jCGdjvPCRDQl9zBrY3P29Tektu4Flfc90ZjeIpLzwygbjmaq1zTc8XMKAfyeOVHVrzXEGgtc7RPcH2RZlAfGTer+v12gz1y19fzjh9fzx\u002FRjRDANIYpbxuHrBaY14shgWSl1t20x+etThBch1OISK2UgsQ67rwEoNLj9T8v4jf94q6InwbPnjYiNzmNlEASGPsi+h51rnZMKdGvnRTn58\u002Ffybj73qC72ZIXMaEyLwo9EcffTgRqitFcM3Z996IgJc1yjLCMH8bY41HMDIuXOd00\u002FspIAbmqVNvzPUiKCLr1gEuItOPO17s+9\u002F\u002F4aRodYJxWuSx6uSOFpWWBkSsUl4yBbxq3uLy7pbwPFHJwt1Ac721qzPmsOjKwVAl9Dk+jCppZwY\u002FvgAbxtSejPROuy2FlMK59zhB8UYGUD1oSz2qk3WfFmQ89V0ZSz1x8\u002F7F0\u002FP5uXPXiyRc3nx1+VqRjDIFGXCEzNEM5z1F1aXzniV821GBu8JZObcYQhp92lEVlVNnh4gJAzpFJODixfMpdhtBH0yE\u002F1rOEqH0SHuqhPGw9Ex3AABAAElEQVTyYBPuMaFDZc611uvtTZDW\u002FN6HfzmdHjgnBJXowYOHRQwmmg7qsXZ0OAwGnxn6cGVMSsDnlKifBCIF7b3NoODBuRRRH6HSeEtQDUrnOvc2wHwwwoMZ9ervpfyWQOkCqEhH9MzoiLJ3vVIoY64U9CrBsJlw6uZt6e8pSiLSrXP9kyLW4Lh9lLcUKkMMjtUqM0rMxrM9kZE+Arm\u002F8NTQQUKMspxjpaORw20+FNkEY\u002FBi3BNYSrhuxcPqzHVYYuwSylrSgbEHrY1JHcfdPXcdVJNBzvgi5ClQ\u002FLNaPTLYbSDneDpZd+dklvpl4CtjQThe2Vtm68mNARYjChwYCmClVdmh+ESt6tMO1iIbZs7Nw3KXEG0etRUV3WVk7cgY1REEjCncUVyc65T9oKnn+zkKRSYmOopQxvkxN7D0PTppetVw9ne\u002Fg641Uh6MU+JqFFEOTDHEPndFn8d3BnDdDNTvxhxa8NGUWvRZP121NUoiOnv1XIbEzuY147fgphDsMzSSDQ6HAdPzJ04H9wyn5lVN2Yy1t44p+1LIxzmB5l1UTQkNGA1PxrtqqsnSJ705uOaH\u002FjmoaAa\u002F6AI0KXyT7jUGWbRmXbJV+IlzJ7LEuIQbDuG2EcngU+4h+6euVjmNPSv2ryj\u002F8AI3z0RboDOn2EaL5qov\u002FbnzF+bk03va1t2RQWsNXXv67XM1B7iQgXMj479oYePu2CHSDbfwxXEM1\u002F1Nrul4NTWsrUVpy+Jdy8b\u002Fi\u002FeV83F4p3NV14kUW+M4o8H\u002FZdEyczX2tk7oolmDcURGZTLV5zNyOYIO23K8Op2hS8rLLWdfVGcefZPfjNcIcIxncNxuwECWC2jZo3X92++GBo7XQ1vLVc6QcjTZOc4BeWI+6wWKKGj7tejJPEf\u002FBjtlKlsR89DyKxlJZpDb8AH\u002FZADDi0xRLz56Lj4nO71dm5k8NDEBtkrkppd2j22I0WV+MnLcu8YVmZWxKToZrzG8vdEEfYmPZ49A8CCvwOLuneyHsq7lEEbONfmuSxejl2BrqTIZV5NXZOFbBX2OlXlkrG3eLvCWrrgajfzxs68ag0G3IspvVb6yv2j6\u002FRoOPI4XDhREGKM1HMa5IzfwmrLDhh0axh8CJl989VV0WqvEsns6rdxMH\u002F\u002Fh08\u002FGYb6f7nz05HrTutmzVtBKTfvTnDuO3Ricdck5enQ5q5t+f1bbkLt3cygfKZmTrU3mC0TE034ywu2neVhE\u002Fkkw2dc1An5KQtAA+fUo4\u002FB6J65yBODvQHxinO1shwYB9yoJ3RE\u002FiPbTayiDP8WZQr94xzP7eGDse3izflQFsV02P8fp6jlkPOd3+CG8GGfd04X9Tuf3dZ+tzyfQ1TiCd90698O1LmTotkfP+MtWILdWhNtjObcvkiNCCubp2buCQTds\u002F59+WTB3nzfa2375GyP5wZjWhnZe3e66kXvxvPm4Zpuj0NrQL3netfhtBfXga8kuMmSynnCWvnpdr9dmqIvkqlGWksYUIldSd2rLpGwQk5deywwBCJVy1cUAczpQQCrt2NGilwlUhDU12EX2AE4KcH8RaIgi2HbWUhBhUTKE4aPHh8fjVRvJA2c0M3QpIBuQEB+DxeYbb4eCEN52Rx+uHMTmEpG6\u002FQfen+suX\u002Fp6hBBkMQQgSJRRSQnjXMs+AllNLqN6O\u002FXCg0POaoPVat7vPV57iGVIOSX1QadbcigOtSaKdtvzEjXQDWA5MlvjfCAARh3hTbjIEihzoOBEp2djTGMR+hwdBjYngnC7dOnSHOqkzvteG2wPFG3bsat7U5DP2qH\u002FwCEICev9fX41JfDV48uNn1KsnMephpTujnaYH2pT4vvvvlWZzluVE53OWP9688fPr2wuX62bSspR54UjKWLtEp80L5G5icQFZ689bXJ7GQOSp4xDjtjjhMXx4zs6cElN\u002FbHKFG5UU6wvfodWZIBgVlGsfW1+AYPtA020kMQAjIC\u002F\u002Fdu\u002FKaJxMph+l8DLyCwCg5ZsvDmQwe5U0YnGBHdHIFMqGBFjo6lhxJ5kPAxP8E+krTlTyoQleDPulGRIsamdnZcf4dTLr9sCgSBbv8ekcbmxl6PQ34RU5KFziLtGIfSZdSrTsVFX1HR7flsJZkoU7TJYpjSjMdXuESBjB2YUEjrWA+YvEzrP2rRrPRTsCJpScmjIvIztPRNJAY0hFD2p6VXLLNopvY2u1YkykG\u002FHP6KA5numMi3wiB0ysmU8rk+Wi6LQZUeHChHXrfDcQ2dDnbIU2SR10neLNjkhUmT1cAab1mz4SNZCKQQe1DrNpqSJdMbrDmjq9p5rw\u002FibE9Gy6U\u002FJEGOJY7vwFyhe4c0ECXlwwbt764qjznq6+ARP4BtHMnzOwT\u002FNFU4YCGAzcr370A8RP33TGfAhfamR8BYYS7zMff7Ft\u002F3vtwY3XrDux2y27nO4XP+hhVcGRlf118zBrS9bj0FHafoODnun0Ya\u002FoG6M6OjRhu7prBV8DyZLHj0pWtYz0JhWZCKd5JFDQSK6VzNvjsF2n7Zv3XPwwZHkWocEBbenTzLc799J1iwHBt9FNtFV0eP4Bw73cipNotEEX3SXkTY2T\u002FJb5lNEi4xkzIgCK+NA12qDT75hb4S64ZVun3GSvaLgujEYR+DFHhr3vEwGMUBE3t9883T09fbmxrfruPd9Mmun1CzvKSN5YxxEtE3OctIYg3iLg4D+0SWjSa0vB4vesL4svXmuz1aEjNJl3JAHa0PgrmQY5M6pg8kk0V90h\u002F58DlZkL3oRvTWPEyfXPieO5pJny\u002FDNpLbskYXmqJxgOnBlXKBP5TPG9zmaIE8n6txpyOCizJCBPuUwPYeTBMbuE8X2Qn1enmt+Srrm93jCf14jB\u002FoVbGZCPux7QTF4IHfISPzjxXmZA2q6x+eMFOzSLcFJVDv4pYcY8LIhHAG8j34HTp7cDQzVFzsZX+ArMJEs7hmyxDYXkrsi0WjI2HSZIN2ePUXCk+vmj\u002Fb2Pl8drfA5OYbX6WXlIkp\u002F1G8fTq7QEefPn9389Cd\u002FWXbnu2wCXbKqJ49u8bJ9OuhYi0ZjDU3LWDaeZzX9nr8nudR5Ecno69kYgWh4\u002FGoBo1YxeuJIxvzb7fEhrO6U9dF84WZRcoY9h0EJKh2O6ARX7tVFbSvD\u002FY344Vnthnelm3fvPjCwpH84yeAAb7trlbmrDZgPcpiyEjYHax95rme98865Gdv+rWfPCxwGT0G33fGUshDlfXt3yZAIlvgsmRtcwenQYWW+a6Pmtg4cI7bnMTh78NDG4J+1+ooO\u002FN1XzZOuSkb0e7fM1y4hH+hZdOS5I8Nas8AOG4CxPtf33TwkmC8KW3\u002F21DVml43MDAGLRpfMhnvXwzfbSWZo2xGBv+3vPBsN09vm7O\u002F52b3bhru5jYPR\u002FNxHx41jnbM+624O27ZBX88is25Gh8\u002Fc4NJao0\u002FPHsOdzIzOt58x9\u002F3\u002F\u002FOe1GeoOZKDUed485VNvpFTbfKnk46utSwMkxCe1ClGMcfXJGJSi1Kec0YzBKWjAeVppxO2nd0bw3j9clCKikor6\u002Fe8\u002FndPAAPjz6mwJAcKdgCZICE0RDYDeNoQJaUbc119\u002FnWK6M4fgSE0SMBPJLwqovo3Bvvq71p+1TUTqLCFQZO7J471jqFNI0qw2GSF+kd19+9YmQITqM4KFkiK8zdNmv2MdtGAD361b5nB3Nu0xitRdW6+ynm4bGN25rUyhjjlnz4fwhSbroRw4GITYGBH9bZOp6I3POSciwOatn7DxtbT87ce\u002F6yTDtzPy9paGvltU8uSkAT\u002F\u002F7A+bHRlCz6rzvlOW4WBG9AfvX6grzTsTtVGmQJkw+vSYffMvP9p8P+P6y8vfbn71m083H1dv\u002F03puscZW3MK4gjqsilBbVuQY6LxNPOeCUUG9f02suk4c\u002Fb8+Tb53JoNsebM4XOwA0Ug0my9oriUEseOQ8Kh+bu\u002F+9vmeHFOlpVet35CX8Rqd1EONDDGKUYcBbxSqpQfeBIwEcjAfYzpmAwO4ruemUNUdBkc\u002FXQtI5iiIjxJmfg3KUKMkyb9634\u002FCZXe67MEzlxD8IjPdGfr8kInHobWOSHmin5FT9HOXNNzZk4eluJh0TXcCC9p7pcZEgPjxtzDOvOlJ20\u002Fn7KLJmwYRue+JVAIEBFVRqnxb++4PbDemQECPwQhIT+bo9sEOo5eTuCnn35a9uLK5v9l7k6aJr+y+75nzfOEqgJQA4DC1M2hSZGSTEu2FQ7LCztsKxzBCG8d4Xfid6SNF\u002FbCG1sKiSZpqdls9oTGUDMKhULN8+Dv59wnQe4bCyeQlU\u002F+8z\u002Fce+4Zfufcc8\u002F99JNPhufQ2DMZWMbvyJF4upkkeZH3n7TJWEbNzMnjKr2I\u002FjPAmvh1DtnhHC259iLvN0u\u002FkgMqor42RGnL9HhfBNQzHj8N+ATKbdZ1uvx7ub7P4leKf2\u002F9IKB6t3q4xsFYGIdZDBbwPX58lTwVdVsVINaGbDujMbpiB8pMG9GFEaC4+VWGJKqNHpNuw8Ysk0B\u002FobnzA\u002FqMkIFqtBu9Pvu345N\u002FPosjHenixs6Qeo1xrK1jGPpVesDwx\u002FzIkASIeuMg6TnaYdpc\u002F+hcAG0ii7VhfzNyorAA56NH97umY1NGtWs9r\u002FatzTqMhw18ol\u002F3NcMBhNxp7HxaEIhn6PKJlEZn0TcRcS8Ot9Qm8mFcfceTdJ50COsJAMwxfH2XG\u002FvqVUC5dUSzIL\u002F2ub9o30yfJ3PoObTo\u002FpztWWzZp+oVjL9UBjM7+i5t6WTOpVG5fu1mhQSujO4H2KYkZLRRUQS\u002Fv2jMV+pKQDcizExoIFPfPJMNsuvr3iLlRkxO9uifph6tdZGiYTOfMejGPjrqM94cp6Uh5\u002FSRGw6CijxPny2ZBg4GkOpqMkqXiCKzEVI7yT++207fk116XKDJdc\u002FLw\u002FZsM77vtLtyjDDP5US7zowIR3e7CPjvgXqN7P\u002Fh0Z3PoW9H\u002FK8tW3AzzOb06KA\u002FPidVorbMq+\u002FaDdTSpU9LhRqwzQHqu\u002FPpTeM5emaHHujqPDX+9Qn9+ilarZx3KVfkzK7W+ASfE59tdNT13l22dGNtXDN9a60D3GAMBMmMF0xhTQCdw8Zr08P49Xm\u002Fnz7z9syY\u002F+3f\u002FXpzt+DSkdZIWB9x7crVUmNvb46FD14kpxYMHwgHALoIONWSohWHWBDL\u002FjBSXM++vfjw2\u002FANrnmnCL42nK3S2onSSqXbfNueFzdaA3azMtPW5z148l20Sv\u002FWD2tOHgWonzb7e\u002F9MlbSSJSUYzxakMJu\u002F0qyydfEoXfbiYLIU9d6Y1ahjp0vTvVjQ7O13wk3Zz5vtH6A60RHVaeJfs2sPH7UZ1L5msVq7dKDxOxh+Ony8IGH2wKySMWE\u002F8B7+FSTUZ1hnxrfxNOZkcoI+HFv6J\u002FvhvLox42bGSsQfH+D3mT0ZPsJTndSLfpwrun4+HR8+7NucU9\u002F6Pg5D\u002FRsQ3Cn4w7O9toB4y7szC9U1270P6EPt04ZtgAY\u002Fd0r8zLbShuvlnC2Qdn\u002F6lT1x\u002FeJFnomX9q032WQz37T+aX6Z\u002FtJfK\u002FiH4cYmdm91YQQ2fqjXDwbUVSAQObZAjtH9\u002FIsviuauEkcANiH1iVgiDAzLELRP9c9FCZ4+Wyva1eRl5BDgWYuG7jXdKQXE9Vb0W817tsoVDC7DS2lbxKGEkgoTFKYyZQT3rVN7y0s\u002F26CsnDSOAqDNm3Y\u002FjCrSJmpu4ADDQylQEb6bLbgTFdd2EcO3Ai2EcSI2Mbndw0QUGcYzRfvlo6vFimEwOmZBE1VZJg3nwoW83vpfzeJvmoZrzAPWJ2qzSjKi++pjWxTXdHC\u002Fqa5y9m3tW1EKRgcjM0SAr+nkFUGvNn0KicKST4fZJq0hWonEy827WjrPZt+xzZUbVzc\u002F\u002FdmvUyjvj0H5j\u002F\u002FhpwlzAlZq0KuiGccz3AwYkIKOb51pTUHa80UG41UG\u002FACjEVg69+7vbz796MLm5798r+owP9384lefl6vOcw3MFpmdFJNAtXJW2NpCn5cJAsVrDCJB0YfzM5Unz9bMg1SEEfQiAHH5+jtQhq4W3RAk\u002FX6bE1hk97PPPtv8+le\u002FamwYkRRT6VM250GLF5yPxogzw3gQWABdRM1Y4z8NGwX0D4wMpcgI4yVTp0BzwzkKc4zQCKBxoMCwMwWz8zbu8zdFM2p1+H3+rt1vakPiW7+WAquL0TijkwMyMtEMgJtabERRoZV7qwE+Ua7+zlJ2h65HVAzkWG\u002FHpMtwqtaME2PY4riOo0G6e\u002FrB4fAGWNxiFKI\u002FGrdnz5vura\u002Fo0y+bfZf3TqqY6eFxcq9e7fEvJ3p3qV0wRb7f7\u002FPMmTPjkAMpEwVLB+jzUqx29atUX88w1QrYmeJ+9M237WsQ+D59dpzpq1evTfqCGRozRXW99Q9F99MLFPLxwCaHjapVxmwiLPVp9EhjhMuGCl1oxkFbjJdPjt+RI8l0swUWCQJq4xACaju0Gyez+3guIgzP9BuD6pDX1kCMkk8mAWo2awust\u002FQE7EXgAeAa1b0YgP40CH0auxnb7Y37EehYx5xj7DuvO7hEm7pkojTjyDXOu5KRcUTSe4IjABSDQn+h+8NA+rXrV7u4mbl3zkR7cky2pSP1PJHMvqPc3vLZj7ZAN8rN+DxNDz22xqPASfOa9c8Uu2n6ct\u002FTm3gVHdFTuyza0sdZBxEN6Sh66ViO\u002FVtFfgVJbtTp7aIvEeC1GymAn9OcXIo6cqrIN1kFOBlPfXkdTzN5nLdtCoJ61sffOpMuedn+HdeKolZlpuvXYBXZ6j7GPm7u3jZdExFPj+0s+PKbc1TJ4TEBKweyzS8CTisij76L9t2kV9Tp\u002FGfV2Qe06BxOBj4UsZ9Zjvh0T7oZT5ITaXvke9\u002Fz2hAAfNkuk+yHQIL0q0kx7BqODV31tBREY2q86V48ukCQBbJvZbOaJexZzkeb4eF4eSLpaBXdlN9czSXfvTFRL5\u002FzXXf7DpjNrIFzHOgEfO3heB8tOaR79wmaGNMAjPfoHKkfO7N\u002F0XRq\u002Fqd\u002F6RvjsW9P+eIdjwrRZjlEPtlE48Mu7mm86YRJo1KKs36jjb6TOfxv7Mf5acy8pEuYvSYneoHHtA3t0JuT5veVsmQ9QPao8+6U3w80nXn3wqSDflPxAg86d\u002F5C9vvbzeXPr29elkbb5Musfdh7v7SS+AVPcGofBLJVTHnUMQGDhTfiz+6Bj+7F\u002F4eOlIMefyqDvDd5edwameMnzrZ4VbGI1sgVjLh5cxWuiBDJX2v30ktf32qtTKmw76Zj7W3xzjvnR5Y4JPSw+7NRnI8HOWQP4gm7cB8OTJ9qvwS7Jz+5L2UoLNTY7+4aTvq9+1JZ6z2SR+gT0obQN+Y1w7e\u002FtON1X+vEAPWtbVo53WRg9vzgUBOEXos30b5bdf6AUsdrI0U1PDW6Cd8t0BzHxAd9N6CUGS40fniu14zl3DKd1HMWj7l2zhy+o49hoLl\u002Fz\u002FWbS+Ahx\u002Ff3pjvoFz\u002FO7Eq843Wg52rnrEDoufQUzCewu69zlwx0Yjdkm5ezUXs9f9vGnqmdsSzAEI5ZupeeQofOjjawyXo2ecBv3zvCGvI7vn4woP6LKqiIELxTlYfTTW\u002FK0\u002F788y9SKhZ9rLQTREEgABuglU9sSk9key1AVBHE6vXAacxV3yOBacwUv45GLNvJ8gYxvo0qGHIKyGJG5xFUCuF1SmOUfMd4ySKy5\u002FJ2362uuCkjkRkVQJ7HZKOI8GJCqSQZoptKMj00A9FzfR48KKob+O06q\u002F6XwX+2+fLLywNGLly4MMBchP5GIB94dy5munTpUotHz2boDm8uffhJO6b+bdd9tVMO7+MM5NGe9zC6fT30ESHGNHdKL2BYGWBgnzHEaMAkOmNex2zywWng3BC6WZBan5Xqu11fVJY5lcPyi99WQ52H\u002FyRoWz+\u002FTSmdbAHmroT\u002FYEpoX1PQj1MgN5siPNV0MgupNjqm0+dvbt6YNBr3+\u002FD9doo9W5TrxOHNuSIMP\u002F2bXxWtL8KTU2WL6Te1eVftBFzGW60\u002FzxNGDoX6+ofqz7elCAHxS9AYGdVYirw1jqa7RcL0cZRx9xRtUVnkq6++nGi6qeBjRUfuRieK+UCKq8fEERRICrHnoYlx5WwxEgPUOwmgYC0G0EVTKUFoi2+20UP3cGyBrSW9y1jhzR1Jnk\u002Ff+q97MmrrPUw1im4cgo5TLltl4HMAs3bU76PJgXGWEy7fHziiLKIAXTV9oXwBrFEq8at7AIp+j0vn3H1FEifCWbqHv80yDTCpH\u002FqibT147j1gJT6wWIYivZ+zdehg+bzxFDnlDMmP5dhyOjkCppbNlL138e5sMHb+3PlxNme9CCDROHCSATSvb6O5snqeKzrPIH1ZlQQA\u002Fp34COC\u002FUTk1KQMi8wNQuof9CKTCnLvwzuZ8ekXZzlevVi18qU1ovYB6NJCznB1gpAAnss2wcOyfFpHn9B46fHe+c2aNMXl5UnpGp01UbIAyxUvRBjQo4sUrgE3v5IPjZgzX23G6QS8p62Vg9sy4bH\u002FjMAE7vkf3Zs9Ent2700ancTK9xhC6T\u002FePU7qmfjWiqpB44a\u002FtLAieHWcu+Zh8z579MkOlEolp9mfpkkdF2gCL1y+LPL9Oxp0bKA7V5MjSkQUT1F5P1qxtQQWLhsmqYIGI9IG2Kz\u002FSNRYWW8cgd5yc4a+ZZeyZDzlWvS2sZ7Qngt3tpI5gzAFo3d2s4q2ccutYyKydl08WpBDZ59iQMcUByJeIvApSB4s4G2cyDTwda8ZQnrnFf+OAxvXW6gBPXsC0l2g+B+1F+kA6Hp7Dl2zRUJIM9CIP5ImOMZNmUzipPvmSBAq2Cdg0DvG9RqB7Q1KbjEttBjhbiIseCziYnchR7XKR7oM5pocOCa4E7Bjy6Ou9HGQOGbrbs6BF+ulFttBsFl0AAGxLHPt7wFjnAOuzU2t9BOQHzOtPbzw0r9rtkG8r7WUdZiv1Y\u002F7r0\u002Fd1aX\u002F1ne1gf5f+6vr6657jQHWu7\u002Fh29CFa1\u002Fzvgx79hr5kQlAHUB8a0aHxhf7PjOK0M27WDu3Uij7RRdrBmhHpeM8VcNscWg6WiLvxMI54dYBi9zKG3rN2pD5vx6FTv6f3w3RNOSsdWakuAnyq7nz00celUn1d8O\u002FJgN8aWLpegLixOxQ\u002FvypV9V5A\u002F3hlMKut1T4WJ3PwCjTEf9aeGR\u002F69W54huNqkf+xggLG\u002FNDhcMfxF\u002FHsW9nf1sE1sw0bPCki\u002FzR54Qi\u002Fwu+bHJvWfB18kjNRZsKR7J\u002FxF4gTpCCPZE6JWdWB1qxBGQDJ5u49qvEUyMgGvyg3HWZ5Wb773fSdEs\u002FP06cJXNutpwOi79P0pxmAcULqkXE0vrDZpOXUf1iHLlRrHT+YxXPO4gk6qHGNknTjlnf8AU+MbTOuDZTf6OPBUJ3PdXMPL59j\u002FwzSznfPmEBXnxhi2tBvzluvOCUe4hxr97zSb2QXDw3Q185+GNu\u002F8yzn6a8+rnVgnOv0VA7erp3+L1uSrHcOHbmeqQ\u002FbdupTQbuKZexu5m3sqBvXT0+cdtW26Wv36CS\u002F\u002FmCvHwyoE3wbEmH09997fwT6i+++zKA\u002FGAUukoYYIu7SF8YDGaNO+FqskQK2IppSBe5NvWVqUk4qN6xoy96Oix5RpHJdn0VokXUrp4\u002F2G+ED5Bl7yuNWUReA4mSGWTUYdVAtfjrbNJixrzk9W\u002FQjBVMUU4miJ6aiyuf++ub1YURgg+GeQe2iiVg1YCKudkBVnQJAsdpbmai3A+fKfVnMCqzI1zdteTgjZxDtWHrqrbej076q49yo2sy1fj+Tcj\u002Fd77tmtbmpU88FaPfsrpJMzxA9wIivXh0uaiH\u002F8+kw38ki8gCUflrsI7pF0W89clxr06Pz71\u002FafHXtu82vfvtFXnkRiH3RKmD0RiStfDcpD2rI2rKYYbrfRjq\u002F+e2X5XN+V1T\u002FVHl0VR\u002FoXk9LOXhSLfM3LRjdEyg4ceL05o9\u002F\u002F4OA+uk2TDq9+Zu\u002F\u002FWzzm89L7XnUOMUTFr8A7fKMn1vAKkqTITtfJNYOo7ebbTC9+LRZmIjSuAVCM4IAtT7Mjp51gmCKrqAnQHA5J4cwmo7UDxU+0M95o8gDWlvFMYt5eqbNMHjbIutMlPEHyBgQgsvIMFLGe0X5Auh9H2W2I\u002FT+HiHNWjEI3WiEmaKgivqyvv+DzzF03X8i6p2vnV6UwRrTgEvrJJQTlXv\u002F5Zdfbm4XITyYwgYEAD0AgYxJB4qNRllxRv3dHZOX+q39gSDpI9YLiH6aLeLUAQLPi3TN4qp5PEBL2ZnGTkF2D5USdu2+N5G77ewRGnIELXR+J0BtkaAF0N9m9Cy6ZhgefPLplCQFwpVmVDbtaEZLuyjzE\u002FEOR0WVhRPlY0r\u002Fevabz2bmjWMvTQ7\u002FaePunAvK0Tisaeb7VTrY1YLBd2bW7Un1++\u002FfXwZhxnoGEU2LZgamTKerK+9eRkQu\u002FJPKMT7NedRuz+EEA4meo3zqqtSEX4uyRGMRJznwnJL9+LE7GTKzcvTvjN8awnkG4xITdT8q25ikvPvbdV3V99hCGLbzXObovDtvzumg+w+fNCSpxcaMkVypG\u002FSjCwQiAJQFZPvMyeR8yjulH+z0aw+DXfX5WAGQs5Uq5VwcSJ7vfvdNDndrcA53LB7Sx0QxfSYVrRx2NLcYPDDwuEXc3vhOCgbQYEdezq6Fe8ADeWGwGUBOLR4y1hbC6qoqU1LvVCtRb11QQyeMy+Mix0dLZTx1qpmjeOQE5BeRxlB3n63zyF3Jd4YKS3FaugGQtX5GCg65FrmShrgFwcCM54yMdJ2othk8M20cT0EetoHsASH0OQfVeDimD4cOdTw+Qm+zfIRcsEW\u002F+TPeIuUiZ0AyWhjYPeUXd5NpmwXVUvlUi9oGByyepTNmVqtr6PHZSp6+qS1oySEGJgQybGwFCNL1ctD1xRoA48whIpt4zth5fv9PH\u002FqoP3q080q\u002Frf\u002FWScNPtXN7xoAjvNmxoUvPBZr9vcDTAlCvmsUhl+6+jXxC7XviCTczBoYLLwCDZjDIgns54ZXF0p1HF7xqBrlBj94Rs+dIAdpX9J7uYFMdq3sdrypQev95vGkcl+7V\u002F8aoWVZ2ecBUdwPkbbJFbvSRzhzdHa\u002Fju9t3vhpQTQfdbk3cnWzO+QuVoU0H\u002FfbXv5qxMetnnQAn\u002FnEzzE8ao4PpArKgTV7sz+NSN6WzDM\u002FECyorHSlweOhQs\u002FqlviixLB3ku8CyUszHTjwJrL8dD7Zur5KxD9vz42V9VYnlTTxkhisXJcB+L3lsbxiyH38fOVYaSjTb\u002F6KNfwpGWNjKmZEm\u002FKQ2vGkN2dGj+zfvnq94RTQu8yedcGRz63bVnpqlVt\u002F8YOByf+99ObpPkkuOhnKu42DVH2M8sxPZSHoLjWEury0foDFaDj2NX\u002Fd4Ec\u002FiW3K0xr9ramsHl1wNXy+aNdQzTp7l5X790+ku6N5zz\u002FisZ+AtmtEmbxF92lcr55o98aBLt0AcQMaTcsK13f2nnX1K7eHMD05IJ7IFZrK89uCbnWdOn3KGBEWAcYEUr2mbPxt3\u002F8Emk5a6f+eZYz\u002F7pd\u002FNIOB3\u002FYjzGk80Wn2dm\u002F2O\u002F\u002FxgQJ0SF3VRcu9OQkAJUTq7T1VZJcYWtdFx25Z\u002F9OGlAbE26Pnyyy9GkR2rBJfO2pDgzZtyXq1MjlntOgfUGm79BjqkiwAPCGgjBj+6N0X8FHBo+twUPFBGKd4x1bW5HP\u002FsGSD9m88+H3BL6Yt+TMQ15cRLvnb1txn0r0cRA9iHyoPE0ATd8wg\u002FgAP8igjafc6UPObGEPcDIwDl0YmIlz9eFPtk4NIz5b6904K7\u002FQfuR4e3J63AJk02Hnn9pghT7bFI6O5dUYWmuvK+OQQUheiByjUWhVqQa7pThF1prpcvRRMpOzRu+jOw9rxFLPLgLTg734ITz\u002F2Lv\u002FrF5qvPPw9wZ3BSlC+a3paTrj5ziGQ89QdJ+uvo\u002FYADEvi\u002FHmB8905TcqW72MFUTXkOCGPxTfl3LyqTduRoecxNw\u002F2TP\u002Fm9BLvBaByv3qxyC0WXwROhf26GJIGS8\u002FnWW2erz36+vny3uVu0X+qQGZHZHEkErXGeDZBq48H4SvUKDpZ1DB9cuFBU9kRAMUW2+2RAUemtB41Lgpcw72san9IBGAFXIr+vcZ\u002Fc9D5nWmqOEqQlxIxe6qDxUx1CPitngSFdU88TRUoRpJZitK6LXpmDxa94NmHGn\u002FP2T\u002FfXllFGPlkcSqlr6QB3EiVBJ+d5PoPGOL8bGFbz3qr+gwEoBoLhMKtCIeADkUZG32+U+EQ9OB8t0BplhYC1g\u002FED1jlyQBWlxRkxrTnVMWqpqgEHqgS0q+vxz8UL5yaSo3KHNQGeB7x4AzXPeu7p05X9PHpiNgH52c9\u002F2ULk25s\u002F\u002FMkfbD7++ONAcNVYcjQ9mwIEkORz1vSJOmkHOXz2tDrnObf6YSErIMjZzOb1u2htfBmd1MgH7LYOOsMx90bLbroi0ylRfTUDk3xaDDnK00hEH\u002F0gt\u002FJ98Yuyjqv066qYsRZ2cfAyREW39uUYTNnAGrOb8o3O2o9G7tugLR7tnsuYNLYZLuPLZhnLzlr80lDMbpf9pkrJTAl3jobV6nUvN3QII3XcIjgziyKTQB5jqK\u002FdasCjy18XyDCW1tTI9d+TU3co58NTp+JD4w50dEU8XRWsb25UpenIprWX0br63UBuAObgAbM4cv4DDbVDHXYl3Q68bD1Qm\u002FLQ3RbyT5Q4EPQqvt0Vvz6Pji\u002F6fijALFcduKST9dss14sX9DPHvshf7dxXOVe8qD\u002FSTaQ4NdcV8+ZEciyzD6olDA2jE16kS4BAcsRAkjvPmUX16b1Tp06PvVEWz7N2k6cihoi6N9oBG6pcjOPdgsXHLeJH6jUDgf7LnqSiyoMXJQzQxCtoOUUOsmFvngAuZKd1EwEl6SeqmngnuKNjAIW9+1GP0U5LFKHXIOkhZnPx6IHkhx4ZYx+v0t92vST\u002F1ihZW7AHkKWLauNe60X2BjxrHMBvkS8dSB45\u002FE9rl6AWu+OZxpBsLCekp8cvo39SEAMYOEPTqvkYPsNrc8xPHuqFh9G\u002F5yyHMJ0CfODdPumOSDs8ziDjyfycLl\u002F0dIsB\u002FrXJ\u002FhocQrd\u002F8TKadO0CUVE6WtBVAiJjf+OLgwcCmuGHF+Sq9m9nG9d4tbagINqz3qq\u002FkFR61VoG7SDD04W6wQR5h4B7ZOe9oY9KQW1m0GGlfa83g3flypWCD+fST+er1vJFZYdLtzv19ubk2XitAIdZuMddf+mjD6s09E2a4fXmuxx7dkgggpP\u002FMD62Rk2t0O++bT1bMnP40Knk7IOCFx9sTmcfpWlxKJ6ny+5WNMH6nIfZcQA9aZ3Zh8cP248imSLlu5MjDq\u002FZfrODXCr6hcNiUeuuZrifFdS8e7+xzV7hrbPNMu8LL0mnebWrnWxLkbmZLDyM5rfLhd\u002FTPQ+nV8hagzm6hX4hq\u002FiYzjLunADPnFS8+KxDnQ4sYxmfKNi78ZaCxSbQi46N09g4+HtmTvzd+f7zP3bDJ39vB\u002FEB\u002FqofHcc389l3fWZvO2N093An+UmmRdBH7\u002FedTTM7WOOH\u002F+kMjjO5YDeVgTW7yrae6Jh1Zxxijj75gBHw2hRy6FljU6PTdGP1ZH5ns8bO9kmGp4\u002FxONnQNjw6Tk66gE3gUP3\u002FEqjbjOLdyua9SqFZ6QzMiaK\u002FfhV4jmCT81SHnkUoOdnKKdqYQr4qBWDDArWW7VZp6l8ONwPJoMoVlnc8Xl\u002FMAzRLZTmY4uJRnQ9cUGaiD\u002FDP9as3ZhGHhanvvPd2A9iQd53ty2++uT2LUeWT\u002FehHP9q8OZ6B32E+0++fFekTxT9bXqdFLrNxRAxzooUnBl+UiJesQoGV+t04xdGOnH36HWikEz+4dCkwS0k4xeYibUDEONVei1EsjPrTP\u002F3Dyiqu\u002FHKC0VgXcX93BEYtegbp7TNvjWKk9O9+F02GMWLqUWYWwh4OmNsRr22MJ0euqbPSaGZqLoDz07\u002F55ebK13cy4qea6Xhv81\u002F8sz8rkv9NOeu32qHxxeajIttop640J+hBz6EgbAxlc6NdKYGvb7cwNVD1ztmmCi9daCwCALXjdYZsb1r6RRH6R133JuPy3oWTCc57eewvS7FpceyLIkWl0+yZCFQR\u002FAS+\u002FViaiTu4uXMrpwbdEpa9PY9hfVJfrB3Q9zB6NAYUAScltg4X9QUKHjW92ILU6PkkZ0O0RTSF8FE2HCYGzlqHMTqEq0EZZU4YU+7ZoYyfnQsJZ1GHQHF6Z0DNgWYY7E7II3cv0UD3OtqUpkjnGCqS3G9UyjaqQEmkr3v17MadEZ5XXxhRY7xVUrNwJ8DtfkDojaLTv67fIiwPWxz7oJmMmDyesBlSEaUCWZT9q4yOsefIyMWmIPYFIBjE5+XAOmaadO\u002FzAG00VwpPFGFPFRgYRRH2SZ2xAUZRlqVwKNacocDPROkygnZ0fVUe4wCDZo3x9tOMzgLWRwJlh5pJrhpMkeojGYOf\u002Fd0vprbwpfcvzsZjAM0YJzQNGEflAd+owmkS8bIJ0pPA077jB0tLu1g6nFxnijkFHV+9qlzZ3iod2ADrZDpAbvMBu+4lbyI6pqb1DQgfOY1WUn0mv7Tn44EHT1q3EEg82AYdj8ob9Vyb5rypP6bVGblZ1Ne1DzOWHBjtfvEcSC7QkAP7tOdabAjEMTpj2+J\u002FOq3W7rzXWKr\u002FDajNORm9IEepLHFCenFXPAzf4aVxMqI+QzRrBmKnBWpEzOK9gBgeKsNnAg4AtMpJInx4Bs8+aTzssPjO+QvZw26cARItf1rbbCDDgD0qcnfr1tVSBa9t9se\u002FUtEOnre2JVmpnXLN6V9rOmKNcer2HQiI5JBr3QCpzntNhhIaEboXr57UqGZAasOLZjYtume0XwXuTzYzSt9BTaeaYZPagk4i2XQfI+fz26LgrKGoYbesP1GyPwDyGZf6eyDaAzOP05eA3fUWMn\u002FxxRf1u+hkCys\u002F\u002FfRHmyvpeiLHUQfU7dw4M2kRTwqOEnbHms0UQLK478KF86PvAGizZeGaATfoOosbu5vc7OfAebwwoLP7f\u002FddvBevHM2hxEMzhtkNYwfc7Kt9\u002FV\u002FfrTdpJiKew3\u002FKyKqEZBb5yZN4IOdk5Z\u002Fj9e4\u002FkDPnI+cwdTBBk2MtKtybTKf5+k7XJ49ykJ\u002FaafNEjpmFh\u002Fvqh3VXy4kXzLIo11qTSRcM+E60MT4XIEHkAUz1ZUXi47z6SS+xj8D\u002FTN+no8zOeeEzjhbZ5xw\u002Fp8caWzM4fttFn0Un7aNbARngB1\u002FOgtzas\u002FJ10SudXP9EPjE2G4kPODmrFvfifw7LK2Hh7jezqdFyV7TYnyw+rpzwve8qZXz8XPcvvbIxM\u002FYzk1SFLHpNHyZVtn6xB8+rhELn9lM0bEft7NGh7KMZfAE56bPvXfpoc\u002FnKzXDBLzeXs43\u002F7D\u002F7Tzc\u002F\u002FqN\u002FtPnLv\u002Frrzf\u002F71\u002F9x812zy\u002FTgvkpIiupLizlqFitavCy\u002F\u002FFXlNundx4FmaYM3vm4jrkPtyPz2pc2pd95r9nqt03ieLrp7+0a2\u002F+Sk0zwuEPc03rZp3N546bDSyckghwxglyZq7V2msX6mOyJdE47ztyDkrmZhnxV8UFaVTj0jLScmfN5ap4OHP6za077N519d31xO1u5lY09kc0+WwiO4R58Zq6msVNvZtL40JoJGVEny3h\u002FsD36WxWCsyKoZaesIGtR4PLvQvSeAUps4Xdu38aUBjXUD2idt5z+960Y934w7nLcFvDCX4MhcscNPs2C5v50nhUwA+BB7XaDN2imYQRAAblj8vNru\u002FnSPLAO8OY5AHYAdZT3g6a1Dq58c56lwlYM3Np1OrbXTtnQL54nOoMPmHY8iFr01eqLn0Xv+m+vJ4w\u002F04gr9IC+dASZPFoU2LlMKqPJUoiyA93hAnfPlF1\u002FOACl1xBsDKGdL5QaVwbXRjSmlhwkHDxJDMhCGbqYYIwZFx1tCFIMhp9ViQwwuOii15ezb11sMenMAMoY0IJNek2E4d+5c9xB9plz2FOE93bNjmC++SPkBKKnPtArwa6qch2njkKlCUZv1FZAW7Z62dx9Rdqka5\u002FLcRMOfpkDteiYdx+LX9z94v\u002FOPj0NiRTrJ+PjjD8uRu9SCkpv1uTJOgQNpAZgNeL5desHN7jcVXronhSl1SH69RSuiXJSulAK7cR1J2PVngGWksaAT3b4qleLf\u002Fpv\u002Fezz8\u002F\u002FFf\u002FbcZzZebf\u002F8Xf9WW23c3H3\u002F6yeZXv\u002F5Nu4\u002F+fJ7rWQ8DT1MbfaJgGZ6A1p7ystRoBtgjTnntTYenCKdGfMbaotHDOVVHjuzfAPPaefjoV5tff3518yQAZkfSE0fOJuyvav\u002FJ6HlvlDtALsdUuxkMCpGCFQXlnKmhfHCnkoXtsnt4VR6ube60BsLiUVGliaanZFLZ651WFiHAX\u002FjHJwDAwKYuhmYWhFBSEwHrXK9R6H26dgB1SossDljtEw+NkWslrPsA5slpL0qHIlrKpy\u002Fzu2vxnu9zbOcejlMMnqOvr4qeSt+xLuJWdFWPF38DhnhNFHOr\u002FLRBlKKeefDIhOgJoI0\u002FePX4d6KJDGwOE5Duep1ZwAMIXfxPmZI71+lnl\u002FY3hWyjsgBYvP+kTWQ4ucqs2rmXbChpKu3qX\u002FyX\u002F6IFpe9trl69POMyTkaOxqUq+pjtEimVnkG+7rYeYbOriHZ\u002F2y\u002FAFLdFgO5loaLIvyhxnDsGh9Ehs6dPnxneBNh271FCsvzdaB+Ra\u002FPicalySM2Zt3bjzOkHdffX3U9ZU5vnSO8IKPRsfSAzX7feYiLGtfOdZshsBHU\u002Fh9WGUvr6uhmdQ7uacYtH6QG0M1PYH8MLY2AkeKWHpJh4vjajndEBQnebIoimS1XFc2EgMIiDJR2GQhedxSH+YdqWwexZZQBgL4ue9sYnziEjeJapsw7leCUvOV+jyzIMk97VVRIUXgVS8AJHkA6S5qaCC52rkoiF4QDwPC+6SE+Lo6KxWYiclJ4FbKLFy+4FtCO6VDzR7QEvnYOHAdHlNKHHjix3\u002FvQPHWobenFQiKqdI+Xbu6cAQX9OW4ffGe7u+zLwpcQjufiuaOjly1\u002FlcNwcXvrwww9zMrItpdWQI3K+AEsGuT6KtKm3jKKj\u002F6PzANJoiSaxzoyh3wB0gPSJcrW1bdrScbLQSd2f\u002FVnAXenYdmYfkKojKsLQ928ed\u002F+t85NzTL7XGqaVtiJ\u002Fmf7RP2PP0I+d6TvDzjkU3VyBoVq3k47j2WZaj1c7fcoXChr0HzDOhq3ZkMBiOomMG4Nur+GjN\u002FQPePXWafrD89erPhoMvzuw\u002FQfYcNg1vbpkrvM7HSPf3IyTZyMRQo2eQ9Re\u002Fja2bGJcPLTmDOJb4wR40Qdk18s9NZqz5lptHD3XlcA65\u002FvlvoUv8PLaELFnpgdXmqxZwqLCAXotnvFKBjkQZisFLowrmj0oj9s6MRunSXG9fPnL9jT5ycw4\u002F90vf1EAqyotRcA\u002F\u002FPjjzX\u002F\u002FP\u002FyrzanT72z+zf\u002F1f+bstStza7nM\u002FKGzcSJrvA\u002FOkufv55yRp17fhnk+z+7+8cl0UUFJa7Do86PZyLfPlzKb\u002FqErv0vX36jAw\u002FVrV8NJtyZX\u002FkUpqIdr35Fmtna1hkSVoD1o3L2fVnp3+CSZty6HQ0jn2VcjzTY8dqj01bq4+ebuw82X1\u002FTn7uZ2QZGzShu\u002FU4GPAoyHstNsGIdftB6dJrWrMV2zno1BMjPgtudO0CXdXDOy1V0TDRLRGdstXzsHJ8EvxoB93LV7gfBhpQaH\u002FC\u002FgHyjumQC0m8yYa1F\u002F4z184NkGdMazvx3DR8D6q1dmRpfsAdfaOjIU7d0TmEcvQH2rUwQUnpNzmDOZYm+01bPZiP6IpsZ2ySjnc+QmD9o5W96v4fM8Mo4I+o+XycOB0mLSar13hGG44Xf\u002FZ0nK736f0hHKsa7TwDWCIcD5yjO+k0K+dv3aKAcezJdffBUobaFmQIQi837vvYszJXGqnEo5VKdbUAHM6rjIN6ClXjgwY8dQubDAGZCnNJ96zgCzAXm27\u002FlKrbh0aQDuZ59VjaQ8eUqaUN8IYPO83qlMmGOuAYq3CmLSJgLlt775ZvLd5bwbbAs\u002FAfOPPvqgfjbt1DT9N9\u002FcnudSpAb66dOiNwFm5x0PlIuQyH+9US46wyH3skNj2ERrTZ3J79TH\u002FTH+w4cWrLT7Zgr43dq3NhEJGHXu5C92LmDByZkyZdGFgXkQUBZlpSReYK64HXN\u002FeOn9+nm2dJwHm8vXrmx+8YufxWCbIvn\u002FSQDoWJVafpUU7Jna6L\u002F57FcJcAtJHwUaq+8KigL6AJA+HMiVP1wUx0KWB3vaIQ2T1lZKc0piBmQ+yoEAaOT\u002Fnj5zZrZrfqsZgb\u002F9xW+LrrfiPdB08lR1sBtfYwlkY\u002FbHReSPn2zhTmMxzJ5hF5EF1NHCwkazJaIAW3o+SugAvZmq6jriMVINEfU3wcJvxgWfMOaOG28CJ40In1pM58Vw6KtPwilSwIgx9qIVpneBDhF4is3dLJZL7fSfL1pAuewYiK4dsD8Kp9\u002F7rEn\u002F4B19Gz\u002F0Y+invYxsA8RZNa5e2v5dkUBK1E6d2rDlVdePEqq9+jRKxUU9Cyia\u002FgFvGTnTou49xhcT0Ii1fiIwOZNr8fWaNpT\u002FaCqQoatHbheblOvceADn588XNW8RqJmxbRqaxZ3SZf72b35Wnzh2ewasSwsT7Zh1AvHvgQOluZQqde78tcD9zYzI182IXQiMVNM7MPPo4a2ZMh\u002F6p8g5rmbfZs1GC67wCxB5p1Ki6K1Pzynsonj4f\u002FpY3+3LwHFHE1PVNlySo66C1OQZJsOiMaKaQKY9IE4dWVtxq0RC\u002F8g\u002Fpp84GmgOJHiOaCpjPYAnxY4PRA4XPSHxfq+d+1volQmYNizHDxiNmJF+j8\u002FSMSj5Cff1bZxAfILq0f5Z\u002FejPRf\u002FahKb4+UXRYT+drSTce60HEh2Xg\u002F+kGQNyKvLLcJie3zs8KmKbA3yQc9UUec5O4aF4ZDkeomjG7EUpMq+blZnyptHH\u002FgdMzvOitNLC8D2nBR+8DvRMak79dD+9l6ZCr0lplOtuIS\u002F9hrcXaKvHyTBwTpcMYI5+eBtRXr3OOehG1gZwXuLWdJ9KNc+zIQVeAun+ZmQ\u002FaM2RcfsOH4xhlVlhhmNuNcfWok7gO+cvOuBhVV84bzMj1RikDoa+dKZr8brxGTCdbtT2\u002FqnvdMySD1Jhyr6D0YVjVjSOHmwM6D8AYAIO\u002Fb1r904K3mE8U4pR55kWd79ZaxRPGRvt2A2cz3gDuvRUuqVPjszsEhyPKce40gRVphIZBDYCqk0NoOM2zWocdmPfNfpAb+gH20W3+3361P0Bi+1r6LfTBkCJfnGd+5A3egadDwY63atRX7qn38iVZ6lrLfo7C5\u002Frb4QaPvc7HR7bTb\u002FwM5ld\u002FQx89Sj6SfvcpybOs8kaerL5NsITxLCO4EVl8hZ4W+2MW6adAKIX2dZeEdc9nWs9AJDIoVMdzqLR69evbH7vx3+w+dGnn1R+9lebXwTW\u002F\u002FIv\u002F2p47F\u002F+y\u002F968+d\u002F\u002FuellZzY\u002FB\u002F\u002F+78uoPbtrNWy4679BDgG1ra9eV1619C5HPPG56m0yzrz+W9\u002FPYvl37v0YWPEia8fAevjR97aHD1RtsDpZ6XIPN68+94nm\u002Fdv32r25UZr266WVpaeK22Fuw3g7x5dUX\u002Fqy67aD6i\u002FLIjwJlouZ8e4Ct1Ys9EYxAcH0mcwzskyHa5du11ALV541Ux+8njmLU52ctb1T7sPLEbazMjTY8Y56R5aGrs9o0M63niwK6\u002F6bo2A2cNJn2mslh3K9uVc4+Gtk2d8+9o4siELwBvb4ckZ43W+di996jlbvnPZ4t0B9RbVd40bjp3uQXARPlr6OJ7pN0Cdzp50VzyX\u002FMiEgBdE1\u002FXXGw6E3VaJ2eXkeR6e2oELNXy1T0vIF37SFpiMCSXT2jD6KtoRFxxsyMbR0Pcf4LXnf+31A9xn8\u002FO\u002F+N+akjo2C9IQDnABKk+Ucz0VSJpKtYgLEY8UaUYgAqN2ODBy8b0LIzzSWXQVkLOTJ2NKOcsHR1y1nV1rV1JT3NIYCCRBVmN9on4pPwzMUIikMYAMnO2YrcQ\u002FlwNhoBkcixBNqYpKqiYiOngsECsSrh\u002FvtADk4sULY3CcL3Ip70lt8ltf20Gz1eE7UW4Kejz+HIJhlgZQ9QQ5UpwBoEROO4WBaad6RikOFhBaIGXwpyauvvbGddqOjh98cGny++VYic4AsKaivPVt63UqM8f4+\u002F1C7f74k4+K5l\u002FcvPf+hWEo6SLqE0tNsitowxGQ2hutvyvifi6wrl58OX0xuClo+cYW5wKgKqrY2IgipFy96FJAY+pe1w8CF58OmDpz5nQpDRbSHpzogc2MlG48EcBTbeObhEeEEyjk4Pgb02sbQdtGwkUUzKIwNqIQd5ppwBOURo+KW5ZyZ7iBOEpg\u002FbY8ZfRxjDIROZgcPAYqzUP4BtwlWQ+LjOi72QBjif74yFimZnp+U2XzRCDFtFlKxRgB540TwMOw+nurSJBHC8kDHTMOQ7fDs97GCi15+5yR90pFwt82DtOGO42LF\u002FA4\u002Fer+nuG5bogmxn4AfPcHzs08zfEdBaYP3mO000Du422gxtDRwH1FY5FSADVqRYf9yeTxWQz93kVrSz7Y\u002FN7v\u002FbgI1KcdPzXjhJ4ifRbX6Q+H9mZ10m0MZlwADPxrcy81gi8GLEUe5Yja4KpeTHoEgCNtDP9ru34AwO+9d25mnQ6XlypyfeRYaUld8+tf\u002FyadwNlfecAdil6lonVDEdj7VTOaGaXoxKm1iyOZpkNWVHrRAA9IpSMTSEKWKW48E1yKJ6U\u002FragyMBbpG28taPYn+Rj+iM7GVX+BH79azGttyYrqdk28DSx26pwrzUVQYAA+ItTOde0CNR1pLOKljqPHiupL56lqVjNUQOgf\u002FeSPN\u002F\u002F4H\u002F9ZstMeFi3efpwToZyce+ErhpTzRO+RxbfOnCsy206MOUt7Sl3ZGw8zjpOParybKl\u002Fjz0kLFHQr92NsPVf\u002FEHiisHgmvpfyQke4hxQEudc3pzLU\u002FeEHs1YzwzjnVMUlfUwve5F3Mql\u002FC2QuB6Ov6379jqfMcly7erVxejI2hPN34cLFdMizgNUvOxf\u002FNgMa\u002F7jn4m1GNHAXLcgimbpXAAa4NFM6eaz161kALhU6Y2pKf2YH0kGcCbp+qxu0j9Nhytzs3\u002FcgttHWfnqvR8355IhNQyf98zc5wyvSaQasdxyQ1VY6jwMzwRah3xw4z7OwEq\u002F6BFLJCLtB5xsT1yy9KHq5wCy50TZtGR2hTfEmWgyY0dae4LcB6z5ry9DQ+PY\u002FkLHVMWinja51jWBXfyybg0F6zTO7aCtX9B\u002F+ZkO61dxw7rGje7p8wJhjIroD5hzrVL\u002FNq8\u002FVLvzPWcMH1nK10LbIMGcSz23bBRhqNzrMWgg07z\u002FRdLNJdbFZnexZ95HnbdZN8AD+WLNxVbzKORd84wxJwbX48Pd\u002F\u002Fw\u002FSdz8KZ7Rm69Y3BQWVU8y5ivboT3eQWzaDbVCxZuhsnJIHjgHa4qsGInCHjvrW13TIvkLf5Pd0G3mdO3+x93uz4J6+lLa4UjOVNlWmuhruBXHoyAcWe3ePrQ4iZ9LdPM+sJOcuFpnAhM0XAcwDs\u002FZGul\u002FFMNKn2u\u002FcKX9dn6TNTfpUDuMC2ju2pb7QpWO7jE8dMPL4Gr3\u002F3vnjyC15H4cquk8p6WR48aIxwpuL740r0GvkRwewU7VpnI14ZeQqHtGncYijI9lbdneNNRvpTbbcl54anRKtBeocdx9OtONeo\u002FNilsXb4ZzGxnnd2P\u002FTz7Gp00uHa8vO\u002FXrE8DtnFd9vF5MLTEgZGxkuUKOf+OG\u002F+fP\u002FeZ75u\u002F7zgwH1n\u002F7bfz0gHchCICD766+LgNQZAgyomtKfjnVMjhslg5nlCwIipu1sIWtqRlQaEB\u002FBS5FRtCKrALzcskgxpQcJlWsB09kSN0UqbxB4YGyBchFcTHU8AG7rZWDcNDxii8RPfd4A8JmiwBcvXpiFogTPAAJ+6sFfunQpLOt8KwAAQABJREFUoPJhQtTunv1HQD3XC7NrJwDtU18nZ7w2MxzoAYgC7FeuXptUD+B8gZuUTUzJ4Fk8uoyejUweTx4njxpwOH++PF3PjmFM9VA+UopE9jGoPlqNzvib9lGdA72mJnXggAN09vSZcXQwIwfHIk6bTnm+vz+qio1IuxxeQNiCLMpWxQ+bzbzVjAfAMylGPYNHuj9620jhrWY55NEeBLL7pKzTYHPu6a45346SFgbfaP3CTIP3u1kLuGIEKhoZL+MBLAHqo\u002FgbZ6ARaJfneLc+28DHtNYYF5LT\u002F4TRbI4+d8tRTASMA+c3QAn4IEh4cIH3FGVTuHJ1GU3RegptosDdy8t4Gm\u002FXEVbKldISxaRq1+NrS21kGLaRqgHmjuwoBzBOexjNUShAvfZ0AzIiuqbv7793ccYQuNU\u002FShkoNs1Pi7jefVw34KnPicrWFo0Zj38HVHXanEvBUtxLcS0QQTGhr0+8wUlAO7J3Mh54uyo+53JS7QR6Npkxk8URJxNy+y9XXpE828jGGwC+du16Ec6747wCZ6Kr+moth8XiFh0ypp\u002F99ovNz\u002F\u002FuF8lBuZyNM6VIoaM\u002FMI0enHhTzXbeO3P2VMagiFhAUk39ZXyraNC4MhKzeUx5n2\u002FlAGo\u002FmvfYdMuaLePAcfAHPMV3fpfihu+NL4UNYHKq0XYctcAkMAAYMJIPikiZmnePuKLjOYHRFHAyToAU2jfMYwgPy6WPVqLDK0JkwdYCM6bg0X2MAx5ClBpsoVXdGZnDw3hy1H393BpFm8ABz5988snmn\u002F\u002Fz\u002FzwH\u002FuN0TPqjPGkVMtwzzLr4PR6ri9hm+mWb8jctdosbchB2nNd4ZRZQR18lcu\u002FfvxMvlvc649cMQnzJGSIz23txTNFJv+WBW4gqiKmvaFqHRh\u002FjYfzixfADpPQevSF\u002Fng4VHaU\u002Ft7JMbzB6Fsk9zZl\u002FmC4F1L+9\u002Fc3oa\u002FrPeJ9qluSry6VbtbZjZK32zC7V6cY1RunlxgM93E9ZR+CBvlEdC23NJll897za6NnW7gNYNtOQ6jLWQJ1cdTYKGOB0Lsd+OS8rZ3cunHHnWHWTeT5ZI1\u002FGE5+uHapXVRjgdFJU6PLuT19yXszevJwocfwRaBJQwLvWNEkxJEcTWR+wYlDxCzC1xmKBtGYVMH\u002F\u002Fd8b3+sJ4eflXi8kA4LLA8AIwfsdvzkIfOmY5mEtO8ClaOoU+pndcL9KLU\u002FV3tYWuW4BH+xavdK\u002FO3UZLNXEAevecG3aBlCmvTuv5HJnVrn7puQUzWnMVyQLZJ0dnCYx4jtTAWdfRII5DlU1aPLD08QSVujd9QNds7b4dS+mwK5fbw6EZX4E0ZRrZH9c718wwHfUn\u002F+iPp5+rWEVrWdj\u002FeGtoEMP4rKvppoV38D3Abm2BGUp6C22UHX3Ve+ScrOK5SMAmHsw+Hg20H2xxvYXSb5XCe+RIexeUyvImecWrN2\u002Fd3lyriMOdAhF9zebm+Gpvz9qXEHqTIXQnu3dyLAB8I3uoaP4CqdLCAFkz5C9yTr6Lx1SRs5YnHs+2Lb6oXbVP8A8OmDfcFm3Y2nEcddrdG0fj7L30acG9jgHeggz0rJFe9mnZ4WG1uW7xCjttQIdHks3hrfoC79D5vvudjcU7Xuyal\u002Fsa1zlv57cRg67Bx2TCOMJGxkY73c\u002Fnso3sEE5boFxb+mna7BxO\u002FDiDtWcch9qgHZ4rYDQLj9MvLsBv+uD13\u002F1P\u002F8t8\u002Fq7\u002FLKT5u96l6ylyKS0WTda\u002FGKRtqYs8U8aMJCICvdI8gFBvxDN9N4tHA20WRR4q+qquMoBtkZdICjDqZZqBYldVhkMg+nm8SLQIPSNAWCyIO9JiHMBhPeN1lSzOD2NdvnwlgX4xC5JMf46hiQFMg7nfdoMJDAwcARscjq+eX65m9MWige8VnQoQJOBn5Z11D1Pk+ro1Dtrhd5Ejnj3BvT+5uSsqgRm+KQfu\u002Fe73TgtWl1JdYI3yO5YnjUEogq\u002FbIIGxUEbq8pWrQ1t0QOvtNI7nMnxAkejcGMuYSnm0e3dTIAmYvLZHzRjI3zhSPvC7PZeRsaMXgHSw6fK3z56cZx+N\u002Ft\u002FcfLf80IxGzxbFRBs1rK22l3d7rMoeZzOUFo4RSgqQIyL\u002FDsg1DnKAbTuv7NTJqsW8ffYPN\u002FuPvrX55Vdft6b2wRKWaAFIpwaGwU+Vu84gLoCup70CSgRVJKfTJ79MjuN42AkkgzPCNork741HhJ3jPtFGOwmRc5Ow+e5YqjPBa5FzSs17FFS\u002FE7atI+bYvE0Bji2hkJaCGlSkmd4JrucRAALfSRNlBJz8PoDCKf23okjLeDHkjDCFcjd+QjuzHaKbHFYbRYnC4SW0RR\u002F9thDndQDN9QPQ+m0bCZtnO6drgPup8xyvAAUMjBZ6nn4AFY7N5j41m74cpSUXsT5xHtX4V\u002FaRAQdIyLYcUXTSNnzPqSD\u002F0mHOtygaL163aVhA7tKHpbSdfjv5Tf6+\u002FCJd0UxBz\u002FK+mUN\u002FQ+5xSs\u002FbDAu+E\u002F09WUSfQZYjf+x4QGdRevPxRx+NowfY4xnt107Xc3hsenK3HM3DR3JCWkSFf42nqL2xPDL6oWtro0g8OtE\u002F1ktQvvSUqHVJbD2zlIPy1jsczUaV77ST0t5JC2kKGX\u002FuPyQ1p\u002FzSZOZARm0BIryH1kA9cFa3Rdejr11cjWmN6jtjn6HSR2zkhsapL3iVvnP8vfcubP70T\u002F601KKPujYA0pqTfS22a6XojCdwxYkDCGeDnkA4fnvecY6HaVrG1jmTk\u002F\u002FAjoktzj0oyGBzmEB\u002F7Xr2FLMzWCtKCchzxukNTTP+r1pXo4\u002FjlAUq5XWaQQX0ydrIac9xzpxX59mE5RiZDWl9RXqPONEFM10dMOASA+t0LB6x3sHsKh4zQ+DYV199Gf3jvYCFaydC2Di6WdQeHWddEZvhfOOvog4Tr4oJ2ZmUl8YUzciTCB99BqCjmXPZXLNAqltI8xO9nJmExsN1AMwM1YyUIA55AGSkCVW5qT46BuRa2IwHRC7Js\u002FTHJ0VHlU0Fml4H1IGsfaVw4tO1QHTX6Pv79x9FHxFEedJmP2x8Vx+SFTaBTjdeeE0vR9d1xMu9Rgf6Yuw6Z86bc\u002Fv7+xcAQretY05DAMBj9JvzOkbu8e32zG65ntEf+BbtpKbsqhDAYm88mD3phr67h3NGj9bf79vaj+t3D+7dF\u002FzPjikb7AUwba+js\u002FWVUyaVC70BZG92Ymx59ljZRuveLJJ8\u002FlyE+Wn2q7UpBSSuX721uVHJROP7ztv2awg\u002FVHXObCZ9wFl6U1nkjz76tAILRza\u002F+PnPNtcufxlfVSe9AJdnsaP2ojAuUl+UX5ST3lxI9vT15usCXa9ettFXDpjqVK8D4IcP28+B3OJ\u002FaV9FmGvn4fYY2NOanXoQzrjYItp7m\u002FuleN399psWqF7c3Lj8+ZQ1xtdXb60F\u002FW8dP1CBBgHN9FzyZTbowJ74rQE6EHg\u002FHF1mxjHZoDPvpBv3BsxtUHW3qjAWLR8\u002F0dq0EwHa9BeaTpSe7I5jngw0roIPxmpku3HAf4JMOA645YAuW0TPwQ\u002F05XrhH+C2UxN2Er6j7\u002FqOz\u002FAovqSXOKm+cxTcd2ax+j6s43z\u002FOZeu6\u002Fg6XxvSA3Rq1zhrntcnGyGY6zq8yymmh9xvdH\u002Ff8ZgXHIWHB5h3\u002Fy5pnLDiAuzSrkau+20WpZdS9PJxei2sQyLwAHtrtuOHev1gQJ3hNY0ERIt+U1S8SKCCUkY8069yXEVogGL5QggoH9mgehl0kTVRk9n9LCWKwXhBjAHvRdTsYkCXsgT0GUUDwyiIuFOGvGLGgnIHKD0b6H\u002FcMQwAnFOypskH8HcO4nsjsCoAmMCUlSlPL9F722B7lufzErWbEzJM2H1930aO7rVY5etbXw\u002F4olAMPiN2f5\u002FyijkqMbpoJsUMpL\u002FKeGIeXAuwn63N0jEohN\u002F+9svaFdDqjWHQBj04NCLpIlsPewPtaG0sGBALZR\u002FdTYnEfKIxL5riEo3WRqD8WfVZ7UT4slKEDwId+0pNsSCUx\u002F10ainrT1xa\u002FdL7D5pebnHn65dnAmMn17Rdz6MUMGf8nMJcQHJ3wGFfJcsAJ+1lSEVsORbPqppjatTYoy9FzGOd2ZjuY1woiRG0lLt80hddNyXXMkYEdBmahIdoEKBo6BMP+M3xEerGZKJ0tWOiA9FGe5aX3r2LcnbK0JPh7NJey9Dw1edZjdMIbQZxyvWJ4Fh0V7+db+xFdbZKwYN7xIzjRAc6aYxaz3kdQHPeKBjjEL8RaqlON8uhxqvGmKOH1+Xxmz1ZhiAlmlwB8cZYm568rOpDynb6rP\u002Fo1rNXdCvF098M4iilaOSlbUuZLUW5DoMkC3TJJ5by8SIgICUEf6PX0KBnTqQxJ87MAtoB0ZOjG4\u002FrB9n48Y9\u002FnAJ8tvnlL3+5+fzzzwMlL0vBKkKYcTArdbb8SaUeycss7szouJeUESD9QKDRQuIjLRIX2bZYCxiBVfEHsHanhYRvOrBIvZwS\u002FTua3sEB3+Xgi15LFzt+ojKvjQOQalHy3j1nZr0KWNwwVn3Igsaiq8mQBYrG50g7a+6LP8dpDwzfrfKHscM\u002FW+MguvImsIg39wckDmYZVcWg0+STihyLojHm0ikAfRVIbMZDqR84XtQ9OX0TaJxodO1RCnByuvFiRpZxoTMB0ZMZ8E8+\u002FnjzwfsfJMdvxjGSe44vngNGEQNMJVPz98hmshG\u002FvHlZulxvlRXouJGDxvlREVv1mJ8FujnG+3sOHYevvc1+olsqJLoYg3TZcMsC6PTwy6LSyrxGhuF1xpY8eZGTWfAa\u002Fel2UUu\u002F4SdgZv1O5ujS9Uz3ku87Gy91T3qekwVIW4iKb6xTsAD2UOBVgyKtIY7GCEcPoXmOjDHo3YNqI8ccd5Rehc8DKC\u002FLt5VTzICrSvJ9Osa0nW4u3791NxzZe6VfmHGge9mXyJyjkHHu2WukOn9vM8Tpt1V9KDnO\u002Fu2rnJ7gkQWHInuIqQ143q7baGA3ywZ8nJ1de5qlmBmYnKSipkAkoK7uvVlPaQpvWgNhwTPHWe49OefoLH2EBose873f8GzN7NnpiWg0ZOoIPvDyffRdnVpX657zvGtoBwFkgIYtm+P6bdD7zf09AB+7P6eIMzrOpxv2\u002Fv4Z\u002FWH86\u002Fbwi+PrBJ+rTXPfdIHjkyoWDeXim4HR14nS1n986Ryyqb0CF16caHr3aDLTkwYXLLmqJGyzc6penT\u002FXJoAHqvT26G4pmc38tnnbmcD7zcqZPirNRIqe9Xc\u002F+9ufl\u002FZ5cCLsf1R0\u002FVBg9sbVy8PH\u002Fk4JxA\u002F6Gi+lM5VfpMMFrzL1lTL+anOkvUsOVmr4mUWvjwoOHBQMaB2JEqm9X1da+HWyySlMYHtX3eRk2Odos+VvnauCXVXafvyPNve+\u002FXpz5dqVZpS+3Hz79bVKVhYsfChSv\u002FLN98Y30muljB7gPNf7PbWPnlGfHRa5W6rcvja3o3vvPoQ5Cq6lY581ZvujLZkZoJ69svmkdFfvcUobXzzT8M0YwCUoz76yZYu9VTlSkSgbOzK3aGNsxpEim92nRw0fYQzciafGjnbvnjK8tmZdm+li2zpOepXh9Vq8S9ctjIH+bBtgjxfcxd9m6PuzPukLTMLWLCwwOI7tT125\u002FvW0Lf0XP2uPV1w\u002F9\u002FXdPi+x7Vrk71nRldytQN+SFbZq+jFX\u002F+7\u002F\u002FGBA3RSkaZYV4W3r6KLoQCNiMHo6CEQDboCvGuWACOAKhH8TsERYxt8AMfwUp0VmapYbLPVyKSWbCdhdVElBKRzuC6iZgpdvBYibdgUEvUS9PZOyB9B5nQbEdWqSAzfAOrDciE57eVwWIBjgie4HLvQB4HHtgHdMU7RKPycCucMsct+w093aZwGbdpj2d78tY92vnTYDOdqugWjE26P8OQNAq7Z+MBsqPd9cL5fXpkoWv3CAKEIChkGAKBF94GCmJRNIIHw2iIgpMaS8cKXUXgUGDpwOGDJeKRNRPdE\u002FGTwqRKjRrm68SgucK1PJGM45a3qx2YF70a3Fq\u002FdKHbjTIt0PP\u002Fp40l5Mv3\u002F+xZfDsNJoLI41DSeqRElqr\u002Fx8gBMDE2xGWn80Uj7gCEm8wsOldOpmoCyG7\u002F1CdCqFQHgmr7cxeEMYG5NRIr7X34kgR\u002F0unbfzBxTHd2mIjhLGFAKZ79oFPo1Wx1M0dl5EP\u002FzkoHO+f3fOnB+YoTOME8MF4DEKjNnUwt55Rh8dW9cwJq7VKAaNoXFfzwAmKAsGCCAzZtps\u002FQRaUXiUFMO1Z0oXpiSiB3qZ6qMglDSkBN3SccoKwHAz\u002FZ0pwX4cWnRvDtIYuhowzgTFV7vGxGUc9QXAFNE0ZugqXxLgVgVGR6T\u002FiLYCbtIJ\u002FH3+wvl5n87JxMvaDFCLUHI43z13cfNHf\u002FyTjHh11eMfOmPyH2unfGJ92B\u002FYtRvungC6xXEAz+5qxAPwgBt6r\u002FYsY8IQ7Ku6jRfDrO2mZqXvKL9m0VcUzdjjx+JUr5dytS6EMRY0MJZopl8ik9LQJh92z7FZ0Po8oP5I5GkUfWcNe9BrUlqsCZE+ViQ9ORR1Ml0MVJJPVXLUlBZNi\u002FQznnQOnXZqp7+vlNUz7oHtmUFKViNMrdGfHODAXLcep8MOy6Jytj+vrMzmwgdVxRmA1s07\u002F+WMX44jI9h\u002FItbKBu7fo14+3la+LcclKTz5zEL0FpNlvA7mHFkwWpOmnyslxZQxx9C6gRb\u002Fq3KSbq7L0bxIYG2jN6f8Xp3Dr5O2RacKTjQerjc7YUYUbS3uU8lLAGYc9TpI31vXIBppjM3gSHGj6zgJ+jFT\u002FOmM8xculD7128XTPQf9AfHhicaHbOmENUsAI54FPPCXdBdgPKp2vBTDePfpM4ABUKjf9af\u002FIyMw0m3iiyl7W4AJMJcGpcwnZ9G4zjkRAd\u002Fq+64cWMCbzjzRfAxdwiaa9b1T5Y3DOWEi6maNOLzaOnn1xV5VkKHTX1caNuHvb21J5htbKXqP2mvi\u002Fh42IAAX0PQbW4dP59nDk0t2HR\u002F9UlemP7q0\u002FXt+68sc2TnYj\u002FhsdJ0T\u002F+GrH+gIL\u002FKFf7zXnekXfLPGXvnO+T73WvR0O3xAxlwzvNL5Xo57j+OgXbXJ+WMLjInzOCycofjn1WN6UZDKuKfnou1aMyUSG2jvXoQTPdhTf9PRdJUAnll2dB17mw0UVX87IH796rfx3qowdLRUTzMcdvS2fu2f\u002FtM\u002FnRnPbytacT8hvVBK4Kc\u002F+lGzuw\u002Faz+NmcstBSsZq\u002FdKZ2tAQNgtnFqrWbO7fubV5fCwddJhMF5RLJ72oDPCrIusHA+Ivn5be0qLsPTndB4q0v94l+msG1ExruqTqU\u002FuOtKeK3dErtXzqwoebD378RzkAlzdfX\u002Ftic+fGV5vHd65vHpRO+LKdmKWbyn9HIwMLJ6EHOr6Ib18\u002Fay+DosBK7j6oNj2gaa8Tevpp8qJkshmCveGbfdFUeWOzT+yHIQGqs8Tphfg7Ho\u002FIRjPaSgs0XvFIb+fTZ7jH90kJojw6AgvO\u002FRpnR9jf4ZP4aXe638E51h\u002FbaLd7Dw\u002FSOQksW4rfhht3eBSvvqztW\u002F7HUZ6tEXAMfiCXgrLDL44P\u002F3bv6KUP7L+d1eEHsj2gvk86xnt7nLzCk\u002FAgfSfTQV+10\u002FuHepGcH+Slw\u002FJZgVYRXtPPiEGhMVgGy7Q4w29a+dKlSzHxwcm9m91EA8CUoNGxhbza6XIu99R53xH1WIxuqvfcuQtjDESVH3aNCMijNhNQQlGajOcAgPK6LWBVGeDpszbrKRIBNEtNAcRFPQAe4JsH6lyRKbueisQDy9uqFsASJpsNkHaUlKkn\u002FTOwGAZjzCLIfRRGG4tEC6UgVWcwoFJ5vinF5+uA952cji++kNeuVFRVTmoX4w7wUYLoKTd+hAqjdQygWMxnkV7S0vMwx7Wr1+Y+SlQOKIvGhBLzzzUJo+jlOCgdBKDNXDxIoA8Gqq3gL9TUBhCXo1t12Yv4AT\u002Fq4boHg0Q4GRhv+bDf3G6HtQzHd9W2\u002FfEf\u002FCQAsG\u002Fzb\u002F\u002FipwPGbYP8kz\u002F4\u002FabmL07dZhCKDN3PwHEqDsXYIpciDsaC4Tbu28htX3qYKBFAkCOUEOAVtCZkhISQeunvAlnAyFiq78fCuQ75\u002FB5U7wgzRU456ZsXYV5Azfn9HYhadXwX+AdSbUJCI4xxFUUtIuM6Qk4BRCUX1+b62z\u002F+I6ye7wmiFhxN1X\u002Fw7Irc5bj0nwgjPhqFVJNstT5OWdc5bjzQA1\u002FtaxbkhX7HExy0NVUYkK2zxgswoGj0w5uy4\u002FSabQBQAFmR8mnSjjLRVlf7r9aPgaSQRPTxykRAo7+L0HmrtNHfd6VHvS++\u002F156oIpF8apFhRy901Kams2x0+hXRYFOlH\u002F5yScf1ZLdm3\u002F\u002F7\u002F6fHNi26G4mQbR1FHyzN4ChMR8gh769DzRLI6KLT8gBRY8uWky+pvUdB+52F7mykNLv8ubv3S3f9K3yTSeyaYF2Nb9b6O4eqmi8riQaQ07GZ6Fh9FLG0H3xmhKS5y9spuTrLMaembD4pKFlAwTVLN6cahg9n\u002FwBExqnlKS1Ny+K3j4oivXgASBnDYbFW\u002Fi2MekexgdoG67CM+k6r36d\u002FnKwrWGgpzjuyrkeOf7WBCgOHw0OdC1HwvocvHKwGQmzXdt0nZeMbQBBXmsP7s5q0bdxUP9JfTkQbThDQBdAvXdvxj064CFt0g4zYxwfkTV0jzrjlFuwpuyZmQT8gJZLf1TWrmDLoYAquu7Zy+EERt0th3V7\u002F+HJctYDUis3ve3Qc\u002FTMLg2P16YaMroUL3755Ze+jg5BqjfJk5e2ylcmdwcaIywL6N6ucpKo+N17twN68u45xaL+ADujmlx3PW1AD4iSq2ENgF1qEfXRQNLlrwJD0dY53ggwAKAGpJJ6Njlt1iCgrlznoYIZhw7tzBg0dmZ5jY0N4jxfBF0uulK7KvRMUYOc4GPN5Egl\u002FO7ON9MP\u002FK6vcmnpe+mYr+LtQ4fZiZ5d3+lEeoJsD3jfsUfTzv7RPzTp\u002F9Xw+Vx\u002F4xn\u002FTYfqlPPoR4Bn6QO8ufjA2Bp3NyL7PreAyD1mtqL0De1okOf7\u002FN53WrDL50na4frlUNBdi9fpYy2Z5\u002FSHWRb9Bsbpwyxe\u002Fb\u002FXjNKFeKd1VDnAdIOr6GttJ9O7cpwFCfCxvPJDhznSgd+A8\u002F5+o8MftQfH4YCxAgqyAKTl3SoNrzts3r14bu75+eefpwOfJ\u002FvnGrPSlJrV+aYUlEPJr3VhNu2TopU4jO7W7hox8o+XDxacOpbdN0P0vOe9mPbRw6U7Volq9\u002FOCl+1GurfIesXXq31e2s3DPttF+PCxAg3Zy\u002F39ZiM\u002F48NWcB7tGLy36+3H8u7Fi5t7tz\u002FefH3lt5tb17\u002FaXPntrze3HjVeyeOTAjgHK+F6uBK99Im0F4GVVqjUxsZIdLjgKN0D85i12t0syNTI3wG7+uSZhnRmug1eOoBuRGvMOfbVeb3N2PuEqba2C4+NrRge3epuuiBKjPxEs3ALunDs6f25V8+aWfJGw\u002F8jaJ3l5evwX7zuHrvjhaFR37ULL3gm3vI7HsFvsg9cC1OuGai+KW\u002Fa5drr9nNt\u002Fdo6IcOn3XPuS6n0YmOn3\u002F1N73ixW5EJC8w95uAP8M8PBtSBUMQFvngXSv3xfEzNM\u002FQihQgv2mKh5d\u002F8zc+mIoioB0Mt5xUjAQDXKtsWPcvFfK+FZG8PcQkj8D4LGDrv1te24b3f8\u002FaPAVYT1WAgbB9FcOWMSS1YEQ2eOcB3+vTKHwdADOJEf1MAy0vDXFJ2KlNYm0W8lIcDogkd4GJqn+NhNDkGmNSsAJXGGVk0UBlg7ZqqWsvFCxfGGRB5AsofF8WTL3\u002Flq6u1l9GTm76i\u002FZ5FsWFsDsqRhOxEbaAwgQ7Ax0wAx8EzMItFUn4jRACCyDrlDrAd7BhD9Cq6UnTPAlCiMQCwKVwG2mJQIebvGofdezKOeeIYliASElP1Nn9Ro57CrCkZsVbhZ1Te7L2Vp1\u002F5yRTs3\u002F7qywHiKsOkCwIF+zaffnxp+sZZsjkJQ3e0\u002FoxXCjgM5RZIpzwZB4KK8eXCEuRDCZRqC3KQ9Zfy5RgBz8ZQgxYob+B3Xst4dPee4V6iy1vB7sD0S6SRADIOPHvXzP2cn4GWG63U2LQ12XxVLXmbqoxhS7BfdZ5nT55y9xFN195OmtKc0xTPr81402sZEtGewFBj5vAA\u002FQALQw7UqPF79cqVAXMA3ZGcKVttU7LG0HkA0YrWrQ17RH\u002FImH5QPhN9ql8D0FO4dW4MCV94FgMO3ZYh5hwA\u002FfQP+uvPREJqn74DfVtA7Pme2+2iw6KrDUkYnZNtzX0Kr0YXC74vX76ckXs2Rs6mL7bS\u002Fjye\u002F\u002Fd\u002F8e82\u002F8W\u002F+K+qWvKHU2VBXj6ATF7x7oDMZJwjjUOWA8dJqbJC90ZLlNcmUc4BEX13zPiJwEaAzcH4SdnIu98tx0RVExtrSRcASMn+s5xxfMcYzziGmPGJHGZ3FHHiXFn3YrHq\u002FQIB9NfkmCcLppYPZCA8cn9\u002Fe772aNsAhtq6J4dO\u002FWDpLvfvS\u002FszkyXlaaVsjD6Jr8aBIwPDsxQ+wLM6Rq9yPN6OjnTgN9\u002Fcq93JaDJpx0V8JZ1lDFKybIzxtgiyrdvpj8mNtnNvz\u002FaahaDRm2Eh1mRqpsczllJV8Nzu6iB36fRrd7RjrFMpARyL9uMNDl\u002FXmZEE1o+l37d8SX+KTIqcez6QqT90C\u002F2DN8y0jWPZeJ0ogHO0MSF3Tx8DQfcae9Pyqu5UjSndeLj7W8\u002FwRUAdrc3YDb3TyfrbwNQbXJPRRI+eZRbgUWDoTLtQHjn6fHO8aOLLV23VXkekBO2t9vGU+BR1bOzIsOvZKwDuQkCI\u002Fn8YkMGLgOMCGGtwEt3Oj\u002F7DMzt8mXzTK7NIMD2sXZy9J09eNo4nxolBD2Dv0geXsm1tgtMs64NmbUjlvsZYW+ga\u002FGlc5dub2VH5w2t3MyRKr\u002FpdC4b3hgZa0\u002FGunaBGzezPjvlnpGSuNxaj+7pm+Kyjo786xbnk0dleA9rj8cVftSn+tkjQmehOj7l9dxpeHB3ZxasMqd\u002F60fX9t3S1+\u002FfeGbOdYVs36dRppX\u002FiE31x7nISbVQn2rvAdiPZ81TgWPTGk2aC6D\u002F0wDtstvbTcVJoyI\u002F1U1Kr1OqnexRM2LXb+O+aGfij5anTo2bWPvvsN5s\u002F+7M\u002FydGzwL+ZnyLpr142yxH2EGB40SzQKtnbyNURbR2ejFfGMYtnE50i3dnprocT4I1XlXV88aJ64E\u002FKRGjdQf9kTxvjYPT+Sjgq+3jnbmtzTr6Tc34mYkTn+m1zM0POpm8KrB09E05I9x6v5vvZix9t3nr3gyqjtYdMwcDCYZu3EtHd+++NfXjdzCfZbi4iHYW3tFkg5\u002FlkFxyruMThUl+PSHEduxhtG6Ow+8jDjFn9qxXpDH3w94qgG\u002F\u002FhWY3rb\u002FIv8IlXJpDZQePsHk4wrjayAnbZGzN1zpOmMzTs7+Hfzp5X17qBsVxyYczxfnyWrBpfr1VoYvGWIIW2GJd5r0dPO3rI3H9r+3dl8xfDe0Y63O+96YHtiy1fYH5hr+nPtKd2xKv4yz2GQtPP7ZW\u002F2+cPBtQpHNVOpLMwQjojGqLRA0QaCJEKNdDVwGbIGeiWBQ3R0E\u002F0ggBKVaEYGZ+PPv5oFDRiz85WDeK3MSAgw2J80u\u002FHUqaiTSeKmCiBdvqtExNFYwCOptyAbaAIWGfsKH0Gnrc+NYe79n5ReIthxxiIAGUYgRQGyKApn0fwXyV0mEdEXKTO4J8+fSZBsiNf7N+9RNWASUrxcACG4mCopipFRovWpNTtvmo1\u002F\u002F1WZT8o\u002F5DiJvjuKZfO9PTBAIKdRk3dubdIh4i8He+ANTnNACwAD2zYXQuYmqhV7QQCLPAUvTMcL+zi+bIptlGsgcVnwEwR68aMwzF5rokxJ0Ht6Vm0Wq66ne9EzbcMCMiYWnsVsPny8o1y+r5rB9NySNtN8lnP+Mv\u002F0E6Vj0uXKAr90UeXNr\u002F54sbm57\u002F8bPgCPSlHvHKndCDOFUApurZVsDxrdCDOeAM\u002FbSPeS1kgY63x45yBj3auwSs7QrI+u1v9peR8H3BeGxrIobPIAtqhlfq4Kzq7Fpm49whycohfzOgAqEDP1LcllDvPm5ZqzzxHu3r1+\u002FY1fel37abQ8Ajwgy89Q+RQjehj5Vhfu3pl+OtEU7PvnmtzsBQAgEi5qb7C6QSIOL6i\u002F2daG3K1qiu34il86xnbdg3fxHP6TmkywPo4NOmfOZ7Ce1mOojFgSEax6ktP1OfJUW48jAE6j9FM4atDD4gBIUAUQ3+3VJebN6\u002F32Y64RavOnn2r6iTvDZ9dax+D6\u002F12\u002FfqVZrzeL5\u002F9XHsrfDHjz+mWSsKZ8ByRUHyx3jtpQY3joRZ0Ue51Y+e3BdI4rgiub3uiCR1OjoFctADEt1OoHHWGxGJ0L3sRSFmQ6wuMeP7QDV2KsFk0ZGwmCp8BpXucR8fYQRNgPxho1Abttfh5gE7ttQCTUX1SxE76DwNo7AQFnCM1w\u002FQ5o4PuUjNeVedcX7ps6YueIYBgnQmgIZXkeRF1DoEqPGTleNE1uld6j8238IB7k5Hdye\u002F0qWul4JBRM4+PH97rt5z1FpSj54tArXsZY2F+LLD4QcpazuzoLhVt0LT24icAwjX1fXYv7W\u002F8rC3KzDHWdqAWCafjpCscbvZvT+fYz4DR3WOKveOcKTR8k57G52YvPGMCJXP+m2b+rmZr2om5yLMoKrnc8nXN1dm0x6IfPQqYnD1zJj48V\u002Fui4WFVhG425gGn6GzRI\u002FnfU6qZxaLbaLKKWCKpHOU7OUNA15Krnf5GI7qEPUAvzhgbgB4RY7aKt5GWPHr8wHF4VhR\u002Fbzn1t6Uo1B9rVN4tL9qGX\u002Fv3\u002Fx1xm3Od7950knvil\u002F05WU9224W6yG5t2dtOt+rmr\u002FSrLu1aYzif\u002Fb0cRk6bUVxj6l6jVzsP3bfvOQXt+gNN+2P+n5vN1etQT+tCPFF\u002FyNnO\u002FRwfuvm9acfRKbX\u002FVb\u002FPeHTLxVfa0buz2Kx5+TK\u002FOxUEdA96Z0ff+Bbvre+cZ45hclo78b\u002FUH8400IhXOXdos\u002FhSW9t0sPO6XWA7+SkNzLoKeKU552b77HJeMC4n6GhO1L1SVr7OGdyX3vD667\u002F+681PfvJJMzRmdcslr91SCfVDSuuzuvg04K88Itl\u002FM2sLAr+1RcDQDqpsxrN2ynqcHKaGCuQYqEB79ndXiz73B1JrdIC6GVJ55C1mffii973G+UXFF17eT47Y8XLP+9wbqKd\u002FsmLxXbaxlJiT77TPyqkqdX3waQtYb\u002FTOHpS6c+T0lYB7e0jkSN9pJm5fuAXP7p5Br+StgMVTM3GPRmcfbVHqoYOn0r\u002FxSrIjqPG6vjqd\u002FUdINgGP49F59WmM8LSx1zY8a8bJOM847Zzrd6+lZ9nbNTPEaRhd0z04xF5zLzzk2dOAZcfGhncenUmveW0B98ywdK7z\u002F+Eb7+NResrYeWnXPKvvHITXgh\u002FxtRe5eUkv9B1GGadBG3auHbnq+e5FDtATz43O7voe84O9fjCgruyhFflAsE+iaHEgZS19hFFcyudVCzJOJxBVe2kBKlAhiqg8Fa\u002FYojHH5Jb+9D\u002F+TUr5yuSoA5EGYiLaCYR8dakpo7AaaANi+hBQT3Vjp1Hucq2r1DygViRaHqQyicDiMuyY48WAixuVPcIAp4q6n6jqy5ruCRjnhSrdJLqitKN8Q0pbW1YVAIs39k8\u002FxznpiRbKyn+V2gGQG+wzovkZSm2zqFb++tUA2c2btybHV+7d3n3L0akjtaXBzks8FlBnFMcIYJQ4QaQKsHNPhupBK8O\u002FSRhFo4yFdkgvwVMABuakMJ6nAJ49yWMPKNugZHIAu7ec\u002Fx9\u002F+nhz9\u002F6TFFj5+Ru5+1Gyt1SXphgmJxy4kH95qPGSwvK6aOqVG7c3n31xJQXXRhiBKLmg1289aEv5X5Zbt29zvejftWtXNlc7j1PAgKhygk84QGYMRggRBrMD0f7uZTy2ykBf8MBS9JQFgUtAehN2bzTyQq91bUqDnAes+7frGT\u002FgL23Z9d8DwXhAjiNvxqMHMFHu\u002Fc2YLS8e+KGQdp5Be8xvjo8mmXb7e3d0g5BcN6CpSwCmOW3nftqiDZ3R8xZYJ\u002FBSxzhbb95YuBwAi89NhXNk8TCndEXVVVGSZsaxPDSy9yAAwwFaAErEm+P49+kci3ZI0bPjI+OfyMyL4yDSP8ZGH+I9UYrZBXTOqKX1QcqOKXszH6JOnAWy4XzASoQXWEf3aV+GQHRcNNtCznffPZP8tuYicKwKkcounF73EmndFZhRkpScuSd9oF3kicOCh4yBcVkG2pistm37R970+3n6R467NBa6gNGJXeqDVBclRjO+XQvQcebr3jzTfYzPGjOl4aJ7vMHQv2xdyZOmsaVHWPxq4bXdcwF17VBP1728GLT99cu0+qrTr1558hPg5qzu3pWTPfy+gAawQe772IpAd2mcuu\u002FQOz2q3Tab6kg\u002FlQZVO8m96LYFZIzK3kBd0KapdsAHOCuKlrOvahPWfJyuudPswNNH96KzyHcR3J4hTcDY+k62OG5SRR634PxpC87B0GPpWdVq8Jj1I4IdNuN68cIGIitfk172Mg764qX90hvddxa7uUeyCFgZG7npW73MyJEMcgDEer9Iz33ZLM3Vazcm\u002FxwIIB\u002F41ZhywmzlvgAj3eVYTmw1qj\u002F86OMBN0+e3J5je+pfeQcjn9KSmj\u002FY7OeI9J\u002FoOqNro6z3S7HA0zbVm4WtPW9kptZxFj0fLwqMmGInK29sJlWfla493Yzwk9IyARD93r+fc5LO6lqLLY33LCiPhniH3tnqqL72zJxCtGtMycOeAZkiyGYjzDa4FzorxLCccIwz+qrr3Y9j6Ji2Gg96Uk9XBZY+Ea\u002Fv838PHdWwvsyxnX86p5t4OSeuIhsLoMSvAIrj23f9Wv2hr6NN\u002F+FhMouH1nnrdv411v6lM7rV\u002FK69diXVng6kP5KzaKrksPz+w0fMkrogGnTfVTM\u002F4BVdpG\u002FsLs2qy+bZKpiVeRevZGNzZAUJLRrfVcnSs2dODNjjvEtLkr56lwMLO9SgL774Yqq\u002FHDu6Fv7Td8+fZhcbE3aVM4yv3wDptYPOTfPOmHPwBbusP3iZ3LxovF4WRX\u002Fds15mj8vQG73YgCbKyUVBAI7ly6cVnCgt5kW2+GVA\u002FtmbUmSkvzSLcuBQ6\u002F8q47gvcL6nQMlschhfvNkXkD\u002FQwvJ016l95b6fPLc5c\u002F7jzYUPb23u3m6d29c3WgB7JfB+bfMw7PV8ZE6ZyRaS5lzAEPeiidKyB2qY2Uj6dgIWhiVZNUr43nv0L2U1r8W7w+fRZG\u002F6kOx+H3irTeTGePhn9EK0YotX4GvxBB7ZRXB70cHDQ53DxkfUGct+mN\u002FYhjhmzt2CdDbfNfhtiwUcG3vfszm+\u002Ft7+5uLBCV0z2KLxpleAf9zeo6bNzhFw7du6dz\u002FgN875yMAw7sIn7uli1\u002F9Qrx8MqDOsk+MdkyMCw7by8dbCDEZ4gXHTpSuthOKZKGYGy2JCuXevh1F1vqoNCZNFpiIobwVIVXcZwBpxVEsBAtSYtR39CEcLKOwUpooB5W\u002FaygJOA3Dm7JlRelevXp2BJGwUOxAgn5aDMUA+8PAgo36+gXnnnXcnGqfmOsdA2TyAXD9F6eyYKG0H0MeEgAHmsj3wnRT7jeu3Nv\u002F0n\u002FyTxWQxCbBg1EXZAfYt2FaZxbMpe9EnQyw6CcCapnb8VUCFMcOEDPW58+eHHiKGPFaGktJQs9XiJ0pOW\u002FQRjZ+VpmLjIlvkSnMRrZoZjBjdRkvvFvmxPfutQPWvP7u8efXV9XFoGEHcyv151jThq3J5MSedIX9exY+bt5pdaBOWdGHTZCKSGc\u002FA\u002FcOvq8n8lz8tgvrNtFHZs5OBTh7srkNLWN2z0+ca09SMlDEhyF51t2sDsY0Ho0YpThlB\u002FaOgO090fxnKJR3oQEoSo2Ucuud2178Bowmqe3kwfnIm475AkqjAdGT4hhD6fd3Np8sWbf1tPAYYUEL6EQrymbrIkEW3ni0asbv2Uzad7bJeO\u002FfsQ2QIzcgLvnX\u002FqWx04d0BvRyaVa7RQs7K2XUtJ3h3qQDAkrzC+zk8rgPqKZkx9tEN7eR+owe51J+hLSurldFh\u002FuurtJM1FV7bu9cYWMoQPQ3EvNYnBUwRW0w0lTsag5E5bSllAeA+o+5+s1sWJd0JmH9XhN0zL1S6cXeRoRs37SoZH0RivCjNh7Nk4Y7ZHAvozLDJiR6DlAwAKIcOSXcRAeJ4NpYdB9gBLoCBvO+N3jV8+srwPmgcyHjdig6BmvjI2KuwIPJDnmfKvPx4nDX06xzDZGxspsNonWxKfKbAi5K+6e03ugf42fIqQEmJ40mA7FWLV6UrPHiQMY8CqiodKb843N\u002F1iIpPGAxvo+HQorP2zlh0zswk1F6ge1L2ymOdRaT95plzbn0z23EgQPNCRNwsSRHOPUVx91nQWR+U9QMeH6crOCxHm\u002FWa9gf2tcGAAIRjZGu\u002FG+PRg+VbWwg4hrsTB7Du\u002FDbGMLmVtjRpIukzzviBZ+VlT3R40cOMpXUxeIoOXEa02ZJ0kypZK4JlBDq\u002FsZRCKZIlxx04sJB9Fs\u002F3\u002FfnzRzU2\u002FRXxtI8zKF3OoAE7nAZ1qW8UCFGq887d6\u002FP3SkGRJmZGrTEeHjfzEfAzE\u002FEU7+xK\u002F1pIfHwCKne+u935Fteljyan3TMWrwzhu4cWu6f2PC29Bm+Sjz0BLe20sY4IJcDTqTPOSoKq6sSJGVBt\u002FOMd75Hj2jfrBjgRvaX6WIv0+HGaJF1Lz+6LH\u002FAbu7prorkrYNEoxl8jEcObnbLu7RnzXqBmtYQe89ylpxxzjguHRad3\u002Fe1Lh31OgGSn3yoQOb5tuxPmOsqwv\u002Fpp7jfVseZec7jT6BmXeo77x2vxRmQcGsEB6MKB40DSixUkrN9mobKN8UQUX8\u002FuGvKzIqT9XkqT9Ay7MlsHYuZZgQflbs1sPXyULmkBODndnzNP\u002Fh88bMFvQYejb47MhnyzADz5tZHb7\u002F3eJ9NKvMg53dWzvgtf3C1l6VljuD+5eY1ByoEXlEASPACoW7fw4k2z3+WKl0laukwOarL6kqPv3J1xVmJSOtaUB+1aRnXX81JtHtbLbHeJjQUf7naDB5tDlXHcvb\u002FCGKXLAOm73iQr9dXsFT47ftL+FydnzdCzR+9v7pV+KtJ+82oLUK9cKbD3dWtubsx6l0dF9B\u002FWMOmcT9IZAgsqxe2rE3v34ok1TmRwUmei2Y7pNLIzXpz6kRFBAUq2a7b8sLigf\u002F3fmKYZu65uPAo4j95Zeps+GB4Y53cYY+yxWYotWHcdHtEON4QX6Hxvz\u002FPseQZ7i+nnFSZJfs3oaeOA\u002FNo37ex31+L\u002FcWL7e2bY0ukCzBMA8Hs8ODZxmhXHxqRE5HXPG\u002FxZG79\u002FXDSpETvP\u002Ft0\u002FfjCgzvMHfqWA6LR8Z8BU9BqBRY9UXGEUCdKLGHvtyFm6Sr3j5VDwFBdQcvzE+c2HH38w0cHZzTNDaktcwFSkWLqLCgsPigrJVWeMlUkDhABXA24wTVFJpRGRpIRWes7j7zcIMjAAB+UnLYawdtkwpml7OzOKIlMYKlvYNOdJUSdVa\u002FSX4iCIFsgC8J77uHMshPs2J+OLz79o+vT8tF1OnFmEo01hM6YAyaTDJPjSF4Bz08NSezCEzRbkmN5rwYpV2EuppXg4PdEBIzCC2muKGTj89naruQNtFoZwLDwnNVC\u002FmrZNCSj4D0SFaTL2RQdjPrmRR8uRZBRPn26auBJkcvnvtakCBQPAikBZiGaB1WZ3dK4m7d3AvwWlX3\u002FTIuF0igoUDyr79ColiqYiSzdutv6gRVN2uTx0EACwG1rVX4rSYe5xFggnXq4\u002FjLIIoYgEITJm23QMgHhAccqfYnfR2IEuJZAMpBeB2p5rPIjqMoKcgOVRu5hjkKx+L6z4kKIHWEW9KCDPcI5\u002F0N+rZqZm\u002FI3bFjDQHm3ocf4a3utjAKVrKLqtApl71jffRUK3vz+Vf9rYeb5x4zxJcbpZugitiK\u002FNSj1rwE2\u002FmnpmnO8\u002FuFOaUdP28aE2zLRmzxuZ6Lvcda0SEdaFUXLxwPzXfb1cB2TpGcW0lDGQXmf1o9\u002FJinsA+vJlgS6Ke6Y343lVgqSPmVZWmvVUIMesD3BN5u8XreFEA5Gffnqp29oIrXJ3EwmON2rcSuOSJvEyJ2WVSZSzf7icScp1OR5rQZS1EwDCOBcZibBapF2K+02R6jRA9FUBZqWN0UtrDFdfRUiVSwPw6Ce6KdPRHWpL9ta5opb4RPs5REeKqhkbNHzyONrlcJJjzyGLzpu1FdFoT\u002FdTpvRRlSru3hVZM+vX4spjB3ouojf2lH\u002F0BUwMxYIrHegFoE1N39oBtB0rqmwtAHmkL4Mes1W7IIn0Gnw5FXoC33teFznP2KGxNuzJs+Y0vMi5UBP+wcMAy6vWPJgdS89NLmklFum0g+W9T63uonWcrBevis6\u002FPhw9V5DlaXratLi0Jzxoyl8Q4XE5uHseVIZw71ozI1K8ynyaxTJFrY0RthenSZ+80A5vAe4THQxI2Sbd4voaMOuXpCVF9ED63ZnF1N6ZAUkB0Jnr3oBeRExPzdqk6E\u002Fer15rzdPVr7NFLbBNxwExnEBLBF68Vum66xpPz1NhQ1Sc7HCGAF\u002FBHwEQsk1verEHy4lPF41MobWIHcCQzqr995JlpSi1oW4MgELXibB3Hj3APs1MT4BqZljIduPLERWQwXsYg4POIT3YIl2zpa\u002Fj12fpi6hnhJf8sgXIWx92x9NE1wwLPqP\u002FPFDb3N\u002FnctI7PK+0QXQnIxGgM4GsYcj51ffuNLw6nzEbGtBreHYBOc\u002Fq\u002Fx1d4Yo5Z85zrWc3tjv03upTF82z+mX0TbcR7ccX81ufL7vWzBSaeD778Sq+5IjQwl41xcPHXjxXRalrJo86vuUIoSks8KiAyFwRqBVk8DqcvvK336WKni2wd7fUMDPmRXk2v\u002FzFrzcftqjYKI8ejHlOtij+229uJ\u002FPp7QJW0mzZ7T09x3jTpZF6xv9xtvIRhD4yWMT8dbLgXuyMXPH0l3Gie3a3FupJGKfHql2w2fVMtTQL3rtvbX5ZvvmbZ9nch0XPS+Pae\u002Fhk71JVWmq2a3+Ltuvd6Gk8ipbxwqx\u002FisfermLUe2UF3Lp2pUDi9c0v\u002Fu7vNo\u002Fordvls3MSej+Krx43A2AGboitJzXT+jTVXwwLmaGb0MI44Rs6CZ9NCkhtpQuXTezsjvvb\u002FcYONlhoRU7xIhkZGzmDiPfqa\u002Fdgx3vU9y9\u002FDt+6VecuwM5eLRlwnb+9vda5y\u002FbhsXV82bAB\u002Fs7pGn1wP7YNmLdBGb6e\u002FWFkJEx71\u002FO0u4v6nwzh6fX2SHtQTHujPdn8oV4\u002FGFAXWaa4RFEQg2Ds2VP1kQbQCv\u002FXgYhXr6ruEJiVS24RDKMrBeTCxYv9\u002FWJzMSEhKIR10jUiDpCuhKKdnxAPyLRJhxKCTwIBpsEwhioDCEWxYSiEHeYswoiZhmw7A+I4gPOocwBXv4u+XLxYDdXSckSxTS0fDog4T\u002FT5zJ\u002F8cW1LcDMwNqHBAF6cDWk50nAYbFO+Bu9UwFcqjnrmouU85hXFBmDlha1d+9zPAkuLauW7qYBDQdSBwFDGMcGYLZD1MZp2eAxTbDKK3TmAA0Ak4sdbFNGccny1Tw48BSByFmUao+q4YsScDg6G530r175oxdl3i9IfO9P23OdSJEU5i8DdShE9omRaBHW\u002F1BaLZgiXqb673ft2Jfa+K1L4uhQX0+qifbFtTEyIOWUtoAvMA99yMwkzJhd95ZzwWAn5CDwj0YsAAIZSPFbqjZxAxhhg6VgGC42XElkCo98rIr6EZit87rMV1q1C8YmQ6qESOnyDrqME+tfv2rD4qAZhnnl1Rvdz5o6sznXryqWIjItIi0jw319C4SwF39Pm8CillEIhjJ6\u002FeDWI03VFzdAlXloOgxQt8qRkpyhzijFaAp+cVdGEb79dkV00EZVX+lM0lCMmRYlC4kjr1wA8fYuWnquVta7nUnAdi+bWQ1jTkNqafsxvddvUMzChLcZtaNg1ZJcjaAZLiVROGaBuoXQmqOcCzMCxCDiQXTWEznmrWuir1COainhbsG2tQJsVVcpuZoCikZkzFaXsmKpco6oFK5rPcLegLuNnjNGYnqT0n8fAeNhrRYEsmFqLY7efZHXWbpTvCQDs359TOhehw3JAyD\u002Fe1EdBBMEEa1BQDl3I05KpZqwCq88Zu2grPcziJC7n3RzfR0XEvI4cNY6cgugyTkYgrrbLR+l283ZeZJ03vhww1OXWqhwuzUm0+2m0fFT9ZA7NWhtQmlH00UYGZk\u002FA4c3udMJUtVA9p8X99cPGZ3e+K8J8z0zjswUuYsPRp\u002FXtgAVtgdgBXsOf4Yj6\u002FqQyji\u002FKmcVDeIa8rRk5JQ4Du31HJ2O8v5rQdlQ06+OYqOc+Br4OSu8zO7F1jPCRwIP0SGNKt5t+5wCc2NkAjXMqHeVeeoqdmfHuXuRkVwtlXwUslvzSG+mGnoWnnXv95u30dtHOALLUyuPVpcYP9KaI4dP4jW4eGega19MH6vcr3zlVhqKpCiOOkxsBBusEyMkW9DZKQwN+tzx9UIaOFTSZmaJ0m3GRwqMs6axVaLwH4EQ79CCv5B5wISdoh7foBOOqqs7Lw82ecpBrjFx\u002FQHXO6Yl7mw2iXr53suufSjRzsOcLZGgvWmG0LTBxYPRWMwXo4Df\u002FRYxOdG5v1\u002FiDXuv\u002F4Umn0JW4vHuw+\u002FQm2Zhx73P4uH\u002FGX9iRUWj\u002F\u002F2Ptzp7syq77zt8EkJmY56EKQxUKLBapokjKpqKtdlt+6bAd0dF\u002Fq18U0U\u002Fd7n7ucNiSKEoka8RUKMwzEkhM\u002Ff2sk0mrn4WLupWZ956zzx7W8FvDXltzu2BKn8g0xpJxkVdTFai2fY7P8OW76oqvt3a6saSTtJYiW2sZ7DvydvrQEKZf4Qs0p\u002FDBwYO101zwxNdsusom4qXwBf1Lv8AFvOxwxpF4adJT79zrwKFXq6+++mb175\u002F\u002F9XjSC2GUnvFmdSL6ONsBSSrBPcypAM+I9g7w7Pf1+m4s41zgOOu9WdqbA4XW95Qr3xyQkA2y\u002Fi\u002F9ev0mfkkuvKx04nqpOy3\u002FFJ9Ao8a2tz7vQbM5N97Gk5ulo20C8R1quKffV+ulnh05WcM8ARlmtZ03w4INrmHgysc\u002FVkru+cuVVv744upwm1CPnvqH2SskJfHuw+fROeO+rIXBMRncPXPKNme0otH36XpWhPWyPvQQubvQFoMV5lg2hw7ptOb6s9DJAphFOdCytMMhqi6B\u002FYYeWqTRVeZn6G0xCrQyFdbQBrrppzkmQ9BcnemKIZGmFb0v9KPP76KdHjfXj5OgdvXbc\u002FTRZ3jJfXgXTTAUzPvUivcsv\u002Fccz9Sx5ed0cZ4tIoK+Fz6ZkevOv\u002Fj1wYC6vFiD3pOHezwBDYQwE4ImjH13N9D3Q\u002FmF8qoBJLXXr169tvqrv\u002Fqrwow88Z0q2AYhHqLxvLfQk5OaZ+NxJ31dv36tAwk+GmWw1NdOKSQUjwZwlV6UN0kRAL9eFs7EWvwhpJQuoKdk4sPSWQALm0hdx4o+t+Mllwdn4w+lfPfu3fFyumc8GW8KKQXK9f1WhyFYXAei8DLdDgwpD+m+o4ePjQLYToA87jOnr35y6cKky\u002FAQ6o9cWwbCHEZSfxk1yIyxwzIFqHnKXcezR8EhoHvNI4H46aefzJt3fQR3xHryVIdKqfm+ujjeS7mVSv3Z7ML7KPeUEdXtAe0lT+85I4pwS5CdrJzTmY8uttHvXAA+4ZPmOX5qlWf88er+o7vDpHIveV\u002FlGL9IoMSf3Vu4rHKPm+XNCfdqbwRLYH32DSDsBiciIYWJUAb4\u002FRwB1zwC\u002F+4h6CYfLmWNGV8ljIWinMqHll55IGE\u002FyiFm6L+pctF9mA5z7r5G4XjuDlMTJKzm\u002Fpy5xm7mnLDxywCULqJ8CPlR+vOTUEjZNUS+71UAAEAASURBVM4dFq3vCYbhxUWxUahe1obEkvoCVPD4+ozMXPo9l82txkORc7GuRVcMR5GnH5obHg9z9XGbSZ2EC\u002FxKg7GR2Zozes0Xw+5hwNYY\u002FC087plozMmAQD1BxXjzlqrFkLLpcDZkNW+8kzzpaBzvUfYiIvIHzcsYNDwqjZn30ty8bU1qKGNWJaIM52SAeROB0o65nnFHQ1OVIZrxOU8lA1s4ewBbxsfs+YgOx7OZ+pr9KnmSGJgAmg3oUhHkuPN+MSbHGKyflpuwt66TJ1x\u002Fjedl47TOADFQzisrYkHJm5tWe7UOiKeUJgd4PCdkBQXv2wyTlFokGlDMU1+b5n\u002F1bqHDk\u002FXHevGGmQObEhGHQ5L29VYtwZw8fmwDqUN71lL+8vltJEVrPQetJ9yNwTUD2pvTZeNA841kepsnlUGOlNO\u002FVvj87TvGA1lXimFjYOQ8fwHsZmThpRT3+z3lSH\u002FECy9iF2gPZL5vg\u002FezvOnPyk0\u002FWN30jSIKKlkw7h9X9u5gIHv74JJSocrT277jzXtZmsmbd8tZE1L2pAsqNWmz\u002FfPkKAMLoYgY4hP0SZ5zSB7MYSFtZ6Ja8YGoJt4lO9GlyAxa0a7a6Y8a\u002FkSOknlYSbuuuZ8M5ciZHPzuo+idMOk5k2fe+qMBKXaLA+TZRGUOZjRYGGl6+w8uG0aBFbxIAb+OPkVS8cXsX+qheM1GY9GgF0WB6I0Tx51u2H34Ohmnb2SVVAMgBU+IUG7GH8bHwQKon95wMqYUggySvJrbX3\u002FX3DnWvTXvHjS15KIn0+Jf9IBuVAvy+f4ikQDgqyLG\u002FmZQ4yN8Vgs9C7jN6ZRc3pVJixzr6z7v1nEemEfGvPQeL+2YLxGx8VwyqhsbPYEEl\u002F\u002FNpdEgKlxo0W9kLPCoTe8pQdqDMl1HjvThjE0bu84Q8mn3vchu1K0tz+26JjSJqsu9l+dpe3TCPGeR3e6hD3nVNypTzIuJU4CsSS2KN+pdz+r\u002F9VP7k8\u002Ff9+htb\u002FJRNR7OKbrwTimaN3+4P\u002FNg\u002Fxw9+zh+IId5wu+nv+9Vjvj+\u002FcfxbxH2wDD6P34kY7JKdCJda2s\u002FRD9FrluL\u002F6FrnLeS3Ii2RBvpx+Or0sFap72t3RqAGu008uYMbBeVFDnv5Ofnyac9IqE2svNMv5tI\u002FEbz8pZxEl2uRftrGdvvA+yreHq1XlR936HViXOXqseebmhsIw8bN7m9rFRzHi4jtw4cP706eOLs6lyVYn79l\u002F\u002Fz6us\u002F\u002FHH193\u002F331fff\u002FN1EXzOtWU9RagYxBogr15XZUcKXObzyBvjFbU1z+TUEgVajFCGgvWzmrOktYG20CEqtD6M1QHc4bDN9CVaGLwWPy6OEyB6AdLaghfKyagvCz3hY\u002Fhnzlepzeln7dpzMxGXnX6bQ9eQkTBqd\u002Fd9Y2xMQ991EH4Y4N7ncKG+OM9krR3D+ohX0JDoDt0uYrT8Q8fpxK4x2JHjf6JhnfqXvT4YULfwhAtBd+hgnou8zkAIgWmAvAV2wFOUwkmI18C++eZqYPjBbNyx6eujj0sp4VlowaWMACjqy94vNEMhEk5HDp1aBE4LPKf6NZnA8XaLBajrg8Un1AhgpSPHY1YfhXZvVTWFsvC9SWZlzsK1oAwOZYJsJiVgEOCzZw9m4gFn4F7Or9z3P\u002F7h60D15tSERqBe0lsIXgul3zdv3q4M5ZnGfmb129\u002F+tqe9H6MEmL5y5bMpQSmNgGGAknnHRBOcqrjkxbYZKuHBGFBS6nb5lk6wVKN6aqI2Bp6Ak3mfCBFeYIBxAXKFwyIm6TU8Qi8TOubwIFBYX1\u002FFCIQEAKDCjD2jKgqsb5ZKkVJ7HpBfy9JXEu59wo8REmXX1z0dkvBq9bg0F+Gy6Lmu86bZZJhCqV3rm+SIMeSGETx50Mt1O7MmbzSlnXLlUZfv7lREYHIB6HWi9SQQxtsUuJsDj\u002FIwrToOnhevYhf1mnAjnFNSwywL0xIWGHkXtPquQc54556uT3oFWJdw9J92s3eNF0FgDGgTkHRMen9Mf9QrZhAAkwDpn5TJ9Ge5nzCYpzUGCt3BDWhBwHdRRjudGTHlmsVj2UWF\u002FjcmfYVBbv6++\u002Fb7DLEL1Qy+NMYXWnv+\u002FGBKx6a+si6iZ\u002FsR7p94GFh36FceuBbDo4HRF60hWnL4mIjNy8pxTlSoMoF09eJtW4STzU7A+TtgTrd6EzqGs8xbY2mtJuTf\u002FABm1pCnjGBzQA3hygjl9e\u002FSuZb3wVHe0rCkxPheGUNpasqEqphC4Y\u002FHLF3QE0YYUmY2HM56dp8UmYcBSeBM+0CeCkYqPry3LyIlx0u1x\u002FP77m2fi7yMUG+tn4nq1A\u002FVQij4McAa265CAMAOJ3f0V8qekqe+k5eNZ4xnmdfoOJ7iTTt2pI3RKUsHn7xqLgqODIjczMMGLL8ouvC43Ojt8lE5FI7lST92pJSK\u002FYAWYGLul1AygLS8gfZ4qrassegMkj13+vSkQh0K9LKP9r9P0aeU+YKkl0h5AR7IgoN53rcdztRcOheB8ewAle08bs8eB3Yz3rdbr5OHTwY2pLqkcFoPKSxT+7h66q\u002FbK2QDHk9fDDDA1WErFBsZaFO+SiiMKJEEMhaf3L93d3Xz+vXVxUsXk+mnkyvqPzcv8Tp+l\u002FNtTRl2DXHWeomOtG7Nq4gpXcKzLqWRrAYmL37ySX1x+Jf7Wrj4kNFvfw2APcA1GYrXntdna41PD+QZF0V4VvrdgeblwicfT9+tZ0TS2Bcn0sv0hVA9UESeAebkgAiRdCyn3R6vZj1gJ+WKMTcAqjGjX7oEP6A3MjhWTObZnP80L36nYLe+eHCjCBedwnAcmmoo6FrkkhOGrvTF6M3GcbDI0+bG0fou\u002FI5vmuZkI6+u+TQPY6igvfrGU6wNbzLQMwx1aAlPN07giW5rukfeLRFA7ZK76LIbvP\u002FZa\u002FejP\u002F2sHYbryLTGO\u002FuGehhAiEYYJp7ludNY4ydPte9lnQck1Ud8Zd1I1eW5SRz97n\u002F2VLnuXdEConyR90ituQ6w7u\u002F7AaM9aaKAIrrJ7De9TRM+F+ldNlzXn+bHXjILJDVsl55vBdQ\u002F7pRSRRW+\u002FS7dV3oYuXn69Il0RU4yZ4BU2Wx\u002FBtr6ydOr52+dCROoTmZa034ZmiAr3zY2dDm6pCjkRC\u002FtWQBmo5s9DnNrbDzOb5JF5mgj2lCS870TfltTuvRp8lsJ5fG2N5f2+5xIz4toAsuM2tn8vZEhqaRy4Fwd9mdrObUO+j0Dvc\u002FJo\u002FW90U+GCUp4nQPm1ejX5jsD\u002FuKVn65++uUvV7\u002F+zf+0+tkvf7X66vf\u002FuPrd3\u002F\u002F31fMnDzrBtCpDImDR28EiAQfjF3JC+rH9EYtslG64VMGhQ\u002FA6vcv4Q3uMT3Thdws8etMfrc2WMTaP6GgM93SguXQN+h0M0Ni9pNtpm47TGMNoAH+04\u002F7FUbNQ3J90M3JLxk5K4j+T40Nb9SkxikhWa63XEu3NiRNdT4ZCY8Vj9JvDsBj1bmB2vNVHt0ZnaHcxgOtWn\u002Fc\u002FBN633h\u002Fm9cGA+m9+85tKyt2YXs2ktTgU3s1KxvH8AMiImCAbQbL\u002FXcL80lx\u002F\u002FfoNy5fw2u5QiR8GgPrio49\u002FCKifTmAXUk\u002FRbsYkt2\u002FdzSPfjueUtYNUmqG+yys+XFxaRwqLBxr4Ffrc3n48Xg4VVmxCknvGAHANhaOk2clAMEJagGEVVCKeO5XPav0invXA9Ccpv65P6DI4ANfdfPvvv\u002F9+vO7A9Mcx+SefXhwiu37thwSzEm8O5ahGcGX2Xmel8gwBWj\u002FcjPgDKQ5buJBSO5F37nH9UV2G4JEzTwFf\u002Ff672TgqVCuctJHg\u002FvKXX65+8atf1D7gmmCKkAFzbMEbwrtz\u002F\u002F6jCG4BTspVdmHG07Fynu+muF6uPrv8SYy7t+fdzTiodnfA6EBM5uRCtdYPl8v5yz\u002F7+dR7fxrI2l8Y7uLHHcJRGUk50bwMisPubx1etPmKwDOeVxkT0gaU8yOs3vezRpdQpjmOiF9F+EjYTv0F\u002FAWcud4omMYi71\u002FKgVBvHybUMGygsDUmAAgJ4xZiJgwHCKcEXDNMFzXtethj7+5rETBsz6NAxgJvXRmM2iEYyAJKEI261pHwNupRDFt5J588er46ebxrQ2PCojzWXd4cy2eX1hPTZ7QwngA5G58o22TuvAA3wGKqgLQWDCfhROtsc52IDENQ5SGpXidT7k96H0LLARdzIxULvfxo134AApAxX+ZQFREVVPYl6Ai8Q4deRQMP5zpgfSn76TRQBmrHrteuyiALyA5EJ8ymukvLRbFsRhsbAbaZ2\u002FrNi2NdW7GUmCPneTkTqk3awwCbTX48kIc6VIT3RUm0KnXW79Y8pWpdjhUx0MbReOFd41fC8UUgdqnf35pn20Uaye9+aU2EM5UVbAlGQG+0OexNoVfGsDMIPv741LTzJsOjssarrZ67CSS9z+hLiK+37kq6ApwA6NOici8yGHm+CfwxLrv3xbvorPxOxrba4espJW+A+fnzJ8PvvKpkANpQw9ycqx7xUjWU+HmERcPdU37w27fAX3tanpRrWsoLGghfB+47JOVoa1NJvbXodbuN1O+a91RMcyRVR5nA6Lj+HT+W97Z1BAqPHDvYeQQ\u002FmTQmAPdNyuJFlXFUdBMF83zjO3x4Ofzq\u002FPlLqz13O\u002FF1f8b7yXMtkTXJw12E4gE5GPg90NqGQFb320x2sn04p5OlDChpKnO+QOMEPm2Mn2oysQWAgzePJIuOXrmyenb2bHLsRmtxNZpsLQfUOsypUPmA3qIs5XaLAAEzw6u1gwdu3743fCEq9Ekg\u002FNzZcztzWBnbk6cC+afi8ypeJMMmpS86u3nrZr+n9JsfYNjmTPuUtsxJgGcOuYkv\u002Fb6RB\u002F9YIOv+0+9Xzxv3u0D3L3\u002Fzi55dfvz9p7N\u002F4sUcu56szFHkkLtdAHH0RF7JnB7juWzxGAbvI0xyqMeO0n6RowJY59RhFJMVUnEYd2QUUME58WOpjxc+\u002FTSb4N3qV3\u002Fxr1Y\u002FXL85Dq2jpX9ONKVZ+O67a8n566NfAF6AuydWFWThV3r\u002FUE6KdzyctQMc9oT+TgZFRxwznvm+vOxJu4mOGOJAlPlT7WucFyit9idahpD7T4UigMcfYyAaLeDSQ4EOzybfxmhv\u002FCIXgNJskow+6CB7C3yvL\u002FpNB2uL42XxOCa\u002Fmn\u002F6lX6SN0+3krbkPkeONuk9fXmb02Ce3XWMLbxmv4axbL2pWEJ07pRcvMrDST6IrvX4muRwiH9rL+Wz2hYtaS7Q36uccEBjXRgDmE4lB8hh\u002FQmd9JxKOBfVlyLzLGPx43OnKgV9deqg\u002F\u002F63v1+dLS\u002F9RbQSFScz2+QcmJMeIsqztYNDrL35RL+Pi0i9bZPnZryYJor3Hq\u002F2nty7OlfqSY9evWy\u002FlzmyhiJ+TXlzmBzLMDSuI+EC1Vk40B6WMiV6IwqPF+mufcnRffUjolyt5VXfSA+8rrIR+t84WA77gbzsB4rul8e+kaG9VnlS9feV+lwLeBs3x9q90iVV8\u002Frpn\u002F9q9eVf\u002FMXqP\u002F7v\u002F1se9n9c\u002Ffa\u002F\u002Fb+rm99\u002FVZsZrK0fmsUD9rO9zdnA8QoTca7upls2kbN+9AgnDZ1rjYcv0F8AHV0hAXOyL2IVuZ\u002FO+Kz5wK\u002FaWS\u002FafCTjAwin18gQOkukyxqRJfOOdtAsfbVrpGoAHXHuuHfBd+aZcSACmJ6nq1vDgy3GGLm1gYfQ48LPbzJWtpLlVfnqGodocj6MrOh+Roa26OExNmrPPpiNUjJ3r5kH\u002FQv\u002F98GAuknW4fPnzw8YZYXZWHrlypX5TFjz+6vfj1Cj5C0wRQA8j6clr68ScyYTiNDO0bwvD9qc9iQCPRmDAOY2fALuT\u002FIMvYyw5YsCKSYWQy8VT3hMeewjqhbIggErcsB5KgEh9dw\u002FKo1Geg6hou+sXNdTmAT3GBm187MvflqObLlo9U+\u002F9fF0Hi6L75j07767WptPMjwuBMiVEjuaIji5+vWvf7n6T\u002F\u002FpP6z+8PvfB5CqaBMzKnl0\u002FPiZ6ZvNad99982ACV4fz5YTefW7bwdEXvnsyjArT6TQ2e02FjJoztUXz48ShhFY2MI30gkQYXQ+c7geYACknFz6IsBh7DxgrjdX+vmbv\u002FxN0beIN2sfcQFiyoadPSP3Lm9sYPEPf\u002Fxq0mQ2eQLzMK496ATYQPT7NslJ1zG\u002F4x1JmHJAp04a03w8vEd4Y1ZeDZ7stTbVvQ\u002F8IXzsaj4Bo37FWvPPeo7HaBiYgI\u002Fh66dmCWffUzr+nheu703weDW8nZb6Y9oFEPTMn4ui0CfGQt2ea7VnTccLnNTnqRMiJRCPlR9+TIk4oLDPCdV6NW8gHegzp8sDKKPqKMfQKpbwoBEqlCwhw0MyOajJInnc1uNVzwYMbEiSysXTeTagMXmBgfhWurV7MHTM2OR1JJTQFYNUuhgpf\u002FhQwCZh4Tm6A5h7LiEp5MdQtAZC91OZJ4+JfQQAPpBm9ca7XdhdtGpv6\u002FI+8Dney9aP9xT\u002FEpg8iYxHnrKps14fKae1vLfv0WTP5d0y7\u002Fo7a9LvNGo+iX50HHv8xECX0sK4cZT8oTzV+wP8QM+rvMADupMfjuO2mZKCttH25InDyQBr1n4NXmHTH495rrV00iaPmvlAkEAJYAVg2XDXN4WgFxpiGAIaojTWQ465Ta7akx8MkEgFUfFjTpVs\u002FVcd4LT9uk1H0c9G86T\u002FDvnaqiaxMpn37lZ9qt+PFP4+mif9aB71zSpC7C1UvwCYgF3zsV1\u002F5GArrweYHO66o8kr8xuMmf4D4g1r+HQtesSr+zPy1t5X2rR53Jsyept3H5BX2pZCP3a0qESpLHvymm1lEN2\u002Fe3f1KKOKuXWs9o\u002F3Fo0AsJWXnH0FgG\u002FyhmI9nBw+VJrOy8D6NrkSdeg3+WJzow3NF1Ncn31yafW0lJRvv\u002Flm8lyP5\u002Fi4ePHipPDZA\u002FNsjFD5\u002FVuzUV5EEti0vhQ+nmFMMwIovGYhXsiLFa2RmWquiyaRreS4Sl9bHXt+KFlK5r1oYzsAti6vNj5cZIBTTM+sLuf1u3n7werPf\u002FXzSiWeCBB\u002FF613INedHEjN0ePHpQ8lW\u002Ffn5fQcaWgncwRJpRS9deokOpBiw7uJ9xmKIlCpl3nWpM9Q2IFOeyiSbq2T30t\u002Fad6++ubb1Z\u002F\u002F4hetyevVD20Mlx4kBC\u002Fdciu646AxbrKJjEwbjUwyDqVxgWK8O5HoQOWApeYLzwApNru+zcP6jodzJNIi05q8oV+pFLPJtvboRJ5OzyIHF57sD6+ZOPze9+Ri60waG08\u002FEg3xSs\u002F1xS7wWrylC2gdsN69+qft5Sb3+93L85Id8yfH3HKmwPSlZ5PDuuBNJ+xrbOMM6AsgnWHC4JmDyZp7Mu5tjhPyaMBZsmYq5CxdnCcuHt4ovj5zZGlcygkw7T5ZAHT\u002F\u002FtYKzVlbxt\u002FLSnfSmefPn82IPVYZ5SJHySly5GAeaka9PTtwxkRvah8o1I9JndOXeDIyHxo25zb7r0tbaz1fkR+BbHInSkpe0iHpjWhujPVkkUiASAo8ZN5FLZ9G6wx8pUOl7CW0Wxb6UBZN3u+HRfzLANjons2A+kZAfd\u002F+ymP33lAlaj15EHDfd\u002FhEKDVdXgetT0s7etVawP2Hjp1cffmr30zE\u002F+4P11bXv\u002F3j6urXv6\u002FE483GHFZo7CLMBzM4FZ7gPBusFi2j1WNlDNR4Y0c91o+8lwGxRDTMlaITTejokk1prY2dwQMorzePsgwmVbP7RCK0Afwu+wzotEVWk+ONYNZT\u002F12DLocC+70PxpCEGXw33v0+nrVqzd9Wy55BYO4P7XGoFb0dwO9aPP06PuUxR28wK7qBM5UYR6ewGcDOyIQlzeeku\u002Fbbh3rRzB\u002FkJRVk1ystrxtw5fUDij8OEH\u002F++U8HsNy4cWM+NwZHjrNqebTVjsZUT6pwogoJkAiQnv84T3Z\u002FX7+m3njeYF7WiF5ZNSkzz3qOPFt542dOn5pwlY1AFuWTS5dmYdRovn79xiyMXDUKYhatCbWRBPhGUKeycs\u002FmJfICbK5cuRxzyP18Pl7zixkPqs4Y1608UQjyyy\u002F\u002FbFJTpBSQQLfzUN\u002FIa3IxLzwiQ7AXLl4YoayUk9BtlJNH\u002Flj93ru6Vr++\u002Fu77mGj\u002FpML82Zdfrv7q3\u002Fyb2TwLZJ0NkGPWg4G3y5cvx8SqfEi\u002FycNbfw9UQUJkQL82Y57X\u002FSRAMABDwOl+juKmVIHAk\u002FUHaPJWCk+qzanat7HGplHRhGjvT0zruSIKZzph9lUK4Vwh9R\u002FulIaUwHm2db3QbgQaw+7Zi+l2JCRJDKlH6MiW4BZuFebnZVHdZNIgAuoDcpuPsNE\u002Fe0Xq3Ut5E3DCnMAlgYr0ZzPHIu2HaYwV8\u002FzzN8bVhpfPAVD\u002FUQauj5\u002F6XNvEt+94Z+QsZlknKDqGlITtuW0ibF5UWDiwP9DYMB0GNUo2pn0X82Jo4yDseFO1iakx7aR2dNMiIAjzRQm5Bg16bSew9cV3Sv8BiodTwusdAvMP177vijerM3tORfsBlLynIia89X4SbE3p7LVAw+hVQ\u002FqEPgdENAYGnL0PdrG7DmAldAhPAs+cTh3iaOJl8w2grvLE6ovXpKfMXNV8c8\u002FL2QWzJsYhMkD58XxIZZDGhocYnubfM5ZqMg2yvxdgbA5sUE2J9rzx\u002FjUX24V\u002F1\u002FI0RTIBmjb+AfEJbZuizcHiQWZs7qxh7RnTKHGT0YssAtJ3\u002F9Xr2ufFXtZFn6wRw8zvcq01SClKUSDo0TVBjN8BIkB+vH+1DfQ\u002Ffw\u002FIO\u002F2YwijvtE2e7+MLINKGwedVhTnQ2A4cyoAKfKv7PHnViKi+NZ3jlVONhLFi\u002FHPgT8oM0GagMPYuXbwYOCjNpb8ZiPLfD6Q89JVnGbvzhj+u\u002FOXLlPgL3mUKMccC\u002FmNIyWW\u002FEzjd2nrauRSnVp+VUnX21PEAA+X\u002FOFqInkp\u002F2Xr8YIC6+WTUHUwuAZ9lj9afDKvAy+0fn85BZdJCGNvHM\u002FiXDaFHK2H3s8kjtwaH21+zmWG1\u002F2CgfvhtVSWrs8muNrTmZWdQ7M4vg1MY34Y74ImnnTLkGQYaRYG8GesMouOBg4f37szvokU2rD\u002FOuSKFTxrBi2j7RvuIfI4v5YYDyN9\u002Ff20A7hgL9bFlLZ2gja95URkD6NomUiBL7Xj9AXLnBOkMxAGwfRdHNLMLL0iHQB\u002FC\u002F4yNV\u002F1kPJ4qGny8PGd67IsvvhjPI1mNnsgGPEEuDH8MH7TujRGtTlpftGX9xpvdeojuegaDZ1fmSI0hsyYNBRRNwJEjDAGyjvc6Eu8+jgA8lsxrDudFRvcsb\u002Fd4lv979bh5L+35PnkcTVnnuaVrBij1Nz22tiPv3DcXuL8xziP6EHjxJP8D0sbJUptqeA\u002Fv1qfJZx7gSW7Ux64D3uLuSt7jv+nk9Ot10UuGz0G5Czr\u002FpzfZ0fjrUxKnyi\u002F+yClR+9Irjc98Gg\u002F+42hDU4cOJS\u002Fqr70yCklwEqkr3oeDCfp4vr9+\u002FebI3q34iXG8GU2o7mZ8AOayXgtt7FEoIJ2nn4ySiYhnEK+3L8Sud7hl9gjhdW1Ff2S2fQ4ANBn9MAygD3hDdM3GWCUjEwULaI9v53yKorKq1pBb+o6mXlaClSG4Fr9tprsOHt5KBgXSS415V132Pe1X25fzYb33ZvKLk+FNURsFHJyAu6eToE+d\u002FiRD5eNSMD9f\u002FfRnX66+C6xf+\u002F7r1d0i\u002F\u002Fce3p2+vW7NOEw3k0n2GaBRJ5FzglprIJYBrTy3ddlOPgHpQ1PxG72x8AJDJ87K4MQfbbJpVpeMAX8Omqj9xUFEb\u002FdZ8p7jA1GM3k22WsfRNxjfiwHUc8aB1HW7PEf+4xvA3wZV+wbGUZMBNE69OrO39mFU\u002FZ59mF0PEyybkZdCGP6esbT+bxvrrv5HZx\u002Fq9f+DR\u002F+SRgmLYwlMgwfUAWpCScqJjp8ttGnBAHhe9GGUJo2X2u8I+Wh1QSmkGzdvrH73u38a5lLT9Ntyda9dvZZiald24BMolTvG+uW5dMAPj6bQEAIF1KXaeBZvpkVzOilgO8CkSTfxFvRoTPry2LK5zOZGwOZk4PjTy5dr7+HqhxtLqNIYbCrgUQEYKRqAn\u002FAcK6vJs8HgxHEeetZe3pTA9H\u002F\u002F27\u002F9U44xb9StW8L9W+O14aUHtOQnUnhCnj92Ipr5kTd+5bPPAjEMg7xGjQNQwMhnWLA9W1havmlfrNYYOlEuD5DQObklD1ApyM31j6LVJaUEkVMGiH6MlJTGpU8vD\u002FEDxYAZhufdB8h4sXhrH5av9jAlzjv3Jga6XWj94M3C6HmBu62HAUsxWPOfeNwRnLsUFZfhNPzUWx1bYWvgMP\u002F1rP9cWZ93iRyjAvVjySaVXiVcCC6WvPXEpeP5qVkv677za+3tWNc+6C39wS2Umw9EDOZXbcwFy4WL4Fys7mmvNr3MxaYNXf3kCed52RczA0r7Alf+RhdaE7q2iYURxGNPCRBc7l36ZeYbVxNBuDPmpMygy0VgMR6fF35lgKmCVApTqTdSSYz5xVbr3Lwp4QkM+jC5lkxbPCMEuv6gb3TZg6ZvhAzgw5jFbwzKXaBqnUVGJqITLenLdpEDUQ\u002F8ZRZ2AT0+5xUBENGSVB90x+NsrfCP9Bw5ftbyRaAVv5hwPIFfDuddFhWjFBk4zgCQkqLfRwprnzpdubE81JNeEJ3Y7AgYMx72ZLwcbm4oYxtNpYdZQyfitsIzjlm71px3noGH9Hr60B768zt5QXmLHrxN0AMG1gEPHmgNx9NrblsfayDiYz3fp3gHPMSL4zmccUnPKd0DeEiOvaxCEq\u002F7Rl66U6cOlu6iihX+BnjqQO2ibacAvyxtDF0PeBjPWKks\u002Fb1VasWB5NH5ZNHlKz9pzIHhnY3glDH+IH9agrzywIcQbgbG3p4fvxwone1Q643WgOs7yZW7AfX3eV6PHjtd31I80dl2hh+wcj85YnP5\u002FuQFhTWLWk+lXR3JWIgrCvkH0O\u002Fdmzx0BiEFB3Ddjh5ETNVsPn3qVPNV+cdA+Gy4bKF4HG2YN7eHM1ZERS5cvDjnZjAgyeaPOrMCjzx7UsndfW02jVbQL5rBN9on0xlRxk2uMwQeJSsftg9AOJpRMceqJ5OAvnvta8puyZny8\u002Fhyb+mMd5Fh\u002FVjf2Ywsktrf1aGmyKUKRgnxQTniRXJEh1QlkhK25P57doZZ0RtG8uvWmCyxGVXUaYzm1nUAZ+0xFk+1fl9++WV9LfrTeNA9Q2RAQuMwN+h+jKL4YOiwPk80sXUVyUKnrtsfYAAkREDsocAPbzspU4olEB1V9ZOxHIU3Zw01xu3THXH8uskYkdYkzH4IpDivRc6NN7oLzDlZFvv6MS80N2320xxOykDrRc4MqHFp1y7rxaBYABOgTi\u002FMnpAu0DL5YxyqOZHl9NHzPMXOApjUmnjTiaauc4P1N5faNs8+NO\u002FDN2R5rI+vB9yJHvTQpmAxBqLc0Um1xYFAJr3O2H3H2Ko\u002FPKboDq8aLxnmOfSm6D3elzK6tnZnCkjwGjPotpPJInunSk1RB116kddsqu2ZswaNkWHPAUYmnUyXngoj8UhHvrYZ9P2y0TRSm\u002FGvRxPve77SpublWfMyJXxHiJHp5Fn7AI8sEelX0YX8+adhBFFAuvs050qCIcmS7qP4HLgkMlR6ZQcpoaP1+EjZ1o2iA2uHlHcsNafNqHNeBa2cLFmMIVihaNuxc6svTp5eXfrs8wz1G6sb166tfvfb3+Zhvz172Z5nuETypWcm5+p7m51GP0hVtDnaxlYSGh+mqiZrgczDcw5l2xu\u002FAs1jOffEHUqx1NOnprg1sGTJ+ugj91bzwrhDpFkttTGGKDluDcMo3AtoCAlbY7Q2umFoG07p3bXo04nuMdvQiIc6KRl9oPtxeKWnBtTXx6XfDpmMl1s4cnDR7zroXkYYPjLiD\u002FP6YED9h\u002FJmfyz3EbB01DUv+qVLFye9ggcBAAXWP\u002Fvs8niICHOeYSkyJnjva0Dj3XiVr\u002FzkyoALh3O4D1C\u002Fcf1WnolKJzZhhLRd87wih6qvjJFnQSLmr7\u002F5rjDVjfFiMxxsYJXioUqLXCoGgVQQhxU5NIigYUz4Xp98b6e+xeXNci9A6cAjVTgoJhtBKVrPBFYIfm1jLj95eAhOOcPffvtdgEOuppD0kh\u002FsnnulK0jZkcJiLJTKkSP3IpHKuXVcMK88r6nwreoBUxFlhHBLFj0AgIA2j+4xnicgpv7wrglD8QQBgQS3tAQWL6\u002Fbu4SAkC7FoArCjebi6nffVeklRRlzEmTPyuW1mfTUqTMD7sw3L8DJTnB72Ka+uG5158yj1akTGRUPzVX\u002FandAD+I2e\u002FXRe+dHfev3Pp6Q0DAHLBBQj4GAVsxiTkeox6\u002F64Y3pBtQE2IQUGWkLw2FSzFS7td1jd17\u002F\u002FA+CfbkGWB\u002FjjESfmxbAP23h85229AUjjsJsTq3H5EHqawJw3742mkTfgJPXbOjNgBvPce0aO1DrKehmjCJj7z1AIK8wIKAPxkVJk2A8yoQY0HQvQPHR2ZONd3v12eVLPSvaChwsnpbuTdKhtZev7o\u002FHkOA9eRqQKzze5ypjAAIEjDFT9ObRJCmHBUSj41d9thsC1g9e8L0JGgDA9RNurnvz6rGUJCVGCfHK2RwlPYGRuaxTvEA81jY+bRr+NB8LjSx8KgULzc\u002FGwGiJF2bASuDxZF7eS3l7gY+n7YdwGimwxNAwlw1n+i\u002FsP8p1pQoHAE8oAiBoqKf1ZsyOB30Ms+X7Wef6hyzIjV2yQYu8Kp6xr+eJNOFPP\u002Ffuq25xrVOYvFk2\u002Fc7aJdxdv1WlBseBS115Vp9flu7ihiNHioyUfnL8pAgDiiDAl7mZyhqFXJcQKRpLkTSvcyBRgl9VkosXz1fzuP0xgW7pMZHL6mCGjgM2rM1a9EH2tCgNprWJPp18uN14jwSG9\u002FQdD6oQ\u002FoMH1RIvzeXY0TzxrbN0jtc9n+HLg6i6zYlXbdJvfQ\u002FkHGEMoj\u002F0bMPlWvTwzt89SoqWQ5PGeCviMUAyA7bZ7z3LMBs4X\u002F7YhuE2cB6Xc37m7ABthpPyd\u002Fpvbt2w8OXCn3gLv3Gy3MsokO9Mn9irRLaeSV7evHlz6EeKmBKy0tNUonqRgSMieCDePHX2eAfWVCu+tTzV8\u002FEDp8O52hnsEh3x4h9oD8X+ak+TldvPjGFR6gyFodn+T9YCiuhKOwDCgITmGVtZQ3Q50St8Fw\u002FGRtHGq2ToTiGAnCrPM14mopos8k9bXvYXTR3veHzt2ULDOjL6pfZfNgf7XkY3ra\u002FIK5nEwLHX6HVAT872gVISgQMHXE3udjRBHxiFKI7vVEdpGJEK73oEqh+1jxf0x3\u002Feu4AGvRqzOQFi3rYJke6yXiJcZDo+CHaN7B9ZO\u002FyfzAk8mRvgH4DGd541jU2DjHZAf\u002FH0j3Lw\u002FF5kDJIeUB29eJ4bR88DepAe473vZp9RxghDoC52mX76e2ffUM9\u002FIz2mr0a2J5REpQEwvKO88hbDeuvRrHPH045Ms27yka9fv1qEpVotgfPH8TanmbmafgdAnweS3yWr8LOo9Z7kmTQKqXicEMsm76L4yTyVZLZyQmy9bNz1U6lF4wbWnb2gJOV2mGhj6KFN3tE0mW6jNOcIZ1BiYHTOs+h6oxLX0oGUhFWvf2+qWfpaArhnBzClCoq6te7v31R1plPHnz+5X7sZzPH42vBNG89LgzlYWeaNTjydyjF50vfuqxRsMiTgMAB1csKbxPUKeVz6yYnV2Qs\u002FWX186YuM9g5Nunk9h+b3q5tXv1ndimfzFLY\u002FqG60zvS1k4x51EXtYBNlphEa3fE+XZhYnZf1dc4KWeindSYvGYX4cXgyekSf5JMIBRk0r9YfPXqmdKihMx\u002FggfqNH12w7OtAk82Jj5onUdshzr73Gd7WP\u002FznmRMx6ie5NHRTW2iXcwtI1xZdI0ogC4CsEJ1f6LamPsDrgwF1YJQgAUhMJCFPUAG7KpZItXgSgBBG4NkjAOR+IvhZiBbJ4IF3HnlCGjE5UfRXv\u002FrlAEuhyxOB5MkjLFz5slDO5G8H2KXOnDlTacI2RiEIkwSMahNzuZc3j3A0qXfu3B3lj1kxg\u002FKLiEiqDkWgNjAPkbFgECE\u002FC2hTh\u002FKI+mlD6fE836dOn5ocdt4eLwpFGgG5RCndvXc3oqzsWCk4dwPkBKiwr7589tnlAevy7ZWKRFFnO9gJ+HnShs3n9d0GU8JBBRzKxiRLHdBmnVq9jNjWCltj6Mkh7ck2hIoIIOaLFz4KVL1d3QqUG48KDQX1hqDONr9bgQ073KUTrefJ460Qjpfyw\u002FtFkWwFQp4\u002FbXNMHgUlH6dCRMCfN+ENIRkjUhoA8fIPqS\u002FEvniyI4zmRFQFsCK0GTPWacKxiD6FGGvUs+5sXH5i3no6CoEXPhZtHYHARYFSAhhqXrisV5941LQ0SsInjdvLpWhvuaCn9QGWHcu8thbwnLBPAbllDIjAjmejK8JefqLQvDWwTifbS0G5ANus7LsARiWzMCta8Dz3vc67rIu8i5gehQBnhIF1JEieNec\u002FFHX5\u002FMon0d12G+0utl4qfVDKtZ\u002FR+yTwSjBbNxua1us3I9MeDA\u002FgcUTHALN+mXPj3P9o8Xrj1V0jCM0b+3jF6ueEuuujORkw0mdoZmlrmT9t8hp6jmsmh73xmVv87PsRcn1gZQbEW\u002FBe5lWkyb3GDbDNZp9+T751sRzggPF7OeHlLRc547kG1J\u002Fk8RXR4G3nEQbm91TNwGZ1IMGzvMzxPL9P3DuetujGFJPrDANpJKIAy7j1d24dnkKHTWnzWVpY0SvKFt8zRGd+6qcNdO\u002Ff5UWvQXTx7i3gyhgDwBwLL+VF2ccAQd66ntyz+xmv6BveYGju9k\u002F1oelCc72ZZ\u002FWTC+dXf\u002Fmv\u002F\u002FU4Cl7iyYyi40gknjHSxfvEcKEUCg83Pl61F9HpwSKT+wPIaF74W3nFAx0LfqGSq5HSGO1jTAL7pepYM0bJicCJkpLrzQvQaW3R4Jtobyu6k1rEs2yvUMlveXZLK6nT1hvfM0TlpONZ6xXllKYjpYR38ljzUYpdYW\u002Fyl5JmJI7CSw5y2JCH1gPf+ByNAqTWnEIFMEQzfI5+GGGcIRvSXvI8PijCtB4w+fTj84GOvIZ5C53OeDMnjOoxvI0ni776ydAcQB34tPY2hes\u002F3vYmR9+9bZ9Ez2C0G6hqYjy\u002F5O7Ii+6rm+m0PPJzRgQFv5TdfVV7IgCXL1+eNbLHxn1LlGBJDzNG0Qt6g2FGnljPkWk9bwALQ16rgQDH3ivX6gwOFUJmczSw3gbL7df4IZAQIN8ouqRUMZ4F2ETFFF9QblUuEdrGI\u002FMTivFa2HPmYocS46mu83X\u002F87V5QHc+QsOzPyW6HNBaP+faeGPkXdfMa+7XhMa6z4fzmUptvNIMQmMko3doqd\u002FJUjWpt7fp50VuzH6XaEq+tnbMk\u002FVZUtwW\u002FraZ1CAaej890MN4VhdvKocA+iHTrM+JY6V8ZKw9fGDfwZKesqSnBkYz6q4GPjlhAHWynmPG2DczmDg0OI9Gg2S8wgkiM0ot8ioPXyR7pbG9avxktyiWvRX7kwsOCNyV\u002FxwA1jvCGuPjXf1FH3DHoUNHA7uHFvpJBj3My+8gwhely82m0nhs1jInUIwyfRoQ26pZe7Q889X6kb\u002Fbpbe8zBmoCsyb7n29VQWbF09KXckRevBk3ToWXdZ2923YyFlazHZ0KaVru7mbdYoXL\u002F4kw\u002FfiZ6tPr\u002FysggA\u002Frr776h9XX\u002F3Tb1c\u002FXPt+df\u002FOrdmAK03U2OjBJn7Z2Nyc2FOHD182t+MY6zsksqdCAnurDCC9bW9rSU+qFjf6u3mnjxcCakzooHsWudG99dHC21RNvjF+Fuzh0dqn3xmVdBZd16w0RpgCuHavTizX4WWz1t+jQ6rKluG0q\u002FfICnrVtVPqtWufdAjVHDrY72r2r7fZ9kO9PhhQ11meZF51QIA3jyfWJALDLCMTuSj2NjMFFoFrFp\u002FNeoh4Nr5li1PArH\u002FhxwN5zH\u002Fy+a9Xn352qXJ1344wE5I6kpdx8moTiISf\u002FMknKdNJX2jyTbI63z9U65zgIAAvJhD1CQOgNt4dNYgP5O06XY47EHy4vPnjKaLnMZQ8cIBHa5hUCN9CaNv4kD+FwVr2mVAsAaA\u002FhOrj+uM6wo1yWjZCVRUlAsHwwmKUNQPCBiwExAggQFj08unfvc9DlOKUfiLv8HYRBv0wp\u002Fr1OuEi\u002FWWqlPSBuRTiI3RskmIw\u002FZiiepXCU8OexxIR24BoDq785MrITQDTJlqHHIg2yPd0NDLQQokDQ9KOJl2h55xss9WZjKab+0tt4j+prVdy0GtDfid+QsReYIklYc0qjbcc0tHnzcMA8S4DDF1v\u002FhZBj5EwULIrJiKQ5efqjzmNv8cj3E3Lc0xGL48cr6nfew9Qdw2PkmvibKBZX\u002FycV98LMbt2POlTqYRQW7w5BC66MuEY1DHUmFQ43uFdjEfpVl737i\u002F7Mx69qbRlD9wfTaAHIXPj89kIcICtcRFE06e8QIv36V1G5J3oDliVfwfMCs+mWNrQCtw8iwanbnn0IbRJaD\u002FK23M04C5H1hygpUTV0PqukBJ2R6+8UDxj5oMnyETJwV28E8u8yGu2iKZsLtD3fmMkDd9FQ9pFu3jLd0CUPNBZw74zl4AsPiOMVZFBG2QChSGCoJdyF6W2ML62ygu+dZORIwq0P4CXkmoOVU060iZTJdka3dD3UhscoJMesDOeeoJ+bITF50p\u002Fepa+mBNGqKj3eBT9rF\u002FdPPSJtqTLCKlLDTCo02dPTJpEYm08+8DD24xiYG42j646pKyS2DaZAn74kvyTo3ywjZjpm3l2umDWHsnZxMtQoOSlNAz4aQ73liMqdA742Kh0sU2aUnCufn+j\u002FgGpogil1hXZMGZrCOzsa355zwFVBvX5T07lVa4yUWN73gY0G5KPVxKVcbGnE1tVMDG+fa153ZrnK9G35Non12ofqCPfurj5kBufQo0kVIfac\u002FzE0DIHx8JrXde4\u002FD259M0xv68Nr5wYh7MO8A8lC9BTuhw4+\u002FLavT260AK5ZT7RDhprOsZYOBej4xceZz9P3j45cvT1dudcxAf3O6n09t0O22s9zl44v7r8k580b+0tag33H1oig9evX2+uHSp0bGjceQw270p1fNN+CGtBpuL\u002FXafR4nnDe8mGeJMBIWKirjZebiD1Z5HdQEgJUekWm4uTC8kI+uLCxQtTCYwxPHSRPCZn8TXnx4CR1kAqBXpiFI3+yqAzB\u002F1\u002Fxmxye\u002FzwufkGftx\u002F+L3TtvW9VKkcMeZW9HQpfQhA4tllPq1lqxQRLnuK9MGx7D4doNvcei0pKl0W7fhoruinNVvAbp\u002FVB40tuk\u002F+fjRT\u002F8gBX+AzMmV0vnt3\u002FrnHe5HD8VM66U2gLInj8sY6TLL8HQ9bDzxJZo7MaC32hQvm4p2+4u2Zs91Ga4icHbmvn5i9eREFxHe+Yxz4G4jlDOSkOnNaZP9ez8nbHoC0eXizKPKpU8fmd0UgGLu7KVFz4qs+Z\u002FjQA2Q53We+El6txfL3ds98Gf\u002FgD2ksZMPLaH+79aYXtuNf0RwH001aYDyqCovJlz7MSK3To9d7XOve2r+KfltzPHOiaBFeepYTgzOBcbz\u002FwJHmNuzSQV+ikWiFE3Vkd\u002Fc4UOlNUb89ySjyaHRrz9o4WGWro1WjO5RjtdKt7YYo55rnPewRWGdgkBvdPvNrXewBOHSs9OMz54oAfrr66Rdfrq5\u002F\u002F83ksl\u002F\u002F\u002FrucjR06Vg36I53NcJSObCzPM9LJLpgx1hqCwF8jnwcAK1lZ2\u002FRjcykNbGirORkdGp34m5xHF+iQY0GVrJa1viVf+5z+Htrbva9HkYki02iI7vXchUa6svH08TwDjcOq2hr92U9YlTG9i\u002FkY3u5hqDOyhk7pvGiW0fYhXx8MqMurVjtd7uJ6IBwT3mvz5AgjhNukzu7lJmby8QKjPpMqQ8CbdKFIR4UfL+\u002FLKYzaIIgelxvNi\u002F7551fKs5Res5Fn41lMdnAqtwD8Ugb++Ic\u002FTO6tCZKeIi9QG1JgPBMvm9SzpcMQ3Lx5d+\u002FeHzDPay0EPLnsedHO7Dud0XFrFoYA4UEFsHm9MdDUDY4MJpew590KQEuZkSqDAY29JR7ldLL2fmy3vxJGJxIKFtphSbuLC+A4xRTxeZZwHLBubnzG82dTKobm7Qe6ETjw4Vh2pf3UaY6iRrB7DsueghC1eFzaDhA2+dURkc\u002F9TcBZL7vLHwT2nwf4jnSAw4lTZ2Ji3oPFSwCgC3fjqVNFEc62IWwr4aNayNXrPwR+npcH2fUpPPnZPKWjlCP7\u002Fqxfw9kJBd5d4DfeFBvDRhhl2CnGaezWaNICunEA8nwmQmNHPm\u002FWq8Bx4bjaHiCIoeY5hM7Oe7htmh0aG0bTkQQ2DnUHBZyMjz6Xv0fIJoHQ5FxVW5jdABZFEz8n2H0vrUiURkiPcHi5FYhq\u002Fs35eLG6TnkwglSeqzQPbZkT+xhGkIwRkHoPFAFnuyAdINc2pe3kTkrXbv8BhrVPwS5h1DYrFnYVPkX7Js4QF6AjH1hKglBcAi\u002F60q9JG6pvpLO1BCa6bPE8EGZ9iC4YLa5B77MmXavPlLf7vAb49veuB928GO+SSpPXJgVjraWGyANFAiMLyqN0z9O8oOhHi9J6BmAM8DHHPC8daJKSsQ9j+8TLDMxT8UTRnRQgsE7hUaTSddAPASxtYzG27LWo7+TOzjoCxSI3Nb0DOnilGQfG2Robe9cal77Oial9vpGX8uzZPM1tpt4+stTZfvxYupeNSKWYBEIJfPXSpXKMUnxSfmaHA20ejB4C6h46KYEHgdGeoS8pcIoJSNd3oNFprbxMW60r+fEkGTcHntXudnWYGdKtcG0JTduEnOGLrhqT1B1Hfr\u002FJMFGajVe6j2tbjfv29RSB2Asc8rg1RqHlAccpQ3QCYD4pNK46hvSbAdY4a2ghoJyHfkLh6quLFrWGvPsjo+MbQJRRZW8NgM4QklMvbcDmTjwqn5PslA\u002FfiiXn8gzXzz17RNhEWB2aJ7d5qZfO2TDpZhEpMcEBsRjvgc+eZ56k1vzil+dXh3N0HOl9NFnL0\u002Fi4uVPN6o9\u002F\u002FCr+fBUYc1hUUYb6gUfGI9r6Sh18l+FFuQ4DdQXgoh+cCjb5Nl0BgIBeNM6gNN8AsGhId7eWjMRFdjTl87eo6JUrVwbEcW5YJ\u002FpNhFVk4HQGDLnCSwnwj3c2fcRjRwL5R\u002Favl0oxoLrP9ds6AftAAaPJvKj57WAqL\u002Fft\u002FDL0PDKha91rzYAffAKQ90e\u002Fu5pDxC\u002Fei4yevOgR1Mu96MszXTdysP7gHQbN3jye5Bp6IgecKUBOTBpAv0x+efeirf6bdvwUWdSme5Yv5vHz65TII6DrJ74cfQ1o72nGWw8v8zf8m4PofWOZobcOkCSaGtXSvebW8+h7vAhkWzOOi715taUCilxyBDlJ3NkJr3NMOW3ZwX8\u002FdrqtE5CVyHzxAkCMbwNsI3MmbwNYb7zkf3TZBMWrDJl0VvSzVZUzM0sGuWcmp7+t\u002FYtkO8DHKRETz\u002FrZ8K+AhMyCO731lfznsBg5kjzQCKMdUN\u002FFVeMka\u002FyHD3eoVkD+xYvHzY+zEdqQn2wxTofNvW8D7tsMjFay+Qh4vi0l5V1lI4tkvt1O17\u002Fu0MZnd6r3nn47UFpcnnZpMXuq579Wacc9e\u002FOSN9apUAR2NN\u002F7irwfbY7UbP\u002Fo40\u002FaePqLDk76avXt13\u002FsXIXvZ+P3y6pkAeuHwzL0G2yiLCMcxEBGn9Ipgdxx1qHV5pqzYC1jUIrK0CAaaqboqcE00Qk5oR1toCcOtbm169hqPts1NgdzNPShy9EZHKatyxjkaLznkljosv+83Es3+JMzSn\u002FJbvoNJtlbSqzrGe2ijmTVeOnn7n\u002F5\u002Fz4YUEf0JphyBIoJkzttWFsA58Z4CBGuNBiTzSsKFKgWYz5GKDXZBISqICxeSvhxZRivXv1+vHVyxpRUdLLp1atXm6xFaFCWNpQCJzZrOozDJOkHIt7tj\u002FAnjxlhIxddLq\u002Fc9Ad5ZXjfWNYfJWAfPT45C3Uno+BJu661gUF4mimUf\u002FrHP0zqC0DM8wV4Ox3y5o0f5m9eMODrUF4s+fnmwJgtrJx5OXIONEKUynidPuXERe9CcRkLky4R8RFEgD9FyrtOmV+8cHH1pjYAwPv37laOqZMAm8e1xs6zgbJsyhGm5iWycYlCsTnGZlptEG5y44\u002FUNuFJijEuED8PvE26lC1PsWspLJU4DoQ6HCqh5GBLufriyuXV9cb8+qurVQpps5nnpcjmkKDWlOwnDAYo17PxyOAHz8F8SVJKiKXPegWkMejyO+LWn5Soh9W7Jd2l8HsKSiShr4eB+mJhKh\u002F4rzUyJv\u002F87K\u002FaJLABMozYZzvzi\u002Fh815Vdl1Loc\u002Fcvii0p1ItX2GfoW18xsfucyHi3zwlbHumabj0dKvR4jMgLrRWP9x\u002F+8McB05ToZpttPEkfKI5XAbD9KYsRMGampgFk9HTh55\u002FXT4LAAVqlHgVOlXuTxmW9RKjqxswZftL+RFui5UlD60na9SyeI\u002FQqiuOal516Z16mjaaeEKLYzIPIje\u002FMHNDk93mZv\u002F6NsjbYnS+Wme7q\u002FjZ\u002FlIRNi0v+ttB8+fcpcuBxVFa0wksp5xPAG4Ohn3ubS0Y3Qw8AHJrsMcuBVymT0qx4SVS+mVrsPUsf6tH88\u002FuykvpiJJafMjLXaARNLop\u002FRtfz3qWw5tImnqJzXT\u002FqH1PwXRGu1ieAC7zhT2t6\u002FdrN5FkVFQKdPL2M+BeBRv09WqRJ355Vo\u002FtAJSb3FIaVd30w5b9ZdZhRjBm5nrU74YwblW0Y7IwJm0kfPlZ\u002F\u002FEny6FLPPxLtNR\u002FxIaB7KP7bSDFu8vI1qNkwFl9KeznaxlWyFEjiHZzyggHrt3lcc5GkZJqUpk1UBN1b3Y2qPgS3Vk9sUM4zN6Uo8\u002FIC62jAtfLaKfu9ax2M9opXPxrJy7+RIWVira+1fJ3SPtBP5TUBdec+MGQMV1k6oX\u002FlFZWUtEGa3B3e7ILFowaIOZjqSXzlTAabNMv1j35VUCEv0B8vuPSCixc\u002FWR1Jrj2NXm50ZseTr7+N\u002FwKyjR+w4WQ40vwD6fQF3SCV4XDOoJEN9Z3CRy36P3I6+qV8GWuz8TP5MyChMS8yC6f5F\u002FiKXlwrFYWhvlEqEXr56U8\u002Fn71YxkCmvquNB+k6AIUOlD5ELj4qcgawoVzfTRSvvpt3gJChjJbNn3YBEylO\u002Flb\u002FnsFhQV\u002FnAW4qcxC0no1jPL61Dxy+jAbJg5HGAFFtD6+HYMh3vIBelrFZzgBtE2LuzccSZcBT7ovb+uw1uqsP\u002FraG3uZDe0u0LlrX8rBh9\u002FmlsfBA40GeTE4J8t6NdMU4SwjAHu4Z7+qTcSrNB0dNFCw9gWZ9DlzJm3\u002FXeql\u002FPvnNiVePJOe0vYCzeGF0SH93L1kOiMMW+P1Ym6tF6Y8fPxxuKZLJCBnZ\u002FCI92SnRVXgD1I91noFqJq\u002FalCu6Z0M6ILmAMvKlv\u002FtMCqmxOKRNJGqcQk0p77p+icig3\u002FethejIeqkyshEYn8\u002FS1zNX+tk\u002Fa26zPZ5m4JHz0nAeNd9wBBwwDpLBXTno4rW4u\u002FFZF6CRQ1QEkkxmzJXCMjnrnBk7kcGhjegv3ZWkaOw5UeLjzTDJ4eNnM8wfrl7sc9JpaWbVgz8IuB\u002Fs72SOTblvGzNUbO3Jkf0ZCuf6\u002FtjJ9iT+9Bc5KW+svv3q95238E0pdE9Wb8iVHAUWcWQ3+ml87zKuxlHU\u002FNM7nDdwoFTFVrt3dGJ+u5YcwLfOaxgM03cLrfkFPUXT3e+FHtCPl89HN6JBvNUX+BDNwowbgewxmqIdBhSDbOi8e+E3fdbXXX37Yu\u002FOevU5Y0p0hZG1L9k34H+e+i\u002F\u002F3wcD6qfPnJoJRIBewsC82gYrH9xkmBib2R6W50wR+5uXwVR+9NG5CFpYvh0Rw7iL98AGDLmpwKvvz310dvWzn\u002F1sALsybdJhvv7m60BlOWX9jJmuAABAAElEQVSBbM+8f\u002F\u002FeeFEQjlxI3v7bgfS1Uj9+7GRPgufCxfMRViXW8tIqe9QZKSmG6vyWEsKzo2Te3bv3BrRgnIe1cSoQ7VAjJ8lp0\u002F2AOI9hXR7m5A21iKezdG0qWUKd7ycHniK3u5jBwvu0vZmABooSxLxxvFFy0r9tTBSy9j\u002F5tPJIp08NtRH6XixuygcdOsb9SYw2BBjB88iYczlqLEwggbrF8EcyKibUU28ZH655oK56a+WQk80MDLnQ0jeOlOdKCQhlS6d48zoruudZ3wcdpPOyMPDHZ0+u\u002FvJf\u002FXKOar9ZFRhAXa4oYwsQI\u002FzNtVATqhjQNONdwrUGhS54o22Wdd+ilKR8YEbP67Pu3Z+gRC8UDwE5Hpbmh0BHMBhXe\u002F7afVEi9WI8wYQexhklAbyOUFmerw\u002FWmPIa8NKDzd1swsLwXasTCw0HFjF1\u002F+Qyvmntt\u002FKoa38Moz6j0D759NO8NJfyBJ8eYG1N1FvVkD44vEtUAvh\u002Fm7dTTqneSmORtiFy8ud\u002F9tPFg1b61WxWbXDALsEsSiSP8GlHwh+N5q2vvFvzQviM5yWhsyvQpEZpA9jDR8Yih4+CG+OoMaZD+9ssLu8BUM2ruVnWUt5dyiWFsgis6Ky58L210SZhJnIArHuWddUaGgNmeJJVLiCgeRp9J+dWriVv4Wy0ba4nt7L+A43zPUMoFY1GxiHQ88wzcKctQNEaoG\u002F04TXriga6Vn65Z\u002FHqe87ua4ACWkjR1P3lmuaXt4p3m1JQIefRo\u002FuVXD1fPew\u002Fn3ZXN4qIRaPA8Hohccr07p2HqwPPCOqEScow8T9zgbdjg\u002FgtOVM\u002Fdj35CM4z1EWnhJcybgxmeZlVACkFa88ede+fzWciXA+STyIVx09Kj1kUeI71AU4U\u002FfmiXQx2z3K654u86fL+5Znfi0eVwztWvvj+zgRgkFkPgMlelH3r8svNHc\u002FrjocrYCii87xNjvKjnSYrLL1ZeP3k3s0ARo6P1h8dqIR16\u002FaPq7c3bk45RBVPDkb3AN94T7uvFRsHjOo51oshbp3Qmv6I+gDMjCL81EfNncpAB8YJwgsnRZHnk2J1GNvvv\u002Fluda2Dwu4kk7drR4ja3iZGI155h8ajeYffkK\u002Fku9WZEmsZyeidkm3wQz\u002FAG7oag3b4xUZvMmABFsZQ16ONwGkyiMwVv2AUA20Mt0\u002Fjf561RxnVLhZh4wCJOQfQ40vGNyNUWuECKmq0Zyx0F83iz8Y4fFnbI6M6SAvwY7RbN1Fl82DNHchkI6k+ADn2EQH\u002F+I1cZQgOyKmvZKN+0zH0JHw3q9Pf9mSQ1Xja27Ve5pPD2otc7qvxLtJ3dAnQaB29lC7En4vHHmCOD+sD2jF3nDFLWlFz2bwvr8U4Qf\u002F9Nn0eHu\u002FaGpjxL+AnSaCN5tALPwHXE2FLDuwtpQNNGZfDdaShjcz2HP3oc50Yp1SpdiqdrK+rFFf6bk6\u002FKf9atM7cifbZK9NT0sNHioTPrRXKcF7MUraPrHpU1P9B5QrRzlpREG0\u002FzthOrPSKz2aegT+nmxchjXYO53BSUcb9DNFZ7xyIHDFbPch+Dwdj2T+3lJxe1lZRCFFxztH7Xb+kyLbJdAzG1uJNVYFyFBw+fGycmkqzPnhg3xReKxUwGSR6QO\u002FKgnAg4oHSjd\u002FlXHlTvvqL10\u002FaW0IupbMeBt0zyNf2ZhQeVFzi3GpfToy9VWFb64yG8HwrushiEbb1TkIdI6n121Obp86fLI\u002F9SoC90o7f\u002FH719R9\u002F1+bTq5XcrmqeeeluJQ1fMyabB7XM0ZVIHrliyaztrOcrfyebWmM0vxZ9jZOvnxPlaM6RF5mCbujZ+aDfAX6focOJPvasMdhmXXJs0ul4J6BtLRDYOKnQ0A59+qkAA9mAzseznnxxHb6iSxT4EHHyHM6dD\u002FX6YECdRX3xwoURINJDAHKbH\u002F2O4Az+woXqkAcGgRbVXIBYYXzpIG\u002Ffdixv1wGj2iJsCSaEJB1FGguPIKAtlEkIYjZ\u002F\u002FxCoIWi\u002F\u002FLOf5zkRJi5\u002FK2F\u002FtIoLL18CK6vKO3aCXmkaFpEg5V32nCd5X+b6GJJQ4gU8lHWtrwAyD58F4llxL+A5CxajEFaTn9QiWZgjjQ1g0m+EpSoNi8yCfnz+oyEaYJ2nBqEBMzajAs02ByISZbdUuZEbj\u002FEopL\u002F+63\u002FXXJ4NMPxYxODWjP38x+cGQKtcY14mnSWCJniF34ZQd4hzISwAgfcspZdFTrjZZHU7I+rjC0UqMkCMbyvv2wC0CFHYnfVol3YsNAzT4Ieh8hE1f2urSx0I8eUXV2KwGwPYHyeEthyDPISe0MrDA9AklkdYrb8FAGKW5nreGNG\u002FhK45My\u002FDqP3te0BNuB5TmU\u002Fr9fRJO+KStdjQeC1wU748c4R3Cz7f+n\u002F\u002FatNv6IAw9JxhwoyJ9zyq+urLRe4PYKCRhLonNF8axdIskI5xl7QRITXKa+Z8wI61XzbMMhClTnmuOUSXlJM+98sAIXQh3zm5NIKCItO37Z4xpQkTHnU+YGGTc6XzovnzF07M0dAvAlhPX9ybZ1PSgPmzwpb2UKjScSiPxsHmDpDc6mAqfMUjBcgDhDx3DX4UKXoFFIAJgMsbcEXnSzjRmtiQxnPm90WAmlvXGNPMXz\u002F9rm3eHqBd28KkBJmxUK6MrSX1JRqrXN8ifAMb0QFqcE23DQ9PuDavtfEBQvJLzTH5ApSbfw8FLMdYqwnrOYK29bM2vDSABN4mTIF6ytNcjAE0Y+VcEIHLMC2lSaoH2uNVvnnzWoa6Ddd5nJJRPSiv6LGpyHT7Fnm0NcDy2YHF0D+1Vo5nSvjOnQero6W74LV8fvWjeW1OJjLUWqBF4FqVB4atUpbIWb7qhKffZJAGaJ9XjYRxUlmT5ERgqLZsFt27rj557TZZ64EG1Z9s1Lc+ZOuLvFd7GltTlvLN+VAovxyYvm+syTuRLxGgt88L3TefjI3zB87Hs81ObZgzfUah5lH0z5xPpa3ASNTQtSnYaIKi2yiqsLbn8dSV9pDDReyMkWxDH8D34nlvDaO3WdOuG0CcTLdm5oPsP16ZWwYWfuiRo\u002FzQEOeB78ewb5kfBGquXu9sjmQlp8SRvtdGj5s5QI8MS3XyAXRGahIpOfJ4rpNyiMfj0jHglNe0Pu6PO2Zc\u002FljoKJnQfKDRSf9A2\u002F0bmo6nAGHyX\u002FQS+LJHiEcfn2\u002FKYx2azghrbl+3FujGCZuAF5nMeYVNevDMv1+6tD\u002Fwm6oZvHsLGMczeJ1MsfcjtTTgWPeA4T0ZfmvteVgqTJFR0UmOgWGNeGZOwc1B5aC7kV\u002FJSKNZAHSGSRVF9mTEDH83zjEsGrex+x3IJxPMtRdnlb0Mnme8aGIivfHqpM9NG4v8nXqy3cOowI8DqPoe0xsXmWH+vUZ+DEEuf08X+rVHDy1JebCBNjIZecF42sNj3P3e9BCAqg8TIaptcsReGXKE5\u002FxJVc72b5ZeEk\u002FYuD8yIS4bIye6kYJ4sxPRVRw6ebIodJ7zjyYdTsnmgHIednxEn5OPNo8C5Db62wOxGKDxTfRPWsI8ZBRe0H\u002F762Aic+EnoK6ogCk4nkPGWBkPLzOYYQRpRm8ypvAmGiAbjN9eIPxhDuylsX5rvfc6iXTjcMUao7fGq1AER9t6\u002FL+v7IWNSuPqey10rTS85qrleJZx\u002F+Z9KTE5LQ4cThb02Ys2zb\u002FeelxfOh0+Z977onv7Mtgj8MbCaOx5dZhhCFDTvfZOHDp+ZvXlr4+sfvblL6a84z\u002F9w9+VFvOHSYl5Wvru6xy0nDWHRQ9aBwZs\u002F1vokYzfWUvzttY+C+nSy56Y9h2ma8ifLSdM93KNudx9IS2yY6GN\u002Fugr30bJc8nQWH3um6FZtKw96ZV+hyXpcLw3EZppu2ewUmpj8Gryk75T1MEa7tlLXibTPtDrgwF1BAPoAbZ+OpmPgFSmkQAijE2WEI+Sg8A30AloC3Nev35tSc2IyTEXQGyDJRAv\u002FYN17GAB9\u002FzDb383QvncuXKpU9Bnq8Hb6jRRrPR3wxAOuOAJ5hV3lDogjSncw+tuASgKHmsLSLHpn8W3QLduGUve6MCqv2\u002FnscFkQDEvPwWyVEA4Of2T92lBLb4awoQCYYYIfqiso34oT\u002FlR1vHxNl989dVXhYRuz7OPpFx5+ZZQ7sUpmehvCw8oAWrLDvny1Lp2MXRuZ8TYYHd4avUuQD0AmKBwTw8eDy5FhqD0GyMAUfF9zLQ286vf2hSxsIkFwxJQTn51VLzDkg6lzGbjX\u002FOLgDdTLPsLHb\u002Fs2rVKvp1rw42QEWX5JI\u002FVo4CF0zd568bLFMMCVIDRRj8JHuDdfNs0HHt0fe9BygvDSN0hfQimOaK6+55FU4\u002Fr0+PH5e\u002FLua0NSsYce\u002FNuTTsYyX8eZNVG+Pe3z\u002FrfGBF+j84IkQHtO9\u002FNRd1D2OgohUMhvSmlBw1iZulD8tPXDgNRCdAAgGumKkVzA5iwrL\u002F77rvo6lmCWc1neYWACAMFUIpWapNypMDRrfEADco8LYAy72wes6dPjo\u002FSR1+MulUeogFSrYXx7+knIGIPA5oLBc33wDcwRujy6Jh\u002F68two4Dni77c9dKbB3yUo6\u002FnL2u0SUiNMmwuRgEvhuoIOU00mP\u002Fx7lkNhoJCZ65ZIhP6EwJJeDeFzZd8aOk8i7KyJtow1+Zo5ikalvrGEDavvIfLOkZ7HcQEDBiDe0cJd7+hj5BufKscpEsYmNCO9hr3pDH01UR5mjPKwBzh4yWszCBYqpRspnjIAkbL82fJtlKU9J8M4jmmZI\u002Fnld4uHYN88Vy89\u002FKJjb\u002Fla6fwH3xftDDFKAwKTL2Lv4RpzSf5IQKCFpq0hHoGlUO1ev5GpwdGMq1VALzw9QbP1ZvSRTJ3x3Bqbqzz7B3puYfyyjFoHpQ73yQFZMv9bh0OBf6qTxhAa6FKvTl6FBh32FnANSUsx1stfnyhYhADn3Hig\u002FHA1s\u002F1wt3kA4A+IJt8iW8pLmuM9luFrm\u002FNc58ORU87zqRo\u002FcxtDgwv+gDvmH\u002FeMLQOzIlKmr8xggNRxuBtbYe+pdkkG8wZ7+3R5h1tLScXxpd9DjCKTDAQ8TdZ3Y8MlZ5Tm9IBPYvxWkuNPYPLc\u002FpsMYyiy4yFMSq61ymn1kdofQEeaHqRL7PvA61avLz14wipfXXKAUC8qWk6j6NGPXw8jq7tJQIIpf5sl9ImrC9ScbgDl+hJ3nR8QD7syjZsOfKtaxcZ0frHSOpxA15vK5QupU5Rl2eNYfZAxIO86k1s\u002FwE85o\u002FBuoBsfCgF43WboL3snRgAa2aXj2YMTUWvZe61YchKENKd9CLD1WZG+uPIkWRZdGGcwOf2MGTtdd+SDlnD\u002FWddhm8B7H43V+ZsJH8PsHrk36S69OzlNVSmdzMXDPahrfa8oDuPQle11jh7Rn8bo+6TLX96eZYH9h36JROdU\u002FH20Lui8vbB7E+\u002FdHXzJs3I\u002Fh944dtOH1e9ScqL1M9DB9u83Smgt38sDS4Zv0QDGQPOJwgSx1scYy1\u002F0dNyl5MHTheedQvI+6lf5stcTbQiOrWxeP0ZvmNkRQfRA2eLA7zQEucQx1k\u002FJv3T2pLvrsWj9IP1MQevSnd7cL8TyaMTxkMzNJPNOTV15IskvG0sz0vPefEcMK5kavtq9hXF22pOlHNdq931dOSqiibP4\u002FWtV9ej8f3tCTmzOvnRhWwu6yVy3x6Qaq0fbBPqvgwDG97JNZVtGLfANGP4cGUgL+fpP9r9X\u002F75X6xu37y2uvrtV51o\u002FG16bonKv68freLoeOlk9kaR3zDbojM4ZVq\u002F+BNfiKKpsoemfG\u002FRzau3OUlsD93t28EM6HjRdfW8a+S\u002Fv7FPpls5X9G1ueYYxIMm+337MHw\u002FtNM96HCeV+O79KUvf4pa9Uxk9qFeHwyoywO\u002Fe7ec9AT+8UKTcqARH0XHi6wazNdff1Nu9qNq2Z6dNI+LFy8OQd68+UNA\u002FeZMCi+2o9qlzniZLAqCh+pInxM0cqsBT+URMZv58DevxJK3xNosvzSl+qhccID39GkAPSsw5ePlwJjmPfCsFOJGudbyTpfa7qO8U2iIAzgAglUX8PvxSvGN1z3h5PAYG0UZEiOU64vn6heDxGYolvadOwDU+xT6\u002FZRS5ZkC\u002F8CRlJDr12\u002FM\u002FABQ+guA2Dh3rlQg\u002FQGyeY+k20h3+OyzK3ndq7VdZRAlHnmXzuVV9\u002FzxYvYT5yqDebT0m6MnTk\u002F\u002FeY4INieVPmkNeHwuffLpeNIBMIrfnHs+K5g33y5yueDbjUHqiSOqeaSEWz0X4NqXonKUuw0i10otUn4SThoFEEgc5RxQeZ0Fv12aBnpggWIgCpBXg9RE+DhCCGsYy6f1yfXbWdDmlUKWK\u002F+sjYj7T5XTVzv6U1PdSrEngLofrw5grx8D7vraz+VFiS5AHMOiHX\u002FrBp7E\u002FMPEc3nfDvMvjE1VdPXco3211KfdBJ8KGkClz3nb7IFg\u002FD1zWmJzxdOG9pw8acxA5NvKZHFpDxDoMz+7aIQNsKt3amjzkr547pTHoguNOcKcPgIeBAn6lhJAYNh0LaeXAn\u002F+PLDc9+ZRFCMjvxdFF4l07Rgy\u002FQEE87Ci8zGsGBEJWoc3UYjaowj0f0KI9cyzZ6zR2njjuw64mPVsLEv4jwLhMW+9CUTPbAp5GhzgNd6haM66aosxrX+7QhYt6pvvlpSnBbz5m4JCJ9MvwK97t+sTQbsLrKyr5y2gRsqZZzQuoK7vjO1QAMkGJ2MEDNAEXuKNBFYZyCp9KAlp7wneF9Z2v6PbASzy7cXzpRwfeQXwvc3zRJAfbZ\u002FKZ599XrGN5MCPVeuJpw2TQhEq5r13fsHT53muUmry0ffmoeJdt1nYuPEAYMTzKj2N5xgdWHcRONVPGIR3S\u002F04fvL06kSy17y8Kh8cIOSlOnC8MH3rZ304N9ZLvTqi3vipM7WDZ0b1YIbhIfM5niRz1T9zSBapUT2eqQ4+W7Oxr7FKl0M3mxkIp0+fK+2lUq\u002FRm7QThpux7kZJ8I81elB6Ihngd7LGnhHeQOkLo1yjBLzIY+mFfoxJTu9JaYXJFClFj5KBAFVL2w2lVeHfamF79pvkpvSPrcaCXvTRQWUtcXIrcBetkW3vWm8yQ0rR1EJONndH9zTm3oyDBTTuOAX0pbWYucJPzR1Zbm+VCBnDfPgjetTOYmT2gIluBKbi0aa5dQBdeKDt04g\u002FZm0AzmQCuq\u002FNkYE79Aak46sm3mB7RmOof9It1gPrQvr2vKxUOvJZczCytXbon2X9fLLz2umD5swNmYA21wIteFAf8VrD6O15xsPo7v+BPLrsdfJYrjNHhDe64TR4MeBTZM69yfzoYHd87se887N+uWfxVNavOjP00uf41f0jn+tjXZnXLm2Kojs1d090+aYvGWj4xQiHXpsbRtUYhq3D\u002FNc1aNJ48ae5o+dfr+PX5QG7esFP\u002FEy\u002Fk9dbebkZv7NJumIX5uv6jWvxaukzaCaATB\u002FgR\u002FJf32ui15Jr7jdteg69BRC+p7ejQYBx2T+2OPzoejyu7yODMmY1eDgeW6IrRYiaZ7KT3F3Kl3boZNkC6\u002FEmA0TJU+9lXNFhTiJyjgyEo6R08sJb1wg\u002FY7K1rK03HVaE5uW006cOv5NOY\u002F\u002FJnIya\u002FEBj63vjr6JTId38ATkEt4vGv+7gpUMn60+58XlLANv1jCmeE1Hm5\u002FG65xw+dmoqxXz++RdV9fti9c3XX5f18P0YPg\u002FuVTo7efg8zz+H3P4DGeZVq3pbBTxGzexlwBtZLaNfmueF1skW3y+OKCXB0THsYK0nOt6622QOiPvMGnJCrhUJMidSk60N\u002FmmiZ03IXteh6x7V\u002FJGIsMuQ1KypVDTPda0+aetDvszgB3nZMPeLX3xZR1UQqfRfL4zjkB\u002FETuizTOV6yxfnpQHUL1y4EIA8ON5HHi9MijHlijuIiGcS0DnTgRly0KWsMAqcGIaYhMApMp6Qb74tt7t8dsxJ2TalMVmbhvopZ\u002FHy5U9H0T4sL\u002Ftswo+CYAlLKzmScXG7yi\u002FPUni8YcrB8fRo\u002F139EyEQKbCAjAkEoNwiMMarMFZj7fWocr5OjiA4V38xppCXDQaEiCozCMQzbRwF3uXpK\u002Fn3j\u002F\u002F4T+P1++KLz1d\u002F8etfj0Hy93\u002F3D1N\u002FeGNDbuXLmcNjbVi70NwB0jyxNqZ6MAJ5H9E9zCXwth3WxzIY7Ao\u002FGfG867qxUveXp17InKeAYcM7hTmlaYy3CyDrb0piK+E4G\u002FmypB2EsyfwQkUAGzayQrfnSm8q7r669sPd1fGE17FAz8NHVYWIpIV4MceAjP15JwIOBKO6tQOgI\u002F5s2JkPJI\u002Fw\u002FQS0MLiSdxjqTSB\u002FBN4wZGsbWKJ0psoKL4okzubU\u002FRhpV7m8y6u\u002Fe2jC0nIX9N+SXtNzugGtoZf+m5splVGyfYDB5Zn5CmsyOnrM\u002FI2+zKGcfQCCcmUkoidRh6XdPV1TukHPACasuxxfD9JHz1eBYV8\u002Fa2Cegb3xuFrp9zuwRVSHkfa0v3livQBmb0rcM0ckpCDU0eeFpgCF1V\u002F0XepoAPeucqDtJvUIEOie2G3aIZwAEwrVmi1jXsDEoux4f2jLBczuAq8F\u002FDR+cxDYeFlI33eABoVg8zGgzjs9J1Uq+hW4Uybx+PGOe8\u002FLJI8aEBAKn6mY+YzWet7S7yVSMMZd35k\u002F4HgUdWPGizOnO\u002FPxtnQRMiGKmM+t56xJ3Wes4kWCdyNQyHDyHHmeSxqATUFF0gao5yhIAAOTHstZQOaorzyGR53dCDAC60+f2uuygMpmrfVOriQnPv74TL9nvCX33433ybwwgABF88ZQYdi9KYr1opM2Sx+J13jf5PiTofiB\u002FFSdhjG+d2Rim0kz3Hjzrn7\u002FdSls9+L7J6u\u002F+rf\u002FyxyUNB45oDFD+k00LHVKhYVlSlrj+u0kaDWarRNvLkVzqAgdusJH6NovqrUodSt6FLcsjpQNKSIZCqXXMFjmDIdoZwFIq+ZkcQy8eP40edC5C60Hr6v5IwOWTenWaQGagAXDiFwgJ98\u002Fle+ZEQLM1BdjndSW+nfiROdlZAzcU6kq8OSgqommNjevag\u002FowR882a9e2JhcG9EA+gPeyS2e7QG90bMIIsPY5Ig6MgZS4f290D8QIJ\u002Fc3OHr8ar1HeMGrZs3vNMyDe8sfNLno\u002FClJRgbSL5zTXyCp\u002FSBcUnGyu\u002FWT4ZCOQldu8iIAetdM7IjPTTzMzIpvu5+9NGX\u002Feye+MwhYPo5B2QlSMZw7hKXmcimd6ItaHAMrmgfz+m\u002Ft4vogV0gi3e0Pe+eIwIw\u002FBREk\u002FpoPjyfDhxATi5Nf3t2Y2TEmOd517EBRjvPtA5TScrE7czrdLN7GEZy2JOGfdX9\u002FVqzPctc1Id+ztx3Dd07jg3fa9PbPwCsdg2rrswc+n4MDWsQnUzFIc6SficDOdes5xip6RZ8TA84b0TxAJErdLQZ\u002Fx5tv9z3V49OFaOJGvU8RKCS2vBp41QDnDHBEcJA8GxzC1BKcXncoFyP2sy7qHYrkXMGUC+qEq+8SK48TaejO0BdqeZxqnW9ecOn9rQ9j9fIyFPtU7EZns5hQEiZZIZL6dmNrOKr7drdDhscji8PcSYxIJPb+QcC5eaMjmkum\u002FzN\u002FTn\u002F8Ea8wHjeenwnk+3VpOBt7O8si9b\u002F0csOjHx6vzSXc6sDec73KYe6UR\u002FCB+TZZlVk0NGCo3jZW5jW+cSZS6tfHzu7svH0bum9N29c6+TT7zpE6VpYo0PLqprDy3+4lGR7H\u002FCrvqMthgwHBMfkGFNjJDnxOu99uGtJMYYFkyFwULSzlSyS4qYvdJ354zRBr2TlUn9dhFyklfNAlodN\u002Ft0TLWjDC\u002F+4lxwYJ2lrxyFnfOSR+f9Qrw8G1H\u002F6089Xlz\u002F7dEDq7wPt0lMoS2UFLdKut5ZAxtQ86LxThDfrkRd6wvdNxvUb1ydVhCcLSLcImIcgwEzA\u002F8084Aj3bGk0JtC9Nq3e+uFmLNpENnl216vksl3uLs+6dBtA6mc\u002F+2KulSdPsRAHBL9NSgADucELYrEpydnw2kX6adOrtglOi6fCB6If70AtUfiiBoSuijCX21R04fyFYRDJnxiQ0uM9lyJDyBjjRxglomDdM2z+z\u002F\u002Frv\u002FTsvatPLn0yRornAfUU6lJj+ZPpx4+lAl3NEjWvjBipNXbL38rouJN3+3UeMBtt9TU5MZJaGTe702fzR2tDsDEmEB1PLEFiU9ebQCKlbT4pDCH8VM0o7Hv370TYNrYezqOuZGNGQd5DYL2py7KmvEaONDcBjbxlDIABwvUlMdB7mUeCt6XsuamnlDWhKVRK4BPASvUxNDAlYAc8m+e9bbgbZdXcWPLld4qlxhrTItBruzZnvTzHFPSw3bf1NTF+BjNGoy1KNwEXg+qvNfG9qI3IBHC2mTK3oZhn7VhpQOZCHjivgY06BCZhb1w8bOhMZQGG46sMHykDY3BQCnmnhDNHOZnhxs+Lcq+UirNnTvbzwVQfEgblRXk\u002F4DcTJ\u002F5qYPFQZxHU16HB\u002Fh7l4rvatuaMAUBpaKC1lTIwuaWNieXvbZzmy7MZHdoyD8t8NWdWq+\u002F1kRfHc3cNBvPuAt\u002Fj6dGqDXw8V30HlAFoTfTMA0GPxtAcQTo8iAlrBA0M39WP6YNn9jh0SA\u002FKRUcHvNo84vqxCzD8vvTTz4R448RTa3uWEKZ+jje9JwEOQ2e1b77GC9q4KEcGETmwbMJ6MG0C4\u002FrMq6aMomejCbmjNrvzqgGNZNaBA46E73CdDPG9ezajkw5HO2zj5cnaSjHH3657ETjfzlP1Ks+hOvgvXizzbSP6Z59dWX2aY2ExAtp4zChsDZVEE0Y2jlNtVBbhe\u002F5sqSDCEXGmaiIvpYdFc6paAIFHevap5GBskPyTf7mAIDIDPRk\u002FhwhatZEQazKsgGMVLHjwrCFPXas666i0pjmyEe9gfRlDNUDqswiuNkU2yBJevuXsBnJg+I5sLcTOg27t8RJ6xzO8YNbA3iR04GC5MSICZtZrDIzaEyG9kazH5\u002FYLOEb9SZE2XDxAsrE5mXHopnEBIJF0tLKAXuQGvKNhCt\u002FvFO8mxd1zjG+cBM3NehEOgCVSmf67d\u002FRRn1kTKTtI8ViRUrIZQKj1aDRPf2+g4lD0T1+hS88j24H1t0UlefVttgVAgN8lhW5JC6ozO3wAmAPBC6Ae3qw9fV7SBxt3\u002FUEXeH0iAHUUP+mL\u002F\u002Fuf+V9+WcAzWveJ9AqAwyDxjb4yUI0TXy33ul9rQJ\u002FPl78BF+DEa+8YJxm2rfUYi43x4Hihk+lkDD7uM\u002F3w83Ve22m0B9TctOmn99LVJra\u002FyO+le8uz6Cl6V3qJNEs5+FP7nziPT\u002FH67oboccT0eb1uPPpQ6zVmNYxdRMM8GAN+8PDpe3OLvhjM53IUfv31NyOnraeCGBcvZoxGYzAJY8zBVXgKP+nvyNKAOoeYSCcemcb7jiyedWqt6DK\u002Fr8fX8ImTY228nz40CfbQPclRqEqcMw4i5mmTLhyHSIN49YrM7qtSSekXBo21R0vSY60ZnWPvkT4c3FocnKProrHD6SXt4bUHOfkYjjDAft5wbbWx9GDpPvsrV0u\u002Ft3RFA3K8tX5vVSVLLu8pZa+dofHNizau\u002F1BlmJNNZDn\u002F7T46fKzDGkst2pNjYq15PVA6X1O7et6eM2dAbIQ1TmzGP0fPrD66cGX1k0D7nZyHALsSj08elsIchvPsA\u002FVpI2cK0ra2XmTxRJz0q7llkEvH9rKuQLrPvaW0mW8vNIYKRh8kPej64YM6tye6phedNE3foD\u002FfWWP0v7EZv2WAbSQjRTfN8ThLE7RScaz\u002Fh3p9MKD+1\u002F\u002F+363+7\u002F\u002Fy\u002F0QceyevHKCluKSxqGZiEBj\u002F4sUL7Yi\u002FNMTMUt7dKEpgsjIxGatPSgkQPBskYoA5Grc2pKzY1HElo0DIxzTf\u002F+F+ltG+1Z\u002F\u002F8hel3RyuDNDVAeY2sfLeAOCIkJeelxwD3GojpQWUfy3FxEFDcsERKk8165Nn3LVqtiMH3jhMReEYJ+t7940xhZUA7\u002Fv37o1CRIgvCg9evnJlFg1Av5qBcuPGD9NvXnHVQSiWa9eu98x3UylEZQKLfPnTy5PHLm1IWtG9wsXmR832y5erBlOKDIG02UayR49vp2Tv5Nx2ZPnJPO6fDLGwqB01DRDJz0TYU5u53wkZisHhCOYb+BhFXb\u002FHi7jDBATb3izaPZXG2S6Ej4Hlx2+1AeRRBxqstz6Hs\u002FI\u002FPnd6davKF99e\u002FZEs6L0IdOuJESiRrR1GWATvXNSFMX7P4hHyuZdQMqbQ3xykozBGrNaW7xz4M6G8vKLmmeBHQ5TGeLBqYwB732lzPE9Lp4Y5MZrPDBGTAwd7c3suojuw2HwR3slgD0+Yd7hRIVDgSwQIuKA41TI+VWlQ9CKSRCgrDweEm\u002FM3gWiCG+My9OzZeJSQf\u002FBwUVq8RsZ4uOts8JHX32PbyBMdZQgoxfY4IY3egE5zCUnteg33MWC6AR0Yk1zcpNGMi4fA+LzML8WlPvECmJqzPlvvM8IdnwyI6voxcDJ2FtXZ\u002F3cEFoBOifhmQG9Sc8Kuzf0i0BgDFASNUTusp97+9iwKz8FmFA9aGFBBeHYVIw4tLu\u002F6mGwgRJeXK1Ks\u002FT0ewv5avkNfFKN1pPiBgyU0X6enjwwE9MuA8JOMIWjHS5LSo4h4u\u002FZN2pIHqrZRRCMjmqxQtUN++dGMLNGQ53n\u002F95TyoczckiMLkB9d\u002FeTKFxnEH63+63\u002F929Xf\u002Fe3vooEib2dOtNH9zupZuayfnD\u002FToR9qXlcNQs316OTzzz8r9ezTTss8V0TvdH3KGGg9GIPHU5wHMwiePn8UHdwe5cJAaaTDoyKK1l0Fl5\u002F\u002F\u002FGczX8BxQ+yK0u+6\u002F1D9ffyk6lSV7gNqGOLmnPdMO0D03hRnvuvV+75vyvo9Xm3uvZrR+hN\u002FReeHDwXI93dX\u002FQPiF8NuAQNNe+uOdm16tQlUHfo8bEUurb0c7H3xKdlJvpJ3FJqT+wawRdv4Dx\u002FzpjuJlXGtupU+7tsXzaPrXgx5KTsXk503bl3PwFmewdDCHx9l5Fhn5U0f3i83N1B1LAcCsAHAANGeiSeH3skGCz6D7\u002Ff4APBTL120TFTv3QYFj+YQYINrwCh7AT15GlvLo7UrSoxPx8EQ6FL1SxQOr4zDo9sBtDEyo3XzhuI4hQ4wULp3b3sJ9BHQHmr0WXPoPm+8iJff1hegA1BDB122XNMcSg2o6Zljz6+nfcdxwuhtTMmcPf0+XvXypw0Jf4rpWV\u002FD3L2W7CQfyTLPnzmoRbrbtOknnp2IR\u002FrRNc\u002FxWMAfMGWMybsWPQjrNHbjsO7eS\u002FqJtKfpcM\u002FXJ5\u002FvTrUvpiJT\u002FWhoHjyTFgvHB9Ih9N1HCyjald9mT7PdnMxjlDRf3WoeZm5bZ3fBF+8zLHnWX1VPnJzwfBfzZpPxHGf0ow74jPyQQmrdFIm4duNmhRTQ5848Rx30nfUFltUuV9rUUtCve+vDkeZqzoWwvvXLM8zhkXQEbyxPL5JkiNE3vOi1mPxV8Sxjf6sofLrXPgUR9sXZeWwcjk7PPRAdJaGmH3vbC7DMNVkffeVwOhSvMEoATPTzsn7Zc8bYVa2GHFrLCFdSUknTZ8\u002FS8\u002FGhUtLnz58KGwXA4yeGqHQ4J6mub2Yg5Ml\u002FVyWdFyntF6+vrx5zPgTgL3\u002F+ZXK0NbLxdAyN7o+3jhYde9szxmEwPoKqfMWvx46fLTX3i2Tbr1fXvvhm9fvf\u002Fd3q9\u002F\u002F4d6uHd3+Mfismksy2qZ2DSuqQCjhoFaZjxFkrHu2FZ6Kd5nwMZXwTD9G5aBrPWatZO7Rk3fwVHTOaFn2rLRtYF+87jIGP4BP0KnV4\u002F\u002FATDJKhHH1LK0WDH+r1wYD63\u002FzN\u002FzFecmFhuYMXL10cAjMZ0gQWYMR71eaaFMXp01UqaSIofwAZQZpkhMz6AWhsOp0QUswCaC8vFqa8yO0I9WFCW05WADAPtpJkly5dWn36yaXA9tOY7lWLWVgmxYDQKd7z5XNTIOqZy++kiEe49PutDiWioCl8jH3nzv2Upb4Wao2BHlZTXahW\u002Fvj++itfaxEIPCt5rlIsogdTdq5FlDcqejCRgsb2JKDOUmXN8aIjjgHlEc3k2MeoFv3osTa99gwVJRgbd+\u002FcC6Tfj4GWHcVSdxgXP7ny2TCo5wB0BM++Nqjm5k35l54Ts\u002FNeCr1RuCQaZX00D\u002FvkbhYqYzyoBmFulKbSJ8J4sSx5G4D5AGnM5nTEra0IG6Aq9Pfm3dHprx3oT0vxOHu6OvSt\u002F1E5tFF78mQEI8ZRnYISmxcBWl\u002F9w1zI2e9NwwANNIEW4oXaybvTfe+y3OWW2ZDnbGLGx4G8nOuVgIq\u002FRn5TKEu1AW22Jr0x0wD1FPWcwhnAsr4TwoqheH\u002FJ\u002Fj7qjXmXt3smraV52yzFSf6lqI\u002FQJ2E\u002FpdZqf\u002FGyt\u002FkvgaWyi+eaP7X5CfVTp06U7lXaQf22MRNoebnlpFmnbvpd5Y53\u002FV1Zq3fSRqQgtHH2+ds57OL+\u002FXPjWb\u002Fwcd7TIkSUHuUkknHixJEiJjYLlR60A2SIB0KIcldtgPcuqZMAYohM78YriwYnNaU+mT8oaQBFvMIQsibTjonpAvwrxYgYw6uUsPUE1IE2FR\u002F8pBTH8zfz3q20Y61RzvL4RMOkvYT1Zt4ZOB4wHup4DpnivUWoLuuyqGhr6RloBl2KBC0Ggud6pv7vAg2CFP\u002Frt6oPvCsM4aZ25A4+WAuwrKIfPOd5S7UGm0634weH8xTOd02AcgGcDjTiVVo8tSZJBSenBZ89c2H1H\u002F\u002FD\u002F5oD4fPSwc5P1ai\u002F\u002Fut\u002Fu\u002Fr7v\u002F1vq7\u002F5z\u002F959eZMxtiRzmeor7y1vMA\u002F\u002F\u002FKXHdbzr8fTrnqCfSBS79DEkwD2rZul9yX2GAIvOzilZWxtgtJ1iYx5nIfJGvNCz5kIfY9vnLrJOysd5XRG+8stlZICtM3RoeiATJD\u002FDsjYZwEMHwnw22PBs2pceG48Qj1rAFqrtBhnQGFrnyKPqIZvPAt94xmye8r01bi5EY5n9J4omglMrB9enu\u002FanlI7VYcp\u002FebYUd7yDICEBnmGJ8FNXkrKcJfGrdNGspNuoJzpgv2tn3aADulBBIkNpIcCMBtk0kdn4sF7RWFvIci5FiBntBibJy3eOHQar2Ss7F6HB8ghwE0qAECrc7PZvd\u002F9YwicyUAgV9DM82etAaNAFGY87EUm69uuwauf73J6mEe6i47arfOuvjTeYngAINYMnesXA2TARbQ7MrLPrD8elJ5AZhuLfgAgdIxQvLFYIzyv3+SNNbbZFNjs8p6x8Ln7JiKR4bXMDbDIWJAGsYBs\u002FfB73exzxnV97N+yptqKl14FZnIAbG5mlPWAcaIE4v4\u002F1u7sx64sy+\u002F7DTIiGME5OU85Z9agrq4yututtrrbMPSgZz8KsP84w882IMOGXwxJMATDGqCGpHZXqyqrkjmQzOQ8DzGQ9PezDkPSe\u002FNmXkbEvefss4c1\u002FNaw14ahPH8xOEQIaqv\u002FRk7VhzHQG8UAy8ZCbnh7kepkw7IG2iHbLXfyjuCQ8b8sz7TrECj13vf3gP1Sx9IbdXu5P3Deb1ocnb7TxklnA+AfTxqnRwDS2IF3RjI+80DRF4aonwxisvxZ0c\u002F1CGXWia6LNozRy\u002FkJ21vWJK92PAHSn8npw7A8ATAnm\u002FCKyBVamCINFqWx4U2GOxqns5YMg2P1qcht0TxpX3THyZyR+saAZ4iQj2TcGG3NSbOFLeYnI2CrfnO4PU\u002FWwBhPSmGb6HXyLjIZGhTpm1rmVXM5spU+zuB\u002F+LCUyuc3VrePbUTzVc8rmsxhYbPrk2rMHyqat13Ea7u0umelA\u002F74\u002FY+tASN\u002Faw5LPHK00rCVds1uqUqL6OLT5owcSQ6UbWAt6U18LYVx82hOkJ\u002F+YnXh0uVk5S\u002FDRN+tvvn6t6tvr3+1upuhkhtvqu0RjmQQ2hDxNnkHa0mnL7S86HrXjEE4E9JaN+D99Aqth8Y4Ddw\u002FOhKF1DdvdIge0LfXYozhDY6GpWoUrGnOJ8UXcb6n13sD6jYWfvHll9Pp4wl9YV6TQ3DbXCSHitUkf4qAshFlgGuAm8dbDtjR8hoBIMIL8bFcD3cPgnYNISXUqF355PLHeesJvu++\u002Fz6v+N3VL3\u002FxB6uf\u002FfQnU4tcNYarVz8cLzzClhfupQybw5Mw49dfX6\u002F82i08kfAPZMZAQI+\u002FMcbZvNZAGsDqOTd+vLu6n4eTN9s4hHn3Y0xHVu+WaoLQjmUBv0lAYQQGh9CasVte9y0pNoGTrEEbsYBkQJ8w3H+4CLa1O4GsiOPAQCGMz2bVu05fMK8+Ykqbq1S5wegsQuAfwRmL4v2sQYrJDm7pLkAMZe8EQ6LkaWuDRHfuvju2vjYIV6\u002FdrNf8AK1HG3aP9Xkgxbkt7nud5cxL2p21F7Fm5V5uDk\u002FHcPSlKAfP80QqUjzpkmmXsHwbY6zLee9D4Gp\u002FNkYF+BLmGJUQNT6n3OlrnBAjJvwbI8UpX\u002F5lf68HejYTwBhpPEzdtd7DjXFOONVSAnKR4P2cYZmdmqwtuadk9pT06ufblIt5X8BOICCv2EmCp3HfunkjEHZx9fGHH6cUVQN5sbpZJORZ3hUpCGqqP8qrzjA7Gc1M\u002Fm19BND3WrM70azDi45WZ\u002FvY8bwsnXTXLPZZQAdzR4\u002Fm8FEA5My57UL7t\u002FIcXoxeGSvCfaUP1dbjDLV7RW3QDU\u002FmoqRakyaWEpSy\u002FzohpKINpQ9gGXDqsXnp38Y5AMCcJUwAMqX5pGS4fxSgtrQTPY9gMoW1GYyYNdQP9D+et9aL8vae00eb16i3pyXgys2lnF8Gvu7erZJQSkH1BCXAdjvtUwUMp4jyeAiJHnZvfX0nK+vLoKRRekC\u002F55ILjIkNwL1n49N1c1fpT2MlL4SOpXcxEO0TWLPhqfuUcuvS2jAbgcnWjEE7gracyWdVLHqSR8nmUM\u002FBz28LcZ794Hz0lGe96ga8hXc7rRAIwstH2wB6PTkiV\u002Fwv\u002F\u002FIvR7Yor3nlSntwLl1d\u002FT\u002F\u002F7F8UNv+2a0svq0za5vGd1Udf\u002FmT1k1\u002F8cnWqFA7nOLx4\u002FmT1dO1J9CYCkHfrxZOFrs0rxQmIBFI2AjPmgbHzMvrbKT8U\u002F0i\u002FkCZCPlpbyonBMcSAF\u002FJ6obPd186tWFLLAG2RqUmBCyS\u002FXeMw4W1eqolYEzSFt2z8HdAS8Yh8LdUlFk\u002FT5L4OEIx3owlKloy6xBny7Fj9yJvf2gJl6FBt6H4b2eaneUZrdcRAq0vPgC0En1FnXWbzevT5JGMDvUvBER2UasLbdyowzMHCWfA0oEKh2v\u002Fz5ZefR6s5HTKij+d9++6bW91rc57j4aOPoenmokcDrAAM0TMGnv0EtSNaM9UvGvO8ugkoXu99PP4VwSUfGBlSJB2I42CmiKVr8E7pUtE8OYI2ORtmU2\u002Fj4siQ73xs+2T9KwKS3riTU8a4VO05XllS\u002FGrOpHjwemrPXLZ0I7\u002FsC1lO+MTH+lq0KnDnWcY39FA\u002FRHulX6B5n42+SQ4cab2A31ZgaEgOerfOmmsAr4yBUb8ZutMZ8rW\u002FRRsWo\u002FqdZxJt9h8j7q0Nrcn4JnHu9zx0wRA014CkPkrn0+b0dZoPMDXvh5PrZNd+bfIw023WSTtOJl7AO5DU\u002FT2DrG2WTFXX1gsX9xoZlRf5Zc9+80pf6nPzcTg57+VZPNRHGOzRBjrf77tFOlS4IEDOiBI5d6jivZx3mz1zL3D9\u002FfXrqy9+9rPVH\u002Fzs89XDf\u002Flv6xNjrDabM\u002FXbp6xxB8sdyRO93sbL2cxr0buGiSDFyKngyxkTsEDX1C3OR+suCsZwVzaXnNE\u002Fuokzk1NSusrRKeywFR66N2siavUwJ9HVq5WXzpjd6HpGH7rJt9Z96Zs2fOIrz9Bnb9Kajjtef8w1J5X9SvZRrTJyNjc7LBH9hqPk6r9o78eDvkLzFy4UrXdgW+s1Tqx48FlZCWuHtlcfBuZv3nm8+rf\u002F4p+vbnz99eqzL3+2+vjzz1cvn+T0GLo\u002F12R4JiOtuUln0FtOuyUPbFo+fDgHYmM\u002FBEuGL65+\u002Funq81s\u002FW\u002F3uq1\u002FH0x1wFu56mz5GL5wo68lQv282R9aNkS\u002Fl6WnGCF2Hjs3DWzT8jqbX4sO3eKY5mbSV5k2aHXoyJmtmHfyEjRgn1ppTYhyzXehaqYnWSCSpQfXJ+3m9N6D+2edfTugPcQmv2DBG4K2X20RxIkJMtrEpl7rjnhNuhNT3N27kaVPfU4pKAG+Ga43y1KVYAHrvyWFsAhCYAwB+9atfDhF\u002F9bvfTcqBjaE84P\u002FqX\u002F2bFmI\u002F4a4O8vZUVeF9V41GO8CrPEIeagLrQsqEF\u002F5h3nml1wABXhyeP4qNwTCKv895BB\u002Flgb4nh6sFAZwdPLTW6VQAM2Hob5a3jYZCmEC65xB2FtjGQc+IjyOAFEFERHAJtToyXDu8\u002F03iCDyC+KPSXBaPeIteOwwUHlVhTcYGYSSdRb+lFsh\u002Fx4RC3BvCqClC0QtUBnRRwNYmeZWQ58E\u002FE+gsdNQ9sVqCbAH8lLSIhvl7WRvMF96vrYwExOjZL\u002Fpcnq4Q2dmLp1Zn25NwNs+vce+8JNwJe0I9QJQAsH7C2iZgPTqhzCL3+svjk3js+oY4TECU4iN1ojEtgPmGEIlWDqs2kJeRclrbjjE4+OKcZMsImDe1m67thrgJd3lM7+WvrovpCAfM1lBaQyqGIEtwRz+bKRsAzvfAJWGG4Z1cd\u002FfunfIF9zq44VZz06x0veoaTxJODtuy7vL2GTFf\u002Ffbr5qpn1faL2pn6yXnS9\u002FYdDOEwm8BitPs08MDYtUHZaZcA7J0f21B9586EKfHIN998N2v2DB3mTbU+NiWilab43aQ1DvPUuJcRLeO2XjN+c9n\u002FUmBmDZvzWZ94cwH6qfIWYPF6NXh0GH3xHqBfwGe8lq7pmZ5DaS\u002FeNAowJd0c1rWlX63zbvPwqHSgx0WkVAMC0pfqAxQFTyxFvAhAoNAqDUDv8WN4zOxpjzpZlI1NaPhyFE4CHkkxpNE95bdl\u002FQKLh0tTWcLtFGggYPr8jiwaGwUP4AFlr8oZf1FN4Z1+qqixESDazJsOrNtHILqzyvvzpM3SN\u002FMUARuHPs7YDPjanHT\u002F\u002Ft0EdCl4f\u002FDzxiQH+8TqUel2x\u002FIKff3brzq34O7q08+uVQe\u002F\u002FPFotyBEUaFAWTJRvx7cuxPNpGAiYl44Y2SnbAIazfGOMHOADd1SppSSSjQUCj5lYAHp5k\u002Fa4J07P44SwYuMxbVkyUb3qBXvOrT7ssNQoD5trL8EsITVl70WADj2FEUim3ncW+H6VMQro8aa78T7rqfMgF+5piJLkz7TvKGZo7MJl2EHAHBIBLDirXEa1FYUNOsX2QyQFS1j3NMXnq+smo1ogN1ejg1gD+gk\u002FwYQtQ7G96iDWpYQtSID5kaqYhGPooyiT1uBMQ6P2eDdSNASehEFkiI17cWPZNYbG926gG5uguZNPgGB1gbwPhGfflA+k7QGcoPgcv2kUsUvSaCpmjVK3XP6TCRSKdv1+oy3PEQdavSllCT5xQh5XT+7PHDeunp6vyvDSB4xpshSepYzxHziYfwxY0AfXY\u002F\u002FOZ3Ic0a+dCsgdfHWLzXYbc4bb3b38\u002Fqb8C5\u002F92Jo9L2\u002FTBYm6y9yw\u002FrqB4MMDWJbnucB8K3bkdLFRMnMKxkh39\u002F8SDkzX8scLePxBJtf3yRTJ2I0c7k8cryT\u002Fd3Q5gOrdiDZDLnZmH4tIDk5Mh1Fm3pKPiUbySq81ETiHd7x0Q1dUdf6zFwL8dWfdy2Mo6fv3Od+RjAPuhvoZPz+MGfJ6+jxQgD+fO+HeZBV\u002FcEjjD4VS9bzmrSU3RvGaRyzn8GavVs3P48fK\u002FKTHgYezZV7RY7p6vEw9zkMIdrxIufY\u002FYxBOnCKVJT2usiu6CReYnj7TtWZnYxdTh79dhLrMqP9QAONCe2bKHgF7zIg7SXkUYa3yHdrLjWI3HOC8UbVXA4fqr85V5y6fP\u002F+j+WO3whXVZXvRBtTe+NNuGacMuWif3IxPHDoyerHb3+zun3jehVN\u002F3L10z\u002F4WeVk76yeb8Bc8WY460h45TBveOtArpO3IkwTjU\u002FWb62dTr5UCrQI49EiksfDX1c\u002F\u002FWz1\u002FVeB9bttLA\u002FDTDQyGR5L1wZabkwRp71jeGGRnaGcxj2\u002FI9xWzFzMRu4+p63JHXSO7mbDc59xKKAvupNO1IbP0Pykz3Sx3+fsgho4cKD1gL\u002Fz670BdbnmhIU3K4v1NwK5iUJkQ\u002FB9d+jQ4jFHGJgBoCbw1Rl3H0sMsdrhT8hjfkrAogOXB4OX6yhtxQmOPteevPiHVQL46re\u002FW\u002F3kJ19GPCemcgxiPJvwA+Zd++rxoghszvRsYVkTLSTsGgtEMR07pr950cqzB9h9B2TLdScIjflMwFS6RTQRMN6qrTbPds3Dh4tXw\u002F1CKJR+VY8m3Ua4yRh5E4SyPsgbS6m8fXMvz1BgPSLnmyDoABx14hkFgPSEQ+ur+ygdim9CPglUFvB4cRLthxMQr\u002FM8PJ1jklnnSgtRrAnr7qcESa4R6DG4Xesj5JoPc4IIgajoblJ8HF2\u002FCIs8AG1O47HEWLxVKj8ABqfLtd1OKZ9vY+npDInnrxYwifHVdh2DJRqo4foWM0TMFNfB5s++mGd7fv\u002FPuy73k8jt7WdCg1C2VvnuGicll3BJuwyITJitu6Z2hT67vdsIG\u002Ff217umPNt3DENRiPFSJXjkb3oTsq6tp1MCjkVurQHIOwF1JfgAczXeVQ+h0IAIVViMCYjyKIoJoGQkiuqM0oq5lZgE\u002FFuBdvXbRGQzkuPoF37QDmEhVPpB+dE2E\u002F54q7Sm7lApQgmwKT9nrlprAk0fmpRFuJAwfWcdB3gQUjU4Rlg\u002FGUvz7vnmW56glz7PnMxv2gLOATleWkJNswAvpeINsL9TjJ7ZizKSt0jhC6OriKJyDS+zMaFb4BF\u002FM6rRhc\u002FGIOgzRi3lU7dmjcYDZl17ey0hzWWc7nOCJ+XEoHzb2sm5dO\u002FmhprC8qaXZzQbM0DrPZOUSJaGsp9Scu+O476bB+NDDzbEjSFYn42T4lyU6aL4X7Xeyq+aF3P4zTffrv71v\u002FzX5bMqP3s+mXVr9Ztf\u002FyYDvxzx1vjmrfaWfP5RPHKs6MyPeYR+v7py+cN4JfkTsN8wOdHs63gqswkyK6JRfxqzMe1He4uXOz7uGqCCDDVL1kN1B\u002F2UBijdTGrHkeZSpQb5sOsZEYdqh8eVgeJac4ru5thza1pzQBjAl2Ab2QZojre5eVShh4wyXjQuqgDcow9GSp1uTkQlqgCRzBg5B4wk52169nLq86vomcyhSLEmwEK2CtfzFlqrpnXGC1i+fIlOrQ0jIUVcv6X24BOcrCIFwMEbtlEUDz04p0LUSYRRBHW8XDGI6j2+RwxkqlC5FMdlHZPVefNeBRp5LuvafD7X1jYalTN86pRKGdIClwiPtAH0YZ7oLGPH0zz9My4IvIXET3hwAHZjtkl+9GY8gE6NSSoFvo1BG080EC8ApPQFb6DnoIeDKIf76QC0QbYfnAo67bq+KBgj5dDhrWnf\u002ForF8WA+yYh+Dn33yCbd3\u002FrqH+NnFHov89\u002Ffvuof\u002FbBe+NNc2cvV4xpbxlkRDIAc4EJn6NS4Dz7vgWNU1UhPSZI3dmWIGTxdPnSDdpZ0NWNe6HJ+8TtemX74iTb60XuOk4+g5u+5hL4wJs9xZTyMtVxg7D1j3kWFzZ0+HPRpogV9Zs3IW3xkLw1a767BK6q4nS4qdu3qR6unX13PKcHZZqM7YyRaSzfBA\u002FKxRbU980DOkZvWSJuzd6K552Tz\u002FIU3F56Q0vSo+eWg20lnKGKw4KJyvNsX4Vo0dux0h0LmJELzaFmf8RYZrKKeNWBsb2+KpJMdaB1vikBySnFS8fzHe92IRvCnqDc5R7\u002FhnaPHbTRPHjXO148PFykuLTfZfup5fFGFlrNnMw7Mc2vZyNORq9WlUp3XOxztZgdH\u002FeY\u002F\u002FKvV7vN7qzPnL\u002FXsZ9Ey\u002FdY81fZmvOXwtk2G+WaYJG8+nc\u002FwfC1CogAAQABJREFU413f36czzIsTq08Vcf589fG1n67utfH0h7DgDze\u002Fn0OUHA5Fpmel1JMWPP6hGyedD10xXND8G3oHfTM+F5ry+5IyOss1\u002FMBYU7rRdzAW5+FC161hozV31pY+s34ToX\u002FXXg\u002F\u002FO7\u002FeG1BHcEDw5MSt2lyYV+V43iKAEMBtFL15k5eKDYAdK+cgpeXOnduBbpVQFqBOOQA4BAGlLY\u002FKd\u002FLfpZGoJU4oOv2URe+6q1eudM3jPHcdwZugdD8AT6B4PG86T7eyX9qk8OV5yvceARsz+OzsyzOrTz\u002F\u002FdJSbXisLJIWEd8ABTJcupaj6T74xoQpk20zE04iZha95fwgTS9+j6kvKLw8WBgOwhOL292OOmOcNAq2fcuEpSMKJkmKZAqRKsIkIYFTW3CiQNjSbS0AF4GNJkl19HfPyskXgMd2jPMAqM0SGJN2sxxvgJIJCXJ5v7ZxqSJASQEKUs38g4iTUbP4gfHi5vDePAMg2EDEuAuTPysFunR\u002FwKFZD9Wh5vKfqw4\u002F3A+q1zWt\u002FOKBOQfubMCUEhOXN46IAWLgLeF+zkdHENW9Ak7VahLe\u002FXbdEIJ7X961NXpy8Nl03lvBMQmxZvw\u002F1z1qMiu4wu7Fp1nOsKxYbJdQ9Dns5vL54LD2TFxwtJKcTXuarSEZrzTts7ghMgm6tqh48SxsJEorp5atlTeUEy42+fLnSn4X6pWGNAuyp4+FsbU80RzspaIdEeam5LcxKuVO8jnsHYp07cO9OW\u002F54DKKHSZNpQurarANBMSAdUO93QnoUWeDPi9AkVBI\u002FQwOmxHgIYPLFZADxXnOv+UGAfTle9ATZIswA9AUsuU+blNyyJtaMUeozc7woOF5bKUJjKPb5ZlUDAH\u002Ft6SMPsfuX57hnHltPFhro33fXJiDjLWs3Bt+75+s37yIaHsHZ2kjdWIAYJR0wHABA6WhLi9peQupK6OkjoT756LVrKswNoCTSR4Z4ea6\u002FKTvlXvHh9H3GcqjqS9VUfv5\u002FRUdAyqlky4tKjN1KidxJGUmN6MjvonHHT3S0fL\u002F\u002F+tf\u002FcfXpJ1+sTv7cuRCtvVSHSh0+rsLBi3i3AdeXANzwEC+c6Fl8bZ6L7JFjj6OzE09P1a\u002F9ImPS9haAyZN27fS1RkopoWMHIZEfgZFA6MsUKzm1vZ1yT05r13iMEaCOYgYM26xIgQnxqmZ1797d+dmqDV2i2fHGJ3jIPPMoqvRj+33sqcHbACUgon88sC1JeysCGafbmJ0DxFot69UcMwYa1zg3ak9q2v0Obbl7e692FoNx55X0t2VDsHVnKJwoBUBur83qc+BLdHgvEPUoPSOCe7IUSaDD83iXb2X0Hmw0RosTmaktzIAH0BK5ih4XgxKd8pjjWydbFxGOvfbbXD+n\u002FjaoMe6SI9I8VX6y52BSwXoucMZwQnd4xk86JxO9a1\u002FUl8Bf8oz8HyBXP8j2Q69aiZ6LFum4xTusn9K8gJfaay4YzfrnhTcXCcfwam77L3XYMxePtgvIa3O8vKzmMu4Za\u002FK3JnBJ9yST4684ot992qs5mR\u002F97bn0vki66hjS2NADuWpN8VIzMzQEJDEEfG6zvQj1PIWsbb3sEVmkGjCWXhpZsvTBOngufjM+5xrQcYxKRo1+6uPSt0WO+MzmyxZ+gBc9wmmxR241Z\u002Fox89NPtGuvCnmylLgloxanAZlHxkpN2qvcoMegHWdkSFU6d\u002FHD1YfXPl5d\u002F+7HRb8HypNsySVGoWhW7YoczrpzYNS\u002Fegs4ozP9BJSHfuL5Rd8FvnsGR4+5ZQS93KzsYHQiLYWOmPHVjjMRGKFOOV87vTZA3T1oGa3pv8p4ZMRSyrCxFUXY6XPrxzu+WQU1NLbf2RuwkxQafdsuWl13+6znB\u002Fw5P52TUzxvdWg7uk5m7XCMNS0cF4+eJCOLRsI7DgPbSD\u002Fv7XT4ZY180qnaxyrzeC9c8Nu\u002F\u002FqvVuQuXV5evfVIKaI7K9N5e87u5U+nJIn775bFv5I0H1g+XI79e\u002Fw43R0vBiYYW\u002FXMUHmmD+4lKQZ6\u002FdG114UrnwlzrcMkOobpXNPH+3dulot5N1vX85g0dM3CXEqN5wsNBr2EStlnr7422lC2Wyhtx9AWDpnnEW9EuDqB\u002FG7FORC\u002F0WesZ3TBwzPch1zd38NT7er03oI7RDYa3CPMQiDZXAhwUHSGFyYAfPzcimrHSeBEKJSJ8eY\u002FAp\u002FABQEjQGzCmFeoH1j\u002F+6NoQrkk5Uf6TyiwEK6B7ppQLZcju3lZOq9KJgXb1g3nM7RC3EQ8Qcj1CBowJccxKmR\u002F0TVqJKjPKO1o4IW7EjpDVgncADbkgnOfnpJ00vle1yfPJuzvh5YhT25Nj12fr5VbW2wGFQkOUIqX0qnGaKxVF5NwT9KxoffJ6kOEhwsDLL1+TV53QnfSBOkgJE9JyJ3l4KTdAmwXMovTTwTmMHMKB8pq6ys3zgP0EiVxd93rttCav+ptglZ6kLCOAkwwZ4iOGetjk1vHemK8TTzqxtZDckeL5h2PQk6z0+vU0phdVrMmeDXvwVALvET3BMF77QFKJuP5G8CPIInYv8z8bjght7wQtgcbgedvJjeOBaU6Ba2DdesyrX\u002FxHJE7qTB+OsTI\u002Fm6\u002Fmb671T29KHJhyUI1+YkXjbJijMPVNjiildKK5nMolMXakFK0xeng0y1l9izZEgjKwOiny1KkPJn+dUplwYDmPPE7o7vMvPi1VqdKhRU2kLuiKCMWSU+i55RAXcrWrf0960ay7KgJ5a6J3a\u002FYkWnGIxJRoI0xMmFHXmLmcP\u002FsEwACMpaVQUObmwEONH5lMpm7mX0dqxt\u002FLixCiIBde1FHfvVuhucfztC\u002FfU1oDZd1jEpJtKIwv5LMKCQInnufueV7\u002FUIgDTppMfLt83zP0oxcBuwB7glQ+KgMLYF8qMLjmoM1FXlDC0kkITGB7MUoPgL5W5\u002FN4ZLkOyNGH+mQc89jFILG+FCb5xjCjsDgh5GQKcwPG2\u002FE1pwBvyg95dpRjVN3l4cPnKcBASzy3dVSVpMfVXf6+kquX49G1wOzd1Ve\u002F+f3qWkqGMeaxQIS13VivlGy0tlNE4FAyhGx93WE25okDhPdJmNtakKPKK\u002FKyj+f9HYid8pc1OvKi\u002FqNB45i56j7gpB\u002F1e\u002FF28ki\u002FSRm+fVvUzaRGFQOYPB9pNZdom6x2r7Jv5pQDhXzVvvl\u002FkFEKxADt\u002FuaoERGVljd80HqoTgUonNgtHze+nlSXhITnkcM2nx3dKpe9eXq2q+rEk6lWAfQ0hOanKEGGR6yUvJHPfbR54ExY9rgcKeqHDp0\u002FgB\u002FmGPl43H4p9LDz7c2Rw9NY7ekn8CjSMF7p5hkdAMsqg4mKcJqgF\u002Fpj0p7KZd5pzwleR80Oo6LrpFotgP509FJt5VKg8PVmp8xymkzEaeYcj5kfQF1qQcAn7+84T1rvAeLN8\u002FBm8oXtqL\u002F2SKBT6TH66Po4ezx9Axr63aX0sJQ+a0yfPOuZxojvjWNSHX3p6mSn3ihxOJ5F7dYHrGq85OvyWnhE36SM6Id1Nm9quDM4GYSih5wKxnQsBwfA6iVSQV6Sox67GCHJde3X37iw38nBDICA1JT9q7\u002F6gW5hA+lz0o+WvTt9Nw0tsmGGMvKFjCLvOAO0v6yxcU+EbXi\u002Fz5IRpmCjCziQpk1MX0MLkEb7ybQ+G0OpOXzdeI8k69H1UmAij\u002FHFq+GMNhSvrtemvlojxpgc6wBbc7mW0a0fxtGPPreHa8mDXq5ZjCX0b85FeTgs\u002FzMfhWGqvrZcu8jWV0dzmh1dohb0OicIGtxsj5xJw6v7+t6z6HROE0Uh1os2TpZCOg0WIms4ovC4w8B2u3eJVtHZ5iP+iIZ3d2GFokXp61PbRfkZZMnO16WiOhxR+tZmvPvBqaJnDipsrWE1TiwbYo\u002FnXt88vxRYuP3t16snbfL+oFz6i5cuTbW6t\u002FvVWt+rHPduVXWk2rT\u002FZ7t9QeW8hBmKwEVzE0krPUEknsNpLYCxfbKMiuTFmQtXVx99+uWA9B9ufNcG8m\u002F7\u002FcdkVKWqq1InGg0+S48kwyYtqH6LdohqTiQrugGylbkWqR66RBvJN89DF5Ni2fdoYvijFd1vTobn8B2ieo+v9wbUCWwvwoxFdn9K0D0YQgRCj3XQzuIJr\u002FRg0mXKOb1evOMTUoiYeKmEiVwnN3dK3L1T4ixLQlx+OU\u002Fu+dpUphHB+5ySIWCX6hGHJi1BdRftEDwmlHAQAj368uhsxtOmCfU8zCO9ZVFmQkkIPuurxTD5FsfcE+iAMS+XcXbbCL4BtOuMkERvSo1Hwc8F8BHjFFzGRF6WqdDQNzw2D2fjxbOZD2PjfaL0H7075IZS2QsQAHkYdDmVMK9ETAMYILSFkWJ+BJSnhJA0dgSkTaDd9WtrxscLz0O+P4Bdvh5LnKDm\u002FTEfy+7vFEWedN7KOl9vqQI0CzTxbPosJqlPIg4XK814qyo1b8s1P1ZpqMsXzqyu3yid6Ye8wNkbezEBMLQYBs1v6SLAr9AuA2iNp7M+IO8w9LzMrfk2j4CV3wkSeUaEoftiuWEq8zze3r7XNy8\u002F0RqBOf13uVF4Dg2HEbvP2lsvij0\u002F2iiI+DFhxsvBIOr5KUcHS1F4Kk6gCSGwE9GM0n2eI\u002FXog\u002FLnRF8ABNUrpMmgf4qb0n+l3m1zdiywf+nilYTj4wTyV835stlqSpKmCOTY8ng+eZjXNE8mmuPFO9WzHEqDf+62cZWyeJpS4y22\u002FubsdYaS\u002FjQDs2b+GaHUT540ykkOvJJwhCg+U\u002Fd+Lc\u002FKzI9Z6f5ZDe017xQkIWau0NV875om2VzOz35nCCz04aRTG6Wd1CkE2efd5wmeoR1\u002FAJ4Vhp\u002F2qC\u002FgwDqLqixjaO67dq11FbGyiZQiI2+MZQ6VWBp91\u002FdoKp4A4oG8Frm\u002Fe9a7MWmbR8RGInSOrkRbRkY0jrrYeLo3LyR6tI9Cf3kfrd+TJ6XI7C6pY+Op7rhsHjibn9BYpkjGiZM32yyfoXbp4vEiaD0jWkOjP7YZnRNAvjCv9t\u002F8f3+7unD2\u002FGr9l5R2fa2yAtmzldJ8VvfHyOgnLxo5ebi5QJfbGd2Ujc3ay+FSlakt7Y8xPrK4exiBA6h6POWGVoTFVYgSRRgDKEOC8aQ9G9TR1aRlNBcA6FItJ+UWz5\u002F9oA3\u002FgdHnGSvWRjoL2mGcOLzFfZ49h4Q1kQAuurAe6Ewb3tT+ttTGZLJ1WW9et7v+dWUQOTasEaVOMcqFd4\u002F0FLLRSy7p0aJRooBb0XE3DThRMvZJpeleBI4Z3eP0CGAD6apbkVXWHp\u002FzxhEzaHJS8+JnfdRXczbArO\u002Fw7ZWrl6u81anS8TOZz4EEfEptAPy8yEL0aLzk\u002FE6nlN65\u002FSCPK6OlSGSAXiUhcgs\u002FbBxW21+Ux910i8pPS8oOcEO\u002FAI1kNdk4ToxoNqw3vCPtYH8voN6TI\u002FSRRUCFfgOWxoL66YzhTz2szZ02VO77rO8WQI53rcjymmji\u002FN0V03Rr4pf\u002F9K7dvucZH4dKlwG+i75czgJxqdzdVz3LPgf0Re7b2yAya9x1JfpY8qcX\u002FqvNZAE5LF8dILKB9lB8Zb3oOXLAvEhN3MrTS456k0\u002FEyWKYe8Y7+dLscNLMabWG10XmZZmfZUjoWOoi3iaL6H8gbdZ19Msy8pmhnjFntuRZPptTzeZ3kTHlVs\u002FnVb9QKocqYDvVF+fAWgx\u002FsqMxJEvQOv01eqq+eJ41bmDzEM8kW8kkfCRyJ0Nhf7\u002FDEtMJwLT+09n4cF7dSp6\u002FzMEkDYfc4\u002FW27vpytPMKGO\u002FHatvcMYhVjVMXXV+kcjoA6E20u7NTOleyyX2MuDdOto6W0I\u002Fo\u002FomqGG2X0oT2yLbDOSs4Fo5WOWr3ZWU5q1RGTr\u002FagY\u002Fou4YVLb9oD5Bo8MvkDr0pZXg7sB4KacP4w9XDqp3tvezwp\u002FtVf2peT5fme7SCJIfi4cN51V\u002FvP03Wda7CkQ6B6ufGZrnqyb3XconjB4Uf3sAq4abjpcMcr9Tt6XOX2zN3dXX5o89KhflxKsU8un979fTR3dLuOhAyGrMhfNKZMgDQqbE2nIXe4yk4ockd\u002FuufoTU0iC5HR4nq4Lnm2pol6YZ28AY6buKWNXoP\u002F74\u002FoB4x8DxRoggOKJ4dyxH+2VcO+ghcNUhWnO+FQhHjG\u002Fcgwt5vMGrXAPsUAOamDCiP2QyaoGQt2mXLi6P2KAbDADys52qX5c6Dd6s66YCS3GBGw1ZEP56xCHs2RTWZwC+mseFoUW4L4NA\u002FG6RKBRtFiHEJJ9UVeMD9PmMMtBF2Fq3Vioj0M29XBEYA8Ba4F+AlUORO+sk\u002FB1hZ0FN5VhkKI2xqhxfdkvOqbUZM2lHz1JI7wIQHBwACvHlmGSgUpP48DLgBFISJjbF1Ldl0MaWUlTpz\u002F2K8HSfKuYdd5M0C9LwXSyWGZfw8XwTt5qZIg7XhSe745Dy5J04U0t22YYYAyuueFWnubJ4kZJ5VLeNIAvjV\u002Fvrq9qP68eTr3lKfgPv\u002FbLGiXfMmvcOu9\u002FUYjlfZ6Yn6evAeYF5fSTLP7J9hipatOQSmF48\u002F0E7J8pQTgJPmwBPQ\u002FI2A7EZrjaGAQWs4J4PGjLxBFNTsf+jZAMr+\u002FnY0Ks88cFR7O3lxzIU8ZilIx4ocfVBKy4mh48MTvSEEj60H3AJhABZwvLPzdPVjp60N7QQaFqOgtIv4RJ30F+U0mjdeLj21SckxyYeieYp7L3CFlq9evrj6pApCs8Gv69EL0HWMID+RAm7efLaMpXE2jihwxtWvKfixbAIIRXsCSUANIYUfbYbtjkUudbE+Sn1ZFLypXxTkAtKHqGZO9Ven0Rk6BVIW8CUFInAUSBcdmrrN774395sp3pqfpXH9rKvH1P9Z99ZoijJ4VJ8fKDZ\u002FHXjRFx6ktKNFfcWHtY2mfOY93rruH8Xcdz2xz81TtNJb5\u002FXdOAeYRU8MIn2bcfmn27TFi8m7ZZwEugiTHG2VOdTRltojcqYiidKLytM9yrOuz9qXKuVhDDL5oo6RJ\u002Feuf\u002F11VT7UTT+5+uSTa4FRhoUUm+jVWKJZG7ukPACZDNupYDF0qx8LiOY951U3foY5GSC1UFoeetUPMpkheO9eqYHR1eRmB6a3bEgz1l4UN0fBWrIX4DEm6y9dazOvGG+Z\u002FTH66BZyYqvDR7a3HXQijWN3AP\u002FRwtcLTZCby\u002FoAQdp2ANfRohJRXN9JZ1kcJgdAuY+Tb0pqVtUmGUUG4E3PAlY4OLSt9Kn5fxwI34wPVNTaTYl+d6Oytsl+zpOF5wN9gF5rKQfYwXAiWgB3LDAylOdxp9Q3YAa9oFOLL0rpOQoL0DUv2iBPzgLWxwMq1gsNv82ZolyeMqX7e2urb7\u002F5rn0IpQk9rHrPRCprNzDw\u002FGmnTG5nNCQ3ndvAGWRDeCImvqBnlrGTH0AcENBgZ33W8lBuNAd7hxfDFy0vVTmon+ZYjwcEA8IZmn1A5gJH9FSzPTzhO8bPwjfL2izLj7bJUfJX6g+jfokwaGvkZv0kY7tw6HrkaIYlvWYe9AltiTjiZXKVrLYXxBwtmy1RWuPsOQOqjU7n64T2arw3B8ois\u002Fr03Xd4szkaEMyj2njrrz6Se\u002FQYhwIZod2uDsD1bGCrn+jQy1woWUxv2V8GZ\u002Fjeo63xgQfZU20cJVsmCpGMZdw\u002Fyxg8UgrMyzxQjx9XgrBqXh9+8tmcsyEdVpWjSW+sLU+EV44gtEXkzBwzbmCciSw0hgZbn0VRGldzO5vXWyPrIV1MutXTrqEj8YszPeg7beJ7RixeZYw7IA\u002FPq1LDmJp67f39Omxi\u002Fhiu+zkEZDDYb2Gc+ixdU4mpra2zE12Hi8ztWo6MI3m3geMpWFHWgD1WaxmvNuF++tGHpZmV6lkb0n0W\u002FWs\u002FggMCi7iVfnvjxne18Xx1udNcX+8vqYpXr17Lmy4q8Xh1\u002F8691Q+VTz2dM+pa5+yc61R31VvKd5kKWBtFpTbzmG9unU6\u002FPu\u002F9Qc9pb0057Ns5xl5XXWxkUnNnzEeLYDL0pVa\u002FvHJldaECJPfv\u002FtAzvqlS2\u002FU2mH+fjFT+VK57WQhkfH83xTPnsyTIvLlZFCNpFSX2gYjD636JDOdv+fzd5MrmN6qLXtCM9\u002Ft6vTegThgQdjppgXQSCBBWkbKymYKQdoKAeCWAU8DZzCxWskMEXoyXz+AAckJ9PMiEVZMCkHohxluVrkOQ6ptTTg\u002Fy6Mj1u3KlDY09n5eGsHO\u002F3Co10hE2ZlWjXL+AiINn6IP+vvKsPJJvAmQ2C\u002FIKqWQhlUXIeUqN8RAkfIFphExB8fIcieE385gD6oR9azbKdgROAvM15ZowobilmahmIGcM2KRYKRdjI7CM4RBPQr97FnB+O88VxYso\u002FE1JCREPkfSZg5q0cTD3xuu49POXrkT028PQhOjJ09U0PXe+v1MabQyzo52AHEDUXAIGFARPSGKvvxlXSq4tUQnfe+Ze+bSHY+wc6CmZtdn5vnbo8epkFq9jhO8+DohUC\u002FrJiztdv4Tdp+ZyFL6XMgOAtvJmbHfi2VphfSF8ghZAaVoTWN1m4ZtHNI8BE8s9emGK5aCN5ruxqe5hsx16Wjw9FFO\u002Fa6QXBvTPgMHuf5vA5WHz+axJD0Ab6Fe\u002FGDxK+rmeggLgeLhfZYjoEkGs8g8D8fmLQHcAgAfz+YulHCUBPIdRVGeWcbfTYUaexXu3pB89WX311e+iiQRECnFAcGNET4s3Lz4KAB76IMXQmh79\u002FJM8e1cqBSkNYDmlEj+cD0ScaBPRzbv3Rp40mll\u002FczbyYwZOKS5Rp3MZVBfb16F8pFKoe8156izhH31G+gANOmAw18TMpfnDY5rSN4vhu1mbfvrdP+iaB5rSpMzsraCglxz+jFXzax4DVaIP\u002FTqfCbdr3Ly86+6MgfKnqMwNhbzUUPd342l98Ni7R\u002FcZTxoveQCh9vwkuAFPewoobqGaJd9wuSuSn+dTLEAG1ucJW4StPsW\u002F8as8YMM2DkADX6qRjR98BoAAYZPXWaj9SGHai50n8OOtDlEzv7Xd7ZprjjIW6iejzlrX8n9af5GY9arM8CLj4eHBaG6zse\u002FW\u002Fnpjxh9yseVhA1tkx4Cl+I8zw5pYK2DWezFADicDm4ue6x7y2X34RmSHDLSZ0xyO06DrdpqMAyDAqwxwvaj2uhSXutZAKCJ7b452gF0HNyWPAF8bN8+dPT+yUvTJmG0wt\u002FbWAc3ynL7s7Aah8jetyXryVaSOZ5CiJ\u002Fvf1L+YY7ywDWj1skUfvh86A6w6bCY5fv58B+PFD6Ib0gJP7XQKarnCvItynscgiVcZRwtwrEP1hbOGXpryrM2v\u002FvE8HiLLWxerJVJhPqXdMNTQCBUEEDpVmiG8EX8DduSj1CjpBTt5F+\u002FfS5cE2lUPQrsA4enKc+5mwNmIvlWayIkToma8cZwhbdbv2eZrHCPNHYN\u002F8shbi6HR2gIYzaHP0f\u002FrPlsgOhay7vRH45l58k8j6PPh5v401+Sjdsi64avm14PHSG7OGYc+Rz++krLW5c15Py16446TWpvF8ws4RjLDv6qX0bdokKOC8+rAS44f9Wt4pvUEdD0H8J4OAD8xyhjRre\u002FwYXQBXOrHtDc6EcBa0hA8Z9ljEohOB4+RUV+kRegvxhvg1INhlPmof6yHtBORRU4dtK5fSxlNtCpxmce1e7oXL9rDUXeT6xnhlXBV\u002FlRKlL0bUkm1jd8io3FG0BdOt+R8OUyW154+uQ4vcCiqAtefAXP9WIyHFsxijiNxX3SoNtHngROUoSwtZsEszlx4Gh9cyPg8OzhCsYvF4WftO2ivdF19gbdOBV4X\u002Fbrw4siCnnsvL\u002FmjR\u002Fej1\u002Fa65MSZFJrWzsqgHjJA\u002F6Q0BuuTizldiyQog3ohD\u002FiTMgCUvOSkOHGSfKHvjUmqMWwlBe91GEEKaNG+gL6yojbSw1fwk02yLxrL\u002Fc6laAUy5osaNC\u002FPn9yvOlbnPByvDOrm4yrFPBygvrV1queU0nvqYvnlpdrUWTLkICrEI59UWx3tOZ9lmJ8rveZ8gP38laurG99+XZWt26td2KZ1fdU8x+KNs7l+Ryf2ZKBPc0gPkfGLzC3yLkOgmRjSjQa7tN9bSR+OMvTz\u002Fb3eG1BHNCww3nCLz\u002Fu05Jwv6RQIzRjkd1MoQLGqLby3JsH1JkmqBivIi6DHHBSgtnjX\u002FU2h2XyBmBcLPuVRe7dv3xmh+eGHV1aff\u002FbZgPEJ2TeRd+7cHcIX9uFJB3YmNyvhqL+U1QC8JhnA9x3LHBawUYM1aQF6ZIy2GCUWjVXM0+oeypjH0jgJxunbO6MkbndjC7wcWnA2QSE6wnsLCPtJ6LCepwJCguhoApPHXD9+TFnINT2aJ04Y+3VAF4NTXjxtLHH9cojTEFt980xlLid3MgvTdb7fq86qzZPLd9UsbgwABGE1HlfgoH6oETwKLCrcbcPmsTxIBBYBzvjA1CrDOOWOXJO7O2AjK32rdVwAYSHuhg4Amh\u002FKACMAKbxlM97y7jCE\u002FNJREk0g5piJbJALaFmYABP2uHnZwEnYEgqzS5sEJPgItuZ2vTbMt3YWhiOQgYHWpp+jOBISGpTjPbVX824NIMgA6eqam5vnO2lZ7n2WMNnbUFGnw3sSMIA943PZZJrXTLm\u002Fnm0spxNa+0+SUlIN6heOnv0Dzd0LIK5+ovPF2DOW0h5aY0qKMpEz7LwBRpV54NFAb2hrUgGSZeqJb2UIjycpoThhunf8ZvCNYBQzcM6j8dG1q+O9++FWmyEDF4h8meNot2fUwNCWsVOsFJVoF\u002Fr0u2td4MeBbJqPjK9VPvCmm5OWdRQsb6prKEObAoGbmQ\u002FrMz3s3+bMk30+7+jkbZJw1lCvNNDLd+gHvc49+lEz\u002FrYeb+srGt3NkARmasYQZ40ZBXhl6Te+eedd655Iu7aXdyMe4fu2DxkVUhCklCkN+LpN4NbG\u002FDB2dna6sXG7zn3aPJPCunb1UqlP96NrZWpLPdG3AMQo3H633+Xq5aur\u002F+pXvwzsfpScAT7K643\u002FeOutHMP\u002F\u002FIU89skHKSsjCwO+ImAM6Zmn2kZTNkmOwdEggF3eZ0qd\u002FEoVTR+VUVOVhuxa0tiA8IUmF35YADVDx2zjra28aUbGW85IB6x4Hr0Bk4PqL\u002FpDRp8sbM0gJcek13DO9IhkT6kj8bz1eCQ6mCwfT2XyB42SpZ4jfcc9zqFAKzvJojGg4xnPxBtA75HCcNc+TOlW3YWn0RuAnWhu0RzzsYDRzt0oBRL92NC6pIEtY3jVXgKpKCO3YkYylOHFMJf3TiHfu5eHXtpKvCIPG5WjWbJQFYy10uN2htaiwYxUhupsjMxoo7fwZah25so9xuglhYE31z4OJz7L38Z\u002Fh8nT3tbavYDaGKwxE3HkfvOJB960FsOT\u002Fo7IraWNluiNHhiecbF3L3yIvrQx\u002FJLMxSsjO0YmLtf5t6mc9uaT+tWtI59saCRHx6BvMtBczVXSMp0w\u002FLzIaCVKAbyuqK3mpXuGRxoP3eFvbeMerzG8Z2o4WYBjY0BDyYMGbr7Qu0f4DL0sfV8M2GWIdajvZuyt50RWA32Ls2y62RxmIEeXuh3LNkh\u002Fk\u002F887OauD+vY0rvmFOhvnchdew7e5L19nsPGpmwbD4H6px3c49RifMPpsfQ1edq4zQl5TfbV\u002FWVt6pvPGMZjfPXsZc04+5Qo5JDMMO6NRqwfRxb9p22ecLqUDh0HW7\u002FLPGjBJ9VSX+l1B++Rx\u002FLP8dQc0BcAPhyNmL9WsXlvpNEn3iGb3GsjNBlifO7nabeGcq\u002FMHWNx0gfTSy\u002FCJi+e5o3P4DzZRnkpMmiLwSYNTlbD9tEPigIU2V+VsllaIN2w17w+KiIhVefKlY8mx\u002F9ZGz\u002Fx2ZMiUSLLHJn1EGOFM1rnNtSuHe6gs05s3svDvlXxiiRHpdg7uK05VeOeEUceo+n9nK7SxpRD3copcT5ZotrMx5\u002F\u002FtL2MP6y+\u002F+ab1XffXl89Sg682G0\u002FS44zMgMOwnf4BIl40399vPBUXbImiBctopVum\u002FWdii\u002F0qpve0+u9AXXEBuwiMgTm2HsvIRtA2MIaGAayafJp1zpyHZDG6ISN6hgD8vtuiKTrKTmLSgABJrxuQA3vByWB0YVzB+y0sFI5pL8QiEKct2465KKTOvM8EnyP94R+742Q4wHSttrVDjviPddHnhGKhieAoGM4nG4TEiEexcSk5RdG3EKaAO0AJoCgby0uK3mYs1xVAldIaqeNDM8BckyQUfKyFJalFJ\u002FcruprJyzNH5CoHuik0NT+gyoo1Fhe+nLOqiQBcTwL+FE2lIkoAsW108ZKG26\u002F\u002FvqbUXSff\u002F7ZrMVWkQBW\u002F6HC03LJFPantNSJd7CCagiYn4X+Nka9ePH8zIGa35iD96gEtpSinDfMy2O6CJ3tvGnt+oi25bLKuXzTPF5avarkkXJNLxJe6oZPvp55tdbNj7rKDsR43CbKN+WynWjjKa+2NUbtiwcEskqANjaAAq8SqJ4BPJhsnjprQNBMqLz1ZdUDu8NiCcaN1nBRdovykragfRuVnj5Tb79NZ\u002FYidN0A3HJfd9qpTjDJf+WJUCvavO\u002FmCVOZ40EHLOwLcTcPmJeCASAYKujzIEzuM4IPbc\u002FG356LhoxhvBrRQtMx4wZyrKka1E+eJOQCRNIjXCu8+vXvv5n69E5HBdichol2AQFl9yhtIJVHYR2Y6FnozueeKaf2ZAKaB0nN91etmfQpZdv2pCoxvrqXsQocLZ7s+lkqwULDlF1tJ5kGDL7jWfzn5T5ry4vIiznh77wuGPQ\u002FgYXWTBuEOI\u002F0AN1oc\u002FgGqKsNCztgqd\u002FMpd997zsyxnjMK2UimrGxAYymUGp3MZoWowM\u002FvSqtyJzacP6oCixvymk0Fkb+AIpAjlKa9KBUBmvhegZb0n3mgKIH0IXKHdnN2\u002FQiZVIa5qw9Ac17J81ClAUtPi\u002FUu+pwsJ\u002F85LORU1\u002F97qsBuJTAdtUMANtzeaF++Ys\u002FXP3qF78c2ePgs9u3pUHFB8kYnmvg+1gVEU4nLx0Ud\u002F5SoLr+W1uefiUQefMAL7KOEwSw4UF98yaw3DjMFb4jY3xOWS8eUH4y41XtpblsvkyAQ9i6sPlY+GU2w8Ub6OpEp4cejz8cTMJzC1iYZ1FGMm2cM7VPNjoh0drxhpLPHDle1p6jYTcdUaPzvVXXGfLHeQGPc+CoPEOBk6\u002FWS6oMWafPfpe+tdFG288\u002F\u002F3z1V\u002F\u002Fur9vrU45rz+HtBOY8R6O8jJvpgxs3vx+54AwEh9jh6zcZBA5KsdZL1DRPf+DiWVUqmub0kbTL0oICZuQgANHUcPQ3tuRPvGfM9IX0LrnKz5Ip0tx8J\u002F2JU4gzAX+jd2+eejJJ\u002Fv96JRO1qQ9oH7ABNOQgMyA2oxVrsLennOsSfRtDT513ICFnxegf9B+Qsikerc68Nc9oBW+QU35aV30nszgWlOOTEy6KE2vNNfoBkIzKHu7rUYFX5zvgW7z4LB3lp74vRh3DbzEMyLuFL4D9npnwxnd+18eNloZ+VgpRXwBbxQUm4lEnGCvohjGvfXOFr+hvNOU10Z2wwYvKAVpnxonqJfgXcGoEwwtNx7TL2w57AHP0yNHmlUzUUzTspwphvKtLzrwR9B+A2ESYU0+6ffvR6vh2OdmthXRItNXoSr96WFS\u002Fw+7q0+mqGdkcrPKPiLMIokIT0pz0z9+z1y7aHiPLJBhFg0W7qte9zDCHj8yTl3ZbucEyy9rSLbUdnVy8uERp74Zr6CQY7CBbwfqLHClF7XUqnrpw6UxR9cUJZy4m6lm\u002FLtD9PYOTEu3BYk3m6DNjIScs2GQ5JBPIjJfRwYMqrJxMj4bgGkSpafuqUcVDpe+h7xrpAL8ryWGHMjqs8ubotOcZPXTm4Ta2bsSGUUIG+Nnhsxedpvy4Cln05pHmeG\u002FjyepR6cjSh099cL51etac3y23\u002FUF46N5q42hn2uQgOJxD8u1bpxk7oyU+qsrYfuV75yCi+Aifr7df8sjx0uZOX1p9cOGTDp\u002F75erGN1+trn\u002F1N0VBb8XHD4ta5rSsrwxsdptsCQbKpBe1R2fwUXMDG9qDZp4ZYtthVHRib9bgFMN6D6\u002F3BtSBc1VSvO4EBAkhyhSAwm1vE1xPS7Eg3G1e\u002FPjjjxvkyRXiul35svuILMX7KGJnMSqDqIoLouOlcR\u002FAzeoDlOVKsw55bYBMwktoBqi6c\u002FtuC7p4m6SQYAPC2QsAksIyhkX3qd1O+UevCe+FwHmJE8cjJIR2HbNt0xZBZoPI4RQz4UF4WiCM45AKOVF2PbMEAQEeM4qS0sFAz58HwkpPQeA2CMqDp9wRozyyJqp0nodjSAhlXb1ytc1oF3ycUn48uZEPmx9zfaDEHI5EWUhfkfP8oBDUeNBj4CVS0PibT8CJUuZdYxDxXhPqasRT3k6lnDzY+k44vcqoeMnK7nfefgp8qxxVwgTzblQuiZcDmELAwui8Sa9K8djq+OBXKcpbt24GOh+u\u002FuDv\u002FaTNpEdW\u002F\u002F7f\u002F7tquHYCW\u002F23K\u002F7Y1vk8Gh0m0cYUVq8QJi9L09x8US7RjY1+rQUhdeCNHSMpyrUZGF14LYCZIvK7+1xvExpja6FDAOHtEaX4lshBcnrGCrioUUzBbp1xXLuNObcHlJ\u002FKA\u002FnkMfBVSlFC1HP2eDEonNpDE7wah8rVmzXs+YcSjKN06td4fVJIFP2iJBlxi\u002FIYMNQzla5E19KejBEAXbz0RagCssb7oMOCvrtBwFWq7u7d3veGrk8Lvdf3vdbTy\u002Fgb\u002FKwLYOb32SRT+xN1aL2WKiBSbNAz4V8qQCDvVYOxGU+fx8vT+NyPOZa8zcUAMG5K2hjNh3H0o0ulvKjyov8AC4VLEeNdilz\u002F3MOA6Puerb\u002FWdpS8rk\u002F3lz7zZKljjseWaxaDxzxrmzxAj4x0QJC8OeiPcRk3ZSYSdO1ayq+UhFt5X6VfHYmWpbEAX46wxrvoQ3\u002FQvPXAxy\u002FbUPXBmVJE4rE3AW1yoUdH\u002F8uY9MO4PWe864V3N1I8J0o3O1K++m4GOT6xtqdPb6\u002F+8A\u002F\u002F3uqPfvWHq0\u002FyoH945VqpS+fr984Y5Eh5fd3alfs6KU6lDG6mkEoJ5H2yt0QEyoFcHBJTAjHjXBoHmrp69eoAQyAVX+B3x97Lp1wcD3X\u002FnafJ3+u1BfgDWgwD66lOOiBBrhgb3scPeGrZ0MkTm1EXAKHQyTNre3CyI14iWzaLOjAO5MN6jYKsT+T102SZND10depkir8QNhmKV63BwQuAQhFSZaKISSFCO3L03z7O6MmBuJ1z5Vyy8kmHnKjFreIKJw7jBQ3q3\u002FlybjkZpEHNviZrHXjm6RMh2K+P422MToA8RIgOp157yh1t2odgo526\u002FAxSNOhS4XopDEqsOjCLgatG917eRfnMeIP3Gb3wvKIhMp\u002FXcSPanrr90R9aVs3kUDyo\u002FfHStTY7zf3oGjT+7i3tIBKIJxhki2Fi38fb5ICN0ONFbs7wzMjrrtOPpM7IWFVm0AgnQEvQVVEFfuk\u002F5x+QNzZSL7Td79HBgPKuVBHsbaDeXDfMaR8PqUutTwepJ1KzRGzR25tkuHQ0Zr6XFFBg+FiOg0VvA+TLHgqAflJd+huoXyKoHAbJjJ5H1xiLtXVq7MmTnHIthNEC6H2HVs3L8Hf00ErmdOlgvwAV\u002FiFbjRZfkkNu9xyTMft1zP+QwUJ7pk6bzoFYDIy826U7ipjudpDRs3hmqYiynLMirYzxlh9g2ufoMi\u002Fr9anexl85TeoLXNMXXcORp6JKhvnFYxnlpbAkL6SRSZ0bXNEoYKlZR3OVDqXT6Yo+HBo1Zl502Mc4tU923g2PSf19XmT2oTmPNleHLsya0q7mFP\u002FxouMJXvjlsMdKxpYLL1uAjELbPNxkBoNjLXojc9HJpXjw9M6p5gGNL6lesLd5QeP4rdls\u002Fhg2hwPCIizxwtEqw8W7r\u002FeX09lFk7cyaKyHCi+KCuy3MfvJ\u002Frv0s\u002FjEAUTbAXKVgp7nCNw8nrMnA+HVm6oEvnJo0vJW3vFQaYjy6NeaE1kE9rDYDKpPq9JlTp7tfaYykVevrb746U9WN77\u002FbnXju28r8fhDm1s7\u002FTsHgGjmTvStxCTefQtPRf+w452cdmfPlf5T1S5nBEhjW9JHw1GY6z29\u002FrNU\u002FDs2+KC8KNYFIgSgz0dsCA9gRUCLxxPwKA+9awgmQp13fT+ARqm6RvUAljNlsZOyGIAeETXqARCIEGPy1F+o+sbURq9NggfQ\u002Fuab66u\u002F\u002FfXfzH0ffthmhTzhFIY8Lf3g2QDMX0TQCJDC2myTpLx1wBgjPCxX62VAlUW05D8HpGI0gsPPujLtU84Tbu3ZmJyCn9zensPbzaOF8JYwuYjBcuqkXOZRjIBEoXQ1m7caF6OEl52CAvx5r3lmHgXSfsiDeuO7GxH+bu3EgBkl0obkAdtYcq6845\u002F\u002F\u002FO9lqZ\u002FMWj5duPzirKjwr41uu3nhpRydyWCh8J8GzK3F8\u002FpOODlkCYDObJm\u002Fjd+a9Efz5h1hPkiIxqBy69++aTNLVQf2EzA2V\u002FDGEpYvAyqbxx228GIMDnnWf\u002FkXf1qZpZPVNr1RuaQfq9ZQvl4AVV73B6dtbDw6XmLHxRGeCJxwJCwHdE8\u002FMG4fNqfWmlIXGueNcf0imBelQtmUsN4aJRha30OtM8FOACgTpbIGRcRoeFberXVyaBKPx+XLAafoUP5afsTVlVJFzpS+8v133xficxxx4bjAzweVTAQIeCtsjrHx88L5s0MzTr19JFoTHaPzpdtUAzKurxFQP2ajk7qwFDNFxQBzrfENAOV1i4e2K7\u002FlJyPMBU5utBE4EsuC68S8PqM0KHehW+IBjddIK+Ll50Jj6v3bnPw8r7ByXg4iunzl3Orv\u002F4M\u002FXf2\u002F\u002F+avGvuyyYnXb\u002FLW6wPjiacHb\u002FgP\u002FwEvlKdx6Ai+sNH1aUBfeFj\u002FgWXGEh5e7tH96V1zkOHSGujX0u7Sy+lt95ojAwEebGydv6MNipKBRkF4LQbzQch2UWT6NgZcnZPi5hlyxp3sCFw+y0BmjHNWkU8UkIiK\u002Fnoxwob26wAaEiXjRVePF0\u002FKVcQzmegD\u002FKT7LcDY5vfSiy5\u002FuPrVL\u002F+w9rY6G+LGeJDeJsI++fja6s+b53\u002FwZ3\u002FWaYZnW6uAcnRa81MqFgAGtBjuZ86eG8DLYG3U0Z0IUB7bnlqnZ30Z3EulJsbiTiHc77onj2DzRC6SCwAiehplWz951njqyAUVsHiDpKDwkD4rAvbtt9+MDL+Y\u002FDh75lz3O6VwMRgpT4cBefOw2iR3u\u002FMvKO3HT3KqpIwZ\u002FvJYAf3DnWJoUyG5MEA\u002FfrPp9U0VKq5\u002F\u002FduhEfNMnpGRCwW06NEZWTgRlEav0s9UPRmCFykKJAFuHX7yQd61L778aTnvpTfeC2CIfqRXOI0Wb\u002F6T9JKTFMnX7QEcUoJQ3m5zdjRHDEg7lSmSeXj3eTJBdYvjzR9w\u002FrB8ZG2KGiBL0V6byMl46ZuPGFKluTiMhRwy\u002FwxSVWHw+15g7kgHs000OJBtM+ZUHBvaa0NpB76IsgAPgNdEDXsQ\u002FhodVdRxAc+x2vw3LOcxc41IEk8x3lhAKuOVzObFZogu8mRoG7hMlsz5BX1A9tGB7pX+Z1PdlFFNH1lXa8IJPelNyU7jAiqlRHjh8yXiRgY3q8kzOpqXf6ONegwAkzbXq9JRe033jGcnoC1PffodjZLFpk\u002FpRS\u002F61uXmvCEsc5Ch7Prhii5bDCsc3n\u002FpKLQDsOPlfo0G7AcLuPX3UoFEKq00sNJt6dho0hgY77OfJWbcyHAi\u002FxgnHBSLEZ9hV6Rst\u002FWj815G1yKuhzKsReWA\u002F3FEphMmAtIc6xUHwhu6qL6OLutZ9AYaosPpE06BRV4b9cIreJaBNHKsz8g0vOPvySxoHcmEI5vaS8f1+US1oh+yli4h28hf7Zgzex4Y9eiLLoHVanloSJ8dnqSdKf0azz8IiDb10099xIOclHTvpUvnk\u002FPhj\u002FSPaIjUkmO9N5LL9tuRKTXc+DM4OJuSbaIeUnZEzzkzpOMorehUbsb7ROaSr6qobbfxTRaBDsxmaw6HnAMvy22\u002FvXdzSY8LZzLUsxzDIgH5Dk2aM2NyIq4H0rfymm8drcjFZtdUi32t6i4OweMs2M1IZuiNOkquqdx1rDMhTp8PB37y2epBkbc7ORpvfHt99f031\u002Fu7ijHpXRFvm1dPhKP2IjBn8PxQeuPDjKAzRSkunj+98Fxjtw7v6\u002FXegDrwrSi\u002FkACCFIqV9zeAI2JE9MryGBiP3Xed4sfji\u002FB4ZD795JNRvvKaF4C85FjyVmzFvRTPAUPPpobuQ8wIkuCgNChhb14OzP3pZ5+NMpISgjmfV7lEeJhX8nY7tW26YLV6HkuSoqGg7Lh+Uu1eXuMpz9ZCAiJRVdeWL9msIeCDN0+0\u002FDGVaADeRF5trae8khS99BtTCEd9oMReJ5GOdyfF8CLQoLMH1xy9cnRC9ZTMeH3KdwbUb9+511G9bdRMqS1g+2SfPxxLWRmy851e+pOf\u002FnT1YZEKzGb8UiNsRH1VlQeMRkHxKMllO1tIuKI2o7Rt6pK3J6Xokd9JxYCUfEKC\u002FFAMMwcCdL0yTvsOYckDtx+Vj4hMni7ehqIKHWjw4OGz1W+\u002Fuj7P\u002F+yzD1dffvlx4erTq7\u002F4B3+8+uf\u002F7P8eD\u002Fq5s9VPztp+UvrLmTOnao\u002FQycXdM1W2OBwz7wKJfQ6Emn+7z4PrY9BN3nB0kwyK3niHKKaEddf06wIQEiwb49UB5pc1VFmBoHnTWspl3i1liAAX8tSm9AQCghK+U6Tn4w8v93k02tvphzanUg5nO5L8RADgcR67O7d5t1OqtUHAz5w1VzxgjDMKj8IFLowF0Kq3Q0CUqfbQ9NSJ93dCGT1IMTnwRgvJy3FeazzKMyrVx7BlVIwnvj4zomp1vF4IgBCmoMya\u002FPTzWf7yBBlkvOoXAq8ffXSlNtc6NfOH6R\u002FlRjkRMpRcU9nLvAIfCz0T9C1S89zP+g7kGtuLwqUUD6VpPJS0sUAUQct60a\u002F9M6C9n8a+jJ8SFjXxjNpzT\u002FTos1qaNXUdoD2e+RqZvMna077vPF9\u002F\u002FA14jwLve0BKtaRz57Ynqvbxx1dXt6rCI\u002Fp0pEM5Zn56pvnSjj0I1p6txzA8VnkzIAXfMYLwxYsiBrz4ys3xLh1P+V0s8vXJJ5\u002FOxsqr1z5effnFz7s2JdkIXr6ouki0+l\u002F\u002F6R+t\u002FvRP\u002Fqh9AueHH6W47QcwuzDFXfpXYE85UKl48rR5n14H\u002Fuwt2U3wU342phmftDNOCP0Asgc89TlwSzFbr4MIg+s5EXjpb964OalvwtdoVW6qdXLEuNQeUb4nVX9glEjHOd9pw9bLdWSkw0uisAGwAPPTclM9yxz7KRLI2zVRyMbEkEALTeWMU44\u002F793nX3wRrSx7VMwNQ2zkefIHrQMd5mDopzX1UztkLV5iKMUhAXKH0\u002F2k\u002FNKMspe\u002Fbm1LSwvgceTIH1\u002FA8ZLacLnNZDzrHCz2HKnG9TyQzWkwh0A1dgZPVDrzhb+k08jN3z5K6UZfzZW0Gel1wBnHCcD0unQ\u002FXmO0a27Pt1mfp60\u002F003Px0mgSta9FP7p5IY1ft3a0YWiHjHh8O5UPKt\u002FdAt5jL\u002FRtb\u002FRtEpNq8DZftV+zPcAxGelNhUZYPCjYa+Zz+bJ+H3Upe94z0884ir8DYzj4XgwZkeD+oxyh7ejJdFGqRrODkAHb9cy6nqeNhbDwLXJ4nQWoO4949E\u002FntPmCa1M5LqbxnnXw3hUGaLS77DgTgUFBtj3B3LBW16qm6013wxoc2GO0cKRI\u002F+FfFkG9E5mMjL0oZtHrtjrleEA0HYvOQ5MklUMmYPIgecxrEQM1qRt9Ez3ALtHS1nb37sdLdTvbE\u002F9XqtE5Nlzpyb6b92koaElVcz2yncmj9eSWfSLqkQpvHn+QT8OInf0iwiftRMt5ZTjAHIdWpmSpc0XJ4B0z8FBTQ1jlqNwNqvXBoMJf5ijl+9SI980VrQAFDvvRModR4DN3IczDNHU4ny0Z2rhTYcPcQzBR7zDp\u002FtbeuHBnHGmcXw8f1nksKyIV3m875YJYJ7gtGP1G\u002FbY3cuJlUMkKkj2qDT1Mr4UFeQUKzoVzaMT+zteZLDBENKh0NTuLiccB1oRt+bm9Gl7ZY4NBqBXX7ypEAKDqXk6Ek9vjNMu\u002FVwkR6WYjaqybb3s5PBj1WOvYsw6wL5RZoYSj7236wN+0XdpPjtvnQjWXCabznJSnDu3+uTTz1Zf\u002FOSnq99\u002F9ZvVd9e\u002FLv30q+RvhSHqJ1o5nAw+kh6EaR\u002Fcyfueo2M7Wl6ccYxbaT\u002Fv5xU1v5+XUM6cqBjhj7UYk1gQ3nWKg3CkkFhtlArAeAC0CUO5t4AABlS60aa5B10nD1MaDWtS1Rj3kio8RQMKCIOICTG+6dkLGJLjaVOfmu1qjx+b+wgoYVI\u002FcbGwDq\u002FuzZu3Vv\u002Fhr\u002F9mvKCffvLxpOYwPJQd8x6LtXZmkwLC7lnj+R\u002FrdQnBR08D0oWq9vqcN5InhxIiL3YSCnsxEWIeoDLMmbKIaTAeUEDwRqOTukIy+x0wu3D5yuoPIqqrHz0c0OcAJx4ZAmEtb4gQl\u002FZvtS9A3qG\u002FMTEGJojOxpyUPqPncakzU54vz9fr1mIOKykloMXokUBFZZcSLASbk8Aw9QLaeDFax9qXH+uI3rev8zIV3ifoH5e+wvO7uZ3HJSH1t78pL7e5+MXPfx4NMKqer\u002F7kj38R461W\u002F\u002Fv\u002F9n+WV\u002FYsIyqvYUrs\u002Fp2iMaWc7BY2AhrTBAk4oE2fzMMifIQSzZN15oEDstDUCLyE09yX4unrQEXh+iTqdusnB36rAyC6s2sXo4gqiNoCO9FGwo6nl9X\u002FyKFNKXGl154+yWNYbXinrPKgna48Yo+v8ku54dHHxbzvp54rx\u002FWs6EFG0628g\u002FEB+pILzvtKS0b+0SGl0jPrpl6rbsFDMYvc58DL0H\u002Fr7BkuolRUL0LLL4pUPGrOjhx91PyXkhGNERajmLvBvd7WsC\u002Fmu6W9FAejLzpkSP8AHCVIeTzlnPJW3shz8LvreWPjUSDI43nzdiNAfKXf5lm\u002FvMco6jEAOiUjhUrYXzh4DNqu1oi7Du7RhPXirZMOZh21M2C872xMargDkvXfuPDD8MTBOGtv5vDdvanwmaMZd9eqgGH4gBpQQLFLdeM8eHH06RyocfVqFQICw8+ft68lRYU7KeTZo9C902+dfvdszgQn8Y3cSkhLZ7h08eLqs08\u002FnYie2vZkHHA2m6c74GrStqIl4eKzbSr9h\u002F\u002Fdfzsem5\u002F97IvVuVL6HFxFpgn\u002FC8vqNL5lyC9e2MLBeY4Anq3yKQHfwyn5Izy6pe0xEMYT2rruby6b12pklKS5YMRRlHh\u002FqDygbUhy9dXO\u002F\u002FSzT8ZJwmGAvzkNjjhlMI\u002FqbrwrDfHho3vNj0O7MmjySMpRt7b7ff8yBfj0CYDX3z1DmsniLFEZyt4DGyT7PaBu3w8P3aTSJOce54Ejr69++OHIb2BUHxmEUvaOWcd4RBrcWmkm5L5DdKTpkAN4YfFCptCj5UzxdMeF1aeftuH+zuPVtzfvzH0WkufsVHLuQYeq4NEPr11t\u002FM1hHm5REjx4IX1w7syFDLc7E01g2Peo2iUnlj1APMVkDMNi6DI54ndpQa6ck1wP2Z8ChC5\u002Fc0pdKkpLBrwsNUJK0eG1JRXKPfgL\u002FRu\u002Fai+vchjgPeNb7wTauHOABBEBkIh08eqTCeaL4yAOWe7Ju8sA8sJn5BpS1tf+n9\u002F7eGgAHahq5ocP1kYvA\u002F3+XHSQErlOeJ2IZGtmfKP7orfxqAdkX7zj9YYwr7hoHjQ8PRFLxjLjd9HPk+KzXDp9cl8iPPrTk8AwGRiWHQ+2BajXxmK8HH5Sp6RRyZUGRB0qSLf2o77H6yOrGldjcCK1N\u002FnICzt56bVoPoDf7WT0+ouioclD9NtTFl1Sh8aIwPu1dyj+5NCxeZQ+SewSTdE4WuRhLnWrdXYGgUPORAScRUCW70zfkpl7jCd9sr9E6VPV7FTCKQLzTt4eys2lQ54AAEAASURBVNOsX+jnu+++H6eJuv8fftg5G107aSbotbUgLyeSaYbqDINkNlzWX0BaRA1AnIhoXnLV5eAgz9P5ifS8wwaeJx3kZAa\u002FyBnnhxQuxiP5tO\u002F72mc0d3PjWJxRog9o1b3HGcNv0+HxD2xzvOossAcHofSw06dzUuVse1i+ubXj7Dh3\u002FszIE5X63lRrH6\u002FPvoxwS8MM04TtkjXGo7odaj71KP2bvHLYn1NKXce4Vv6UAelN3pAThxu3E57fxhP7OWflpG+VprxW5Gpjq0PXtntvVo+dhz3P\u002FcmMkNet9V7GNmfmOD166onW9oNkprSYR7\u002F6owD7b4tafrP65vrXZQfcjg6j+u2cYD3P\u002Fr+N5OeTsAHDCo5NbL+313sD6j\u002Fe+nEmVvqLkCtixSgGjUgoDoyyKIsWPsICoIWLAAgCC+PxSsrfnnz37kN0vBby3ikQOe2Tw9dEaM+mG0oScJ+DkEqH+enPfjZWDsFGKQwxR4hKFdpAqT\u002FnyymSVkKR\u002F\u002F7rr6vzeWM+l\u002F+uBrDKBcIoPLEIbQiIKz3ho01EuZlnIz6e9nlqDzzQO42VJFxqDi+bt9wzgrylI2gJ4EMtMLBtPAwMIJkX1TgWD3ipOYHGUxHB8bzmBMt4bVO8DIHZUNX9PGVft3tZNAFjAYtj2QYgCLUPTp2JiPOwx7APmr\u002FtV0sIzdyPUi4Ujhl4GoAam2oI2SV1JO9F85XIby5i1hSWPMtXeRZ4xA8dK2zUM3fbRLhWicStwkmv69\u002F9B04r7HCgC21cKc\u002F7Yd7\u002FixdO5VH81erR\u002FTurf\u002FpP\u002F015ufcnB98mW6G3Vyl3AoFHnSKkkFtiEsnHM3MHntIFqNTrrp3QYfRE4Ab1+psXK6CZYH9ejvHxY\u002FLeCrl3zrHNrdpCb9o6UfUIljsFiy4IBsLtYmksD+591\u002F6Ju3mxLg3gcpiRQ45epHwJvORUQrvNbRki0mrMl3Je1k8qjPbUeKZstD8CtgGZz\u002FEao4N+F23iKdaxCVPrYONGMzPsnnm4Pkp5udHR5xOmTVCitykJGvB1wyhm45h2NdfdhHPz8vD+o8ppPY22S0\u002FIM8MAMM88tc+iG17DJymjrQAbcAHyjxKLjvVRR\u002FxgtAG48scPR4Pj9U3p+oxncaHz5WIKcuEPninRKMqmVdJc\u002FRqQXh\u002F95wHkhRA5JbmE6\u002Ft4vusec9Cz\u002FZw0n34eROOmJFf32D+CRo1bX9Sdpgxn\u002FgGt1v5EfHTu3AcZ5WdTiHf7XtQlHuYJi6eXeVycCkLeUviEYimvx0W0rl69vPqzP\u002F3T1R\u002F\u002F0R9NhNDBVPrKQMeTnm1jNU+NjaOff\u002FZxIdGl5vGxDMYn8YF1Er4+2vkGPEsjnxrbPD7lP56+njcRomiWAfImJTAOqHrY9HnMjNXa6KefPOiUOa+w\u002FEkylxwexR0N8sZydhwpZY0seqqkXDQEHM0pxsHls0W3lAw8kNvkgNKD8tOVwn375lg8UVm6Krh4AXH2E5lnHneAXMlHa0SOKms7HtDmlwLdaCehDe67GTwGFDd0bznt0QpZDtRvBvb13brhJffhbWO2aXe84V0vKkTBbh453ga5a6Vw3V5dbk3Xyz19AdAlU+1zulME5dHDvG\u002FRORrjSJG+9jKlenxLfjx5K6UD8F8OWxLOB5KCa4Gtehm9TS52dCT\u002F+HUgwZqjY1E8csNGM55VqUW8kT\u002F8cHNo3mFHDPdLeSGXtJN0XXTO4aBPxr+W7Dha3vpmcgQwlQ60mRHGEObkWsvjN8C+e7wAG9ETnEN31M2RGXM6czqr\u002F6fvPAPohbNs5HiTiL+sCTlBbJoTVGW+6TVmk3S38RpHd4xTG04flz6pPfQpbcWcuU4n4sp0AxoUuV14HDt4eYZHkB\u002FerreWPt\u002FK80lPA75kCR6nc12HbumkyW+eNpS21N9kfuvgGvf28LpVr3vPptJSM9H0QZQNUBaZeBMWMfatI3l1m2P6yTziR50yRzrayGq3CGq4wmZN0YLf\u002Fuab+N8+L3xbxZXy3m1yPJZswKei3goUHEsfcuwxgHPpjTOGEQF4mnH8iN\u002FxqlMyX7Xp8EnPVO5TCpKXKJn+2j8h+q\u002FsqOWVGXDgXce\u002FdXiMhBNVPFGJieGI74FLtGKePQ9g5qwzXwxfEXWHtr3tGeZWSiyc8DiaddAiGUqeSFPhPODdn1K+6WR6V0UUuMlBSU4mVVbb3MMeyhCT6yJpolroXsTXmTZtept5kd7LmSIa7aRUe\u002FasO3w2DrjWrkaG5p6mk2RL2PdUd8MSHL9Sx5SZLZWHLMGH+HJrcRowIDZrM4DS\u002F1WJedWhi21O3bCR\u002F3he\u002Fr2ihaXlbSQ3tjr51PtQ6\u002F2m9LT91vTVKxGBaKX5C6StjoWfNo+erOb75dXHX\u002Fxs9Ulg\u002FdaN74q4dwp1ETL7Kp8\u002Fa89NBupuDhobnY3v7ThhrOjf\u002FfXegDoQSWjzPs0m0BaYoh+CjEEmVJxQcx3molC8MSMP+ijYxoOIEQ0Q6Xsv3jGVWhCHPE1MBHADONNO4JZQHg9Kz\u002F\u002F8s88D9HdbxEIiPWtR3hFtvyNwIdEBNTEPpvow7865Qh2874h6M2YMw4wVTxiN9VheJqsYYGXpsYB5kgh2oG3yt+oHo0Gtc4xiE8I6RVO7JKnhsDZ5FHGNnN7xBkcRE7LqGnl9GynvnhqhyfeKABv3ogh4mWokgVpnAkrNcULg1g8\u002FjGIjuE8XmeDtZ\u002Fw46RWzqlYiH3hO8MJc9c2hHXJavw3giyooRXa1GvQYlDAT8po8s8b2unEBA4AtACcUeQBK4v1h\u002FjNn2nAZI64dyvBIqVMY5ljawOlyt+pFfVnA0D\u002F6R\u002F+wfL8nq7\u002F+979t3QKcjWUOyGidKRBrRDkNsZOhPXUUS+W+eKsJ4QNPP25CLxSmFyFvrnlphO4fPyrsHC0C69aB\u002FJLesABznskuLZe0IZuquYYgOXRqffX7390oVF0FntZTWcw7WelLesySFvQkmthrjYS7LreTnvfQ5mPKixLgxaaMeQh65PTKM4wF3U5kpy8WfuhQpTQcugEKKJ9FgTSS+m9D8IAhqUu1K3S+KKwG1LWECiHuQZ5L8I0CN64G97zIRRJ6AMIPT+4kHDsCuijGuYttXEoJE4g8iAtoxE8ELoFtTsz\u002Fosg9zLPQCX7hZeVJsonUplqA3Uog0brQfC3efFUT0H+9HEXftzM+NMVj5Ke1Mz8D2Pvp2ctrURzmxVrz9gyIrSMHHrtRXF2s\u002FzNfzbY6x6poTI5pCoOHGFg\u002FEhAVuhXJU2YN6fDYWQf1uMkLXjMVEsgytK6Wve\u002F\u002F5I\u002F\u002FZPXnf\u002F4Xld08tTgDjK+2yTplVjc7CGVosEabzmmDEc9Ts1\u002FEyDXmTp88B8i3ERlAGi\u002FdOwUsn9qJrepwE\u002FyHCvOXRDDe1+mfcVrj1pFR28Uzd8AWx8akqaTZpB2gEx6zDUqagZbckXIn9UBag6omThu0\u002FkC5zbcO+TGXPKH2EAFRx3MR2Qd0qtz4+\u002FernFVfyXzhb316llG6AMiMg2SjylUUNgCsjrsRHClflIGn2givE1lhboBIwN3c8KzPRsTatP+CETnyIPrGM+SuqC3PGh6fKiE9R0UIqTcnU6y3KyjA4UMGXn58KWrIK5fzxd6bzL36fXx1+\u002FXd1fXr3xTS\u002Fi6AvYTp5abzeOoj\u002FiFXGDMLgGwuyBpr1Mv4fc8ApegPORui\u002FObdPM74eCnT6uezZNB6+xIuFB3otNZ3QHCHx6\u002F5Vn1JdOXQ4XRPz5beMHor\u002FjvU\u002FFrTvcDUpL8NHdFFUt16ZmuLUdbJDYZPgAk94we6RVdx1YGuPJA5ZALvsZ+u8Pm02bPW37ThMLpxvxexIm\u002FfAWbW2fV4Wdue5e+R9wH117NpdD708cgOkYsWSS9GZiDU8QzX\u002FpEinpwtNi\u002FOfpAMFk\u002FgeFOVZVIJer7vGTSzHo3XT\u002F2zD4Rzq2XpteiF7WPSJqxD\u002FWp+niebbJRslDko2j8RXY4hmqF2kNeur1QHPayfdPCxvMPmTfTghx+cDm2DZjQdPjiZd\u002FbMuYpMRIcP2th9r02FymsyxGACkUNKhZ4xN4yeI82tSDjZT17kVxi6ehVof9Z98sc5Os8nm5QR9TfnG5lJHsEA1ktEbTn0rAyF2lHoAfZBB3QLQ8o6mR+0OpX30mF+x78khaoyImmkNTqYCkDdZ+P2MbgpeSEjAjDnULtXSo4FlzojSo3OnhRxtpnyQU4gxqUTu6USi9jYdwcXjXe+tbPB3BrZ7PowB0FdaL7rY22S53W9\u002FuXAjf5hq\u002FV+MhDXj1SDvrlz8uh+8tBeFOl2G0UhOAGn5GOOQ47CXOjJdw7D9PRG5Vk5KnJMrSW319arjhXv7QXaNwLmh8tZXy+VZjdnyW4e93VyKeDOSXA8mbjZGqn8spP8O8Aim4374pWPwljSYsKYlXe8+d03q++\u002FvV61mBsZXRk5gXUbZUUmI4f39npvQP3zzz4bYAz4IsLx5LR4iBLT+Tm5PC36CNmuYyl5+Z7QE4aXG+Re5R1v3rw5DIW4tLt4TglHgPdAWLPiSpF5ZfPe4i2lqCZvN+Vn0SlzBoN2EQ6wjIHt1tZXBHmunELfu14uNIDOw7Z4CA8UeX1AYQkA9x3srsaYcraFumt4gCCmb9ATOgOmCf0BNxFrBuEiaDBdz+JRnxSYCJOHaGd+UlgR0RsLnrcqoWKjqs2Qc9hSgv9NfXWy6bUMDda0PFrerR\u002FKN2YQDeCru5QzICzszbJ2YMvtGO+b69dXTtBjtfP8CfOvxdAs1LqUMq2jzds+j16\u002FLx4Z+ZqtZ6CJ8UV4UioflPO+ey+FFDPsjFAmtBdQhtmB9bUY7cV6JZm2r63+x\u002F\u002FhH6\u002F+p93\u002FOTD8bQJxiWxANoDdnsnDyI03ldCEpZTqStCwfqWoGzcwql0vQhtNuBpIEgmxWeVNeWyPypfX1pvznSJ6PMMqRUJCjsebMIGmrEN9BQKV25qDpLK+5af\u002F7qubecgepzRi+ATBseYf0KNs1zcoTGUiy83L63GiajcE2IPCcaro8NzxYgpNjhBVgzZlNvWr+3yUJqWA5hh7eOAdXeEXbwMH\u002FCfPPTogiC9cDHyU5yw3+U4ef4K25WiYqZgBMsDXotzeBMJ9Iz1jq+d4MWCvfnS2cn8Xoq3d1e3SdrRfV+o\u002FXgmk1w+\u002Fo6HDNizVX20D5nVz1sFc87Q9fVrlg0DaHK2sH70J3rm3NZpyjjoYnwAwwycZUsYPAGmbEp20GR3vNff7p9fSj9rVN7yQMnAvY8ia\u002FZdlKIHm8SBH4zYIqlgiBYzBmBoO7CSo43cbmEX+9nbbqdEj0Zb9KPkSuy7vZmlBjHceKPtb7paDyMD+5JPPpvb5pIh1HTkz4dJ+8rAyBo\u002FmUXYAF1BokxTnxXZKILWUrEOjZB4gwTAzvualNyXOS7fk4UfrVT1QUtL499owJRSN\u002FpuImR\u002F8AeSYWmNyv7S8rRTe5EC3hgM2u89MypF+2\u002FMBUTJrqfTSfGY0A6qUK5DOWQEw8KhZTPtEeEvlUktt2biggsYH9WuJ+IzsBppK2bAeXmiMoeGkTiHiBGF9FVnZSu4G6POIMY7I8bV+4pWpsd69lt1n+uyP4Y3utX6LTEFH9pQsJfCACyF\u002FHl8nDV45V4paqRicFTzSl8o53Wq+z2Z03U1eqZACjEg5EVm7f6\u002FDWmLRs20EczYDoxRNPufV79q30fjIUrNGDtWxMWKAwbzr5lIVHIYPo8h36tfz1NtDZdPabmCFTuHEWc8rTYZIIxrjWH5yzxyvb\u002FMHNKElkRFtTSpjMpa3Hu3bpG6dLfx686K\u002F4OV4pKMZaw6soS\u002FyBIGTJXh8jNhoCKAcQDc8bsxkqTWq3cZonIssje+bX6AP7\u002FZtjyUjlnnAN9ZZhI381V9i603nASQwa5fxxYAg3xYe9wx\u002F939tc6hIaXH+iiIDycPaoBOUws0UXb3IwF72ogVU+8848D+5x0jlzRXlfevd+NczmOjV5Z5Sq2pznCfN6SJLFyeieQRwRW3QEF2201oDsC38vAHLewFRPLkVD6N7EWDyVDlDOv2H9jLdzaFDtzjvgnFc95a5RMTT19ROzyKbyHtA2N6WIxEe+eLZHIicH3hv5rHrl+pwy2Z1c8lJBqijdwawam+qfjFurbP2rblKePhcP+EL+gjof\u002FU2o782rKX5QcxKT4vAW3oZBfrG0+7gxoOyyxMJSvb6yalgb0MkUZGFHzJ0b4QrikxldGuEI6Dp7Dq8a\u002Fylh6Qbc7A3B5VuDm8wEIb\u002Fw1w2lzrVVwSB3DWnJ07m0GxMx47DWYuRcTjZc7jr364lVxvL605DfVjK7emcVgpDqJq01JXXxzDiVmAdXkr229f1cr8qOtVfXw9wb+Uh3z52qr0IRUR2mqON5ryDGveKvG\u002FmbHOA0sEJ82RDkKxxJX9bk+3jos5lOhSdvXLlyuqLL74sfffHwPr3q6+\u002F+o\u002FOMu\u002FhnRpe6sz7etWF9\u002FM6\u002FcHZAYdPsnZ4WRDcdhsLERzBvx1nY\u002Fb9lN0war87bc+LcBtAHOMROE6MBG7kDttEiXkREuG\u002FWHIplRhcHuBWG8IQHO\u002FYel4vnsdRRC22XE2eYfedKYTtJ7DBwrxZXi5Pud9tENUn4anZ\u002FNCi8AQBgwhtV26qvO3+w2TAMgZSkurQmrEmGJJsPJqzmbafKgZQJDzXmEcEAGCxafNNBO\u002FZhA0DJJUcYdjV3UYEE4Ih86BhFuCHt6Q7hwmAbgB1UQ5vSxE6l9evHcgJrJPlxOszBav82QDZnnfmg\u002FMxN2+PlJ0URH3VZ4Lckdq8ZspX2gCm+oxQjmN\u002FiV6KjoBlERMEivmvZ6j0mPqfAIbKavNUSu4tyzThACCZLwBKSNL43sZELWMVRwCmyjld+MnqH\u002F\u002Fj\u002F371v\u002F4v\u002F2T1zbffJ0gadopvreornoOJGQb91s8AZs9jLFBi6EGYcLxbAG53tGTzlsqxlbLeTCGax8edjrp2+HnrrEoDTzjvQ0ZQtHks4E45PEvYTbgx4bebwHhw59Zq\u002FcLlclovVWLyRyJlLO6tqhEcDmwrweQkVqep8WKdKyXm5HhaGIB5TfK47L78cfU4Q4FnhJdGFIYCWDzTlFZ0QFHVziiG+j8bdjL4CHq\u002Fe1lPz+uGBEfgtHXgoWWUMdwedkobsGH8IhCAHu8LL8A8QCPNI88CkEv4fPLl53NQjMo0XxdVeVRKjFWiIE2mTa3uJWNbsnc\u002F628f87IzdO3W9wghyVflzye\u002Fe0cbAZ0Dz7x+AM5LFAK4WpS9ZwEBFC76wmvLq3lpTD1paMuTVRPy9mw8wyjnJTdeEaKtFNH0K1pjcEuTAJR5vZ6+qq5x4HQ7cMiwcnIcL9ahaNK5AB+UkvUyb6c0GV6gXd7NnnW02uU2W2\u002FneXn04PmU7FL15c\u002F\u002F\u002FL8pp\u002FlSfTRN5aeWNkV2MZLJOQZrzBCNBEDxwesXHcyx7Pmw38JdJ+tvt4+RoXQZZ8WDB0uYm2cMKAPyKHdjON4mbJ85KpssaBLH6N5r0OutgyjOGKr9zYBFX9bbs\u002FCK\u002FFRha8rbOr16RT6miGqfQnagD0+qzWzyeoWWKaYZT8+P05NzyY7AD+\u002F+YUAo\u002Fjp79lL3lusfaHmefARKz6X8FgDGodAz+o8MyM6rTTWNeYrJL+ue8UTp9p2UPHuRpLsAEOQouawiGGeI8eiviJMytf4mU03k79q0\u002Fte\u002F\u002FtupfsWxALTdv5+8jieOVWlqz4mDgeTPProWg7RngMOg6bmfXD5T2c3zF5rfqlCJdNjUKFKnrh5emRSr1g3AMo5Jd+zkWH237+N1n3d1si4dRL4li8wJ2uAAsBlexQupWfjozu02p390cXX0ZPQYsB+nwEoaAAOE7iHLGmvyzToukRGnRttfcG7mjuFovQA0tCOFTRUtPCPyYP7czxDAC6mF0Q1D\u002F+YxPsAwnh9cy36iC5K1ddDaDRhvXo2Fx3MMkNbfdzWcDK1v\u002FbdEauptfcPHwPyk9xkDHp6xzC0zV03XXOt680NWiWwC1xNJqnl59rtSMgLna22QFVE+lMy02c8cDnisD1JmPevevbvRBJlEJ8TTjfl1MuhpVXroCPP6shxoemonGepkzIkcVe\u002FeS\u002FrVYYZuBCrXWtpVVw8\u002Fk+v2Yj1vnp9K28zRs6RULZWfrl67OikwN3+41brazG39MxySzwD0B6W7Sb9cXy\u002FtqflZixeB5+0MVMUKpBcy2o71zP1+WktyzJpLXQXaVU6zsdOa81hbG7LfUfc86pvveH700Nbb9losKS+wEKejNDeyA5PBHFL3XmQQMI4Z4AxH88WI3C6CoIreTmWvbWiVYutZ6NAZNMqTynLAhy969tGiUwwK1HC8czjoJxiEfJYi5nd0wUmxGB4LH8MfDM5JnWv9XWdPhD12o9ujI4cyku9RTIGmtEXtiEjsNw578rZ7dh6\u002F4ZfHT+1x6f66AO9wlAweM2anAO8GLOj3ZC1ekWr8pnz1t4H2t3ud41Ia8Abnw5GMfIcppdfWNwH59gEeC1\u002F2O4etkqKMQH2XchcDTdrTycojn23ernz40eraJ5+tLn\u002F48RQq+e67G+OYnmG8h3\u002FImffyEvZxgA3QHM8NoRC4Ju3lSxa8Hb2dugeYtkCu4+VGhID8UtVCebc2KTb1ly5fCUidrIzX9cJOHfUa0+w1uYs3rap0heGUGEJEXgfPvl\u002Fah\u002FQP3qXNcjG\u002Fu3EjhVsN5PqCwVnPwnqtYwxR6L9JZikNcQCCCRiA0CZO\u002FoMMc+JslMmrPCBqllNiiJGiS4SN4mR5UobjycAMjW0O6XhxbxZ2Ni+14AyF2fSQEGX1Jy8TFJR83oSMjiVU1vN7LqJW2QHBYhxWt\u002Fkk7AhKwIXY6+sI61jGQaGd5ng2QFy+ECMSTrwG0m8S2gkLoGK\u002FXPBXHcBE8QH3H3\u002F04fRdFONMcwcg8JwBVoCHPqcC51k8oHOoxhg3+L1ygbW5eyjib23DE4WaGmOMTTBp50jPf3u4uel5L1vfrUKaAO1f\u002FPmfzGf\u002F5J\u002F8H6UqdSADZdCb0hhwH7fOBsGEJvGdWIk51aJdNt8YOOG1KLiubVFnU9UongA5JX84YR84D9Yk+Ai6htHrWIDkzPkOPciDSFD04ARo\u002FQQ2A+PrgfqLbXpRC\u002F9+6TNPC3\u002FuBVR22kh3qgoQR6uJ3bTXr7yHgemtADdKIVTeNvYBTeaOQh+lZZ2MbVk\u002FJbuSbZN7PCU6m1fzcoQQy7NA2bl2eEjTXWyD0OtO2nmSkXjj+9YkOkXH2pcLCAzKrwdYlZKUDqZSgHxXXk8G1YXLF1cXr13JE\u002Fhm9dvf\u002F351\u002FdsbPWeJUuir69AX+newjT5MWkIP4r0dZd14XxfiF9p\u002F2Ny8KH3EOrkP71L8QLq3nP7JH+ze6UNXUCJADz7yZpR5ORhrDOautdpIbomW1GaCcjy3PIF5KHca+\u002FqR1jsgVGcba4oiYzTcmpFfhYLA\u002FAOgrnmlFBt64UzrFb1E+zYdHQuYbafcgW2ARNiex9GGqMOHj5XX\u002F3xKdNmn8PkXH67+7O\u002F\u002FeRsEmzsewIDdobzm0hQcAuS8BqHayGg888L9x0QUjzfuPIKidMYMhJM3UqIOBY4ZBoDLXiU+yUOVI9bKVxUtAPzPnW8d355LUTdnTXAkNPWQHf6jgok9P4x3Mg1\u002FMfDG+G\u002FeI5d5k1FC\u002FGQWELEYOwGgnmHNT5xq09cZlUgwL28gsFe\u002F+h3Z7AXUIsvARKubR+5oG7OBRY6HQ0WuMo8GUAvV84bVxZ5HcScH+3sUXfLbc0f+JFecyQDwuc4NZKcxKQW5yNCMyub2VOuBsMgqh7\u002FZq2QOGVKMhtu3763+6q\u002F+evX9zdutQdG8vP\u002FOgDBfmxkeh4tE9KjVR5faGxOwm42U0en9ckvtK7nUhvaT8fLNmz\u002F2XFGyKATpBSDGsdKaDX3RCdEZUICv5JhvxDfrOR6SFqv15ki6jAiV\u002FO3dZK80KrmuUW9t9cz\u002Fn7n7eLIs2+77fstmee+6TFdV+2cAPIAwBETIkaKokQaKkMYSIxTSQKIGCk2lCA31r5AMKeRCFgKlQBDAA0CAeOzX3a9tVXV5k1WVWSbL6PtZp4vUHD3Q7ZcvKzPvPWefvdde67d+y+x03Mnj+0ofoI\u002FbXzsCCD2fLkKYWJEZEup3CvjMh1a+Uhnd0\u002F3JBADEAX4aEMHKvxTxaty7ciI2a5lXfKVr24xka7ERA54jxl7YW+NMdCd6trc5q0DUQstSskkvvWHgLQ+baA3IsJ+tF\u002FIEGTOpGH3AuouI0cEjA80PXS0Sarz9uc9xdpqN9uTy\u002FpzHugixKUeO1lWpZyCr2p\u002FCEz1ca9yW6joKlL2PE2Lc5sPe2d7ptA25e8AcOW+9MNQIG87C8+bIODgtO9LvFuJJUR5zwBl7+Uo3rZ67O9OdiKchoLq2DkvPkke25+xbx6pju9kz7Fi99+777ZXD6c4rpY9Wm9e+MF\u002FAr2ikwslTAfu1WFrnKOhc8qxe4WuRGDqOLYByJqT7ceya++aNffbzRDDSSZxDBxKePvPW7NMBwQFONUr0MD2\u002FNN6InIgYOBrAp0N0bWMXm8jWrMXqZb5kE8AMiMmx8enJHcmU\u002FHgpKzr10cfTIS\u002Fn+XnO8pCMXZfzoJhdw5B71cQ9a27py7eyJxcunIvsejy2xueBaoSSuTh4EOEIM0UKNKbBTJFkGjJwNjn6TXDOgwgrYexvPQOC1c\u002FW3jP1w+hyjPrasN45uL3HKeGb7TcpwuZWDdbaHPiXHKbHRHY47Y8jAjjir7bCQSnGrSdFH+ta87Ic9wWoFw0tXSYwloh06GEFp\u002FsC5HsiShSjwmdJYVim60bYsbkw0Tik2co9RVrO7Du4Olo072Ik6dmL1+aci5n87+H\u002FdvxXvb6H66x+9of\u002F0wiHzYSVECYGkBWIyiNUYIOFJp7YEkoEw2AR\u002FCy0pChSegylIt0F2JEmA2zw5BVKrFe0QQnz7giHDfc0YONz2CMpH5gZXWWEq6\u002FX6F+BBEHFjGBDHtY9g0JaGDDKJ0WXIPFi5z29T6h8mJ\u002FG5Tsj6B42i2fE2huf6wrlCLNiiya3rOsAPzYvgz0ttWzENor3L4quxU5RDFPQvX0WIPZHpm6iDCmQMdBtdEACUJKb5dQzygqSEWbiLZJj43xTPKfHso41u1NOb3I8\u002FZ3xYRAw\u002FTanFn0\u002F+Oij1uLm\u002FIxVnfnuGRkaQE2PUeDKHLmGsWLlAPZQeaCnlmfZgwfrecIpMhv4Sv3SefDaXZ4qT5RyAvf1ULahHj1+MHP19tsXR+gpKQyCECQvXrg8Ndz1sT2LNz6h9jEk8u50w8AyCO\u002FnePUfZQdEmdM+GBiy2WufJ6LTM0yeP0XX+z3biYz9sfJZn5R\u002F+TKlsq9nBK6kiABgCpqFCxUdirTIR9f6kxFkrygiL\u002FIzaUApqFHUhePu3Y+JSRlt5ii9UcaT4tSczTpn9BgE212Brnkl8wynQ47sAfvHv5fPcVbsHkpQd5p6+vas5NDnB8FlbKeFWgpa2P5ohYHvvPP2OLOiU9jJY6VGUeJfff316suvrsw17DFzN2xs17fmUxg9RqV79j9\u002Fx1YC4dtac6currfe0oLkcBrX1A0wmABw883wklnOk3VipEUI7HXyIP3D9zeGSzqVZ\u002FWaA1f6TlGbizdKXM6gFAlhzgMBNqHO6ceekWwIMcIOEimHuvQjhhUQnbSfdAbATl9MoWJzD4ABZ2StO8+6MCTGpRvRrRvfBuju9\u002Fntq3+lzi3\u002Fxt\u002F+mznOB9Mx9EAAKRkyrikMDSQOk68AnRFL9jgXS66svPXFAGMFlx2ec52MyXkVLXSCpqIuZMJELNIFwLD30yVDgHQNki3Fz97Fvpkb62l9sVM+Yy+4n7Ex+n4HvM\u002F+t2eTJIZUupI0FJ+zT3SxIOcYSmBZFGijvvjC4WRuHM72n3xhDDQARAfShyaf7LrfzF9jpC\u002FtWXpQKsf9+51P0R5fIkgLA0f+rTsn4k3UiUzTQZPK03iQINpGah95714OfeP0N+lHk9+ezkLASAdwjoYD9F5Ilyi1UZs8rVTPnT3V\u002Fe+VxqCjTceqB1joMbIvPUqe7Iy939mvnr9JGX1pf5Mje1E3G\u002Ftw6jZ6Zt81BfDVj80TZ8SeRhr0dKl7jgq5Jmu6+tiDCCrXxSQa98YGVtbpuRUp5kDYS\u002FZNq9s4sOJFkooIAN5Ed4B4sw7MLfU9jSnAIKoFwLADgFEf9RitDQDaD\u002FOzfcw+AffLHIw949ykIwZQdS3RLjLUu+f5vX90kP3Ydca2tZfJPyaT3CV4\u002Fe27G\u002FXvxSFPf\u002FenZb+Yy\u002F6d3Up8muuctnSFXGO2jtxK7TBec+Ye5p6scebcA+n3uCgRxwDAo08mJSswhVlTIK5OQL7yOMLde21sJpvGuQC5+q\u002FxuY+zDNzTl+iLU0S14ZuWvY3B2ETEH0REiqi9\u002Ffal5Oje6rPPPsuOLTUnXXTmK++i+z+ZVJATx+tkFvvtpVPXgUDkiYgwTLe9IlJoTs2z+fO89uqi81q33iRixtZZL3qFrtdOeelUBgvk8H433eSXQ7vU8CzzZd\u002FCRIo5YS06gC4gVLAZ+ac\u002F7pdnb4\u002F6t3lGiNIt5GPG3+\u002F9zb7QKc6hSK4Ju2lNS89LnVXfhX23jp6DLRkitDHASfQYW4CYhffYfc\u002Fgs744Bhh\u002F86GOgY1zX2PhaKhThGHoSWs3eipbJ+2Mk8DJRWBJSSRzMB4ZNAZ7RQvIx3PWB32ZvmsNfB\u002FHoj1GHuEqxMbz6ple9KUJhV7tSU\u002FOF+xnvVppa9H4rAsZNR7PCxtpQ3mqrk\u002Fnz12c+fur\u002Fh+t\u002Fb28eP02EMXs5DPK3wY6uq\u002FwyPaOQ\u002F5ugQjcHDWdd3at41qFPJf2W7uGOWhuE\u002FTnq+v9bekNK2dLp4YltWaZlMBvCsUC2niqp3mBlDeGXLcV\u002FZNv37o7C7zWBl47W1irRcG88Qr9+37CJkXA+\u002FXjPRIwE7LN1rYwoJjNlyJroyjcIkQWg5J1L884nVZ6Jiy5anDtwCg3zytMeyDh8\u002FOcgNf7o2wraEjY+09eqUpnyu8NwMbK2EAEnxHC7BBGxV\u002FAu01AoXlRqECvyvlRYjZGik1awePyhvUbBbyBK0agYXTtBWhrHQaI2giE7cKF822kHKkE0Gafo5ST9DdsyMLklG6SMI\u002FQpwzfAPbDgV3M2tZrEZUytNrcuqw8Lez8+edfTT71iQoX99d39ujhcudqiXTvwa0M6tUYrUurX\u002FnJj2cN7qYs1mOQ2pONtXHm+c4mC\u002Fiba4bO6bUNoE2HMUm59mYGz7OZR\u002FCeTMgRNnbrhIn2Xkohl7p5rP1d6R5nU7pvdbTx3p05jmuddsYTb963UlhPUkKro4XML59b\u002FaI8\u002Fkc5gQcb+1o5dE+wtzHJvX2UgTFSfNsSnBcp0VuBO\u002Fmy8hvVFzgG3FvGMKYo5\u002Fl6RmlclEkfTc4o7HLzAihaV2LiVgf6ozcnq4oxPQOg66AFAPXNz5mrAU7T6SCFRel4\u002F8VL52I8zsRC3omlWELwN3LIfFY0iuLG3DEIWym2nTl1FM18NSayMANsL1jzZYaB2xRh0QlrDTCb1p3DylFSGftYaoVhQBjjjCHz7GQVE+haYyj7u++YKAuILbae21rPnf1OB5hX46T27xlLxqwx7trN2U0xb2+8refu5FtYk9GhIDHb93OUOI8AiPWZtJlEJ+u4GLkUq24hh3JoFVNOCk9G4EkGaiO5oYM2KrA90OFdP\u002FrRD1Z\u002F\u002FXd+o\u002F1ysLSKwu3ptwOlTAFGjKL9c6i13JN8Wy77z\u002FcBGjE0UlqAe+kWDgQ6WDgYIYAdBGIn+tIzSOOREy0XlSHDqtOX1gfrNc5We8uhZhyKibK1F6SeWDN61XvpAmkyZN+87GluAQBB4m0xQgfqPtMl+sqANy4AUEj35YPndU45noHUDnBhvx8\u002FCvBuMIIaBZzsGQ\u002F387L36HqrbL8B2VvP00U5z2XGzXgnBJ+hpEtnzRvbABOM1qQZNZ6Ye3PQY47MHCw6IYoox57eA\u002FbpKE4WgmJv7dnUF3CY7t99uLp8+eLqfM7+o9buT\u002F70L8bZf3JiY\u002FWrP\u002Fnl1anyZlcvngSODjZ2Rd6KzFZT\u002FwSwiPhhuddLlZio1MiKfGbimPPQIsqfJfoDHvqMFxBi3\u002Fr+rPmX3vf6u2iQlAlpJezKawfnJHvDxvW8vbV5ScbSi4frCw1EAn\u002FmaTOwkajPa2Oj8zhK1TCvUtmGEOrDA5R6nmfpdjKC3WWfnscmPt3M4WmsyJSG1p4DdO3DFE\u002FPARz5PHmiFxcgZR+xGam\u002FmV92JbD4qtalA3I9ZyCk3\u002FrMAsYDXk2QtBLr5n5AykSTYpaBJGtNF7\u002FiUfSviZi17xLJuW+D7\u002FdA1PLAC5vPhpf6ku4dGqTJ8H7EjecBilqS7rXsZTp\u002Fd+mhvWPmwO+Bc\u002FUUT2s37N\u002FtwIVdrehfxDH16en6d3ggXeGzfskJoHe2AnEi0r7onbVk\u002FmCH4CC9bt2+u\u002Frwgw\u002FTJ6XNXr26+sUXdYHpvAG6a1JYGydbOyB0c0kzOX+2wsuc8fUHyV3r5H2cGrKHSHz8olSSHu5UZ8fsqu6LnHP02FXrSyY9vM5sU4\u002FTnHM46A4YxP4AZh8lQ7CAw76AXnsGwLfWALe54gyoX+sxZ6\u002Fa7xpfSI1xTySn6\u002FmyrhzlAcfZCH+35gAyeYJlHqSPSMblrmH9xllKVp02a1U4DQ7BRIoAzc3STPfOJ0hczgVbUQQ5nSXv289k0rNZHw6ZOdpePvoboO5ZYLfevOi\u002FbAvCwnkUooqAvhWWHYGIVDvGWXJ4komk080jWdpZ9ykHlL0oErZrdz+v1bZ437PVXmmmfTl1frVZqkvtl\u002Fc8rUtQ9YIHwznbSotkg7Tu3J2M7OiZkZVILHhrZL+1m6YirdH39fregPrPP\u002F54hGZybwGKJu52xRZnKlhbjGV5tTFHwOZ4di0IsPhmwbQA0qtYbjpmibBIibHIQBpF8XYpGhbZ0dkEiVLAoMmDApgxhqc71EJolLBqrQbYnyvhXw72OA55tHdu3xkjahzSPZzu6X6nOzTo\u002FQ8+qGVg6TAMSYJA2G1qAnq4fGNAfZTfdytA2fOQgSaOCvaJ4qIACawxMmjDevYez0P5Y6P3tWsov2E+NlNefQBwIuwKPrRJdFQ4wC\u002Fn3GXnZKzAEMNrjqXvOBDgSUpS7hTWJ7M8o1NAArg7ZAl753mmwrq\u002FmhtGZDZSG0\u002FhzpUr2+dectQxRULr2oWZp1FGsUZACCdH+zlMJKeGYtndJnn7wLHVg8dthsgonrw8NEoXw7ZRRfS921VFnzmap9mhVg3x2tUrq+u3OiihUNPld9+tt\u002FLbq83PPx822PUd9yvFwmbiPDxLEZk76p8Tp0ND09B8dxdKjWPVeuF0GJ8Js\u002Fbd\u002FGMJbdaGP+FZSlAB0N49N5uTQuUZjcNtwn2FtbYfWJhKzsrpWvmdf+vE6s9\u002Fdq1nzhnMmI9T1Rzr9LC2t8hF4bO1lIH0I4pjjnZOZjlbgIhxdetG1Xw1YDI0ACflSlHrCqPIEKglawcqpNJFBYPAKZv6DXKUTLna5H2bwJ4FQJq2h\u002F1MOQrnAhgKYjGuVzIqV4tuPCgvc4DjjiUnG5BgBM2N62gNB1i7xpI7+p0D1P0YVvuAMdSOazMAe\u002F++AtIiWj2akwSlPYi8aO8olC6\u002FN0GZfTBFQ8kIcAnIYDawWdaC0vWimK2hfWTPjuLuT922eW5N7ZNk4VUT9loYvPmiyDk3FLKc8CMVSu\u002FPqN6+u766U19j3VT0IbdHXhfJAUrN+\u002Fyv4ZlfgMNArIPiQmkI\u002Fp7IBsa3rz768N3V7wTS33vvUutfKkLGWXiVPtKSi\u002FEYoJLM790n\u002FJoREi2ZPeipFGgeyKivTxRDj\u002F4PPvywvMYT\u002FSUHKTAmtUAI3jwD++oIJm0sWTAP1pPxGvDHmCVDWDZ5rXOCsL8DWs0xtozxpmfV+vg81hYYFMHbV5Rt777AfqyPQ2wObh5qb8X6FSYGnBAOL16a37ovlLKmldnTzQ6M43SmX+R904N0An1q\u002Fpc55JBxpK09fZcD1RyJKJBXbSh9rqGOweRUkmfA3WtXekaBtxedo++4vWT+vGX0cc7DvmQMw+l3eiqrVWJEOZmirH\u002F+56enSO\u002Ff+3f\u002FndXb9cy\u002FfuWr5qWONA8dhLRZZ4oiaD3Heu8l65waMmdPsl3AMad59k+yoc0jx1QR7BuQa4+qw3oV481pQ168LsfDXqDrdjePL58my7P\u002FA4hAauCALDuJ82FAu94FrbdIQ4ROPfOn0LTUR+Do6dMl4mFvam27FhGzvXS854H0cf4D5l6TRtA1RDHd+3UOKr1tnwNmupf5N\u002FDQNC5f7XHRC888EZI+M3qqvUavI0jIjHkBasikVAlOqbXrZiP7QKkfATg25VnRRfvae9gV9yQPimRtLuvNsVAHkYjOayEFsnnJh5x4rDMZHUeibTlseB8zf3AB+w7MuS8iooEml42xvYb0QOTY03LL2SvpaNK61saB7vrZE7oI++5ZN0ufBY7ZUaTY4\u002Fa2\u002FPEzp46HKaQ7AI+er\u002FSM5uvC+bcrHL3Tyecfr+5EBDR1jTGbs1t3s2pPGgM56ttE\u002Ftliv7\u002F19HagfwHpU3PRiOGETbojHcCmbwfqmjxz4iAuNR30CgB9OyfhfpFcNvBoqZjHs+cALqwAREsXJvvSLqVqTo1LsyRSA+SOvKoZaU4ULHP4Z4+Ovm3NkxEEJdmzdvbFge7v3mNPenZjc0+EneuvhWMgnIk25MwsJJFifXO66FVpbnAZ\u002FedkeHtdijJmnYMg1aYFSa7V6Hy3Fl1zR+s1DmfjI4fsGIu5p\u002FaLMJY9OtkTnIvu5bWcs0DXqUtwwBLdmFyEUfal7w4ebM3tk9dhhiL09sfr8nSfVsMgkr9rTyly6SxR981dkaiRu2pxdHp5Vcr1i3LZn23cKzc\u002FLFUtjmJTX7uni1XRrxb9eXp\u002FZzV2k4bZGDlt39frewPqIyhNenI6wiHdxUPfuaNNohyl2JC+a+EDeNvgPCr9zIV6AaDDMbwKHm0ei+owCqBYiGUJZTgIJC66n4HPEagW\u002FJd++cfdF1hbgDAFdK4c9wvnziWku8erHbAbeH9WiJkRVIg6eY5thseffLr6+quvJ2RKsSn4AACFdylvYVVKGqglGO41IaHvBJvQDcOesrJxCD4jhbEG0Hnswu80zAC5imM8Vx9vHpZnFc59Y+CEP5e2abH+eaUPM\u002FJCn9gmOb88fgLL+xRCZEAxsJr\u002FixIcPXIsx+TEgFo9fBU2cXrckPKkZGl2\u002FYUpqPPnz6dgAhrN1fjJvZ+HSsESNobW89u0AIjUBzL4vPAy1mPfwariMx4n37pU5OPQ6uq1TlfLmbIZfviDj\u002Fr6sOjG1dXd5+tFJrp1Bg4I1tXnde21Tp+9tHr3wuXVBx\u002F9cHXjdr1cM2Qb5fRtYDjSwy9i1If1aAKNk1GSx0bp7OkeWERpLmTK38egJj+MCm9\u002FlHvfzUN6d+ZZB4pffHalrjNXMrYvVmdPH1p99P7F1dvnT67OJZP7KpAxd5nB5Ojk6qtvbsYQ1Koxw8l4pa0yHh1y0iEmj2NwlrC0POOMYLuTbCoW29WA7AkKvyls3TMy\u002FU1RrhAtZbd0hemZMngU\u002FQDBxkrejnVgjucjV5Mz278BscU5qXAqJQ3gAG+TnpI82Vfe+9VXV9srWqoZz6zcfNa6YurME+PmDQwfo0e2l\u002FkEmhm2xehP8VyKaKM0l\u002Ft10rlzpw4CgZHdhRU41hgeAKuZGFl12JS12NN1FSgDMOQf42UkALsuIgDAgKT+FnSYsXC1AE2Fbi1Tz1I4s\u002Fc+24w9Si4Uv6oL0Hf\u002FzJnSRVLECpHlPcttvJFDeJMDGFAXstbPvBZJORZ192gN5M4zWsK36+s5fwmxPEont46AxIjua35OnDy++uVf+aX0yw\u002F6jNS7CttbWwBV2gU2luPKyEmfkKe\u002Fe5f93HP1PmULOqkcyQE0R8gIxck6NR2NOBDdAm7MMX3C6FtnoBgoJzj2OLB6oEiB1nLmxfs5HAvQ6Sb9m34dp6u\u002F+Xl+25zKfb51+3YtXL8tX7u0i1ihlrVrBygHcMrRtNcDHH0boMoA9e8XO5KHw4HSWEQhDd0XFGrHq839bYM+MTK9r7asdMX0NO7+idvMtflcnOSFLSOLz2I7nzcugHHC2OljB96ReymS3357ZQy3CKUuVcCn8L2CHsAAO\u002FrttSsjn9qp7U8hHDkKTJIbRj3nNt10q\u002FZpN29dn6O9l4LfiJwOqzrV\u002FgZiAAp2hU6kj82fvTotEtOFCkGdg6DwEeABPgEGzhCbMB2kpKLQPY1BpxrP0Nv6TI4X5dj8WE9T5XN0\u002FN0iAWfO5HS0Z6bxwo5Ode0zL18CovPOrkEWAGpFrdJERC2kH43GmD3jFFFEEBncqS1uk\u002F78efPUWgIjuQd9IQC8hzMCtAM7xkpClpc1QT68Lrxvb3pW4Oh5e1UkYUmVSP83Vwq5vcheyzxzIvVG4Sy5YvvMoy9yuwBrDCZHMlZH56u+RDm9zLfmDAdLV9ufM7eRbSeDRqeOCVgnq9ppitQ96AAurK9xmQvjoPvGngaWXqZXNWYg0\u002FK3HTp46Oi+5EeqLF24EFqb0h9KTaR7dvhde1M+\u002FanjR1aXL13Inm9Pd0oHqRVzz\u002FSjH\u002F1oOmx9\u002FLOfT7RoL93e\u002FmkAAp6zXzk29qVzCMyVlMqjFS83FUMOsYfWayEfl6gLXHLtqkYS7cPmaJ6jMe0O\u002FNMZfp7oXqQXcGr\u002Fs8dSTmCmfZFch18cnrlGiALvcAeC72md8Oh4Xw8j+hAbsJGIN51lvdiPYaytfMpxCqibj5mnwWFLBH5sanqY7tOZTxcVGAoxCkz77Mv2FKZeijKcpoaJM2lcurlwomAqjLznVWT6OCfIKbDWkEOBbGhYyfoC8u1RY1mcepG3Ig3Jp7mQbkw\u002FIgCcOM\u002FJk6uOZDhwsPayzaPIooYSGxGIU8eRHqd3W7i5j57s7KnDGR8XyXJ\u002FTUccXCXTIyu9ehpQf9IBbzuTzxdPi0QfOJq9yfHRi70I41r2ZXukBmJjV8AdUecgp0Xvdavv4fW9AXUbhgG0w5KLEQ7GDGBrpkcxSNuwyQ43qQCBxfKzVA9hiwuXLs3Ef\u002F75F6uff\u002FzJCDRFfayK9+lK0uTdrb0jQZ3N3DUwzX6nqMqJnQ5Eepanio0eQLMtdrolkd9IULBgWJAnVQ3zwk7X6g4o1vIO2MUAyYNc8modYOAER8IhZQaDpu3hkvdqY21VOXyzU6qGCew55Rkr5twFxKVIKCiKYNKCugbmUaqNRv9y9vvTRBocrABUKix8VejsRUrb9QEcCmfH9rzSPFegTO4UB8KcA6jrpfncL3f\u002FbsAD43ziRCAgpc3L1e2Ec3E\u002FwXeAx9KRp43QHMjDogTWyx21ofysCwYFsKd72ZyMsaOHpbIoIAKwdAUZdj6GmyIBAofhrJAJw\u002F7lV5\u002FHAtyYPqdHS3lZX48RuN9BJL3vEKcmb9X9rMfhNr0w342bd2JB16c48cEDzGUh3sVZHjAL\u002FHaj3gt8p\u002Fn6t8EBXLOR27wMbiKRCAKBwAsF4D39zlfzha191pwdOnSk48PLIU9pbGxkyG5IAfhq2Iv1S2dW775zrvneO\u002F34d3eNC2ePrj7\u002F+m42sM4dsQP7Khxxzdsxty87\u002FSwV1zpRNOUTp7CwQAtYF2KVB7cURmH8MXa0REPs2YyLglzy\u002F7ZFbmKCFlY9x7Cx2h+MPQAodxWAp3D9u3yjReE0AqlCWCOGU3gV8MYGCv1xJLtTslPoLxBt\u002Fq0zh2xYOsolY05WjQvUs0ex6BwzRVZY\u002Fjux1Q\u002FWOVALSBfZWhwFhjWDHUCSy6+70aRxNQ6OobmyZ4F\u002F9x0wO7JD+baG\u002FX5xEhj65BI4ahyMtBoF+OBhB2vcjVl6tF5KwIn0jc49BzuHoXVyuAQ2xV64fUeRUsa+NXh4QH5zzksOAwXejgm8xuCklDEvHJmmPpC+t4Kx08Ok7UzGtOO8cOHc6td\u002F89fTDad7n1af94btZnlFHaS5ySFPGFsPJhpwwWZnWExi8sbBwabKRRdCv9tR25PqkNwdOFgYP+PCAQaaAa6pf2ju6AtsOx3G+eNQOQERSF\u002FSwDJgo1+kVix6gj4AjLBaDhERCqevbt68maN8264IIC\u002FgVI62lEKAx7gxjJPq0e+n0LP1cly6YjwGyPiAVPraZ8c4dz\u002FpTPYYJw2wxBTak3Sf\u002FS1yuLmxhPrVFtCxdPaTdAUd5EXHIwvohm7R77Xq21fKXNFR89IcjA5Lj93JQCumFgl1UNex4ydXJyIu7LU51CQW9GRF4ofqyLPV9e0RoG3XrkPJxKP+dmL141\u002F6pdl3X339TTJVe7ucRSk75FBh4VapPbtaswE17SmA29xYDwW4wMiebEawsLnLYUqvzYZu3c3Dvlc5jIFcIKG\u002FpmMWlt6+Zyf0nb5RHv2lS2dH9++7d7Mj0d+AY3qd02AeGktyr2Wv7lDIBX3Dpb\u002FRt+TMOgDiOo4Uj8+XWVjt1+1BwCVxmK8FCAGCnHg1Ez1Tnyf701kpVQKkc54nPbL0shelQHEL6Awy4vknqtdnNXcAPBfHJRuQDLKLNvrMVTIr\u002F3c64fRsmPo9gVvj9bXUWrEBHHpEVulYbGDX3sg50kJTVxbHsr\u002FJQ2ebR9a2aQ\u002FqbA4EBuBPRzQnkHYDpWc4LZy1Bw+S11dFULLd0sdasoS9eSvyo8jzaHsAi77Vz0gwxMNWnUKWoua6t5Q2dfjY6VI9nq9++tO\u002FaO8uh3opGpaedeny5f72cPXpp5\u002FPXiUu5GnY8JwB5NeenMmXyehS1yViEWOdPtjd+zi2Tkb3Gpa5vQAojl1tPBye0deNURQNUBZNxoqT16nlSJ8ej2TweYy6tdZQAyvtmaUlOwUUw+93R8Inh8JK1t9+bsrnfgvRudRHAcDml21yPfgHOOYIcBLgGL8XNb8T5poISteT8UDfs1dIQM\u002FBHjoAzO96y+hBz0hO3JvO9A+f40xqgCFaiLRg08ndoksWW08\u002FGDeixcs9pBCLflG7Otg4CIkNFKWhP9TH\u002FH8P3SNTosgHwkcOZtvqtOJnW6UJda9XRa7ULbyyh\u002FcupCqssTeiYANGqgPYtoD67qLpe5Ox16XUSYfZ2Wmn7Puc7B7R4QTw7+v1vQH1AUztkskrSsAwgdtjcTEZvPgFKKxWX3zxZRtoawDjyUAaI6a4EyNEeE6Wr0WInYL3eMdmR7XeKdXl5rDrb1+8GBjal4K7ODnoJuFhAPVP\u002FvhPJhf3TIaWN3nx4vkxdF9++eVU93ufwkZ9k03yjYrEtB8EiIRlLr59roLKDxKIwiZtAkqf0APZBIqnR+iGFctTJFjAhrQbwnTnzu0JTQll8QR1PHGaWHovZbcUr\u002FDYJpc1Yy10RPgcQiN9QIcA+WOcAtf1OQqpNZ+0HaF5IFpBKYZe8dyewO4btuN1ikguvE0oNHX27JlRFjb5PHOCrRZggHdzsbRr26rQ4ewoRo7OZgqR8cHcPxTeD6hITcJ8+JwdQA8nhqPrGGLryj5MoWWpQusxWPdiKH\u002F\u002F93+vNX62+slv\u002F2oAKK\u002F58b2UQuxUm+WPbn67+uiHP1y998GHw0bfffh09f\u002F84592suqNupCUCx4Y2wxMPIutZWQYQS2abPBlY6cMMlIYUDn+mGosRfahOev\u002F2vCAnjSJmchMDZYAEPaSD7ej\u002FuePM+JP+92OnKZdbbTn3ez67YetZb3J6yzxNKD0d\u002F72787796eMGLDNcnXvxCbvKKd5dwaTGTZWLHEqobmroNhtGwyGyfoYDwfBoU4cRorEeBvgsI7AaUHiMR5OfFuiAoGNFO\u002FzZwp8pfjEGiYbQJsXYNYyjIz4PIXkF0ANWZn85kAoBmt7OdbWSv6ndQQW+sTIMFBF2Zo7IG+6NkAII285ORa8J5OG5FCj+zHZDx+b27rm1CEEK0Pv8aMpAABAAElEQVQxDzhMxiaEHljoFjOmAehdwX5x\u002FRlrE8TxWGSK7OQkzej7v8Y3zEwgQI4oRtxhFc9jXO4Xzbh5s2LEWPX9+7bFih5L4WN4Yu3r3LNz7eDq+i3tJjuco1MoHbwlqqWYuq1Wq0Rsi+5NPUPhV505DuWM2m\u002F2JRH3ha09mAI\u002FW3rWD3740erDD9\u002FveUudCPCaX3Pq\u002Fdoj7kmf6B0s9WM6R7Q\u002FpajsjFFTQC5ywlnUBrNJDTweXp09dy7jUAoIUbWI\u002FQ9YfBrrLcWAbmDkMUnuS+YBeaDbvxkuOoY+akpHLhzMJGphr3JSd3ScvQgakAqQSRkEjp5mqLGIdI8113FByNneGAej31kz+ehYqr17Did\u002Fj9NR2Mj0XvL3smfHhru3ueP801VAlGsCKtm05TrJ1py+3F59EqAil4rWpAEpNsbOTnvH7uE+p2O6AY3Lly4tYKXPj4M7chuBUgTjq6++mmdzE\u002FNpfu\u002FeuzOg\u002Fauvv2heNlbnzp9Z\u002FfCHH9Za8077rXmMkabH6Qv1Ah9+9GHr9bwaqRtzvynY7RmAH\u002FpctG53zqwWrwrWN58+nnQGD8h5lDpjy3Ho1GaoA6CsOKhW1d92BfiAdiTE69eK0Zqc3mMc7MQ3X1+dXPuDOZkOz6p31jiQG0XnXmUf6Yx87FJocnp3VYA\u002F60tX2CfJ3uixrmkh+nl7HXqAOP20h2VPVUgH0V3Kfp3IWJ+ZJgm7Op8j\u002FQZk6XOvi1LGqHGXNhng3ZlM+544Nic5Jpjcxk9X6BJCz9JBgB3wxYmUiikKKcWScyYlDAifzmPJ7h6tmrsgmW+7JOcLeYC8EXV6nZMvVQ0RoumCNJ6dpWGRQ2rIGgJwQP3L9pne\u002F\u002FbD40fJdbZiZI+66kXHIQ0B9Y0H6Stn9fSIdO+e8tox+PU2HFu2o1Qc3ZvW+r02pE87EOf+A80KOmvivAOq9g2B9Pu\u002F\u002F5dFVzrw52R5yj3fozsbgc87RcacJ5Au756jH9jLxuiAJUDycYw5EvFF8+OwKyeeHw7fcPSfs8sBaPYGoLYHNaOwZ4cIS844s\u002F4NIJMdusH+HdKwdUHEIebo4eWVvgnrkBdOFV0BKFs7edMUDpBL98M1MIOx+0726TK62b3k18MQPsNZo5O8D9P8+P5G9Wef5yAcn9vCXQA08kBE1z6m7xOk2VeAPGf\u002FrfL2YRQOnv0vaoa4kNrjvmMz3bHPYtyNUf0hR2sAOflK5idq3FzQncY2eCpdtpWeeVFtl5Omyf1zdjA9uFYKpCJtsrvgFTZRdCLiKBLHQWzGBf\u002Fo9vN4Xfrv\u002FXBcrb3DsrrePAq\u002FpGSHWd\u002Fd9ZydQ8aex7LrHLNzT33Ym6Oo9j5HB3Mmv5\u002FX9wbUtQeTQ4XpsLgtUYulAwNmVgN7xQ1LUdSN67cS8prVl6qxv5AIAbWQ12\u002FeXn1z5erknGvCz3MTXvE3BuXnH\u002F98fvf2hQtjsChFgNpGEV65c\u002FvOCDXmXvjlm6+\u002Fnr+diRHDpMjvSm3F4ByNPTs7vc4nvzKhINiuZWNadGFegkPhCFfPKX4pp90JCuejPT+hbMpOGOhHP\u002F5RhQvHx\u002FAoolCYed9XoVxCbMw2oHZCcmUnbaPNZ67MC7CDAZd3bYO5h24Hm683A9tHZp6EkYHsZ3mOQsSMHOE9noE7E\u002Fskr001\u002FHQiyFi2Nxs3Rfo8cJC3XRhQqs3DGFFdBl4mZEI9WI8bhcZ\u002F7dd+rXGeW\u002F3RH\u002F3x5KqbE7llDDIjIGVIiFXIF0h\u002F8lS7K0q33\u002FUM5n39m+u1DrwyQOqv\u002F9avl+P7TmPuOO1r9RG+8vXqXq3u5Fz+5m\u002F\u002F7ur0uXdWf\u002FDHf7764z\u002F6k9U\u002F\u002FfndMUKnYsPkfT3aVi51G\u002FBVG91cKyzk5fOKX8Z4MCRYWQ7MMME9LBDu+RiOibi0kY1z2L3nDE8AKoXmOr0tABho6b1Aut7nTnrdytB\u002Fe7v0hZ99vno7h++3fuMnyUQ9ZFNsjhj+v\u002F7RH0\u002F+ofy2EHtGvJadgZQ5Sj5nxXgGtKT89gYgnei3ANZ2RA\u002FyUrpLinwY5OZMXiGDY7\u002FIR8duc8Qohwftj9t3HibTL1YXcibv64ObI0lGyIx0i4WdArxTyv0svexQe46BZdjoSvd\u002FnSzbZ+aUHFKErpHkNVdSd2L9mh9KuUv1\u002F\u002F6y1Ac8qqDwZukkehIPAIkZk2vNkR0AmEHx3Fg+vbHJsUhQlx\u002F5NscDIno+7KbnBfoyuU3IMg57jTHBqAiuv45Flx+oTSSQfLdUlvu3a\u002Fe1f3sOZn1r6+Jx8uTh1TWC1XvX9qRIH92Jnbod5kg2unpbIIdCi7H9\u002FS0mu0iNOfU6feZ4Y+N8SpmpqKlnalQ9w\u002FZxUH\u002FtV38l5vXH7dMUd8qX0Tr+7omJBtrfv\u002Fjkk9XXX36Zfqo9Yn8b+WjdGFqGWY6znFWRhweBCkaO3F2+fDky4vTCxgdEOC3m0XoA5L5EIrG2ZFVIlwHBRj8K4M569rMom2JSByo9Kh0AEaIvMz0IRGGMgCCLMH9r\u002Fx8+1qzE0k4KX+vtRW4YbXqO7DnAY3eF4dtjLem86+nqf\u002FKnf7r65ptvRl4OBwwwkHQDosI9CTaWVw0SPXP8+Ml51gd1PwIoHFCypzzyC+cvrD744KMxZkgH4yIXQCN9ySDrdGT+XNM8cxAm7zuQ\u002Fc7ld2beyLHIKcCsTz6C5djxE8mPcXAsN2I4P57o4NsXLzQ\u002FD6buiOxx\u002FAGbjYzxJ5\u002F+YvXll1+nj5dcXGu\u002Ft3XbFxuvzeBG+2e9iIu2n2v0cwZ\u002FdykR1pFOImC7mmfPQcdKFaHPxxHv+VzPnhg93B7okq1b6Z0B2Hv3Flk8efz8nFi6tvawQnpFrevtqXZeunx74frNao8exuK2HWftu3W2oPuXBomV3qrDiPvpf3+8wjm6n7MPdMrPpW\u002FsvzfRRgARacABfh1IQvIEBRt7Oc0VpLIXz9Jj+w9KWSjNrxuLygE9OwO1WxVxc+hNACeJPCLZADgPiAklw6J50niATGPYt3eJ4snh3bG9qHqyA4RK53Qat65DCBZ7UC3So8D3jt0VW6aSgGzRjd3l8B85UhQwmZuUpebp+PGKIQNjzsc4fLiUsvACO3yi2iIR6ms3rq3+2WefzPqQr4bbWDjSkRoY\u002F+6og5YzMt59\u002F3zR+8M9n1Sd7F2gWuTj\u002F\u002Fy9T8p1b2+lz5\u002FQz62xtsaIto9\u002F\u002FvORKc+FRJwIZWQggHn\u002F7vWaFrxanf3dM2MjjNnciZ7vMf8B3oPtY4AUXiFDIkl0KgZ6IrNNvL1ML3IoseHSBa93Gvno+OaZXWDvboa9JgMg5\u002FJ2WEj0jn0Hpn0BtOwH50obU+BzAfiIkxa4FwAMB9HF7ATw7rufvXfIxPSW19lzbw04v9\u002F8Afbkmy4DyK2XDbKQAKKYS3SYo7G9k0OB2DM18Fh\u002FeH+uwYYfKbqBvGUL3Bebz+F6lJCJfkk1vNPhZGpsPvzg\u002FdGBxntSY4zmhcw9e9Z5Oo1B6gpA4XlfdCqy2gQ6CFZxGjDcJjpy9x4C0wF3pV9Vz4Ck2RtTvra7yGP46+G67IvsatF+hBk8tDedTNdsPry7unn9avY8Jyw7c+joW6sDRyLrAu17d3buQbbq+3oVaTK9f\u002FXXf\u002FRv\u002FyiBfzAhGLuYggUM9Tmn1G3oN7ciVEIZbwSRoqMUcGty1oFzCzoh1JSOyfYztv1ECllu89\u002F\u002F+\u002F9wBOPddy8ngNinjOx4hhmM7ns8hhqwlAPJ07UB\u002FGxhv\u002FryqwEmrm9R3Xu6MbQAA\u002FbGiSRQQi3BCZulZwBY5VjdKwT+1ZdftEEKJ7WYnBHdNYRqhXAZq5s3Sv1oc1Bcf\u002F7nfzGFsgATZgO7f72UIAr27NlzKZtjI6yuTbm\u002FMYI2xcMHj8vH\u002FHZCMrxUikAbKYJN+QpDS6V5KwO71vMNcOs9S84qT194KnCXcpA\u002Fqe0U9ly7s\u002FsxAozgRx9+sPr5J5\u002Fm2d8epaH47g8D69c64XSATM9t3k+0ifYqzutEL2v28PH9cswer45VfHPw8PHV51\u002FdWP2P\u002F\u002FPvVZR6Y\u002FXv\u002F93\u002FYPUv\u002F43fHKOyfu\u002FW6tOf\u002F2UHELxYXb5QNCQDvj3W5sTZC6sjJ8+t\u002Fu5\u002F\u002FPdWf\u002Fgn\u002F6zjgfOEC81ulUOJXXaSqpxjynErMX2VDCiae1YIO5u5+uijy6UWKPapOKUiRtByWmu1YXkQCs2kUHAgGdfDHULBUD9o3Ug9ZaJ7ia4fSULzmkHOMOyO4XmZUt8XK\u002FbLPz6\u002F+rf+zr82CuNx7PnnX11b\u002Fd7v\u002F2HmpHzf08cCIYUm9crN0OyPJdpXYaON74sjgXGnMBrasCjYHuExsjVMe+BYTqUUCGMd5goQCPQ5svtRYWDFZvvr1KFft8+IQo1zMrKy3I\u002FDiVm33hxXwJvB9j57z+888+SDN5xha5MjLwrRdYG6R6W3AOmUJsBGUekas\u002F4wxqs5FyrUAotc2HdAJeCk7RymitM3jFtyRbbsydmXvX8KpLuXefflGhhOczHP1Bjdey12fFtOkRNPAcXrgW\u002FF0seO7oodPle6mkLo2kMGgHdnNLbHmn995c7q08+u5hxn7PvszgzPybp+fPTBewNoP\u002FukYvcU9KVLbzf+ne3hO6OsdVx4\u002F\u002F13PHrr\u002F2L1u7\u002Fz26t\u002F82\u002F9rWE1dVpy1LYIn2haFzZxPVeOXs\u002F+oBQ5YWhgBjWhFSfQaW8c6xCsAxlMLzrGs\u002FpaDKBia0Y7gqE9K7K3RCSTvYwxXYeY4CAwjvTTpMZ0j2G9khVzC9QC+FhLa0AH7s343v72Wjrnz9s7S+SSLlAbJBz8bDr1SDeUPhBT1LNhQI1F5IlT5KVAPhSXjruX86qbhL0UKLh3OwB9qwLlK6PjFsYb0WB9IiSKel5+593IiWPJYEeVdz+53oTnVIeIAaDGqoaJo4GQsDk8C9CuIF6aIoaNrpyccnoHqCS\u002F\u002Fc57Hax2s4PJOMrG359W\u002F91\u002F+9+vfvrHf5pe+HB1+dKlMbTvvfvORBTUK\u002F2v\u002F9v\u002F0nurfRob0\u002FkIgaF\u002F8A\u002F+4epP\u002F+wvRibYjbRqOnWJmDzMgTFu0Re9m59UaHz3zr2Z+6O9d++e1kDxdPfm\u002FMj9BngfFQV7rFNOcmbtpfElNtmADj8LtEq50zL32OHdq1\u002F+pQ9W7757vkNkHpVGd331MJb0QYWKjwPpnhUAlNPP4SdnUpSW+coxC1z06Mkupj6gEQsMcGFMt4oeIVRcy4nQ1o4DhxgbBrsZY9eMS2qZ9DZdjh4U3T6Ys6kDkfxlQEtaQW\u002F4Lopjf6r70uVMLYNanlJMcsikhwGB8sq3q1nIWXCvxK85iyA7poOK3P8HjbeOGgFaAO9oAFvE8n4g7N6d0kGTQ+kIBwLHO2O6RZPUAJHjfUWqPQenyHr0WPPds87pl8ktoO2AMuxoj5aOKeUox6npzMlsvez1Hjwt3Lg4WUVcep4BYYExe+NBkfovvvwmWS\u002Fi3Zr50st9f+BdB7BxINr1MIu9KTVUBBBLTi+8\u002F+7b2YIdq2+KAIkS\u002FOqv\u002FHD1m3\u002Ftl1aXzp8eG64P\u002F+Mc79vViQGjJ8IAwDogicSgJ65evTZyxYm+XlYBTPP+hx\u002F1PPqZr8+8LxkLAEvr2WTAIhzmK1eujj0AfEV+kTbGCcA62PFhdsVzcx6mkLN1k8ojvca9EYDyzLHz8NOZ8A0Hly6CMbQ5xdYjBm5FsNrXsNVCQFXL1N6Rq22t7F26T0Rt9Esi7CT40zUasaa655B1TgVGXVbD9fATfHT+QgdLJX83cky0VVXjp9YHNtL2WTqgqBX5u3377ujHY5EnWi9TGAgWGRw+ZyyPI0nNlecU2fu27oL03MGc80PVEzioaikkTmbSn85kIEtkcA4ZTHjYSpgLKXM4rLqczZMFqF7g6IlzPUvP0Zr6+tG\u002F9B92v7\u002F6q23+\u002Fby+\u002FvpKmycvuv9sZBNxOk9HTrSJsSAWA\u002FAFFrBES5FpRq+Ft8EpCNwib9CJmRSTXFrsEoGSu06ILDpgzPNTOaw\u002FLqUCjAMP3167Pk7DpYtvp6TfHiX12ae\u002FmPt\u002F+CHF+N4oIBtA7pbvGAEhaUyhU6i2Ndm8YoBL3rjNY2wU2MmE2IYALoC+23cqnsybvdV3IdUf\u002FuAHw7IL1wgT8WalBFFklBsFaS48s\u002Fx2mw6oE2YV8tOnVMshDgsv8saNvOee\u002F+HDg3P62MlA8+EjxxtNyrO5w+jt339wwBkhB8727OlUvsaCeR+w2ucfP8ygJnzDfqasdHWRI3c1tuze7Qxw4xeCPhKYBwjGu855UbhrXtyP8MtVe1QXl+exOWuxuwwQ8GaOrxd9OBobLBT\u002F7bVvEvbN2IMORiiqsRZwPlDhxYEqp2\u002Fculsh5+erdwuz\u002F73\u002F9D9Z\u002FZf\u002F9X+z+qcffz5KzAYZ1q\u002FNoTMJYCVEll88wrpn15HW937HF18LHBRiiiEhK2OgAjFe5AQAJXeT+tLvecYKPKf1Y8DS+jGub0AsmLjV2gOxHjU7s\u002FrZJ9dSav9D8ryvosJfHiDy7vu3V3\u002Fxs0\u002Fyxu\u002FlzVe4e\u002FRU6aF5821qrOS0KEwpANs29bDXXRCbBXz0rTVqp2QEX+a8bMtBSLgGLGm1hiHsgyMjjC9maNJFetsSdgaUM4IY065DnjBpjLF1W56HQe8yvcXLnlssVD\u002F0Gb8mg5ia2ZvNE1YYq+8wDCBLChSQkb5MKZXm0t9cQzToeSB2nGMseiBhWmlmCAeY9x5sbkvXPYyBVlgcBQ4F58WJbuRWy0xpRgAUdhJgZegxWV99UaFv9QMnTuxb\u002FeD9U8N2DBApPH27PfLWuXMp6qOrq9fvlIOt3WRsVXL3KiZPCosDlD7\u002FxWc9q1BpqWE76pQS+4bdkc8IVJ4pxYVzDDiezqjNiYP0SEaFk38v47A+qXkOcIoNbB5FDY6mqy5evBToqFtBssVJpjdcx4mOis10erAXMYt0lrVhMAAbjgqQwqnXqUYqiz3uu\u002FvSobo\u002FMVbIADLE0CiQellkTVRNDrZXUzx7BJh+Grv+aSzfP\u002FmzP5nriCSSh88\u002F+3R17tzb6c0MX8b6XzD1C8NGIoAWLDmQfD2wj9lk2OgLelB9z7qQcNvtRKlZnCYkg0glp5A+o8fWixrSOQc7BGTC1829NoS3b3duRvLNcf766y+7HwdhScNxKuLF9DU2nUF8Px1N99OFUiMdIjPOTLJrnp7UbvbYqaKuyRFbAlQwsr\u002FyKz9a\u002Fdqv\u002FlqM2wfjiPm9HF0ggDNCJyuufe+99+brw3T1Z7XaA5K2J\u002F\u002FbkmdgXcGdTaJbEjsDFCTdjV9kQ9qFqKuiZKBUp56c8nTnxkNdKXJ0qldhK+yVMqMbI9kQVjeX1R3VsWYjMP\u002Fzf\u002FaLkad33j\u002FbQrIzwEE6InA9HSly1u35t3pW9SfrtYV9rNC+a7mR6NoacqCxJRYTZVgcoDZtcidXXqogJ17et3kQ8WrgrVHkQHttd6cv7ksvHzmk7qKc6dIT7VMydzhgiq30jOaSI0XP3lm\u002FObpNvRKbC9Av+ja5by5c80lpPGpBNgLZa6UYHDqATQfuG0PXO9J6vRVYO9jhQbfqpvJw2NWiIxV\u002Fnjl1oj3VGF\u002FXkaxo\u002FLZtAfBssPmcLiw9m6YPG+k8umcne52dcU4HsLyVfJi3g9nUozkI9MaudL5opzWUg55Yz57aUTSCznPS7472+LNA+fWchs+\u002Fqu93uetvv318tRVrzF68TM\u002FvDoDb4xw6MiyysFXxsGYFdA69R4qAf2TBo1LfFDavXteGuJQY6RE379waoP40W7r1PMc0klNE+uq1a9n2CM6AprQfOheuMmdsiSJfRY1YeXYKwUMOOe4iBggpL3sJYAdSAX7448RJKbnmUb2B1NUlU8G92UuRRc4rcE7X0BvWVmaDeQe8pfFh7r8NOAPpyFN63PjoEIdakgXyw4kD7AF1DisSAjEhpRJJ4PfXi3jAKZwV++PuN\u002FfS2V+kK+6NbuY8Tdvrog6Kr8meKB0d6h6jM\u002FsOH3L0E9nG3WF3pakghOkTnaysDV3sGdwHuLcWHAaEiP2spa8oBd18sogMGfbv\u002Fc3p4R1HK\u002Fr9duQHWWjen2VHHhetozPJqBl4eOubrtv9Guuu9v\u002F39fregDqhBM55EQQLECBIlPfCEB8eppvHRVABMQdnaJ0lJOk4d+whw0iw7hW2AZSnmreF4I1RFhabAF+8dGk2DkOp\u002FRilwrvC5Fy82AZJsRKwCa1m\u002FISol04NFVZQ+v0H4GDrgSuMxbSws\u002FECpYd7P6Aqv8nDgBpvDCiBmVMkG9\u002F5Cxe6Ri2U7tzu8+VZ9fnb5Xxj1P\u002Fg\u002F\u002F6DDpy5XMj3fOM6vnq2Z6ky5+Vp9aQYjbDpk+oaM9aEiKIhzOZQ+sWJkynpBIOy3dvYeMXmYTOmfIpxUlL3my\u002FsM2XCGw7GtXkxnCn8DD0ADzxpZUejT6\u002FwwNZmDsGtGzkhbV5t4Wbd2sCevaUaw8vo7o2VUCRjvC9bP0WdO\u002Fudddcx4P4DTFsbPgbqBzFaxwL3A9baoPubJ7l6n139OuX4asDCW+curM6XknAv5+X9dy6u\u002Fov\u002F\u002FD9b\u002FeM\u002F+YvV\u002F\u002FG\u002F\u002F6NOo\u002F1mtT8Afui7PH85iS9jMzYC1cJbcttGMbVur1\u002FHZAQOpCgAoMJTQrXep7+xfEuM29OM24tXtQDdXni453AipbaPrzt6eat+qoxr+jn16jIYwgBja+B965i0gMbjZ39a3\u002FezVYFvrQ7GmD6K2b\u002FZ2r3YyhMPUDuJViEJZuMxFjGZofwoxFeFn32P\u002FGqOME3NtMluzNtjg+yRUbgZm2fNp\u002FV442y8qmOJtdVGr1TU2S9rrbk2gJhzylR4GzRvi8z6k6UxF8k4g0zpejjvcW17s1vPGEQHgBM0EYUKkGw2X+oFFGv5HYdbcSilJiXCfd1LWFbaj38r2lkiBp6Po7E4KW4y9+3\u002FyKM1Uij3MOaRjHFQh0lqEZzEeP3b9ck9PVio+a0T5TuWx3v4gNCr6McCLqSWONBr\u002FcGT1ddf3MjJbE83H7Yr9iN7sdrcHkBo\u002FdVp2A8cYkr6ePvpQpE+IVRFn0LYk5vY3wC2OzFijhTn\u002FP7kJ38tNuv6MOf23b7k3dPYoyJO5hVB4JWP0SzSb1KgKtptLS0xVhkrZA4Aen3Up2iq98lNFX0kGwPEA1NvWDIM2GIwpbypISnPunUFhJ61Bj5H52xm7AFe+s0+UNwlP19OqqJeHXimr+\u002FMs1xXJ2MmZz0DgoO+Zsx2V9yKPXreIUFAjfMRztZXHVAH2K9e0Xc9x6U5AsCfdLIfkkSkYfRvcyYaRxbvlWKkQPxgTrmwsFz+hVkD4mKSf\u002FyD5mOZK2BCtFIajfWR4iPFj2Nk0gACe54xlroFsCvMxaqxBeZWi96\u002F+a\u002F\u002Fq81dQKb9fr81xPiJAjLqwOZPAvBk4NPPPh29LxpyNEDEcblZNNF5B3QnI+xU4yPtcSl2j2OaRXEV1RqrgvH9jVWYfLZL+uZ17zsY2H15mnTkyfTzk3TQ7Zyegwc4h0uaGv1JZ2tJyMCTmY8\u002F\u002FiLw\u002FXD10Y8uro4dSqeliDa2p6sSqx0ni8K01xXya4e7v3FxXJ7m7E69QlGnZxsB2ielH3btPfsKwwdu9lfsfqBuQ8A90M\u002FOja1IIIFMUQ39ptkGvfIf7dQRhTNZ2h9ZJjephBfZziftSbZSnZNIrAYEnGKy7Ys+0xUJSGR\u002FnOb5vNSVVy8DkK3F3p51b2krSCtrun0b8KZzCbbzRezvlemowjE5dMix84D1st5Ox5XrLzpBxuQV06+Io0kvy9F41XjUbtHnalLUsMx9mtuw72pn9VHme1\u002F3RCRsNCep\u002FE7RziFuP+\u002FKkURM3Kv+6O4Xne2SXnKM\u002FNls79Wrt1dXvu38g5yMOfGzfU1WJ5JalG9PoB1hok5pWmkmEM52aFA5XI9ydAKDR\u002Fb3\u002FGurn\u002F3lz2LQb06kfX96gOxtNSdffvH5YJ7TtYV2YB17Jq0LeXjiRAcINUZkCpb62yLxe\u002FcvUXxnLqjr49jCKXSXTnucYvaEjh+CMHlBhNin0ry00rTnrRfbCLTaSwCmfHntfAeEn6xNZVEyOIpzidBUUycTwvwOvkuu7W3dpYBmewcJJUpIpwDm0266zwPK0w0l2VvSf71fl7L0XM+CzDhYa+SpS0g\u002FqTnE5iNW5LHTVyKbb731VnK6HEA54D4nyjNoasDuIDvu5Aj5zEb67GRg3FySH8+8LdvFmTC2Q6VYIyeLQzU+gD\u002FiMqL3djoUfjFm6XRIzXff\u002F3D0kmYj5mLIoDbw893prGzfrl1qMXKgnmaEnmX3N5eIalvkr\u002Fxizb+X1wcfvj+bgAJgKEyMhaMkGRcKEPBg8DEghE6qDHaF0eKN78mwAAVCk7xBwuE6jCHlbKObXIuL1b3yzZXx8BRUnKsw8mTtHAkQwywvHBMlhLUPML5wcQwaVkBRB3CD4T16TE4UIVqA0YSeuyc1ROm8qEMEIbfIWYkBPe5vs8pt04OT4Tt79nxs3IWUHQZNvvDzitF+lJHjuSoOkf+qwGWr0FghHAq299g8OsBMBwf9oPcH2NqU2Er57Xv2nh7Qi8XDrjmF1YEY6+W+yUkO5rV+dRZImBU1CV8xbo\u002FanNgDHr+vDWxEa7MWs6N4QtXji+eB+dYEK299jlcprgiScrVxXtSW6FHpLQ7HMYd7Gc7mJQjWRkwJB9Q9\u002F2NjSoF++snnMRkvxzEh5PrSrmJEXjffACoPe7PKauFqbN2d5uHQ8ZOrG9e+Wb17+ULs2LHVXxSGvtq6noiJOFmrLCD9QUzL\u002FUCjOaPMB5AlUxsbbfiec9\u002FaoTZV65eM6NaD4cSi27S6bgDmcoU36uawbRvWOOWa0l7rQ9uTR23OnhQqfsW4NE4dPOTGP+5Z3jAneiPfKOy90bWPHD+xOnP+rdXaww7WShncjoXYeJQsxbo7lp6okHU58S8op+YeC4pV1tVAkZf\u002F+qF17yujZ8xTvOnX3wFcbPNWDLCIgsRteYWeq6T67+6xRKhcg9IEjAEw606xe8l39XtAsKHMawA61NgXA6zFJ8ulCJoSF5aX90muKFvyD5g\u002FDQRqOcVJWyuKMSxd92qKe5oulih674D0nmMG6TnnaX23j\u002FrqrfQCUCtPkiIHwoQu79wBQmJjA3dnykE\u002FJJ0mJbozttH6uoc1OvvWueb98eqzz28UubnbftZhqTnnQMbEYdk4+p7V6YCMidAxRb+vNCKha10t1HlM55LmSwuzL7\u002F+cnU5pv3oxaI2ikAzTJy9U6fq8JJuMr+J9jCCjCInCCB81vdNxqMidTptwFxsp321P8DEMHhGhoUR29O8zmebB7qBzsA+eT8jgPmlY7SoZShNLwcbIADKJ92FrGdY9HYHXughaWN6jT\u002FxFbgHFoDUD957twjEhZytnr155FT1KBMZ9DO9yTlnQPcHFuxfBwxxvPQUPnwIMCo3vrkDFuh5Tgb2DZuOfDh5conGABsAn7mni4\u002FHlktlcB\u002FRUV\u002FOVbBPyCbAiam3TxhErRoZZaydbjVIBu37RAPOnT\u002Ff3C758\u002FuPlA5T6tlGOl1BPJChEMz7ARSOL2Bu7dkGutEcLWTGEqo\u002F0\u002FHs2vR+VXteNkjutAYAGSW7dfUydSpfH4nzYkescQ+lm4NuHpyhHd2fAwtQ0O+KMzfaP5wAOcJ0Z59qXOnr1uZQ4H5\u002FOv55JJVUqSYy4iPipOik\u002FPdTp46s3r14uXVYDxjfb82lWpXiAvjXGrXOhpXGtE\u002FTCSJvHBN784V9G9k09R\u002F1wVdEJwpBH9PY06KxfQOojj5IX\u002Fgs544effEie4GZ7l4iyFI22a0nOxX6atqbDct2GQ+9eShZwMyzS0No9fx0k+I+OcvsCPZZdFRnsnZ9uizZa+xyuQ8lT\u002FTGlSu17e08i6Y7WY+cSdbN75w7kry7H+ZyK1s1NjgZEVXiSHAg2bOXgWWAf60mAYA5kDp9XVM0u1ofwPmFNakmyd8A36nxeIHgqVC9KMV1NTDZko3WRU\u002Fso+W+67DzdKv5av2dSbC7AYt4KBbkyO7oszu7v\u002Fl8It2pvb8rB9KBV3rsb3vVgTsxs6dPlq\u002Fc5z\u002F99IvmejlnZf954Dryoz0BsMMjwOaZaufegG6YwHrRWac6\u002FfPKlWvVMYQbkgH45EiRayAdQcoRkKLHyUcSiiJNVkLrDAiLenOQRfQ4kGrwEI6HkgH6Z4rP6bdsv1aKyAcna3KA6XPrT39RQw6VnEyF5hwWEu3dyCH1d7qePO6sTS0H2mf93vvs+wXIJyfpWik3rMK771waGeqfycTS3QbRepEeTmezFcgBetGeJiPb4MPkAIHLJGLCyQC751nodMBdRAKxxLmwh9gnRejG9QYjAO+6w\u002FibKNikFPfz0\u002FaOmdYVTktV++9EBM+5cxf7tf11N8crm3XrbjprqQHc+o5wfdGcv0wnfl+v7w2oA9uAJGHgnREOi2ryeCkmG0iWMgL0ASMMCMPnfRZX\u002F1ohx5dHl7x0udzL0bbSCXiV\u002FS3Bo4QxHBbfhtO6UREUZUlQgBJC4d8Ej\u002FKQAiLs8+5777XBhfUzwo152DAGpAW3mIAKAcbkM8DCbQDJwjQCPW3QNpRnxcJgAxjX8xcqCmozUQLdtWerH3cLCmwLl2O9GHrCBQTJ1XqVImUgoQYFMvszRtImgCHFnndjq7746puMFPYwRdimUozKGAHSWKVDhZe1K9QaLzU8G3sKeDLmr5tPIP3s2bemyOZ+ebmOxJUPeDRhPdg9HyScPHGtm1wT87KRA0DJ370TW9cmU+X+dE\u002FebE7SnsZrDp5V0PmqjgprNnTz8bqQJgfk+Mmzk6uPZQ1TBxQC8s3VmRNnVpcv7V\u002F94svPE\u002FrbpcKcWd389uo4Xu2Y1WY9a\u002FcFXvaVuzhpAynCXKWUXk5RoUV9rYUkd1XE8XC9QrtAEGaHYcLybmFe2pzQASVG6S0FpzrhBCbTCPKct29LmRwKuHcf4JvB1XpQ\u002F2VMaORY6xHQ6\u002FdYGF0ksDhHj4g2NFcpixfN6bYUwp5AxelSsLYyJPrw3qsS\u002FlE3chCLrgbbix4oUqTkrQNZNw6bH0AG3sRNABgyO6f79fdxbEdWUhQZjedYo9hi6VgTDQl8yz8ehqD1I+PAlSen3HVxYIR7jNbK9clFmAA0Tvbn5feY0H7w\u002F696s+s9TYkLCyuEdOCDeSRPQq6cDewRxbw4381r98Q6DFCfuW\u002FIbuF6Xd8q+k8Y3k++9\u002Fbmtv0c4NqVE\u002FWoedMhAYu0LyfqZAVdQOueDO+2OlEs3TUocdGE0kUqNn4Yy\u002FnlN\u002FXJvl1Oa1fmGC3dFpZCS2klfscJ9rU35v\u002Fi2+o4kvmALd2xO6cKi+LzDMT0HG9PMyLuZTyKOA8W+dqxc+ndO0eBt+5z8E5srtmbtJauR62vbXXf1lqHAXuA4bA+3uPx3wBV4VykxVKPo4WfvvRLvigSAtOZuDRXzj3Q\u002FUQR+PqwRBgjtSp0jcNPDkVUcLYQE6dOVjfRf1999WVh5RuzTqdKU8E+YoDUCYiQkTk6RfekWff0pdQDBt++wOBfay6Mg+FTgG+87733frruUut1f\u002FSG6wAIviNURN3oQ7raGvjye0Vj0tXoXfPrGXu6+TubIE0BUN\u002FYEJGNrWpsnIKdO072+8BG0RP6W0TFqb+PGt\u002FWDZHZ9GpzIbrAmL9JIeIEjZP5aEeph50ulNDtq5jM7xE+s3da5MuB4h\u002F\u002F6Jcifeo4lZOiM84cpNZckeNtHNL061ps+lo1G8LfT2PpUj4BwOxRBflPksXHWPXkHTNbpWZi3r63b9uLDrTysh9FYs2N\u002FTT7v3nTevFJKTG\u002F+Ozrrv2kOqfTM8btPevjAPurWsfZJ6naZCGgMSAXqGJjdQHhwLsvYgGQDGCnw+V7P3wYYE5vYr1TFcnhv\u002FiuCw7QvL3I02YgROqFlAsgiV41PnqJfkXIcDLtZXp2oqWumVxPuhu9UGTwVU7I69dSfrLTPZN0Q3hbRPZQBaoH+3uuc45EhXoiJ+pvigIcyzkT0dW1g2Mt9UuuryPfrRm8MLnxyWvbasaxo+fUdefQoWS2ntb2hOcckN\u002FMKHDmmElBwwQ\u002FTHcb14lqrPbsrRvZ3Se1Er5ZwWntg9ebN\u002FplGHJjRK6JVHLyybYi1LXmNV2fXthRyma3Sqz6QwvLrm9vzrr5OPJH2pMnigqfKCqzL90DIGOxg0PDeB862OFrvb9pC3Afm70liuRyQKc19Rz3IjMBSPLK0XSexNOegX7nIIuSXH98s3mQShSZkNxKR7Hn3mQ2wAnIAe+Hx2CpEyfr6JaN6TGX\u002FdXv2HVstboQ98NsDyufbkIkmPV5xOSZXFgXzPbYnf5gfeAkgHqcOvPTf2r57Hd6UV43ovbOnTrlpQ+0QxSdQtpy\u002Fr3PdaU0w2ZwJcecw+\u002Fv7OhSD5JMhgONk7NizvTKHwKi+1r3RQ8FcbN\u002FtwLTmxsPZu+drpjfyN404yBbbIAXvcxmknU61wtwd+roo\u002Fb5k02NUNYnj13Nz4lTajTq6Z7eeLJ5JxmWZeCE7HTyQRbh+3l9b0D9448\u002FmYU4e\u002FZ0QGEJy3lAioFAWzygWy6Sh1B4JCwpGV94VzHShk0AEGRICBXwzDuX2025+TeA7AXofvjh+1PkQPCwMH6HiVFs8PLb8vcyEhZYeGvHFuYPwEywRuYwC4EG+q3FFmZmTPUsHqGMAmZkd7bIAKzFNCbj9Jm9pW2cPv1Wz7bkWTICOysmsduBoTkUKMW9L\u002FC9NwAKYGjZxhiVFbs6lhAMQ9jFeNNYMoCRUGFQD2bc3zq7FRDJMIwQSlOJbfRsbTYOisMc1qRwDGgD0PI81xcjzKgqyKNEiaDQ98P17atvC70JFR7r5DVKbT1ngNG1CX3JT5VrK\u002FXobooeM7KzDagt2+s20Ot9KW8bVBpGBX2Hex6e+\u002F06yWBj3ssRkhe21d+1LmrWCoXWMz7gvzt2NNM14EjR4fvvXu75bq62Nzdj4DNGjJOUh6OH8sb77JM2gZ7AO1qP3KPmOICcgbEWPVqfU3iJHe3nZI18cXTkvbXHm28sEiN3IGVZCDdDukMYOWUnNRy77rkp\u002FB0Vpm6h\u002FgsBB+ljHtw3uQmk4YT65WzYF4ECN9+WTHNM1xqT48Jf9KUQalt5jTq7bK+AyomaPkgpjzJvzo2LHBFD49+l+bz7MrTJzovuD9B2pQF3OiqRs10crz6jVz4lDOyTFwrQeE2EFolkCVuQWI8sYf48I2fOwSyUr58pQZ8dZ7m9MEW71th4Yx+GnUs2yZeTFzHWwCPMufSzd50Z4jyPf1sL6skeo\u002F68g1h72WcGpQ4DWyfXdECG5+vCJwMJ09a0ufAMO1uPnc2hdcXeDSigK9pnP\u002Fv441gwKSNFodrfrxUVxqYzVOQ6C9C1pMzUXq1IiLzFbQ5a6TnkkcqrfNl9pGIZ4xie9NXD1vZa+dnvv3O5QvgOBwI+PFPz6Uuu5uZmv3C9VmjSpPq83vxIBOkpThkE1IEZhtz1e3MyuABEObKT2tb8M6hIDLpRJwJGyhwN69m\u002FpbYwGgwUYHPn9u103LMBWAwpEG8\u002FNss5D4rmtSGsWLacyfV1+cvayDpMhTNQgV3yb8ycB6HuF2tLWpTe5q4PNAPDdzOkV69+0555PCzz2XNnY5OkidQrOLAkpeXAAJ7lRMMb6RUHUXku0czJ222uFN5fr2DrTvnpWFoOHtmX7khf364gVPoU\u002FS3vXUTzRe1S23KzltN9xp61JZKsliAAWMFlBaeAtUI0BAK9b56ABSlz5pEuB2SA+Mc5CPRSN59n4hhh3o8dO1m04f3V+m\u002F99Tn\u002F4UGEgfaA1oXd2NO19tVaUAeVtdIhHuVQvsp5TxhyzusEVW7yjmR5l7VsFeSvrpUCU9\u002FXdOCqdc3paq+KED\u002FvmlrxPklP7002Dx04E5Cvr3ps7tOKSVcdzPL181oHFwU+0wnOJ05EQsWabpWKBBwCKoq2rZv5s+exfq8jEuTgcqpFgYAUtVCrY5FhR5K+1hvZxK4iy4BfWwSgwNbub46czi016eRJvfXlx0s1TczbyNbD2R32JF1hJcgP+deG90l94sdZbw7I+lpF+G3TsU2HSxlx78PZm1Mn67rRXEqre5Lz\u002FCiHy4nMmk6QUVEGjiF5Brjsnac5EPa\u002F\u002FHpAXg0NTLFolma8\u002F7HTTucGzK1vW3NeCBogm3OxtOVVY1NRYwzSRvri2vX11TdXyw9v3vlXCLUXzeWOnTkA7TeHjB27fzAHsJqE1phjxJ4ibnaW7uClAJ2edDbMhbcu1rY36qWFP2xe8yiQOI+bo8c9r7nbSkeI8iOqjhytrWJjd66L4m1g+vatTsrOUeE02d8YcuQZZ1Rv9NWOogtFAMb5T0eLxEoVRraZR\u002FL\u002FVky4vy+ROLoOiSMlUAOPSM\u002Fs4ZCSrTlMhSCgf+EwWArR6mf6mmM9aTKeK5tt36ibs7\u002FMxey3SD8kpM\u002F7EpnC0rN31hHmEZn+5yRPkTpMN+ZexNs16T9yxSbRWez77SJk7s35pjM4jnSfnH8RR0AdaXQsvQTrLbqwPdb72Uz62jyIiHLa78Az7TOpbhwbut5+JVPSmhe5IltJTHZVxIatnHSqHDt6W\u002FqX6Jp0MXtFkwetGpFOL9sj1nKafbAVjf37en1vQP1WxVxO83IcLi\u002FLDvJgDK8vio+iGVDQwzfvA8RfvLjbBC2s4J2UOq\u002FXeykXAmqy\u002Fchj8hnCNwa7id3fv+VEUkrTszLBwFgB2vqbCmNaePdlWAgVofB54c+XKUlMQZI1wkxRYVKBPH3WgTCCa8N7pdsG2PDwXONEaTPHKup8Y1wJKEdC3isFZMyYDYqRoFGwQj97A43YLGOzqCIOGPR+kcLoIVOoNsGRgItTKxWoqSSnyLL1Te3iWQJlquEJk2KZp71vY\u002FNhSpwyE92wuUQXlq4vrmku9KB1pLpcVwrZ+ClxkEs4e0eCbUNgVqXFbO85XqYovoOD3S\u002FD0P0AoYMpWADjZ3\u002F5i5iRCi5\u002F\u002FOMxuLfvXO3aVceXXvC6tAoG\u002F0VhT8fMKz7DYL1z+d0Zw0bj270vlqPxABsfvv9+OawfZgR0\u002FagQpuvcLRf5WfmDzx48TcYOBgB0hbAmC6uze\u002FdMTIpL\u002FiQQ2zw2t5iHJW+xdlr7dJqIoY+do\u002Fzb+vPMQDIlpJPIjoQtMrlNilGhkDGEy6FAawPac+YCIPI+FaDI+XsdcN4VsN4FNHdbp3eOwY7117nF\u002FE5bxMaDeaQ8KAZf22LAttWuijxRjGR3AdINH\u002FhrvcjMKNLG4TMDGDOus5\u002F63FphxrBZf3sDaAG9nB5OQWvKoI\u002Fwdm+HovRwPXe\u002FGuNuq9mPS2ERAO1exrAc+tV7+9gw6MkTtm7+6\u002F0NbYzbKPVuwPXwN3t\u002FnM5keZEqz+Ue\u002FmpfZ6iT5Skiak8oApSvO4q2ffk0RnVnSE3eK0Dh+jtmv+ytR3rF4te\u002F6qTYjtROD5KnAea9p+lLZkq5ar72rb1enTq2tBCUHqLw99kTEb1ATOvCcG9mEF3b+poT60J3YaOvvXOp9oy\u002FEthdUgCwQPKyn3ZQmut5n8JVjr+98tJezuhwGobFywAsQEbuI2dcXYX8bEZocUQwOnfvPs1RvjsGkWwA2pik1z0MvQDMTl50C+w7QGrMW\u002F2MgWMIMT90lH3lgJgDHfImhYSxRwLMAW7NK2bXyX0Oh+HgWVj\u002Fdr1FzpZ6IusOWN8KfLunUxz7eM\u002FeIUlHMvQpoaVILIav5f62XP1PPv1s7iVt8UA6+XUki\u002FQ2px9fu3ZlnGTGUdtRueBvFeWz\u002Ftj19ZwR7TMXJh2TGtufI4XMUVukUwl5elV0jb5smkce6TXP\u002FirZGJluLl62HooCHV7zrJ8xdq7\u002Fbc4Xlm7ks\u002FWwFlPYn6xcunCxFonHk6srq08++3j1i88\u002FjUCo01Eg5vXruqbkGDpF+MC+AGTX2934XvW5zRcBhfbTiaIaR1uz58JxzWuatxSFhdjYn01Ry3Mwp+9BRMG90lmkBk3Hi+b+9vX0eg502idHWZpKudKlC0qdfPbkSOx6IKTWo63UdwygTjPSRnLc6gxzp\u002FatDyr4DlpmX4oUZgMG7DQHorPqoERtJ+0wYOP8QYB7ASP9f\u002FuZc6sF7c72W7G6gKte4us0RM\u002FPMTLPemib+IipfkmmATG6U\u002FoRcoSTZg85ybNv3ZNsRRh1De3stra0msXGAt+B25jwZaxds3lFQLwhDewpazq55aJBb\u002FZ5o\u002FJ7eoFzIMLgGaR+iRgianb1fgTL6LB01Fbjeum03ZwG83yvsyA0cfi2Wpi7nbmwPaLEuLdazx45+yzaREael35Zmsze9k24odvFxFfQ+CKCwFjp3NaQreA4Kbz17Pe7HoLPc2+m\u002F183v0g69vFmB+Qhtu6dik0mh43XQWqILfpvamRKHb7Y6aicKAQiXGF\u002FwiM7Oy2YLvI5dmHpNOTgtupHApGin\u002FasCAUSyMscsyV0lv2yPZuIkFOfgsGW+uvFOQG0fffyXjaQ7ndPuoQ9BXDhBl3t6ERMv\u002FH1uMtcfPd5DrWxs0P0kUXTkrOP9nrVfhRFCWukK+As9gFmhP\u002FMgy9j8BpCrLkY3dc4zDmSyRp7tiazvS6FS9pN9nXs6VKb8bJOZidP1Xxk\u002F+PVvWf3m5\u002FkP3vt2jDEVuMydtcOTXQv6cfJSpHFsb3tLSTs8\u002FCWXv8ezyFk66Xi6gCEIJIKrOXmtuwWDLdZOtuzHNzv67WsyPdwtbNnT\u002F7zxeKhASomywuwkbPYMq6eB0ww5XIbtduxIQEUIWk5nnL7CI6FswhYbgV5fsdrulCKCUEyyUA5oT93XsW8zg7fGbkW+lRV4xgxLA4vyEaXR6lif9Jy7LrGw3hRHA5N8N\u002FkZvcz5gOYW1hpl08JNQaCZ7yKm6QH9IuuA2T1vUsC6kCSwtZdAbndbWxMuDSNbTHOuS8j9FhrQJ5i2ZOH96IxG8fSagxDIm8Ua1IYRg5sgN8G3DEnraYYzSlgvgGYS5\u002FpaRiyhIkQPik3FWu9a9exrsu74ywErotmwFvChtgAbAejJRTJQxUi3Ls\u002FhyGht\u002FkAXmEfp3N2i5kTxX9agx0qR9TprnersL7TYUF7YpLMMfBwMED0+kXt\u002FVrnR6WqbMWMnj50ZnX25JkJ4159eGW6zVy8dHl1K7Z9W2P55ovPV4+Tibcvv7\u002F6rd\u002F8jQk537xdm6aud\u002FVGwOz5H2R0fzGb6Ui95S9cONmmCow\u002FLTwYWzpGuLWxRpwSMgO0B1+bhzzfNt+zQLRWXmuKPhyZTaE3ZxYPCzjwKmMCxNqUlAdP\u002FnlGVD4i4P4kOXWYDQDc1DY\u002F0m8CQIwVo0QhtSS72qccHTIBAJOXhtfXwnb73gwPUB4lYQ2b74G3XWec2+8MGF3UH3ouCiVvv3\u002F7YmD21FFhb2kiY0czCgy0dm26QXgxaMNKp4QBfS8y7EU2KDcnDQIa3X7Gav29B\u002FPBAZiR9nzC9POfee7z5sc4GQN7dcKI84cmZv7GqPdPz9U4sLnWE9vsaHodgkSHesfINxajR6itWnPdl3l53Ro1vAzEZgem1cP883v9LvCUnPd\u002FHf6SkUlJbrVPtLU7UHRLa0+haK0FdybrcoPVZkhxcrx7W23AOgBk7JP73zjNhZZdn3z680mZ2Ar4S0kCnkXnGAzFmWi7yXW2IOmqgVitBQMqnYSyn\u002F3XnlfUhMmUzkF3jXOcvC+dEhbHSFrHku7BOMfONA5sGsdZUe\u002FjR1j45sQ9GOBkFstq3jj9Tmqkb3Xq2ZKO0X5u6tqTQBp9GfBpHqVkaTOnSJhxl5pAeTDGCJONx0Xm0lWPK+zn5Mnvlu9860bFmR02pUbkyLH0+P4mq8gUICEH\u002F2ShdFEtbSClDS5paTlMGWidYcw\u002FKToYaUPCX5YvbM81TT0357c2pLVtHZIm+eHQPJvOHfYyOcDW9SzNr\u002F2x4zE9nKw2T3LU5UKLWnGcFLsz1sDbAj4ysu3Zm3XPwiQiKpbuExnr9IMI2r4iIdJgpBI5Qv6bq1fmTI8bdSNRpCh6cOJ47eR67Ht3RPUY+oBk7QMPBwwP9CCbkRLmwLHo90rJelANRcUw6cTlYL2t5P958neo0y6BYk0E7qQ7cSTSxIT4XrzsuZ9Lj1SQGaMYcDl9KjKqnswcSpCCjFI8vgPN5JPTkvFsnOZtAVT0jmgukGjOJn0tuQMq2U+gyZ6UrjAilb16mMOUqiq63emLTTD90h1n3zuCfTlyHRFijxZx7mtHDHorNrrFfI+c7izFIrBLhnT6GZC3ILTWcbFtcsC7fffJ8QGyGtMbXWJtd7d3FJyK8mA7paK6DuZ7ZKKr0zH2gNNVQcVX7YEdyYiccDb1aQN9lPzeLdqjIH9vNmqjfvHXb9d29h7mtRSJ\u002Fmt2uxS5QepJSyN3z\u002Fp3e6N5f1U+OzxyuDSSsYsRXVh+p2DCMOrNHiW\u002Fh9ITLOUhNRUnO7Rx\u002Fc7oHDOxd19795HTNktpCSh\u002F882VZO7t2UMPyEGYAzkpukG4R2+a2faC1Fn2WRQVO2x\u002FX7lytbFE\u002FEVuaadrj79JsREBMIdvHCDpInSQMe+p2BYmo4cAUVEaTgP9AaiPzUu2ZEEgNt\u002FoBrrYv+EwOpNOlHbMvkzqcPfwfisiXcr1e2N2KKcxPUR+OXTe4FrWdQsu7GcsvrV9GjZkQ8iBn31fao1cNY3RGkqThg+RO+ZjIWq1Lkb+FsPvd6IxovR0Bj0Ivx0\u002Frh4xBz2ilIO5p3ReTqr7TaF1fxOBgQ+8tEbdPSlOftdHQge7O5F0W2tu\u002FyrcR4w4e8Dp2EfScTt6o9QwuE4q9\u002Ff1Wiz593C10\u002FUQ57ERHCE4wiQ\u002FF2AaoJkCtZ0HFLQAcq9MzoDVDJOCiMmZ6j1SQkw0gIhBEdoUOhQeOtLiLAv3aoqHnse2OiGKQbaBHBtuHHcKm2z13XUoMX2PHyWIBBbT\u002FrLF6UYJuaKucqMSsM02kZ8nB7e10h\u002F7YZ7usAS82BYdKJ7DImIRtHADwPQQVSzlmXcNk5kiT8nsK1R6IAPKY9QdgaF6HZBlOLXmC8kmvDYi9lOelRz5Cs4az77xzvp9XXF2J2RHjp2aDSt\u002FTz\u002FoHbuE3lPSgE\u002FvN88Uro4S1sCGp1RfpFAUGmnLqLAsnFVUtly72DjM4KRjBN4OV7x5NwZJ26+XCdqLwM2cDjmKOsXYM0ohobz7Z0ApZjQb\u002F7Iw4K1Ywc2+7157vrrx7WcxTw40IPQBssa4+ah+08\u002FuVIS5d3X+8rkUzpPVpXdLe6mVIyZBDuhG+WM\u002F\u002FeM\u002FyUB+s3rnBz\u002FqOXIoGv\u002Fa7g6HaQOcPvm4A68+qwXkZzFJd2Pkzq1++7d+I2Vyf\u002FVnf\u002FZHdWCp4joQIrKyO9BKAcyx6ABKABm4WcKuMYMxq6vYfYzoyzaZ+cIW7Z6UFzoSlOh7k+U60kXg5GcZ5qDK5IzvygiNU9ZnRC5e5CS9CMyPciVbDGjyO4ane09YjWPHIJOEbsBBCBqPYpxWjckEp8A7xmFzjRCqQtj0aeMcvZcCyXD2JooY7uZMPedcuHLpImu7dflweEaheykYPYcxYl3JsnaE1tF+cbiJ\u002FFhMK9bQC6j2okylnFBkWAvK3MSMA9vv3M+LYkcfUd5e\u002FXN5zvl14+q7\u002FPExsI1F5xQsy0QdAjqvXi2dR1ybgtvRvvE0FC4QolD5buFGJ4\u002FevFXOeXOxu249r\u002FOKXuT4mzFrSZE+z6FV5OzgmofCzRllTOzh2ku+997F5mX\u002F6uNPPg+IlH7QfpUKk7sVs9Mde1YgfDOQIv3lbkz3xUvvRSo8bC11GahYrD1A2dNjdAmdNDnijd2hXwuD5IfFcVTjwsjKPZayxtAxnphDABvj6mRKANSEzhQnb9bH\u002FD899jRWucOaYmKlH3gTWdaVZBj69jwjN6kV6bvdARFO+UbnA+yqH73CL4QFkuFN+znpRgoPl1RB+6PxNuMcbN8BifV0pJQRjq76FREQAGJNNDBgHgTq\u002FQqzto0BPFae7VKkCdAsUULXPXTwaHMbZ\u002F5hqwAAQABJREFUCVP0gB2QT8pYY7ink0NjZnT35LTVhnieDzABGHQ5+err26vtpSccDogotEsrBIQDoj2DA27o1oe1SDN2rN0wkDZGssgZ1HHmxImaDLTW6+WWqlfy3ADFozOPSjE527hyWtKNOzLSCpsvvv1OjPf5QNTdIno3Z\u002F+dKc2RM\u002FLTP\u002Fyj1Sc\u002F\u002F1kpiDGYD3v+gPGh0iB3Fv3bZr8nr1uRAfovz94tWqYr2YET2a\u002FauOxIb+hi8iwZc7jaHF6UvCqYFOx6+TpdGnaxZ15UU\u002FPy5oN+3koGqu3SN72o36ueedlzSz0MAO2sjM26UyXCo7P0GJ9\u002FH672itbaWJySg4GrtQgLJNmAte63s7lcU7TdZ0VHnSbr+hNda99yKEceZ2Mv+8VexQBLc1lqYBYmcklF5LhLV1nWc0dysrs94zUMaDYd8bGw+BmT3ssmcMww7k7I1gFIrZKUFqko9lGSOXrU3ll0Tfu13xobvYbA2HpZl67HvXNqjgLpNYO4XarIzdLfOBeHj6SnX2qC0CQnH1IqtYC0pw7EuO\u002FbGxht4E8zbhjwowfrFhdgf1RqJ70J0+zb0oUocNkYd\u002Fe5l508+7JfPC+aHZ4fWRT5P1+k5lF2jI2atpbbnq7OnoBf1M\u002FsnBSSU9VPXHr7fIW2T1c\u002FT640RzCHZHJakqZTrMuiCxXVtxbp8Qd3A+pfX0kHPa0WrgMdIyalFJ84cXz0wUTkctisk7S\u002F9RxvnbbWKnrc1f1fJ1MYaadpc4DYJxkH5hmRYp2WdMEu0EUQersD1l72kvRmDgI9SFZ8xp6yt+hAegOmcj3XffVS9kN7PFkaBzOZQ5JMPjt80pblYCK26Gipurv795Aa333naCCWAHX6zsnBnDw1dHDZ\u002FsaoHgwx+zh50iXMPCOupP1JzZUexB6q01HQj8ClLqSWsntwor3oqekl9Sxkg16moz2jZzJf9KTe+eRu544cttKr4S73OxhIev3q\u002F4ddX5w0CnBSwgYu39VJh4TbIvDiAVQPa5MRsK05GTKra8lSaDsDn1jkZiHFonI\u002F5dcsyvc6puVUC4gFxobx\u002Fk7UFSQ57tMpL4Cs2XyRkfL1vD\u002FcbdKn52YTT0CAAOFPTBVBIwQL81JuaqyX1dlRXlgmNAHWsjEhBmYbDwDo+F+KPxQQ2JM7xRgHylPUEkMAc06Fl\u002FA2xY\u002FxI5Dych9kUHhf0jsOB+CxH1j0ttIo8YOB9VtFCB7eq21dp7eVAxBbU8eU2GheoOrwjY1OiIyxMQ+MEwUgNQZs4ugwNIoqUj\u002FNvdNTe3\u002FziDHSdxlzzYF5UKcSnrC8twNtoAMJ8EMbNnbrSZ59PHBjYO9aw74wlgzzbJzu+7x89x1rVU\u002Fv2l8LssbQcx6syOnBvaurzz8p571w7vFjqtFDkhmxl7EOTwPjBN1hC2utH8b02pUvm8M29mqt6v8bk76zM+8bo03Zbo\u002Fl2BHAbarKW28z1ubr8aNyPg+Um1be42bt4p5sWEssbaxq4gMMORqYo1dYo40pX64DHWI0Xm6pI8gxaI52pkQtOqU0a5+z052TLewOprt3BgaBRgWtPWJr3vUaN2WzY1uAsw0uH51VFNGwnpnr5rb5ad6wTpwcGx1jBIj7vZSmyX9vDfzn\u002FjqvOIHV\u002FewBSulZoEcudWcy9Zl+31wBzL4wN422tTJGLn8Az32StRdZ+2cxgXvWhC4bR88PYNtfutHQToAV5oOCBNIxkowEVkxnBWyb5\u002FSimLSJG1Y85xSzYX4YkWHSu7G\u002FTYFqnzU2QJP8+LdUML2kRSIw9JwhaT8MnPfphe+9LcY80\u002FNnDO6T1b3Y5DsdunRnvRqXHOm2XBqzrZF8yXGc523GXydPx07W6SkWSNrXpECV1ra36x6o9euZMydWv\u002FPbvx7wvrzaVwvQz37x5Rw7T1a21QpO2oBR29faevq8iyuipIPIw7P2oznThQM7jZluuM0FNspzWTugguFu\u002FpofBouRQz5sBHS9T3vK0XPWvBdQCnxMDmbrwegJNXO0jh3v8LaYoLv3an96L4Y1sG+NgHxMkvcxVtsDX3jBk6cPBKrTawFfBlPu91Ls2Zwzkt1vK2ZuZ\u002FvoVIBbMbX0AXUrnBHzQbfO+RC3HAqVHs75WfJYy3sNHGPQRTkZNp2vOKTyaTUJsJbDjDZHmy9bi+bIYUGb7VH6Zu++Y62Jw6yQKI1nL8B9ZIzzYhO0uVt6dzPIN0u\u002FEaJXJ7IzhvrGraKw6SmFuoAzp+9+bKTcZo6g8RsXRrqprt4ltv\u002FYyfa7UwYfF57OeJYn\u002FU09+h2UcOLIieZSQXndn9pDb9L9WsZkFUFQAXIgwJi0edPv\u002FerXsX85L7uqATrY8xxIdra35hm4FEZ2rw8faI2fpbvuB46e1C9948n6an\u002Fgwj6QHMM5PFi4fFsy3LRkL4oQpXfN5USzkkb1OJR4U7V6GhlyOBC6tNdtcF2b84sNtXemteWzus48JcPpjXSRZ5UC9KoxiQAfiOXdV2Tgfm0IRVMAjkml63vLlry1HoXruWvABr1AMZFfXyJEfevf7fnufaD3i9x5ACw6dpLQA+FdfJ7L3ml2xvZLN2vjpHMAsBy0UhCBOI4lmQH47FcsujXBvG8PpOtRTifKnacIJ3UsHWfeHFbXx\u002FpH+jJZQ6borPJYel17eSM2\u002FYHe9tkudu75s10RUnUQCX+M3krX69yzK5mYA28qAAXWtHDWceviuYurE+feqsNUOdRN0hy8lC7cLaqcXKjdYlEO1Pv8VGQXW68jk3Sh541xz\u002F5SdVsjbP1a9z1apHlnrOyrxn0\u002Flv\u002FbazdWZyM57QFzBxtxenV0M4aJgDevnFcPzJEh34iJY9ns9ebdnvMltVZvesy1znuKqxVHju1ubnYVekSCPDX\u002FjY++URco2qRfuegIvQdTsFHAMMDM8UZIAOjwm2gbXQ\u002Fv2WeiU0DvMPL9HelFP9F1nFSAXgoWHWGpJpLXPRCICCDgml7jdG1PR6VOi4Ykd11rV\u002FfGrOt\u002F7nM+7z7yzJFZusJtNga59+RnSNbGwrJ7HxvaxC17K4woBQw555kRXNszKJ6D7pKlIPd9PaDvPjMn3WNXpKOCesScjkg6L5nv10VOJ3Ww53WNJxj2nO\u002FHPdNG2OX1Pfvn+3nZOd\u002FL69at2ykCRUsBh8DKK63keqhJgRljvjC+wroMjQc1Gzt22qS6nCwVvDauhyYcwjJTJNDigSQT9kow2\u002Fvznjm+u\u002Ffz\u002FLCiFkbls43LC8Ksaz\u002F1os8D6e4pZASkYfQoCEwPYZOr5TWgt+u\u002F6ZyCTZQq8+K5sHKhwboXtEyB4QQtpSAky0PWGULFvJz5CfE0iC0KsDEB\u002FY7InpNMu58ODOfOnhklBXQTJoD57PkLq3OxRvLg5D4r6Dy4Ty9cocPCNM3t8bqnMED6GjvZjKAolhD2IswPv\u002Fl25sMmuT+HdaR4EhxG00af1IfkR5hbuNDzK2IhnCIcBFkrxAcp8ydRl9jzOXGSYKbCscATWs3IbY+tF05c76CAdNfqSCHDFr5DP3ilhc1i0gH1123Iw91D1TzmeL388hvXOnUtA7ynccyR6qccqrEAG56zOXOy49NYlimgLb1E94rz587kJz1e\u002Ffpf+0nv72CK69\u002F2fEsoDEji0Svk2xPzgRmRFwtITQef5lm+KyAKUFuTU0657Fm0gMRMAUe84qWt4sJcc7isI+WE2SB\u002F2amAkK9Fufat3zMqmKhlnkSDRFiWcB8gm1KCLLuAgr0ul272cyLV7zy\u002FdWOU+m3v8UTL34epnc8FklvPweXu7TMs59zfNwDY9Tk6xpP6c532iA897b0A+4yh9wJP\u002Fu46gAHAaAxZDINy93nZL+4hfWc+0\u002FVm\u002FN2HXBizMS6hb+bK2AIljcUaMORNYbftnjOW7pc825cmcsbZY2FANsshvXNnY3Xjdu3tYrOf5EQkiV2TyacXMqytrc4xmDspL015ax4LE2B90l4W9j5RS74zp4+sLl16a\u002FXDH31Y8fmHMU4nV7\u002F7N34nPbW2+qOf\u002FnQAAmD\u002FJP3B8TX7\u002FkYnKKiU88vwLnm+C9M1jmsnL2K0sSpkbjyGno3u05GHIybkS1cAOXSXOg0sjXSQcdaak9FD6al7\u002FW2YmuaQwVVzgrGn9+SA6pawLacRy+nFaPgXM4TxnBP6ei8HblubVp0JcoKhdY0BDmpOmijhZZFGhWyb9eDuAXtHcxpg90z2iLDyUlSmNzY9gViRJ4u1duz7kn6IyGgJ0h3Ij1jH1poxB7TkmBMS6YzmiE4HHPYXITt3Lsb68jsjq4psMeF3Ig8UlSFFTpVTKnKqfeImMiJ9QCfTC+aPLtRm7UjzcjwWUToLAqKhjD2R4uicDiCFXKoHECkpESX92thOHCZJFRRenV7KB7qOqO725kQhmlQGYIl9MtET4eriz\u002FrbrVpBSq85UdGeI+C3XpZS0DpbWx05evRymyOV6k1+f+N289tppT2XuZniy\u002FTAtD8MGKifIW\u002F2waQ6SuW1D\u002F9f1u60ya4sO+\u002F7xZAYE2MCqAIKqAHVVV3V3WxOoiiGzJC\u002FgBUKf01bYdnh1w4paIuiKbKbbPZY1TUBKAyJeUYCyPT\u002Ftw6SdvitcKsSefPec\u002FbZwxqeNey14wOLy9DjVFKa9X6e4VfN3bE8v9Z8O+NgAbkigt0XGMPbqk7tvM57Hxv38OgvHizaeEiVo0DKs+cAj+hOPNma721dpIUpv3ngwPFkZRHdjI+tnBoDpBo\u002FEQOA4WFylzfdyZt+Ju0T3dVh8pEhMpvEo1Hf0ctjxCaLrAUjYNk03hCTg8o4ioKdaC6sjT0keIZJQ79xLAyo7hNVYZ7k+CEvyPVxMkSXParPotMMo8ccN+kcdeHlEptDm8dPlC7JmeX0VSJoodXmsT6MUVT7ZBpD\u002FGg6eLv2Nm8yVp9OlbSHpZmSBROdjHe3i0YqdLBRtOMHH3+cZ\u002FyDUkDvrm5dv9aG4LtzwNfGxpIup83j0e3TdNudNhg7iMop4d9881Xzvra6WBGOixdVZ4tu6od5BKTx6tr+JS3Os\u002FVhog7JlgsZEGeiIQdFLnv3APZFT6kAJb3mwb6HrRtDdJFrr7dF5mxQjZa6F\u002FgdzBXR8mTvI0ujcTRPF1gv7\u002FG0614WTeBskzp3tCpIcBd9QA\u002FiVy9OWelCHBKeC\u002FCrbsW4l3JFR6B345Oegk+HbiJYtGX85BU9GpFHp6KGi8EAE9adaVe6Ij03RglHay+nw4suwGz0ILlLcXFoSOu15lLzpAjdvLk5xgyMKctCuhSMSMaIHsIM2pC2w1HF+28ytEFnclZxdKkN\u002FyJ5Twty4HCUiV7IFnlbr7cG1AlPynPC6ylzQtWUm+zZcNHAMBWl8SrvCEVDkazHiKxr3pTx0nUd4HEohSs0o\u002F6nvEfta08+K8VF8VNsQB3vj+cNQWSZsu4QinuWw1WyuFp4myAslhApiw\u002Fw4p2hRBAf5eWwjcWT3tHhEQeL9tVWeaalrggVEjz6LbSISBYhlcJNsCLUsXwT6ItF2KEAjQdxetZYYf1WEvHu7evNBKWyhKAuXHgvAXx8dS6gfra8r\u002FUs8cMpxClx1+I7nGIB0w4EKHwVkxzrcIhTp0AiaUA3V7dLL7lfPWLEhKlevHwa8zlZtGoHzQ+gAKBSrJiGkBdxkHPNa\u002Fbw4eIBk8cNbG9VW9ymmcMpxf2tE92BbwGl7bw7o4DaePQwz8CBBP7BruO1l8fMY8Ribv9ZqTsBgMbMSwu4sbAfZu3fuPZ9XomlzOQHCRsCfQy9mJHXBDh61WfPM4r2lC\u002F2o88\u002Fm4ofUiH+6E\u002F+xernP\u002F+HPBJX60\u002FKtBDUqwyNJf+bRztLORqg0Ops9BHDWrvaG1ppDoVazUkfjyDi6cWAQNTBSclYhEaNj6cD0OBRHcDdZ9aPl4mQosQmx72wKsPIei8AGI14T\u002FBRDhRbd\u002FY3AUczLMAaS48IIpuibSC7dJSUhf6pVALU9fGsgSbMudSWujsCyWcDit+McxRkC+Y+fRzYPUAZyKuhrqcAl+t48BbgqD\u002F+Q7t+jGMGoIu9eN6nq73vluHFeW4DdOIi3pzma8dbzx0jh+Dtb8Y7XmAsUqTq2MsFB0Z4Vm7efJqSy3jmyY0GI4XW3TyIWgVikwv2kLxKQHoQg\u002Fl1skUKD+DuCHch\u002Fj\u002F90z9b\u002FfjHHxd5O1aJ0k7Qiz8pXcL8QodpMEAddjS1nnkojQdwqU2bEIVAl1Sz9pXUHgfDyKgWaOYavUdn1okXHG9Js3NOABk2m8GiYXX\u002F9Yu3R39HATWFDPrJ8W0eXr1ysIe8cmXsnN6rNFp03A\u002FFQej31JE9pl+ePbmyJx6jsIR+gTtrRykBqCI5FDfg+bJrbBB8GL2TvZFBY4zP2zTP4CdDAHTzwiutn\u002FongsgAApaWfTPKX6qqQgaoPsWrv5QbJDvJU8\u002FEZ6MAA9OUpjQ7+eGegeal+FGA+jxGV\u002FLIdXjCBlNzxekBwL9z4mxtLhEg7eofgHBnc3NkMsUu4nggb790JvQqesH5AqQM+A6Z7c3gvnXnZvK+iGPrJV1T+pTN7FL9niZHjufoIS8PvZOHvbnliabsOVOeR5u8dw+LtJqDix99OJHBx9cbW7RLLipvineOBtpP5zW924azJ6XavSgy8eqocp9oykZbCxDw72Cjvf0Y5+7mOExCr9AvnDRoAA89zrU+ecovO7q8NBpghxOB4YsWFtnOCYZOWsKhnfKEowkSee8zBnHjLUVj0hq6bnEYxEP2bSS7VL86XDqL8yCSMAMo9UELPNxAP3njd+p+4nlOGTXneAPdxKa916+e2XeAmTUwhyIGxeVmzTnNpjxqa75+zEm8yyFSUoO086rwKN07B9gF5iYaG8hWLUaftI2XGBOAuz02Kro8U3Wr++l+keQeW\u002F\u002FwDD2cbO1avwH9rWSGSGW9zAhof0FOqsPpJPqOk2\u002Fzwa3VoUcdoPheNLhfIQty0ty2LjmPjkSjH71\u002FYfX5Dz\u002FJo97+jIyQa99+m37fXN0sup2ISLesqhDXpujGZb\u002FMnTaU2ntgjwCwuKfUmQP7ftx1RRPeOTtOBqch0\u002FevW7ulOpyUTSUAS3+LNtT7dmI4PcEhgNdGjidL0P3IgcbBCTplC1u\u002F9XXzZY5K7eg+shamAZhttrdJuccNLUkf4XXWrqoxh1+3D6e8HvPOICcb9+VcRJui7Hh+0YOcY3iabKObMubqK3lorQacRw8wHBp3yCWdRp4szrB4In7jpGBMMBac7wLPuV7\u002FZz9RS+C51hHtPwyHANZkEZk6PNNg0AgHMiMcz8Nn0punAEAyxL30AsdMiK6\u002FizzXV1E\u002FgNyGWA5W9DgyLf0jHRYtkgswFPwKi67VjrXY7m\u002FyddatO9\u002FGC0e8ldcHH77\u002FhhGyqDHzCIGEeQPobRMa83jfwnmPkCygcIpJFVY2SSZaLhNAzorztx+AAdhWe5MXhfJhNXqOSdxVLryrL7cKlbZArEwbwCzMZgsyOZgJBZPrNkqFR8jvySHrGp4bDMrza8MlTxOvE6KgaMYabEEoQ5vGJmxc\u002F193+pnF32ojEIIktIVuhPMRgzEjetECoPj2zZRIBC18zYN2787tNmxd75rmJGueha8cFSGjzqqjxm9kqcu1whByPXneKT3jOn36bFbrRiehflz4pkN4Nm+1HjakVZM0ZansobJKjBAb7eTOv9zqxNCYmqXIAzIbS\u002FLuYAreNgDIRrKXh3gbgaLddQQaE215i58\u002FpejbRLZReC4JJtfuQCHRo7NpzZrzhRLzbQbM6n3x3bfj3Xg3gXQsobYT4Jo86ObaGoqE2JG+efPW6qRNZs35rE0eoBPHz6x++gc\u002FWR0snH2sUxP\u002F43\u002F8TyOECAmCjzfzUDmGcsq3CnsyCKkSKSYOI5FfDKTIhz9ezrLc3TvNuz7aIGsDHOaztrxbQMSSqwdcJSBivv0JCzOBfnfn3nqYD14j9LBD0XStF9pefnywWOwUMUEJoBI+c2x5SmP2O9ROb+c96kuEDcgazm+O0O3eQqnKWjFCGECuqtPDCwwd3i4eR30xt2NMDC3XcL+B5gHgddI4tKAN8xCZLn\u002F1uR772z9+GbKBaW8AbQpL+55JiOF7njl9XG58c083U4422nntUWWh\u002FlLAjkPfrqwlQ+tRlTJultpwPaD+ZGre6wtlrx1AgYCXI31kTjC+V0QEr1EKgNvt6IbBoNLOO0VfLrx3sdMo\u002FzT6KYwdL9g4uVVOpuO3gQTAgyX5ovJ3+wux6xOADnStl66x1kAcGgRYdRh516QEMuakwagpP7TRbzIIzUxFgObC\u002FL4I9JFXgJ4x8AiRd2TPzEH\u002FkAUDOqMR8oFXCV34oRCtEXoEPsZ5Eb\u002FzzJkLMmNSTAiI5ptjwMYmG+rNBzrnQSZ7RBd2aZB84aSwXipZAOv6ydNqLkVGedw8l4f4bDWVebVVzTrS\u002FIioSKfj3HCKLAOEXIuM+65Qf8aPag0AhTH3mD6rckabrY6Ws6k6AiDhyG1RB3P4IAfKvWSDSBZaIlelNaGtV3ktyVT8aG19b37tFzBnPIJkmjGd3TgzhsXI1YD78eSx9umRU8m4EzuV8G1OVPs5e\u002FZ0m9YvRQ9q2+fwaS4eBfwPtLcJgD\u002FViYX781APfzY4ubP48f3LH63+4i\u002F\u002FcuTvD3r\u002FIIDz1cNbAbOb6QmgOJ6LFoAgmzjP52R6Eb08bZ7Xm4c8H3mwiwZFbza40RMMzK2848q5otPdqIlUCKzECUAHcngpyrB56+4AhdNtSj1emgiaeF7FEtFH801m4Fj51H5EZ5SlRQvP0gc89MPMNY7WunSMEl5GT8SrUovkaDscDAAHhvG3\u002FHF15nntd3Vm4mDaYdgAUdoAgsllKWXACxC5FG5YZACA2VC7fpFBxrcqFep5fP8kQxuAfPrEe0Bw2WSJpqQ4cl6MoRDAJnvRQaQX\u002FzRqE9aPvHl6dAFoGaTR3Fbzw3BjlDotdQoKdLmIp+gnALaWU4VRfiLa5WB6sGX\u002Fw6s86sdKBT2aDittJtpbj84\u002F\u002FOD86tPL769++PGHOQaO5S1\u002FWpquk5SPltJ5bfTdnebRab4Or7p4vs2MtU9e7M6l97fSdVe+W4\u002FPKo6wlvd8+DejsD4fz\u002FEIc1gDaz8YIt5XnW5SWlo8RjwshNYtJn4gWy5dem\u002FWzcFb1mUj\u002FiA3gEwGMfnxuGuBYtjFaZxLlFC+uWjeMpf4Z\u002FRdbeNBdLEYzIvDhfcbPS3OiNax9\u002FTlRO3rkrbIEzrSugLi3gPIaBK9WH\u002FOzkWmRhcRB3kLQG+GW2ASMlCVGXoZ38OMIxeTUyI0EwGoj0uOOnyV0yP8pxIh7MmwHSwZsZhT+fwwj\u002FZETuEgWRhoymFSPocH7S+EsT799JPBEDDoo0d4bFlLxiYcmWicql9kvjNITuU4eFuvtwbULd4yyJ0R0CwSxEDoC6WYKNYdi8pvVEChIDxM\u002FLr63BbPD0+4KgiEJAYTwrHQFo+QRpSImOV0ruL+nuVF0ZhYE7WENm5OWwhG3xDX\u002FhgH0QHnLLbxxjbhPar2gK2EUMKFV5DlOEq6vvI22txCAdq4Ktz+8oB0lCWlJlkxC4wA1hJo0VRjKbxcW6\u002F7wQgvX0RcbW4jHJX40p4NNUMQLfTdFMWJDjA6dgIJpBAjRqWyKMuzAY9Lhdac4GfDLOYBLLVb11KO1ceN6S7GnO+\u002FfypP+8aM79e\u002F+uV4ss+dORkASWAVwgbwCKsBTt0sZUbeoFqvO+UyTym5xrWWPN8qvWU7QIWplYJSP5tA5CGZEz+7byvhylMuZ+75kzbt1K\u002FXKR1zyvvcpM5vh6g8SNCeSAmeKFKxUaqMTVdT7qu1++Gnn67+5h++yEt+rWOVv15tlJh+rKVFW3KVn5busy8AxfNwPaPFdZjcXMjLJad4jNQjB0h5WPa2uRLgamVj9uY6b5F1FS47fPS9YcjFOm4OMGnj2C5neTaK5FUfEEsTxZb+9X1UOiBqAG\u002FzGEl2fZ+3pqxwP7yPLcsoo+VGar7\u002FfEix9CHPLSWx3Rw2\u002FNrwBJ\u002FyUPWuiwnOqa\u002FeN\u002FNhffEZYa4UmBPwKPcu6mtP0JmAWTzXYX71qda6B43olxCedruw6xcANyPreX29jK9rRBeWdJXFU6LjoLt7KZcJpweklvG61r09uv7szhNlhOfMy7YweylGs5ExAav2s8NHBjME3F93AqBDR4D0x1Vg6tKUZ32qj4daM1WE1kuJAIjtCTgWz9+\u002FB0CUr1m+NeX9vMYYoZTYw+TD7778cvXTP\u002FxR9B591hdpG4dLsxDZu95mRkoXTcqBLQcrCqk\u002F9U3Z1hNtysRf31\u002F9rk8BlPg8wQuobMc\u002FPPN2\u002FcuNNt9klnC535QkuQV4o0mATB4nWbHU95V2kGIylzHJnFrbgjPayUdpGvKyeVjdo9LQ1H1fZnbW6GD9deBGsxTIUi2KsaTSjyoH7TNJnqALSpzi0ZbUPCkynCDWbau+OzWRJ9zppubCoUg8fZwm2hRB4m2bMqTRFx4hL7woLzT0ajMZkDwkz51kOH2I\u002Fx8F6F93KJEIlftEyJy\u002FIC8WQNvpN9lvg+dmso\u002FT5vLly8mvD5LFGewpxIflwAPlvO\u002FaNUdoV\u002F\u002FMJW+W+x\u002FtUYOepz5jvXbIWErYXKyXluiodYb8xfffX71fVRcpbnh03d6n9Y1msYhDz6Gs0S9nylopUSq2AHf5BmcOP\u002FvxT1aXPvywdSnam466XfnJ10+rOhUN3dmUK18qJwDaP9LnAMJ3Mwo2M15EJpW5ZR+OrhugHjDch2cyAOszZ8LwGrqIFgDkhT9LIWhupT+IIt+5vYCrrRcdXJcsVaFCfjd5S7fhO+lLx\u002FJU85Y\u002F6bAW3n5zJNp6kEwgF4duREvJhp6VPEqU5f0tPSh5Dujg692I99HmTUleUcKHbabl1DIWcvHVgeggWTbGUTaJFCx0vnhCm9X5Hw0FLKtdDmhNbnJ8sq89arlyhpbxJznOkPd7xFvfLqk6jNQ3Mqz+jxxF341jb5ErpZGdxUL22yB\u002FdF0udQYRY2+AfSvdHHJC7a8yjU2XYwCSqS3MsQzEs6dPLfXry\u002Fe+Hz8\u002Fj2YdFpiAyIl0d\u002FT7J598uvo3\u002F\u002Fpfrn7wwcUiBK\u002FT3XfTfZ3IWt\u002FV8YdJ6G9rp9Qzx9na3k\u002Fba7c+zsPjx6Of5naM42hIeebDhy9OX+T6K23K4F02bkZQrSv+IQuS8MPTk56Ww44sos94fqV8oRlnEshEoEfMDXqWPseQxz\u002FkA4fou6XgwmYcYviZEfek9xxX5BgDgb4cQ6D3eFlZRkQB\u002FJNrDoozbo4IRrkXOYYmjG\u002FBbSq\u002F2OMk5VRa2vMZD9qYPO9oCC5kEPtM+htHwbIRf0mLRtOq23imdCZ56TzkaznkpDwzysY5UB\u002FJJTgHSNcODMkgGXlQ29L6RFYZxfT\u002F06fpXPMA53QdGXC0fXDGM7yarBg6H96NZsI\u002F9hnU1cYqtWjBr4wS3n2nj59rD83ber01oG5BKARCAPiefKa8IULaBg3cjde2CXbtgPMWmnXFAzLgoessAAvZYmlvNy3FgAnv5rKFz\u002FKlFGIkOZgWhdAR6uKR5fFCHI6VXjxDNgMdm+u1\u002FSxF6HMhVvdGtz3vjUe3Z\u002FCmv0oBIAxgxWJof1IVjCYCRLCULK+X0DnC9P5VC2rsALtNKS+z4hHshKK790kESomoNXwAIOozypHSuZt3l8V7OsLfKL\u002F2fCedArGYlrdMyghCJKylH5gHnkTCZvP25uq3v\u002F1tdXJvrD66\u002FGG5ucvR47\u002F61a\u002FKw7zZmlBMrNbC1DGyPH3ePZt+nUrJmyil4H6A2Nwswi3lH2BrxnuWsOlizNj8MRVgSK6U94GAlPJwx2KAna0lj493rWZ7Jarqq\u002FFhBBuFjibEbIb57ptvMlyeNNZ3WoOd8vyqtlAd5l\u002F87rtKN15ZfdQGwIPtkj\u002FXRh0nspWNU\u002Fh6CXt\u002F8\u002FXXs77oirge703ziGEIeIqnrxJiKcEU1d76+eqojWttTC616EFK5vuqzrxTnunJDAc0obSk+WTA1f0EOq8rAJQiQwetbbqg+V+MHErCUdaMt4Y4dLKdwHn9hqmNfjyaKZsuezMfcF00Q9r2gs1txN3920ZWBh5GB9yBb3TYZX0GGOENwLP2GveAFQfw9KqL87k1WwxFdLo8dwHN6JDXf+G3yT9043TOXgQK1zi6rxvRsHn1t3X0r\u002FZ2gbo2vR8Orw19W+Zh+dx3TUdt1V68MmCgnfE2ej3p53We9INtetzeaV\u002FEvaerGzcDZY8yXhrb\u002FsPxc4M4khHGE7mesLUO5IMKJKotMKgJ\u002FpmJmd8AsXznhLe9H\u002F\u002F0q9+U+vLZ6s\u002F\u002F\u002FE\u002Fych2J5h\u002FUpja2RnGKpqiMpKYz2nSQiePcD8QjvC8Mzt9\u002F8dt4Umj0WafQ8S5fSM7YsElAl1ISXU8oOGUO4AImaB\u002FABiylpKBHypP8YHSaW6HSUWDmtUmnVPaVbkA28iAiD59ZWSD3EedEMomn3SJZQ4AbKKVMGfs8VDxZgA7DlQyVPkJRSdfTFh7nuPBSSlKaB28Uw4vRIT1GmhiltNNcb94OgJBZ0aGf4ePu5UjZVYxz2mlVZh61V+VensMPAsO85SJb0g1nf06gW3\u002Fko1OONpSjrbPJObqAgjycbENkDklS+x24mVSJZIXoKGABiDLMyVge3DNn8qI3D8A6MHlz69bMhe\u002FME2XJa70vIwYxnt44m6zq7Ic863PISkb5sTzVx9Ilp9q\u002FIGo6oezWSyTO\u002FB4vt1nk8VnyUpv7W9N+DWh6971SFg\u002F+69WlvKG\u002FKBXv7\u002F\u002F278pTbhNf4xQ5etZzRL04bxwtz8kyfAs01y+ldOWWMwac4eCF0wb4tkxJzXkWQ4uu8seMvXrajFMbEqV9iDIfLc2RISSdxRHx6+ttJAbUy+nOMl495YQpHRKNcXLha954Fcts1NwuBWPKowZQbK6Tink0TzG6fZnx+gyNlx5yID7hgNq3t6oZ3TeRoUA5wxRgYyBKtTIaOp9z6HEpQAyFxSFkz0KezJ5vDDPsNzKR\u002FOjj0TueIbXvFUDdf2geBiBvyGngFZ3iJx50qXGKEEh9ec2RlsIis45n5HOSLQeepZ\u002FTV8ChevZ1s\u002FEF0ESRArOvX0T\u002Fz6t3f0td7AzVxnMnut6qY0dP5ISrD\u002FLR\u002F81\u002F9xerv\u002FiXf5x9v736\u002FpuvpqiBfPWd5IEDh263EfSL33+7uh\u002F9f1jk5lTRj3NVDjpeJMKGXofkOJzqQXR7\u002F25Oo7DL2bNq5suHli6ybMwegz0QTl\u002FS\u002FeTLoxxyxjblqDMsyFg0YUOx\u002FTkiZdJkRLDxPP4l8+j83ZLW+BK4fbe+2uSJni0EAG\u002FSyDAykcMBwGXAAuL2nYjm18nV48AvuUPmaA\u002FNinjSGxFCdMh5ysknJTGZ19qReZyLk8KTPFHcgyd99tHFK55DLkiNMVZnptjIOhHG+uQz7Ru\u002FcdnzaK7sf5tIQdeguyVTYalexNvNoLx69fuueVZkoWjrhfdaEx7vZFpyHvA+0d\u002FkI8cEve05jB1yGL3dKtpmHBPJjCei3JHj9Jy5T5PUfvSf3GSkkUdv6\u002FXWgLoDhgxuV5jwxLDeJxwzzLd4JIRgCWbC1kRQ7l68YMqXUQSTS9ZnQhkW1nUWCEPKQzoRoR8PcC2eKznqbdSBTJq8oynRYMFcT2EjOC8LLYxicRcgtuRWsaYX66jrMgLGU0MhNtna9wMYyanUN4wql5JQItQRTA\u002FuJ\u002FHbWBZQkpKtP04mI\u002FSN+UgCh8I80jhtzNoTEwB58rr96KcNmDfy9N2PwV42fx9\u002Fsp4iOjV5pd9f+26U14M2qTj9ynh4\u002FIA4JwYCAH\u002Fyx3+4WLS1C4RIl7n88Uer6+WCS7M4kDd6\u002F4GEdeMIO0SUzXmeoiMxw+wXyFp99d33Q6xTg\u002FRA3sIBjQnYBOradmsWoRIkUwe+DVc8Y0fLfXPQCW8KwZvYbO0CuHkwsE3dycvR\u002FCf09jePTio9e+rdiUoYtxSNm3kVDhx7Z4TAszwECJ01fQtY3k6QOL20OQUuDtbfzbxXD8vj2wpY8fL30JYAesU8ifU3\u002FXjdQOWuE0JbrQXj5HRH1PPqf38jr0VCWC1vhyDxEo03cYTM4q3ljY5Ehk4beiOLXnpO+iDjAdDuea3V0Hl\u002FE5pBnFlbtE0Z6Ru29hpy722fDq3w8oSPZ44ILCEzFQx4g8YD1twxAufu2jKXmvR8m192SoNBR+bas\u002FDM8EtzijakD+g\u002FfqzhPvP9G+9AbVDWhA+w6oAh\u002FEspAvH4jQHtb0YCYQ7QLV51\u002FQApFm\u002F9DMgyaGv3Xh3tiwnld633BPvhPODbhbmVUlO14cH9QPqNOwE6m\u002FcAoOaknfYbPHp5dqTbxmjRe3wDlPZMwlMt61J\u002Fh3f6qDc9r0UBKG3ytq\u002Fj17\u002F53eoP\u002F\u002FAPVmtnOlXySQf4RAdCvE8CpQTtjIfoaNxK6xkzRfROAvpMSuTq91cCwp3+d+WbNx4unqG8Ut1rPo8WFVKxA82SB+QVo4QCEa6VvtYMVEkJPQU4ol\u002FgAlAHaKztAj6WdabUACO04DqOjIn4kA\u002F\u002FH1nTRautDrpanByASrn5KX1ycLxNyTnt2ihO7gDnCx0FYnqutbQ6niFKIcRuDm7dAthtEKXAREIbVxujrGGPbMTNfe0x9p\u002FGz3JlGboqUpHN4zxo\u002FqVpHK+qkvlwrRr4wDhQKTrw7nqHw7SGFDVd8O7rNok3r5779TdfD8iwl0GKDJ6RZ3vvvlrT6Qj9CgCIVJyt9KIQNnC0GMwLnTGMGNQA7iKjqriSIb8ccNdcBsZOnXonGXmqteKBj6dar6MqmVTFiwwbcNG4VR\u002FjgVWlxObv\u002FW94AV2YxY1OmTyRA6IAUWUAo+PHvy6fPWOnNaMztmpj43TVxBqvCO7+aPRZ\u002Fd+qHYswPCmayyPcPdYBfaCbbpn1YfQtkT+RjsB6coLsBLpFQhn2IzNadxHsvVWkeVZkav9UvZJyxBiTBhR4aI5tuGekisIcrWABx0xSOnogsxjy+J88pZvSEqXqoKcxskpH2ZMDhOwVvV6qXYme83LSk3QTQ7TPyP1omBedB7buNgecTLUXr49DrgUemU22JavQBUPZOCfi2PPNC2CuYgfaxaeLHFvk0ax696L\u002F+bxriB8pgHTug\u002Fs9eNKLqoTUhs0zZ8+3ufzHgbMzdUJFNgeidapr1V\u002F2tF\u002FlVYeuOdXYWQxf5VBaz5DbU4d5r99ts+KJjD1pLLzzKoJ5xot9zwewORPmk08\u002FndLJX3719RiA\u002F+JP\u002FnB1pvSvvRVb2K8aT9VXnpQqNWlGAc13cqwZI1DJuOftFRVwOjgP9Ivap09OhkeAcu+lwT786kG44O7wMY+5g45squZY+D6e6bI4tvWOZ3mHGYT4THUToB3on30y6WtRAN8t2QxNS3fCLxOxa2EAUvQq5Y2hLULPIEXjm5u3B5iSDYzq0YfdrwPGxdmwi5nIEMa1iAKMAqSjY3QGf6EbfA57eaZUzsGC0ZJ+H6jfUnbgCcbLkfS3a8ahEW5AAxyTogQM7MOPRTkZ9+nWXvSjeb5zx3Ok+UiJKvJWX8j2U6Uay8wwDv0kk6RkjcEDG9ZXOlBGgn6iYbKF0b2dbmMkSL+8dvXaPO9t\u002FPPWgPqFC+cDTg9nEQmZ2GQYndW3E8Dz2d4mblk7gJaS5kHPCk0DAGCECSY1edHDTIJJsejKG036TBPDEmTpDEMCDjEt5gWUERaQ6bVYWuqkpyAS7vKaWM4mF7Hb2LTkLSWACvmxhAhyBDUeqNrTvzh3lMB4UgMLnrHbT0QINLD+CTd92bXwKG\u002FeFOE4pX92EnRC6BS5MSEOtK+cJOV5QD3exvO4UNnVK98mHPeuPv70h6XCyEUXrv8u4ro1IWohKvm0PHc8+hcvXFhdunw54j82xA7sC2cLgcnRVx5Jzpe+P8qzCKR7\u002FuNnWYkx4dNqDLNi1SPXN3Woj1RrPBbqeYXCWwe5lizOfBc9I89zc\u002FUksM57ZvPb4wSPMmxrCXUeJKUG5wSgZKywrtfLnv\u002F7a9f7vs+aE+NlaD2tLuyf\u002F5sfD0A62HyejIlPBx6ePVJm6sHqyMlI1Vyat0CMUDkBhoaAPwbB5P+mfDB3VDEKZ4BogI7rmhX\u002FQt39hOup5uVchy85Ov3mzTsxlxAaOkoh86yLWnSYEsPMQ9AM2gWGJ+0ngnttXXuStBeCEw2aS8\u002F0t58x6hI8+u01HgZtdR\u002FhYY3B8C5tHIxRoeqe9zogWW4y4CaqwjjybEIXQDZvlK0DGF4dakOy53p+PwTLApZ51ru+4aNnA3CNVign87SABBGSxtOYJ1VJO\u002FrEAGoNGaq7PxowksheQ91X473ZBfVjnAfU5gAXwLl599In80Lx4885wbhw9J27No7ebY2LevS1UoKHjmXId8CLVAHRkGcBwNCex9WOEDUAenC1WZ\u002FNK0FJAcmfBioBKIYxQf6Pv\u002Fjl6o\u002F+6A9H6Cqj6mTSr776ovm1iSgQPaU4yaBWsjFRWvKdHTd\u002F4fz5aKroW3R6M8OQgf3Bhx8mZ+KDxk048\u002FiYa0blyLEU3gCoZBh5Iryvzu8AkqZqIm9tkB2DqHUlP5rp+r+IYrKHBwvoAWjxJK+z4+elUuzW9CUvPHc2WTUvaEnNX8oNWALatTvOhtbeUsy69e\u002FQZ+1RPDZdPs9BYM6s5IcfXh7vk8k2t2fP2mgvVUW\u002FUnwpNfSvSpXSj3MyYUBDuoW66GSCdTqaN5bHCic6ZAYgBqR53NyDr\u002FTZ+KVymONJa2odyFIy\u002FnQpCLx9vGzXq+70SPpGc2N+ltSW1iFpZPOtWvTGK13mblEA64F2ecPpmtPl52q\u002F8vtD9w\u002FXAmLtc+GFnjSL6MvcA\u002FjTl9bs0Dh60HJNNSZyFC3OOkc71oMxPU6dnvHxZ5\u002F1yHRAcvbv\u002F\u002Fbvx7hgBKgQc\u002FTIyZwdcToQ3TV01+Tb1\u002F9mOlpZ0on6o1drZDRFi4Ze8pAnEeb60OLopKn8VL\u002FqcnMvz91Jjh2+kqzRVxHQF9HZyOIx4m3oBYjbj5NsVxXLgW945vDBjLrWdE8ed+UeEcuuJ5Tco1fpNvRDZo+h1Nitp7nivR2A3uZKYo7cc3GP6nlkF\u002FnQzWiqz3lMVX5B4\u002FQo2bEdHy7PIZNcnFyMJqciS9\u002Fvja7H6WEx8IHIYJ9573k89zvJYfPhPuVmxzCuE5wQhzJErI3SqWrvHyl69dM\u002F+Gz1p3\u002F258PHd+5Ur7\u002Fxb5xWArrI0p0bOdqao2Ti3\u002F3d35cu9WHR5kerL7\u002F8JuOxdCnRMgKr506qZ+un1\u002FYlvKgf779\u002FcbUR2H5YdHa81D2bnsJjUkhfhCN40\u002FGWqJfIrtr2TilVIeXCe++vPk1e\u002Ffr1F+WwO3SLQbak++KP5SyW7Q7xurH65psr3VMhitLYTpYKLCVrNsKmI0eOBBw5ppx0TqYAo3iYDBMVoxvgiZelH8Iy5pUMpLvk7gPA1h3dmlsA9Nsr16pSd7HogNOJRchUSUmvxrO7hkRDJbBrr2hWL9eRe7MHzjNqfwHx7e9D\u002F00nXmXcmTO0Za\u002FE8WQgbz55pQ+cTrAgOew9vic\u002F3UunwXTAsn4zsj2Ds8I+yiXtr43C0QA8KOogLYZ+PdXzyCf9FUWVBSHNb3EAFLVqDu9OlkZYztpHipNZ0TyS76\u002FjJREgONZ+qavN09t6vTWg3npEBAdbrKzECNXEmMw55roFAhIJOIMz2UKKXsATIsTsJhEIM8G7ITQCYmq1diNPOIEg1DvAKbJHWHsjNsyKiFQpedhmFDlVPqNMEdlYTU0oS+tg4Se\u002FCS3MPD\u002F1VZssJWEMBMrq8hlBop21hCTlLzRNlCIMipOnAVBYgHdCJ3DyOA8SZnGvRawrMwesOp9ROEAzgXi0\u002Fs+msrwFx4+fmxqgjqa9vXljNn2ei+GdmLWRJ3h\u002FOdeA\u002FJQfq31Efyyvo1D\u002FF7\u002F7zRC\u002F+TP3FODFSxcb69Hx0q+1Pu+9f6lnn2kcz0axngms8gB8+93VOVSG90doapi1DTMU05FCnPFXzNwctflvYZbXhbnLN+1aJ7nZpHSYMCxXUq14TuxX5YrvCbSr1XywPgKcm21Ws7nlVOkshI21sdaPm9OrV65M20JdogUY7kAGwP271\u002FNAtS4blaZs3oWsrefieWy+eVpq2+bdvQllSmyATGsjr+95AAsDO\u002FDm888+KT3o2upaAk76BaECNPDCPpmNjZWFLDeeAuFdkpOMJqzX075\u002FFc3ot2hNkzw0TLGgfy99MvczYa35LigGdF1krwNeQBOEi1QaXhugwi9gOfavLzbq8Q7VQuMZg0H7\u002FfhsSlAmFORoe7Swrn4CYQtIx2cUrBSkGkaxXWgelu8ZMkA84M87WRueVYeAasrV9TtvvltLgWt\u002Frus33iLAeBq1p68Rtv97LWOZYXWtdoy3u7uORyjQUErco4yme7fvdXpfQKF5ICQpwT2dpxAEqPxn8xhPp4WLYjT2\u002Fjycx3O7NjxfTvjBA+QBpdzmyc5lsN7KNnaix3i\u002F8Mp\u002F\u002Fs9\u002F3caqC6sftfb3H2wmhJdonkNeeBXNj\u002FQD9dMZ0cqtApr6CYiTacfWy4XOS4LueLBsEqd4KFcbv60PXkQLiyGe\u002FEimqSqzL4Hvh6xY1pnCaja6z1xbQF5IfICkeHbrjUlrPhP8FG0\u002FIBjv1Rjpuw6Mfo8R1OXW03tnOUxuZ4oNiCw+NV5NvIw+0R\u002FaI0cZt5Q5ftGVI82BSlELgFJV6kxrTCEu3icn2OoHTxPl6TrG3fZr42+dojlzceiAcmcqwgSO36kW\u002FOnzb+SrihU8d+p05zQxjubxWaDiaf0Yr19z+ORFedilvwCFXvqsAtg7pR9RjjybT5PzNsjJI3fStajctWtXRvm6h8I91FqqQf\u002FZZz9afXT5cpGb69MP800Wffvku565pNwoA8l4AJR28np2YevJycTgaX9B\u002FZWqJyIJwOHG7fr3nDGXnDued+\u002FzP\u002FjxePTM5Zdf\u002FH711ddXY4doPVnMOfDkic206aZodjYNNt8cIPTi8F03itKRIbHgIh+aUzyPTqW1WDccHamikrgKX4KA5B3jp7zoh1IfirAMP9ZTxn9ATPSRkXss727LVDpEa9AUq+KxsVFlDEZBjfsBcPTDs5YXIAwYL31dZADwP92fS4zbj8fqEnkHIM9PHyxg25cjLpbxzCBy3pFRI2CajxqZaKbv8OcbB8zIq9pbIteLs2FOlaxBINA4yVOOInrAuF4VoeOIYcR4vj0tHF+3bl3r+yqWtYHzkEPSwiwnj4cPkiHnTkfX6bEnj0pjOpiOLv\u002F+VQfpXTzXPpWi9qfyqHMY7FTdxqndc\u002FBRePR1xpAUsro7KZafffaD1S9\u002F9avVX\u002F3Vf1p9\u002FtFHs0FVCckn6bvvMz5tlLx08dxMFnq9mzwBeI9m2O6N9tA9b7gZlnUAvD5qrxYavXTpkmms8MLm7OVQgEGKzPl3SyeLR6RD4YuD0ffReMeC4HNe6MsfX65tRl9yLbAqxcUBZ9bOAu\u002Fpcg7HkXPRExlxt75yAAC5DhTCtyczxvHS7QAsIM3jDTwvqX9Lfjdnq\u002F7DefrFAEdUcMRU2QsDcvzhM+uvC4xmexLIGJ53oB5Guh7\u002F8nyfKNoqLQjmu3nj5uBJ+Otc+\u002FnInwHz9dOzRO1gNS8ynXz3QzbBXxww9uDcTheJ+IlMTN86qAr96xGZe\u002FbMmembfQNTJaa1OJGBBCs53AlPw6f+ll4rHe9tvd4aUCdUF3Cz5J3xRJtEC4D3KKUJLTY5uy+Mjgh3AnvCMJu3VOBYPEpAgLyt3WO7MaFFm1ft8cLyjPLU804gMB4sTKvMEmEGbDjenXLj5eIBWSzDJawrzEJZuLf\u002F59kWZdoaAUUi9UU\u002FuwKK5XWw8JjNTePNivjdAyjwnk0Ip3EBaspl8aDLfaZwGSqAPoU8OVq1K0yjcqpqCZT5O++kGLv\u002FybdSXTZXhwu\u002F+U66i9NFVdXYVzg43N7WG3MV07QJSjWHh42HYsMw+nd783Zz2obaFK+2T8XcGykLYWoEbEy3ugajHSz8aTMeQMp7ZaMdbjpoA0ie3RfloL6MEH3GCyuvmrChXA\u002FEgPflnFbNoMZSHIuXkA\u002F30FjuWewJrucpjnt3efC2Yoq79ed4AqANgClF4VqK0\u002FMnBBbBm0NrwaBZddrmvoyBx+3C31PY19qhn6Qynh+PIQMIOJWH7RRGHlIeLKHKn\u002Fz4x7NR7ZNPLq++\u002FOr3q\u002F\u002Fwv\u002F3veUlvtx6Lp+p4xoYqOgCHdgl1lQ3QLYXBINw5vHjcCDIhbPQEaBMQBAFFO7nl9VlZLR3joQeEXTcfBdCWHkej9Y+geBn4l2M5NcpT3Iw+9D8HA+Vvp6SVZwwaj6I5nPEwFUsMsM96\u002FCiuodWu2gXnlOPMSQ82Jvd7AYn66b9R812nL\u002Fo3ne5Kn\u002Ft69Cbh2Y82BrQ0F+P1ejPxA06bJzeIoswcxD+TamGOuq8nztMikMYmGvMygytvUwJf1B2fTNnGvm9Supay7gE8YrV8JO9WzYwQfJpHiudqDAc97dk78Tqvmk3NY\u002FDbRNyGRnPz7Xffrf7L3\u002FzN6uMqNEjRuhdYPxJfraq6ZQjLPDXHntQ8SDGRP+pE0skBb3J4mDYT5FevXh3P6Eb5zM4veNR1vDaeSx7wZp2Jv4RNVS\u002FhAZ1okvnrWXhujKnoZdYmmp15jd7N0hK6b32tVz94U974Ts9poLWgFTNN5iyVIWzkNBeuZ0CqKw6QcDgANsLgKjPYk7OVDCErJi+5dQTsxivU\u002FeiYAjqUsW39J2WpOWEoAAwIxNrmjut5+mI8Abk+O6RKzoZKB200q49ogvHjkDRyjxxW0naZ68be7WQVsGAD6hzClkx\u002FElhwUMv1778fRbr\u002Fg\u002F3jgVf\u002FXqSLEW8OH5f2xnGw5LxX2\u002FxWnvTS\u002FSh+6Wvj1atfdyuFJ29b\u002Fu+li++NzrhTvXbVbeSikjcMgAN57gCh80VR9iUn9zL+ozOOBnMxpftSxlIFmvrAwtHkeuV4mzNlDR93sqnKXcDmkb77kz\u002F74yn1eLd1s8GVvFIKts7nja3eeh583njLibcnMmRC8V3PZvyMATafAaRd2PwPgVqC3jF+RWvREx6QMrdvf2veuPFKj+q76Kg1epmj45VUs3hvO96bDcqqajVGByQ9fpS+7fApqSWkhFH7Vzvez8\u002FuP\u002FVjPOy+S5bMy2fRp\u002FVFc\u002FZQAcwjY\u002FpuyKVLFyDW58B3PLsYyb1vQIbn7\u002FnpzpqZzxZwTsZpewHpk3bnBs+oHzXVK\u002FrspmVPwHJvwqa5YkSS6+nj+APA3KrS07Wr32Tcxc8vgFhpqFVoycB5nsG51oGDnGKHOkn2RZuFXz8tQpRO3etkzwPpiXju2nffrPY3X3t7hkMMlYu1DwFPcTU8LnLtNNrj\u002FXAY\u002FPrXv+nsv\u002FbGZWA+TXdKv5vU2tYOPjh69GTnC7yXXHyw+jb9v0Yv4q\u002F+g6WOHdvos4V30OxGcobMEfH+9ptvh76+z4vLUD9\u002F\u002Ft1K5RYhP1051uaJDCJH7tvo2N+Ot38WgUhjuV8UigMCGDXnQDGZAsSvZ5TgUbhmznapb6K8FhQW4nk+XzYF\u002FEY2OgwJyDYHgDQdQDYxwE\u002FU58lJbw1FxGeDamsBvynigV7pw3HA1RHRNMVCeMcnz7z54vzEe7Ih0JLXiyJ9vOOiNEAy\u002FDPRzPo\u002Fm\u002FGTc\u002Fo\u002Fn72wV6ZKPtEMnjN\u002F5y9cWB3JwDA\u002F0iWlHpHf9jEwqmFJT7oTZmHkKEfqhT\u002Ftf5m0wNQVBxCIdLiIsbK2595hoLyd11sD6lerwEHg7npiEKADByw+YuBl4jGzuIDzpFMkqDGyRVZShyf3UAssFINYeDEmLNN10ldYVDMZiCaBrsYlReFzosQCyU12ZDWPOU+3SfYdNWmxgL6xeiJ438lFsmqIaRQogRfnj4epBZE6AOQ7YUs7+kRAUxoImCdxFGrEq\u002F+A5+Ltjxki4tZtcrkwik1wI8zqDetZmH0U5dOkhLMAAEAASURBVBulbcxqycrp5DlxeIKQ7aMIiPKxOVWOOA\u002FQWr\u002F31CbPP8YhnGKbSbFBRojJ7\u002FspI6kjjKTn5bQB\u002FLwMvDnvVHbtyFGlLpvDg0vIB\u002FF9+eUX1ShvU1Qg\u002F0DjJNiEZpfUkJ7TvCbfmxMRjgB7xsJmXvLHVeE4SLgFlG3YOVTuemV2Gmfz3oldzx5L15GjmuFhLK2z6jxAgKPc5ZTxpEsFwsQiKCVCDUOxdDfL17vZJp3TedUm\u002FM1jj1n7mdrejddaUnQ2j6Kls+9sVKLvj1c\u002F\u002FekfTajxzt1brUNGD8pr7TAab4G1HUYPFPOQ8sxLQ9kVkjz2hOnumQBLKcOeHX2MoAFMGu4ibKKn3lj7bomelm4NmOqPZZMohdQ10S9QTjmNtdGqjSfcmAaI10bvJyWlpuSiK7km93LA74B4HtKe3bin7a4zLXWpz3lleeaZTaYmY6Nn6ii6rQM9h1Jc6N9H+tuf\u002FVC8fuMBv+39SOmh3YSYsY5Wr89kN4\u002FJ5O0NTS4hcnw0gq718B+IMd7vwIKwIoV\u002FrNI+hKJHb9v42zMXRdw89qE1xndAASC7B4BqbhzgIq\u002F+eWFkHaQsj7d5bv0oZba3Q8U6RKRDQb6\u002F+u3q17\u002F6p0LIf9nmqR8N7fOs4MUamnFNiL6\u002F9RGf8mwpGyhETqATvEfXOzQn74sTLs+dq2JQqRPZEdFwex3ynuDPJ3nieWHx1eHD7ZcpVx4\u002F84T5mRRAs2CBZnKttzWlrJrXxifk6mU+hcalFN4pJI4GRXOm+gn5E3FR4BPZaE3J0OW1M2kp4+1OxlkDhg0v+FrODRsIPRPgleqxRBLrR\u002F2ResSzaM0nHN0ak3OAr3ngUQ96j1xEV0A6eS6Kau\u002FGnnjf3GsbfRkmI9VELeXxhP9VwCky0mdkK4AsZQ84wPfSop7nqfNcaS08nGjRBscBp41Z3fS1Tio+mDGkDKUqERt5vHheH7ShVUUexuzhHBDueV7+8dNn9\u002FvMeBjagEm5qRHY6zZbPq+87t7K79n8f7e0hzGU6ymeR3do02ZScms2CTMCk01kjeo55v5hJ6S+KlLpxMoaGyfL+YvnVx9+eHmiiN9+e6X2lxJ7a8mXF23wBLDJdAbU0MM8aQHIg0AtqIfjg9bEGjHEsZL3dc4V855MW\u002FQW+dVnaCn+V898qmFVSqkljGWZ7L1Jdu3BT\u002F2u8elzqzjrS+5Zvz7t1fvezKO86VNzOt\u002FUlfnIWrfYwPf8jh5n82zt6rf28fHyVhsA2vLdROSGFd98Pw2Tj0DeIv+kaSzXvZFJ0zPXkG\u002FaIz\u002Fi+7mekUjOBM4mWmGfSF\u002FUVw4BfWck3su5aIP5xmkRJOVKH0\u002F1loPpq1Mn2kRcZPVoTrKnGbh70nWnS0EVdXMK8sOqwNykH6OB852Qvn9P\u002FGhOomcgel+0KmJ4OE\u002F9+bzw9t89exQ+GV4qpdSk9T88o68M6UMHj7fJ8ULjWVtduXo9A6KUz+gaXpFWBiS+c25j9mRIDcNj5Nh7712Ih8NIjQkdXr1ydZyDPM\u002FkjXRWOdN3Sse4R0ZEm4dygsJLS5odp5foSe2Fm3jrvZyrwpHF8WGfh4O5pHWobNRU1q9KFyYn8aiTVW\u002FlaA0NDE2TrWqkw2le+nsmLMNRAid9992VQHDnEQS6GWBSxIwbPpT6gk6k5QDMZLvxoUlAnLwyLhhzMVClC9fX9DgjYXESw1BkaI7MDAayavGeS39dHKrkmTQg1bBsvnaq7ZRe3C8tzkbsnJf19UkRMznwOjV6tIadc8OgmD1EOULQtnKfpzLkhsd6dv+\u002FtddbA+ryFXleBow0EJMvn1QOk8nzWpRt0425G4WJomh8b9OPY98Rl3ZciwgBccSEsQAUSr8AbpOwLIgFjN56RWh9Nxth4lYLOiEQK97VmJziAQYpllcV7x+vT9zi+fKNY\u002FPxUIz3vecag8WZutw9nwA60oLJGx0i8Lyat3hHY2qbMHY92gwUYGLAS8LCbnd\u002FAzosdyCVcMCsrvVb9RZWLG\u002FwyVOLhxsYuzdhpYB6IFa4jfUP1\u002FHysZofBsSBBELLBsM9mN\u002F3zUGTQoqPDuCRtxlVFQabLChdlSxsMn333YvjdR\u002FiD2jwNkkxoRSOdL8Djl4GwgF+px6+SOHzsLMgX7aO9wPcz9ooczTg9Lp1cmTzdnN1sGcciAGkJPEiAM\u002FHC1tZK3MwJboGKJvqpf+Aqd3rPGvq0mJgh9h8WxWI3393dXX5Bx\u002FnHewksiZBjrd5A\u002F7qTWudogDUo7F3Utz\u002F6s\u002F+qLD3Z83\u002Fk9Uvf\u002FmzPGLtYA8kTvm1Do0CiqUBEUpCf0LyvCBHiiTUxWmvFrU6VMdDNX+lwCmibNH6l7Kgt1rDut44eEm9Wb7zZkDxsG7KZRhg5OWsk\u002FFSRH0y900bmtOe7\u002FqqaZ6flje6JjConr7o\u002F30Bj9inOW0GGjh2ozNcu3s\u002FYwJvovPBFzrXW3M+Hqx5DkAyKm36Q2ju8gDhYxzjIZb\u002FmhJ80TyqBmE4hOCAUcAvmhMhmehSffLIujPPXwyCpUb\u002FvkAsGiZEeV54j9F7PZ17HJAln50xrFc2gpqbA9GXPssHBNSfFUrGh8cC6H72VxEDYGFkU2wvMxJv37qeIrmRx+y9mZMlUsdzXP\u002FrH2BmAyeBu93aiS4ZM6PYITdAL+\u002FtvTy523lWLl2K3+rnsYS5sevnlGOrz4D+k+iMYWMhlDrbm\u002FzYUzsTCRpKas7Iv94bPy8OsM4IAg6XF2PfQW+lZXWvvHoyi1wDnEXqSkJp\u002FnlkgZo216aUGNV+jxep51rnI8ksJQkPl8ZG7qKRZcOltdKLPmgiGArCuDzrvEno43jGBwCPHhjaokWvVfNq4YHr5RTB\u002F3ejvb6QaeaVDOfl35cckSdMVto8Pxsxu056kHXi\u002FVc5ikJ0QMkCFprh5nAO+RnjrzFihl6MJAcxLYaGqFMpgOkOVZMYcE5urptTfnWprqISA29aVUA6Q+Fs4En6hwO0TMbsg0CHPK1XltMoD2bQWAvAQbgbqAVmtPHg7s3p9+ij5DJRcaj0yMmBjYbG0SD0fmZj9T\u002F823+b53Zz9b\u002F8+\u002F+w2ryxmac+Om9y0CzZhVfHULdQregiK2Y5Zu26rE93f\u002FCrP3DE8n7umg8BExFNkMZctabNF\u002F4EKl4G1OnNfdG39WZA7W0tgOsuGXqX6jAP7RNXe2lt15Gw9HC3NzXQ5fqLFlxjeUQI6Dp875+52mczzjf9f9N3NEt+Wlfv59ru0yZe31dVFTTofT1c5qbJ1if\u002Fk7X2w\u002FDkLxV00sfRjLbsq7IRcmfbScAB+fLT3YN3Xr\u002FOY5zc39l+OWmY2\u002F2W730vR86JjP0zJ3Mw9dC63E+yoev3Btb3pddeVa3KUfGbpVrt1MZaeu\u002FMqfO1Vf\u002FotcbDi37gSHXYHxYVr5yk2uxnKu96YO1o9JQxWWosL7YB0znODlGq2HsnZx458qAqWFeiS1HupQTpte+vB4rbCLvR6eUZ07sVWczPRqkW9Mg3X7\u002FovJWbs19FOU9A+QHdHO5RfQeW4nhbUpSBWXKU4zEejb6B7nPt\u002FwPiv\u002F76m\u002FEyw2M8z1ZynSOius0wE54gIzi69KWpDRst5SfJNCnCMir8wHNALzykv9rze7IdunOyLTJKyEHVe8gf3+svXSITgeOVd32ht56VV73uDw04I8MzXUOXmFjjJJO1Y7PukpodPbQXQf9twuYsEvk83tocO3ZixvsoGS+aKgVGf9Yan7klC8hOss0pt+MgzgndA+ZZDIS+7ifOefNZHXkrr12N8N\u002Fc2Kc\u002F\u002FBR3NaFtOGpyLByhQYDKIxyF3\u002FcWCtOY1PG6tEi7DGrxAGoLLyQJVKsOYZF5V3gMvXjgdze9TVi1hSRsEJs6tBZmci+7f7yHPRdA0D8CYcmPX54rZN7H\u002FRA2eYnzeLiX4FlSGgiAvug1QiFBRphJXeEd0R6CdVIdL7vw\u002FYSQX7DgEKgQ71LxxCJPS\u002FrS\u002F4glrBfjEvSJzj7jRT6dtft+ueUbG2eby0XpUogE2naADggxN2m78bABY4\u002Fzuml90hC6hhAiaP0A7OYk\u002F1tVMxav2L3y3681XzZt8DptlKtOee6UvqKKzGefflYFGikwdwsnNmcHEvwASYwgF\u002FxBoF3Ix8l4rOztwooE\u002FzI+c7XMN4+GH+ALLSyh\u002FU7sCxg\u002FyDN5917lHEO7LyrRd\u002FBYzPgGhCB69ZMdLNHirq5f21z9w6++Xn33\u002Fc0xEGwkJUUB9VEpwEf9UVscUx3K83yx8o4\u002F\u002FuGH9fNp+aK\u002FK3SVIM6rcffBIiT3FXlhIB6sQgLFZlMQL8H2\u002FcLSz8oHzEhQSlJ+o9A4YW6OxriM5lq98bAMyOn5M2ZL29jRt3WZz\u002FpuSQMBkJZ+oidK0wttrmUcoaVJN5i5o\u002FBqLFvLui+KiBKghBgGi\u002Fdom9epligUIJNh1SOQ19zjHUVdt4e+WsyuiR7y6C3t6Gufubfn1+FaG1bpvsAxodOPHGXryDA2zy86CIsC2crjQkEBq+RjjtWE1CxN7S9jSP5Pu4bVQ\u002FofMLWvI2M1WjIncv8pdf3QHwBIA\u002FsDdxOlq5HngV9+M4pWepgw\u002Fb7Gv34EoI0PS0nb2VHXmcfqVZ70qjVUW9r6vVtkRR3+zcC6+ZTjaLyezVNUiKo1SBz22O3GiQ4YBjzp9xLaPGDyGl+\u002FejRpW0p9SRsAzA5Wkej0qTaWVo3KnFKiS1m6gEB\u002FH2Vs9CwRNl7OMWBalF2wMTTRpPOQA\u002Fc8aGTgosxsTmdIv9t6mhLARsSq\u002FRsZ\u002FCIys+G4BV4OA1nkG+8aJa0ttIg2yNF5fuNDF9o\u002F3JhmXSx6869O9JM8i1IL7YNhwPAQ8oQphei5ZLxQNI8YOS8nFzgfT3+KlMEr3UaTZC2v2Gxgq+\u002F68LB6+S8zOshm0T4pjoA5vgIZ0f2RPOzmRZ4n44bspS+MBc8CnvdzONy9e7+5KkLWenNkUPiikIwj\u002FV8OH1m8cP5WR5\u002FHfivHEhlzqj0RYcgB6jaI+Wx5XnQQMUxd\u002FebA2EQzAJy7pc5IZRhjsMmz0fGoDYalLZ7Ic0iGWffDRRkPByDOX\u002FqgNJg2+Z38q0TZEhnCAwxDlV+2rWltv1Y2ZuHchQH7yyfLC\u002FPs\u002FsxSLX92RdKh7xZZz4DHxiNZgOX5DiAbaTWfAzDmj9OBrqorfb98Fmk118Oo3enp7vPqXx8v\u002F7hhoZs+G\u002FptbQD1+cHj8Qvvs8u1h\u002F52f89nb1qd63svgjZRtDePmNSZ7iUPvKYX0YPxTDva7HO8xOCNpZdndb25BKKAwDGssiZEwWfvVtdPFRG6NHm+VVqU1tEzOoY\u002FYIipn9\u002F6MPJOSLeKthRn2LO20Kla7ebYXjL1948fPzsGvYO79uTAsK4O\u002Fms5Zq8Ng\u002FJElX94xZ92wBV5d\u002Fhwezmi\u002FZ3OKpHmqnyiSOknn3zSd4fjrSI16Um8sVGqqjFZO+vBKSLaNjnh4Qvrq0qVtDabTpVLbKLGyGRg88yvhU\u002F2J5t8b24Y0caLXqXKAuyibv6G3eS385KT07CV\u002FR5TBSX8diB5CZTrz41yxDn\u002F4ByRMekt6IXTUq64lBP3Sfm9ejVvf2Nb2tG\u002FpVgAOSKSKAq5bNBfPOBy4gFjRUCkz3jegQiWs9SBhbz2e\u002FYseeGcXfq6v70EOxl4dK55stFVeoucdLTjmlalOVuAuk29a41tUuuSdfYgXb9+Y+7Vz+P2TTUexTuk2Nj\u002FMyl4FdswvnEom4eMcSfKHm6u7bWafWw96W283hpQp5y8ppZ53icD2KrwNUYyOTqNAPCTBZvNgIg5IUfwor7ZYTxWV+EJgKnvjyXYEWpNjALxmUodhAPCyj3TImZVd4HND0LyL+Uy51HSBoHCA+U5hBIiEdqlxMa71ffaovy0ARDbKDGgNxBoMyEGsciuIdAmZ7r+Ur79OQTJCzWGSUzhZayup1j2x+xL2GXZPOU5iGqEde9dKwJAKDFQWJMnUiROA\u002Fz22bXVVoJcbl2\u002FhmBMIkAwHsaeRQg9wRQR0pR8rIwYdLanz5+lTPfkAair7a9LMPcc5aQIB15GeVlredQ\u002FIVgTUCxF83j58uXVt9983QZVFSTyrDcjyZDxFmBuQAojTj5Xluer6tQeykN6IAaR2nI4r9a+SoOZW+BTePvYbNSJBhKAvI7Xrt2KsJW1yzO3JwV2YL2xL545gsdcYP6nKbvff\u002F3d6je\u002F+7qc+CoTfHdlcslGZCXghziMr+cQ34SjA6UOCi93AJNc9JdtTnvvvXOrB19cmY0vz8rLPCCMWXlAkZr1tWo0Bx7QxFQxaA1GaScQeGrWq7nrIApIjtBgNFrpZU2wcf9FDOh7AczAdJ3yt\u002FXuG4Kd3gmL9RnaaI7qg8OAgC6NARYUj3bm2poYz\u002FbwSIDL\u002Fe5NWNkr8HpOBrLurgfI6qOL5nn1qbasgVxh7eiSPsupBojmGdMmxdVz+9I91uFZhqiUIz8AuQjMlFjjVYX1GhBFOJ78BfvVidpPCcYyw294x4m1wwu1DWj6Dz\u002FU5cVY7Z17unXmUR99L10MTVJmzhqQfjaKKtkCgL4ivEuxOo6uojke507RSXDGszVy++bN1dcZlH\u002Fxr\u002F7l6tNPLsdPhaPzqh4u+oXX\u002FNdjer8Y3zqPrnlQyQ8Kbcectk7ZAymHDNqNnQHqjJTbba5KHOXdPTlg\u002FVjpLnhZexbQHgbj2IrHfL6\u002FMcwZBM0BOTZgqTG7dqJ6zaWTfYVfRbN2vfjkDEcEGQRkLLTTM5pA7eNDINd1DoUaIBodaxNA1o7UELJo6Kv10x8yhSJyHwPsZVEyz5mFjb6d1iftxmEvTzt2XiiGgfM4+atIwHi7mi\u002FP9vfNTlseEB\u002FgIRi16zm88YwICs1L\u002F1WfaHlT8jeiR+Vdz05fAPmpuABANo9S9PavLacEHsigYlQZlz0EN250Imhg+Gi8ab+LCB2gfiRacAw9oEOxinTiTTJfm\u002F4GuvExOYmXlKY7lIcOT\u002FKkccQAV8AK42k5aOXQzMerwN3T6Mi4laMTNR4Q0VxwIpF1a837RhvbNu8\u002FWd3Ux+pmbwu\u002F1Zb+7+oUQJFBoFKMaAVZ4YU3vPxlvuZn\u002FpqP3\u002FyzexV50fsu1m6X9wxtAL+12W\u002FN4vW5w+8+xwPLIX+z4sP\u002FIm8unPbqWZdOO3MfZacFlngPEY1c+kv2kW5ejcXX8RKHlvsXcdQnGNx3PtQn7RNcBIlm\u002Fe6lzd37vHfF3NK\u002FIz9Gd\u002Fb8+qBevnYYoDyZDj2SHjjzkPyCP8g1IOwQ47G5t+bGqVqaCDP9BqjjycExPXBP7SS1AuqBzNZS1bZXDezkqUp05oR7KrUqOnse3zzp3j21JzXq62++6bM9q3cfvLs6fqqUka47WH8nLfZ50bgAuv05HIKA7uki51sT8dsao1V6Kf7fn\u002FG\u002FGMUvZxPj7CmL3valhG8ld8wW3hdt4hglA2Zumgf0Sy47iMhioGm1\u002Fw\u002F2fn+GMz40L+QCHSu6jv9nomuZNx14la8tkr13DzzWqcrt0YqimrtoNfkA83CakBG3N+8078t+Er+1D0fYgEkOwIVPAtVfffX1gHkVoQavtcEZnYpwywFfqxqTvT\u002FuwavW3uojvdnb15jo1+NronxVt+m+8pIGhwwFdeGQaXSjDY4gf4v6idjKsx\u002F5Wdsq2CnUwKhx1gWnDDnFgcBBwFmysZFRUd97ZBFkRnob3GvH2JcSkS+qpnNq9BvDyd6X9RyOIs+7WypnCP+N\u002F0Aeb+VFQGMmikHoBhEBH35bND+UCMG9tl8IhJc54NpEAdQIxmZSfEtYY1CEhOEAbH9PhZc2Oo2Si+Dn2NiYgFd4vClAcUTJ8Y7YeDwIaIDJ\u002FQS5NvQTAOQh1LZnIJqxKJtd1z5MUePpul1\u002FlmsQCNApT1Xdch4p\u002FWcxPux5KMLz5Z1Ja7Hg2nadzWu8LDbP7SoB4d59\u002Fbhnwtj13zzyZk0IPIId8FeHeaJtTsVQhAyF\u002FapNs5SFvLtV4b2XHSYDaCIqoPJIu\u002FsfAtn16yDC7AtpIQj3ZUDZvO\u002FZ\u002F7i8tPXVt19\u002FOcJh3wcfdp1SRFVYyEN05buOBL9rL0EeswzRwYHmoXHzNsjVkuP1opO9ShldHQkcHz\u002FqkJrmuU05yt+pS3y0Em08m8LvaGK9TS337z6sr\u002FLzKqOUQHu9t\u002FzxUmyMSaqNVCUMcTsP1pUr3\u002Fe7CjQ9hCe+kfdfrxZItZI63boR9ABoaxBdPEmA\u002FP53vy3\u002F8\u002FXq3LsXVs\u002FbKLr922+jjUBnexnKMGuNeBasGbpojrrPHBvb006R3d4mxBYaZWjwgqCjIdSI1Vx7WafdHwSGhgi1Zf14AaOhN3Soj4QI4MQIWCqtiDDVJy5piielNm20Vubamg0N1w5A3oDn2kiM3hldN+tbm7sCDuDGd4Q2d\u002FpOdDOeK\u002F3tMVK6xtPW94SlHD9j40FnHAmVvmjDnvxW3mPAygtP2F\u002FB6MVbvIxN2BgCDHTjp8gBMD8mSd\u002F7f77zrKUGbR7QUtDWxhhu\u002FrtOdMkGOfWq9S0OnkiAGsYA8xKdsktfJKi85DyYUhJEduakuIDmlJ7rsTbdnq660E9\u002F8vnqD\u002F\u002FoJ3WxHOPykakGKVgE8Ms8IDagT7ULBkhzzXMihYwCI9Qd\u002FCJlCrC2qXEtJXqm+t3SYhzyxftmfckW8s3aMijMu70K+Nm8HtwOaDLI0Yb56D9Tam5212xJAZIql0c\u002FPgFMyQKyzDxaT+uK7siNiYrU13luffU3BUa2UtCLLCJH23SWomGAjfGWHMOH5rNbWl9nQrwYIC6NT4hdKcsb1\u002FeNt8weE6cikw1krbngZab0rROe3by92SaxDhxq\u002FOTp7nrao6Tf5gW4pwDPFF7392aHiOARa6OCBI+0zfXmSf65Z6BHfSUb0Si5BUDfLxdd5ET1nvWqcCz7GpZyuebz5InA1L7qRwembUJ7FkDa2XnU32o3R1\u002FxGmNsmy6gT7aq5pEsmyoRZ+PH5uhYKQl4bUpfNlZGBzJW5cN5EErJHirlZk\u002F9Je+3moctmwqjg+NFJvcdvLb64utvVp98+Ekpd3kP638Pz+PXmqcb7Ct6WerEGMn4ZPc\u002FD+mFTxf6ePOBv\u002Fvcms0PcDtfuTN+811EBROjwVr45x9yxgVLe8kffJOsFGHyAp3Ru7nTyAK++45CbY21tLRH1rrO89AwWbq80J9+oU\u002F90HKXzpsun99Lv33j\u002FqVV9DRe+Df3kxv2CU2qYQ3M336\u002FeS69MTKl69Azo4BDoUH3jHqUZY2XOIHQjX6TWXiqW+OHos6tO5pG2xwJ+Fc1GI44NHq4NQ01DP2ZS4b2wfQ+nh4x3fpN4Yf4IQ9hp14XaQ40P8pj7gT0Z0V6RGSVRt57PNwQT9obgZ9Ppw\u002FlQZ9IPrXVLppTshSozgFXe05Rfv\u002FSe13\u002Furz189HyiejXgWT3hs+ARXjF2MkKuelAs8g+xyZH6OMAv+ukKXIQOAzOuQcODiO3YIUbnRzMQ4xnyQi4jIOKs4gRv77OKRUfRPdSzfQdrXLwHbyh+EUGds6sha+TWd2\u002F2wYetQdNKhs5ASzfvHlrjGf8bE+YyBcnAiNL1ZXHjze7tgjbOCp7Zs87nJGBh+Ef42KAIzKFSBgJorv6ZY3JSXRhnZG\u002FvokK6i+6ZuCTj2vJDPdYZ+ex3LhxO94\u002FXVnNSxM5VLiEIbUY9cnP1lf0VPu7pVTRlbF6ECeKw6CcLSDNWSRAWu\u002Fber01oL5YaUsIZkKxEfNsemzxhS6AWUrcJAIoiIAic5AFT4eFtghHU36UzgiTiNaCTppDi4CZDsccJo8lzhtAmADDkAqB7wXoT7g14uAh40lcQP6SbgMom2AbToENz\u002FJ+GGoI4HAbRTbfLAKvQpxNyNU8omWVj4LrWca1MDZhu4RmD7wg\u002FAIwKT9tnz59MoJ+dxTRrcIjt2\u002Fdadx54FOGBBplyuI0HgoN45iP\u002FVl5wJcwsnGockNoHonIeEQX8bhcM\u002Flaq0OzgxtDU5wqvMznKbYjzdGkbzRfL\u002FouCTMbmAacJtTk5gnvv1OFFIbJ65T0CNYR0nmPk937Y9AJVdZnYAdQOFVt0YsXL5aWkAAoPeZY+Xin8lweK+y3Kld4Tyf\u002FHWyX\u002FKE81qqY0AHW6fyF7ebh3upkjPSoU+uMT17t8zzcLNdnCWlpQLORLo\u002FUg6xxSutgoD+qqB8AbIKh\u002FklZEEYe7dQaEf9H8hwQtC8K4x\u002FqGSIj165s4qlKVbVp7L4d6cLvMXdGzp7SQUbxWBAvvzwjHfW0nfo8FjahHjkqLNr6elydGK90a43G3EJp\u002Ff9f48lOOwxdv1Esu7SKroBz40dTUiamVj1FXoQCaNTmAqhSGx7cCLcy0lTK4GVACUvoeOmH5+k8WtUuD56+jRKdu6nkrqB8+27K63UtQE5w2kRrk\u002FCL5xktVbTwvFHmXasajnlbi7cOH7Gm9b\u002FGpgZv8z3Hy9cWOunyf+Z5dDbglPbuf6BGvyjUtaIpgNme5sFBXzondzYCmjzTB\u002FGKSiw2LTOgHIfu0JQTxzO8453X0QDQwWuUtu\u002F25efsmVNV+\u002Fls9ckPPmpzmFMtbdRWiWVnNpn+5rcnAnzRXAJ1jrSn6Os72mYwMBIJ9zOdbvl6e3N193lpGhmm+9sgDbDbPHQgI3ypLBB\u002FJetmr8GML75sCDZ9H+lEXKCVgQ3YDOjoGQCo+ff3nAwcPTkhkqLltQK0ySd9eCnNJzpDNyJuQrrkjY2WopWU9Kx19ILOGO3kIAVHBjFA0MocPNNcChcPTScLzR1et2ZLBLH+NI87O8f7eZm8XfYRHMpI5UV1GjQlSY6LVAL560+rdnNWykm81MpxHuAEnkpefIABGJP7z0vJKz+h6OT2APpAjIotokTGucg9+4kCW60PzxkHidx\u002FEVjlzzbOVhe654xR0EPHyEPvraM12Tj9TsZalTW65tkhKQ6LA+dZ\u002FGxzCQeCkotkzH39uVfpxJ5xsgNP6CdlPnn+FzAk4hBt9qInIog2x1er3mfJVnXu\u002Fbe\u002FfS82Gx5qjo4dLxXhi29WX1bB40h11G\u002FlMRSl2tO1r6Pl\u002Fe2voFaa7NYuegE+PWD+sR7LW+vnxwfDw9aqy\u002FB8xDr8tMhq\u002FL5EVuhFt7h+oToN93fXEw9knfUjY5rO5ZE1J3pgT9Aixxj5noSjgPUu8KPF+joRPA\u002FpMxtW\u002F\u002FmZta1rw4d97xKAexmHZ7z50ZnuNb+96cc9xqhfZBkdTw7q0+KAcIXrzRf6J+O88AWZIsq85Ag3x33FsUa+DZ\u002F1XHSFztHYnuTdszZ8iqwoAXhEzvNUxlmehVfW4z+KB6i3mftuqS0Vq0qHJqej\u002FX3p4pd9\u002FiyaPp6e\u002F+wnP1ptqjTEqIzfTufwOi31q2sfPg24tll53\u002F6i+qXJLfneGXiv9o3evXjh3Oj\u002Fq20kpb8d4sW4ks6C56WUcUouMvJNhC2ZwztNTph\u002FfImOeI7JCLnpt0sPe9jfQPq5qsEcPHBxtda5JLz7sNOk72UQcz5KE5Hu4plSPswlY2GcrPEUmWQN7o7BcHvKEzIkeKKvl0Nv3awFXASU3+oHXjtzZmPkk\u002FU1FukynJlnwxtSWKTX3c1xBzTv2bMUe+CE2k53n+KMqd1XRSrkk9soPqcK15YNsuToOE7i1cVR1LVhKI6+xclrM3V6lH7tBz0B6XgcHXMUzj6n5tf4j4UPjEe\u002FrcP92uJUFalEh5MB0iyI0tB\u002F5k1bDk3clyP56jVpMza8d\u002F7NW3qZ9bfyehE4ZJGpRDJElUVhQQ0CQxHYUlYoEdaK9BPhQjlWkxqR5+iHn1Xzu8ED7neEGBKovHWYC2PxoK+1kY1l7CWcJK8M6Mb8FE4sOd4wpfV2IjYWEAYeIJTXz+\u002FYvGfnHWlyLeSyIaLNTzE\u002FxSbkJBTLKy8VZqx9TP5GgXjWgLo3n1msA3vLo28RtdewG7MKKAez4NqgWD+BEh48i\u002F8k4DGKqzEQJja9+JuHhfL0I5R8oNqthyj\u002F+itEqu77APT62cNmrsYTX4d2FRyB51TSpezkTvnmJ9vJfnty5lQa49lj+a+lAJ8g0AyCxynSE6crMRYYttP89asA7osYorHPnoI2VQ2oi2gH2DnYOk\u002FW+pH9q\u002FNnT6wuvlPe3osE6qvHqxN9dqJSh4dt+CsNptyO+uZUPEyUUZOgktN\u002FYuNsHt6AXcbIyxhtT2OX6sD7rU7xk6dLSMp6PBeiDriulW+8r3Ypn\u002FEUpyOb1qYbMFtEvXnfIoAOnlq9+977q7Pt6He40+2k6xdfXulKSjEJEIPywLhPW2hH7V05qc8qRblVObljgXIVMljT2wGlJ+W3P8\u002FTfKB0Cx4Z+aA8r5h+2ZuweFNHqepP84329dCTbL5dcmmB8iUsq1pG0zo8MNZ5tM6rKMzf7fPi9eqCGmucCW6pTITn\u002FXuBzCciLNFjcwIYLoqo+awdAnPAuvv0on9cFxkv18\u002FfyzP0eakoU4SndXEHI5mCpSycmhjJDD+Zv+3WiBdmKuQ0l4BRPQi4BpZr1zOWCEcKs+d7rg9t\u002FBqAXmeFi3nJrY\u002F9AjsZdXvzSODXetiPTU\u002Fle5Yeha+ATWlsvlovsrJT7XhrONWTRERS7NI3tsmI1oWA\u002F+D98\u002FFz4eKb1wfQ2ayuH+fOXki4FnZ+eTVa5+1dAMpgH\u002FPWuqgxfb\u002FozQcffrA6EY8A6ZwPUoB4gShyipOwBwallZFvM+cBUvNPZvAeAxfGRZmaH9MxMimDwP1zymzXu0daBlnhIusJaIgQUaoDUPpsAIq2+tHmEmUEUuInSqn\u002FJo2kdUFXgAOHCV5p2YYueYb0Qf7pwZ7Hw2Uuea7KCm3NKjd5fKN5PDdyA43wMnu2g0jkn5PLeR3yPvFqFTH1t1fXjAewyhocLaJUAMR6Brw5oStmPmoT\u002FwmzO3ZelSn53qpNyF+dqjfpgwHrgWieMZ4uB8QA0TaQog16YOrWB54bYkrV50URkr3qSJ84FajPoKFbnP5L4eJZB6CZP8DLaaLW+3k0uLb\u002F\u002FsgpazPtpKzxrFQcnszDAXFAwyb+Z933HDBonvfEtwfSPQcPF5E8f7G1P7\u002F6m7\u002F+29XDytJevX59PJvmbGRaMmbfIXywTBm6aNqGNtCHvxMcfbZIguHd7sV3XmjDRfhrOe8gY5gwISP8V8OAlepr+4tu2mjbV61RUcHA+L4MZBWK9u5Fg2TGwu\u002FOZEAn9KQIyjxfP7p3F1TP\u002FhkT7VU3dmUeGTA\u002FMdJIPd\u002FVz119OT1+c\u002F3IhAXRG+TICGNbQHntNC+Ch+MEWUK5I++BMYBrdHvr5vnSlwaUe3pzhCYisT4nq5uH+k53NlU9qxuGDXmvGYIiSarSAdRF+LpWKt2TotEn22DIIH9WKtqjzmx49qSobw4xEZSDlfN1iFCh7bzoL1bvFmX71\u002F\u002F9X66utJ\u002Fq5z\u002F\u002Fh9p+PjJD+p7KT07RPdDeBrS+9byTQXNSqPTEMWXc68kjU7q51r6wwKjUVXJpKwcBMLmk4vES0695nfPIA5DKNALxTiCnL\u002FEMx6nsBkOVVrUVb9FFLzMe5pRfsrf5WKq\u002FdXZLWIi8l2d99cr1oe9LlxwQlIOjOaWDJsrXOOxJYyBfvXq1NJtjA7aXg8nCcn1v\u002FRadWP+jNVEwBvpkLMSvk1sfLqJz9VEk7Z9TyHIUOeGc8f8wXgaUR+7V9530unF59uuHGcqN835GCAzlZOXjGUVr7bEbbBBPk3vkMUr2HGt9+MhiyCJbfTze965f9GZR1NZHZTxAXdaCFEh15hlDdMqimziglnGaG+M7dHh5hqo5h9dLN0wvMUDe1mtXRPw3t3d3c3M8QVF1+VyllCTgMM7zJtPgeMsdyoOQeFaZ3EtIqlB1IezxCiVQMRLgqtKCDQq8BgjzRBUBAL1Hlfjz4uGrlfESUQjCMUseuoWMsCIYi0zgzaLnrbHgciw3UpyYw+Yi4JSniUBDxAT8wUA8IW4HdtlQQ9CYf5RSBGA8wjl+KEjtIGL3UXoEuvARK\u002Ffqle\u002Fn0CG1lpV7U7\u002F0wsULqwObd6ZfOSJipoRtgkq7GA7hmKujzcvRvJYnG\u002F\u002FL0jN4mCnhOSI6AWQuEaKNpbxJ8p1FBvShj+tbBCS81P0IWuUIdZ4pWLV212N2G2ecnvawzSyY6daNKwEatUh59DK0AiSvSnvYU5mj1ym153kh7iPeh3fzmhf6Ol0oMHB\u002FaH\u002FHCedxO7FO+DemgG1c2pu8vxFtnLA6kGDbH5Op6X4kI+b8+x+s\u002Fub\u002F\u002FK89L2s1Rog\u002FCwMHvOr\u002FiwD9nfos3+5A83o48L96Ur5oa2t+XgTe5dMeaZ0Ig4niiDjUvyOnEh7VQz7eIStnK0HpMKZf\u002Fpf\u002Fo9q0m6uPP\u002F9hnhNzEX203kfr80R7GrsUCsIK2HjK+k6REtoUBYUmj5oSI+RfOjU0+lsq4dQfirD7KZ8FHCcYa2uh8aahe2B2Sm90Re+F3xvKKJHZWNba4o2zeXCF2u8o99b3ysmNFzZhCejuzwu2p\u002FkrU7JGVdIprSrDiVcajXoGXY5me2LP0FOfUZiWwm9jmZ50fUIQN9X2odKWKL0XKYq9GVn7ht55+4r8uLn1rJuNLdASUAEGd153ImYC9Ps8KkLQ6HItcMxjoyTf89YFH1KeQI90BnMzRnWaWF18P\u002FLoX1Umj9eUkUh+AIbz7OoZM9RtVpJP\u002FCya1T45sgqAPG+PhHEAmnhMulemWKNyut3+ImT36t\u002F30dOp1XpCeE\u002FVT06cOFcbv4kPeaajI0ZxzclbrJX4DF\u002FaNHV89V18\u002FNnnn09eekMdD5GNTJSu8Vh7oV35maINcWn3AuaBsR3r1diTiZSluSf0ncao+wxwTgL9J6vkOVN4jOrx2Nf+nmTDvi6m8L1Pzw6gt\u002FnMPDwuyiBV53hggyePs4RSIyUptHuVd0RD682fygnA2ii0ofelioznAVWrvSniPMPreYHRJdnIQ2RdJqWwe3hd+zfZwMkgPdHm3BReC60M2+TXZsTcP3W3vM7qm1OAbXCX4sIjuBUR2dC2t3ac8yANgAMHqN6b0+NA3qn1ynaeOFmaXF4ufITGAHwvhiHP34M2fnGqKPP2NMX+IDlPFtAVHAJoiFdRCpdqG0qwXb\u002F5\u002FegbxtDhgPKJPOgHk7V3myPpQY8z0F68eDhjpcwpaQaN\u002FksXUAr3SDRu7jE2ajkWXZ1LVh4vfC7thcNB5atPf\u002Fj56t\u002F\u002Fz\u002F\u002Fr6n\u002F6q\u002F9QFarTq5Mbp1ZP0xedBlcfzBsDeInsLRGWmqzNMYqiHVGuiXjVnjklPXzfr7kmt87QBP13qKpp4xjoPvf3q7\u002FxetGeMgMYOy1dACRjoxONk8jdU4Rp517rXnvR477KTioMEEGOzDDX1tT3ntG3XUj\u002FLkY7vTUP6rf+Lx74DAY0XT\u002FHAxn94H0ywLX6RsZOmmY0uevgAlanHx7Q61UyDd1JTdqRHjTjIXsWXjFWxsAi52pHakpy2gmR5m1tf5HaZDh9ycHEyJfTjUdrqufi8UBehwu9886F9Hj1tWuP0Y02Re0aaXRUakeRXvXm16oGc7B65w8D9+4\u002F233Pc6qlTtIF6aN49Uxe6582FhHiR3mer7QxEc9e2nM+GUo2tQk78Pei2vtA777Ss\u002FAbwwm9fR7N3L9\u002FO6Ox1C7OJHMUnawXqZZq87AosQPx0I\u002Fot+8+ypmgBKvxMUbxEr1FFtlIerb9EpZqNmKHC570bDJA29bIXJI7T5IVDx6WR\u002F9cG\u002FdXH\u002F\u002FgB+mjnJbxxbVrV\u002FOSV8wh3rVO9K+9Ql988UWnOL87cpnTU+QfcOegUBYSRlGBhnHFu+8wSHL8XFkGTjIdMA97hc0+OfyD+rEcYodO\u002FGcPwJKWlAGeEc\u002FQKN6SDMzpm7x40VrBTqJ5cNeTdANjzomvopM2qipvyegR9eM4eH7PhvhkSvKEUXahUr7oijFEjqBPzoinraE9APQxpyXnwOkzZ2Ztr2YYOdXUWD759Aer8+9dXL136b2wx7urr775dvV9zqG39XprQF0404+8wsMJSLJkPNUJNopphGLAd1JN+tvEXbt2Pavs+9IumrgWnBXvOoyCVXks1rNOvF82d2WFda\u002FJxfSzQaMF9plcJNUX5rCYOFrdcYKAJnTv1CGtLZsxePSU\u002FpOnzavuuHCAg8dH2xSWCgAYABEnXWZsyyZDaTMxcQTBQBjF3PXHA8iEKJAOLClXaWEvva96y5nVteffT14ljwRr7d0L7w7A5wGj6IVvhd4IY\u002FPFsKHgHufhuXTxUl4tBkOhtwhDHqQxAJW7z1T9wXNdYy52toH4Jsn\u002F5izFIp+SJU7iCYvNugR6DgRkHgUydgKAyt2Zc7lhQAaPUo\u002FKo1eo6HggJMHxNGUnVQBDJn+bw6IThNuzcuJSZtspX8qdYcRDdqBTCvdVlopg4WWnNA+Vo\u002FfHf\u002Fovhtl+\u002FrNfrL4r3PdOhO7UWB6A1evWOGUMKD0FPCjf+sOYsBl2PLEpkwmTds3evEZqVu9vA6tDdw6keE\u002Fmzbr7+OXqn375m9Vvvvi2sJYwPIMiAHAiAPPCgSdtCMsTu1TAKGdNqb+ef6A0HnM8nssogDJBn+jBHBPozgZAm65h5L1IkJsrCsU6j2AE7inBCHa3Dr33BOPr\u002FYBcNBYwmQ2Y0ZXfU7mhhtF\u002FU9BvXuqe3pyLbFA8lATFo9\u002F6xGO1680EEAFcPKKv+k2ojqHZe\u002FTs+UZhjfXZZ06Cq\u002FdjOI4nq7\u002FV41fOLbHcevfsFCbjwvWuRbeMQ3NmU86Nys\u002Fdu8dbot8UtKd7hv5Qgu2XaG2UPlNW0lwJ0yqHNXzagSMvS7uRr7leHf6T5XBK32KE15V55qR2BQQAXH0ArmeclEfCeLxoftcGhXY3r+7tzVJXqjC03Xw\u002FaY2\u002F+ua71c9+9o\u002FxcMZaikwaBiCtnBtFd\u002F9FpUFPdMploVh8LPL3X\u002F76r2eM5ATF8\u002F6lD6Y+9vUUsaoCFAOCsMmI4YyfyQcgMwptfRaeQBv4W+qWNQFQVBxiaPHibOObDGqhZ0BFhOxI35FJADgjxoN2AlaUkHl38BkDiVIh2\u002FzN6SBvkqJc1q+c3ICDw8ys6GyijD9F+XZEaeJLXkoyCU1T9HhJKVa84Do52nJPgfytPNzoyBpaf5EegIjxAiCTqadPn0vmHBmgbr8MMPQsGXG0FJ\u002FZENzcUqaX3n9\u002Fqlwx5NAjI4MMcc2xNribJyCdfEUnsym2PpDDqjTIr0dn2hovXO2YD1VenJ4LrEqXEYkiu6yFChwbp9tjoC+1w6PKO43QKHyGF17lbeSUAZgdxPTdN1+ns+7Mke2XL3\u002FYpsEzgeUAYbeSs1PFhS4sSvTxh5dX\u002F+O\u002F+3erX\u002F\u002Fjr6xYbdSX9MpEYMixPouEh51Gfrf+a4HCPh1AJLpBjjAU8DNaWZwBC5hf+H4YcmjP\u002FgwGN+CybPxmDjMGky0amOcBrW0wDuQwem28bamiE+uoT\u002FWqJs0TOeL5u6\u002FdNgb89uGA64RFZBMNRzsM1P6YsyB63uJgWPQofbPbmLHuLwVkIrQtOLn8ornRvzEMeveyTrxsHB5PitFF6FgfvI88+yH7eHwX+TfP6DFKJIqQZiOn07swOQifzHNb+xF5rTValmryXrx8OJ20WTU0xt\u002FJHENnz+YBj+bXGHyB\u002F\u002F2tJzpSuvhuYPNw6Ro88KdOn8lAropQ415r\u002Fd8riq3ssQ2oWzncvvj1L1e\u002F+PnPVv\u002F0q99GMxsZlifyIh8dUEy2cGosZViTA62dyJITNj\u002F86FK81EFa9fHJ0+Ynh8KLvjvaWFVL+t3vvkqXJXsLPazn0JOKcbMN1ngUzRorPn5WKq4MAmkx5JH9GmSA9JEHebatkdQfRjOetYFSrrW5XWR4Rn3r8KCMiLvlvZPFx5PLQLKIKplzo\u002F+kjMAX+kFXwH\u002FYyZ5F8nLX2874wL\u002Fyw4HmqKw5aF9MfSCHpZ\u002FQB5wCZJR+kKFkH4MPRiIfrDXvujQzegjd+O6fN9M2Tl71Ae\u002F1RURNn7U39FZ7ZIV26HfPsml37xkHSzHibCot8pHxMnisddeWPqDJw83xua4jR4z122+\u002FzSB6d9ZPpG+jdt7W660B9SXHeinrg6kItpPlL\u002Fd2CCZaSNndD5xfG2vVojg9a3PzdsKYB0kR+SzUs6cK6QhJF6JpwSwO9lRjVxrNWMYJbIwZXczkE8iEyaRxZG1qj1eJd8pCLQIXEFk2fyICBoX6wLNAfb6b50kJU1TuGwMCsUTws2GzfgAHQAcCe\u002FzYhjo1OPP6tmDuW450NwMEarW8z78TES05ZqqzyLVUq9RKU7gMiEcPl9xQHkNM4AcBYhqpBH57sdwoc0CCd8sYMZI+U6YIm3FhrseTG+A5VptqPSfWhjhZtbyH2lqAc8ClfjxJeQI8SiICnTtH8u5lcfLgmptmrr7U7RHmyqE1FwkNBHojoJJKXZ3dUG0mj3YGmQMMeFts\u002FDyQF\u002FzkSRa+3eKAsM1m66sfXP7B6pOPLs9c\u002Faf\u002F629jhgBIiqZmaztBLf2gjSIP83ClXxMCKlc4fr4oTbnTdWHKW3qOo6P35MEidA523VqC62YG4N\u002F\u002F15+t\u002Fuvf\u002Fay1ql7uhm1qhPhSzeeo8GaeyNmUm1DdiQ4GmDdm18z7rqcfGDv7UkhT6cBEIewUDOXdu8ZGv3u3+wLiedcXhUqxLOHf+h39qAgCKgst7wuwey+fnxJ62fjUfWfha5dgpUDR2LL5Cwi2LqUrtS7C9xSuZ3kBrZ4F9KEHxKb\u002FNT3vARrrNAckJYBn86Zv+h7I98aYrZPn86JPBYcWYa18ykMpb23ZwHnsxPrQN+G3FQ0ywu5X6ULagjYGkHSd68fz1XNv3bzT45uDxrcVjQJ15g7d6uKZM+0xSdngAT\u002FGIHIlrYVHdiIENg7rq368MW7sVVhSEzJiojVgBL37WRQ7b\u002F\u002Fh6Onp6v\u002F+m79to\u002FS1Ur5Oz1zNcc+tS1M3XtWnyZ7r1SO+cuXq6uPLH9VPVV4260eKMgF99\u002Fbt8bJYD1ErwMWGeKFPfRAl4t0XsQPYdj1C0k3IHJs1X71yXkFtpixOld8KbOJhmy+VHWTAmDhpgo6qPxSv84hNVK1+kAVCulNyMB4HOm7Vr2tXrw6NfVDEiqE8Oe89897d27Vb6D7Fg2\u002FJOOFo+3nMM2OfLEM75nXWK5pnJAPI0iVOnDw9m8wpLOl11sXaka1+0IFQ8ZwQ3T1Am4ihw0Mo7O0iXaJhdx\u002FcGQ\u002F2vTx0vG6AEGMBmJYfyzid0mo2ZY1y5NkHuNBmwDJw\u002Femnn3YPr+1S8UvkFa0AZFKSyFrjfLrdJvTmiZdPWD3S6xmqORzKGXKzH5VdgOfWrnmQF0+XMO6WVBnPS2YG2ihlz8Xqoq4279WJ6E0N\u002FzbNFxkweTdudfJpYyPnfvjxD1bvd\u002FAWTz9vvA39sVGv9EVAXFt4r3+n\u002F7uyYr9Tkrtm5EAX4SG0wgiTmkcmMISNefQXHRQIMr7tvMGibGQ0sKTtxHgFMkrviwbv30vvdlCUcd2\u002FHz92Bb1jj8KcJtvz1DBnkA2YHs40sjphDfqPB33WROvRQUGCvuLMAKL1t7VJgCx01PXTi3is3ww\u002FPKVtNDSOjT43FyMLeoYN5d6TV+4yL+S7NslnZLpUnnFf8sMP0u238oGHipbsNB9oRV9gigV4Zlj0XHRpA6P01LU82gD9MZ7yPeGC5Coj8furVww6etpafXR5Y3X03PnV3va1HDudUXimlLbWA2xzIu\u002FzNiv\u002F\u002FGf\u002FED23MTrsc+nihdU7Z0+vfvzTzweY\u002FzKgjqf3hR1OV8u\u002F3rbPQWpF4K+0GlWBpKOKJp\u002FJgDx50qbnHJ39R4bw0H9ztSpw3QlDbOSIOpq8Ce+WM55zpP8eZkBwZJw9azOo9DmyurS95uJo0W5j2Sk1cDv6f5ps4vjhsHzanPLun0guXf7w\u002FSqlLRF\u002FToKJFqaDRKtu3+UN358hUUpcTkirc+vWrdlY\u002FfhhjsYwzp34SV3zW7XBOHi3qPbFi+8NrcBtAPAXv\u002Fty9fsvfx8N4NP2JnIC5DBxvgUHgcjAwwfhj9YI9lqMi\u002FaRJP9OhF3oD0Y3nbhx7swYSNKl7zM+Atd4DU5rW9LQ9fmPLw8vcFqQZZiCvIKtxqCHIeOVZY9VMOSYktuLs4QjgFwmK8lMDgRzcmw93NZ4HeZkDFfysH+dA2hqs9feR5cvR9Fv5\u002FXWgPovfvFPc\u002FztgMIGcjwviHxOjEboUbIm5Eeffx5hqRt6L4Cx1YmRP1k+iymUA6PgWEu84bs1elleFCTAbTIPHsyTV9s2IHjeKIfxKlXsv80LQoksGod8EAJH8hAT0rzclMijrTYsRDCYX71kgu\u002F5wRdjCCAEi0mZ6gfhxegg6CkAYRWCjqKKhrpXdYybcx0hbuEQIxBN6NtMcTXmomw+buHOB9wRACOEkJ9NgF3PY6L0j3Sf0\u002FXTJguefh6\u002FZwFYXij9YRjMgxNaBDhCI5jNwdRGrb+Ye5hH\u002Fuyq2r4R\u002F6FDAZ1yaoEWAAZwAMSEuyhclv6zvnsWg6jnevrU2WEo88fAeF1sT6h\u002FK+H8fLzOEWqbsXjZbILdm5L1fivhb16tfTg7r9tSNaXlG6v5QPcIwQ7xZ2yczYL9yU9+srreqaO\u002F\u002Ff2VRFKCJ9CtOsWjBN9aNc9tznleHrEc2NRSY6AYEtwByKbAH4PZls1NhbfOXVidTohdvXVn9Y+\u002F\u002FXJ1695WtBJ4SrjVwADYfJNFKdowVqiXJ8ja8m7QmIuXsFG0LuGUfvesFMCiMPq3h1KC6YrmnXJYvDqzLi0G5TgKrvcTrrZAvSgaL0pKa+hnLSWCxtDs\u002FqwgER+b9g6XepQoGiU7ClbHG6fwu0M1bFShqA8XgaDwxxOmwTcvb60dz8Y8yxjefE3I+cx9S9d8ESTo0vHCBSR4dRhAPbKOpzC9762xHji0jFGaAG+uS\u002FANw0Z1AZthIREpbI5KP1ikg5ebV4aQfPiIJ7wnarNGnWJ7LOFP4OE1tb0pJzKAgORhWVJhWvh6QXj3mOV3c+Bvz5\u002Fc4Wh1wFYG3pOqLlDqwyPdKaypfNbdjMevv\u002F52PJ8n8sDiRcd2i5DwQvMOC8cKjTJCeVXwIu+V2uHkGDp5FK+qPHMu7xmAyxvr0BLjBk58pk\u002FkwdM8Y8ZKjtjfMCcEx3eUUORXf74KYF8Z8IrYrAW5BICZlzkobP3MkpsdoAQ6AAnX\u002Fj+s3VmvXWma4PVtH8+zfWxHOGxH2DFkZGVVV9ZAdUtNQaMGCaRW33CDkLgEvgDfpS+5QQxXDIJrkBrRDXRXV2VlVmVGRkY4HJ59PNvH88D\u002F96xzIrMRd3jZ++y9117rXe\u002FwzNOLzu0vrKyZ6b5lfliMJbyqTcydbd7E5x8pSRxDu\u002Fri2liFH7XO8ouOHVc+UViJtVGdJQEXvYVx0Qrtomn3EvYPFSqwWNcZFlRnao2i56xOGCQ493x5FixsB3suQZaCRZmROHu8MJBz3ffhRuErCS4qSijLZofAg4XCgCUWe\u002FHkqkCMy75z8EkyK8HuZbABRoQEqv++hFYWQhXQotFNzgg03NYHspZSZO8XTsYggEY+fnQ\u002FWscVrwa0Em8Uw6ym9dW48QvwCD7MH7ow3poUJvSawDEWtuZL1aBndwvX27gd\u002FXozOzXDvdOnPxwF61Txqpu1M\u002FXl6weaUpMDu\u002FC\u002FZWge5a0s88eoYT12ri0ud\u002FTd8wkKg5P1CP0ZOt5v+gy\u002FeeG0iybvySs5HoLGAk7gCdpEWWHIefgQT6EArRLsFAZQXjRBHlx5\u002FtCMRLHaG6GnOfcvjIsORHtTsB1+o5BpR394xSkYFM+p7hTt1jcNWRsf9eVlODpCeeNgAV+E7zC\u002F31yj5CIeVfPz0g8NeTa6a\u002FzaJSx2qvvQpz73zjMshLOOjSLjuYwq4MhnB1oGNy5fvjJWdRVMxPXrE55IGN6Vt\u002FPcx+dXX\u002F\u002FirxOMS04u1+FV+VY7gpMjeavgzq2Mj4Tocx993P0JlZPzkuU96\u002FO333wdPWtDohTx3\u002F+x8CsEAABAAElEQVTpH05C8etKne6L7h9oQyT7Wty8\u002FXB1t1CXF\u002FE99JdX5E74dOnSpYGzc2c\u002FSp6qslrzdf367dWVaNjZEjh\u002F78svU0IOrK5nUGChJl\u002F86EdfFory1fAyRkDrMLBQeGTTOTTYfKFLcnjQJqFo+MlU62tqlKcWX23\u002FiAXuKxJRVaUPPjwVLX5gwqddAvPjnrGnhhn+yD7kIZEHaKhdVinowtrIHQwEYB0c8IRZBzlg4I2hBP1YD489gIINxxyEdHxAJIN70XM0Zsqr1hd7TPDCs2gz\u002FBLyyXunojFLaFEywfrJZB218imHBOylGhRDku9GBIfMC6ASrQHeGDEuHL0wsig6wFuKp+Dvci4ppXfulrdkDPEX+LaxkRW+vAIG4fd1vDdB\u002FWkCBGucMoSYxs4AHoMjkN28eWMYnIoSYsRNCuJMAGdttlgkLe4ZlTW4qhEmDOpUAiRiqMTZozRfcYmIAYuIsn3DQBL8CMIEk8yqxTTnqgkIXo8QKpFTGcasbS2OpAxM5mGTiOgdS4g9EiOBnCxVFmtvLwQAU7AQmA2XLOJyvIWllSN0iKo6vXe2NDkAxCpOUHAtwDPm+1nHCGc3Sia6ntal1BIrGSuEZwBejOVu1jAMY7Mxa9vcEEgxW0A9u3E+Jphg5EJIGnfXj7spwfhgYxiiX3w4JGXVevgorTlGwro6isu4fqvykvVtknIaM+ciTf5t99+4dScgzjJUVrrd\u002Fbh4I4kzl7ZSJqjfzVK9WRLjkWOJ1Y3j5HolGo+2hm0s9KT4tldv2nI3GDhEOcotKJF0V3F43GkTPxwTIChT4F48V7P94uqPswh8f71Y1hBast7z3HybhaXsXHteImiusBIK32S5fJt1ACGfjXsiQrEfSx78RH4iOm9TGO537VfVXb+doL7xMEWhy23cI+8B8itbCWnF9K1KnC3RfxictbZuhIQu73Ptei2xFfNxOdd1CdU23EFLVMgId+sX5a9\u002FISskJ4jS2q0lOJ1+a89zEl6J2DTzZQCLZZLAHfgNA33bJlCYt2culnRKZONvPYap6VrPXtyU+uteVnTMZhkLXHOAb4d+sXrNvxQdvyPcHiLHQk39Bb5UXtJvlwRBCV7t3LHa07hV\u002F5EQzRolzIVCY+yqpPCCqD2e1DteDjBahwf+CEeSBAPn+ghWC4VrTeWCEEq8dsdgn1Vv+GVK2rjvI86UqO0QAHOxbbVjSST0gvnl\u002FvDVfHYQKtVU5rkTY2mO4IJxYBxf\u002FOhHq1\u002F\u002F5psh6gwG5sVGKQRjSqZz5h6+Uu49Q9a\u002F2HzjOFZMspllTGClFifetJjoEfhYPjdTYsRVnxCOUT9Vc3pQKThWoFFsuodA8Dg8e1RIChqA4XNJCzsQG\u002F1hLvAPep0utnJJkExIbFEwwoNoUuvNss4dezpXPePFh3kqrYd1xAAJ5pidLdGPRp90VEjMfnSqLlP+Wf\u002FRz6tXLo8SwKoPP7e3FMfIF+ZYNYcbxcFmPbb\u002FANp8L+H3dgIqiz66+Pu\u002F\u002F3eKWT3bPGZhq22VGkzwhG4F93W78bUBTNb5o4WNYJ7wg3jGLc4drza5nQLdC38waoqJdbKGw+hrwzw\u002Fb2w2P3odPsILMADeB46bR27s9XUGHp5XicALk8b4nzxehF+Md8cIm8FnQKbv+vCDlyBrogR\u002FQsCtm4\u002FGuujZFC\u002FXoRkUQeP3HDxQPgR1m3dJciBD1NM8vq5ZFGt0g4CaQN74CWnovPG2dANzKjC93MlQhaYI4VksxaUzDu3VP3xLm88Lj7Dr9Qi6waHFhfbdOjgjbGOxIqIPBOnWfgxj4CccDnXkSKGDDFWeNd6VGhrlvnaAuLkCG\u002FjnEMrOPQ+vn1XO9lW7Vu5cU2nHyIXvwN3lRrAGf7Xb45pjNMYzCN09f+iIq6br0w+KkbGP1xQM+a15YB2YzyzGhhqNQhfcTUmm\u002FL9NUH+X5xWNpEjtjOa4llGkmQ\u002FhU8i6T45KFCrD2bHVw4TlWze\u002Fj49tZCX\u002FovXdM4Ira\u002FeevVUBSbBWKYcSNjX8o19w6Wn08GG88lweo4NHTsZvVvH7lPxox82NW1Nj\u002FczZj1effPppcBa8FxKjdOHDDFF3g\u002Fdf\u002FPJSgv3jYObw6kxlkQ+mQIl9t3\u002FEowwLr6vi9DIviU3HHiZEom94mHmj0D+ObogfF7qBtt24fm313eWrQ6uOF4qjhKl5ZIxaLMo8SIVtRA+sJ68cuYiVmlxGjgFXrMPP6+taeSsKU7x7m9AavlmDjSq3wIGjyU9n8xiBLRv+2NTraDsHPw5XVLe7n+xGJmopV3texjdr93VzwKuoBLQIiCtXr68uF9f9\u002FfdX6+v+EfyF8ABeoXzg+219X3AgPtvz0UmK1tnz58tzrNZ94yAzUrDJTov81Hr3POFK5moxDlGGlnwnyjkrPHhG49F\u002FPOtOshil48OS1m32Zs7utr7oKZlnlMX4LB7F6+bZDAjCKMWx4x3owvs63pugfvbcmQSrJ034lbSoNLUEdZYLTOJ2AKTqyxLb0053hbGwLNPoDPzGjWshebXJc9UgEg6xVAgWYDRJkE\u002FCkElkySD42h1MJi+ghbSIg5JOi7CTEBlBPnl6PeTN4taCyJI+GvFkJWumh4ATzKHpuAhbUG5PzwOIiJbnYayTaR0AYWo0R8Rf1ZqFKNtFbCHAEEGfEKQ7GxKd1OVNo2zh9NtWwSwrgGmIawwI0zbu5bVUJrh29e1Yz5RwwlAwRIjjudvWE3MwVuDGR3FBv\u002FSdtUFtcwetD7LtDvEkkb5qcwDaorYIxA7CszKH4vUPHxRWkuUhisayfyzCYTOAXa3NyQjSq4SwHftYJV8MwBIUUEfr9WQzJhUQi+Vjio7vTHmrg\u002FuPd0mCenGSFCXEmbWPK\u002F9NSKrjNGCI8qL62EqYPav+rbCXnWslyiWwbz6L2LZJk8oKE7JDSO8+yY6RzvlnTXckTH71mzZq+v77xhHzrC111p9CnOawhQ3hs57VbUKWuvasG9bAQIbpWasIxC4E3r+e0deFIfSMRQiKeaQhULbA3gi0qiY0b+bCNaOhNx\u002FWbpKCAEWvHWX7s1CPxb7+WF8EhJVNe5ibOTUf401qHJKzCODTT4LzMDfMIyWuPhIItY3BIpijcNQpQp3G9HGbSDmFaBPMhvX1o6seZF3cm9vWxWPdC14XAQEjxdxZuBZr88R6h7OUFXGsc9Qnm8awwCql9TzmSICBu4jYjh3FPkZwEVmwbh1VByK0i30XAqFP47ZPQR2Bo3kAYoQZ7muMtiUY2BtBPY7P6oa2aNMYzRmXulAG82A9VAkpW7SX0JF3qwsXLhQz+qspISYcRlgdOmG8+q+U2RJWULuNexKYdoj5jpknFFLOWGtsmHLj+oMR4iSdfhijPpnATOjC0Nx3K\u002Fr2YVtYn44p8d5sbGz03OpzNw\u002FCaIT6Hc+iffHNhTFu8MB9++2lEVivX7sWPUmZDiZuNM0UcLSGBYk3gDDPcj\u002FlaBsHAVsNXzRKjDua+upVOSKtzduYI4Gd1YiAubd5acJmTlnQH2VhJnQ\u002Fz+iynZC1c3NtrOjmhrFCHO\u002F+\u002FUfrUyECrZ\u002FwKYqL8J\u002Fj1YI2f7yBksT2KVcWzDIIgH\u002FzeDzLlhrTm0\u002FuBxdLoqs4\u002FLoxv1tbHMAaqkICD+Gxdx6zpqzx5\u002FWLNvew4GIRJq3f8ypPsbLhNZgzmjthj7VoTo6XNGptGTYoXEsVCXH0zi+GHHGsXNtwEdxiyGju4hHJom\u002FuDn4wSWlKp8JDPIKH48MssniFtTiQoE4YMBoWT5tzyUkg2ASSA6+wznw1tQOnktoWi3f8DG42WNfCYXSdJ\u002FSHo98YHexUXRemH+aOAuOe6X8nYObgcO\u002FC14zNQXhlTafXDl51ThEIHgrVfiYcbhT5hW501TxjMQQI+ZQQTjFehH88Re6AdWRwY8x6FQ1AXyQZ16XBz1GkQmh0an5t\u002FMZnrGNBbTCeMV5KN\u002FV7JHJgwsCMaxmbMfR7c+iyIVrRxeln1y35Njwf5sD8yQHhKVl4JmFbGCvl5dixk\u002FHiQjg25KUcqfrcH6we3r\u002FeA5ZNBeUdCM0irO\u002FPkHEkw5OCClev32wjq92rk4Wo4EV3SlJmjV7bu1H8cjJQsHB8\u002FVRdSoCMj0o4ZmHeHc68K7zxZd7yHVnsL0cLduy5mjzzbnX5+0LeMlqdWT+y+uzC2crIfjRr9iReuJYRYypQnSrMJrlh4Q8vWot9I0v87Gd\u002FvTp\u002F\u002Fmw7m36WwPy4MIwr9TmEaaKOJGvt3gM3bNpzv3lZaA+451W\u002Fe\u002FWqqW6KzRd5qTUMOF40+bxEdzaWMI8jGSsYul5spnyGX6dOViaV5Tr6PhsnBaevU9pUM7PRIGMqr9Sp5KBjWd0ZZIUz43noP6\u002FFye7f5lf3G\u002Fvbdwpp5HkMtnjgbrUpGhgRRQG2xaOzopN\u002FbveMa+WNCJODI+vr62OcgQdjhSfjdBNhmtEGfDASU27wCvT3abSPtZzswvtG\u002FkE3GAzwV7IjQR6d2uYnYJS8uci0+PNCq+423hZ1jCtf\u002FvjHAPO9HO9NUP+wrNlvvrkUgW8CmgxEmmDxQQwK8GMuBMj1st5tpmOAiOlYcyI2FpTQrjSdxScAC5chTD0RPtEijPaSRYKl2CSzRiOcKlXM0SIicBi2dtfTPi0ctwuXyK1KDxEcuCQI2RLl1Oe+E+DqzyIEJegHnDZL0T\u002FPeVPsMKHad3H2gBzAIEaEIuPswgEmgoi6qDTSTz45W18j4rTfND8Axh0D6GxqgGkCGM\u002FmVgewgBoz9vsIKs0mqxtlxHMQc4wD0+Qq1hfjGzdsAAZAETBAJCyIsrOH1TGCwvoxm9wgZM0vZo+QA0YJTipCyNpXqedWXpBIU8Cd6zfhOdJZPFyWo2LE75TwRxBXTlGt0htZmO5uvFytH21b33Za21+ZKVbV5yHyq5BCTWelHCkEbzHfkBRzYWG68t23Qyw3e8Z4ROoRoUK\u002FVGjY3avhxexDhsa3xJ5F+EP4eM0Q8MCqe7Km63HnJCGx6CLCtTbzm9owAkqgsXq0mUsKY2DZ6FLMw\u002Fph7GNxIBjUDrJuvmyG4lDeUrz2CAc9SwIQJmc9F2bTBc0ta83b3hE9c7yjxpr5EUS043eITVAfF27X5B0dwYCQvvSJpbk1ax4JSRQIgspUzKifXLSEk3ErgtPaRWAGXvtinsDMAsO61QO6CtMGM0ufR0yfsYvXxJdbnWmDZWWuNaH9J5gSyl+nLME5AgVrn1A1bXsunHpdDsK4u+uLg1ywdx9BPc8R5v1q8R55kmkfYQzcJvjBb90E583yfG7orTXrcG21pl4EPER+rID9MJa0ZXjNa+NrzQhY8EolD8YCa4WevGrN3zV3cMrAWEi3YyMRc9YdyfDox5ssoTx5wj1ULbl2lYXldPjwaHWF8hv9IVDqnP6gXVafF8p6IdjKBoKvr776ZXGZO8cdLJn86NsjYylST3wS32sHLqEnn5z\u002FONf2uQwcbUldn5raroHXwUu\u002FH87gwOKL8Qi345kwZ0JMhAi9yAIGRvcliNnD4FBr9Opl+ULRgkjBrJWx3r2rekQbuzX\u002FLyr\u002FalzGOwJis4O+UjbHiNG8Yk7mV2gcC9nxFAUhhhKgWcgxTnNx5EhCekLqbvk10Sjwq43FwBJcRNsIeKzgjCZoIGWJRc99lMEn0UbCPQOEZ40Lu\u002FGDcQx4R\u002FGhEnBtNb8oD2AyhT7+wDjxIA8FC7f5tEas4fJvZp4wYzhbWxNulRWMwG1sY6Sob+AZLWed18YYQuBP98AtL1jNM2ZvhSNVvSFcsGhLsLNjprA\u002F5SGvXr40gvoC701Rc0vY7HG1seBgHwde8a4567foGCUFL0Cb0MUuH9pRN5rqrWTkkGx\u002FOPkuxV7\u002FvDwEvFiPWb\u002Fuo3i4H+4Twub38JDhghUUvojbN49wyNzil+iF+VhwCl7ax2FJMN79dvE6e55rVLIS3rN7d5bF+tPjp78Ec+0bg3YMhXKzbGzWHHSvzvXr\u002FDZz1TUmqcdFi8N9jfWyVs7Be\u002FXwF0u6ew17eXdNSMDxWtvi0\u002FN+FAKrpKo5VYyAcdDV31+5tvqv\u002Fuv\u002FbnDn7\u002F29P1v943\u002F077ZB3tkU7Euma6oCvWtNN59Wye14NLi2UlvJnKubFcS4f6v8sfDwaLz7VR6zpwmqmwnhSdbzvqe5OHjgeIUhnpXbUvWRDBiH827xUh1IeTzzySerHxcus36qvIaSQSves\u002FoopffCRx9l0DwTRQ6Xm+\u002Fn9VvUwv5o6SQ3JjORK46lkIOPe+UdCIVkVNyI5ik12q3jkd5TBZenKSP4wUYKybPwhLWYwZAn+k5hOrfypgtZgxPiyg\u002FHXyjzu5pzStibZAt8jSi\u002Fu\u002Fk9krwymzElz4m9J1Sjnwx2z19mfU62cv5pURJv4gvoixwNsBBURT8XJf5ghSbQEtbxMZwGC3hMgDM4KORn8cBmJLLwHQR1myJ9lBfvWt4DhUnQXFZ0Fm+eSfi1TRt5NtDMMZZmQR\u002F8bjyUdEI46zyatEqv8mz0hoGTArCEDgYH0e23KRbo\u002FLbxVMgPmY2SoOwk4xAYg4OiSd7X8d4EdSErGOiJiDRrqUx7ljYETjWEoy+PhLgSrxDUxbUA2BY3ncohrNWLG5Frk5YHccVVQjAJArbWRTj25MYZZA0K47kxL5bUCB\u002FhAeHsGYjSaPhaiX8g2vgIq7LJJOI9aWJlTwNeRFbipXYRdtvJs4RjHp7JOkbLYr3DwDByfUfUWEz1tV5krcnK3vMJ6hYT8QA8t0NuVgfXieEaAaoOyZRm9ZK4icEQZhBRcZfc7mfPnk2AbjOG+gdwuMvW2tlVshU3DQuJuQZsNqvAVFiUxNcGjQEdD4CNU8T9R\u002Fg7x2sQ2Ws+QrohfBHf\u002FpkngH0loN+x8zej6Jw8Jc4rC9ujkCiE3kHwTAAWjrPeOn9cWajVy5jigxhua\u002FbwkaoaMbOEq5et83OWtx03ikX\u002FqM0WPljtichAdEL6q\u002FqsCgXLn1jdSeYJ6I8eXcI59PJFzPpl2jnewz2sn+F4LWB0RPMORDkERlQJDM4m0gxBJuAT7qaaSjCBd8kLQCiU7av65mjqlIQeVTNdQ\u002FCQjDWPSqnKEzAac+2\u002F6ffdJVkhGFyRBPX+9H\u002FrpV\u002F6NES16yLaYkIdY6FrvRI3cMuZT8\u002FS\u002FXHX17+XCVAIk36Mi74qKca1O+q9WBQS\u002Flpba2XsLIjgUtUKDGSboRKyxS2CeWNGhEag7vxY2LasT1qp6zOfiNIiqHMXYs5gwlOW36eqTp31vqPzwk4ky1kHcOn52TFHmBfDv78YTIL8kSMR\u002FIR1nK2V7bpgqTVQDlOoEuXa\u002FJsHMc9xg+avVRzYND+tZj8ulnPCOnyfaZ+eGc+sQ613etZNGAvBgFBHIHADgh7ory5c\u002FHySmzCpjcKjKDzwBA4huItlM09OMP8gmoMBIciXLt2OyQilqPwe+A22RxkOp1Q0GdwD0xkcPI\u002F17PbtW2MtJxw9a41+lcB+IGHUpjnaYQBA14bxRtjREpbfTz65sPrss88Gv3m+5KiMINz4KOroCxq0MJzmvH4TDAlaazurqxyjuvLdpXHh+oyu8YidqZQhhiM\u002FhhKhzOXT6MWTlFfWf9Z2oTTww1wQyuziN6EgzdOBAyWFZi1U+5iiEJTk4k6ZiEGzwrlOSEsQNxZa0EuhgbvPK3l4e6P5jFeoiCPeE76qCLG+3mZJw0i3vIQBvfU3LxQt68gCitGir6e2LGfPagOdGyMGC1cwSYFjDCC81MhY0N1\u002F69bNYcJCHdF11kSWby52tG1bSGepZGWTf4GG79pld9JFgZyxJLSZGzX+5RBFEhujikGVxGxtDlJSwnPW9eftyfCoMnvgBT0TdqE6SFJwLW7BeHCqJCiBEp7urc8MBr7jL0IFFpzF38TRCq2EK9ZK+JLrhRMk\u002FDSmrh58Mn\u002F4Yg8bvEB\u002F0A0wM8aGaI\u002FiB2ibH\u002FBrFv8xIiRMjUDd3aHMzA0cVbIQzwAf1qKFHzwzd\u002Fo4L3jetSoGjeAMd9E5yOlOikDveJ2+vDP+7u3LjGv6XbcnxGXmqS\u002Fudc5wunv5vygcc33taWv7cJnnmRtjszfH4eL94ZCr3CM\u002F7U11tyVgXr32fdbsK8HnvfDj4Oof\u002FFt\u002F2iMWxVjeScS70JSMdFWWux7NWC8cQtWn68Hk3VvXMuIEx4XyTFW5PhOEdySgnypXaq1+PQ2WNu7cHkOBcJq3b8vVar7N0Yfnz7Vx0qHVrfXrq9sJgmp7n0zm2Rk9vfybb1b7M3QeKPRtZ\u002FCk3CNBH5lci\u002FccyACHj9nng1eLDHHl6pVCRYNdNKdKZC+\u002FT5koxIbhkmdTeURC81pwLjRNSKwk7vtVxUKPKGEP8vy\u002FOfx6cPyTc+eC24o6JINR5BkY0fyKA9eWOG2FQuJb0QA0l+HvReWch6cGl03d3C+0b0c4eqQCBFNVLhoPL9F3IcQqbjGWTjhf7YB7sKbACLgnRzHcXrr03SgZElC3lWjLTMZjkCUwa1cSPe+ZBbfm4ANME8TRQ+0Rsn3nFaNUbNy52z1LpMS5xk1xILcJ68MHeK4ZHBlEH5HXGg9jMI8f\u002FsdCX7OFe99e\u002FeqXv+qp7+d4b4I6QYNFTWlAi6gKDBMdoddAuUrv35fhWxWELD2Yh8k8d66yZrlTEew9LRik4lr2O4ZMWBa3tXvPiSFQiCzLE6s6ImSSLZZnEkwgaOje\u002FRIQShJ6faNnL9YP8V3rJxXoP9194r4LjQiBCIsYAi0IIViEmohoiyquGRCJj0SMxupACI8QsZRZeAQGUGEMGDLiilAtGpYyYdw2zUeoP8l6tUPYAixDnGvDgltormtEBBHcZlB2NZ2NWpqfcT32XH15+aqY2zQVBJvXgltXffixwEQslKrEdAhKnrXWnKkN\u002Fu5dAkmfubjN8ZtNiUD1JReddTuT1dBEQg7x9AcPVgFnLcQlmOb6s8mD0kQEIMB+7uLJ1e3rCaCeWXs72rlxF2tz0PUsS93Lp4MmjaeEmdtZZIs7eZfAcCDFjfB27+7G6uDxiEgutVtpvieqg25tnifwQyBEwjRzu2Ea+oYovH5NOVn66fQQ+8bRIsxagr+dEUPzTiDGNLiftYWhLNYyHpjuaW4J+OaedX535Rkn9jfGP1tZ1x\u002FYvljCskw0\u002F8PCCOodwyy6d951UMd6f5ollALp+9rOJezH2o3QVZvmmGdnGGq3gO1hODGoyS+YtV4sBY20NW2NrWOCwqIscLsLY+Ju9Bzz0Ku+6pnhNx1T\u002FUAfzBHF0zOwb90cGMYQ+yyWk3AmZtn7SL2141nTZvfbrXJRUGICbYmtrcjUWDSS4YMBwzVewgQcRRwXRZpgEEjOMcK6Rnt1aY\u002FvX8qBe52YNx9rbxSarXMsjaq6wB3P1n9r1qX1gyCx4CXYIQwS7NT0ff3zv0mZXFzgn356cXXhk\u002FPlhdwtjGKpJoB5iHe+c2dj2jtRTObnn18IDpZSfidPrjeeBJgeNNb8ngnX4d2ThN2\u002F+du\u002FGSF6aow3LET79sZGYTeng234H12Kltx5e2fiyT+IDhEw9VvejTKsBHWeEIyBe\u002F5EyWs2NJE\u002FAuY8z1gpLQvNSQlpHlifH9zn1lb5oIoqCf2sSl4Yimdcqw+\u002FiXGxOFHIMSG0k2JydJdqCxQ\u002FghdFfEmm3\u002FasgBvjomB8+MHZEarXmtcR8mpbaFRDJtpUAQKcyxchlIGzRalGb2x49iph9XUVTVjj0R+eVIImhqeUIwa\u002F7cEEq8JyVJzgaSSIgBcM1q6vL2KeQi14OtDAA4U7MqQY49Dx+kQQZ5n0YgAhoMsLsKsyYfxBcbXmf4n1T9jammtzoW+gSv8oSMZPGVFNB7o9T1CFM5TxJ5NbUYiniWzsLKZnznxUGyUqt2b4ATq8CDBgOoC2dhkiBuY9qTU212DMOBf4Bh\u002FxiPpt3TpdG2icdWdp37Yqd0\u002FnCTc9aPDHxdux22ittZiwE+0PYYjq1YftkBm0aVlHmLTgljAUJ\u002FXFseB2NDyDhc+LoE9ZIowv9HN5pr64sZt6hkcu45zGZp6n3aDGhk3LZ\u002FAyN3Ttcv3ybenPNj2axjTbj6O4b\u002FXDtUs75qBXF+g3Gj\u002FGq370BEYvoUCHUzx523g+Q73VN+U2\u002Fcu\u002F+KvVl19+UlWyM+HrrR5ZO7lTcxC1rLz5vBaFjhyofvYXX66OJw88uHsznloCat5kuTFCLT0Tf3yTDMEIwLt0Jksww5k65qrEHE2+Of3Bmbau37F6lGX90vFfrjbjk2+jW7yNTzartPIw5SFP4KHkF0YFyfZCedBviiR4J5eQv4SfkCEYAM9UAvpmVvJHj4LjxyVtl6Mj38VOw8PXM7KMIS8jBUOEhFdVqgjL6NR4ccKxyYHrmudVpgGbwnt4m3auL\u002FLR\u002Flf7Rz4yT7xh+KIQkqBn5pXyCGfABlhS1UkI4ey3g27UprBHBlqhfJJaLSK5C20\u002FuZ7sFz6jVSPrdb14\u002FLVoHdpLxjzUvDAWPQmXyXHkJOOgkNvnZl8y0nCI+igR14GHEuzhCyPB0OfaUCRBXxhDhz+jh722DSXC6KwneYbyIseGAsSYCy6s58VPDw0Nnwe9hz\u002FvTVA\u002FVkwiqx739c1iipTS455\u002FUDWFx4U\u002FqAzAAiV+XB1rDMcCQqJnAfiUC0vYsBAW1G8IpSQAAiGiLradZZjb9tGKS5h1q4WP0SDKEJCAC8BMNKDgMh6BI4AjCG+UJLDt3gEsAIMwq2oAixLmR4BTc1yiJoDl+nANIuAz7TzUHcWBZUpfMVfXTshBfcRUEWeWEcmkCBXgIXBoC7H2rBct8lNIFtOjPDSoWVZIN27n7qe1ElYpJZO4VNwdge5pDBFw2dDAXOwJgCksSx31rPTNG+u6DTzEkhqAcBUEalcC1Fq\u002F68NmwK12+ttNFndJV1xrS7KnhCjITHvFdHfuPZKLThJS7rWsYzTc9fXzNVw1jOZhmESlrnbHcDMlZA3v2cWOruUi3cyS9u3lb1c3i+t9UnjAycJkuNEfBR9vQ9g9CR82yNmfK01yoKTVqeRSf3kdeF1YCVQVWattiYkSMY2HRlvu48x5tLRxNd8zkxGH5sZnDGA2yRkRlhhL0DPlBPm+Nj4EkMeh7oywYr3EGJpfnGMY07TkO8nR\u002FRH\u002Fnj8T7DlzXb\u002F1I4bqGKLaGlofjG2xPCFlwVueEG0Q1kcRCNkJKG\u002Fe2kynGPeUC2FOL6pW5BkLEa20XjCDSZmTzBD9x5x7Uv1yv5CbFq3Pnu9fzxnFot\u002F0KfiEI+C0SZorFkufHuv\u002Fb8cGr2ec2toWprvjVZaTHpmQY26a\u002F\u002FAb3i+KiGtbjF49qS+s5kpqtRLa8BSM3Lhjbk5oG\u002F7zgAyz12bfyTTWyDMczs1W4d3uswORNPY9hQwRHOWKgHt95668+Okn4w6Gr6zdEjR53ySqqt6w7G65Ga05PJsbfVod4+PVUwbjrwqDIWy3KuEGS3D4GOcm8PFkUZQo\u002FGpxn\u002FnobL3Rp6xBCfeYqFwbihSBb9Zn1mwpEzhWpAaGIaJRrlNNpiUc5iNfgOt9dzRBBSbXgwNClcP4JxShPj24t7H6ZQoDCzvLq7CG\u002FWJzg7uXlfHcrGrDkkMjdMuGQkcTJj\u002FMgCHW9PgI+EJStsNGhI\u002Fp84SmEShLJubxwcDQqEm4JCh03TZzm8o\u002F\u002Fa7\u002FDBNo0IR0ZX1UXUa4jgMTxiwZZowZ7SfcjpGn6RvDS+su6ezUqfVob8m4eR8IInYERbcmfDC6MvBQ+zt2iI1f6OThQ2LVg7f6N4pJz7t69Uozx2MnproymCXwHT22vrp48cLQNO3drT\u002FbAhCrHFpNGEC\u002FJRqDD2O1VgTc1+HA6+jci3jD0wQV5W0fFJZA2WIUQgMoAa9SNGpkyAYhXXvCsXiybGxlwtCtpm1gBC4b1w4GjY7xtga78PBloRLgVu36NbS8696FM4MDte0fXNGWvz8o59rr30KzwhdXhINjAe\u002FKfh5aOkaruTW6MP1oITp8BtfmJMCez854vlAX7VpX7SArI1h3Di4bn9uniX7CE53rT10w7t7npYddp6+9liv86kpP9+rfDw353MP6YcY1vy7XRE7mwPOtId5BYLN\u002Fxs6dWUcTetFOeVWSox9WiOCvfvaLEqI\u002FT1i\u002FmIUcTuaparOhdyX1rhc7bofilzyBNX7yxOnV4fDsSjTu+ZOU\u002FjxrL6v8srYzwbRn86i9SAjlMTl\u002F7tyEWqhpD6fuRS\u002Fe3iskI16pctSpPFSvuv9G1apKEwiOMqQlOvDW3S3\u002F71Rw\u002FvlnX07COEMmYZuBT9isfD3K7d0s4ay54PPwy8MJ0OXY7QWjpsG4m4Omam8eWrIKwZxxD8wuwrsCFuhO4SrRT0U3fOeh5DGHT+inNYb7VozSQxk+dITX8taEGJvT2RwoI8N4KMNNSang5kF4gO8Qno8mfzFooHcHD98aT5a5YThl4MWbeA557+RoEIiDrGSPjXDHoJaojY+rzAMvx0LfPWDD0lMozJUQR\u002F0+lrcPLUAf9WOj0Dt0VL6Pftjh1NjMjYOgT0FnDEW3GMo8k0EFD99oIz04xxgDBvF562ATNbLT+zoWCvAeWhsrTIN4VhzXjZJnXr68kUC8t4lLoCz+WGyoqgknDh8bFyQ35qefXigG04IkzDVYQt643kIAm8PsbkMEkwbHAdIgen0VK71HWZ8QD+bu6TmTvJNWZPGGMEb0m7mZTAiFEQgRYEEXj2RBEWpA7sBQAADAI2TIBMeMiXsyogEbgkr2WSxRaVwteJJJ17VwLax6w5LFCPqIeAOYtgAnwkcAwbQdAEk7oEnf9JkAL5TFNebT2BGY+TwEHgCJf1r6inBDCCDJ2qRNwgTlwUEZ8twHacB+wwhnU5P6w2J2oDg5BOtJiSFPe1fO62kEYWLfCz8Qq04AXSzPjbXNhFjRCDkY1ubT6xG2XF\u002F1d8JXKCD17XUJMmvlKOysPrj0d73dlaAuTv78m7Orr7Iwyap+kcv8aILQ6YD8SDF5X3xxcbWrjSN2H1rPsnG9a2zOUoKSMIsQBTNZLDSYJpc6S0wT6NVDRlBtvTANQRhq6Oo\u002FggmFepv1bWKHcbnNEiwW9RjBMA5Wp86Zr8a1llWjRlofS9VYZvfFWqtRQu+wj2FC3dQxBALCdv88sWct55cebAvl3ThMZcI8PKJ\u002F1ttc+gZmPGNgJhhABDBmhFKFBfXHVzuyfraOlBTwO32cMWmjp\u002Fdolld9mQS5TthgCTNb+tQ1nVssUrVRP4ah15Dna1ebMy3msf6wmi1jrG\u002FGuNXHPs5560O5YfGmRJlDjSwCDY8ODwMsa00aL6F12jAh+mm+euACNVttGscINl3fZ88yR9vPNBxwDhYIsZ4Nt5w30qvXrsxuchcvRm+yKvFI1EzW0Yhw8\u002FMsOiAO81gu2QufnJuQkx\u002F\u002F3o\u002F7vXyRrNMbt28254W\u002F9Dv6RPlfQh8SsrKkokNNzzAuFjR4hqDzwp2PgaA7xkhogb\u002FmEwMgmLvePBr39Pdd7uOsp5jTJMr3LEaAV920ryammeYTzFpH\u002FWFtllOiBjZLsyR9sAr\u002FeTGVe\u002FNZPO8SAicenlVbacOE3QSAasykvOd5KBHUrrTCYd51jcRn1Q\u002FAnTESbJrqxsBinJBTHxgGHKxpe5p3a25tdNabOG2WbGEfLFeENvQRHDE+CO\u002FzWe1pRgJM3Jy82s16Cc8lHWchX\u002FuwuTYfEjOjWyV7PUuJYnGn2Jszhhu03fp4OkscGLuT50TuwC9+\u002FosJe7IRnXOEAsYaygqr+sM6rCLF5hOKaR7GCbPMnd9vLGzWlWGgP30v7CQjiR2g3fP2aLDAMBKPQbP1dWCyvsHvoRW1aU70bfCod7Qfr6GkDg3qd4AOZpqJLTxxPTiPrgGUCB4+AdYIHp3U0mwQ5EL3ut4xtKXf51\u002FPcNDX9c0mWuDSVfNL5xq5Ds5zlv70RZte067P5mBaGlhERygfTlFARjCvP0Nbt9rX58jKD8\u002FCl\u002FV7Xp6pDx7Vp3mH617OONH70Pu5xfVbt89Y5u4557rl5a851d\u002Fl8xh+6ic69iqD13hGW6cxrDWXEiQvX7m6+hdZ1f\u002FhP\u002FzzPDWnVnfbeftgdc9fvMlbUgjfnhorei+cZXBjeAvn8nzdKhmfcrYjwfvkR230laB2L2PTy+j0vmLH8b+NYPAp5b6xHj10dLr5OGH9BR6dTIT\u002F7oivnT17fjZeut\u002F3kHh149rG0OcT7ab84kXhj9EjuHKk6iqH46Fiw+0+jK4cPx4shp9o7csXKZbhpxKnzj2K\u002Fm0WirUZHD4Pd+7ezqLcHLPUr2e5PpqwS0Fm6OBNsqvvm3g8esqgitbZ1OlweLynF2PJrdv3JonVrqFXryVsN5bHjws9yUJ\u002FJg8DD8B472tTLo\u002FiFKr3Sdy2p8bH7fdAEBcyt5nSIEGU8Y5gLdkU3DHAjuwTAEn0Z2DAK8egFUFiBSdojwcjHGH4ZZGf98ZBpmOY4qFEOxjALoT35Kv7KUzoBTp9op3W4VO+v55bud76hUYJhSNbwmv9AeMMQIe6hzdCtRfXi\u002FS4EvzcqCz3qZSv93W8N0EdM2FlQWQxgRdtsU4IHk11fwy+zT1YZfcmwD2oZB6hQ81cwi4Bwc6e+yKym+PitFvVu1kk7kzE1oGgsUjSrBBfxB7TRGh2KhuXJgvq3mUdZJlZKmIs8XuEYcDwruTWJZ5WmAqOg2kk8HcsAmlT0nOWWtX7V8cT0FuBIaQs+ZIpWDIdFl\u002FyLCGBhQepQ0ieYayvS1xqLsSN0XoxNpb+nEcjPFlwgEgAQWL8H0KIxnSM9abnPK\u002F9mkwwFpPeXCXkoG1ixNWJZb1EzSRkYTo0QdroctjwqFjMNYm4pmaLgMWzhS4IU9gT87YRAsTYtaukiMrYscTN7pEYbwrRWtaGpzuWHVkJsIviotKNUprFzPV8zFpyZ7Na30t45WI\u002FkGDwLkvw4yz7D3MnhVgXQso6mXBUzFfuvXNnz0xSyJ4A\u002FeSZs6vPbNN8cH310a8uRSiexlh\u002F1dgIDNZJHCxlo7nO3SwkBa0n1pk7jEu1IULXywY8SpvfzG2vEWx678aBI5VtrLk1sG7hXnOcAhMx3h1RPRiTbpVn7d5VLUcbLfG8unXrw3JippY60A811WXzZywprrTA+urqOXzQnrcWFGyDkSlhVwM+s4ba2AQDHJd01y2Ce73CJxPWFuWkxe3\u002Fdt+8L0J0Ct+MK6FVe9qvjbGebX3Wh9dZSg3OHIOtfprr9W3Ac5glwaHvLnWtc57Tuz5tw26nJpTHvA6M9btNQSTkLvC57QJfuktADXvDWU\u002FT7z7rVB3RFoZmbpfnbD2rc54989Wlc20n0B53IOqUDIT0aVacy99\u002FP0Tzs89\u002FNDQHk+DdE0o1G4aEOx+lLP7Z3\u002F27q5\u002F8\u002Fk8mtlFom937MK8jMUKWc0KL+UCzHsbsJkk1GgYXza2kVAoTa4++8GhNtZl6JcyCIGp8k6vS+JYQO0JDDCxaQAgk\u002FGEwQlgkvbG2CTXbFX1MJogRxCzRlzyUj6OVNjGiSNy6cX0U9M8+vTBuZTGoNsJaqqK0pvWLMDjz01rYVGUzJvMqYf3Ys6OFf2S1a+Mbgp+xs5az7kq4473D6NdPnqzs4rmE5kLQMLvohCQwzFeIjXj3F9EECopdhHndePskwKn\u002Fj1mLhb91GwymrMSE0eSz5z6ataQMMJ5s44K5YrwAETxh1lwei3KvY\u002Fhozo\u002FlaSW4bytys5OjJLuEdWtg3ikH5uxoe3t8XCm3D8uVEXZkLk4WQ2xcSmc+bL3wJflK5k340HeXLg2dPlxFH94Sgt5i1BGLKybfTofNb30xJhWr7iWsActj6+tD89AnsGBuCQvGaf4C3IFxOAdmJ2Sms8sBF\u002FsB7HeC8QGcG7d5gDeUTLwF7MAFuGLutu93L1zqbesYqtTn2oWXc9ZFvmxdp\u002FFe882NXUQYmt+3Ghqc7RaYuzTS793jPFqAd43nsvusIVq00N5moknSzDStr\u002FPcpSdjhOna\u002Fvf71vtc3OehMSDBLcbZ+wzVPPnsl6XlZSaWNvz1O6OAD+beGsC1dwmO1s2+B5RJHvTdwXQq6YTA\u002FMVf\u002FWL153\u002F\u002FT9ttMvjMYLM7TfnxpspIuPih5r7wjfrAG8goKS+BlXhXcE94PpL1\u002FXDGgM1jJXMHf1PZKp53pyRxOzOf++ijwR8erCvFXduAamduYUbNx\u002FG6U+cLeV1vd+IGakOjN8k63\u002FzmUnlSt8a6C47XdgnLXcI5WbbxCdEHcFMeixC9h8WeK1cJhw9U4exx4ssoyo1C1TMeL0rmerhsDG8Zwcgm0aU38dkmb5S358GsUOA9lQ3eGQ3cFX2Aj\u002FYNeJFwb5eT9fWTq4sXXo\u002FAbh1Y5lmYk9ymTfvrEL6dUxbx619\u002FUxnJa3nMCutJVqHYLVbtBOHolXWztvCTXGPtXCcU+HACst\u002FQW+UdwT6heRTXoAFddQ8hnrJCxhGKaI6UXDwV3oPVE49PTP7BvaI\u002FpozjGMZSwIYWC8uDc+h5MkDPH49m7+gbuYfXjYIEllQ6vNdzhFiSyd7X8d4EdbGMiHLrV8dPxEiaqGpn24L7WdZarsQdO+t4gtSRXI2Y\u002FZvcR93W4Aj2xeEWu86CoMyZSW9+iq1qE43eLa7EtHE5hB0EbxYi1laMj4BJ7hYGgDGom0ygJoDRlFh0ICzCJlMaMUA4TToCw7UBuCe2sUXh9mGhIexrj5VGtYg1QN13WcQTrgNJamzqQTd4yor+bHa9xC7WKErMQjDF8XGzsdDEmHtHdAj8XMM7XtapdxAaUC+73gFmfbTJDsAkgNiMZq3+AR7IwNKDKbE6GZe5xghYhAhQDkqChKZIXNcjfC1FU4j+m9dI6zDFuwnQNhI5UHLL29yySZoJZ\u002FUxBsbKtmO\u002FZK7cXJXgZM2HpFxce5qbB1XPiTMlWKZQZEnnTdmViw2j3LczQaO+Ey4\u002F\u002FfSznvdmdfnSN5Moy00nGeVtllBxfMJwzp39cPVJ1sjbt9s1LyXsaAzXZjUEJsJFDaAfCS+12boaJmY2GeV9f9s8v47o9XFek0TbvFEKDd7cjYAezHR185uyVv+M1WYZhA+MsB9mjt9lgemyZtvRTZTDfjaBi5Dql99+3p73sSjXCf3wZ\u002FoDEH84sbSLGCyKozWr4bQeITL4ubnyeZjeMGcKW3PQMV6T+oUojVW5trFZDBHM6ROLkrbh1BJ6M0MdIjeN1IV6HmGebwMTJHJzivGO5dtga1s\u002FjG0Rzn\u002Fndxf38jshB4NwHRikGExvml\u002Fwpluet9yyvC+M1vO1P5PTFQ5jWZ5rrbe1HWsHnhZPXIwyfGL1JEixcu9JQWY1YT0fmlEbBEjVqAhv9xLm4O0fJpjzBoHJL370RfGFp8OxJUZa5SdjVkXh9kZewu5H8AmdkqrOnFk298KMMD6CpzmmICLo5nws5xF025F7Ls+GdtAgQje6EsANLL6c8JvFGkwIFOepjjickXcCEvWH9ViI2Mbt26vL332bhe5x+F3oXWv+m2++SSA9HN3hZi6MLUHS+CWiEaysz742P+EBfBZtecIlXGjbzuYPDWE1Wzx2QDuLbXSRC\u002FfEiTZbavMewq61e9UYrO3zZz27CDxWbcL6tvtdYpY47uMpGfubFwrlKG\u002FNy8S+RuvBqLlwaJORYbyW4QIcYDAAZ66bBLb6Dmacg6uqi1C2hYJBGfSawAsuGHMoPZ4ldM9LhQd1pq2LMCebWEmMXtpnPOKpSnlpvnh8bUr1JAVGyI11ACcEjQPFJqO5LHxP3y7zbM3NBxr7MiIzRQsa\u002F7sEAYYN4xG2BDvxA\u002FkTYJ4S3pL2CsbRk61jvteeH+E9JR8KEizA\u002FoJ\u002FC242Q\u002F2In+EnrLx4ykJPjLWWp9WhSSZwZru3Qca+N7\u002Fmvw9zpXAnZ\u002FRh7m\u002FefXZflwaHiOhWn+dZS4vb4Tzmc2mze8aO5BldQ9Ps+bOG\u002FcFHB9Wdnhb9tvTENe7xXN1cDA8z0vo0T\u002FdjH5Z+kgPcs9yHXvTTzKeG0KMU0DbRU01oJ6E6OmBNhLHuatM73p4nRQPYxZSQ+s2336\u002F++\u002F\u002Fhf6mdt6v\u002F+D\u002F692NrWa0zmqijTj55Xj1wyijDXaPofrSVEa8S08EaIe1ZVlXC7p5i+YX7YTUExP3JCd9fvrz6l\u002F\u002FqLzOEFSef0GntFlhPRokf30l4P1FJw4vnzgcXyQJtMnb\u002F7qPVr7+7sbpy80qyVvvI3LnV8\u002FZUvOP48ErwRC4yLd557CRdwxV4wAh1\u002FNjJckxOznf0gVxEmF3yOhimTDo8W0J0GSF21d+XFMTkKHBIxpJILQfQuohtl7MGTk8n\u002FKIve0u6Hct4xgS0wX1q9ltBeR4E+kCztdidoH5j9W0e9DMfnZzSkhM62DOE\u002FKIPw4cbA1gQG36j\u002FWhWNytcsl4YSzTiypVr0bHNkd14Achx8lHQ3lutwcgd1qk2GVvNy7SzVfaRzOf6Ayni8nkU+6D0qE0PTyX3w7sp37gVrbB5fzPZNs\u002FI4NCSW6aU9rlz58YzQCaSJP++jvcmqAMOhB6q064ePhDS8iBmcjfLU+VwmmgxYOsnT6w++\u002FxijLX6sjfbxjjGcLPC+TYMOFqSwwcBHSsWzU5cJ0bGqiJ+irBOGMUUaU123DyYawWhJhSqfiKWSlkwgotkrMVi2ucWamKS2gVMSTLIaMHEM5psQEBgB+CvIrQPH1QG8tWdEDBJqXuFvszmACkHdjG8206asoARpX31j2AtIYWwyBJGWHj8OCv0lrWeC9XuXmMZD5A8cwSNgAe12tm2vu3vPEyShX8tK7g5M14VYRT9h1i0OM9Copb4zBfDRAgJ+4SkxAxopYR145RM93aqpqQMxYQaSvOyLDsBStjRu1y3J4oLN0cv0ggnfCFi\u002FKxSUy\u002FS8vUBk2BpQ8Ax4CMJHQd73p4Qcuolv22dIn4UsRdxHEmUO+Lg+8LQPZ7zWMw7t77t4XNd1V9MjyCAeN7KghhFSFMv7i1CCqERIcz3zEcX2sH2p6uf\u002F\u002Fznq3\u002F1l38x26nvDH6iC6Px8zKgTu4ZJoE2E3R7N09DXHp\u002FkXJDyenHIaAESgqZhCyKhURHZR9l07MhvInpYktruf8xxx3a7DnWRbse4\u002FA+r\u002F4s57TjZAy1M652\u002Fod7ti\u002FurDnXnmOptGJ9MB1cBj5huPWCxN61qXfL87tluW9hbJ5jZPBwO84VfDnW1DEGXj23pjXrf4fndMJ\u002FLz8aX7f1aX7f7stikeqUa\u002FqPKE97tbstNOiJkbpE77Wx9GkZv\u002FmuM4NjfiPMzjD7vMzoMlPzCI1rrYkkAM1Y6hde75hSbXV0GHvXetdHeO8zIY0lEAEfmIs58P68fXN\u002FlMGrV66OsPnF558PkaYgPkn5Vl97YrfLnzh67HSEu6SqhD8z9mGJgSw2kpOOHz81rlax3NshFKzQ8BNzNicsNxiCmuIERULky5Krp5\u002FRn5flbrCeYWSz42zrhaGyylg6DIIVfuYpnBf7Db8p7DwBPC50SaUHeQjMlb6xEJ45y\u002FK9dylPmbvdM1mEJS6DCmEub5t8RgyMmHeTm\u002FdY84uWjjAdDd7bvJgbieksU29et3HILBpK0HieSw7uphG6uq\u002FKLqtCBF6\u002FeJx1PCE3xfpQtPtwY1k\u002FVcWZ3nkkuKg9Z5SI2sMsJ444IdacCuUTqkJ49iI84wdoIF7wwVQWK6epPspz0SVwA\u002F9Zpnn0KEXWnEEFXLgW3BK8r169OmFJBJ5tmIVBz6K9TyrFqT2hUafjV2LieW6FA\u002FDCHE\u002FAJ4hMNZ7Om0+JtjsKLBYWeCIhBOQT+glvFCFwMQIAGlj\u002F3tYXSvMoFsEpOuAz5LPeA\u002Fta7nsTvowv3FmMPEIkWRq7H01OqVhgH\u002FwXMlU7cm1eqrzmfq9Wq0cMTvZljsGdecZMXOcWWkWpdq0+gOM5XxNz\u002F9b5oYO1698WiwxDCImLkOfepZzi8vhpefoxzU1HtumeLz\u002FgsZ970HJp\u002FQjhlXCcY+ttvoYg+mA93e\u002F67fFt02gn0EXrRibI59wakA7bhbyw2h0hD8PXi2iEuPE1cNx41T9\u002FnaHv5z\u002F\u002FauD\u002FwvlTGZROZgG+sfo7f3g6nKwU9XfV9jYXrZW1F\u002FsOjihwh+JruaRXN4K9u4XO7c1gtLffX7+pZPSpPDolMzIs3Lh+Y\u002FXVr75qg6NTq8\u002FKn5mE+WSJUx9kyIxAP44WvM44tT\u002Fa9Yd\u002F9CfhVOVET3+z2vXXv2yH0hurX\u002F7iV8Hym9VHZ9trpfWmhIIL88ETxiKswpPQDXQB7uxJQabEvn4tUTLBulC3kXuCIbIWnDR\u002F2pGED36HG9YXNFh4m8RQNGMjIfhOeWp\u002F9NMfB2uFPFemuYuDh6UajXGhlzwG93s9ytNEQRY+w5rNgGTPiWcZaYXkKJV9s\u002FGC\u002FxPlsqhEo5zjNq1HK1TIuvfLX3VdtCW8PpLc0nAztFzsWUcq03h9rjl8uBro6Fp0U4lwhhkKkSVjjSd485htw3EnyvXIOJJwT6C\u002FkUx6u2coxIH+a0eI3PCVcE7bhxXw6D5r6R7J4rfq\u002Fz6VpKIDx6J17+t4b4L62XMfR2DLzk\u002FAfVCCzte\u002F\u002Fi4CK44vBlBc+pIg0EIknCPWhHYWUsiFCXIhsjy8zsp+PyGfcE6YPti9LnmY0Pu4WPePz59rYQBRrqWYGAJ\u002F8BDt5nGEMStjDbKOmzzEAjEQf6ViwwdbljDCn2MIXUxN39w7gBohFf8rHOBRcVY0LAwC8TgKKBLWLDBLA8ayByCF8BIbH7zhukrgSpGYZISuMT4WMEzceEAV4DAG75AHghKSWNv7szCVAIML9mDju5fCsOykynodsod8hA\u002F1zY2bNr8Q1MUCgmh7ll1gJWEaFyvZixdZGAN2LmhaNCuymCri4OPCkbjrbHVtU6I33G8h97OnD2JoZ1YvKif1yD3NJ0XJmiFKTUjtFnucQC8BVab6qwiXslN+31O1j50tC8ZBKOAJUKnhbe50zP9wRE2i3DFT0nw+q7LM637brXJMSAAxDxxSCi7BPuGeZX+UkYgqAh7Odwh16K027F4WdbHyaIZTUzHjVeeepTypzT6CxQAeyMJcmv+uRBQod+LxlnAT7vaE9NaXB8Qcm0cx1tZvdrjzsXuX18JgPdRz9UDso+Vejm2GtLiDR1lzbczNGGpkaadxUbYmrGlaWtzJlEjPX94bYdcsseAJfK3rtjDbdM5BaQS3o2QY6rS1\u002FObzD93aOrVMiXucWJjcMNDgac51g7Pzq772asp61xLmbhYwT59dbF7m6rmWIu+aMGTOgtPlgsY\u002FuQBdv9Vn7mTz5\u002FJpA664y2T2H84SvpYa+E735F7b3jF3ycLHiIXBEXpVK7if0eBlljUbj2mDZ4xbmgVUoqPNezzweWEjByK2hLHNmMuEekRz3qWog30Ma7PcDmt09uzH82zMyviXNedq3jeu1Gt\u002Fc2MYA6VY\u002FOco2q0ji7DZHEtw0g6DxRKbuaeQmQ9TUNvlMAsOnFX5iqBunZ9m6YEbx6MDB\u002Fd\u002FMe2ohoJ+UMwvX\u002F5uhEX3H9q4vToQo79RaMzdYmHhB+OFpKyPPjrf+CiAjShcRVMvVG5V2Ai6gL6BdQlnGDhLsDFhZjYDo8xKFM751LwzWDT\u002FxeNysx8q\u002F6Wpy1If3avdndFkNJaHEA0TkjelIJtHCg0v5O2Ht8cCdjsBAFM2Rt7EJYm3+vQp83aBPhkDP5ggLvaVdU5b6IsQnal2EwO3vwDGyoth\u002FjyLAsWiBn8owgTjUQCy2lF2KOysjjagAmTC68CDqhN2qp18hAxL+mGu8DbCv0Q4FtoRtAIPVWAIz8+e8Xw8X339m2+iHdEUNMP6dw9haaHFDCUBdPcJcwPva1lge3ifF1z0bi7MEx8hmEcfoM+CHQREfGOxpi+8YBGauU3xKtcNfkKfLWG6M1v\u002FtONYcGys6PPs5fmL8FcLnRvBeBBy+Q7n4JFjoTPb8W99pwAAQABJREFUfI1Rp4fVZ3SpW4HZvLOcUCD8c0K7P1zQNZ2dv\u002FPukl5LGyhA98Yz56LOL2N19revhRZ0TfOND\u002FkFieUhgiM78viaq53xWB6PBxndXqboKoeLtEuSPHn+7PD2X\u002F\u002F629U\u002F+Sf\u002F5eo\u002F\u002FMd\u002FHi+zB8reKqncLQZ5Y3X85Jms6ipQhetZi4VlTt5Zi2lTNblEr8p1e\u002Fa0ghqTaJ5QWmgnKnk6\u002FP4H\u002F94\u002FXJ375ONKNz6acI9DJaxeuXqpUI67q\u002FMlsl\u002F79tvV7Zsb8eRTJaweLrH9+OqP\u002F+SnlUQ+t\u002Fr1179JyP86S3S7qMa7f\u002FaXP48OVdkonJ947yMJucEET72KW3tOJfM055Re62VaGN72xKttJMmwJw4bjBmHSARzPkJ66+XwG9wxvxRLArXdXhkf4R\u002FFmlA9sfuB3JEMchL2nzzLGx4duh+tpUTeKfzkyuXvE\u002FbrU8qtNTqRgZbwfL1kVHLhxXKF\u002FuAnv5cnsl2lo5PwFtyS9+ThHIq2o42MiGLTyXgUFUo8JZzxBN1SPvfAsSVnDw0wJn03F94ZZQjYBHkyAgs9eNGm3YxZ5dFKtPByfZ78mOaB4VYFH0n4ig1cr\u002FTv40J1g7JRzEWXSLD9T\u002F8LM\u002Ff\u002F\u002F3hvgvpxtXNjYkdKBPz442qSfner4e5eXfz0iwZ9JAJbLGWLZUOKa9duJqCZgAL109oI0Z+cP59r9RR6tYX4TWTAZHEmgWZL6AXkUyM3y4edr4AQZEVA9gQwGMxCVAmkMZesopSC47lnCHiIPsEbQ3eMRSPEDz9HALVr1aPiqSEUjU02tXrrj6qpvPdOWllWcVYMxHLcVQEX4MM8WWcJRwQ+oTAX2vBI35wzDpUGAIWt4fe2HXGjG+BHLrcF4MWS2k8NDEFa6pbqjzrCS\u002FlEWh2tVviGTOfF4sfCXmJVsMJt2yMTAGiIgCzhup0fbQm\u002FN9fezsJQ3jR\u002Fr2p\u002FV4mfyiXawhwTkVdg8ymeibvFth08vC8NX0UfLts2Msiy\u002FyrKSYCmGbMCs7Q9SVuW1Mv1d2B\u002FMWgN4dmLe133aHWg7HoIt75+Oo2zZJqSSG0yZWdAG7ggGNxE0ba2Vl5c\u002FKeDhT\u002F+o5\u002FG5C5HPBdmbj4QdURmrL\u002FNn3FCOEJfYkLzGeMI4Wi4vS1Wj24Yd11CCUEdQxELPv+6KDo7grndL23UtNZ6es7oIy2ExCOCepeNu7Mb53fc9Qem1\u002FWzaP027UYIXIchI2w13O\u002FLMWMwDveIP\u002FK5edhdX8ABpo4wmFt3WWvzCq4Jntpi\u002FTf21wlIxg5ubEqkTQLswHe\u002FD\u002FwNk88y2TxPp+rPdh+na\u002F507bxt3bONU0PUtvoK9+Yiw3Cd7\u002FOaIUxfF0G7MXWMID5zBP63BQ\u002F9DMvdr90FDZd1bED6jTGTAT1h\u002Fs56L8+YE1ttzbrXBqYy\u002FaxRhBhc8tI8zDIroelqVpaf\u002FexnWY8Ivrlo6xMX9NMIOfeqDUM+u3ghxf\u002FolNzCVChhLGthdHi+d2jBzZjziQS\u002F3VlTMa1rCb8E\u002FHNnz6c4Cxt52f33xkuIvqnTjlEQ9IV\u002Feba1Y+kmMPPIjYAVAKoOwYO0b29W54l5VNu7dYbLvb+ivGbFUV70QQq0EmG8deiZPB73SM5CC+5VZeqXX\u002F06i2HlzoSe5JJ91pw8iqFbh32FtU31g\u002FrOe8caqGqBeHqCDEWd8io+XqjL7vNLDL5FC3Uag5ycLGMp5\u002FoT+47pZrHfX5jHnmJqo4MUmF0Jr7sLk1trvp6ngN+JFtwrAXQzhUlfR4AMACifQoEkppuTRYBPmA0nhKdg9pQLSbJ7Ll2aPt+sPNv5j84NjWSIsGZc4sq2Ee4\u002F+2xXLv4Ps9x9MLhBkBhvy8CIykM2j1NJiReAcpHAUkL77MERABK0WdKVYFN2j\u002FGHQoduyZnZl\u002FLHACUkZv+BNrA6cXoElpdv8uwWlsZpyerGav63v\u002Fpq6OWhjFHK9OJVQnxeNce7uzCoNam9vIcYWwdDUpf0i38LP+AFfRm8O7s7vB4cgDctzOJJXYxDPoNJyBQZmXlacLeW+q8J+Dy0aPt5CIDftr5vt\u002F3bM\u002F3YMff2h2ClZ1usdPBae2ivpPURxn3WaK0u9G4eMe1Afm3N0fvSet\u002Fqx2\u002FpxdYPpibY05ZuOtwLN9DMGcv03BWUk+giQtLvJpExqVMJdPHdaCv8fa5iVZZ2dBEdIicQrimkLMnHSjxUUOGXv7y0+uenjq\u002F+0X\u002Fw71TVpJ1Dg4vHnd+1\u002F8lEAewLBjyT4Uj98isbj1YbyQv3C+k9dWq9a45U+WVzdbsKIzeulSiZrLA74e\u002Fi55+ujiX7\u002FPpv\u002FiZlQbJoOS3B7PdXL8+u5oo6HKkP69GtsGF1p8TUfc\u002FjyeHZjz47Gy06uPr04rni1r8rpv7K6tK3lyd64Q\u002F+4A+iPXl1GpTwDCFG5B\u002FGLnAyRrPkMF566pR5tcuwsGDH\u002FizCQnZ37BDuy2glt6L8weQhpQjJCW0yPSE3n3\u002F+yerLLz6dTdVOHCtmPPrzJh4rkuJBOS9vecXCAYr92TOnm3rV3EqOVXAkmiAk1b4saI315B17WgiSXUGFnlBQ74XbErT1nZDOoEKZUGkQDLJi\u002F7pdYin4dm5FMxhibvZ9YuR5CVr8mh+lXo6i\u002FCL8SblKGzyRhS5fvbZ6cVeFwSON7eR4Wo0bLwaP6Ozr10IJi7lvTAwOdrsH13gOefNMeXbcITyxnv++jvcmqP9P\u002F+P\u002FHKLuWv3dP\u002Fv7EcgSBGNo0caxZrHGKIsomfB0E3M\u002FdxDrBmvq9bZ\u002FhdQfn7\u002FYAhannMZn4IQVn8VQib1Vokt5RgyLe4\u002Fb6fHmwxhFyT8BvbqhQ9jXTyV45v6L0SIUrBxL5QuWLokakJBQHuMKiO+leemfe7mKAMy9e0\u002FbfjftqQHQuAgf0F+9WxZXQhPLLkHZogyJCSl2ZeUl6B6KIYtzlvHNQsOqLQ58CAFrVRYeGysoU8nazgKnP6o8sFYjMgDQrmBnyzo\u002FGbLTOGmzdWM0UgBEuGUp1Iayke6jccI8gK2s044St8SwiVm9l0VNdvrZ4rHelJF8PyZ0KxcaCqaGNKv9xDk3QeLOENxbN2533z9d7W2Tk8qxJBjmgn7X5lMhIaFR6Mp4MAiWzYkkuzdZGuPQTc0StylW\u002FNWenhHjXo\u002FpqnVs90Qa+N2IBYb5YYghLoxwfDePzOHDTyt9VdZ4AsSN3Gt2hH38tJrGrScml327uV+sRRAQwUaYfOZ6s\u002FbDIrpMDWqC7YS3JACCN3PkCjdYW5LhuPli0KxsLCOEqKagY1GowvbWjit+YXAEeOsEXocJubKmILWXg4CBSIx1ovkaxRMA9mB9RdztCgt3RjDrGa5h9YD8L3J31vi077sxNqK5VilEMfCImZAj6+9YBORG1\u002FexgDQmzGhhftNcz+M90JbvC3wjPvrgNOuT\u002Fi2HPmGGfts+uzDH7Su232uqBpd51f60HbIav\u002FlzaGOZn8buRPcsz6VkNF+jsWF8yxwZ8tKWix2sikgXoWBZC4qltRArbLMRhPdMyVbozbUI8O3bd1Z\u002F\u002Fuf\u002F9upP\u002FuhP2hWwMDGCYvh27erVsZgQ0rdjHu3Quzfc1A2COLj8+te\u002FmbH89Kc\u002FTTA\u002FNzgHl6wTS9TaS5uUSVzKG5hVhnUHYzxYvsXpXMDgQGK4cUg+oljZBGW2oY8BCY85eoyQ2ZbkKbUsfgTLg\u002FUVrSRYeBbhnFV77dhiYXWNlZhn108z\u002FMd\u002F+m+Enw9GKX6U1818nShU59zfP7d61TW3i21Hj1++yjod3n0Wc2OJ40VyrJ8sHIRpsXZtcb6WMLNnmFWKYUluFPaabI5SIKuGUdxe+94UfkhwH4HYPRLRhPq00ythNpp4KkumXYvhlnAmVjIhNuMV7XdGB3DJEIGmW090TNnLxwn5aPTFCxfmPorKP\u002Fvn\u002FyxysHNxrWc4IOyDK1YuFi20efGmHJ94\u002FiMxWsIzGLNhk1hWFsbF8yTUrlChaNK9uxujHAjB5KoXouB6IYPi5vG2D2PI2rb74uUr11ffXZGwnOUzzwd3PCVE9QtKA56hlO3hi8dqx+6xlZZ8quKMfKEs\u002FeEFy+fu8JlgPbjXx7Fst6AMQWtrKUPBeKcty4LbvROmCaquHU9ubVo5f\u002FxGuHnLO9Uz4CCyNG24iCC7fUDcra+D4\u002FGXbfz1A1riOWimOfYaxafbwCY8R301gW9TKllc9d29mt\u002F28OmD\u002FrjY9du000WeMO33vpaw7Lfl39bFru837S33dgLY1ujixetz\u002FURrFjo\u002FN4zwjW7jV696V53lcR7gnfGk5wxswZochL0JqTbesUnV3ujykYS23VV7+t\u002F\u002F6V+s\u002Fu1\u002F8x801uernyQIPwourDmaaf+PBzcy6iWbEPJfvkoRi088bYfOF20adCwadKo8j0cPXyS83YsXtZFRXi\u002F5IKdTjn\u002F6Z3+6uvT116t\u002F+X\u002F9nwN3e1JuX9XG\u002Fn3Haq9ZzdB18uTpCTM5Wv\u002FOnjvZjr63x1N+7EefVbLxs9X332dFTom8W1gu0ngnwV\u002FFFvN\u002FKLlJeOhzoTMJ04fqy9t7bTJEZqgvO\u002FJsg9P9Bwu3bRsjgrMCEwR0Uyl0iyAvP4yHyO6n67Uz8lz8XELqEMsp3RqPGvgQkkfmqNRp8MBgIsyMPPTJxx9NhTfr8KTQncvfXx+LtjBoeEDBlCD7m28uzVxtJqfZP+eTKjWpDKNYCbpPXgMDZCB08mp0\u002Fp\u002F9H\u002F883MzSnddN7ht6+qMf\u002FWjo6ZUrVwYYhC7rF6F\u002F4swDJhuVrdeOfRX2NBfgAZ2Ao+QOkQtghmBPRtTWvebbGHk7RS+g2Sz7Ij32H0hWyWjwvo73Jqhf\u002F\u002F5azKJwiQfP0siOhqxpKJevlqzxevX5j76MefzhEBoCK6FBbUsZv5cvX4sQ3lldvXKrRcp1HOAT0rcFZysBsBENVhDVDsRzArj9acAEUNUluCK6pMoxEeIwl5CpGL54JFvNcgnTiE4GWAiMjSjuP9hcffX1d7W7e\u002FXlj74YRqGe+lR2KQzk9WbWuYTPXRHaA1mWETBMSjkzROf5s4ClxWRZZy0jWFImJjwhV9qLNvo5d\u002F5Mmmiu44S\u002F2TWwMSBGku2GiAZw0ZwhRgRD1kbMC4ECPFzCZCPjFydJaHADCx3rCqEEsKJc5iybwfTlWDG2e3K9YuAsgydz4Rw\u002Ffno8Dteu3MildisESyBOaFZhQvwkgorwPC804Okm13Pln3Jhnw2xjhw7PfHj+459sHr0qnKQj560wcu3zXsudFrkq5KGnwfkKTFP2yb+WVr1\u002FgjAof2StyJcIeWL1kA4AiIqYebJjeI1E4i4vq5evT6JGIlqEco2NEiBqxurD04da6fUa6tf\u002FO1ft6FIa996HDt2qP5W7i2p3pog2moZS\u002FRZQlea28a8dz9BNfhJuDG35ufB3cergzbPyspX0E4ESDxiGmWHGt\u002Fa25OSBX5qtbaxpoZX\u002F4cZtW47VJsx6T0X7GFIDarX9rFo735HKOenPhOEYp3T34U5bTE2F\u002FaiEApl8Y3AieV6tjKQrxO2WS0Xps1a56p+K\u002Fk4aBoLre\u002FmIrCYw+e5qq6JDycc+j7Mb2ve5rmuc\u002FHvHMblmOv97fe5b+sa4+\u002FM1rflbax\u002FnZr3eiXuk\u002FXQffBlORaGPxZ\u002F44sws\u002F4RZLXIK7W7+VyLoC\u002FNL\u002FdtCwfLySVpi3cKQRWKAedk7WOUXLmqCOxPWKN8vsxK9tmnXwwDB+sTY93wCG6PnxzLyvugmNNLMaystglkhzpP+NgM1zazIBEK1TlGs7761a8T+u4MrHoG6y9YQbtUYThTEjT6IClVtZuNO4uAKbxl7WD1fxOSr8XgMRDPkqtBcF3PwKC6i3km5BIoJ+61iRYuw0qF+dtV+XAKelMXLAQj4ZI4+IfRmPsZHViGJa4qFQs\u002F9hNEYoB7E5ZPxIjsKUDQPxBj097RmPbRcZNn0Wre0QACKwukOWAb2MwymJrb9YXKFRLEKyfRVvhd7qe6XGcw83BTch7jyps3cgPEf1fHOAv02p52QW0dhNgwMhDEzYGdodFUIT+Lh8DOxK1LSWis2eaLQC+OnyWLUI\u002F2uUfCsGQziaqqddSLMaxIPA+RC5fMet\u002FcqMtuB0aWd\u002FwAPLKKbtx5trp5\u002FWp0eU807MzQw7u55RmDGG\u002FsAWLePv30s8F3fMP6CBe6d+9WvKs67FnuCDrnLlwslIhVffF+mdt9heb8xb\u002F6yww31WausMKvv748\u002FT8SvO7Nq9ECD30mZI+SFKhPiEy4MhbAEaQXAZtxRygp5QJfAwDWA3bgi7BH+ALBinI+a9f6gQ8TM\u002FsTzF396Ri8bI4Gh2tkrPdRRBRn6MTQhwX3RsDXcMdUdmsOHGMx71lKzsJD86odbY\u002FK17Pl\u002FPAYODP0w7M6j3fhaQ78cJoPNn+L535xP\u002F7Yv\u002FqzrTh4OistxYGi5bveKbgwX\u002FoMh6Y\u002F0za78RKG+Opp96W4HAhe91a9KKK6upcguBndeN3mbSqzTCWUlOpHVVQ6WvjCT5Jf7t99uvrf\u002Ftf\u002Fe\u002FWf\u002Fef\u002Fyeqbb75ffX3pN6sz5z4amJVEfSzlbJP3On54Lh75x8c+XN1qA7IbWdHVa7944eNoXeu359ti1wsDCbav376xOnzl6BgPLv7kx6tnrddXf\u002FNVnpt2UT32UV76hOLd8b\u002FLN1d\u002F8S9+FszbZOdQO5Z\u002FP8bAjz+5MKFdd4ossKHk4UJnTsUvkf\u002FrwfVGYX7yBXeEZ8bMmo1Xf1xYzb5y5vZVChkE4M1P82QnRRUOlAE0izPruTnn5XtXXo08tlNVoDl2RA5ERsWX7dZa6bE3Lw6v\u002FuYXX68ufXM1+rI+RtoD4RNctRyesz8P+wcqLfUC50pUPnxyp7ajAdH+9ari7N19PBmt3YAfpcTXJ572p9GLRxkchCvykp8qlv1alvi7GRkI0RKIKcf7wm+w6P3SpcvRzoXGsMovpWVXWdovpFAJaevzJ2Qh9dR3Dx24liJOCadcHi\u002FO3bhvV+5WqI4QOkoAPrKRkmUfCbKE+vk8Z\u002FBfaVa7p3722YlkVcnyGVyjNQeShd7X8d4EdczPBhTfbH7T5C1JV6fLWka0f\u002FGLv46QFjPdjpOszRjp4WqIflRMlYm8m7XhRvU3GTqTU2bSEMiDBzH4koWKT6f5CFNBI8Q\u002FqkRgM4J9PVc9bbudSgSz9a36oLUS4MU\u002FYqSsVZi6OPEjxchLvFTv8\u002FJ3uZjKpP6wxQbIklHVRUUId7N0P1beLUtGcWYEo+1EUBZMsYtcSAQq1vXWNqRY4rA3c3tw4R6maceATuRSxVi4oDDsVwl7iNUWvZu1NH9j7YmJjWWEwBIwLsC2CCQ0SQyExXjnWjGpCHRtaWgEy\u002FqAkBNAJJFIHsPYzNvjNsvZkSALuN9mKnyZ0L9RrN3DvACI3WxCFZElPCwbKe0aq\u002FrJAJClse7E\u002FCOukYGjrd\u002Fp02mxESZhRGLZEQp8jMUBkjPk7XydRSuLXFx61mIIe30kELzrRSBqscdzcb+QgakrHQM7FLPbVbJPM7C6VozegzZI2oyB7sqasLv15N4nsGJGIxXWJqLNJR\u002FlRZpbR8R\u002FeU05tcb2ukV61fNeq5GfIKrCy9ymT72GyIPBiAdhcw6\u002F9QEjQPhdOFtbu9EPXkhL7z2ur797fuuS4UfuXa4bhrV9HVIZ7A2DmjaNqf\u002F1F8EAd4sywjuU1yY42Vso0I423zBGAvDOxsJztH3MWPqy9LfGtj4vz63\u002FxuByXVp+3Or377Qx9\u002FjRNf7968e0vTT9ww+8Ayo9QgbtL89Bdn3eeparB2SdX+Z5LH\u002F61NoQFMG9WEe4ZS0lBe6OoWLUE9rUeclH8IXHiyALv3laCG9KZtnm2fyAE0I8y+z1q1dLDsy6ndD9IEFQLV5WIW5SAsijhDcMgmVX1v6bgIAiivBLXNcOmJoKCcEo\u002FIdvFHW1gQlI9BtK5N3ctRiBKjHffffd0C80DF3QjjHzChD+MAjC8whgzRMPm7UXK3tU+Eyu84PtCHwgl7drxNa+YL2n9NaO6z45cCFhoeoL0RdlItE9yhD8ZxG+VWjN7d4P1u\u002F15uCLz78coV\u002FJtqnq0NzJL9LnMGDmeTtfQ5w62EZveP6WnJ0EoebMfIwwFj0TJrRTKEEMVoWo5w+j29Hu5+Hbu0rncnUr+6pP6AwFg\u002FLDyCFu29xwx1\u002F+7lJ07lk0U6x8IXv1iGAvJl8iqOvcz6MoLwCz5Pa+V\u002Fw7IdF8UKwIzXaelVAs2Q5i3Sg8Rsyp+f\u002Fmm2\u002FyGFZBI1r\u002FoBrUnkMpoNBza09lnmg6OIafznG5u9D6EM7W2712T1Y0G7fs3dd8JOjFt3tUHpPG9qu\u002F\u002FaoNqL7KQPTB0EU5ETeLQd4f3EyoU+EwaAbj1auEobGMB8+D\u002FzXDmDNCcGvpmdYbref5pNjA\u002F8GX1gKdoCDoK5qPPi58Bj4ugrL7oa3xO7d98F4tNG\u002F5PVSecfrdvPgNvi73OdN3QDHt9IuPc9Lnrd87SYkr6mF5d89c0x9j2TqG9m19rrmuXX4jRHptX+l9fvLMYO0turc9BP3dOobu9Nn1ujjtg8\u002F43Kusyjynqv0QNvy+3jqeil5QmFly8yuvEinG44ZHEMTh9\u002FVqmf\u002FqV18Xclto77Xvy52KNlw4Ozj8YlMYqJCNLOtvd69O7z8xORQUZQrVvbu8\u002FyUoh6OHE3gft4vt1Vs3spLfrmb7v2iDtd9fffbj3+v3D1a\u002F\u002FPkvuwetI9MkPldF5dy588F+PUtovh+eKhCBBorD3gxmJV+y7L+5+bJIAxu0hT+Fp71IaFxrkOmWXX83D+Lt1ZVC9j770cWE6sI+omvPs4hT5k0l+UchCBPLeIIm+w395AVDz3aEy6qpXL16I4GUMF2YSrufvnze5pSFyJ5MWTh6NNqVwrxv38mE2PWxqKNNzzK0vtkoTCUFHD23MSa+f\u002FToqcaXYtMaCL2zFrOCXbMro03TMMVAwDh+LqrBO6XiWTi6K7zk4ZoS3K2pnMdPPrkwBsDvio7gURAzjvYsslENBiAHmhvPIg+Ru8AMiz6DhxxB1d8oBXjKvvZ0OVC7ns0wzDhoo7+jx+2zsxiNnz7OsBsNZMBZdqOvwfdwvDdBXYiCeB2JFvfSRCECqzehSu1NdXvv37VL1IPVnvvLVsxTUilLzaFDNrPIWp2wBzgwPC4WxMiOd4twGsAFSawpXNpiuWgyj8rQX+U+EU7Rmg6hUtkDU2Gd4MaR2PE47XTjzsNxSQzCN3ksLKw6qpVgIvHLFjoFIMR4FcCKOXr5Uv3kAH08Oly+3JUt3hYBJR+hOYR3C8o6\u002F5qQENKypIu5oukaD7fKkWLcF5em8SCemgxYLGYAthYgAUbWhO2dFQHk64RsggsmPuEMvT9nUUG0XO+WXs\u002FSjCWZIgyAC3JI3rQRE+VoXwx\u002FnpOWr9ID4iIW7mnmawC7J2H4Xb89CChvbYgTY01LIYq5UUTsrpdjewBZDVVVHe7fp9EX7pILnKCDCdWpmG8Wv7F4hGwBr5hZJHaIba2ejnlJ4tL9RTnpWfsIZgnxCRB70oAJH6ykt27dWa1\u002FeDYXWN6RYAixJeo1ZYa9zEMNj1A7ONic9oNrXEQGnmd0kiXyVZVQbIGNAw3Dal0d+kbo5YV2D0LuCdvMY+l731uwLvmdl2vYhjrmj7Y05t1J1\u002FahL75vf17adx+lAQNm8SEYLcmtrLzaMRawBsbWIpSqd2A8rtPetnVqnuOE5y1vv\u002FN5ebYf\u002FDS\u002Fb312gpXrt\u002Ff8Tj+nhd\u002F+mWYb42+vXX4jqHvNmLfad62+L0+c1fBL9y4vn5ckvC1Bou+EdUoJodF1S3nJZY4ISiykSxxp7tw8QZPc3DMI2IwAYN5zCWcL\u002FLXRR3Dr9cUXn0doFyGWl63Gh7h3+Qj6Nr9YlIWsveGrEArCkERmsOW54EdIhPnHaK0b1zFXqjjPpynq9+5s9P3Q6uLFLDl5jR4+FJO+GT1Z9pugcMgp4T3j7q0bw0TQrFH+mwPWXztbEkoPhLeskqqlYEYO8yr0701MHU1SkYTiYB2XHZMT6ps\u002FblkGkxfh95GYFSs6pkXQxogpQgeyjrOQbwuF5nQR7qI7Y00XEiYUS1KlJFptlzsSDqVmznO46Blkju+xDs1RQtG+g8KBui\u002F6qrYwizqaq60RqqPn5pbLWBInGjMeyOZXX9DTsdLWT2PTLwoSYVzd67FyZ0BnTYU7cnmGvrYmmKUQJHNz7eqV1q2Y\u002FujYk0u5pTvMP8ORXBnJZ5QQ3lsKABiQN0I4pxBye8sNwH9U3QFrQpzmuhZCHLsYdp4INPh14+WZ\u002FPWv\u002FjavqOTWI43z4PAwygk40B8CAUG7yZjxam8E7IgPOojQjIGD0N1M7zDOgAVcW3sGj1eveWIX\u002FCHEjzU9GMArHPDUBnHme3BvzsE\u002FvzoWXPR71KevW68+LzSsvqV4LHRoubYr9GbgVjPTlvvc2ol5uaYP3TpwNrS57wwT7tGGBrbp3dCEftm2nAedcRqXzJVb7aIXGnR+nrzcr7X5v1y7NF3\u002Fm1fzO2OPxIuvlh8itAtPfNk873lTaGpVxMge+xLMdsSjd4R77xLO7dopTJOx7TfffLX6b\u002F7bBO53z8pJKKfqzU+mL\u002FBkQlebb\u002FDos6TnXQnrcrNSq6Mt8cfGTXncnZC3xjvaGqLnBNQrCZPrCavnzletKXnkUd6cZ8EJbwSvD3r\u002F8UcfVS4UHcuLk3zFiKeU8uPCQoXXqqh34ZPzVdO7OQotb9LzYtp5LY\u002FGN3kHXr5ohTMs2iDtcPccilYycOKkcHD37jYoij7yfEuwtY7pjyPDkWHMp5BcISEE3g9LqNy372h3K\u002FyQx7xyrbsfZ2BKcF0\u002FUQWk5mlf3nMbKr6uMhz84z3cCN+U7t4tbK68DgoCPEcrHRRNuT2eaWw2m7PxGdwXUvc0nHouDC\u002F5BY5SChgmVVeSsE7xFUkhVty+FAw5yieiX4wde98JaVSBSyWtjDLh\u002FRTRSE4dg1P0I\u002FLTq7FE006dqpRr\u002FRIKNXjZN7Sobg7dGQPGUzs4R+PWCuFlaCVQvqfjvQnqmN\u002FZs+ci0Eey3lSjOEsqEi5UA0HdLH7xSWEaamKyAL7NbSA7+HAxnAg1yxfLDiRVRvF2iVuzY2luNZsPoWWsRBYeQ\u002FSbTT3ECSlNhjkLJ5Gpj8BzG2M8KouYTCWA7j94vjoy7sPCLQIKdd4xvlcR1du3s7zsfxqgZIEO7JYQHBaphUANsfgdgrEI0wkTdQwhoHk5MO2xsu3KXXKvcT9Jmch1zvLzIPcJ4Z+Qr69clsH9uPsxmRdpki\u002F2hRy1MwkbEb546IRd1N1Bjm3rFgbrWPrF\u002FckVvQh1kIhVe9xXYdrL2rV5z4EIQGLBAOexdjQz13fvtTlLc3s0pQow32hL3I2N6itX8YYW+niTu\u002F3o6sJnSj8WpxazfbGjcJvWRFlKCTtvWkvjh9iSB3ZnQX+XFpzK1XUhYp92DkNfQpoQb4KO+N+p2Z7gRdPFUI19rElb8wg2Jp64vlDslMDk\u002FZg66CpPDCVnfWY56PfaNqcTWoGe9\u002FubkG2Jue0zBtZrV\u002FPtWSy32upv\u002FYyIkdf7YeaXpO7YYgjLl37rnk7+YEXyPKeIofOL73Nx32eZtr4tb8v9nts1Y5Hcalg7TmK2xrHAyRJ7rnfLi1KI0TW7tY2xgwHEY7q19VztaO53vvbxtye3r13GslyG6W\u002Ff5F49\u002FG0bfdpiqq5GsPHlHw7jcaLwoSW5c2HSMzdbrfzQVjfNo7ZOwCXCsD5tP9H8w3fKI9ogSZyF3EVjee7KsaYE2xgsoZjVFeNjwXr7dkmInD73PPDGgisvgoAkuWoRzgqf6h8ljuLO+qoXqomwshPKl6Nn93\u002FxjCHiS24APEHwCVwRteC4Xe1q41rMlcAkcfpo1i45H5J9VReQzDSVg8BbTEdVAwzkeYIjodmacN2\u002FeNqOmlywuXqFRMm9UQv8VcL7JKb2PMmcm\u002FXBPbwLRC0MhHC5WaKsMofmEKMxTm2oriWeUhlHz578lga3Pb\u002Fmc1EYwRqPQXS0Nt700q9dPDrhDI\u002FDeOkg2awcnMqwktv7bcC5oz4frOTu7r3RthjXrmiSJcTAJPB6jnwQvAP+79yxxKVbC6VlMWXPhQsEW8xQTXYeDcoN6zrDgBAkibti04WroGvggKfT\u002FDyLgU5bnTvRdZi\u002FECiKwfGheyXWNU88MvpHwBXewqvCO0HIFttMeIGvjE+Ps2S+ja5PZaGeAc8XC\u002FWOaKdYeZvQlVx853bPVEI4A0djJHTwggqn4hmYHaGbU3kqNHFKRg3N91GaCM8RJefn1eepK916oQjTn\u002FpKUanrPVcuVnCBLsyqLH98du0A8ZxCJ3umdYN34Z\u002FvzhCEOr2c95T5jL64dpA03O\u002F5kHto43Lt3DS9WmiwG60FHHSfdfQ+\u002FWpdJx+qJuZEb797nfsGqjzHDX7WdjSmJuqvnjozt3VN7WKS05\u002FlvHvc7FL8yejwgRcJhy593jpuV\u002F15VliJPAq5LlMJJbkAlX2VMgb3vvjss9ZuX+Ft7fpb6eQ98VNwQbHMfDg4whNzosTinfHLN2vlbmSc4r0\u002F0I7eryt1LMGaERG9sxGgDYZ4iZ5Gr4TYKXdI+VW+UVv36zd83rWR1znYu\u002FHo3oSKUUB5oG4lI2FYDBI8QYwEH2YwVaXIDBjj0\u002FLFNtWHD75Olli9lly2WT7J08J8eJHeCFHJA0ZpWb0Rumsnzj1jRX\u002FzfCSh5jq+Hc5J7pTrI08DPvze7\u002F1k9fkXXzYHlUxdP1le35Vo6mLoYOV+Gb9+VhjrwyfFclOKM1iKMz918sOhdxK\u002F3+UZUD3r6eaDFhUfjj6ED28Swid\u002Fp\u002FUeZTbZRkTCjKsx382gQpaSTL8\u002FK7e9C2y+NvktzTmBnadVnw\u002F2XUlVirU4drHr6AN8Uttd0Q1KAP7PS4meTwIsmt7zbbTIu4iePHx4b2jVkn9UFbBkHG2h2zsr7ACm7aZuh1XjeF\u002FHe2uJkIUY6ihiKDSFpqiCyMFCVY4eVapM7O1iQbLpzvFcTgAHQD3MfSK0BBKy4bx9VdLNS5avFi2EYlW3iHtzNTzdbAv6jbTNTkwNc0l1ATYkfmMTpDCc0IFtqHYgvmrJXg5VYzzqy0JQQhoGqbLKtquDAI2giU2nDBCAMREHoQjCS95cEIRFJ+ty32m8ypoRCFxHMD5xUqWZGFcAtWhmMfEQkqAF6RE2hKs1HoKCwLIIIS4Tl99vu4sHJVyywCFKQ0wjqMbe3f4M4te7uoQIBm4RA0A+lvfaQlQP1B8Kztu3zWclMNemXnlu40eylbMG7QCwkk4qs9ROoneKrRVjuXf\u002F69WtPp\u002F44HnC\u002FIHarN3GgDGokKBijAUkoKxVB15bL0LOt7W3b2+KTkx+R1Y0TF2SjjURU6qCyfQxAqF\u002FaL75JkCEh4F\u002F6zAWB\u002FOdxyVEeVW74vQssEQXRFlc+TIzTY5jxguGzI3JIQQm7KbAOTCw0XbrtmcuDKovXTtMLk7tNrdv\u002FZl533bzOuv8WBuNpot\u002FeA0HqgtzxfJnsfr8bnOzattNd29XN2CMqdGU+KpfnatdMIPJDHNrXIS63ubQve3fPHAUx+nz7z7Lpfo3t\u002FRn62Znt0961v\u002FH8cMtfuuL79tX+jy\u002FOz8ftn7vM2bcMDx15neYszbm2Bp7LS33eV\u002F65\u002FsI\u002F\u002F0mSQgj8jywrA1CO7z0fdy9uWtdP\u002FHH\u002Fcb6PpbuYIhApz3n4Msyf3DodYzmVgwu1+9nXwxeEeweZ9kh3G\u002FjC1pz4ICEON62cDbC\u002FTyhC3zwfjnHXUuQIjTZ\u002FZRwjvFRmDAAlUQ2NjZGQPv8y8\u002FDncJXYiqPH6GTWVx63ghKrT1hNE465yiu2sVoWL42w0VCqlDAo3n79kVr7tyuGhQmUH+Mbbx50al34TzrtvNrWbcfJxxeufL9eNZY5QkpT96E189y3wq5aG4wFNVWltyXFOieT7iwBpQSiY2SZnm2CJiY2r790dowFBMjXPKIsPxR3tGqXGeF57QAsLChrVW2cXc03J4LGOAYFRoj6yNrNqOIPJIGPmOhtBE+xIujg6owsHxL7qXMCD2jMBDYCb+YJsVkvRj\u002FMYo0X5No1jw8ir4JXdBvU4NHfVByr3AldHiB1CXnAbPFD5xTy36JWy2puDW3W+KhlAsCkRKQ99ojZOC1+X9WstmD8SpS1IrLjy6x3tnn4lWhCmBEnP9m4REseHVjjCqJGAMrQkUIIbxDxm5e0INWt1nVHXyLEYqwHm\u002FoJHwfxaBpXviDeVzgwTWesVzjOmsRLvW7uXa4d7lmKOU8r8fNAU4ILbjJgp9LG\u002FN5uWS5tzaWG1xfa\u002FP8ztTOct9yf8PrlDacXz57ti\u002FdEq9wr69oxnLd0BGturB7Zmzu2Tr0bRrbPvHD9617ts5Tct4U\u002FgEezMcI7OY2RWpnvAc82sVav17jgy3\u002Fu4TQPV27N150MFg\u002FVAL0vv27Vn\u002Fwd368+qM\u002F\u002FjIe+XR1tdhzB6WSINsCJds0t4U+HdqfRziYrXhcFe6uFbZWwuORwmSSBeA8WcPK8sK4d38C7N5d0YRw79tvvg42d2UNTtiPF2\u002FcSLBsmk+k6H\u002F3m40pviHJmTBNmcQjedJe16bShvdLkrz46YViqE\u002F2HOULDySDlWsRLxcaw6qvGtOh+LO+qCGvss3rDCGEdhZ7Hr2n4b65oUzvDFfknlFc1UIH36rKnDhR6UQeiuZB7ffZAKp5kzj9pPZ2lAD+IKWV1x5PM887d93u3gTp4taPHMn7lJC+c0fV+qKHQnuNyT4mg9utGd6InlJqn6XoCzfazyuGJofnSio+rg2ld7c9jeQ1yaZ2mwU+Z8+dnRK6LOs3b\u002F9VNK9rKVDRY6GSIguORT\u002F39mLFV5lQbuUoz60UmWxzU+Io2Sz4bIy7drHglxjf2gh7kUf2LKMm2Y\u002FHDD2lNLyv470J6pBMxjyXhiQBk8Waur+4PYk8E06wK0tEg2AJa\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\u002FqzMKDeXdO\u002FnjDj9Nl\u002FKwK2rJ1jez22v08jLtTYHMsagnvP3Fkf+j\u002FPxVgQOFf6O2PVoa1bF\u002FjwvP9Xe9sP611f5qidf\u002F3Y+o7wdPvy7bfXTJs\u002F3KNz+un3ZYQe6anmw\u002FG7704tr2V+livmsuVB\u002FWi800LvmDKC5x4\u002FeN8WyhcG3Xp30hpjhotA\u002FmJihIVAjOU6Yqrx\u002F4e1P\u002FnZ9NwTPK8n5nl2hMMRYTuO7WOfk1NldlaV1LSqG1WpWZSQoKXeABL\u002FQO961RsQEhvEgi0SGyTECsEaCQlEF01XpQp1nsw8s2c7HA7H4HDMox39\u002Ffyu9wn7JAWb9B3xvu\u002Fz3MN1X8Nvni5zpl3tjfeuD6ZscliqgUyY\u002FuijD6Y8I48OBeBOVYy8B80CB97DG0UJf07JD8aWBSamHp3iPrYF+K5oDIbrs9cSItEOG2uMlxAjGYvug+iIpKpDWbtOzf1rp806FmyzBGKO97OyKg\u002FLiEAfhb88Q4Hnmq+UTW7vG9evjVA\u002FlRpqUy1hfTeWVaUqgTqaJDFe8v3z51nDsq6jTZOE2X2sUHBIAtc3udDNt7nk+TtSIj09+FExsA\u002FHCk5p4eFofuqP+uHwUucpzBQX845+CStAItAq6zRhHM3f7sLg9uzlKs7aH62c8rAJBrwL5vZF\u002FTcebUgQNRfqzMPjB7vvzxyAvvspFfdK\u002FhWeoh1zNGEk0WO8AZ\u002FhukdbwbDkfryFFVKOwDdVhxnBvmfN2RKW4glZEgn\u002FYuJ5JLZ5AxLw5BlZH3SGgjXCRPR7JY4m\u002FKRsXB9m3vr3PE\u002Fu\u002Fp4TktAAFozETyhFnmXRU56SkICGG2OnB\u002FaWpTha53zv6+Ghl+NZ6LnBESBudHAmmPdvi+fo+1xtXrRlHdy1aCRF3ywGr63dWKH7zjKu3cEd7+uqfs3hfD9LifbkQuERpKcz64T7V9t97\u002Fw801+0zFMLj9272tXO9nF8wn1wXB9cW2\u002Fx2\u002F2Nbx6YC\u002FN9mvGrC9s+jeL48hbX+gK\u002F8IjgDm9wAsx47kAK5XeFQBz03oQ0\u002FF846YvgRbjL8+7fHU68SAZ4Vrz3V9evRhcuFPq0rLBTsCAYwtfs1KkEsCToB21kdvhxAuudZ9VFJ6grTdjOvhWwEJ5hrZRwPhI+kWmmilnPph+V17CqtamQcriQ4H2TVI827Z+YcrDeJE0Iidw7ZZVtzEX5\u002Fbu\u002F\u002FZt46ePNGbjTfaIFfvr2W1mwtXl\u002F\u002FYTrvXxz4pVyKuKB8gf2N\u002F4n7Rqv3OeTBNWb4Qgh90ACsSTtXVWggZvHphRhq9W8C5e9VjjqjV\u002F9NpU9w2SCb0MpHKW9DMIz8Hw7GSPwDxa6nmFyf4KyjYROFxJzKuVaiJv1UQI2mbmIh5QESlUE5FAGSvBLLmIIkYeCdqnGNZXmmrtDR1d4iegDgvG33+W1iibLM+ChoIjYbfRsYdIXEtbF1QuTYfSsW6OA304eM1fHjDVaRtHmseVVAi4LBwnrT8ZbYa2BHQ8cozPjJ6PKGCt2rZwh\u002FUZPxMz\u002FWMePJqiruDA1Nluhh2mcT59cm0lTGmiy81tAcZPKKI6lJisnjWPcVZEGTPVFGiTN5HiF\u002FcVXjzu6SacNH861DWdVBzBRewulIOT5jBkh2mdzfd5\u002FcnjzVQyKBVc2ejO4mEMAt2dvyUu5LKe+eIzKOwl7rLS0PpYJgrci\u002FuMWibhjupICguUhehNeUkcehtRiLVnJEH6WrmW5bofDrC6MNQg+jVNCx97cS4R+zG4xA5alJbBLcnU\u002FqKbcYNQYAuLGIvAsqzHhAdEFfIBnYjL97R\u002Fys4jZInRc3YThFQ6BKHW17zYsevqMhT6hIK3x1+9\u002FtrlyrcxwSaK58x48\u002FWJz9ORrJa5UXvOVr4r\u002F+jLNNRfvN43jebXPb5YIXHmk3QnqNwsjutM837\u002F5bPObMtWfvnG2tbkxzO70OVa35iil7E4hT7LO903SWkQxywRCqdwSJQkC37j5VfMfA8xifvdu6xrC7NrHvViiS4THfLDySL6zpqxse\u002FY27tqx\u002Fk3RwMaah4VcCGDT09hxgNa58VtT6yxmVqKvB3c3r81afcSs1r0Dk54NfLRPiHHYk2cAYUeA9T5wsdyx6+1\u002F8LsvnnXPHx6rPefwDO+ZAcy9+rHzQH9mfbtprG762j3fP+35bupn4VHNzKPrjtWK6z98wru2R+fn2mJ2O4A0XXn5uVvnFfOIvvnww7\u002FN3jrpdD\u002FmcI15GK97O72YuPet27b91hrmDK5HGOgWuRkE4HH994nAxwtiGUa5DS8puvDGuGePgfCGIIzBrfmDn0tIhy8r3j0LUsLhRx99FLM9sXnnnXeHAcLvB8Wd8soRzOCadwmRuldJU8RY\u002Fg1hhHIpeUt8szaF0xjbJPQFYzxFGPGJaMLRaMPjoU21Gb3gdZPMqgzYuFiDbW1aAsaH+8clVlaGtPb1wfgYI4yZtR\u002F+sw6z6KIhh2M6hE1MmpBOuJzwjN6vEo6dFwnfU4mqd7COJULOvBI8uXSF+ghZM58EGjT0lbN23rQRSMloMUBeRsL0oieEv9a0vrRyE3O+J8F9aFNcv6III5wD0hcllm8KSaNsSpb3DEEdBO9JWHiWl4JivztBYBhi8wi37yesUBAIpxgrfnG1OQEzqkmgBww+pwp52ZdQTngxf+NJafYl\u002F+q\u002F\u002FoKJA69RqGxicjjhQOWpBzMGte6fPjZ3EjsLX2g9CfvW3ntZNtHSTz75ZCyZ4EwCsjhVQjrvH1pFCRDfiybLjTIWa\u002FT5Z1dAfopM659CAi4pA1HyERJYra0\u002FQZ3gwDvQRcgyc+i8uQILfibvitbWPYMrgzfd34lJ4NRxxgo41rvQs6Fp3TEo6tx89td1X\u002FpxAMJ5JjjpHSpxLZxd+NnXuVV\u002F5\u002Fadez3e28lbPeMTXO6ZfvSRtDN8rLvA1\u002FTdi+cemNIxHfGhY13qvvWedU5f188oE53Uplv0a46d73PeiZ02XQ9iV\u002F\u002Fw1\u002Fow+U07czoezXphzGMg6rOpICDi3amKw5fFRF+\u002F+WVw8t1Y1pVyPBpNGH4ezFC+DpcobadQseO37rY7e1XhwKsVF7NuA7UDCW9y9gheZCEhJ2SnF\u002FElc3c8fvii3LsvPv90xnau2uMPH9xtn5I8OOHMqxdeDWcexRv3TegNTwzBFR04Ug7amYT3PYX0Ci0WPMRAgHc26FGOH4H\u002Fnr\u002F7jfC+45tj5aTtj7591\u002FPkqTsJ0wHb4NTuYJnywVIut0XYnVh3eXeqyXx57frmw2ipimRn2uH04OH2T0luISjfKRyPARbdjoI3N7yk1qI5fXB686ioC7vR2\u002FW4IOBZr1XEQoIp3MLn4+HRDEY1\u002FUdDwdN4PxOYD+QZIJi\u002FSI4qK7RxR6O6XwjvnRJnGWIYJFjSedrgwsVLl2acPLHau5Vx+Va4yitxiOEFzeiakpSEdV7EU6cYYpNds6Cju5SGr1I4wJpSrUalpO7RSljfTTkh6POo2en5xzp+NEH9m0JXuIy5SrnoZBhP4lOl9BAPmiLifFq1ltw4NBMLY1K5oZTEUirwuzJp92ZNPZTV9NuImu3bDyVUiW9CuI4ctuMWa3mEK0JJFb9d8oAYVRrr\u002FSw9VWCaXf7ELamQIguae2MqBmRx\u002F\u002FrrGG7x6DYlgpD61TLPnCKGa8fNxSgnRjpmgOgg\u002FD0w7mHWaUCxGOWaRu5J7pQhUrWorjrvAQb6qMQiFgwx84+KGZPc6iAc7M3StD9BcRhabSDswdwAAgK9K20dwDsIJgAMM0Dmomv9XsQVQ\u002F2ema7Pk3hTP7mvHsTw7t0vvCbh+9r1B5sPP7uWIBGOtFERpvjFV\u002Fc2f\u002FebTysxVdWIvA4nS055UOLmRtIlghcie9nj+v4ohed57d29e3vzaSWRjoYs3z5\u002FNMzQPSxm90KCu7mE1Vt+pSoMxmpb7bBuFCAK1r6yw+30p2oM7wJLHQUnfE5If9TnFKiYd5MxVqrnESUbyyCs\u002FiHIwwCbdHGz4I8zDkMZIah+L+t7jCdEVYrRpkcss6F+8EXhWzkDiPoIwlHqmdnWy3vxFwOfkCrfO78IvPPrsA76MhPk4\u002FRt55RrPzws2M4BrnrtYsa1rQUEZTGkxaCH4YK\u002F+ll3Bw8anpe8ZFS66tjhTztf\u002FFkv+4Pzc\u002FUHndjeM2\u002FvonZ32nOrz\u002FPVrxn7umjeCU\u002F+rvtAZB3sqzPmYJ7tVf7OG\u002FvlmZeCus\u002Fgc+cH8cMoCO4Ir2ck0LmOkRC8EFIxwuLWEXPMF3G3Q6VsfM\u002FYWVd5yKWwqf4iObI+RIu+aBc5VixhDkJgCPcUqsl9GBivTQPqnLrodtsllK+NL\u002FLoxVQJkyy\u002F8JFXcE9CoDFTrCmihHvC8\u002F28VTxWBN4n+1bJLpUD4JvxEAzNU3ptz4ilbJMVHqZh\u002FgwYa7t4Vh\u002Fvuhd9wvwfz3wkgDQuzAxsEGCvfP7ZMFfVYk7EtCVUocMYkNK43gVo0BOhegTOtUi11XjVfDe\u002FcAezJExIyBSP2434ZXQtC3qCiWNP9Oy7EENYGj4alNb3bmoeHtmuvflWHxwME4QWM3UPwuN5Hq9lFaeg3LXdeBY9YzGvDCUWQ9K5NbTfAzpCeL9Z7P7xxof2gw8H2jg0o79oIfpMERPSI5Zd6AMYUD9+hKjebwM4ypA29pVUyMXPUMQbQPFRBOBOjN58sJIRtvVRv9VrZkgSa6ycLsFeyOdX19ujQgxuazzjC94oKtZ9cgN8D5mtBxhlPKEoLGG2AXdePs4czeV4QivFii7oB0+GfjTExQ+iZ3jC0Pv11MBwUL2+7eAZGIVbDvigb87NAQf6ADdZ2fEeh\u002Fv6Ch267ld0qnE55\u002Fm5b4T0vnd92uz84HjfkU90awnX2vTO9V5tzwv6M8e8cl7ktmnLeW2OgjgP7PSl8YKrH\u002FZrHtfHebg\u002FfRxDS3xeR7ZwAr\u002F86Dsvh11\u002FxzPknTUIh3nVifhKIH\u002Fb+MDBb37z6+Z\u002Fs\u002FlHf\u002FmPC90tFrzwtF0pqEePnSjHrepF++PrMdWWbGgS3NtXha5E1tkzZHcC4N7aPxAsfBdcPk3+kTQKbr6rH4TcZ3ne72UQYLG98Gd\u002Ftrn89k82H\u002F7u95svr9hk8GF8sjyc6NvVqsaoVvLdkVVq1R4Fe9pj5mjCND5IHhDWdzcrP+PkqcuvB\u002Fcn4\u002FOVOAyeGRz2Nv5jhbxSNs2H8DXrBnfQnCf1T7nqo71D+Neh+n+9sJ\u002FrCenWg4L7XTKaZ4WVigV\u002F+Div9dOvygNhBMS3TWrhe8lDxwns4YnlQCcoDg1zlgtcojPCdUwgo5x+7wrH4e+dOyV+MvgVBjvFKZpHERNwihEUTXjUvDgI6OgvSPgaPQk\u002FKFevZChBP8ABiz5LPHr7tHYAEtp3\u002FkKKfjLn45QztALPOXqssLjudVAO4LIynjdufF17lcw9osJNRunmh2fGLuzdNPf\u002FGL9+NEFdrez7CXCIDuKIkbIuqcIg5AMjQeVZ3dv7po\u002FiEBOkuSEiwCb8WK4e2ptqAQ\u002FaLIAgrhavDTeURyLA0WBteHTs+OkBHmE2Z89JJmVNKzM4S8zuXbZzbeewgI1wP\u002FXHY7hqriOGCKT4L0mkGPDRElq\u002Ffb6IIkKHaDsvZn7iVFsY2cqQd5VYW+M81s5gQm4QdGM1RhZ5CzkxkBFUmf+Yk6olGJX2AM2jiLm+jSUxcHqS4ElQPxCjGEvgEKb6MrGea6kpHQglJPpeKAdfW9d8VxGjAGQIYUqMxM6nzfXtNlv4phJKkpceVyXi+te5tSWLEG6D5vvNt9h9WvKlG+dbi2Lsz2DOuXNiIsdPlFVeKbJ9xbbfL7OZ644VkcJ1N2WEVf54WiQX3QiWjWXi2SNkgXb9SaCIOXN1d8PMvzCTW7eqmtFfQo8kFRZN8\u002FltREKsF+aNlrNuLSa2LHQGOhYnA258u3Njei+MX0KXmYKmfrTgT\u002FfVfrM+SuLREoVdRVgl8agPTRkZRSg4dLU\u002FPbaeX6zFA\u002FOU5qblOb\u002FzeZ3BrNZz9W4+e2p7eFq7c8yHbvZ3\u002Fe\u002F+9d753nlEBVEcpa1rYHQUCvf3M917+f6ddjvZpZ3Dp3o5Nzq10\u002F7O1e2fXuG2OXb+rK87bc84m+J1bbXn88tm16MzjvVRB33SwDw99y5GvhqimoBXFl1jBE+UMM8NI535yWASIWYlJhSx2rBawSWCHAGdgs3qvMrTsZphHoVaEGSjOyyw1nZ\u002FiY02ohHT+CQvF+Xu8uW3hqiP+3pHgGe12RPu8aAhvHdidtYBfZNwtjvucufmvfA92tBQWN9ZwLlAKeYOggkFglD3uPufBWfwnrCHRoSp7uqf99RmY7bhyqkzysXKx4hG1X9zvCcPk\u002FlZlprKFGYlwmDQziMxJdUlWKdVqlFm8ki0EE30\u002FL2YoZAYewdIJvW+ffvKKylOFI1lPSZ4mSvWZZ5FOTpic9NhGkN16tOV4SWBf3fhjAJLVmK75MVFx5\u002FmOaIkyGMAAEAASURBVFyhNoV3tN4s3WLQnzYwyeT2vfAudI53yzt9t9YYMUavLXSegLzixQu5SxjGdFnDeQ9YAt17rYo7qiJRoFgVF29YArda1OiFebZ+aIkXSWojkFHO5Cu4Z\u002FoazcfAh4agr09jzClE6D2mrEStcnbq49+8oWJFmzUFK2jQvhQ5u9yCa3ziQPP1TZY18CTHSLIu2Aywkar6s0K4rCe4J64LDezC0J46NbCKvhLKKWhdmHVB2wiG\u002FZmfQHvg2xjdB462B8haQvTCJ+eNBRyDqfVr\u002FVnUwn2eqtF+9G\u002Fd1hmErHPOGKdL\u002Fdn5vu7d3uO+aUczf+9YuP89Ldp+dxvlMMydJ7St9e1132fM3TPGjemABMPWz3iiIay\u002FBM3VwE572vSg5\u002FpnrT1vHsyjcc94O+\u002FbGMRq52CwQMGz74C5hRelq0d37m5+8Yu\u002FyaJdLe6SIo8X0krZ3DM5UGj0ei8h+8jJMxPrfCSeiI\u002FfSTax\u002F8jh6NbTbpTQ\u002FCh8BaNyQCQc\u002F+q3vwtnn1SX\u002F3L8uZKE8ueC\u002FYtvvhmPfbb59JMPCoMPGYMlYbQiBO4mcB6JbmB\u002FN9tMkkIuSVzS9J0UX8YGyrYNJk+eyBjWdMi3wIsfZdV+Hl3yPLpo11B0AN36JpwRjsIjfioDK3ynPKva8qD3Cik7nyVdxMStjKUvkgHOnW2zsUMS8TP+NcdgX0GOo0fCOaHO3Xu6dytsYafer65XxGM8XEtIV1a3ZRjcGs97nsnxEtTWZ59\u002FPvIVuhbEjVLz8EHhfeEZIzEvlhAVcsr5NpKiRMBRtA8NRtPl5ojOAGvC\u002FhZoJPD3vKIbEsXPnAsikp0e53lHcw4cFGZdlZjmUa6MRP5TWdJtooie2zzpVkrJuTanRIPQIj+MQT\u002FW8T1W\u002FwNb1KfI\u002F2idUfOZAADONcz1qooCt\u002FHtqrSoXawkoh3TuD4eRBDvAZispymBNSROMSbYBJvkh1VswSRG4wvIWKVZ0+4dJszTzhJwMYDdJZkG+F98cT3LTG6VrCcYmZ2mUJXWpvcl8EX0gvOeqdRbgDFKBHSFZR2jTQcYnRotbWJBax9R5\u002FrAVFhcAIONZJTfYh0jYNNMCdIESwrC4RB6NL0UEVrpY2PpNWIQxYAT4ke4D5H160WJno2wscDFRagQF3QJkRdPTZEgqCOkrCiIsfchMpQfVicCCCBUfedRQvgnV74Omepnz+3JjdPUF+NlR9MsCglHYWPPFKOX8GKe1EiHiPfuRrwmfKcKBY3zSNqssowTB1pfzBEB6HhEgFuLAkZA3ybdUnjqZQyymK7WsGVrrVMSSsA6HUJdzbp58cL5CUeg4fJ8mBsMmMXss9zOBGdxeBJCH+cRIVB\u002Fl7WUZZOQj\u002FHTqkfAnflICKhr5m0stHVSYoxxzbbwCXF37j3c7Cuh5nAuRAm0LBn7UgAR8JfxoSiG\u002F1HAaa85G\u002F5g0B3DROZDvzo1BH\u002FnvOfWs2sN5wb3zrGe3+Ef9YtlaPV3Pmipi677i1nXSvOaYND4zLe1N89gcvXPC\u002F\u002Fe8fdObfs3d7m2uvH9Q53TD8diW+vLy3NzfefcPLsdxw8b2r6lczunPb9luKt1MEMNWm0ZDzwAx2BtCR1r\u002FNOX5n+8aMG9azdvlpVeo7Z+fq2NalithGmoqKLkIjwZYb83WHNCHQZJiNkfofI+MPXF1avt6PfpWFm4URH7WZPQgZC4O7py5uzxniMsxbB79mkwh4Ej1gRKIVuzDimjqo4Y12zWE2Nw\u002F8ksrebhcd7D249UNrg5CgfBWkkxuGyaCK0sduaJ5UcfH1adgcDqszwPghsP3\u002Flc6M9OB7OFYvBcoTk2ciNgn8pSfO2ra7P5BzpLaOfa9Y7jbbxz4piNPoSgESiVxUUbCS0s7isGeoX9FTtaCKKYUfXEb92UPxKdidk+C+5Yc1vF5gs9iilHx1mfKD8slIRenkn0TAWeoVNNLoWL93Q2qbpHwGe5EkfPcrVym+wDQRFxnE6AeaV59bya6IQIeykwq1CIMF8l2A4dUuO5sokJ8Szbk9AV7zF37qGwoCdoM5z5+ONPJl6dJc784S\u002FwEFwtc0h9650UMF4JIS92JaQoWjN90m9tfn3z+oQr2BzFpiqn80QeNV9oobVH9OpHndmZa5+DS4DqlYWBrpwo+EwhCjOaY4Bsfkdgjp6rTOEzOkehmXKXfYarAH09uxVcgV3\u002FIMDOAbbmJvf3+SX98r0DNhJizbV3LIOPR+BRHe0YXtQ4hmf2mHcs4bd57ZlFt9b9u1I+\u002FHOMcI3pdEy7vQe\u002FZUlefCwajf\u002F1rtWPda\u002F3KgbgJCGcIW+8UeGy5xiXCIR7mpsWea1jfdKGZ60hr089mvehHzOvXQcLdaYYbOFY6CnjUn3q2yiltctg5LAvwAjkPUNR+8Uv\u002FjaB7sLmT\u002F\u002Fkj+K35XZEt6aaSHD\u002F3YvH0ZXPN2e\u002FzfMT7B15vbCIjFgvwhN4JwT424RodAJcjtco4+H9vNPX44f47puVWTxbPstsTFgf7LD81s9+Fv+3GeBnOj8es6eN50ltHK1fUPno\u002FqObr9t35H4x1JRMHmRyFCH888+uTH8OpqS++fobkwfy\u002Fu9+P5VQVFa7nwx2p7yUQxk\u002FjtpjovGzIj8tlPmLK1+kkIbTrcWrecfJVFc++yT6Zufk3V1vd9GiKvZnWD1x6tzm7cuXU2zPzn4VTyoReeBA1nd8LH5NWD\u002FJC5YR0Zxdy\u002FsEFgnpYMj+CQRkZSXJGmrEv9Zuo2g8zxaZbh+aWJ+Ppjjc77wQPsL2o8KN0FGlbR8Km40+nuleu8ASzE\u002FnsTxSiNLiP81X9BTM2TX62\u002F5OoZFg6klymjLXLObcQa+21w5rP6WKgQTsoUXghfH5TpVeXq2PJwtrfKv3GZcQmR\u002FrQG1\u002FlCM6WwJTFpqEMMLzoeJ6jpWUdKGYKkXyxUECfpYIE7ov686+mCPr+J20MyUdB0FDEgfgwgz9hcCEOGEyhFHEBwJwIcNgWhQXMcL9OAJnR8E9CZ5Psh43n2TQPldCbRiukmkxjoAASVZBgFWcpUZCCYCRHIYpWhTIiTArp0W7vV0yGkL\u002FaiXSWHZUeZnEIK5ugkA\u002FXKqYA9eRpAyaK4YocYEwAFFZvAAjIs4ajZgQLoRnZDOefrB2IzZKOo0w3WghiO18AcoQUJOF3mStP5S1jATOcm9DBFnKt28+2Fy9UZm2rOkY7RDPiBcNn5CqAoX5o0HuDUkgkd3CJFkRhhFB8e0EF4nCz463HflJtZ1jSnkimujZ8OMVYUeVLlIe80nAcC8t+X5zg8DtbQezFykBR1qI\u002FWWii5+7fftBTNXGJ9UXDtmFDCmX9yRkx\u002FhPnIngBOiftCkV2DkUcuUAaHzWNDbdmPfkxQm3gg8MifLFQtW65ZWIqjd3zWXzgFmCKnNLiOAaT3\u002FIJVaFi7w4R4vtU50B81MJqMmfNR\u002FrlfndOYbpDJD2qbmaw+0DuesrxjWdiknhw9uz20\u002Fbv3PJs91uLb12WpoPa231epjrujSf1307757G1kte3jfnfvire3faXM9ur+28fOerVqYfP7z8cmTbd+jhDx7Yfu7vy\u002FM7z+iPc37goD7M++sOmKZcwKt1tC4EvHBGLVtCwIREzLysNRZO8OjRdQ3Nev\u002FsZ++NcElYVlkKEYdn6IKXkotMLphHdxxEDZU8evWcZ\u002F0F07fD61MnCZRKbe0fCz2r95NKmA1BD8iMZ1spxQvQpYsXL0YTbF1fdY9gHhPRBu8QwZMV\u002F1Z9O5UAxxW9QuqAh+oqWVvRrQS\u002FXjJhZLeDfUKSylXiqZ8HQ0GkXidUJ1hHWyiynlFBxe6iU1at\u002FsF\u002F7nt1188ktBM2nwTnxx5VGhAja25GCGocwoPg27igWw\u002FCAoZOiKEUUvqtzVoj4SO5n+sF2sVKx9Ut3GTc3k0qnEdvCFDK7R5MmB+LZX0g9Gx2ZQErbENYCU8jRjvhBs2J+d495fKWkIcuCktBz829NvWJZ03JXZ4kgi2vkvVgyLFz4KLhzWVzCwYeJJiwgKG7EmSNXezodhwYuHOULrRc5ZvrWeiFAslf8FyQM+s+ddNTAvAjScbi\u002FuUsmDf9lFeEnzDe8IgwQtn1Ek0fo4sE+kD9uwBvvH3mZH5a3\u002FmYQlB\u002FJrG19fHuhRu2ol\u002F9BH9CQK3Z7izBQod4LJT8VK3CM+L\u002FrdkMcn5p3Po0Z\u002FPJZ4YdINd9Hev8uo6moUdT\u002FtWFntOCj3Gk2vZ54XWn5vvc4EvH0KBu8r6xYntYdzrnn\u002FPrfvQazK6YYtflpnXLHB5zfZQ7ne0Cfoy2E+6dl782Y6jN8VbEQx3u6SZdn\u002FdS1NCAebWGO\u002FQDDmoZnuAfLL8TmtX8sqY\u002FDXYkYO6urRlouMHDXkC05gutvb75\u002Fe8+SBg9N3IOvqEsrWiCo0fX+OTTITbCT\u002FYK\u002F0qw9A4wb\u002FdlZVKFrnnOwVr99luX27\u002Fk5ubW9RubNxLuKUF27+Vpfv3Ny5t3f\u002FZHE0\u002FNyCC84vUs7XImwM6TYPNkAur93mt\u002FE+vJA6Di07FCcwiuYqh5lYWWMaLxFN3NO3kjj\u002F8tpa4xy+Za6BNZ49VoyW0x9\u002FXpXsKoghVH\u002FunhkvHz+sXHCeqE+G87\u002Fzga88n7H+QRvFss\u002FaXN66+dTdk4Gl8vSTWjgwiY\u002FYXZ8sZL7rVWctQOHZbrQzhXUSaZo\u002FNP48fycey\u002F87TNm1iwVa0Bv+QhNF1OiD1b0ILxctbnO7sZFFblFTSabPPo0RfNLhjanxftRgp\u002Fsmbz7\u002F3gY6vcH+p+u1mrMrVylexLw4iQkTV6JwzQbskS8+HJkWgdAy0F737nyKivXnx1hP9f\u002Ffq3my93KgPN4v4Df2055T+wmQZUuAr3EIvsmVcOjgvkaIuA8I7m2rbzqrAg7lPTvNI9Dx7dbJAJhQZa2AxrzNrkZ1kFDhy4O8CEsbNkExZbmwg9Rps7\u002FDBhm4uV5pVykGWNxcuGAurfKjUkxulw9ZG4giR3sZbvT6DDUFUVYN3hrsC4WOYkIEBkAoDF4SLFWK6VPPDpp8V\u002FZtW0uZMSSaxGd++wxLIo587pvSx1BAZxUVycmB9CwMV8MyvL46RNrlxeBoIhL4PkRoR5f7FnmPOu5iRRJhLSv55\u002FylJeG2Pt6DzXFbqG6GGFiPN3Ca+Y+IuE10cpKDTC218\u002F3Fz9sg2oKpG090BacuNhnADUJ+r7qZNq\u002FgoxydrXZgWTuJnV\u002FEa79935uvEfoaxkPe9Z\u002FefaBoylGAyBOn8hQfrTTyvnmPKVYHIuwUU834OIxs2EHxUWJMHwOhx6GGz0\u002FIkTEu92NpMqXp2L0AZZSuBJ+lCT9ejRlKwUGOFClLOzWa9uBx8PqgrEfS7+GKZYy12t+5YpLIYgJCdmNwTaJjZiirnsWa2WN+Dp4xC8Mp\u002FKcXmnyjzWUJvgaZRD64aZz5ku7RBT15HV+dsHq+S3w3oFPMN83T7C\u002FLo016eJndv9cTt+uQh1Lf7BvbU8zc2d3bcsazaGmAf7vb1\u002FGJ32\u002Fv8cqz8\u002FeMEP7l1ja6Rddscaofb\u002F8P7t9R88+vIjwuV4KQBoa9ve\u002FF1tUV7Uu0ck\u002FWCy1ppgC09wdtZLa8ACokzeEGUPdnB7SnY0cazkBCxwy7qxGPC2I72fkNC8OYxFua2VJFeUQXBxNwPB1WBdopfSh2Dc2M016\u002FuD8OhGOLtgTRxktCt4FP7iPuUAjfd2LyKsfxG8ww9C47kY3NlDJYJ1\u002F94E0pMJ2ugLGqXvE+JRn+8lUIJfQ7+f1R2TOXiksJMTWZ1eKT68thkRjiQARFxGUJmxdh+hxYYmt2627f2VhNEES\u002F1+NU8fq7T46XP7zo2FCVPfF5Nk8dL3lQsS\u002Fax9Ah4rFEOE9xOgJqSnvqrIYHMfyVbo7\u002F08YTamGwGcxNL91vC7SrPaBKnJ6lneLXfUVvOORoVK\u002FfAILeu26jDWmgKDWbLQEx6W19T8L8v1rFuMWLWMc+f1m+WyPjd36J018+x4EOedva\u002FJNL9+tji0wmyyaMajhChJ1vcsrwK4Ecdro5QznSOogk3X9YfwLjQBvRd+CG\u002FxG2NTOYNVT4iB9eXR4F08fPRWNCeLf\u002FdTtoS2PGuu0CJKijnTN4fwGfXeudL1Zd9eO45SFCQjNl9Za906Cm59owjp2+Q0BeMUK+tQA83Dwt6B+h4iiG7fo+PmRlt+3Aut5t4+bw\u002FtLYF+wZgry5iAJm2f9lcbtdU5f1+20Droz\u002FYdnnUMuDi7\u002Fs\u002F75yHPzvOr79rzD+6i44v2LeNVKNAw4V\u002FjjmYzxsycxkOnkZ7xvLma948g1Rro9\u002FzM66d9ODd7AYSPT1KceVYpYWQH8CkHSxtkBW2Cu\u002FG01VkhJ+SBr278tO3pXw+3rHFrS2FLybbr+pET5+PbLK53Sj5sk6Qzr\u002FSO3hkeHUkusc+AHAayMaXzjTfe2FzIQ\u002Fi3v\u002FzV5v3f\u002FS6Fz6Z\u002FhVrAw0JPKNsHomGvXXizdasc45dXRyjkwbFpESv9oYRvhrDnlYm0jmfPChuTE7O\u002Fz\u002FYaeC15KwNeRjD9fP3SpRGCf\u002F\u002F79+t7ckOwOZtHNtZj0eGLFy\u002FEm5+OYqLKi3KTH3zwfrD39lSwUk6WEfS9n75TZZuLXb9WtaiSLevP3dvXUlwzClSW8nT7tjDYqvb2MKv9k\u002FL0GEmPHz+0ufH1rmSjO0Mr9YkRsCWJBgidub95\u002F4O7Y1HX1xNtfMT4uSec4Fm9H384lhA\u002FpR+bSxZyXjKKBPpnydFgRkuefEI6oyuaR8kmpAsLQi\u002F3ng7nw2shK7ei5QyHPO2jZAVwgwP1i+cQ7hyv5CYlX5TE9a94Wf568+7T97Kqn6os7ucpBQxLP87xownqLAlc80rfScaxVe7z2e72mwgLjX9VIIi1BfxZSO5\u002FNYtzJ\u002Fcnt594U0Jq09f1iGwE7gmBrAkebOmXSXes8I+FZIilDF2WlYkNzTU0yUvd770nsuqL2XrUBNv1SgIpi+qywBEECqeoMslsOhIA0IhZ9FjGty5RLk6La3EI2T+5fDl3zOkQh+a6QmwA4bcIZp10H6JhHNyVCDwGiPgcKF5LiSEAwuKGgWLQiMDhNkFQ4xxyI0KhXgQJcTfWCFVUNYUzjhe21\u002F5W2EHMdrVt8aYd6ngLruedePjAJghtknCt2MnGfvYEppugXmyqOFrWAWEx354hLO0KgDH8ALM4\u002Fkclv92tLOOus1m6z9maWA32XEQ19Ph+1qPWSfkjFjzW9ptp3FdDAAmrMsy\u002FSygW9nO3cX19u3JQAbZ1IKjr06spOkpesq6xlit1NHPcXEZ+p1\u002Ff9Nxnn37R5z2bi5ff3Nz+1W9D2juDBCPYYHQDDBF3AzQfrRttfEpxNYcUhAVtMbGsgHuy3O3r3j0JEhJFjheHf7d4+xcvCsM5rW6\u002FZGilpLJmEvzAmne8PLbf\u002FF3wuLWGuAV8LhjdAdTOfc82d1rbNrF6Py\u002FY4WMNYV0EJxiDdzjjOjinmBBv5lrn3O66v+t+3\u002F4dh7bmpp1rnptbv7\u002FfJ30Ftd77w2Pbr3X337v2wxv7jLl+36+dzx7ceWzeM8JZK9O5SWoMlli4WCSFs0iEhC+PUtwfPy2Rq7VmBAALLMd7s0xd\u002FbIa5QnFBGdMea7NRIYxGm7JzVmi4IKLcJNrlbJGSFODF\u002F6wpGGABFyWrvvBp3h0TaAR99u2mwV6LMzNziizISQBinXz+PElKHIRHzliB7yYaX0VBgMW0Y1DCZR6gkbx0tW1ESL180jSgu\u002FCJA4fPTljpRAcOVLVgCw7jAgEdVLOs5TZeT\u002Fhr2cJn5j8vRQapXHvVLqRwPmTrHLvxDgv7b2YNysXrFhYgnqeqsPR6dlKO8GAFZYS9DjGefMmQ8SnI0xj8O6xFo9jlHe+kSCfdyopA9ZJvidYskpRVMwDmj+x5\u002FqTYWBrsWbNtCujylo8XqxSxvNd7mVrzLDB03BKPC9PZPyDCx5coOdgCe8w\u002F96xtxK\u002FkmAJDxPqh95EG\u002FfvF1+PpglBlG+i+g9PxEqW5cW1pt4lxEb8uR+wwCJ4rd0cWcjBOt7DEoKsoN08psJrbMJ3L8VQGOe5QpcwdbG8Fy62iUuhCTDIXEjoI4QxEjwo5FH\u002FuNTFGKuWwQhEqFuoVv8Jz4CgQwla+QB2dV7W8wwM8TSC81Cz7nOvOQHL5ty4\u002FALP+m\u002FO4FkYEM+Yi27o\u002F8Ju8+762rCoez3Q4SoKgM7wsFIgpo\u002Fa27lnbtRmP+u1i0bNea2u\u002FwMXrntu3a6f60cH4ebwxPqkaXMApj0zJzpnzY0J3KEBxqwtz8EtyqTKPQQw3mo0e6p7dc+qLlRT2V+6fdrf1Tscqz+dMx99EU9cvmcFLwqVeF4YVWvKuv1da7+rddLWc\u002FiX3PDNbaFvKYjhjrKdV69+OeFlx87Ez+L195IJ9uxO5ugefMR63\u002Fn6WuOqb9Yr2N6Vpet0uCVE9XE0hsHBGIXAUorfeuudzf\u002Ft\u002F\u002F7\u002FmAiFPdGOOz1jLwPlPb8pjO3dd95qs6E\u002FLhzmfDQwI1k8m6BOufgqK+6TaBDvkbwJEypUgyX40htvhtP2t8k7FUxNfl4x4DZ6EhpyMGOleaacMihMOGt9VvSDZ115V6VcCaGiJU6+92510nm69m3ee+\u002FNrPIZDBJshX2IJvgqA8LelEoJ6t+mYARZQ9cOZix4dkQZU1bDlJ\u002FkREUdeDd57ez\u002FAJcPJuQfSMhn8RdiyMtq7YQajucy\u002FGXthucL7jPCNm4KM2PPhQsX5hor+qlTxfRXXUcuoYpSlGX7Gjx5ciu6Uxghr378gVGBAYcScC9ZCjwfO7Y2e3p932ubqHH0icEgw0Ryk\u002F6hJ+OVaI4\u002F\u002FvjDzVu735m1p1j8WMePJqgr5cOabXfRwzSnmJu4ZDvzEY65DQnjg6yWrAlVuvH5C8XhhbK0nW5hEcOQYW4rAiEhCYs2gu6cRCAADQKFjkjM9F0ChoxobtjWM4G7LbUDpoPFM7OgHy7OCQFSTlH4yv6AKVNx71tWHwzn2xDxTgAbfR4CPUlgMUcH7ewnly+3+OfTMl8bhiBOHmCxzBMI79eesoO21j2WhnbvfgJvgAy4Dj5Noz3XdtbND4IkHgoyiJkW\u002FoJp2haYsrJ\u002FQjoiIhEYWtyT6jYDLJxjmCHC0\u002FOYEsuKzaN271YR4NvGFvH44sZo\u002Fu4v6qR2JC8tqwACR0OMDOfWizhkoT58MK0y5nPhnLJxhelU+vD6jS+nfTWjxZjeyfIOoc+efDUrEq22WN8Em+NleX+d2+cXuXpU13keUxYOIyzmZDuhcVk9CPEeZg0Xk0\u002FwqPcxvJAG8w5ueFleORMy19n792kirAXXIwjXNoeFDdTnoKG1T8BuhzdEkGCvkg4rLGvahDSkge\u002FuZ+rOl7yGuOzlemjuhFawkEDo2Fma\u002FbLOstDz\u002FAiXeVjfkXL3UJzGLdmJxWy2jAYrA4p9B6bzrRPbc90\u002FbcwVDGldG4x\u002F+XG1sRpaV+a22nx5+FjXHUHCwC6i9rwb8c8AYLW9bX+e\u002FcHz8+QPfgEmL2xsW+s3NNse6\u002FNilHN6e83fbb88+8OHujS3rQFPUy4T1pHl+bzTzg4Lnidc3\u002FZ0yxgInQjsq+dfSzh+mEWjLbRbs6B07mWRVONYkt7NYJyQOJbIaIS1kL+ARvjsmo6BmSVI8uRJkrRaCbvhLAEfrbELMos6KwqrlWli4ceIlTY78rjdkIsVJfw5RlCOVilVRpBGowiFwjMIUxNfGQ4h\u002FpQAQsQrb5yLhi1FfTZXaawHE5i5vtUprlszxcJb4DWPHKFxypv1LpuCfFOSmPCUJbwQTAt1Y5yIjqKr5x+eT7H9dLPnqxSSzmNsE5YTk\u002F7ggw8S5G3GVLxndOz14lNVPzDnFAzu3T0lRL76Kg9BuNHzdvnjgVNVwgZR4nIpJxOrndWPUOQdDgyXAoJhmuPZVbq+bkNTMFZ0nGWQgYAg9LR+7Z0wpDUW\u002FMFcii03h4DHfKrUdbc1knvAqyqMhXDtMA6GFRbvtT6LFqAHCguwlpsbFncGEetBMaEIUQqEJamZrS9o5OHmH7D5THBUs11yqJABnlaWbQl86jzbgGrCX6ItxmYrc6F64nT3tnkNz\u002FIURUj4E8L4JIvv7NYYnLH0v0QAA4EMOzBg\u002FoVb8z6PxX\u002FCJcxv36NRcnIIJyO4FvZif3dhf\u002FKj3AOQfoiiQ2kG4efTwknv3OnAOjsnenQ9O1b3Pg9QTsfgK9zpaF78s1ZzdB+Y1Y7rW9xDPxkxBjdnPheeDm3tvPsoc\u002FrhSVMwx7bz85cwT9HjYUgxySPkeWNnxPJXjsqhQkNYPq0v5QTh7LF5dteEQK7e6cs6doiSkUTE8d5DhyntlMTvNrf339kcPn+++U7pau4Krx7ZRlnEh8UtM6Ltz9AkHOv999\u002Ff\u002FPS9tzbnjr85HrvBywS3w1WpO3T07IRp7Ik3pzoUC\u002F5lck7rFcwdDp54btAaO5buDZ5CvvA+Q1EhL0qMfptyR6a5m6fnRgK4GWeRFu9OiFbOU3jXBx+G3wm5NixiOb525ermVHKIsI9b12+OcC7PQjjJnTvWYck8cP\u002FOLuE5lWrs+k\u002FeeTtY+m7z4QcftiJyVlRLKgE+5eN+HqPntW8+VY379LPPNp9+\u002FvnsMPzaufPh2cFkD170b1Jcz9fHcOzbBN3GBFS+\u002FKJcjlv3Nm+8XpWZ6Ip9bqa0ZMt1sRCZ1159ZXMzGvXZ519MKCOlSNTBqQRuFm\u002FGSLgvPIdlPwAKDypgkZwFZ4RBkwNFPIArRkd\u002F0esvvrgabXttvIOMhGgovgCW0Jv7KeG34gF3w6GpYhWvQTtEetzLkPcwgf7hkeLVUzyeF4bDuHiq99qE8WFG3udVvDqUMfPs7tON\u002F3Z0+JPm0c7GQt9+nONHE9R\u002F\u002FZvfBlxiKHPTJqhjFlMyp0UFTAQr2i5NfbkTVSpIk027+vprBfJDiAQwDFkc5Li3QhATKplLeSRa1Lj7hpCxihJWq4SQxmPSn+aCwGj3J7i+UsWSc2UkPw0Ye2mLpAamXbAqQZa1S1vLNYqB0tK4JFd4DQDmGvfuLT3i6uRWscgSM4RrENA97N0YvzAWwoItfE8Wey3M5E6bXkAYi3Yh5AEA3GbizFnVD6ctYswEdLI4a8uThMz4d+9etY7FRSJEBHMxbiw+klcwRdYvjHXGUGdZo2wGhWrKtj5QDDZGP7snPo4gxcAoTvHs+t71niesHg+xXs1NBnlYk45kbeY+W1LdqtbzIER7+qgwnxK39mVxO1Bb+48c29wqefc3H3w8iocNE5QxfKW2zr7z6ubVBPVnwcCd5uvenZutTwwrxsjNLlHOTmMnK3N14kRu+rOvFuZyoK2Ir5X4QlFQK\u002FbUMEBCxySyYdSFUWH+mAHLwUpgNSeYVue5HVoHhA2PsqHD0WOSD3vHuWrEpxQ8CyZ++dvfjFJXM6NIgF0bU3Ft7U5Z2h7DwPoysNBzBPTALlrB39HflzcOOOx8e3m29sDpaq+uYA895MMStsHPHxydn8Npt\u002FZvGwNJAKbkueS5dcvO\u002Feupf\u002Fdvt3TzliV6brU8H9a3dfL7E9tP85z3+fn+pvm00+5q4Af9mHs7u729Pm8ZOiI7rumZvMbTxD5LsPmmGMjDZdCL0fw6axXhixcn1BjFcJKyYxzWYZXZw2hXjCr64Uf3KK7WRugZr8rhI3mmLPL0XRja3rF4s6ygRaoijMU5WMIUHsWwCQHozrE8Ua\u002FFtDE3gtp3xxkPWL8qJVs\u002FBg\u002F7bl5Y\u002FMY6F3PwPKX0leB5Qq8aB2WS8EKIcO67aMazmMTEjzdRr2YhEyrIDDhxz2heAjHaqdSZtbPDKTe7ft8vyQsc2mzkXAzobO5ehhFMjmWPlXhoad+F0Nl1jxAMlwgnhCAWZkYI4TIXL73W+QQWiVz1nyfMRlHHs4ILEaTgzK7M0c5WrXsSjrrXu4T8TGhiz\u002FEUsmRfvtxmK2cvR0uq6b7DGAl4rFoE0ZPFzYKDofWpz+Mdjc4SUJUrhM+8HObqdoobwchc6CNjyGtZzChLhHwHIYHS9aRdQ0fhSBhgGCHYWI8XL242b\u002FZrWNV0rOONL79K+FnwAEYoVGstm+OuqyoGbiSKSsJ95Uzx880dI83VL74cYeBJbdqXYuUgPU0ZOtd78zC03mCakUVcrVwkJekGZVq3eU9giRYrDsAaOIpHcLMN3UM35lzWPhvzqaamYhmjxeHoNp6AlxGu0Tp9RTSGMvTR80NO0AyXOsCRz+t+39e56Vht4IXbA71xs3u0M73vr+fhnvV0ftrUznxZuGB8cN495n\u002F6VX+2lPWlsD8v9sbeM51ZVGo4c+MCp4QwgpuefFNTaAEhEq\u002F2Yz3gpwRqSOHdTU1\u002FrWkdNGZvmBfo+3qf3wsPUsqD0wd50O60pejhg22ewwOUQM6yezBagB7swRsaA4MXwZ7A+tFHH27eviT5koDH81eoZ4KjTcfG27+\u002Fet15rChT3z2vOl5w\u002FPvf\u002Fm6ESHNw4cJrmzPJQQT3M2fBzt7Nf\u002Fgf\u002FXcHD\u002FQJrsqjuXLli81Pf1ZCaQP5V\u002F\u002FqX42H5o\u002F\u002F5I\u002FD3YuNvzC9a19GH14pVv3x5la4z3qubCjFVELmrgxw+9M6jpUkfiMaeyX4lfdx4eKF5BU776qG0l4KyU23Uswfh9Pybm5WBvJuCapy\u002FI5kzIMnH5aM\u002Feln36Qsn9m89\u002FajaGyJ3L0LT\u002F78ypX6Hlw298cKA9nVRpN376VEXG+PiATfE5VkPnUy+SHF83hx5xSAUeqCO1Zte1Cgb+ZZ\u002F44lM9lx9YMPPx5FmbJjTuKewx9s3ijigBHgTEYVBhgeRgoHecpaf\u002FzxxxMFgd5JBD9XQqx1J1ijB3CKnAo\u002F5azZ3Elkwm9\u002F95vASThudDkIYhgJQ+ZdBPUXyXZoJU+hXLuEj4wa1zN48iIugwIY+4ceP5qg\u002FuVXlREq7vfSxVcG7SaOkebZpD1OcBrkj1DtLeGRhUMWsI2FHiRc79lroiP83cdS87QkL8S5dVrJk9qp7VVAv93dQtI9LYo5O1C9dQXpIeHTdgTbGzAeLLTh9KnqgBf\u002F9KgRssRgKhI\u002F3fdqCSAIhwUai32ETqbDgSZewpOKJqwy6nki7DQzygdLjhgnFh67\u002FgmpGUtHCEjLJiRKthD\u002FJUmz5hJeS2hIgKe4AF5tE6wlLGFYx3N7hRshqV3SlH9UH1qmdhpnF2jx49KrP+aNy\u002FlBWv3UKG4wyz0UEwjYMTZUcJ+dO7vWqIOt5qPSSDUfUEvgiOhNjGP3tDvJ1B1vHgDdWCxinDT1c6+92v3cfSxAxatnyr39zf22Ly9E5nkhKiH\u002Fk+ZKTfK99fVBhOKDT65M7N2xhIlb3fvLX3+w+WgY8uHNT16\u002FOHGu7\u002F\u002FubyNmLBhV6WneWMNYTLiajhxpm\u002FL68eVVVXvuB0tvbs6\u002Ffmnz0eefjYCxq90REcsnrPYNlNVhd1YWVgiaNCWMZc+Ob\u002FvzLiC0xyOWZ7J+nk04P\u002F\u002FqhTT6n2zOXXh9c7U1+urWjc21L79IuBHn\u002FLxtl9c29RSnsToAwJ0DU3KE2x2xq+Z3V8QhWjRzPBO+LvUdlPnjr5\u002F17Hyvj5iN9nz3j6dne8xrumcxwXmTu4f4i+2eJjXXI9P6zq+GOn3atvP3\u002F3rOrY55r3d\u002Ff2LesS7O73XvPKOHO+fmmfVtWOlOP3Yu98e1Ndb11\u002Fd+GtT8M7i5ZeWAEMIRdusoYUh4QbFaWa+y+AQ38gommTkGbM2FE0hAxnwJUd5EaMM0x0o\u002F\u002FSEkbL8Hm+GcmuZCreQMsMy9Fv6\u002F8calqSyCLtmAiDIsplBtZM\u002FA9efRpEPhDuV7kuBTMNGEbSjbCoPh1UFLwvfa9iygIMizPsNrJbxYqFRLIZSzYHMPowmepVxjGpKoJSZN4mnCqmcNUhUT4RaUaGEYYGNrGOBJnM3eXpwegdVW4zduXMtCBIfu1EabcWQ44IVSam223W5sjS6aQDCkQFiU2E80d2Ltv\u002FgiOndzFCWJaFPPPMVc7C6gYUAYq2LCxb7oyfOSbu8m3MghQbt4PlYJXHNSPkiCDgVGzsGV2r6bR+TN196o8kO7iyaIP+x5BhV05jHa3hxSpo4cLVSH16F+ShhdNE7IEpqvbvFy1ROErauqUtZRtQvfeTdVfyD4yyHS7nZHVQK\u002FuPdPH35UiMMQx54Rorh2pT2akK2KDAZNGbBmxiYhjUAt5PFqY7nRbodlBlYpg0eAgKbu\u002FJnait4XF6wixKqqFaFoLevWzLcx+Ax2hWiCBbTLmCgC+JOfbciRpEDGIVbjHq3v8VB8By0HEwxPrR\u002F6OBjbks4mSHA22EOnBt\u002FhYD+dmX6MYO3cHIsuyQOATyMoeVmXl1C9hN1pSLse2\u002FnZfkx0mpbGKu\u002FzfO3e7p\u002FX9N0cexgeowvrwrqnbs0zQ297dTdOewxS1mGs0M0p4ZwQdvXqtcEfxjMGjJlUT\u002FSZckiREVD7\u002FbHeay5mPlxFS4Jp\u002FPVgu6I\u002Fqf6\u002FkDVJjzbBSeSK0OAt5XZlSZU46VnJliyyv3\u002F\u002F95s\u002Fyij1xrnD8aKKLiSQ7j\u002FIYHUnuC8EJms9+kDZeNEaycV4FE1DC\u002FCxEycoHWvOv85j89N332lTpWO1U3JzcKHS0928P3vq56cff7j55POP21X8yih\u002FPEeXL79d5bTLm5vXbmcMe7C5\u002FMZPN9\u002FGz16vkMfp9rH5JiH7m+LGlYfdu79a6O1FI2H7WvXUn4Zzz+Kd91I0H0dj0RrKOCPnt\u002FF0tI\u002FwbPd08zRem+YFLp27dHrzbTjzcZ4C\u002FTidoC+uXdlTxsH90coX9lhIdniQUfWbaMT9Rzc2x8Odg+HVmWq6P88ifTvr9zfN94TT1i6LO8F9JYVXaS5FHN1SAhIuX7x0LiPiKo0oGuEBb1khZnCA0vrWW4UmR\u002FN4S8EdpZ4lXqz6njZ2hJ8HGpMkXR47dO1wmxXdTrhXZhE9QYsp6UIFVcNTTU90wLFjB2ZnaFZ43hjhhEKc9rbJFFlGyONXrdv1rP7yp36sIwr14xznX61If0InAGa9fZHbY3cDDHVmIKxLkE+y4KOnwkEsugoBmY77bCOc7xJoxZ9LYLSDJQsL5vqSqCSs7t+PWLA4J5RH5Fjtj1VmEMNlaVLJZF9E5tuATrmjWogyVJGhZElZ2GOtSRkgiCGECJCSQL3M\u002F6EL+1MmjhxWtmdp7gg0ws+65T0EQvFxiLi+SIoA3IQlll7WpUdlKx8t2cAmG96DaLCGeP8rr5wbwN69azGLqefcKFkF7oRod7KI8wqYux5tjJJVjyUg2Ab7YSEm7dxXGSJM9qBdyHKd2QDhQWEqh0sAPZFgKgaSu5hL9lza8oE6J0aUBUvSyHfFwhuuqhGPHrFArcQq4UsnY\u002FZiyyTlPoko3ksxEH4jEfZAtZd3FaLyVUjwDcTOPXY8a\u002Fjnn11tGYt9bx723eKKTKiJ4Rypzxdza+0tHv7Sa8dHe3\u002Feplbx49Z9WR5smKI\u002FJ7MG\u002FPKXH+aq\u002F3iUFhUsWBjNnS157z4u3r0DLJkXHgHKlgoaSnQeS1O\u002FUDzcW2+8ujn\u002FyvHN0SxOr0YMzqc9H61qTNQ2GInopCi83o5vP33rJyW75iLL4r8\u002FizuBcetWH429ueol\u002FcdOmi0ffWr98Zqgp7OEwsVOzOf2QCD+8LCa20MbfcZMBsa3jGydHybVZffM9R981sK2ZX+3n7fCluv\u002FXwf43jkGH+adO23vfNYSnPhhv73f+e071rX6+H1j2087f0ccb1y11cPe6t45aw53fnJaDxEmrAr\u002FOF7i5MSOJ6CHjn1PKG1SMWKTsLfkOt6jHh98X4K6mNWV4Cmuk5uWYDGKvuc6CM0YioRywiyPF1f25Tff2Pz5P\u002FqziK7t5SUC3dhczVqlJOC7P30vC9fF8D9mUTiN3TsJxdcTyPy1oQfr6oofjpFHnAngN2\u002FcGCvOWGt7P7rk2v6ETV4fMCvURBnD\u002FQcK++gcqxtB\u002FdRJlae6N5qiXfMs12MqgfAgBeM2A7OXBIs4GsOiKASC9VyCplrEvh+I3pifowk1hBuGAd5E8fY24cHw9AWsz3uaJ+\u002FFrDA08eyzQVDrQmAjaKqgZSwjRNbvCVeLbh8Mv7ybm5u1kBAlhluyJqS4W8z8Z598XJtZ4xorweS3v\u002FtdG6ZUROCPK0t3qHfG2CkISuASqqwhiNM\u002F1kn02Xh5uwjvhHnGA2uOFgvV44oeZotR5h0w99qjUBFeJayDZQpbwY89v5QCsIm28IoIjTmRUORGISwswecLqxie1VxjxqH7uNQxfEmHP3333XZxfn02tPpO9ZWS9ljdT506Gy2\u002FOmsLAcAZ7y0Y9h1czj4YMRzl5yhRhETjUmVEeT4Km3VBh+Ri3Ly5Eu4bctfq+ANeDQaFQiyiueOtieYPdvaOGdv83cHDPuOnO9g482GenRp6o2vr8oydB4+SYD26wWND7\u002Foz7QzsdP\u002FQhK6bL29FMTUz3rPOzdnamvs67xie2zXzQGhfSsB6zgOLTuzw5r7zILuP8mA+HIRG82mjRQIdeJPzxKI+15q\u002FJLf50Z6xOrb9mLHOmW5pbYRpSCyFf9+F89ropY2jWWYd7dyJvGsng\u002FVnwQOYZIRUh\u002FzjTz4vBObDzenD7wwME+bPnX99c+tO\u002FDyawlPGgvznf\u002FpnCXnFMX\u002F06ebLFAz0RGUZYCHMhlLJWk0ZowQKDz1TCFoAMVZnCd2\u002F\u002FfiDzf7kip8kjN7IuPXRBx\u002FVz32bn7378yIFqkJVnHStbf7i3\u002FsnySwE7WSJwjJ2PWiew2dVVK5WMUY0glrqohjweXToYIYQ1mHGyDMJpSdPtwFb+Hk2of7I8Q82v\u002FzN75vvKtAEl2iZcJljba4kifWDNj08lCGNlXxPuKrq27MXKScJ0JKodyenqDsvP29\u002FhsS9CcHfJs+p2DVVahozoVvYNMVEGCABHA9Q5UkpW8UsWP5fe+3ieO0kANv80B4wD1NCbmTJFuLHWHE+\u002Fv7mG2+M8YUnkHdh5IbBw8r1Ng67i5oLspxnJK5evfpVeFeOUnxdaADlUCUaGzt+\u002FvkXm8uXL9T\u002FZaBtWC1N4XkZB548KUwumqlM7omeUY53Wd93gOwf+OdHE9TPxcD2xti4hp5zTx44FjDI4s\u002FiE5Nh6cY0MT7a694I24vv0rpKmjkVM9uX9fYRQIqwYrYZYkbow2gmiSRghRxDVEK6HFoR3mIeuZp6J1esDUp6eIgFJv4i7cmkHo4Ab7VCZbswZ0wIorEMsa5EkkJEJcey7qVMPEjD4w6H2H5upiVJUmQNxzBYa759VlLIaRUqxN4vZeN5jMtmIbfLYt57ozrGCd3IFUHzWRUaPr7+WQLBKsumFB0BWeLYN1mZ1DB9EjDazctYzNfRgH7qiCY8qKrwSVbrza5bAUFCrhj3xukYy1HCtV0UMbDQcjR+Gt+x5ml3c06LrEZUmqZYPs+r\u002F\u002FpsarSac1ajx\u002FX9ky+uVMM5d1AEbohUjMyGQizuh6sZe+xw2ycXI\u002FcgLfXmlyWwRYz2Zp2\u002Ff+\u002FbXGHvzLp8ltZ\u002FL2H+aWsgxODr7v35u+dzk51tvDH21kVC4MGDueQa18EDx2NG9zZ\u002F9Vf\u002FTQmod9oe\u002FNxYAa7fuZWAcS1CkoIU8hDIafl2A+NaakkaZwJasHcsIvCPfv7u5r\u002FzT\u002F7R5tWSQ7+NKL1IKaBYffu4rdfTlmntr2eBeNFY\u002Fv0\u002F++PNt+28+tHHe\u002FIAtClNmejgyZyx8FJskHcWTtpzkzoM41vx0MHnd2EPi+LuruFnhOVlxfEZU2Dx3WF0O8Lygt8ldGqP1yIy1oe+dCwm5fpiTCOAd5mCFS8a4cVOtlsGN8psRHMYi97Oe\u002FR6Hfpgrdd79Qk8r\u002FcM8+vzWM7qO8YJVv3zfx3D+jXRf8962P+XN3Rb93TasYSBPtR\u002FxN87tscPrXSHS7gzpywg8IkVRaLx7aqsfJ2yeiRhGMNDRB\u002FtzuIcXTAHd3JVihsm1IiNppA\u002FLjnK82qWI46S2gmkzy1CfXt0Twxj3pe+3ilM41flOXwXbFCiuXo\u002F\u002FeSzCWN4NY\u002FLmxdfzyMXPQoGnuTZIxjj9wRBRFl4BysMeByhoTYJ5\u002FrGKirsA23hXmX1wxAIb6fPJEyBk\u002FBVOBemQTB1DNw0gdoQywqnn+UBzO8Q87oXY\u002F9orKlvvPF69KZnExb274uewNmUD8liaNOLcFDi1McJx6ezOB\u002FNxe14lhJ86OipzYVqLEuUUvbskSoZvYE3i6DE5Xsgw8mhygqePJFrNzx3XTgBwfRBsdYqxhxKUWdxup7VkGfu62Ln92VYOXa8CgsSwXddz9BQdSb5BhkkGCmuRU+YWzB5uxpGquuzOdTnZWEEN+gdi7dtvcET6zDlitJvvY0XnRIKIkeA8iX0hvHjySgmKUQJCsdzz1MqHOM1TTC32zNBXfiM8CHvfq2QA2rB7QQTWPikOaSEmP993R8lbT2FLqqJXBxq1jWVQd7\u002F4MOmZtfm7bffWZU6goGJoW9eCNjfVKb29t2vq9zT9uVZZy\u002F95Mz0G5zz1qErLJTCiVZ5xZSyYpF39\u002F6DCTtJa9XcFkZVmGU89G45QMrc1nz4zwMlwTKL7IN6XfhTwL8j7Nfn4YXN9tCBHdxt9odeNafGxsA1J4I3yrlj8DoCY97heY\u002FU5yhT+LtoEA656Ihn4M3L5+pyk1VbcF04AkWTEUM\u002FXIxadA18a3va6+zwqSEP+tk7d44RyDPCDOL1nPwhFmm1uvWT4MWtgLTc7zMa453mvhd7W7SyMXbOPXO9850eGjc0Wb\u002FiI2QKwineovvqfEcK57Oa7V8Xmnr0WBbT8HWst\u002FHXli44CG+CASFO9+492\u002Fz6159uXk9JtHFQ3Ghg99XzhbYWq34yOkYBFkYib+O1ixcSWMPh+PEHH340HjDdvXjxYnuznB1v\u002FS9\u002F+cuRfxSA+PzqlQoz3A3Hjm7+\u002FC\u002F\u002FtA3Hopdt+AjGf\u002F3L9zcfPvtwc+vLbzY\u002Fe+\u002FnhZOdyip8dXP11lfBTApyLF\u002FIyoH6ofhD3d5cK978esUj8HezZW7JWe9kuBIm+sUnX2y+PnBz8xd\u002F8eeF4mT0uvTm5siZc5u7xWL\u002F9V\u002F\u002FcnP181ubY6crARtvfVzlvj4UJnM3Y9gq3iGU8F6GgedVl7lTztmzbytCkUwjNOb8pQvNwf7NtZvyOUrYvPHV5knwLbzubAY9xkiW\u002FIfP5Mol26XACEX0+ezZ80NX8H1y075w5VZy043aOphhhZdA1ARPJ\u002FhTOpP3669\u002F8Tet3fMS7N9Ntlq5KWMc6JrcvEcpwpJ0XaPgM4rcvHZ1ZJ9V3OBUbd4dpcI6XagEI5ntjnLb0SuewhvXbwUXGTHq1+XLl4eW8iz+WMePJqi\u002F9dZ7TfC9NLA0wJiYeEFMTrKisBVAyqqD4LJyiAEnyLPYFG63OVioytdZi1+EeETt4GWsX+KDupyFDfKlhTe5EIlAJX4Ms+DyGGsFRERsws5BzhDRzmIs3vrE4gMgEXlhJywWjrslOyI8hPnZXTAGqXwQqwKLP2tOEl\u002FPDNZnZX64+SZCyQ3EPXbg7OmxOLGSwH9W6Rdfl6SW0HEwK4uFVEXFoGiBBMazCaJKcIlrpDzYWATDORGDPXz0WVZFSRIEwehwTI+WScuzEZEwHMAqPAZRw8CUVDq8VxjJKvJvfo7UxsH6aGzcx2od3\u002F5GoppqNMWgV1KNZW5vVjBuZQcmLLtciBLXqe3PbzUWsaI2b7rbM19eVztaHd\u002FmN+A8sKf+NMf37kqoShEqvltz\u002Fu7uPYSaq1ktj2e1\u002Fvl752PYd3MRvRpind988vGXWTDfDC6ebv7L\u002F\u002FJfT4KoOtA2sHgovyF4YTVDnLEGMWtgSAgPOCI87Q17KGsHY4BnImbHG\u002FuLGNu3udV2pTgJzWGxSlrPAvLN5tmjFIEzJSHlGjz+L\u002F55seq\u002F3fzrv\u002Fq3m8+LV8WACXtgTRlIcNj\u002FYTjh\u002FsylfjjJaiT2dHcubx4X\u002FG9cvx7qWss3a96XPuyIthrztcNtGtr5OufdNd+7Bpa8x\u002FyNBwTguzrPraf8\u002Fr6F7xnearuL6+aXz00T61tNrafnrtocpt1fTNO7t2P3wT+3\u002F+CRbSsen9fM\u002FTtd3N4797vs\u002FM4NRkg5GLSEu62j9ilhBMPbt6tSkNJ6Mg\u002FYtnoCAXUx\u002FgTv8E\u002FsuXr\u002FrMh3IvR3SxC\u002Fd7u1TyGWT6KjGC0hVEWE5wlb8JOA+CIB\u002FIsE94dZSQhyVyspJgfk9QuXWuf2H+CS3mXtWf1WjV+WHYI4YZJwSzGi+Mo1AVuqXKEdlAeCOs\u002FMJ598Ms8TWiktrJ4gRCKpXB1Cx1KSCEUY\u002F\u002FL0EbLU6pUDQxC98sVHI9Q9fpgLfI9kSF7E461RbfX+gxlFtCU8B554D\u002FwFN\u002FB7NiKp79y4Bw4kSKj2lIAyC9BaECB5B1kTJfRSrJ8VjkIQOHVO0mmixw7TEXt5NTyxiRKBU4WGkwm+3VLb+7J2XRraxBNnHilQl4rxp6zcOprwmqCCob3z1tsTT+rdwgfu3o259k8VC3H2xs0za7fVVnH6aK6s56PogXvOSwwL556meH2VArbKSqLh0ciMEIwX4EfuEeEQ3NxOsThwIEa7Y+TRF2E13nuz0JLH9WO8oAkfV774vDEKHTo7a0ppJLxLKptE1K6dTCE7mbeTsnQtYw7h9mDvPt6u1W++9frm0L\u002F969z0WWBrb3\u002F3c52Pi7713iMUsXUj8LwIjvc3vhfPMw61fgwRw3NSKIWCYnqHjqRsRN\u002FGO9RYCBgUrAmbyOpnb4yD3SOElPCpYgnBtQkcWkWOpRxSMEOFfrJs9q4tWUHPhKxQ2MGTeadoqUIW8vm\u002Ffg3iojXTtOaD5+72YV7WbdHPPdFF8rZ2J46+v16GMnr2DyzpHp0XfP+eUQa8uvMUkwf9eOu0t95U\u002Fxpf56YP23f3AJjlWUIHJsQGHdiRC0Yxrh\u002FLqIKa7ygedbYlau5bhxo0h4\u002Fis3v2C30tuTA4I8McSmBRpKHL9YU3e1ceuVubjz68tvmzP\u002FlpHqx2LE8Y3ZNwb7yUzU+K6QYbPEWUTbTWWr7z07cGtpT0O1UInpLAvHvXKhsLn\u002FSNB4gctffZCqkD5+qkW8N3336nyIEUhb\u002F7VZEEBzf\u002F+J\u002F8RQriwc3vPyz35btvqkTXuBn1Dtrhs9zBF+V8pLi\u002F8dauqrLcnIRQe9jc3\u002FNo89rZ+H74vy\u002FD2e1klA8\u002F+GjzWvT49bff2rx26Y3NT39+Z3P12p1i00ssT9A\u002FWOjai12VhExxiG0mo2U0YxCJBkqaFw6nItXjvPGUTJ78jNTNSfkk926HNwfj18ktWe15nSg0B5IzJOze7P3CagngilaYd+HR6CbZhTcWjWPRv5KH7l5jYWYSmfEw2oEPK6HNcIJuMMqSccT6Ux5fq2jBK8mBD6PbVz\u002F7vPLSj8PZFbUQVc7afr31bq0PVmb3ldPRkKzm4SGFgRz2IsMlJdpGR+BKn8iMN6\u002FfHHoBx\u002F7oT\u002F+kwf44x57\u002FRceP0dT1a1c2v\u002FrFX02IhtI8gvQhJ2CDGOpV37yhLvbaGhozG0ELtIdokOYpht1fiIIYcd0iJmJ4tz8A1+ft9S4PQgF+yGwREBsERkLO1v0w1teQWtwnNztrOSat1BcrC6XC4dmlTLBsZYkrlnoYcMSLYLw\u002FxWDdGPGpPQzWzlxc7yw9I7zXb0ySWwdSzU5+neOuHRduDFF5R+6uL3O1cMFwLQMscWwnSko4+0oxmDHhQ72PS48lBB0zTqE43LmQnQWFq5T1BVOZ+sgBFC+GthAyiSY2GnoaUYcwyoXdKDyFmweRVzpMtZgn1cKXgY5JHE5jjJQ3T8ofIea5s+61QUxCOkVDOAxXPAWJW5fgYoOVSRxubpWM4iIkUPF8YNjGdKGkNTXbb4boZ9vZbb3\u002F+ebvIjQ2CfjZz9\u002FLbfXqxM6piMEK8HUWuvtZ9RC9SR6N6BrrhBTVy14xytjJCORbb14sgSb3dkI+a6tSncJxKDS0ijw7AABAAElEQVQsoYjEJdUiIgBKtp3LvX0jJP\u002F9Bx+OMmkHU3HT3PqsZ+YcoQdLiPd4daBq7foOXuZD9+2I2PNMX\u002Fuuy+7rytzsLGjX5vpAQB1blTE411PrUlf6sJ5vJRJoMHXrybrMYIaZziPTlPvXM56bNn74fact7W2fm\u002FuaD3MJR\u002FXRNTjlu\u002FOLmXmmk3pnUP+OY9qaznTvy+urPz282mmhVjvmQ1szQ82hJOplrVZyT9KduQTXEq+FgIjV1Df1cRFewrLviOQo\u002Fs0J5Z+HiAGA8oqhe9YPq5EfNAn9YMkVw836C98JZz\u002F7+c8LZbg0z6r4pGyY9Vau8WYuZVWcHPoi9EHs5DD9Bmx9VggJYTglGE5GZzAf1\u002FRHbg2lBO4qdUYY5c0T16pcKCHyet6ju1m8vo05Wwd9FjvPCk6w0QcwoHKKeHXvkqA+YTRoaVOKznjntN3YCJUMIubJ6hDKjVepWSEdaBIax+LMY4iGTh5N92kbnZP4jelx81Ja9GVoH\u002FzOGsaKhk6dyoVMaZ0wxJi+uE4\u002F6KDVVqXj8pvlnmTtojhJdqVsAYIp7xvtgKcYq3rK6pdb80sXL2VxvJRyfzZauxLsMHffJdxZa8oWo4h4bmE2M94dGDZG68xar+8+mwvCIJzAJ6zLk9aDgGq9P\u002F74o+by+Fg691vL+sOzYvzCLSg1XN322ngcvRETy9JqgySCF1p45cono1hYR\u002FCMH1IAWdN77aJjna8rO8JEdL0LlEKCnTAI9JUgIBQIP9IGWygFNFCeH3ANVudac8lYxaqIRrI0Aw327OXFIjhvcRAehkeu6VB0Ds7DLetlXimZfgZbuwb\u002F0L1FF5dAPM\u002FUGc8ZC0D00a\u002Fhx56vAXPu9Eua6Nadd2nfRRQQ\u002Fjs845hn+uv7nNv5CzZZ6vXTc3PMn52+uG\u002FevXDD9W0fGsJ8MxdwylfyAdxxz3gOapsRCR6LBPiuz26UP0NYC6Way2hmvOJgxqMzwX\u002FTE33SnpLUcuXyGvcMIxg4w+vNDRkEjHg35QguwsOvg72bKYNgZsJXoxvkk08+\u002FbT7H094177yHxioLr9ZPHbeR7ggh0EEw6uFfTQjrVk0sbZnM7l4+ybDmbDek6df2Zy\u002FcGGMgWcSQu35wHh5MiOHvWZUxnPw5DxIyWA1ZryDT+gzeUm7+AML9vPkDUYtMgp6NCV0s4yfOVPVt9Nn8xwYb4Jt96KlBGlyyxEyT1Z2\u002FReaatdTRhayobAennV4wAiiopy65uQ1spzqNpT\u002FMynRElntVsyrSObQpxYr+rjKKk4URPNOeCY\u002FDd42XiW1cTW4yIPpCws8Xm\u002Fu0WvynERR8h0aIgTZ+itD+WXeQWUZ7Th\u002FOE8kmi523Zoa6z\u002F\u002Fl\u002F\u002FDzc\u002F+9C9mLv+hv340Qf2VLMT\u002F5\u002F\u002Fj\u002F24EInGKYv5GmApYMAwThBAikAgdy9SKe2Q5wJASeBNmEWhWYEKmiiSs4Evz3woTyzKOyLsGawdZQ8ZhHrWDGSImhDqI5\u002FNy+fU5YBIbxoqN0QzShTSus4xBIH2FpKzSU288LdB3jEhojB8HhUQ8+jCsecd6DwWDYMgzcCegpm2aCwTG+1lxMHoCBUGd5m7L4FNlZtMIxRxy1UO6RMPGpT+rwgthAGJ7L+aJuY1g2bwJKRHz6F1cSSxvhJemvD6rQpO7vZCPp7mh1DennR7LDa9m+Y2yvMXH19PaTjMsVEXst9jyfT1nE6VvssbbSInFTn4BRBFzi4mMUN2YJw64tQHQqssgudbFz4kY6s\u002FffS9CcHzz2WdZ0l97vT4f3\u002Fw3f\u002F03m19XJ\u002F3SpQubf\u002FxP\u002FzJLQzXpm+\u002FjadrKeN7IbUhQRxwxAj8jINVbc00o6AVtCrOvpNG2+j5T2ISSi7nGJBabP\u002FFns6NYc6MEIMakFjNr0X\u002F1r\u002F91mftZPFh0gwmKlyRgcw\u002Fhh7CHvI5F0Jey2KUut6g7fdr2bf2d2+fXCKTdttjNzm+AVsuEomm\u002Fr84ASH8XA\u002F5+nAgglzVYGeGi\u002FoBZQsYcujHPTWtrjjrh8vrZaevvfR9PQLALR1jB1NgfXGiejMMBbreMfU78O369fM+MZr1zbusChg5GvcO6raPzcCZYikQM8RUrPO\u002FKi7Y2manWcOOGj4QcCV6EN\u002FM58Zy1i5awwluXxUgSoiKivpsQTNb94NDciqXWBUxSLDIh\u002Fljw9kZx6+9kncIUWKUJenDefKx2VrUQ8Cb0xlqwVrMGMz7w+vgOzp\u002FE1KwR5sfCTkkd+pGw5zNmQKjSRwxan1wXFshCzZKOvgn9ISAwSmA6yhsO\u002FNX2CL4NiQJAeEcPWMDRHUL8suC3UVCCgvWU3EroRj8OxXTEoTvEdH7ZxilotvkZAbY1E5qDfmKaE4MZ4zIPmBxvoKQpQqMayRfD2\u002FHgRdPgizmVzyP0h7BgLswpD4RNXSgSjCCS3O7Xd4oTRqht8wWWCC0SRp1j6fdysOEzC7jdGMWj8y4K4RPiiBELeSAgoc2s\u002FlezTNpx1DpZm4HpXmC+JJ1iuMbsvYQka3sq7424fvOkIgccJ5yYe3Go4v\u002Fxrtkcp7HgVfosvAbNxfCFJLHgsf5fi6GbA8IWkXhQIMnNuD034Sp9tqb6jeaxvK568Rk7gptD9YswTuILlcKZcKUfbWknCGqOCNPRphrl6TXW2bgnJVjy3ViyhdV0t6a2gteKn0ftagWu6lR3jeDex1HWa48AA5a2SjvaNTi9g9vuAyMvj53PYLv\u002Fmpw+uWlo4s6N1tWPw58lpH\u002Ff0Fqz2natvs398w38E0gXfdoK7IxH2t\u002FSLM\u002FrJ5xF77S83r\u002FO6\u002Fd6P4Vt7ZmwTqx2nrRB3tFCR5CCYuZmLCy6ktu924LvtsFQdOtsOVF4t3GoRGIdCcCUVQqyPBDeQUY9uE+WQBMp7XAFzKMnBEV0z0FYdE6IHhi2BrxVko4Ju3bF5Dn69OOP4sUUiEJte4+4booEY9soY32+Fc377PMrGzubfpNBAE5evHihZNSqoeUZO1S\u002FGCDwG56ox9HdW93HC25uxHpTnhkVf\u002Fbeu8G+xGd5L0tWoljeqZDEnhSJs1VYO1tZRFWQlJNEHxlHwOzR8Fp5WeUmT1T96WD0idwW+A7toHCzwB+l9DZfWzokj0+u35cZN8knSuNefP316Eo14hszuonPPwhf0TrzRtgXnsswSwljkLCIjxgdmmf9kRsZJM38mnP8wv2Eb7QavbROQ6Oaf7B\u002FtznhYaT8BFnjVSP\u002FqK\u002FPE\u002Fif\u002F8\u002F\u002FV8kwK\u002FxQm\u002F+Q40cT1E9UkP+LTz\u002FcfPT7XzWBxQU3KBOAwGGKAAhBQ\u002FSGATZQk8bq5C\u002FgG6u0xYtQEYoxMARdOxBnm9U7xAHCBrSAe5hXE29yuc+591gfVghDSFTbqg7Md8RlCHpt916IgriyiviMYBPUhNQc7RxkGu0Ko+rQLwBQh2ZRvXsIASyuj8aBiA+Tq293YhCYJqI4\u002FQjYKSWInbjta7mRAc5PLr8xQK\u002FmuJhPXgVuS1o86J35wRxy60JWzPl+Fm4E5nBuNlZrpYlOhWwIhRJHNEbjQaRVHhC3yxIpfOR8iPlHf\u002FxHI0woMXWnsCOhLK+czaofsi4vg9jbEoBDMFoiQsgFp2ILiz3BTmKmGD5lFl0bN23PeD\u002FEORQDJTo+r23xe+++\u002FW7E6kzPFzcfMn\u002F22eeb\u002F\u002Fq\u002F\u002FjfDcP\u002F8L\u002F5smD6kwTRPJwxIRPms2EQaPQY2cZMxhiHC1qP1QXpZl1RBOBFBPVvewMljKSURTj\u002FjZUD0BpCCp9aoWlUxv7Y3jnD9q\u002F\u002FXf5XGXi384pIxWPGpYJWgj6D7GaaEkfXZPKDEfZxj1n+YAVjFIGsezHbTMASammP+mI31z03zrO+e2d7Sc4u51F59dp7ASjG19sZOGcN43KcjYJ+QZohOjeVce\u002FOOvmvH5513+Py9kL7zfs\u002FHtOZZDXUYo3eu+M\u002FVr7nw93555\u002Fz0hnnSu5oLx+pX33f60Jm5ebxb4aI1VcKUgO19RsPbZEdasdbwHtPaCktCPMayPgKCxDzKeO5oihbBvR9Jh1NuNVqkX5gdQQpjMTRCFMHJvNob4b2YDusUQWwU9frNgsJwAPckqWGuLGTmjpJM0IMbaMDtchw+D5Z5Egl+mM542IJZ6+Y+8Y9og\u002Fbt5aCEmE3TnnGphksUW7h7NKEM4yNsseZgjCzg50qu1heGBhZ\u002Fblx9UIbx6hdXh84QprYwopwsdzrhgDKtP84R+tFNQrLqVUqlao\u002Fl3l+COcY4ykRrD6YxdIqCjZAI2gRptNH6UMqPxtydZ5G2iOgGJtliznsJ\u002FvqB0X322Sebjz\u002F8YOoNs3Bbp+EJLQx6NTQYbPcd3RTbrlrMF20uo0IOniGcyJ4dqsQwHNginQCtFOOUtGuuGYuUa1Qj2ZbvtxM4WALHuxENRof1D40a4bz+wRNzQ1gx35SfWzdvZuFrh+c8E2CXEKS0LgEADxlDSg15r01jCF2TpNYavhIMX6tsnjVDz0cR2hEat3TEmhKW9SvUDlZVnyo8IIbPe+o91mzCE5vXrUcIXuCPaMHit4VBNqY9rRdYg4nj8WSs4U3tHWgH4ZKlndK\u002FPKLxh3BHqAFleYxKjacutAaJINakOd8KtGOc0MHan5v8DSeGNg59WgoRuHHP4LRfvu3QhHWuxzu9c+nlX21uzy1qUvsdw+F3rnm99+FtYM13P8Yz32esrPgMXGh5Cmo8Ba2YtroXfIFh8sDMS89s59Fz5hmNtDb48Hito\u002F1jLGkcLOoNt3fEf3hv6+HFwinf+skbwVOljuMX8jvkqfAM1uTQJrBu7dFveOSdFEm4Q4HEa\u002FHzNa0p3sGU0aMbvGiP4lWqJMHHWzdvVIDhb\u002FN0f5n35tN4\u002FuHg\u002FM7MxclTFXGIzwrPuFeOCS+Q6mqfxe+vV\u002FHlRvHhV7+4UpJk3\u002FPkCd8Ci+bJ3FCuv0nopfCSG45ktVchy0ZCFxrnf\u002FQf\u002FgcZxk7mmTuZoHwxHGw3+PDT3hFNWfMTv2putrjE28PaPbvwxq9t9hTkhn+s+OXbAaMWn7C9q3WZ9Yleo8F+0CD0i0Kuigv5ieIh1O3NNkXkpTtRH7zDvIAatNnas8ir8269wMMk8jZPU7K7sR7MMCe8CZ7hfxMh0Ho8zMCHT6AJ5DRGFuOxhwIFTYifql7gh7yln7y1\u002F8n\u002F+H+6+e\u002F\u002Fp\u002F8ToPajHD+aoK43b737R5v\u002F6\u002F\u002Fl\u002FzCTbeJ1mpDLEmByHJimAyNDhA0Qw+ae2Ia67GbZ654RPtzf7BLK\u002FYxmHLJBosWQmvkWdwQMRCVA27qvRjuOyCAw3jWxpf21sOHM9A0isWIsRsEKnyDuJ0EdwGCwGA7Emr6HbfMPIgdMK9RlxcRiGgiLsl6yqe8X\u002FoGhL3e8kmw0MfVXhY08j1GnqX5dLGgxbwAMMRAyojJFTQc0iAohnaYvJIXLs0SsAIiLBSNyYu0cWkZ6ITPCPAimYt3013xIoLzRu1hoWNjefvenm3\u002FvL\u002F+yGM\u002FzWZtuVPf08+YkS1VJaj\u002Ft2js\u002FfSfmW6WIGDYmh4BM34Uk1ScZ0lxmFArVbVRdGIZROAjmDlGWploy7OFqPBeP\u002FvrF1zcXz18ssbd40IiGWq7\u002F9t\u002F+f7Km\u002F2LmVmydTG1Cup+jWRIxXiWZ3v\u002Fg48aaZSnrvTVEXHkxeFIQUvCxq59jWdFfLbzmSJV\u002FxBPanKAeNUWq8lTmqjYxHgoL99yxto2\u002Fdv3G5m\u002F\u002F7tdj\u002FRACxGVFUYkFhJhZx3q2hWkud4RwUNl3ype5X8JvfR7gWGylh7rUW4HmnHcGPANm9y7onmc7RdFw2\u002Fx1h8\u002F9GqZhfMEaqyrGZ34HD1zvJ1B5+YpQYj5vn1993mnLtWnbuzzb+X6Zv2mn73DRv7mxe9dhHJ3rv2ONc33+4W\u002FvnJ8Zy3rH3Ls938X1bHjbeOpB7w\u002FIszotV6ZQtGVRJ6SbI0ST8kxYEdbWY+FHrtiUKTgAryjg4rUJ0PB95hbjbPKFlBAqjJFCB0YNhDXSPPJAUcaVavzTP\u002FuTzeXLl5vnVTIRM4DbBBRrrT34Bw8JVJgm3NrSNQLul1lvJTJZJ0oFIZr7FDNUag2+EtQkFCrhyhLGI0YpZ5GGW4R19aL11U6jPAks1zMfwTCYF67zVYyWgI2hEKyVAuM9YLVzzrgpHQQTgh8atjWgEMSslXUfK3L0UL+GITenwyAbP2HFeWM1+daLZ8RcaMsP692Nm9cbtw2kljGEQoCZMSqwevNSbOFGCOSvf\u002FV3m1\u002F98m+ar5LWcvPfGYWjOukpDjwTcJAgae7NL9ozIRzh0yopyRCyf\u002Fo7+0vUV4mewn8YSNB7FnbvPVNojL88ZTeidfcSos2XOUELeTj84BlgwxxSHihclB5j5xkAs3CA0CwcRglbY2oqZp581k8wwRK3qk+c2rwXPSXoE44oM+YU\u002FfDXfXV2+ox3EAjxTEoVevdNlklzDQ61TzDHk8BgYuKgKVo4xgq43No8HxyqU\u002F0P46ZPBFGW6KUMLKFdu5IJ4XZ68oSdPtkx5hgofCP0ApStYUuL7n9JDzzfLdujr9PfrTcHT\u002FaM8w25ptAa9Mx38+DDetpHx\u002Fbv9vN61r2LPml7\u002FayQnLmvPvaa1W43rmeW0O7L4EBzJqwCbK9woDpkfvSxPglLoTCSVWphmls8F8\u002FOMFbC6IH4nTwD66BCjMpUI6Tre4J6KvIIrpcvl5sQ7j3Mks0y\u002FPFHH29+85vfzs\u002FHxaoLzYLHDAfkDB4o4V5w9Pfvv9+77k4JaWNDT\u002FBiSi5r+\u002FFgVSjNa4WQWverV68kuLdrenyOkez3v\u002F\u002F99N6mQHY5P3Gy0JOE9YfFT4\u002Fi3HDHMBmdsfHhzQTaX\u002F7q15tf\u002FPXfbT755KNZd3wSnMOVz69WTjVjAgPDKDrBN4HUJoGXClE1N+fzqjGcmFfjvnz5rcJvLg2uysETQsNSf+7smdkoSPGHh7V552s7qpLrCtcLN1TnAsNjsEjhIIvZERY9Qwco+0ornjlTDlu0gUV9BPaMHoTo03lb9cVmRBrFxylC+gSO4T3cQiMoROrZk13AyNab7D0MK2ATb3UN7hP4B2eSH3nz1GE\u002FmfxwsMgCMfU8sAwWZ5I\u002FhAL+z\u002F7X\u002F9vkC8L8j3P8qIL68WoQv5K74xf\u002F5v9ZJ6th2yRNzE8DB5isNIQDE8HlDUngl0nA0IaIhYgmBKUZRN5BaPdhEpj3S2t5TyPKiOwsQExJWTNCsGeXFn3YXaNBEcqXxU1892JCgJfG5J0QVP+6OMIuIX0laJUUG+Bq7yVyt4hLwCGArDKOENAzGBVB3c9DzKwxiBEVm42hUVL0BYKqM+x9g\u002FwxbX2h3IQPQ5C7OIIGAZNAoxayrXAJLMsSlcUqwfRIzJy1326f97PKL5cNRvAiRFtuJIAkvMZOi7wXV658njb+yxEqIBqrkr5DOAALTs2PuZkQgDRFMedj5SsOnIDB7SV5aVdJpojF8UpHHU075WC15bmYMcqDjRdsmYwBfvTRh1Wm+KTk0f93fTmx+ff\u002Fg3+6+clbl7NwH6qtGHTjGORqzJ9fubb5ze8+HMZla24EdU8E0zrOWmTVEIspPOp8Vse3f\u002FJmGnrKSckqkvJ4ZQhWiDuhbmhqDEnCFo2fcPLp518UWvO4eaq\u002FMXRWMaX5Dh9ZlUJGyOhBRHkEwVpZMFoXQBfg7Idi6Z81a0nnwAfm4vx2Y9\u002FmgflUH5fAPE2sy9OeW5byuRQDAoCDwjl4Md\u002F65T3TXh96xkfMyOft9\u002FVXPzsJ1lzqnmk\u002FnJp7O2eOvj92BuDenpt2m6\u002F\u002FX8e6vu5deLHadf6Hh1aH0Xtp88l1zZouDCn+V78kJYppXAKhdcU8MSw4iLDDdQnOhGEWHJYfg1K15FgJTjbQkiwIxl9JoUQ4rQ2hi3AEv7xM9j56wo0r9OVg72XFHByOMYEXQorNe5bFHtywLq+auXCFQEgBZjVrloZGELrg6I0bbSpy5cowXgIoJRNubY+16RkL9Yp1J8CNdR29TGkn\u002FBMcKSD6DaY8P+NIeQETq7Yv71nhIDF0lQ\u002FQVsxtrDvRHgYF+DLVXuor6xBDh3lEnwl7rNjaEPohdAYe2lWZwEm4Nu\u002FLKxFuo0XNodwbf3\u002F729+OK906jDLc2umb+aMsmBdMkseDckUQgZvmEj4Lc1sWW4IxqzPLsn4LRymRPsZ7MkseoZ+lkqBsDdRNp1CJ21WBYcWvivdnZS\u002FRM5qz9UQIZRHG6LscA2UhKRIsz6zQ1766NiEy3suTYp6ftF5c2xQ9Ln9CPyZNSFhx39HFDC\u002FmEZwY29YrREkzT+cLs6Mg\u002FM0v\u002FnbykgiL6DillCcJXQfr3mU+eAp8595\u002FXMUY1b3wnS2u8vQR1gE81CLY+Jk1rA9g47vaJWhDbDgjjEytdVu9h\u002FWDK2iINYV\u002FK3yk70MZEtrLaRKLDIaEBnbbS5xFC+CCsWmfMKNv+qz\u002FzjnWua2Qjpe7su6bd9euc\u002F2fv55Z39dJnwPddW4+L4FpCU3o7+rTvLN3a31RX3\u002Fn68u2rWUg1jONlXehdeJxW9Z376GsuMYTN0\u002FH55ZSuuQV1YUUn2DES27p2netO2F9rUIyTQLrgQRfHrGzCaSMQXfu3h8+Bn+uFaohvFK4HXlH6B5vCxoFH9FecOav+SEILvr2IKG9eujBPfym7J05vWBY8jMvzXvvvRNsScg8vPnkk0\u002FrZxb4+nftRnXVK114qaotb72d8S08QgtPMejFY7cJ1cYlH+vrr9dmaWDQDsYo1YMKMrjvdHSURXvyvRr1oyzNX9\u002F6KmX7SjCnrPSd3v3J4NU\u002F\u002Fxf\u002FYvPP\u002Ftk\u002FG5oqEfZaoXVkEv17M6PIpYuvgcJklHszR+it8pV+5JQ1vVMRh\u002FwUYC28DqfNh\u002FlBn3i0lnV9d3j7VUr+3eSpSmgmd77++sXNq9WBV5kPzQJLW6POueYSzWYsYThh9CLrkKVWeNwycEggn5KOaHz4hw59mUcPrOBPvlP0hfRYzxsUo+Q3O5\u002F+Z\u002F\u002FF\u002F3Lzx3\u002F+T0Dhj3bsZEb+aO1t\u002Fnv\u002Fg\u002F\u002FR1C\u002F\u002FP\u002F3v\u002FzctxMq256pUCxjTxhi4dRFYgg\u002FCbPMI5aeIUbQdSA5dEHBAANEQe\u002F+HYeVkQjDEprpO6NgT8mlfXfAXCFULZAFMsndCCIwLQSEkS3o6u+fsWL2m3FqIS8CAJIS15wGYBUZ4HWO5CEmdG0G8dlnit0xh\u002F7fCMtYmBuKn6OXncg+9\u002FdY7M3aJtJJGMRWEwoY+tOMzp86PxVoS0qNHhJblIj2WdRsAOBDiId4x++tf3RqhFbEgnOsry68fQj\u002Fh\u002F3CC8r59BOmlwDyL4tmEyCZOH3\u002F8weav\u002Fs0vArRldUJ0ufQw3UO956uYyo3rvwkRsoQXi3pO8mfERbIb9zyt\u002FdNPPty8\u002F4Srd\u002Fe4nH5+\u002Fs1Zr2WxS0SP2H0bQbyTMKUm66e980ra+uOYntJLBBO7nv7knTc3\u002F\u002FJf\u002FsebN6pNqk7pt98+KSkjV2CMyPqz5Ftvis2z4up31yYhT915iccHClVBKL0Lc+V6Pns27f5UibMPQ6ZCVwj91vdurkXP7IlRPq\u002F6zb5DErXuT834S69f2NwoTn8IuvaCN7WhEe6DPCvB45MXJZd0Hoyw0CD6fgJhYDm\u002FhmzPFye2DGjBlBtULmolB8bWHe7ZeWD7HM7XAZa\u002F\u002F\u002FHMYpjr2mrD+8HFWKm6edvE9h5\u002FnZzz\u002FQLbWp83OB+19A6HcxThOXb64P7tofXvv23P\u002FuFfa7HepfH13tVE7+1hhN\u002F1URj6ZJ6tJZestiXoqi4089pMgWXjJnARMjFPeKjW8Kl2\u002Fr2fC\u002Fh2HqmrX9if4KsY2LGpWTyMLIa5d49ExFcGl7+8pi5xFui8Jnb3tRsvrx9BGKMU1nC7HZK\u002FDmZPFcb3k5+8M8lNrXCheCxxcY8mDJyxLjkQ\u002FxVjGtOO5nx3tvEEs5iAjZMokBTnSxfPB0fCTSgLKrE8TeH+OpdzoTKFY2CEly5dGCWasj3bZqdMixm198NHH0lqbHOg4jitCRfz2++8PYum5BlaCo\u002FBpZwU80fBZiBYYSR7a\u002FPUMC3eCIrPbC5UhRP0w31opd1JhWysUBhlCcVfKg\u002FbboQxRutGAKfI7m0exFYP7axPQsgIIYRWyWloOEEUTlt7CWWEdgoNa\u002FjrJZSaK7RYuMprr10YBmpuMEP0zc8IX72XcYbCFJR2fo33XEIw5v1FYTE8g5n2ayvm2fwQhCjoYkXBjHj\u002F06f\u002FrDk9UdWKT4dBY+J3cp\u002FHaFrHyuxlQbz+2eczJ4v2RuNYCOsrqzxvi3n9ujAaeCcGWKigz3hBs7O5X+UzsMAwowIEODiuQk947oeQsWf3vRHwByYa6yOb3WRw4EnE6TzLAgrkvHOUnsYAeYRljnQ89MdzgUHvH9xrvih1StUSGigDu\u002Fek4EX3hQ3aY4QnAU3Fj58xCkXjmvDBzQHq2iKgO3hL0GlK9OSUJbQcjeccwr\u002FjufIQVCpyjAAPuevm0InGZd3BK5rts6Nu99OziEEDctpj1tnv9XmdRE3M7ZDIacBg0Ty0ZD0JVlyav9NCv3badSPYRmPICv9te+cdJVeRpfmQ995USSpJJW9ABm8kvGsQIGga35iGhvYz3TtzdnZ3ztkz5+w5+8es6+mZ7qYN0I13AoSVR0gIKwTy3lbJlrxFBmm\u002F330ZqVevMqsypSxJVR0Bpcx8L15EvBsRN75r4sa+\u002FeIv4h22nmp8khgjrAnm5qZGHUsJwLj7AOKwKMEvWurQItaDQ+oH23ulchnf1maVxUjFDeew5haupRYLXeBtgOZt3379LIABYQZZ+xHasZhxtP3effg5HxDga2NnjIwYOVJa4u3iMS01pomJDkUail8ARBVKWYI4fbxJp4Vybk3nzu0MB6xfv1W4qpEbM+Y6uYkpDnrXXu7zOUvciy+8otCRy9xd994tS\u002FkQ8bj2blfFBtdR69uOHVvV\u002F\u002FvlbqoTwbt2kJVOB2rJ2r22vFyR0nSCp+bx4KFDNC8JvcyetmOut\u002FzB94gnbViv8I8iITyC2OyM4a0VcsGTG57FEtc866eoR7iPtpfybumSpXINXC0hcL8iPvWVe1Cp8bbde5aJrbKXpqVp5Y8qZPeuHRU6E0aeBuKz8DroulvvCt2gK4JPx45dxOujjdyHFLEFt7g9O\u002FWccMQF55+jQ+1kSRNo3yaL3T4JBBVbKhSRBpdCMJP2mohPIHiAF8EFdigZs6\u002FBAdXJyexy79PcR0GwTW5vuN8ROtIsDWrL4kVLbFzAN5jvbB6Hlrfe+4gbfc0Y9VlhU0E16r5pQ0ZcIH+mDm78K8\u002FbQmULryYYGx4wUUQbhMSYNAm99s1AgiYWiw1AnoUHhgHjZnB7LRyDxQN5CG4SqAaz+tKAMscF29C2ichEZwe9TvYz7UoX0zihZQDQoVlBqjL\u002FMEl1aJFY9AC4LFAsXgZkNTHMb5BK9D9AnY1EtuBpoiMMYNqhvbikMJDQxOOqUdJDJiC9C9dZ1BFaAB+tRAs2xhF2EbM37891EwzUZvzNYdAwG0ICRaYeYurK1038AToyuAnLiIYcTTmmczTexHbvogXE4pXrmtFQtALQRdoWAWYtTggWaDkws25VLFIivxDyqKkkRjQ6G7QJCqBNXkCSWmOLHhtVu3ZtZ35q3SRBFmmSd+woc5nEvp3btrht8ndrJA0DJ8N2K+rk+vfvJUm6m7SXEW0HDRkgYNLN3Xnn7dps0drGSHtJ02jzTAsoGgvjqF2HXJkYwtp1G8QI5E+qxcyYIdoQa1OkISJ0XFP1G4cd9dGm3F4qu5NoYO4E0uazsJt2TxIw78cKyEYgGHT3khJbHLfo\u002FSsUzWaHDtBg0eig9\u002FlWG4csupAWRyxCtv9BNKQ\u002FbdyyZoreaF34A0AiNKrLoj\u002FdNwuN\u002FfbXozFpYFUZ7Vl9qlgbqwxenrdPytIfFyINVTTD7Fl9FZmsTxk7jN30MxRAGSrTPrXgqqToO5esSJWp56LKoouMt6j9PKzyqcA+oUjqhxWYKlYF+QXa3j9VLtd8G62AqLioDWqUarbGM3\u002FRLrIA0ljmG0APYrD0ASjQMqFJApDxEG1kTsIPAMxsPOZYbAT2PbsZx9tt8x7uBvAdNgHxyULDZyvNF\u002FZxEHKLRRgXmB74XPboYe1gQYD54ouNppEThJkf0eZSmhZtYKXd9AntgDdwnH1vbWhCg8qGyS4WQ1zCpN4HLSgaXXy4KQ\u002FNMFphaA1gBjCyKZJoCCtWLDOLE+2Cr6DRXrhokfti9pdutv5WrFxp78pJpWiVaAP+ltCb0zfhO4APTO4AY3xa4UsII5iuUVCwSZt2MWZ43n9HKACkQ3e0arxLiRZmXORwQ4Nfm1VA74y2G3cjAA19w2YtgLptsFS7WGThpSJ5BAbpd\u002FXbJh0chRsIIJ1Fs6sOg+k3YJABGVwzWOjxJ0dbjg86Y4HIT9SH1p1rNk51jVHoeXl7bYonAczgiyzw8HDGJdZKeDXWyp3aS7Bo4UKKVX9pM7tCzoIE0dAD7s1aov7nUKuSkp5uxPDh9k6cMspm5nVl68WPyozO5GWBRvCgbWjYokbIP1\u002FCGlbiYr1fG21+\u002FXDGDNNgM3YBjdASwQs+xm+iVjDHGE\u002Fm1rhfFhFcokQjBA0ELuYr70O\u002FMd4jJZaELvW3adJVFqCS+cVsZQwhBPMHbcUsjI9THpZGc+VgzdB3LBxWv\u002FKxP4uxR1tZXznsjj\u002FKw1XNeIn+NeFU+amL8ccngDlaq5VV7URrH63\u002Floucdj\u002FKk2YMuh6VodvpxFzj\u002FA7rLJWvSqwey2M\u002FI8Af1ZmqW9XAt1CAREhAGfWbMJYI6bSCscQffSByG7A2i469A7yW8Ya7FRY4rTuqEFdJgj\u002Fgf4wyUaRO0TWy\u002Fhwl8IPGLP7a\u002Ffv3NcFx1sef2x4JNMMlWmcQRrHA4G6C6wVKJBNGU5gGmgDCaQuC4tq1uKQSWaiLAUWiCrG5efDgQXYGAMo0hGU2oDMHmbsA\u002FKLi7rrPvO2hNh41axdaa9ssqrYckPb5wL5d1s9YxcEN4AeiGhGtZqPmHy6nLYRxSnr2EC9oboIB+8B69SwRvxFglpvawAH9VGZ7KQ36uxEjRhiuW7lylVswf74pF7AO9lT+s88+y\u002FasLV+23C2Umw2KN0BvZM3ROTqqd\u002FCg\u002Fm7QgL6aQzoxVC5\u002FCN7moqZ5gUDMKaEIuXhPmAVVPWl7ZaTkQJDYvWen5hyH08k\u002FX0pW3Jd5Z2hCOQTHQJjeL808imHmbkcpZBgrFRKo9+I5oDETCcnsFZC2XfeY0\u002FAwTnFFG89zumz8kXLXaIMve3vguf\u002FwL\u002F9Tvuk\u002FSI\u002FfQn6pFaBOAwcMGeFuGHuPmNsut3r5Qlsk2srkAgPwmmfzcdTgZFACJvHnZnKyoDBgYbpI\u002FDAZmDPXWFjQxOGbyALENVsUNPHIZ+xClISpMZDx6wIAsPgwwThalsGMydZCBWmRg0HRLv5gBtTFAk\u002FZLIgwbSYRWnAGCZ2CTA9zQjpnQmOaN+CryY8wgTl\u002FfdlG63A2HuCKQmx5JHoEAUxIfIeLqBi9q5fe8Y8nrJC05xXbNUARAGCUuPOwsUSuJVo0iQLQSoCZxQWNuG2U04DFbxw3FSYwZicGJbHbG4lBFEtD3ksMo6RHT0m1\u002FQXmi8U0dppmspVcBjZukqSsgxN2a+Jz8BKTo70GM7HgG4thttHCj0RfJMaB1g8zn15Fid3acinQoUK9Srq6YWcNlORdLI0N8UwPu3PPGepGjbrAwHlvaaeGDR\u002FqzjlvuAY9mjHRXpoAW1Q0sQh3xCQhPupehWCaowMWyss3q0NFrxTIbi4XmYbqS7ApHBNzMjvri7rIfw2BRZpZ\u002FP0BedAS0NVK9xF4BE0YHCpLbVd\u002Fo43q3Vc+dWJqGzbJVUHaOXtGgE7sXQsNGkeNM40v6olAOswNAUALB7KUFsBogYn60sAui4yuM16jP42V1DXGOHkM3Ko59D9jid8GRDUubExobLDIGTCxOlRfuryoXKjPwh2VF12L6mdR464Sn9Th26Pyre3KYHn41L3jC6o9ZW0yYTpVp3IZ8\u002FLjnvdhQYtAVLS4MfZtZaQ+qqVOq0\u002F3Na9s\u002FgoAMz84UY5xRh6bf9BXjLipWUo0cjRHEdwZawi5uE2Z+5ZctBj\u002FLHIITwAtFld1pb5rNusSIJzNkliy0IjAa5irADgETcAKjJxEdBYE6u7dS6QNVkgxaVFYIFnoGYNovACZmFoBv7SR9zQLDNWLN+DHzFyDDyB4QCu02IQPZG7TR7jVlEuLhn85AADwBbVsH4\u002FuE5aVQ3gQ3lEg4HoCjTtrzqHcoH8AwwgN8AUovHbtOtPM0RbK7Cz\u002FTRZCIrPY5lPRj3yAxr2yIFk4OMaz5g+KE\u002FoSn3BoBfAD7AMiAMCATIQKtMm4ikDjLVsqdEDYWvEnQqyJBnr3rRIm1suXFS1VkcIv8s6UA9+AZ2HJ4zenuuJfigsJfAygjx8nGnUsKbhmwNs6oUTBJUDlw+e3a7FFYGF9gPfyu6y8PN330IVxhTDEBmTGJCfFsjeATbtbKwhvuVvaRJ1CLAsKwIQYyhwBT98BmHG1Y68DpyH36tlbAKOn8X02wcNnmPfEv8daw8mIjBMOrTE3J2nbcG0oLys3ywydWqrNbUMGDzagigD0wbTpVo5X8uBewmFyVq5ogU8\u002F\u002FIg+xD0DhQsgHSEKJYmtD4BzjWt4O7yCuUGfMP4B1DzH84x\u002F6MG8ZFJEQDZy7SA0JCBdOEaWIsA6QR4i5Rg8jXnI8xpO9slYB5ygPKOeaBOeNjwKpKBAgx+xnjEXme+sk9THD\u002FqFuYA1lPnCWIOf6K7yUAcMPGIU8Aj4AHlUUfSfbpPFyuMp7sX+qBPttc19XWe+Wv20gT+9BH3Hff6Y\u002Fzx\u002FROMfgZM\u002FxhPjjDXWlH6qhraa4JNqM21kDNv7iHeBV46m6uNdSKw5nJYeuXf0lKVWEZ9ET5Q37B\u002FhdFkAIRsg4UUk5rT5nWvc2p4OjUFA35w5c924cePlLrVA\u002FdHEDRgw0A07e5jWqGL17yG5Scm6S9uFO4w3iBdSB5GbSkp6uD59+glAlmksF8vi3dc09ADog7KKwxO6Fcs9TjH8D+qQLdxNivQbyxjzC2tiT4UvJjIa71CkA5jYO9avb6nmVgf52+vk8OXLlY+DHpu58W++rXfj8DgOMmxtggR8bJcshcuWLjHBuId4wqBBg8zaWa7AEGVlG9QfjXXwk8KtSmuPQI2g00L75Iq66lwCPU\u002FoZIJIVMh9h3lngrBCOILhsAahyRdXFb+QokY4go2grXTgEif7YikiIhK0Y91G8dJJ\u002FBCFHWEfN2mdJ9Qjh0wyPtpKyEdw2CXl5PYd7B\u002FC5W+bCeMaAjaWcEPEnQkrCK4zxRK6ULowx64dM9b9j1\u002F\u002Fzl18+dXWr7Xxj8Gs2iiYMnv2GeD++V\u002F\u002F7B7+2X91s2dNcmuXz3WbN6x222QiYSHlaFZb8DQbmRgwCTqfRYQJyyRgUpAXkzGLEZOFawB4JjFgnWsshIBoTqcktJ75YGrhpxzKZmA31mRBe475hMUMpgZgZ+FjApCXBZwNZm00+GGqLDBo7gCPTFZ29MNQqAtplPai8cO1Bg2RmSq14GC6nKMNGiuX64ROTSBM8N26FauMYxoIRA8QE7FBEAF+gBOMRxmsDcfsZAAdkKQ2YmIzBqf8MFAYB\u002F9DO96LhXbffjFKlQ2wBLijcUeTF4UZJCqCwEhJLw1M+YsKJBUV9XDttOj0HzBUhyOsduU60viI7sGwWHBZGCh\u002Fj8DHIU2K\u002FdJEHRPDbSGXmWbNtAhobzBAu5004p06yV9MprS20m5y2ENn+Z3TOVsrtPDIhLVf0vuuXVvVjwcE\u002FBUhQr5qTEq11voUJsqpitAegISvKdc4lCoK8SawKvCG5vKY3g+GwthAi45WorFoxgX6BF\u002FVTu208QWQoDw2viC0LWYR02fcwCT3Kf8R9WcXLbw9pV3DT3nuvHkRSFKftWypMSh3IrQgACZM11Sk7hetI+2UFEw29oxerD6qi3s0ibzUn0yVr\u002FDLMkd9aq2Oxr5Vl3xYWdNFph6LZ2GJq5TIE7vEfbUunSWqPZYhfedEv\u002FiyopJPpBTmMwAPYA8YYVxEfwCPlOVMtIYP8HKAEngGY7uxYhlradb8ltWIzaT6yZ9fwA00+4Vcn4CWCPDgqiGB2+Y1cdIlMAOGpUllvFAXm6s3yMTKPhPcrIqlYeFZ+FPU55rD1vdIDOpDmqL2IQiwaMCzAL3s1cHsSuoga9hSLWgLFsx36yW8Yw2DT\u002FTt21eLKPGRJRxoTpSVlWtRLjNAyMJTWlpqggA0YqGEBx1Px\u002Fs3PbZ0k0NUNik6BIn8xXJ16aoFNopu0lxzZ6eNDsy7gEQ2mrIwMmZ4RwAGdITPwTP3rFxph7b0Eii98OKLjCZov3cKGAOUiYgQbShV9AnRCV5N2wcPGSJBWxZTueFAoyZ6P3UgzFzyvlyRdBEhhsgPhBckEhO8Gm0aiy08nPfi3X1izPDW8MkU4UWrTW7e3LkSENq5Af37WSjJIkWGQDBi\u002FxTC3\u002FqyTQLxiviksgCL5tok3sA7klh3eG9cErGUEr0D\u002FsMfwhR7kLCO4ENMXGusmLwrbWXu8yzt5T0ZX9ANfo7AxUmXKJmaGwgELKIdjzTkCKCNG2ldtDGuhmh948AXXlJsXu8ZzXTb+yVQgmaeZ+BTzHAyMvyi73xGyfiRGgPvpSByws9sz4B9RhrniNcBcsXr4X32n8pW\u002Fx+RO9O+fVqPpaU2gUF0i\u002FJFaxjrIxYMtThVq\u002F+gNqUqjI3r0b3orfhOi1P57Veca+lCKlEvvJY3iUQFzX1Zc6E3yd4DK4AVRa6IKrj1+KRWkzP1M2qB\u002FbQs\u002FvpxGkYZY9f1lbHTVO50WJQAn8Waw81YyyRoIsxZtKSWOiBIbpc7pTFGK219pTrgDeAHxhH5wBpF2jMGlkDgNsWiysC6\u002Fdnnnwhb7DWhl2f69u0lzXBbm8+48w2WcLh+fYUESm2g1jjfvEkHfKl8NqVPnTJNLiiL3Nibr3GXXHi25rTG8j5Z0nVSOQItPAzewwZUDvPBBWejrOoaua6zgDlzDNcv5g8C74cfzjDgW9x9j1sj\u002F3TimZdqDe0lZVxp2Xo7ETRyNZKrqfFwzWmVhoIEwYU\u002FBCVzT9McYF8FfLyhaMg7I8RuJ5jEshUmNCPQw4fNeiDhl02qKBVLJUQQ3rqnNrcepEwB9ZaavxxuqREqHtXEdRceaKJY5\u002Fjs7xU2A1fYGBG\u002FQAhgZNhBdJoWFvpU7QQnsocNTT5Kls3LVqq+Y3IHaugGDB3uLrlolBt99fUKD9k7GhK1+G8DTdzjI7YWKwpFBwoECgQKBAoECgQKBAoECgQKBArkTgFEyZACBQIFAgUCBQIFAgUCBQIFAgUCBc4wCgSgfoZ1SGhOoECgQKBAoECgQKBAoECgQKAAFAhAPYyDQIFAgUCBQIFAgUCBQIFAgUCBM5ACAaifgZ0SmhQoECgQKBAoECgQKBAoECgQKBCAehgDgQKBAoECgQKBAoECgQKBAoECZyAFAlA\u002FAzslNClQIFAgUCBQIFAgUCBQIFAgUCAA9TAGAgUCBQIFAgUCBQIFAgUCBQIFzkAKBKB+BnZKaFKgQKBAoECgQKBAoECgQKBAoEAA6mEMBAoECgQKBAoECgQKBAoECgQKnIEUCED9DOyU0KRAgUCBQIFAgUCBQIFAgUCBQIEA1MMYCBQIFAgUCBQIFAgUCBQIFAgUOAMpEID6GdgpoUmBAoECgQKBAoECgQKBAoECgQIBqIcxECgQKBAoECgQKBAoECgQKBAocAZSIAD1M7BTQpMKS4GjR4\u002FlVeDRo0fzyh8yBwrkSoFj+Q3FrMWGMZqVNPX2Rujzetu1J\u002FxiheInJ9yA8OApoUDjU1JLqCRQ4BRSYM\u002FevW7ZshVuXXm5W7Z8hbtlzI1u6OBBWVtw+PARt2jxYrd+w0a3ctVqV1zU1d15x+1Z84cbgQInQoHy9evd1Gkfuge\u002Ff69r0KBB3kVsqahwq1atcWvWrXPLV6x0v\u002Fz5T12bNq3zLic8UHcosHnLFuvz1WvXuRUrV7r\u002F\u002FJ\u002F+3jVv3rzuvEBoaa1S4LU33nQXX3iB61nSo1brCYWfXgoEoH566V\u002Frtc\u002F86GO3c\u002FfuKvVceP65rqhrV\u002FfF7DlukxaDZGrcqJFr17ata9e+nevapbPr0rlzMkv698TJU92hw4fTv7N9GTJooOvfr2+22wW7fkTAGyC0SqB79+49rmP79tWW\u002Fe23R+z+tm3b3abNW9zQIYMr5d+9Z4+rqNjq+vXtU+n6mfBjxcpV1o\u002F1AbBt3LTJNdB\u002FxcVFJ03aM4kuaL1mzvrYffX1XPfg\u002FRFI37dvv5v24Ywq78m8a9umjevUqaMbOKC\u002Fa9jwuNHzsObYMRU2f8Ei17p1q3oB0hctXuJWrl5ThQ79+pTaPFylewuVJ5kaan63bt3adRB\u002F6tChgyvp0UNzPpkr+j17zldu46bNmW\u002FGrnYVj7vowvNjV6r\u002Fukll0j4UAlu2VFjm7t2KxeP6uZEjhlX\u002FcI53Dx067Bo0bOAWL1nqmjVrqr\u002FKIL2QcybHJlXKhiDxudaQZGqvteOy0ZcmL4ffBabApRdf6J557iX3k8cfde01F0KqnxRo9C9K9fPVwltBgY4dOxghJkya4srXb3DdBIJGXXyR69yps4FZwPihQ4fc5Kkf2P3u3bu5gf376X4nd+DAAbdMmru3333PlZWt14LY3rVvV5UZkHfjxk3u408+c5u1YF1z5eVaOLtLM12UKucbN\u002FOjWa5vnz6umxay2k4tWjS3ehYsXOz27z\u002FgbvrODdVqMBs3bmxtZdFZu67MXXn56DTdaOsTf3rKffTxpwIOg1wbgYMzJc1fuMg998LLbtv2HW74sLNqrVnffhu5Ap2IFjjXRiFQ\u002Fea3T7iv5y1wl48elRV05VLeqaJLLm0hz8TJU9zCRYvdow8\u002F6Nq1a2uPMeY6aW4uEOj+et58t19zbfSlF9s43LVrt3t3wmT3pQBmz5ISE5h5CADPfJ31yaeun+bS8GFnW1mF\u002FudU9Ldvc9u2bVyrVq3c9BkfuZUrV5tgQv\u002F36lniGkloadWqpWvWtKmb\u002FuFHBoqb6vtZEqThU98e+datF995b8JEN2\u002F+AtM0d+3Spcpcb9+uvTsmd7YJk6Yajxs5fJgJQfAn8jdRX8z6+DPXtGmTKkK6b2f8ExeUSVOmuTfffsd17drFnTtyhLvumqvcsLOiOTj+HfhluSklKPNkEv1dXFTsPpw505X26uXOGTk8XVwh50y60Dy\u002FNJfg0FHrwlzN23nzF7odO3fa\u002FEUp06TJyb17TU05cuRIJUG2pvz18T48YbWERZRtgwcOqI+vGN5JFDiurgnkqJcUAFieNWSIMbSG0szceMP1rnPnTvodqZ\u002FQzJ0zYrj9btSoobvphuvcYDHZAQLrl0hav+fO77of\u002FfARV7F1q\u002Fvjk3+Ri8iSKnRCkic\u002FCYCO1hxTHH99Snsb8O3erVsapFQpoBYu4JeOtgkNl3\u002FXmqrZoEUfMIp2Lp5atGghgaOjCR3x66f7OwCmSZPGon3fWmvK3r373FN\u002FfdYdPnyo1uqgYEBZkyZNtdj0PymQTlmngi7Uk0tasmy5Aes7br\u002FVtOD+GcYkVirmB+m8c0bavOndq6cbPeoSad7vcdt37HQvvvKaCdL+uQ0a06SeArK1kU5Vf\u002Fu2N2vWzPHOnTp2tEtXXnGZ8RAP8gDmWLLgWSSE6GFnnyWhv9Sdf9457uYbb3C\u002F\u002FIVcgMTnXhn3hnt\u002F4iTLF\u002F+nZcsWAuBDbG7D4y684Lw0f6LucwS0AcDtMigh4uXwHXD856efsT69967vuRuuu8aECvgGQgWa9Ecf\u002Fr4pOJ5\u002F6ZXk4yf0Gz4GPysRP42nQs6ZeLn5fG\u002FcuJFZ9KAjCaEFRQ88szbTl3O+dh98OLM2q6gzZQ8dOtisdfv3768zbQ4NzY8CAajnR686mXvHjh1i9EdNe4T5NJm2SyPLQmDapQxaEAD3HbePNQA17s23BCB2JItwW7dts2vZNOZo9jNp46sUVKALFfLnxWxM23NNG+SjjptP8+bNKj3y2CMPGRjw4KHSzdP4A9eI\u002F\u002F7f\u002FslddEHu5vp8m\u002FvHJ592Bw8elMm9Mk3yLaem\u002FICcf\u002F6nfyjI3oBTQZea3of7O3ftcuNeH+8uPP8816N794yPbJEATOohDXE8AXy6CJyiXccS5tP61Pd8xrV\u002FNpfPU9XfybZs3Rrxj54JIdnn8\u002FeTdOI+Wue777zDgPLHn35u1gv\u002FnP\u002Fcvn27uQ3B4wC4yQR\u002F8taO5D3\u002FGxcmBCesbndpD8ugLBpMBP0hgwdavrnz5vvHT\u002FiTvQ0klCDxVMg5Ey\u002F3RL57\u002Fl9bAmS8TV\u002FPne9eH\u002F+265GgRzzP39J3hH32WeGGFVL9pEAA6vWzXyu9ldfCZQPRaGxIaJ+zJZjB4IED3TffHDS\u002F9mQ+7wPavThzGWNvHiN3kkhrlny2Nn6XZVncstUFqNonjQQm92RCW1abbh\u002FJ+vL5Hfdhzue5XPICjnCr6ZXSluXyzMnkKeS7FLKsE32nKdOmm3\u002FxdddcnbUIhENSprmHSwhp585d9sk\u002F5GcsZgP+6Ywn8OVU97dv4r59+xz7QBDk0X4nE1p+NojjepdtIyXPXXHZaHt05qxPkkWYdY2LmejM9XNGSKuuv+rSnK++duvk0lLau5c7+6yh1WV1I1JuSbPkDniyyQtqSUsf5Z4J45x24PpIysb\u002F7WaB\u002Flm6fLmV1DsDry5QFXWqGFy74AkEQwipflIgbCatn\u002F1a6a1qYqK4fJC6ZQHZvjCA\u002FuKlyxybqJKpOsDBJjj8xnNJaxTdgE13B6UNv1gbu1gUkwkNE1qVCgHJ9vL5HSXfXjRl8eQ1j5kWN\u002FJhYWCTGpu0MGc3TVkSkhohNpjOkH895vFMbQFgzP7yK0d9aHhoc8uWLdNNoa1o+W5V5BlABq4QbODFhO+1ouwR+OSzL9w6aerwvQVwYFKuLmEBATis37jRjb35pnRWtH4LFi1y0PGWm76Tvr5DbhRfKj+aL7SB1S3w+Ch\u002FPW+e+dlSwCFp1HlHNJGY9lkU8ElFGML1gDo\u002F+vgTaX7XW1vi78\u002FzZeXrLZoOIAe6oynGDzm+ARZt0OezvxSdbqoE1nj2iy\u002FnuBuuvcY0ppR38OAhN+frr92KFavcGNXv92Fwr9B0YW5AZzYTU88F2oRNHQi3zJeklpM2kL755hu3QHsIzjv3nCoWmiiHc0fkY00kF+jgQbm\u002Fx2d8g6K\u002FzmKM1SduGWPj7LwFC+Ur3MHGlc\u002FrP2nvkmXL3GKN99179to+FcafB7259LcvK5e55\u002FPm+pnmP1kUBWlFQ038KbUJmQ3hbLqNC9fV1YE2siZf8gMHvtFeg6n2SvCbmhJCBYn+jbeFuf6F5hKuT5dcdGG6GObGV3PnudYSzq656or0db4A1BFicFOMp0LNGV9mTbzM50t+wt\u002FhxYwn\u002F97kOVFeBK\u002F69PMvxKu2236Ec8+JBKj1GzZIIIg28GL1XLxkmTWlpCTaDxVvVy48h\u002Fy5zO9ceLivu6Z6ocn8hQtdufjaTd+53j9mIHuWeGh7BT64\u002Ftrjgv0ezdcPZ34k69xuc0Nlb0sy4c7FuPH8Ink\u002F\u002FK77FKja63X\u002FncIbJChQ3SJFVg\u002Fks2ncfXH4aVv+zZWBOuCLTaQwkS4CEfFE3YA4wGFN6b0Jk2TCOyzg0sYt\u002FuJLgc217r\u002F846\u002FSj7HIsVELgHPFZZcq9OJKMbFZbq42Mf39z35caZFgccM0HF84fEEAm2nTZ0grNsQ0X1sEwj5KaeHiGvVPBZ7fnzRF9R2RL3Gpc719CdHnJ5997pYuW+HYeU+7p37wodsr7SCgnIQ2bcKkyQbsWJR3SWv\u002F0quv28INwAOos5C\u002F\u002Fe4E8+s8Ki5OuwBuuEtkS2j\u002FX1Y5LO5xkApdXn9zvNEDwcgDdTZXsvltt6L\u002FkOdG7UPA6MMVvgAAGjhJREFUXSBb2qT+BZgSEo4EiMTawPgA1Pk66G+A+rvvTzBBg7y8pxdoWGQmaCMlG556S+ACbEz9YLpA+yp37dVXkd1o+\u002Fa777vZ8jkl0TbnWth3Nie\u002FN3Gy0Qsa05+07dVxb5qGlcgp+Ct7GhSaLu+rbsYvbWKOvKP3JMJFKwliAPbzBcKzJUAXAHBYNZrXzVs2Gz0zaSFZ8NlgygJcpHChJARKNMuDBkWbxhAG3hLtaBtjmLEOAI+nbXL5gF64A12svkEYQuNM2NKf\u002F+RHBhir628PdnOde\u002FjJvip3H4SJqC\u002Fjrcn83fOnbNpuz5+y3felsqmdxFzkvf1vrh2vo7KLEXMbd5+f\u002FfgxsmVNy6TFZQ4wb9goWVNq3SradM4YwCJC3+zS\u002FHvmuRfTkaWYKwhRU6Z9YIIv45exHAfq9PE2CddnDR2SrpI2F2rO+EJr4mU+X6ZPLxgRqMCnE+VF8yVwooSBXxCCFFdLeDJ7FFZoszG0wMKCCxSCBftR4i6VufAc38Zc5ncuPJzycqmXfnvtjfEmwDOv2C+mD21k\u002FtR9+sVshwsqwo4H6sxR2si4wI0Tl9OkQsq\u002FC8Ig63BI9ZMCwfWlfvZrpbfaIK0rDCGbxhyNVXT\u002FOKOtVEDqB24vpGNaXOIJUAcTAlSgoSbCBeDwMzGfl18dJ3Nz5cUx\u002Fqz\u002FjrZ3qRjT2FvGCMRd6R5\u002F9GHTovr7AMS\u002FapHbI7Byj\u002FxRKRNQMuzsobYwf\u002FzpZz6rASQWj0zadBaBV157w9126xgB7IvMz\u002FQybd4jegNaSqLhkNDqs+D361PKT0VeiMCS\u002FdA\u002FRKlgQ9P999xlIOiaq6400LMr5aZAFApM+lddcbk98u2331rkGGJoX3HZKHfBeWhmj7pnFbUF0Ecos4d079abb8zq+0pBPPPehMkWO5ff8XZNnjrNDVdEC3xt0a6S2HC1es1a93c\u002F\u002FbFD2GCBaNniuMbfMiX+YRH8zvXXOkIFosUDcNFmNolNmjLV2gfwa6eIHfTzHi2c9997l\u002FVbr57RpjLcKP7jiT\u002FaxmQ23BGRAG08CwrRNrxGGAFisGLcI1i01Aa0tm0iAQLf3iOiGf1L4n0QsHj3hx+43426JNJqei1joemC4Dbnq7nu+3ovAOJ55440+tEW+pAoHx7Eci2ZGBtscPSb7JL3+e1N1UkBGSDyymuvmwXjnrvuSNeD9YSEHzcghfmAsPDznzxu8xcBIp7wb\u002F\u002FDn5+28Xm1IjHRr7fferNF6UCwRstOqq6\u002FuZ\u002FP3ENwBWAg0NDXuaTjILo4Y3Z\u002FPw4EM2X85uA36ctJHuXBPhYy+BPWDvqXqEkIkjUl79pH6NDq+t2Xs2\u002F\u002FPv\u002FVNZJ1DFq8+\u002F7ENAgj4g90fUEbTgHn\u002F\u002FirX5iiAx4aT4wRyBj33S\u002FUnPH11MTLfL5sn96ayjjy6UR4EevIa2+8Jd58syxul1oQA3gP4TdJ8KBBKSGJcc+YxrrhLUO58hzKymV+IzTUxMMpK9d6ibzGfiJcQBEiWXNN8SQ+96tf\u002FMx4ubfsElKUMfqTx3+YDtTQqmXlsUHdPsErrUB\u002FIXzWKwoEoF6vurPqy6CFQ\u002FMIs0tukiR3\u002FH5NGwb9xrdkvFYEARJgi3CO\u002FC1dtlxgd56ZL2vShPHskqXLTfPkd66jQYmHIkMTizsHrg4wOJ\u002F6CnySYPI+RVESjlZxS8B0+vr4twxQxjUTaLUwbyLI+LJxdQE8E24MAFkkcOkT2k60YCwiRF0heb\u002FJSy+5yH6frVBtaEbQokFXXFvu+t7tBna5DsBEm44Wxbvp8CCMvDptNy4r9939PYG4aOr6qCE8+53rr3O9BZTRnLNo4jKCgICGn3aiZSSUmm8zz2RLaFABc3GAQF7qGCFhAM1WW2kXAaR33XGbHSh11RWXmbDCs08\u002F+7wtMHGNMtrgHRJk4u5FmH97lfRQKNBvXGlprzT9hw8bZos1\u002FcpYwGUH8PfAffeYxYHNgSTfj4WkCyB4gtwcAOfxOVEkYY5Uk+aK+4T67Nevj94nNljt6eP\u002FeACKiR8Bd5H+AGH\u002F9ze\u002FNdD2wH13u3j\u002F+nFCjPXxb72rDZTftegnuAoA5hA24+klCcnUn9Sy9+1TatnicyZbf5Mxn7nXp09vN0BRn66\u002FtnpBxhqQ+mdjin8kBRafp6b7Pl\u002F8feIRXNBoe+vE2rKyiEdJmAAIrVy9xtzNfBnZPr27HwA7l8S8JuE7jyBAP9x7153uW40NEjxx\u002FDvvWgQaQCdjDmVHsg\u002FhNaQSzRGfCjVnKC8XXubrzfaZyTXpRHgRgjg08AIpwjwhSz2vo35cRkhxevA7H56T6\u002FzOhYfnUy9rFwomgjvAA2d89LEi5nQxAQRXKNYK5jaCLoqm28feai5ZzG+sifxlSiiUDkpI9cqPTHnCtbpNgeD6Urf7r8bWeyaaDSzXdD9egV8I40CL+x5wcFgImmKfAA\u002F\u002F+n9+bczJX8v2ibsEoR+ffuZ5aZbvq+SPiU8yPou8g3cD8OV45tU0Fs3GM3PvA+7zvvv+JNMmA8DiCdM\u002FpsW4Roj7CA24FBA\u002FPY63AFOYtgkbx8KCeRSLwCMPPZAGVjBeEtom8tAWr+W2G\u002FqH8HxoQXme8HSEjcs1ebcUL6jwHG1cJyAC3b85eNDqxkJBAiQDHkYOzy32dqTJqxoSjvfCsoIZloXlsUceNs2vVZL6B3ckwFESIOKDT0qCfwQwUhyU8i5Em2HBAlhOnvKBu+eu76WFjDUqixjc\u002FMVTIeiyevVa04AmLVAIQET+SY6TeP18hy4If3GTfDIPv70mEmDL3g9i\u002FuMycqcEn0EDBpjQE38Ody4EElxXcDny5ZfpwB0SQppPWFFwjRolwTG5H8H7w8f9srP1d75zjzY9\u002FOD9vhk1ftLHjCXmQSYBlfqrux+vgLlKwsoUfzfP4xCcsCjEE65o7AupKfmoJsk5nO05hC8S1iOfbH6m5gDWQ\u002FodyxSJSDKk5NyI+rxBFR5aqDmTCy+zhlXzj7dWxNeYE+FFuLuQxsk9hIPBkvybewgWKBrilkSu58Nzcp3fufDwfOpFWGOuwhtQkLWQm8vlo6+j+cYvUVZgeZkjBdfdUupEPPCQufsNFD\u002FIllDAwPOrO5Qw27Phet2gQNCo141+OuFWeiaaBB2+wJru+3xoltfq6HLS+Qmg64F6nFGTD0aDljWTJp\u002F78XSeNgzBfCkLn1G0CD6hbWTBzhR9BIZHikfByBTxhXJZDAcO6FcFWKJZIyVddDIthrglAILQlL36+pvumedfMpefv\u002FvpjyoBTcrDTxPNKsIEm0yTic2Z1193tV3GBJpPXOA1tCGh6acgv+ADym+RJt0n\u002Fy69dWhKLslr8jItllhQWBgGKQpQcjMl5vxPP59tgDPuI0ydXCf16FEZGGUC1+SjDSxcgEjM4V5jRB9gbs70LoWgC5YOUuOUtYTv9OUqAXjOGMgU3o88PvkoLUkhwt\u002FnEzohhNCHxAP\u002F7thbzM0Gaws+0B4k+Gegd0SPo7Ynwvvlc9\u002F3edzN5mv5yJPi1+yC\u002FkHgIMVdw7L1d75zzwrO4x9cSni3rNp0ueXZfbmcVJcAP7ibkZJ7BzyPy7QXANeqXiVVIz0l6\u002FIa+kPSXuaSfFvie154zvcVLi4jRwxPF8W4JfXufVzY4jdKB6xGccGD64WYM\u002FnwMurMlBjH8DjAc2cpHuLJv2uuvIj1AysqAuuTf3nWfNTj5dHHWEXh03HhM1+ek8\u002F8ro6H51sv7+Jpgib+huuuTb+ev84+JoRJb4nzwL60V+VxkX5QX7xQmLTGxPOE73WbAgGo1+3+q7H13i0lm9bIg+xsC6WvYOLkaQZW2LwX1xKxiLLYwjiLulb24+bZXLXE+BminUWzTkjAJ\u002F\u002FyjIE0yvDarEy+pJzIRooDRhY3TNTxQzcAHCSvtbEf+geXFx\u002FOLakpzbQYwjgBj131rkQieeSh75uLRKbd+H6zIIeAZLpPGwAVaE+g35Rp000z79uW7RPNC4tj3FXE54XhEzEmGdkF4YKUBAL+ueQnwA1BKy4A+TxeE3zh+cetJ\u002F7e6jVrLOJJks5sYqQNaKSTmp+awPUtN91QKcY1m4xJycWrUHTxFiM2s\u002FmEqxOuXbffGlko\u002FPVMnzsl1JJwDcqW6D\u002Fckmryu\u002FbPb9221ehK2D8OFIsnNOcIjnGg5BfvTG1AQGC8xevO1t\u002F5zr14u3L5nuZPAmmZkgfZNfGn2XLzQqPOvE9azPx4zVQGp5x6q1ym+v017\u002FaEtaSmxDiHxpQ7+tJL0tnNrUNCJ1aTZMhOnsGq4PfI8BB7DLCEJd08uFeIOZMPL6POTKlCQi1gljUhKVyeCC+647ax6c35z77wkgnkvt4tFVsyno2RL8\u002FJZ35Xx8PzrZf3gCbMPQTzOL1wySLdKguoV0jwe03K2pjkp9zzyY\u002FvokTkM38\u002FfNZ9CgSgXvf7sNo38EA8kzaJB9P+n9VorPAdZGMN\u002Fs23pVwpfKXbd2w3FwUWn2xg1Oet6RPNO24vaHHxZUZ7Qtoj\u002F01SnIHZBf2DuwyLqNccoo3hRMekJtibxePmdUzqk6dOt3CBaKzwhY6nTIshu\u002FtJXZS3Oo0pedJaSvkjVpcQfjgBlrRg4eLqsto9LBsISH0U2z6eWDAxlbOhE1\u002FHePLv0rVLVWEqns9\u002FR9gBUGeyhmCxQOOTpDHP4tdOigtVLE64vQB0AYdeW0Q+oloAajIJHSxSjCl8RePJC1AIdfFUKLrgToRbE2E0n\u002Frrc3YSJS4ajz\u002F6sMZgs3iVGb\u002FTN6Tm1eT1i2sm8Bg9XfnfsrLINzcJ0qEfGkL6HMHKJ\u002FxwSUTFiCcsVQjW50pzGZ+v2fo7n7kXryfX7x6IJ61x\u002FnnvtpLNIkg+3nXKB9NNQMVvn9NM4ymXMuL5M33v37+fXV61arXNvUx5uEbf43tMYhM1Y94n5ibCGfM9Hn4VFztOfkaIjvchSgRS0h2mUHMmH17m3yH56deX5Dg+UV7E++PLfclFF5jVyStYqNfz06Tgki\u002FPyWd++zo9uI+\u002Ff771ooFHqEYhlFxr1orXYV0b0C8aZ74ezwOT1l5\u002Fn0\u002FWZsrrEoB6nCz16nsA6vWqOyu\u002FDJtIMcOj2fHRMeI5uA8gZtGIA6t4HkJHPfP8iwbKHv\u002FhD6oAt\u002FLyCEwnwzLGy6juO+HLiL4AEyMBmNlQidahU8cIOLdu3drueaZpP\u002FQPLiuYb1mcPejwGjpimqORIvIMiVjg9pkyXaPRHKcIA7ePvdmAPRohFlHaQgKYAWjQZPAdYYXkF17uxRMCAqcW8ukTAJWUXGi5xj0viPCb8GuEcEPgqSl5LQtAnU27aOpILOx8TwLYAwrzB5hjsTlwYH+NJ9gxLgA\u002Ffj8AEVjwg\u002FRp7doyE1Qygda90gCSPBinz6ZNn2Ebc6EN7k2ARcokQQcsFH1697Y2erM0fYHGD2EgDmrsGS1q1M2YQ1DzqVB0YQwS7YW2DheoevD+eywakY8u4evL9tkytemLcZMt8W6kXOeNd+dKnsbIwg84xMUCwXOzhB6Sjx6yLlWPXdQ\u002FM2d9bIv6mBuPx9ivrr\u002FzmXu4JizReMQtKdcEeCX5sZZ8zm+gjbv6xPOsFHD+7e\u002F\u002F5Bo2aOh++IOHqliAGMe4x0EPrA4nmoYqMhFCEvHCV6w8bmlJlvfexEm2GRD3pXNHVt4L461aSQGb\u002FRb0Ia5c8C\u002F6kYTLFwlrIc96HlSoOZMPL7OGZPinPKVMKU5YU\u002FPlRQsUiccLl1QzelRkiYjPD89zqQteQvhcUr48J5\u002F5XR0Pz7deaMLGz759Sml2OsGfWY9QNsUFNdZE+CfAHn7IWE8m7qOYulhrZvzZZL7wu25TIAD1ut1\u002F1baeg29IhHxiIUgm70fJPb\u002FAA5oAS4QnJPwbYaKIMsAi2CYFmOPlEJ6P5IF2\u002FF4u39EGECv3hZdftXixMC0A+A3XXp0GxRzHTVqpOLreFA8YeHfCJNtUF3e58UCPGOvPvfhyerOW1\u002Fh8qcNGiHf+1jvvWxQWGCd\u002FMF1C2Xktud9chz\u002FvX597Ie164SPDLFVoO2IPA7YJ9fWnp\u002F5ibixxMACgpbxMpvVXxr2hZ56xd4UJ42YBuL1s1KU1ks0LLNOmzzTQ7YUUDwSSfrFovehj\u002FB9fePm19Dtmq2jHzggoAKgRPqiPza4k\u002FE0xx2fTgHowu0SbI9loNU20vveu75k7E88DLOnrUgFzkn8XIgW9P3FKeoMkAA4hLvkuCCIsao0kyBGTGoHOJ19WIejC2EfLybhJamh9fdk+fWQQr7FM5kMjCqAl1RRBxj9bJroBMJJuQ36D90oJkm+9\u002FZ7GWit7BGBJmqczBnAJIhFV5ut5C+Rqhda5iV3jn+r6O5+5h\u002FD1rPZsPCOXhVwScxUak3CJSiYirfj57E9PJg8COAIaMeSZR7i6EKIyk4Vn\u002FoKIP\u002FFcrrQmb6ZE6FSEaeLSx4Vs8sL\u002FJk\u002F9wMAj+wzuv\u002FfuKsCJ+Ym7Q9KdzAsjCN3TZ8xKC1meNh\u002FMmGnueV4A9+P8ZOdMPrwsEz2Yi7SZlOy\u002FfHgR+59eFF\u002F681N\u002FNbqijUdhgrAT30Tp9y0RzerpZ55zRBgi5ctzeCbX+V0dD8+3Xg6oInnrr\u002F3QP1gI4c9Jrf2u3btM8UL8ftaXJI15niAG8Cd\u002FKJQvM3zWLwo0rl+vE94GCgB0iSTitXZozf\u002FtP35nh+gQPhAQxcZFr80CKP777\u002F9oLiRMerSVxMgmNFbfPoSYq0rXmTLvAuK9LywL529++4QYxkh7ruoTma8MHjTANAa0iT+iRlx79ZWVQjOy6Y1DQKZN\u002F1Dv8XsDeQgUxFNPMj0fPxnw+oMH75cWLQppxSZAO9Rj+XLXVnHGiVnOu3qNCUwQ7bo3MXqTP8AHf0J\u002FiiYmRsA05u133ptoC++QwYMttnYHnSrnE5YM\u002FFlHDKvstuHvXzF6lASNiQLC42xzIpFlHpMwlMny4Z\u002Fxn7QNbZhp7VKn9nGPxRFBIQlY2LhEQjuK73omwcEypP7xwJS+ZaNjPJIP7iWAjUwbe3kcgAhAB8igCbxPcebZaHZQ4JTEprw7brslDSgB\u002FZSH+xIAx2\u002FUZFHjuaT2ieg80te7FnrP65Q\u002FvjehkHRhYxYa+j\u002F8+SnzM77y8ssqgVt7mSz\u002FAKbpR79\u002FwmdD4\u002Fy8hEeEFcIFkji4hjCmuEl4IObz+0\u002FeGeGkn83FypPxgOgK\u002FVq3aS23tJvTbbxYrgO0H4Hgf\u002F\u002F6341OzGsOBiPOfjxV19\u002F5zD1v2fFCXbyO+HeEi3cUUzzSDEd3nvjTUxa69I7bx5rF5Y3xb7u1ohMAhjReQsgMjSt87hHO2up9B\u002FTv527SoTFJiwv5AbEIiR7UchDZ\u002F\u002Fp\u002Fv7HxdOd3byNL3on3YtM4B7PhEgXQZfwheCEMM78ee+ShKsIlFcFj6fc+paXpPvINOHT4sMa99vjIgnPTDdfZ+3GP8cJ16oUneqG0UHMmV17m2+k\u002FaVckwJfbQT9cf+vd93TQ2gIL1QrPzIcX0ce4YhHt5Hd\u002FeNLWH1xfOEOAse2TH6e4MX7\u002FvrvTUYLy5TmUl8v8romH51svGnHmYFL5AK1Yr5Lz31vkULQR2jcppKNM+lJrMGd4UG5I9ZcCDQR4Uqyw\u002Fr5keLMzmwKMQEy+HLCDn12cOcdbHrlwbDWGFddcx\u002FPA3ADIPr52\u002FB6auAZi\u002FHE3HxYdQCVarni9gCPi3WYzyaPZR2MKwPTCQLwu2kEYwyQoiufB5QCtGW3N9j7x\u002FP47WsZ2bduJOTf1l+yTNuEulEmwQhOezX2gUiGpH9CkS+eq0SagLb7X1S0MuBpgHfDCDUVmo6ffnBffO0B+tGxtWrfJCMJwDejQvkOV9ywUXQBdaEcBg4sWLzVQjWXkjtturbKRk7ZmSq+\u002F+ZaBNzS9J5vQMLJBFWCVTFiD0Jh7S1DyPmADYIdrF4JPtpStv33+XOYeeQl1CqDwApd\u002Fvr59op1H4NiufmETX01zC407GtJM4R2ZGwcPHaxisaTvoGN8HkHHQs4ZyquJl5En33QivAj3usg9LvNYhd\u002FCVzPNg3x4Tq7zOxcenk+98PrOnTpX4VvwZs4m8YJYnNZYuglckOTprFtP\u002FOlJEw45WyJ5P15G+F73KRCAet3vw\u002FAGgQKBAgWgAOCLyDu4IRHLHAEKgMrhR7PlMoXwgcY0acXJVDUg7t9kYfrlz3+SEVhkeiZcCxQIFKg9ChRyftdeK3MreaJ4Em6nP\u002FvRY2kX0dyeDLnqIgUa\u002FYtSXWx4aHOgQKBAoEAhKYAWnM3HbB71IUhxicLFCK0mp+eyl4GTWWtKuBexv2GVzNpDFQIwpECBQIHTS4FCzu\u002FT9SY4QOAux8baB8SncnGVPF1tDfUWjgLHd2IVrsxQUqBAoECgQJ2iAP7VX82dL\u002FNzI7knVA5tyYsQ7x5f6HwOFbllzE3OIqqkDuWqUwQJjQ0UqEcUqI35fTrI88mnn9s+jUcffiDto3862hHqPLUUCBr1U0vvUFugQKDAGUgB\u002FEPZnIXLyjodPlKiPQtoq9g\u002FsUUbOacqTjcHaBHjuTpf7\u002FirsedhpLTv1fnzx\u002FOH74ECgQK1Q4HamN+109LqSyUyDJtOffjb6nOHu\u002FWFAsFHvb70ZHiPQIFAgZOiAJs2pysUHv7obMBkg28jadiJ5YxGfbgi+IQF8qRIHB4OFDhtFAjz+7SRPlR8khQIQP0kCRgeDxQIFKh\u002FFCD6xKHDhxT5hXCAx0PE1b83DW8UKPC3R4Ewv\u002F\u002F2+rwuv3EA6nW590LbAwUCBQIFAgUCBQIFAgUCBeotBcJm0nrbteHFAgUCBQIFAgUCBQIFAgUCBeoyBQJQr8u9F9oeKBAoECgQKBAoECgQKBAoUG8pEIB6ve3a8GKBAoECgQKBAoECgQKBAoECdZkCAajX5d4LbQ8UCBQIFAgUCBQIFAgUCBSotxQIQL3edm14sUCBQIFAgUCBQIFAgUCBQIG6TIEA1Oty74W2BwoECgQKBAoECgQKBAoECtRbCvx\u002Ft7IGxyBLV2wAAAAASUVORK5CYII=\" width=\"60%\">\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">\"For over a decade, the Israel Defense Force (IDF) has offered companies, groups and individuals the chance to \"Adopt-a-Battalion\". This unique program builds deep and lasting relationships between IDF soldiers and civilians who support them...\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">Those wishing to adopt a battalion make a significant commitment to the welfare of Israeli soldiers. Donors must agree to give 100,000 NIS (about $27,000) annually for\u003Cbr>three years. Not only does the adoption of a battalion increase army morale and help the well-being of soldiers, but it also builds a true bond between donors and soldiers...\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">Over the years, several Israeli companies, including Israeli banks and Teva Pharmaceuticals, have adopted a battalion. With the deep relationships developed through this program, soldiers are often invited to work at these companies during their off-times and after their service is completed, allowing them to earn much-needed money as well as ensuring a better future in the job market.\"\u003C\u002Fp>\n\u003Ch3 style=\"text-align: left;\">How prescription pharmaceuticals get from the manufacturer to the patient in the UK\u003C\u002Fh3>\n\u003Cp style=\"text-align: left;\">Once a prescription drug has a licensed indication (in the UK, these licenses are given by the MHRA), any fully registered doctor can legally prescribe the drug.\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">A pharmacist will check that t h e prescription has been written correctly and is safe for the patient, will obtain the drug and prepare it for the patient.\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">Most medicationsare tablets \u002F capsules and produced in bulk, nearly all are supplied by pharmaceutical wholesellers.\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">Pharmacies order common medications in volumes so they are kept in stock .\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">The main wholesellers for the UK are AAH, Phoenix and Alliance .\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">Pharmacies purchase the drug on an open market, specialist price comparison tools are used to look up the cheapest version of the drug from the various wholesellers.\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">The NHS sets a publicly advertised drug tariff, along with a fixed national dispensing tariff, and the pharmacist is paid by the NHS by combining these 2 tariffs for the drug dispensed.\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">If the cost paid for the drug is less than the reimbursement tariff, the pharmacist keeps the difference.\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">Though wholesellers will try to respect the wishes of pharmacies, there is no mechanism by which pharmacies can refuse\u002Fdemand the products of a particular pharma company. This includes scenarios where the doctor has made specific instructions regarding the manufacturer on their prescription, e.g. do not dispense leva.\u003C\u002Fp>\n\u003Cp style=\"text-align: left;\">The same applies to patients, i.e. if a patient said that they do not want to have a particular medicine from Teva, the patient may be told to try a different pharmacy if only Teva versions are in stock.\u003C\u002Fp>\n\u003Cp style=\"text-align: center;\">\u003Cstrong>Overall, these scenarios are rare, and pharmacies are usually able to fulfil \u003C\u002Fstrong>\u003Cstrong>the request on the prescription, or the request of the patient.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Ch3 style=\"text-align: left;\">Teva's UK product lines\u003C\u002Fh3>\n\u003Cp>There are 3 core streams by which Teva gains its income\u003C\u002Fp>\n\u003Cp style=\"padding-left: 40px;\">• Novel proprietary drugs - Austedo, Ajovy, Uzedy, Treanda\u002FBendeka\u003C\u002Fp>\n\u003Cp style=\"padding-left: 40px;\">• OTC products - Sudocrem, Infacol, Peptac\u003C\u002Fp>\n\u003Cp style=\"padding-left: 40px;\">• Generic drugs - approx 80% of Teva's income\u003C\u002Fp>\n\u003Cp style=\"padding-left: 40px;\"> \u003C\u002Fp>\n\u003Ch4> \u003C\u002Fh4>\n\u003Ctable style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\u003Ccolgroup>\u003Ccol style=\"width: 54.9853%;\">\u003Ccol style=\"width: 45.0147%;\">\u003C\u002Fcolgroup>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>\n\u003Ch4>Sudocrem (15% zinc oxide)\u003C\u002Fh4>\n• Invented in 1931 by an Irish pharmacist and originally manufactured in Ireland.\u003Cbr>• Company acquired by Actavis in 2014, Actavis then acquired by Teva in 2015.\u003Cbr>• Irish production plant closed in 2021 leading to the loss of 110 jobs, production moved to Bulgaria.\u003Cbr>• 15% zinc oxide cream, mainly used to treat nappy rash but has also gained popularity with adults as a treatment for acne.\u003Cbr>• There are many alternative nappy creams, with no evidence of superiority\u002Finferiority of any alternatives.\u003C\u002Ftd>\n\u003Ctd>\u003Cimg src=\"https:\u002F\u002Fwww.evanspharmacy.com\u002Fimages\u002Fsudocrem-cream-p305-679_zoom.jpg\" alt=\"Sudocrem Cream - Medicines from Evans Pharmacy UK\" width=\"100%\">\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\n\u003Ch4>Infacol (Simeticone)\u003C\u002Fh4>\n\u003Cp>• Simeticone is also used for adults with IBS, but the convenient dropper applicator makes Infacol suited for babies with colic.\u003Cbr>• Most pharmacy chains have their own brand versions of this medication.\u003C\u002Fp>\n\u003C\u002Ftd>\n\u003Ctd>\u003Cimg src=\"https:\u002F\u002Fm.media-amazon.com\u002Fimages\u002FI\u002F618NU09aQsL._UF1000,1000_QL80_.jpg\" alt=\"Infacol Simeticone Colic Relief Drops, 55 ml : Amazon.se: Baby Products\" width=\"100%\">\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\n\u003Ch4>Peptac (Alkaline\u002Fsodium\u003Cbr>alginate solution)\u003C\u002Fh4>\n\u003Cp>• An antacid solution.\u003Cbr>• Not only an OTC medicine, also commonly prescribed by doctors.\u003Cbr>• There are several popular alternatives available (Gaviscon, Pepto-Bismol, Rennie).\u003C\u002Fp>\n\u003C\u002Ftd>\n\u003Ctd>\u003Cimg src=\"https:\u002F\u002Fwww.pharmacyprime.com\u002Fcdn\u002Fshop\u002Fproducts\u002FPeptac-Peppermint-Flavour-Antacid-500ml_58d682f7-7cd1-4ec3-add6-21f191967c88.jpg?v=1708701516\" alt=\"Peptac Peppermint Flavour - 500ml | Pharmacy Prime\" width=\"100%\">\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Ch3>How to get Teva off your prescription list\u003C\u002Fh3>\n\u003Cp>\u003Cspan data-teams=\"true\">Teva, like other big pharma companies, are experienced with how the drug market works, and are likely to drop their prices if their revenue falls to force their drugs into medicine cabinets.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan data-teams=\"true\">\u003Cbr>\u003Cstrong>How to get Teva off your prescription:\u003C\u002Fstrong>\u003Cbr>• Write to or ask your pharmacist or doctor - \"Please leave a note on my records stating that I do not want Teva medicines, unless there are no alternatives\".\u003Cbr>• Write to your pharmacy\u002Fdoctor to ask that they stop doing business with pharmaceutical companies that support genocide.\u003Cbr>• Ask your doctor to switch your medicine to a similar alternative if they cannot supply a non-Teva version of the same medicine. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan data-teams=\"true\"> Read here about alternatives: \u003Ca href=\"https:\u002F\u002Fimasa.org.za\u002Fwp-content\u002Fuploads\u002F2024\u002F06\u002FTEVA-Alternatives-2023-1_240314_102844_240611_185404.pdf\" target=\"_blank\" rel=\"noopener\">Teva Alternatives\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>","British Islamic Medical Association Webinar, Oct 1, 2025","BIMA Webinar - TEVA Boycott & Global Health BDS for Palestine",1760439802141,"mgqgbe2axe46p19blt",[15],{"imageUrl":333,"slug":334,"type":7,"content":335,"videoUrl":12,"subtitle":336,"title":337,"timestamp":338,"id":339,"tags":340,"user":13,"link":12},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1760520465\u002Facgwa2lhp9sh4lz4b8wg.webp","glatiramer-o-copaxone-teva-riesgos-ciertos-beneficios-dudosos-certain-risks-dubious-benefits-esp-eng","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.cochrane.org\u002Fes\u002Fevidence\u002FCD004678_use-glatiramer-acetate-copaxone-r-people-multiple-sclerosis\">\u003Cstrong>No utilice el acetato de glatiramero (Copaxone ®, TEVA) en pacientes con esclerosis múltiple DICIEMBRE 2021\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F418-glatiramere-pas-mieux-qu-un-interferon-beta-dans-la-sclerose-en-plaques\">\u003Cem>\u003Cstrong>Rev Prescrire: \u003Cspan class=\"ryNqvb\">Glatiramer: No mejor que el interferón beta en la esclerosis múltiple AGOSTO 2018\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Feffets-indesirables\u002F495-glatiramere-reactions-anaphylactiques-parfois-des-annees-apres-le-debut-du-traitement\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Glatiramer: Reacciones anafilácticas, a veces años después de iniciar el tratamiento.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El glatiramer (Copaxone° u otro) es una mezcla de polipéptidos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En Francia, está aprobado para uso subcutáneo en pacientes con esclerosis múltiple remitente-recurrente (es decir, progresión de brotes intercalados con períodos de remisión más o menos completa de los síntomas, de duración variable).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En esta situación, \u003Cem>su relación beneficio-riesgo no es más favorable que la del interferón beta (Avonex°, Rebif°, Betaferon° u otros), pero su perfil de efectos adversos es diferente.\u003C\u002Fem>\u003C\u002Fspan>\u003Cem> \u003C\u002Fem>\u003Cspan class=\"ryNqvb\">El glatiramer se expone principalmente a reacciones locales en el lugar de la inyección (eritema, dolor, induración, prurito, edema inflamatorio, necrosis cutánea, lipodistrofia), así como a reacciones sistémicas distintas de las alérgicas en los minutos posteriores a la inyección (vasodilatación, dolor torácico, disnea, palpitaciones, taquicardia), generalmente transitorias y con una evolución espontáneamente favorable.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">También expone a reacciones alérgicas de tipo anafiláctico, cuyo tratamiento se basa en la adrenalina.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Fwww.saludyfarmacos.org\u002Flang\u002Fes\u002Fboletin-farmacos\u002Fboletines\u002Fmay202501\u002F15_ac\u002F\">22 enero 2025. La FDA ha emitido una alerta de seguridad\u003C\u002Fa> importante y agregó un recuadro de advertencia, el nivel más alto de alerta, en la información para la prescripción del \u003Cem>acetato de glatiramero\u003C\u002Fem>, comercializado bajo los nombres Copaxone, Glatopa y como genéricos.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Fsante-et-societe\u002F422-sclerose-en-plaques-le-gachis\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Rev Prescrire \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Diciembre de 2018 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Fsante-et-societe\u002F422-sclerose-en-plaques-le-gachis\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esclerosis Múltiple: Un Potencial Desaprovechado \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En los últimos quince años se han comercializado aproximadamente diez fármacos para el tratamiento de la esclerosis múltiple (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">¿Ha contribuido su evaluación a determinar una estrategia terapéutica óptima para las diversas situaciones clínicas de los pacientes?\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Datos Limitados Antes de la Comercialización \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los autores analizaron ensayos clínicos aleatorizados realizados antes y después de la comercialización de fármacos para la esclerosis múltiple, hasta julio de 2017 (1).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Desde la comercialización del interferón beta (Avonex®, Betaferon® u otros) y del glatiramer (Copaxone® u otros), se han concedido autorizaciones de comercialización en Europa para ocho fármacos (a)(1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Estos ocho fármacos fueron autorizados con base en dieciséis ensayos clínicos en los que participaron aproximadamente 16 000 pacientes.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Más de dos tercios de los ensayos (once ensayos) compararon el fármaco con placebo; los demás, con interferón beta-1a (Avonex®), el tratamiento estándar a falta de una mejor alternativa.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Once ensayos clínicos utilizaron la tasa anual de recaídas de la esclerosis múltiple como criterio de valoración principal.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los únicos ensayos que evaluaron la progresión de la discapacidad como criterio de valoración principal se referían a alemtuzumab (Lemtrada®), sin demostrar eficacia (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En otras palabras, en el momento de su comercialización, la mayoría de los fármacos no se habían comparado con el tratamiento estándar, y su efecto sobre la progresión a largo plazo de la enfermedad no se había evaluado (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Demasiadas incógnitas \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los autores analizaron los 52 ensayos clínicos aleatorizados realizados tras la autorización de comercialización de estos ocho fármacos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">De estos 52 ensayos (21 de los cuales incluían fampridina sola), solo 24 se habían completado y se publicaron sus resultados.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Dos tercios de los ensayos (34) se realizaron frente a placebo, y el 17 % (9) frente a interferón o glatiramer.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Entre los ensayos con resultados finales publicados, solo uno comparó dos fármacos: natalizumab frente a fingolimod;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">y solo un ensayo utilizó la progresión de la enfermedad como criterio de valoración (fingolimod), sin demostrar eficacia (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En resumen, desconocemos qué fármacos constituyen el tratamiento de primera línea debido a la falta de comparaciones entre los nuevos medicamentos, y los ensayos posteriores a la comercialización no han brindado la oportunidad de evaluar mejor su eficacia en la progresión de la enfermedad (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los autores instan a las autoridades públicas a financiar ensayos que respondan a las preguntas de pacientes y profesionales sanitarios: ¿qué fármacos elegir?, ¿cuál es su eficacia?\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">y ¿cuáles son los efectos secundarios? (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Despilfarro humano y financiero \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Siguiendo con el campo de la oncología, este es otro ejemplo de una situación en la que, debido a la falta de una evaluación adecuada y ante numerosas preguntas sin respuesta, los profesionales sanitarios se ven obligados a basar sus decisiones de tratamiento más en la experiencia personal, a veces influenciada por líderes de opinión, que en datos basados ​​en la evidencia (2).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Para la comunidad, esto representa un despilfarro de recursos y, para los pacientes, una oportunidad perdida para una mejor atención.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">©Prescrire \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">a- Estos son alemtuzumab, daclizumab (Zynbrita°, retirado del mercado mundial en marzo de 2018), dimetilfumarato (Tecfidera°), fampridina (Fampyra°), fingolimod (Gilenya°), peginterferón beta-1a (Plegridy°), natalizumab (Tysabri°) y teriflunomida (Aubagio°) (ref. 1).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La autorización de comercialización de ocrelizumab (Ocrevus°) es más reciente: véase también «Ocrelizumab (Ocrevus°) y esclerosis múltiple».\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Extractos de la revisión bibliográfica de Prescrire \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">1- Gerardi C et al.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">«Evidencia pre y post aprobación de fármacos para la esclerosis múltiple». Neurology 2018;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">10.1212\u002FWNL.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">5561: 10 páginas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">2- Personal editorial de Prescrire \"Nuevos fármacos contra el cáncer: mal evaluados, ineficaces y demasiado caros\" Rev Prescrire 2018;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">38 (412): 134.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"VO9ucd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cnav class=\"VlPnLc\" aria-labelledby=\"ucj-38\">\u003C\u002Fnav>\n\u003Cp>\u003Cstrong>COCHRANE\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Esta es una revisión Cochrane actualizada de la versión anterior publicada (Base de datos Cochrane de revisiones sistemáticas 2004, número 1). Art. No.: CD004678. DOI: 10.1002\u002F14651858.CD004678)  \u003C\u002Fp>\n\u003Cp>El tratamiento con acetato de glatiramero (Copaxone ® TEVA) de los pacientes con esclerosis múltiple remitente recurrente (EMRR) y con esclerosis múltiple progresiva (EMP) parece tener pocos efectos beneficiosos en la EMRR, mientras que el fármaco no es efectivo en pacientes con EMP.  \u003C\u002Fp>\n\u003Cp>Estudios anteriores indican que el acetato de glatiramero, un fármaco sintético, es eficaz en modelos animales de EM, y muestra algunos efectos beneficiosos en pacientes con EM.\u003C\u002Fp>\n\u003Cp>El objetivo de esta revisión fue evaluar la eficacia del acetato de glatiramero en pacientes con EMRR y EMP.  \u003C\u002Fp>\n\u003Cp>Entre la bibliografía médica pertinente, seis estudios cumplieron los criterios de calidad metodológica necesarios para su inclusión en esta revisión.\u003C\u002Fp>\n\u003Cp>Contribuyeron a este análisis 540 pacientes con EMRR y 1049 pacientes con EMP.  \u003C\u002Fp>\n\u003Cp>Los datos no mostraron efectos beneficiosos en la progresión de la enfermedad en ambas formas de EM, un ligero efecto beneficioso en la reducción del riesgo de recurrencias en los pacientes con EMRR y ningún efecto beneficioso en los pacientes con EMP.\u003C\u002Fp>\n\u003Cp>Con bastante frecuencia se produjeron eventos adversos como rubor, opresión torácica, sudoración, palpitaciones, ansiedad y reacciones locales en el lugar de la inyección, pero no se observaron efectos adversos graves.\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.drugpatentwatch.com\u002Fp\u002Fdrug-sales\u002Fdrugname\u002FCOPAXONE\">Vea las ventas de Copaxone en Estados Unidos\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FG4lAlB5WIAAvmPJ?format=jpg&name=large\" alt=\"\" width=\"1408\" height=\"425\">\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fwww.cochrane.org\u002Fevidence\u002FCD004678_use-glatiramer-acetate-copaxone-r-people-multiple-sclerosis\">ENGLISH\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.cochrane.org\u002Fevidence\u002FCD004678_use-glatiramer-acetate-copaxone-r-people-multiple-sclerosis\">\u003Cstrong>Do not use of glatiramer acetate (Copaxone ® TEVA) in people with multiple sclerosis 1st December 2021\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F418-glatiramere-pas-mieux-qu-un-interferon-beta-dans-la-sclerose-en-plaques\">\u003Cem>\u003Cstrong>Rev Prescrire: \u003Cspan class=\"ryNqvb\">Glatiramer: No better than beta interferon in multiple sclerosis. August 2018\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Feffets-indesirables\u002F495-glatiramere-reactions-anaphylactiques-parfois-des-annees-apres-le-debut-du-traitement\">\u003Cem>\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">Glatiramer: Anaphylactic reactions, sometimes years after starting treatment \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.drugpatentwatch.com\u002Fp\u002Fdrug-sales\u002Fdrugname\u002FCOPAXONE\">\u003Cem>\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">See sales of Copaxone in the USA\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FG4lAlB5WIAAvmPJ?format=jpg&name=large\" alt=\"\" width=\"1408\" height=\"425\">\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">Glatiramer (Copaxone° or other) is a mixture of polypeptides. In France, it is approved for subcutaneous use in patients with a form known as relapsing-remitting multiple sclerosis (i.e., progression of flare-ups interspersed with periods of more or less complete remission of symptoms, and of varying duration). In this situation,\u003Cem> its benefit-risk balance is no more favorable than that of beta interferon (Avonex°, Rebif°, Betaferon° or other), but its adverse effect profile is different.\u003C\u002Fem> Glatiramer mainly exposes to local reactions at the injection site (erythema, pain, indurations, pruritus, inflammatory edema, skin necrosis, lipodystrophy), as well as to systemic reactions other than allergic in the minutes following the injection (vasodilation, chest pain, dyspnea, palpitations, tachycardia), generally transient and with a spontaneously favorable evolution. It also exposes to allergic reactions of the anaphylactic type, the treatment of which is based on adrenaline.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-adds-boxed-warning-about-rare-serious-allergic-reaction-called-anaphylaxis-multiple-sclerosis\">22 Jan 2025. FDA adds Boxed Warning\u003C\u002Fa> about a rare but serious allergic reaction called anaphylaxis with the multiple sclerosis medicine glatiramer acetate (Copaxone, Glatopa)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Fsante-et-societe\u002F422-sclerose-en-plaques-le-gachis\">\u003Cstrong>Revue Prescrire. \u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">December 2018 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Fsante-et-societe\u002F422-sclerose-en-plaques-le-gachis\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Multiple Sclerosis: A Waste of Potential \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">About ten drugs have been marketed for the treatment of multiple sclerosis over the past fifteen years (1).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Has their evaluation helped to determine an optimal therapeutic strategy for the various clinical situations of patients?  \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Limited Data Before Marketing \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Authors analyzed randomized clinical trials conducted before and after the marketing of multiple sclerosis drugs, up to July 2017 (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Since the marketing of interferon beta (Avonex®, Betaferon®, or other) and glatiramer (Copaxone®, or other), European marketing authorizations have been granted for eight drugs (a)(1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">These eight drugs were authorized based on sixteen clinical trials in which approximately 16,000 patients participated in total.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">More than two-thirds of the trials (eleven trials) compared the drug versus placebo, the others versus interferon beta-1a (Avonex®), the standard treatment for lack of a better alternative.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Eleven trials had the annual relapse rate of multiple sclerosis as their primary endpoint.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The only trials that assessed disability progression as a primary endpoint concerned alemtuzumab (Lemtrada®), without demonstrating efficacy (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In other words, at the time of their market launch, most of the drugs had not been compared to the standard treatment, and their effect on the long-term progression of the disease had not been evaluated (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Too many unknowns \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The authors analyzed the 52 randomized clinical trials conducted after marketing authorization was granted for these eight drugs.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Of these 52 trials (21 of which included fampridine alone), only 24 had been completed, with published results.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Two-thirds of the trials (34 trials) were conducted against placebo, and 17% (9 trials) against interferon or glatiramer.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Among the trials with published final results, only one compared two drugs: natalizumab versus fingolimod;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">and only one trial used disease progression as an endpoint (fingolimod), without demonstrating efficacy (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In short, we do not know which drugs are the first-line treatment, due to a lack of comparisons between new drugs, and post-marketing trials have not provided an opportunity to better assess their efficacy on disease progression (1).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The authors call on public authorities to fund trials that answer the questions of patients and healthcare professionals: which drugs to choose?\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">what efficacy?\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">and what are the side effects (1)?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Human and Financial Waste \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Following the field of oncology, here is another example of a condition where, due to a lack of appropriate assessment and faced with numerous unanswered questions, healthcare professionals are forced to base their treatment decisions more on personal experience, sometimes influenced by opinion leaders, than on evidence-based data (2).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For the community, this represents a waste of resources and, for patients, a missed opportunity for better care.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">©Prescrire a- \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">These are alemtuzumab, daclizumab (Zynbrita°, withdrawn from the global market in March 2018), dimethyl fumarate (Tecfidera°), fampridine (Fampyra°), fingolimod (Gilenya°), peginterferon beta-1a (Plegridy°), natalizumab (Tysabri°), and teriflunomide (Aubagio°) (ref. 1).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The marketing authorization for ocrelizumab (Ocrevus°) is more recent: see also \"Ocrelizumab (Ocrevus°) and multiple sclerosis.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Excerpts from Prescrire's literature review \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1- Gerardi C et al.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"Preapproval and postapproval evidence on drugs for multiple sclerosis\" Neurology 2018;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">10.1212\u002FWNL.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">5561: 10 pages.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2- Prescrire Editorial Staff \"New cancer drugs: poorly evaluated, ineffective and too expensive\" Rev Prescrire 2018;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">38 (412): 134.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>COCHRANE\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2004 , Issue 1 . Art. No.: CD004678. DOI: 10.1002\u002F14651858.CD004678) \u003C\u002Fp>\n\u003Cp>Treatment with glatiramer acetate (Copaxone ® TEVA) of patients with Relapsing-Remitting (RRMS) and with Progressive Multiple Sclerosis (PMS) seems to have few beneficial effects in  RRMS, while the drug is not effective in PMS patients  \u003C\u002Fp>\n\u003Cp>Previous studies indicate that glatiramer acetate, a synthetic drug, is effective in animal models of MS, and shows some benefits in MS patients.\u003C\u002Fp>\n\u003Cp>The objective of this review was to assess the efficacy of glatiramer acetate in RRMS and PMS patients.  Among the pertinent medical literature six studies met the criteria of the methodological quality necessary for their inclusion in this review. 540 RRMS patients and 1049 PMS patients contributed to this analysis.  \u003C\u002Fp>\n\u003Cp>The data showed no beneficial effects on disease progression in both MS forms, a slight beneficial effect  in the reduction of risk of relapses in RRMS patients and no benefits in PMS patients. Adverse events such as flushing, chest tightness, sweating, palpitations, anxiety and  local injection-site reactions occurred quite frequently, but no major adverse effects were observed.\u003C\u002Fp>","No use Copaxone, su relación beneficio-riesgo no es más favorable que la del interferón beta . Do not use Copaxone, its benefit-risk balance is no more favorable than that of beta interferon "," Glatiramer\u002Fo (Copaxone ®, TEVA). Riesgos ciertos, beneficios dudosos. Certain risks, dubious benefits. ESP ENG",1760518811611,"mgrqi8f9jy44tywwzkn",[15],{"subtitle":342,"timestamp":343,"link":12,"user":13,"tags":344,"id":345,"content":346,"title":347,"imageUrl":348,"type":7,"videoUrl":99,"slug":349},"Teva, corrupta y corruptora; sin ética. Teva, corrupt, that corrupts; without ethic.",1760795507027,[15],"mgwa6msmkxz53ezt4mh","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Carta al Pacto Mundial de las Naciones Unidas para la expulsión de Teva Pharmaceuticals  \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Por favor, firme\u003Ca href=\"https:\u002F\u002Factionnetwork.org\u002Fpetitions\u002Fletter-to-un-global-compact-for-removal-of-teva-pharmaceuticals-from-list-of-participants\"> aquí\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>NOTA\u003C\u002Fstrong>. Pacto Mundial de las Naciones Unidas: Un pacto de las empresas para alinear sus estrategias y operaciones con los principios universales sobre derechos humanos, trabajo, medio ambiente y anticorrupción, y tomar acciones que promuevan los objetivos sociales.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"es\">Petición de Global Health BDS for Palestine. Global Health BDS for Palestine \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"es\">Patrocinada por Ghbds4p Global Health BDS for Palestine\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sra. Ingvild Sørensen, Directora del Pacto Mundial de las Naciones Unidas \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva Pharmaceuticals participa en la Iniciativa del Pacto Mundial de las Naciones Unidas, que permite a las empresas figurar públicamente como adheridas a una lista de 10 principios éticos.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva Pharmaceuticals ha demostrado un patrón de prácticas corruptas y anticompetitivas que abarca múltiples jurisdicciones y décadas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Su historial incluye multas por colusión, soborno a funcionarios públicos, uso indebido de procedimientos de patentes, manipulación del mercado y fijación de precios.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Si bien Teva a menudo resuelve los casos antes de que se llegue a una conclusión legal, las constantes conclusiones de tribunales y organismos reguladores en Estados Unidos y Europa revelan corrupción y un desprecio sistémico por el estado de derecho y las normas éticas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">Instamos al Pacto Mundial de las Naciones Unidas a que elimine a Teva Pharmaceuticals de su lista de participantes.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Para: Sra. Ingvild Sørensen, Responsable del Pacto Mundial de la ONU De: [Su nombre] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Le escribimos para expresar nuestra preocupación por la inclusión de Teva Pharmaceuticals en la lista de participantes del Pacto Mundial de la ONU.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ser signatario del Pacto Mundial refleja «el sistema de valores de una empresa y un enfoque basado en principios para hacer negocios.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Esto significa operar de manera que, como mínimo, cumpla con las responsabilidades fundamentales en materia de derechos humanos, trabajo, medio ambiente y anticorrupción.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Las empresas responsables aplican los mismos valores y principios dondequiera que estén presentes y saben que las buenas prácticas en un área no compensan los perjuicios en otra». (1) Existe evidencia contundente de que Teva Pharmaceuticals incumple varios de los 10 Principios fundamentales del Pacto Mundial.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Principio 1: Las empresas deben apoyar y respetar la protección de los derechos humanos reconocidos internacionalmente.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Principio 2: Asegurarse de que no sean cómplices de violaciones de derechos humanos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Desde el inicio de los ataques israelíes contra la población civil de la Franja de Gaza en 2023, Teva ha mostrado un apoyo inquebrantable al ejército israelí.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El 9 de octubre, el ministro de Defensa israelí declaró el asedio total de Gaza: «No habrá electricidad, ni alimentos, ni combustible, todo está cerrado […] Estamos luchando contra animales humanos y actuamos en consecuencia». (2)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Al día siguiente, Teva proclamó su apoyo al ejército israelí, justo cuando el portavoz principal del ejército, Daniel Hagari, declaró que el objetivo del ataque contra Gaza no era la precisión, sino causar el máximo daño posible (3,4).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">A pesar de la terrible evidencia de constantes violaciones de derechos humanos, incluyendo hambruna deliberada, ataques contra civiles e infraestructuras civiles, tortura de prisioneros, abusos sexuales y pruebas abrumadoras de ataques contra niños (5-9), el 26 de octubre de 2023, el director ejecutivo de Teva, Richard Francis, se refirió a Teva como la \"compañía farmacéutica y sanitaria nacional\" de Israel, y el tenor de estas declaraciones no ha flaqueado ante el aumento del número de víctimas del genocidio (10).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En 2024, Yossi Ofek, director ejecutivo regional de Teva Israel, Ucrania, África y Oriente Medio, declaró: \"Como compañía farmacéutica nacional de Israel, hemos sido utilizados, desde el comienzo de la guerra, para el beneficio de Israel, los heridos, las familias de los evacuados y las fuerzas de seguridad\".\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">[…] donamos medicamentos esenciales, compuestos de alimentos para bebés y computadoras... (traducido del hebreo - 11) Ofek declaró recientemente que alrededor del 20% del personal de Teva fue reclutado para el esfuerzo militar desde octubre de 2023 (12).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Principio 7: Las empresas deben adoptar un enfoque preventivo ante los desafíos ambientales. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Principio 8: Emprender iniciativas para promover una mayor responsabilidad ambiental. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Entre 2007 y 2009, se determinó que Teva había violado múltiples elementos de la Ley de Aire Limpio (Ley Federal de Aire Limpio), la Ley de Agua Limpia y la Ley de Conservación y Recuperación de Recursos (Ley Federal de Conservación y Recuperación de Recursos) de EE. UU., así como varios términos de la ley estatal de Misuri, debido a la contaminación de sus instalaciones en Misuri, EE. UU., lo que resultó en una multa de 2,25 millones de dólares.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Además, se ordenó a Teva tomar medidas por valor de 2,5 millones de dólares para mejorar sus instalaciones y prevenir futuras infracciones.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Con numerosas infracciones a lo largo de los años, las acciones de Teva provocaron importantes daños ambientales al aire y al agua.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">[…] La sanción y la medida cautelar exigidas por este acuerdo envían un mensaje contundente a Teva y a otras empresas: las empresas deben cumplir con las leyes ambientales. (Agencia de Protección Ambiental de EE. UU., 2013) (13) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Principio 10: Las empresas deben trabajar contra la corrupción en todas sus formas, incluidas la extorsión y el soborno.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En 2014, Teva recibió una multa de 15,5 millones de euros por conspirar con la farmacéutica Servier para retrasar la entrada de un competidor genérico del antihipertensivo Perindopril de Servier, infringiendo así las leyes antimonopolio de la UE.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(14) En 2016, Teva recibió una multa de más de 500 millones de dólares estadounidenses para resolver los cargos penales presentados en virtud de la Ley de Protección Ambiental de EE. UU. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Ley de Prácticas Corruptas en el Extranjero, que incluye una sanción penal de 283 millones de dólares estadounidenses, por soborno a funcionarios gubernamentales y la omisión deliberada de implementar un sistema de controles internos que previniera el soborno.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(15) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según sus propias declaraciones, empleados de Teva y Teva Rusia pagaron sobornos a un alto funcionario del gobierno ruso para aumentar las ventas de Copaxone, el medicamento de Teva para la esclerosis múltiple, en las subastas anuales de compra de medicamentos celebradas por el Ministerio de Salud ruso, a pesar de que el gobierno ruso buscaba reducir su gasto en costosos productos farmacéuticos extranjeros.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva se benefició de este acuerdo con ganancias de 200 millones de dólares.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(16) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva también admitió haber pagado sobornos a un alto funcionario del Ministerio de Salud de Ucrania para influir en la aprobación gubernamental de los registros de medicamentos de Teva, incluyendo Copaxone e insulinas, lo que les permitió ingresar al mercado ucraniano.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Entre 2001 y 2011, contrataron al funcionario como \"consultor de registro\", pagando una cuota mensual y cubriendo gastos por un total aproximado de 200.000 dólares estadounidenses.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(16) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva admitió además no haber implementado un sistema adecuado de control contable interno ni haber aplicado los controles que tenía establecidos en su filial mexicana.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Esto permitió el pago de sobornos a médicos empleados por el gobierno mexicano para recetar Copaxone desde al menos 2005. Los ejecutivos de Teva en Israel, responsables del desarrollo de su programa de cumplimiento anticorrupción en 2009, estaban al tanto de ello.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los ejecutivos de Teva aprobaron políticas y procedimientos que sabían que no eran suficientes para afrontar los riesgos que representaba el negocio de Teva ni para prevenir o detectar pagos a funcionarios extranjeros.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva también admitió que sus ejecutivos designaron gerentes para supervisar la función de cumplimiento, quienes no pudieron o no quisieron hacer cumplir las políticas anticorrupción establecidas. (Comunicado de prensa de la Oficina de Asuntos Públicos de EE. UU.) (16) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En 2020, la Comisión Europea multó a Teva y Cephalon (una empresa adquirida por Teva tras estas infracciones) con 30 y 30,5 millones de euros, respectivamente, por retrasar deliberadamente la entrada de un competidor genérico del Modafinil de Cephalon para no afectar sus beneficios.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva poseía patentes para la producción de Modafinil y estaba lista para entrar en el mercado con su propia versión genérica, que ya vendía en el Reino Unido.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En cambio, acordó con Cephalon, a cambio de un paquete beneficioso de acuerdos comerciales complementarios y pagos en efectivo, detener su entrada y evitar impugnar las patentes de Cephalon (17).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En 2020, el Gobierno Federal de EE. UU. inició una investigación antimonopolio contra Teva y otras compañías farmacéuticas debido a la evidencia de fijación de precios. En 2023, se alcanzó un acuerdo de enjuiciamiento diferido, mediante el cual Teva admitió su participación en colusión con otras compañías farmacéuticas para fijar el precio de pravastatina, clotrimazol y tobramicina (18).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Este acuerdo incluye la admisión por parte de Teva de su participación en la fijación de precios, tal como había alegado el Gobierno Federal de EE. UU. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En 2024, la Comisión Europea multó a Teva con 462,6 millones de euros por «abusar de su posición dominante para retrasar la competencia de su exitoso medicamento para el tratamiento de la esclerosis múltiple, Copaxone».\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La Comisión concluyó que Teva extendió artificialmente la protección de la patente de Copaxone y difundió sistemáticamente información engañosa sobre un producto de la competencia para obstaculizar su entrada en el mercado y su adopción. (19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esta es la mayor multa impuesta jamás por la Comisión Europea a una empresa, y sus conclusiones legales destacan por su crítica mordaz a Teva, una empresa que suele resolver sus disputas extrajudicialmente, evitando así responsabilidades legales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La Comisión concluyó que Teva era responsable de un uso indebido de los procedimientos de patentes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En particular, cuando su patente de acetato de glatiramer para el tratamiento de la esclerosis múltiple estaba a punto de expirar, Teva la extendió artificialmente mediante un uso indebido de las normas y procedimientos de la Oficina Europea de Patentes sobre patentes divisionales.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Crearon una red de patentes secundarias en torno a Copaxone al presentar múltiples patentes relacionadas de forma escalonada.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A pesar de las impugnaciones de la competencia y de una revisión pendiente por parte de la oficina de patentes, Teva comenzó a hacer valer estas patentes contra sus competidores para obtener medidas cautelares.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Cuando parecía que las patentes serían revocadas, Teva las retiró para evitar una sentencia formal de invalidez, que habría amenazado otras patentes divisionales.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">De esta manera, Teva obligó a sus competidores a iniciar repetidamente nuevos y prolongados recursos legales, lo que le permitió prolongar artificialmente la incertidumbre jurídica sobre sus patentes y potencialmente obstaculizar la entrada de medicamentos de la competencia.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Todas las patentes divisionales de Teva fueron posteriormente anuladas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(19) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Además, la Comisión determinó que Teva implementó una campaña sistemática de desprestigio contra su competidor al difundir información engañosa sobre su seguridad, eficacia y equivalencia terapéutica con Copaxone, a pesar de que todo lo anterior estaba aprobado por l\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">as autoridades sanitarias pertinentes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva se dirigió a partes interesadas clave, como médicos y responsables de la toma de decisiones a nivel nacional, para frenar o incluso bloquear la entrada de este producto rival en varios Estados miembros (19).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Es importante destacar que el historial de Teva en presuntos casos de fraude, soborno y fijación de precios es extenso, pero Teva ha logrado evitar numerosas conclusiones legales sobre las acusaciones al llegar repetidamente a acuerdos antes de que se llegara a ellas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En 2022, Teva alcanzó un acuerdo multiestatal de 4.250 millones de dólares por su papel en la epidemia de adicción a los opioides en Estados Unidos, que incluyó el apoyo a las víctimas de la drogadicción mediante el suministro de kits de naloxona por un valor de hasta 1.200 millones de dólares.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Este acuerdo no incluyó ninguna admisión de irregularidades ni responsabilidad, y es uno de los acuerdos legales de mayor valor con una compañía farmacéutica en la historia mundial.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Ese mismo año, se alcanzó otro acuerdo con el estado de Nueva York por un total de más de 2.000 millones de dólares por el papel de Teva en el agravamiento de la crisis de los opioides.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En respuesta a la resolución, la gobernadora del estado de Nueva York, Kathy Hochul, declaró: “Exigimos responsabilidades a Teva Pharmaceuticals por su papel en la crisis de opioides y el daño irreparable que ha causado a los neoyorquinos, sus familias y sus comunidades. Esta empresa tergiversó sus productos durante décadas, inundando el mercado con medicamentos recetados peligrosos y poniendo en peligro innumerables vidas”.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(20) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En 2024, Teva llegó a un nuevo acuerdo de conciliación, también significativo por su inusual admisión de su comportamiento poco ético. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Entre 2006 y 2017, Teva fue acusada de violar y conspirar para violar la Ley Antisoborno (AKS) y la Ley de Reclamaciones Falsas al pagar las obligaciones de costos compartidos (copagos) de los pacientes de Medicare por el medicamento para la esclerosis múltiple Copaxone entre 2006 y 2017, mientras aumentaba progresivamente el precio de Copaxone.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Además, Teva coordinó y conspiró con múltiples terceros, incluyendo una farmacia especializada y dos fundaciones de asistencia para copagos supuestamente independientes, para garantizar que las supuestas donaciones a las fundaciones se utilizaran específicamente para cubrir los copagos de los pacientes de Medicare Copaxone, algo que Teva sabía que estaba prohibido por la AKS.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">De este modo, Teva provocó la presentación de reclamaciones falsas a Medicare.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\"> «Durante demasiado tiempo, Teva manipuló el proceso de las fundaciones benéficas pagando sobornos a través de dos fundaciones y con la ayuda de una farmacia especializada.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Dichos sobornos socavaron el propósito del sistema de copagos de Medicare y violaron la AKS» (Fiscal Federal Interino Joshua S. Levy para el Distrito de Massachusetts) (21). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Afirmamos que Teva ha violado claramente 5 de los 10 Principios del Pacto Mundial, y que los Principios 1 y 2 constituyen una violación activa, dado el firme apoyo que la compañía ha expresado al ejército israelí.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Esto no ha cambiado desde que la Corte Internacional de Justicia emitió su sentencia provisional en enero de 2024, en la que se establecía que los palestinos corrían un riesgo plausible de genocidio, y a pesar de la continua letanía de ataques contra civiles desde entonces, así como del informe más reciente del Consejo de Derechos Humanos de la ONU, que concluye que: «El Estado de Israel es responsable de no haber prevenido, cometido y castigado el genocidio».\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(9) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Permitir que una empresa con semejante historial siga siendo miembro perjudica la integridad de la propia iniciativa del Pacto Mundial.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> El Pacto Mundial de las Naciones Unidas es a menudo criticado por permitir que las empresas utilicen su membresía para «blanquear la imagen pública», es decir, usar la bandera azul de la ONU para obtener buenas relaciones públicas sin realizar cambios sustanciales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La permanencia de TEVA como miembro es un claro ejemplo que los críticos podrían utilizar para acusar al Pacto Mundial de ser un foro de debate sin mecanismos de cumplimiento.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Para los demás miembros y el público en general, ver a una empresa que ha pagado miles de millones en acuerdos legales por prácticas perjudiciales junto a organizaciones genuinamente comprometidas erosiona la confianza en todo el pacto.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sugiere que la carta de compromiso es una mera formalidad.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Mantener a miembros con infracciones tan flagrantes y reiteradas sienta un precedente peligroso, señalando que incluso las infracciones graves de los principios no conllevan la expulsión.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Esto diluye el valor de la membresía para todas las empresas que se esfuerzan diligentemente por alinear sus operaciones con los Diez Principios.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Si bien TEVA puede presentar su COP anual, la esencia de sus acciones contradice el espíritu del informe.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Una empresa puede elaborar una extensa COP que detalle sus iniciativas ambientales y subvenciones comunitarias, pero si sus operaciones comerciales principales implican prácticas corruptas y contribuyen a una crisis de salud pública, la COP se convierte en un documento de relaciones públicas vacío.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El verdadero progreso se mide por un cambio fundamental en la conducta empresarial, no solo en la presentación de informes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\u003Cstrong>Si bien TEVA ha pagado multas y acuerdos, la falta de un cambio sustancial en el comportamiento indica que estas sanciones se han integrado en sus costos operativos, en lugar de ser un arrepentimiento genuino\u003C\u002Fstrong>.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La expulsión del Pacto Mundial de las Naciones Unidas sería un acto de poder, u\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">na consecuencia no financiera grave, lo que indica que un verdadero compromiso requiere más que simplemente pagar sanciones.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">- Las Naciones Unidas defienden la paz, la justicia, los derechos humanos y el derecho internacional.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Una empresa miembro que ha sido declarada culpable de soborno generalizado en varios países y cuyos productos se han vinculado a una crisis sanitaria masiva crea una contradicción ética flagrante e insostenible.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">- El argumento para la eliminación de TEVA no se basa en infracciones menores, sino en casos legales resueltos, prácticas atroces bien documentadas y transgresiones legales admitidas que atentan contra la esencia misma de los principios del Pacto Mundial de las Naciones Unidas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Al seguir siendo miembro, TEVA socava la credibilidad del Pacto Mundial de las Naciones Unidas, que corre el riesgo de ser visto como cómplice del lavado de imagen de la empresa.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Eliminar a TEVA enviaría un mensaje contundente: la membresía requiere una adhesión genuina y sustancial a sus principios, no solo una firma en una página.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Instamos al Pacto Mundial de las Naciones Unidas a eliminar a Teva de su lista de participantes para evitar que la iniciativa del Pacto Mundial de las Naciones Unidas pierda su sentido.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Atentamente, BDS de Salud Global para Palestina \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Referencias: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">1. Los Diez Principios del Pacto Mundial de las Naciones Unidas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Pacto Mundial de las Naciones Unidas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Consultado el 11 de septiembre de 2025. unglobalcompact.org\u002Fwhat-is-gc\u002Fmission\u002Fprinciples \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">2. Fabian E. El ministro de Defensa anuncia un \"asedio total\" a Gaza: Sin electricidad, alimentos ni combustible.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The Times of Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">9 de octubre de 2023. Consultado el 11 de septiembre de 2025. www.timesofisrael.com\u002Fliveblog_entry\u002Fdefense-minister-announces-complete-siege-of-gaza-no-power-food-or-fuel\u002F \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">3. Sfard M. Los israelíes deben mantener su humanidad incluso cuando les hierve la sangre: Opinión.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Haaretz.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">11 de octubre de 2023. Consultado el 11 de septiembre de 2025. www.haaretz.com\u002Fopinion\u002F2023-10-11\u002Fty-article-opinion\u002F.premium\u002Fisraelis-must-maintain-their-humanity-even-when-their-blood-boils\u002F0000018b-1e18-d465-abbb-1ebe62c80000 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">4. McKernan B, Kierszenbaum Q. «Nos centramos en causar el máximo daño»: la ofensiva terrestre en Gaza parece inminente.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The Guardian.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">10 de octubre de 2023. Consultado el 11 de septiembre de 2025. www.theguardian.com\u002Fworld\u002F2023\u002Foct\u002F10\u002Fright-now-it-is-one-day-at-a-time-life-on-israels-frontline-with-gaza \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">5. Organización Mundial de la Salud.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Hambruna confirmada por primera vez en Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">22 de agosto de 2025. Consultado el 16 de septiembre de 2025. www.who.int\u002Fnews\u002Fitem\u002F22-08-2025-famine-confirmed-for-first-time-in-gaza \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">6. Oficina del Alto Comisionado de las Naciones Unidas para los Derechos Humanos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El patrón de ataques israelíes contra hospitales de Gaza suscita gran preocupación – 31 de diciembre de 2024. Consultado el 16 de septiembre de 2025. www.ohchr.org\u002Fen\u002Fpress-releases\u002F2024\u002F12\u002Fpattern-israeli-attacks-gaza-hospitals-raises-grave-concerns-report \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">7. Oficina del Alto Comisionado de las Naciones Unidas para los Derechos Humanos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Informe Temático - Detención en el contexto de la escalada de hostilidades en Gaza (octubre de 2023-junio de 2024) - 31 de julio de 2024. Consultado el 16 de septiembre de 2025. www.ohchr.org\u002Fsites\u002Fdefault\u002Ffiles\u002Fdocuments\u002Fcountries\u002Fopt\u002F20240731-Thematic-report-Detention-context-Gaza-hostilities.pdf \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">8. Effting M, Feenstra W. Lo que dicen las heridas (traducido del neerlandés).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">DeVolkskrant.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">13 de septiembre de 2025. Consultado el 16 de septiembre de 2025. www.volkskrant.nl\u002Fkijkverder\u002Fv\u002F2025\u002Fschotwonden-palestijnse-kinderen-israel-oorlog~v1778945 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">9. Consejo de Derechos Humanos de la ONU.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Análisis jurídico de la conducta de Israel en Gaza de conformidad con la Convención para la Prevención y la Sanción del Delito de Genocidio.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">16 de septiembre de 2025. Consultado el 18 de septiembre de 2025. www.ohchr.org\u002Fsites\u002Fdefault\u002Ffiles\u002Fdocuments\u002Fhrbodies\u002Fhrcouncil\u002Fsessions-regular\u002Fsession60\u002Fadvance-version\u002Fa-hrc-60-crp-3.pdf \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">10. Nature for Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">26 de octubre de 2023. Consultado el 11 de septiembre de 2025. www.teva.co.il\u002Fnews-and-media\u002Flatest-news\u002Fteva-together-for-Israel\u002F \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">11. Teva establece una nueva fundación: \"Tratamiento del Trauma Nacional\".\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">ice.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Consultado el 11 de septiembre de 2025. www.ice.co.il\u002Farticle\u002Fprintpage\u002F993690 (Traducido del hebreo) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">12. Levanon A. “Israel puede aportar valor a la naturaleza global más allá de su tamaño”.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ynet.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">3 de abril de 2025. Consultado el 11 de septiembre de 2025. www.ynet.co.il\u002Feconomy\u002Farticle\u002Fsknw00ts6jl (Traducido del hebreo) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">13. Oficina de Asuntos Públicos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva Pharmaceuticals USA pagará una multa civil de 2,25 millones de dólares por infracciones relacionadas con el aire, el agua y los residuos peligrosos en sus instalaciones de Misuri.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Archivos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Departamento de Justicia de EE. UU. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">14 de marzo de 2013. Actualizado el 6 de febrero de 2025. Consultado el 11 de septiembre de 2025. www.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fteva-pharmaceuticals-usa-pay-225-million-civil-penalty-air-water-and-hazardous-waste \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">14. Comisión Europea.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Antimonopolio: La Comisión multa a Servier y a cinco compañías de genéricos por frenar la entrada de versiones más económicas de medicamentos cardiovasculares.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">9 de julio de 2014, consultado el 15 de agosto de 2025. ec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_14_799 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">15. Comisión de Bolsa y Valores de EE. UU. (SEC).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva Pharmaceutical paga 519 millones de dólares para resolver los cargos de la FCPA.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">22 de diciembre de 2016, consultado el 15 de agosto de 2025. www.sec.gov\u002Fnewsroom\u002Fpress-releases\u002F2016-277 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">16. Oficina de Asuntos Públicos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva Pharmaceutical Industries Ltd. acuerda pagar más de 283 millones de dólares para resolver conflictos extranjeros. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Acusaciones de la Ley de Prácticas Corruptas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Archivos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Departamento de Justicia de EE. UU. 22 de diciembre de 2016. Actualizado el 5 de febrero de 2025. Consultado el 11 de septiembre de 2025. www.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fteva-pharmaceutical-industries-ltd-agrees-pay-more-283-million-resolve-foreign-corrupt \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">17. Antimonopolio: La Comisión multa a Teva y Cephalon con 60,5 millones de euros por retrasar la entrada de medicamentos genéricos más económicos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Comisión Europea.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">26 de noviembre de 2020. Consultado el 11 de septiembre de 2025. ec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_20_2220 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">18. Principales compañías de medicamentos genéricos pagarán más de 250 millones de dólares para resolver los cargos de fijación de precios y desinvertir en un medicamento clave en el centro de su conspiración.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">21 de agosto de 2023. Consultado el 15 de octubre de 2025. www.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fmajor-generic-drug-companies-pay-over-quarter-billion-dollars-resolve-price-fixing-charges \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">19. La Comisión multa a Teva con 462,6 millones de euros por abuso del sistema de patentes y menosprecio para retrasar el medicamento rival para la esclerosis múltiple.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Comisión Europea.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">31 de octubre de 2023. Consultado el 11 de septiembre de 2025. ec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_24_5581 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">20. La Fiscal General James obtiene 523 millones de dólares del principal fabricante de opioides, Teva, lo que eleva los fondos totales para los neoyorquinos a más de 2000 millones de dólares.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Fiscal General del Estado de Nueva York.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">3 de noviembre de 2022. Consultado el 11 de septiembre de 2025. ag.ny.gov\u002Fpress-release\u002F2022\u002Fattorney-general-james-secures-523-million-top-opioid-manufacturer-teva-bringing \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">21. Oficina de Asuntos Públicos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La farmacéutica Teva Pharmaceuticals acepta pagar 450 millones de dólares en un acuerdo amparado por la Ley de Reclamaciones Falsas para resolver las acusaciones de sobornos relacionadas con copagos y fijación de precios.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Archivos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Departamento de Justicia de EE. UU. 10 de octubre de 2024. Actualizado el 6 de febrero de 2025. Consultado el 11 de septiembre de 2025. www.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"Las autoridades sanitarias pertinentes. Teva se dirigió a partes interesadas clave, como médicos y responsables de la toma de decisiones a nivel nacional, para frenar o incluso bloquear la entrada de este producto rival en varios Estados miembros (19).\nEs importante destacar que el historial de Teva en presuntos casos de fraude, soborno y fijación de precios es extenso, pero Teva ha logrado evitar numerosas conclusiones legales sobre las acusaciones al llegar repetidamente a acuerdos antes de que se llegara a ellas. En 2022, Teva alcanzó un acuerdo multiestatal de 4.250 millones de dólares por su papel en la epidemia de adicción a los opioides en Estados Unidos, que incluyó el apoyo a las víctimas de la drogadicción mediante el suministro de kits de naloxona por un valor de hasta 1.200 millones de dólares. Este acuerdo no incluyó ninguna admisión de irregularidades ni responsabilidad, y es uno de los acuerdos legales de mayor valor con una compañía farmacéutica en la historia mundial.\nEse mismo año, se alcanzó otro acuerdo con el estado de Nueva York por un total de más de 2.000 millones de dólares por el papel de Teva en el agravamiento de la crisis de los opioides. En respuesta a la resolución, la gobernadora del estado de Nueva York, Kathy Hochul, declaró:\n\n“Exigimos responsabilidades a Teva Pharmaceuticals por su papel en la crisis de opioides y el daño irreparable que ha causado a los neoyorquinos, sus familias y sus comunidades. Esta empresa tergiversó sus productos durante décadas, inundando el mercado con medicamentos recetados peligrosos y poniendo en peligro innumerables vidas”. (20)\n\nEn 2024, Teva llegó a un nuevo acuerdo de conciliación, también significativo por su inusual admisión de su comportamiento poco ético. Entre 2006 y 2017, Teva fue acusada de violar y conspirar para violar la Ley Antisoborno (AKS) y la Ley de Reclamaciones Falsas al pagar las obligaciones de costos compartidos (copagos) de los pacientes de Medicare por el medicamento para la esclerosis múltiple Copaxone entre 2006 y 2017, mientras aumentaba progresivamente el precio de Copaxone. Además, Teva coordinó y conspiró con múltiples terceros, incluyendo una farmacia especializada y dos fundaciones de asistencia para copagos supuestamente independientes, para garantizar que las supuestas donaciones a las fundaciones se utilizaran específicamente para cubrir los copagos de los pacientes de Medicare Copaxone, algo que Teva sabía que estaba prohibido por la AKS. De este modo, Teva provocó la presentación de reclamaciones falsas a Medicare.\n\n«Durante demasiado tiempo, Teva manipuló el proceso de las fundaciones benéficas pagando sobornos a través de dos fundaciones y con la ayuda de una farmacia especializada. Dichos sobornos socavaron el propósito del sistema de copagos de Medicare y violaron la AKS» (Fiscal Federal Interino Joshua S. Levy para el Distrito de Massachusetts) (21).\n\nAfirmamos que Teva ha violado claramente 5 de los 10 Principios del Pacto Mundial, y que los Principios 1 y 2 constituyen una violación activa, dado el firme apoyo que la compañía ha expresado al ejército israelí. Esto no ha cambiado desde que la Corte Internacional de Justicia emitió su sentencia provisional en enero de 2024, en la que se establecía que los palestinos corrían un riesgo plausible de genocidio, y a pesar de la continua letanía de ataques contra civiles desde entonces, así como del informe más reciente del Consejo de Derechos Humanos de la ONU, que concluye que:\n\n«El Estado de Israel es responsable de no haber prevenido, cometido y castigado el genocidio». (9)\n\nPermitir que una empresa con semejante historial siga siendo miembro perjudica la integridad de la propia iniciativa del Pacto Mundial.\n\nEl Pacto Mundial de las Naciones Unidas es a menudo criticado por permitir que las empresas utilicen su membresía para «blanquear la imagen pública», es decir, usar la bandera azul de la ONU para obtener buenas relaciones públicas sin realizar cambios sustanciales. La permanencia de TEVA como miembro es un claro ejemplo que los críticos podrían utilizar para acusar al Pacto Mundial de ser un foro de debate sin mecanismos de cumplimiento.\n\nPara los demás miembros y el público en general, ver a una empresa que ha pagado miles de millones en acuerdos legales por prácticas perjudiciales junto a organizaciones genuinamente comprometidas erosiona la confianza en todo el pacto. Sugiere que la carta de compromiso es una mera formalidad. Retener a miembros con infracciones tan flagrantes y reiteradas sienta un precedente peligroso, señalando que incluso las infracciones graves de los principios no conllevan la expulsión. Esto diluye el valor de la membresía para todas las empresas que se esfuerzan diligentemente por alinear sus operaciones con los Diez Principios.\n\n\nSi bien TEVA puede presentar su COP anual, la esencia de sus acciones contradice el espíritu del informe. Una empresa puede elaborar una extensa COP que detalle sus iniciativas ambientales y subvenciones comunitarias, pero si sus operaciones comerciales principales implican prácticas corruptas y contribuyen a una crisis de salud pública, la COP se convierte en un documento de relaciones públicas vacío. El verdadero progreso se mide por un cambio fundamental en la conducta empresarial, no solo en la presentación de informes. Si bien TEVA ha pagado multas y acuerdos, la falta de un cambio sustancial en el comportamiento indica que estas sanciones se han integrado en sus costos operativos, en lugar de ser un arrepentimiento genuino. La expulsión del Pacto Mundial de las Naciones Unidas sería un acto de poder.\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp> \u003C\u002Fp>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp>\u003Cstrong>INGLÉS\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>United Nations. Global Compact\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>NOTE. Global \u003Cem>Compact, UN initiative. A call to companies to align strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Please, sign \u003Ca href=\"https:\u002F\u002Factionnetwork.org\u002Fpetitions\u002Fletter-to-un-global-compact-for-removal-of-teva-pharmaceuticals-from-list-of-participants\">here\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Letter to UN Global Compact for removal of Teva Pharmaceuticals from list of participants\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Ms. Ingvild Sørensen, Lead for UN Global Compact\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Teva Pharmaceuticals is a participant in the UN's Global Compact Initiative, which allows companies to be publicly listed as subscribing to a list of 10 ethical principles.\u003C\u002Fp>\n\u003Cp>Teva Pharmaceuticals has demonstrated a pattern of corrupt and anti-competitive practices spanning multiple jurisdictions and decades. Its record includes fines for collusion, bribery of government officials, misuse of patent procedures, market manipulation and price fixing. While Teva often settles cases before legal conclusions are reached, the consistent findings by courts and regulators across the US and Europe reveal corruption and a systemic disregard for the rule of law and ethical standards. We urge the UN Global Compact to remove Teva Pharmaceuticals from their participant list.\u003Cbr>Petition by\u003Cbr>Global Health BDS for Palestine .\u003Cbr>Global Health BDS for Palestine\u003Cbr>Sponsored by\u003Cbr>Ghbds4p\u003Cbr>Global Health BDS for Palestine\u003C\u002Fp>\n\u003Cp>To: Ms. Ingvild Sørensen, Lead for UN Global Compact\u003Cbr>From: [Your Name]\u003C\u002Fp>\n\u003Cp>We write expressing concerns over the inclusion of Teva Pharmaceuticals as a participant in the UN’s Global Compact list. Being a signatory to the Global Compact reflects ‘a company’s value system and a principles-based approach to doing business. This means operating in ways that, at a minimum, meet fundamental responsibilities in the areas of human rights, labour, environment and anti-corruption. Responsible businesses enact the same values and principles wherever they have a presence, and know that good practices in one area do not offset harm in another.’ (1) There is overwhelming evidence that Teva Pharmaceuticals is in breach of several of the 10 Principles that are fundamental to the Global Compact.\u003C\u002Fp>\n\u003Cp>\u003Cem>Principle 1: Businesses should support and respect the protection of internationally proclaimed human rights.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>Principle 2: Make sure that they are not complicit in human rights abuses.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Since the start of Israel’s attacks on the civilian population of the Gaza strip in 2023, Teva has shown unremitting support for the Israeli military. On 9th October the Israeli Defence Minister declared a complete siege of Gaza, ‘There will be no electricity, no food, no fuel, everything is closed […] We are fighting human animals and we are acting accordingly.’ (2) The next day Teva proclaimed its support for the Israeli military, just as the military’s Head Spokesperson, Daniel Hagari, stated that the aim of the attack on Gaza was not accuracy but to cause ‘maximum damage’ (3,4). Despite the appalling evidence of unrelenting human rights violations, including deliberate starvation, targeting of civilians and civilian infrastructure, torturing of prisoners, sexual abuse and overwhelming evidence for the targeting of children (5-9), on 26th October 2023, Teva’s CEO Richard Francis, referred to Teva as Israel’s ‘national pharmaceutical and healthcare company’, and the tenor of these statements has not wavered as the genocide’s death toll has escalated (10).\u003C\u002Fp>\n\u003Cp>In 2024 Yossi Ofek, the regional CEO of Teva Israel, Ukraine, Africa and the Middle East Clusters stated:\u003Cbr>‘As the national pharmaceutical company of Israel, we have been harnessed - since the beginning of the war - for the benefit of Israel, the wounded and the families of the evacuees and the security forces. […] we donated essential medicines, baby food compounds and computers...’ (translated from Hebrew - 11)\u003C\u002Fp>\n\u003Cp>Ofek more recently stated that around 20% of Teva’s staff were recruited into the military effort since October 2023 (12).\u003C\u002Fp>\n\u003Cp>\u003Cem>Principle 7: Businesses should support a precautionary approach to environmental challenges\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cem>Principle 8: Undertake initiatives to promote greater environmental responsibility\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Between 2007 and 2009, Teva was found to have violated multiple elements of the US federal Clean Air Act, Clean Water Act and the Resource Conservation and Recovery Act as well as multiple terms of Missouri state law due to its polluting of facilities in Missouri, USA resulting in a fine of $2.25 million USD. In addition, Teva was ordered to take actions worth $2.5 million USD on improvements to its facility to prevent future violations.\u003C\u002Fp>\n\u003Cp>‘With numerous violations over a period of years, Teva’s actions resulted in significant environmental damage to the air and water. […] The penalty and injunctive relief required by this agreement send a strong message to Teva and others that businesses must comply with environmental laws.’ (US Environmental Protection Agency, 2013) (13)\u003C\u002Fp>\n\u003Cp>\u003Cem>Principle 10: Businesses should work against corruption in all its forms, including extortion and bribery.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>In 2014 Teva was fined €15.5 million for colluding with the pharma company Servier to delay the entry of a generic oreign Corrupt Practices Act, including a criminal penalty of $283 million USD, for bribery of government officials and a deliberate failure to implement a system of internal controls that would prevent bribery. (15)\u003C\u002Fp>\n\u003Cp>\u003Cbr>By its own admission, Teva and Teva Russia employees paid bribes to a high-ranking Russian government official to increase sales of Teva’s multiple sclerosis drug, Copaxone, in annual drug purchase auctions held by the Russian Ministry of Health, despite the Russian government seeking to reduce its expenditure on costly foreign pharmaceutical products; Teva benefited from this deal to the tune of $200 million in profits. (16)\u003C\u002Fp>\n\u003Cp>\u003Cbr>Teva also admitted to paying bribes to a senior government official within the Ukrainian Ministry of Health to influence the government’s approval of Teva drug registrations, including Copaxone and insulins, allowing them to enter the Ukrainian market. Between 2001 and 2011, they engaged the official as a “registration consultant,” paying a monthly fee and covering expenses totalling approximately $200,000 USD. (16)\u003C\u002Fp>\n\u003Cp>\u003Cbr>Teva further admitted to failing to implement an adequate system of internal accounting controls and failing to enforce the controls it had in place at its Mexican subsidiary. This allowed bribes to be paid to doctors employed by the Mexican government to prescribe Copaxone since at least 2005, Teva executives in Israel responsible for the development of their anti-corruption compliance program in 2009 were aware of this.\u003C\u002Fp>\n\u003Cp>\u003Cbr>‘Teva executives approved policies and procedures that they knew were not sufficient to meet the risks posed by Teva’s business and were not adequate to prevent or detect payments to foreign officials. Teva also admitted that its executives put in place managers to oversee the compliance function who were unable or unwilling to enforce the anti-corruption policies that had been put in place.’ (Press release US Office of Public Affairs) (16)\u003C\u002Fp>\n\u003Cp>\u003Cbr>In 2020, the European Commission fined Teva and Cephalon (a company acquired by Teva after these violations) €30 and €30.5 million, respectively, for deliberately delaying the entry of a generic competitor to Cephalon’s Modafinil preparation in order to not disrupt Cephalon’s Modafinil profits. Teva held patents for the production of Modafinil and was ready to enter the market with its own generic version, which it was already selling in the UK. Instead, it agreed with Cephalon, in exchange for a beneficial package of commercial side-deals and cash payments, to stop its entry and avoid challenging Cephalon’s patents (17).\u003C\u002Fp>\n\u003Cp>\u003Cbr>In 2020 the US Federal Government launched an anti-trust investigation into Teva and other pharmaceutical companies due to evidence of price-fixing, a deferred prosecution agreement was reached in 2023, whereby Teva conceded that it was involved in colluding with other pharmaceutical companies in fixing the price of Pravastatin, Clotrimazole and Tobramycin (18). This agreement includes an admission by Teva that it was involved in price-fixing as the US Federal Government had alleged.\u003C\u002Fp>\n\u003Cp>\u003Cbr>In 2024, the European Commission fined Teva €462.6 million for ‘abusing its dominant position to delay competition to its blockbuster medicine for the treatment of multiple sclerosis, Copaxone. The Commission found that Teva artificially extended the patent protection of Copaxone and systematically spread misleading information about a competing product to hinder its market entry and uptake.’ (19)\u003C\u002Fp>\n\u003Cp>\u003Cstrong>This is the largest fine that the European Commission has ever levied on any company, and its legal conclusions are notable for their scathing criticism of Teva, a company that usually settles its disputes out of court, thereby avoiding legal liability.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>The Commission found that Teva was responsible for misusing patent procedures. In particular, when its patent for glatiramer acetate for the treatment of multiple sclerosis was about to expire, Teva artificially extended it by misusing the European Patent Office’s rules and procedures on divisional patents. They created a web of secondary patents around Copaxone by filing multiple related patents in a staggered fashion.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Despite challenges from competitors and a pending review by the patent office, Teva started enforcing these patents against competitors to obtain interim injunctions. When it appeared the patents would be revoked, Teva withdrew them to avoid a formal invalidity ruling, which would have threatened other divisional patents. In this way, Teva forced competitors to repeatedly start new lengthy legal challenges, allowing Teva to artificially prolong legal uncertainty over its patents and potentially hinder the entry of competing medicines. All Teva's divisional patents were later annulled. (19)\u003C\u002Fp>\n\u003Cp>Furthermore, the Commission found that Teva implemented a systematic disparagement campaign against their competitor by spreading misleading information about its safety, efficacy and therapeutic equivalence with Copaxone, despite all of the above being approved by the relevant health authorities. Teva targeted key stakeholder, including doctors and nation decision-makers for pricing and reimbursement of medicines to slow down or even block the entry of this rival product in several Member States (19).\u003C\u002Fp>\n\u003Cp>\u003Cbr>It is of significance that Teva’s history of alleged fraud, bribery and price fixing is extensive, but Teva has been able to avoid many legal conclusions on the allegations by repeatedly settling cases before legal conclusions are reached. In 2022 Teva reached a $4.25 billion USD multi-state settlement for its role in the US opioid addiction epidemic, including providing support for drug-addicted victims by providing up to Naloxone kits up to a value of $1.2 billion USD. This included no admission of wrongdoing or liability, and is one of the highest valued legal settlements with a pharmaceutical company in world history.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Later that year, another settlement was reached with the state of New York totalling more than $2 billion for Teva’s role in fuelling the opioid crisis. In response to the resolution, New York State Governor Kathy Hochul stated:\u003C\u002Fp>\n\u003Cp>‘We are holding Teva Pharmaceuticals accountable for its role in the opioid crisis and the irreparable harm it has done to New Yorkers, their families, and their communities. This company misrepresented its products for decades, flooding the market with dangerous prescription drugs and endangering countless lives.’ (20)\u003C\u002Fp>\n\u003Cp>In 2024, Teva again reached a settlement agreement, also significant for an unusual admission by Teva of its unethical behaviour. Between 2006 and 2017, Teva was alleged to have violated and conspired to violate the Anti-Kickback Statute (AKS) and False Claims Act by paying Medicare patients’ cost sharing obligations (copays) for the multiple sclerosis drug Copaxone from 2006 through 2017, while progressively raising Copaxone’s price.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Furthermore, Teva coordinated and conspired with multiple third parties, including a specialty pharmacy and two allegedly independent copay assistance foundations, to ensure that purported donations to the foundations were used specifically to cover the copays of Medicare Copaxone patients, which Teva knew was prohibited by the AKS. Teva thereby caused the submission of false claims to Medicare.\u003C\u002Fp>\n\u003Cp>‘For far too long, Teva gamed the charitable foundation process by paying kickbacks through two foundations, and with the aid of a specialty pharmacy. Those kickbacks undermined the purpose of the Medicare co-pay system and violated the AKS,’ (Acting U.S. Attorney Joshua S. Levy for the District of Massachusetts) (21)\u003C\u002Fp>\n\u003Cp>We submit that fully 5 out of 10 of the Global Compact Principles have been clearly violated by Teva, with Principles 1 and 2 in active violation given the unwavering support the company has expressed for Israel’s military. This has not changed since the International Court of Justice rendered its interim judgement in January 2024 that the Palestinians were plausibly at risk of genocide, and despite the ongoing litany of attacks against civilians since then, as well as the more recent UN Human Rights Council report concluding that:\u003C\u002Fp>\n\u003Cp>'the State of Israel bears responsibility for the failure to prevent genocide, the commission of genocide and the failure to punish genocide.' (9)\u003C\u002Fp>\n\u003Cp>Allowing a company with such a record to remain a member damages the integrity of the Global Compact initiative itself.\u003C\u002Fp>\n\u003Cp>- The UNGC is often criticized for allowing companies to use their membership for \"bluewashing\"\u003C\u002Fp>\n\u003Cp> – Using the UN's blue flag for positive public relations without making substantive changes. TEVA's continued membership is a prime example that critics could use to accuse the UNGC of being a \"talking shop\" without enforcement mechanisms.\u003C\u002Fp>\n\u003Cp>- For other members and the public, seeing a company that has paid billions in legal settlements for harmful practices listed alongside genuinely committed organizations erodes trust in the entire compact. It suggests that the commitment letter is merely a formality. Retaining members with such egregious, repeated violations sets a dangerous precedent, signaling that even serious breaches of the principles do not lead to expulsion. This dilutes the value of membership for all companies that are diligently trying to align their operations with the Ten Principles.\u003C\u002Fp>\n\u003Cp>- While TEVA may file its annual COP, the substance of its actions contradicts the report's intended spirit. A company can produce a lengthy COP detailing its environmental initiatives and community grants, but if its core business operations involve corrupt practices and contributing to a public health crisis, the COP becomes a hollow public relations document. True progress is measured by a fundamental change in business conduct, not just in reporting. While TEVA has paid fines and settlements, a lack of substantive change in behaviour indicates that these sanctions have been integrated into their costs of doing business rather than genuine contrition. Expulsion from the UNGC would be a powerful non-financial consequence, signaling that true commitment requires more than just paying penalties.\u003C\u002Fp>\n\u003Cp>- The United Nations stands for peace, justice, human rights, and international law. A member company that has been found guilty of widespread bribery in multiple countries and whose products have been linked to a massive health crisis creates a stark and untenable ethical contradiction.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>- The argument for TEVA's removal is not based on minor infractions but on settled legal cases, well-documented egregious practices and admitted legal transgressions that strike at the very heart of the UN Global Compact's principles. By remaining a member, TEVA undermines the credibility of the UNGC, which risks being seen as an accomplice in \"bluewashing\" the company's reputation. Removing TEVA would send a strong message that membership requires genuine, substantive adherence to its principles, not just a signature on a page.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>We urge the UN Global Compact to remove Teva from its list of participants to avoid rendering the UN Global Compact initiative meaningless.\u003Cbr>Yours sincerely,\u003C\u002Fp>\n\u003Cp>Global Health BDS for Palestine\u003C\u002Fp>\n\u003Cp>\u003Cstrong>References:\u003C\u002Fstrong>\u003Cbr>1. The Ten Principles of the UN Global Compact. United Nations Global Compact. Accessed September 11, 2025. unglobalcompact.org\u002Fwhat-is-gc\u002Fmission\u002Fprinciples\u003C\u002Fp>\n\u003Cp>2. Fabian E. Defense minister announces ‘Complete siege’ of Gaza: No Power, food or fuel. The Times of Israel. October 9, 2023. Accessed September 11, 2025. www.timesofisrael.com\u002Fliveblog_entry\u002Fdefense-minister-announces-complete-siege-of-gaza-no-power-food-or-fuel\u002F\u003C\u002Fp>\n\u003Cp>3. Sfard M. Israelis must maintain their humanity even when their blood boils: Opinion. Haaretz. October 11, 2023. Accessed September 11, 2025. www.haaretz.com\u002Fopinion\u002F2023-10-11\u002Fty-article-opinion\u002F.premium\u002Fisraelis-must-maintain-their-humanity-even-when-their-blood-boils\u002F0000018b-1e18-d465-abbb-1ebe62c80000\u003C\u002Fp>\n\u003Cp>4. McKernan B, Kierszenbaum Q. ‘We’re focused on maximum damage’: ground offensive into Gaza seems imminent. The Guardian. October 10, 2023. Accessed September 11, 2025. www.theguardian.com\u002Fworld\u002F2023\u002Foct\u002F10\u002Fright-now-it-is-one-day-at-a-time-life-on-israels-frontline-with-gaza\u003C\u002Fp>\n\u003Cp>5. World Health Organisation. Famine confirmed for first time in Gaza. 22nd August 2025. Accessed 16th September 2025. www.who.int\u002Fnews\u002Fitem\u002F22-08-2025-famine-confirmed-for-first-time-in-gaza\u003C\u002Fp>\n\u003Cp>6. UN Office of the High Commissioner for Human Rights. Pattern of Israeli attacks on Gaza hospitals raises grave concerns – 31st December 2024. Accessed 16th September 2025. www.ohchr.org\u002Fen\u002Fpress-releases\u002F2024\u002F12\u002Fpattern-israeli-attacks-gaza-hospitals-raises-grave-concerns-report\u003C\u002Fp>\n\u003Cp>7. UN Office of the High Commissioner for Human Rights. Thematic Report - Detention in the context of the escalation of hostilities in Gaza (October 2023-June 2024) - 31st July 2024. Accessed 16th September 2025. www.ohchr.org\u002Fsites\u002Fdefault\u002Ffiles\u002Fdocuments\u002Fcountries\u002Fopt\u002F20240731-Thematic-report-Detention-context-Gaza-hostilities.pdf\u003C\u002Fp>\n\u003Cp>8. Effting M, Feenstra W. What the wounds tell (translated from Dutch). DeVolkskrant. 13th September 2025. Accessed 16th September 2025. www.volkskrant.nl\u002Fkijkverder\u002Fv\u002F2025\u002Fschotwonden-palestijnse-kinderen-israel-oorlog~v1778945\u003C\u002Fp>\n\u003Cp>9. UN Human Rights Council. Legal analysis of the conduct of Israel in Gaza pursuant to the Convention on the Prevention and Punishment of the Crime of Genocide. 16th September 2025. Accessed 18th September 2025. www.ohchr.org\u002Fsites\u002Fdefault\u002Ffiles\u002Fdocuments\u002Fhrbodies\u002Fhrcouncil\u002Fsessions-regular\u002Fsession60\u002Fadvance-version\u002Fa-hrc-60-crp-3.pdf\u003C\u002Fp>\n\u003Cp>10. Nature for Israel. Teva. October 26, 2023. Accessed September 11, 2025. www.teva.co.il\u002Fnews-and-media\u002Flatest-news\u002Fteva-together-for-Israel\u002F\u003C\u002Fp>\n\u003Cp>11. Teva establishes a new foundation: \"Treatment of National Trauma\". ice. Accessed September 11, 2025. www.ice.co.il\u002Farticle\u002Fprintpage\u002F993690 (Translated from Hebrew)\u003C\u002Fp>\n\u003Cp>12. Levanon A. “Israel can give value to global nature beyond its size.” Ynet. April 03, 2025. Accessed September 11, 2025. www.ynet.co.il\u002Feconomy\u002Farticle\u002Fsknw00ts6jl (Translated from Hebrew)\u003C\u002Fp>\n\u003Cp>13. Office of Public Affairs. Teva Pharmaceuticals USA to pay $2.25 million civil penalty for air, water and hazardous waste violations at Missouri Facility. Archives. US Department of Justice. March 14, 2013. Updated February 6, 2025. Accessed September 11, 2025. www.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fteva-pharmaceuticals-usa-pay-225-million-civil-penalty-air-water-and-hazardous-waste\u003C\u002Fp>\n\u003Cp>14. European Commission. Antitrust: Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine. 9th July 2014, accessed 15th August 2025. ec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_14_799\u003C\u002Fp>\n\u003Cp>15. US Securities and Exchanges Commission. Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges. 22nd December 2016, accessed 15th August 2025. www.sec.gov\u002Fnewsroom\u002Fpress-releases\u002F2016-277\u003C\u002Fp>\n\u003Cp>16. Office of Public Affairs. Teva Pharmaceutical Industries Ltd. Agrees to Pay More Than $283 Million to Resolve Foreig \u003C\u002Fp>\n\u003Cp>n Corrupt Practices Act Charges. Archives. US Department of Justice. December 22, 2016. Updated February 5, 2025. Accessed September 11, 2025. www.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fteva-pharmaceutical-industries-ltd-agrees-pay-more-283-million-resolve-foreign-corrupt\u003C\u002Fp>\n\u003Cp>17. Antitrust: Commission fines Teva and Cephalon €60.5 million for delaying entry of cheaper generic medicine. European Commission. November 26, 2020. Accessed September 11, 2025. ec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_20_2220\u003C\u002Fp>\n\u003Cp>18. Major Generic Drug Companies to Pay Over Quarter of a Billion Dollars to Resolve Price-Fixing Charges and Divest Key Drug at the Center of Their Conspiracy. August 21, 2023. Accessed 15th October 2025. www.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fmajor-generic-drug-companies-pay-over-quarter-billion-dollars-resolve-price-fixing-charges\u003C\u002Fp>\n\u003Cp>19. Commission fines Teva €462.6 million over misuse of the patent system and disparagement to delay rival multiple sclerosis medicine. European Commission. October 31, 2023. Accessed September 11, 2025. ec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_24_5581\u003C\u002Fp>\n\u003Cp>20. Attorney General James Secures $523 Million from Top Opioid Manufacturer Teva, Bringing Total Funds for New Yorkers to More Than $2 Billion. New York State Attorney General. November 3, 2022. Accessed September 11, 2025. ag.ny.gov\u002Fpress-release\u002F2022\u002Fattorney-general-james-secures-523-million-top-opioid-manufacturer-teva-bringing\u003C\u002Fp>\n\u003Cp>21. Office of Public Affairs. Drug Maker Teva Pharmaceuticals Agrees to Pay $450M in False Claims Act Settlement to Resolve Kickback Allegations Relating to Copayments and Price Fixing. Archives. US Department of Justice. October 10, 2024. Updated February 6, 2025. Accessed September 11, 2025. www.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback\u003C\u002Fp>","Firme, por favor: Teva fuera del Pacto Mundial empresarial de las Naciones Unidas. Sign please: Teva out of UN Global Compact, business. ESP ENG","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1760794475\u002Fi6hgltddpcd3sy1wlaha.png","firme-por-favor-teva-fuera-del-pacto-mundial-empresarial-de-las-naciones-unidas-sign-please-teva-out-of-un-global-compact-business-esp-eng",{"subtitle":351,"link":12,"user":13,"tags":352,"timestamp":353,"content":354,"type":7,"slug":355,"imageUrl":356,"id":357,"videoUrl":358,"title":359},"LAB pide a Osakidetza que no compre a Teva.  Basque union LAB demands that the Basque Health Service, Osakidetza, do not buy Teva",[15],1762017114339,"\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>30 octubre 2025\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.naiz.eus\u002Fes\u002Finfo\u002Fnoticia\u002F20251030\u002Flab-exige-a-la-direccion-de-osakidetza-que-explore-alternativas-a-los-medicamentos-de-la-israeli-teva\">\u003Cstrong>El sindicato vasco LAB exige al Servicio Vasco de Salud, Osakidetza, que explore alternativas a los medicamentos de la israelí Teva\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>El sindicato LAB ha instado a la dirección de Osakidetza, como ya lo están haciendo en Osasunbidea, a que deje de adquirir productos farmacéuticos de la compañía israelí Teva.\u003C\u002Fp>\n\u003Cp>\u003Cem>«No debemos permitir que dinero público termine en manos de un Estado genocida», sostienen desde el sindicato.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>El sindicato LAB ha solicitado por escrito a la dirección de Osakidetza que explore alternativas a los productos que se adquieren a empresas israelíes para reemplazarlos por otros. Con este objetivo, exige que se deje de dispensar, comprar o prescribir medicamentos de la compañía Teva, una de las más importantes del Estado sionista.\u003C\u002Fp>\n\u003Cp>No es la primera iniciativa en este sentido, ya que en mayo 200 trabajadores de Cruces pidieron la retirada de los productos de Teva.\u003C\u002Fp>\n\u003Cp>Apuntan desde LAB que Osakidetza ha comprado medicamentos a esta farmacéutica por valor de más de 7 millones de euros entre 2023 y lo que lleva de 2025.\u003Cem> «Esto debe parar y no debemos permitir que dinero público termine en manos de un Estado genocida como el israelí»\u003C\u002Fem>, sostienen.\u003C\u002Fp>\n\u003Cp>Desde el sindicato exponen que la gran mayoría de los medicamentos adquiridos por esta firma tienen alternativas en el mercado, «muchas de ellas en forma de genérico y con origen europeo».\u003C\u002Fp>\n\u003Cp>«El Servicio Público Vasco de Salud no debe colaborar con la economía del genocidio que hace posible la ocupación israelí de los territorios palestinos ocupados ilegalmente. Para ello, se deben revisar las relaciones de todo tipo, en especial las comerciales, ya que son esas relaciones las que financian la ocupación de palestina y el genocidio de su pueblo», defiende LAB.\u003C\u002Fp>\n\u003Cp>\u003Cem>Añaden que profesionales y pacientes deben ser conscientes de que cuando se prescribe o consume un medicamento de la farmacéutica Teva «estamos financiando el genocidio».\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fel-servicio-navarro-de-salud-deja-de-comprar-medicamentos-de-teva-the-navarre-health-service-spain-stop-buying-israel-drugs-esp-eng\">\u003Cstrong>En Osasunbidea (Servicio Navarro de Salud) se han dado pasos\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>El sindicato ha indicado que en Osasunbidea ya han comenzado a adoptar medidas, como las que solicitan ahora para Osakidetza, por lo que entienden que «es posible y es necesario».\u003C\u002Fp>\n\u003Cp>Por ello, este jueves, mediante una petición escrita y el viernes de manera presencial en la mesa sectorial de Osakidetza, van a solicitar la adopción de medidas que «busquen mantener a Osakidetza fuera de los entes financiadores del genocidio palestino», cuestión que para LAB es de suma gravedad.\u003C\u002Fp>\n\u003Cp>Asimismo, anuncian que presentarán iniciativas en todos los órganos de representación de la plantilla en las OSIs [organizaciones sanitarias públicas prácticas] para impedir que el genocidio palestino tenga en Osakidetza un colaborador.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Sobre Osakidetza\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Osakidetza-Servicio Vasco de Salud es el organismo creado en 1984 por encargado del sistema de prestaciones sanitarias públicas en la comunidad autónoma del País Vasco, Euskadi, España. Cuenta con 50.000 profesionales para atender a una población de 2.200.000 personas.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Sobre el sindicato LAB\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Las siglas LAB son el acrónimo de “Langile Abertzaleen Batzordeak” (\"Comités de Trabajadores Abertzales\") en Euskara o lengua vasca. LAB es una central o sindicato que se creó en 1974, en Hegoalde (Territorio Vasco dentro del Estado Español), en la clandestinidad y en plena lucha contra el franquismo, y que en el año 2000 se extendió a Iparralde (País Vasco norte, en territorio del estado Francés) , a petición de las trabajadoras y los trabajadores de esa zona del Euskal Herria Pais Vasco. \u003C\u002Fp>\n\u003Cp>LAB a nivel internacional forma parte de la Federación Sindical Mundial (FSM) y del secretariado de su Oficina Regional Europea (Eurof) desde 2004. Igualmente, desde el año 2010 forma parte del Consejo Regional Presidencial de la FSM, su máximo órgano de dirección.\u003C\u002Fp>\n\u003Cp>En la actualidad, el sindicato cuenta con mas de 42.000 afiliaciones, y más de 4.400 representantes en diferentes centros de trabajo. Es un sindicato confederal, que desarrolla su trabajo en todos los sectores de la economía. LAB ostenta un grado de representatividad de más de alrededor del 19% siendo actualmente el segundo sindicato principal de Euskadi.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv id=\"ow12\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fwww.archyde.com\u002Flab-demands-osakidetza-to-explore-alternatives-to-israeli-tevas-medicines-euskal-herria\u002F\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Basque union LAB demands that the Basque Health Service, Osakidetza, explore alternatives to medications from the Israeli company Teva. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The LAB union has urged Osakidetza's management, as is already being done at Osasunbidea (the Navarre Health Service), to stop purchasing pharmaceutical products from the Israeli company Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">\"We must not allow public money to end up in the hands of a genocidal state,\" the union maintains.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The LAB union has formally requested in writing that Osakidetza's management explore alternatives to the products purchased from Israeli companies and replace them with others.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">To this end, it demands that medications from Teva, one of the largest companies in the Zionist state, no longer be dispensed, purchased, or prescribed.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This is not the first initiative of its kind, as in May, 200 workers at Cruces Hospital requested the withdrawal of Teva products.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The LAB union points out that Osakidetza (the Basque Health Service) has purchased over €7 million worth of medications from this pharmaceutical company between 2023 and the present day. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"This must stop, and we cannot allow public money to end up in the hands of a genocidal state like Israel,\" they maintain.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> The union explains that the vast majority of the medications acquired by this company have alternatives on the market, \"many of them generics and of European origin.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">\"The Basque Public Health Service must not collaborate with the genocidal economy that enables the Israeli occupation of the illegally occupied Palestinian territories. To this end, all types of relationships, especially commercial ones, must be reviewed, since it is these relationships that finance the occupation of Palestine and the genocide of its people,\" LAB argues.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">They add that professionals and patients must be aware that when a medication from the pharmaceutical company Teva is prescribed or consumed, \"we are financing genocide.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fel-servicio-navarro-de-salud-deja-de-comprar-medicamentos-de-teva-the-navarre-health-service-spain-stop-buying-israel-drugs-esp-eng\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Steps have been taken at Osasunbidea (Navarre Health Service). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The union has indicated that Osasunbidea has already begun to adopt measures, similar to those they are now requesting for Osakidetza (the Basque Health Service), and therefore they believe that \"it is both possible and necessary.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For this reason, this Thursday, through a written request, and on Friday in person at the Osakidetza sectoral committee meeting, they will request the adoption of measures that \"seek to keep Osakidetza out of the entities that finance the Palestinian genocide,\" a matter that LAB considers extremely serious.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">They also announce that they will present initiatives in all staff representative bodies within the Integrated Health Organizations (OSIs) to prevent the Palestinian genocide from having a collaborator in Osakidetza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>About Osakidetza\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Osakidetza—the Basque Health Service—is the organization created in 1984 responsible for the public healthcare system in the autonomous community of the Basque Country, Euskadi, Spain.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">It has 50,000 professionals to serve a population of 2,200,000.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">About the LAB union \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The acronym LAB stands for “Langile Abertzaleen Batzordeak” (“Basque Workers' Committees”) in Basque.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">LAB is a labor union that was created in 1974 in Hegoalde (the Basque Country within Spain), clandestinely and during the struggle against the Franco regime. In 2000, it expanded to Iparralde (the Northern Basque Country, in French territory) at the request of workers in that area of ​​the Basque Country.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">LAB, at the international level, is part of the World Federation of Trade Unions (WFTU) and the secretariat of its European Regional Office (Eurof) since 2004. It has also been part of the WFTU's Regional Presidential Council, its highest governing body, since 2010. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Currently, the union has over 42,000 members and more than 4,400 representatives in various workplaces.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">It is a confederal union, working across all sectors of the economy.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">LAB holds a representation rate of over 19%, making it the second largest union in the Basque Country.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","lab-sindicato-vasco-pide-no-comprar-teva-lab-basque-union-demands-not-to-buy-teva-esp-eng","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1762016589\u002Fgcldejimy8jdsogmrvnl.jpg","mhghwfvdjt9bdi1qkj","B1dM0nUV99E","LAB, sindicato vasco, pide no comprar Teva. LAB, Basque union, demands not to buy Teva. ESP ENG",{"subtitle":361,"link":12,"user":13,"tags":362,"timestamp":363,"content":364,"type":7,"imageUrl":365,"slug":366,"videoUrl":367,"title":368,"id":369},"Los contratos terminan en septiembre, noviembre y enero. Some of these contracts expire in September, others in November, and others in January",[15],1762109434166,"\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.eldiario.es\u002Fasturias\u002Fservicio-salud-asturias-deja-comprar-medicamentos-farmaceutica-israeli-teva_1_12777026.amp.html\">\u003Cstrong>ACTUALIZACIÓN 18 nov 2025: \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp class=\"article-text\">Hasta el momento se han finalizado dos contratos, uno el 30 de septiembre, cuando se cumplía la cuarta y última prórroga para el suministro de uno de los principios activos que fabrica la multinacional israelí, y otra el pasado día 14, al vencer otra adjudicación al Hospital Universitario Central de Asturias (HUCA) y no haberse comunicado la prórroga.  El 31 de enero y el 31 de julio del próximo año vencen los contratos de otros dos medicamentos para los que hay alternativas en el mercado, por lo que no se aplicarán las prórrogas.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Vea también: 20 sept 2025: \u003C\u002Fstrong>Asturias, España: todos unidos para evitar Teva. Asturias, Spain: all united to avoid Teva ESP ENG Médicos de familia, neurólogos, sociedad civil, políticos...Family doctors, neurologists, civil society, politicians...https:\u002F\u002F\u003Ca class=\"text-entity-link word-break-all\" dir=\"auto\" title=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fasturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng\" href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fasturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng\" target=\"_blank\" rel=\"noopener noreferrer\" data-entity-type=\"MessageEntityUrl\">hw4p.es\u002Fblog\u002Fasturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.consalud.es\u002Fautonomias\u002Fasturias\u002Fbarbon-renuncia-a-las-prorrogas-de-los-contratos-con-la-farmaceutica-israeli-teva-pharma.html\">\u003Cstrong>Adrián Barbón (Presidente del Gobierno de Asturias, España, Comunidad Autónoma con 1.100.000 habitantes) se compromete a romper los contratos con la farmacéutica israelí Teva Pharma\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cem>Algunos de estos contratos vencen en septiembre, otros en noviembre y otros en enero, según ha anunciado Adrián Barbón.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Ander Azpiroz. Publicado el \u003Cstrong>25 de septiembre de 2025\u003C\u002Fstrong> a las 13:38\u003C\u002Fp>\n\u003Cp>El presidente del Principado de Asturias, Adrián Barbón, ha señalado este miércoles su agradecimiento al portavoz de IU-Convocatoria y socio de gobierno, Xabel Vegas, por su \"posicionamiento de estabilidad\", al considerar que \"es importantísimo en el tiempo en el que vivimos\". Además, coincidió con él en la necesidad de avanzar en la ruptura de los contratos con la farmacéutica israelí Teva Pharma.\u003C\u002Fp>\n\u003Cp>Barbón ha realizado estas declaraciones en respuesta a Vegas durante la segunda jornada del Debate de Orientación Política. En su intervención, ha confirmado la coincidencia con IU-Convocatoria en cuanto a no prorrogar los acuerdos con Teva Pharma y ha manifestado su \"compromiso cierto\" de suspender cualquier extensión contractual con la compañía.\u003C\u002Fp>\n\u003Cp>\"Planteó usted romper el vínculo con las farmacéuticas de Israel y, en honor a la verdad, también Covadonga Tomé lo planteó el otro día públicamente, y le digo que estamos estudiando hacerlo porque no es tan fácil. Jurídicamente necesitamos dar unos pasos\", ha señalado el presidente de Asturias.\u003C\u002Fp>\n\u003Cp>\"Estamos estudiando romper el vínculo con las farmacéuticas de Israel porque no es tan fácil. Jurídicamente necesitamos dar unos pasos\"\u003C\u002Fp>\n\u003Cp>\"Lo que sí hemos tomado la decisión de que todas las prórrogas que había posibilidad de ellas en los contratos con la empresa farmacéutica israelí, todas ellas hemos renunciado a hacerlas. De hecho, la consejera [Concepción Saavedra] ha dirigido una carta a la empresa para decir que no vamos a renovar ni una sola de los contratos que tenemos con esta empresa\", ha explicado Barbón, detallando que algunos contratos vencen en septiembre, otros en noviembre y otros en enero.\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.lavozdeasturias.es\u002Fnoticia\u002Fasturias\u002F2025\u002F09\u002F18\u002Fconsejeria-salud-principado-asturias-analizara-contrato-farmaceutica-israeli-teva\u002F00031758209722129813350.htm\">\u003Cem>La respuesta de Salud llega después de que la diputada del Grupo Mixto y portavoz de Somos Asturies, Covadonga Tomé, registrase en la Junta General del Principado de Asturias una proposición no de ley que pide al Gobierno asturiano que resuelva de manera inmediata todos los contratos que puedan existir «con empresas que, directa o indirectamente, realicen actividades comerciales o económicas en asentamientos ilegales en territorios palestinos ocupados».\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>José Coto. 18 de septiembre de 2025\u003C\u002Fp>\n\u003Cp>Según informó Tomé, eso incluye a la farmacéutica Teva, con la que mantiene contratos el Servicio de Salud del Principado de Asturias (Sespa).\u003C\u002Fp>\n\u003Cp>Covadonga Tomé acusó a Teva de ser «cómplice del genocidio en Palestina» y dijo que el Sespa ya ha destinado aproximadamente dos millones de euros en los últimos dos años a comprarle productos. «No podemos permitir que ni un solo euro de dinero público se vaya a una empresa que sostiene y es cómplice de la masacre del pueblo palestino», aseguró.\u003C\u002Fp>\n\u003Cp>La iniciativa registrada por Tomé pide, además, implementar de manera inmediata medidas en la contratación que «eviten que empresas que, directa o indirectamente, realicen actividades comerciales o económicas en asentamientos ilegales en territorios palestinos ocupados puedan presentarse a las nuevas licitaciones».\u003C\u002Fp>\n\u003Cp>Reclama, asimismo, al Gobierno asturiano que inste al Gobierno de España a tomar cuantas medidas sean necesarias para que no opten a la contratación pública empresas que realicen actividades comerciales o económicas, de manera directa o indirecta, en asentamientos ilegales en territorios palestinos ocupados, así como la rescisión de contratos con tales empresas, informa Europa Press.\u003C\u002Fp>\n\u003Cp>Tomé argumentó su posición con referencias a resoluciones internacionales que declaran ilegales los asentamientos israelíes, así como a la directiva europea sobre contratación pública, que permite considerar cuestiones de derechos humanos en procedimientos públicos. «La Corte Internacional de Justicia ha señalado que los Estados que mantienen relaciones económicas con estos asentamientos son cómplices de su expansión», indicó.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">UPDATE November 18, 2025: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">To date, two contracts have ended: one on September 30, when the fourth and final extension for the supply of one of the active ingredients manufactured by the Israeli multinational expired, and another on the 14th, when another contract with the Central University Hospital of Asturias (HUCA) expired without notification of an extension.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The contracts for two other medications, for which there are alternatives on the market, expire on January 31 and July 31 of next year, and therefore extensions will not be applied.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>See also: 20 Sep 2025: Asturias, España: todos unidos para evitar Teva.\u003Cstrong data-entity-type=\"MessageEntityBold\"> Asturias, Spain: all united to avoid Teva ESP ENG \u003C\u002Fstrong>Médicos de familia, neurólogos, sociedad civil, políticos...\u003Cstrong data-entity-type=\"MessageEntityBold\">Family doctors, neurologists, civil society, politicians...\u003C\u002Fstrong>https:\u002F\u002F\u003Ca class=\"text-entity-link word-break-all\" dir=\"auto\" title=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fasturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng\" href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fasturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng\" target=\"_blank\" rel=\"noopener noreferrer\" data-entity-type=\"MessageEntityUrl\">hw4p.es\u002Fblog\u002Fasturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Adrián Barbón (President of the Government of Asturias, Spain, an Autonomous Community with 1,100,000 inhabitants) pledges to terminate contracts with the Israeli pharmaceutical company Teva Pharma \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Some of these contracts expire in September, others in November, and others in January, as announced by Adrián Barbón \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Ander Azpiroz Published on September 25, 2025 at 1:38 PM \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The President of the Principality of Asturias, Adrián Barbón, expressed his gratitude this Wednesday to the spokesperson for IU-Convocatoria and coalition partner, Xabel Vegas, for his \"stance of stability,\" considering it \"crucial in these times.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">He also agreed with Vegas on the need to move forward with terminating the contracts with the Israeli pharmaceutical company Teva Pharma.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Barbón made these statements in response to Vegas during the second day of the Policy Debate.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In his address, he confirmed his agreement with IU-Convocatoria regarding not extending the agreements with Teva Pharma and expressed his \"firm commitment\" to suspending any contractual extensions with the company.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"You raised the issue of severing ties with Israeli pharmaceutical companies, and, to be honest, Covadonga Tomé also raised it publicly the other day. I can tell you that we are studying the possibility of doing so because it's not so simple. Legally, we need to take some steps,\" the President of Asturias stated.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"We are considering severing ties with the Israeli pharmaceutical companies because it's not so simple. Legally, we need to take certain steps.\" \"What we have decided is that we have waived all possible extensions to the contracts with the Israeli pharmaceutical company. In fact, the regional minister [Concepción Saavedra] has sent a letter to the company stating that we will not renew a single one of our contracts with them,\" Barbón explained, specifying that some contracts expire in September, others in November, and others in January.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The response from the Health Department comes after Covadonga Tomé, a member of the Mixed Group and spokesperson for Somos Asturies, submitted a non-binding motion to the General Assembly of the Principality of Asturias calling on the Asturian government to immediately terminate all existing contracts \"with companies that, directly or indirectly, carry out commercial or economic activities in illegal settlements in occupied Palestinian territories.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">José Coto, 18 September 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to Covadonga Tomé, this includes the pharmaceutical company Teva, with which the Health Service of the Principality of Asturias (Sespa) has contracts.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tomé accused Teva of being \"complicit in the genocide in Palestine\" and stated that Sespa has already spent approximately two million euros in the last two years purchasing products from them.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"We cannot allow a single euro of public money to go to a company that supports and is complicit in the massacre of the Palestinian people,\" she asserted.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The initiative registered by Tomé also calls for the immediate implementation of measures in public procurement that \"prevent companies that directly or indirectly conduct commercial or economic activities in illegal settlements in occupied Palestinian territories from bidding on new tenders.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It also demands that the Asturian government urge the Spanish government to take all necessary measures to prevent companies that conduct commercial or economic activities, directly or indirectly, in illegal settlements in occupied Palestinian territories from participating in public procurement processes, as well as the termination of contracts with such companies, Europa Press reports.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tomé argued his position with references to international resolutions declaring Israeli settlements illegal, as well as to the European directive on public procurement, which allows for the consideration of human rights issues in public procedures.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"The International Court of Justice has indicated that states that maintain economic relations with these settlements are complicit in their expansion,\" he stated.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1762109068\u002Fxqqpejeoigh5qnyiyp7r.png","asturias-espana-no-renovara-los-contratos-con-teva-asturias-spain-terminates-contracts-with-teva-esp-eng","9wkdxHJV8LQ","Asturias (España) no renovará los contratos con Teva. Asturias (Spain) terminates contracts with Teva. ESP ENG","mhi1i1rbqmwnjjn4ddd",{"tags":371,"user":13,"imageUrl":372,"link":12,"content":373,"videoUrl":374,"title":375,"id":376,"subtitle":377,"timestamp":378,"slug":379,"type":7},[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763134862\u002Fdkpb7oc5mfzu7bcb13np.png","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>España, Teva, 2025: vuelve la Inquisición de manos del sionismo. Granada, España. Pablo Simón (de HW4PS, Health Workers For Palestine, Spain) contra Teva.\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Intento de censura sionista contra los derechos humanos.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>El Colegio de Médicos de Granada está estudiando \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fpablo-simon-hw4ps-versus-teva-por-favor-manda-un-correo-e-al-colegio-de-medicos-de-granada-please-send-an-e-mail-to-colegio-oficial-medicos-granada-spain-esp-eng\">una queja \u003C\u002Fa>presentada el 11 de noviembre de 2025 por una entidad sionista autodenominada \"Comisión Sanitaria contra el Antisemitismo, de la Coordinadora Estatal de Lucha contra el Antisemitismo\", en la que protesta por el hecho de que un médico de Granada, España (Pablo Simón Lorda, médico rural, especialista en Medicina de Familia, ejerce en Chauchina, experto en ética médica) haya emitido una receta que incluye una advertencia para los farmacéuticos, en la que les pide que no dispensen medicinas de un Teva, por ser una empresa israelí que financia el apartheid y el genocidio en Palestina por Israel.\u003C\u002Fp>\n\u003Cp>El Colegio granadino indicó se valorará el asunto cuando se reúna la Junta Directiva, el lunes 17 de noviembre, y se tomará una decisión al respecto.\u003C\u002Fp>\n\u003Cp>El médico en cuestión compartió en su red social X una captura de pantalla de una receta digital que incluía la advertencia para los farmacéuticos, acompañada de un texto en el que se puede leer: «Desde Andalucía me sumo al boicot a Teva que plantea HW4PalestinaSpain. Hacer prescripción responsable contra el genocidio en Gaza es una obligación ética de cualquier profesional sanitario».\u003C\u002Fp>\n\u003Cp>En la misma red, el doctor muestra otras imágenes en las que es crítico con el genocidio. Incluye también un email enviado a su colegio profesional en abril en el que solicitaba un «pronunciamiento público» a la institución «ante las incalculables consecuencias en salud que se están produciendo en el genocidio en curso de Israel frente a la población palestina y la destrucción deliberada del sistema sanitario».\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Pablo Simón Lorda ejerce su profesión médica con pasión, ciencia, conciencia, coraje y ternura, y defiende posturas éticas comprometidas con los derechos humanos.\u003C\u002Fstrong> Por ejemplo, con la publicación en el verano de 2025, en la revista AMF (Actualización en Medicina de Familia, de la Sociedad Española de Medicina de Familia, SEMFYC), de un artículo titulado:\u003Cem> \u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Famf-semfyc.com\u002Fes\u002Fweb\u002Farticulo\u002Feti\">\u003Cem>\"Ética médica y genocidio en Gaza. Los retos para los profesionales y sus organizaciones\"\u003C\u002Fem> \u003C\u002Fa>cuyo RESUMEN es:\u003C\u002Fp>\n\u003Cp>\"El genocidio actualmente en curso en Gaza supone un reto moral de primer orden. Existen diferentes actitudes posibles ante los conflictos morales: una es la negación de su relevancia (adiáfora), otra es la del escape autoexculpatorio usando diferentes tipos de justificación. Ninguna de estas actitudes es aceptable para el o la profesional de la salud, dada la relevancia social que tiene precisamente por su definición como «profesional».\u003C\u002Fp>\n\u003Cp>Cualquier profesional de la medicina tiene, en primer lugar, las obligaciones morales que derivan de su condición de persona y que están vinculadas al respeto a la Carta Internacional de Derechos Humanos. Pero, además, tiene las obligaciones específicas derivadas de sus códigos de ética médica y deontología. Todas estas obligaciones han sido puestas en jaque por las actuaciones del gobierno israelí en su represión de la población de Gaza tras el ataque de Hamás del 7 de octubre de 2023. Dichas actuaciones son etiquetables como genocidio. \u003C\u002Fp>\n\u003Cp>La tolerancia que han mostrado la mayoría de los países occidentales ante esa bárbara actuación genera un reto moral sin precedentes desde el final de la Segunda Guerra Mundial. Los médicos y las médicas, especialmente los especialistas en Medicina de Familia y Comunitaria, estamos llamados a ser un punto de resistencia ante esta gravísima situación\".\u003C\u002Fp>\n\u003Cp>\u003Cstrong>CV\u003C\u002Fstrong>\u003Cbr>Pablo Simón Lorda estudió medicina, MD, en la Facultad de Santiago de Compostela (Galicia, España, 1983-89), donde obtuvo el grado de Doctor en Medicina, PhD, en 1996 con sobresaliente cum laude. Realizó la residencia en Medicina de Familia en Madrid y obtuvo el título de especialista en 1993. Es magister en bioética (Universidad Complutense de Madrid) y en administración y dirección de servicios sanitarios (Universidad Pompeu Fabra de Barcelona). Fue profesor de la Escuela Andaluza de Salud Pública de 2004 a 2010. En 2008 tuvo una estancia de dos meses en el Ethox Centre del Departamento de Salud Pública y Atención Primaria de la Universidad de Oxford, Reino Unido. En la actualidad es médico en Chauchilla (pueblo de 6.000 habitantes, del Área Metropolitana de Granada). Es fundador y miembro activo de Profesionales de la Sanidad por Palestina, desde octubre de 2024.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>NOTA\u003C\u002Fstrong>\u003Cbr>Probablemente Teva está notando el impacto nacional e internacional \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\">del boicot \u003C\u002Fa>que promueve Health Workers For Palestine, Spain, y de ahí el intento de amedrentamiento de Pablo Simón Lorda. También para asustar a posibles profesionales que se sumen al boicot. De ahí la importancia de apoyar a Pablo Simón Lorda.\u003C\u002Fp>\n\u003Cp>A destacar la movilización instantánea de la \u003Ca href=\"https:\u002F\u002Fwww.lavanguardia.com\u002Flocal\u002Fandalucia\u002F20251113\u002F11258845\u002Ftsunami-apoyos-medico-granada-niega-recetar-farmacos-israelies.html\">Asociación Pro Derechos Humanos de Andalucía (APDHA) que logró en unas horas el apoyo a Pablo Simón Lorda \u003C\u002Fa>de más de 160 organizaciones de derechos humanos, que se amplió a 400 en un día (\"un tsunami\").\u003C\u002Fp>\n\u003Cp>En apoyo a Pablo Simón y su compromiso ético (Teva no)\u003Cbr>\"Son precisamente su compromiso y sus valores profesionales los que le llevaron a implicarse en la denuncia a través especialmente de HW4PS (Profesionales de la Sanidad por Palestina, España)\"\u003Cbr>\u003Ca class=\"text-entity-link word-break-all\" dir=\"auto\" title=\"https:\u002F\u002Fgerentedemediado.blogspot.com\u002F2025\u002F11\u002Fen-apoyo-al-compromiso-etico-de-pablo.html\" href=\"https:\u002F\u002Fgerentedemediado.blogspot.com\u002F2025\u002F11\u002Fen-apoyo-al-compromiso-etico-de-pablo.html\" target=\"_blank\" rel=\"noopener noreferrer\" data-entity-type=\"MessageEntityUrl\">https:\u002F\u002Fgerentedemediado.blogspot.com\u002F2025\u002F11\u002Fen-apoyo-al-compromiso-etico-de-pablo.html\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Spain, Teva, 2025: The Inquisition returns at the hands of Zionism.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Granada, Spain.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Pablo Simón (HW4PS, Health Workers For Palestine, Spain) against Teva.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Zionist attempt at censorship against human rights.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Granada Medical Association (Colegio Oficial de Médicos de Granada, Spain) is reviewing \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fpablo-simon-hw4ps-versus-teva-por-favor-manda-un-correo-e-al-colegio-de-medicos-de-granada-please-send-an-e-mail-to-colegio-oficial-medicos-granada-spain-esp-eng\">a complaint \u003C\u002Fa>filed on November 11, 2025, by a Zionist organization calling itself the \"Health Commission Against Antisemitism, of the State Coordinator for the Fight Against Antisemitism.\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The complaint protests the fact that a doctor in Granada, Spain (Pablo Simón Lorda, a rural physician specialist in Family Medicine, practicing in Chauchina, and an expert in medical ethics) issued a prescription that included a warning to pharmacists, instructing them not to dispense medications from Teva, because it is an Israeli company that finances apartheid and genocide in Palestine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Granada Medical Association (Colegio Oficial de Médicos) indicated that the matter will be assessed at the Board of Directors meeting on Monday, November 17, and a decision will be made.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The doctor in question shared a screenshot on his social media account of a digital prescription that included a warning for pharmacists, accompanied by text that reads: “From Andalusia, I join the boycott of Teva proposed by HW4PalestinaSpain. Prescribing responsibly against the genocide in Gaza is an ethical obligation of every healthcare professional.”\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">On the same platform, the doctor shared other images in which he is critical of the genocide.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">He also included an email sent to his professional association in April requesting a “public statement” from the institution “regarding the incalculable health consequences of Israel’s ongoing genocide against the Palestinian population and the deliberate destruction of the healthcare system.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Pablo Simón Lorda practices his medical profession with passion, science, conscience, courage and tenderness, and defends ethical positions committed to human rights.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For example, with the publication in the summer of 2025, in the journal AMF (Update in Family Medicine, of the Spanish Society of Family Medicine, SEMFYC), of an article entitled: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>\u003Ca href=\"https:\u002F\u002Famf-semfyc.com\u002Fes\u002Fweb\u002Farticulo\u002Feti\">\"Medical Ethics and Genocide in Gaza: Challenges for Professionals and Their Organizations\"\u003C\u002Fa> \u003C\u002Fstrong>whose ABSTRACT is: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"The ongoing genocide in Gaza poses a moral challenge of the highest order. There are different possible attitudes toward moral conflicts: one is the denial of its relevance (adiaphora), another is self-exculpatory escape using different types of justification. Neither of these attitudes is acceptable for healthcare professionals, given the social relevance they have precisely because of their definition as 'professionals.'\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Any medical professional has, first and foremost, the moral obligations that derive from their status as a person and that are linked to respect for the International Bill of Human Rights. But, in addition, they have the specific obligations derived from their codes of medical ethics and professional conduct. All these obligations have been jeopardized by the actions of the government.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Israeli repression of the Gaza population following the Hamas attack of October 7, 2023, constitutes genocide.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> The tolerance shown by most Western countries toward this barbaric action poses an unprecedented moral challenge since the end of World War II.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We, as physicians, especially family and community medicine specialists, are called upon to be a point of resistance in the face of this extremely serious situation\".\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">CV \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">Pablo Simón Lorda studied medicine (MD) at the University of Santiago de Compostela (Galicia, Spain, 1983-89), where he earned his PhD in 1996 with highest honors (summa cum laude). He completed his residency in Family Medicine in Madrid and obtained his specialist certification in 1993. He holds a Master's degree in Bioethics (Complutense University of Madrid) and in Health Services Administration and Management (Pompeu Fabra University of Barcelona). He was a professor at the Andalusian School of Public Health from 2004 to 2010.  In 2008, he spent two months at the Ethox Centre of the Department of Public Health and Primary Care at the University of Oxford, United Kingdom. He currently practices medicine in Chauchilla (a town of 6,000 inhabitants in the Granada Metropolitan Area). He is a founder and active member of Healthcare Professionals for Palestine, since October 2024.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"HwtZe\" lang=\"en\">NOTE \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"HwtZe\" lang=\"en\">Teva is likely aware of the national and international impact of\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\"> the boycott promoted\u003C\u002Fa> by Health Workers For Palestine, Spain, and this explains the attempt to intimidate Pablo Simón Lorda. It's also intended to scare off potential professionals who might join the boycott. This underscores the importance of supporting Pablo Simón Lorda.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"HwtZe\" lang=\"en\">Of particular note is the instant \u003Ca href=\"https:\u002F\u002Fwww.lavanguardia.com\u002Flocal\u002Fandalucia\u002F20251113\u002F11258845\u002Ftsunami-apoyos-medico-granada-niega-recetar-farmacos-israelies.html\">mobilization of the Andalusian Association for Human Rights (APDHA), which in a few hours secured the support\u003C\u002Fa> of more than 160 human rights organizations for Pablo Simón Lorda, a number that increased to 400 in a single day (\"a tsunami\").\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","rmccxTG93e4","España, Teva, 2025: vuelve la Inquisición de manos del sionismo. Spain, Teva, 2025: The Inquisition returns at the hands of Zionism. ESP ENG","mhz0quwqzryz9lj734","Intento de censura sionista contra los derechos humanos. Granada. Pablo Simón versus Teva. Zionist attempt at censorship against human rights.  Granada, Pablo Simón (HW4PS) versus Teva.",1763138304573,"espana-teva-2025-vuelve-la-inquisicion-de-manos-del-sionismo-spain-teva-2025-the-inquisition-returns-at-the-hands-of-zionism-esp-eng",{"imageUrl":381,"slug":382,"type":7,"content":383,"timestamp":384,"videoUrl":385,"title":386,"subtitle":387,"id":388,"user":13,"tags":389,"link":12},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763407871\u002Fcmjak2pmqphyrjjc3vkz.png","boycott-teva-boycott-ajovy-boicot-teva-boicot-ajovy-eng-esp","\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cspan lang=\"en-US\">Boycott Teva, boycott Ajovy (a medication that offers nothing new to \"prevent\" migraine attacks) \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Health Workers for Palestine, Spain HW4PS\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fhw4p.es\u002F hcw4palestinespain@gmail.com \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cspan lang=\"en-US\">Why boycott Teva and Ajovy? \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Teva is an Israeli pharmaceutical company that earned $16.4 billion in 2024. It is a corrupt and corrupting company, with billions of dollars in convictions and fines for various criminal acts, in some cases even resulting in deaths (for example, with the overuse of opiates in the United States), 1. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Teva serves as a source of income for Israel, which thus allows it to commit and sustain apartheid and genocide in Palestine, 2. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">In Spain, Teva's three best-selling drugs in primary care are omeprazole, atorvastatin, and pantoprazole, which is why Health Workers for Palestine, Spain (HW4PS) is promoting a boycott and their replacement with equivalent drugs, 3.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">In hospitals, the best-selling drug is Ajovy, prescribed by hospital specialists and dispensed by hospital pharmacies. Hence this specific boycott proposal.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cspan lang=\"en-US\">Ajovy offers nothing new\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">The French journal Prescrire is probably the best pharmacotherapeutic bulletin in the world. In 2020, its assessment of fremanezumab (Ajovy) concluded with \"It offers nothing new\"iv (literally, \"N'apporte rien de nouveau\") in the \"prevention\" of migraine, 4. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">It should be corrected to say “It offers nothing new and beneficial” since it has the adverse effects of other drugs in its class, ranging from constipation and muscle pain to Raynaud's syndrome (adverse effects that are only partially known given its recent introduction to the market), 5, 6. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cspan lang=\"en-US\">Ajovy, mechanism of action \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Ajovy is a monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor, blocking the action of this neuropeptide,7,8. CGRP is located throughout the nervous system, but is concentrated in the perivascular sensory afferents of the trigeminal nerve and its caudal nucleus. CGRP, which has a vasodilatory effect, appears to be involved in the onset of migraine attacks. Gepants, CGRP inhibitor drugs, are used in the “prevention” of migraine attacks. Ajovy is produced in Chinese hamster ovary cells using recombinant DNA technology,9.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cspan lang=\"en-US\">A\u003C\u002Fspan>\u003Cspan lang=\"en-US\">nti-CGRPs \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Among the anti-CGRPs, erenumab (Aimovig° - Novartis Pharma), fremanezumab (Ajovy° - Teva Santé), and galcanezumab (Emgality° - Lilly) are administered subcutaneously; eptinezumab (Vyepti° - Lundbeck) is administered intravenously; and rimegepant (Vydura° - Pfizer) and atogepant (Aquipta – AbbVie) are both administered orally. Rimegepant is the only anti-CGRP also authorized for the treatment of migraine attacks. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">All of them present problems of excessive price not adjusted to effectiveness,10. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Inhibition of the vasodilatory action of CGRP creates uncertainty regarding the safety of these drugs in the cardiovascular system of patients with present or latent cardiovascular disease, due to the potential worsening of ischemic events such as stroke, transient ischemic attack, or myocardial infarction, and the possible risk of eclampsia during pregnancy. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cspan lang=\"en-US\">Use in practice \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">The French National Authority for Health (HAS), in 2025, clarified that: “To date, the superiority of anti-CGRP antibodies (including fremanezumab) in terms of efficacy compared to other prophylactic treatments has not been demonstrated.”, 11.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">There are no differences in efficacy in the use of eptinezumab, galcanezumab, fremanezumab, and erenumab in chronic migraine, 12. However, it appears that eptinezumab (Vyepti) may reduce migraine days more than fremanezumab (Ajovy) due to its better affinity and specificity when binding to the calcitonin gene-related peptide receptor (CGRP), 13.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">As summarized in the Navarre Pharmacotherapeutic Information Bulletin, similarly to the UK's NICE guidelines and the Spanish Therapeutic Positioning guidelines 14,15,16: \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">“\u003Cspan lang=\"en-US\">Anti-CGRP monoclonal antibodies represent a new treatment alternative for patients with eight or more migraine days per month who have experienced three or more treatment failures over at least three months, including the administration of botulinum toxin A in the case of chronic migraine. These antibodies show modest efficacy compared to placebo, and there are no comparative studies against standard therapies. Caution should also be exercised in patients with a history of cardiovascular disease.”\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">The Bulletin highlighted the therapeutic effect of the placebo (almost 40%). \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Ajovy is administered subcutaneously, in 225 mg doses, as an injectable solution in a pre-filled syringe, at a price of €498 in the Spanish National Health System (a price that can be reduced by more than 50% in specific offers, as Teva negotiates with this product to gain a strong market position). In the United States, the price is $746. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>\u003Cspan lang=\"en-US\">Boycott Ajovy \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Teva presented its shareholder report in November 2025, and regarding Ajovy, it reiterated its projected earnings of around $640 million in 2025 (17). \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">Ajovy offers nothing new and, in any case, can be replaced by other anti-CGRP drugs. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">If you are a patient, refuse this treatment; do not contribute to the suffering of the Palestinian people. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">If you are a doctor, choose an alternative that does not support apartheid and genocide in Palestine by Israel.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Patricia Pozo-Reich\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">In the world of headaches, Patricia Pozo-Rosich holds a key position.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">A key opinion leader (KOL, a person elevated by industries to influence their colleagues) and neurologist at Vall d’Hebron University Hospital in Barcelona, a public hospital, she is the head of the Headache Unit at Vall d’Hebron University Hospital in Barcelona. She directs the Migraine Adaptive Brain Center and the Headache and Neurological Pain Research Group - Laboratory at the VHIR (Vall d’Hebron Research Institute), which belongs to the Autonomous University of Barcelona, 18.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">She also sees patients at the private QuirónSalud Hospital in Barcelona and is a member of the Scientific Council of the Lilly Foundation.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Patricia Pozo-Rosich received almost €32,000 from Teva in 2023 and €45,000 in 2024, in “transfers of value.” \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">In 2023, the SEN Foundation (Spanish Society of Neurology), in Barcelona, ​​received €149,645 and the Vall d'Hebron University Hospital Foundation, Research Institute, Barcelona, received €112,850, (19).\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The conflicts of interest declared by Patricia Pozo-Rosich are, for example, in the “Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache”, 20:\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">“In the last 36 months, she received fees as a consultant and speaker for: AbbVie, Amgen, Dr. Reddy's, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Pfizer, and Teva. Her research group has received research grants from Novartis, Teva, AbbVie, EraNET Neuron, RIS3CAT FEDER, AGAUR, and ISCIII; and funding for clinical trials from Amgen, Biohaven, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva.”\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">In 2024, for example, she participated in the publicity-labeled presentation of a gepant, an anti-CGRP, atogepant (Aquipta – AbbVie).\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cem>Logically, 21, such conflicts of interest invalidate all consensus statements, clinical trials, guidelines, and reviews on headaches in which Patricia Pozo-Reich has participated, is participating, or will participate.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>NOTE:\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In Spain, as we mentioned, Patricia Pozo Rosich, a neurologist at Vall d'Hebron Hospital in Barcelona, ​​stands out.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">She received €77,000 directly from Teva in what they call \"transfers of value,\" totaling €77,000 in 2023 and 2024. The Vall d'Hebron University Hospital Foundation, Research Institute, also in Barcelona, ​​received €138,000.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> It should be noted that the Vall d'Hebron University Hospital Foundation (VHIR) has the aforementioned neurologist Patricia Pozo Rosich as vice president of its Internal Scientific Committee and Ronit Satchi-Fainaro, an Israeli from Tel Aviv, on its External Scientific Committee. Satchi-Fainaro is a member of Teva's Board of Directors (a fact omitted from her curriculum vitae on the VHIR website).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv>\u003Cspan style=\"font-size: large;\"> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"font-family: helvetica; font-size: large;\">-Scientific Internal Committee VHIR\u003Cbr>\u003Ca href=\"https:\u002F\u002Fvhir.vallhebron.com\u002Fes\u002Finstituto\u002Forganos-de-gobierno\u002Fcomite-cientifico-interno\">https:\u002F\u002Fvhir.vallhebron.com\u002Fes\u002Finstituto\u002Forganos-de-gobierno\u002Fcomite-cientifico-interno\u003C\u002Fa>\u003Cbr>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv>\u003Cspan style=\"font-family: helvetica; font-size: large;\">\u003Cbr>-Scientific External Committee VHIR\u003Cbr>\u003Ca href=\"https:\u002F\u002Fvhir.vallhebron.com\u002Fes\u002Finstituto\u002Forganos-de-gobierno\u002Fcomite-cientifico-externo\">https:\u002F\u002Fvhir.vallhebron.com\u002Fes\u002Finstituto\u002Forganos-de-gobierno\u002Fcomite-cientifico-externo\u003C\u002Fa>\u003Cbr>\u003Cbr>\u003C\u002Fspan>\n\u003Cdiv>\u003Cspan style=\"font-family: helvetica; font-size: large;\">-Teva web\u003Cbr>Board of Directors: Prof. Ronit Satchi-Fainaro Independent Director\u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.tevapharm.com\u002Four-company\u002Fleadership-governance\u002Fboard-of-directors\u002Fprof-ronit-satchi-fainaro\u002F\">https:\u002F\u002Fwww.tevapharm.com\u002Four-company\u002Fleadership-governance\u002Fboard-of-directors\u002Fprof-ronit-satchi-fainaro\u002F\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Much of the scientific literature on Ajovy is authored by individuals who declare conflicts of interest regarding Teva, or are directly employed by Teva (or Otsuka, the company that markets the drug in Japan), and in many cases, this literature is written by third parties and directly funded by Teva.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Some examples:\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">- US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs12325-024-03063-w#Fun\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">- This study, the journal's rapid service, and the open access fee were funded by Teva Pharmaceuticals.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">-Patrick Eugeni, Megan E. Rooney, Nicolas P. Saikali, Zhongzheng Niu, and Jennifer W. McVige are employees of the Dent Neurological Institute, which conducted this study funded by Teva Pharmaceuticals. Jennifer W. McVige has received research funding from AbbVie, Teva Pharmaceuticals, Eli Lilly, Amgen, and Lundbeck; and lecture and consulting fees from AbbVie, Teva Pharmaceuticals, Eli Lilly, Amgen, Lundbeck, Avanir, Theranica, and Amneal. Maurice T. Driessen and Lynda J. Krasenbaum are employees of Teva Pharmaceuticals. Karen Carr and Michael J. Seminerio are former employees of Teva Pharmaceuticals (current affiliation: AbbVie, North Chicago, IL, USA).\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">-Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs40273-024-01380-0\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">-This work was funded by Otsuka Pharmaceuticals Co., Ltd. The funding entity oversaw the conduct of the study and the preparation of the manuscript. Otsuka Pharmaceuticals Co., Ltd. paid the open access fee.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">-Takao Takeshima declares having received consulting fees from Otsuka, Amgen, Eli Lilly, Daiichi Sankyo, Shionogi, Bioheaven, and Lundbeck, and being an advisor to Hedgehog MedTech and Sawai. Fumihiko Sakai declares having received consulting fees from Otsuka, Amgen, Eli Lilly, and Daiichi Sankyo. Xinyu Wang worked for Otsuka Pharmaceutical Co., Ltd. during the conduct of the study and declares no conflicts of interest. Kentaro Yamato, Yoshitsugu Kojima, and Yilong Zhang work for Otsuka Pharmaceutical Co., Ltd. and declare no conflicts of interest. Otsuka Pharmaceutical Co., Ltd. marketed fremanezumab in Japan. Craig Bennison and Martijn Simons work for OPEN Health and report having received consulting fees from Otsuka. OPEN Health is a consulting firm contracted by Otsuka to conduct the study and draft the manuscript.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">-Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37987641\u002F\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">-Medical writing and editorial support for the development of this manuscript, under the authors' direction, were provided by Molly Clark, Sophie Roberts, and Olivia Morris of Ashfield MedComms, an Inizio company, and funded by Teva Pharmaceuticals.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">-The authors declare the following potential conflicts of interest with respect to the research, authorship, and\u002For publication of this article: MA declares having received personal fees and having been a principal investigator in clinical trials for AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; and research grants from the Lundbeck Foundation, the Novo Nordisk Foundation, and Novartis. DDM has received honoraria, research grants, and travel expenses from Allergan\u002FAbbVie, Amgen, Biogen, Cefaly, Genesis Pharma, Electrocore, Eli Lilly, Lundbeck, Merck-Serono, Mertz, Novartis, Roche, Sanofi, Specifar, and Teva Pharmaceuticals. He served as a principal investigator in clinical trials for Amgen, Cefaly, Electrocore, Eli Lilly, Genesis Pharma, Lundbeck, Mertz, Novartis, Specifar, and Teva Pharmaceuticals; and he is chairman of the board of the Hellenic Headache Society and co-chair of the steering group of the European Academy of Neurology's Headache Panel. FMA reports having lectured, served on advisory boards, and\u002For served as a principal investigator in clinical trials for Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals. PK, VRC, and AHA are employees and\u002For shareholders of Teva Pharmaceuticals. LL is a former employee of Teva Pharmaceuticals. CJS reports having received consulting services, participation on advisory boards, presentations, and travel funding from Novartis, Eli Lilly, Teva Pharmaceuticals, AbbVie, Allergan, Almirall, Amgen, Lundbeck, MindMed, and Grünenthal; and is a part-time employee of Zynnon. GS reports having received research funding from the Swiss Heart Foundation, the Eye on Vision Foundation, the Baasch-Medicus Foundation, and the German Migraine and Headache Society. GS reports having participated on advisory committees and\u002For been a principal investigator in clinical trials for AbbVie, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; and having received research funding from Vinnova (the Swedish innovation agency), Lund University, and the Swedish Neurological Association. PPR declares having received research grants\u002Ffunding from AbbVie, AGAUR, EraNet NEURON, the Carlos III Health Institute, MINECO, Novartis, RIS3CAT FEDER, and Teva Pharmaceuticals; and having carried out consultancies or training activities for AbbVie, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals. PJD declares having participated in training meetings and\u002For collaborated on clinical trials for Allergan\u002FAbbVie, electroCore, Novartis, Teva Pharmaceuticals, and Lundbeck. TN declares having received fees for consultancy, speaking engagements, and travel grants from Eli Lilly, Glenmark, Lundbeck, Novartis, Pfizer, St. Jude Medical, Teva Pharmaceuticals, and UCB. and have participated on advisory committees or as principal investigator in clinical trials for AbbVie, Amgen, Eli Lilly, Lundbeck, Neurocrine, Novartis, Teva Pharmaceuticals, and UCB. ACP reports having lectured, participated on advisory committees, or served as principal investigator in clinical trials for Allergan, AbbVie, Pfizer, Teva Pharmaceuticals, Novartis, Lundbeck, Eli Lilly, and Roche. IPM reports having lectured, participated on advisory committees, or served as principal investigator in clinical trials for Allergan-AbbVie, Teva Pharmaceuticals, Novartis, Lundbeck, and Eli Lilly. MLS reports having lectured, participated on advisory committees, or served as principal investigator in clinical trials for Pfizer, Teva Pharmaceuticals, Novartis, Lundbeck, AbbVie, and Eli Lilly. CT reports personal fees for participation in advisory boards or symposia for AbbVie, Dompé, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva Pharmaceuticals; reports institutional fees for conducting clinical trials for AbbVie, Dompé, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva Pharmaceuticals; received funding for research projects from the European Commission, the Italian Ministry of Health, the Migraine Research Foundation and the Italian Multiple Sclerosis Foundation.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">-A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy. https:\u002F\u002Fbmcneurol.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12883-024-03697-x ---This work was supported by Teva Pharmaceuticals.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">-SW is an employee of Asc Academics and a consultant to the MH Pronk Health Care Consultancy Foundation. -JAC has received remuneration for serving on advisory boards and for speaking engagements with Teva Pharmaceuticals, Lilly, Novartis, Lundbeck, and Pfizer. MP is the managing director of the MH Pronk Health Care Consultancy Foundation and an external consultant to Teva Netherlands B.V. KWMZ is an employee of Teva Netherlands B.V. MTD is an employee of Teva Pharmaceuticals. LL is a former employee of Teva Pharmaceuticals. MJP is a consultant to Asc Academics.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">-Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache. https:\u002F\u002Fjournals.sagepub.com\u002Fdoi\u002F10.1177\u002F03331024251318016\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">-The authors declared the following potential conflicts of interest with respect to the research, authorship, and\u002For publication of this article: P.P.R. reports having received consulting and speaking fees in the last 36 months from: AbbVie, Amgen, Dr. Reddy's, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Pfizer, and Teva. Her research group has received research grants from Novartis, Teva, AbbVie, EraNET Neuron, RIS3CAT FEDER, AGAUR, and ISCIII; and clinical trial funding from Amgen, Biohaven, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva. She is Honorary Secretary of the International Headache Society. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She is an associate editor of Cephalalgia, Headache, The Journal of Headache and Pain, Neurologia, and Revista de Neurologia. She is the founder of www.midolordecabeza.org. P.P.R. does not own shares in any pharmaceutical company. N.v.V. has no conflicts of interest. E.C. has received fees from Novartis, Chiesi, Lundbeck, and MedScape; her salary has been partially funded by the Rio Hortega Strategic Action in Health 2017–2020 and Juan Rodés 2024–2028 grants from the Carlos III Health Institute (CM20\u002F00217). She is a junior editor of Cephalalgia. G.V. has no conflicts of interest. M.T.F. has received fees from AbbVie, Novartis, Chiesi, and Teva. B.W.H.v.d.A. P.J.G. reports having received independent support from the Netherlands Research Council (849200007) and the Netherlands Brain Foundation (HA2017.01.05). P.J.G. also reports having received, during the last 36 months, a grant from Celgene; personal fees from Aeon Biopharma, Abbvie, Amgen, CoolTech LLC, Dr. Reddy's, Eli Lilly and Company, Epalex, Lundbeck, Novartis, Pfizer, Praxis, Sanofi, Satsuma, Shiratronics, Teva Pharmaceuticals, and Tremeau; personal fees for consulting through Gerson Lehrman Group, Guidepoint, SAI Med Partners, and Vector Metric; fees for educational materials from CME Outfitters; and royalties or fees for publications from the Massachusetts Medical Society, Oxford University Press, UpToDate, and Wolters Kluwer. and a patent for magnetic stimulation for headache (no. WO2016090333 A1) assigned to eNeura free of charge. M.A. declares having received fees from AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals, outside the scope of the submitted work. M.A. is also an associate editor of Brain, Cephalalgia, and The Journal of Headache and Pain. S.J.W. has served on the advisory boards of Allergan and Eli Lilly Taiwan. He has received speaking fees from the Taiwanese subsidiaries of Pfizer, Eli Lilly, and GSK, as well as research grants from the National Science and Technology Council of Taiwan, Taipei Veterans General Hospital, and the Taiwan Headache Society. H.C.D. is a member of the Clinical Guidelines Committee of the German Society of Neurology and the Clinical Trials Committee of the IHS. C.T. has received fees for participation on advisory boards and\u002For at scientific symposia for AbbVie, Dompé, Eli Lilly, Medscape, Novartis, Lundbeck, and Teva. His institution has received payments from AbbVie, Eli Lilly, Novartis, Lundbeck, and Teva for investigator-sponsored or clinical trials. G.M.T. reports receiving consulting or industry support from AbbVie, Lilly, Lundbeck, Novartis, Pfizer, Teva, and Interactive Studios BV, as well as independent support from the European Community, the Dutch Heart and Brain Foundation, the Netherlands Research Council, and Dioraphte. -Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. https:\u002F\u002Fwww.mdpi.com\u002F2076-3425\u002F14\u002F9\u002F948 -Piero Barbanti has received remuneration for consulting services, participation on a scientific advisory board, lectures, research support, and participation in clinical trialsor other activities with companies such as Abbvie, Alder, Allergan, Amgen, Angelini, Assosalute, Bayer, Biohaven, Eli Lilly, Fondazione Ricerca e Salute, GSK, Lundbeck, New Penta, Noema Pharma, Novartis, Pfizer, Organon, Teva, Visufarma, and Zambon. She is also president of the Italian Association of Headache Sufferers. Cinzia Aurilia has received travel grants from Eli Lilly, FB-Health, Lusofarmaco, and Teva, as well as fees from Novartis, Eli Lilly, and Teva. Gabriella Egeo has received travel grants and fees from Eli Lilly, Novartis, New Penta, and Ecupharma. Bianca Orlando and Giulia Fiorentini have nothing to declare.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">1.-Teva en España. Un gigante farmacéutico israelí cuyas ganancias financian en genocidio en Palestina. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">2.-\u003C\u002Fspan>The heroes of Teva. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.jpost.com\u002Fspecial-content\u002Fthe-heroes-of-teva-779380\">https:\u002F\u002Fwww.jpost.com\u002Fspecial-content\u002Fthe-heroes-of-teva-779380\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">3.-\u003C\u002Fspan>Boicot (acción directa) a Teva. Dirigida contra sus 3 \"superventas\". 1\u002F omeprazol, 2\u002F atorvastatina, 3\u002F pantoprazol. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboicot-accion-directa-a-teva-dirigida-contra-sus-3-superventas-1-omeprazol-2-atorvastatina-3-pantoprazol\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboicot-accion-directa-a-teva-dirigida-contra-sus-3-superventas-1-omeprazol-2-atorvastatina-3-pantoprazol\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">4.-\u003C\u002Fspan>Frémanezumab (Ajovy°) et prévention des crises de migraine. Rev Prescrire 2020 ; 40 (444): 731-732. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\">https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">5.-\u003C\u002Fspan>CGRP Monoclonal Antibodies (MABs): Risks and Side Effects. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fmigrainecanada.org\u002Fcgrp-monoclonal-antibodies-mabs-risks-and-side-effects\u002F\">https:\u002F\u002Fmigrainecanada.org\u002Fcgrp-monoclonal-antibodies-mabs-risks-and-side-effects\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">6.-\u003C\u002Fspan>Disproportionality analysis of Raynaud’s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41598-025-87421-w\">https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41598-025-87421-w\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">7.-\u003C\u002Fspan>CGRP inhibitors. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.drugs.com\u002Fdrug-class\u002Fcgrp-inhibitors.html\">https:\u002F\u002Fwww.drugs.com\u002Fdrug-class\u002Fcgrp-inhibitors.html\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">8.-\u003C\u002Fspan>Calcitonin Gene-Related Peptide Receptor. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fsites\u002Fbooks\u002FNBK560648\u002F\">https:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fsites\u002Fbooks\u002FNBK560648\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">9.-\u003C\u002Fspan>Ficha Técnica Ajovy 225 mg solución inyectable en jeringa precargada. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fcima.aemps.es\u002Fcima\u002Fdochtml\u002Fft\u002F1191358001\u002FFT_1191358001.html\">https:\u002F\u002Fcima.aemps.es\u002Fcima\u002Fdochtml\u002Fft\u002F1191358001\u002FFT_1191358001.html\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">10.-\u003C\u002Fspan>Antimigraineux anti-CGRP : mi-2024, un accès au prix fort en ville. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Fstrategies-de-soins\u002F487-antimigraineux-anti-cgrp-mi-2024-un-acces-au-prix-fort-en-ville\">https:\u002F\u002Fwww.prescrire.org\u002Fstrategies-de-soins\u002F487-antimigraineux-anti-cgrp-mi-2024-un-acces-au-prix-fort-en-ville\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">11.-\u003C\u002Fspan>AJOVY (frémanezumab) - Migraine. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.has-sante.fr\u002Fjcms\u002Fp_3601431\u002Ffr\u002Fajovy-fremanezumab-migraine\">https:\u002F\u002Fwww.has-sante.fr\u002Fjcms\u002Fp_3601431\u002Ffr\u002Fajovy-fremanezumab-migraine\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">12.\u003C\u002Fspan>Comparación de la eficacia de eptinezumab, galcanezumab, fremanezumab y erenumab en migraña crónica \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.ilaphar.org\u002Fwp-content\u002Fuploads\u002F2024\u002F01\u002FOrg_tto_migrana_2311091.pdf\">https:\u002F\u002Fwww.ilaphar.org\u002Fwp-content\u002Fuploads\u002F2024\u002F01\u002FOrg_tto_migrana_2311091.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Cspan style=\"color: #000080;\">13-\u003C\u002Fspan>A Comparison of Fremanezumab and Eptinezumab in the Prevention of Chronic Episodic Migraine. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwjbphs.com\u002Fcontent\u002Fcomparison-fremanezumab-and-eptinezumab-prevention-chronic-episodic-migraine\">https:\u002F\u002Fwjbphs.com\u002Fcontent\u002Fcomparison-fremanezumab-and-eptinezumab-prevention-chronic-episodic-migraine\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">14.-\u003C\u002Fspan>Fremanezumab for preventing migraine NICE \u003Cbr>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nice.org.uk\u002Fguidance\u002FTA764\u002Fchapter\u002F1-Recommendations\">https:\u002F\u002Fwww.nice.org.uk\u002Fguidance\u002FTA764\u002Fchapter\u002F1-Recommendations\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">15.-Informe de Posicionamiento Terapéutico de fremanezumab (Ajovy®) en la profilaxis de migraña \u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.aemps.gob.es\u002FmedicamentosUsoHumano\u002FinformesPublicos\u002Fdocs\u002FIPT_11-2020-fremanezumab-Ajovy.pdf\">https:\u002F\u002Fwww.aemps.gob.es\u002FmedicamentosUsoHumano\u002FinformesPublicos\u002Fdocs\u002FIPT_11-2020-fremanezumab-Ajovy.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">16.-\u003C\u002Fspan>Qué queda y qué hay de nuevo en el manejo farmacológico de la migraña.\u003Cbr>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.navarra.es\u002FNR\u002Frdonlyres\u002F9B1E99CB-9C9E-4939-B978-856C45827EAE\u002F491139\u002FBit_v29n1Mod.pdf\">https:\u002F\u002Fwww.navarra.es\u002FNR\u002Frdonlyres\u002F9B1E99CB-9C9E-4939-B978-856C45827EAE\u002F491139\u002FBit_v29n1Mod.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">17.-\u003C\u002Fspan>Teva Third quarter 2025 Teva Pharmaceutical Industries Ltd. November 5, 2025 \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fs24.q4cdn.com\u002F720828402\u002Ffiles\u002Fdoc_financials\u002F2025\u002Fq3\u002FQ325-Earnings-Presentation.pdf\">https:\u002F\u002Fs24.q4cdn.com\u002F720828402\u002Ffiles\u002Fdoc_financials\u002F2025\u002Fq3\u002FQ325-Earnings-Presentation.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">18.-\u003C\u002Fspan>Patricia Pozo-Rosich. Bio. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"http:\u002F\u002Fpozorosich.com\u002Fbio\">http:\u002F\u002Fpozorosich.com\u002Fbio\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">19.-\u003C\u002Fspan>Teva en España. Un gigante farmacéutico cuyas ganancias dañan la salud de la población de Palestina. https:\u002F\u002Fwww.sinpermiso.info\u002Ftextos\u002Fteva-en-espana-un-gigante-farmaceutico-israeli-cuyas-ganancias-financian-el-genocidio-en-palestina \u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\" align=\"left\">20.-Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fjournals.sagepub.com\u002Fdoi\u002F10.1177\u002F03331024251318016\">https:\u002F\u002Fjournals.sagepub.com\u002Fdoi\u002F10.1177\u002F03331024251318016\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">21.-\u003C\u002Fspan>Industrias sanitarias, profesionales y pacientes. Cómo evitar una relación con frecuencia tóxica (corrupta). \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Faccesojustomedicamento.org\u002Findustrias-sanitarias-profesionales-y-pacientes-como-evitar-una-relacion-con-frecuencia-toxica-corrupta\u002F\">https:\u002F\u002Faccesojustomedicamento.org\u002Findustrias-sanitarias-profesionales-y-pacientes-como-evitar-una-relacion-con-frecuencia-toxica-corrupta\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000080;\">ESPAÑOL\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F11\u002F17\u002Fboicot-a-teva-boicot-a-ajovy-un-medicamento-que-no-aporta-nada-bueno-nuevo-para-prevenir-crisis-de-migrana-por-profesionales-de-la-sanidad-por-palestina-health-workers-for-pales\u002F\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Boicot a Teva, boicot a Ajovy (un medicamento que no aporta nada bueno nuevo para “prevenir” crisis de migraña)\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Profesionales de la Sanidad por Palestina (Health Workers for Palestine, Spain HW4PS) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002F\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">https:\u002F\u002Fhw4p.es\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"mailto:hcw4palestinespain@gmail.com\">hcw4palestinespain@gmail.com\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">¿Por qué el boicot a Teva y el boicot a Ajovy?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Teva es una industria farmacética israelí que ganó 16.400 millones de dólares en 2024. Es una empresa corrupta y corruptora, con miles de millones de dólares en condenas y multas por actos criminales varios, en algunos casos incluso con muertos (por ejemplo, con el sobreuso de opiáceos en Estados Unidos). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Teva sirve de fuente de ingresos a Israel, que así puede cometer y sostener el apartheid y el genocidio en Palestina\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote1sym\" name=\"sdendnote1anc\">\u003Csup>i\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote2sym\" name=\"sdendnote2anc\">\u003Csup>ii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">En España, los tres superventas de Teva en atención primaria son omeprazol, atorvastatina y pantoprazol, y por ello se promueve por Profesionales de la Sanidad Por Palestina (HW4PS, Health Workers for Palestine, Spain) su boicot y su sustitución por fármacos equivalentes\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote3sym\" name=\"sdendnote3anc\">\u003Csup>iii\u003C\u002Fsup>\u003C\u002Fa>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">En hospitales, el superventa es Ajovy, de prescripción por especialistas hospitalarios y dispensación por la farmacia hospitalaria. De ahí esta propuesta concreta de boicot. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Ajovy, no aporta nada bueno nuevo\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">La revista francesa Prescrire es, probablemente, el mejor boletín farmacoterapéutico del mundo. En 2020, su valoración de fremanezumab (Ajovy) concluyó con “No aporta nada nuevo”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote4sym\" name=\"sdendnote4anc\">\u003Csup>iv\u003C\u002Fsup>\u003C\u002Fa> (en francés, literal, “N'apporte rien de nouveau”) en la “prevención” de la migraña. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Habría que corregir y decir “No aporta nada bueno nuevo” puesto que tiene los efectos adversos de los medicamentos de su grupo, desde estreñimiento y dolores musculares a sindrome de Raynaud (efectos adversos que se conocen sólo en parte dada su reciente introducción en el mercado)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote5sym\" name=\"sdendnote5anc\">\u003Csup>v\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote6sym\" name=\"sdendnote6anc\">\u003Csup>vi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Ajovy, mecanismo de acción\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Ajovy es un \u003C\u002Fspan>\u003Cspan style=\"background: transparent;\">anticuerpo monoclonal que se une al receptor del péptido relacionado con el gen de la calcitonina (CGRP, por su denominación en inglés: “calcitonin gene-related peptide”), bloqueando la acción de este neuropéptido\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote7sym\" name=\"sdendnote7anc\">\u003Csup>vii\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote8sym\" name=\"sdendnote8anc\">\u003Csup>viii\u003C\u002Fsup>\u003C\u002Fa>. El CGRP está ubicado en todo el sistema nervioso, pero se concentra en las aferentes perivasculares sensoriales del nervio trigémino y su núcleo caudalis. El CGRP, que tiene un efecto vasodilatador, parece estar implicado en el inicio de las crisis de migraña.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Los gepantes, medicamentos inhibidores del CGRP, se emplean en la “prevención” de las crisis de migraña.\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Ajovy es producido en células de ovario de hámster chino mediante tecnología de ADN recombinante\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote9sym\" name=\"sdendnote9anc\">\u003Csup>ix\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Anti-CGRP\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Entre los anti-CGRP, e\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\">renumab (Aimovig° - Novartis Pharma), fremanezumab (Ajovy° - Teva Santé) y galcanezumab (Emgality° - Lilly) se administran por vía subcutánea; eptinezumab (Vyepti° - Lundbeck) se administra por vía intravenosa; y rimegepant (Vydura° - Pfizer) y atogepant (Aquipta – AbbVie), ambos por vía oral. Rimegepant es el único anti-CGRP autorizado también para el tratamiento de las crisis de migraña.\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Todos ellos plantean problemas de excesivo precio no ajustado a la efectividad\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote10sym\" name=\"sdendnote10anc\">\u003Csup>x\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">La inhibición de la acción vasodilatadora del CGRP, crea incertidumbre sobre la seguridad de estos fármacos en el aparato cardiovascular en pacientes con enfermedad cardiovascular presente o latente, por posible empeoramiento de acontecimientos isquémicos como ictus, accidente isquémico transitorio o infarto de miocardio y el posible riesgo de eclampsia en el embarazo. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Utilización en la práctica\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">La Haute Autorité de Santé (HAS) francesa, en 2025, dejó claro que: “H\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\">asta la fecha, no se ha demostrado la superioridad de los anticuerpos anti-CGRP (incluido el fremanezumab) en términos de eficacia en comparación con otros tratamientos profilácticos”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote11sym\" name=\"sdendnote11anc\">\u003Csup>xi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">No hay diferencias de eficacia en el uso de eptinezumab, galcanezumab, fremanezumab y erenumab en migraña crónica\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote12sym\" name=\"sdendnote12anc\">\u003Csup>xii\u003C\u002Fsup>\u003C\u002Fa>. No obstante, parece que eptinezumab (\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\">Vyepti)\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> podría reducir más los días de migraña que fremanezumab (Ajovy) por su mejor afinidad y especificidad al ligarse con el receptor del péptido \u003C\u002Fspan>\u003Cspan style=\"background: transparent;\">relacionado con el gen de la calcitonina\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote13sym\" name=\"sdendnote13anc\">\u003Csup>xiii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Como resumió el Boletín de Información Farmacoterapéutica de Navarra, en forma parecida al NICE inglés\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote14sym\" name=\"sdendnote14anc\">\u003Csup>xiv\u003C\u002Fsup>\u003C\u002Fa> y al Posicionamiento Terapéutico español\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote15sym\" name=\"sdendnote15anc\">\u003Csup>xv\u003C\u002Fsup>\u003C\u002Fa>: “Los anticuerpos monoclonales anti-CGRP suponen una nueva alternativa de tratamiento en pacientes con ocho o más días de migraña al mes y que hayan presentado tres o más fracasos a tratamientos previos durante al menos tres meses, entre los que debe incluirse la administración de toxina botulínica A en el caso de migraña crónica. Estos anticuerpos presentan una eficacia modesta frente a placebo, no existiendo estudios comparativos frente a terapias estándar, debiendo además tener precaución en pacientes con antecedentes cardiovasculares”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote16sym\" name=\"sdendnote16anc\">\u003Csup>xvi\u003C\u002Fsup>\u003C\u002Fa>. Dicho Boletín destacó el efecto terapéutico del placebo (casi del 40%).\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Ajovy se administra por vía subcutánea, en dosis de 225 mg, solución inyectable en jeringa precargada, a un precio en el Sistema Nacional de Salud en España de 498 euros (precio que puede rebajarse más del 50% en ofertas concretas, como mercancia con la que negocia Teva para conseguir una buena posición de mercado). En Estados Unidos el precio es de 746 dólares.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Boicot a Ajovy\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Teva presentó el informe para accionistas en noviembre de 2025, y sobre Ajovy insistió en su proyección de ganancias en torno a los 640 millones de dólares en 2025\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote17sym\" name=\"sdendnote17anc\">\u003Csup>xvii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Ajovy no aporta nada nuevo y, en todo caso, puede ser substituido por otros anti-\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\">CGRP. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Si es paciente, rechace tal tratamiento, no contribuya al sufrimiento del pueblo palestino. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Si es médico, seleccione una alternativa que no apoye el apartheid y el genocidio en Palestina por Israel.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">Patricia Pozo-Reich\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">En el “mundo” de las cefaleas y en España es clave la posición de Patricia Pozo-Rosich, “key opinion leader” (KOL, “líder de opinión”, persona que encumbran las industrias para influir en sus colegas) y neuróloga en el Hospital Universitario Vall d’Hebron University de Barcelona\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote18sym\" name=\"sdendnote18anc\">\u003Csup>xviii\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote19sym\" name=\"sdendnote19anc\">\u003Csup>xix\u003C\u002Fsup>\u003C\u002Fa>. Es la responsable de la Unidad de Cefalea del Hospital Universitario Vall d’Hebron en Barcelona. Dirige el Migraine Adaptive Brain Center y el Grupo de Investigación - Laboratorio de Investigación en Cefalea y Dolor Neurológico del VHIR (Instituto de Investigación del Vall d’Hebron) que pertenece a la Universitat Autònoma de Barcelona.También pasa consulta en el Hospital QuirónSalud de Barcelona\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote20sym\" name=\"sdendnote20anc\">\u003Csup>xx\u003C\u002Fsup>\u003C\u002Fa> y es vocal del Consejo Científico de la Fundación Lilly\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote21sym\" name=\"sdendnote21anc\">\u003Csup>xxi\u003C\u002Fsup>\u003C\u002Fa>. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Patricia Pozo-Rosich recibió de Teva casi 32.000 euros en 2023, y 45.000 en 2024, en “transferencias de valor”. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">En 2023, la Fundación SEN (Sociedad Española de Neurología), en Barcelona, recibió 149.645 euros y la Fundació Hospital Universitari Valle D’Hebron, Institut de Recerca, Barcelona, 112.850\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote22sym\" name=\"sdendnote22anc\">\u003Csup>xxii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Los conflictos de interés declarados por Patricia Pozo-Rosich son, por ejemplo en las “Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote23sym\" name=\"sdendnote23anc\">\u003Csup>xxiii\u003C\u002Fsup>\u003C\u002Fa>”,: \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">“\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\">En los últimos 36 meses, recibió honorarios como consultora y ponente para: AbbVie, Amgen, Dr. Reddy's, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Pfizer y Teva. Su grupo de investigación ha recibido subvenciones de investigación de Novartis, Teva, AbbVie, EraNET Neuron, RIS3CAT FEDER, AGAUR e ISCIII; y financiación para ensayos clínicos de Amgen, Biohaven, Eli Lilly, Lundbeck, Novartis, Pfizer y Teva”.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">En 2024, por ejemplo, participó en la presentación con publicidad de un gepante, anti-CGRP, el atogepant (Aquipta – AbbVie)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote24sym\" name=\"sdendnote24anc\">\u003Csup>xxiv\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote25sym\" name=\"sdendnote25anc\">\u003Csup>xxv\u003C\u002Fsup>\u003C\u002Fa>. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">En buena lógica\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote26sym\" name=\"sdendnote26anc\">\u003Csup>xxvi\u003C\u002Fsup>\u003C\u002Fa>, tales conflictos de interés invalidan todas los consensos, ensayos clínicos, guías y revisiones sobre cefaleas en que ha participado, participa o participará Patricia Pozo-Reich.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"background: transparent;\">NOTA\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Como hemos comentado, en España destaca, sumando el total en 2023 y 2024, Patricia Pozo Rosich, Barcelona, neuróloga del Valle D’Hebron, que recibió directamente de Teva 77.000 euros en lo que llaman “transferencias de valor”. También la Fundació Hospital Universitari Valle D'Hebron, Institut de Recerca, Barcelona, 138.000.\u003C\u002Fp>\n\u003Cp>Hay que destacar que la Fundación Hospital Universitari Vall d´Hebrón (Vall d’Hebron Institut de Recerca, VHIR) tiene en su Comité Científico Interno como vicepresidenta a la citada neuróloga Patricia Pozo Rosich y en su Comité Científico Externo a Ronit Satchi-Fainaro, israelí de Tel Aviv, que pertenece al Consejo de Administración de Teva (lo que se oculta en su curriculum que aparece en la página del VHIR).\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-family: helvetica; font-size: large;\">-Comité Científico Interno del VHIR\u003Cbr>\u003Ca href=\"https:\u002F\u002Fvhir.vallhebron.com\u002Fes\u002Finstituto\u002Forganos-de-gobierno\u002Fcomite-cientifico-interno\">https:\u002F\u002Fvhir.vallhebron.com\u002Fes\u002Finstituto\u002Forganos-de-gobierno\u002Fcomite-cientifico-interno\u003C\u002Fa>\u003Cbr>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv>\u003Cspan style=\"font-family: helvetica; font-size: large;\">\u003Cbr>-Comité Científico Externo del VHIR\u003Cbr>\u003Ca href=\"https:\u002F\u002Fvhir.vallhebron.com\u002Fes\u002Finstituto\u002Forganos-de-gobierno\u002Fcomite-cientifico-externo\">https:\u002F\u002Fvhir.vallhebron.com\u002Fes\u002Finstituto\u002Forganos-de-gobierno\u002Fcomite-cientifico-externo\u003C\u002Fa>\u003Cbr>\u003Cbr>\u003C\u002Fspan>\n\u003Cdiv>\u003Cspan style=\"font-family: helvetica; font-size: large;\">-Página de Teva\u003Cbr>Board of Directors: Prof. Ronit Satchi-Fainaro Independent Director\u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.tevapharm.com\u002Four-company\u002Fleadership-governance\u002Fboard-of-directors\u002Fprof-ronit-satchi-fainaro\u002F\">https:\u002F\u002Fwww.tevapharm.com\u002Four-company\u002Fleadership-governance\u002Fboard-of-directors\u002Fprof-ronit-satchi-fainaro\u002F\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cdiv class=\"separator\" style=\"clear: both; text-align: center;\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Gran parte de la literatura científica sobre Ajovy va firmada por autores que declaran conflictos de interés respecto a Teva, o son directamente empleados de Teva (o de Otsuka, la firma que comercializa el medicamento en Japón) y en muchos dicha literatura está escrita por terceros y directamente financiada por Teva. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">Algunos ejemplos:\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"background: transparent;\"> US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs12325-024-03063-w#Fun\">\u003Cspan style=\"background: transparent;\">https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs12325-024-03063-w#Fun\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-Este estudio, el servicio rápido de la revista y la tarifa de acceso abierto fueron financiados por Teva Pharmaceuticals.\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-Patrick Eugeni, Megan E. Rooney, Nicolas P. Saikali, Zhongzheng Niu y Jennifer W. McVige son empleados del Dent Neuroological Institute, que realizó este estudio financiado por Teva Pharmaceuticals. Jennifer W. McVige ha recibido financiación para investigación de AbbVie, Teva Pharmaceuticals, Eli Lilly, Amgen y Lundbeck; y honorarios por conferencias y consultoría de AbbVie, Teva Pharmaceuticals, Eli Lilly, Amgen, Lundbeck, Avanir, Theranica y Amneal. Maurice T. Driessen y Lynda J. Krasenbaum son empleados de Teva Pharmaceuticals. Karen Carr y Michael J. Seminerio son ex empleados de Teva Pharmaceuticals (afiliación actual: AbbVie, North Chicago, IL, EE. UU.).\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"background: transparent;\">Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. \u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs40273-024-01380-0\">\u003Cspan style=\"background: transparent;\">https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs40273-024-01380-0\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"background: transparent;\">-Este trabajo fue financiado por Otsuka Pharmaceuticals Co., Ltd. La entidad financiadora supervisó la realización del estudio y la preparación del manuscrito. Otsuka Pharmaceuticals Co., Ltd. pagó la tarifa de acceso abierto. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"background: transparent;\">-Takao Takeshima declara haber recibido honorarios por consultoría de Otsuka, Amgen, Eli Lilly, Daiichi Sankyo, Shionogi, Bioheaven y Lundbeck, y ser asesor de Hedgehog MedTech y Sawai. Fumihiko Sakai declara haber recibido honorarios por consultoría de Otsuka, Amgen, Eli Lilly y Daiichi Sankyo. Xinyu Wang trabajaba para Otsuka Pharmaceutical Co., Ltd. durante la realización del estudio y declara no tener conflictos de interés. Kentaro Yamato, Yoshitsugu Kojima e Yilong Zhang trabajan para Otsuka Pharmaceutical Co., Ltd. y declaran no tener conflictos de interés. Otsuka Pharmaceutical Co., Ltd. comercializó fremanezumab en Japón. Craig Bennison y Martijn Simons trabajan para OPEN Health y declaran haber recibido honorarios de consultoría de Otsuka. OPEN Health es una consultora contratada por Otsuka para realizar el estudio y redactar el manuscrito.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-\u003C\u002Fspan>\u003Cem>\u003Cspan style=\"background: transparent;\">Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37987641\u002F\">\u003Cspan style=\"background: transparent;\">https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37987641\u002F\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"background: transparent;\">-La redacción médica y el apoyo editorial para el desarrollo de este manuscrito, bajo la dirección de los autores, fueron proporcionados por Molly Clark, Sophie Roberts y Olivia Morris de Ashfield MedComms, una empresa de Inizio, y financiados por Teva Pharmaceuticals. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"background: transparent;\">-Los autores declaran los siguientes posibles conflictos de interés con respecto a la investigación, la autoría y\u002Fo la publicación de este artículo: MA declara haber recibido honorarios personales y haber sido investigador principal en ensayos clínicos para AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer y Teva Pharmaceuticals; y subvenciones para investigación de la Fundación Lundbeck, la Fundación Novo Nordisk y Novartis. DDM ha recibido honorarios, subvenciones para investigación y viajes de Allergan\u002FAbbVie, Amgen, Biogen, Cefaly, Genesis Pharma, Electrocore, Eli Lilly, Lundbeck, Merck-Serono, Mertz, Novartis, Roche, Sanofi, Specifar y Teva Pharmaceuticals. Participó como investigador principal en ensayos clínicos para Amgen, Cefaly, Electrocore, Eli Lilly, Genesis Pharma, Lundbeck, Mertz, Novartis, Specifar y Teva Pharmaceuticals; y es presidente de la junta directiva de la Sociedad Helénica de Cefaleas y copresidente del grupo directivo del Panel de Cefaleas de la Academia Europea de Neurología. FMA declara haber impartido conferencias, participado en consejos asesores y\u002Fo haber sido investigador principal en ensayos clínicos para Eli Lilly, Lundbeck, Novartis, Pfizer y Teva Pharmaceuticals. PK, VRC y AHA son empleados y\u002Fo accionistas de Teva Pharmaceuticals. LL es un exempleado de Teva Pharmaceuticals. CJS declara haber recibido servicios de consultoría, participación en consejos asesores, presentaciones y financiación para viajes de Novartis, Eli Lilly, Teva Pharmaceuticals, AbbVie, Allergan, Almirall, Amgen, Lundbeck, MindMed y Grünenthal; y es empleado a tiempo parcial de Zynnon. GS declara haber recibido financiación para investigación de la Fundación Suiza del Corazón, la Fundación Eye on Vision, la Fundación Baasch-Medicus y la Sociedad Alemana de Migraña y Cefalea. GS declara haber participado en comités asesores y\u002Fo ser investigador principal en ensayos clínicos para AbbVie, Lundbeck, Novartis, Pfizer y Teva Pharmaceuticals; y haber recibido financiación para investigación de Vinnova (la agencia de innovación de Suecia), la Universidad de Lund y la Asociación Neurológica Sueca. PPR declara haber recibido subvenciones\u002Ffinanciación para investigación de AbbVie, AGAUR, EraNet NEURON, el Instituto de Investigación Carlos III, MINECO, Novartis, RIS3CAT FEDER y Teva Pharmaceuticals; y haber realizado consultorías o actividades formativas para AbbVie, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Novartis, Pfizer y Teva Pharmaceuticals. PJD declara haber participado en reuniones formativas y\u002Fo haber colaborado en ensayos clínicos para Allergan\u002FAbbVie, electroCore, Novartis, Teva Pharmaceuticals y Lundbeck. TN declara haber recibido honorarios por consultoría, ponencias y becas de viaje de Eli Lilly, Glenmark, Lundbeck, Novartis, Pfizer, St. Jude Medical, Teva Pharmaceuticals y UCB; y haber participado en comités asesores o como investigador principal en ensayos clínicos para AbbVie, Amgen, Eli Lilly, Lundbeck, Neurocrine, Novartis, Teva Pharmaceuticals y UCB. ACP declara haber impartido conferencias, participado en comités asesores o haber sido investigador principal en ensayos clínicos para Allergan, AbbVie, Pfizer, Teva Pharmaceuticals, Novartis, Lundbeck, Eli Lilly y Roche. IPM declara haber impartido conferencias, participado en comités asesores o haber sido investigador principal en ensayos clínicos para Allergan-AbbVie, Teva Pharmaceuticals, Novartis, Lundbeck y Eli Lilly. MLS declara haber impartido conferencias, participado en comités asesores o haber sido investigador principal en ensayos clínicos para Pfizer, Teva Pharmaceuticals, Novartis, Lundbeck, AbbVie y Eli Lilly. CT declara honorarios personales por su participación en consejos asesores o simposios para AbbVie, Dompé, Eli Lilly, Lundbeck, Novartis, Pfizer y Teva Pharmaceuticals; declara honorarios institucionales por la realización de ensayos clínicos para AbbVie, Dompé, Eli Lilly, Lundbeck, Novartis, Pfizer y Teva Pharmaceuticals; recibió financiación para proyectos de investigación de la Comisión Europea, el Ministerio de Salud italiano, la Fundación para la Investigación de la Migraña y la Fundación Italiana de Esclerosis Múltiple.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cem>\u003Cspan style=\"background: transparent;\">-A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy.\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fbmcneurol.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12883-024-03697-x\">\u003Cspan style=\"background: transparent;\">https:\u002F\u002Fbmcneurol.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12883-024-03697-x\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-Este trabajo contó con el apoyo de Teva Pharmaceuticals. SW es ​​empleado de Asc Academics y consultor de la Fundación MH Pronk Health Care Consultancy. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-JAC ha recibido remuneración por su participación en consejos asesores y por impartir conferencias para Teva Pharmaceuticals, Lilly, Novartis, Lundbeck y Pfizer. MP es director general de la Fundación MH Pronk Health Care Consultancy y consultor externo de Teva Netherlands B.V. KWMZ es empleado de Teva Netherlands B.V. MTD es empleado de Teva Pharmaceuticals. LL es exempleado de Teva Pharmaceuticals. MJP es consultor de Asc Academics.\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cem>\u003Cspan style=\"background: transparent;\">-Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache.\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fjournals.sagepub.com\u002Fdoi\u002F10.1177\u002F03331024251318016\">\u003Cspan style=\"background: transparent;\">https:\u002F\u002Fjournals.sagepub.com\u002Fdoi\u002F10.1177\u002F03331024251318016\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-Los autores declararon los siguientes posibles conflictos de interés con respecto a la investigación, la autoría y\u002Fo la publicación de este artículo: P.P.R. informa en los últimos 36 meses haber recibido honorarios como consultora y ponente para: AbbVie, Amgen, Dr. Reddy's, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Pfizer y Teva. Su grupo de investigación ha recibido subvenciones de investigación de Novartis, Teva, AbbVie, EraNET Neuron, RIS3CAT FEDER, AGAUR e ISCIII; y financiación para ensayos clínicos de Amgen, Biohaven, Eli Lilly, Lundbeck, Novartis, Pfizer y Teva. Es Secretaria Honoraria de la Sociedad Internacional de Cefaleas. Es miembro del Comité de Guías de Ensayos Clínicos de la Sociedad Internacional de Cefaleas. Es editora asociada de Cephalalgia, Headache, The Journal of Headache and Pain, Neurologia y Revista de Neurologia. Es la fundadora de www.midolordecabeza.org. P.P.R. no posee acciones de ninguna compañía farmacéutica. N.v.V. no tiene conflictos de interés. E.C. ha recibido honorarios de Novartis, Chiesi, Lundbeck y MedScape; su salario ha sido financiado parcialmente por la beca Rio Hortega Acción Estratégica en Salud 2017–2020 y Juan Rodés 2024–2028, del Instituto de Salud Carlos III (CM20\u002F00217). Es editor junior de Cephalalgia. G.V. no tiene conflictos de interés. M.T.F. ha recibido honorarios de AbbVie, Novartis, Chiesi y Teva. B.W.H.v.d.A. P.J.G. informa haber recibido apoyo independiente del Consejo Neerlandés de Investigación (849200007) y de la Fundación Neerlandesa del Cerebro (HA2017.01.05). P.J.G. también informa haber recibido, durante los últimos 36 meses, una subvención de Celgene; honorarios personales de Aeon Biopharma, Abbvie, Amgen, CoolTech LLC, Dr. Reddy's, Eli Lilly and Company, Epalex, Lundbeck, Novartis, Pfizer, Praxis, Sanofi, Satsuma, Shiratronics, Teva Pharmaceuticals y Tremeau; honorarios personales por asesoramiento a través de Gerson Lehrman Group, Guidepoint, SAI Med Partners y Vector Metric; honorarios por materiales educativos de CME Outfitters; regalías o honorarios por publicaciones de la Massachusetts Medical Society, Oxford University Press, UpToDate y Wolters Kluwer; y una patente para estimulación magnética para el dolor de cabeza (n.º WO2016090333 A1) cedida a eNeura sin costo alguno. M.A. declara haber recibido honorarios de AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer y Teva Pharmaceuticals, fuera del ámbito del trabajo presentado. M.A. también es editor asociado de Brain, Cephalalgia y The Journal of Headache and Pain. S.J.W. ha formado parte de los consejos asesores de Allergan y Eli Lilly Taiwán. Ha recibido honorarios por ponencias de las filiales taiwanesas de Pfizer, Eli Lilly y GSK, así como subvenciones para investigación del Consejo Nacional de Ciencia y Tecnología de Taiwán, el Hospital General de Veteranos de Taipéi y la Sociedad Taiwanesa de Cefaleas. H.C.D. es miembro del Comité de Guías Clínicas de la Sociedad Alemana de Neurología y del Comité de Ensayos Clínicos de la IHS. C.T. ha recibido honorarios por su participación en consejos asesores y\u002Fo simposios científicos de AbbVie, Dompé, Eli Lilly, Medscape, Novartis, Lundbeck y Teva. Su institución ha recibido pagos de Abbvie, Eli Lilly, Novartis, Lundbeck y Teva por ensayos clínicos patrocinados o iniciados por investigadores. G.M.T. declara haber recibido apoyo de consultoría o de la industria por parte de Abbvie, Lilly, Lundbeck, Novartis, Pfizer, Teva e Interactive Studios BV, así como apoyo independiente de la Comunidad Europea, la Fundación Holandesa del Corazón y el Cerebro, el Consejo Holandés de Investigación y Dioraphte.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cem>\u003Cspan style=\"background: transparent;\">-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.mdpi.com\u002F2076-3425\u002F14\u002F9\u002F948#Funding\">\u003Cspan style=\"background: transparent;\">https:\u002F\u002Fwww.mdpi.com\u002F2076-3425\u002F14\u002F9\u002F948\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"background: transparent;\">-Piero Barbanti ha recibido remuneración por servicios de consultoría, participación en un consejo asesor científico, ponencias, apoyo a la investigación y participación en ensayos clínicos u otras actividades con empresas como Abbvie, Alder, Allergan, Amgen, Angelini, Assosalute, Bayer, Biohaven, Eli Lilly, Fondazione Ricerca e Salute, GSK, Lundbeck, New Penta, Noema Pharma, Novartis, Pfizer, Organon, Teva, Visufarma y Zambon. Además, es presidente de la Asociación Italiana de Personas con Cefaleas. Cinzia Aurilia ha recibido becas de viaje de Eli Lilly, FB-Health, Lusofarmaco y Teva, así como honorarios de Novartis, Eli Lilly y Teva. Gabriella Egeo ha recibido becas de viaje y honorarios de Eli Lilly, Novartis, New Penta y Ecupharma. Bianca Orlando y Giulia Fiorentini no tienen nada que declarar.\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cdiv id=\"sdendnote1\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote1anc\" name=\"sdendnote1sym\">i\u003C\u002Fa>Teva en España. Un gigante farmacéutico israelí cuyas ganancias financian en genocidio en Palestina. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote2\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote2anc\" name=\"sdendnote2sym\">ii\u003C\u002Fa>The heroes of Teva. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.jpost.com\u002Fspecial-content\u002Fthe-heroes-of-teva-779380\">https:\u002F\u002Fwww.jpost.com\u002Fspecial-content\u002Fthe-heroes-of-teva-779380\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote3\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote3anc\" name=\"sdendnote3sym\">iii\u003C\u002Fa>Boicot (acción directa) a Teva. Dirigida contra sus 3 \"superventas\". 1\u002F omeprazol, 2\u002F atorvastatina, 3\u002F pantoprazol. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboicot-accion-directa-a-teva-dirigida-contra-sus-3-superventas-1-omeprazol-2-atorvastatina-3-pantoprazol\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboicot-accion-directa-a-teva-dirigida-contra-sus-3-superventas-1-omeprazol-2-atorvastatina-3-pantoprazol\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote4\">\n\u003Cp class=\"sdfootnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote4anc\" name=\"sdendnote4sym\">iv\u003C\u002Fa>Frémanezumab (Ajovy°) et prévention des crises de migraine. Rev Prescrire 2020 ; 40 (444): 731-732. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\">https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote5\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote5anc\" name=\"sdendnote5sym\">v\u003C\u002Fa>CGRP Monoclonal Antibodies (MABs): Risks and Side Effects. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fmigrainecanada.org\u002Fcgrp-monoclonal-antibodies-mabs-risks-and-side-effects\u002F\">https:\u002F\u002Fmigrainecanada.org\u002Fcgrp-monoclonal-antibodies-mabs-risks-and-side-effects\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote6\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote6anc\" name=\"sdendnote6sym\">vi\u003C\u002Fa>Disproportionality analysis of Raynaud’s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41598-025-87421-w\">https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41598-025-87421-w\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote7\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote7anc\" name=\"sdendnote7sym\">vii\u003C\u002Fa>CGRP inhibitors. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.drugs.com\u002Fdrug-class\u002Fcgrp-inhibitors.html\">https:\u002F\u002Fwww.drugs.com\u002Fdrug-class\u002Fcgrp-inhibitors.html\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote8\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote8anc\" name=\"sdendnote8sym\">viii\u003C\u002Fa>Calcitonin Gene-Related Peptide Receptor. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fsites\u002Fbooks\u002FNBK560648\u002F\">https:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fsites\u002Fbooks\u002FNBK560648\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote9\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote9anc\" name=\"sdendnote9sym\">ix\u003C\u002Fa>Ficha Técnica Ajovy 225 mg solución inyectable en jeringa precargada. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fcima.aemps.es\u002Fcima\u002Fdochtml\u002Fft\u002F1191358001\u002FFT_1191358001.html\">https:\u002F\u002Fcima.aemps.es\u002Fcima\u002Fdochtml\u002Fft\u002F1191358001\u002FFT_1191358001.html\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote10\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote10anc\" name=\"sdendnote10sym\">x\u003C\u002Fa>Antimigraineux anti-CGRP : mi-2024, un accès au prix fort en ville. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Fstrategies-de-soins\u002F487-antimigraineux-anti-cgrp-mi-2024-un-acces-au-prix-fort-en-ville\">https:\u002F\u002Fwww.prescrire.org\u002Fstrategies-de-soins\u002F487-antimigraineux-anti-cgrp-mi-2024-un-acces-au-prix-fort-en-ville\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote11\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote11anc\" name=\"sdendnote11sym\">xi\u003C\u002Fa>AJOVY (frémanezumab) - Migraine. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.has-sante.fr\u002Fjcms\u002Fp_3601431\u002Ffr\u002Fajovy-fremanezumab-migraine\">https:\u002F\u002Fwww.has-sante.fr\u002Fjcms\u002Fp_3601431\u002Ffr\u002Fajovy-fremanezumab-migraine\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote12\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote12anc\" name=\"sdendnote12sym\">xii\u003C\u002Fa>Comparación de la eficacia de eptinezumab, galcanezumab, fremanezumab y erenumab en migraña crónica \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.ilaphar.org\u002Fwp-content\u002Fuploads\u002F2024\u002F01\u002FOrg_tto_migrana_2311091.pdf\">https:\u002F\u002Fwww.ilaphar.org\u002Fwp-content\u002Fuploads\u002F2024\u002F01\u002FOrg_tto_migrana_2311091.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote13\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote13anc\" name=\"sdendnote13sym\">xiii\u003C\u002Fa>A Comparison of Fremanezumab and Eptinezumab in the Prevention of Chronic Episodic Migraine. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwjbphs.com\u002Fcontent\u002Fcomparison-fremanezumab-and-eptinezumab-prevention-chronic-episodic-migraine\">https:\u002F\u002Fwjbphs.com\u002Fcontent\u002Fcomparison-fremanezumab-and-eptinezumab-prevention-chronic-episodic-migraine\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote14\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote14anc\" name=\"sdendnote14sym\">xiv\u003C\u002Fa>Fremanezumab for preventing migraine NICE \u003Cbr>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nice.org.uk\u002Fguidance\u002FTA764\u002Fchapter\u002F1-Recommendations\">https:\u002F\u002Fwww.nice.org.uk\u002Fguidance\u002FTA764\u002Fchapter\u002F1-Recommendations\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote15\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote15anc\" name=\"sdendnote15sym\">xv\u003C\u002Fa>Informe de Posicionamiento Terapéutico de fremanezumab (Ajovy®) en la profilaxis de migraña \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.aemps.gob.es\u002FmedicamentosUsoHumano\u002FinformesPublicos\u002Fdocs\u002FIPT_11-2020-fremanezumab-Ajovy.pdf\">https:\u002F\u002Fwww.aemps.gob.es\u002FmedicamentosUsoHumano\u002FinformesPublicos\u002Fdocs\u002FIPT_11-2020-fremanezumab-Ajovy.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote16\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote16anc\" name=\"sdendnote16sym\">xvi\u003C\u002Fa>Qué queda y qué hay de nuevo en el manejo farmacológico de la migraña.\u003Cbr>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.navarra.es\u002FNR\u002Frdonlyres\u002F9B1E99CB-9C9E-4939-B978-856C45827EAE\u002F491139\u002FBit_v29n1Mod.pdf\">https:\u002F\u002Fwww.navarra.es\u002FNR\u002Frdonlyres\u002F9B1E99CB-9C9E-4939-B978-856C45827EAE\u002F491139\u002FBit_v29n1Mod.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote17\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote17anc\" name=\"sdendnote17sym\">xvii\u003C\u002Fa>Teva Third quarter 2025 Teva Pharmaceutical Industries Ltd. November 5, 2025 \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fs24.q4cdn.com\u002F720828402\u002Ffiles\u002Fdoc_financials\u002F2025\u002Fq3\u002FQ325-Earnings-Presentation.pdf\">https:\u002F\u002Fs24.q4cdn.com\u002F720828402\u002Ffiles\u002Fdoc_financials\u002F2025\u002Fq3\u002FQ325-Earnings-Presentation.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote18\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote18anc\" name=\"sdendnote18sym\">xviii\u003C\u002Fa>Patricia Pozo-Rosich. Bio. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"http:\u002F\u002Fpozorosich.com\u002Fbio\">http:\u002F\u002Fpozorosich.com\u002Fbio\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote19\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote19anc\" name=\"sdendnote19sym\">xix\u003C\u002Fa>Vall d’Hebron. Patricia Pozo Rosich. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.vallhebron.com\u002Fen\u002Fprofessionals\u002Fpatricia-pozo-rosich\">https:\u002F\u002Fwww.vallhebron.com\u002Fen\u002Fprofessionals\u002Fpatricia-pozo-rosich\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote20\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote20anc\" name=\"sdendnote20sym\">xx\u003C\u002Fa>Hospital QuirónSalud Barcelona. Patricia Pozo Rosich. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.quironsalud.com\u002Fhospital-barcelona\u002Fes\u002Fcuadro-medico\u002Fpatricia-pozo-rosich\">https:\u002F\u002Fwww.quironsalud.com\u002Fhospital-barcelona\u002Fes\u002Fcuadro-medico\u002Fpatricia-pozo-rosich\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote21\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote21anc\" name=\"sdendnote21sym\">xxi\u003C\u002Fa>Patricia Pozo Rosich. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.fundacionlilly.com\u002Fconocenos\u002Forganos-de-gobierno\u002Fpatriciapozorosich\">https:\u002F\u002Fwww.fundacionlilly.com\u002Fconocenos\u002Forganos-de-gobierno\u002Fpatriciapozorosich\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote22\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote22anc\" name=\"sdendnote22sym\">xxii\u003C\u002Fa>Teva en España. Un gigante farmacéutico cuyas ganancias dañan la salud de la población de Palestina. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote23\">\n\u003Cp class=\"sdendnote-western\" align=\"left\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote23anc\" name=\"sdendnote23sym\">xxiii\u003C\u002Fa>Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fjournals.sagepub.com\u002Fdoi\u002F10.1177\u002F03331024251318016\">https:\u002F\u002Fjournals.sagepub.com\u002Fdoi\u002F10.1177\u002F03331024251318016\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote24\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote24anc\" name=\"sdendnote24sym\">xxiv\u003C\u002Fa>Llega a España un nuevo medicamento preventivo contra la migraña: un comprimido al día. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.elconfidencial.com\u002Fbienestar\u002F2024-05-09\u002Fllega-a-espana-atogepant_3880524\u002F\">https:\u002F\u002Fwww.elconfidencial.com\u002Fbienestar\u002F2024-05-09\u002Fllega-a-espana-atogepant_3880524\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote25\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote25anc\" name=\"sdendnote25sym\">xxv\u003C\u002Fa>La española que más sabe de migrañas te explica su origen, las nuevas terapias y los mitos más extendidos. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.elconfidencial.com\u002Fbienestar\u002F2024-05-20\u002Fentrevista-a-patricia-pozo-rosich_3885270\u002F\">https:\u002F\u002Fwww.elconfidencial.com\u002Fbienestar\u002F2024-05-20\u002Fentrevista-a-patricia-pozo-rosich_3885270\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote26\">\n\u003Cp class=\"sdendnote-western\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote26anc\" name=\"sdendnote26sym\">xxvi\u003C\u002Fa>Industrias sanitarias, profesionales y pacientes. Cómo evitar una relación con frecuencia tóxica (corrupta). \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Faccesojustomedicamento.org\u002Findustrias-sanitarias-profesionales-y-pacientes-como-evitar-una-relacion-con-frecuencia-toxica-corrupta\u002F\">https:\u002F\u002Faccesojustomedicamento.org\u002Findustrias-sanitarias-profesionales-y-pacientes-como-evitar-una-relacion-con-frecuencia-toxica-corrupta\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>",1763408348626,"paw248Eka20","Boycott Teva, boycott Ajovy. Boicot Teva, boicot Ajovy ENG ESP","A medication that offers nothing new to \"prevent\" migraine attacks). Un medicamento que no aporta nada bueno nuevo para “prevenir” crisis de migraña","mi3i102dqbmw9bl4shk",[15],{"type":7,"slug":391,"title":392,"subtitle":393,"id":394,"videoUrl":128,"imageUrl":395,"link":12,"content":396,"timestamp":397,"user":13,"tags":398},"usa-teva-boycott-italy-teva-boycott-eeuu-boicot-a-teva-italia-boicot-a-teva-eng-esp","USA. Teva boycott. Italy, Teva boycott. EEUU boicot a Teva. Italia boicot a Teva. ENG ESP","Flyers. Pharmacies. General practitioners. Municipal goverments. Panfletos. Farmacias. Médicos de cabecera. Gobiernos municipales.","mi7m8d2id66kswzw0df","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763654876\u002Feu4suwbhgivvxptj75ap.webp","\u003Cp>\u003Cimg src=\"https:\u002F\u002Fpbs.twimg.com\u002Fmedia\u002FG6Nge8xXIAMyQxf?format=jpg&name=900x900\" alt=\"\" width=\"640\" height=\"800\">\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>USA. Boycott Teva campaign\u003C\u002Fstrong>\u003Cbr>By Marie Kelly\u003Cbr>November 14, 2025 Philadelphia\u003C\u002Fp>\n\u003Cp>Earlier this year, Health Care Workers for Palestine (HCW4P) launched a worldwide campaign to boycott the Israel-based Teva Pharmaceuticals, a major distributor of generic medications here in the U.S. and throughout the Western hemisphere. The campaign in the U.S. was adopted by local chapters of HCW4P in major areas, including the San Francisco Bay Area, New York and Philadelphia.\u003C\u002Fp>\n\u003Cp>Since the campaign launch, the “No Teva” boycott has been endorsed by and included in the targets of the Boycott, Divestment and Sanctions Movement.\u003C\u002Fp>\n\u003Cp>The initial thrust of the campaign centered on getting individuals to speak to their pharmacist about the boycott. HCW4P members held actions outside pharmacies, approaching individuals and engaging in conversation while handing out flyers.\u003C\u002Fp>\n\u003Cp>The 3-fold pamphlet was designed by HCW4P members of the “No Teva” boycott campaign. In bold graphics, it lists examples of how Teva Pharmaceuticals was complicit in genocide through their support and funding of the Israel Occupation Forces.\u003C\u002Fp>\n\u003Cp>The pamphlet also bullet-points other shady dealings by Teva, including their role in the opioid epidemic. The company has had to shell out millions of dollars to compensate victims of Teva Pharmaceuticals profit-driven marketing of highly addictive medications to individuals suffering from painful injuries and diseases.\u003C\u002Fp>\n\u003Cp>Recently, some Teva medications have been recalled due to contamination with carcinogens. Included in the pamphlet is an easy to follow script that individuals can use when talking to their pharmacists. The suggested “ask” is to switch any prescribed medications to a non-Teva supplier, if available and not cost prohibitive.\u003C\u002Fp>\n\u003Cp>Second, ask the pharmacist to note on the individual’s account that non-Teva drugs are preferred. HCW4P emphasizes that no one should discontinue any medication if Teva is the only option.\u003C\u002Fp>\n\u003Cp>This author’s experience is worth mentioning, because of how easy it was. At the local CVS, her pharmacist looked up each of her medication’s suppliers and was able to recommend a suitable substitute for one of them. It was altogether a positive experience, including that her pharmacist understood that she was boycotting Teva because of their role in the Gaza genocide.\u003C\u002Fp>\n\u003Cp>Distributing flyers by the Philadelphia chapter of HCW4P continues several times each month at local pharmacies. The response from the public has been enthusiastic. People were unfamiliar with Teva Pharmaceuticals and their connection to the IOF. After some conversation, people welcome the ability to do something constructive to cut a source of funding to the Zionist regime.\u003C\u002Fp>\n\u003Cp>Next steps for the boycott are to broaden the scope. The campaign will target independent pharmacies next. HCW4P will visit independent pharmacies to educate them about the boycott and encourage them to seek out non-Teva suppliers. The logic is that the independent pharmacist has more control over suppliers than pharmacists working at some of the major pharmacy chains like CVS and Walgreen’s.\u003C\u002Fp>\n\u003Cp>As momentum for the boycott grows, the push will be for prescribing doctors and nurses to ask for non-Teva alternative medications for their patients.\u003C\u002Fp>\n\u003Cp>The HCW4P has called for days of an outreach campaign to pharmacies from Nov. 17 to Nov. 23. For more information on the HCW4P and the “Boycott Teva” campaign: Health Workers 4 Palestine and BoycottTeva.org.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Italy.\u003C\u002Fstrong>\u003Cbr>\u003Ca href=\"https:\u002F\u002Fonaquietday.org\u002F2025\u002F11\u002F12\u002Feuropes-palestine-solidarity-movement-strengthens-call-to-boycott-israeli-pharmaceutical-company-teva\u002F\">\u003Cstrong>Europe’s Palestine solidarity movement strengthens call to boycott Israeli pharmaceutical company Teva\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>Original article by Ana Vračar\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cem>Pressure is mounting on local governments and public pharmacies to replace Teva products with alternatives not complicit in Israel’s occupation and genocide.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Israeli pharmaceutical giant Teva is facing mounting pressure from Palestine solidarity groups across Europe. One of Israel’s largest drugs manufacturers and a major global producer of generic medicines, Teva has actively supported the genocide in the Gaza Strip since October 2023 and contributed to the erosion of Palestinian healthcare long before that, Giorgia Gusciglio, Europe Coordinator for Boycott, Divestment and Sanctions (BDS) Campaigns at the Palestinian BDS National Committee.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Last year, as Gaza’s health services and workers faced near-total annihilation from Israeli attacks, Teva reported over USD 16.5 billion in revenue. Part of that revenue comes from the Palestinian market, where the company profits from the double standards imposed by the apartheid regime.\u003Cbr>In contrast to Palestinian pharmaceutical producers, who face severe restrictions, prolonged import procedures, and arbitrary “dual-use” designations for essential components, Teva is free to market its products in the occupied territories, many times without adapting packaging or documentation. According to sources collected by BDS Italy, the company even sells medicines in boxes and with instruction leaflets not translated into Arabic.\u003C\u002Fp>\n\u003Cp>\u003Cbr>The exploitation of pharmaceutical needs in occupied territories is not unique to Teva or the time since 2023. The 2012 report “Captive economy: The pharmaceutical industry and the Israeli occupation” concluded that “all Israeli pharmaceutical companies sell their products on the Palestinian market and profit from it, without paying any price for the occupation and its damage.”\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>A matter of Palestine solidarity and access to medicines\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Beyond usurping the Palestinian market, Teva also holds an important share of Europe’s pharmaceutical landscape: not only through its large generics portfolio, but also through proprietary products for multiple sclerosis and cancer. The contradiction between Teva’s stated “commitment toward better health” and its well-documented complicity in war crimes has driven the growth of groups mobilizing to boycott and expose the company. As Gusciglio explains, these initiatives vary by country: in Ireland they have a strong trade union dimension, while in Belgium and Italy, they are primarily led by BDS chapters and activist networks. But the local campaigns still share the same goal – securing justice for Palestine.\u003C\u002Fp>\n\u003Cp>\u003Cbr>A key moment in achieving that goal is reaching out to patients and medics. Throughout the genocide, BDS Italy has been working closely with the local collective Health Workers for Gaza (Sanitari per Gaza), achieving major milestones.\u003C\u002Fp>\n\u003Cp>\u003Cem>According to activists, one of their first actions under the Teva boycott campaign was to distribute leaflets in front of pharmacies to raise awareness among patients and pharmacists about the company’s role in the genocide.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>“All activists took responsibility for visiting a pharmacy, arranging meetings with the chemist, and trying to raise awareness about boycotting Teva products,” the activists explained. The same approach was extended to general practitioners and, by now, the understanding of Teva’s complicity has grown significantly among health professionals and patients alike, BDS Italy members said.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cem>The campaign then moved to engage professional associations and pressure local governments to suspend purchases of Teva products in public pharmacies. \u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Over recent months, several municipalities have responded, issuing guidance for pharmacies under their jurisdiction to seek alternatives. “Teva sells mostly generics, but there are also some drugs that it developed itself and are therefore not replaceable,” BDS Italy activists note. “It’s important to emphasize that we call for suspending purchases except in the case of medicines that are essential or cannot be substituted.”\u003C\u002Fp>\n\u003Cp>\u003Cbr>The fact that some Teva products are not replaceable is often used as a misleading argument against the boycott. In reality, it points to systemic problems in the global pharmaceutical and patent system more than it identifies a concrete issue within the BDS call. One example of this is Copaxone, Teva’s multiple sclerosis treatment.\u003C\u002Fp>\n\u003Cp>Even Israel’s trusted ally, the European Union, called out the company’s attempts to shield itself from competition by artificially extending the drug’s patent protection. Through such actions, BDS Italy pointed out, Teva has likely inflated public health expenditures for multiple sclerosis drugs, with Copaxone alone costing about €500 million a year in 2022. Efforts to mobilize for alternatives to Teva’s products therefore represent a possible meeting point between Palestine solidarity and public pharma initiatives, opening the door to more just and accessible health systems.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Italian municipalities adopt guidance to replace Teva\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>“The first local administration to issue a recommendation to move away from Teva products was Sesto Fiorentino, near Florence,” BDS Italy activists noted. “They were soon attacked by the media, accused of antisemitism and mismanaging public funds. Some claimed that Teva drugs are cheaper, and that discouraging their purchase would raise costs for patients and the health system.”\u003C\u002Fp>\n\u003Cp>Despite such attacks, an increasing number of municipalities have since joined the boycott call, including in Emilia-Romagna, Tuscany, Marche, and Trentino-Alto Adige. While many have urged public pharmacies to look for substitutes for Teva products, others have opted for different approaches.\u003C\u002Fp>\n\u003Cp>In Rovereto, after a successful grassroots campaign, the local government asked pharmacies to display infographics informing customers that they have the right to choose safe, effective alternatives to Teva products.\u003C\u002Fp>\n\u003Cp>While more municipalities in Italy are discussing similar moves, the global BDS campaign and the European Legal Support Center (ELSC) are considering support for municipalities wishing to introduce ethical public procurement in line with EU legislation as well as human rights standards. Meanwhile, campaigners in Europe are keeping up the pressure, turning to, among other things, Teva’s presence in hospital pharmacies and its attempts to whitewash its image through initiatives like the Humanizing Health Awards. Activists are also continuing their partnerships with health workers’ collectives, such as the Health Workers for Gaza fasting action held in Italy earlier this year, while expanding international networks.\u003C\u002Fp>\n\u003Cp>Their campaigns might already be showing signs of success. While the company proudly reported its 2024 revenue, it was more restrained about the fact that it had also recorded net losses amounting to 1.4 billion dollars in the first nine months of the year alone. As BDS Italy noted, “Israel’s genocidal assault since October 2023 and its various consequences could be considered potential factors influencing these results.” \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">EE. UU. Campaña de boicot a Teva \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Por Marie Kelly 14 de noviembre de 2025, Filadelfia \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A principios de este año, la organización Trabajadores de la Salud por Palestina (HCW4P) lanzó una campaña mundial para boicotear a la farmacéutica israelí Teva, una importante distribuidora de medicamentos genéricos en Estados Unidos y en todo el hemisferio occidental.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La campaña en EE. UU. fue adoptada por las secciones locales de HCW4P en áreas clave, como el Área de la Bahía de San Francisco, Nueva York y Filadelfia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Desde el lanzamiento de la campaña, el boicot «No a Teva» ha recibido el respaldo del Movimiento de Boicot, Desinversión y Sanciones (BDS) y se ha incluido entre sus objetivos.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> El enfoque inicial de la campaña se centró en lograr que las personas hablaran con sus farmacéuticos sobre el boicot.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Miembros de HCW4P realizaron acciones frente a las farmacias, abordando a los clientes y conversando con ellos mientras repartían folletos.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> El folleto tríptico fue diseñado por miembros de HCW4P de la campaña de boicot «No a Teva».\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En gráficos impactantes, se enumeran ejemplos de cómo Teva Pharmaceuticals fue cómplice de genocidio mediante su apoyo y financiación a las Fuerzas de Ocupación Israelíes.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El folleto también detalla otras prácticas turbias de Teva, incluyendo su papel en la epidemia de opioides.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La compañía ha tenido que desembolsar millones de dólares para compensar a las víctimas de la comercialización, motivada por el afán de lucro, de medicamentos altamente adictivos a personas que sufrían lesiones y enfermedades dolorosas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Recientemente, algunos medicamentos de Teva han sido retirados del mercado debido a la contaminación con carcinógenos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El folleto incluye un guion sencillo que las personas pueden usar al hablar con sus farmacéuticos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La sugerencia es solicitar que se cambien los medicamentos recetados a un proveedor que no sea Teva, si está disponible y no resulta demasiado caro.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En segundo lugar, se recomienda pedir al farmacéutico que anote en la cuenta del paciente que se prefieren medicamentos que no sean de Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">HCW4P enfatiza que nadie debe interrumpir ningún medicamento si Teva es la única opción.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Vale la pena mencionar la experiencia de esta autora, debido a lo fácil que fue.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En la farmacia CVS local, su farmacéutico buscó a cada uno de los proveedores de su medicamento y pudo recomendarle un sustituto adecuado para uno de ellos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Fue una experiencia totalmente positiva, sobre todo porque su farmacéutico comprendió que estaba boicoteando a Teva debido a su papel en el genocidio de Gaza.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La sección de Filadelfia de HCW4P sigue distribuyendo folletos varias veces al mes en las farmacias locales.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La respuesta del público ha sido entusiasta.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La gente desconocía a Teva Pharmaceuticals y su conexión con las Fuerzas de Liberación de Israel (FLI).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Tras conversar un rato, la gente valora la posibilidad de hacer algo constructivo para cortar una fuente de financiación al régimen sionista.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los próximos pasos del boicot consisten en ampliar su alcance.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La campaña se centrará ahora en las farmacias independientes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">HCW4P visitará farmacias independientes para informarles sobre el boicot y animarlas a buscar proveedores que no sean de Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La lógica es que el farmacéutico independiente tiene mayor control sobre los proveedores que los farmacéuticos que trabajan en grandes cadenas como CVS y Walgreens.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A medida que el boicot cobra fuerza, se presionará a los médicos y enfermeros para que soliciten medicamentos alternativos que no sean de Teva para sus pacientes.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\">\u003Cem> HCW4P ha convocado una campaña de información a las farmacias del 17 al 23 de noviembre.\u003C\u002Fem> Para más información sobre HCW4P y la campaña «Boicot a Teva»: Health Workers 4 Palestine y BoycottTeva.org.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp> \u003C\u002Fp>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">Italia.\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan class=\"ryNqvb\">\u003Cstrong> El movimiento europeo de solidaridad con Palestina intensifica el llamado a boicotear a la farmacéutica israelí Teva.\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Artículo original de Ana Vračar \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">Aumenta la presión sobre los gobiernos locales y las farmacias públicas para que reemplacen los productos de Teva con alternativas que no sean cómplices de la ocupación y el genocidio israelíes.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El gigante farmacéutico israelí Teva enfrenta una creciente presión por parte de grupos de solidaridad con Palestina en toda Europa.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva, uno de los mayores fabricantes de medicamentos de Israel y un importante productor mundial de medicamentos genéricos, ha apoyado activamente el genocidio en la Franja de Gaza desde octubre de 2023 y contribuyó al deterioro de la atención médica palestina mucho antes, según Giorgia Gusciglio, Coordinadora para Europa de las Campañas de Boicot, Desinversión y Sanciones (BDS) del Comité Nacional Palestino de BDS.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El año pasado, mientras los servicios y trabajadores de la salud en Gaza sufrían una aniquilación casi total a causa de los ataques israelíes, Teva reportó ingresos superiores a los 16.500 millones de dólares.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Parte de esos ingresos provienen del mercado palestino, donde la empresa se beneficia de la doble moral impuesta por el régimen del apartheid.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A diferencia de los productores farmacéuticos palestinos, que se enfrentan a severas restricciones, prolongados trámites de importación y designaciones arbitrarias de «doble uso» para componentes esenciales, Teva puede comercializar libremente sus productos en los territorios ocupados, muchas veces sin adaptar el empaque ni la documentación.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según fuentes recopiladas por BDS Italia, la empresa incluso vende medicamentos en cajas y con prospectos sin traducir al árabe.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La explotación de las necesidades farmacéuticas en los territorios ocupados no es exclusiva de Teva ni del período posterior a 2023. El informe de 2012 «Economía cautiva: La industria farmacéutica y la ocupación israelí» concluyó que «todas las empresas farmacéuticas israelíes venden sus productos en el mercado palestino y se benefician de ello, sin pagar ningún precio por la ocupación ni sus daños».\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Una cuestión de solidaridad con Palestina y acceso a los medicamentos \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Más allá de acaparar el mercado palestino, Teva también ostenta una importante cuota del panorama farmacéutico europeo: no solo a través de su amplio catálogo de genéricos, sino también mediante productos propios para la esclerosis múltiple y el cáncer.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La contradicción entre el supuesto “compromiso con la salud” de Teva y su bien documentada complicidad en crímenes de guerra ha impulsado el crecimiento de grupos que se movilizan para boicotear y denunciar a la empresa.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Como explica Gusciglio, estas iniciativas varían según el país: en Irlanda tienen una fuerte dimensión sindical, mientras que en Bélgica e Italia están lideradas principalmente por secciones de BDS y redes de activistas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sin embargo, las campañas locales comparten el mismo objetivo: lograr justicia para Palestina.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Un momento clave para alcanzar ese objetivo es el contacto con pacientes y personal sanitario.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Durante todo el genocidio, BDS Italia ha colaborado estrechamente con el colectivo local Trabajadores Sanitarios por Gaza (Sanitari per Gaza), logrando importantes avances.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según los activistas, \u003Cem>una de sus primeras acciones en el marco de la campaña de boicot a Teva fue distribuir folletos frente a las farmacias para concienciar a pacientes y farmacéuticos sobre el papel de la empresa en el genocidio\u003C\u002Fem>.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">“Todos los activistas se responsabilizaron de visitar una farmacia, concertar reuniones con el farmacéutico e intentar concienciar sobre el boicot a los productos Teva”, explicaron.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El mismo enfoque se extendió a los médicos de cabecera y, a día de hoy, la comprensión de la complicidad de Teva ha aumentado significativamente tanto entre los profesionales sanitarios como entre los pacientes, según indicaron los miembros de BDS Italia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cem>La campaña se centró entonces en involucrar a las asociaciones profesionales y presionar a los gobiernos locales para que suspendieran la compra de productos Teva en las farmacias públicas.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En los últimos meses, varios municipios han respondido, publicando directrices para que las farmacias de su jurisdicción busquen alternativas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">“Teva vende principalmente genéricos, pero también hay algunos medicamentos que ha desarrollado internamente y que, por lo tanto, no son sustituibles”, señalan los activistas de BDS Italia.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">“Es importante destacar que pedimos que se suspendan las compras, excepto en el caso de medicamentos esenciales o que no puedan sustituirse”.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El hecho de que algunos productos Teva no sean sustituibles se utiliza a menudo como un argumento engañoso contra el boicot.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En realidad, esto apunta más a problemas sistémicos en el sistema farmacéutico y de patentes global que a un problema concreto dentro del llamado del BDS.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Un ejemplo de ello es Copaxone, el tratamiento para la esclerosis múltiple de Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Incluso la Unión Europea, aliado de confianza de Israel, criticó los intentos de la compañía por protegerse de la competencia extendiendo artificialmente la protección de la patente del fármaco.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Mediante estas acciones, señaló BDS Italia, Teva probablemente ha inflado el gasto público en salud para medicamentos contra la esclerosis múltiple, ya que solo Copaxone costó alrededor de 500 millones de euros al año en 2022. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"Italia.\n\nEl movimiento europeo de solidaridad con Palestina intensifica el llamado a boicotear a la farmacéutica israelí Teva.\n\nArtículo original de Ana Vračar\n\nAumenta la presión sobre los gobiernos locales y las farmacias públicas para que reemplacen los productos de Teva con alternativas que no sean cómplices de la ocupación y el genocidio israelíes.\n\nEl gigante farmacéutico israelí Teva enfrenta una creciente presión por parte de grupos de solidaridad con Palestina en toda Europa. Teva, uno de los mayores fabricantes de medicamentos de Israel y un importante productor mundial de medicamentos genéricos, ha apoyado activamente el genocidio en la Franja de Gaza desde octubre de 2023 y contribuyó al deterioro de la atención médica palestina mucho antes, según Giorgia Gusciglio, Coordinadora para Europa de las Campañas de Boicot, Desinversión y Sanciones (BDS) del Comité Nacional Palestino de BDS.\n\nEl año pasado, mientras los servicios y trabajadores de la salud en Gaza sufrían una aniquilación casi total a causa de los ataques israelíes, Teva reportó ingresos superiores a los 16.500 millones de dólares. Parte de esos ingresos provienen del mercado palestino, donde la empresa se beneficia de la doble moral impuesta por el régimen del apartheid. A diferencia de los productores farmacéuticos palestinos, que se enfrentan a severas restricciones, prolongados trámites de importación y designaciones arbitrarias de «doble uso» para componentes esenciales, Teva puede comercializar libremente sus productos en los territorios ocupados, muchas veces sin adaptar el empaque ni la documentación. Según fuentes recopiladas por BDS Italia, la empresa incluso vende medicamentos en cajas y con prospectos sin traducir al árabe.\n\nLa explotación de las necesidades farmacéuticas en los territorios ocupados no es exclusiva de Teva ni del período posterior a 2023. El informe de 2012 «Economía cautiva: La industria farmacéutica y la ocupación israelí» concluyó que «todas las empresas farmacéuticas israelíes venden sus productos en el mercado palestino y se benefician de ello, sin pagar ningún precio por la ocupación ni sus daños».\n\nUna cuestión de solidaridad con Palestina y acceso a los medicamentos\n\nMás allá de acaparar el mercado palestino, Teva también ostenta una importante cuota del panorama farmacéutico europeo: no solo a través de su amplio catálogo de genéricos, sino también mediante productos propios para la esclerosis múltiple y el cáncer. La contradicción entre el supuesto “compromiso con la salud” de Teva y su bien documentada complicidad en crímenes de guerra ha impulsado el crecimiento de grupos que se movilizan para boicotear y denunciar a la empresa. Como explica Gusciglio, estas iniciativas varían según el país: en Irlanda tienen una fuerte dimensión sindical, mientras que en Bélgica e Italia están lideradas principalmente por secciones de BDS y redes de activistas. Sin embargo, las campañas locales comparten el mismo objetivo: lograr justicia para Palestina.\n\nUn momento clave para alcanzar ese objetivo es el contacto con pacientes y personal sanitario. Durante todo el genocidio, BDS Italia ha colaborado estrechamente con el colectivo local Trabajadores Sanitarios por Gaza (Sanitari per Gaza), logrando importantes avances. Según los activistas, una de sus primeras acciones en el marco de la campaña de boicot a Teva fue distribuir folletos frente a las farmacias para concienciar a pacientes y farmacéuticos sobre el papel de la empresa en el genocidio. “Todos los activistas se responsabilizaron de visitar una farmacia, concertar reuniones con el farmacéutico e intentar concienciar sobre el boicot a los productos Teva”, explicaron. El mismo enfoque se extendió a los médicos de cabecera y, a día de hoy, la comprensión de la complicidad de Teva ha aumentado significativamente tanto entre los profesionales sanitarios como entre los pacientes, según indicaron los miembros de BDS Italia.\n\nLa campaña se centró entonces en involucrar a las asociaciones profesionales y presionar a los gobiernos locales para que suspendieran la compra de productos Teva en las farmacias públicas. En los últimos meses, varios municipios han respondido, publicando directrices para que las farmacias de su jurisdicción busquen alternativas. “Teva vende principalmente genéricos, pero también hay algunos medicamentos que ha desarrollado internamente y que, por lo tanto, no son sustituibles”, señalan los activistas de BDS Italia. “Es importante destacar que pedimos que se suspendan las compras, excepto en el caso de medicamentos esenciales o que no puedan sustituirse”.\n\nEl hecho de que algunos productos Teva no sean sustituibles se utiliza a menudo como un argumento engañoso contra el boicot. En realidad, esto apunta más a problemas sistémicos en el sistema farmacéutico y de patentes global que a un problema concreto dentro del llamado del BDS. Un ejemplo de ello es Copaxone, el tratamiento para la esclerosis múltiple de Teva. Incluso la Unión Europea, aliado de confianza de Israel, criticó los intentos de la compañía por protegerse de la competencia extendiendo artificialmente la protección de la patente del fármaco. Mediante estas acciones, señaló BDS Italia, Teva probablemente ha inflado el gasto público en salud para medicamentos contra la esclerosis múltiple, ya que solo Copaxone costó alrededor de 500 millones de euros al año en 2022. Por lo tanto, los esfuerzos para movilizar alternativas a los productos de Teva representan un posible punto de encuentro entre Palestina y Israel.\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"kGmWO\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"OwOEge\">\n\u003Cdiv class=\"cJ1Ndf\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",1763654456059,[15],{"subtitle":400,"timestamp":401,"slug":402,"type":7,"tags":403,"user":13,"link":12,"imageUrl":404,"title":405,"id":406,"content":407,"videoUrl":408},"13 empresas del sector sanitario. 139 millones de euros. 13 companies of the health sector. 130 million euros",1763887749865,"peru-multa-por-formar-cartel-teva-incluida-peru-fine-for-forming-a-cartel-teva-included-esp-eng",[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763889342\u002Fwbwzmjcck50dheqhczan.png","Perú. Multa por formar cartel. Teva incluida. Peru. Fine for forming a cartel. Teva included. ESP ENG","mibh6axe4k145cm2gc6","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"g2s2\" data-offset-key=\"1v9np-0-0\">\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"1v9np-0-0\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\">\u003Cem>\u003Cspan data-text=\"true\">Teva, la corrupción que no cesa. \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"g2s2\" data-offset-key=\"e440e-0-0\">\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"e440e-0-0\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp>\u003Cstrong>[\u003Ca href=\"https:\u002F\u002Fsaludconlupa.com\u002Fnoticias\u002Fsancionan-con-s-539-millones-a-13-farmaceuticas-por-colusion-en-la-venta-de-medicinas-al-estado-como-operaba-el-cartel\u002F\">Gráfico de Salud con Lupa\u003C\u002Fa>]\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Flarepublica.pe\u002Fsociedad\u002F2025\u002F11\u002F21\u002Findecopi-multa-con-mas-de-s539-millones-a-13-empresas-farmaceuticas-por-manipular-licitaciones-de-medicamentos-del-estado-ntpe-502467\">Lia Peralta. 22 Noviembre 2025\u003C\u002Fa>\u003Cbr>\u003Ca href=\"https:\u002F\u002Flarepublica.pe\u002Fsociedad\u002F2025\u002F11\u002F21\u002Findecopi-multa-con-mas-de-s539-millones-a-13-empresas-farmaceuticas-por-manipular-licitaciones-de-medicamentos-del-estado-ntpe-502467\">Lima (Perú)\u003C\u002Fa>\u003Cbr>El Instituto Nacional de Defensa de la Competencia y de la Protección de la Propiedad Intelectual (Indecopi) informó, a través de la Comisión de Defensa de la Libre Competencia (CLC), la imposición en primera instancia administrativa de una multa total de más de 539 millones de soles (139 millones de euros, o 159 millones de dólares) a 13 empresas, entre laboratorios\u002Findustrias y distribuidoras, por haberse coludido en procesos de contratación del Estado. Asimismo, irnformó de cinco ejecutivos involucrados en dicha infracción, quienes fueron sancionados con una multa conjunta de más 1.4 millones de soles (360.000 euros o 415.000 dólares).\u003C\u002Fp>\n\u003Cp>De acuerdo a la investigación, las empresas coordinaron tanto sus ofertas como sus decisiones de no participar con el fin de asegurarse la adjudicación de licitaciones de medicamentos entre diciembre de 2006 y febrero de 2020. Este esquema colusorio considerado un \"cártel\" impactó la compra de diversos productos farmacéuticos destinados al abastecimiento de hospitales públicos, algunos usados para administar medicamentos, reponer fluidos y combatir infecciones, así como otros destinados para tratamientos de cánceres agudos y para combatir la anemia. \u003Cbr> El Instituto Nacional de Defensa de la Competencia y de la Protección de la Propiedad Intelectual (Indecopi) informó, a través de la Comisión de Defensa de la Libre Competencia (CLC), la imposición en primera instancia administrativa de una multa total de más de 539 millones de soles (139 millones de euros, 159 millones de dólares) a 13 empresas, entre laboratorios y distribuidoras, por haberse coludido en procesos de contratación del Estado. Asimismo, irnformó de cinco ejecutivos involucrados en dicha infracción, quienes fueron sancionados con una multa conjunta de 1.4 millones de soles (360.000 euros o 415.000 dólares).\u003C\u002Fp>\n\u003Cp>De acuerdo a la investigación, las empresas coordinaron tanto sus ofertas como sus decisiones de no participar con el fin de asegurarse la adjudicación de licitaciones de medicamentos entre diciembre de 2006 y febrero de 2020. Este esquema colusorio considerado un \"cártel\" impactó la compra de diversos productos farmacéuticos destinados al abastecimiento de hospitales públicos, algunos usados para administar medicamentos, reponer fluidos y combatir infecciones, así como otros destinados para tratamientos de cánceres agudos y para combatir la anemia. \u003Cbr>tras analizar más de 14 años de procesos de compra, miles de ofertas y pujas, información de organismos públicos, comunicaciones internas, patrones de participación y declaraciones de los involucrados, la Dirección consideró que existían suficientes indicios para iniciar un procedimiento sancionador.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>El 11 de julio de 2024, Indecopi emitió la Resolución 048-2024\u002FDLC-INDECOPI, iniciando el procedimiento sancionador contra 15 empresas: Medifarma, AC Farma, Droguería Sagitario, IQ Farma, Perulab,\u003Cstrong> Teva,\u003C\u002Fstrong> Laboratorios Portugal, Laboratorios Americanos, B Braun, LUSA, Pharmagen, OQ Pharma, Jobal, Laboratorios Lansier y Pereda. Esto formalizó una investigación por presunta práctica colusoria horizontal en el establecimiento de posturas o abstenciones en licitaciones de medicamentos del Estado entre 2006 y 2020.\u003C\u002Fp>\n\u003Cp>La resolución también imputó cargos a cinco personas naturales por su presunta participación activa o planificadora en la conducta: Angélica Palomares, John Mac Dowall, Mario Mongilardi, Gabriel Apéstegui y Nataly Llanos. \u003C\u002Fp>\n\u003Cp>La resolución aún puede ser impugnada ante la Sala Especialzada en Defensa de la Competencia del Tribunal del Indecopi, la cual definirá si confirma, revoca o anula la decisión. Una vez agotada esta vía, la medida solo podrá ser cuestionada ante el Poder Judicial.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Hernando Cevallos, ex-ministro de Salud: \"El problema es integral\"\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Para Hernando Cevallos, la multa de Indecopi no solo evidencia una colusión empresarial, sino un colapso deliberado de la capacidad del Estado para proteger la salud pública. El exministro afirma que durante años se permitió que “dos o tres empresas manejen el 80 o 90% de la comercialización de medicamentos”, creando un escenario donde la manipulación de licitaciones era prácticamente inevitable. Según Cevallos, prácticas como las que advierte Indecopi prosperaron porque el propio Estado “ha privilegiado los intereses de grandes empresas farmacéuticas”, generando un mercado donde la salud de los peruanos quedó subordinada a acuerdos privados y precios inflados.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>Por otro lado, explica que este caso no es un hecho aislado, sino el resultado de fallas estructurales en la regulación y el abastecimiento estatal. Señala que entidades clave como la Dirección General de Medicamentos (Digemid) y el Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud (Cenares) operan con “controles de calidad y abastecimiento muy deficientes” y con direcciones altamente inestables, \"incluso se pone a algunos directores con investigaciones abiertas\", lo que abre espacio a pposibles actos de corrupción y a compras mal fiscalizadas. “Cenares compra y distribuye, pero nadie controla las compras que hace el Estado a las grandes empresas que se coluden”, advierte, resaltando una debilidad institucional facilitaría que las farmacéuticas dominen las licitaciones durante años sin ser detectadas.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>El exministro es especialmente contundente sobre la posibilidad de que el propio Ministerio de Salud conociera lo que ocurría. Asegura que “no solo es posible, sino su responsabilidad”, dado que Cenares depende directamente del Minsa. Para Cevallos, el patron de cambio de cabezas en las instituciones designadas podría responder a determinados intereses. Esa cadena de decisiones, insiste, permitió que la manipulación de licitaciones pasara desapercibida durante más de una década, comprometiendo el presupuesto público y afectando el acceso de los pacientes a tratamientos básicos. \"El problema es integral… necesitamos construir un Estado que proteja a la gente, no uno complaciente con grandes empresas”, concluye.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Empresas sancionadas\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"MainContent_main__body__i6gEa\">\n\u003Cul class=\"list-content\">\n\u003Cli>B Braun Medical Peru S.A.\u003C\u002Fli>\n\u003Cli>Instituto Quimioterápico S.A.\u003C\u002Fli>\n\u003Cli>Laboratorios AC Farma S.A.\u003C\u002Fli>\n\u003Cli>Distribuidora Droguería Sagitario S.R.L.\u003C\u002Fli>\n\u003Cli>Laboratorios Americanos S.A.\u003C\u002Fli>\n\u003Cli>Laboratorios Lansier S.A.C.\u003C\u002Fli>\n\u003Cli>Pharmagen S.A.C.\u003C\u002Fli>\n\u003Cli>OQ Pharma S.A.C.\u003C\u002Fli>\n\u003Cli>Laboratorios Portugal S.R.L.\u003C\u002Fli>\n\u003Cli>Laboratorios Unidos S.A.\u003C\u002Fli>\n\u003Cli>Medifarma S.A.\u003C\u002Fli>\n\u003Cli>Pereda Distribuidores S.R.L.\u003C\u002Fli>\n\u003Cli style=\"font-weight: bold;\">\u003Cstrong>Teva Perú S.A.\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Finalmente, 13 empresas fueron sancionadas, y otras fueron retiradas debido a que no se consignaron elementos suficientes que permitan acreditar su participación en dicha conducta infractoria o determinar su responsabilidad.\u003C\u002Fp>\n\u003Cdiv class=\"container container-header datawrapper-3xOee-rpmls8\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"container container-footer datawrapper-3xOee-1glppcz\">\n\u003Cdiv class=\"block-notes datawrapper-3xOee-dqwksv\">\u003Ca href=\"https:\u002F\u002Fsaludconlupa.com\u002Fnoticias\u002Fsancionan-con-s-539-millones-a-13-farmaceuticas-por-colusion-en-la-venta-de-medicinas-al-estado-como-operaba-el-cartel\u002F\">¿Cuánto deberá pagar cada empresa?\u003C\u002Fa>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"show-first-flowcards\">\u003C\u002Fdiv>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"g2s2\" data-offset-key=\"1v9np-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"g2s2\" data-offset-key=\"e440e-0-0\">\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"e440e-0-0\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\">\u003Cem>\u003Cspan data-text=\"true\">Teva, the corruption that never stops. \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fsaludconlupa.com\u002Fnoticias\u002Fsancionan-con-s-539-millones-a-13-farmaceuticas-por-colusion-en-la-venta-de-medicinas-al-estado-como-operaba-el-cartel\u002F\">\u003Cstrong>[Graphic \"Salud con lupa\"]\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Lia Peralta.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">November 22, 2025 Lima, Peru \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The National Institute for the Defense of Competition and the Protection of Intellectual Property (Indecopi), through its Commission for the Defense of Free Competition (CLC), announced the imposition, in the first administrative instance, of a total fine of more than 539 million soles (approximately 139 million euros, or 159 million dollars) on 13 companies, including laboratories\u002Findustries and distributors, for colluding in government procurement processes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Indecopi also reported that five executives involved in the infraction were sanctioned with a combined fine of more than 1.4 million soles (approximately 360,000 euros, or 415,000 dollars).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to the investigation, the companies coordinated both their bids and their decisions not to participate in order to secure the awarding of drug tenders between December 2006 and February 2020. This collusive scheme, considered a \"cartel,\" impacted the purchase of various pharmaceutical products intended for supplying public hospitals, some used to administer medications, replace fluids, and combat infections, as well as others intended for the treatment of acute cancers and to combat anemia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The National Institute for the Defense of Competition and the Protection of Intellectual Property (Indecopi), through the Commission for the Defense of Free Competition (CLC), reported the imposition, in the first administrative instance, of a total fine of more than S\u002F 539 million (100,852.72 Tax Units) on 13 companies, including laboratories and distributors, for colluding in government procurement processes.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The agency also reported that five executives involved in the infraction were sanctioned with a combined fine of 262.67 UIT (Tax Units), equivalent to more than S\u002F1.4 million.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> According to the investigation, the companies coordinated both their bids and their decisions not to participate in order to secure the awarding of drug tenders between December 2006 and February 2020. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This collusive scheme, considered a \"cartel,\" impacted the purchase of various pharmaceutical products intended for supplying public hospitals. Some of these products are used to administer medications, replenish fluids, and combat infections, while others are used to treat acute cancers and anemia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">After analyzing more than 14 years of procurement processes, thousands of bids and offers, information from public agencies, internal communications, participation patterns, and statements from those involved, the agency determined that there was sufficient evidence to initiate a sanctioning procedure.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">On July 11, 2024, Indecopi issued Resolution 048-2024\u002FDLC-INDECOPI, initiating sanction proceedings against 15 companies: Medifarma, AC Farma, Droguería Sagitario, IQ Farma, Perulab, \u003Cstrong>Teva, \u003C\u002Fstrong>Laboratorios Portugal, Laboratorios Americanos, B. Braun, LUSA, Pharmagen, OQ Pharma, Jobal, Laboratorios Lansier, and Pereda.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This formalized an investigation into alleged horizontal collusion in the establishment of bids or abstentions in government drug tenders between 2006 and 2020. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The resolution also brought charges against five individuals for their alleged active or planning participation in the conduct: Angélica Palomares, John Mac Dowall, Mario Mongilardi, Gabriel Apéstegui, and Nataly Llanos.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The resolution can still be appealed to the Specialized Chamber for the Defense of Competition of the Indecopi Tribunal, which will decide whether to uphold, revoke, or annul the decision.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Once this avenue is exhausted, the measure can only be challenged before the Judiciary.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Former Health Minister Hernando Cevallos: \"The problem is comprehensive\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For Hernando Cevallos, the Indecopi fine not only demonstrates corporate collusion, but also a deliberate collapse of the State's capacity to protect public health.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The former minister asserts that for years, \"two or three companies were allowed to control 80 or 90% of the drug market,\" creating a scenario where bid rigging was practically inevitable.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to Cevallos, practices like those denounced by Indecopi flourished because the State itself \"has prioritized the interests of large pharmaceutical companies,\" generating a market where the health of Peruvians was subordinated to private agreements and inflated prices.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> On the other hand, he explains that this case is not an isolated incident, but rather the result of structural failures in regulation and state procurement.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">He points out that key entities such as the General Directorate of Medicines (Digemid) and the National Center for the Supply of Strategic Health Resources (Cenares) operate with “very deficient quality and supply controls” and highly unstable leadership, “even appointing some directors with open investigations,” which creates opportunities for potential acts of corruption and poorly overseen purchases.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">“Cenares buys and distributes, but no one controls the purchases the State makes from large companies that collude,” he warns, highlighting an institutional weakness that allows pharmaceutical companies to dominate bidding processes for years without being detected.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> The former minister is particularly emphatic about the possibility that the Ministry of Health itself knew what was happening.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">He asserts that “it is not only possible, but also their responsibility,” given that Cenares reports directly to the Ministry of Health.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">For Cevallos, the pattern of changing leadership in the designated institutions could be driven by specific interests.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This chain of decisions, he insists, allowed the manipulation of bidding processes to go unnoticed for over a decade, jeopardizing the public budget and affecting patients' access to basic treatments.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"The problem is multifaceted… we need to build a state that protects people, not one that panders to large corporations,\" he concludes.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Companies Sanctioned \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">B Braun Medical Peru S.A. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Instituto Quimioterápico S.A. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Laboratorios AC Farma S.A. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Distribuidora Droguería Sagitario S.R.L.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Laboratorios Americanos S.A. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Laboratorios Lansier S.A.C.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Pharmagen S.A.C.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">OQ Pharma S.A.C.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Laboratorios Portugal S.R.L.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Laboratorios Unidos S.A. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Medifarma S.A. Pereda \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Distribuidores S.R.L.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva Perú S.A. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Ultimately, 13 companies were sanctioned, and others were removed from the list due to insufficient evidence to prove their involvement in the alleged infraction or to determine their liability.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fsaludconlupa.com\u002Fnoticias\u002Fsancionan-con-s-539-millones-a-13-farmaceuticas-por-colusion-en-la-venta-de-medicinas-al-estado-como-operaba-el-cartel\u002F\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">How much will each company have to pay?\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","0YKpHGWp4Bs",{"content":410,"timestamp":411,"subtitle":412,"slug":413,"type":7,"id":414,"title":415,"imageUrl":416,"user":13,"tags":417,"link":12,"videoUrl":374},"\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Denuncia en Granada (España): gana Palestina, pierde Teva. \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fespana-teva-2025-vuelve-la-inquisicion-de-manos-del-sionismo-spain-teva-2025-the-inquisition-returns-at-the-hands-of-zionism-esp-eng\">\u003Cstrong>Teva fracasa en su intento de censura por el boicot en España a sus productos, que sustentan el genocidio y el apartheid.\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.elindependientedegranada.es\u002Fpolitica\u002Fcolegio-medicos-granada-archiva-denuncia-medico-acusado-antisemitismo\">\u003Cstrong>El Colegio de Médicos de Granada archiva la denuncia contra el médico acusado de \"antisemitismo\". \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Denunciado por una desconocida entidad sionista por negarse a prescribir medicamentos de Teva (Teva, Actavis, Belmac, Davur, Ratiopharm, Teva, Tevagen) para sus pacientes, en el sistema nacional de salud.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Cumpliendo su obligación, como persona y profesional sanitario, el médico invitaba a no dispensar ni consumir medicamentos del laboratorio israelí TEVA por considerarlo colaborador con el genocidio de Gaza. \u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.elindependientedegranada.es\u002Fciudadania\u002Fgaza-es-auschwitz-retransmitido-directo-grito-etico-medico-pablo-simon-habladurias\">Gana Pablo Simón, médico rural, en Chauchina, Granada, y miembro de Profesionales de la Sanidad por Palestina (Health Workers for Palestine, Spain, HW4PS).\u003C\u002Fa> \u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cem>Gana la dignidad, la ética y la profesionalidad.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cem>El silencio es complicidad con el genocidio palestino, y por ello va contra el Código Ético Médico, que exige no colabarar con ningún genocidio.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Gana Palestina, pierde Teva.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Gana el compromiso, pierde el sionismo.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>En Gaza se está exterminando a un pueblo y se está demoliendo el último muro que protege los derechos humanos universales.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>El Colegio Oficial de Médicos de Granada ha acordado por unanimidad el archivo sin más trámite de la denuncia presentada contra médico de familia a quien una autodenominada “Comisión Sanitaria contra el Antisemitismo” acusaba de “antisemitismo”.\u003C\u002Fp>\n\u003Cp>El motivo de la denuncia era mostrar en su consulta mensajes de apoyo a Palestina e invitar a no consumir ni dispensar medicamentos del laboratorio israelí TEVA, por considerar a esta empresa colaboradora del genocidio en Gaza.\u003C\u002Fp>\n\u003Cp>Según una nota de prensa difundida por la Asociación Pro Derechos Humanos de Andalucía (APDHA), el acuerdo de la Junta Directiva comunicado el día 25 de noviembre concluye que \"de los hechos recogidos en dicho escrito no resulta conducta contraria a la normativa estatutaria ni deontológica, quedando en consecuencia fuera de las competencias de esta Corporación\".\u003C\u002Fp>\n\u003Cp>Con ello, el Colegio desautoriza íntegramente las graves acusaciones vertidas por las entidades denunciantes, cuyo escrito -anónimo y sin firma- fue presentado el 30 de octubre y ampliamente difundido en el medio digital \u003Ca href=\"https:\u002F\u002Fenfoquejudio.es\u002Fqueja-contra-un-medico-de-granada-por-carteles-politicos-anti-israelies-y-promover-el-boicot-a-teva\u002F\">\"Enfoque Judío\"\u003C\u002Fa>, que llegó a acusar al facultativo de \"incitación al odio\" y \"denegación de prestaciones por motivos ideológicos o religiosos\". \u003C\u002Fp>\n\u003Cp>La confirmación a la prensa de la existencia de una denuncia anónima, antes de su verificación formal, supone una vulneración de las garantías básicas recogidas en los Estatutos de la Organización Médica Colegial y pone en entredicho la imparcialidad y el rigor de las actuaciones iniciales del Colegio de Médicos de Granada en este caso\u003C\u002Fp>\n\u003Cp>No obstante, la actuación del colegio profesional ha generado preocupación en el ámbito médico y deontológico al haberse conocido que el médico se enteró de la existencia de la denuncia a través de los medios de comunicación antes de recibir comunicación alguna del propio Colegio. La confirmación a la prensa de la existencia de una denuncia anónima, antes de su verificación formal, supone una vulneración de las garantías básicas recogidas en los Estatutos de la Organización Médica Colegial y pone en entredicho la imparcialidad y el rigor de las actuaciones iniciales del Colegio de Médicos de Granada en este caso, advierte Pro Derechos Humanos.\u003C\u002Fp>\n\u003Cp>Con el archivo definitivo, la corporación reconoce la inexistencia de infracción deontológica y, en la práctica, respalda el derecho de los profesionales sanitarios a la objeción ética y a la libertad de conciencia frente a empresas o productos implicados en vulneraciones de derechos humanos.\u003C\u002Fp>\n\u003Cp>\u003Cem>El médico afectado, Pablo Simón, ha manifestado que \"estas acusaciones sólo tratan de intimidar y desmovilizar a una ciudadanía cada vez más sensibilizada con el genocidio de Gaza\" y que \"la acusación de antisemitismo se utiliza como instrumento para desautorizar toda crítica al sistema colonial y de apartheid del Gobierno israelí\"\u003C\u002Fem>.\u003C\u002Fp>\n\u003Cp>Además, el médico ha confirmado que mantendrá los carteles de su consulta y no descarta emprender acciones legales contra los promotores de la denuncia por vulneración de su honor y por daños a su reputación profesional.\u003C\u002Fp>\n\u003Cp>La Asociación Pro Derechos Humanos de Andalucía (APDHA) ha valorado la resolución como \"un precedente fundamental para la defensa de la libertad de expresión, la ética profesional y la objeción de conciencia en el ejercicio sanitario\", recordando que más de 150 organizaciones nacionales e internacionales respaldaron públicamente al médico granadino.\u003C\u002Fp>\n\u003Cp>El ejercicio de la medicina no solo implica proveer tratamiento: implica también reflexión ética. La objeción de Pablo Simón no es caprichosa ni ideológica: se articula desde principios de bioética, responsabilidad social y el reconocimiento de que los profesionales sanitarios no estamos al margen de los grandes dilemas morales de nuestro tiempo.\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.granadadigital.es\u002Fpablo-simon-colegio-medicos-granada\u002F\">\u003Cem>Cuando Pablo Simón dice que «explicar a sus pacientes que no acepten medicamentos de Teva» es «pedagogía, es resistencia», está apelando a la conciencia del profesional sanitario. Esta es una forma de actuar que respeta su deber asistencial —no ha abandonado a ningún paciente— y al mismo tiempo ejerce su libertad científica, de pensamiento y profesional.\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Granada Medical Association (Spain) has dismissed the complaint against the doctor accused of \"anti-Semitism.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fespana-teva-2025-vuelve-la-inquisicion-de-manos-del-sionismo-spain-teva-2025-the-inquisition-returns-at-the-hands-of-zionism-esp-eng\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva fails in its attempt at censorship due to the boycott in Spain of its products, which support genocide and apartheid.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">The complaint was filed by an unknown Zionist entity for refusing to prescribe Teva medications (Teva, Actavis, Belmac, Davur, Ratiopharm, Teva, Tevagen) to his patients within the national health system. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">Fulfilling his duty as a person and a healthcare professional, the doctor advised against dispensing or consuming medications from the Israeli industria Teva, considering it complicit in the genocide in Gaza.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Pablo Simón, a rural doctor in Chauchina, Granada, and member of Health Workers for Palestine, Spain (HW4PS), has won.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Dignity, ethics, and professionalism have prevailed.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Silence is complicity with the Palestinian genocide, and therefore violates the Medical Code of Ethics, which requires non-collaboration with any genocide.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Palestine wins, Teva loses.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Commitment wins, Zionism loses.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In Gaza, a people are being exterminated and the last wall protecting universal human rights is being demolished.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Granada Medical Association has unanimously agreed to dismiss without further proceedings the complaint filed against a family doctor (Pablo Simón, rural doctor, Chauchina, Granada, and member of HW4PS) accused of \"anti-Semitism\" by a self-styled \"Health Commission Against Anti-Semitism.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The complaint stemmed from the doctor displaying messages of support for Palestine in his office and urging patients not to consume or dispense medications from the Israeli laboratory Teva, which he considered a collaborator in the genocide in Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to a press release issued by the Andalusian Association for Human Rights (APDHA), the Board of Directors' decision, communicated on November 25, concludes that \"the facts presented in the complaint do not constitute conduct contrary to the bylaws or code of ethics, and therefore fall outside the jurisdiction of this Association.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">With this statement, the College completely disavows the serious accusations made by the complaining entities, whose anonymous and unsigned complaint was submitted on October 30 and widely disseminated in the online publication \"Enfoque Judío\", which went so far as to accuse the doctor of \"incitement to hatred\" and \"denying services for ideological or religious reasons.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Confirming the existence of an anonymous complaint to the press, before its formal verification, constitutes a violation of the basic guarantees enshrined in the Statutes of the General Medical Council and calls into question the impartiality and rigor of the initial actions of the Granada Medical Association in this case. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">However, the professional association's actions have generated concern within the medical and professional ethics community, given that it has come to light that the doctor learned of the complaint through the media before receiving any communication from the Association itself.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The confirmation to the press of the existence of an anonymous complaint, before its formal verification, constitutes a violation of the basic guarantees enshrined in the Statutes of the Spanish Medical Association and calls into question the impartiality and rigor of the initial actions taken by the Granada Medical Association in this case, warns Pro Derechos Humanos (Human Rights).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">With the final dismissal of the case, the association acknowledges the absence of any ethical violation and, in practice, upholds the right of healthcare professionals to ethical objection and freedom of conscience regarding companies or products implicated in human rights abuses.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The doctor involved, Pablo Simón, stated that \"these accusations are merely an attempt to intimidate and demobilize a citizenry that is increasingly aware of the genocide in Gaza\" and that \"the accusation of antisemitism is being used as a tool to discredit any criticism of the Israeli government's colonial and apartheid system.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Furthermore, the doctor has confirmed that he will keep the signs at his practice up and has not ruled out taking legal action against those who filed the complaint for defamation and damage to his professional reputation.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Andalusian Association for Human Rights (APDHA) has praised the ruling as \"a fundamental precedent for the defense of freedom of expression, professional ethics, and conscientious objection in healthcare,\" noting that more than 150 national and international organizations publicly supported the doctor from Granada.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The practice of medicine involves more than just providing treatment; it also involves ethical reflection.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Pablo Simón's objection is neither capricious nor ideological: it stems from principles of bioethics, social responsibility, and the recognition that healthcare professionals are not immune to the major moral dilemmas of our time.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">When Pablo Simón says that \"explaining to his patients not to accept Teva medications\" is \"pedagogy, it's resistance,\" he is appealing to the conscience of the healthcare professional.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This is a way of acting that respects his duty to care—he has not abandoned any patient—and at the same time exercises his scientific, intellectual, and professional freedom.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",1764233182129,"Gana Palestina, pierde Teva. Gana la dignidad y el profesionalismo, pierde el sionismo. Palestine wins, Teva loses. Dignity and professionalism win, Zionism loses.","denuncia-por-no-prescribir-teva-archivada-colegio-de-medicos-granada-espana-complaint-for-refusing-to-prescribe-teva-dismissed-granada-medical-association-spain-esp-engl","mih5nngoqkbk7wg5t1","Denuncia (por no prescribir Teva) archivada. Colegio de Médicos Granada (España). Complaint (for refusing to prescribe Teva) dismissed. Granada Medical Association (Spain). ESP ENGL","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1764233675\u002Ft3jolw8k7pbhqxalpui7.jpg",[15],{"subtitle":419,"content":420,"timestamp":421,"slug":422,"type":7,"user":13,"tags":423,"id":425,"link":12,"imageUrl":426,"title":427,"videoUrl":428},"Huntington disease. Tardive dyskinesia. Discinesia tardía. Enfermedad de Huntington","\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Introduction\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Austedo (deutetrabenazine) is marketed in Australia, China, and the United States, and is currently under review for approval in the European Union, for the treatment of Huntington's disease and tardive dyskinesia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Three drugs are available for the treatment of tardive dyskinesia: tetrabenazine (brand name, USA, Xenazine, several generics are available), valbenazine (Ingrezza), and deutetrabenazine (Austedo).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In the United States, valbenazine (Ingrezza) can be used to boycott Teva with better results than deutetrabenazine (Austedo).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Tetrabenazine (brand name: Xenazine, several generics are available) can also be used off-label. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">In general, the best way to boycott Teva, which saves immense suffering, is the rational use of neuroleptics (antipsychotics) to avoid the adverse effect of tardive dyskinesia.\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Incidentally, Teva markets Uzed, risperidone (with a \"Steady Teq Technology\" mechanism for slow release), and will market olanzapine with the same mechanism in 2026. Both neuroleptics cause tardive dyskinesia.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Boycott Austedo, a Teva medication for involuntary movements \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Health Workers for Palestine, Spain HW4PS 30 Nov 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">https:\u002F\u002Fhw4p.es\u002F hcw4palestinespain@gmail.com \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Chorea \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The term chorea alludes to “dance” (“choreia” in Greek).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Chorea is a neurological disorder characterized by involuntary and unpredictable body movements.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Spasms, tics, and muscle twitches occur, usually located in the distal parts of the limbs, especially the hands, and also in the face.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The severity of chorea can range from mild and barely perceptible movements to severe and debilitating symptoms that interfere with daily activities, such as speaking and swallowing.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Although there are many causes of chorea, the most important are Huntington's disease, rheumatic fever, chorea induced by prolonged drug treatment (\"tardive dyskinesia,\" especially neuroleptics, used to treat mental illnesses such as schizophrenia, bipolar disorder, etc.), metabolic disorders (such as hyperthyroidism and hypoparathyroidism), autoimmune diseases (for example, lupus erythematosus, etc.), etc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Huntington's Disease \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Huntington's disease is a serious and rare, inherited, and degenerative neurological disorder that affects motor coordination, mood, and memory.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It is caused by a genetic mutation on chromosome 4 and has an average survival prognosis of 15-20 years after the onset of symptoms (which usually appear between 30 and 50 years of age). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It presents with a progressive pattern of abnormal, involuntary, choreic-type movements that most frequently affect the lower limbs and face (sudden grimaces), making speech and swallowing increasingly difficult.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It is an autosomal dominant genetic disease (the presence of a single copy of the mutated gene, inherited from either the father or the mother, triggers the disease).\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Its prevalence is low, at 5 cases per 100,000 inhabitants (1).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">That is, approximately 23,000 patients in the European Union and about 17,000 in the United States.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tardive dyskinesia \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tardive dyskinesia is a generally irreversible neurological disorder characterized by repetitive, involuntary movements in the orofacial region that can also affect the limbs and trunk.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tardive dyskinesia occurs as an adverse effect of the prolonged use (hence the term \"tard\") of neuroleptics, medications used to treat mental illnesses such as schizophrenia, recurrent psychosis, and bipolar disorder, and in many other conditions such as dementia, agitation, depression, Tourette syndrome, childhood behavioral disorders, delirium, etc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tardive dyskinesia is also an adverse effect of levodopa (a medication for Parkinson's disease), metoclopamide (used for vomiting, nausea, and vertigo), etc. It occurs in approximately 20% of patients treated chronically, and is more common in women and the elderly.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv id=\"ow14\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Prevalence of Tardive Dyskinesia \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The prevalence of tardive dyskinesia parallels the increasing use of neuroleptics.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In other words, tardive dyskinesia is a disease of “medical” origin, created by the increasingly frequent chronic treatment with neuroleptic medications.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to Heather DeMyers, Vice President of US Innovative Medicines Marketing at Teva, there may be almost 800,000 people with tardive dyskinesia in the United States, but only 15% are diagnosed and only 5% are treated (2).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">If this were true, there would be almost 1,000,000 patients with tardive dyskinesia in the European Union.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Perhaps these figures are part of Teva's strategy to use innovative media and social tactics to increase brand recognition and support disease awareness (3).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In any case, the growing number of patients suffering from tardive dyskinesia is undeniable, linked to the adverse effects of prolonged use of neuroleptics in their recommended applications, and in many others.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">For this reason, the analysis of the growing \"market\" created by tardive dyskinesia is even a commercial product (4).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Tardive dyskinesia leads to the typical cascade (prescribing cascade) (5) of medication use, which then leads to the use of another medication to alleviate the adverse effects of the first.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Treatment of Tardive Dyskinesia (and other choreas)\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The key is to reduce the duration and quantity of neuroleptic use to prevent adverse effects.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">However, the current biological approach in Psychiatry leads to the opposite: an increase in the prevalence of their prescription.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Three drugs are available for the treatment of tardive dyskinesia: tetrabenazine (in the USA brand name: Xenazine, several generics are available, brand name in Spain, Nitoman, and generics), valbenazine (Ingrezza), and deutetrabenazine (Austedo).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">These are vesicular monoamine transporter 2 (VMAT2) inhibitors.v\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">VMAT2 is a protein that reduces the amount of neurotransmitters in nerve cells (6).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Inhibition of VMAT2 leads to depletion of presynaptic dopamine and reduces the amount of dopamine released at the synapse.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ingrezza is metabolized and acts selectively with greater affinity on VMAT2 (7).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Deutetrabenazine is the deuterated form of tetrabenazine. The precise mechanism by which deutetrabenazine and tetrabenazine exert their effects in the treatment of tardive dyskinesia and chorea in patients with Huntington's disease is unknown but is believed to be related to the reversible depletion of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. The major circulating metabolites (α-dihydrotetrabenazine (HTBZ) and β-HTBZ) of deutetrabenazine, are reversible inhibitors of vesicular monoamine transporter 2 (VMAT2), resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This is believed to help control involuntary body movements, but the final mechanism of action is unknown (8).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In Spain, only tetrabenazine (Nitoman) is marketed for the treatment of Huntington's disease and is not indicated for tardive dyskinesia (its use is off-label).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Its worst adverse effect is akathisia (an uncontrollable feeling of restlessness and a constant need to move that affects physical and mental well-being). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Valbenazine (Ingrezza) and deutetrabenazine (Austedo) are indicated for tardive dyskinesia, but are not marketed in the European Union.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Austedo is currently under review (9).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It is not a new drug, as the European Medicines Agency points out, but rather Nitoman with an added hydrogen atom (deuterium) to prolong its half-life (10).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Mild tardive dyskinesia does not usually require specific treatment, other than monitoring the evolution of symptoms and considering reducing the neuroleptic dose.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In cases of severe tardive dyskinesia, reducing the dose or replacing it with another, preferably clozapine, should be considered.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In specific cases, dyskinetic symptoms may improve with benzodiazepines, such as clonazepam, or tetrabenazine may be used.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv id=\"ow14\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Adverse effects of tetrabenazine (USA Xenazine and various generics, in Spain Nitoman, and two generics), valbenazine (Ingrezza), and deutetrabenazine (Austedo) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The most common side effects of Xenazine-Nitoman (10% or more of patients) are sedation (drowsiness or extreme sleepiness), fatigue, difficulty sleeping, depression, and akathisia.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Austedo can also cause serious side effects such as heart rhythm disorders (prolongation of the QT interval on the electrocardiogram, which can trigger an arrhythmia called torsades de pointes, manifesting as fainting, dizziness, or palpitations, and usually resolving spontaneously, although occasionally it can lead to ventricular fibrillation and death), akathisia, tremors, muscle rigidity;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">balance or coordination problems;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">or a severe nervous system reaction: muscle rigidity, high fever, sweating, confusion, and changes in heart rhythm.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Common side effects of Austedo include drowsiness;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">tiredness;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">dry mouth;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">runny or stuffy nose; sore throat;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">trouble sleeping; and diarrhea.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Ingreza can cause serious side effects, including heart rhythm problems (prolongation of the QT interval on the electrocardiogram, which can trigger an arrhythmia called torsades de pointes, manifesting as fainting, dizziness, or palpitations, and usually resolving spontaneously, although occasionally it can lead to ventricular fibrillation and death) and parkinsonism (tremors, body rigidity, difficulty moving or walking, or difficulty maintaining balance).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The most common side effect of valbenazine is drowsiness, but other side effects include balance problems, headache, restlessness, dry mouth, constipation, and blurred vision.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">These three medications should be avoided in patients with a history of suicidal thoughts and behaviors, severe depression, or poorly controlled depression.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">They should also be avoided in patients taking potent inhibitors of the CYP2D6 enzyme (paroxetine, fluoxetine, quinidine, etc.), drinking alcohol, or taking other sedative medications.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva's Campaign to Introduce Austedo \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Austedo is simply a modified version of Nitoman, developed in the 1960s, but it is Teva's flagship product, projecting revenues of over $1.2 billion by 2025 (despite not being authorized in the European Union) (11).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Its sales strategy focuses on the treatment of tardive dyskinesia.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> To this end, it seeks to expand the \"market\" by producing advertisements featuring celebrities, promoting websites with thinly veiled propaganda, and conducting \"scientific\" studies that, by \"raising awareness\" of the disease, increase diagnoses and lead to treatment.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Diseases-awareness activities targeting professionals (12), patients (13), and the general public (14) can be found.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Multiple \"scientific\" publications also appear to increase alarm about tardive dyskinesia, always authored by individuals with conflicts of interest due to their relationship with Teva (see NOTE at the end).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In the near future, we can expect the drafting of consensus statements on tardive dyskinesia, expanding diagnostic criteria, separating diagnosis from life experience (biometrics), and advancing treatment, in conjunction with Teva's funding of neurology and psychiatry societies.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Consequently, there will be an increase in meetings, courses, and conference panels on this topic for healthcare professionals and patients\u002Ffamilies.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Austedo versus Ingrezza\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In the United States, the cost of 60 Austedo 12 mg tablets is approximately $7,465, and patients take 2 or 3 tablets daily, depending on their response.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The cost of 60 Austedo XR 12 mg tablets (extended-release) is also $7,465, and patients take 1 or 2 tablets daily, depending on their response.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This equates to an annual treatment cost of approximately $80,000–$90,000.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In the United States, Ingrezza (valbenazine) costs approximately $6,252 for thirty 40 mg capsules and $7,038 for thirty 80 mg capsules, with a daily dose of 80 mg.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This equates to an annual cost of approximately $70,000-$80,000 per year of treatment.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In the United States, tetrabenazine (Xenazine) costs approximately $400 per month;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">that is, a cost of approximately $4,000-$5,000 per year.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In Spain, there are three medications containing tetrabenazine 25 mg, with 112 tablets priced at €123.54: the brand name, Nitoman, and the generics produced by Aristo and Sun.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Three tablets are taken daily, which equates to an annual cost of approximately €1,200.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to a study whose authors have conflicts of interest with Neurocrine Biosciences (which produces Ingrezza), in the treatment of tardive dyskinesia, patients treated with Ingrezza had a better treatment response at one year, lived longer, and accumulated more QALYs (quality-adjusted life years) than patients who received Austedo.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Using the Abnormal Involuntary Movement Scale (AIMS) response criterion, the incremental cost-effectiveness ratio was $9,951\u002FQALY for Ingrezza compared to Austedo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In comparison, patients treated with Ingrezza \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">accumulated more QALYs and incurred lower lifetime costs ($252,311 vs. $283,208) than patients treated with Austedo (15).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In another study, Ingrezza also had advantages, for example, due to its administration method in patients with swallowing difficulties (16).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Boycott of Austedo\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In the European Union, for now, the only specific treatment for tardive dyskinesia is tetrabenazine (in Spain, Nitoman and its generics), used off-label because, according to its product information, it is only authorized to treat Huntington's chorea.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In the near future, the marketing of deutetrabenazine (Austedo) will be approved in the European Union for both tardive dyskinesia and Huntington's chorea.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For now, the marketing of valbenazine (Ingrezza), which obtains better results than deutetrabenazine (Austedo), is not planned.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott of Austedo is therefore being considered in conjunction with the movements of neurology and psychiatry associations and scientific societies (and patients) to prevent the broadening of the definition of tardive dyskinesia and to reduce the use of the medications that cause it.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Furthermore, it is worth bearing in mind that neuroleptics in psychoses, such as schizophrenia, can cause more harm than good (17,18), that their prolonged use can be avoided, or at least the dose reduced (19), and that the long-term outlook is better the less they are used (a first year of treatment with antipsychotics, even at moderate doses, probably induces iatrogenic changes in the brain that persist and have a long-term impact)\u003C\u002Fspan>\u003C\u002Fspan> (20)\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In the case of elderly people living with dementia, for every 1,000 people living with dementia who have hallucinations, delusions or agitation and who take an antipsychotic for 6 to 12 weeks, while they are taking it on average: 980 people do not have a stroke, whether they take an antipsychotic or not. 8 people have a stroke, whether they take an antipsychotic or not. 12 people have a stroke because they take an antipsychotic.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For every 1,000 people living with dementia who have hallucinations, delusions or agitation and who take an antipsychotic for 6 to 12 weeks, while they are taking it on average: 967 people do not die, whether they take an antipsychotic or not. 22 people die, whether they take an antipsychotic or not. 11 people die because they take an antipsychotic (21).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Ironically, Teva also markets a neuroleptic, Uzed, risperidone (with a \"Steady Teq Technology\" mechanism for its slow release) and will market olanzapine with the same mechanism in 2026.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In other words, Teva makes a business out of neuroleptics and their adverse effect, tardive dyskinesia.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv id=\"ow14\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">NOTE \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">Teva develops a frenetic “scientific agenda” with publications in medical journals, generally through “key opinion leaders” linked to the company.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Some examples: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- Undiagnosed and untreated tardive dyskinesia hinders adherence to antipsychotic treatment. Dr. Daniel Kremens.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> https:\u002F\u002Fespanol.medscape.com\u002Fverarticulo\u002F5913032?form=fpf \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Conflicts of interest: Dr. Daniel Kremens has declared the following relevant financial conflicts of interest: He is or has been a consultant for: Teva Pharmaceuticals;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Amneal;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Acadia;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Supernus;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Adamas;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">AbbVie;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Merz;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Allergan;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Acorda;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Kyowa Kirin;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Neurocrine;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Bial;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Cerevel. He is or has been a speaker or member of a speakers' panel for: Teva Pharmaceuticals;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Amneal;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Acadia;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Supernus;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Adamas;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Acorda;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Kyowa Kirin;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Neurocrine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Re: Ganz ML, Chavan A, Dhanda R, et al.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">J Med Econ.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2021;24(1):103–113.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948230 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Conflicts of interest: SL and RR are employees of Teva Pharmaceuticals and hold shares and options on them.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">WX, ZZ, and RA are employees of Analysis Group, Inc., which has received consulting fees from Teva Pharmaceuticals.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40671306\u002F Conflicts of interest: Mark J. Edwards has served on advisory boards for Teva Pharmaceuticals and has received fees for educational events on behalf of Teva Pharmaceuticals.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Pierre Michel Llorca has been a consultant to Teva Pharmaceuticals and a member of Data Safety Monitoring Boards or advisory boards for Teva Pharmaceuticals, and has received fees for educational events on behalf of Teva Pharmaceuticals.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Maurice T. Driessen, Krzysztof Duma, and Nayla Chaijale are employees and shareholders of Teva Pharmaceuticals.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Liza Sopina has received payments from Yorker Health.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sameer Kotak is an employee of Yorker Health and has received payments from Teva Pharmaceuticals in connection with this study.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Andrea Fagiolini is or has been a consultant and\u002For speaker and\u002For has received research grants from Angelini Pharma, Boehringer Ingelheim, Idorsia Pharmaceuticals, Italfarmaco SpA, Lundbeck, Janssen Pharmaceuticals, Medicamenta, Mylan, Otsuka Pharmaceutical, Pfizer, Recordati, Rovi, Sunovion, Teva Pharmaceuticals, and Viatris.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">David Taylor has received personal fees from Lundbeck, Otsuka, and Janssen;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">served as a consultant for Viatris and Teva Pharmaceuticals;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">and holds shares in 428 Pharma, Myogenes, and Saladax.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Christoph Correll has been a consultant or advisor to, or has received fees from, AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk,\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">IntraCellular Therapies, Jamjoom Pharma, Janssen\u002FJ&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Saladax,\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sanofi, Seqirus, SK Life Science,\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva Pharmaceuticals, Terran, Tolmar, Vertex, Viatris, and Xenon Pharmaceuticals.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">He has provided expert testimony for Janssen, Lundbeck, and Otsuka, and has served on the Data Safety Monitoring Boards of Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi, and Teva Pharmaceuticals.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Dr. Correll has also received grants from Boehringer-Ingelheim, Janssen, and Takeda Pharmaceuticals, and royalties from UpToDate.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">He holds stock options in Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Prevalence, pre-existing conditions, and prior treatments among European adults diagnosed with tardive dyskinesia.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2772408524003211?via%3Dihub \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Conflicts of interest: Nayla Chaijale is an employee and shareholder of Teva Pharmaceuticals.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">S. Reshef, Teva Branded Pharmaceutical Products R&D- Inc., Epidemiology, Economics and Global Health Outcomes, Parsippany, USA.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">M. Forrest Gordon, Teva Branded Pharmaceutical Products R&D- Inc., Breakthrough Medicines - Global Clinical Development, West Chester, USA.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">A. Kurzeja, Teva Pharmaceuticals Europe B.V., EU Medical Affairs, Amsterdam, Netherlands. T. D. Maurice, Teva Pharmaceuticals Europe B.V., Global Health Economics and Outcomes Research, Amsterdam, Netherlands.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">REFERENCES\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1.- \u003C\u002Fspan>\u003C\u002Fspan>Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐Analysis. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10086981\u002F\">https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10086981\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">2.-\u003C\u002Fspan>Teva drafts NFL star Terrell Davis for tardive dyskinesia awareness drive \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.fiercepharma.com\u002Fmarketing\u002Fteva-drafts-nfl-star-terrell-davis-tardive-dyskinesia-awareness-drive\">https:\u002F\u002Fwww.fiercepharma.com\u002Fmarketing\u002Fteva-drafts-nfl-star-terrell-davis-tardive-dyskinesia-awareness-drive\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">3.-\u003C\u002Fspan>Interview with Heather DeMyers See what Heather DeMyers has to say on Teva’s \"Pivot to Growth\" strategy and its impact on major products like AUSTEDO and AJOVY. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.newproductplanning.com\u002Fnewproductplanningcom\u002Fexclusive-interview-heather-demyers-teva\">https:\u002F\u002Fwww.newproductplanning.com\u002Fnewproductplanningcom\u002Fexclusive-interview-heather-demyers-teva\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">4.-\u003C\u002Fspan>Tardive Dyskinesia - Epidemiology Forecast to 2032. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fpdf.marketpublishers.com\u002Fdelveinsight\u002Ftardive-dyskinesia-epidemiology-insights-to-2025.pdf\">https:\u002F\u002Fpdf.marketpublishers.com\u002Fdelveinsight\u002Ftardive-dyskinesia-epidemiology-insights-to-2025.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">5.-Prescribing Cascades: How to Detect Them, Prevent Them, and Use Them Appropriately https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC9853235\u002F \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">6.-\u003C\u002Fspan>Finally, Effective Treatments for Tardive Dyskinesia. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.thecarlatreport.com\u002Farticles\u002F3453-finally-effective-treatments-for-tardive-dyskinesia\">https:\u002F\u002Fwww.thecarlatreport.com\u002Farticles\u002F3453-finally-effective-treatments-for-tardive-dyskinesia\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">7.-\u003C\u002Fspan>Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System.\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Fpcn5.79\">https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Fpcn5.79\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">8.-\u003C\u002Fspan>Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia.\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41537-025-00618-w\">https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41537-025-00618-w\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">9.-\u003C\u002Fspan>Austedo. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Faustedo\">https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Faustedo\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">10.-Austedo vs Xenazine: How do they compare? https:\u002F\u002Fwww.drugs.com\u002Fmedical-answers\u002Fdifference-between-deutetrabenazine-tetrabenazine-3574387\u002F\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">11.-\u003C\u002Fspan>Teva Third quarter 2025 Teva Pharmaceutical Industries Ltd. November 5, 2025 \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fs24.q4cdn.com\u002F720828402\u002Ffiles\u002Fdoc_financials\u002F2025\u002Fq3\u002FQ325-Earnings-Presentation.pdf\">https:\u002F\u002Fs24.q4cdn.com\u002F720828402\u002Ffiles\u002Fdoc_financials\u002F2025\u002Fq3\u002FQ325-Earnings-Presentation.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">12.-\u003C\u002Fspan>Do you recognize the magnitude of tardive dyskinesia (TD) impact? \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.magnitude-of-td.com\u002F\">https:\u002F\u002Fwww.magnitude-of-td.com\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">13.-\u003C\u002Fspan>TouchDown. You know this TD moves. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.theothertd.com\u002F\">https:\u002F\u002Fwww.theothertd.com\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">14.-Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis. https:\u002F\u002Fwww.stocktitan.net\u002Fnews\u002FTEVA\u002Fteva-kicks-off-the-other-td-to-raise-awareness-of-tardive-dyskinesia-v9ocbkfs3wou.html\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">15.-\u003C\u002Fspan>Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2020.1867443#abstract\">https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2020.1867443#abstract\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> Crítica: \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948230\">https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948230\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> Respuesta: \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948233\">https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948233\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">16.-\u003C\u002Fspan>VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.cambridge.org\u002Fcore\u002Fjournals\u002Fcns-spectrums\u002Farticle\u002Fvmat2-inhibitors-for-the-treatment-of-tardive-dyskinesia-a-narrative-review\u002F76877F677766141404FC42B8030D9C51#article\">https:\u002F\u002Fwww.cambridge.org\u002Fcore\u002Fjournals\u002Fcns-spectrums\u002Farticle\u002Fvmat2-inhibitors-for-the-treatment-of-tardive-dyskinesia-a-narrative-review\u002F76877F677766141404FC42B8030D9C51#article\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">17 -\u003C\u002Fspan>Healy D, Le Noury J, Harris M, et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875–1924 and 1994–2010. BMJ Open 2012;2:e001810. doi:10.1136\u002Fbmjopen-2012- 001810\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">18.-\u003C\u002Fspan>Lessons from the RADAR trial. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fjoannamoncrieff.com\u002F2023\u002F10\u002F02\u002Flessons-from-the-radar-trial\u002F\">https:\u002F\u002Fjoannamoncrieff.com\u002F2023\u002F10\u002F02\u002Flessons-from-the-radar-trial\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">19.-\u003C\u002Fspan>Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode RemissionA Randomized Clinical Trial. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fjamanetwork.com\u002Fjournals\u002Fjamapsychiatry\u002Ffullarticle\u002F2839607\">https:\u002F\u002Fjamanetwork.com\u002Fjournals\u002Fjamapsychiatry\u002Ffullarticle\u002F2839607\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">20.-Commentary: Does First Year Treatment With an Antipsychotic Lead to Long-Term Harm? \u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.madinamerica.com\u002F2025\u002F11\u002Fcommentary-does-first-year-treatment-with-an-antipsychotic-lead-to-long-term-harm\u002F\">https:\u002F\u002Fwww.madinamerica.com\u002F2025\u002F11\u002Fcommentary-does-first-year-treatment-with-an-antipsychotic-lead-to-long-term-harm\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"color: #000080;\">21.-Antipsychotic medicines for treating agitation, aggression and distress in people living with dementia NICE. 2018 \u003Ca href=\"https:\u002F\u002Fwww.nice.org.uk\u002Fguidance\u002Fng97\u002Fresources\u002Fpatient-decision-aid-pdf-4852697005\">https:\u002F\u002Fwww.nice.org.uk\u002Fguidance\u002Fng97\u002Fresources\u002Fpatient-decision-aid-pdf-4852697005\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"OwOEge\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cnav class=\"VlPnLc\" aria-labelledby=\"ucj-38\">\u003C\u002Fnav>\n\u003Cp> \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Introducción\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Austedo (deutetrabenazine) está comercializado en Australia, China y Estados Unidos, y en proceso de aprobación en la Unión Europea, para el tratamiento de la corea de Huntignton y de la discinesia tardía.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Se dispone de tres fármacos para el tratamiento de la discinesia tardía: tetrabenazina (brand name: Xenazine, hay genéricos varios), valbenazina (Ingrezza) y deutetrabenazina (Austedo). \u003C\u002Fp>\n\u003Cp>\u003Cem>En Estados Unidos, para hacer boicot a Teva se puede emplear valbenazine (Ingrezza) con mejores resultados que deutetrabenazine (Austedo). También, off label, tetrabenazina (brand name: Xenazine, hay genéricos varios).\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>En general, el mejor boicot a Teva, que ahorra sufrimientos inmensos, es el uso racional de los neurolépticos (antipsicóticos) y así evitar el efecto adverso de la discinesia tardía.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Por cierto, Teva comercializa Uzed, risperidona (con un mecanismo \"Steady Teq Technology” para su liberación lenta) y en 2026 comercializará olanzapina con el mismo mecanismo. Ambos neurolépticos producen discinesia tardía.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Boicot a Austedo, un medicamento de Teva para los movimientos involuntarios\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Health Workers for Palestine, Spain HW4PS, 30 noviembre 2025\u003C\u002Fp>\n\u003Cp>https:\u002F\u002Fhw4p.es\u002F   hcw4palestinespain@gmail.com \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Corea\u003C\u002Fstrong>\u003Cbr>El término corea alude a “danza” (“choreia”, en griego).  \u003Cbr>La corea es un trastorno neurológico que se caracteriza por movimientos corporales involuntarios e impredecibles. \u003C\u002Fp>\n\u003Cp>\u003Cbr>Se producen espasmos, tic y tirones musculares que suelen localizarse en las partes distales de los miembros, especialmente en las manos, y también en la cara.  \u003Cbr>La gravedad de la corea puede variar desde movimientos leves y apenas perceptibles hasta síntomas graves y debilitantes que interfieren con las actividades diarias, como hablar y deglutir.   \u003Cbr>Aunque existen muchas causas de corea, las más importantes son la enfermedad de Huntington, fiebre reumática, la corea inducida por tratamiento prolongado con fármacos (“discinesia tardía”, especialmente neurolépticos, empleados para el tratamiento de enfermedades mentales como esquizofrenia, trastorno bipolar, etc), trastornos metabólicos (como hipertiroidismo e hipoparatiroidismo), enfermedades autoinmunes (por ejemplo, lupus eritematoso, etc), etc.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Enfermedad de Huntington\u003C\u002Fstrong>\u003Cbr>La enfermedad de Huntington es una grave y rara enfermedad neurológica, hereditaria y degenerativa que afecta a la coordinación motora, el ánimo y la memoria. \u003C\u002Fp>\n\u003Cp>\u003Cbr>Se debe a una mutación genética en el cromosoma 4 y tiene un pronóstico de 15-20 años de media de supervivencia tras el comienzo de los síntomas (que suelen aparecer entre los 30 y 50 años de edad), con un cuadro progresivo de movimientos anormales e involuntarios de tipo coreico que afectan con mayor frecuencia a los miembros inferiores y a la cara (muecas repentinas), haciéndose cada vez más difícil el habla y la deglución. \u003C\u002Fp>\n\u003Cp>\u003Cbr>Es enfermedad genética autosómica dominante (desencadena la enfermedad la presencia de una sola copia del gen mutado, del padre o de la madre). \u003Cbr>Su prevalencia es baja, de 5 casos por cada 100.000 habitantes (1). Es decir, unas 23.000 pacientes en la Unión Europea y unos 17.000 en Estados Unidos. \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Discinesia tardía\u003C\u002Fstrong>\u003Cbr>La discinesia tardía es un trastorno neurológico generalmente irreversible, caracterizado por movimientos involuntarios repetitivos en la región orofacial que también puede afectar extremidades y tronco.\u003C\u002Fp>\n\u003Cp>\u003Cbr>La discinesia tardía se produce como efecto adverso del empleo prolongado (de ahí lo de “tardía”) de neurolépticos, medicamentos para el tratamiento de enfermedades mentales como esquizofrenia, psicosis recurrente y trastorno bipolar, y en otras muchas situaciones como demencia, agitación, depresión, síndrome de Tourette, trastornos conductuales en infancia, cuadro de delirio, etc.\u003C\u002Fp>\n\u003Cp>\u003Cbr>La discinesia tardía es también efecto adverso de levodopa (medicamento para la enfermedad de Parkinson), metoclopamida (empleada para vómitos, naúseas y vértigo), etc. \u003Cbr>Se da en un 20% de los pacientes tratados crónicamente, siendo más frecuente en mujeres y en la ancianidad.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Prevalencia de la discinesia tardía\u003C\u002Fstrong>\u003Cbr>La prevalencia de la discinesia tardía va paralela a la del uso de neurolépticos, que es creciente. Es decir, la discinesia tardía es enfermedad de causa “médica”, creada por el cada vez más frecuente tratamiento crónico con medicamentos neurolépticos.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Según Heather DeMyers, vicepresidente de US Innovative Medicines Marketing, de Teva, en Estados Unidos puede haber casi 800.000 personas con discinesia tardía, pero sólo el 15% está diagnosticado y sólo el 5% tratado (2). Si fuera cierto, en la Unión Europea habría casi 1.000.000 de pacientes con discinesia tardía.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Quizá estas cifras formen parte de la estrategia de Teva de utilizar medios innovadores y tácticas sociales para incrementar el reconocimiento de marca y apoyar la concienciación sobre la enfermedad (disease-awareness) (3).\u003C\u002Fp>\n\u003Cp>\u003Cbr>En todo caso, es innegable el creciente número de pacientes que sufren discinesia tardía, ligado al efecto adverso del uso prolongado de los neurolépticos en sus aplicaciones recomendadas, y en otras muchas más. Por ello, incluso es producto comercial el análisis del “mercado” en aumento creado por la discinesia tardía (4). \u003C\u002Fp>\n\u003Cp>\u003Cbr>La discinesia tardía lleva a la típica cascadaiv de uso de un medicamento que conlleva el empleo de otro medicamento para paliar los efectos adversos del primero.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Tratamiento de la discinesia tardía (y otras coreas)\u003C\u002Fstrong>\u003Cbr>Lo clave es disminuir en duración y cantidad el uso de neurolépticos, para prevenir el efecto adverso. Pero el actual enfoque biológico de la Psiquiatría lleva a lo contrario, al incremento de la prevalencia de su prescripción.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Se dispone de tres fármacos para el tratamiento de la discinesia tardía: tetrabenazina (En EEUU, Xenazine, hay genéricos varios, y en España Nitoman, y dos genéricos), valbenazina (Ingrezza) y deutetrabenazina (Austedo). \u003C\u002Fp>\n\u003Cp>\u003Cbr>Son medicamentos inhibidores del transportador vesicular de monoaminas 2 (VMAT2) (6). VMAT2 es una proteína que reduce la cantidad de neurotransmisores en las células nerviosas. La inhibición de VMAT2 conduce a un agotamiento de la dopamina presináptica y reduce la cantidad de dopamina liberada en la sinapsis (7). Ingrezza se metaboliza y actua selectivamente con mayor afinidad sobre VMAT2vi. Se cree que esto ayuda a controlar los movimientos corporales involuntarios pero se desconoce el mecanismo final de acciónvii. \u003C\u002Fp>\n\u003Cp>\u003Cbr>En España sólo está comercializada la tetrabenazina (Nitoman, y genéricos, en Estados Unidos Xenazine, hay genéricos varios) para el tratamiento de la enfermedad de Huntington y no tiene indicación en ficha técnica para discinesia tardía (su uso es off-label). Su peor efecto adverso es akatisia (sensación incontrolable de inquietud y necesidad constante de moverse que afecta al bienestar físico y mental).\u003C\u002Fp>\n\u003Cp> \u003Cbr>Valbenazina (Ingrezza) y deutetrabenazina (Austedo) sí tienen indicación en discinesia tardía, pero no están comercializadas en la Unión Europea. Austedo está en proceso de aprobación (9). No es un medicamento nuevo, como señala la Agencia Europea del Medicamento, sino el mismo Nitoman con un hidrógeno (deuterio) añadido, con el propósito de prolongar su vida media (10).\u003C\u002Fp>\n\u003Cp>La discinesia tardía leve no suele recibir tratamiento específico, salvo monitorizar la evolución de los síntomas y valorar la posibilidad de reducir la dosis del neuroléptico. En el caso de la discinesia tardía grave, se debe valorar disminuir la dosis del mismo, o sustituirlo por otro, a ser posible clozapina. En casos concretos, los síntomas discinéticos pueden mejorar con las benzodiacepinas, como clonazepam, o se puede emplear tetrabenazina.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Efectos adversos de tetrabenazina (en España Nitoman, y dos genéricos, en Estados Unidos Xenazine, hay genéricos varios), valbenazina (Ingrezza) y deutetrabenazina (Austedo) \u003C\u002Fstrong>\u003Cbr>Los efectos secundarios más comunes de Nitoman (10 % o más de los pacientes): sedación (somnolencia o somnolencia extrema), fatiga, dificultad para dormir, depresión y akatisia.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Austedo también puede provocar efectos secundarios graves como trastornos del ritmo cardíaco (prolongación del intervalo QT del electrocardiograma que puede desencadenar una arritmia denominada torsión de puntas que se manifiesta como síncope, mareos o palpitaciones y suele resolverse espontáneamente, si bien en ocasiones puede originar una fibrilación ventricular y causar la muerte), akatisia, temblores, rigidez muscular; problemas de equilibrio o coordinación; o reacción grave del sistema nervioso: rigidez muscular, fiebre alta, sudoración, confusión, cambio del ritmo cardíaco.\u003C\u002Fp>\n\u003Cp> \u003Cbr>Los efectos secundarios comunes de Austedo: somnolencia; cansancio; boca seca; secreción o congestión nasal, dolor de garganta; problemas para dormir y diarrea.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Ingreza puede causar efectos secundarios graves que incluyen: problemas del ritmo cardíaco (prolongación del intervalo QT del electrocardiograma que puede desencadenar una arritmia denominada torsión de puntas que se manifiesta como síncope, mareos o palpitaciones y suele resolverse espontáneamente, si bien en ocasiones puede originar una fibrilación ventricular y causar la muerte) y parkinsonismo (temblores, rigidez corporal, dificultad para moverse o caminar, o para mantener el equilibrio).\u003C\u002Fp>\n\u003Cp>El efecto secundario más común de la valbenazina es la somnolencia, también problemas de equilibrio, dolor de cabeza, inquietud, boca seca, estreñimiento, visión borrosa.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cem>Estos tres medicamentos deben evitarse en pacientes con antecedentes de ideas y comportamientos suicidas, con depresión grave o con depresión mal controlada. También en pacientes que tomen inhibidores potentes de la enzima CYP2D6 (paroxetina, fluoxetina, quinidina, etc), beban alcohol o tomen otros medicamentos sedantes.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Campaña de Teva para introducir Austedo\u003C\u002Fstrong>\u003Cbr>Austedo no es más que el Nitoman\u002FXenazine, desarrollado en los 60 del siglo XX, modificado, pero es el producto estrella de Teva del que prevé ingresos de más de 1.200 millones de dólares en 2025 (sin estar autorizado en la Unión Europea) (11). Su estrategia de ventas se centra en el tratamiento de la discinesia tardía. \u003C\u002Fp>\n\u003Cp>\u003Cbr>Para ello busca incrementar el “mercado” y produce anuncios con personajes famosos, promociona páginas de propaganda disimulada y realiza estudios “científicos” que, al “alertar” de la enfermedad, incrementan el diagnóstico y llevan al tratamiento.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Se puede encontrar actividad de concienciación sobre la enfermedad (disease-awareness) para profesionales (12), pacientes (13) y público en general (14). También publicaciones “científicas” múltiples para incrementar la alarma sobre la discinesia tardía, siempre firmadas por autores con conflictos de interés por su relación con Teva (vea la NOTA al final).\u003C\u002Fp>\n\u003Cp>\u003Cbr>En un próximo futuro es de esperar la redacción de “consensos” acerca de la discinesia tardía ampliando los criterios diagnósticos, separando el diagnóstico de la experiencia vital (“biometría”) y adelantando el tratamiento, en relación con la financiación por Teva de sociedades de neurología y psiquiatría. Por lo mismo se incrementarán las reuniones, cursos y mesas en congresos sobre dicha cuestión para profesionales de la sanidad y pacientes-familiares.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Austedo versus Ingrezza\u003C\u002Fstrong>\u003Cbr>En Estados Unidos, el costo de 60 tabletas de Austedo de 12 mg es de alrededor de $7.465, y se toman 2 o 3 al día, según la respuesta. El costo de 60 tabletas de 12 mg de Austedo XR (de liberación prolongada) es de $7,465 y se toman 1 o 2 al día, según la respuesta. Esto equivale un costo anual de unos $80-90.000 por año de tratamiento.\u003C\u002Fp>\n\u003Cp>\u003Cbr>En Estados Unidos, Ingrezza (valbenazina) cuesta aproximadamente $6.252 por treinta cápsulas de 40 mg y $7.038 por treinta cápsulas de 80 mg, y se toman 80 mg al día. Esto equivale a un costo anual de unos $70-80.000 por año de tratamiento.\u003C\u002Fp>\n\u003Cp>\u003Cbr>En Estados Unidos, tetrabenazine (allí Xenazine) cuesta unos $400 al mes; es decir, un coste de unos $4-5.000 al año.\u003C\u002Fp>\n\u003Cp>\u003Cbr>En España, hay 3 medicamentos con tetrabenazina 25mg, con 112 comprimidos de precio de 123,54€: el de marca, Nitoman, y los genéricos que los producen Aristo y Sun. Se toman 3 comprimidos al día lo que equivale a un costo anual de unos 1.200€. \u003C\u002Fp>\n\u003Cp>\u003Cbr>Según un estudio cuyos autores tienen conflictos de interés con Neurocrine Biosciences (que produce Ingrezza), en el tratamiento de la discinesia tardía, los pacientes tratados con Ingrezza tuvieron mejor respuesta al tratamiento al año, vivieron más tiempo y acumularon más AVAC (años de vida ajustados por calidad) que los pacientes que recibieron Austedo (15).\u003C\u002Fp>\n\u003Cp>Utilizando el criterio de respuesta AIMS (Abnormal Involuntary Movement Scale), la razón costo-efectividad incremental fue de $9,951\u002FAVAC para Ingrezza en comparación con Austedo. En comparación, los pacientes tratados con Ingrezza acumularon más AVAC e incurrieron en menores costos a lo largo de la vida ($252,311 frente a $283,208) que los pacientes tratados con Austedo.\u003C\u002Fp>\n\u003Cp>\u003Cbr>En otro estudio, Ingrezza tuvo también ventajas, por ejemplo por la forma de administración en pacientes con dificultades para deglutir (16).\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Boicot a Austedo\u003C\u002Fstrong>\u003Cbr>En la Unión Europea, por ahora, el único tratamiento específico de la discinesia tardía es tetrabenazina (Nitoman en España y sus genéricos) empleada off-label pues según su ficha técnica sólo está autorizado para tratar la corea de Huntington.\u003C\u002Fp>\n\u003Cp>\u003Cbr>En el próximo futuro se aprobará en la Unión Europea la comercialización de deutetrabenazina (Austedo) tanto para la discinesia tardía como para la corea de Huntington.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Por ahora no se prevé la comercialización de valbenazina (Ingrezza), que obtiene mejores resultados que deutetrabenazina (Austedo).\u003C\u002Fp>\n\u003Cp>\u003Cbr>El boicot a Austedo se plantea, pues, en el seguimiento de los movimientos de asociaciones y sociedades científicas de neurología y psiquiatría (y de pacientes) para evitar la ampliación de la definición de discinesia tardía y para disminuir el uso de los medicamentos que la producen. \u003C\u002Fp>\n\u003Cp>\u003Cbr>Además, conviene tener presente que los neurolépticos en las psicosis, como esquizofrenia, pueden producir más daños que beneficios (17) (18), que se puede evitar su uso prolongado, o al menos disminuir la dosis (19) y que las perspectivas a largo plazo son mejores cuanto menos se utilicen (un primer año de tratamiento con antipsicóticos, incluso en dosis moderadas, probablemente induce cambios iatrogénicos en el cerebro que persisten y tienen un impacto a largo plazo) (20). Respecto al uso de neurolépticos en la demencia senil, desde 2004 se viene alertando del particular riesgo de seguridad de los antipsicóticos en personas mayores (riesgo cerebrovascular, neumonías, caídas, muerte…). En particular preocupa la incidencia de casos de ictus y mortalidad en personas con demencia (21).\u003C\u002Fp>\n\u003Cp>\u003Cbr>Irónicamente, Teva también comercializa un neuroléptico, Uzed, risperidona (con un mecanismo \"Steady Teq Technology” para su liberación lenta) y en 2026 comercializará olanzapina con el mismo mecanismo. Es decir, Teva hace negocio con neurolépticos y con el efecto adverso de los mismos, la discinesia tardía.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>NOTA\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Teva desarrolla una frenética “línea científica” con publicaciones en revistas médicas, generalmente a través de “key opinion leaders” (líderes de opinión) ligados a la empresa.\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Algunos ejemplos:\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>- La discinesia tardía no diagnosticada ni tratada dificulta el cumplimiento del tratamiento con antipsicóticos  Dr. Daniel Kremens.\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>https:\u002F\u002Fespanol.medscape.com\u002Fverarticulo\u002F5913032?form=fpf \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>-Conflictos de interés: El Dr. Daniel Kremens ha declarado los siguientes conflictos de interés económico pertinentes: Se desempeña o se ha desempeñado como consultor para: Teva Pharmaceuticals; Amneal; Acadia; Supernus; Adamas; AbbVie; Merz; Allergan; Acorda; Kyowa Kirin; Neurocrine; Bial; Cerevel Se desempeña o se ha desempeñado como conferenciante o miembro de un gabinete de conferenciantes para: Teva Pharmaceuticals; Amneal; Acadia; Supernus; Adamas; Acorda; Kyowa Kirin; Neurocrine.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>-Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103–113. https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948230 \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>-Conflictos de interés: SL y RR son empleados de Teva Pharmaceuticals y poseen acciones y opciones sobre ellas. WX, ZZ y RA son empleados de Analysis Group, Inc., que ha recibido honorarios de consultoría de Teva Pharmaceuticals.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>-Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review  \u003C\u002Fstrong>\u003Cbr>\u003Cstrong>https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40671306\u002F \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>-Conflictos de interés: Mark J. Edwards ha formado parte de consejos asesores de Teva Pharmaceuticals y ha recibido honorarios por eventos educativos en nombre de Teva Pharmaceuticals. Pierre Michel Llorca ha sido consultor de Teva Pharmaceuticals y miembro de Consejos de Monitoreo de Seguridad de Datos o consejos asesores de Teva Pharmaceuticals, y ha recibido honorarios por eventos educativos en nombre de Teva Pharmaceuticals. Maurice T. Driessen, Krzysztof Duma y Nayla Chaijale son empleados y accionistas de Teva Pharmaceuticals. Liza Sopina ha recibido pagos de Yorker Health. Sameer Kotak es empleado de Yorker Health y ha recibido pagos de Teva Pharmaceuticals en relación con este estudio. Andrea Fagiolini es o ha sido consultor y\u002Fo ponente y\u002Fo ha recibido becas de investigación de Angelini Pharma, Boehringer Ingelheim, Idorsia Pharmaceuticals, Italfarmaco SpA, Lundbeck, Janssen Pharmaceuticals, Medicamenta, Mylan, Otsuka Pharmaceutical, Pfizer, Recordati, Rovi, Sunovion, Teva Pharmaceuticals y Viatris. David Taylor ha recibido honorarios personales de Lundbeck, Otsuka y Janssen; se desempeñó como consultor para Viatris y Teva Pharmaceuticals; y posee acciones en 428 Pharma, Myogenes y Saladax. Christoph Correll ha sido consultor o asesor, o ha recibido honorarios, de AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\u002FJ&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Saladax, Sanofi, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva Pharmaceuticals, Terran, Tolmar, Vertex, Viatris y Xenon Pharmaceuticals. Ha prestado testimonio pericial para Janssen, Lundbeck y Otsuka, y ha formado parte de las Juntas de Monitoreo de Seguridad de Datos de Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi y Teva Pharmaceuticals. El Dr. Correll también ha recibido subvenciones de Boehringer-Ingelheim, Janssen y Takeda Pharmaceuticals, y ha recibido regalías de UpToDate. Es titular de opciones sobre acciones de Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic y Terran.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>-Prevalence, pre-existing conditions, and prior treatments among European adults diagnosed with tardive dyskinesia. https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2772408524003211?via%3Dihub \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>-Conflictos de interés: Nayla Chaijale es empleada y accionista de Teva Pharmaceuticals. S. Reshef, Teva Branded Pharmaceutical Products R&D- Inc., Epidemiología, Economía y Resultados de la Salud Global, Parsippany, Estados Unidos. M. Forrest Gordon, Teva Branded Pharmaceutical Products R&D- Inc., Medicamentos Innovadores - Desarrollo Clínico Global, West Chester, Estados Unidos. A. Kurzeja, Teva Pharmaceuticals Europe B.V., Asuntos Médicos de la UE, Ámsterdam, Países Bajos, T. D. Maurice, Teva Pharmaceuticals Europe B.V., Investigación de Economía y Resultados de la Salud Global, Ámsterdam, Países Bajos.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>REFERENCIAS\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>1.- Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐Analysis. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10086981\u002F\">https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10086981\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">2.-\u003C\u002Fspan>Teva drafts NFL star Terrell Davis for tardive dyskinesia awareness drive \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.fiercepharma.com\u002Fmarketing\u002Fteva-drafts-nfl-star-terrell-davis-tardive-dyskinesia-awareness-drive\">https:\u002F\u002Fwww.fiercepharma.com\u002Fmarketing\u002Fteva-drafts-nfl-star-terrell-davis-tardive-dyskinesia-awareness-drive\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">3.-\u003C\u002Fspan>Interview with Heather DeMyers See what Heather DeMyers has to say on Teva’s \"Pivot to Growth\" strategy and its impact on major products like AUSTEDO and AJOVY. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.newproductplanning.com\u002Fnewproductplanningcom\u002Fexclusive-interview-heather-demyers-teva\">https:\u002F\u002Fwww.newproductplanning.com\u002Fnewproductplanningcom\u002Fexclusive-interview-heather-demyers-teva\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">4.-\u003C\u002Fspan>Tardive Dyskinesia - Epidemiology Forecast to 2032. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fpdf.marketpublishers.com\u002Fdelveinsight\u002Ftardive-dyskinesia-epidemiology-insights-to-2025.pdf\">https:\u002F\u002Fpdf.marketpublishers.com\u002Fdelveinsight\u002Ftardive-dyskinesia-epidemiology-insights-to-2025.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">5.-\u003C\u002Fspan>Cascadas terapéuticas y reacciones adversas a medicamentos. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.euskadi.eus\u002Fcontenidos\u002Finformacion\u002Fuso_responsable_medicamentos\u002Fes_def\u002Fadjuntos\u002Fcascadas-terapeuticas.pdf\">https:\u002F\u002Fwww.euskadi.eus\u002Fcontenidos\u002Finformacion\u002Fuso_responsable_medicamentos\u002Fes_def\u002Fadjuntos\u002Fcascadas-terapeuticas.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">6.-\u003C\u002Fspan>Finally, Effective Treatments for Tardive Dyskinesia. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.thecarlatreport.com\u002Farticles\u002F3453-finally-effective-treatments-for-tardive-dyskinesia\">https:\u002F\u002Fwww.thecarlatreport.com\u002Farticles\u002F3453-finally-effective-treatments-for-tardive-dyskinesia\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">7.-\u003C\u002Fspan>Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System.\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Fpcn5.79\">https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Fpcn5.79\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">8.-\u003C\u002Fspan>Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia.\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41537-025-00618-w\">https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41537-025-00618-w\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">9.-\u003C\u002Fspan>Austedo. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Faustedo\">https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Faustedo\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">10.-\u003C\u002Fspan>¿Cuál es la diferencia entre deutetrabenazina y tetrabenazina? \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fdrugslib.com\u002Fmedical-q-a\u002Fwhat039s-the-difference-between-deutetrabenazine-and-tetrabenazine-330\u002Fes\u002F#gsc.tab=0\">https:\u002F\u002Fdrugslib.com\u002Fmedical-q-a\u002Fwhat039s-the-difference-between-deutetrabenazine-and-tetrabenazine-330\u002Fes\u002F#gsc.tab=0\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">11.-\u003C\u002Fspan>Teva Third quarter 2025 Teva Pharmaceutical Industries Ltd. November 5, 2025 \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fs24.q4cdn.com\u002F720828402\u002Ffiles\u002Fdoc_financials\u002F2025\u002Fq3\u002FQ325-Earnings-Presentation.pdf\">https:\u002F\u002Fs24.q4cdn.com\u002F720828402\u002Ffiles\u002Fdoc_financials\u002F2025\u002Fq3\u002FQ325-Earnings-Presentation.pdf\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">12.-\u003C\u002Fspan>Do you recognize the magnitude of tardive dyskinesia (TD) impact? \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.magnitude-of-td.com\u002F\">https:\u002F\u002Fwww.magnitude-of-td.com\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">13.-\u003C\u002Fspan>TouchDown. You know this TD moves. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.theothertd.com\u002F\">https:\u002F\u002Fwww.theothertd.com\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">14.-\u003C\u002Fspan>Teva lanza la campaña “The Other TD” para crear conciencia sobre la discinesia tardía con el apoyo del miembro del Salón de la Fama del Fútbol Americano Terrell Davis. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fnuevaprensa.web.ve\u002Fteva-lanza-la-campana-the-other-td-para-crear-conciencia-sobre-la-discinesia-tardia-con-el-apoyo-del-miembro-del-salon-de-la-fama-del-futbol-americano-terrell-davis\u002F\">https:\u002F\u002Fnuevaprensa.web.ve\u002Fteva-lanza-la-campana-the-other-td-para-crear-conciencia-sobre-la-discinesia-tardia-con-el-apoyo-del-miembro-del-salon-de-la-fama-del-futbol-americano-terrell-davis\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">15.-\u003C\u002Fspan>Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2020.1867443#abstract\">https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2020.1867443#abstract\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> Crítica: \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948230\">https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948230\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> Respuesta: \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948233\">https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F13696998.2021.1948233\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">16.-\u003C\u002Fspan>VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.cambridge.org\u002Fcore\u002Fjournals\u002Fcns-spectrums\u002Farticle\u002Fvmat2-inhibitors-for-the-treatment-of-tardive-dyskinesia-a-narrative-review\u002F76877F677766141404FC42B8030D9C51#article\">https:\u002F\u002Fwww.cambridge.org\u002Fcore\u002Fjournals\u002Fcns-spectrums\u002Farticle\u002Fvmat2-inhibitors-for-the-treatment-of-tardive-dyskinesia-a-narrative-review\u002F76877F677766141404FC42B8030D9C51#article\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">17.-\u003C\u002Fspan>Healy D, Le Noury J, Harris M, et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875–1924 and 1994–2010. BMJ Open 2012;2:e001810. doi:10.1136\u002Fbmjopen-2012- 001810\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">18.--Lessons from the RADAR trial. \u003Cu>\u003Ca href=\"https:\u002F\u002Fjoannamoncrieff.com\u002F2023\u002F10\u002F02\u002Flessons-from-the-radar-trial\u002F\">https:\u002F\u002Fjoannamoncrieff.com\u002F2023\u002F10\u002F02\u002Flessons-from-the-radar-trial\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>19.- Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode RemissionA Randomized Clinical Trial. \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fjamanetwork.com\u002Fjournals\u002Fjamapsychiatry\u002Ffullarticle\u002F2839607\">https:\u002F\u002Fjamanetwork.com\u002Fjournals\u002Fjamapsychiatry\u002Ffullarticle\u002F2839607\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>20.- Commentary: Does First Year Treatment With an Antipsychotic Lead to Long-Term Harm? \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.madinamerica.com\u002F2025\u002F11\u002Fcommentary-does-first-year-treatment-with-an-antipsychotic-lead-to-long-term-harm\u002F\">https:\u002F\u002Fwww.madinamerica.com\u002F2025\u002F11\u002Fcommentary-does-first-year-treatment-with-an-antipsychotic-lead-to-long-term-harm\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #000080;\">21.- Antipsicóticos como contención farmacológica en residencias geriátricas: desde el despropósito legal hasta la ética necesaria. \u003Ca href=\"https:\u002F\u002Faccesojustomedicamento.org\u002Fantipsicoticos-como-contencion-farmacologica-en-residencias-geriatricas-desde-el-desproposito-legal-hasta-la-etica-necesaria\u002F\">https:\u002F\u002Faccesojustomedicamento.org\u002Fantipsicoticos-como-contencion-farmacologica-en-residencias-geriatricas-desde-el-desproposito-legal-hasta-la-etica-necesaria\u002F \u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>",1764524288334,"boycott-austedo-teva-boicot-austedo-teva-eng-esp",[15,424],"Austedo","milzgf828cvb34yz678","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1764523262\u002Fuour7ho1oxxknmqxlelq.png","Boicot Austedo (Teva). Boycott Austedo (Teva). ENG ESP","AKcN6190y3M",{"user":13,"tags":430,"imageUrl":431,"link":12,"timestamp":432,"videoUrl":433,"content":434,"subtitle":435,"id":436,"title":437,"slug":438,"type":7},[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1764532355\u002Fn0ykt2devz3qkaxkivft.png",1764532485442,"AXUGvR55ESo","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv data-contents=\"true\">\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"5ra14\" data-offset-key=\"uvnt-0-0\">\u003Ca href=\"https:\u002F\u002Fradioalmaina.org\u002F2025\u002F12\u002F08\u002F266o-hoy-desde-aqui-boicot-teva-boicot-israel\u002F\">Actualizaci&oacute;n: entrevista en la radio Almania (Salud y Anarquía). 8 diciembre 2025\u003C\u002Fa> \u003Cem>Hola salud, bienvenidos y bienvenidas a Hoy desde Aquí, en este programa vamos a hablar con Pablo Simón, médico de familia que ha sido acusado de antisemitismo por una organización pro- israelí. Empezaremos explicando cuál es la actitud del ejército de israel contra el personal sanitario palestino que se encuentra en Gaza. Luego os explicaremos que en España hay una empresa farmacéutica que produce genéricos que se llama Teva, y que colabora activamente con el genocidio israelí contra los Gazatíes. Qué fue lo que hizo Pablo que provocó que un lobby sionista, lo denunciara en el colegio de médicos de Granada.\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"5ra14\" data-offset-key=\"uvnt-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"5ra14\" data-offset-key=\"uvnt-0-0\"> https:\u002F\u002Fradioalmaina.org\u002F2025\u002F12\u002F08\u002F266o-hoy-desde-aqui-boicot-teva-boicot-israel\u002F\u003C\u002Fdiv>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"5ra14\" data-offset-key=\"uvnt-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"5ra14\" data-offset-key=\"8rsf0-0-0\">\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cstrong>CARTA DE AGRADECIMIENTO\u003C\u002Fstrong>\u003Cbr>Pablo Simón Lorda\u003Cbr>Médico de Familia.\u003Cbr>Consultorio de Chauchina, Granada\u003Cbr>Heatlh Workers for Palestine – Spain\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>En Granada, 29 de Noviembre de 2025.\u003Cbr>Día Internacional de Solidaridad con el Pueblo Palestino.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>A todas las personas y organizaciones que me han expresado su apoyo.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>Hola a todos y todas:\u003Cbr>\u003Cem>Como sabéis el pasado 11 de Noviembre el periódico Ideal de Granada publicó una noticia sobre mi persona, con el titular “El colegio de Médicos estudia una queja por un doctor que pide no dar medicinas de una marca israelí”.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>En ella se me señalaba con mi nombre y apellidos. En la noticia, la periodista firmante se hacía eco de una queja interpuesta ante el Colegio de Médicos de Granada por “una entidad contra el antisemitismo” - la“Comisión Sanitaria contra el Antisemitismo” y la ”Coordinadora Estatal de Lucha contra el Antisemitismo- hacia mi persona- . \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">En el texto se recogían acusaciones muy graves contra mí, por mi recomendación a pacientes y\u003Cbr>farmacéuticos de que eviten dispensar y consumir medicamentos del laboratorio israelí TEVA, una empresa bien conocida por su apoyo al Genocidio de Gaza y sus prácticas corruptas. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">Se trataba de un escrito anónimo, sin firma, que aun así el Colegio de Granada accedió a estudiar. El procedimiento seguido por el Colegio en los días siguientes en la tramitación de esta queja estuvo plagado de irregularidades,\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fdenuncia-por-no-prescribir-teva-archivada-colegio-de-medicos-granada-espana-complaint-for-refusing-to-prescribe-teva-dismissed-granada-medical-association-spain-esp-engl\"> pero finalmente se ha saldado con el cierre del expediente y el archivo de la denuncia.\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>Estoy seguro de que uno de los factores clave para este desenlace fue el masivo apoyo que recibí de cientos de organizaciones como la vuestra, en respuesta a una solicitud gestionada y liderada por la Asociación Pro-Derechos Humanos de Andalucía en Granada. Muchas gracias de corazón por este apoyo tan generoso y solidario. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">El soporte emocional y técnico que me proporcionó el equipo de la APDH-A ha sido abrumador y mi agradecimiento hacia ellos y ellas, es también inmenso. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">El Colegio de Médicos de Granada ha salido con el prestigio muy tocado y el sionismo ha sido simbólicamente derrotado por vuestra cerrada unidad de acción.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>\u003Cstrong>No creo que esta agresión sea tanto una acción dirigida a mi persona, como una actuación dirigida a todas las personas implicadas en la causa palestina. No creo ser una persona tan importante. \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cstrong>\u003Cspan data-text=\"true\">Se trata más bien de una advertencia intimidatoria dirigida a cuantas personas deseen implicarse activamente en la lucha con el genocidio que no cesa. Quieren que tengamos miedo. No pueden conseguirlo. \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">Cualquiera de las cosas que puedan hacernos es bien pequeña en comparación a la represión feroz, mortal, que están llevando a cabo con el pueblo\u003Cbr>palestino y los miembros de la resistencia. Su tesón, su fortaleza asombrosa, tiene que ser motor de la nuestra.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>\u003Cem>La reacción de apoyo de la que vuestra organización ha formado parte también demuestra una cosa muy importante: que en un momento en que la propaganda israelí y sus cómplices occidentales extienden la idea de que “llegó la paz a Gaza” y, por tanto, la lucha carece de sentido, hay mucha gente, muchas organizaciones como la vuestra, que no se creen esta mentira cruel, esta manipulación. \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">Por eso se levantan en cuanto hay posibilidad de denunciar esta distopía en la forma que sea: por ejemplo, apoyando a un simple médico de familia que es acosado por defender el boicot a Teva. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">Y la unión de los insurrectos derriba el hormigón más armado.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>Por último quiero señalar la importancia de las acciones de boicot, no solo al laboratorio israelí TEVA, sino a todas las empresas que colaboran directamente o indirectamente con el genocidio y que el movimiento BDS nos señala. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">El boicot fue clave para acabar con el régimen de apartheid de Sudáfrica y será clave para el\u003Cbr>desmantelamiento del régimen colonial, racista y supremacista del sionismo israelí. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cem>Cada acto de boicot, por pequeño que sea, cuenta y se convierte en marea que derribará sus muros ensangrentados.\u003C\u002Fem>\u003Cbr>Termino ya agradeciéndoos de nuevo vuestro apoyo, a mi persona pero, sobre todo, a la lucha del pueblo palestino en unas horas muy difíciles.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cbr>\u003Cstrong>Un gran y fraterno abrazo a todos y todas. ¡Viva Palestina libre, desde el río hasta el mar!\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Pablo Simón Lorda\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\u003Cspan data-text=\"true\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"8rsf0-0-0\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv id=\"ow14\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">THANKS \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Pablo Simón Lorda Family Physician Chauchina Clinic, Granada, Spain, Health Workers for Palestine – Spain \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Granada, November 29, 2025 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">International Day of Solidarity with the Palestinian People \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">To all the people and organizations who have expressed their support.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Hello everyone.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> As you know, on November 11, the Granada newspaper Ideal published an article about me, with the headline “The College of Physicians (Colegio de Médicos de Granada) is studying a complaint against a doctor who asks that medicines from an Israeli brand not be prescribed.”\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In it, I was mentioned by name.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In the news article, the journalist reported on a complaint filed with the Granada Medical Association by an anti-Semitism organization—the \"Health Commission Against Anti-Semitism\" and the \"State Coordinator for the Fight Against Anti-Semitism\"—against me. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The text contained very serious accusations against me for my recommendation to patients and pharmacists to avoid dispensing and using medications from the Israeli laboratory TEVA, a company well-known for its support of the Gaza Genocide and its corrupt practices. It was an anonymous, unsigned document, which the Granada Medical Association nevertheless agreed to review. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The procedure followed by the Association in the following days in processing this complaint was riddled with irregularities,\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fdenuncia-por-no-prescribir-teva-archivada-colegio-de-medicos-granada-espana-complaint-for-refusing-to-prescribe-teva-dismissed-granada-medical-association-spain-esp-engl\"> but it ultimately resulted in the closure of the case and the dismissal of the complaint. \u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">I am certain that one of the key factors in this outcome was the massive support I received from hundreds of organizations like yours, in response to a\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Request managed and led by the Association for Human Rights of Andalusia in Granada.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Thank you from the bottom of my heart for this generous and supportive assistance.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The emotional and technical support provided by the APDH-A team has been overwhelming, and my gratitude towards them is also immense.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Granada Medical Association (Colegio de Médicos de Granada) has suffered a severe blow to its reputation, and Zionism has been symbolically defeated by your unwavering unity of action.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">I don't believe this attack is so much directed at me personally as it is at all those involved in the Palestinian cause.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">I don't consider myself that important.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">It is more of an intimidating warning aimed at all those who wish to actively participate in the fight against the ongoing genocide.\u003C\u002Fspan> \u003Cstrong>\u003Cspan class=\"ryNqvb\">They want us to be afraid.\u003C\u002Fspan> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">They cannot succeed.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Anything they can do to us is insignificant compared to the fierce, deadly repression they are carrying out against the Palestinian people and the members of the resistance.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Their tenacity,\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Its astonishing strength must be the driving force behind ours.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> The outpouring of support in which your organization has participated also demonstrates something very important: that at a time when Israeli propaganda and its Western accomplices are spreading the idea that “peace has come to Gaza” and, therefore, the struggle is pointless, there are many people, many organizations like yours, who do not believe this cruel lie, this manipulation.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">That is why they rise up as soon as there is a possibility to denounce this dystopia in whatever form: for example, by supporting a simple family doctor who is harassed for defending the boycott of Teva.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">And the unity of the insurgents can bring down even the most reinforced concrete.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Finally, I want to emphasize the importance of boycott actions, not only against the Israeli laboratory Teva, but against all the companies that collaborate directly or indirectly with the genocide and that the BDS movement points out to us.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The boycott was key to ending the apartheid regime in South Africa and will be key to dismantling the\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The colonial, racist, and supremacist regime of Israeli Zionism.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Every act of boycott, however small, counts and becomes a tide that will bring down its bloodstained walls.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">I conclude by thanking you again for your support, both for me personally and, above all, for the struggle of the Palestinian people in these very difficult times.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">A big, fraternal hug to everyone.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Long live a free Palestine, from the river to the sea!\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Pablo Simón Lorda\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","Al sionismo y a Teva se les vence con la unión. Boicot. Zionism and Teva can be defeated through unity. Boycott.","mim4j6fvcojkakbfvm6","Carta de agradecimiento, Pablo Simón. Pablo Simón., thanks. ESP ENG","carta-de-agradecimiento-pablo-simon-pablo-simon-thanks-esp-eng",{"imageUrl":440,"content":441,"timestamp":442,"type":7,"videoUrl":443,"slug":444,"link":12,"user":13,"tags":445,"title":446,"subtitle":447,"id":448},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1764604668\u002Fym1tufvk6iemjdwjflbq.png","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"neOZNc C9DxTc\" style=\"vertical-align: baseline;\">\u003Cspan class=\"jgG6ef C9DxTc\" style=\"color: #000000; font-family: Comfortaa, Arial; font-weight: 500; vertical-align: baseline;\">\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Ftribunal-de-los-pueblos-sobre-la-complicidad-con-el-genocidio-palestino-en-el-estado-espanol-tpcgp-25\">ADVERTENCIA DE HW4PS (Health Workers For Palestine, Spain):\u003C\u002Fa>\u003C\u002Fstrong> \u003Cem>El tribunal no pretende simplemente condenar\u002Fabsolver sino, sobre todo, convencer a la opinión pública española con pruebas que demuestren la implicación de España, la intencionalidad y las acciones sistemáticas que hacen posible el genocidio del pueblo palestino en Gaza, dónde actores españoles (o con responsabilidad penal en España) están actuando conscientemente en favor del estado de Israel y beneficiándose del Genocidio propiamente dicho. \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan class=\"neOZNc C9DxTc\" style=\"vertical-align: baseline;\">\u003Cspan class=\"jgG6ef C9DxTc\" style=\"color: #000000; font-family: Comfortaa, Arial; font-weight: 500; vertical-align: baseline;\">No se enjuicia a Israel sino a España.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"neOZNc C9DxTc\" style=\"vertical-align: baseline;\">\u003Cspan class=\"jgG6ef C9DxTc\" style=\"color: #000000; font-family: Comfortaa, Arial; font-weight: 500; vertical-align: baseline;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cspan style=\"font-size: 20.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #660000;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan style=\"font-size: 11.0pt; line-height: 115%; font-family: 'Arial',sans-serif;\"> \u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: 10.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: black; background: #cccccc;\">[English below]\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cspan style=\"font-size: 11.0pt; line-height: 115%; font-family: 'Arial',sans-serif;\"> \u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: 20.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #660000;\">EL TPCGP-25 (Tribunal de los Pueblos sobre la Complicidad del Estado español con el Genocidio en Palestina) CONCLUYE CON UNA LLAMADA URGENTE A LA ACCIÓN POR Y PARA LA JUSTICIA EN PALESTINA\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cspan style=\"font-size: 23.0pt; line-height: 115%; font-family: 'Comfortaa',serif;\">NOTA DE PRENSA Y SENTENCIA (\"DECLARACIÓN DE MADRID\")\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cspan style=\"font-size: 13.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #274e13;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cspan style=\"font-size: 13.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #274e13;\">El tribunal, presidido por Raji Sourani (Centro Palestino para los Derechos Humanos, Palestina), Rabab I. Abdulhadi (San Francisco State University, California, Estados Unidos) y\u003Ca href=\"https:\u002F\u002Fcausaarabeblog.blogspot.com\u002F2025\u002F12\u002Ftribunal-de-los-pueblos-sobre-la.html?m=1\"> Luz Gómez\u003C\u002Fa> (Universidad Autónoma de Madrid, España), se ha celebrado los días 28 y 29 de noviembre en la Facultad de Políticas y Sociología  de la Universidad Complutense de Madrid.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"line-height: 115%;\">\u003Cspan style=\"font-size: 13.0pt; line-height: 115%; font-family: 'Comfortaa',serif;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">Nota de prensa y sentencia (\"Declaración de Madrid\"), en Madrid, España, Facultad de Ciencias Políticas y Sociología de la Universidad Complutense de MadriD, a 29 de noviembre de 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">Durante los días 28 y 29 de noviembre, 220 personas han asistido a las nueve sesiones del \u003C\u002Fspan>\u003Cspan style=\"font-size: 11.0pt; line-height: 115%; font-family: 'Arial',sans-serif;\">\u003Ca href=\"https:\u002F\u002Ftribunaldelospueblos.org\u002F\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Ftribunaldelospueblos.org\u002F&source=gmail&ust=1764685409459000&usg=AOvVaw38yZfE2nE5hJlPBLlb4A_Z\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-size: 12.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #1155cc;\">Tribunal de los Pueblos sobre la Complicidad con el Genocidio Palestino en el estado español\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fspan>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">, foro independiente y autónomo en el que, colectivos, organizaciones y campañas de la sociedad civil, han aportado testimonios, informes y documentación que desvela el entramado de intereses económicos, políticos y culturales que, \u003Cem>desde el Estado español,\u003C\u002Fem> permite la comisión y normalización de crímenes de lesa humanidad contra las y los palestinos. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">Las decenas de testimonios compartidos han evidenciado cómo el carácter estructural, profundo y sistémico de las relaciones con el estado sionista de Israel se ha combinado, necesariamente, con una ausencia de decisiones individuales, por parte de los agentes capaces de tomarlas, para romper las inercias del entramado criminal. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">La complicidad y la cooperación necesaria se ha sido documentada con informes que se han puesto a disposición de los presidentes de cada mesa, informes que en conjunto superan las 600 páginas, apelan a: \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-size: 11.0pt; line-height: 115%; font-family: 'Arial',sans-serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">El gobierno de España y las instituciones estatales\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">, porque, parapetados tras condenas vacías y reconocimientos sin contenido, han contribuido a mantener el \u003Cem>business as usual \u003C\u002Fem>con Israel, violador sistemático del derecho internacional. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">La Banca Armada\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">, \u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">por financiar la producción de todos los tipos de armas utilizadas en Gaza y Cisjordania. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\"> Las universidades\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">, por iniciar y mantener contratos, convenios y proyectos de investigación, incluyendo tecnología de doble uso. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">Las empresas, \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">por continuar el comercio con empresas asentadas en territorios ocupados violando así la legislación internacional. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">Los colegios y asociaciones profesionales médicas,\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\"> por ignorar todos los códigos deontológicos de la profesión mediante un silencio activo y tenaz frente a la barbarie y destrucción de la vida. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">A la cultura, el deporte y los medios de comunicación,\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">por contribuir a la narrativa de que el estado que en más ocasiones ha violado el Derecho Internacional es un \u003Cem>estado más \u003C\u002Fem>y tiene derecho a la \u003Cem>normalidad\u003C\u002Fem> en sus relaciones con otros estados. \u003Cstrong>\u003Cem> \u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">A todas las anteriores, y otras muchas, \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">por ignorar por completo el llamado urgente de la Corte Internacional de Justicia, la Corte Penal Internacional, la ONU y la relatora Francesca Albanese \u003Cstrong>a cumplir la ley y detener el genocidio. \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">Como gesto de soberanía popular, el \u003Cstrong>TPCGP-25, en esta su primera sesión pública, culmina con una resolución final de 20 puntos que se fundamenta en las investigaciones previas y las aportaciones añadidas en todas las sesiones. Sin embargo, como consideración final, se propone su continuidad \u003C\u002Fstrong>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">Las presidentas del Tribunal sentenciaron:\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>TPCGP-25\u003Cbr>Tribunal de los Pueblos sobre la Complicidad con el Genocidio Palestino en el Estado Español\u003Cbr>\u003Cstrong>RESOLUCIÓN FINAL\u003C\u002Fstrong>\u003Cbr>Presidencia: Rabab Abdulhadi, Luz Gómez y Raji Sourani\u003Cbr>Secretaría: Pablo Gutiérrez Vega (Universidad de Sevilla, España)\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>\u003Cstrong>RESOLUCIÓN FINAL: “DECLARACIÓN DE MADRID” DE 29.11.2025\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>\u003Cem>I. Naturaleza y Mandato del Tribunal\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>1. El Tribunal de los Pueblos sobre la Complicidad con el Genocidio\u003Cbr>Palestino en el Estado Español (TPCGP-25) es un tribunal de\u003Cbr>conciencia, integrado por personalidades del ámbito jurídico,\u003Cbr>académico, cultural y de defensa de los derechos humanos,\u003Cbr>convocado por la Red Universitaria por Palestina (RUxP) y\u003Cbr>organizaciones de la sociedad civil con el fin de examinar, desde la\u003Cbr>perspectiva del derecho internacional y la ética pública, la conducta\u003Cbr>de actores estatales y no estatales en sus vínculos con la ocupación,\u003Cbr>el apartheid y genocidio del pueblo palestino.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>2. Este Tribunal no posee autoridad jurisdiccional estatal ni aspira\u003Cbr>a ello. Sigue la tradición de los Tribunales Russell I y II, reconocidos\u003Cbr>internacionalmente por su contribución a la denuncia de\u003Cbr>violaciones masivas de derechos humanos y al fortalecimiento de la\u003Cbr>conciencia moral universal. Su objetivo es estudiar, comprender y\u003Cbr>movilizar a la sociedad civil española.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>3. El Tribunal examina la posible responsabilidad, por acción u\u003Cbr>omisión, del Estado español y de las empresas, organizaciones e\u003Cbr>instituciones de su jurisdicción que contribuyen a y\u002Fo se benefician\u003Cbr>de las graves violaciones del derecho internacional humanitario y el\u003Cbr>derecho internacional de los derechos humanos en el contexto\u003Cbr>citado, incluyendo su eventual incumplimiento del deber de prevenir\u003Cbr>crímenes internacionales como crímenes de guerra, lesa humanidad\u003Cbr>o genocidio.\u003Cbr>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>\u003Cem>II. Competencia Material y Marco Normativo\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>4. El Tribunal examina los hechos a la luz de los principios y normas\u003Cbr>reconocidas por:\u003Cbr>* La Carta de las Naciones Unidas.\u003Cbr>* Los Convenios de Ginebra de 1949 y sus Protocolos Adicionales.\u003Cbr>* La Convención para la Prevención y Sanción del Delito de Genocidio\u003Cbr>(1948).\u003Cbr>* El Estatuto de Roma de la Corte Penal Internacional, en cuanto\u003Cbr>expresión codificada del derecho penal internacional.\u003Cbr>* El corpus del derecho internacional de los derechos humanos y los\u003Cbr>principios generales del derecho reconocidos por la comunidad de\u003Cbr>naciones.\u003Cbr>* Los principios rectores sobre las empresas y los derechos Humanos\u003Cbr>de Naciones Unidas para “proteger, respetar y remediar” (Resolución\u003Cbr>17\u002F4 2011)\u003Cbr>* La doctrina consolidada por los Tribunales Russell y el Tribunal\u003Cbr>Permanente de los Pueblos sobre derechos de los pueblos,\u003Cbr>autodeterminación y responsabilidad indirecta o por complicidad.\u003Cbr>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\"> \u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cem>III. Sobre los Hechos y las Evidencias Consideradas\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>Tras las investigaciones, el análisis y la evaluación de los informes\u003Cbr>presentados por los equipos de trabajo de las siete mesas\u003Cbr>temáticas, \u003C\u002Fspan>e\u003Cspan style=\"font-family: 'Comfortaa',serif;\">l Tribunal considera acreditados los hechos\u003Cbr>presentados y emite las siguientes conclusiones:\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>5. \u003Cstrong>Se ha expuesto y documentado que el Estado español lleva\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>décadas colaborando con la ocupación, el apartheid y la\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Nakba permanente, y con el genocidio en último término, violando la\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>legalidad internacional y, con ella, la prohibición a los estados\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>terceros de ayudar o asistir a otro en la comisión de crímenes\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>internacionales. El gobierno español tenía y tiene pleno\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>conocimiento de las ilegalidades y crímenes de guerra cometidos\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>por el Estado israelí, sin que esta información haya motivado las\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>medidas correspondientes para suspender relaciones económicas\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>ni diplomáticas, ni para imponer las sanciones obligadas por\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>numerosas resoluciones internacionales.\u003C\u002Fstrong>\u003Cbr>\u003Cbr>6. Un caso de especial relevancia es el relativo a la\u003Cbr>Global Sumud Flotilla, atacada por las fuerzas de ocupación israelí, que\u003Cbr>secuestraron, maltrataron y deportaron a 49 personas con\u003Cbr>pasaporte español. El gobierno “actuó” abandonando la obligación\u003Cbr>legal de tomar las medidas necesarias para proteger los derechos\u003Cbr>de sus ciudadanos.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>7. La expansión de la industria bélico-policial-securitaria, junto con\u003Cbr>las prácticas de cabildeo del sionismo, alimenta la trama de\u003Cbr>intereses empresariales, sociales y políticos que marcan las\u003Cbr>agendas de los agentes implicados. Esta trama de intereses se\u003Cbr>sostiene y refuerza sobre una “simbiosis estatal-corporativa” en la\u003Cbr>que las administraciones públicas de estados cómplices como el\u003Cbr>español actúan a modo de apéndices instrumentales de los\u003Cbr>mercados, muy especialmente de las corporaciones dedicadas a la\u003Cbr>producción de daño y muerte.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>8. Una red de empresas estatales, nacionales e internacionales\u003Cbr>participa activamente del negocio del genocidio, prestando\u003Cbr>servicios, fabricando productos, alimentando la maquinaria\u003Cbr>económica y logística de la ocupación y reforzando sus lógicas de\u003Cbr>captura del espacio y opresión sistemática.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>9. Durante los últimos dos años, los puertos del Estado español se\u003Cbr>han convertido en enclaves cruciales de las rutas que abastecen de\u003Cbr>armas y energía al régimen genocida de Israel. Estos puertos,\u003Cbr>infraestructuras públicas financiadas con recursos colectivos, se\u003Cbr>han convertido en nodos logísticos de una maquinaria genocida\u003Cbr>que sostiene la ocupación, el apartheid y la destrucción sistemática\u003Cbr>de Palestina. Rutas y escalas se repiten regularmente, con los\u003Cbr>puertos de Algeciras, Valencia, Barcelona, Cartagena y la base naval\u003Cbr>de Rota desempeñando papeles distintos en una misma red. Los\u003Cbr>puertos españoles son piezas de una logística genocida integrada.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>10. La evidencia presentada demuestra que la Banca Armada ha\u003Cbr>desempeñado un papel crucial en la producción y uso de las armas\u003Cbr>utilizadas en Gaza. Los bancos Santander y BBVA, seguidos por\u003Cbr>Caixabank, Ibercaja, Banca March… son a la vez beneficiarios y\u003Cbr>facilitadores imprescindibles del exterminio del pueblo palestino.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>11. Ha sido documentado que empresas del sector de la obra civil y\u003Cbr>las infraestructuras se han beneficiado de la ocupación y el\u003Cbr>apartheid, puesto que han colaborado y participado en proyectos\u003Cbr>desarrollados en los territorios ocupados que violan los principios\u003Cbr>los derechos de la población palestina. Constructoras españolas\u003Cbr>están asociadas a proyectos energéticos y de infraestructuras\u003Cbr>viarias o ferroviarias.\u003Cbr>\u003Cbr>12. Se ha documentado que hay corporaciones multinacionales\u003Cbr>extractivas israelíes con filiales en España y directamente cómplices\u003Cbr>con el genocidio. Se ha constatado que entidades públicas,\u003Cbr>académicas y financieras funcionan de forma entrelazada y\u003Cbr>mantienen relaciones con estas empresas cerrando los ojos ante\u003Cbr>sus violaciones de los derechos humanos.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>13. Se ha documentado que, en ámbitos fundamentales para la\u003Cbr>supervivencia del pueblo palestino –como el agua, la energía y los\u003Cbr>bienes y servicios básicos–, empresas españolas e israelíes obtienen\u003Cbr>importantes beneficios.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>14. Se entiende probada la conexión del capital inmobiliario, los\u003Cbr>fondos de inversión y ciertas instituciones españolas con fondos de\u003Cbr>inversión israelís y estodounidenses responsables de la violación de\u003Cbr>los derechos de las y los palestinos, siendo numerosas las filiales de\u003Cbr>empresas israelíes que operan en el territorio español. El sector\u003Cbr>turístico se presenta como una de las áreas de negocio más\u003Cbr>lucrativas para ambas partes.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>15. Queda documentado que el mercado de la ciberseguridad en\u003Cbr>España está dominado por la tecnología israelí, directa e\u003Cbr>indirectamente –a través de empresas estadounidenses vinculadas\u003Cbr>a capital israelí–, en el ámbito de las administraciones públicas y en\u003Cbr>el privado, y que las empresas tecnológicas son actores clave en la\u003Cbr>perpetración del genocidio palestino, así como para el régimen de\u003Cbr>apartheid preexistente.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>16. Se expone que los medios de comunicación no son espectadores\u003Cbr>sino actores estructurales del genocidio: seleccionan, enmarcan,\u003Cbr>silencian o amplifican mensajes de blanqueamiento del sionismo y\u003Cbr>de deshumanización de la resistencia palestina. La cobertura\u003Cbr>mediática de Gaza en 2023–2025 muestra enfoques y posiciones\u003Cbr>políticas de complicidad con el genocidio presentadas\u003Cbr>frecuentemente como “neutrales”.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>17. La incitación al genocidio se produce mediante la difusión por los\u003Cbr>medios de comunicación masiva de discursos que deshumanizan al\u003Cbr>pueblo palestino y potencian o justifican las acciones de Israel.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>18. Israel ejecuta un culturicidio que busca desarticular la memoria\u003Cbr>colectiva, quebrar la transmisión intergeneracional y destruir la\u003Cbr>identidad nacional del pueblo palestino. El Estado español participa\u003Cbr>en la legitimación de la ocupación israelí, el apartheid y el genocidio\u003Cbr>mediante la promoción cultural, proyectando una imagen\u003Cbr>distorsionada y favorable de Israel. La colaboración cultural toma\u003Cbr>así un carácter estratégico.\u003Cbr>\u003Cbr>19. Ha quedado documentado que la influencia de Israel en espacios\u003Cbr>culturales contribuye a la aceptación social de políticas ilegales y la\u003Cbr>invisibilización de los crímenes cometidos contra las y los palestinos.\u003Cbr>Una red cultural de complicidad integra los campos económico,\u003Cbr>simbólico y mediático bajo una estrategia de legitimación efectiva y\u003Cbr>estructural.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>20. La presencia de Israel en el contexto deportivo español se\u003Cbr>observa en multitud de áreas. Entre ellas destaca la inversión de\u003Cbr>capital israelí y\u002Fo sionista en clubes como el Atlético de Madrid o el\u003Cbr>Movistar Team, el negocio de la retransmisión de eventos deportivos\u003Cbr>por empresas cercanas a Netanyahu, como DAZN, o la compra de\u003Cbr>tecnología israelí por organismos españoles como La Liga o el FC\u003Cbr>Barcelona. En España, numerosos clubes y eventos deportivos\u003Cbr>cuentan con patrocinadores vinculados a las prácticas genocidas,\u003Cbr>de ocupación ilegal y de apartheid que Israel lleva a cabo en\u003Cbr>Palestina. Junto al patrocinio privado, la participación de\u003Cbr>organismos públicos, corporaciones municipales y gobiernos de\u003Cbr>comunidades autónomas evidencia su colaboración en la\u003Cbr>vulneración de los derechos fundamentales del pueblo palestino.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>21. \u003Cem>En el ámbito del mercado sanitario queda documentado que,\u003C\u002Fem>\u003Cbr>\u003Cem>pese a las reiteradas declaraciones de personal sanitario y\u003C\u002Fem>\u003Cbr>\u003Cem>personas expertas en salud pública sobre las atrocidades\u003C\u002Fem>\u003Cbr>\u003Cem>cometidas contra la población civil en Gaza, una gran mayoría de\u003C\u002Fem>\u003Cbr>\u003Cem>academias, asociaciones y sociedades científicas de medicina,\u003C\u002Fem>\u003Cbr>\u003Cem>enfermería o farmacia, así como organizaciones profesionales de la\u003C\u002Fem>\u003Cbr>\u003Cem>salud, se ha mantenido en silencio y ha ignorado por completo las\u003C\u002Fem>\u003Cbr>\u003Cem>obligaciones impuestas por sus códigos deontológicos. En términos\u003C\u002Fem>\u003Cbr>\u003Cem>materiales, la complicidad con el genocidio en el ámbito médico\u003C\u002Fem>\u003Cbr>\u003Cem>tiene su principal exponente en el gigante farmacéutico TEVA.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>22. Una parte significativa de las universidades del Estado español\u003Cbr>sigue participando en consorcios de investigación, manteniendo\u003Cbr>convenios de colaboración, cátedras y programas de movilidad con\u003Cbr>universidades e instituciones de investigación israelíes. Está\u003Cbr>documentado que algunas de estas colaboraciones implican la\u003Cbr>investigación para el desarrollo de tecnología de doble uso.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>23. Así mismo, se ha documentado la amplia colaboración de las\u003Cbr>universidades y centros de investigación españolas con empresas\u003Cbr>presentes en los territorios ocupados o que participan de la\u003Cbr>economía del apartheid y el genocidio.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>24. Centros educativos y universidades del estado español replican\u003Cbr>la lógica de eliminación colonial que se implementa en Gaza y en\u003Cbr>Palestina, mediante una censura disfrazada de imparcialidad.\u003Cbr>\u003Cbr>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cstrong>IV. Consideración Final\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>25\u003Cem>. El Tribunal declara que esta Resolución se emite con la\u003C\u002Fem>\u003Cbr>\u003Cem>convicción de que la voz de la conciencia colectiva es un\u003C\u002Fem>\u003Cbr>\u003Cem>instrumento indispensable frente a la impunidad, especialmente\u003C\u002Fem>\u003Cbr>\u003Cem>cuando los mecanismos institucionales formales son insuficientes o\u003C\u002Fem>\u003Cbr>\u003Cem>lentos para responder a la gravedad de los hechos.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>La actual fase del genocidio nos obliga a continuar con este trabajo\u003Cbr>de documentación, denuncia y memoria. Instamos a todos los\u003Cbr>participantes y colaboradores en este Tribunal a seguir con\u003Cbr>trabajos iniciados.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>En Madrid, España, Facultad de Ciencias Políticas y Sociología de la Universidad Complutense de Madrid, a 29 de noviembre de 2025\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #274e13;\">“Nuestra tarea es crear conocimiento, y ningún conocimiento es neutral. Creemos conocimiento por y para la justicia”.  \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #274e13;\">Rabab I. Abdulhadi\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #274e13;\"> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cem>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #274e13;\">“Palestina ha renacido de sus cenizas tras Karameh, tras Beirut, tras Oslo. Lo hará tras Gaza”.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #274e13;\"> Luz Gómez.\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cstrong>\u003Cspan style=\"font-size: 24.0pt; line-height: 150%; font-family: 'Comfortaa',serif; color: #660000;\">Más información y material \u002F More information and material: \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cspan style=\"font-size: 13.5pt; line-height: 150%; font-family: 'Arial',sans-serif;\">\u003Ca href=\"https:\u002F\u002Ftribunaldelospueblos.org\u002F\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Ftribunaldelospueblos.org\u002F&source=gmail&ust=1764685409459000&usg=AOvVaw38yZfE2nE5hJlPBLlb4A_Z\">\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #1155cc;\">https:\u002F\u002Ftribunaldelospueblos.\u003Cwbr>org\u002F\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cspan style=\"font-size: 13.5pt; line-height: 150%; font-family: 'Arial',sans-serif;\">\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002F@RUxP2024\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Fwww.youtube.com\u002F@RUxP2024&source=gmail&ust=1764685409459000&usg=AOvVaw3SUTXn6ELoM3Eoy2BzqS8O\">\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #1155cc;\">https:\u002F\u002Fwww.youtube.com\u002F@\u003Cwbr>RUxP2024\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cspan style=\"font-size: 13.5pt; line-height: 150%; font-family: 'Arial',sans-serif;\">\u003Ca href=\"http:\u002F\u002Fwww.redxpalestina.org\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=http:\u002F\u002Fwww.redxpalestina.org&source=gmail&ust=1764685409459000&usg=AOvVaw3s6TOwjoSey8bXx18jnHBJ\">\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #1155cc;\">www.redxpalestina.org\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cstrong>\u003Cu>\u003Cspan style=\"font-size: 13.5pt; line-height: 150%; font-family: 'Comfortaa',serif; color: #1155cc;\">\u003Ca href=\"https:\u002F\u002Fx.com\u002FRedxPalestina\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Fx.com\u002FRedxPalestina&source=gmail&ust=1764685409459000&usg=AOvVaw3begkgtY3t18BHMHBX7for\">https:\u002F\u002Fx.com\u002FRedxPalestina\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cspan style=\"font-size: 13.5pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #660000;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cspan style=\"font-size: 13.5pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #660000;\">Contacto:\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Ch3 style=\"margin-right: 0cm; margin-bottom: 4.0pt; margin-left: 0cm; text-align: center; line-height: 115%; break-after: auto;\" align=\"center\">\u003Ca name=\"m_3510617878888220523_m_-6209836626524266887__5eqpno6ansth\">\u003C\u002Fa>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #274e13;\">\u003Ca href=\"mailto:ruxp@tribunaldelospueblos.org\" target=\"_blank\" rel=\"noopener\">ruxp@tribunaldelospueblos.org\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fh3>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cspan style=\"font-size: 13.5pt; line-height: 115%; font-family: 'Comfortaa',serif;\">*\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Cem>\u003Cspan style=\"font-size: 10.0pt;\">El genocidio de Gaza es tan europeo y estadounidense como israelí\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Cspan style=\"font-size: 10.0pt;\">(Ghassan Abu Sittah, rector de Glasgow University)\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Cstrong>Tribunal de los Pueblos sobre la Complicidad del Estado español \u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Cstrong>con el Genocidio en Palestina (TPCGP-25)\u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Ca href=\"https:\u002F\u002Ftribunaldelospueblos.org\u002F\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Ftribunaldelospueblos.org\u002F&source=gmail&ust=1764685409459000&usg=AOvVaw38yZfE2nE5hJlPBLlb4A_Z\">\u003Cstrong>https:\u002F\u002Ftribunaldelospueblos.\u003Cwbr>org\u002F\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Ca href=\"http:\u002F\u002Fwww.redxpalestina.org\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=http:\u002F\u002Fwww.redxpalestina.org&source=gmail&ust=1764685409459000&usg=AOvVaw3s6TOwjoSey8bXx18jnHBJ\">www.redxpalestina.org\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002F@RUxP2024\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Fwww.youtube.com\u002F@RUxP2024&source=gmail&ust=1764685409459000&usg=AOvVaw3SUTXn6ELoM3Eoy2BzqS8O\">https:\u002F\u002Fwww.youtube.com\u002F@\u003Cwbr>RUxP2024\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Ca href=\"https:\u002F\u002Ftwitter.com\u002FRedxPalestina\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Ftwitter.com\u002FRedxPalestina&source=gmail&ust=1764685409459000&usg=AOvVaw0z2BbdiVJd-XLw-ONIH1AB\">@RedxPalestina\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\"> \u003C\u002Fp>\n\u003Cp class=\"MsoNormal\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Ftribunal-de-los-pueblos-sobre-la-complicidad-con-el-genocidio-palestino-en-el-estado-espanol-tpcgp-25\">HW4PS WARNING (Health Workers For Palestine, Spain)\u003C\u002Fa>: The court does not simply intend to convict-acquit, but above all, to convince Spanish public opinion with evidence demonstrating Spain's involvement, intent, and systematic actions that enable the genocide of the Palestinian people in Gaza, where Spanish actors (or those with criminal responsibility in Spain) are knowingly acting in favor of the State of Israel and profiting from the genocide itself.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">It is not Israel that is being tried, but Spain.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\"> \u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cspan lang=\"EN-US\" style=\"font-size: 20.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #660000;\">TPCGP-25 (People's Tribunal on Complicity with the Palestinian Genocide in the Spanish State) CONCLUDES WITH AN URGENT CALL FOR ACTION FOR AND BY JUSTICE IN PALESTINE\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cspan lang=\"EN-US\" style=\"font-size: 20.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #660000;\">\u003Cspan style=\"font-size: 23.0pt; line-height: 115%; font-family: 'Comfortaa',serif;\">PRESS RELEASE AND VERDICT (\"MADRID DECLARATION\")\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\"> \u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cspan lang=\"EN-US\" style=\"font-size: 13.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #274e13;\">The tribunal, presided over by Raji Sourani (Palestinian Centre for Human Rights, Palestine), Rabab I. Abdulhadi (San Francisco State Universiy, California, USA) and Luz Gómez (Universidad Autónoma de Madrid, Spain), was held on 28 and 29 November at the Faculty of Politics and Sociology of the Complutense University of Madrid, Spain.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cspan lang=\"EN-US\" style=\"font-size: 13.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #274e13;\">\u003Cspan class=\"ryNqvb\">In Madrid, Spain, Faculty of Political Science and Sociology of the Complutense University of Madrid, on November 29, 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-size: 13.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #274e13;\"> \u003C\u002Fspan>\u003Cspan lang=\"EN-US\" style=\"font-size: 13.0pt; line-height: 115%; font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">On 28 and 29 November, 220 people attended the nine sessions of \u003C\u002Fspan>\u003Cspan style=\"font-size: 11.0pt; line-height: 115%; font-family: 'Arial',sans-serif;\">\u003Ca href=\"https:\u002F\u002Ftribunaldelospueblos.org\u002F\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Ftribunaldelospueblos.org\u002F&source=gmail&ust=1764685409459000&usg=AOvVaw38yZfE2nE5hJlPBLlb4A_Z\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-size: 12.0pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #1155cc;\">the People's Tribunal on Complicity with the Palestinian Genocide within the Spanish\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fspan>\u003Cstrong>\u003Cem>\u003Cu>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif; color: #1155cc;\"> State\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">, an independent and autonomous forum in which civil society groups, organisations and campaigns have provided testimonies, reports and documentation revealing the network of economic, political and cultural interests that, \u003Cem>from within the Spanish state, \u003C\u002Fem>allows the commission and normalisation of crimes against humanity against Palestinians. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">The dozens of testimonies shared have shown how the structural, deep-rooted and systemic nature of relations with the Zionist state of Israel has necessarily been combined with a lack of individual decisions by those capable of taking them to break the inertia of the criminal network. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">The necessary complicity and cooperation has been documented in reports made available to the chairpersons of each panel, reports that together exceed 600 pages and call upon: \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">The Spanish government and state institutions\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">, because, hiding behind empty condemnations and meaningless acknowledgements, they have contributed to maintaining \u003Cem>business as usual \u003C\u002Fem>with Israel, a systematic violator of international law. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">The Armed Banking System\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">, \u003C\u002Fspan>\u003C\u002Fem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">for financing the production of all types of weapons used in Gaza and the West Bank. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">Universities\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">, for initiating and maintaining contracts, agreements and research projects, including dual-use technology. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">Companies, \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">for continuing to trade with companies based in occupied territories, thereby violating international law. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">Medical schools and professional associations, \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">for ignoring all the ethical codes of the profession through active and stubborn silence in the face of barbarism and destruction of life. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">Culture, sport and the media, \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">for contributing to the narrative that the state that has most often violated international law is \u003Cem>just another state \u003C\u002Fem>and has the right to \u003Cem>normal \u003C\u002Fem>relations with other states.  \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">To all of the above, and many others, \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">for completely ignoring the urgent call from the International Court of Justice, the International Criminal Court, the UN and UN rapporteur Francesca Albanese \u003Cstrong>to comply with the law and stop the genocide. \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">As a gesture of popular sovereignty, the \u003Cstrong>TPCGP-25, in its first public session, concludes with a final 20-point resolution based on previous investigations and contributions added in all sessions. However, as a final consideration, its continuation is proposed\u003C\u002Fstrong>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">The presidents of the Tribunal stated:\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>TPCGP-25\u003Cbr>People's Tribunal on Complicity with the Palestinian Genocide in the Spanish State\u003Cbr>\u003Cem>FINAL RESOLUTION\u003C\u002Fem>\u003Cbr>Presiding: Rabab Abdulhadi, Luz Gómez and Raji Sourani\u003Cbr>Secretary: Pablo Gutiérrez Vega (Universidad de Sevilla, Spain)\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>\u003Cstrong>FINAL RESOLUTION: \"MADRID DECLARATION\" OF 29.11.2025\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>\u003Cem>I. Nature and Mandate of the Tribunal\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>1. The the People's Tribunal on Complicity with the Palestinian\u003Cbr>Genocide within the Spanish State (TPCGP-25) is a tribunal of\u003Cbr>conscience, composed of figures from the legal, academic, cultural\u003Cbr>and human rights fields, convened by the University Network for\u003Cbr>Palestine (RUxP) and civil society organisations with the aim of\u003Cbr>examining, from the perspective of international law and public\u003Cbr>ethics, the conduct of state and non-state actors in their links to the\u003Cbr>occupation, apartheid and genocide of the Palestinian people.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>2. This Tribunal does not have state jurisdictional authority, nor does\u003Cbr>it aspire to it. It follows the tradition of the Russell I and II Tribunals,\u003Cbr>internationally recognized for their contribution to denouncing\u003Cbr>massive human rights violations and strengthening universal moral\u003Cbr>conscience. Its objective is to study, understand and mobilise\u003Cbr>Spanish civil society.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>3. The Tribunal examines the possible responsibility, by action or\u003Cbr>omission, of the Spanish State and the companies, organisations\u003Cbr>and institutions under its jurisdiction that contribute to and\u002For\u003Cbr>benefit from serious violations of international humanitarian law\u003Cbr>and international human rights law in the aforementioned context,\u003Cbr>including their possible failure to fulfil their duty to prevent\u003Cbr>international crimes such as war crimes, crimes against humanity or\u003Cbr>genocide.\u003Cbr>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>\u003Cem>II. Material Jurisdiction and Regulatory Framework\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>4. The Tribunal examines the facts in light of the principles and\u003Cbr>norms recognised by:\u003Cbr>* The Charter of the United Nations.\u003Cbr>* The 1949 Geneva Conventions and their Additional Protocols.\u003Cbr>* The Convention on the Prevention and Punishment of the Crime of\u003Cbr>Genocide (1948).\u003Cbr>* The Rome Statute of the International Criminal Court, as a codified\u003Cbr>expression of international criminal law.\u003Cbr>* The body of international human rights law and the general\u003Cbr>principles of law recognised by the community of nations.\u003Cbr>* The United Nations Guiding Principles on Business and Human\u003Cbr>Rights to \"protect, respect and remedy\" (Resolution 17\u002F4 2011)\u003Cbr>* The doctrine consolidated by the Russell Tribunal and the\u003Cbr>Permanent Peoples' Tribunal on the rights of peoples, self-\u003Cbr>determination and indirect responsibility or complicity.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>\u003Cem>III. On the Facts and Evidence Considered\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>Following the investigations, analysis and evaluation of the reports\u003Cbr>presented by the working groups of the seven thematic panels, the\u003Cbr>Tribunal considers the facts presented to be proven and issues the\u003Cbr>following conclusions:\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>5. It has been demonstrated and documented that the Spanish State\u003Cbr>has been collaborating for decades with the occupation, apartheid\u003Cbr>and ongoing Nakba and, ultimately, with genocide, in violation of\u003Cbr>international law and, with it, the prohibition on third states aiding\u003Cbr>or assisting another in the commission of international crimes. The\u003Cbr>Spanish government was and is fully aware of the illegalities and war\u003Cbr>crimes committed by the Israeli state, yet this information has not led\u003Cbr>to the corresponding measures being taken to suspend economic\u003Cbr>and diplomatic relations or to impose the sanctions required by\u003Cbr>numerous international resolutions.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>6. A case of particular relevance is that of the\u003Cbr>Global Sumud Flotilla, attacked by Israeli occupation forces, who kidnapped, mistreated\u003Cbr>and deported 49 people with Spanish passports. The government\u003Cbr>\"acted\" by abandoning its legal obligation to take the necessary\u003Cbr>measures to protect the rights of its citizens.\u003Cbr>\u003Cbr>7. The expansion of the military-police-security industry, together\u003Cbr>with Zionist lobbying practices, fuels the web of business, social and\u003Cbr>political interests that shape the agendas of the actors involved. This\u003Cbr>web of interests is sustained and reinforced by a \"state-corporate\u003Cbr>symbiosis\" in which the public administrations of complicit states\u003Cbr>such as Spain act as instrumental appendages of the markets,\u003Cbr>especially corporations dedicated to the production of harm and\u003Cbr>death.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>8. A network of state, national and international companies actively\u003Cbr>participates in the business of genocide, providing services,\u003Cbr>manufacturing products, feeding the economic and logistical\u003Cbr>machinery of the occupation and reinforcing its logic of spatial\u003Cbr>capture and systematic oppression.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>9. Over the last two years, Spanish ports have become crucial\u003Cbr>enclaves on the routes that supply weapons and energy to Israel's\u003Cbr>genocidal regime. These ports, public infrastructures financed with\u003Cbr>collective resources, have become logistical hubs for a genocidal\u003Cbr>machinery that sustains the occupation, apartheid and systematic\u003Cbr>destruction of Palestine. Routes and stopovers are repeated\u003Cbr>regularly, with the ports of Algeciras, Valencia, Barcelona, Cartagena\u003Cbr>and the naval base at Rota playing different roles in the same\u003Cbr>network. Spanish ports are part of an integrated genocidal logistics\u003Cbr>system.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>10. The evidence presented shows that the Armed Bank has played a\u003Cbr>crucial role in the production and use of weapons used in Gaza.\u003Cbr>Santander and BBVA banks, followed by Caixabank, Ibercaja, Banca\u003Cbr>March, etc., are both beneficiaries and essential facilitators of the\u003Cbr>extermination of the Palestinian people.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>11. It has been documented that companies in the civil engineering\u003Cbr>and infrastructure sector have benefited from the occupation and\u003Cbr>apartheid, as they have collaborated and participated in projects\u003Cbr>developed in the occupied territories that violate the principles of\u003Cbr>the rights of the Palestinian population. Spanish construction\u003Cbr>companies are associated with energy and road or rail\u003Cbr>infrastructure projects.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>12. It has been documented that there are Israeli extractive\u003Cbr>multinational corporations with subsidiaries in Spain that are\u003Cbr>directly complicit in the genocide. It has been found that public,\u003Cbr>academic and financial entities operate in an intertwined manner\u003Cbr>and maintain relationships with these companies, turning a blind eye\u003Cbr>to their human rights violations.\u003Cbr>\u003Cbr>13. It has been documented that Spanish and Israeli companies make\u003Cbr>significant profits in areas that are fundamental to the survival of\u003Cbr>the Palestinian people, such as water, energy and basic goods and\u003Cbr>services.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>14. The connection between real estate capital, investment funds and\u003Cbr>certain Spanish institutions with Israeli and US investment funds\u003Cbr>responsible for the violation of Palestinian rights has been proven,\u003Cbr>with numerous subsidiaries of Israeli companies operating in\u003Cbr>Spanish territory. The tourism sector is one of the most lucrative\u003Cbr>areas of business for both parties.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>15. It has been documented that the cybersecurity market in Spain is\u003Cbr>dominated by Israeli technology, directly and indirectly – through US\u003Cbr>companies linked to Israeli capital – in the public and private sectors,\u003Cbr>and that technology companies are key players in the perpetration\u003Cbr>of the Palestinian genocide, as well as in the pre-existing apartheid\u003Cbr>regime.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>16. It is argued that the media are not spectators but structural\u003Cbr>actors in the genocide: they select, frame, silence or amplify\u003Cbr>messages that whitewash Zionism and dehumanise the Palestinian\u003Cbr>resistance. Media coverage of Gaza in 2023–2025 shows approaches\u003Cbr>and political positions of complicity with genocide that are often\u003Cbr>presented as 'neutral'.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>17. Incitement to genocide occurs through the dissemination by the\u003Cbr>mass media of discourses that dehumanise the Palestinian people\u003Cbr>and empower or justify Israel's actions.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>18. Israel is carrying out a cultural genocide that seeks to dismantle\u003Cbr>collective memory, break intergenerational transmission and\u003Cbr>destroy the national identity of the Palestinian people. The Spanish\u003Cbr>State participates in legitimising the Israeli occupation, apartheid\u003Cbr>and genocide through cultural promotion, projecting a distorted\u003Cbr>and favourable image of Israel. Cultural collaboration thus takes on\u003Cbr>a strategic character.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>19. It has been documented that Israel's influence in cultural spaces\u003Cbr>contributes to the social acceptance of illegal policies and the\u003Cbr>invisibility of crimes committed against Palestinians. A cultural\u003Cbr>network of complicity integrates the economic, symbolic and media\u003Cbr>fields under a strategy of effective and structural legitimisation.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>20. Israel's presence in the Spanish sporting context can be seen in\u003Cbr>a multitude of areas. These include Israeli and\u002For Zionist capital\u003Cbr>investment in clubs such as Atlético de Madrid and Movistar Team,\u003Cbr>the broadcasting of sporting events by companies close to\u003Cbr>Netanyahu, such as DAZN, and the purchase of Israeli technology by\u003Cbr>Spanish organisations such as La Liga and FC Barcelona. In Spain,\u003Cbr>numerous clubs and sporting events have sponsors linked to Israel's\u003Cbr>genocidal practices, illegal occupation and apartheid in Palestine.\u003Cbr>Alongside private sponsorship, the participation of public bodies,\u003Cbr>municipal corporations and regional governments demonstrates\u003Cbr>their collaboration in the violation of the fundamental rights of the\u003Cbr>Palestinian people.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>\u003Cem>21. In the healthcare market, it has been documented that, despite\u003C\u002Fem>\u003Cbr>\u003Cem>repeated statements by healthcare personnel and public health\u003C\u002Fem>\u003Cbr>\u003Cem>experts about the atrocities committed against the civilian\u003C\u002Fem>\u003Cbr>\u003Cem>population in Gaza, the vast majority of academies, associations and\u003C\u002Fem>\u003Cbr>\u003Cem>scientific societies in medicine, nursing and pharmacy, as well as\u003C\u002Fem>\u003Cbr>\u003Cem>professional health organisations, have remained silent and\u003C\u002Fem>\u003Cbr>\u003Cem>completely ignored the obligations imposed by their codes of ethics.\u003C\u002Fem>\u003Cbr>\u003Cem>In material terms, complicity with genocide in the medical field is best\u003C\u002Fem>\u003Cbr>\u003Cem>exemplified by the pharmaceutical giant TEVA.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>22. A significant number of universities in Spain continue to\u003Cbr>participate in research consortia, maintaining collaboration\u003Cbr>agreements, chairs and mobility programmes with Israeli universities\u003Cbr>and research institutions. It is documented that some of these\u003Cbr>collaborations involve research for the development of dual-use\u003Cbr>technology.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>23. Likewise, the extensive collaboration of Spanish universities and\u003Cbr>research centres with companies present in the occupied territories\u003Cbr>or participating in the economy of apartheid and genocide has been\u003Cbr>documented.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>24. Educational centres and universities in Spain replicate the logic\u003Cbr>of colonial elimination implemented in Gaza and Palestine through\u003Cbr>censorship disguised as impartiality.\u003Cbr>\u003Cbr>\u003Cem>IV. Final Consideration\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>25. \u003Cem>The Tribunal declares that this Resolution is issued with the\u003C\u002Fem>\u003Cbr>\u003Cem>conviction that the voice of collective conscience is an indispensable\u003C\u002Fem>\u003Cbr>\u003Cem>instrument in the face of impunity, especially when formal\u003C\u002Fem>\u003Cbr>\u003Cem>institutional mechanisms are insufficient or slow to respond to the\u003C\u002Fem>\u003Cbr>\u003Cem>gravity of the facts.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>The current phase of genocide compels us to continue this work of\u003Cbr>documentation, denunciation, and remembrance. We urge all\u003Cbr>participants and collaborators in this Tribunal to continue the work\u003Cbr>that has been begun.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\">\u003Cbr>In Madrid, Spain, Faculty of Political Science and Sociology of the UCM,\u003Cbr>29th November 2025\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: justify; line-height: 115%;\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif;\"> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif; color: #274e13;\">\"Our task is to create knowledge, and no knowledge is neutral. We shall create knowledge for and through justice.\"  \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif; color: #274e13;\">Rabab I. Abdulhadi\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif; color: #274e13;\"> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cem>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif; color: #274e13;\">\"Palestine has risen from the ashes after Karameh, after Beirut, after Oslo. It will do so after Gaza.\" \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan lang=\"EN-US\" style=\"font-family: 'Comfortaa',serif; color: #274e13;\">Luz Gómez.\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cstrong>\u003Cspan style=\"font-size: 24.0pt; line-height: 150%; font-family: 'Comfortaa',serif; color: #660000;\">More information and material: \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cspan style=\"font-size: 13.5pt; line-height: 150%; font-family: 'Arial',sans-serif;\">\u003Ca href=\"https:\u002F\u002Ftribunaldelospueblos.org\u002F\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Ftribunaldelospueblos.org\u002F&source=gmail&ust=1764685409459000&usg=AOvVaw38yZfE2nE5hJlPBLlb4A_Z\">\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #1155cc;\">https:\u002F\u002Ftribunaldelospueblos.\u003Cwbr>org\u002F\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cspan style=\"font-size: 13.5pt; line-height: 150%; font-family: 'Arial',sans-serif;\">\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002F@RUxP2024\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Fwww.youtube.com\u002F@RUxP2024&source=gmail&ust=1764685409459000&usg=AOvVaw3SUTXn6ELoM3Eoy2BzqS8O\">\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #1155cc;\">https:\u002F\u002Fwww.youtube.com\u002F@\u003Cwbr>RUxP2024\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cspan style=\"font-size: 13.5pt; line-height: 150%; font-family: 'Arial',sans-serif;\">\u003Ca href=\"http:\u002F\u002Fwww.redxpalestina.org\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=http:\u002F\u002Fwww.redxpalestina.org&source=gmail&ust=1764685409459000&usg=AOvVaw3s6TOwjoSey8bXx18jnHBJ\">\u003Cstrong>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #1155cc;\">www.redxpalestina.org\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 150%;\" align=\"center\">\u003Cstrong>\u003Cu>\u003Cspan style=\"font-size: 13.5pt; line-height: 150%; font-family: 'Comfortaa',serif; color: #1155cc;\">\u003Ca href=\"https:\u002F\u002Fx.com\u002FRedxPalestina\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Fx.com\u002FRedxPalestina&source=gmail&ust=1764685409459000&usg=AOvVaw3begkgtY3t18BHMHBX7for\">https:\u002F\u002Fx.com\u002FRedxPalestina\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cspan style=\"font-size: 13.5pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #660000;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cstrong>\u003Cspan style=\"font-size: 13.5pt; line-height: 115%; font-family: 'Comfortaa',serif; color: #660000;\">Contacto:\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Ch3 style=\"margin-right: 0cm; margin-bottom: 4.0pt; margin-left: 0cm; text-align: center; line-height: 115%; break-after: auto;\" align=\"center\">\u003Ca name=\"m_3510617878888220523_m_-6209836626524266887__5eqpno6ansth\">\u003C\u002Fa>\u003Cspan style=\"font-family: 'Comfortaa',serif; color: #274e13;\">\u003Ca href=\"mailto:ruxp@tribunaldelospueblos.org\" target=\"_blank\" rel=\"noopener\">ruxp@tribunaldelospueblos.org\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fh3>\n\u003Cp class=\"MsoNormal\" style=\"text-align: center; line-height: 115%;\" align=\"center\">\u003Cspan style=\"font-family: 'Arial',sans-serif;\"> \u003C\u002Fspan>\u003Cspan style=\"font-size: 13.5pt; line-height: 115%; font-family: 'Comfortaa',serif;\">*\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Cem>\u003Cspan style=\"font-size: 10.0pt;\">\u003Cspan class=\"ryNqvb\">The Gaza genocide is as much European and American as it is Israeli. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"MsoNormal\">\u003Cem>\u003Cspan style=\"font-size: 10.0pt;\">\u003Cspan class=\"ryNqvb\">(Ghassan Abu Sittah, Chancellor of Glasgow University, UK)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Cspan style=\"font-size: 10.0pt;\">*\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Cstrong>People's Tribunal on Complicity with the Palestinian Genocide in the Spanish State (TPCGP-25)\u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Ca href=\"https:\u002F\u002Ftribunaldelospueblos.org\u002F\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Ftribunaldelospueblos.org\u002F&source=gmail&ust=1764685409459000&usg=AOvVaw38yZfE2nE5hJlPBLlb4A_Z\">\u003Cstrong>https:\u002F\u002Ftribunaldelospueblos.\u003Cwbr>org\u002F\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Ca href=\"http:\u002F\u002Fwww.redxpalestina.org\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=http:\u002F\u002Fwww.redxpalestina.org&source=gmail&ust=1764685409459000&usg=AOvVaw3s6TOwjoSey8bXx18jnHBJ\">www.redxpalestina.org\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002F@RUxP2024\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Fwww.youtube.com\u002F@RUxP2024&source=gmail&ust=1764685409459000&usg=AOvVaw3SUTXn6ELoM3Eoy2BzqS8O\">https:\u002F\u002Fwww.youtube.com\u002F@\u003Cwbr>RUxP2024\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cp class=\"MsoNormal\">\u003Ca href=\"https:\u002F\u002Ftwitter.com\u002FRedxPalestina\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Ftwitter.com\u002FRedxPalestina&source=gmail&ust=1764685409459000&usg=AOvVaw0z2BbdiVJd-XLw-ONIH1AB\">@RedxPalestina\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",1764602691046,"_jZUIjYZQGI","sentencia-tribunal-de-los-pueblos-sobre-la-complicidad-del-estado-espanol-con-el-genocidio-en-palestina-tpcgp-25-verdict-people-s-tribunal-on-complicity-with-the-palestinian-genocide-in-the-spanish-state-esp-eng",[15],"Sentencia. Tribunal de los Pueblos sobre la Complicidad del Estado español con el Genocidio en Palestina.  TPCGP-25. Verdict. People's Tribunal on Complicity with the Palestinian Genocide in the Spanish State. ESP ENG"," TPCGP-25. Nota de prensa y sentencia. \"Declaración de Madrid\": 20 puntos. Press release and verdict. \"Madrid Declaration\": 20 point resolution","min9ab00b3d2mssij8f",{"content":450,"imageUrl":451,"timestamp":452,"type":7,"slug":453,"videoUrl":454,"link":12,"user":13,"tags":455,"title":459,"subtitle":460,"id":461},"\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>December 08, 2025\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"ryNqvb\">Zionism is corrupting Israel and the world: its prime minister and its companies (Elbit weapons manufacturer, Teva pharmaceuticals, for example), etc. Israel is a danger to global integrity.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fwww.thenationalnews.com\u002Fnews\u002Feurope\u002F2025\u002F12\u002F08\u002Fisraels-elbit-suspended-from-nato-tenders-amid-corruption-probe\u002F\">Israeli defence company Elbit 'suspended from Nato tenders' amid corruption probe.\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Sunniva Rose\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cem>Israeli defence company Elbit has been suspended by Nato from bidding for new tenders amid a wide-ranging corruption investigation that involves at least three current or former staff members.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Defence companies are alleged to have paid millions of euros to help secure contracts. Elbit, Israel's biggest defence company, is thought to have sold at least €50 million ($58.2 million) in ammunition to Nato allies over the past decade. It has also provided services for amounts that have not been disclosed.\u003C\u002Fp>\n\u003Cp>This decision may disrupt the supply of several Nato armies. “Affected contracts include ammunition for truck-mounted howitzers, mobile rocket artillery systems, and defence systems for military aircraft and helicopters,” wrote the investigative website Follow the Money, which reported on the suspension alongside La Lettre and the Belgian newspapers Le Soir and Knack.\u003C\u002Fp>\n\u003Cp>“Elbit also equipped the fleet of Airbus MRTT [Multi Role Tanker Transport] tanker aircraft of eight Nato countries, including Germany, the Netherlands, Belgium and Denmark, a huge programme awarded in 2023 worth tens of millions of dollars,” wrote La Lettre.\u003Cbr>'Serious allegations'\u003C\u002Fp>\n\u003Cp>A letter dated July 31 and written by a manager at the alliance's Support and Procurement Agency (NSPA) described “serious allegations” indicating “suppliers engaged in sanctionable practices, including irregularities in the award of contracts”.\u003C\u002Fp>\n\u003Cp>Other companies besides Elbit could undergo the same process in the near future, the letter warned.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Elbit is not under investigation. But in September a Belgian judge issued a European arrest warrant for a 60-year-old Italian consultant, Eliau Eluasvili, who is suspected of bribing NSPA staff. Mr Eluasvili is believed to play an important role as a consultant for Elbit, people close to the investigation have said. He may currently be travelling under a false identity.\u003C\u002Fp>\n\u003Cp>The decision to suspend Elbit and its subsidiary, Orion Advanced Systems, comes against a backdrop of suspicions that former NSPA employees have used inside knowledge to secure lucrative contracts for defence companies in exchange for kickbacks. Investigations are continuing in Belgium and Luxembourg.\u003C\u002Fp>\n\u003Cp>The NSPA plays a strategic role in securing contracts for Nato allies which have collectively increased their defence spending since Russia's full-scale invasion of Ukraine in 2022. \u003Cem>Its budget has nearly tripled since 2021 to €9.5 billion yearly, according to Follow the Money.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>In a statement to The National, a Nato official said that, as a general rule, the alliance does not comment on leaks or continuing investigations. They added, however, that the alliance has “no tolerance for fraud or corruption” and that the NSPA “proactively initiated co-operation with national law enforcement agencies”.\u003C\u002Fp>\n\u003Cp>“The Nato Secretary General on 12 May 2025 received a request from the Belgian federal prosecutor to lift the functional immunity of three former and current NSPA staff, which he granted that same day,” they said.\u003C\u002Fp>\n\u003Cp>“More recently, the Secretary General and the NSPA general manager initiated a joint investigative task force between Nato headquarters and NSPA personnel to increase investigative capacity and fully investigate any potential fraud and corruption by agency personnel or contractors doing business with the agency.”\u003C\u002Fp>\n\u003Cp>The National has also contacted Elbit for comment.\u003C\u002Fp>\n\u003Cp>Guy Moeraert, a former Belgian soldier and ex-NSPA agent turned consultant, is accused of having received €1.9 million in exchange for confidential documents that were then forwarded to companies to rig calls for tenders. He has served six months in prison and currently wears an electronic tag.\u003C\u002Fp>\n\u003Cp>Moeraert is believed to have close links to Mr Eluasvili. They reportedly met via a Turkish former employee of NSPA, Ismail Terlemez, who was arrested at Zaventem Airport in Brussels in May but was released this summer.\u003C\u002Fp>\n\u003Cp>Mr Terlemez had been awaiting extradition to the United States. The FBI suspected him of being involved in a corruption scheme of more than €1 million paid by an Italian defence company to secure a contract to sell TNT explosives to the US army in 2019 and 2020.\u003C\u002Fp>\n\u003Cp>Launched in 2024, the US investigation triggered subsequent European investigations. Earlier this year, a dozen suspects, including five employees or ex-NSPA staff, were arrested in seven European countries, from the Netherlands to Spain.\u003C\u002Fp>\n\u003Cp>\u003Cem>However, the US investigation was abruptly halted in July, raising questions about political interference, according to the media behind the investigation.\u003C\u002Fem> They have reported that the US dropped charges against Mr Terlemez two weeks after a meeting between the US President Donald Trump and his Turkish President Recep Tayyip Erdogan at the Nato summit in The Hague in July.\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>El sionismo pudre Israel y el mundo: su primer ministro y sus empresas (Elbit de armamento, Teva de medicamentos, por ejemplo), etc. Israel es un peligro para la integridad mundial.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">La empresa israelí de defensa Elbit ha sido suspendida de las licitaciones de la OTAN en medio de una investigación por corrupción.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">La OTAN ha suspendido a la empresa israelí de defensa Elbit de participar en nuevas licitaciones en medio de una amplia investigación por corrupción que involucra al menos a tres empleados, actuales o anteriores.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Se alega que empresas de defensa han pagado millones de euros para obtener contratos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Se cree que Elbit, la mayor empresa de defensa de Israel, vendió al menos 50 millones de euros (58,2 millones de dólares) en municiones a aliados de la OTAN durante la última década.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">También ha prestado servicios por importes no revelados.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esta decisión podría interrumpir el suministro a varios ejércitos de la OTAN.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"Los contratos afectados incluyen municiones para obuses montados en camiones, sistemas móviles de artillería de cohetes y sistemas de defensa para aviones y helicópteros militares\", escribió el sitio web de investigación Follow the Money, que informó sobre la suspensión junto con La Lettre y los periódicos belgas Le Soir y Knack.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">“Elbit también equipó la flota de aviones cisterna Airbus MRTT [Multi Role Tanker Transport] de ocho países de la OTAN, entre ellos Alemania, Países Bajos, Bélgica y Dinamarca, un enorme programa adjudicado en 2023 por un valor de decenas de millones de dólares”, escribió La Lettre.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">'Graves acusaciones' \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Una carta fechada el 31 de julio, escrita por un directivo de la Agencia de Apoyo y Adquisiciones (NSPA) de la alianza, describía “graves acusaciones” que indicaban que “proveedores participaron en prácticas sancionables, incluyendo irregularidades en la adjudicación de contratos”.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La carta advertía que otras empresas, además de Elbit, podrían someterse al mismo proceso próximamente.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Elbit no está siendo investigada.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sin embargo, en septiembre, un juez belga emitió una orden de arresto europea contra Eliau Eluasvili, consultor italiano de 60 años, sospechoso de sobornar al personal de la NSPA.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Se cree que Eluasvili desempeña un papel importante como consultor de Elbit, según han afirmado personas cercanas a la investigación.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Actualmente, podría estar viajando con una identidad falsa.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">La decisión de suspender a Elbit y a su filial, Orion Advanced Systems, se produce en un contexto de sospechas de que exempleados de la NSPA han utilizado información privilegiada para conseguir lucrativos contratos para empresas de defensa a cambio de sobornos.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Las investigaciones continúan en Bélgica y Luxemburgo.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La NSPA desempeña un papel estratégico en la obtención de contratos para los aliados de la OTAN, que han incrementado colectivamente su gasto en defensa desde la invasión a gran escala de Ucrania por parte de Rusia en 2022. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Su presupuesto casi se ha triplicado desde 2021, alcanzando los 9.500 millones de euros anuales, según Follow the Money.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> En una declaración a The National, un funcionario de la OTAN afirmó que, por regla general, la alianza no comenta sobre filtraciones ni investigaciones en curso.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Añadió, sin embargo, que la alianza no tolera el fraude ni la corrupción y que la NSPA ha iniciado de forma proactiva la cooperación con las fuerzas de seguridad nacionales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">“El 12 de mayo de 2025, el Secretario General de la OTAN recibió una solicitud del fiscal federal belga para levantar la inmunidad funcional de tres empleados, antiguos y actuales, de la NSPA, la cual concedió ese mismo día”, declararon.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">“Más recientemente, el Secretario General y el director general de la NSPA pusieron en marcha un grupo de trabajo conjunto de investigación entre la sede de la OTAN y el personal de la NSPA para aumentar la capacidad investigativa e investigar a fondo cualquier posible fraude o corrupción por parte del personal de la agencia o de contratistas que hacen negocios con ella”.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">The National también se ha puesto en contacto con Elbit para solicitarle sus comentarios.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Guy Moeraert, exsoldado belga y exagente de la NSPA convertido en consultor, está acusado de haber recibido 1,9 millones de euros a cambio de documentos confidenciales que posteriormente se enviaron a empresas para manipular licitaciones.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ha cumplido seis meses de prisión y actualmente lleva una pulsera electrónica.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Se cree que Moeraert mantiene estrechos vínculos con el Sr. Eluasvili.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Al parecer, se conocieron a través de un exempleado turco de la NSPA, Ismail Terlemez, quien fue arrestado en el aeropuerto de Zaventem en Bruselas en mayo, pero fue liberado este verano.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> El Sr. Terlemez se encontraba a la espera de su extradición a Estados Unidos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El FBI sospechaba que estaba involucrado en una trama de corrupción por más de un millón de euros, pagada por una empresa italiana de defensa para obtener un contrato de venta de explosivos TNT al ejército estadounidense en 2019 y 2020. Iniciada en 2024, la investigación estadounidense desencadenó posteriores investigaciones europeas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A principios de este año, una docena de sospechosos, incluidos cinco empleados o exmiembros de la NSPA, fueron arrestados en siete países europeos, desde los Países Bajos hasta España.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">Sin embargo, la investigación estadounidense se detuvo abruptamente en julio, lo que generó dudas sobre la posible injerencia política, según los medios de comunicación responsables de la investigación.\u003C\u002Fspan>\u003C\u002Fem> \u003Cspan class=\"ryNqvb\">Estos informaron que Estados Unidos retiró los cargos contra el Sr. Terlemez dos semanas después de una reunión entre el presidente estadounidense Donald Trump y su presidente turco Recep Tayyip Erdogan en la cumbre de la OTAN en La Haya en julio.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1765361256\u002Fzxgdm3cjyyb5qwzmr4ir.jpg",1765361399545,"zionism-is-corrupting-israel-elbit-weapons-and-more-el-sionismo-corrompe-israel-elbit-armas-y-mas-engl-esp","FKrjGMkL7w8",[456,457,15,458],"Arms","Armas","Corruption","Zionism is corrupting Israel (Elbit, weapons and more). El sionismo corrompe Israel (Elbit, armas, y más) ENGL ESP","Zionism is corrupting Israel: its prime minister and its companies (Elbit weapons, Teva pharmaceuticals, for example), etc. El sionismo pudre Israel: su primer ministro y sus empresas (Elbit de armamento, Teva de medicamentos, por ejemplo), etc","miztvl4w4yxc8nnux8q",{"title":463,"content":464,"type":7,"slug":465,"subtitle":466,"timestamp":467,"imageUrl":468,"id":469,"link":12,"user":13,"tags":470,"videoUrl":472},"Boycott Teva for beginners. Boicot Teva para principiantes. ENG ESP","\u003Cdiv class=\"VjFXz\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">How to Boycott Teva Medicines: A Guide to “Direct Action” for Those Who Know Nothing About It but Want to Help Palestine \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"nidPne\">\n\u003Cdiv id=\"ow14\" data-show-delay-ms=\"250\" data-append-to-body=\"true\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-left\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-left\">\n\u003Cdiv class=\"dig2sb\">\n\u003Cdiv class=\"scLCMd\">\n\u003Cdiv id=\"itamenu\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"FFpbKc\">\n\u003Cdiv class=\"xMmqsf\">\n\u003Cdiv class=\"nidPne\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">By Juan Gérvas (MD, retired rural general practitioner, CESCA Team, Madrid, Spain, former professor of public health, Johns Hopkins University, Baltimore, USA) and Mercedes Pérez-Fernández, specialist in Internal Medicine and retired rural physician,\u003Ca href=\"https:\u002F\u002Fequipocesca.org\u002F\"> CESCA Team, Madrid, Spain\u003C\u002Fa>.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">From \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002F\">Health Workers For Palestine, Spain\u003C\u002Fa> https:\u002F\u002Fhw4p.es\u002F jjgervas@gmail.com mpf1945@gmail.com www.equipocesca.org @JuanGrvas @juangrvas.bsky.social\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">“D\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">irect Action” \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Boycott Teva Products \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Do you feel powerless in the face of the genocide in Palestine?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Do you feel that our smallness is immense compared to its immense strength, to Israel backed by the United States, the European Union, Canada, Australia, New Zealand, Japan, and other “wealthy” countries?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Do you want your actions to “make an impact” and weaken Israel’s power?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Boycotting Teva products gives you the opportunity for “direct action,” without intermediaries, without the commitments of politicians and institutions distorting your own commitment.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">“Direct action” leads to social and political change through collective mobilization.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Its main objective is to pressure the established power using immediate and direct action, without resorting to intermediaries or representatives.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">“Direct action” is based on solidarity (“today for you, tomorrow for me”) and tenderness (an inner emotion that deeply unites us with those who suffer, a state of mind that predisposes us to help). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Why Teva? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva is an Israeli pharmaceutical company. The world’s largest generic (unbranded) drug company. It also sells brand-name drugs. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva is Teva, and many other companies like Actavis, Davur, Belmac, Ratiopharm, and Tevagen. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva is a corrupt and corrupting company in every country in the world where it operates. It has been convicted and fined billions of dollars for its criminal activities (some of which have resulted in countless deaths, such as the opioid “epidemic” in the United States). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva generates immense profits that are used in Israel to sustain the Zionist regime, apartheid, and the genocide against Palestine. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Furthermore, Teva directly supports the Israeli army, for example.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">with special support programs for its soldiers.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> By boycotting Teva, you are directly diminishing Israel's power.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Ten Key Ideas \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1. Teva is a criminal, corrupt, and corrupting company. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2. Teva generates revenue for the State of Israel and directly supports apartheid and genocide against Palestine. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3. Almost all Teva medications have equally or more effective alternatives. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">4. When picking up medications at the pharmacy, it is legal to request that they not be from Teva. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">5. When the medication is hospital-prescribed (or prescribed by hospital specialists), you can also request a prescription for alternatives to Teva. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">6. When you use a Teva medication, you are bringing suffering, hunger, mutilation, disease, torture, death, and destruction to Palestine; you are directly participating with Israeli Zionism. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">7. When you avoid a Teva medication, you are preventing suffering, hunger, mutilation, disease, torture, death, and destruction in Palestine; you are directly harming Israeli Zionism. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">8. When you weaken Israel and protect Palestine, you are weakening\u003C\u002Fspan> t\u003Cspan class=\"ryNqvb\">he “export” of Israeli methods that harm the population and that could one day be applied to populations in other countries, including Spain and other European countries. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">9. Much of the use of Teva medications is due to the money Teva gives to “key opinion leaders” and key healthcare organizations.\u003C\u002Fspan> In Spain, n\u003Cspan class=\"ryNqvb\">otable among these, totaling 2023 and 2024, are Patricia Pozo Rosich, a neurologist at Vall d’Hebron Hospital in Barcelona, ​​who received €77,000 directly from Teva in what they call “transfers of value.”\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Other recipients include the SEN Foundation (Spanish Society of Neurology), Barcelona, ​​€238,000; the Vall d’Hebron University Hospital Research Institute, Barcelona, ​​€138,000; and the Spanish Society of Clinical, Family, and Community Pharmacy (SEFAC), Madrid, €143,000.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">10. Develop a basic vocabulary;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">don't be afraid of the names of medications.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In the end, very few are of interest.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Concrete actions \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For example, focus the boycott on Teva's three best-selling medications in Spanish pharmacies: omeprazole, atorvastatin, and pantoprazole.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The next best-sellers are: rosuvastatin, rasaglycine, apixaban, fentanyl, and budesonide\u002Fformoterol.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">If possible, remember that Teva is Teva, but so are Actavis, Davur, Belmac, Ratiopharm, and Tevagen, so you can ask for alternatives to these brands.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Discuss the Teva issue with family, friends, and colleagues.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Among prescription medications prescribed by hospital specialists, there are several brand-name (not generic) drugs: Austedo (deutetrabenazine) for Huntington's disease and tardive dyskinesia, Ajovy (fremanezumab) for migraines (it offers no benefit), Copaxone (glatiramer) for multiple sclerosis (it offers no benefit), and Uzedy (risperidone) for...\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Schizophrenia and Azilect (rasagiline) for Parkinson's disease.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\">To learn more and access educational materials (talks, seminars, debates, and self-study), you'll find a wealth of information and data at:\u003C\u002Fa> https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">A good start \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fboycott-teva-think-global-act-local-teva-no-thanks-eng\">\"Boycott Teva. Think global, act local\" \u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">ESPAÑOL\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fahoramqnunca.blogspot.com\u002F2025\u002F12\u002Fcomo-hacer-boicot-los-medicamentos-de.html\">\u003Cstrong>Cómo hacer boicot a los medicamentos de Teva. Una guía para la “acción directa” de quien no sabe nada al respecto pero quiere ayudar a Palestina.\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\" align=\"left\">Por Juan Gérvas (Doctor en Medicina, médico general rural jubilado, Equipo CESCA, Madrid, España, exprofesor de salud pública, Universidad Johns Hopkins, Baltimore, Estados Unidos) y Mercedes Pérez-Fernández, especialista en Medicina Interna y médica rural jubilada, \u003Ca href=\"https:\u002F\u002Fequipocesca.org\u002F\">Equipo CESCA, Madrid, España\u003C\u002Fa>. De Health Workers For Palestine, Spain \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002F\">https:\u002F\u002Fhw4p.es\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"mailto:jjgervas@gmail.com\">jjgervas@gmail.com\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"mailto:mpf1945@gmail.com\">mpf1945@gmail.com\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> \u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"http:\u002F\u002Fwww.equipocesca.org\u002F\">www.equipocesca.org\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan> @JuanGrvas @juangrvas.bsky.social\u003C\u002Fp>\n\u003Cp class=\"sdendnote-western\" align=\"left\"> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>“Acción directa”: boicot a los productos de Teva\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>¿Te sientes impotente frente al genocidio en Palestina? \u003Cbr>¿Sientes que nuestra pequeñez es inmensa frente a su inmensa fortaleza, al Israel respaldado por Estados Unidos, Unión Europea, Canadá, Australia, Nueva Zelanda, Japón y demás países “enriquecidos”?\u003Cbr>¿Quieres que tus acciones “se noten” y debiliten el poder de Israel?\u003C\u002Fp>\n\u003Cp>\u003Cbr>El boicot a los productos de Teva te da la oportunidad de la “acción directa”, sin intermediarios, sin que el compromiso de los políticos e instituciones  tergiverse tu propio compromiso. \u003Cbr>La “acción directa” lleva a cambios sociales y políticos a través de la movilización colectiva. Su objetivo principal es presionar al poder establecido utilizando la acción inmediata y directa, sin recurrir a intermediarios ni representantes. \u003C\u002Fp>\n\u003Cp>\u003Cbr>La “acción directa” se fundamenta en la solidaridad (“hoy por ti, mañana por mí) y en la ternura (conmoción interior que nos une entrañablemente a quien sufre, un estado de ánimo que nos predispone a la ayuda).\u003C\u002Fp>\n\u003Cp>\u003Cstrong>¿Por qué Teva?\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Teva es un empresa israelí de medicamentos. La mayor empresa de medicamentos genéricos (sin marca) del mundo. También vende medicamentos de marca.\u003Cbr>Teva es Teva, y muchas otras industrias como Actavis, Davur, Belmac, Ratiopharm y Tevagen.\u003Cbr>Teva es una empresa corrupta y corruptora en todos los países del mundo en los que opera. Ha sido condenada y multada con miles de millones de dólares por sus actividades delictivas (algunas han conllevado muertes incontables, como en la “epidemia” de mortalidad por opiodes en Estados Unidos).\u003C\u002Fp>\n\u003Cp>\u003Cbr>Teva genera inmensos beneficios que se emplean en Israel para sostener el régimen sionista, el apartheid y el genocidio contra Palestina. \u003Cbr>Además, Teva apoya directamente al ejército israelí, por ejemplo con programas especiales de soporte a sus soldados.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Al hacer boicot a Teva estás disminuyendo directamente el poder de Israel.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Diez ideas clave\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>1.- Teva es una empresa criminal, corrupta y corruptora\u003C\u002Fp>\n\u003Cp>\u003Cbr>2.- Teva genera ingresos para el estado de Israel y apoya directamente el apartheid y el genocidio contra Palestina\u003C\u002Fp>\n\u003Cp>\u003Cbr>3.- Casi todos los medicamentos de Teva cuentan con alternativas tan eficaces o más\u003C\u002Fp>\n\u003Cp>\u003Cbr>4.- Al retirar los medicamentos en la farmacia es legal pedir que no sean de Teva\u003C\u002Fp>\n\u003Cp>\u003Cbr>5.- Cuando la medicación sea hospitalaria (o de especialistas hospitalarios) también puedes pedir la prescripción de las alternativas a Teva\u003C\u002Fp>\n\u003Cp>\u003Cbr>6.- Cuando utilizas un medicamento de Teva está llevando sufrimiento, hambre, mutilaciones, enfermedades, torturas, muerte y destrucción a Palestina, estás participando directamente con el sionismo de Israel\u003C\u002Fp>\n\u003Cp>\u003Cbr>7.- Cuando evitas un medicamento de Teva estás evitando sufrimiento, hambre, mutilaciones, enfermedades, torturas, muerte y destrucción en Palestina, estás perjudicando directamente al sionismo de Israel\u003C\u002Fp>\n\u003Cp>\u003Cbr>8.- Cuando debilitas a Israel y proteges Palestina estás debilitando la “exportación” de los métodos de Israel que dañan la población y que un día se nos pueden aplicar a las poblaciones en otros países, incluida España\u003C\u002Fp>\n\u003Cp>\u003Cbr>9.- Gran parte del uso de medicamentos de Teva se debe al dinero que Teva da a médicos “creadores de opinión” (key opinion leaders) y organizaciones sanitarias clave. Destacan, sumando el total en 2023 y 2024, Patricia Pozo Rosich, Barcelona, neuróloga del Valle D’Hebron, que recibió directamente de Teva 77.000 euros en lo que llaman “transferencias de valor”. También la Fundación SEN (Sociedad Española de Neurología), Barcelona, 238.000, Fundació Hospital Universitari Valle D'Hebron, Institut de Recerca, Barcelona, 138.000 y la Sociedad Española de Farmacia Clínica, Familiar y Comunitaria, SEFAC, Madrid, 143.000 euros.\u003C\u002Fp>\n\u003Cp>\u003Cbr>10.- Hazte con un vocabulario básico, no tengas miedo a los nombres de los medicamentos. Al final son muy pocos los que interesan.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Acciones concretas\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Centra el boicot en los tres medicamentos más vendidos de Teva en las farmacias españolas: omeprazol, atorvastatina y pantoprazol.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Los siguientes más vendidos son: rosuvastatina, rasaglicina, apixaban, fentanilo y budenosida\u002Fformoterol.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Si puedes, recuerda que Teva es Teva pero también Actavis, Davur, Belmac, Ratiopharm y Tevagen, para pedir alternativas a estas marcas.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Comenta la cuestión de Teva en la familia, con las amistades y en el trabajo.\u003C\u002Fp>\n\u003Cp>\u003Cbr>En medicamentos de prescripción por especialistas hospitalarios, hay varios de marca (no genéricos): Austedo (deutetrabenazine) para la enfermedad de Huntington y la discinesia tardía, Ajovy (fremanezumab) para la migraña (no aporta nada), Copaxone (glatiramero) para la esclerosis múltiple (no aporta nada), Uzedy (risperidona) para la esquizofrenia y Azilect (rasagilina) para el parkinson.\u003C\u002Fp>\n\u003Cp>Para saber más y para tener material docente (charlas, seminarios, debates y autoformación) tienes abundatísimo material gráfico y con datos en\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\"> \"Teva crea ganancias para sostener el genocidio en Palestina\" \u003C\u002Fa>\u003Cbr>https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\u003Cbr>Un buen comienzo puede ser leer este informe: \u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\">“Teva en España. Un gigante farmacéutico cuyas ganancias dañan la salud de la población de Palestina”. \u003C\u002Fa>\u003Cbr>https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F \u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","boycott-teva-for-beginners-boicot-teva-para-principiantes-eng-esp","How to Boycott Teva Medicines: A Guide to “Direct Action”. Como hacer boicot a Teva: una guía de \"acción directa\"",1765364757528,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1765364642\u002Fp5oya3rrkqmfukpglxfs.png","mizviwzukxu1h52tnl",[15,471,164],"Boycott","aVHlug0Pq44",{"videoUrl":474,"content":475,"id":476,"title":477,"imageUrl":478,"link":12,"user":13,"tags":479,"type":7,"slug":481,"timestamp":482,"subtitle":483},"Gpa4S2qWthE","\u003Cp>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fsentencia-tribunal-de-los-pueblos-sobre-la-complicidad-del-estado-espanol-con-el-genocidio-en-palestina-tpcgp-25-verdict-people-s-tribunal-on-complicity-with-the-palestinian-genocide-in-the-spanish-state-esp-eng\">TPCGP-25 (Tribunal de los Pueblos sobre la Complicidad del Estado español con el Genocidio en Palestina)\u003C\u002Fa>. \u003Cem>Mesa 4. Sistema y mercado sanitario.\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"neOZNc C9DxTc\" style=\"vertical-align: baseline;\">\u003Cspan class=\"jgG6ef C9DxTc\" style=\"color: #000000; font-family: Comfortaa, Arial; font-weight: 500; vertical-align: baseline;\">\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Ftribunal-de-los-pueblos-sobre-la-complicidad-con-el-genocidio-palestino-en-el-estado-espanol-tpcgp-25\">ADVERTENCIA DE HW4PS (Health Workers For Palestine, Spain):\u003C\u002Fa>\u003C\u002Fstrong> \u003Cem>El tribunal no pretende simplemente condenar\u002Fabsolver sino, sobre todo, convencer a la opinión pública española con pruebas que demuestren la implicación de España, la intencionalidad y las acciones sistemáticas que hacen posible el genocidio del pueblo palestino en Gaza, dónde actores españoles (o con responsabilidad penal en España) están actuando conscientemente en favor del estado de Israel y beneficiándose del Genocidio propiamente dicho. \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cem>\u003Cspan class=\"neOZNc C9DxTc\" style=\"vertical-align: baseline;\">\u003Cspan class=\"jgG6ef C9DxTc\" style=\"color: #000000; font-family: Comfortaa, Arial; font-weight: 500; vertical-align: baseline;\">No se enjuicia a Israel sino a España.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"neOZNc C9DxTc\" style=\"vertical-align: baseline;\">\u003Cspan class=\"jgG6ef C9DxTc\" style=\"color: #000000; font-family: Comfortaa, Arial; font-weight: 500; vertical-align: baseline;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Teva. Sistema \u002Fmercado sanitario, sociosanitario y farmacéutico.. \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>INFORME TPCGP-25 Mesa 4 * \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cem>3.3. El gigante farmacéutico TEVA\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Teva es un gigante farmacéutico, con sede central en Tel Aviv,\u003Cbr>fundado en 1901 y que, actualmente, es la mayor empresa del mundo\u003Cbr>en el campo de los medicamentos genéricos (es decir, de los\u003Cbr>medicamentos producidos por compañías ajenas a las que\u003Cbr>desarrollaron el original, al acabar sus patentes, y que son vendidos\u003Cbr>bajo el nombre del principio activo).\u003Cbr>Teva cuenta con una cartera de más de 3.600 medicamentos, que\u003Cbr>produce en 53 plantas situadas en 33 países, incluyendo España,\u003Cbr>donde tiene una planta situada en Zaragoza (58).\u003C\u002Fp>\n\u003Cp>Con 600 trabajadores\u003Cbr>y una producción de 8.700 millones de fármacos al año, la\u003Cbr>producción de la planta de Zaragoza supone el 8,7% del total de la\u003Cbr>empresa (59). \u003C\u002Fp>\n\u003Cp>Teva tiene además firmada una cátedra con la\u003Cbr>universidad privada San Jorge, también de Zaragoza, desde finales\u003Cbr>de octubre de 2023 (60).\u003C\u002Fp>\n\u003Cp>\u003Cbr>Teva tuvo unos ingresos globales por encima de los 16.400 millones\u003Cbr>de dólares en 2024, apoyándose en el bajo coste y la alta demanda\u003Cbr>de los medicamentos genéricos. Los medicamentos de Teva son\u003Cbr>comercializados bajo las marcas Teva, Tevagen, Actavis, Davur,\u003Cbr>Belmac y Ratiopharm. Sus productos “estrella” son Austedo\u003Cbr>(deutetrabenazine) para la enfermedad de Huntington, el corea y la\u003Cbr>discinesia tardía, Ajovy (fremanezumab) para la migraña, Copaxone\u003Cbr>(glatiramero) para la esclerosis múltiple, Uzedy (risperidona) para la\u003Cbr>esquizofrenia y Azilect (rasagilina) para el parkinson.\u003C\u002Fp>\n\u003Cp>También\u003Cbr>comercializa otros medicamentos como varios GLP-1 (gliclazida,\u003Cbr>sitagliptina, liraglutida, etc) para la diabetes-obesidad61. En atención\u003Cbr>primaria, en España, sus “superventas” son omeprazol, atorvastatina\u003Cbr>y pantoprazol.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>¿A quién pertenece Teva?\u003C\u002Fstrong>\u003Cbr>En cuanto a sus propietarios, Teva cuenta con una combinación de\u003Cbr>accionistas institucionales y particulares:\u003Cbr>Principales accionistas Institucionales :\u003Cbr>● Fmr Llc: una de las mayores gestoras de activos del mundo,\u003Cbr>con una significativa participación en Teva.\u003Cbr>● BlackRock, Inc.: otra importante gestora de activos, con una\u003Cbr>participación considerable en la empresa.\u003Cbr>● Ion Asset Management Ltd.: una firma de inversión con sede en\u003Cbr>Israel.\u003Cbr>● Clal Insurance Enterprises Holdings Ltd: una compañía de\u003Cbr>seguros israelí.\u003Cbr>● Menora Mivtachim Holdings Ltd.: una aseguradora israelí.\u003Cbr>● Exor Capital LLP: una firma de inversión con sede en Reino\u003Cbr>Unido.\u003Cbr>● Phoenix Holdings Ltd.: una aseguradora israelí.\u003Cbr>● Migdal Insurance & Financial Holdings Ltd.: una aseguradora\u003Cbr>israelí.\u003Cbr>● Rubric Capital Management LP: una firma de inversión con\u003Cbr>sede en Estados Unidos.\u003Cbr>● Harel Insurance Investments & Financial Services Ltd.: una\u003Cbr>aseguradora israelí.\u003Cbr>Berkshire Hathaway, la compañía de Warren Buffett, mantuvo una\u003Cbr>participación en Teva hasta el cuarto trimestre de 2021, cuando la\u003Cbr>vendió.\u003Cbr>Si bien no se especifican en la información proporcionada, existen\u003Cbr>accionistas individuales que pueden incluir a empleados de Teva,\u003Cbr>inversores particulares y otras personas que poseen acciones a\u003Cbr>través de fondos de inversión o de cuentas de corretaje.\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Las “transferencias de valor” de Teva en España\u003C\u002Fstrong>\u003Cbr>En 2023, en España, Teva fue, por volumen de ventas al Sistema\u003Cbr>Nacional de Salud (el sistema sanitario público), la tercera compañía\u003Cbr>farmacéutica, con 70 millones de envases y gasto de más de 500\u003Cbr>millones de euros.\u003Cbr>La propaganda de medicamentos se hace a los médicos y otros\u003Cbr>profesionales, especialmente a los médicos “principales” o “key\u003Cbr>opinion leaders” (KOL): los que crean opinión, que son especialmente\u003Cbr>eficaces para transmitir mensajes a sus compañeros, a quienes se\u003Cbr>financian estudios y publicaciones, y a quienes se promueven en\u003Cbr>todas las actividades docentes financiadas por las industrias\u003Cbr>(congresos, jornadas, cursos, encuentros, etc).\u003C\u002Fp>\n\u003Cp>Las industrias llaman\u003Cbr>“transferencias de valor” (62) a esta financiación de propaganda que\u003Cbr>incluye viajes, estancias, comidas y remuneraciones por asesoría,\u003Cbr>conferencias y otras actividades63.\u003Cbr>En España, en 2023, Teva declaró 2.010.412 € en “transferencias de\u003Cbr>valor”, según su informe de transparencia64, distribuidas de la\u003Cbr>siguiente manera:.\u003Cbr>● Pagos a profesionales sanitarios: 961.819 €\u003Cbr>● Pagos a asociaciones: 811.811 €\u003Cbr>● Pagos relacionados con investigación: 236.782 €\u003Cbr>Teva declaró pagos (transferencias de valor) a casi 1,500\u003Cbr>profesionales de la sanidad en el año 2023 (la amplia mayoría en\u003Cbr>torno a los 600 euros).\u003C\u002Fp>\n\u003Cp>Destacan como KOL:\u003Cbr>● Patricia Pozo Rosich, Barcelona, neuróloga, 31.654 €\u003Cbr>● José Miguel Laínez Andrés, Valencia, neurólogo, 14.619 €\u003Cbr>● Roberto Chacón Puig, Barcelona, farmacéutico, 14.324 €\u003Cbr>● Rogelio Leira Muiño, Santiago de Compostela, neurólogo,\u003Cbr>13.720 €\u003Cbr>● Pablo Irimia Sieira, Pamplona, neurólogo, 13.173 €\u003Cbr>● María Carmen González Oria, Sevilla, neuróloga 13.629 €\u003Cbr>\u003Cbr>En cuanto a las organizaciones, Teva declaró transferencias de valor\u003Cbr>a un total de 45 organizaciones, la mayoría de ellas menores de\u003Cbr>10.000 euros. Destacan, sin embargo, por los altos importes, las\u003Cbr>siguientes:\u003Cbr>● Fundación SEN (Sociedad Española de Neurología), Barcelona,\u003Cbr>149.645 €\u003Cbr>● Fundació Hospital Universitari Vall D'Hebron. Institut de\u003Cbr>Recerca, Barcelona, 112.850 €\u003Cbr>● Sociedad Española de Farmacia Clínica, Familiar y\u003Cbr>Comunitaria, SEFAC, Madrid, 90.985 €\u003Cbr>● Fundación Investigación y Formación de la SMEG (Sociedad\u003Cbr>Española de Médicos Generales y de Familia), Madrid, 87.483 €\u003Cbr>● Fundació Institut de Recerca del Hospital de la Santa Creu i\u003Cbr>Sant Pau, Barcelona, 53.800 €\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Cstrong>Teva y la corrupción\u003C\u002Fstrong>\u003Cbr>Teva arrastra un historial de prácticas delictivas que ha empleado\u003Cbr>para tratar de promover la venta de sus medicamentos y controlar el\u003Cbr>mercado, especialmente en EEUU. Así, entre 2010 y 2024, Teva ha\u003Cbr>pagado 9.000 millones de dólares por condenas y multas por\u003Cbr>corrupción demostrada en tribunales de todo el mundo65.\u003Cbr>En 2016, Teva fue condenada a pagar una multa de 519 millones de\u003Cbr>dólares por un delito de sobornos para vender uno de sus\u003Cbr>medicamentos, Copaxone (66), repitiéndose en 2024 un delito similar,\u003Cbr>por el mismo medicamento, por el que fue condenada a pagar 450\u003Cbr>millones de dólares (67).\u003C\u002Fp>\n\u003Cp>\u003Cbr>En 2022, también en Estados Unidos, la empresa fue condenada a\u003Cbr>pagar 4.250 millones por la promoción fuera de indicación de sus\u003Cbr>medicamentos opioides, lo que contribuyó a la epidemia de muertes\u003Cbr>por sobredosis (68). En 2023, Teva fue multada con 225 millones de\u003Cbr>dólares (la mayor multa impuesta en EEUU hasta la fecha a un cartel\u003Cbr>antitrust) por sus prácticas anticompetitivas vinculadas a uno de\u003Cbr>sus medicamentos anticolesterol, la pravastatina (69).\u003C\u002Fp>\n\u003Cp>\u003Cbr>A finales de 2024, Teva fue investigada en Estados Unidos (70, 71) por\u003Cbr>incrementar los precios e impedir la libre competencia al introducir\u003Cbr>cambios en sus medicamentos genéricos para el asma y la EPOC\u003Cbr>(enfermedad pulmonar obstructiva crónica), lo que se confirmó en\u003Cbr>mayo de 2025, con la correspondiente amonestación (72).\u003C\u002Fp>\n\u003Cp>Por su parte, la Unión Europea multó a Teva en 2024 con 462,6\u003Cbr>millones de euros por abuso de posición dominante también con\u003Cbr>relación a Copaxane (73).\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Referencias\u003C\u002Fstrong>\u003Cbr>72\u003C\u002Fp>\n\u003Cp>\u003Cbr>https:\u002F\u002Fwww.ftc.gov\u002Fsystem\u002Ffiles\u002Fftc_gov\u002Fpdf\u002F2025-05-21-teva-branded-phar\u003Cbr>m-orange-book-warning-letter.pdf\u003C\u002Fp>\n\u003Cp>\u003Cbr>71\u003C\u002Fp>\n\u003Cp>https:\u002F\u002Fwww.saludyfarmacos.org\u002Fboletin-farmacos\u002Fboletines\u002Fago202407\u002F27_la\u002F\u003C\u002Fp>\n\u003Cp>\u003Cbr>70\u003Cbr>https:\u002F\u002Fwww.washingtonpost.com\u002Fhealth\u002F2024\u002F07\u002F01\u002Fteva-patent-pharma-g\u003Cbr>eneric-inhaler\u002F\u003C\u002Fp>\n\u003Cp>\u003Cbr>69\u003Cbr>https:\u002F\u002Fedition.cnn.com\u002F2023\u002F08\u002F21\u002Finvesting\u002Fteva-pharmaceuticals-price-fi\u003Cbr>xing-settlement\u002Findex.html\u003C\u002Fp>\n\u003Cp>\u003Cbr>68\u003Cbr>https:\u002F\u002Fwww.texasattorneygeneral.gov\u002Fnews\u002Freleases\u002Fopioids-maker-teva-agrees-4\u003Cbr>25-billion-settlement-preliminary-agreement-will-provide-cash-and\u003C\u002Fp>\n\u003Cp>\u003Cbr>67\u003Cbr>https:\u002F\u002Fwww.justice.gov\u002Farchives\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees\u003Cbr>-pay-450m-false-claims-act-settlement-resolve-kickback\u003C\u002Fp>\n\u003Cp>\u003Cbr>66\u003Cbr>https:\u002F\u002Fpharmaceutical-journal.com\u002Farticle\u002Fnews\u002Fteva-agrees-to-pay-us519m-to-se\u003Cbr>ttle-corruption-charge\u003C\u002Fp>\n\u003Cp>65\u003Cbr>https:\u002F\u002Fviolationtrackerglobal.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-indus\u003Cbr>tries\u003C\u002Fp>\n\u003Cp>63\u003Cbr>https:\u002F\u002Faccesojustomedicamento.org\u002Fla-red-oscura-que-las-multinacionales-farma\u003Cbr>ceuticas-ocultan-tras-los-pagos-a-profesionales-sanitarios-sus-lideres-de-opinion\u003Cbr>-en-el-sns-y-su-red-de-intereses-al-descubierto\u002F\u003C\u002Fp>\n\u003Cp>\u003Cbr>62\u003Cbr>https:\u002F\u002Faccesojustomedicamento.org\u002Flos-pagos-a-profesionales-y-organiz\u003Cbr>aciones-sanitarias-el-mercado-de-pulgas-de-las-multinacionales-farmaceu\u003Cbr>ticas\u002F\u003C\u002Fp>\n\u003Cp>61\u003Cbr>https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-eleva-sus-previsiones-aupada-por-los-f\u003Cbr>armacos-contra-la-enfermedad-de-huntington\u003C\u002Fp>\n\u003Cp>60\u003Cbr>https:\u002F\u002Fwww.elperiodicodearagon.com\u002Faragon\u002F2023\u002F10\u002F23\u002Funiversidad-san-jorge-fi\u003Cbr>rma-nueva-93706080.html\u003Cbr>59\u003Cbr>https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-acelera-en-espana-crece-un-10-hasta-1\u003Cbr>60-millones-en-el-primer-semestre\u003C\u002Fp>\n\u003Cp>58\u003C\u002Fp>\n\u003Cp>El origen de la planta en Zaragoza es la aragonesa Industrial Farmacéutica de\u003Cbr>Zaragoza (INFAR), promovida por el farmacéutico Julio Gracia Zatorre en los años\u003Cbr>40 del siglo XX, quien industrializó las fórmulas magistrales que habitualmente\u003Cbr>dispensaba desde su oficina de farmacia Zatorre, ubicada en la calle Balmes 3 de\u003Cbr>Zaragoza. La compañía se asoció después con la compañía alemana\u003Cbr>NATTERMANN GmbH. En 1973, construyó en el polígono de Malpica de Zaragoza\u003Cbr>una planta de fabricación, con 70 trabajadores, donde mantiene su ubicación.\u003Cbr>Después, ha pasado por diferentes dueños hasta su adquisición por TEVA. Fuente:\u003Cbr>https:\u002F\u002Fwww.aragonhoy.es\u002Fsanidad\u002Fconsejero-sanidad-visita-planta-teva-pharma-\u003Cbr>zaragoza-produce-8-700-millones-dosis-farmacos-ano-96176\u003C\u002Fp>","mkba51a5gm9k54426va","Teva. Sistema \u002Fmercado sanitario, sociosanitario y farmacéutico.","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1768229976\u002Fojlmzep1tixma6gocdx1.png",[15,480],"Tribunal Pueblos","teva-sistema-mercado-sanitario-sociosanitario-y-farmaceutico",1768229986280,"INFORME TPCGP-25 Mesa 4 * Tribunal de los Pueblos sobre la Complicidad con el Genocidio Palestino en el Estado Español (TPCGP-25)",{"content":485,"type":7,"subtitle":486,"slug":487,"link":12,"user":13,"tags":488,"title":489,"timestamp":490,"videoUrl":294,"imageUrl":491,"id":492},"\u003Cp>\u003Ca href=\"https:\u002F\u002Farainfo.org\u002Fteva-pharma-despide-a-una-trabajadora-por-defender-el-derecho-a-la-vivienda-con-la-pah-de-zaragoza\u002F\">\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Farainfo.org\u002Fteva-pharma-despide-a-una-trabajadora-por-defender-el-derecho-a-la-vivienda-con-la-pah-de-zaragoza\u002F\">\u003Cstrong>Teva Pharma despide a una trabajadora \"por razones ideológicas\" con la PAH de Zaragoza\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>La Intersindical de Aragón denuncia que la multinacional farmacéutica israelí Teva Pharma “ha vulnerado la libertad ideológica” y subraya que “es inadmisible que cometa represalias por motivos ajenos a lo laboral”\u003C\u002Fp>\n\u003Cp>20 enero, 2026, 10:53\u003C\u002Fp>\n\u003Cp>Fotografía: El consejero de Sanidad del Gobierno de Aragón, José Luis Bancalero, posando en Zaragoza con los directivos del la multinacional israelí | Foto: DGA\u003C\u002Fp>\n\u003Cp>Desde la Intersindical de Aragón relatan como “durante las vacaciones de Navidad, Teva, multinacional farmacéutica israelí, ha despedido a una trabajadora con casi tres años de antigüedad.\u003C\u002Fp>\n\u003Cp>\u003Cem>¿El motivo?, pedir un permiso retribuido para asistir a un juicio donde La Caixa le pide tres años de cárcel por tratar de impedir pacíficamente un desahucio de una familia con menores a cargo”.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Dicho permiso fue concedido “pero nada más darse a conocer los motivos del juicio, la empresa actuó rápidamente redactando una carta de despido procedente ‘prototipo’ totalmente vacía de contenido, donde se alega ‘disminución de rendimiento’. Además, no se comunicó a la trabajadora la apertura del correspondiente expediente disciplinario contradictorio donde se podía defender de estos hechos y que supone un requisito formal”, recalcan desde la Intersindical.\u003C\u002Fp>\n\u003Cp>La trabajadora represaliada es afiliada a Intersindical de Aragón (INAR) y simpatizante de la Plataforma de Afectados por la Hipoteca (PAH Zaragoza). Desde ambas organizaciones creen necesario denunciar “la doble represión que ha sufrido la compañera, por un lado por parte de la banca y del Estado al participar de la campaña contra el desahucio de Mariano, y, por otro, por parte de Teva por el mismo motivo.\u003C\u002Fp>\n\u003Cp>Es evidente que Teva ha vulnerado la libertad ideológica de la compañera y que es inadmisible que una empresa cometa represalias hacia su trabajadora por motivos ajenos al laboral. Necesitamos más que nunca espacios de autoorganización obrera que nos enseñen a defendernos de los abusos patronales, porque si la compañera no hubiera conocido sus derechos habría acatado un despido procedente sin indemnización y no habría tenido herramientas para denunciar su doble represión”, enfatizan desde ambas entidades sociales.\u003C\u002Fp>\n\u003Cp>Esta situación, les lleva a señalar que “las organizaciones que estamos a pie de calle debemos tener una perspectiva amplia sobre los problemas de la clase trabajadora, pues se demuestra que nuestra clase no tiene problemas exclusivamente de vivienda o laborales, sino que se entremezclan a merced de los capitalistas. Por este motivo, debemos aunar nuestro trabajo y apoyarnos cuando sea necesario, respondiendo a la realidad de la clase trabajadora”.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Teva Pharma: represión para las trabajadoras aragonesas, premios económicos para las sionistas\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>“Obligatoriamente debemos incidir en el carácter sionista que tiene esta multinacional, que desde el 7 de octubre de hace dos años ha estado enviando correos corporativos internos declarándose abiertamente sionista o dando la ‘oportunidad’ de donar parte del sueldo como trabajador de Teva para Israel.\u003C\u002Fem> Es más, el 10% de los y las trabajadoras de Teva en Israel fueron enviados al frente desde aquel 7 de octubre y estos fueron recompensados económicamente por la farmacéutica”, explican desde INAR.\u003C\u002Fp>\n\u003Cp>Esta multinacional, incluida en la lista de empresas implicadas en el negocio de la ocupación sionista de Palestina elaborada por el movimiento Boicot, Desinversión y Sanciones (BDS), obtuvo, tan solo en 2024, 16.400 millones de dólares en ingresos, que tributa en Israel y que sirven para inflar las arcas de un Estado genocida basado en la ocupación ilegal de territorio palestino y la voluntad supremacista de exterminar a su población.\u003C\u002Fp>\n\u003Cp>“Además, con su capacidad de injerencia en la legislación israelí, Teva disfruta de todo el mercado de Jordania y Palestina debido a que las farmacéuticas palestinas no pueden competir gracias a las restricciones israelíes, como prohibir que se envíen farmacéuticos desde el aeropuerto Ben Gurion o añadir impuestos abusivos a productos que entran a Cisjordania”, subrayan desde INAR.\u003C\u002Fp>\n\u003Cp>\u003Cem>Desde el 2024, en Aragón se han realizado dos huelgas generales por Palestina “en las que tanto la compañera como otro afiliado ejercieron su derecho de secundarla. Qué casualidad que la empresa haya despedido a la compañera, y además haya puesto una sanción grave al otro afiliado que las secundó.\u003C\u002Fem> No es el primer caso de represión por parte de esta farmacéutica por no apoyar el genocidio: el médico Pablo Simón en Granada fue denunciado por Teva por no querer vender sus fármacos, pero la presión popular obligó al Colegio de Médicos a archivar la querella”, recuerdan desde la Intersindical de Aragón.\u003C\u002Fp>\n\u003Cp>\u003Cem>“Estamos en el deber de denunciar que esta empresa ubicada en el Polígono de Malpica en Zaragoza, de más de 500 trabajadores y trabajadoras, es una empresa que financia el genocidio y reprime a los y las trabajadoras por estar en contra de ello. ¡No dejemos que salgan impunes ante sus prácticas represivas! La denuncia popular puede presionar para hacer un boicot realmente efectivo, como se demuestra en la cancelación de contratos con Teva por parte del gobierno asturiano o el navarro”\u003C\u002Fem>, aseguran desde INAR.\u003C\u002Fp>\n\u003Cp>“Defender a una familia a la que se le está arrebatando un derecho fundamental como es la vivienda, no debería ser un motivo ni por el que ir a juicio, ni de despido, sino un acto de solidaridad de clase. Está claro: Teva aplaude acciones genocidas y reprime a las que defendemos a nuestra gente, a la clase obrera, una encarnación más de la lucha de clases”, concluyen desde la Intersindical de Aragón.\u003C\u002Fp>\n\u003Cp class=\"article-text continue-read-break\" data-t=\"{"n":"blueLinks","t":13,"a":"click","b":76}\">La trabajadora, M.B., ha explicado que recibió un burofax de la empresa en plenas fechas navideñas tras haber solicitado un permiso retribuido para asistir a un juicio los días 18 y 19 de diciembre por tratar de impedir pacíficamente un desahucio de una familia con menores a cargo. Dicho permiso fue concedido, pero nada más conocerse los motivos del proceso judicial y ver la foto de la trabajadora en la prensa, esta sostiene que “la empresa actuó rápidamente redactando una carta de despido procedente 'prototipo', totalmente vacía de contenido, donde se alega ”disminución de rendimiento“.\u003C\u002Fp>\n\u003Cp class=\"article-text\" data-t=\"{"n":"blueLinks","t":13,"a":"click","b":76}\">Aunque ella trató de demostrar que es un despido nulo, finalmente se llegó a un acuerdo en el Servicio Aragonés de Mediación y Arbitraje (Sama) por despido improcedente con derecho a indemnización tras tres años en la empresa.\u003C\u002Fp>\n\u003Cp class=\"article-text\" data-t=\"{"n":"blueLinks","t":13,"a":"click","b":76}\">Según relata la trabajadora, “es evidente que Teva ha vulnerado mi libertad ideológica y garantía de indemnidad” y sostiene que, además de la asistencia al juicio, la empresa ha tomado represalias contra ella también por haber participado durante dos años en huelgas por Palestina, \u003Cstrong>convocatorias que solo fueron secundadas por dos de los 500 trabajadores de la planta zaragozana\u003C\u002Fstrong>, y razón por la que, según la Intersindical, también impuso una sanción grave al otro trabajador y afiliado que participó en dichas protestas de 2024 y 2025.\u003C\u002Fp>\n\u003Cp class=\"article-text\" data-t=\"{"n":"blueLinks","t":13,"a":"click","b":76}\">\u003Cem>Ambos trabajadores denuncian las prácticas de esta multinacional, “que desde el 7 de octubre de hace dos años ha estado enviando correos corporativos internos, declarándose abiertamente sionistas o dando la 'oportunidad' de donar parte del sueldo como trabajador de Teva para Israel”.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp class=\"article-text\" data-t=\"{"n":"blueLinks","t":13,"a":"click","b":76}\">Fuentes de la empresa zaragozana, la más productiva del grupo farmacéutico, han negado las acusaciones asegurando que Teva “respeta la opinión de cada trabajador, no se mete, ni conoce ni le interesa sus opiniones o manifestaciones”.\u003C\u002Fp>\n\u003Cp class=\"article-text\" data-t=\"{"n":"blueLinks","t":13,"a":"click","b":76}\">Por su parte, la Intersindical de Aragón se reafirma en su denuncia e ironiza sobre la “casualidad” de que la empresa haya despedido a la compañera y, además, haya puesto una sanción grave al otro afiliado que secundó las movilizaciones. Con respecto al despido, considera “inadmisible” que una empresa cometa represalias hacia su trabajadora por motivos ajenos al laboral y critica que tampoco comunicara a la trabajadora la apertura del correspondiente expediente disciplinario contradictorio donde se podía defender de estos hechos y que supone un requisito formal.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>20 January 2026\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva Pharma fires a worker \"for ideological reasons\" with the Zaragoza PAH (Platform of People Affected by Mortgages) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Intersindical de Aragón (Aragon Inter-Union) denounces that the Israeli multinational pharmaceutical company Teva Pharma “has violated freedom of expression” and emphasizes that “it is unacceptable for it to retaliate for reasons unrelated to work.” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">January 20, 2026, 10:53 AM \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Intersindical de Aragón union reports how “during the Christmas holidays, Teva, an Israeli multinational pharmaceutical company, dismissed a worker with almost three years of service. \u003Cem>The reason? She requested paid leave to attend a trial where La Caixa bank is seeking a three-year prison sentence for her for peacefully trying to prevent the eviction of a family with dependent children.”\u003C\u002Fem>\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This leave was granted, “but as soon as the reasons for the trial became public, the company acted swiftly, drafting a ‘standard’ dismissal letter completely devoid of content, alleging ‘decreased performance.’ Furthermore, the worker was not informed of the opening of the corresponding disciplinary proceedings, a formal requirement for her to defend herself against these actions,” the Intersindical union emphasizes.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The worker who was punished is a member of the Intersindical de Aragón (INAR) and a supporter of the Platform of People Affected by Mortgages (PAH Zaragoza).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Both organizations believe it is necessary to denounce “the double repression suffered by our colleague, firstly by the banks and the State for participating in the campaign against Mariano's eviction, and secondly by Teva for the same reason. It is clear that Teva has violated our colleague's ideological freedom and that it is unacceptable for a company to retaliate against its employee for reasons unrelated to work. Now more than ever, we need spaces for workers' self-organization that teach us how to defend ourselves against employer abuses, because if our colleague had not known her rights, she would have accepted a justified dismissal without compensation and would not have had the means to denounce this double repression,” both social organizations emphasize.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This situation leads them to point out that “organizations like ours, working on the ground, must have a broad perspective on the problems of the working class, as it is clear that our class does not exclusively face housing or employment issues, but rather that these problems are intertwined and at the mercy of capitalists. For this reason, we must unite our efforts and support each other when necessary, responding to the reality of the working class.”\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva Pharma: Repression for Aragonese Workers, Financial Incentives for Zionists \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">“We must emphasize the Zionist nature of this multinational, which since October 7th two years ago has been sending internal corporate emails openly declaring itself Zionist or offering the ‘opportunity’ to donate part of one's salary as a Teva employee to Israel. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Furthermore, 10% of Teva's workers in Israel were sent to the front lines after that October 7th, and they were financially rewarded by the pharmaceutical company,” explains INAR.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> This multinational, included on the list of companies involved in the Zionist occupation of Palestine compiled by the Boycott, Divestment, and Sanctions (BDS) movement, earned $16.4 billion in revenue in 2024 alone. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This revenue, which is taxed in Israel, serves to inflate the coffers of a genocidal state based on the illegal occupation of Palestinian territory and the supremacist desire to exterminate its population.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> “Furthermore, with its ability to interfere in Israeli legislation, Teva enjoys control of the entire Jordanian and Palestinian market because Palestinian pharmaceutical companies cannot compete due to Israeli restrictions, such as prohibiting the shipment of pharmaceuticals from Ben Gurion Airport or imposing exorbitant taxes on products entering the West Bank,” INAR emphasizes.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Since 2024, two general strikes for Palestine have been held in Aragon, “in which both our colleague and another member exercised their right to participate. What a coincidence that the company has fired our colleague and also imposed a serious sanction on the other member who participated. This is not the first case of  \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">repression by this pharmaceutical company for not supporting genocide: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Dr. Pablo Simón in Granada was sued by Teva for refusing to sell their drugs, but public pressure forced the Medical Association to drop the case,” recalls the Intersindical de Aragón (Aragon Inter-Union).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">“We have a duty to denounce this company, located in the Malpica Industrial Park in Zaragoza, with more than 500 employees, as a company that finances genocide and represses workers for opposing it. Let's not allow them to go unpunished for their repressive practices!”\u003C\u002Fspan> \u003Cem>\u003Cspan class=\"ryNqvb\">Public outcry can exert pressure to create a truly effective boycott, as demonstrated by the cancellation of contracts with Teva by the Asturian and Navarrese governments,” INAR asserts. \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">“Defending a family whose fundamental right to housing is being taken away should not be grounds for legal action or dismissal, but rather an act of class solidarity.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">It’s clear: Teva applauds genocidal actions and represses those of us who defend our people, the working class—yet another embodiment of the class struggle,” concludes the Intersindical de Aragón (Aragon Inter-Union).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The worker, M.B., explained that she received a registered letter from the company in the middle of the Christmas holidays after having requested paid leave to attend a trial on December 18 and 19 for trying to peacefully prevent the eviction of a family with minor children in their care.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The leave was granted, but as soon as the reasons for the legal proceedings became known and the worker's photo appeared in the press, she maintains that \"the company acted quickly, drafting a 'standard' dismissal letter, completely devoid of content, alleging 'decreased performance.'\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Although she tried to prove that the dismissal was invalid, an agreement was finally reached at the Aragonese Mediation and Arbitration Service (SAMA) for unfair dismissal with the right to compensation after three years with the company. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to the worker, \"it is clear that Teva has violated my freedom of thought and my right to protection against retaliation,\" and she maintains that, in addition to forcing her to attend the trial,\u003Cstrong> the company has also retaliated against her for having participated for two years in strikes for Palestine, actions that were only supported by two of the 500 workers at the Zaragoza plant, and for which, according to the Intersindical union, the other worker also received a severe sanction.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Both workers denounce the practices of this multinational corporation, “which, since October 7th two years ago, has been sending internal corporate emails, openly declaring itself Zionist or offering the 'opportunity' to donate part of one's salary as a Teva employee to Israel.”\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Sources at the Zaragoza-based company, the most productive in the pharmaceutical group, have denied the accusations, asserting that Teva “respects the opinion of each worker, does not interfere, nor is it aware of or interested in their opinions or demonstrations.”\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For its part, the Intersindical de Aragón (Aragon Inter-Union) reaffirms its denunciation and ironically comments on the “coincidence” that the company dismissed the colleague and, furthermore, imposed a serious sanction on the other union member who supported the mobilizations.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Regarding the dismissal, it considers it “unacceptable” that a company would retaliate against its employee for reasons unrelated to work and criticizes the fact that the company also failed to inform the employee of the opening of the corresponding disciplinary proceedings.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">contradictory disciplinary proceedings where he could defend himself against these facts, which constitutes a formal requirement.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","Despedida “por razones ideológicas”. Fired for ideological reasons unrelated to work","teva-pharma-zaragoza-espana-despide-razon-extralaboral-fires-a-worker-for-ideological-reasons-esp-eng",[15],"Teva Pharma (Zaragoza, España) despide, razón extralaboral\u002F fires a worker for ideological reasons. ESP ENG",1769096391183,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1769095595\u002Fb7o7hjssldeztfhkdwwx.jpg","mkplca8kwxm5edp97a",{"videoUrl":494,"title":495,"type":7,"imageUrl":496,"slug":497,"timestamp":498,"link":12,"user":13,"tags":499,"id":500,"subtitle":501,"content":502},"otgLdH5Atlo","Teva, growing global backlash. Teva, boicot creciente ENG ESP","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1770721368\u002Fogjyqbadahtcorlrz4fm.png","teva-growing-global-backlash-teva-boicot-creciente-eng-esp",1770721819629,[15],"mlggj9lhl52a2orzsc","Teva: politics and business over compassion and ethics. Teva: política y negocio sobre compasión y ética","\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Teva Pharmaceutical Industries, an Israeli company and one of the world’s largest producers of generic drugs, is facing growing global backlash. \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Nov 2025\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Once seen as a leader in affordable medicine, Teva is now widely criticized for ethical contradictions and its indifference to humanitarian crises.\u003C\u002Fp>\n\u003Cp>The company has come under fire for its complicity in the Israeli regime’s war on Gaza. Many doctors, nurses, and activists accuse Teva of ignoring the suffering of Palestinian civilians, especially children, and have begun boycotting its products.\u003C\u002Fp>\n\u003Cp>\u003Cem>As the humanitarian crisis in Gaza worsens—with widespread shortages of medicine and destruction of healthcare infrastructure—Teva has been criticized for failing to provide aid or support. Instead, its public statements have focused solely on supporting Israel and meeting domestic needs.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Despite repeated calls from the UN and human rights organizations to deliver life-saving drugs to Gaza, Teva has not taken practical steps to help. Critics say this silence, while children die from treatable conditions, has severely damaged the company’s reputation.\u003C\u002Fp>\n\u003Cp>Teva’s alignment with Israeli policies, including its financial contributions through taxes and support for military-linked aid programs, has raised ethical concerns. The company is now being questioned not only politically but also morally.\u003C\u002Fp>\n\u003Cp>\u003Cem>In response, medical professionals in countries like Canada, Belgium, Ireland, Italy, the Netherlands, Spain and the USA have called for a boycott of Teva’s drugs. Irish doctors urged their government to stop using Israeli medications, especially for children, citing ethical violations.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>In Canada, the campaign started in 2019 in Vancouver \"Boycott TEVA, the Israeli pharmaceutical company that is one of the largest generic drug manufacturers in the world. Order a strip of our “No TEVA” stickers for free by clicking on the Send Message button at the top right of this page and letting us know where to send your Boycott TEVA kit. Or just tell your regular pharmacy to put a permanent “No TEVA” note on your file!\"\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In Belgium, 319 healthcare providers and 12 institutions say NO to TEVA. For example, Genk supports boycott of Israeli pharmaceutical manufacturer Teva: \"Don't buy products from companies that actively support the Israeli army\" Stop buying Teva medications.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This unmistakable message was delivered by an action group at the weekly market in Genk.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">During the protest, Mayor Wim Dries (CD&V) signed an open letter to all pharmacists urging them to offer a different version if their customers request Teva medication.  Following her party colleague Wim Dries, CD&V parliamentary group leader Nawal Farih is also calling on Minister of Health Frank Vandenbroucke (Vooruit) to ban Teva medications from the Belgian healthcare system if equivalent alternatives exist.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>Staff at Dublin’s National Orthopedic Hospital joined the boycott, and viral videos from Italy showed doctors discarding Teva products in protest. These acts reflect widespread anger at a company expected to save lives but accused of ignoring a humanitarian disaster.\u003C\u002Fp>\n\u003Cp>Throughout the genocide, BDS Italy has been working closely with the local collective Health Workers for Gaza (Sanitari per Gaza), achieving major milestones. One of their first actions under the Teva boycott campaign was to distribute leaflets in front of pharmacies to raise awareness among patients and pharmacists about the company’s role in the genocide.\u003C\u002Fp>\n\u003Cp>\"Mediant\" (mental health institution, Twente, Netherlands) boycotts Israeli products for humanity, compassion, and the protection of mental well-being in Gaza. \u003C\u002Fp>\n\u003Cp>In Spain, doctors from the Basque Country, Navarre, and Madrid have called for the cancellation of Teva purchases, the professional association Health Workers For Palestine Spain is promoting a boycott, and two regional governments (Navarre and Asturias) have terminated their contracts with Teva.\u003C\u002Fp>\n\u003Cp>In America earlier this year [2025], Health Care Workers for Palestine (HCW4P) launched a worldwide campaign to boycott the Israel-based Teva Pharmaceuticals, a major distributor of generic medications here in the U.S. and throughout the Western hemisphere. The campaign in the U.S. was adopted by local chapters of HCW4P in major areas, including the San Francisco Bay Area, New York and Philadelphia.\u003C\u002Fp>\n\u003Cp>Teva reportedly paid $750 million in taxes to the Israeli government in 2024, which critics say helps fund military operations in Gaza. This financial link has intensified calls for accountability.\u003C\u002Fp>\n\u003Cp>\u003Cem>For many, Teva is no longer just a pharmaceutical brand—it has become a symbol of profit-driven disregard for human rights. Its silence amid Gaza’s suffering is seen as prioritizing politics and business over compassion and ethics\u003C\u002Fem>.\u003C\u002Fp>\n\u003Cp>Teva has actively supported the genocide in the Gaza Strip since October 2023 and contributed to the erosion of Palestinian healthcare long before that, Giorgia Gusciglio, Europe Coordinator for Boycott, Divestment and Sanctions (BDS) Campaigns at the Palestinian BDS National Committee, told People’s Health Dispatch.\u003C\u002Fp>\n\u003Cp>Last year [2024], as Gaza’s health services and workers faced near-total annihilation from Israeli attacks, Teva reported over USD 16.5 billion in revenue. Part of that revenue comes from the Palestinian market, where the company profits from the double standards imposed by the apartheid regime.\u003C\u002Fp>\n\u003Cp>In contrast to Palestinian pharmaceutical producers, who face severe restrictions, prolonged import procedures, and arbitrary “dual-use” designations for essential components, Teva is free to market its products in the occupied territories, many times without adapting packaging or documentation. According to sources collected by BDS Italy, the company even sells medicines in boxes and with instruction leaflets not translated into Arabic.\u003C\u002Fp>\n\u003Cp>The exploitation of pharmaceutical needs in occupied territories is not unique to Teva or the time since 2023. The 2012 report \u003Ca href=\"https:\u002F\u002Fwww.bdsmovement.net\u002Fnews\u002Fcaptive-economy-pharmaceutical-industry-and-israeli-occupation\">“Captive economy: The pharmaceutical industry and the Israeli occupation”\u003C\u002Fa> [Who Profits?] concluded that “all Israeli pharmaceutical companies sell their products on the Palestinian market and profit from it, without paying any price for the occupation and its damage.”\u003C\u002Fp>\n\u003Cp>\u003Cstrong>A matter of Palestine solidarity and access to medicines\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Beyond usurping the Palestinian market, Teva also holds an important share of Europe’s pharmaceutical landscape: not only through its large generics portfolio, but also through proprietary products for multiple sclerosis and cancer. The contradiction between Teva’s stated “commitment toward better health” and its well-documented complicity in war crimes has driven the growth of groups mobilizing to boycott and expose the company. \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva Pharmaceutical Industries, empresa israelí y uno de los mayores productores mundiales de medicamentos genéricos, se enfrenta a una creciente reacción internacional.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Nov 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Considerada en su día líder en medicamentos asequibles, Teva es ahora ampliamente criticada por sus contradicciones éticas y su indiferencia ante las crisis humanitarias.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La empresa ha sido duramente criticada por su complicidad en la guerra del régimen israelí contra Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">Numerosos médicos, enfermeras y activistas acusan a Teva de ignorar el sufrimiento de los civiles palestinos, especialmente de los niños, y han comenzado a boicotear sus productos.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A medida que la crisis humanitaria en Gaza se agrava —con una escasez generalizada de medicamentos y la destrucción de la infraestructura sanitaria—, Teva ha sido criticada por no proporcionar ayuda ni apoyo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En cambio, sus declaraciones públicas se han centrado únicamente en apoyar a Israel y satisfacer las necesidades internas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A pesar de los reiterados llamamientos de la ONU y de organizaciones de derechos humanos para que se entreguen medicamentos vitales a Gaza, Teva no ha tomado medidas prácticas para ayudar.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Los críticos afirman que este silencio, mientras niños mueren por enfermedades tratables, ha dañado gravemente la reputación de la empresa.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La alineación de Teva con las políticas israelíes, incluyendo sus contribuciones financieras a través de impuestos y el apoyo a programas de ayuda vinculados al ejército, ha suscitado inquietudes éticas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La empresa se encuentra ahora bajo cuestionamiento no solo político, sino también moral.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En respuesta, profesionales médicos de países como Irlanda, Italia, Países Bajos, España y Estados Unidos han llamado a boicotear los medicamentos de Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En Bégica, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\">319 profesionales sanitarios y 12 instituciones dicen NO a TEVA. Por ejemplo, \u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">en Genk hay una campaña de \u003Cspan class=\"HwtZe\" lang=\"es\">boicot a la farmacéutica israelí Teva: \"No compren productos de empresas que apoyan activamente al ejército israelí\". Dejen de comprar medicamentos de Teva. Este mensaje inequívoco fue transmitido por un grupo de acción en el mercado semanal de Genk. Durante la protesta, el alcalde Wim Dries (CD&V) firmó una carta abierta a todos los farmacéuticos instándolos a ofrecer una versión diferente si sus clientes solicitan medicamentos de Teva.  Following her party colleague Wim Dries, CD&V parliamentary group leader Nawal Farih is also calling on Minister of Health Frank Vandenbroucke (Vooruit) to ban Teva medications from the Belgian healthcare system if equivalent alternatives exist.  Siguiendo el ejemplo de su compañero de partido, Wim Dries, la líder del grupo parlamentario de CD&V, Nawal Farih, también pide al ministro de Salud, Frank Vandenbroucke (Vooruit), que prohíba los medicamentos de Teva del sistema sanitario belga si existen alternativas equivalentes.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"es\">En Canadá la campaña de boicot comenzó en 2019 en Vancouver: \"Boycott TEVA, the Israeli pharmaceutical company that is one of the largest generic drug manufacturers in the world. Order a strip of our “No TEVA” stickers for free by clicking on the Send Message button at the top right of this page and letting us know where to send your Boycott TEVA kit. Or just tell your regular pharmacy to put a permanent “No TEVA” note on your file!\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Médicos irlandeses instaron a su gobierno a dejar de usar medicamentos israelíes, especialmente para niños, alegando violaciones éticas.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> El personal del Hospital Nacional de Ortopedia de Dublín se unió al boicot, y videos virales desde Italia mostraron a médicos desechando productos de Teva en protesta.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Estos actos reflejan la indignación generalizada contra una empresa que se espera que salve vidas, pero que ha sido acusada de ignorar un desastre humanitario.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Durante el genocidio, BDS Italia ha colaborado estrechamente con el colectivo local de Trabajadores de la Salud por Gaza (Sanitari per Gaza), logrando importantes logros.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Una de sus primeras acciones en el marco de la campaña de boicot a Teva fue distribuir folletos frente a las farmacias para concienciar a pacientes y farmacéuticos sobre el papel de la empresa en el genocidio.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Mediant (institución de salud mental de Twente, Países Bajos) boicotea productos israelíes por humanidad, compasión y la protección del bienestar mental en Gaza. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En España, médicos del País Vasco, Navarra y Madrid han pedido la cancelación de las compras de Teva, la asociación profesional Trabajadores de la Salud por Palestina España promueve un boicot, y dos gobiernos regionales (Navarra y Asturias) han rescindido sus contratos con Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En Estados Unidos, a principios de este año [2025], Trabajadores de la Salud por Palestina (HCW4P) lanzó una campaña mundial para boicotear a Teva Pharmaceuticals, con sede en Israel, un importante distribuidor de medicamentos genéricos en Estados Unidos y en todo el hemisferio occidental.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La campaña en Estados Unidos fue adoptada por las delegaciones locales de HCW4P en importantes zonas, como el área de la Bahía de San Francisco, Nueva York y Filadelfia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según se informa, Teva pagó 750 millones de dólares en impuestos al gobierno israelí en 2024, lo que, según los críticos, ayuda a financiar las operaciones militares en Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Este vínculo financiero ha intensificado las demandas de rendición de cuentas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">Para muchos, Teva ya no es solo una marca farmacéutica; se ha convertido en un símbolo de la indiferencia hacia los derechos humanos, impulsada por el lucro.\u003C\u002Fspan> \u003C\u002Fem>\u003Cspan class=\"ryNqvb\">\u003Cem>Su silencio ante el sufrimiento de Gaza se percibe como una priorización de la política y los negocios sobre la compasión y la ética\u003C\u002Fem>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El gigante farmacéutico israelí Teva se enfrenta a una creciente presión por parte de grupos solidarios con Palestina en Europa y Estados Unidos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva, uno de los mayores fabricantes de medicamentos de Israel y un importante productor mundial de medicamentos genéricos, ha apoyado activamente el genocidio en la Franja de Gaza desde octubre de 2023 y ha contribuido al deterioro de la atención sanitaria palestina mucho antes, según declaró Giorgia Gusciglio, coordinadora europea de las Campañas de Boicot, Desinversión y Sanciones (BDS) del Comité Nacional Palestino de BDS..\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El año pasado [2024], mientras los servicios y trabajadores sanitarios de Gaza se enfrentaban a una aniquilación casi total por los ataques israelíes, Teva reportó más de 16.500 millones de dólares en ingresos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Parte de estos ingresos proviene del mercado palestino, donde la empresa se beneficia de la doble moral impuesta por el régimen del apartheid.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> A diferencia de los productores farmacéuticos palestinos, que se enfrentan a severas restricciones, prolongados procedimientos de importación y designaciones arbitrarias de \"doble uso\" para componentes esenciales, Teva tiene libertad para comercializar sus productos en los territorios ocupados, muchas veces sin adaptar el embalaje ni la documentación.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según fuentes recopiladas por BDS Italia, la empresa incluso vende medicamentos en cajas y con folletos de instrucciones sin traducir al árabe.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La explotación de las necesidades farmacéuticas en los territorios ocupados no es exclusiva de Teva ni de la época desde 2023. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El informe de 2012 “Economía cautiva: La industria farmacéutica y la ocupación israelí” concluyó que “todas las empresas farmacéuticas israelíes venden sus productos en el mercado palestino y se benefician de ello, sin pagar ningún precio por la ocupación y sus daños”.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Una cuestión de solidaridad con Palestina y acceso a medicamentos \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Además de usurpar el mercado palestino, Teva también posee una importante cuota del mercado farmacéutico europeo: no solo a través de su amplia cartera de genéricos, sino también a través de productos patentados para la esclerosis múltiple y el cáncer.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La contradicción entre el declarado “compromiso con una mejor salud” de Teva y su bien documentada complicidad en crímenes de guerra ha impulsado el crecimiento de grupos que se movilizan para boicotear y exponer a la empresa.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Como explica Gusciglio, estas iniciativas varían según el país: en Irlanda tienen una fuerte dimensión sindical, mientras que en Bélgica e Italia están lideradas principalmente por secciones del BDS y redes de activistas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sin embargo, las campañas locales comparten el mismo objetivo: garantizar la justicia para Palestina.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",{"content":504,"title":505,"imageUrl":506,"id":507,"type":7,"videoUrl":508,"slug":509,"timestamp":510,"subtitle":511,"link":12,"tags":512,"user":13},"\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fbdsnederland.nl\u002Fstop-teva\u002F\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva y el ejército de Israel. Teva apoya el genocidio contra los palestinos en Palestina\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según su director, Teva es \"la voz de Israel\" durante la guerra.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Por ejemplo, los soldados que trabajan para Teva siguen recibiendo sus salarios cuando son desplegados en Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva también organiza diversas actividades para los soldados, como apoyo psicológico y eventos sociales, que deberían permitirles participar con renovado vigor en los ataques genocidas en Gaza y otros lugares.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva, por iniciativa propia, dona equipo al ejército de ocupación israelí.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva paga cientos de millones de dólares en impuestos al tesoro israelí anualmente (721 millones de dólares en 2024).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Esto ayuda a financiar, entre otras cosas, el armamento del ejército israelí.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El fundador y varios directores de Teva contribuyeron como soldados a la limpieza étnica en Palestina antes y después del establecimiento de Israel en 1948. Gracias, en parte, a sus vínculos especiales con el Estado israelí, Teva goza de una posición política, fiscal y comercial muy sólida en Israel.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva aporta miles de millones al Estado israelí de apartheid e invierte en instituciones gubernamentales que trabajan, entre otras cosas, en el desarrollo de armas, drones y tecnología de vigilancia utilizada para el genocidio en Gaza y las violaciones de derechos humanos en Cisjordania.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.markcurtis.info\u002F2025\u002F11\u002F14\u002Fthe-israel-firms-aiding-the-nhs-and-idf\u002F\">\u003Cstrong>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">14 nov 2025\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.markcurtis.info\u002F2025\u002F11\u002F14\u002Fthe-israel-firms-aiding-the-nhs-and-idf\u002F\">\u003Cstrong>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Apoyo a los soldados de combate \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Cientos de empleados de Teva en Israel, que representan al menos el 10% de su plantilla, fueron llamados a filas en la reserva militar tras los ataques de Hamás del 7 de octubre.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Uno de ellos fue Hadar Mama, director ejecutivo de la empresa de logística de Teva en Israel, quien, según se informó, se encontraba \"combatiendo en la Franja de Gaza, pero aún mantiene un contacto directo con el SLE\", la división logística de Teva.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \"Hadar se mueve entre tres puestos de mando: su familia, que permaneció en casa bajo la amenaza de un ataque con misiles, el SLE y su puesto en el ejército\", informó el Jerusalem Post en diciembre de 2023. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El periódico añadió: \"Entre los combates en Gaza y el descanso en la base, Hadar encuentra tiempo para reuniones virtuales con su equipo directivo, recibe actualizaciones de estado y toma decisiones clave\".\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Mama declaró: \"Nuestra brigada también recibió entregas de equipo que los trabajadores de Teva recolectaron para nosotros\".\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esto podría haber sido una referencia a la colaboración de Teva con el grupo israelí contra la pobreza Pitchon-Lev para recolectar \"equipo\" para los soldados del ejército de Israel (FDI).\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Se establecieron puntos de recolección en las cinco sedes de Teva en Israel, lo que permitió a los empleados donar: alrededor de 1,5 toneladas de equipo (cuyos detalles no se especifican) se habían donado a las FDI a finales de octubre de 2023. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Apoya el alma\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva también se ha asociado con Momentum, una organización sin fines de lucro en Israel que ayuda a los soldados de combate israelíes a abordar sus necesidades de salud mental, como el síndrome de estrés postraumático.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El programa \"Apoya el alma\" de Teva, lanzado en respuesta a los atentados del 7 de octubre, apoya a los terapeutas que tratan a los soldados.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En otra colaboración, la farmacéutica se ha asociado con una organización llamada Thank Israeli Soldiers (TIS), dedicada a apoyar a los soldados de las FDI mediante asociaciones con organizaciones israelíes sin fines de lucro.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">TIS ha desarrollado programas “en coordinación con las Fuerzas de Defensa de Israel” para apoyar el bienestar mental y físico de “los valientes hombres y mujeres que defienden a Israel”.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> En junio de este año, TIS publicó que “Teva ha financiado la supervisión profesional de nuestros facilitadores, garantizando que tengan un espacio seguro para procesar y recargar energías”.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">“Parte de una guerra” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Tres días después de los atentados del 7 de octubre, Teva emitió un comunicado en el que se mostraba “profundamente entristecido” por los ataques.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Añadió: “Como empresa israelí, condenamos este atroz ataque y Teva apoya a Israel en estos momentos de gran pérdida y desafío”.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Quizá en reconocimiento al apoyo de su empresa a las Fuerzas de Defensa de Israel (FDI), su director ejecutivo, Richard Francis, declaró a finales de 2023: “¿Existe alguna otra empresa en un país que pudiera haber participado en una guerra y aun así haber tenido el mismo desempeño?”, refiriéndose al éxito comercial de la empresa ese año.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Los vínculos de la empresa con las FDI son de larga data.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En años anteriores, Teva participó en el programa “Adopta un Batallón” de las FDI, en el que los soldados reciben apoyo financiero y de salud mental.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> En 2009, Teva fue una de las empresas israelíes reconocidas por las FDI por tener una relación “ejemplar” con sus empleados reservistas.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La empresa tiene conexiones de alto nivel en Israel.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Al exdirector ejecutivo Shlomo Yanai, quien anteriormente fue general de división del ejército israelí, Benjamin Netanyahu le ofreció la dirección de la agencia de espionaje Mossad en 2010, pero la rechazó.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F07\u002F20250615_Teva_and_the_IDF_Repill-.pdf\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Junio 2025\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F07\u002F20250615_Teva_and_the_IDF_Repill-.pdf\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Informe: Relación de Teva con las Fuerzas de Defensa de Israel (FDI) y sus contribuciones al esfuerzo bélico israelí desde el 7 de octubre de 2023. TEVA Y LAS FDI \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sección 1: Teva se movilizó para la \"Guerra de las Espadas de Hierro\" israelí en el contexto del 7 de octubre de 2023 Teva incrementó la producción y distribución de medicamentos en un 300 % tras los atentados del 7 de octubre de 2023. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Simultáneamente, el gobierno israelí impuso un bloqueo casi total a la entrada de bienes y medicamentos vitales a la Franja de Gaza, al tiempo que lanzaba ataques selectivos contra su sistema de salud, profundizando así el apartheid médico para los palestinos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En el contexto de la guerra, al menos el 10 % de la plantilla de Teva fue llamada a filas en la reserva militar de las FDI.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Mientras que el director ejecutivo de Teva, Richard Francis, encontró su nuevo rol al presentar al mundo \"la voz de Israel\". El director ejecutivo local de los clústeres de Teva en Israel, Ucrania, África y Oriente Medio, Yossi Ofek, declaró: \"Como compañía farmacéutica nacional de Israel, hemos sido movilizados, desde el comienzo de la guerra, para beneficio de Israel, los heridos, las familias de los evacuados y las fuerzas de seguridad. […] Donamos medicamentos esenciales, compuestos de alimentos para bebés y computadoras, […] ayudamos con la cosecha y la agricultura, transportamos productos de la fábrica y nuestros empleados donaron toneladas de \"equipo necesario\". \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sus declaraciones se reflejan en los comunicados de prensa sobre la guerra en el sitio web israelí de Teva: Teva ahora se comprometerá plenamente a ayudar en el esfuerzo bélico a través de su papel en la industria, así como a través del voluntariado (lista a continuación adaptada de Teva para Israel): \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Teva actuó rápidamente para establecer un programa de capacitación en tratamiento de TEPT y trauma para capacitar al menos a 200 profesionales de la salud mental en este campo (ver imagen 26). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• También proporcionó recursos de forma voluntaria.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Al servicio del esfuerzo bélico, por ejemplo, proporcionando materiales a soldados y empleados de las FDI.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Teva realizó importantes donaciones de equipo para el Magan David Adom, \"para satisfacer las necesidades de Israel en este momento\";\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Teva amplió su larga colaboración con Petachon Lev y Amigos de la Medicina, quienes tienen redes con las FDI;\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Donación de computadoras;\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Desde el comienzo de la guerra, se establecieron puntos de recolección para el equipo necesario, incluyendo productos eléctricos y otros, para las FDI en cada una de las cinco sedes de Teva en Israel;\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Petachon Lev recolectó 1,5 toneladas de equipo donado por trabajadores de Teva y se depositó en el centro logístico de Shoham;\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• El centro de Shoham está actualmente iluminado con iluminación exterior con los colores de la bandera israelí.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Sección 2: Contribuciones a las Fuerzas de Defensa de Israel (FDI) durante la guerra y conflicto de intereses con su rol como principal proveedor de medicamentos para los Territorios Palestinos Ocupados (TPO) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva, a través de las comunicaciones de su sitio web y de sus comunicaciones oficiales con los accionistas, demuestra su apoyo a la guerra de Israel contra Gaza mediante: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Apoyando a los reservistas que trabajan en Teva y que ahora participan en la guerra como soldados;\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Recolectando dispositivos no especificados para las FDI;\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Brindando apoyo psicológico y social a los miembros de las FDI a través de eventos y programas sociales. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Además, los reservistas que trabajan para Teva, ahora en activo en el ejército, informan que Teva los apoyó de diversas maneras durante la guerra genocida contra Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva actúa con un conflicto de intereses. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva desempeña un papel dominante en la sociedad israelí y en el sector sanitario.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sus contribuciones selectivas al esfuerzo bélico, en beneficio exclusivo de la sociedad israelí, sin reconocer en ningún momento, mediante declaraciones o acciones organizativas, el sufrimiento de los palestinos (aun cuando constituyen una importante fuente de ingresos y clientes para Teva\u002FSLE), demuestran una tendencia a ignorar a los palestinos y su experiencia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Si bien Teva triplicó su producción para el esfuerzo bélico israelí, a la vez que ofrecía abundantes donaciones y voluntariado a la sociedad israelí y a las Fuerzas de Defensa de Israel (FDI), no tomó medidas para mejorar la situación de los palestinos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Una postura ética exigiría que Teva no discriminara a sus clientes por motivos de religión, raza o identidad política, especialmente considerando la relativa dependencia de israelíes y palestinos de Teva para satisfacer sus necesidades básicas de medicamentos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A Teva le interesa que Israel salga ganando en esta guerra, ya que muchos de sus empleados sirven en el ejército y sus intereses financieros están vinculados a la economía israelí.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva se beneficiará de la expansión de los asentamientos israelíes en los Territorios Palestinos Ocupados (TPO) como resultado de la guerra israelí contra Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La limpieza étnica con fines de anexión de territorio palestino ha sido citada públicamente con frecuencia por los líderes políticos israelíes como un propósito de la actual guerra contra Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva se beneficiaría del desplazamiento palestino y de una mayor expansión israelí en los actuales territorios palestinos: la privación de derechos de los palestinos, la restricción de la actividad de las ONG y el actual ataque a la salud palestina los hace aún más dependientes del sector farmacéutico israelí. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Por otro lado, la expansión israelí de sus territorios mediante la anexión de más tierras palestinas permitiría a Teva y SLE continuar expandiendo su red y base de clientes a nuevos colonos en las tierras recién anexadas (cuyo precedente son las actuales actividades egoístas de Teva\u002FSLE en los Territorios Palestinos Ocupados).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Por consiguiente, a Teva le interesa que la guerra contra los palestinos siga dando resultados a favor de Israel, con el posible resultado de un mayor desplazamiento forzoso de palestinos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Es muy cuestionable que una corporación tan comprometida con un esfuerzo bélico, tanto de forma voluntaria como existencial, pueda actuar de forma ética y responsable con una parte de su base de clientes, contra la cual apoya un esfuerzo bélico.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La falta de esfuerzo para abastecer a los palestinos, a la vez que invierte abundante y voluntariamente en sus soldados, programas de trauma, viajes de donación y producción para ayudar a los israelíes, profundiza la división del apartheid médico entre dos de sus principales bases de clientes bajo administración israelí;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">especialmente en el contexto de la cantidad desproporcionada de lesiones y muertes palestinas, posiblemente perpetradas en parte por los reservistas de Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Por lo tanto, Teva actúa con un conflicto de intereses, ya que sirve (o no sirve) a su base de clientes palestinos, al tiempo que contribuye a los esfuerzos dirigidos a su eliminación colonial.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El actual director de la empresa SLE, Hadar Mama, ha sido un soldado activo que lucha en la Franja de Gaza desde unos meses después del inicio de la guerra, mientras conserva su puesto y continúa trabajando en su rol de liderazgo como director ejecutivo de la empresa de logística SLE16, propiedad de Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Como director de esta empresa, también es la única persona autorizada para distribuir medicamentos a los territorios palestinos.\u003C\u002Fspan> \u003C\u002Fspan>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\u003Cbr>\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Es dudoso que Hadar Mama pueda actuar éticamente y tomar decisiones como director ejecutivo de SLE, mientras que esta empresa ostenta el monopolio de facto sobre los productos farmacéuticos y la distribución de medicamentos en la zona donde él combate en la guerra, actuando también como soldado.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La situación actual en Gaza, donde la gente muere por falta de medicamentos básicos y suministros médicos en medio de los bombardeos israelíes, sugiere firmemente que no se están tomando decisiones éticas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva y su filial SLE actúan claramente con un conflicto de intereses en este caso.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Relación histórica de Teva con el liderazgo de las FDI \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Entre muchas personas que ocuparon puestos de liderazgo en Teva, se encuentran quienes ocuparon altos cargos en las Fuerzas de Defensa de Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Las contribuciones actuales e históricas del liderazgo de Teva al liderazgo de las Fuerzas de Defensa de Israel tienen un largo legado: Eli Hurvitz, el primer director oficial de Teva, propietario y director ejecutivo de la empresa, fue llamado a luchar en la Nakba en 1948 y sirvió en todas las guerras más importantes de Israel.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Entre otros, Yanai Shlomo, ex director de Teva, es general (reservista) de las FDI y ha sido jefe de la División de Planificación (FDI).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"QFw9Te BLojaf\">\n\u003Cdiv class=\"cEWAef\">\u003Ca href=\"https:\u002F\u002Fwww.facebook.com\u002FThankIsraeliSoldiers\u002Fposts\u002Fwe-were-honored-to-partner-with-teva_israel_-teva-pharmaceuticals-on-a-beautiful\u002F1032698839045059\u002F\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">DOS EJEMPLOS \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"cEWAef\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fwww.jpost.com\u002Fconferences\u002Farticle-862845\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">The Jerusalem Post, 31 de julio de 2025 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La iniciativa \"Apoya el Alma\" de Teva fortalece a los terapeutas de Israel después del 7 de octubre \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Yarden Abarbanel señala cómo el programa de Teva, centrado en el trauma, empodera a los profesionales de la salud mental de todo el país. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En la serie especial del Jerusalem Post \"Sanando a Israel: Una Nación en Trauma\", Yarden Abarbanel, director del programa \"Apoya el Alma\" de Teva Pharmaceutical, se unió a Shanna Fuld, directora ejecutiva de *JPost Israel Daily News*, para hablar sobre la evolución de las iniciativas de salud mental de la compañía después del 7 de octubre.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\"Apoya el Alma\" se lanzó rápidamente después del 7 de octubre, con el objetivo de hacer más durante los tiempos difíciles que enfrenta Israel\", explicó Abarbanel, destacando el énfasis del programa en apoyar a los terapeutas especializados en trauma de todo el país. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\"Nos centramos en los terapeutas, entendiendo que ellos soportan gran parte de la carga emocional de la sociedad israelí\".\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El proyecto, que colabora con 17 ONG, entre ellas la Coalición Israelí de Trauma y Natal, ofrece formación específica sobre trauma, supervisión clínica y estrategias de resiliencia para prevenir el agotamiento y el trauma secundario.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\"No todos los terapeutas recibieron formación sobre trauma durante sus estudios, así que aquí es donde empezamos\", señaló.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Abarbanel también mencionó una formación reciente con terapeutas beduinos en la Universidad Ben-Gurion: \"Dicen que este curso beneficia no solo a sus pacientes, sino también a ellos mismos. Es un espacio para la reflexión y la sanación de sus propias almas\".\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">De cara al futuro, Abarbanel enfatizó la necesidad de innovación tecnológica y planificación a largo plazo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\"No se pueden tener nuevos psicólogos de la noche a la mañana; lleva años. Por eso es crucial brindar apoyo y herramientas continuas a los terapeutas actuales\", concluyó.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Escrito en colaboración con Teva\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"Otro ejemplo\nThe Jerusalem Post, 31 de julio de 2025\nLa iniciativa "Apoya el Alma" de Teva fortalece a los terapeutas de Israel después del 7 de octubre\nYarden Abarbanel señala cómo el programa de Teva, centrado en el trauma, empodera a los profesionales de la salud mental de todo el país.\n\nEn la serie especial del Jerusalem Post "Sanando a Israel: Una Nación en Trauma", Yarden Abarbanel, director del programa "Apoya el Alma" de Teva Pharmaceutical, se unió a Shanna Fuld, directora ejecutiva de *JPost Israel Daily News*, para hablar sobre la evolución de las iniciativas de salud mental de la compañía después del 7 de octubre.\n\n"Apoya el Alma" se lanzó rápidamente después del 7 de octubre, con el objetivo de hacer más durante los tiempos difíciles que enfrenta Israel", explicó Abarbanel, destacando el énfasis del programa en apoyar a los terapeutas especializados en trauma de todo el país. "Nos centramos en los terapeutas, entendiendo que ellos soportan gran parte de la carga emocional de la sociedad israelí".\n\nEl proyecto, que colabora con 17 ONG, entre ellas la Coalición Israelí de Trauma y Natal, ofrece formación específica sobre trauma, supervisión clínica y estrategias de resiliencia para prevenir el agotamiento y el trauma secundario. "No todos los terapeutas recibieron formación sobre trauma durante sus estudios, así que aquí es donde empezamos", señaló.\nDejaron que un robot de IA gestionara 250 £: así son los primeros resultados.\nAbarbanel también mencionó una formación reciente con terapeutas beduinos en la Universidad Ben-Gurion: "Dicen que este curso beneficia no solo a sus pacientes, sino también a ellos mismos. Es un espacio para la reflexión y la sanación de sus propias almas".\nDe cara al futuro, Abarbanel enfatizó la necesidad de innovación tecnológica y planificación a largo plazo. "No se pueden tener nuevos psicólogos de la noche a la mañana; lleva años. Por eso es crucial brindar apoyo y herramientas continuas a los terapeutas actuales", concluyó.\nEscrito en colaboración con Teva\" data-crosslingual-hint=\"en\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"cEWAef\">\u003Ca href=\"https:\u002F\u002Fwww.facebook.com\u002FThankIsraeliSoldiers\u002Fposts\u002Fwe-were-honored-to-partner-with-teva_israel_-teva-pharmaceuticals-on-a-beautiful\u002F1032698839045059\u002F\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">4 de junio de 2025 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"cEWAef\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\"Tuvimos el honor de colaborar con @teva_israel_ Teva Pharmaceuticals en una hermosa Noche de Agradecimiento a los Facilitadores en Netanya, para más de 180 especialistas en trauma, terapeutas y trabajadores de la salud mental.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"cEWAef\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Durante la guerra, Teva financió la supervisión profesional de nuestros facilitadores, garantizando un espacio seguro para procesar y recargar energías.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La noche incluyó una cena, música en vivo y una mesa redonda en la que se reconoció a los facilitadores de salud mental por meses de arduo y agotador trabajo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Avi Cirt, director ejecutivo de TIS y Momentum;\u003Cstrong> Yossi Ofek, director ejecutivo de Teva; Yarden Abarbanel, director del Programa de Supervisión de Facilitadores financiado por Teva\u003C\u002Fstrong>; y Anat Kuchinsky, directora de la Dirección de Puerta al Futuro, hablaron agradeciendo a los facilitadores su papel fundamental en la sanación de Israel durante la guerra.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> ¡Estamos muy agradecidos de contar con personas tan profesionales y conmovedoras cuidando de los héroes que defienden la Tierra y el Pueblo de Israel!\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">¡Merecen todo nuestro amor, aprecio y apoyo!\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"cEWAef\">\u003Cimg src=\"https:\u002F\u002Fscontent.fmad5-1.fna.fbcdn.net\u002Fv\u002Ft51.75761-15\u002F503775196_18331757845165878_3522733479752887650_n.jpg?_nc_cat=104&ccb=1-7&_nc_sid=13d280&_nc_ohc=kJjuyt-MrIcQ7kNvwEGlu_z&_nc_oc=AdkdwRHJ_A7Qb-TyYrFIGuSUMzw5Q4J2NaXZOVs9yE7noq4wcFWvWKPDKnURpDTwg7c&_nc_zt=23&_nc_ht=scontent.fmad5-1.fna&_nc_gid=2RYtjpX-yC6aHEdMDD9_Ig&oh=00_Afs3anWGsWItTJY0CzArfRrOZnCzk4hDNRHYezGRp2z9EA&oe=699B3E76\" alt=\"\" width=\"1065\" height=\"710\">\u003C\u002Fdiv>\n\u003Cdiv id=\"ow12\" class=\"NQSJo\">\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F08\u002Fkpmg-targeted-research-teva-december-2024.pdf\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">19 de diciembre de 2024 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F08\u002Fkpmg-targeted-research-teva-december-2024.pdf\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Vínculos con las FDI \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva ha expresado abiertamente su apoyo a las FDI en la guerra en curso.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Yossi Ofek, vicepresidente sénior regional y director general de Teva Israel, concedió una entrevista al medio de comunicación israelí Ynet en septiembre de 2024, donde explicó cómo Teva había triplicado la entrega de medicamentos críticos y buscaba explícitamente ayudar tanto a los civiles como a las FDI con suministros médicos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Otro artículo de Ynetnews de octubre de 2023 afirma que Teva realizó varias contribuciones, como la donación de medicamentos en colaboración con organizaciones benéficas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Estas donaciones también incluían presuntamente la donación de equipo por parte de empleados de Teva para los soldados de las Fuerzas de Defensa de Israel (FDI) en colaboración con la organización benéfica Pitchon-Lev, dedicada a la lucha contra la pobreza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El artículo también afirma que varios empleados de Teva han sido llamados a filas para servir en la reserva de las FDI.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En otro artículo publicado por el Jerusalem Post el 24 de diciembre de 2023, se informa que el director ejecutivo de SLE, la filial logística de Teva en Israel, presuntamente combatía en Gaza tras ser llamado a la reserva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Se cita al director ejecutivo diciendo: «Nuestra brigada también recibió entregas de equipo recolectado por trabajadores de Teva para nosotros».\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según un artículo de Israel365News, del 26 de septiembre de 2016, Teva es una de las varias empresas que han participado en el programa «Adopta un Batallón».\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">A través de este programa, las empresas pueden desarrollar relaciones profundas y duraderas entre los soldados de las FDI y los civiles que los apoyan mediante una donación anual de aproximadamente 27.000 dólares durante tres años.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Se informa que los donantes son invitados a ceremonias de adopción y reciben comunicación directa con los comandantes, incluyendo informes sobre su batallón, el progreso de los soldados, actualizaciones sobre las actividades realizadas durante la adopción, fotos, cartas personales de los soldados, regalos con la insignia del batallón y oportunidades de unirse a los soldados en las bases y durante sus vacaciones.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Otro artículo en Israel National News del 8 de junio de 2014 afirma de manera similar que Teva ha participado en el programa \"Adopta un Batallón\".60 Sin embargo, Teva ya no aparece como un \"socio\" activo en el sitio web oficial del programa.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En conclusión, Teva es un partidario activo de las Fuerzas de Defensa de Israel (FDI).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">ENGLISH\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Fbdsnederland.nl\u002Fstop-teva\u002F\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva directly supports the genocide against Palestinians\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">According to its director, Teva is “the voice of Israel” during the war.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">For example, soldiers working for Teva continue to receive their salaries when deployed to Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva also organizes various activities for soldiers, such as psychological support and social events, which should enable them to participate with renewed energy in the genocidal attacks on Gaza and elsewhere.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva, on its own initiative, donates equipment to the Israeli occupation army.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva pays hundreds of millions of dollars in taxes to the Israeli treasury annually (721 million dollars in 2024).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This helps finance, among other things, the Israeli army's weapons.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva's founder and several directors contributed as soldiers to the ethnic cleansing in Palestine before and after the establishment of Israel in 1948. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Thanks in part to its special ties with the Israeli state, Teva enjoys a very strong political, fiscal, and commercial position in Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva contributes billions to the Israeli apartheid state and invests in (government) institutions that work on, among other things, the development of weapons, drones, and surveillance technology used for genocide in Gaza and human rights violations in the West Bank.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">Nov 14, 2025 \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.markcurtis.info\u002F2025\u002F11\u002F14\u002Fthe-israel-firms-aiding-the-nhs-and-idf\u002F\">\u003Cstrong>Supporting combat soldiers\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Several hundred Teva employees in Israel – amounting to at least 10% of its workforce there – were called up for reserve army duty after the Hamas attacks of 7 October.\u003C\u002Fp>\n\u003Cp>One of those was Hadar Mama, the CEO of Teva’s logistics company in Israel who was reported to be “fighting in the Gaza Strip but still has his finger on the pulse of SLE”, Teva’s logistics arm.  \u003C\u002Fp>\n\u003Cp>“Hadar moves between three command posts: his family, which remained at home under the threat of missile attack, SLE, and his army position”, the Jerusalem Post reported in December 2023.\u003C\u002Fp>\n\u003Cp>The paper added: “Between fighting in Gaza and resting on the base, Hadar finds time for virtual meetings with his management team, receives status updates, and makes key decisions”.\u003C\u002Fp>\n\u003Cp>Mama was quoted as saying that “Our brigade also received deliveries of equipment collected by Teva workers for us”.\u003C\u002Fp>\n\u003Cp>This may have been a reference to Teva’s collaboration with Israeli anti-poverty group Pitchon-Lev to collect “equipment” for IDF (The Israel Defense Forces) soldiers. \u003C\u002Fp>\n\u003Cp>Collection points were established at Teva’s five sites across Israel, enabling employees to donate: around 1.5 tons of equipment – details of which are not specified – had been donated to the IDF by the end of October 2023. \u003C\u002Fp>\n\u003Cp>\u003Cstrong>‘Support the soul’\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Teva has also partnered with Momentum, a non-profit group in Israel which helps Israeli combat soldiers address their mental health needs such as post-traumatic stress syndrome.\u003C\u002Fp>\n\u003Cp>Teva’s ‘Support the Soul’ programme, launched in response to the 7 October attacks, supports the therapists treating the soldiers.\u003C\u002Fp>\n\u003Cp>In a further collaboration the drugs firm has partnered with an organisation called Thank Israeli Soldiers (TIS), which is “dedicated to supporting IDF soldiers through partnerships with Israeli nonprofits”. \u003C\u002Fp>\n\u003Cp>TIS has developed programmes “in coordination with the IDF” to support the mental or physical well-being of “the brave men and women who defend Israel”.\u003C\u002Fp>\n\u003Cp>In June this year, TIS posted that “Teva has funded professional supervision for our facilitators, ensuring that they have a safe space to process and recharge”.\u003C\u002Fp>\n\u003Cp>Three days after the 7 October attacks, Teva issued a statement saying it was “deeply saddened” by the attacks. It added: “As an Israeli company we condemn this appalling assault and Teva stands with Israel in this time of great loss and challenge”.\u003C\u002Fp>\n\u003Cp>Perhaps in recognition of his company’s backing of the IDF, the company’s CEO, Richard Francis, said in late 2023: “Is there any other company in a country that could have been part of a war and still performed the way it did?”, referring to the company’s commercial success that year. \u003C\u002Fp>\n\u003Cp>The firm’s links to the IDF are long standing. In past years Teva participated in the IDF’s ‘Adopt a Battalion’ programme, in which soldiers are given financial and mental health support.\u003C\u002Fp>\n\u003Cp>In 2009 Teva was one of the Israeli companies recognised by the IDF as having an “exemplary” relationship with their reservist employees. \u003C\u002Fp>\n\u003Cp>The company has high-level connections in Israel. Former CEO Shlomo Yanai, who was previously a major general in the Israeli military, was reportedly offered the directorship of spy agency Mossad by Benjamin Netanyahu in 2010, but turned it down.\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F07\u002F20250615_Teva_and_the_IDF_Repill-.pdf\">\u003Cstrong>June 2025\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F07\u002F20250615_Teva_and_the_IDF_Repill-.pdf\">\u003Cstrong>Report: Teva’s relationship with the Israeli Defense Forces (IDF) and her\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F07\u002F20250615_Teva_and_the_IDF_Repill-.pdf\">\u003Cstrong>contributions to the Israeli war effort since \u003Cem>October 7th, 2023.\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>\u003Cem>\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F07\u002F20250615_Teva_and_the_IDF_Repill-.pdf\">\u003Cstrong>TEVA AND THE IDF\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>Section 1: Teva mobilized for Israeli “War of Iron Swords”\u003C\u002Fem>\u003Cbr>\u003Cem>Effort in the context of October 7th, 2023\u003C\u002Fem>\u003Cbr>Teva ramped up production of medication and distribution thereof by 300% in the context of the aftermath of October 7th, 2023. The Israeli government contemporaneously imposed a near-complete blockade on the entrance of vital goods and medicines into the Gaza Strip, while initiating targeted attacks on its health care system1, thereby deepening the medical apartheid for Palestinians.\u003C\u002Fp>\n\u003Cp>In the context of the war, at least 10% of Teva’s workforce were called up to the IDF’s reserve army duty; while Teva’s CEO Richard Francis found his new role in presenting to the world “a voice of Israel”.\u003C\u002Fp>\n\u003Cp>The local CEO of Teva Israel, Ukraine, Africa and Middle East Clusters, Yossi Ofek, said, \"As the national pharmaceutical company of Israel, we have been harnessed - since the beginning of the war - for the benefit of Israel, the wounded and the wounded, the families of the evacuees and the security forces. […] we donated essential medicines, baby food compounds and computers, […] we helped with harvesting and agriculture, we transported produce from the wrap and our employees donated tons of \"necessary equipment”.\u003C\u002Fp>\n\u003Cp>His statements are echoed by the press releases about the war on Teva’s Israeli website: Teva will now fully commit to aid the war effort through its role in the industry as well as through volunteerism (list below adapted from Teva for Israel):\u003C\u002Fp>\n\u003Cp>\u003Cbr>• Teva swiftly moved to establish a PTSD and trauma treatment training programme to train at\u003Cbr>least 200 mental health providers in this field, see image 26.\u003Cbr>• It also voluntarily provided resources in service of the war effort, for example by providing materials to IDF soldiers and employees.\u003Cbr>• Teva made significant donations for equipment for the Magan David Adom, “to meet Israel’s needs at this time”;\u003Cbr>• Teva expanded its long-standing collaborations with Petachon Lev and Friends for medicine who have networks with the IDF;\u003Cbr>• Donation of computers;\u003Cbr>• From the beginning of the war, collection points were set up for required equipment, including electrical products and more, for the IDF at each of the five Teva sites in Israel;\u003Cbr>• Petachon Lev collected 1.5 tons of equipment donated by Teva workers and collected at the logistics center in Shoham;\u003Cbr>• The center at Shoham is currently illuminated with outdoor lighting in the colours of the Israeli flag.\u003C\u002Fp>\n\u003Cp>\u003Cem>Section 2: Contributions to the IDF during war effort and conflict of interest with role as major provider of medication to oPT\u003C\u002Fem>\u003Cbr>Teva, through its website communications and official shareholder communications, demonstrates its support for Israel’s war on Gaza by:\u003Cbr>• Supporting reservists working at Teva who are now participating in the war as soldiers;\u003Cbr>• Collecting unspecified devices for the IDF;\u003Cbr>• Providing psychological and social support to IDF members through social events and programs.\u003C\u002Fp>\n\u003Cp>In addition, reservists working for Teva, now active in the army, report that Teva supported them in various ways during the genocidal war on Gaza.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Teva acting with a conflict of interest\u003C\u002Fstrong>\u003Cbr>Teva plays a dominant role in Israeli society and the health sector. Its selective contributions to the war effort in the interest of Israeli society only – while failing to acknowledge anywhere through organizational statements or action, the suffering of Palestinians (even while they constitute a major source of income and customers for Teva\u002F SLE) – demonstrates a tendency to erase Palestinians and their experience.\u003C\u002Fp>\n\u003Cp>As Teva increased production three-fold for the Israeli war effort, while volunteering and donating to Israeli society and the IDF abundantly, it failed to take any ameliorating actions with\u003Cbr>respect to Palestinians. An ethical stance would require Teva not to discriminate between its customers based on any religious, racial or politicized identity; especially seen both Israeli and Palestinian’s relative dependency on Teva for the fulfilment of their basic need for medicine. It is in Teva’s interest that Israel stands to gain in this war, with many of its employees serving in the army, and its financial interests tied to the Israeli economy.\u003C\u002Fp>\n\u003Cp>Teva stands to make gains from expansion of Israeli settlement in the oPT as an outcome of the Israeli war on Gaza.\u003Cbr>Ethnic cleansing for the purpose of annexation of Palestinian land has frequently been publicly cited as a purpose of the current war on Gaza by Israeli political leadership. Teva would stand to gain from Palestinian displacement and further Israeli expansion across current Palestinian territories: disenfranchisement of Palestinians, the restriction of NGO activity, and the current assault on Palestinian health makes them all the more dependent on the Israeli pharmaceutical sector, while Israel’s expansion of its territories through annexation of more Palestinian land would allow Teva and SLE to continue expanding its network and customer base to new settlers on the newly annexed land (the precedent for which is Teva\u002F SLE’s current self-serving activities in the oPT).\u003C\u002Fp>\n\u003Cp>It follows that it is in Teva’s interest that the war on Palestinians continues to yield results in Israel’s favor, with a possible outcome of more forcible displacement of Palestinians.\u003Cbr>It is highly questionable whether a corporation so fully invested in a war effort – in voluntary ways, as well as existentially – can act ethically and responsibly towards a part of its customer base, against whom it supports a war effort.\u003C\u002Fp>\n\u003Cp>The absence of any effort towards supplying Palestinians, while simultaneously investing abundantly and voluntarily in its soldiers, trauma programs, donation runs and production for aid of Israelis, deepens the divide of medical apartheid between two of its major customer bases under Israeli administration; especially in the context of the disproportionate amount of\u003Cbr>Palestinian injury and death, potentially perpetrated in part by Teva’s reservists.\u003C\u002Fp>\n\u003Cp>Teva thus acts with a conflict of interest, as it serves (or fails to serve) its Palestinian customer base, while contributing to efforts directed at their colonial erasure.\u003C\u002Fp>\n\u003Cp>The current director of the company SLE, Hadar Mama, has been an active soldier fighting in the Gaza Strip since a few months after the war started, while retaining his position and continuing to work in his leadership role of CEO at Teva-owned logistics company SLE.\u003C\u002Fp>\n\u003Cp>As the director of this company, he is also the one person authorized to distribute medication to Palestinian territories. It is questionable, possibly  doubtful, that Hadar Mama can act ethically make decisions in his capacity as CEO of SLE, while this company holds a de facto monopoly on pharmaceutical products and distribution of medication in the area where he is fighting in the war in double capacity as soldier.\u003C\u002Fp>\n\u003Cp>The current situation in Gaza, where people are dying from lack of simple medicines and medical supplies amidst the Israeli bombardments, strongly suggests that ethical decisions are not being made. Teva and its subsidiary SLE are clearly acting with a conflict of interest in this case.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Teva's Historical Relationship with the IDF leadership\u003C\u002Fstrong>\u003Cbr>Among many people that served in Teva’s leadership roles, are those that served in top leadership positions in the Israeli Defense Forces.\u003C\u002Fp>\n\u003Cp>Current and historic contributions of Teva’s leadership to the Israeli Defense Force’s leadership have a long legacy: Eli Hurvitz, Teva’s first official director, owner and CEO of the company, was called upon to fight in the Nakba in 1948, and served in all of Israel’s most important wars. Among others, Yanai Shlomo, former director of Teva, is a General (reservist) in the IDF and has been Head of Planning Division (IDF).\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.facebook.com\u002FThankIsraeliSoldiers\u002Fposts\u002Fwe-were-honored-to-partner-with-teva_israel_-teva-pharmaceuticals-on-a-beautiful\u002F1032698839045059\u002F\">\u003Cstrong>TWO EXAMPLES\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.jpost.com\u002Fconferences\u002Farticle-862845\">The Jerusalem Post, 31 July 2025\u003C\u002Fa>\u003Cbr>Teva’s ‘Support the Soul’ initiative strengthens Israel’s therapists post-October 7\u003Cbr>Yarden Abarbanel notes how Teva's trauma-focused program empowers mental health providers nationwide\u003C\u002Fp>\n\u003Cp>In the Jerusalem Post’s special broadcast series “Healing Israel: A Nation in Trauma,” Yarden Abarbanel, program lead of Teva Pharmaceutical’s “Support the Soul” initiative, joined *JPost Israel Daily News* CEO Shanna Fuld to discuss the company’s evolving mental health efforts after October 7.\u003C\u002Fp>\n\u003Cp>“Support the Soul was launched swiftly following October 7, aiming to do more during the challenging times Israel faces,” Abarbanel explained, highlighting the program’s emphasis on supporting trauma therapists nationwide. “Our focus is on the therapists, understanding they bear much of the emotional burden of Israeli society.”\u003C\u002Fp>\n\u003Cp>The project, collaborating with 17 NGOs including the Israeli Trauma Coalition and Natal, offers trauma-specific training, clinical supervision, and resilience strategies to prevent burnout and secondary trauma. “Not all therapists received trauma training during their studies, so this is where we began,” she noted.\u003Cbr>\u003Cbr>Abarbanel also mentioned a recent training with Bedouin therapists at Ben-Gurion University: “They say this course benefits not only their patients but also themselves. It’s a space for reflection and healing their own souls.”\u003Cbr>Looking forward, Abarbanel emphasized the need for technological innovation and long-term planning. “You can't have new psychologists overnight; it takes years. That’s why providing ongoing support and tools to current therapists is crucial,” she concluded.\u003Cbr>\u003Cstrong>Written in collaboration with Teva\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.facebook.com\u002FThankIsraeliSoldiers\u002Fposts\u002Fwe-were-honored-to-partner-with-teva_israel_-teva-pharmaceuticals-on-a-beautiful\u002F1032698839045059\u002F\">\u003Cstrong>4 June 2025\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>\"We were honored to partner with @teva_israel_ Teva Pharmaceuticals on a beautiful Facilitator Appreciation Evening in Netanya for 180+ trauma specialists, therapists, and mental health workers. \u003Cbr>Throughout the war, Teva has funded professional supervision for our facilitators, ensuring that they have a safe space to process and recharge. \u003Cbr>The night included dinner, live music, and a panel discussion recognizing mental health facilitators for months of grueling, difficult work. Avi Cirt, the CEO of TIS and Momentum,\u003Cstrong> Yossi Ofek, CEO of Teva, Yarden Abarbanel, Head of the Teva funded Facilitator Supervision Program\u003C\u002Fstrong>, and Anat Kuchinsky, Head of Gate to the Future Directorate, all spoke thanking facilitators for their critical role in healing Israel throughout the war.\u003Cbr>We are so grateful to have the most soulful, professional individuals caring for the heroes defending the Land and the People of Israel! They deserve all of our love, appreciation, and support!\"\u003C\u002Fp>\n\u003Cp>\u003Cimg src=\"https:\u002F\u002Fscontent.fmad5-1.fna.fbcdn.net\u002Fv\u002Ft51.75761-15\u002F503775196_18331757845165878_3522733479752887650_n.jpg?_nc_cat=104&ccb=1-7&_nc_sid=13d280&_nc_ohc=kJjuyt-MrIcQ7kNvwEGlu_z&_nc_oc=AdkdwRHJ_A7Qb-TyYrFIGuSUMzw5Q4J2NaXZOVs9yE7noq4wcFWvWKPDKnURpDTwg7c&_nc_zt=23&_nc_ht=scontent.fmad5-1.fna&_nc_gid=2RYtjpX-yC6aHEdMDD9_Ig&oh=00_Afs3anWGsWItTJY0CzArfRrOZnCzk4hDNRHYezGRp2z9EA&oe=699B3E76\" alt=\"\" width=\"1065\" height=\"710\">\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F08\u002Fkpmg-targeted-research-teva-december-2024.pdf\">\u003Cstrong>19 December 2024\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fstopteva.nl\u002Fwp-content\u002Fuploads\u002F2025\u002F08\u002Fkpmg-targeted-research-teva-december-2024.pdf\">\u003Cstrong>Links to the IDF\u003C\u002Fstrong>\u003C\u002Fa>\u003Cbr>Teva is outspoken in its support for the IDF in the ongoing war. Yossi Ofek, the regional SVP and General Manager of Teva Israel,54 gave an interview to the Israeli news outlet Ynet in September 2024 where he\u003Cbr>explained how Teva had “tripled” the delivery of critical medicines and explicitly sought to aid both civilians and the IDF with medical supplies.\u003Cbr>Another Ynetnews article from October 2023 states that Teva made several contributions such as donating medicines in collaboration with charities. These donations also allegedly included Teva employees donating equirement for Israeli Defense Force (IDF) soldiers in collaboraiton with the Pitchon-Lev charity, a poverty alleviation charity. The article also states that several Teva employees have been called up to serve as part of IDF’s reserve force. In a different article posten by the Jerusalem Post on 24 December 2023, it appears\u003Cbr>that the CEO of SLE, Teva’s logistics subsidiary in Israel, was allegedly fighting in Gaza after being called into the reserve force. The CEO is quoted saying that “Our brigade also received deliveries of equipment\u003Cbr>collected by Teva workers for us”.\u003Cbr>According to an article in Israel365News, dated 26 September 2016, Teva is one of several companies that have participated in the “Adopt-a-Battalion” program. Through this program, companies can develop “deep and lasting relationships between IDF soldiers and civilians who support them” by provding an annual donation of about $27,000 for three years. Donors are reportedly invited to adoption cermonies and “receive direct communication with commanders including reports on their battalion, soldier progress, updates about activities done through the adoption, pictures, personal letters from soldiers, gifts bearing the battalion’s insignia and opportunities to join soldiers on bases and during their vacation time.” Another article in Israel\u003Cbr>National News from 8 June 2014 similarly states that Teva has participated in the “Adopt-a-Battalion” program.60 However, Teva no longer appears to be an active “partner” on the programme’s official website.\u003Cbr>\u003Cstrong>In conclusionTeva is an active supporter of the IDF.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"en\" data-language-name=\"inglés\" data-text=\"Teva supports the genocide against Palestinians in Gaza. According to its director, Teva is “the voice of Israel” during the war. For example, soldiers working for Teva continue to receive their salaries when deployed to Gaza. Teva also organizes various activities for soldiers, such as psychological support and social events, which should enable them to participate with renewed energy in the genocidal attacks on Gaza and elsewhere. Teva, on its own initiative, donates equipment to the Israeli occupation army. Teva pays hundreds of millions of dollars in taxes to the Israeli treasury annually (721 million dollars in 2024). This helps finance, among other things, the Israeli army's weapons.\n\nTeva's founder and several directors contributed as soldiers to the ethnic cleansing in Palestine before and after the establishment of Israel in 1948. Thanks in part to its special ties with the Israeli state, Teva enjoys a very strong political, fiscal, and commercial position in Israel. Teva contributes billions to the Israeli apartheid state and invests in (government) institutions that work on, among other things, the development of weapons, drones, and surveillance technology used for genocide in Gaza and human rights violations in the West Bank. (More on the above here.)\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"kGmWO\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"OwOEge\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cnav class=\"VlPnLc\" aria-labelledby=\"ucj-38\">\u003C\u002Fnav>","Teva y el ejército de Israel (IDF). Teva and the Israel Defense Forces (IDF). ESP ENG","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1771357596\u002Fzh76qh8b7vpfb8fsabqi.jpg","mlqwzbb45k9t14d28qg","NPBVwYEn6RU","teva-y-el-ejercito-de-israel-idf-teva-and-the-israel-defense-forces-idf-esp-eng",1771357619736,"Teva apoya directamente el genocidio palestino. Teva directly supports the genocide against Palestinians.",[15,513],"IDF",{"id":515,"timestamp":516,"slug":517,"type":7,"imageUrl":518,"title":519,"content":520,"videoUrl":176,"subtitle":521,"user":13,"tags":522,"link":12},"mmlrmdcvcs75kx8j0y4",1773221053452,"carta-de-paciente-con-migrana-ajovy-letter-from-a-migraine-patient-esp-eng","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1773220690\u002Fnmuaukzywhzmnh6tohea.png","Carta de paciente con migraña. Ajovy. Letter from a migraine patient. ESP ENG","\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>INTRODUCCIÓN\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>Teva tiene múltiples mecanismos para mantener el negocio, desde la corrupción a la propaganda directa a la población, pasando por creadores de opinión (profesionales y pacientes). Nada como el impacto de quien sufre y \"juega\" a favor de Teva y en contra de la ciencia y la ética. Una narración personal de sufrimiento anula todo el trabajo que fundamenta decisiones racionales y sensatas. \u003C\u002Fem>\u003Cbr>\u003Cem>Presentamos un \"caso clínico\":  paciente que sufre migraña y Ajovy (de Teva), le ha devuelto \"la normalidad\" (aunque sea un medicamento que no es ni eficaz ni seguro).\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>RESPUESTA Y CARTA ORIGINAL ENVIADA A \"NOGRACIAS\" (a Carlos Ponte Mittelbrunn, primer presidente de \"NoGracias\")\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cstrong>En general, respuesta con consideraciones básicas:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>1\u002F Comprendemos el sufrimiento que conlleva la migraña crónica y promovemos la mejor atención sanitaria posible para paliar en lo factible tal sufrimiento.\u003Cbr>2\u002F Aceptamos la discrepancia, claro, pero no la aseveración de que sea falso el contenido de nuestras publicaciones.\u003Cbr>3\u002F No somos nosotros quienes evaluamos la falta de eficacia de Ajovy, en este caso fue el mejor boletín farmacoterapeútico del mundo, la revista Prescrire.\u003Cbr>4\u002F La experiencia personal no es criterio de evaluación objetiva pues el efecto placebo logra resultados increíbles de forma que su mejoría puede ser innegable pero no tiene nada que ver con Ajovy propiamente dicho.\u003Cbr>5\u002F El boicot a Teva lo exige la ética médica, por razones de no maleficencia, beneficencia y justicia (no es cuestión pues, \"de presión política\" sino de deontología médica).\u003Cbr>6\u002F Incidentalmente, en el caso de Ajovy, el boicot a Teva y el ahorro consiguiente permitirá el mejor abordaje de la migraña en más población y con mejores alternativas.\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cstrong>En lo concreto, respuesta de Carlos Ponte Mittelbrunn:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\"\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">Gracias por sus comentarios. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">Nos congratulamos de que le hayan disminuido los episodios de migraña, que usted asocia al inicio del tratamiento con fremanezumab (Ajovy) . \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">Nuestra valoración de este medicamento está basada exclusivamente en la evidencia científica, sin ningún tipo de contaminación política, moral o de cualquier otra circunstancia. Nos basamos, entre otras referencias, en el informe de la revista Prescrire, reconocida como una de la revistas independientes más rigurosas en la evaluación de los medicamentos. Un informe de esta revista, concluye que Fremanezumab (Ajovy) “NO APORTA NADA NUEVO” en la prevención de la migraña. @RevuePrescrire <\u003C\u002Fspan>\u003Ca style=\"color: #2271b1; outline: 0px; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\" href=\"https:\u002F\u002Fx.com\u002FRevuePrescrire\" target=\"_blank\" rel=\"nofollow noopener ugc\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Fx.com\u002FRevuePrescrire&source=gmail&ust=1773303600458000&usg=AOvVaw2egbUpnkdWw1pabr4ZYjky\">https:\u002F\u002Fx.com\u002FRevuePrescrire\u003C\u002Fa>\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">>\u003C\u002Fspan>\u003Cbr style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">\u003Ca style=\"color: #2271b1; outline: 0px; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\" href=\"https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\" target=\"_blank\" rel=\"nofollow noopener ugc\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine&source=gmail&ust=1773303600458000&usg=AOvVaw2SgaGr0emzqfrtp3nKUhcx\">https:\u002F\u002Fwww.prescrire.org\u002F\u003Cwbr>avis-sur-les-medicaments\u002F444-\u003Cwbr>fremanezumab-ajovy-et-\u003Cwbr>prevention-des-crises-de-\u003Cwbr>migraine\u003C\u002Fa>\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">Cuestión diferente es la valoración moral y política que nos merece la compañía farmacéutica TEVA, en su condición de colaboradora del estado genocida de Israel.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">Por último, indicarle que soy el presidente de la Plataforma por la Salud y la Sanidad Pública de Asturias, pero ya no de la Plataforma NoGracias, aunque sigo siendo miembro de esta organización.\u003C\u002Fspan>\u003Cbr style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">Atentamente\u003C\u002Fspan>\u003Cbr style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">\u003Cspan style=\"color: #2c3338; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Oxygen-Sans,Ubuntu,Cantarell,'Helvetica Neue',sans-serif; font-size: 13px; background-color: #f6f7f7;\">Carlos Ponte Mittelbrunn\"\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>NOTAS\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>1\u002F El redactado de la carta recuerda a las publicaciones oficiales de Teva.\u003C\u002Fp>\n\u003Cp>2\u002F \u003Ca href=\"https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0213911121001783\">La \"Plataforma NoGracias\" es una organización de la sociedad civil\u003C\u002Fa> que ejerce acción en defensa de un sistema sanitario público democrático (transparente y responsable ante los ciudadanos) y soberano (sus decisiones no quedan dictadas por los intereses de otros actores, como las industrias). Queda inscrita en el racionalismo respecto a su confianza en la ciencia y su método, pero a la vez es crítica con las derivas que ha tomado el encaje racionalista de la medicina contemporánea, esto es, la medicina basada en la evidencia. Fundada en 2008 fue presidida por Carlos Ponte \u003Cspan class=\"ryNqvb\">Mittelbrunn\u003C\u002Fspan> hasta 2013, cuando Abel Novoa Jurado tomó las riendas hasta 2020 en que se hizo cargo Roberto Sánchez Sánchez. \u003Ca href=\"https:\u002F\u002Fisdbweb.org\u002Fsites\u002Fdefault\u002Ffiles\u002Fimported\u002FisdbNewsletter%20Vol.%2031%20Number%201%20September%202018.pdf\">\"NoGracias\" pertenece a la International Society of Drugs Bulletins.\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>3\u002F Sobre Ajovy en \"NoGracias\": \u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F11\u002F17\u002Fboicot-a-teva-boicot-a-ajovy-un-medicamento-que-no-aporta-nada-bueno-nuevo-para-prevenir-crisis-de-migrana-por-profesionales-de-la-sanidad-por-palestina-health-workers-for-pales\u002F\">\"Boicot a Teva, boicot a Ajovy (un medicamento que no aporta nada bueno nuevo para “prevenir” crisis de migraña). Por Profesionales de la Sanidad por Palestina (Health Workers for Palestine, Spain HW4PS)\"\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp>4\u002F En España, Ajovy ha sido promovido en febrero de 2026 directamente al público, en contra de la Ley (y sin castigo alguno): \u003Ca href=\"https:\u002F\u002Fahoramqnunca.blogspot.com\u002F2026\u002F03\u002Fla-migrana-y-su-tratamiento-propaganda.html\">\"La migraña y su tratamiento. Propaganda de fremanezumab (Ajovy, un medicamento que no aporta nada) al público general\".\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"text-decoration: underline;\">\u003Cem>\u003Cstrong>Carta de una paciente, por correo electrónico, el 5 de marzo de 2026, con el título de: \"Boicot a Teva, un gigante farmacéutico contra el pueblo palestino\"\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>A la atención de Carlos Ponte Mittelbrunn, presidente de La Plataforma NoGracias (PNG), \u003C\u002Fp>\n\u003Cp>Me dirijo a ustedes como paciente con migraña crónica, diagnosticada de cefalea mixta, tensional y migraña, con una trayectoria de años de dolor incapacitante. \u003C\u002Fp>\n\u003Cp>Antes de iniciar tratamiento preventivo con Ajovy, sufría 2-3 crisis semanales, muchas de ellas de intensidad severa, que condicionaban mi vida personal, familiar y laboral. El impacto acumulado de esta enfermedad derivó además en un cuadro depresivo significativo, del que aún me encuentro en proceso de recuperación. \u003C\u002Fp>\n\u003Cp>Desde el inicio del tratamiento con Ajovy (fremanezumab), mi evolución ha sido clínica y \u003Cbr>objetivamente notable: en los últimos dos meses he presentado una única crisis. Esta reducción \u003Cbr>sustancial en la frecuencia e intensidad de las migrañas ha supuesto una mejora radical de mi calidad de vida, permitiéndome recuperar autonomía, estabilidad emocional y funcionalidad. \u003Cbr>Por ello, no puedo compartir la afirmación de que este medicamento “no aporta nada bueno nuevo” en la prevención de la migraña. En mi caso —y en el de muchos otros pacientes— ha supuesto un cambio terapéutico determinante tras años de fracaso con otros tratamientos preventivos.\u003C\u002Fp>\n\u003Cp>La experiencia clínica real y la evidencia científica disponible respaldan su utilidad en pacientes con alta carga de enfermedad. \u003C\u002Fp>\n\u003Cp>Comprendo que puedan existir posicionamientos éticos o políticos en relación con conflictos \u003Cbr>internacionales. Sin embargo, considero profundamente preocupante que un conflicto bélico, \u003Cbr>independientemente de sus circunstancias, se utilice como argumento para promover el boicot a un medicamento que está proporcionando alivio efectivo a pacientes con enfermedades graves y discapacitantes. \u003C\u002Fp>\n\u003Cp>La salud no debería convertirse en un instrumento de presión política. Proteger a unos no puede implicar castigar indirectamente a otros, especialmente cuando hablamos de personas enfermas cuya única aspiración es vivir sin dolor o con una discapacidad reducida.\u003C\u002Fp>\n\u003Cp>Vincular el acceso a tratamientos sanitarios con conflictos geopolíticos introduce un precedente peligroso que pone en riesgo principios básicos de equidad y protección de la salud pública. \u003Cbr>La migraña crónica no es una molestia menor: es una enfermedad neurológica incapacitante que deteriora profundamente la calidad de vida y la salud mental. Para quienes hemos recuperado \u003Cbr>estabilidad gracias a estos tratamientos, el acceso a ellos no es un lujo ni una cuestión ideológica: es una necesidad sanitaria. \u003C\u002Fp>\n\u003Cp>Les pido que, en este debate, se tenga en cuenta la realidad de los pacientes. Las decisiones y los mensajes públicos en materia de salud deben basarse en evidencia científica y en el bienestar de quienes padecen la enfermedad, no en consideraciones ajenas al ámbito clínico. \u003Cbr>Atentamente, \u003Cbr>H.R.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>INTRODUCTION\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva employs multiple mechanisms to maintain its business, from corruption to direct publicity, including the manipulation of opinion leaders (professionals and patients).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Nothing compares to the impact of someone who suffers and \"plays\" in favor of Teva and against science and ethics.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">A personal narrative of suffering negates all the work that underpins rational and sensible decisions.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> We present a \"clinical case\": a patient suffering from migraines, for whom Ajovy (from Teva) has restored \"normality\" (even though it is a medication that is neither effective nor safe).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">RESPONSE AND ORIGINAL LETTER SENT TO \"NOGRACIAS\" (to Carlos Ponte Mittelbrunn, first president of NoGracias) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>\u003Cem>In general, a response with basic considerations:\u003C\u002Fem> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1\u002F We understand the suffering caused by chronic migraines and we promote the best possible healthcare to alleviate that suffering as much as possible.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2\u002F We accept disagreement, of course, but not the assertion that the content of our publications is false.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3\u002F We are not the ones who evaluate the lack of efficacy of Ajovy; in this case, it was the best pharmacotherapeutic bulletin in the world, the journal Prescrire.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">4\u002F Personal experience is not a criterion for objective evaluation, since the placebo effect achieves incredible results, so its improvement may be undeniable, but it has nothing to do with Ajovy itself.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">5\u002F The boycott of Teva is required by medical ethics, for reasons of non-maleficence, beneficence, and justice (it is not, therefore, a matter of \"political pressure\" but of medical deontology).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">6\u002F Incidentally, in the case of Ajovy, the boycott of Teva and the resulting savings will allow for better migraine treatment for a larger population with improved alternatives.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Specifically, Carlos Ponte Mittelbrunn's response: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\"Thank you for your comments. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We are pleased that your migraine episodes have decreased, which you attribute to the start of treatment with fremanezumab (Ajovy). Our assessment of this medication is based exclusively on scientific evidence, without any political, moral, or other bias.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We rely, among other references, on the report from the journal Prescrire, recognized as one of the most rigorous independent journals in drug evaluation. A report from this journal concludes that Fremanezumab (Ajovy) 'DOES NOT OFFER ANYTHING NEW' in migraine prevention. @RevuePrescrire <https:\u002F\u002Fx.com\u002FRevuePrescrire> https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The moral and political assessment we have of the pharmaceutical company is a different matter.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">TEVA, in its capacity as a collaborator of the genocidal state of Israel.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Finally, I would like to inform you that I am the president of the Platform for Health and Public Healthcare of Asturias, but no longer of the NoThanks Platform, although I remain a member of this organization.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Sincerely, Carlos Ponte Mittelbrunn.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>NOTES\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1\u002FThe wording of the letter is reminiscent of Teva's official publications.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2\u002F\u003Ca href=\"https:\u002F\u002Fisdbweb.org\u002Fsites\u002Fdefault\u002Ffiles\u002Fimported\u002FisdbNewsletter%20Vol.%2031%20Number%201%20September%202018.pdf\"> The \"NoGracias Platform\" is an associate member of the International Society of Drugs Bulletins.\u003C\u002Fa> \"NoGracias\" is a civil non-profit association, whose ultimate goal is to promote a democratic health system at the service of society, that is, public, sustainable, based on the best scientific knowledge and in which transparency, integrity and equity presides over the actions of all its agents. Founded in 2008, it was chaired by Carlos Ponte Mittelbrunn until 2013, when Abel Novoa Jurado took over until 2020 when Roberto Sánchez Sánchez took charge.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3\u002F \"NoGracias\" promote the boycott to Teva and Ajovy. In Spanish: \u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F11\u002F17\u002Fboicot-a-teva-boicot-a-ajovy-un-medicamento-que-no-aporta-nada-bueno-nuevo-para-prevenir-crisis-de-migrana-por-profesionales-de-la-sanidad-por-palestina-health-workers-for-pales\u002F\">\"Boicot a Teva, boicot a Ajovy (un medicamento que no aporta nada bueno nuevo para “prevenir” crisis de migraña)\"\u003C\u002Fa>. English version in:\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboycott-teva-boycott-ajovy-boicot-teva-boicot-ajovy-eng-esp\"> \"Boycott Teva, boycott Ajovy. Boicot Teva, boicot Ajovy ENG ESP\"\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan style=\"text-decoration: underline;\">\u003Cstrong>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Letter from a patient, via email, March 5, 2026, with the title: \"Boycott Teva, a pharmaceutical giant against the Palestinian people\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">To the attention of Carlos Ponte Mittelbrunn, president of the NoThanks Platform (PNG), I am writing to you as a patient with chronic migraine, diagnosed with mixed headache, tension headache, and migraine, with a history of years of debilitating pain.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Before starting preventive treatment with Ajovy, I suffered 2-3 attacks per week, many of them severe, which affected my personal, family, and work life.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The cumulative impact of this disease also led to a significant depressive episode, from which I am still recovering.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Since starting treatment with Ajovy (fremanezumab), my progress has been clinically and objectively remarkable: in the last two months, I have had only one attack.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This substantial reduction in the frequency and intensity of migraines has meant a radical improvement in my quality of life, allowing me to regain autonomy, emotional stability, and functionality.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, I cannot agree with the assertion that this medication “doesn't offer anything new” in migraine prevention.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In my case—and in that of many other patients—it has represented a decisive therapeutic change after years of failure with other preventive treatments.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Real-world clinical experience and the available scientific evidence support its usefulness in patients with a high disease burden.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">I understand that ethical or political positions may exist regarding international conflicts.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">However, I find it deeply concerning that an armed conflict, regardless of its circumstances, is used as an argument for\u003C\u002Fspan> p\u003Cspan class=\"ryNqvb\">romoting a boycott of a medication that is providing effective relief to patients with serious and disabling illnesses is unacceptable.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Health should not become a tool for political pressure.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Protecting some cannot mean indirectly punishing others, especially when we are talking about sick people whose only aspiration is to live without pain or with reduced disability.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Linking access to healthcare treatments with geopolitical conflicts sets a dangerous precedent that jeopardizes basic principles of equity and the protection of public health.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Chronic migraine is not a minor inconvenience: it is a debilitating neurological disease that profoundly impairs quality of life and mental health.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For those of us who have recovered s\u003Cspan class=\"HwtZe\" lang=\"en\">tability thanks to these treatments means that access to them is not a luxury or an ideological issue: it is a healthcare necessity. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">I ask that, in this debate, the reality of patients be taken into account. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">Decisions and public messages regarding health must be based on scientific evidence and the well-being of those suffering from the disease, not on considerations unrelated to the clinical field. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">Sincerely, H.R.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>"," Teva y el boicot a Boicot a Teva, Ajovy (fremanezumab). Un caso clínico. Teva and the boycott of Ajovy (fremanezumab). A clinical case",[523,15,164,471,524,525,526],"Ajovy","Patient","Migraine","Migraña",{"subtitle":528,"id":529,"timestamp":530,"content":531,"slug":532,"type":7,"user":13,"tags":533,"imageUrl":536,"link":12,"title":537,"videoUrl":538}," Fremanezumab (Ajovy, TEVA), February 2026. Migraine. Febrero 2026, migraña","mmqmmf9qftcgbzluq7d",1773513209516,"\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cimg src=\"https:\u002F\u002Fcdn.bsky.app\u002Fimg\u002Ffeed_fullsize\u002Fplain\u002Fdid:plc:sijrnjskilwxv3a4lmvqw2eg\u002Fbafkreicxvzmau4pxhjkt7yyie64yiizslvhvrr5unilfofmy5v5y6qybye\" alt=\"\" width=\"987\" height=\"819\">\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cdiv>The promotion of prescription drugs directly to the public is not allowed in the European Union. But see the Ajovy case in Spain: direct-to-consumer news, the blurred margin between propaganda and information.\u003C\u002Fdiv>\n\u003Cdiv>In Spain, direct-to-consumer advertising of Ajovy. \u003Cspan lang=\"en\">With the cooperation of Vall d'Hebron Hospital, Barcelona, Spain (and of the media and journalists who don't even declare conflicts of interest)\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan lang=\"en-US\">\u003Cstrong>In Spain, \u003C\u002Fstrong>\u003C\u002Fspan>\u003Cstrong>direct-to-consumer advertising of \u003C\u002Fstrong>\u003Cspan lang=\"en-US\">\u003Cstrong>fremanezumab (Ajovy), \u003C\u002Fstrong>\u003C\u002Fspan>\u003Cspan lang=\"en-US\">\u003Cstrong>February 2026. Migraine. \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Juan Gérvas Doctor of Medicine, retired rural general practitioner, CESCA Team, Madrid, Spain, former professor of public health, Johns Hopkins University, Baltimore, USA.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">From Health Workers for Palestine, Spain HW4PS https:\u002F\u002Fhw4p.es\u002F jjgervas@gmail.com www.equipocesca.org @JuanGrvas @juangrvas.bsky.social\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Introduction\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Migraine is a chronic, idiopathic pain condition, generally characterized by intense headaches lasting between 4 and 72 hours, sometimes severely debilitating due to frequent recurring attacks. It is three times more prevalent in women and is often accompanied by various neurological symptoms. Since its cause is unknown, treatment is symptomatic.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">In the European Union, direct marketing to consumers of products that are only available with a prescription is prohibited. Prohibited products: Member States must prohibit advertising to the general public for prescription-only medicinal products and those containing psychotropic or narcotic substances. Permitted Products: Only medicinal products designed for use without medical practitioner intervention may be advertised to the public, with pharmacist advice as needed\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote1sym\" name=\"sdendnote1anc\">\u003Csup>i\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Migraine is a fertile field of professional and monetary benefits\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Migraine can be a living hell for the patient, but it is a goldmine for industries, professionals, and patient associations—a field in which to obtain social and monetary benefits.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Among the healthcare professionals who \"benefit\" are primary care physicians, neurologists, nurses, pharmacists, psychologists, psychiatrists, etc., and their associations, groups, and societies. Other \"beneficiaries\" include journalists, communicators, patient associations and the media.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Bestselling medications that shouldn't be used\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Two pharmaceutical companies have a particular interest in the field of migraines: Teva and Lundbeck (Israeli and Danish, respectively).\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">They are two corrupt and corrupting companies.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The Teva case has led to fines and penalties of up to €10 billion worldwide\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote2sym\" name=\"sdendnote2anc\">\u003Csup>ii\u003C\u002Fsup>\u003C\u002Fa>. Teva is a leading multinational in the field of generic (unbranded) medicines, although currently its \"flagship\" products are branded, including Ajovy (fremanezumab), for preventing recurrent migraine attacks, a prescription only medication\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote3sym\" name=\"sdendnote3anc\">\u003Csup>iii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The world's leading pharmacotherapeutic bulletin, the French journal Prescrire, considered that Ajovy offers nothing new or beneficial (literally, \"N'apporte rien de nouveau\")\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote4sym\" name=\"sdendnote4anc\">\u003Csup>iv\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">In 2025, the French National Authority for Health (HAS) made it clear that: “To date, the superiority of anti-CGRP antibodies (including fremanezumab) in terms of efficacy compared to other prophylactic treatments has not been demonstrated”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote5sym\" name=\"sdendnote5anc\">\u003Csup>v\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The most well-known case involving Lundbeck is that of its corrupt anti-competitive practices regarding citalopram and escitalopram, for which it was fined €93 million in the European Union\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote6sym\" name=\"sdendnote6anc\">\u003Csup>vi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Ironically, these are also two drugs that are best avoided because their harms far outweigh their benefits\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote7sym\" name=\"sdendnote7anc\">\u003Csup>vii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Lundbeck also produces medication to prevent migraines, Vyepti (eptinezumab), which has received a similar assessment of offering nothing new.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Direct to consumer fremanezumab (Ajovy) promotion\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The publication in January 2026 in the New England Journal of Medicine of a clinical trial using Ajovy to prevent migraine attacks in childhood and adolescence\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote8sym\" name=\"sdendnote8anc\">\u003Csup>viii\u003C\u002Fsup>\u003C\u002Fa> led to a press release from Vall d’Hebron Hospital (Barcelona, ​​Spain) was disseminated in the Spanish media.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The published article describes a clinical trial fully funded by Teva, the company that produces Ajovy\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote9sym\" name=\"sdendnote9anc\">\u003Csup>ix\u003C\u002Fsup>\u003C\u002Fa>. Teva contracted 89 centers worldwide to recruit 237 patients for the study.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Of the 11 authors of the article in the New England Journal of Medicine, 6 are Teva employees (including two from its headquarters in Tel Aviv, Israel), and the others have significant conflicts of interest, primarily with Teva\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote10sym\" name=\"sdendnote10anc\">\u003Csup>x\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Even the article's writing was paid for by Teva.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The key figure in the press release was the head neurologist at Vall d’Hebron, Patricia Pozo-Rosich, who has substantial conflicts of interest with the pharmaceutical industry. She received €77,000 directly from Teva (in 2023 and 2024) and is vice president of the Vall d'Hebron Research Institute (VHIR)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote11sym\" name=\"sdendnote11anc\">\u003Csup>xi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The research institute, VHIR, has Ronit Satchi-Fainaro on its External Scientific Committee\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote12sym\" name=\"sdendnote12anc\">\u003Csup>xii\u003C\u002Fsup>\u003C\u002Fa>, an Israeli from Tel Aviv, who is a member of Teva's Board of Directors\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote13sym\" name=\"sdendnote13anc\">\u003Csup>xiii\u003C\u002Fsup>\u003C\u002Fa> (a fact not mentioned in the curriculum vitae on the VHIR website).\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">In other words, everything revolves around Teva, a Teva product, authors paid by Teva or directly employed by Teva, a study funded by Teva, and the writing of the article supported by Teva, all concerning a drug that offers nothing new to patients but generates enormous revenue for Teva. Is there any doubt what the cited study demonstrates about Ajovy?\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Fremanezumab (Ajovy) in the Spanish media during the last week of February 2026\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The impact of the press release, a piece of propaganda from Vall d'Hebron Hospital, was impressive.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The headlines leave no room for doubt.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">For example, in the journal \"El Periódico\": \"Spain will have fremanezumab this year, the first drug against pediatric migraine: one injection once a month. An international trial in which Vall d'Hebron Hospital participated demonstrates that fremanezumab is effective and safe in preventing the disease in children aged 6 to 17\". The video and photograph are worth watching\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote14sym\" name=\"sdendnote14anc\">\u003Csup>xiv\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">In \"El Diario de Sevilla,\" a photograph of Ajovy is included directly, with the headline: \"Fremanezumab, the drug against pediatric migraine, will arrive in Spain in 2026 with a single monthly injection\"\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote15sym\" name=\"sdendnote15anc\">\u003Csup>xv\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">On “Antena 3” tv: “First treatment for migraines in children and adolescents: \"It has been a miracle for my daughter.\" Noa Bonet, 11, is one of the Spanish patients who participated in the trial”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote16sym\" name=\"sdendnote16anc\">\u003Csup>xvi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The same was reported in other media outlets such as EFE, El Heraldo de Aragón, El Mundo, Infobae, El Economista, HuffPost, Marca, COPE radio, Diario de Córdoba, Cuatro, La Vanguardia, etc.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Fremanezumab (Ajovy): Hospital use is no hinder to its bestseller status\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">In Spain, Ajovy requires a prescription from a hospital specialist, usually a neurologist. But this hasn't slowed its sales.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">For example, the Consorci Sanitari de Terrassa (Barcelona, ​​Spain) purchased Ajovy from Teva (“anticossos pel tractament de la migranya”) in 2025 for almost one million euros (€745,418.28). The same Consorci spent exactly the same amount—incredibly, exactly the same amount, down to the decimal point—on Lundbeck, also for a monoclonal antibody for migraine, and on another product for the same purpose supplied by Organon Salud. SL\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote17sym\" name=\"sdendnote17anc\">\u003Csup>xvii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">A lot of money spent on medications that offer no benefit.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Comment\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">It seems that Teva's commercial strategy includes promoting fremanezumab (Ajovy) to the general public (direct-to-consumer).\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Vall d'Hebron Hospital (Barcelona, Spain) supports and presents as a novelty something that \"offers nothing new\".\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">Such promotion is clearly prohibited by Spanish and European legislation.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">It is also accompanied by an incredible and constant \"apparatus\" of pressure on those who \"benefit\" socially and financially through conferences, consensus statements, guidelines, publications, seminars, and other means.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cdiv id=\"sdendnote1\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote1anc\" name=\"sdendnote1sym\">i\u003C\u002Fa>European Pharmaceutical Ad Bans: Laws And Regulations Explained. \u003Ca href=\"https:\u002F\u002Flawshun.com\u002Farticle\u002Fdo-european-countries-have-laws-that-ban-pharmaceutical-ads\">https:\u002F\u002Flawshun.com\u002Farticle\u002Fdo-european-countries-have-laws-that-ban-pharmaceutical-ads\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote2\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote2anc\" name=\"sdendnote2sym\">ii\u003C\u002Fa>Teva. Penalty total since 2000: $10,695,276,796. \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-penalty-total-since-2000-10-695-276-796-casi-11-000-millones-de-dolares-en-multas-desde-2000\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-penalty-total-since-2000-10-695-276-796-casi-11-000-millones-de-dolares-en-multas-desde-2000\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote3\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote3anc\" name=\"sdendnote3sym\">iii\u003C\u002Fa>What are the top-selling drugs of Teva? \u003Ca href=\"https:\u002F\u002Fsynapse.patsnap.com\u002Farticle\u002Fwhat-are-the-top-selling-drugs-of-teva\">https:\u002F\u002Fsynapse.patsnap.com\u002Farticle\u002Fwhat-are-the-top-selling-drugs-of-teva\u003C\u002Fa>?\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote4\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote4anc\" name=\"sdendnote4sym\">iv\u003C\u002Fa>Frémanezumab (Ajovy°) et prévention des crises de migraine. Rev Prescrire 2020 ; 40 (444): 731-732. \u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\">https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote5\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote5anc\" name=\"sdendnote5sym\">v\u003C\u002Fa> AJOVY (frémanezumab) - Migraine. \u003Ca href=\"https:\u002F\u002Fwww.has-sante.fr\u002Fjcms\u002Fp_3601431\u002Ffr\u002Fajovy-fremanezumab-migraine\">https:\u002F\u002Fwww.has-sante.fr\u002Fjcms\u002Fp_3601431\u002Ffr\u002Fajovy-fremanezumab-migraine\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote6\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote6anc\" name=\"sdendnote6sym\">vi\u003C\u002Fa>Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines: statement by Vice-President Almunia. \u003Ca href=\"https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002FSPEECH_13_553\">https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002FSPEECH_13_553\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote7\">\n\u003Cp>\u003Ca class=\"sdendnotesym\" href=\"#sdendnote7anc\" name=\"sdendnote7sym\">vii\u003C\u002Fa>\u003Cspan style=\"font-size: small;\">Drugs to avoid. In the name of better patient care - 2026 update. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fenglish.prescrire.org\u002Fen\u002F1256\u002F3059\u002F60687\u002F0\u002FPositionDetails.aspx\">\u003Cspan style=\"font-size: small;\">h\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">ttps:\u002F\u002Fenglish.prescrire.org\u002Fen\u002F1256\u002F3059\u002F60687\u002F0\u002FPositionDetails.aspx\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote8\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote8anc\" name=\"sdendnote8sym\">viii\u003C\u002Fa>Fremanezumab in Children and Adolescents with Episodic Migraine \u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2504546\">https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2504546\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote9\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote9anc\" name=\"sdendnote9sym\">ix\u003C\u002Fa>A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age. \u003Ca href=\"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04458857#publications\">https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04458857#publications\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote10\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote10anc\" name=\"sdendnote10sym\">x\u003C\u002Fa>Disclosure forms.  \u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Fsuppl\u002F10.1056\u002FNEJMoa2504546\u002Fsuppl_file\u002Fnejmoa2504546_disclosures.pdf\">https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Fsuppl\u002F10.1056\u002FNEJMoa2504546\u002Fsuppl_file\u002Fnejmoa2504546_disclosures.pdf\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote11\">\n\u003Cp>\u003Ca class=\"sdendnotesym\" href=\"#sdendnote11anc\" name=\"sdendnote11sym\">xi\u003C\u002Fa>\u003Cspan style=\"font-size: small;\">Boycott Teva, boycott Ajovy. A medication that offers nothing new to \"prevent\" migraine attacks). \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboycott-teva-boycott-ajovy-boicot-teva-boicot-ajovy-eng-esp\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboycott-teva-boycott-ajovy-boicot-teva-boicot-ajovy-eng-esp\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote12\">\n\u003Cp>\u003Ca class=\"sdendnotesym\" href=\"#sdendnote12anc\" name=\"sdendnote12sym\">xii\u003C\u002Fa>\u003Cspan style=\"font-size: small;\">Ronit Satchi-Fainaro. External Scientific Committee. VHIR. \u003Ca href=\"https:\u002F\u002Fvhir.vallhebron.com\u002Fen\u002Finstitute\u002Fgoverning-bodies\u002Fexternal-scientific-committee\">https:\u002F\u002Fvhir.vallhebron.com\u002Fen\u002Finstitute\u002Fgoverning-bodies\u002Fexternal-scientific-committee\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote13\">\n\u003Cp>\u003Cspan style=\"font-size: small;\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote13anc\" name=\"sdendnote13sym\">xiii\u003C\u002Fa>Ronit Satchi-Fainaro. Teva Board of Directors \u003Ca href=\"https:\u002F\u002Fwww.tevapharm.com\u002Four-company\u002Fleadership-governance\u002Fboard-of-directors\u002Fprof-ronit-satchi-fainaro\u002F\">https:\u002F\u002Fwww.tevapharm.com\u002Four-company\u002Fleadership-governance\u002Fboard-of-directors\u002Fprof-ronit-satchi-fainaro\u002F\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote\" style=\"margin-left: 0cm; text-indent: 0cm;\"> \u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote14\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote14anc\" name=\"sdendnote14sym\">xiv\u003C\u002Fa>España tendrá este año el fremanezumab, el primer fármaco contra la migraña pediátrica: una inyección una vez al mes. \u003Cspan style=\"color: #1d9bf0;\">https:\u002F\u002Famp.elperiodico.com\u002Fes\u002Fsanidad\u002F20260225\u002Fprimer-farmaco-migrana-pediatrica-fremanezumab-inyeccion-espana-vall-hebron-127081489#amp_tf=De%20%251%24s&aoh=17720826807635&csi=0&referrer=https%3A%2F%2Fwww.google.com\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote15\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote15anc\" name=\"sdendnote15sym\">xv\u003C\u002Fa>Fremanezumab, el medicamento contra la migraña pediátrica, llegará a España en 2026 con una sola inyección mensual. \u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.diariodesevilla.es\u002Fsalud\u002Ffremanezumab-medicamento-migrana-pediatrica-llegara-espana-2026_0_2006012510.html\">https:\u002F\u002Fwww.diariodesevilla.es\u002Fsalud\u002Ffremanezumab-medicamento-migrana-pediatrica-llegara-espana-2026_0_2006012510.html\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote16\">\n\u003Cp>\u003Cspan style=\"font-size: small;\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote16anc\" name=\"sdendnote16sym\">xvi\u003C\u002Fa>Primer tratamiento contra la migraña en niños y adolescentes: \"Ha sido un milagro para mi hija\". Noa Bonet, de 11 años, es una de las pacientes españolas que ha participado en el ensayo. \u003Ca href=\"https:\u002F\u002Fwww.antena3.com\u002Fnoticias\u002Fsalud\u002Fprimer-tratamiento-migrana-ninos-adolescentes-sido-milagro-hija_20260225699f08352f00a0468827a619.html\">https:\u002F\u002Fwww.antena3.com\u002Fnoticias\u002Fsalud\u002Fprimer-tratamiento-migrana-ninos-adolescentes-sido-milagro-hija_20260225699f08352f00a0468827a619.html\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote\"> \u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote17\">\n\u003Cp class=\"sdendnote\" style=\"margin-left: 0cm; text-indent: 0cm;\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote17anc\" name=\"sdendnote17sym\">xvii\u003C\u002Fa> Plataforma de Serveis de Contractació Pública \u003Cspan style=\"color: #1d9bf0;\">https:\u002F\u002Fcontractaciopublica.cat\u002Fca\u002Finici\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"sdendnote\" style=\"margin-left: 0cm; text-indent: 0cm;\"> \u003C\u002Fp>\n\u003Cp class=\"sdendnote\" style=\"margin-left: 0cm; text-indent: 0cm;\">\u003Cstrong>\u003Cspan style=\"color: #1d9bf0;\">ESPAÑOL\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Propaganda de fremanezumab (Ajovy) al público general. España, febrero 2026\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"orphans: 2; line-height: 100%; widows: 2; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cu>\u003Cspan style=\"background: #ffffff;\">Juan Gérvas\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"background: #ffffff;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"orphans: 2; line-height: 100%; widows: 2; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: #ffffff;\">Doctor en Medicina, médico general rural jubilado, Equipo CESCA, Madrid, España, exprofesor de salud pública, Universidad Johns Hopkins, Baltimore, Estados Unidos.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"orphans: 2; line-height: 100%; widows: 2; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: transparent;\">De Health Workers for Palestine, Spain HW4PS https:\u002F\u002Fhw4p.es\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"orphans: 2; line-height: 100%; widows: 2; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: #ffffff;\">jjgervas@gmail.com www.equipocesca.org @JuanGrvas @juangrvas.bsky.social\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Introducción\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">La migraña es un proceso doloroso crónico e idiopático, generalmente con cefalea intensa que dura entre 4 y 72 horas, a veces muy limitante por las frecuentes crisis recurrentes. Tiene triple prevalencia en mujeres y suele acompañarse de síntomas neurológicos varios. Puesto que desconocemos su causa, el tratamiento es sintomático.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Hay quien ve la migraña como un fértil campo de beneficios\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">La migraña puede llegar a ser un infierno para el paciente, pero es una \"mina\" para industrias, profesionales y asociaciones de pacientes, un campo en el que obtener beneficios sociales y monetarios.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Entre los profesionales sanitarios “beneficiados”, de atención primaria, de neurología, de enfermería, de farmacia, de psicología, de psiquiatría, etc, y sus asociaciones, grupos y sociedades. Entre otros “beneficiados”, periodistas y divulgadores y asociaciones de pacientes.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Medicamentos superventas que no habría que utilizar\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Dos industrias farmacéuticas tienen especial interés en el campo de las migrañas, Teva y Lundbeck (israelí y danesa, respectivamente).\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Son dos empresas corruptas y corruptoras.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">El caso de Teva ha llevado a multas y sanciones de hasta 10.000 millones de euros en el mundo entero\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote1sym\" name=\"sdendnote1anc\">\u003Csup>i\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Teva es una multinacional líder en el campo de los medicamentos genéricos (sin marca), aunque en la actualidad sus productos “estrella” son de marca, entre ellos Ajovy (fremanezumab), para prevenir las recurrencias de las crisis de migraña, un medicamento de uso hospitalario\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote2sym\" name=\"sdendnote2anc\">\u003Csup>ii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">El mejor boletín farmacoterapéutico del mundo, la revista francesa Prescrire, consideró que Ajovy no aporta nada nuevo bueno (\u003Cspan style=\"background: transparent;\">en francés, literal, “N'apporte rien de nouveau”\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\">)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote3sym\" name=\"sdendnote3anc\">\u003Csup>iii\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote4sym\" name=\"sdendnote4anc\">\u003Csup>iv\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"background: transparent;\">La Haute Autorité de Santé (HAS) francesa, en 2025, dejó claro que: “Hasta la fecha, no se ha demostrado la superioridad de los anticuerpos anti-CGRP (incluido el fremanezumab) en términos de eficacia en comparación con otros tratamientos profilácticos\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote5sym\" name=\"sdendnote5anc\">\u003Csup>v\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">El caso más conocido de Lundbeck es el de sus prácticas corruptas anti-competencia respecto a citalopram y escitalopram, por las que fue multada con 93 millones de euros en la Unión Europea\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote6sym\" name=\"sdendnote6anc\">\u003Csup>vi\u003C\u002Fsup>\u003C\u002Fa>. Irónicamente, además, son dos medicamentos que es mejor no utilizar porque sus daños superan en mucho a sus beneficios\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote7sym\" name=\"sdendnote7anc\">\u003Csup>vii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Lundbeck también produce medicación para prevenir la migraña, Vyepti\u003Cspan style=\"font-weight: normal;\"> \u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\">(\u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\">eptinezumab\u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\">), con valoración similar de no aportar nada nuevo.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Propaganda de fremanezumab (Ajovy)\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm; font-weight: normal;\">La publicación en enero 2026, en el New England, de un ensayo clínico de uso del Ajovy en la prevención de crisis de migraña en infancia y adolescencia\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote8sym\" name=\"sdendnote8anc\">\u003Csup>viii\u003C\u002Fsup>\u003C\u002Fa> conllevó una nota de prensa del Hospital Vall d’Hebron \u003Cspan style=\"background: transparent;\">(Barcelona)\u003C\u002Fspan>\u003Cspan style=\"background: transparent;\"> \u003C\u002Fspan>que se difundió en los medios de comunicación españoles.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"font-weight: normal;\">Lo publicado e\u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\">s un ensayo clínico financiado íntegramente por Teva, la compañía que produce Ajovy\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote9sym\" name=\"sdendnote9anc\">\u003Csup>ix\u003C\u002Fsup>\u003C\u002Fa>, \u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\">que contrató a 89 centros del mundo entero para captar a \u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\">237\u003C\u002Fspan>\u003Cspan style=\"font-weight: normal;\"> pacientes y llevar a cabo el estudio.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">De los 11 autores firmantes del artículo en el New England, 6 son empleados de Teva (incluso dos de su central en Tel Aviv, Israel) y los demás tienen importantes conflictos de interés, básicamente con Teva\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote10sym\" name=\"sdendnote10anc\">\u003Csup>x\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Incluso el redactado del artículo fue pagado por Teva.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">En la nota de prensa la figura clave fue la neuróloga jefe del Vall d’Hebron. Patricia Pozo-Rosich, con fortísimos conflictos de interés con las industrias farmacéuticas, quien recibió 77.000 euros directamente de Teva (2023 y 2024) y es vicepresidenta del \"Vall d'Hebron Institut de Recerca, VHIR\". Dicho instituto de investigación, el VHIR, tiene en su Comité Científico Externo a Ronit Satchi-Fainaro, israelí de Tel Aviv, que pertenece al Consejo de Administración de Teva (lo que no consta en el curriculum que aparece en la página del VHIR)\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote11sym\" name=\"sdendnote11anc\">\u003Csup>xi\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Es decir, todo gira en torno a Teva, sobre un producto de Teva, autores pagados por Teva o directamente empleados de Teva, estudio financiado por Teva, redacción del artículo sostenida por Teva, en torno a un medicamento que no añade nada nuevo a los pacientes, pero genera ingentes ingresos a Teva. ¿Cabe duda de qué se demuestra en el estudio citado sobre un medicamento de Teva?\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Fremanezumab (Ajovy) en la prensa la última semana de febrero de 2026\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Fue impresionante el impacto de la nota de prensa, de propaganda del Hospital Vall d’Hebron.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Los titulares no dejan lugar a duda.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">En “El Periódico”: “España tendrá este año el fremanezumab, el primer fármaco contra la migraña pediátrica: una inyección una vez al mes Un ensayo internacional en el que ha participado el hospital Vall d'Hebron demuestra que el fremanezumab es eficaz y seguro a la hora de prevenir la enfermedad en niños de 6 a 17 años”. Vale a pena ver el vídeo y la fotografía\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote12sym\" name=\"sdendnote12anc\">\u003Csup>xii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">En “El Diario de Sevilla” se incluye una fotografía de Ajovy, directamente, con el titular de: “Fremanezumab, el medicamento contra la migraña pediátrica, llegará a España en 2026 con una sola inyección mensual”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote13sym\" name=\"sdendnote13anc\">\u003Csup>xiii\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">En “Antena 3” televisión: Primer tratamiento contra la migraña en niños y adolescentes: \"Ha sido un milagro para mi hija\". Noa Bonet, de 11 años, es una de las pacientes españolas que ha participado en el ensayo”\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote14sym\" name=\"sdendnote14anc\">\u003Csup>xiv\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Lo mismo en otros medios como EFE, El Heraldo de Aragón, El Mundo, Infobae, El Economista, HuffPost, Cope radio, Marca, La Vanguardia, etc.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Fremanezumab (Ajovy), el uso hospitalario no es freno a sus superventas\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Ajovy precisa de receta por especialista focal hospitalario, generalmente de neurología. Pero ello no frena sus ventas.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Sirva de ejemplo la compra \u003Cspan style=\"font-size: large;\">de \u003C\u002Fspan>\u003Cspan style=\"font-size: large;\">Ajovy \u003C\u002Fspan>\u003Cspan style=\"font-size: large;\">a Teva\u003C\u002Fspan>\u003Cspan style=\"font-size: large;\"> (“\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">anticossos pel tractament de la migranya”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"text-decoration: none;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-style: normal;\">\u003Cspan style=\"font-weight: normal;\">) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: large;\">en 2025\u003C\u002Fspan>\u003Cspan style=\"font-size: large;\"> por el Consorci S\u003C\u002Fspan>anitari de Terrassa (Barcelonal), en total casi un millón de euros (745.418,28).\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">El mismo Consorci se gastó exactamente la misma cantidad, increíblemente exactamente la misma cantidad, incluso decimales, en Lundbeck, también para anticuerpo monoclonal para la migraña, y en otro producto para lo mismo suministrado por Organon Salud SL\u003Ca class=\"sdendnoteanc\" href=\"#sdendnote15sym\" name=\"sdendnote15anc\">\u003Csup>xv\u003C\u002Fsup>\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">Mucho dinero en medicamentos que no aportan nada bueno,\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Comentario\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0.5cm;\">Parece que la estrategia comercial de Teva incluye la propaganda de fremanezumab (Ajovy) al público general. El Hospital Vall d’Hebron (Barcelona) apoya y presenta como novedad algo que “no aporta nada nuevo”. Tal propaganda está claramente prohibida por la legislación española y europea. Se acompaña, además, por un “aparato” increíble y constante de presión sobre los “beneficiados” social y monetariamente mediante congresos, consensos, guías, publicaciones, seminarios y otros medios.\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0.5cm;\">\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0.5cm;\">\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cdiv id=\"sdendnote1\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote1anc\" name=\"sdendnote1sym\">i\u003C\u002Fa>Teva. Penalty total since 2000: $10,695,276,796. Casi 11.000 millones de dólares en multas desde 2000.\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-penalty-total-since-2000-10-695-276-796-casi-11-000-millones-de-dolares-en-multas-desde-2000\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fteva-penalty-total-since-2000-10-695-276-796-casi-11-000-millones-de-dolares-en-multas-desde-2000\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote2\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote2anc\" name=\"sdendnote2sym\">ii\u003C\u002Fa>Los medicamentos estrella de Teva. \u003Ca href=\"https:\u002F\u002Fineurociencias.org\u002Fteva-neuroscience-products\u002F\">https:\u002F\u002Fineurociencias.org\u002Fteva-neuroscience-products\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote3\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote3anc\" name=\"sdendnote3sym\">iii\u003C\u002Fa>Frémanezumab (Ajovy°) et prévention des crises de migraine. Rev Prescrire 2020 ; 40 (444): 731-732. \u003Ca href=\"https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\">https:\u002F\u002Fwww.prescrire.org\u002Favis-sur-les-medicaments\u002F444-fremanezumab-ajovy-et-prevention-des-crises-de-migraine\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote4\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote4anc\" name=\"sdendnote4sym\">iv\u003C\u002Fa>Boycott Teva, boycott Ajovy. Boicot Teva, boicot Ajovy ENG ESP \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboycott-teva-boycott-ajovy-boicot-teva-boicot-ajovy-eng-esp#sdendnote11sym\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fboycott-teva-boycott-ajovy-boicot-teva-boicot-ajovy-eng-esp#sdendnote11sym\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote5\">\n\u003Cp class=\"sdendnote\" style=\"margin-left: 0cm; text-indent: 0cm;\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote5anc\" name=\"sdendnote5sym\">v\u003C\u002Fa> AJOVY (frémanezumab) - Migraine.\u003C\u002Fp>\n\u003Cp class=\"sdendnote\" style=\"margin-left: 0cm; text-indent: 0cm;\">\u003Ca href=\"https:\u002F\u002Fwww.has-sante.fr\u002Fjcms\u002Fp_3601431\u002Ffr\u002Fajovy-fremanezumab-migraine\">\u003Cspan style=\"color: #000080;\">\u003Cu>https:\u002F\u002Fwww.has-sante.fr\u002Fjcms\u002Fp_3601431\u002Ffr\u002Fajovy-fremanezumab-migraine\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote6\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote6anc\" name=\"sdendnote6sym\">vi\u003C\u002Fa>Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines: statement by Vice-President Almunia. \u003Ca href=\"https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002FSPEECH_13_553\">https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002FSPEECH_13_553\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote7\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote7anc\" name=\"sdendnote7sym\">vii\u003C\u002Fa>Citalopram y escitalopram. Ambos pertenecen al grupo de antidepresivos inhibidores selectivos de la recaptación de serotonina (ISRS). Exponen a los pacientes a un mayor riesgo de prolongación del intervalo QT en el electrocardiograma, torsades de pointes y muerte súbita en comparación con otros antidepresivos ISRS, así como a sobredosis con consecuencias más graves. \u003Ca href=\"https:\u002F\u002Fgrupmedicament.wordpress.com\u002F2026\u002F01\u002F02\u002Flista-prescrire-2026-medicamentos-a-evitar\u002F\">https:\u002F\u002Fgrupmedicament.wordpress.com\u002F2026\u002F01\u002F02\u002Flista-prescrire-2026-medicamentos-a-evitar\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote8\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote8anc\" name=\"sdendnote8sym\">viii\u003C\u002Fa>Fremanezumab in Children and Adolescents with Episodic Migraine \u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2504546\">https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2504546\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote9\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote9anc\" name=\"sdendnote9sym\">ix\u003C\u002Fa>A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age. \u003Ca href=\"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04458857#publications\">https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04458857#publications\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote10\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote10anc\" name=\"sdendnote10sym\">x\u003C\u002Fa>Disclosure forms.  \u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Fsuppl\u002F10.1056\u002FNEJMoa2504546\u002Fsuppl_file\u002Fnejmoa2504546_disclosures.pdf\">https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Fsuppl\u002F10.1056\u002FNEJMoa2504546\u002Fsuppl_file\u002Fnejmoa2504546_disclosures.pdf\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote11\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote11anc\" name=\"sdendnote11sym\">xi\u003C\u002Fa>NoGracias, más allá de la campaña estatal de boicot a Teva. \u003Ca href=\"https:\u002F\u002Fahoramqnunca.blogspot.com\u002F2026\u002F02\u002Fnogracias-mas-alla-de-la-campana.html\">https:\u002F\u002Fahoramqnunca.blogspot.com\u002F2026\u002F02\u002Fnogracias-mas-alla-de-la-campana.html\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote12\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote12anc\" name=\"sdendnote12sym\">xii\u003C\u002Fa>España tendrá este año el fremanezumab, el primer fármaco contra la migraña pediátrica: una inyección una vez al mes. \u003Cspan style=\"color: #1d9bf0;\">https:\u002F\u002Famp.elperiodico.com\u002Fes\u002Fsanidad\u002F20260225\u002Fprimer-farmaco-migrana-pediatrica-fremanezumab-inyeccion-espana-vall-hebron-127081489#amp_tf=De%20%251%24s&aoh=17720826807635&csi=0&referrer=https%3A%2F%2Fwww.google.com\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote13\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote13anc\" name=\"sdendnote13sym\">xiii\u003C\u002Fa>Fremanezumab, el medicamento contra la migraña pediátrica, llegará a España en 2026 con una sola inyección mensual. \u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.diariodesevilla.es\u002Fsalud\u002Ffremanezumab-medicamento-migrana-pediatrica-llegara-espana-2026_0_2006012510.html\">https:\u002F\u002Fwww.diariodesevilla.es\u002Fsalud\u002Ffremanezumab-medicamento-migrana-pediatrica-llegara-espana-2026_0_2006012510.html\u003C\u002Fa>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote14\">\n\u003Cp class=\"sdendnote\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote14anc\" name=\"sdendnote14sym\">xiv\u003C\u002Fa>Primer tratamiento contra la migraña en niños y adolescentes. “Ha sido un milagro para mi hija”.\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-size: small;\">\u003Ca href=\"https:\u002F\u002Fwww.antena3.com\u002Fnoticias\u002Fsalud\u002Fprimer-tratamiento-migrana-ninos-adolescentes-sido-milagro-hija_20260225699f08352f00a0468827a619.html\">https:\u002F\u002Fwww.antena3.com\u002Fnoticias\u002Fsalud\u002Fprimer-tratamiento-migrana-ninos-adolescentes-sido-milagro-hija_20260225699f08352f00a0468827a619.html\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"sdendnote15\">\n\u003Cp class=\"sdendnote\" style=\"margin-left: 0cm; text-indent: 0cm;\">\u003Ca class=\"sdendnotesym\" href=\"#sdendnote15anc\" name=\"sdendnote15sym\">xv\u003C\u002Fa> Plataforma de Serveis de Contractació Pública \u003Cspan style=\"color: #1d9bf0;\">https:\u002F\u002Fcontractaciopublica.cat\u002Fca\u002Finici\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","in-spain-direct-to-consumer-advertising-of-ajovy-en-espana-propaganda-al-publico-de-ajovy-eng-esp",[15,523,534,535],"Direct-to-consumer","Propaganda","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1773511572\u002Fwqmad9gjkpawqhepewcd.png","In Spain, direct-to-consumer advertising of Ajovy. En España, propaganda al público de Ajovy. ENG ESP","tIxLU8WUK1Y",{"subtitle":540,"id":541,"timestamp":542,"content":543,"slug":544,"type":7,"tags":545,"user":13,"imageUrl":546,"link":12,"title":547,"videoUrl":385},"Ajovy, campaña periodística, migraña infancia-adolescencia. Ajovy, journalistic campaign, childhood-adolescent migraine.","mmuhtjcouhsqdr4p98n",1773747584915,"\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Ministra de Sanidad @Monica_Garcia_G @sanidadgob : decencia, dignidad e independencia en el cumplimiento de la Ley contra Teva. Por su publicidad directa al consumidor de Ajovy para infancia\u002Fadolescencia con migraña. #TevaNoGracias #boicotTeva\u003C\u002Fp>\n\u003Cp>En España, como en toda la Unión Europea, \u003Ca href=\"https:\u002F\u002Fwww.boe.es\u002Fbuscar\u002Fact.php?id=BOE-A-1994-17681\">está prohibida la propaganda directa al público de medicamentos que necesitan prescripción médica.\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002Fnoticias\u002Fteva-expandiendo-desinformaci%C3%B3n-sobre-fremanezumab-en-menores\">\u003Cspan style=\"background-color: #f1c40f;\">Noticia: Teva expandiendo desinformación sobre fremanezumab (Ajovy) en menores\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>9 marzo 2026. Campaña estatal de boicot a Teva, \"TevaNoGracias\"\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>Desde la \u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002F\">Campaña de boicot estatal “¿Teva? No, gracias”\u003C\u002Fa> se ha enviado al Ministerio de Sanidad \u003Ca href=\"https:\u002F\u002Fdrive.proton.me\u002Furls\u002FMP1EZB0G1M#eneMHbiq8fQN\">un escrito\u003C\u002Fa> expresando nuestro estupor por la campaña publicitaria de Teva respecto a su fármaco fremanezumab, (Ajovy), un medicamento para la prevención de la migraña. Esta campaña publicitaria comenzó el pasado 25 de febrero de 2026 y sigue todavía en curso.\u003C\u002Fp>\n\u003Cp>Esta campaña publicitaria  se ha realizado con el apoyo de un grupo numeroso de medios de comunicación españoles, tanto de ámbito general como de ámbito médico especializado. Organizaciones científicas como la \u003Ca href=\"https:\u002F\u002Fsepeap.org\u002Ffremanezumab-en-ninos-y-adolescentes-con-migrana-episodica\u002F\">Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria (SEPEAP)\u003C\u002Fa> o foros digitales ciudadanos como\u003Ca href=\"https:\u002F\u002Fwww.serpadres.es\u002Fsalud\u002Fsalud-infantil\u002Fciencia-descubre-farmaco-migrana-ninos-alentador.html\"> Ser Padres\u003C\u002Fa>, también se han hecho eco de esta noticia.\u003C\u002Fp>\n\u003Cp>La campaña publicitaria pretende divulgar los resultados de \u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2504546\">un ensayo clínico de fremanezumab en niños y adolescentes con migraña\u003C\u002Fa>, publicado recientemente en la revista New England Journal of Medicine.\u003C\u002Fp>\n\u003Cp>En nuestra opinión, aunque esta campaña publicitaria ha adoptado la forma de \"aséptica\" divulgación científica a la población de los resultados de este estudio, evitando en principio utilizar el nombre comercial de este producto, su manera de presentarlo hace muy fácil reconocerlo. De hecho en algunas noticias, como por ejemplo la publicada en la \u003Ca href=\"https:\u002F\u002Fefe.com\u002Fcataluna\u002F2026-02-25\u002Fdemuestran-la-eficacia-de-un-farmaco-para-tratar-la-migrana-en-la-poblacion-pediatrica\u002F\">Agencia Efe\u003C\u002Fa>, el \u003Ca href=\"https:\u002F\u002Fwww.diariodesevilla.es\u002Fsalud\u002Ffremanezumab-medicamento-migrana-pediatrica-llegara-espana-2026_0_2006012510.html\">Diario de Sevilla\u003C\u002Fa>, \u003Ca href=\"https:\u002F\u002Fwww.hoyaragon.es\u002Farticulo\u002Fnoticias-espana\u002Fllega-espana-fremanezumab-primer-farmaco-migrana-pediatrica-inyeccion-fin\u002F20260301134316124076.html\">Hoy Aragón\u003C\u002Fa> o en la web de \u003Ca href=\"https:\u002F\u002Fwww.antena3.com\u002Fnoticias\u002Fsalud\u002Fprimer-tratamiento-migrana-ninos-adolescentes-sido-milagro-hija_20260225699f08352f00a0468827a619.html\">Antena 3\u003C\u002Fa>, el texto se acompaña de una foto de una inyección de \"Ajovy\".\u003C\u002Fp>\n\u003Cp>A nuestro parecer el objetivo directo de la campaña de propaganda es preparar el terreno para reclamar al Ministerio una ampliación de las indicaciones a la población pediátrica y adolescente con migraña, un intento de aumentar la cuota de mercado de este producto, disfrazándolo de \"ciencia\" y de cálida preocupación por la salud de un segmento tan vulnerable como el de los menores. La noticia es un buen ejemplo de \u003Ca href=\"https:\u002F\u002Fwww.lamoncloa.gob.es\u002Fpaginas\u002Finformacion\u002Fque-es-la-desinformacion-y-que-diferencias-existen.aspx#:~:text=Suele%20ser%20fruto%20de%20errores,accidental%20de%20informaci%C3%B3n%20no%20ver%C3%ADdica.\">desinformación\u003C\u002Fa>. \u003C\u002Fp>\n\u003Cp>Pensamos que esta campaña publicitaria incumple lo establecido por el Artículo 78 de la Ley 29\u002F2006, de 26 de julio, de garantías y uso racional de los medicamentos y productos sanitarios. \u003C\u002Fp>\n\u003Cp>    Está haciendo, de forma encubierta, publicidad de un medicamento comercializado -aunque sea en presentación o indicación diferente- y financiado por el Sistema Nacional de salud (Art. 78.6). \u003C\u002Fp>\n\u003Cp>    Es además un medicamento destinado a ser utilizado o aplicado exclusivamente por profesionales sanitarios (art.78.7). \u003C\u002Fp>\n\u003Cp>    La publicidad incluye \"testimonios sobre las virtudes del producto (...) de profesionales o personas cuya notoriedad pueda inducir al consumo\", como es el caso de la Dra. Pozo Rosich, una prestigiosa neuróloga que es la principal KOL de Teva en España (art.78.2.d). \u003C\u002Fp>\n\u003Cp>Además, el público objetivo último de esta propaganda son los menores, que están especialmente protegidos por el Artículo 3.b de la Ley 34\u002F1988, de 11 de noviembre, General de Publicidad.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Minister of Health @Monica_Garcia_G @sanidadgob: Decency, dignity, and independence in enforcing the law against Teva.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> For their direct-to-consumer advertising of Ajovy for children\u002Fadolescents with migraines.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">#NoThanksTeva #BoycottTeva\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In Spain, as in the rest of the European Union, \u003Ca href=\"https:\u002F\u002Flawshun.com\u002Farticle\u002Fdo-european-countries-have-laws-that-ban-pharmaceutical-ads\">direct-to-consumer advertising of medicines that require a medical prescription is prohibited\u003C\u002Fa>. The rule is t\u003Cspan class=\"kY2IgmnCmOGjharHErah\" style=\"-webkit-line-clamp: 3;\">he prohibition of \u003Cstrong>direct-to-consumer\u003C\u002Fstrong> advertising for \u003Cstrong>prescription\u003C\u002Fstrong> \u003Cstrong>drugs.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002Fnoticias\u002Fteva-expandiendo-desinformaci%C3%B3n-sobre-fremanezumab-en-menores\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan style=\"background-color: #f1c40f;\">News: Teva Spreading Misinformation About Fremanezumab in Children and adolescents\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">March 9, 2026 Boycott Teva #TevaNoGracias #TevaNoThanks\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">INTRODUCTION\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The \u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002F\">state-level boycott campaign “Teva? No, thanks”\u003C\u002Fa> has sent \u003Ca href=\"https:\u002F\u002Fdrive.proton.me\u002Furls\u002FMP1EZB0G1M#eneMHbiq8fQN\">a letter to the Ministry of Health\u003C\u002Fa>  \u003Cstrong>\u003Cem>[you can read the English translation at the end of this introduction]\u003C\u002Fem> \u003C\u002Fstrong>expressing our outrage at Teva’s advertising campaign regarding its drug fremanezumab (Ajovy), a medication for migraine prevention.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This advertising campaign began on February 25, 2016, and is still ongoing.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> This advertising campaign has been carried out with the support of a large number of Spanish media outlets, both general and specialized medical.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Scientific organizations such as the Spanish Society of Outpatient Pediatrics and Primary Care (SEPEAP) and citizen online forums such as Ser Padres have also reported on this news.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The advertising campaign aims to disseminate the results of a clinical trial of fremanezumab in children and adolescents with migraines, recently published in the New England Journal of Medicine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In our opinion, although this advertising campaign has adopted the form of an \"aseptic\" scientific dissemination to the public of the results of this study, avoiding in principle the use of the product's brand name, its presentation makes it very easy to recognize.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In fact, in some news articles, such as those published by the EFE news agency, the Diario de Sevilla newspaper, Hoy Aragón, and on the Antena 3 website, the text is accompanied by a photo of an \"Ajovy\" injection.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In our view, the direct objective of the propaganda campaign is to prepare the ground for demanding that the Ministry expand the indications for the product to include pediatric and adolescent patients with migraines, an attempt to increase the market share of this product, disguising it as \"science\" and genuine concern for the health of such a vulnerable segment as minors.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The news item is a prime example of misinformation.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We believe that this advertising campaign violates the provisions of Article 78 of Law 29\u002F2006, of July 26, on guarantees and rational use of medicines and health products.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It is covertly advertising a marketed medicine—albeit in a different presentation or for a different indication—that is financed by the National Health System (Art. 78.6).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Furthermore, it is a medicine intended to be used or administered exclusively by healthcare professionals (Art. 78.7).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The advertising includes \"testimonials about the virtues of the product (...) from professionals or individuals whose notoriety may induce consumption,\" as is the case with Dr. Pozo Rosich, a prestigious neurologist who is Teva's main Key Opinion Leader in Spain (Art. 78.2.d).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In addition, the ultimate target audience of this advertising is minors, who are especially protected by Article 3.b of Law 34\u002F1988, of November 11, General Advertising Law.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">LETTER TO THE MINISTRY OF HEALTH\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Dr. Mónica García Gómez Minister of Health of the Government of Spain Ministry of Health Paseo del Prado, 18 28014 – Madrid \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Dear Minister, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We wish to inform you that we are witnessing with considerable dismay an advertising campaign by the Israeli pharmaceutical company Teva regarding its drug fremanezumab, marketed in our country, as you know, under the name Ajovy, a medication for the prevention of migraines.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This advertising campaign began on February 25, 2016, and is still ongoing.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> This campaign has been carried out with the support of a large number of Spanish media outlets, both general and specialized medical (see the list of news articles at the end of this document).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Scientific organizations such as the Spanish Society of Outpatient and Primary Care Pediatrics (SEPEAP) and online forums such as Ser Padres have also reported on this matter.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The advertising campaign aims to disseminate the results of a clinical trial of fremanezumab in\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> children and adolescents with migraine, recently published in the New England Journal of\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Medicine [\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2504546\">Fremanezumab in Children and Adolescents with Episodic Migraine\u003C\u002Fa>].\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Regarding this propaganda campaign, the State Boycott Campaign \"Teva? No, thanks,\" which to date has been joined by 402 organizations from all regions of Spain, wishes to state the following: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1) In our opinion, although this advertising campaign has adopted the form of an \"aseptic\" scientific dissemination to the public of the results of this study, avoiding in principle using the trade name of this product, its presentation makes it very easy to recognize.\u003C\u002Fspan> \u003Cem>\u003Cspan class=\"ryNqvb\">In fact, in some news articles, such as those published by the EFE news agency, the Diario de Sevilla newspaper, Hoy Aragón, or on the Antena 3 website, the text is accompanied by a photo of an \"Ajovy\" injection (See list of news articles at the end).\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2) We will not assess the scientific and technical quality of this study, conducted with 234 patients between 6 and 17 years old, of whom 123 received treatment for 3 months and the remaining 111 received a placebo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">We do, however, question whether the results obtained justify such a campaign of propaganda and the excessive generation of expectations among the general population and among patients who suffer from migraines and their parents.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In our opinion, this is not the case, and therefore we believe that misleading advertising is being used.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3) It should be noted that this clinical trial is funded by Teva Pharmaceuticals itself (Funded by Teva Pharmaceuticals; ClinicalTrials.gov number, NCT04458857).\u003Cem> Of the 11 authors who signed the article, no fewer than 10 declare potential conflicts of interest due to their relationship with Teva.\u003C\u002Fem>\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The only one who does not declare any is the article's first author, Dr. Andrew Hershey.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Given this situation, it seems prudent to distance oneself from the results obtained, and it is somewhat scandalous that this publication was included in the prestigious New England Journal of Medicine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">4) \u003Cem>A particularly important case is that of the Spanish representative in this trial, Dr. Patricia Pozo Rosich, as she is repeatedly cited and \"interviewed\" in the various texts that make up the promotional campaign.\u003C\u002Fem>\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Patricia Pozo Rosich is a neurologist specializing in migraines.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Since July 2025, she has been Head of the Neurology Department at Vall d'Hebron University Hospital in Barcelona.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">She leads the headache research group at the VHIR (Vall d'Hebron Research Institute) and is a person of considerable public presence and impact.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">She is also the main KOL (Key Opinion Leader) for the Teva laboratory in Spain, from which she received \"transfers of value\" totaling €44,652 in 2024. In 2023, the figure was €31,654.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Furthermore, she has a very serious conflict of interest.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In reality, it is the management of the Vall d'Hebron Research Institute that has the conflict.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>The Internal Scientific Committee of this institution lists Dr. Patricia Pozo Rosich as Vice President… and on its External Scientific Committee is Professor Ronit Satchi-Fainaro, an Israeli pharmacist and member of the Board of Directors of Teva, a fact which is conveniently omitted from her brief curriculum vitae description on the website\u003C\u002Fstrong>.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">With this structure, it is difficult to give much credence to anything Dr. Pozo Rosich says in defense of fremanezumab.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">5) \u003Cem>To our understanding \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cem>the direct objective of the propaganda campaign is to pave the way for demanding an expansion of the indications to include the pediatric and adolescent population with migraine, an attempt to increase the market share of this product, disguising it as \"science\" and genuine concern for the health of such a vulnerable segment as children\u003C\u002Fem>.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">As you are well aware, in Spain Ajovy is currently indicated for the prophylaxis of migraine in adults with at least four migraine days per month.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">It is covered by the National Health System for patients with 8 or more migraine days per month (high-frequency episodic migraine and chronic migraine) and 3 or more failed previous treatments at sufficient doses for at least 3 months, one of which was botulinum toxin in the case of chronic migraine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It is a hospital diagnostic (HD) and hospital-dispensed drug without a tamper-evident coupon (HDSC), meaning it must be prescribed by neurology specialists and dispensed, free of charge to the patient, in hospital pharmacy departments.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> It is administered subcutaneously, in a 225 mg dose (monthly), as an injectable solution in a pre-filled syringe, at a price of €498 in the Spanish National Health System (a price that can be reduced by more than 50% in specific offers, such as those Teva uses to negotiate a favorable market position). In the United States, the price is $746.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">A 675 mg dose is available for quarterly administration.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">There are three other similar antibodies authorized in the Spanish pharmaceutical market.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003C\u002Fspan>\u003Cspan class=\"ryNqvb\">\u003Cem>The Spanish Agency for Medicines and Health Products (AEMPS), in its 2020 Therapeutic Positioning Report on Ajovy, stated the following:\u003C\u002Fem> “There is a lack of direct comparative data with other prophylactic alternatives, such as topiramate, botulinum toxin, beta-blockers, flunarizine, or amitriptyline, or even other drugs with the same mechanism of action (erenumab, galcanezumab). The limited evidence available shows a modest clinical benefit and does not allow us to consider it superior to other available options for migraine prophylaxis.”\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For its part, the Navarre Pharmacotherapeutic Information Bulletin (2021) concluded the following: “Having demonstrated their efficacy and safety in migraine prevention compared to placebo, their efficacy remains modest, there are no comparative studies against standard therapies, and data on long-term effectiveness and safety in real-world clinical practice are scarce. Furthermore, the incorporation of ACs into migraine treatment carries a significant economic impact, motivated not only by their cost, which is around €150-200 per month per patient (€1800-2300 per year per patient), but also by the high prevalence of the disease and its chronic nature. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, it is necessary to position ACs in relation to other preventive treatments and develop guidelines for action that guide local clinical practice and include the approval and funding requirements of each country.” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">6) \u003Cem>We believe that this advertising campaign violates the provisions of Article\u003C\u002Fem>\u003C\u002Fspan>\u003Cem> \u003C\u002Fem>\u003Cspan class=\"ryNqvb\">\u003Cem>Article 78 of Law 29\u002F2006, of July 26, on guarantees and rational use of medicines and medical devices\u003C\u002Fem>.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It is covertly advertising a marketed medicine—albeit in a different presentation or with a different indication—and financed by the National Health System (Art. 78.6).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">It is also a medicine intended to be used or applied exclusively by healthcare professionals (Art. 78.7).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The advertising includes \"testimonials about the virtues of the product (...) from professionals or individuals whose notoriety may induce consumption,\" as is the case of the aforementioned Dr. Pozo Rosich (Art. 78.2.d).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">Furthermore, the ultimate target audience of this advertising is minors, who are specially protected by Article 3.b of Law 34\u002F1988, of November 11, the General Advertising Law.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">7) Finally, we want to point out the close ties between the pharmaceutical company Teva and the Zionist government of Israel, its armed forces (IDF), and the ongoing genocide in Gaza.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva is lying when it denies these ties.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We have clearly explained this in Report 5 of the \"Teva Reports\" series, entitled \"The Darkness of Teva,\" available on our website (\u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002F\">www.tevanogracias.com\u003C\u002Fa>), which we have also attached as an enclosed file.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva is the largest company by market capitalization on the Tel Aviv Stock Exchange.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, it is not just any company, nor simply a company concerned only with its business, as they claim.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva is, above all, a key component of the Zionist financial network that sustains the occupation of the land of Palestine and the plan of ethnic cleansing and extermination of its population.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Therefore, there are powerful ethical and deontological arguments for boycotting it and limiting its use.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">We demand that Teva cease all possible activity in Spain.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">To do otherwise is to collaborate with someone who supports the most atrocious barbarity.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The vast majority of their medications can be perfectly substituted by other brands without any impact on people's health, as is even the case with fremanezumab.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva's argument of alleged harm to public health if their medications lose market share is another fallacious argument.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cem>\u003Cstrong>Therefore, we REQUEST: \u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1\u002F The opening of an investigation to clarify whether the Teva company and the media outlets that have participated in this propaganda campaign have committed any legal or administrative infraction.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">If so, we request that the corresponding sanctions be applied. And\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2\u002F That, in compliance with the recommendations of the International Court of Justice and the United Nations, the Ministry implement legal, administrative, economic, and political measures to limit the activities of this pharmaceutical company in our country due to its proven ties to the State of Israel and its policies of extermination of the Palestinian people.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Thank you for listening.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Sincerely, State Boycott Campaign \"Teva? No, thanks.\"\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Contact: tevanogracias@proton.me \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">LIST OF NEWS ITEMS DETECTED AS PART OF TEVA'S ADVERTISING CAMPAIGN \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This is an incomplete list, as it is impossible to compile all the news items, since this information has been widely disseminated in all types of forums and media.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Many of these news items reproduce almost verbatim the news published by the EFE Agency in Catalonia or are based on it.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This EFE news report already includes a photo of the Ajovy injection.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-EFE News Agency (Catalonia) https:\u002F\u002Fefe.com\u002Fcataluna\u002F2026-02-25\u002Fdemuestran-la-eficacia-de-un-farmaco-para-tratar-la-migrana-en- la-poblacion-pediatrica\u002F \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Spanish Society of Outpatient Pediatrics and Primary Care (SEPEAP) https:\u002F\u002Fsepeap.org\u002Ffremanezumab-en-ninos-y-adolescentes-con-migrana-episodica\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-The\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La Vanguardia https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.lavanguardia.com\u002Fvida\u002F20260225\u002F11473658\u002Fprimer-tratamiento- preventivo-migrana-ninos-adolescentes.amp.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-TV3 https:\u002F\u002Fwww.3cat.cat\u002F3catinfo\u002Fun-estudi-obre-la-porta-al-primer-tractament-eficac-contra-la-migranya- en-infants-i-adolescents\u002Fnoticia\u002F3396463\u002F Diario de Sevilla https:\u002F\u002Fwww.diariodesevilla.es\u002Fsalud\u002Ffremanezumab-medicamento-migrana-pediatrica-llegara-espana- 2026_0_2006012510.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-El Periódido\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Famp.elperiodico.com\u002Fes\u002Fsanidad\u002F20260225\u002Fprimer-farmaco-migrana- pediatrica-fremanezumab-inyeccion-espana-vall-hebron-127081489 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Diario Farma https:\u002F\u002Fdiariofarma.com\u002F2026\u002F02\u002F25\u002Fun-estudio-avala-fremanezumab-para-reducir-los-dias-de-migrana- en-ninos-y-jovenes \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-IM Medico https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.immedicohospitalario.es\u002Famp\u002F55316\u002Fnuevo-tratamiento-con- fremanezumab-demuestra-eficacia-y-seguridad-en-l.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-The\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Huffington Post https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.huffingtonpost.es\u002Flife\u002Fsalud\u002Fpatricia-pozorosich-neurologa- sobrefremanezumab-para-migrana-infantil-habia-ningun-tratamiento-preventivo-aprobado- f202602.html%3foutputType=amp \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-El Mundo https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Famp.elmundo.es\u002Fciencia-y- salud\u002Fsalud\u002F2026\u002F02\u002F25\u002F699ed17d21efa043168b4575.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Faro de Vigo https:\u002F\u002Fwww.farodevigo.es\u002Fsociedad\u002F2026\u002F02\u002F26\u002Fespana-tendra-ano-primer-farmaco-127290644.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Hoy\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Aragon https:\u002F\u002Fwww.hoyaragon.es\u002Farticulo\u002Fnoticias-espana\u002Fllega-espana-fremanezumab-primer-farmaco- migrana-pediatrica-inyeccion-fin\u002F20260301134316124076.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-El Economista https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.eleconomista.es\u002Fsalud-bienestar\u002Fultimas- noticias\u002Famp\u002F13796750\u002Fespana-consigue-el-primer-farmaco-contra-las-migranas-para-ninos-asi-es-el- fremanezumab-que-se-administra-con-una-inyeccion-al-mes \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-20\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">minutos https:\u002F\u002Fwww.20minutos.es\u002Fsalud\u002Ffremanezumab-primer-tratamiento-contra-migranas- ninos_6939511_0.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Heraldo https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.heraldo.es\u002Fnoticias\u002Fsalud\u002F2026\u002F02\u002F26\u002Fadios-migrana-descubren- medicamento-fremanezumab-eficaz-ninos-adolescentes-1897530.amp.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-La Razón https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.larazon.es\u002Fsociedad\u002Fprimer-tratamiento-preventivo-migrana- pediatrica-llegara-espana-inyeccion-mensual- b50m_2026022769a163d59243cc133c668cfd.html%3foutputType=amp Antena\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">3 https:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Famp.antena3.com\u002Fnoticias\u002Fsalud\u002Fprimer-tratamiento-migrana-ninos- adolescentes-sido-milagro-hija_20260225699f08352f00a0468827a619.html \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-Tele 5 https:\u002F\u002Fwww.telecinco.es\u002Fnoticias\u002Fsalud\u002F20260225\u002Ffarmaco-reduce-primera-vez-preventiva-migrana- ninos-adolescentes- \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-El Periódico - Extremadura https:\u002F\u002Fwww.elperiodicoextremadura.com\u002Fsociedad\u002F2026\u002F03\u002F07\u002Fespana-tendra-ano-fremanezumab- primer-dv-127683422.html\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"en\" data-language-name=\"inglés\" data-text=\"We demand that Teva cease all possible activity in Spain. To do otherwise is to collaborate with someone who supports the most atrocious barbarity.\nThe vast majority of their medications can be perfectly substituted by other brands without any impact on people's health, as is even the case with fremanezumab. Therefore, Teva's argument of alleged harm to public health if their medications lose market share is another fallacious argument.\n\nwww.tevanogracias.com ----- tevanogracias@proton.me\nPage 4\nTherefore, we REQUEST:\n\n• The opening of an investigation to clarify whether the Teva company and the media outlets that have participated in this propaganda campaign have committed any legal or administrative infraction. If so, we request that the corresponding sanctions be applied.\n\nThat, in compliance with the recommendations of the International Court of Justice and the United Nations, the Ministry implement legal, administrative, economic, and political measures to limit the activities of this pharmaceutical company in our country due to its proven ties to the State of Israel and its policies of extermination of the Palestinian people.\n\nThank you for listening.\n\nSincerely, State Boycott Campaign "Teva? No, thanks."\n\nContact:\ntevanogracias@proton.me\n_____________________________________________\nLIST OF NEWS ITEMS DETECTED AS PART OF TEVA'S ADVERTISING CAMPAIGN\nThis is an incomplete list, as it is impossible to compile all the news items, since this information has been widely disseminated in all types of forums and media.\nMany of these news items reproduce almost verbatim the news published by the EFE Agency in Catalonia or are based on it. This EFE news report already includes a photo of the Ajovy injection.\nEFE News Agency (Catalonia)\nhttps:\u002F\u002Fefe.com\u002Fcataluna\u002F2026-02-25\u002Fdemuestran-la-eficacia-de-un-farmaco-para-tratar-la-migrana-en-\nla-poblacion-pediatrica\u002F\nSpanish Society of Outpatient Pediatrics and Primary Care (SEPEAP)\nhttps:\u002F\u002Fsepeap.org\u002Ffremanezumab-en-ninos-y-adolescentes-con-migrana-episodica\u002F\nwww.tevanogracias.com ----- tevanogracias@proton.me\nPage 5\nThe La Vanguardia\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.lavanguardia.com\u002Fvida\u002F20260225\u002F11473658\u002Fprimer-tratamiento-\npreventivo-migrana-ninos-adolescentes.amp.html\nTV3\nhttps:\u002F\u002Fwww.3cat.cat\u002F3catinfo\u002Fun-estudi-obre-la-porta-al-primer-tractament-eficac-contra-la-migranya-\nen-infants-i-adolescents\u002Fnoticia\u002F3396463\u002F\nDiario de Sevilla\nhttps:\u002F\u002Fwww.diariodesevilla.es\u002Fsalud\u002Ffremanezumab-medicamento-migrana-pediatrica-llegara-espana-\n2026_0_2006012510.html\nThe Newspaper\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Famp.elperiodico.com\u002Fes\u002Fsanidad\u002F20260225\u002Fprimer-farmaco-migrana-\npediatrica-fremanezumab-inyeccion-espana-vall-hebron-127081489\nDiario Farma\nhttps:\u002F\u002Fdiariofarma.com\u002F2026\u002F02\u002F25\u002Fun-estudio-avala-fremanezumab-para-reducir-los-dias-de-migrana-\nen-ninos-y-jovenes\nIM Medico\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.immedicohospitalario.es\u002Famp\u002F55316\u002Fnuevo-tratamiento-con-\nfremanezumab-demuestra-eficacia-y-seguridad-en-l.html\nThe Huffington Post\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.huffingtonpost.es\u002Flife\u002Fsalud\u002Fpatricia-pozorosich-neurologa-\nsobrefremanezumab-para-migrana-infantil-habia-ningun-tratamiento-preventivo-aprobado-\nf202602.html%3foutputType=amp\nEl Mundo\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Famp.elmundo.es\u002Fciencia-y-\nsalud\u002Fsalud\u002F2026\u002F02\u002F25\u002F699ed17d21efa043168b4575.html\nFaro de Vigo\nhttps:\u002F\u002Fwww.farodevigo.es\u002Fsociedad\u002F2026\u002F02\u002F26\u002Fespana-tendra-ano-primer-farmaco-127290644.html\nHoy Aragon\nhttps:\u002F\u002Fwww.hoyaragon.es\u002Farticulo\u002Fnoticias-espana\u002Fllega-espana-fremanezumab-primer-farmaco-\nmigrana-pediatrica-inyeccion-fin\u002F20260301134316124076.html\nwww.tevanogracias.com ----- tevanogracias@proton.me\nPage 6\nEl Economista\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.eleconomista.es\u002Fsalud-bienestar\u002Fultimas-\nnoticias\u002Famp\u002F13796750\u002Fespana-consigue-el-primer-farmaco-contra-las-migranas-para-ninos-asi-es-el-\nfremanezumab-que-se-administra-con-una-inyeccion-al-mes\n20 minutes\nhttps:\u002F\u002Fwww.20minutos.es\u002Fsalud\u002Ffremanezumab-primer-tratamiento-contra-migranas-\nninos_6939511_0.html\nHeraldo\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.heraldo.es\u002Fnoticias\u002Fsalud\u002F2026\u002F02\u002F26\u002Fadios-migrana-descubren-\nmedicamento-fremanezumab-eficaz-ninos-adolescentes-1897530.amp.html\nLa Razón\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Fwww.larazon.es\u002Fsociedad\u002Fprimer-tratamiento-preventivo-migrana-\npediatrica-llegara-espana-inyeccion-mensual-\nb50m_2026022769a163d59243cc133c668cfd.html%3foutputType=amp\nAntena 3\nhttps:\u002F\u002Fwww.google.com\u002Famp\u002Fs\u002Famp.antena3.com\u002Fnoticias\u002Fsalud\u002Fprimer-tratamiento-migrana-ninos-\nadolescentes-sido-milagro-hija_20260225699f08352f00a0468827a619.html\nTele 5\nhttps:\u002F\u002Fwww.telecinco.es\u002Fnoticias\u002Fsalud\u002F20260225\u002Ffarmaco-reduce-primera-vez-preventiva-migrana-\nninos-adolescentes-\nEl Periódico - Extremadura\nhttps:\u002F\u002Fwww.elperiodicoextremadura.com\u002Fsociedad\u002F2026\u002F03\u002F07\u002Fespana-tendra-ano-fremanezumab-\nprimer-dv-127683422.html\" data-crosslingual-hint=\"es\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","carta-a-la-ministra-de-sanidad-ajovy-teva-ilegal-propaganda-directa-al-consumidor-letter-to-the-minister-of-health-ajovy-teva-illegal-direct-to-consumer-advertising-esp-eng",[15,523,534,535],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1773767836\u002Fn3v5odzojtqkb2umpjaz.jpg","Carta a la ministra de Sanidad, España: Ajovy (Teva) ilegal propaganda directa al consumidor. Letter to the Minister of Health, Spain: Ajovy (Teva) illegal direct-to-consumer advertising. ESP ENG",{"id":549,"title":550,"timestamp":551,"slug":552,"type":7,"subtitle":553,"content":554,"videoUrl":294,"tags":555,"user":13,"link":12,"imageUrl":556},"mncyvd1vjuf0ydx87ob","Teva: one of the most hated pharmaceutical firms in the world. Teva, una repugnante industria farmacéutica ENG ESP",1774863196813,"teva-one-of-the-most-hated-pharmaceutical-firms-in-the-world-teva-una-repugnante-industria-farmaceutica-eng-esp","Teva:  symbol of corruption and disregard for human-centered principles. Teva: símbolo de corrupción y desprecio por los principios humanitarios.","\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003Cbr>\u003Ca href=\"https:\u002F\u002Fparstoday.ir\u002Fen\u002Fnews\u002Fwest_asia-i238706-why_israeli_company_teva_is_becoming_one_of_the_most_hated_pharmaceutical_firms_in_the_world\">\u003Cstrong>Why Israeli company “Teva” is becoming one of the most hated pharmaceutical firms in the world\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Teva Pharmaceutical Industries, the Israeli pharmaceutical giant and the world’s largest producer of generic drugs, has faced a wave of public anger in recent years. The company has increasingly become a symbol of ethical contradictions in the pharmaceutical industry. While Teva presents itself as committed to “global health,” it has faced severe criticism over its business practices. \u003Cstrong>These protests have turned Teva into a symbol of corruption and disregard for human-centered principles.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>The company’s complicity with the crimes of the Israeli regime in the genocide in Gaza and its indifference to humanitarian crises have sparked global outrage against Teva. In particular, many people, doctors, and nurses have boycotted Teva’s drugs, accusing the company of participating in the killing of children in Gaza.\u003C\u002Fp>\n\u003Cp>Over the past years, the genocide in Gaza has reached its peak. The killing of Palestinian women and children by Israeli forces has created an acute emergency. Shortages of medicine and medical personnel, along with the destruction of healthcare facilities, have made life extremely difficult for many Palestinian patients, particularly children, women, and those with chronic illnesses.\u003C\u002Fp>\n\u003Cp>In this context, Teva, as a pharmaceutical company, was expected to remain neutral and support the people and civilians of Gaza. Instead, the company has taken no action to facilitate access to essential medicines. Its statements have focused solely on supporting Israel and meeting domestic needs. This silence and bias, while Palestinian children die due to lack of medicine, have severely tarnished the company’s image.\u003C\u002Fp>\n\u003Cp>In fact, Teva has taken no practical measures to provide the essential medicines needed by Gaza’s residents, even as UN reports and independent human rights organizations have repeatedly emphasized that thousands of children in Gaza urgently require life-saving drugs. The comprehensive Israeli blockade has prevented these critical supplies from reaching those in need.\u003C\u002Fp>\n\u003Cp>Under these circumstances, Teva’s statements focused solely on “supporting Israel” and meeting its domestic needs. This stance not only demonstrated blatant indifference to the deaths of thousands of innocent children but also sent a dangerous message to the international community: that \u003Cstrong>the world’s largest generic drug manufacturer is willing to sacrifice ethical and humanitarian principles for political considerations.\u003C\u002Fstrong> This policy continues, with the Israeli pharmaceutical company persisting in ignoring human-centered values while actively aligning with Israel’s deadly policies.\u003C\u002Fp>\n\u003Cp>Moreover, reports indicate that in recent years, Teva has provided direct support to the Israeli military and participated in aid programs linked to military units. This close association with the army, in violation of the principle of medical neutrality, has severely damaged Teva’s reputation. As a result, the company is now being questioned not only in the political arena but also on ethical grounds.\u003C\u002Fp>\n\u003Cp>Teva’s actions have prompted doctors and medical advisors in various countries, including Ireland, Spain and others, to call for a boycott of the company’s drugs starting in 2025. These sanctions are driven not only by Teva’s collaboration with the Israeli regime’s war policies but also by violations of ethical and professional standards in the pharmaceutical industry. Dozens of Irish doctors and advisors urged the government in August and September 2025 to halt the use of Israeli medicines, even emphasizing that “Israeli drugs” should not be given to sick children.\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Furthermore, staff at the National Orthopaedic Hospital in Dublin (Ireland), Cruces Hospital (Bilbao, Spain), and Vallecas Hospital (Madrid, Spain) officially called for a boycott of Teva medications.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In fact, public healthcare systems in Asturias and Navarre (Spain) have cancelled their contracts with Teva.\u003C\u002Fspan>\u003C\u002Fspan> Mediant \u003Cspan class=\"ryNqvb\">(mental health institution, Twente, Netherlands) boycotts Israeli products for  humanity, compassion, and the protection of mental well-being in Gaza.\u003C\u002Fspan>\u003Cstrong> \u003C\u002Fstrong>Additionally, videos showing Italian doctors discarding Teva medications in trash bins have become a symbol of widespread public anger, highlighting the contradiction in the behavior and statements of a pharmaceutical company that is supposed to save lives but remains silent in the face of a humanitarian disaster.\u003C\u002Fp>\n\u003Cp>Moreover, as an Israeli company, Teva pays a significant portion of its revenue in taxes to the Israeli government. In 2024, the company paid $750 million in taxes, which critics describe as “fueling the war machine.” These payments continue while Israel persists in committing acts widely regarded as genocidal in Gaza.\u003C\u002Fp>\n\u003Cp>This situation has sparked public outrage against Teva. For many, the company is no longer seen merely as a pharmaceutical firm but as a symbol of ruthless profiteering and disregard for human rights. Teva’s silence in the face of the humanitarian catastrophe in Gaza stands as proof of prioritizing profit over human life—a record that history will never forget.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad GeWPTc BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">¿Por qué la empresa israelí Teva se está convirtiendo en una de las farmacéuticas más odiadas del mundo? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva Pharmaceutical Industries, el gigante farmacéutico israelí y el mayor productor mundial de medicamentos genéricos, se ha enfrentado a una ola de indignación pública en los últimos años.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La empresa se ha convertido cada vez más en un símbolo de las contradicciones éticas en la industria farmacéutica.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Si bien Teva se presenta como comprometida con la \"salud global\", ha recibido duras críticas por sus prácticas comerciales.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Estas protestas han convertido a Teva en un símbolo de corrupción y desprecio por los principios humanitarios.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La complicidad de la empresa con los crímenes del régimen israelí en la guerra contra Gaza y su indiferencia ante las crisis humanitarias han desatado la indignación mundial contra Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En particular, muchas personas, médicos y enfermeros han boicoteado los medicamentos de Teva, acusando a la empresa de participar en el asesinato de niños en Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Durante los dos últimos años el genocidio en Gaza ha alcanzado su punto álgido.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El asesinato de mujeres y niños palestinos por las fuerzas israelíes ha creado una grave emergencia.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La escasez de medicamentos y personal médico, junto con la destrucción de instalaciones sanitarias, ha dificultado enormemente la vida de muchos pacientes palestinos, en particular niños, mujeres y personas con enfermedades crónicas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En este contexto, se esperaba que Teva, como empresa farmacéutica, mantuviera la neutralidad y apoyara a la población civil de Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sin embargo, la empresa no ha tomado ninguna medida para facilitar el acceso a medicamentos esenciales.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sus declaraciones se han centrado exclusivamente en apoyar a Israel y satisfacer las necesidades internas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Este silencio y parcialidad, mientras niños palestinos mueren por falta de medicamentos, han dañado gravemente la imagen de la empresa.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> De hecho, Teva no ha tomado ninguna medida práctica para proporcionar los medicamentos esenciales que necesitan los residentes de Gaza, a pesar de que informes de la ONU y organizaciones independientes de derechos humanos han recalcado repetidamente que miles de niños en Gaza necesitan urgentemente medicamentos que les salven la vida.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El bloqueo israelí integral ha impedido que estos suministros vitales lleguen a quienes los necesitan.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> En estas circunstancias, las declaraciones de Teva se centraron exclusivamente en \"apoyar a Israel\" y satisfacer sus necesidades internas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Esta postura no solo demostró una flagrante indiferencia ante la muerte de miles de niños inocentes, sino que también envió un peligroso mensaje a la comunidad internacional: que \u003Cstrong>el mayor fabricante mundial de medicamentos genéricos está dispuesto a sacrificar los principios éticos y humanitarios por consideraciones políticas.\u003C\u002Fstrong>\u003C\u002Fspan>\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esta política persiste, y la farmacéutica israelí continúa ignorando los valores centrados en el ser humano mientras se alinea activamente con las políticas letales de Israel.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Además, informes indican que en los últimos años, Teva ha brindado apoyo directo al ejército israelí y ha participado en programas de ayuda vinculados a unidades militares.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esta estrecha relación con el ejército, en violación del principio de neutralidad médica, ha dañado gravemente la reputación de Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Como resultado, la empresa está siendo cuestionada no solo en el ámbito político, sino también desde el punto de vista ético.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Las acciones de Teva han llevado a médicos y asesores médicos de varios países, incluida Irlanda, España y otros, a pedir un boicot a los medicamentos de la compañía a partir de 2025. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Estas sanciones se deben no solo a la colaboración de Teva con las políticas bélicas del régimen israelí, sino también a las violaciones de las normas éticas y profesionales de la industria farmacéutica.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Decenas de médicos y asesores irlandeses y españoles instaron al gobierno en agosto y septiembre de 2025 a detener el uso de medicamentos israelíes, incluso enfatizando que los medicamentos israelíes no deberían administrarse a niños enfermos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Por otra parte, el personal del Hospital Nacional Ortopédico de Dublín (Irlanda), el del Hospital de Cruces (Bilbao, España) y el del Hospital de Vallecas (Madrid, España) pidieron oficialmente un boicot a los medicamentos de Teva.\u003C\u002Fspan> De hecho, los servicios públicos de Asturias y Navarra (España) han cancelado los contratos con Teva. Mediant (institución de salud mental, Twente, Países Bajos) canceló la compra de medicamentos de Teva por humanidad y compasión y para proteger la salud mental en Gaza. \u003Cspan class=\"ryNqvb\">Además, los videos que muestran a médicos italianos desechando medicamentos de Teva en contenedores de basura se han convertido en un símbolo de la indignación pública generalizada, lo que pone de manifiesto la contradicción entre el comportamiento y las declaraciones de una compañía farmacéutica que supuestamente debe salvar vidas, pero que permanece en silencio ante una catástrofe humanitaria.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Además, como empresa israelí, Teva paga una parte significativa de sus ingresos en impuestos al gobierno de Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En 2024, la empresa pagó 750 millones de dólares en impuestos, lo que, según los críticos, constituye un financiamiento para la maquinaria de guerra.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Estos pagos continúan mientras Israel persiste en cometer actos ampliamente considerados genocidas en Gaza.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esta situación ha desatado la indignación pública contra Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\u003Cstrong>Para muchos, la empresa ya no es vista simplemente como una farmacéutica, sino como un símbolo de lucro despiadado y deshonesto, sin r\u003C\u002Fstrong>e\u003Cspan class=\"HwtZe\" lang=\"es\">speto por los derechos humanos. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"es\">El silencio de Teva ante la catástrofe humanitaria en Gaza es prueba de que prioriza las ganancias sobre la vida humana, un hecho que la historia jamás olvidará.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ef1twd\">\n\u003Cdiv class=\"ZJGYz\">\n\u003Cdiv class=\"cHEsi\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1774863050\u002Fseos0fu5jazekb4zdbsm.png",{"user":13,"tags":558,"link":12,"subtitle":561,"title":562,"content":563,"id":564,"imageUrl":565,"videoUrl":474,"timestamp":566,"slug":567,"type":7},[15,559,560],"Spain","España","Teva and more. Complicity make us criminals. Teva y más. La complicidad nos hace criminales","Spain: health institutional complicity in the ongoing Palestinian Genocide. Gaza: complicidad institucional sanitaria de España. ENG ESP","\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>The Spanish health system: experience regarding Palestine. \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>AUTHORS\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">Fernández Lozano  I, Hamdan Nassar T; Pérez-Palomares s, Álvarez CS, Rodríguez Sendín JJ, Pérez-Fernández M, Gérvas J (corresponding author jjgervas@gmail.com)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cstrong>ABSTRACT\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: small;\">\u003Cspan lang=\"en-US\">\u003Cem>A People’s Tribunal convened in Madrid on 28-29 November 2025 examined allegations of institutional complicity in the ongoing Palestinian Genocide by Spanish institutions. The Tribunal’s section dedicated to the healthcare system highlights the persistent silence of major professional health associations. Material complicity was further identified in the case of TEVA, a leading Israeli pharmaceutical firm. Additionally, Spain’s limited efforts to evacuate wounded Gazans and its endorsement of an Israeli amendment at the 2024 WHO Assembly were criticized. The People’s Tribunal concluded that such systematic silence, action in public-private alliances and inaction constitute complicity with the Palestinian’ Genocide.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\" align=\"justify\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\" align=\"justify\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-style: normal;\">\u003Cstrong>MAIN TEXT\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>Spain\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Spain is an European Union country located in southwestern Europe, whose capital is\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: medium;\"> \u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Madrid. Spain is a high-income country (gross domestic product per capita EUR 30,500) home to just under 50 million people. The population is urbanized and diverse, with markedly differentiated regions and nearly a fifth of residents born outside Spain. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Governance is highly decentralized, with the central government taking on a regulatory and strategic – rather than operational or management – role (e.g. regional health authorities have jurisdiction over operational planning, resource allocation, and purchasing and provision decisions).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Spain has the highest life expectancy in the European Union, at 83.2 years (Madrid Region, 85.2). Indicators for both population health and health system performance are very favourable, thanks in large part to a high-quality, universally accessible health system based on a primary health care model (salaried family physicians working in public health centers with “patients lists”). Healthcare is free, there are no co-payments for healthcare in primary and hospital settings. Co-payments for medications are very low in primary care, and they are free in hospitals. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Spain has low rates of preventable mortality. Cancer screening and vaccination rates are generally above the European Union averages. Spain’s low rates of hospital admissions for congestive heart failure and diabetes reflect some well-functioning primary care and integrated care systems in the country. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">At the same time, public health also faces major challenges, including an ageing population and health-care workforce; the intensifying effects of the climate crisis; the accelerating cost-of-living crisis, especially in relation to housing; the ever-present threat of health emergencies; and persistent inequalities rooted in the social determinants of health. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">While Spain’s health expenditure – at EUR 2,771 per capita – falls below the European Union average, the health system provides universal health coverage. Public expenditure is the primary source of financing, but levels of out-of-pocket spending (21 %, mainly for dental care) are higher than the European Union average (15 %) [1,2].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>People's Tribunal on Complicity with the Palestinian Genocide in the Spanish State\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The People's Tribunal on Complicity with the Palestinian Genocide within the Spanish State is a tribunal of conscience, composed of figures from the legal, academic, cultural and human rights fields, convened by the University Network for Palestine (RUxP) and civil society organizations with the aim of examining, from the perspective of international law and public ethics, the conduct of state and non-state actors in their links to the occupation, apartheid and genocide of the Palestinian people.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The Tribunal does not simply intend to convict-acquit, but above all, to convince Spanish public opinion with evidence demonstrating Spain's involvement, intent, and systematic actions that enable the genocide of the Palestinian people in Gaza, where Spanish actors (or those with criminal responsibility in Spain) are knowingly acting in favor of the Zionist state of Israel and profiting from the genocide itself. It is not Israel that is being tried, but Spain.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The necessary complicity and cooperation has been documented about:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The Spanish government and state institution.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The Armed Banking System, for financing the production of all types of weapons used in Gaza and the West Bank. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Universities, for initiating and maintaining contracts, agreements and research projects, including dual-use technology. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Companies, for continuing to trade with companies based in occupied territories, thereby violating international law. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Health organizations and professional associations, for ignoring all the ethical codes of the profession through active and stubborn silence in the face of barbarism and destruction of life. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Culture, sport and the media, for contributing to the narrative that the state that has most often violated international law is not a criminal state but just one that has the right to normal relations with other states. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The Court met in Madrid on November 28 and 29, 2025. In its verdict (“Madrid Declaration”) on the healthcare system, it declared that:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cstrong>“\u003C\u002Fstrong>\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>In the healthcare sector, it has been documented that, despite repeated statements by healthcare personnel and public health experts about the atrocities committed against the civilian population in Gaza, the vast majority of academies, associations and scientific societies in medicine, nursing and pharmacy, as well as professional health organizations, have remained silent and completely ignored the obligations imposed by their ethicals codes. In material terms, complicity with genocide in the medical field is best exemplified by the pharmaceutical giant TEVA”\u003C\u002Fstrong> [3].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cstrong>Spanish health organizations and associations and Palestine\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">We have studied the complicity and normalization of the genocide of the Palestinian people within the healthcare sector through a joint effort between the University Network for Palestine and Health Workers for Palestine Spain (HW4PS), based on the research conducted by the latter organization since the beginning of the genocide. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The results are summarized in three main areas. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>The first is the symbolic support for the genocide within the healthcare sector\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">; that is, the normalizing silence surrounding the genocide that has prevailed in healthcare associations and professional bodies. This silence is especially scandalous coming from a sector that, regulated by stricter codes of ethics than any other, is focused precisely on contributing to the preservation of human life. It is not a matter of sympathy or solidarity, but an obligation, an ethical matter, since doctors have the obligation to put health, life and human dignity above any political or institutional interests.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>The second area concerns the lack of sufficient action\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\"> in a specific area where the healthcare sector could have made a crucial contribution to alleviate suffering: the transfer and care of sick and wounded people from Gaza to Spain. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>The third point concerns the material relations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\"> within the healthcare ecosystem between Spain and the Zionist state of Israel: commercial relations in the healthcare sector, with an emphasis on the pharmaceutical sector, research projects, the \"transfers of value\" (payments) received by doctors from the Israeli pharmaceutical company Teva, which has a significant presence in the sale of generic drugs in Spain. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Cases of complicity, collaboration, silence, or normalization are contrasted—as is only fair—with cases in which individuals, civil society organizations, or institutions have reacted by denouncing or taking action against the genocide and other violations of international law perpetrated by the Zioniast of Israel.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cem>\u003Cstrong>Spain's support for the Zionist state of Israel at the World Health Assembly.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The bombing of Al-Ahli Al-Arabi Al-Mamadani Hospital in Gaza City on October 17, 2023, in which 471 people were killed and 342 wounded, symbolically marked the moment when the “war” against the Palestinian people (if it ever was one) began to be a genocide. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Since then, the Zionist state has completely disregarded the Fourth Geneva Convention (which establishes the protection, during wars, of hospitals and the particularly vulnerable populations they house: the wounded, the sick, pregnant women, and children) through systematic and deliberate attacks on healthcare infrastructure and professionals, including attacks on ambulances and paramedics, and the murder, imprisonment, and torture of healthcare professionals and their families. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>As a key determinant of social health and an expression of solidarity among people, the healthcare sector is one of the main targets, if not the main target, of any genocidal project.\u003C\u002Fstrong> Today, the Palestinian healthcare system is completely collapsed. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">On a positive note: the commitment and professionalism of Gaza's healthcare workers who, despite unimaginable material constraints, continue to provide essential care for the sick and wounded.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">This brutality has been justified in the eyes of the public, to a large extent, thanks to the support and legitimization that the narrative of the “militarization of hospitals, health centers and ambulances” received on May 31, 2024 at the 77th World Health Assembly of the World Health Organization (WHO), through the introduction by the Zionist state of Israel of an amendment to the final resolution. Verbatim: “Calls for the immediate and unconditional release of all hostages held in Gaza, including children, women and older persons, and condemns the use, by armed groups, of health facilities, including hospitals and ambulances, that endangers the civilian population” [4].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">According to Israeli media: “Israeli amendment surprisingly passes World Health Assembly. The amendment, which calls for release of the hostages and condemns Gazan terror groups for militarizing hospitals, roiled the group of Arab countries. The amendment received a wide range of support—from traditional allies, like the United States, United Kingdom and Germany, to countries that often oppose Israel in international forums, such as Iceland, Spain and the Philippines” [5]. And: “The amendment put forth by the Israeli delegation condemned Hamas’s use of health facilities, including ambulances and hospitals for terror purposes, while putting the civilian population at risk” [6].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>Spain voted, through its representative, the Minister of Health, who was in turn proposed, shortly afterwards (November), by WHO-Europe (in which the Zionist state of Israel participates) as a member of the WHO Executive Board (a position confirmed in May 2025, at the new World Health Assembly of the WHO).\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The 2025 WHO World Health Assembly concluded in June 2025 without any changes being made to Israel's 2024 amendment. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">There is no reliable evidence whatsoever of the alleged militarization of the Gazan healthcare system, nor have the infamous \"tunnels\" ever been discovered under the hospitals. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">As a positive contrast : the complaint filed by the Healthcare Workers with Palestine Platform, Valencia [7], and HW4PS [8].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cem>\u003Cstrong>Silence is complicity, and action is obligation\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Despite repeated statements from healthcare personnel and public health experts regarding the atrocities committed against the civilian population in Gaza, most academies, associations, and scientific societies of medicine, nursing, pharmacy, psychology, dentistry, physiotherapy, etc., and professional health organizations that claim to be committed to social justice have remained silent, at least until well into the genocide, completely ignoring the obligations imposed on them by their ethical codes.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The silence of other professional healthcare associations is striking, even more so than that of medical associations. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">In any case, in general, the statements and declarations have employed the \"art\" of writing about Gaza (and Palestine) without mentioning: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">1) the harm (apartheid and genocide), \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">2) the cause (the Zionist state of Israel), \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">3) the root causes (Zionism and \"Western\" colonialism), \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">and without taking any decisive action, such as suspending ties with Israeli healthcare associations and expelling them from international organizations.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Since the beginning of the current phase of the genocide, Spain has hosted at least three medical congresses with Israeli participation (including the one held in Zaragoza, co-organized with the Zionist state of Israel, as it should have been held in Tel Aviv) [9]. One of these congresses even had the Israeli pharmaceutical giant TEVA as a \"platinum sponsor\"[10]. According to the abstracts of the presentations, no mention is made of the state of health of the Gazan population years after the start of the genocide. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Only from the summer of 2025 onwards did the condemnation of the International Humanitarian Law violations that had been occurring for months become widespread,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">t. As a positive contrast, the early declarations in 2023 and 2024, of FoCAP (Catalan Forum of Primary Care), Spanish Association of Pediatrics, Spanish Society of Family Medicine (SEMFYC), Ethic`s group of the Catalan Society of Family and Community Medicine, Spanish Society of Public Health (SESPAS), etc. and the manifests and actions, in mid-to-late 2025, of Toledo Medical Association, Spanish Medical Association, Spanish Society of Palliative Care, and Medical Associations of Ourense and Barcelona.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cem>\u003Cstrong>Teva \u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cem>\u003Cstrong>and other experiences\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Complicity with genocide in the medical field, in its commercial dimension, finds its prime example in the pharmaceutical giant Teva. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Teva is a corrupt and corrupting company, forced to pay since 2000 more than $10 billion for its criminal activity [11]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Although its main activity is in the field of generic drugs, its flagship branded products are Austedo (deutetrabenazine) for Huntington's disease, chorea, and tardive dyskinesia; Ajovy (fremanezumab) for migraines; Copaxone (glatiramer) for multiple sclerosis; Uzedy (risperidone) for schizophrenia; and Azilect (rasagiline) for Parkinson's disease. In primary care in Spain, its \"best sellers\" are three generic drugs: omeprazole, atorvastatin, and pantoprazole [12]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The Israeli company declared €2,010,412 in \"transfers of value\" (payments to doctors and their associations) in Spain in 2023, according to its transparency report. Nearly one million euros of this amount corresponds to payments to professionals to promote its products [13]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Teva has a major factory in Zaragoza, which also coordinates all aspects of clinical trials for medicines worldwide\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">. TEVA operates 58 manufacturing facilities worldwide. Its plant in Zaragoza accounts the 5,91% of Teva’s global pharmaceutical production and supplies approximately 40% of generic drugs used within the Spanish health system [14]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Teva is directly involved in the genocide in Gaza [15], for example, by funding a project to help in \"the recovery\" of the mental health of Israeli soldiers upon their home return. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Another case illustrating the connection and alliances between Israeli health industries and Spanish health system concerns patient management software. Israeli health technology companies Assuta Medical Centers Ltd and Ewawe Ltd participate in CONNECARE which is an EU-funded consortium that develop integrated systems for chronic patient care in collaboration with European, including Spanish, partners. Likewise, the pan-European DAPHNE initiative for lifestyle monitoring and preventive health is co-led by Spanish firm Treelogic and Israel’s Nevet Ltd (Maccabi Group), together with IBM Israel and other Spanish technology partners. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The complicit silence regarding Palestine ultimately backfires on the \"silent\" o\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">nes, as \"local\" Zionists operate under the cloak of tolerance towards the Zionist state of Israel. The case of Pablo Simón, a rural doctor from Granada and member of HW4PS, clearly demonstrates this. He was anonymously denounced by Zionists seeking to censor dignity, in this case to prevent him from not prescribing Teva medications, which generate profits that sustain apartheid and Palestinian genocide. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The denunciation had no punishment for Pablo Simon , but it illustrates how the Zionist state of Israel poses a danger to humanity [16]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">As a positive contrast , given Teva's role as a source of income for the Zionist state of Israel, apartheid, and the Palestinian genocide, there have been boycott campaigns against Teva products by Yala Nafarroa con Palestina and HW4PS, protests by hospital professionals in the Basque Country and Madrid, and decisions by the public healthcare systems in Asturias and Navarrea to terminate their contracts with Teva.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cem>\u003Cstrong>Sick and wounded\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Spain has also failed in its duty to assist sick and wounded Gazans who required urgent medical attention (around 16,000), carrying out medical evacuations far below its capacity and even that of other countries like Italy. By the end of August 2025, a year and a half after the start of the genocide, only about 45 patients had been transferred to Spain (an about 200 to Italy). As a positive contrast , some autonomous communities have shown themselves to be very receptive in this regard, such as the Basque Country, which has shown willingness to receive more wounded or sick Gazans. Also on a positive note, Spain has not reached the level of ethical degradation of Germany, which has transferred more donkeys (600) than children (two) from Gaza [17].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cem>\u003Cstrong>Import\u002Fexport\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Import\u002Fexport relations for health and pharmaceutical goods and services between Spain and the Zionist state of Israel resulted in a positive balance for Spain of US$1,300,784,000 in 2024 [18].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Regarding patents linked to Spain and Israel, a total of 53 have been identified in the health sector (in 43 cases the inventor is Israeli and the patent holder is Spanish, and in 17 cases the reverse is true) [19]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">R&D&I in the health sector has continued even with the Advisory Opinion of the International Court of Justice (ICJ) in effect. There are 101 health projects with European funding and Spanish and Israeli participation active as of October 1, 2025 (26 projects have a start date after the ICJ's Advisory Opinion of July 2024) [20].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cem>\u003Cstrong>Complicity in the face of war crimes, such as genocide, make us criminals\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Health Workers for Palestine Spain (HW4PS) has systematically and consistently denounced complicity with genocide within the healthcare sector and repeatedly demanded that the government and healthcare organizations\u002Fsocieties fulfill their obligations a\u002F to denounce the amendment approved by the WHO World Health Assembly (2024), b\u002F to evacuate wounded civilians, c\u002F to boycott Teva products, d\u002F to demand respect for human rights in Palestine, including the cessation of destruction and the siege of Gaza (and in the Zionist state of Israel itself, with an emphasis on prisons and detention centers), and d\u002F to sever ties with a state that systematically and openly violates International Law. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">We reiterate that any decision other than to denounce and act promptly against a crime can only be described as complicity. We believe that silence, neutrality, insensitivity, and complicity in the face of war crimes, such as genocide, make us criminals. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.42cm; margin-bottom: 0cm;\">\u003Ca name=\"_Hlk215823769\">\u003C\u002Fa> \u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Assessing the \"Western\" reaction when compared with the rest of the world, Spain's deplorable stance is far better than that of almost every other country in the world, with perhaps a few exceptions as Ireland and the United Kingdom (and South Africa).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">As for the People's Tribunal on Complicity with the Palestinian Genocide within the Spanish State,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">its research activities are ongoing, as it intends to be a permanent structure of denounce of complicity with the Zionist state of Israel’s international crimes, and to serve as an inspiration for similar initiatives elsewhere.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cstrong>AUTHORS AFFILIATION\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: medium;\">Irina Fernández Lozano (lecturer and researcher, department of Sociology II, Universidad Nacional de Educación a Distancia UNED,Spain, University Network for Palestine, RUxP, https:\u002F\u002Forcid.org\u002F0000-0003-4310-5526), Tamer Hamdan Nassar (student of Medicine, Universidad de Valencia, Spain, University Network for Palestine, RUxP); Sara Pérez-Palomares (lecturer and researcher, Department of Physiatry and Nursing of Zaragoza University, Spain University Network for Palestine, RUxP, https:\u002F\u002Forcid.org\u002F0000-0002-5770-5146), César S. Álvarez (professor and researcher, Department of Psychology and Sociology of Zaragoza University, Spain, University Network for Palestine, RUxP, https:\u002F\u002Forcid.org\u002F0000-0001-8274-6217), Juan José Rodríguez Sendín (retired rural doctor, President of the Ethics and Professional Conduct Committee, Toledo Medical Association, Spain ), Mercedes Pérez-Fernández (retired rural doctor, Health Workers for Palestine, Spain \u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Forcid.org\u002F0000-0002-9285-1739\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"color: #085c77;\">\u003Cspan style=\"font-size: medium;\">(https:\u002F\u002Forcid.org\u002F0000-0002-9285-1739)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"font-size: medium;\"> ) and Juan Gérvas (retired rural doctor, Health Workers For Palestine, Spain, \u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Forcid.org\u002F0000-0002-7802-5457\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"color: #085c77;\">\u003Cspan style=\"font-size: medium;\">(https:\u002F\u002Forcid.org\u002F0000-0002-7802-5457) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"font-size: medium;\">)\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>AUTHORS CONTRIBUTION\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">JG, MPF and CSA had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Concept and design: IFL, THN, SPP, CSA \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Drafting of the manuscript: JG, CSA, SPP, THN, IFL\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Critical review of the manuscript for important intellectual content: All authors. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-right: 0.25cm; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Supervision: JJRS.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">\u003Cstrong>DISCLOCURE OF CONFLICT OF INTEREST \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">None declared\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan lang=\"en-US\">\u003Cstrong>FUNDING:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan lang=\"en-US\"> None\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 150%; margin-top: 0.21cm; margin-bottom: 0cm;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cstrong>NOTE\u003C\u002Fstrong>: This text is the final version of a paper that was submitted for possible publication to the Indian Journal of Medical Ethics on December 15, 2025. After acknowledging receipt, the journal's next communication was on March 27, 2026: \"Decision: Decline submission. Your manuscript was screened internally and the final comments for you are: While the subject you have chosen is important, the manuscript falls short of doing full justice to the subject at hand. In light of the above comments, we regret we are unable to consider it for publication\".\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm; page-break-before: always;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan lang=\"en-US\">\u003Cstrong>References\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000000;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan lang=\"en-US\">: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Col>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">European Observatory on Health Systems and Policies, Spain: Country Health Profile 2023, State of Health in the EU, OECD Publishing, Paris\u002FEuropean Observatory on Health Systems and Policies, Brussels [Internet]. 2023 [cited 2025 Dec 5]. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Feurohealthobservatory.who.int\u002Fpublications\u002Fm\u002Fspain-country-health-profile-2023\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Feurohealthobservatory.who.int\u002Fpublications\u002Fm\u002Fspain-country-health-profile-2023\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">WHO Regional Office for Europe; 2025 [Internet]. 2025 [cited 2025 Dec 5]. WHO Country Cooperation Strategy, Spain 2024–2030. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Firis.who.int\u002Fserver\u002Fapi\u002Fcore\u002Fbitstreams\u002F874e2524-febf-4628-a799-3b6e39301dbc\u002Fcontent\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Firis.who.int\u002Fserver\u002Fapi\u002Fcore\u002Fbitstreams\u002F874e2524-febf-4628-a799-3b6e39301dbc\u002Fcontent\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Abdulhadi R, Gómez L, Sourani R. [cited 2025 Dec 5]. Verdict. People’s Tribunal on Complicity with the Palestinian Genocide in the Spanish State. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fsentencia-tribunal-de-los-pueblos-sobre-la-complicidad-del-estado-espanol-con-el-genocidio-en-palestina-tpcgp-25-verdict-people-s-tribunal-on-complicity-with-the-palestinian-genocide-in-the-spanish-state-esp-eng\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fsentencia-tribunal-de-los-pueblos-sobre-la-complicidad-del-estado-espanol-con-el-genocidio-en-palestina-tpcgp-25-verdict-people-s-tribunal-on-complicity-with-the-palestinian-genocide-in-the-spanish-state-esp-eng\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp lang=\"en-US\" style=\"text-indent: -0.63cm; line-height: 150%; margin-left: 1.26cm; margin-bottom: 0cm;\"> \u003C\u002Fp>\n\u003Col start=\"4\">\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">SEVENTY-SEVENTH WORLD HEALTH ASSEMBLY [Internet]. 2024 [cited 2025 Dec 5]. Health conditions in the occupied Palestinian territory, including east Jerusalem, and in the occupied Syrian Golan. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fapps.who.int\u002Fgb\u002Febwha\u002Fpdf_files\u002FWHA77\u002FA77_BCONF3-en.pdf\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fapps.who.int\u002Fgb\u002Febwha\u002Fpdf_files\u002FWHA77\u002FA77_BCONF3-en.pdf\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Mike Wagenheim. Israeli amendment surprisingly passes World Health Assembly. Jewish News Syndicate (JNS). Jewis News Syndicate [Internet]. 2024 May 31 [cited 2025 Dec 6]; Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.jns.org\u002Fisraeli-amendment-surprisingly-passes-world-health-assembly\u002F\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fwww.jns.org\u002Fisraeli-amendment-surprisingly-passes-world-health-assembly\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Gay I. Israeli delegation introduces amendment to WHO resolution, calls to free hostages. The Jerusalem Post [Internet]. 2024 May 31 [cited 2025 Dec 5]; Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.jpost.com\u002Fisrael-hamas-war\u002Farticle-804474\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fwww.jpost.com\u002Fisrael-hamas-war\u002Farticle-804474\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Rebelion.org [Internet]. 2024 [cited 2025 Dec 5]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">Organismo internacional -responsable de los sistemas sanitarios en el mundo- en manos del sionismo. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Frebelion.org\u002Forganismo-internacional-responsable-de-los-sistemas-sanitarios-en-el-mundo-en-manos-del-sionismo\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Frebelion.org\u002Forganismo-internacional-responsable-de-los-sistemas-sanitarios-en-el-mundo-en-manos-del-sionismo\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Health Workers for Palestine-Spain [Internet]. 2025 [cited 2025 Dec 5]. WHO approval. Destruction of the Palestinian health system ESP . Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Faprobacion-oms-destruccion-del-sistema-sanitario-palestino-who-approval-destruction-of-the-palestinian-health-system-esp-eng\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Faprobacion-oms-destruccion-del-sistema-sanitario-palestino-who-approval-destruction-of-the-palestinian-health-system-esp-eng\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Transoforming sickcare to health care. Available from: Medicine 2044. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fthefuturehealthcare.org\u002F\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fthefuturehealthcare.org\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">[Internet]. 2025 [cited 2025 Dec 5].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">European Psychiatric Association - EPA [Internet]. 2025 [cited 2025 Dec 5]. 33rd EUROPEAN CONGRESS of PSYCHIATRY. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002F2025.epa-congress.org\u002Fsponsorship-and-exhibition\u002Fconfirmed-sponsors-exhibitors\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002F2025.epa-congress.org\u002Fsponsorship-and-exhibition\u002Fconfirmed-sponsors-exhibitors\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">2025 Good Jobs First [Internet]. [cited 2025 Dec 5]. Violation Tracker Current Parent Company Summary. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fviolationtracker.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">Nogracias.org. 2025 [cited 2025 Dec 5]. Teva en España. Un gigante farmacéutico cuyas ganancias dañan la salud de la población de Palestina. Por Profesionales de la sanidad por Palestina, España (HealthWorkers4PalestineSpain). Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">Pérez Bozal P. Golpe a la farmaceútica israelí Teva: El boicot sanitario tumba sus interes en España. El cierre digital [Internet]. 2025 Jun 17 [cited 2025 Dec 5]; Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Felcierredigital.com\u002Finvestigacion\u002Fgolpe-farmaceutica-israeli-teva-boicot-sanitario-tumba-intereses-espana\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">https:\u002F\u002Felcierredigital.com\u002Finvestigacion\u002Fgolpe-farmaceutica-israeli-teva-boicot-sanitario-tumba-intereses-espana\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Arahealth Aragon Health Cluster [Internet]. [cited 2025 Dec 6]. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Farahealth.com\u002Fasociados\u002Fteva\u002F\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Farahealth.com\u002Fasociados\u002Fteva\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Sørensen I. Letter to UN Global Compact for removal of Teva Pharmaceuticals from list of participants Ms. Ingvild Sørensen, Lead for UN Global Compact. [Internet]. 2025 [cited 2025 Dec 5]. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Factionnetwork.org\u002Fpetitions\u002Fletter-to-un-global-compact-for-removal-of-teva-pharmaceuticals-from-list-of-participants\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Factionnetwork.org\u002Fpetitions\u002Fletter-to-un-global-compact-for-removal-of-teva-pharmaceuticals-from-list-of-participants\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">Campaña de apoyo al médico Pablo Simón, señalado por sus acciones contra el genocidio en Gaza. El independiente de granada [Internet]. 2025 Nov 12 [cited 2025 Dec 5]; Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.elindependientedegranada.es\u002Fimplicados\u002Fcampana-apoyo-medico-pablo-simon-senalado-acciones-genocidio-gaza\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">https:\u002F\u002Fwww.elindependientedegranada.es\u002Fimplicados\u002Fcampana-apoyo-medico-pablo-simon-senalado-acciones-genocidio-gaza\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">Wystrychowski L. Germany’s decision to take in donkeys from Gaza for treatment – but not children – has sparked outrage. Middle East Monitor (MEMO) [Internet]. [cited 2025 Dec 5]; Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.middleeastmonitor.com\u002F20251118-germanys-decision-to-take-in-donkeys-from-gaza-for-treatment-but-not-children-has-sparked-outrage\u002F\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fwww.middleeastmonitor.com\u002F20251118-germanys-decision-to-take-in-donkeys-from-gaza-for-treatment-but-not-children-has-sparked-outrage\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">The official website of the European Union https:\u002F\u002Fec.europa.eu\u002F [Internet]. 2025 [cited 2025 Dec 5]. International trade in medicinal and pharmaceutical products. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fec.europa.eu\u002Feurostat\u002Fstatistics-explained\u002Findex.php?title=International_trade_in_medicinal_and_pharmaceutical_products\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fec.europa.eu\u002Feurostat\u002Fstatistics-explained\u002Findex.php?title=International_trade_in_medicinal_and_pharmaceutical_products\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">OEPM [Internet]. 2025 [cited 2025 Dec 6]. Oficina Española de Patentes y Marcas (2025). \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">INVENES data base. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fconsultas2.oepm.es\u002FInvenesWeb\u002Ffaces\u002FbusquedaInternet.jsp\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fconsultas2.oepm.es\u002FInvenesWeb\u002Ffaces\u002FbusquedaInternet.jsp\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli>\n\u003Cp style=\"line-height: 150%; margin-bottom: 0cm;\">\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">health projects with European funding and Spanish and Israeli [Internet]. [cited 2025 Dec 5]. Available from: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fcordis.europa.eu\u002Fsearch?q='Spain'%20AND%20'israel'&p=1&num=10&srt=Relevance:decreasing\">\u003Cspan style=\"font-family: Comfortaa, cursive;\">\u003Cspan style=\"font-size: medium;\">\u003Cspan lang=\"en-US\">https:\u002F\u002Fcordis.europa.eu\u002Fsearch?q=%27Spain%27%20AND%20%27israel%27&p=1&num=10&srt=Relevance:decreasing\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad GeWPTc BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">El sistema sanitario español: experiencia en relación con Palestina.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">AUTORES: Fernández Lozano I, Hamdan Nassar T, Pérez-Palomares S, Álvarez CS, Rodríguez Sendín JJ, Pérez-Fernández M, Gérvas J (autor para correspondencia: jjgervas@gmail.com) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">RESUMEN \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Un Tribunal Popular, convocado en Madrid los días 28 y 29 de noviembre de 2025, examinó las acusaciones de complicidad institucional de instituciones españolas en el genocidio palestino.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La sección del Tribunal dedicada al sistema sanitario puso de relieve el persistente silencio de las principales asociaciones profesionales de salud.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Se identificó además complicidad material en el caso de TEVA, una importante farmacéutica israelí.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Asimismo, se criticaron los limitados esfuerzos de España para evacuar a los heridos de Gaza y su respaldo a una enmienda israelí en la Asamblea General de la OMS de 2024. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El Tribunal Popular concluyó que dicho silencio sistemático, la actuación en alianzas público-privadas y la inacción constituyen complicidad con el genocidio palestino.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">TEXTO PRINCIPAL \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">España \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">España es un país de la Unión Europea situado en el suroeste de Europa, cuya capital es Madrid.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Es un país de altos ingresos (producto interior bruto per cápita de 30.500 euros) con una población de casi 50 millones de habitantes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Su población es urbanizada y diversa, con regiones marcadamente diferenciadas y casi una quinta parte de sus residentes nacidos fuera de España.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La gobernanza está altamente descentralizada, con el gobierno central desempeñando un papel regulador y estratégico, más que operativo o de gestión (por ejemplo, las autoridades sanitarias regionales tienen competencia sobre la planificación operativa, la asignación de recursos y las decisiones de compra y prestación de servicios).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">España tiene la mayor esperanza de vida de la Unión Europea, con 83,2 años (la Comunidad de Madrid, 85,2).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Los indicadores de salud pública y del rendimiento del sistema sanitario son muy favorables, gracias en gran medida a un sistema sanitario de alta calidad y universalmente accesible, basado en un modelo de atención primaria (médicos de familia asalariados que trabajan en centros de salud públicos con listas de pacientes).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La asistencia sanitaria es gratuita y no existen copagos en atención primaria ni hospitalaria.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Los copagos por medicamentos son muy bajos en atención primaria y gratuitos en hospitales.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> España presenta bajas tasas de mortalidad prevenible.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Las tasas de cribado oncológico y vacunación se sitúan generalmente por encima de la media de la Unión Europea.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Las bajas tasas de hospitalización por insuficiencia cardíaca congestiva y diabetes en España reflejan el buen funcionamiento de algunos sistemas de atención primaria y asistencial integrados en el país.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Al mismo tiempo, la salud pública también se enfrenta a importantes retos, como el envejecimiento de la población y del personal sanitario;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">los efectos cada vez más graves de la crisis climática;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">la creciente crisis del coste de la vida, especialmente en lo que respecta a la vivienda;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">la amenaza constante de emergencias sanitarias;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">y las persistentes desigualdades arraigadas en los determinantes sociales de la salud.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Si bien el gasto sanitario de España —2771 euros per cápita— se sitúa por debajo de la media de la Unión Europea, el sistema sanitario ofrece cobertura sanitaria universal.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El gasto público es la principal fuente de financiación, pero los niveles de gasto de bolsillo (21 %, principalmente en odontología) son superiores a la media de la Unión Europea (15 %) [1,2].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Tribunal Popular sobre la Complicidad con el Genocidio Palestino en el Estado Español \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El Tribunal Popular sobre la Complicidad con el Genocidio Palestino en el Estado Español es un tribunal de conciencia, integrado por figuras del ámbito jurídico, académico, cultural y de derechos humanos, convocado por la Red Universitaria para Palestina (RUxP) y organizaciones de la sociedad civil con el objetivo de examinar, desde la perspectiva del derecho internacional y la ética pública, la conducta de actores estatales y no estatales en su relación con la ocupación, el apartheid y el genocidio del pueblo palestino.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El Tribunal no se limita a condenar o absolver, sino que, sobre todo, busca convencer a la opinión pública española con pruebas que demuestren la implicación, la intención y las acciones sistemáticas de España que permiten el genocidio del pueblo palestino en Gaza, donde actores españoles (o aquellos con responsabilidad penal en España) actúan a sabiendas en favor del Estado sionista de Israel y se benefician del propio genocidio.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">No se juzga a Israel, sino a España.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Se ha documentado la complicidad y cooperación necesarias en relación con: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• El gobierno y las instituciones estatales españolas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• El Sistema Bancario Armado, por financiar la producción de todo tipo de armas utilizadas en Gaza y Cisjordania.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Universidades, por iniciar y mantener contratos, acuerdos y proyectos de investigación, incluyendo tecnología de doble uso.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Empresas, por continuar comerciando con empresas con sede en territorios ocupados, violando así el derecho internacional.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Organizaciones de salud y asociaciones profesionales, por ignorar todos los códigos éticos de la profesión mediante un silencio activo y obstinado ante la barbarie y la destrucción de vidas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">• Cultura, deporte y medios de comunicación, \u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad GeWPTc BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">contribuyendo a la narrativa de que el Estado que con mayor frecuencia ha violado el derecho internacional no es un Estado criminal, sino simplemente uno que tiene derecho a mantener relaciones normales con otros Estados.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La Corte se reunió en Madrid los días 28 y 29 de noviembre de 2025. En su veredicto («Declaración de Madrid») sobre el sistema sanitario, declaró que: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">«En el sector sanitario, se ha documentado que, a pesar de las reiteradas declaraciones del personal sanitario y de expertos en salud pública sobre las atrocidades cometidas contra la población civil en Gaza, la gran mayoría de las academias, asociaciones y sociedades científicas de medicina, enfermería y farmacia, así como las organizaciones profesionales de la salud, han guardado silencio e ignorado por completo las obligaciones impuestas por sus códigos éticos. En términos materiales, la complicidad con el genocidio en el ámbito médico se ejemplifica mejor con el gigante farmacéutico TEVA» [3].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Organizaciones y asociaciones sanitarias españolas y Palestina \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Hemos estudiado la complicidad y la normalización del genocidio del pueblo palestino en el sector sanitario mediante un esfuerzo conjunto entre la Red Universitaria para Palestina y Trabajadores Sanitarios por Palestina España (Health Workers For Palestine, Spain HW4PS), basándonos en la investigación realizada por esta última organización desde el inicio del genocidio.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Los resultados se resumen en tres áreas principales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>La primera es el apoyo simbólico al genocidio dentro del sector sanitario;\u003C\u002Fstrong>\u003C\u002Fspan>\u003Cstrong> \u003Cspan class=\"ryNqvb\">es decir, el silencio normalizador que ha prevalecido en las asociaciones y organismos profesionales sanitarios.\u003C\u002Fspan> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Este silencio resulta especialmente escandaloso viniendo de un sector que, regulado por códigos éticos más estrictos que ningún otro, se centra precisamente en contribuir a la preservación de la vida humana.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">No se trata de simpatía ni solidaridad, sino de una obligación, una cuestión ética, ya que los médicos tienen la obligación de anteponer la salud, la vida y la dignidad humana a cualquier interés político o institucional.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">La segunda área se refiere a la falta de actuación suficiente en un ámbito específico donde el sector sanitario podría haber contribuido de manera crucial a aliviar el sufrimiento: el traslado y la atención de personas enfermas y heridas de Gaza a España.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>El tercer punto se refiere a las relaciones materiales dentro del ecosistema sanitario entre España y el Estado sionista de Israel\u003C\u002Fstrong>: relaciones comerciales en el sector sanitario, con especial énfasis en el sector farmacéutico, proyectos de investigación y las \"transferencias de valor\" (pagos) recibidas por los médicos de la farmacéutica israelí Teva, que tiene una presencia significativa en la venta de medicamentos genéricos en España.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Se contrastan, como es justo, los casos de complicidad, colaboración, silencio o normalización con aquellos en los que individuos, organizaciones de la sociedad civil o instituciones han reaccionado denunciando o actuando contra el genocidio y otras violaciones del derecho internacional perpetradas por el Estado sionista de Israel.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">El apoyo de España al Estado sionista de Israel en la Asamblea Mundial de la Salud.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El bombardeo del Hospital Al-Ahli Al-Arabi Al-Mamadani en la ciudad de Gaza el 17 de octubre de 2023, en el que murieron 471 personas y 342 resultaron heridas, marcó simbólicamente el momento en que la “guerra” contra el pueblo palestino (si es que alguna vez lo fue) comenzó a convertirse en un genocidio.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Desde entonces, el Estado sionista ha ignorado por completo el Cuarto Convenio de Ginebra (que establece la protección, durante las guerras, de los hospitales y de las poblaciones especialmente vulnerables que albergan: los heridos, los enfermos, las mujeres embarazadas y los niños) mediante ataques sistemáticos y deliberados contra la infraestructura y el personal sanitario, incluyendo ataques contra ambulancias y paramédicos, así como el asesinato, el encarcelamiento y la tortura de profesionales sanitarios y sus familias.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Como determinante clave de la salud social y expresión de solidaridad entre las personas, el sector sanitario es uno de los principales objetivos, si no el principal, de cualquier proyecto genocida.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Hoy, el sistema sanitario palestino está completamente colapsado.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En un aspecto positivo: el compromiso y la profesionalidad del personal sanitario de Gaza, que, a pesar de las inimaginables limitaciones materiales, continúa prestando atención esencial a los enfermos y heridos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esta brutalidad se ha justificado ante la opinión pública, en gran medida, gracias al apoyo y la legitimación que recibió el discurso de la “militarización de hospitales, centros de salud y ambulancias” el 31 de mayo de 2024 en la 77.ª Asamblea Mundial de la Salud de la Organización Mundial de la Salud (OMS), mediante la presentación por parte del Estado sionista de Israel de una enmienda a la resolución final.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Textualmente: “Exige la liberación inmediata e incondicional de todos los rehenes retenidos en Gaza, incluidos niños, mujeres y ancianos, y condena el uso, por parte de grupos armados, de instalaciones sanitarias, incluidos hospitales y ambulancias, que pone en peligro a la población civil” [4].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según los medios israelíes: “Enmienda israelí se aprueba sorpresivamente en la Asamblea Mundial de la Salud. La enmienda, exige la liberación de los rehenes, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">y la condena a los grupos terroristas de Gaza por militarizar los hospitales, lo que provocó la indignación del grupo de países árabes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La enmienda recibió un amplio respaldo, desde aliados tradicionales como Estados Unidos, Reino Unido y Alemania, hasta países que suelen oponerse a Israel en foros internacionales, como Islandia, España y Filipinas [5]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Además: «La enmienda presentada por la delegación israelí condenaba el uso que hacía Hamás de las instalaciones sanitarias, incluidas ambulancias y hospitales, con fines terroristas, poniendo en riesgo a la población civil» [6]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">España votó, a través de su representante, la Ministra de Sanidad, quien, poco después (en noviembre), fue propuesta por la OMS Europa (en la que participa el Estado sionista de Israel) como miembro del Consejo Ejecutivo de la OMS (cargo que se confirmó en mayo de 2025, en la nueva Asamblea Mundial de la Salud de la OMS). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La Asamblea Mundial de la Salud de la OMS de 2025 concluyó en junio de ese mismo año sin que se introdujeran cambios en la enmienda israelí de 2024. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">No existe ninguna prueba fiable de la supuesta militarización del sistema sanitario de Gaza, ni se han descubierto jamás los infames «túneles» bajo los hospitales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Como aspecto positivo y c\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\">ontraste: la denuncia presentada por la Plataforma de Trabajadores de la Salud con Palestina, Valencia [7], y HW4PS [8].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">El silencio es complicidad, la acción es obligación.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A pesar de las reiteradas declaraciones del personal sanitario y los expertos en salud pública sobre las atrocidades cometidas contra la población civil en Gaza, la mayoría de las academias, asociaciones y sociedades científicas de medicina, enfermería, farmacia, psicología, odontología, fisioterapia, etc., y las organizaciones profesionales de la salud que afirman estar comprometidas con la justicia social han guardado silencio, al menos hasta bien entrado el genocidio, ignorando por completo las obligaciones que les imponen sus códigos éticos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El silencio de otras asociaciones profesionales de la salud es sorprendente, incluso más que el de las asociaciones médicas.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">\u003Cem>En cualquier caso, en general, las declaraciones han recurrido al «arte» de escribir sobre Gaza (y Palestina) sin mencionar: \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">1) el daño (apartheid y genocidio), \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">2) la causa (el Estado sionista de Israel), \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">3) las causas profundas (sionismo y colonialismo «occidental»), y \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">sin tomar ninguna medida decisiva, como\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">suspendiendo los vínculos con las asociaciones sanitarias israelíes y expulsándolas de las organizaciones internacionales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Desde el inicio de la fase actual del genocidio, España ha acogido al menos tres congresos médicos con participación israelí (incluido el celebrado en Zaragoza, coorganizado con el Estado sionista de Israel, cuando debería haberse celebrado en Tel Aviv) [9].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Uno de estos congresos incluso contó con el gigante farmacéutico israelí TEVA como «patrocinador platino» [10].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Según los resúmenes de las presentaciones, no se menciona el estado de salud de la población de Gaza años después del inicio del genocidio.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Solo a partir del verano de 2025 se generalizó la condena de las violaciones del Derecho Internacional Humanitario que se habían estado produciendo durante meses.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Como contraste positivo, las primeras declaraciones de 2023 y 2024 del FoCAP (Foro Catalán de Atención Primaria), la Asociación Española de Pediatría, la Sociedad Española de Medicina de Familia (SEMFYC), el grupo de ética de la Sociedad Catalana de Medicina de Familia y Comunitaria,\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sociedad Española de Salud Pública (SESPAS), etc., y los manifiestos y acciones, a mediados y finales de 2025, del Colegio Médico de Toledo, la Organización Médica Colegial, la Sociedad Española de Cuidados Paliativos y los Colegios Médicos de Ourense y Barcelona.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva y otras experiencias \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La complicidad con el genocidio en el ámbito médico, en su dimensión comercial, encuentra su principal ejemplo en el gigante farmacéutico Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva es una empresa corrupta y corruptora, obligada desde el año 2000 a pagar más de 10.000 millones de dólares por su actividad delictiva [11].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Aunque su actividad principal se centra en los medicamentos genéricos, sus productos estrella de marca son Austedo (deutetrabenazina) para la enfermedad de Huntington, la corea y la discinesia tardía;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ajovy (fremanezumab) para las migrañas;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Copaxone (glatiramero) para la esclerosis múltiple;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Uzedy (risperidona) para la esquizofrenia;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">y Azilect (rasagilina) para la enfermedad de Parkinson.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En atención primaria\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En España, sus productos más vendidos son tres medicamentos genéricos: omeprazol, atorvastatina y pantoprazol [12].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Según su informe de transparencia, la empresa israelí declaró 2.010.412 € en «transferencias de valor» (pagos a médicos y sus asociaciones) en España en 2023. Casi un millón de euros de esta cantidad corresponde a pagos a profesionales para la promoción de sus productos [13].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva cuenta con una importante fábrica en Zaragoza, que también coordina todos los aspectos de los ensayos clínicos de medicamentos a nivel mundial.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">TEVA opera 58 plantas de fabricación en todo el mundo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Su planta en Zaragoza representa el 5,91 % de la producción farmacéutica global de Teva y suministra aproximadamente el 40 % de los medicamentos genéricos utilizados en el sistema sanitario español [14].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva participa directamente en el genocidio en Gaza\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad GeWPTc BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">[15]; por ejemplo, se financia un proyecto para ayudar en la recuperación de la salud mental de los soldados israelíes a su regreso a casa.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Otro caso que ilustra la conexión y las alianzas entre las industrias sanitarias israelíes y el sistema sanitario español se refiere al software de gestión de pacientes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Las empresas israelíes de tecnología sanitaria Assuta Medical Centers Ltd y Ewawe Ltd participan en CONNECARE, un consorcio financiado por la UE que desarrolla sistemas integrados para la atención de pacientes crónicos en colaboración con socios europeos, incluidos los españoles.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Asimismo, la iniciativa paneuropea DAPHNE para el seguimiento del estilo de vida y la salud preventiva está codirigida por la empresa española Treelogic y la israelí Nevet Ltd (Grupo Maccabi), junto con IBM Israel y otros socios tecnológicos españoles.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El silencio cómplice respecto a Palestina acaba volviéndose en contra de los «silenciados», ya que los sionistas «locales» operan bajo el manto de la tolerancia hacia el Estado sionista de Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El caso de Pablo Simón, médico rural de Granada y miembro de HW4PS, lo demuestra claramente.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Fue denunciado anónimamente por sionistas que buscaban censurar la dignidad, en este caso para impedirle recetar medicamentos de Teva, cuyas ganancias financian el apartheid y el genocidio palestino.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La denuncia no tuvo consecuencias para Pablo Simón, pero ilustra cómo el Estado sionista de Israel representa un peligro para la humanidad [16].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Como contraste positivo, dado el papel de Teva como fuente de ingresos para el Estado sionista de Israel, el apartheid y el genocidio palestino, se han llevado a cabo campañas de boicot contra los productos Teva por parte de Yala Nafarroa con Palestina y HW4PS, protestas de profesionales hospitalarios en el País Vasco y Madrid, y decisiones de los sistemas públicos de salud de Asturias y Navarrea de rescindir sus contratos con Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Enfermos y heridos \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">España también ha incumplido su deber de asistir a los gazatíes enfermos y heridos que requerían atención médica urgente (alrededor de 16.000), realizando evacuaciones médicas muy por debajo de su capacidad e incluso de la de otros países como Italia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A finales de agosto de 2025, un año y medio después del inicio del genocidio, solo unos 45 pacientes habían sido trasladados a España (y unos 200 a Italia).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Como contraste positivo, algunas comunidades autónomas se han mostrado muy receptivas en este sentido, como el País Vasco, que ha manifestado su disposición a acoger a más gazatíes heridos o enfermos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Asimismo, cabe destacar que España no ha alcanzado el nivel de degradación ética de Alemania, que ha trasladado más burros (600) que niños (dos) desde Gaza [17].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Importación\u002Fexportación \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Las relaciones de importación y exportación de bienes y servicios sanitarios y farmacéuticos entre España y el Estado sionista de Israel arrojaron un saldo positivo para España de 1.300.784.000 dólares estadounidenses en 2024 [18].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En cuanto a las patentes vinculadas a España e Israel, se han identificado un total de 53 en el sector sanitario (en 43 casos el inventor es israelí y el titular de la patente es español, y en 17 casos ocurre lo contrario) [19].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">La I+D+i en el sector sanitario ha continuado incluso con la Opinión Consultiva de la Corte Internacional de Justicia (CIJ) en vigor.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">A fecha de 1 de octubre de 2025, existen 101 proyectos sanitarios con financiación europea y participación española e israelí en activo (26 proyectos tienen fecha de inicio posterior a la Opinión Consultiva de la CIJ de julio de 2024) [20].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>La complicidad ante crímenes de guerra, como el genocidio, nos convierte en criminales.\u003C\u002Fstrong> Trabajadores de la Salud por Palestina España (HW4PS) ha denunciado sistemática y consistentemente la complicidad con el genocidio dentro del sector sanitario y ha exigido reiteradamente al gobierno y a las organizaciones\u002Fsociedades sanitarias que cumplan con sus obligaciones: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">a) denunciar la enmienda aprobada por la Asamblea Mundial de la Salud de la OMS (2024), \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">b) evacuar a los civiles heridos, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">c) boicotear los productos de Teva, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">d) exigir el respeto de los derechos humanos en Palestina, incluyendo el cese de la destrucción y el bloqueo de Gaza (y en el propio Estado sionista de Israel, con especial énfasis en las cárceles y centros de detención), y \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">e) romper relaciones con un Estado que viola sistemática y abiertamente el Derecho Internacional.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Reiteramos que cualquier decisión que no sea denunciar y actuar con prontitud contra un crimen solo puede calificarse de complicidad.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cem>\u003Cspan class=\"ryNqvb\">Creemos que el silencio, la neutralidad, la insensibilidad y la complicidad ante crímenes de guerra, como el genocidio, nos convierten en criminales.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Comparando la reacción occidental con la del resto del mundo, la postura de España, por deplorable que parezca, es mucho mejor que la de casi todos los demás países, con algunas excepciones como Irlanda, el Reino Unido y Sudáfrica.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En cuanto al Tribunal Popular sobre la Complicidad con el Genocidio Palestino en el Estado español, sus actividades de investigación continúan, con la intención de convertirse en una estructura permanente para denunciar la complicidad con los crímenes internacionales del Estado sionista de Israel y servir de inspiración para iniciativas similares en otros lugares.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>AFILIACIÓN DE LOS AUTORES\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Irina Fe\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">rnández Lozano (docente e investigador, departamento de Sociología II, Universidad Nacional de Educación a Distancia UNED, España, Red Universitaria por Palestina, RUxP, https:\u002F\u002Forcid.org\u002F0000-0003-4310-5526), ​​Tamer Hamdan Nassar (estudiante de Medicina, Universidad de Valencia, España, Red Universitaria por Palestina, RUxP);\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sara Pérez-Palomares (profesora e investigadora, Departamento de Fisiatría y Enfermería de la Universidad de Zaragoza, España Red Universitaria para Palestina, RUxP, https:\u002F\u002Forcid.org\u002F0000-0002-5770-5146), César S. Álvarez (profesor e investigador, Departamento de Psicología y Sociología de la Universidad de Zaragoza, España, Red Universitaria para Palestina, RUxP, https:\u002F\u002Forcid.org\u002F0000-0001-8274-6217), Juan José Rodríguez Sendín (médico rural jubilado, Presidente del Comité de Ética y Conducta Profesional, Colegio Médico de Toledo, España), Mercedes Pérez-Fernández (médica rural jubilada, Trabajadores de la Salud para Palestina, España (https:\u002F\u002Forcid.org\u002F0000-0002-9285-1739)) y Juan Gérvas (médico rural jubilado, Trabajadores de la Salud para Palestina, España,\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">(https:\u002F\u002Forcid.org\u002F0000-0002-7802-5457) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>CONTRIBUCIÓN DE LOS AUTORES\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">JG, MPF y CSA tuvieron acceso completo a todos los datos del estudio y son responsables de la integridad y la precisión del análisis de los datos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Concepto y diseño: IFL, THN, SPP, CSA Redacción del manuscrito: JG, CSA, SPP, THN, IFL \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Revisión crítica del manuscrito para contenido intelectual importante: Todos los autores.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Supervisión: JJRS.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">DECLARACIÓN DE CONFLICTO DE INTERESES: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Ninguno declarado \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">FINANCIACIÓN: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Ninguna \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>NOTA\u003C\u002Fstrong>: Este texto es la versión final de un artículo que se envió para su posible publicación al Indian Journal of Medical Ethics el 15 de diciembre de 2025. Tras la confirmación de recepción, la siguiente comunicación de la revista fue el 27 de marzo de 2026: \"Decisión: Rechazar la publicación.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Su manuscrito fue evaluado internamente y los comentarios finales son los siguientes: Si bien el tema elegido es importante, el manuscrito no le hace justicia.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">En vista de los comentarios anteriores, lamentamos no poder considerarlo para su publicación\".\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Referencias: \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">1. Observatorio Europeo de Sistemas y Políticas de Salud, España: Perfil de Salud del País 2023, Estado de la Salud en la UE, OECD Publishing, París\u002FObservatorio Europeo de Sistemas y Políticas de Salud, Bruselas [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2023 [citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Feurohealthobservatory.who.int\u002Fpublications\u002Fm\u002Fspain-country-health-profile-2023 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">2. Oficina Regional para Europa de la OMS;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Estrategia de Cooperación con el País de la OMS, España 2024-2030.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Firis.who.int\u002Fserver\u002Fapi\u002Fcore\u002Fbitstreams\u002F874e2524-febf-4628-a799-3b6e39301dbc\u002Fcontent \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">3. Abdulhadi R, Gómez L, Sourani R. [citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Veredicto.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Tribunal Popular sobre la Complicidad con el Genocidio Palestino en el Estado Español.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fhw4p.es\u002Fblog\u002Fsentencia-tribunal-de-los-pueblos-sobre-la-complicidad-del-estado-espanol-con-el-genocidio-en-palestina-tpcgp-25-verdict-people-s-tribunal-on-complicity-with-the-palestinian-genocide-in-the-spanish-state-esp-eng \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">4. SEPTUAGÉSIMA SÉPTIMA ASAMBLEA MUNDIAL DE LA SALUD [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2024 [citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Condiciones de salud en el territorio palestino ocupado, incluida Jerusalén Este, y en el Golán sirio ocupado.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fapps.who.int\u002Fgb\u002Febwha\u002Fpdf_files\u002FWHA77\u002FA77_BCONF3-en.pdf \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">5. Mike Wagenheim.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Sorprendentemente, la enmienda israelí se aprueba en la Asamblea Mundial de la Salud.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Jewish News Syndicate (JNS).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Jewish News Syndicate [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">31 de mayo de 2024 [citado el 6 de diciembre de 2025];\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fwww.jns.org\u002Fisraeli-amendment-surprisingly-passes-world-health-assembly\u002F \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">6. Gay I. La delegación israelí presenta una enmienda a la resolución de la OMS y pide la liberación de los rehenes.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The Jerusalem Post [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">31 de mayo de 2024 [citado el 5 de diciembre de 2025];\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fwww.jpost.com\u002Fisrael-hamas-war\u002Farticle-804474\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">7. Rebelion.org [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2024 [consultado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Organismo internacional -responsable de los sistemas sanitarios en el mundo- en manos del sionismo.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Frebelion.org\u002Forganismo-internacional-responsable-de-los-sistemas-sanitarios-en-el-mundo-en-manos-del-sionismo\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">8. Trabajadores Sanitarios para Palestina-España [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [consultado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Aprobación de la OMS.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Destrucción del sistema de salud palestino ESP.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fhw4p.es\u002Fblog\u002Faprobacion-oms-destruccion-del-sistema-sanitario-palestino-who-approval-destruction-of-the-palestinian-health-system-esp-eng \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">9. Transformando la atención a la enfermedad en atención sanitaria.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: Medicine 2044. https:\u002F\u002Fthefuturehealthcare.org\u002F[Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">10. Asociación Europea de Psiquiatría - EPA [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">33.º Congreso Europeo de Psiquiatría.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002F2025.epa-congress.org\u002Fsponsorship-and-exhibition\u002Fconfirmed-sponsors-exhibitors \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">11. 2025 Good Jobs First [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">[citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Resumen de la empresa matriz actual del sistema de seguimiento de infracciones.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fviolationtracke\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"n4sEPd\">\n\u003Cdiv class=\"QFw9Te BLojaf\">\n\u003Cdiv class=\"hlJJmd\">\n\u003Cdiv class=\"Bmcqed\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">r.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">12. Nogracias.org.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [consultado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Teva en España.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Un gigante farmacéutico cuyas ganancias dañan la salud de la población de Palestina.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Por Profesionales de la sanidad por Palestina, España (HealthWorkers4PalestineSpain).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">13. Pérez Bozal P. Golpe a la farmaceútica israelí Teva: El boicot sanitario tumba sus intereses en España.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El cierre digital [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">17 de junio de 2025 [citado el 5 de diciembre de 2025];\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Felcierredigital.com\u002Finvestigacion\u002Fgolpe-farmaceutica-israeli-teva-boicot-sanitario-tumba-intereses-espana \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">14. Arahealth Aragon Health Cluster [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">[citado el 6 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Farahealth.com\u002Fasociados\u002Fteva\u002F \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">15. Sørensen I. Carta al Pacto Mundial de la ONU para la exclusión de Teva Pharmaceuticals de la lista de participantes. Sra. Ingvild Sørensen, Responsable del Pacto Mundial de la ONU.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">[Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Factionnetwork.org\u002Fpetitions\u002Fletter-to-un-global-compact-for-removal-of-teva-pharmaceuticals-from-list-of-participants\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">16. Campaña de apoyo al médico Pablo Simón, señalado por sus acciones contra el genocidio en Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El independiente de granada [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">12 de noviembre de 2025 [consultado el 5 de diciembre de 2025];\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fwww.elindependientedegranada.es\u002Fimplicados\u002Fcampana-apoyo-medico-pablo-simon-senalado-acciones-genocidio-gaza\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">17. Wystrychowski L. La decisión de Alemania de recibir burros de Gaza para recibir tratamiento (pero no niños) ha provocado indignación.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Monitor de Oriente Medio (MEMO) [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">[consultado el 5 de diciembre de 2025];\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fwww.middleeastmonitor.com\u002F20251118-germanys-decision-to-take-in-donkeys-from-gaza-for-treatment-but-not-children-has-sparked-outrage\u002F \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">18. Sitio web oficial de la Unión Europea https:\u002F\u002Fec.europa.eu\u002F [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [citado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Comercio internacional de medicamentos y productos farmacéuticos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fec.europa.eu\u002Feurostat\u002Fstatistics-explained\u002Findex.php?title=International_trade_in_medicinal_and_pharmaceutical_products \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">19. OEPM [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2025 [citado el 6 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Oficina Española de Patentes y Marcas (2025).\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Base de datos INVENES.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fconsultas2.oepm.es\u002FInvenesWeb\u002Ffaces\u002FbusquedaInternet.jsp.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">20. Proyectos de salud con financiación europea, española e israelí [Internet].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">[Consultado el 5 de diciembre de 2025].\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Disponible en: https:\u002F\u002Fcordis.europa.eu\u002Fsearch?q=%27Spain%27%20AND%20%27israel%27&p=1&num=10&srt=Relevance:decreasing\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"FFpbKc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad GeWPTc BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"rnández Lozano (docente e investigador, departamento de Sociología II, Universidad Nacional de Educación a Distancia UNED, España, Red Universitaria por Palestina, RUxP, https:\u002F\u002Forcid.org\u002F0000-0003-4310-5526), ​​Tamer Hamdan Nassar (estudiante de Medicina, Universidad de Valencia, España, Red Universitaria por Palestina, RUxP); Sara Pérez-Palomares (profesora e investigadora, Departamento de Fisiatría y Enfermería de la Universidad de Zaragoza, España Red Universitaria para Palestina, RUxP, https:\u002F\u002Forcid.org\u002F0000-0002-5770-5146), César S. Álvarez (profesor e investigador, Departamento de Psicología y Sociología de la Universidad de Zaragoza, España, Red Universitaria para Palestina, RUxP, https:\u002F\u002Forcid.org\u002F0000-0001-8274-6217), Juan José Rodríguez Sendín (médico rural jubilado, Presidente del Comité de Ética y Conducta Profesional, Colegio Médico de Toledo, España), Mercedes Pérez-Fernández (médica rural jubilada, Trabajadores de la Salud para Palestina, España (https:\u002F\u002Forcid.org\u002F0000-0002-9285-1739)) y Juan Gérvas (médico rural jubilado, Trabajadores de la Salud para Palestina, España, (https:\u002F\u002Forcid.org\u002F0000-0002-7802-5457)\nCONTRIBUCIÓN DE LOS AUTORES\nJG, MPF y CSA tuvieron acceso completo a todos los datos del estudio y son responsables de la integridad y la precisión del análisis de los datos.\nConcepto y diseño: IFL, THN, SPP, CSA\nRedacción del manuscrito: JG, CSA, SPP, THN, IFL\nRevisión crítica del manuscrito para contenido intelectual importante: Todos los autores.\nSupervisión: JJRS.\nDECLARACIÓN DE CONFLICTO DE INTERESES: Ninguno declarado\nFINANCIACIÓN: Ninguna\nNOTA: Este texto es la versión final de un artículo que se envió para su posible publicación al Indian Journal of Medical Ethics el 15 de diciembre de 2025. Tras la confirmación de recepción, la siguiente comunicación de la revista fue el 27 de marzo de 2026: Decisión: Rechazar la publicación. Su manuscrito fue evaluado internamente y los comentarios finales son los siguientes: Si bien el tema elegido es importante, el manuscrito no le hace justicia. En vista de los comentarios anteriores, lamentamos no poder considerarlo para su publicación.\n\nReferencias:\n\n1. Observatorio Europeo de Sistemas y Políticas de Salud, España: Perfil de Salud del País 2023, Estado de la Salud en la UE, OECD Publishing, París\u002FObservatorio Europeo de Sistemas y Políticas de Salud, Bruselas [Internet]. 2023 [citado el 5 de diciembre de 2025]. Disponible en: https:\u002F\u002Feurohealthobservatory.who.int\u002Fpublications\u002Fm\u002Fspain-country-health-profile-2023\n\n2. Oficina Regional para Europa de la OMS; 2025 [Internet]. 2025 [citado el 5 de diciembre de 2025]. Estrategia de Cooperación con el País de la OMS, España 2024-2030. Disponible en: https:\u002F\u002Firis.who.int\u002Fserver\u002Fapi\u002Fcore\u002Fbitstreams\u002F874e2524-febf-4628-a799-3b6e39301dbc\u002Fcontent\n\n3. Abdulhadi R, Gómez L, Sourani R. [citado el 5 de diciembre de 2025]. Veredicto. Tribunal Popular sobre la Complicidad con el Genocidio Palestino en el Estado Español. Disponible en: https:\u002F\u002Fhw4p.es\u002Fblog\u002Fsentencia-tribunal-de-los-pueblos-sobre-la-complicidad-del-estado-espanol-con-el-genocidio-en-palestina-tpcgp-25-verdict-people-s-tribunal-on-complicity-with-the-palestinian-genocide-in-the-spanish-state-esp-eng\n\n4. SEPTUAGÉSIMA SÉPTIMA ASAMBLEA MUNDIAL DE LA SALUD [Internet]. 2024 [citado el 5 de diciembre de 2025]. Condiciones de salud en el territorio palestino ocupado, incluida Jerusalén Este, y en el Golán sirio ocupado. Disponible en: https:\u002F\u002Fapps.who.int\u002Fgb\u002Febwha\u002Fpdf_files\u002FWHA77\u002FA77_BCONF3-en.pdf\n\n5. Mike Wagenheim. Sorprendentemente, la enmienda israelí se aprueba en la Asamblea Mundial de la Salud. Jewish News Syndicate (JNS). Jewish News Syndicate [Internet]. 31 de mayo de 2024 [citado el 6 de diciembre de 2025]; Disponible en: https:\u002F\u002Fwww.jns.org\u002Fisraeli-amendment-surprisingly-passes-world-health-assembly\u002F\n\n6. Gay I. La delegación israelí presenta una enmienda a la resolución de la OMS y pide la liberación de los rehenes. The Jerusalem Post [Internet]. 31 de mayo de 2024 [citado el 5 de diciembre de 2025]; Disponible en: https:\u002F\u002Fwww.jpost.com\u002Fisrael-hamas-war\u002Farticle-804474 \n7. Rebelion.org [Internet]. 2024 [consultado el 5 de diciembre de 2025]. Organismo internacional -responsable de los sistemas sanitarios en el mundo- en manos del sionismo. Disponible en: https:\u002F\u002Frebelion.org\u002Forganismo-internacional-responsable-de-los-sistemas-sanitarios-en-el-mundo-en-manos-del-sionismo \n8. Trabajadores Sanitarios para Palestina-España [Internet]. 2025 [consultado el 5 de diciembre de 2025]. Aprobación de la OMS. Destrucción del sistema de salud palestino ESP. Disponible en: https:\u002F\u002Fhw4p.es\u002Fblog\u002Faprobacion-oms-destruccion-del-sistema-sanitario-palestino-who-approval-destruction-of-the-palestinian-health-system-esp-eng\n\n9. Transformando la atención a la enfermedad en atención sanitaria. Disponible en: Medicine 2044. https:\u002F\u002Fthefuturehealthcare.org\u002F[Internet]. 2025 [citado el 5 de diciembre de 2025].\n\n10. Asociación Europea de Psiquiatría - EPA [Internet]. 2025 [citado el 5 de diciembre de 2025]. 33.º Congreso Europeo de Psiquiatría. Disponible en: https:\u002F\u002F2025.epa-congress.org\u002Fsponsorship-and-exhibition\u002Fconfirmed-sponsors-exhibitors\n\n11. 2025 Good Jobs First [Internet]. [citado el 5 de diciembre de 2025]. Resumen de la empresa matriz actual del sistema de seguimiento de infracciones. Disponible en: https:\u002F\u002Fviolationtracke\" data-crosslingual-hint=\"en\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ef1twd\">\n\u003Cdiv class=\"ZJGYz\">\n\u003Cdiv class=\"cHEsi\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad GeWPTc BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"El secuestro de rehenes y la condena a los grupos terroristas de Gaza por militarizar los hospitales provocaron la indignación del grupo de países árabes. La enmienda recibió un amplio respaldo, desde aliados tradicionales como Estados Unidos, Reino Unido y Alemania, hasta países que suelen oponerse a Israel en foros internacionales, como Islandia, España y Filipinas [5]. Además: «La enmienda presentada por la delegación israelí condenaba el uso que hacía Hamás de las instalaciones sanitarias, incluidas ambulancias y hospitales, con fines terroristas, poniendo en riesgo a la población civil» [6]. España votó, a través de su representante, el Ministro de Sanidad, quien, poco después (en noviembre), fue propuesto por la OMS Europa (en la que participa el Estado sionista de Israel) como miembro del Consejo Ejecutivo de la OMS (cargo que se confirmó en mayo de 2025, en la nueva Asamblea Mundial de la Salud de la OMS). La Asamblea Mundial de la Salud de la OMS de 2025 concluyó en junio de ese mismo año sin que se introdujeran cambios en la enmienda israelí de 2024. No existe ninguna prueba fiable de la supuesta militarización del sistema sanitario de Gaza, ni se han descubierto jamás los infames «túneles» bajo los hospitales.\nComo aspecto positivo, Contraste: la denuncia presentada por la Plataforma de Trabajadores de la Salud con Palestina, Valencia [7], y HW4PS [8].\n\nEl silencio es complicidad, la acción es obligación.\n\nA pesar de las reiteradas declaraciones del personal sanitario y los expertos en salud pública sobre las atrocidades cometidas contra la población civil en Gaza, la mayoría de las academias, asociaciones y sociedades científicas de medicina, enfermería, farmacia, psicología, odontología, fisioterapia, etc., y las organizaciones profesionales de la salud que afirman estar comprometidas con la justicia social han guardado silencio, al menos hasta bien entrado el genocidio, ignorando por completo las obligaciones que les imponen sus códigos éticos.\n\nEl silencio de otras asociaciones profesionales de la salud es sorprendente, incluso más que el de las asociaciones médicas. En cualquier caso, en general, las declaraciones han recurrido al «arte» de escribir sobre Gaza (y Palestina) sin mencionar: 1) el daño (apartheid y genocidio), 2) la causa (el Estado sionista de Israel), 3) las causas profundas (sionismo y colonialismo «occidental»), y sin tomar ninguna medida decisiva, como suspendiendo los vínculos con las asociaciones sanitarias israelíes y expulsándolas de las organizaciones internacionales.\n\nDesde el inicio de la fase actual del genocidio, España ha acogido al menos tres congresos médicos con participación israelí (incluido el celebrado en Zaragoza, coorganizado con el Estado sionista de Israel, cuando debería haberse celebrado en Tel Aviv) [9]. Uno de estos congresos incluso contó con el gigante farmacéutico israelí TEVA como «patrocinador platino» [10]. Según los resúmenes de las presentaciones, no se menciona el estado de salud de la población de Gaza años después del inicio del genocidio.\nSolo a partir del verano de 2025 se generalizó la condena de las violaciones del Derecho Internacional Humanitario que se habían estado produciendo durante meses.\nComo contraste positivo, las primeras declaraciones de 2023 y 2024 del FoCAP (Foro Catalán de Atención Primaria), la Asociación Española de Pediatría, la Sociedad Española de Medicina de Familia (SEMFYC), el grupo de ética de la Sociedad Catalana de Medicina de Familia y Comunitaria, Sociedad Española de Salud Pública (SESPAS), etc., y los manifiestos y acciones, a mediados y finales de 2025, del Colegio Médico de Toledo, la Asociación Médica Española, la Sociedad Española de Cuidados Paliativos y los Colegios Médicos de Ourense y Barcelona.\n\nTeva y otras experiencias\nLa complicidad con el genocidio en el ámbito médico, en su dimensión comercial, encuentra su principal ejemplo en el gigante farmacéutico Teva.\n\nTeva es una empresa corrupta y corruptora, obligada desde el año 2000 a pagar más de 10.000 millones de dólares por su actividad delictiva [11].\n\nAunque su actividad principal se centra en los medicamentos genéricos, sus productos estrella de marca son Austedo (deutetrabenazina) para la enfermedad de Huntington, la corea y la discinesia tardía; Ajovy (fremanezumab) para las migrañas; Copaxone (glatiramero) para la esclerosis múltiple; Uzedy (risperidona) para la esquizofrenia; y Azilect (rasagilina) para la enfermedad de Parkinson. En atención primaria En España, sus productos más vendidos son tres medicamentos genéricos: omeprazol, atorvastatina y pantoprazol [12].\nSegún su informe de transparencia, la empresa israelí declaró 2.010.412 € en «transferencias de valor» (pagos a médicos y sus asociaciones) en España en 2023. Casi un millón de euros de esta cantidad corresponde a pagos a profesionales para la promoción de sus productos [13].\nTeva cuenta con una importante fábrica en Zaragoza, que también coordina todos los aspectos de los ensayos clínicos de medicamentos a nivel mundial. TEVA opera 58 plantas de fabricación en todo el mundo. Su planta en Zaragoza representa el 5,91 % de la producción farmacéutica global de Teva y suministra aproximadamente el 40 % de los medicamentos genéricos utilizados en el sistema sanitario español [14].\nTeva participa directamente en la producción de medicamentos genéricos.\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"kGmWO\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ef1twd\">\n\u003Cdiv class=\"ZJGYz\">\n\u003Cdiv class=\"cHEsi\">.\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"El sistema sanitario español: experiencia en relación con Palestina.\n\nAUTORS: Fernández Lozano I, Hamdan Nassar T, Pérez-Palomares S, Álvarez CS, Rodríguez Sendín JJ, Pérez-Fernández M, Gérvas J (autor de correspondencia: jjgervas@gmail.com)\n\nRESUMEN\nUn Tribunal Popular, convocado en Madrid los días 28 y 29 de noviembre de 2025, examinó las acusaciones de complicidad institucional de instituciones españolas en el genocidio palestino. La sección del Tribunal dedicada al sistema sanitario puso de relieve el persistente silencio de las principales asociaciones profesionales de salud. Se identificó además complicidad material en el caso de TEVA, una importante farmacéutica israelí. Asimismo, se criticaron los limitados esfuerzos de España para evacuar a los heridos de Gaza y su respaldo a una enmienda israelí en la Asamblea General de la OMS de 2024. El Tribunal Popular concluyó que dicho silencio sistemático, la actuación en alianzas público-privadas y la inacción constituyen complicidad con el genocidio palestino.\n\nTEXTO PRINCIPAL\nEspaña\nEspaña es un país de la Unión Europea situado en el suroeste de Europa, cuya capital es Madrid. Es un país de altos ingresos (producto interior bruto per cápita de 30.500 euros) con una población de casi 50 millones de habitantes. Su población es urbanizada y diversa, con regiones marcadamente diferenciadas y casi una quinta parte de sus residentes nacidos fuera de España.\nLa gobernanza está altamente descentralizada, con el gobierno central desempeñando un papel regulador y estratégico, más que operativo o de gestión (por ejemplo, las autoridades sanitarias regionales tienen competencia sobre la planificación operativa, la asignación de recursos y las decisiones de compra y prestación de servicios).\nEspaña tiene la mayor esperanza de vida de la Unión Europea, con 83,2 años (la Comunidad de Madrid, 85,2). Los indicadores de salud pública y del rendimiento del sistema sanitario son muy favorables, gracias en gran medida a un sistema sanitario de alta calidad y universalmente accesible, basado en un modelo de atención primaria (médicos de familia asalariados que trabajan en centros de salud públicos con listas de pacientes). La asistencia sanitaria es gratuita y no existen copagos en atención primaria ni hospitalaria. Los copagos por medicamentos son muy bajos en atención primaria y gratuitos en hospitales.\nEspaña presenta bajas tasas de mortalidad prevenible. Las tasas de cribado oncológico y vacunación se sitúan generalmente por encima de la media de la Unión Europea. Las bajas tasas de hospitalización por insuficiencia cardíaca congestiva y diabetes en España reflejan el buen funcionamiento de algunos sistemas de atención primaria y asistencial integrados en el país.\n\nAl mismo tiempo, la salud pública también se enfrenta a importantes retos, como el envejecimiento de la población y del personal sanitario; los efectos cada vez más graves de la crisis climática; la creciente crisis del coste de la vida, especialmente en lo que respecta a la vivienda; la amenaza constante de emergencias sanitarias; y las persistentes desigualdades arraigadas en los determinantes sociales de la salud.\nSi bien el gasto sanitario de España —2771 euros per cápita— se sitúa por debajo de la media de la Unión Europea, el sistema sanitario ofrece cobertura sanitaria universal. El gasto público es la principal fuente de financiación, pero los niveles de gasto de bolsillo (21 %, principalmente en odontología) son superiores a la media de la Unión Europea (15 %) [1,2].\n\nTribunal Popular sobre la Complicidad con el Genocidio Palestino en el Estado Español\nEl Tribunal Popular sobre la Complicidad con el Genocidio Palestino en el Estado Español es un tribunal de conciencia, integrado por figuras del ámbito jurídico, académico, cultural y de derechos humanos, convocado por la Red Universitaria para Palestina (RUxP) y organizaciones de la sociedad civil con el objetivo de examinar, desde la perspectiva del derecho internacional y la ética pública, la conducta de actores estatales y no estatales en su relación con la ocupación, el apartheid y el genocidio del pueblo palestino.\n\nEl Tribunal no se limita a condenar o absolver, sino que, sobre todo, busca convencer a la opinión pública española con pruebas que demuestren la implicación, la intención y las acciones sistemáticas de España que permiten el genocidio del pueblo palestino en Gaza, donde actores españoles (o aquellos con responsabilidad penal en España) actúan a sabiendas en favor del Estado sionista de Israel y se benefician del propio genocidio. No se juzga a Israel, sino a España.\n\nSe ha documentado la complicidad y cooperación necesarias en relación con:\n\n• El gobierno y las instituciones estatales españolas. • El Sistema Bancario Armado, por financiar la producción de todo tipo de armas utilizadas en Gaza y Cisjordania.\n\n• Universidades, por iniciar y mantener contratos, acuerdos y proyectos de investigación, incluyendo tecnología de doble uso.\n\n• Empresas, por continuar comerciando con empresas con sede en territorios ocupados, violando así el derecho internacional.\n\n• Organizaciones de salud y asociaciones profesionales, por ignorar todos los códigos éticos de la profesión mediante un silencio activo y obstinado ante la barbarie y la destrucción de vidas.\n\n• Cultura, deporte y medios de comunicación,\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"kGmWO\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"OwOEge\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ef1twd\">\n\u003Cdiv class=\"ZJGYz\">\n\u003Cdiv class=\"cHEsi\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","mnisgmhzdpkm759zqbh","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1775224847\u002Fn5h2sfcykqxbmvfm5m9b.png",1775215383554,"spain-health-institutional-complicity-in-the-ongoing-palestinian-genocide-gaza-complicidad-institucional-sanitario-de-espana",{"title":569,"timestamp":570,"subtitle":571,"slug":572,"type":7,"videoUrl":573,"user":13,"tags":574,"link":12,"id":575,"content":576,"imageUrl":577},"From The Netherlands: Call to action: Boycott Teva. Desde los Países Bajos. Pase a la acción, boicot a Teva. ENG ESP",1777487987960,"Teva, a pharmaceutical company complicit- and benefitting from the policies of its government. Teva, una compañía farmacéutica que se beneficia del genocidio en Gaza ","from-the-netherlands-call-to-action-boycott-teva-desde-los-paises-bajos-pase-a-la-accion-boicot-a-teva-eng-esp","call-to-action-boycott-teva?utm_campaign=post&utm_medium=web&timestamp=17.2",[15],"mokdwxpbovpg50c8wy","\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fopen.substack.com\u002Fpub\u002Fartsenvoorgaza\u002Fp\u002Fcall-to-action-boycott-teva?utm_campaign=post&utm_medium=web&timestamp=17.2\">\u003Cstrong>From The Netherlands: Call to action: Boycott Teva\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cem>Speech at \u003Ca href=\"https:\u002F\u002Fwww.degezondheidszaak.nl\">De Gezondheidszaak\u003C\u002Fa>, Utrecht (The Netherlands), on April 19, 2026. De Gezondheidszaak is the Dutch affiliate of the \u003Ca href=\"https:\u002F\u002Fphmovement.org\">People’s Health Movement\u003C\u002Fa>. \u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>“Teva is one of the world’s largest producers of generic medicine. One in five to one in twelve prescriptions in Western countries such as Germany, the US and the UK, is filled by Teva. You would think that such a pharmaceutical company, that states its commitment to health for all worldwide, has a stellar track record for corporate social responsibility. Nothing could be further from the truth.\u003C\u002Fp>\n\u003Cp>From the inception of Israel in 1948, Teva’s leadership have steered the company towards furthering the entrenchment of the Zionist project and settler- colonialism. It is also historically and currently one of the biggest companies in the country. Its factories stand on ethnically cleansed land.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Since a few days after the beginning of the genocide in October 2023, Teva chose to politically align itself with the genocide state\u003C\u002Fstrong>. It released supportive statements, and materially committed itself fully to aiding the IDF with donations and access to their distribution network. They recommitted investments with government organisations that produce drones, weapons and surveillance tech. The role that Teva plays in Israel cannot be understated.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>The cruel irony is that a pharmaceutical company is complicit- and benefitting from the policies of its government which so inhumanely withholds medicine from an oppressed population. This cannot continue.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>We call upon health care workers worldwide to boycott Teva. 95% of Teva’s billions in profits come from abroad, which makes us uniquely positioned to exert pressure from abroad. Where a boycott is not possible, make it known to decision-makers that Teva is not welcome. In the Netherlands, significant reductions in the purchase of Teva by insurance companies have been made, by asking the population to send complaints and e-mails. If you are in the Netherlands, you can join this campaign, by going to \u003Ca href=\"http:\u002F\u002Fwww.stopteva.nl\u002F\">www.stopteva.nl\u003C\u002Fa> or \u003Ca href=\"http:\u002F\u002Fwww.stopfundinggenocide.nl\u002Fstopteva\">www.stopfundinggenocide.nl\u002Fstopteva\u003C\u002Fa>. Worldwide, boycott Teva campaigns are escalating. If you want to join a local campaign, please do contact us or the international \u003Ca href=\"https:\u002F\u002Fbdsmovement.net\u002F\">BDS movement\u003C\u002Fa>. They can put you in touch with local groups.\u003C\u002Fp>\n\u003Cp>We will continue to escalate against this pharmaceutical giant. \u003Cstrong>Join us, because medicine is meant to cure.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>This month, we will be launching our local Teva boycotts series, titled “Anatomy of a Healthcare Boycott”. Do subscribe to stay up to date.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Discurso pronunciado en De Gezondheidszaak, Utrecht (Países Bajos), el 19 de abril de 2026. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">De Gezondheidszaak es la filial holandesa del Movimiento por la Salud Popular.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva es uno de los mayores productores de medicamentos genéricos del mundo. Entre una de cada cinco y una de cada doce recetas en países occidentales como Alemania, Estados Unidos y el Reino Unido, son dispensadas por Teva. Cabría esperar que una farmacéutica de este calibre, que declara su compromiso con la salud para todos a nivel mundial, tuviera un historial impecable en materia de responsabilidad social corporativa. Nada más lejos de la realidad. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Desde la fundación de Israel en 1948, la dirección de Teva ha orientado a la empresa hacia el afianzamiento del proyecto sionista y el colonialismo de asentamiento. Históricamente y en la actualidad, es una de las mayores empresas del país. Sus fábricas se asientan en tierras donde se llevó a cabo una limpieza étnica. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Desde pocos días después del inicio del genocidio en octubre de 2023, Teva optó por alinearse políticamente con el Estado genocida. Emitió declaraciones de apoyo y se comprometió plenamente a ayudar a las Fuerzas de Defensa de Israel (FDI) con donaciones y acceso a su red de distribución. Reiteró sus inversiones con organizaciones gubernamentales que producen drones, armas y tecnología de vigilancia.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">El papel que desempeña Teva en\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La situación en Israel es innegable.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La cruel ironía reside en que una farmacéutica es cómplice —y se beneficia— de las políticas de su gobierno, que de forma tan inhumana niega el acceso a medicamentos a una población oprimida.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Esto no puede continuar.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Hacemos un llamamiento a los profesionales de la salud de todo el mundo para que boicoteen a Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El 95% de los miles de millones de dólares en ganancias de Teva provienen del extranjero, lo que nos posiciona de manera única para ejercer presión desde fuera.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Si el boicot no es posible, hagan saber a quienes toman las decisiones que Teva no es bienvenida.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En los Países Bajos, las compañías de seguros han logrado reducciones significativas en la compra de Teva, gracias a las quejas y correos electrónicos enviados por la población.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Si se encuentra en los Países Bajos, puede unirse a esta campaña visitando www.stopteva.nl o www.stopfundinggenocide.nl\u002Fstopteva. En España la campaña\u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002F\"> TevaNoGracias\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">A nivel mundial, se están intensificanco las campañas de boicot a Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Si desea unirse a una campaña local, contáctenos o al movimiento internacional BDS.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Ellos pueden ponerle en contacto con grupos locales.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Seguiremos intensificando nuestra lucha contra esto.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Gigante farmacéutico.\u003C\u002Fspan>\u003Cstrong> \u003Cspan class=\"ryNqvb\">Únete a nosotros, porque la medicina está para curar.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Este mes, lanzaremos nuestra serie local sobre boicots a Teva, titulada «Anatomía de un boicot a la atención médica». Suscríbete para mantenerte al día.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1777487811\u002Fztpgowpc5tmxoqtxr9uv.png",{"videoUrl":579,"content":580,"title":581,"link":12,"tags":582,"user":13,"imageUrl":583,"type":7,"slug":584,"timestamp":585,"subtitle":586,"id":587},"T5Se7SwWFCQ","\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>Teva, apartheid, genocidio y ocupación en Palestina.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Resumen de la sesión en Santander, 3 de junio de 2026. 19,30 h. Librería La Vorágine.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Puede verse el vídeo \u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=T5Se7SwWFCQ\">aquí,\u003C\u002Fa> 81 minutos incluyendo el debate\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El vídeo inicial que no se registró en la presentación \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fvideo-al-abrir-una-caja-de-teva-oyes-el-genocidio-en-palestina\">aquí\u003C\u002Fa> vídeo 55 sg, al abrir una caja de Teva escuchas la brutalidad del genocidio\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"font-weight: normal;\">Sesión coorganizada por @__EyS  @PasajeSeguroCAN Cabezón por Gaza y @cantcontrareame \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"text-decoration: underline;\">\u003Cem>\u003Cspan style=\"font-family: Times New Roman, serif;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: #ffffff;\">Juan Gérvas\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: #ffffff;\"> (Doctor en Medicina, médico general rural jubilado, Equipo CESCA, Madrid, España, exprofesor de salud pública, Universidad Johns Hopkins, Baltimore, Estados Unidos) y\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"text-decoration: underline;\">\u003Cem>\u003Cspan style=\"font-family: Times New Roman, serif;\">\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: #ffffff;\">Mercedes Pérez-Fernández\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-family: Arial, sans-serif;\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: #ffffff;\"> (especialista en Medicina Interna y médica rural jubilada) Equipo CESCA, Madrid, España.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: #ffffff;\">jjgervas@gmail.com mpf1945@gmail.com www.equipocesca.org @JuanGrvas \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: #ffffff;\">@juangrvas.bsky.social\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-weight: normal;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>Síntesis\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">Las ganancias de Teva, industria farmacéutica sionista, provienen directamente de décadas de colonización y explotación de la tierra y del pueblo palestino.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">Es nuestro deber hacer todo lo posible para asegurarnos de que nuestro dinero no se utiliza para fomentar la opresión genocida y el apartheid colonial.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">Tenemos que preguntarnos, f\u003C\u002Fspan>rente a Israel (causa), apartheid y genocidio (diagnóstico) y sionismo (causa de la causa) ¿qué estás haciendo?\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">“Ustedes lo vieron todo y no hicieron nada”. O, al menos “ustedes lo intentaron”. Tú eliges ahora.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>1.- ¿Quiénes somos?\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Somos gente corriente.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Gente sin poder aparente.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Gente que observa con asombro e impotencia lo que sucede en el mundo, cercano y lejano.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Lo que sucede es muchas veces horrible e indecente.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">En este caso el genocidio del pueblo palestino.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Creemos que la unión hace la fuerza y que la esperanza, la solidaridad y la ternura son valores clave para defender la dignidad de todo ser humano.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Creemos, con Albert Camus, que hacer lo que hay que hacer en el quehacer diario es cosa heroica.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"justify\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Tenemos que aceptar tantas derrotas, tantos fracasos en lo personal y profesional, que acabamos siendo perdedores de fondo, de largo recorrido. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"justify\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Perdedores sí, pero no agotados. Sin cejar pues sabemos que la virtud revolucionaria es la constancia. Así que perdedores, sí, pero incombustibles e indomables en pos de un utopía que nos mueve. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"justify\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\">Y\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: #ffffff;\">a sabemos que la utopía es como la Osa Mayor, que nos ayuda a orientarnos y a \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"justify\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: #ffffff;\">localizar la Estrella Polar, y con ello a encontrar la ruta a seguir guiándonos por\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-weight: normal;\">\u003Cspan style=\"background: transparent;\"> nuestro compromiso ético, profesional y social con los marginados, sabiendo que no callar es mantener la esperanza y de que la desesperanza en una forma de deslealtad (que dijo Gabriel Marcel).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"justify\">\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: transparent;\">La derrota no vuelve injusta una causa, al contrario debería enardecernos para continuar por aquello de \"estamos en derrota, nunca en doma\", del poeta \u003C\u002Fspan>\u003C\u002Fspan>Claudio Rodríguez\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"background: transparent;\">.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"justify\">\u003Cspan style=\"background: transparent;\"> \u003Cspan style=\"font-size: large;\">«Pienso que es necesario educar a las nuevas generaciones en el valor de la derrota. En manejarse en ella. En la humanidad que de ella emerge. En... que se puede fracasar y volver a empezar sin que el valor y la dignidad se vean afectados\" que escribió Pier Paolo Pasolini.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>2.- ¿Cuándo empezamos?\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Participamos en el grupo Trabajadores de la Sanidad por Palestina (España) y llevamos su página en Internet.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El 19 de octubre de 2024, tras la publicación de una poesía por Sunera Sadacali en NoGracias titulada “Gaza: La Humanidad Herida” y a raíz de un seminario de HW4P UK (Health Workers For Palestine, United Kingdom) con Francesca Albanese, se propuso crear un grupo en España y emprender un proyecto a nivel estatal. Creamos, pues, Trabajadores de la Sanidad por Palestina (España), con un grupo de profesionales de la sanidad unidos en su comienzo a través de los Seminarios de Innovación en Atención Primaria.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Sunera Sadacali es médica de familia de origen hindú que trabaja desde 2015 en Suecia. Nacida en Mozambique a los dos años pasó a vivir en Lisboa. Estudió medicina en Badajoz, París y Córdoba.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">La poesía acaba con: “No nos olvidemos; escribamos su legado, porque el trauma más profundo es el Olvido, es el Silencio”.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>3.- ¿Tenemos conflictos de interés?\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Sí. Tenemos un fuerte conflicto de interés por nuestro compromiso personal y profesional con la dignidad, la solidaridad y la ternura humanas.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Creemos que es intolerable el sufrimiento y las muertes evitables y por ello estamos en contra de las guerras en general y de las coloniales en especial.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Escribimos y hablamos para que se nos entienda, con rigor y sensibilidad, a sabiendas de que el hablar claro (parresía) implica un compromiso con la verdad de lo que se dice, un compromiso radical, porque a menudo nos pone en peligro.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">No tenemos ningún conflicto de interés material, ni financiero.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Como grupo, tenemos total independencia de cualquier organización industrial, institucional, académica, científica, política, sindical y otras. Intentamos difundir hechos, escritos, fotografías y documentos que busquen la verdad con honradez.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Pero si erramos, agradeceríamos se nos señale.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>4.- ¿Cuándo empezamos con Teva?\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Empezamos a promover el boicot a los productos sanitarios de Teva el 6 de diciembre de 2024, sumándonos a un movimiento internacional contra la empresa sionista con el lema “¿Teva? ¡No gracias!”.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El boicot es “acción directa” para obstaculizar el desarrollo y funcionamiento de la actividad comercial y social de Teva. El boicot funciona. El boicot es ético. El boicot es legal. El boicot es legítimo. El boicot es obligación moral. El boicot es oportuno. El boicot es proporcional. El boicot es solidario.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Hay tres argumentos éticos fundamentales para el boicot a Teva:\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">1\u002F Los beneficios de Teva sirven para pagar impuestos en Israel y financiar la actividad terrorista de su ejército,\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">2\u002F Teva monopoliza el mercado palestino de medicamentos, e impone precios abusivos y\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">3\u002F Teva es una empresa corrupta y corruptora; entre 2010 y 2024, Teva pagó unos 11.000 millones de dólares en condenas y multas por corrupción probada en tribunales de todo el mundo.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva fue fundada en 1901 y es sionista desde sus “cimientos”.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El sionismo es un ideología política desarrollada en Europa a finales del siglo XIX, en medio de la eclosión de los nacionalismos, de la idea de “un pueblo, una nación, un Estado” (en este caso en torno a Sión, la antigua Jerusalén), de la teoría de la evolución, de la noción de raza y de la eugenesia. El sionismo ve a los judíos como una raza, no como un grupo religioso ni cultural y por ello va contra la historia judía.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El sionismo es violento. El sionismo es vengativo. El sionismo es terrorista. El sionismo es supremacista. El sionismo en racista. El sionismo es machista. El sionismo es fanático. El sionismo es colonialista.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">La mayor parte de los judíos del mundo no son sionistas.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El sionismo es una cultura de violación sexual y, por ejemplo, el 65% de la población judía actual de Israel apoya que no se juzgue a los torturadores israelíes que violan a prisioneros en los centros de detención.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El sionismo es una ideología colonialista y, así, el 85% de la población judía actual de Israel apoya la expulsión de todos los palestinos de Gaza (y el 56% apoya la expulsión de los palestinos que viven en Israel). El 75% cree que no hay inocentes en Gaza, nadie (ni los recién nacidos ni sus madres, todos merecen ser asesinados).\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El sionismo gobierna Israel, de la mano de la ultraderecha. El sionismo “infecta” a la población judía de Israel.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Las oficinas centrales de Teva están en Israel, y el grupo más fuerte de accionariado es el de BlackRock (un fondo buitre con casi nueve veces el producto interior bruto de España). Tiene una cartera de más de 3.600 medicamentos que produce en 53 plantas, en 33 países, incluyendo una planta en Zaragoza, España (con 600 trabajadores). Zaragoza concentra una parte fundamental respecto a los ensayos clínicos y sustancial respecto a la producción de Teva en el mundo (produce el 8,7% del total de sus medicamentos).\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Al monopolizar el sector farmacéutico israelí y con sus inmensos ingresos en el mundo, Teva contribuye a la ocupación, al colonialismo, al régimen de apartheid y al genocidio palestino. La empresa también proporciona suministros médicos, personal y donaciones a las Fuerzas de Ocupación Israelíes.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>5.- Sobre Teva\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El primer seminario sobre Teva lo tuvimos en virtual, el 12 de diciembre de 2024 pues Teva es la empresa sionista más potente del mercado sanitario y está implicada en múltiples formas con el genocidio del pueblo palestino.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva es un gigante farmacéutico, la mayor empresa de medicamentos genéricos (sin marca) del mundo. Los genéricos son medicamentos que han perdido la patente y se venden sin nombre de fantasía, sólo el nombre del principio activo, tipo paracetamol, omeprazol, enalapril, metformina, budesonida, monteluskat, etc.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">En 2024 las ventas estimadas de Teva al Sistema Nacional de Salud (no en hospitales) fueron de casi 600 millones de euros. Los 3 primeros productos: 1\u002F omeprazol, 2\u002F atorvastatina, 3\u002F pantoprazol, más de 120 millones. Por eso promovimos el boicot de estos 3 medicamentos de Teva, Tevagen, Davue, Belmac y Ratiopharm. No es dejar de tomar los medicamentos recetados, es que no nos dispensen los que matan en Palestina, es cambiar a otra compañía farmacéutica.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva también produce medicamentos con nombre de marca (nombres “de fantasía”, de medicamento patentado), como Austedo (deutetrabenazine) para la enfermedad de Huntington y la discinesia tardía, Ajovy (fremanezumab) para la migraña (no aporta nada), Copaxone (glatiramero) para la esclerosis múltiple (no aporta nada), Uzedy (risperidona) para la esquizofrenia y Azilect (rasagilina) para el parkinson.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">En la actualidad, en España, es especialmente intensa la campaña de Teva para promover el empleo de Ajovy en la migraña, con impacto en todos los medios de comunicación y publicidad ilegal directa del producto al público general.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva tiene ingresos mundiales de más de 16.000 millones de dólares anuales, basándose sobre todo en los genéricos (medicamentos sin marca).\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>6.- Teva y el ejército de Israel\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Según su director, Teva es \"la voz de Israel\" durante la guerra.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Por ejemplo, los soldados que trabajan para Teva siguen recibiendo sus salarios cuando son desplegados en Gaza.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva también organiza diversas actividades para los soldados, como apoyo psicológico y eventos sociales, que deberían permitirles participar con renovado vigor en los ataques genocidas en Gaza y otros lugares.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva, por iniciativa propia, dona equipo al ejército de ocupación israelí.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva paga cientos de millones de dólares en impuestos al tesoro israelí anualmente (721 millones de dólares en 2024). Esto ayuda a financiar, entre otras cosas, el armamento del ejército israelí.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El fundador y varios directores de Teva contribuyeron como soldados sionistas a la limpieza étnica en Palestina antes y después del establecimiento de Israel en 1948.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Gracias, en parte, a sus vínculos especiales con el Estado israelí, Teva goza de una posición política, fiscal y comercial muy sólida en Israel.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva aporta miles de millones al Estado israelí de apartheid e invierte en instituciones gubernamentales que trabajan, entre otras cosas, en el desarrollo de armas, drones y tecnología de vigilancia utilizada para el genocidio en Gaza y las violaciones de derechos humanos en Cisjordania.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>7.- 2025: el boicot a Teva, un largo camino de éxitos\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">La Ministra de Sanidad ni siquiera dio acuse de recibo de nuestra carta sobre el boicot a Teva, del 30 de abril de 2025.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Sin embargo, el 11 de mayo de 2025, 200 profesionales de las Urgencias Generales del Hospital Universitario de Cruces reclamaron a Osakidetza que retirase los productos de la farmacéutica israelí Teva y los reemplazase por «una alternativa que respete los derechos humanos».\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El 21 de julio de 2025, 390 sanitarios de los hospitales de Vallecas piden al Gobierno de la Comunidad de Madrid que los hospitales no compren más material a empresas israelíes, Teva incluida.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Desde septiembre de 2025 el Movimiento internacional BDS (Boicot, Desinversión y Sanciones) eligió a Teva como uno de los objetivos prioritarios para realizar boicot económico a Israel.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El 20 de septiembre de 2026, en Asturias, todos unidos, Consejería de Salud, Sociedad Asturiana de Medicina Familiar y Comunitaria, Neurología del Hospital Universitario Central de Asturias, Plataforma para la Defensa de la Salud y la Sanidad Pública de Asturias, Somos Asturias...a favor de la ética y del cese de compras a Teva. El 25 de septiembre, Adrián Barbón (Presidente del Gobierno de Asturias, España) se compromete a romper los contratos con la farmacéutica israelí Teva Pharma.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">En Navarra, tras meses de trabajo coordinado y con una campaña que logró el apoyo de más de 5.000 ciudadanos, Yala Nafarroa consigue que el 8 de octubre de 2025 el Servicio Navarro de Salud no prorrogue el contrato de tres fármacos suministrados por empresas Teva sustituyéndolos por otros de compañías que no tienen relación con el genocidio en Palestina.\u003C\u002Fp>\n\u003Cp>11 de Noviembre el periódico \"Ideal\" de Granada publicó una noticia sobre Pablo Simón Lorda (médico de un pueblo (Chauchina), que hace boicot a Teva), con el titular “El colegio de Médicos estudia una queja por un doctor que pide no dar medicinas de una marca israelí”. La periodista firmante se hacía eco de una queja interpuesta ante el Colegio de Médicos de Granada por “una entidad contra el antisemitismo” - la“Comisión Sanitaria contra el Antisemitismo” y la ”Coordinadora Estatal de Lucha contra el Antisemitismo\". Hubo una fuerte respuesta de profesionales de la sanidad, organizaciones civiles y pacientes del propio pueblo en apoyo de Pablo Simón Lorda. El 25 de noviembre el Colegio de Médicos de Granada archivó la denuncia, sin tramitar ningún expediente porque  \"de los hechos recogidos en dicha denuncia no resulta conducta contraria a la normativa estatutaria ni deontológica, quedando en consecuencia fuera de las competencias de esta Corporación\".\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El 1 de diciembre de 2025, el TPCGP-25 (Tribunal de los Pueblos sobre la Complicidad del Estado español con el Genocidio en Palestina) condenó a España y concluyó que en el ámbito del mercado sanitario queda documentado que, pese a las reiteradas declaraciones de personal sanitario y personas expertas en salud pública sobre las atrocidades cometidas contra la población civil en Gaza, una gran mayoría de academias, asociaciones y sociedades científicas de medicina, enfermería o farmacia, así como organizaciones profesionales de la salud, se ha mantenido en silencio y ha ignorado por completo las obligaciones impuestas por sus códigos deontológicos. En términos materiales, la complicidad con el genocidio en el ámbito médico tiene su principal exponente en el gigante farmacéutico Teva.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>8.- 2026. Campaña estatal de boicot a Teva: “Que tus medicamentos no sean sus balas”, “¿Teva? ¡No gracias!”\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Las más de 400 asociaciones, organizaciones, colectivos y movimientos sociales comprometidos con los derechos humanos promueven una campaña de boicot contra la farmacéutica Teva como medida de solidaridad con el pueblo palestino y por el fin del apartheid, la ocupación y el genocidio en Palestina.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Lanzaron dicha iniciativa para devolver a la sociedad civil el poder que los gobiernos le han negado frente al exterminio palestino.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Israel es una entidad sionista ocupante que está cometiendo un genocidio en Palestina.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El movimiento Boicot, Desinversión y Sanciones (BDS) es un movimiento de liderazgo palestino por la libertad, la justicia y la igualdad. Inspirado en el movimiento anti-apartheid sudafricano, insta a actuar para presionar a Israel a que respete el derecho internacional. El BDS identifica a Teva como uno de los objetivos prioritarios para realizar boicot económico a Israel.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Existen multitud de contratos de suministros de fármacos de Teva a centros sanitarios en el territorio español.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva financia a Israel, régimen que lleva a cabo la ocupación, el apartheid y el genocidio en Palestina.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva se beneficia de la ocupación ilegal, del sistema de apartheid y del mercado cautivo, ya que goza de posiciones privilegiadas en el mercado farmacéutico de los territorios palestinos ocupados. Israel controla y limita la importación y exportación de medicamentos y permite a empresas israelíes operar sin pagar aranceles ni enfrentar restricciones en los puntos fronterizos de control. Esto le permite a Teva comercializar ampliamente sus productos farmacéuticos en estos territorios, compitiendo de manera directa y desleal con el resto de empresas farmacéuticas, incluidas las palestinas, a las que a su vez Israel dificulta su desarrollo y crecimiento.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva muestra un abierto apoyo y colaboración con el genocidio que está perpetrando Israel: al menos un 10% de su plantilla en Israel se ha unido al ejército, ha donado material a las Fuerzas de Defensa de Israel, apoya recursos para dar “recuperar” a soldados del “trauma de guerra”, en sus sedes recolecta de materiales para el ejército y en sus oficinas tienen colocados carteles que muestran apoyos al ejército, entre otras acciones de soporte al ejército israelí.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El boicot es una herramienta legítima e histórica. Hacer boicot a empresas que sustentan a un régimen que perpetra crímenes contra la Humanidad es una obligación moral, ética y legal ineludible. Y lo es aún más cuando un negocio sanitario como es el de Teva es parte de un sistema que extermina a las personas palestinas.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Por todo ello, las organizaciones que apoyan la campaña estatal de boicot a Teva pedimos:\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">-A la ciudadanía: que pida activamente alternativas a Teva, en las recetas y en las farmacias. No consumir Teva.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">-A profesionales de la salud: que no prescriban Teva cuando existan equivalentes. Romper la cadena de complicidad desde la consulta. No prescribir Teva.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">-A las farmacias: que no comercialicen o dispensen Teva. Priorizar otros laboratorios no manchados con sangre palestina. No dispensar Teva.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">-A administraciones públicas, hospitales y otros compradores institucionales: que no escojan a Teva como proveedor en sus compras públicas y licitaciones sanitarias. No contratar Teva.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">-A colectivos, organizaciones y movimientos sociales: que firmen el manifiesto de boicot a Teva como acto de adhesión a la campaña y lo difundan entre sus colectivos y en la sociedad en general desde sus ámbitos de actuación. Acción directa contra Teva.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Por justicia para Palestina, únete a la campaña de boicot a Teva.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Esta campaña estará activa desde el 1 de marzo al 1 de diciembre de 2026.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>9.- “Transferencias de valor” de Teva en España\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Conviene que los poderes públicos denuncien y boicoteen a profesionales y organizaciones sanitarias que cooperan “especialmente” con Teva, que reciben pagos directos de Teva para promocionar sus productos.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Gran parte del uso de medicamentos de Teva se debe a los millones de euros que Teva da a médicos “creadores de opinión” (key opinion leaders) y organizaciones sanitarias clave.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">En España destacan, sumando el total en 2023 y 2024, Patricia Pozo Rosich, Barcelona, neuróloga del Valle D’Hebron, que recibió directamente de Teva 77.000 euros en lo que llaman “transferencias de valor”.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">También la Fundación SEN (Sociedad Española de Neurología), Barcelona, 238.000, Fundació Hospital Universitari Valle D'Hebron, Institut de Recerca, Barcelona, 138.000 y la Sociedad Española de Farmacia Clínica, Familiar y Comunitaria, SEFAC, Madrid, 143.000 euros.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Hay que destacar que la Fundación Hospital Universitari Vall d´Hebrón (Vall d’Hebron Institut de Recerca, VHIR) tiene en su Comité Científico Interno como vicepresidenta a la citada neuróloga Patricia Pozo Rosich y en su Comité Científico Externo a Ronit Satchi-Fainaro, israelí de Tel Aviv, que pertenece al Consejo de Administración de Teva (lo que se oculta en su curriculum que aparece en la página del VHIR).\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>10.- Más allá de la campaña estatal de boicot a Teva\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Además del boicot a Teva hay que preguntarse:\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">¿Hasta cuándo abusará Teva de nuestra paciencia por la connivencia de autoridades administrativas y políticas españolas con sus actividades en general?\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">¿Hasta cuándo abusará de nuestra paciencia manteniendo abiertas la fábrica de Teva en Zaragoza y las demás instalaciones de Teva en España?\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">¿Hasta cuándo se seguirán financiando los productos de Teva por el Sistema Nacional de Salud, hasta cuándo se mantendrán las autorizaciones de comercialización?\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">¿Hasta cuándo seguirán los poderes públicos españoles sin analizar las implicaciones de otras empresas farmacéuticas y tecnológicas que trabajan en el campo sanitario con la ocupación, el apartheid y el genocidio en Palestina, y actuar en consecuencia? Por ejemplo Pfizer, AstraZeneca, Lilly, Phillips, Merck, BMS, Novartis, Google, Telefónica, Sanofi, GSK, Medtronic. Siemens, Indra, Hewlett-Packard, Microsoft y otras empresas que quizá hayan participado y participan apoyando la ocupación, el apartheid y el genocidio en Palestina.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Además del boicot a Teva podemos establecer redes de apoyo y solidaridad con quienes se comprometen, como los casos citados en Cruces, Vallecas, Asturias, Navarra, etc.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">También con otros, tipo revista “Acceso Justo al Medicamento”, el Colegio de Médicos de Toledo, la Federación de Asociaciones para la Defensa de la Salud Pública, etc.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En nuestras campañas, intentamos trabajar \"desde la raíz\", como en la salud pública.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">1. El nivel más alto, el ideal, casi imposible, es que el Ministerio de Salud deje de incluir los medicamentos de Teva en el formulario público.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">2. Dado que el sistema sanitario español está descentralizado en las Comunidades Autónomas, el siguiente nivel, donde hemos tenido éxito (Comunidades Autónomas, Asturias y Navarra), es que los servicios sanitarios dejen de comprar Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">3. Si descendemos a ese nivel, implica influir en las asociaciones médicas y los profesionales sanitarios para que no utilicen Teva.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">4. El siguiente nivel, dentro de la comunidad, son las farmacias.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">5. El nivel final son los pacientes en las farmacias.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Creemos que es importante tener esta idea de \"niveles\" para no cargar con todo el peso del boicot sobre los hombros de los pacientes en las oficinas de farmacia.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">A no olvidar: la virtud revolucionaria es la constancia. Saben que nos cansamos y agotamos, hay que volverse por ello incansables e inagotables, sin nunca callar pues “el trauma más profundo es el Olvido, es el Silencio”.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>PARA SABER MÁS\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Campaña estatal\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002Fla-campa%C3%B1a\">https:\u002F\u002Ftevanogracias.com\u002Fla-campa%C3%B1a\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Información general sobre Teva\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\">https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Teva, información relevante\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\">https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-family: Segoe UI, sans-serif;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>","Boicot a Teva. Apartheid, genocidio y ocupación en Palestina.",[15,164],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1781791738\u002Fhdmwgjo184poiw9bfjog.jpg","boicot-a-teva-apartheid-genocidio-y-ocupacion-en-palestina",1781791788107,"El boicot a Teva, la campaña estatal (España) y la historia de Profesionales de la Sanidad Por Palestina (Health Workers for Paletine, Spain, HW4PS)","mqjjsc8l94r8jgp3aqd",{"videoUrl":385,"content":589,"title":590,"link":12,"user":13,"tags":591,"imageUrl":592,"type":7,"slug":593,"timestamp":594,"subtitle":595,"id":596},"\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"hgbeOc EjH7wc\">\u003Cnav class=\"U0xwnf\" aria-labelledby=\"ucj-2\">\n\u003Cdiv class=\"cWQYBc\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fvideo-55-sg-the-sound-of-teva-genocide-in-palestine\">Video 55 seconds\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>When you open a box of Teva, the sound of genocide in Palestine comes through.\u003C\u002Fdiv>\n\u003Cdiv class=\"cWQYBc\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"cWQYBc\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">2026. From March to December. Spain. Statewide Boycott Campaign Against Teva: “Don’t Let Your Medicines Be Their Bullets,” “Teva? No Thanks!”\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"cWQYBc\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"cWQYBc\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">Web of the campaign, with material and more\u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002Fla-campa%C3%B1a\"> here\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fnav>\u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">More than 400 associations, organizations, collectives, and social movements committed to human rights are promoting from March to December 2026 a boycott campaign against the pharmaceutical company Teva as a compromise of solidarity with the Palestinian people and for the end of apartheid, occupation, and genocide in Palestine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem> \u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">They launched this initiative to return to civil society the power that governments have denied it in the face of the Palestinian extermination.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Israel is an occupying Zionist entity that is committing genocide in Palestine.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Boycott, Divestment, and Sanctions (BDS) movement is a Palestinian-led movement for freedom, justice, and equality. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Inspired by the South African anti-apartheid movement, it urges action to pressure Israel to respect international law.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">BDS identifies Teva as one of the priority targets for an economic boycott of Israel.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> There are numerous contracts for the supply of pharmaceuticals from Teva to healthcare centers in Spain.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva finances Israel, the regime that carries out occupation, apartheid, and genocide in Palestine.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003Cstrong>Teva benefits from the illegal occupation, the apartheid system, and the captive market, as it enjoys privileged positions in the pharmaceutical market of the occupied Palestinian territories.\u003C\u002Fstrong>\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel controls and limits the import and export of medicines and allows Israeli companies to operate without paying tariffs or facing restrictions at border checkpoints.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This allows Teva to widely market its pharmaceutical products in these territories, competing directly and unfairly with other pharmaceutical companies, including Palestinian ones, whose development and growth are, in turn, hindered by Israel.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">Teva openly supports and collaborates with the genocide being perpetrated by Israel: at least 10% of its workforce in Israel has joined the army, it has donated equipment to the Israel Defense Forces, supports resources to \"recover\" soldiers from \"war trauma,\" collects supplies for the army at its headquarters, and displays posters in its offices showing support for the army, among other actions supporting the Israeli military.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is a legitimate and historical tool.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Boycotting companies that support a regime that perpetrates crimes against humanity is an unavoidable moral, ethical, and legal obligation.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This is even more true when a healthcare business like Teva is part of a system that exterminates Palestinians.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">The boycott is “direct action” to hinder the development and operation of Teva's commercial and social activities. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">The boycott works. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">The boycott is ethical. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">The boycott is legal. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">The boycott is legitimate. The boycott is a moral obligation. The boycott is timely. The boycott is proportionate. The boycott is based on solidarity. There are three fundamental ethical arguments for boycotting Teva: 1\u002F Teva's profits are used to pay taxes in Israel and finance the terrorist activities of its army, 2\u002F Teva monopolizes the Palestinian market for medicines and imposes exorbitant prices, and 3\u002F Teva is a corrupt and corrupting company; between 2010 and 2024, Teva paid approximately $11 billion in judgments and fines for proven corruption in courts around the world.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, the organizations supporting the statewide boycott campaign against Teva call on the public to: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">- Actively request alternatives to Teva, both on prescriptions and at pharmacies.\u003C\u002Fspan>\u003Cstrong> \u003Cspan class=\"ryNqvb\">Do not use Teva. \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-To healthcare professionals: Do not prescribe Teva when equivalent products exist.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Break the chain of complicity from the consultation room.\u003C\u002Fspan> \u003Cstrong>\u003Cspan class=\"ryNqvb\">Do not prescribe Teva.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-To pharmacies: Do not sell or dispense Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Prioritize other laboratories not tainted by Palestinian blood.\u003C\u002Fspan>\u003Cstrong> \u003Cspan class=\"ryNqvb\">Do not sell\u002Fdispense Teva.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-To public administrations, hospitals, and other institutional buyers: Do not choose Teva as a supplier in your public procurement and healthcare tenders.\u003C\u002Fspan> \u003Cstrong>\u003Cspan class=\"ryNqvb\">Do not contract with Teva.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">-To groups, organizations, and social movements:\u003Ca href=\"https:\u002F\u002Ftevanogracias.limesurvey.net\u002F783363?lang=es&newtest=Y\"> \u003Cstrong>Sign the Teva boycott manifesto\u003C\u002Fstrong> \u003C\u002Fa>as an act of support for the campaign and disseminate it among your groups and in society at large within your spheres of influence.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Direct action against Teva.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> For justice for Palestine, join the Teva boycott campaign.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> This campaign will be active from March 1 to December 1, 2026.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Beyond the Spanish State-Ruled Boycott of Teva \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In addition to the boycott of Teva, we must ask ourselves: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">How long will Teva abuse our patience through the complicity of Spanish administrative and political authorities with its activities in general?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">How long will it abuse our patience by keeping the Teva factory in Zaragoza and its other facilities in Spain open?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">How long will Teva products continue to be funded by the National Health System, and how long will its marketing authorizations be maintained?\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">How long will Spanish public authorities continue to fail to analyze the implications of other pharmaceutical and technology companies working in the healthcare sector with the occupation, apartheid, and genocide in Palestine, and to act accordingly?\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">For example, Pfizer, AstraZeneca, Lilly, Philips, Palantir, Merck, BMS, Novartis, Google, Telefónica, Sanofi, GSK, and Medtronic.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Siemens, Indra, Hewlett-Packard, Microsoft, and other companies that may have participated and continue to participate in supporting the occupation, apartheid, and genocide in Palestine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In addition to the boycott of Teva, we can establish support and solidarity networks with those who are committed, such as the cases mentioned in Cruces, Vallecas, Asturias, Navarra, etc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We can also work with others, such as the magazine \"Fair Access to Medicines,\" the Toledo Medical Association, the Federation of Associations for the Defense of Public Health, etc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Let us not forget: the revolutionary virtue is perseverance.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">They know that we tire and become exhausted;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">therefore, we must become tireless and inexhaustible, never remaining silent, because \"the deepest trauma is oblivion, it is silence.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"en\" data-language-name=\"inglés\" data-text=\"Beyond the State-Ruled Boycott of Teva\nIn addition to the boycott of Teva, we must ask ourselves:\nHow long will Teva abuse our patience through the complicity of Spanish administrative and political authorities with its activities in general?\nHow long will it abuse our patience by keeping the Teva factory in Zaragoza and its other facilities in Spain open?\nHow long will Teva products continue to be funded by the National Health System, and how long will its marketing authorizations be maintained?\nHow long will Spanish public authorities continue to fail to analyze the implications of other pharmaceutical and technology companies working in the healthcare sector with the occupation, apartheid, and genocide in Palestine, and to act accordingly? For example, Pfizer, AstraZeneca, Lilly, Philips, Merck, BMS, Novartis, Google, Telefónica, Sanofi, GSK, and Medtronic. Siemens, Indra, Hewlett-Packard, Microsoft, and other companies that may have participated and continue to participate in supporting the occupation, apartheid, and genocide in Palestine.\n\nIn addition to the boycott of Teva, we can establish support and solidarity networks with those who are committed, such as the cases mentioned in Cruces, Vallecas, Asturias, Navarra, etc.\n\nWe can also work with others, such as the magazine "Fair Access to Medicines," the Toledo Medical Association, the Federation of Associations for the Defense of Public Health, etc.\n\nLet us not forget: the revolutionary virtue is perseverance. They know that we tire and become exhausted; therefore, we must become tireless and inexhaustible, never remaining silent, because "the deepest trauma is oblivion, it is silence."\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"OwOEge\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In our campaigns, we try to work \"from the ground up,\" as in public health.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">1. The highest level, the ideal, almost impossible, is for the Ministry of Health to stop including Teva medicines on the public formulary.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">2. Given that the Spanish healthcare system is decentralized across the Autonomous Communities, the next level, where we have had success (Autonomous Communities, Asturias, and Navarre), is for healthcare services to stop purchasing Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">3. If we descend to that level, it involves influencing medical associations and healthcare professionals to stop using Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">4. The next level, within the community, is the pharmacies.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">5. The final level is patients in pharmacies.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">We believe it is important to have this idea of ​​\"levels\" so as not to place the entire burden of the boycott on the shoulders of patients in pharmacies.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>","Spain. Statewide Boycott Campaign Against Teva: “Don’t Let Your Medicines Be Their Bullets,” “Teva? No Thanks!”",[15,164],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1781794947\u002Fz5eloldnbdvsr1koknsl.png","spain-statewide-boycott-campaign-against-teva-don-t-let-your-medicines-be-their-bullets-teva-no-thanks",1781795519215,"Do not use Teva. Do not prescribe Teva. Do not sell\u002Fdispense Teva.  Do not contract with Teva.","mqjlba9b4zveg2nsohk",{"videoUrl":294,"id":598,"slug":599,"type":7,"imageUrl":600,"user":13,"tags":601,"title":603,"link":12,"subtitle":604,"content":605,"timestamp":606},"msnam8idpquqg25a2vn","teva-feels-the-pressure-against-israel-and-the-palestinian-genocide-on-its-neck-teva-siente-en-la-nuca-el-aliento-contra-israel-y-el-genocidio-palestino-eng-esp","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1786386625\u002Fcfvhxz5tjfiapgdfj9xc.jpg",[15,602],"Jury","Teva feels the pressure against Israel and the Palestinian genocide on its neck. Teva siente en la nuca el aliento contra Israel y el genocidio palestino. ENG ESP"," In a US trial, it is asking to conceal its Zionist nature. En un juicio en Estados Unidos pide ocultar su carácter sionista.","\u003Cp>\u003Cimg src=\"https:\u002F\u002Fcdn.bsky.app\u002Fimg\u002Ffeed_fullsize\u002Fplain\u002Fdid:plc:sijrnjskilwxv3a4lmvqw2eg\u002Fbafkreietnewukx2wflealetb5txsjpjn6rdbaymjdqatfagddqe4id3kzm\" alt=\"\" width=\"1253\" height=\"803\">\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fwww.reuters.com\u002Flegal\u002Flitigation\u002Fteva-seeks-keep-israel-ties-jury-cites-gaza-war-2026-08-06\u002F\">Teva seeks to keep Israel ties from jury, \u003C\u002Fa>cites Palestinian genocide\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>By Mike Scarcella, August 6, 2026\u003C\u002Fp>\n\u003Cp>Teva points to animosity toward Israel since Gaza genocide. Drugmaker says corporate origin is irrelevant to case. Trial over pricing allegations set for next month.\u003C\u002Fp>\n\u003Cp>Teva Pharmaceuticals (TEVA.TA), opens new tab has asked a U.S. judge to ​prevent insurer Humana (HUM.N), opens new tab from telling jurors it is an Israeli company at a major drug ‌price-fixing trial, arguing that\u003Cstrong> strong negative public views over the Gaza genocide\u003C\u002Fstrong> could prejudice proceedings and affect its ability to receive a fair hearing.\u003C\u002Fp>\n\u003Cp>In \u003Ca href=\"https:\u002F\u002Ffingfx.thomsonreuters.com\u002Fgfx\u002Flegaldocs\u002Fgdvzeaxxdpw\u002FTeva-%20Israeli%20-%20motion%20limine.pdf\">a filing\u003C\u002Fa>, opens new tab in a federal court in Philadelphia on Wednesday, Tel Aviv-based Teva said its national origins have no bearing ​on whether it took part in an alleged conspiracy to inflate generic drug prices, the central ​claim in the litigation.\u003C\u002Fp>\n\u003Cp>Teva, one of Israel's largest companies, is set to be one ⁠of several drug makers to face the first trial in the long-running case. The trial is scheduled ​to begin on September 15 and end by late October.\u003C\u002Fp>\n\u003Cp>The filing underscored how far-reaching tensions over the war in ​Gaza have become in the United States, including potentially complicating a company's ability to defend itself before randomly selected jurors.\u003Cbr>\u003Cbr>“In the period of almost three years since the start of the Gaza genocide, anything connected with ​Israel has been subject to the highest levels of controversy, with emotions running high,” Teva said in its filing.\u003Cbr>\u003Cbr>In a ‌statement, it ⁠said its corporate origin was irrelevant to the case and that \"references to a foreign parent company are potentially prejudicial.” Teva's U.S.-based subsidiary is a defendant in the lawsuit.\u003C\u002Fp>\n\u003Cp>Teva has denied Humana's allegations that it conspired with other drug makers to keep the prices of some drugs artificially high. The drugs include the muscle relaxant ​baclofen and blood pressure medication ​propranolol.\u003Cbr>Louisville, Kentucky-based Humana declined ⁠to comment.\u003C\u002Fp>\n\u003Cp>Companies and other parties in lawsuits routinely ask judges to limit what jurors can hear during trials, arguing that some evidence could unfairly sway a jury.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Teva ​pointed to a recent opinion poll that said it found 60% of Americans ​have a ⁠negative view of Israel.\u003C\u002Fstrong> The drug maker also cited U.S. college campus protests over Israel and acts of violence against individuals and institutions deemed affiliated with the country.\u003C\u002Fp>\n\u003Cp>Humana in a separate filing, opens new tab urged the court to bar the drug ⁠company defendants ​from introducing “inflammatory argument or evidence regarding health insurance companies generally,” ​including any evidence of denied claims.\u003Cbr>Its filing cited the 2024 shooting death of UnitedHealthcare chief executive Brian Thompson. The alleged shooter in that case ​allegedly wrote the word “deny” on a bullet casing.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\" data-hveid=\"4\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva busca impedir que el jurado conozca sus vínculos con Israel, citando el genocidio palestino\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Por Mike Scarcella, 6 de agosto de 2026 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva señala la animosidad hacia Israel desde la matanza de Gaza.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La farmacéutica afirma que el origen corporativo es irrelevante para el caso.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El juicio por acusaciones de fijación de precios está programado para el próximo mes. Teva Pharmaceuticals (TEVA.TA) ha solicitado a un juez estadounidense que impida que la aseguradora Humana (HUM.N) revele al jurado que es una empresa israelí en un importante juicio por fijación de precios de medicamentos, \u003Cstrong>argumentando que la fuerte negativa opinión pública sobre el genocidio en Gaza podría perjudicar el proceso y afectar su capacidad para recibir una audiencia justa.\u003C\u002Fstrong>\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">En un documento presentado el miércoles ante un tribunal federal de Filadelfia, Teva, con sede en Tel Aviv, afirmó que su origen nacional no influye en si participó en una supuesta conspiración para inflar los precios de los medicamentos genéricos, la principal alegación del litigio.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Comience su mañana con las últimas noticias legales directamente en su bandeja de entrada con el boletín informativo The Daily Docket.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Regístrese aquí.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Anuncio · Desplácese para continuar Teva, una de las mayores empresas de Israel, será una de las farmacéuticas que se enfrentarán al primer juicio en este caso de larga duración.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El juicio está programado para comenzar el 15 de septiembre y finalizar a finales de octubre.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> La demanda puso de manifiesto el alcance de las tensiones en Estados Unidos en torno a la guerra de Gaza, que podrían dificultar la capacidad de una empresa para defenderse ante un jurado seleccionado al azar.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> El ataque militar israelí contra la Franja de Gaza, desencadenado por el ataque de Hamás contra Israel en octubre de 2023, se ha convertido en un tema divisivo en la política estadounidense.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> «En los casi tres años transcurridos desde el inicio de la guerra de Gaza, todo lo relacionado con Israel ha sido objeto de la mayor controversia, con emociones a flor de piel», declaró Teva en su demanda.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Anuncio · Desplácese para continuar En un comunicado, la empresa afirmó que su origen corporativo era irrelevante para el caso y que \"las referencias a una empresa matriz extranjera podrían ser perjudiciales\".\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">La filial estadounidense de Teva es demandada en el litigio.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva ha negado las acusaciones de Humana de haber conspirado con otros fabricantes de medicamentos para mantener artificialmente altos los precios de algunos fármacos.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Entre estos fármacos se encuentran el relajante muscular baclofeno y el medicamento para la presión arterial propranolol.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Humana, con sede en Louisville, Kentucky, declinó hacer comentarios.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Las empresas y otras partes involucradas en litigios suelen solicitar a los jueces que limiten la información que los jurados pueden escuchar durante los juicios, argumentando que algunas pruebas podrían influir injustamente en el jurado.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva citó una encuesta de opinión reciente que reveló que el 60% de los estadounidenses tiene una visión negativa de Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El fabricante de medicamentos también mencionó las protestas en campus universitarios estadounidenses contra Israel y los actos de violencia contra personas e instituciones consideradas afiliadas al país.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Humana, en una demanda aparte (se abre en una nueva pestaña), instó al tribunal a impedir que las compañías farmacéuticas demandadas presentaran “argumentos o pruebas incendiarias sobre las compañías de seguros de salud en general”, incluyendo cualquier prueba de reclamaciones denegadas.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> En su demanda, citó el asesinato a tiros en 2024 del director ejecutivo de UnitedHealthcare, Brian Thompson.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El presunto autor del tiroteo en ese caso supuestamente escribió la palabra “negar” en un casquillo de bala.\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"es\" data-language-name=\"español\" data-text=\"Teva busca impedir que el jurado conozca sus vínculos con Israel, citando la guerra de Gaza\nPor Mike Scarcella, 6 de agosto de 2026\n\nTeva señala la animosidad hacia Israel desde la guerra de Gaza. La farmacéutica afirma que el origen corporativo es irrelevante para el caso. El juicio por acusaciones de fijación de precios está programado para el próximo mes.\nTeva Pharmaceuticals (TEVA.TA) ha solicitado a un juez estadounidense que impida que la aseguradora Humana (HUM.N) revele al jurado que es una empresa israelí en un importante juicio por fijación de precios de medicamentos, argumentando que la fuerte opinión pública sobre la guerra de Gaza podría perjudicar el proceso y afectar su capacidad para recibir una audiencia justa.\n\nEn un documento presentado el miércoles ante un tribunal federal de Filadelfia, Teva, con sede en Tel Aviv, afirmó que su origen nacional no influye en si participó en una supuesta conspiración para inflar los precios de los medicamentos genéricos, la principal alegación del litigio.\n\nComience su mañana con las últimas noticias legales directamente en su bandeja de entrada con el boletín informativo The Daily Docket. Regístrese aquí. Anuncio · Desplácese para continuar\nTeva, una de las mayores empresas de Israel, será una de las farmacéuticas que se enfrentarán al primer juicio en este caso de larga duración. El juicio está programado para comenzar el 15 de septiembre y finalizar a finales de octubre.\n\nLa demanda puso de manifiesto el alcance de las tensiones en Estados Unidos en torno a la guerra de Gaza, que podrían dificultar la capacidad de una empresa para defenderse ante un jurado seleccionado al azar.\nEl ataque militar israelí contra la Franja de Gaza, desencadenado por el ataque de Hamás contra Israel en octubre de 2023, se ha convertido en un tema divisivo en la política estadounidense.\n\n«En los casi tres años transcurridos desde el inicio de la guerra de Gaza, todo lo relacionado con Israel ha sido objeto de la mayor controversia, con emociones a flor de piel», declaró Teva en su demanda.\nAnuncio · Desplácese para continuar\nEn un comunicado, la empresa afirmó que su origen corporativo era irrelevante para el caso y que "las referencias a una empresa matriz extranjera podrían ser perjudiciales". La filial estadounidense de Teva es demandada en el litigio.\nTeva ha negado las acusaciones de Humana de haber conspirado con otros fabricantes de medicamentos para mantener artificialmente altos los precios de algunos fármacos. Entre estos fármacos se encuentran el relajante muscular baclofeno y el medicamento para la presión arterial propranolol.\n\nHumana, con sede en Louisville, Kentucky, declinó hacer comentarios.\n\nLas empresas y otras partes involucradas en litigios suelen solicitar a los jueces que limiten la información que los jurados pueden escuchar durante los juicios, argumentando que algunas pruebas podrían influir injustamente en el jurado.\n\nTeva citó una encuesta de opinión reciente que reveló que el 60% de los estadounidenses tiene una visión negativa de Israel. El fabricante de medicamentos también mencionó las protestas en campus universitarios estadounidenses contra Israel y los actos de violencia contra personas e instituciones consideradas afiliadas al país. Humana, en una demanda aparte (se abre en una nueva pestaña), instó al tribunal a impedir que las compañías farmacéuticas demandadas presentaran “argumentos o pruebas incendiarias sobre las compañías de seguros de salud en general”, incluyendo cualquier prueba de reclamaciones denegadas.\n\nEn su demanda, citó el asesinato a tiros en 2024 del director ejecutivo de UnitedHealthcare, Brian Thompson. El presunto autor del tiroteo en ese caso supuestamente escribió la palabra “negar” en un casquillo de bala.\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"kGmWO\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"OwOEge\">\n\u003Cdiv class=\"cJ1Ndf\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",1786386638331,{"content":608,"imageUrl":609,"videoUrl":176,"slug":610,"type":7,"user":13,"tags":611,"subtitle":614,"link":12,"timestamp":615,"title":616,"id":617},"\u003Csection class=\"framer-1du447r\" data-framer-name=\"Hero Section\">\n\u003Cdiv class=\"framer-z4o9ka\" data-framer-name=\"Main Wrapper\">\n\u003Cdiv class=\"framer-1julg73\" data-framer-name=\"Container\">\n\u003Cdiv class=\"framer-1oaj59i\" style=\"will-change: transform; opacity: 1; transform: none;\" data-framer-component-type=\"RichTextContainer\">\n\u003Ch4 class=\"framer-text framer-styles-preset-aze0he\" style=\"--framer-text-color: var(--token-03a2e07c-b209-46b6-8771-3d1df3069dd5, rgb(255, 255, 255));\" data-styles-preset=\"XDyIZJYP6\">ESPAÑOL\u003C\u002Fh4>\n\u003Ch4 class=\"framer-text framer-styles-preset-aze0he\" style=\"--framer-text-color: var(--token-03a2e07c-b209-46b6-8771-3d1df3069dd5, rgb(255, 255, 255));\" data-styles-preset=\"XDyIZJYP6\">\u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002Fnoticias\u002Fesperando-al-vall-d-hebron-institut-de-recerca-(vhir)\">Esperando al \"Vall d'Hebron Institut de Recerca\" (VHIR)\u003C\u002Fa>\u003C\u002Fh4>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fsection>\n\u003Csection class=\"framer-1u9flyv\" data-framer-name=\"Content Wrapper\">\n\u003Cdiv class=\"framer-xwdwzm\" data-framer-name=\"Container\">\n\u003Cdiv class=\"framer-11jv9px\" style=\"will-change: transform; opacity: 1; transform: none;\" data-framer-component-type=\"RichTextContainer\">\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">20 septiembre 2026\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">El pasado mes de Abril nos pusimos en contacto con diferentes responsables y autoridades del mundo de la Investigación Médica en Cataluña para denunciar la anomalía ética que se estaba produciendo en el Instituto de Investigación del Hospital Vall D`Hebrón de Barcelona.\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">El punto conflictivo que señalábamos consistía en la presencia de dos personas vinculadas estrechamente a Teva en los dos principales órganos rectores del VIHR, el \u003Ca class=\"framer-text\" href=\"https:\u002F\u002Fvhir.vallhebron.com\u002Fca\u002Finstitut\u002Forgans-de-govern\u002Fcomite-cientific-intern\" target=\"_blank\" rel=\"noopener\">Comité Científico Interno\u003C\u002Fa> y el \u003Ca class=\"framer-text\" href=\"https:\u002F\u002Fvhir.vallhebron.com\u002Fca\u002Finstitut\u002Forgans-de-govern\u002Fcomite-cientific-extern\" target=\"_blank\" rel=\"noopener\">Comité Científico Externo\u003C\u002Fa>.\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">.\u003C\u002Fp>\n\u003Cimg class=\"framer-text framer-image framer-styles-preset-ae9yzm\" style=\"aspect-ratio: 1080 \u002F 832;\" src=\"https:\u002F\u002Fframerusercontent.com\u002Fimages\u002FCLNpQFbpqLp1PEEF1od89i2GU.jpg\" sizes=\"(min-width: 1200px) 100vw, (min-width: 810px) and (max-width: 1199.98px) 100vw, (max-width: 809.98px) 100vw\" srcset=\"https:\u002F\u002Fframerusercontent.com\u002Fimages\u002FCLNpQFbpqLp1PEEF1od89i2GU.jpg?scale-down-to=512&width=1080&height=832 512w,https:\u002F\u002Fframerusercontent.com\u002Fimages\u002FCLNpQFbpqLp1PEEF1od89i2GU.jpg?scale-down-to=1024&width=1080&height=832 1024w,https:\u002F\u002Fframerusercontent.com\u002Fimages\u002FCLNpQFbpqLp1PEEF1od89i2GU.jpg?width=1080&height=832 1080w\" alt=\"\" width=\"540\" height=\"416\">\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">.En el \u003Cstrong class=\"framer-text\">Comité Científico Interno\u003C\u002Fstrong> se sienta la \u003Cstrong class=\"framer-text\">Dra. Patricia Pozo Rosich, \u003C\u002Fstrong>con el cargo de Vicepresidenta del Comité,\u003Cstrong class=\"framer-text\"> \u003C\u002Fstrong>que es Responsable del Área Brain, Mind & Behaviour, Responsable del Grupo de Investigación Cefalea y Dolor Neurológico y Jefa del Servicio de Neurología del Hospital Vall d´Hebron. Pero además de todos estos prestigiosos cargos, la Doctora Pozo es hoy en día la\u003Ca class=\"framer-text\" href=\"https:\u002F\u002Fdrive.proton.me\u002Furls\u002FQ8AQMJAEBC#TPEJ2OQJRNoS\" target=\"_blank\" rel=\"noopener\"> principal KOL (\u003Cem class=\"framer-text\">Key Opinion Leader\u003C\u002Fem>) de la empresa Teva en Españ\u003C\u002Fa>a. Esta Doctora recibe anualmente del Laboratorio Teva generosas cantidades en forma de Transferencias de Valor (TOV).\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">Pero es que en el \u003Cstrong class=\"framer-text\">Comité Científico Externo\u003C\u002Fstrong> del VHIR se sienta la \u003Cstrong class=\"framer-text\">Prof. Ronit Satchi-Fainaro\u003C\u002Fstrong>, que se presenta en la web del VHIR como Jefa del Laboratorio de Investigación en Cáncer y Nanomedicina,  Catedrática de The Hermann and Kurt Lion en Nanociencia y Nanotecnología del Departamento de Fisiología y Farmacología de Sackler School of Medicine en Tel Aviv University (Israel). \u003Cstrong class=\"framer-text\">Pero lo que se OCULTA en esa presentación es que esta profesora forma parte del \u003C\u002Fstrong>\u003Ca class=\"framer-text\" href=\"https:\u002F\u002Fwww.tevapharm.com\u002Four-company\u002Fleadership-governance\u002Fboard-of-directors\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cstrong class=\"framer-text\">Consejo de Administración de Teva\u003C\u002Fstrong>\u003C\u002Fa>\u003Cstrong class=\"framer-text\">, el máximo órgano decisorio de la compañía israelí.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">La carta que se remitió esta disponible \u003Ca class=\"framer-text\" href=\"https:\u002F\u002Fdrive.proton.me\u002Furls\u002F5XRB2DRA28#Fc3QZUjyL3mi\" target=\"_blank\" rel=\"noopener\">AQUÍ.\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">Desde entonces se han dirigido a la Campaña diferentes correos comentando que se iba a investigar este suceso y que adoptarían decisiones al respetco.\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">El último correo es del Comité de Integridad de la Investigación del VHIR y es de Junio 2026. Por ahora, todo sigue igual….\u003C\u002Fp>\n\u003Cdiv class=\"VjFXz\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"hgbeOc EjH7wc\">\u003Cnav class=\"U0xwnf\" aria-labelledby=\"ucj-4\">\n\u003Cdiv class=\"cWQYBc\">\n\u003Cdiv class=\"VfPpkd-dgl2Hf-ppHlrf-sM5MNb\" data-is-touch-wrapper=\"true\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"VfPpkd-dgl2Hf-ppHlrf-sM5MNb\" data-is-touch-wrapper=\"true\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fnav>\u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Waiting for the Vall d'Hebron Research Institute (VHIR) \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">September 20, 2026 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Last April, we contacted various officials and authorities in the field of Medical Research in Catalonia to report the ethical irregularity occurring at the Vall d'Hebron Research Institute in Barcelona.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The point we raised was the presence of two individuals closely linked to Teva on the two main governing bodies of the VHIR: the Internal Scientific Committee and the External Scientific Committee.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Patricia Pozo Rosich \u003C\u002Fstrong>sits on the Internal Scientific Committee as Vice President. She is Head of the Brain, Mind & Behavior Area, Head of the Headache and Neurological Pain Research Group, and Head of the Neurology Department at Vall d'Hebron Hospital.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">But in addition to all these prestigious positions, Dr. Pozo is currently Teva's main KOL (Key Opinion Leader) in Spain.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">She receives generous annual payments from Teva in the form of Transfers of Value (TOV).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Also, \u003Cstrong>Ronit Satchi-Fainaro\u003C\u002Fstrong> sits on the VHIR's External Scientific Committee. She presents herself on the VHIR website as Head of the Cancer and Nanomedicine Research Laboratory and The Hermann and Kurt Lion Professor of Nanoscience and Nanotechnology in the Department of Physiology and Pharmacology at the Sackler School of Medicine, Tel Aviv University (Israel).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cem>\u003Cspan class=\"ryNqvb\">But what is HIDDEN in this presentation is that this professor is a member of Teva's Board of Directors, the highest decision-making body of the Israeli company.\u003C\u002Fspan>\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The letter that was sent is available HERE.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Since then, the Campaign has received several emails stating that this incident would be investigated and that decisions would be made accordingly.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> The most recent email is from the VHIR Research Integrity Committee and is dated June 2026. For now, everything remains the same…\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fsection>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1790785513\u002Fp09oihtewpxciwldbv3t.png","vall-d-hebron-institut-de-recerca-vhir-barcelona-espana-y-sus-conflictos-de-interes-con-teva-vall-d-hebron-institute-of-research-vhir-barcelona-spain-and-its-conflicts-of-interest-with-teva-esp-eng",[15,612,613],"Patricia Pozo Rosich","Ronit Satchi-Fainaro","Dinero (de Teva España) e influencia (de Teva Israel). Money (from Teva Spain) and influence (from Teva Israel).",1790786661658,"Vall d'Hebron Institut de Recerca (VHIR), Barcelona, España, y sus conflictos de interés con Teva. Vall d'Hebron Institute of Research (VHIR), Barcelona, ​​Spain, and its conflicts of interest with Teva. ESP ENG","muob5pe079r9wgwyi1o",{"subtitle":619,"type":7,"content":620,"slug":621,"id":622,"timestamp":623,"imageUrl":624,"link":12,"title":625,"tags":626,"user":13,"videoUrl":385},"No one is \"innocent,\" not even Spain. Nadie es \"inocente\", tampoco España.","\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">SPAIN. Boycott Teva. October 2026. Update. Summary 250 words\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The activities against the genocide of the Palestinian people and the boycott of Teva involve hundreds of organizations, not just healthcare organizations. These activities have years of experience and culminated in a nationwide campaign in 2026, which began in February and will conclude with a march and demonstration in front of the Teva factory in Zaragoza on November 14.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">The boycott of Teva has four main aspects:\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">1\u002F \u003Cstrong>The political aspect,\u003C\u002Fstrong> since Spain has a decentralized, universal public healthcare system (managed by the Autonomous Communities), and therefore public procurement is crucial for the industry. Contracts with Teva have been cancelled in two Autonomous Communities: Asturias and Navarre. Professionals have also filed complaints in these two Communities, as well as in Madrid and the Basque Country, to cancel public purchases. \u003Cspan class=\"ryNqvb\">Of particular note is the Terrassa City Council, Barcelona.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">2\u002F \u003Cstrong>Dissemination of public data on the money Teva \"donates\" \u003C\u002Fstrong>to professionals and institutions, revealing significant conflicts of interest and \"key opinion leaders\" working for Teva.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">3\u002F The afore mentioned grouping of numerous associations working against the Palestinian genocide in a \u003Cstrong>strong state boycott campaign against Teva\u003C\u002Fstrong>, focusing on a) the best-selling medications and b) the most expensive medications.\u003C\u002Fp>\n\u003Cp lang=\"en-US\" style=\"line-height: 100%; margin-bottom: 0cm;\">4\u002F \u003Cstrong>Working with universities, academics, and students\u003C\u002Fstrong> to denounce, with data, figures, and names, the connections between Spain and Israel, including in the healthcare sector (with Teva specifically mentioned)\u003Cem>, because no one is \"innocent,\" not even Spain\u003C\u002Fem>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\">\u003Cstrong>To know more:\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">In Spanish Campaña “Teva NoGracias” \u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002F\">https:\u002F\u002Ftevanogracias.com\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">Contact in Spanish and English: Pablo Simón <psimoneasp@gmail.com> \u003C\u002Fp>\n\u003Cp lang=\"en-US\">In Spanish and English Teva creates value to sustain genocide in Palestine \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\">https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">\u003Cstrong>Doubts?\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">Contact Health Workers For Palestine Spain\u003C\u002Fp>\n\u003Cp lang=\"en-US\">HW4P España <hcw4palestinespain@gmail.com> \u003C\u002Fp>\n\u003Cp lang=\"en-US\">In Spanish and English Juan Gérvas <\u003Ca href=\"mailto:jjgervas@gmail.com\">jjgervas@gmail.com\u003C\u002Fa>>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">\u003Cstrong>ESPAÑA. Boicot a Teva. Resumen. Octubre 2026. Actualización. Resumen 250 palabras.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">Las actividades contra el genocidio del pueblo palestino y de boicot a Teva cuentan con la participación de cientos de organizaciones, no sólo sanitarias. Dichas actividades cuentan con años de experiencia y se ha concretado, en 2026, con una campaña en toda España, desde febrero, que culminará con una marcha y manifestación ante la fábrica de Teva en Zaragoza el 14 de noviembre,\u003C\u002Fp>\n\u003Cp lang=\"en-US\">Son cuatro los ejes del boicot a Teva:\u003C\u002Fp>\n\u003Cp lang=\"en-US\">1\u002F\u003Cstrong> el político, \u003C\u002Fstrong>pues en España existe un sistema sanitario público de cobertura universal y descentralizado (son las Comunidades Autónomas las que gestionan), y por ello las compras públicas son clave para la industrias. En dos Comunidades Autónomas se ha logrado anular los contratos con Teva: en Asturias y en Navarra. También en estas dos Comunidades, y en Madrid y el País Vasco, ha habido reclamaciones profesionales para anular las compras públicas. A destacar el Ayuntamiento de Terrassa, Barcelona.\u003C\u002Fp>\n\u003Cp lang=\"en-US\">2\u002F\u003Cstrong> difusión de datos públicos sobre el dinero que Teva \"dona\"\u003C\u002Fstrong>a profesionales e instituciones que permiten demostrar fuertes conflictos de interés y \"key opinion leaders\" al servicio de Teva,\u003C\u002Fp>\n\u003Cp lang=\"en-US\">3\u002F el agrupamiento citado de las múltiples asociaciones que trabajan contra el genocidio palestino en una fuerte \u003Cstrong>campaña estatal de boicot a Teva \u003C\u002Fstrong>centrada en a\u002F los medicamentos más vendidos y 2\u002F los medicamentos con mayor precio\u003C\u002Fp>\n\u003Cp lang=\"en-US\">4\u002F \u003Cstrong>el trabajo con las Univesidades, académicos y estudiantes\u003C\u002Fstrong> para denunciar con datos, cifras y nombres, las conexiones , entre España e Israel, también en el campo sanitario (Teva especialmente mencionada) pues \u003Cem>nadie es \"inocente\", tampoco España\u003C\u002Fem>.\u003C\u002Fp>\n\u003Cp lang=\"en-US\">\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">\u003Cstrong>Para saber más:\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">En español, Campaña “Teva NoGracias” \u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002F\">https:\u002F\u002Ftevanogracias.com\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">Contacto, Pablo Simón <psimoneasp@gmail.com>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">En español e inglés: Teva crea valor para sostener el genocidio en Palestina \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\">https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">\u003Cbr>\u003Cbr>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">\u003Cstrong>Dudas?\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">Contacte Health Workers For Palestine Spain\u003C\u002Fp>\n\u003Cp lang=\"en-US\">HW4P España <hcw4palestinespain@gmail.com>\u003C\u002Fp>\n\u003Cp lang=\"en-US\">Juan Gérvas <\u003Ca href=\"mailto:jjgervas@gmail.com\">jjgervas@gmail.com\u003C\u002Fa>>\u003C\u002Fp>","spain-boycott-teva-october-2026-update-espana-boicot-a-teva-resumen-octubre-2026-actualizacion-eng-esp","muwxd2nb75scdk0km0d",1791306576412,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1791306570\u002Fyztc6q4pzxwkenydgcby.png","SPAIN. Boycott Teva. October 2026. Update. ESPAÑA. Boicot a Teva. Resumen. Octubre 2026. Actualización. ENG ESP",[15,471,164,560,559],{"subtitle":628,"content":629,"user":13,"tags":630,"title":637,"link":12,"timestamp":638,"imageUrl":639,"slug":640,"id":641,"type":7,"videoUrl":12},"After concerns over Teva Pharmaceuticals activities. Por las preocupaciones surgidas por sus actividades\".","\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>8 October 2026\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.theguardian.com\u002Fsociety\u002F2026\u002Foct\u002F02\u002Froyal-college-of-nursing-cuts-ties-with-israeli-drug-company\">\u003Cstrong>The Royal College of Nursing (RCN), Britain’s nursing union has cut its ties with TEVA (an Israeli drug company) over the firm’s links to the country’s military and track record of corporate misconduct.\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>The Royal College of Nursing (RCN) has axed Teva UK as a commercial partner and as sponsor of a forthcoming event on migraine and headaches at the union’s London headquarters.\u003C\u002Fp>\n\u003Cp>Pro-Palestine groups who were pushing the RCN to drop Teva UK claimed the decision was “a major breakthrough for grassroots healthcare organising and the international boycott, divestment and sanctions movement” aimed at isolating Israel worldwide.\u003C\u002Fp>\n\u003Cp>The RCN represents more than 500,000 nurses in the UK.\u003C\u002Fp>\n\u003Cp>Teva UK is the British arm of the global drug giant Teva Pharmaceuticals, which is one of the NHS’s biggest suppliers of medicines.\u003C\u002Fp>\n\u003Cp>It acted after coming under pressure from campaign groups Nurses for Palestine and UK Healthcare Petitions to Royal Colleges (UKHPRC) to end its relationship with Teva UK.\u003C\u002Fp>\n\u003Cp>Carmel O’Boyle, the chair of the RCN’s ruling council, confirmed the decision in a letter to Nurses for Palestine.\u003C\u002Fp>\n\u003Cp>“Going forward [the] RCN is ending its commercial partnership with Teva UK. Teva UK will no longer be a sponsor of the RCNi nursing leadership summit: \u003Cstrong>migraine and headache\u003C\u002Fstrong> services event on 30 October 2026. The event will go ahead as planned,” she said.\u003C\u002Fp>\n\u003Cp>“We are taking this action because further due diligence showed that there are a number of Teva Pharmaceuticals’ operations, which have been the subject of legal sanction and public scrutiny, which are not in line with RCNi [the union’s publishing and education arm] and RCN values.\u003C\u002Fp>\n\u003Cp>“We know how important it is that the RCN only enters commercial relationships with companies that represent the values of the nursing profession.”\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.theguardian.com\u002Fsociety\u002F2026\u002Foct\u002F09\u002Froyal-college-pharmacy-cuts-ties-teva-israel-palestine-campaigners\">\u003Cstrong>The Royal College of Pharmacy has dropped Teva UK, the British arm of the global medicines producer Teva Pharmaceuticals, as a sponsor of and exhibitor at its annual conference next month.\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cbr>Its decision comes after that of the Royal College of Nursing (RCN) last week to cut its longstanding ties with Teva UK. The RCN, which represents 500,000 UK nurses, dropped Teva as a sponsor of both the union and an event on headache and migraine.\u003C\u002Fp>\n\u003Cp>The Royal College of Pharmacy is the professional body for Britain’s 34,000 pharmacists.\u003C\u002Fp>\n\u003Cp>Teva UK was due to be an exhibitor at four of its events as part of a £15,000 deal, the college said.\u003C\u002Fp>\n\u003Cp>A spokesperson said it had taken its decision after realising that unspecified Teva Pharmaceuticals’ “activities”, uncovered by a “due diligence review”, did not align with its values.\u003C\u002Fp>\n\u003Cp>“The Royal College of Pharmacy has decided to end Teva UK’s current sponsorship and exhibition presence for our forthcoming annual conference with immediate effect.\u003C\u002Fp>\n\u003Cp>“This follows a further due diligence review which has brought to our attention the possibility of certain Teva Pharmaceuticals activities which do not align with our values”, the spokesperson said.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>8 octubre 2026\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">El Real Colegio de Enfermería, sindicato de enfermería británico, ha roto sus vínculos con una farmacéutica israelí TEVA debido a la relación de la empresa con el ejército del país y su historial de mala conducta corporativa.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El Real Colegio de Enfermería (RCN, por sus siglas en inglés) ha rescindido el contrato con Teva UK como socio comercial y patrocinador de un próximo evento sobre migraña y dolores de cabeza que se celebraría en la sede del sindicato en Londres.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Grupos propalestinos que presionaban al RCN para que rompiera su relación con Teva UK afirmaron que la decisión representaba «un gran avance para la organización de base del sector sanitario y el movimiento internacional de boicot, desinversión y sanciones» destinado a aislar a Israel en todo el mundo.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El RCN representa a más de 500.000 enfermeros en el Reino Unido.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva UK es la filial británica del gigante farmacéutico mundial Teva Pharmaceuticals, uno de los mayores proveedores de medicamentos del NHS (Servicio Nacional de Salud del Reino Unido).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El RCN tomó esta decisión tras la presión ejercida por las organizaciones Nurses for Palestine y UK Healthcare Petitions to Royal Colleges (UKHPRC) para que pusiera fin a su relación con Teva UK.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Carmel O’Boyle, presidenta del consejo directivo del RCN, confirmó la decisión en una carta dirigida a Enfermeras por Palestina.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> «A partir de ahora, el RCN pone fin a su colaboración comercial con Teva UK. Teva UK dejará de patrocinar la cumbre de liderazgo en enfermería de RCNi sobre servicios para la \u003Cstrong>migraña y el dolor de cabeza\u003C\u002Fstrong>, que tendrá lugar el 30 de octubre de 2026. El evento se celebrará según lo previsto», declaró.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">«Tomamos esta medida porque un análisis más exhaustivo ha revelado que varias operaciones de Teva Pharmaceuticals, que han sido objeto de sanciones legales y escrutinio público, no se ajustan a los valores de RCNi (el brazo editorial y educativo del sindicato) ni del RCN. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">«Sabemos lo importante que es para el RCN establecer relaciones comerciales únicamente con empresas que representen los valores de la profesión de enfermería».\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">El Real Colegio de Farmacia ha retirado a Teva UK, la filial británica del fabricante mundial de medicamentos Teva Pharmaceuticals, como patrocinador y expositor en su congreso anual del próximo mes.\u003C\u002Fspan>\u003C\u002Fstrong> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Esta decisión se produce después de que el Real Colegio de Enfermería (RCN) rompiera la semana pasada su larga relación con Teva UK.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">El RCN, que representa a 500.000 enfermeros y enfermeras del Reino Unido, retiró a Teva como patrocinador tanto del sindicato como de un evento sobre cefaleas y migrañas.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">El Real Colegio de Farmacia es la organización profesional que representa a los 34.000 farmacéuticos británicos.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Teva UK iba a participar como expositor en cuatro de sus eventos como parte de un acuerdo de 15.000 libras esterlinas, según informó el colegio.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Un portavoz declaró que la decisión se tomó tras constatar que las \"actividades\" de Teva Pharmaceuticals, no especificadas y descubiertas durante una \"revisión de diligencia debida\", no se ajustaban a sus valores.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">\"El Real Colegio de Farmacia ha decidido poner fin al patrocinio y la presencia expositiva de Teva UK en nuestro próximo congreso anual\".\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"es\">\u003Cspan class=\"ryNqvb\">Con efecto inmediato.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> «Esto se produce tras una revisión exhaustiva que nos ha permitido detectar la posibilidad de que ciertas actividades de Teva Pharmaceuticals no se ajusten a nuestros valores», declaró el portavoz.\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cimg src=\"https:\u002F\u002Fcdn.bsky.app\u002Fimg\u002Ffeed_fullsize\u002Fplain\u002Fdid:plc:sijrnjskilwxv3a4lmvqw2eg\u002Fbafkreie5s5rzjywh6zb23r7x7l3ebqeuklswdnx5ydyknuwbq4i52yvnoi\" alt=\"\" width=\"1224\" height=\"1876\">\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>",[15,631,632,633,634,635,636],"UK","Nursing","Pharmacists","Enfermeras","Farmacéuticos","Reino Unido","UK. Royal College of Pharmacy and Royal College of Nursing end Teva sponsorship. Reino Unido. El Real Colegio de Farmacia y el Real Colegio de Enfermería ponen fin al patrocinio de Teva",1791543977020,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1791543525\u002Fuehzx7t4ksaizt3ddm4z.jpg","uk-royal-college-of-pharmacy-and-royal-college-of-nursing-end-teva-sponsorship-reino-unido-el-real-colegio-de-farmacia-y-el-real-colegio-de-enfermeria-ponen-fin-al-patrocinio-de-teva","mv0uhfuy82g3fo707f9",[643,653,661,669,677,686,694,702,710,720,730,739,747,757],{"subtitle":12,"title":644,"type":645,"content":646,"slug":647,"link":12,"timestamp":648,"user":13,"tags":649,"imageUrl":651,"videoUrl":12,"id":652},"Sesión virtual 12 diciembre. Boicot a Teva-Ratiopharm. Tele-encuentro","alerts","\u003Cp>\u003Cspan style=\"background-color: #f1c40f;\">REGISTRO del encuentro \u003Ca style=\"background-color: #f1c40f;\" href=\"https:\u002F\u002Fdrive.google.com\u002Ffile\u002Fd\u002F19OeDb25fsq_oghSRdoa4YWPcV80W4_OE\u002Fview\">aquí\u003C\u002Fa> 63 min vídeo\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>¿Prescribir, dispensar, consumir medicamentos-productos de TEVA-RATIOPHARM? NO\u003Cbr>\u003Ca dir=\"auto\">@Teva_es\u003C\u002Fa>\u003Cbr>Implica colaborar con el \u003Ca dir=\"auto\">#GenocidioEnGaza\u003C\u002Fa>  con asesinatos por Israel \u003Ca dir=\"auto\">#TEVABOICOT \u003C\u002Fa>\u003Ca dir=\"auto\">@Farmaindustria\u003C\u002Fa>\u003Cbr>¿Más? \u003Cbr>Participa el 12 de DICIEMBRE, en el teleencuentro \u003Ca dir=\"auto\" title=\"https:\u002F\u002Facortar.link\u002F8TZGdd\" href=\"https:\u002F\u002Facortar.link\u002F8TZGdd\" target=\"_blank\" rel=\"noopener noreferrer\" data-saferedirecturl=\"https:\u002F\u002Fwww.google.com\u002Furl?q=https:\u002F\u002Facortar.link\u002F8TZGdd&source=gmail&ust=1733143204012000&usg=AOvVaw1tuBPn_3Sh-KkkHqt4KQ5I\">https:\u002F\u002Facortar.link\u002F8TZGdd\u003C\u002Fa>\u003C\u002Fp>\n\u003Cdiv>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"font-size: small;\">Virtual. Enlace \u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Facortar.link\u002F8TZGdd\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-size: small;\">\u003Cstrong>https:\u002F\u002Facortar.link\u002F8TZGdd\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"font-size: small;\">Sesión y debate:\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cu>“\u003Cstrong>\u003Cspan style=\"font-size: small;\">¿Por qué y cómo hacer boicot a los medicamentos y productos de Teva-Ratiopharm?” \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cstrong>\u003Cspan style=\"font-size: small;\">Organiza: HW4PalestineSpain (Profesionales de la sanidad por Palestina, España) HW4PS \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"color: #000080;\">\u003Cu>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002F\">\u003Cspan style=\"font-size: small;\">\u003Cstrong>https:\u002F\u002Fhw4p.es\u002F\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fu>\u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">\u003Cbr>12\u002F12\u002F2024\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">19,00 h, \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">60 min de duración\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">PRIMERA PARTE\u003Cbr>\u003Cbr>-Presenta \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">Juan Gérvas, médico general rural jubilado, ex-profesor de salud pública, Equipo CESCA, Madrid.\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\"> De \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">HWP4PS.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">-1 min\u003Cbr>\u003Cbr>-”Vídeo de Boicot a Teva-Ratiopharm, de\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">HWP4PS”.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">Marina Hoyos, secretaria académica en escuela del ámbito sanitario. De formación periodismo y humanidades. Familia por la Paz y Terrassa con Palestina. \u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">De \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">HW4PS.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">-2 min\u003Cbr>\u003Cbr>-”¿Por qué hacer boicot a Teva-Ratiopharm?”\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">Victoria, química farmacéutica por la Universidad Autónoma Metropolitana Xochimilco (Ciudad de México) y Doctora en Ciencias por la Universidad Autónoma de Madrid. De Samidoun, red de solidaridad con los presos políticos palestinos. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">-15 min\u003Cbr>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">SEGUNDA PARTE\u003Cbr>\u003Cbr>Estrategias sugeridas y en marcha de \u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">HWP4PS \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">para hacer boicot a los medicamentos y productos de Teva-Ratipharm.\u003Cbr>\u003Cbr>- “Carta a las farmacias comunitarias”. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">Eva Mayor, médica de familia, pertenece a Rebelió Atenció Primària y Famílies per la Pau. \u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">De \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">HW4PS.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">-4 min\u003Cbr>\u003Cbr>-”Al prescribir medicamentos genéricos, ¿cómo podemos concienciar a la farmacia comunitaria para hacer boicot a Teva-Ratiopharm?” \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">Vídeo\u002Fcartel de cómo informar\u002Fsolicitar a la farmacia no dispensar fármacos Teva-Ratiopharm. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">Pablo Simón, médico de familia en Chauchina, Granada. Coordinador de Médicos del Mundo en Granada. Un raro. \u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">De \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">HW4PS.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan style=\"font-size: small;\">\u003Cbr>4 min\u003Cbr>\u003Cbr>-”Campaña en Redes Sociales y estrategias de coordinación con otros grupos” \u003Cbr>Carteles hechos\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">\u003Cspan style=\"font-size: small;\">Soledad Ascoeta, cardióloga en Sabadell. Perteneciente a la Red de Mujeres Sanitarias (Red CAPS) y al colectivo Famílies per la Pau. \u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">De \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: small;\">\u003Cspan style=\"font-weight: normal;\">HW4PS.\u003C\u002Fspan>\u003C\u002Fspan>\u003Cstrong>\u003Cspan style=\"font-size: small;\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan style=\"font-size: small;\">\u003Cbr>4 min \u003Cbr>\u003Cbr>DEBATE GENERAL\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"line-height: 100%; margin-bottom: 0cm;\" align=\"left\">Participantes y pontentes, 30 min\u003C\u002Fp>\n\u003Cbr>\n\u003Cdiv>\u003Cspan style=\"color: #000000;\">\u003Cstrong>¿Farmacia comunitaria? Difunde la carta que sigue:\u003C\u002Fstrong>\u003Cbr>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv>\u003Cspan style=\"color: #000000;\">Para: Farmacias comunitarias\u003Cbr>Asunto: Sensibilización sobre los desafíos éticos relacionados con la compañía farmacéutica Teva\u003Cbr>Para usted, como colega que dispensa medicamentos:\u003Cbr>Somos un grupo de profesionales de la sanidad conmovidos por la catástrofe humanitaria y la destrucción total del sistema de salud en Gaza. Como tales profesionales de la salud no podemos permanecer indiferentes ante el sufrimiento y la muerte de decenas de miles de niños, mujeres y civiles palestinos durante más de un año, ni ante el asesinato selectivo de profesionales de la sanidad. Por lo tanto, escribimos con la esperanza de comprometernos juntos en una solución concreta que tenga como objetivo reducir este sufrimiento, o al menos no contribuir a él.\u003Cbr>Teva se encuentra entre las compañías de medicamentos genéricos más grandes del mundo y genera millones de dólares en ingresos para el régimen militar y colonial israelí. Con sede en Tel Aviv, Teva tiene cuatro centros de producción en Israel y opera también en asentamientos ilegales en Cisjordania. En 2019, en medio de repetidas violaciones de derechos humanos en los territorios palestinos ocupados, las Naciones Unidas amenazaron con agregar a Teva a su lista negra de empresas israelíes con la intención de promover la desinversión internacional.\u003Cbr>Desde octubre de 2023, mientras el estado de Israel comete un genocidio en Gaza, se han alzado voces en todo el mundo para pedir el boicot a Teva, como la campaña “Teva j'en veux pas” en Francia, \"non à Teva\" en Bélgica, “Teva, no grazie!” en Italia, \"Boikot Teva Israeldar Farmazeutikarik EZ!\" en Euskadi o la acción de protesta frente a la empresa Teva en Zaragoza . \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv>\u003Cspan style=\"color: #000000;\">El boicot de empresas de un país que desprecia los derechos humanos es una herramienta de presión que ha demostrado su eficacia en el pasado; por ejemplo, el movimiento de boicot, que instó a los ciudadanos del mundo a evitar la compra de productos procedentes de Sudáfrica, desempeñó un papel importante en la caída del apartheid sudafricano en 1991.\u003Cbr>Desde nuestro punto de vista, como prescriptores, dispensadores y consumidores de productos\u003Cbr>farmacéuticos, pero también como simples personas, es nuestra responsabilidad colectiva participar en el boicot de empresas como Teva, que apoyan la posición de Israel a pesar de los crímenes de guerra en curso. Por otra parte, el Tribunal Europeo de Derechos Humanos, en su sentencia de 11 de junio de 2020, confirmó que el boicot es una forma legal y legítima de expresión. Además, en el caso Zemor contra Teva de 2022, un tribunal francés reconoció y protegió el derecho al boicot como forma de libertad de expresión y desestimó la demanda por difamación presentada por Teva.\u003Cbr>Según la reciente declaración de la Corte Internacional de Justicia, Israel ocupa ilegalmente Palestina y los Estados miembros de la ONU tienen la obligación de evitar la ayuda a las actividades israelíes, reforzando así la legitimidad de los llamamientos internacionales al boicot, la desinversión y las sanciones (BDS).\u003Cbr>En las farmacias comunitarias se ejerce una función clave para la salud y la dignidad humana y por ello le animamos encarecidamente a adoptar una actitud ética, evitando dispensar y ofrecer a sus pacientes los productos presentes en la lista del movimiento BDS, incluidos los de Teva. Existen varios medicamentos alternativos y equivalentes disponibles, por lo que le sugerimos considerarlos cuando sea posible y apropiado para sus pacientes.\u003Cbr>Esperamos aunar esfuerzos en esta importante causa humanitaria.\u003Cbr>Gracias por su solidaridad.\u003Cbr>Health Workers For Palestine Spain Profesionales de la sanidad por Palestina. España\u003Cbr>hcw4palestinespain@gmail.com\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>","sesion-virtual-12-diciembre-boicot-a-teva-ratiopharm-tele-encuentro",1733057131440,[15,650],"Vídeo","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1733057125\u002Fchgo4x9z8jaf4qjiewuf.jpg","m45l9omxsuta4yqj9xk",{"type":645,"slug":654,"content":655,"subtitle":12,"id":656,"title":657,"videoUrl":12,"imageUrl":658,"timestamp":659,"link":12,"tags":660,"user":13},"boicot-a-la-farmaceutica-teva-y-todas-sus-marcas-tevagen-dalvur-belmac-y-ratiopharm","\u003Cp>Teva es el mayor proveedor farmacéutico y empresa comercial de Israel, además de ser uno de los mayores fabricantes de medicamentos genéricos del mundo. Proporciona millones de dólares en ingresos fiscales al régimen colonial israelí y a su ejército.\u003C\u002Fp>\n\u003Cp>Este dinero financia directamente la maquinaria asesina utilizada por las fuerzas israelíes para destruir vidas palestinas, y que actualmente se está utilizando para masacrar a decenas de miles de palestinos después de que Israel lanzara su último ataque brutal y genocida contra Gaza.\u003C\u002Fp>\n\u003Cp>\u003Cimg style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1733155460\u002Fqjp3ttm6amom9i1rzb45.jpg\" alt=\"\" width=\"300\" height=\"309\">\u003C\u002Fp>\n\u003Ch3>Teva: cómplice de genocidio\u003C\u002Fh3>\n\u003Cp>Al monopolizar el sector farmacéutico israelí, Teva contribuye al colonialismo de colonos israelí y al régimen de apartheid, incluidas las colonias construidas en tierras palestinas robadas. La empresa también proporciona suministros médicos y donaciones a las Fuerzas de Ocupación Israelíes.\u003C\u002Fp>\n\u003Cp>Teva contribuye a la opresión de los palestinos por parte de Israel de muchas otras maneras:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Teva disfruta de acceso total al mercado cautivo palestino en Cisjordania y Gaza, donde las empresas farmacéuticas palestinas no pueden funcionar debido a las restricciones israelíes y, por lo tanto, dependen del ocupante israelí para obtener medicamentos.\u003C\u002Fli>\n\u003Cli>La industria farmacéutica palestina sufre numerosos obstáculos opresivos como resultado directo del régimen israelí y su monopolio en la industria a través de empresas como Teva, incluyendo, pero no limitado a:\n\u003Cul>\n\u003Cli>Las empresas farmacéuticas palestinas se ven obligadas a enviar medicamentos a granel a cadenas farmacéuticas internacionales a través de Jordania con costos adicionales significativos, debido a que Israel niega el envío de medicamentos a granel por el Aeropuerto Ben Gurion.\u003C\u002Fli>\n\u003Cli>Israel no permite que los productos farmacéuticos palestinos se distribuyan en hospitales y farmacias de Jerusalén Este ocupado, ni que las vacunas se administren en escuelas gestionadas por palestinos.\u003C\u002Fli>\n\u003Cli>Los representantes palestinos de grandes empresas multinacionales deben obtener una carta de “no objeción” de sus colegas israelíes para recibir una licencia de importación del Ministerio de Salud de Israel.\u003C\u002Fli>\n\u003C\u002Ful>\n\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>En consecuencia, la ocupación de Palestina se infiltra en cada aspecto de la vida diaria, incluida la capacidad de las empresas farmacéuticas palestinas de funcionar y operar sin represión ni restricciones.\u003C\u002Fp>\n\u003Ch3>Contribuyendo a una catástrofe\u003C\u002Fh3>\n\u003Cp>Teva también es una de las empresas cómplices en limitar el suministro de medicamentos a Palestina, agravando la carga sanitaria que enfrentan las personas en los territorios ocupados.\u003C\u002Fp>\n\u003Cp>Israel controla la importación de todas las materias primas y equipos en los territorios palestinos ocupados. Como resultado, los medicamentos israelíes, como los fabricados y distribuidos por Teva, son más asequibles debido a los altos impuestos que Israel impone a los productos que ingresan a Cisjordania. En Gaza, esta situación es aún más grave debido a que Israel ha impedido la entrada de materiales necesarios durante los 16 años de bloqueo que ha impuesto a la franja.\u003C\u002Fp>\n\u003Cp>Se ha informado que el Ministerio de Salud de Israel ha permitido que grandes empresas farmacéuticas israelíes prueben sus productos en prisioneros palestinos detenidos en cárceles israelíes. En 1997, se reportó que se habían realizado más de 5,000 pruebas en prisioneros palestinos.\u003C\u002Fp>\n\u003Ch3>Teva: obteniendo ganancias del colonialismo\u003C\u002Fh3>\n\u003Cp>Las autoridades israelíes se han negado históricamente a devolver los cuerpos de palestinos fallecidos, como Fares Baroud, quien murió debido a la negativa del régimen israelí a brindarle tratamiento médico. Esto ha generado sospechas de que los cuerpos palestinos están siendo utilizados para realizar experimentos médicos.\u003C\u002Fp>\n\u003Cp>Las ganancias de Teva provienen directamente de décadas de colonización y explotación de la tierra y del pueblo palestino. Es nuestro deber hacer todo lo posible para asegurarnos de que nuestro dinero no se utilice para fomentar la opresión genocida y colonial.\u003C\u002Fp>\n\u003Cp>Puedes \u003Ca href=\"https:\u002F\u002Fwww.thecanary.co\u002Fuk\u002Fnews\u002F2024\u002F03\u002F05\u002Fteva-uk-protest\u002F\" target=\"_blank\" rel=\"noopener\">leer aquí\u003C\u002Fa> el artículo en inglés, del medio CANARY.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>","m4cs82jm4ijo8jfqeff","Boicot a la farmacéutica TEVA, y todas sus marcas, Tevagen, Dalvur, Belmac y Ratiopharm","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1733492136\u002Fukjmounwcsspievvsns9.jpg",1733492178614,[15],{"title":662,"slug":663,"type":645,"subtitle":12,"timestamp":664,"videoUrl":12,"id":665,"user":13,"tags":666,"link":12,"content":667,"imageUrl":668},"Boycott Teva. Think global, act local. Teva No Thanks ENG","boycott-teva-think-global-act-local-teva-no-thanks-eng",1736156870225,"m5k1mgmnzouycuxeax",[15],"\u003Cp style=\"line-height: 100%; margin-bottom: 0cm;\">\u003Cstrong>Boycott Teva. Think global, act local.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">Most professionals, patients and their families know nothing about Teva. \u003Cbr>Pedagogy is needed to explain the connection between Teva's drugs and the selective destruction of healthcare institutions and the detention, torture and murder of healthcare professionals in Gaza.\u003Cbr>The issue is moral in two senses:\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">1\u002F in the financing with Teva money of the genocide in Palestine and\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">2\u002F in the support of a company that is corrupt, with frequent and gigantic convictions and fines.\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>With the current situation, Teva's business is growing and flourishing. It must be stopped.\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>It is necessary to produce very specific local material that helps not to prescribe (doctors), not to dispense (pharmacists) and not to consume (patients and relatives) Teva's products. It is a non-violent and very effective “direct action”. We must achieve a “social” response, not just a professional one. For example, by denouncing community pharmacies that “prefer” to dispense Teva products, due to discounts.\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Cbr>Teva's KOLs and the scientific societies that receive money from Teva should also be denounced with names and amounts.\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">Avoid teaching activities, meetings, conferences and \u003Ca href=\"https:\u002F\u002Fwww.tevamedical.com\u002Fmedical-congress\u002F\">congresses sponsored by Teva\u003C\u002Fa>.\u003Cbr>See, in 2024, in the United States https:\u002F\u002Fwww.tevamedical.com\u002Fmedical-congress\u002F\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">MORE INFORMATION IN ENGLISH:\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"\u002Fblog\u002Fteva-letter-ethical-challenges-in-primary-care-eng\">Teva. Letter. Ethical challenges in primary care.\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"\u002Fblog\u002Fteva-corruption-in-the-world-a-case-study-teva-in-spain\">-Teva, corruption in the world. A case study: “Teva in Spain\". “Teva in Spain. A pharmaceutical giant whose profits harm the health of the people of Palestine.\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"font-weight: normal; line-height: 100%; margin-bottom: 0cm;\">\u003Ca href=\"\u002Fblog\u002Fsanctions-our-best-direct-action-weapon-is-the-boycott-of-teva-products-and-medicines\">-Sanctions? Our best ‘direct action’ weapon is the boycott of Teva products and medicines.\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1736155570\u002Fvaq62uj8kfsnhz1ukrsf.jpg",{"imageUrl":670,"timestamp":671,"videoUrl":12,"slug":672,"type":645,"subtitle":12,"id":673,"user":13,"tags":674,"link":12,"title":675,"content":676},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1746004309\u002Frwsayvlchtmq4pmpo7pq.webp",1746004051704,"teva-carta-a-la-ministra-de-sanidad-de-espana-esp","ma3pfdooyjkz9cyiw6",[15],"Teva. Carta a la ministra de Sanidad de España. ESP","\u003Cp>\u003Cstrong>LA MINISTRA DE SANIDAD TIENE QUIEN LE ESCRIBA. ¿CUÁNDO Y QUÉ RESPONDERÁ?\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>28 de abril de 2025. Por registro oficial\u003C\u002Fp>\n\u003Cp>Dña. Mónica García Gómez\u003Cbr>Ministra de Sanidad\u003Cbr>P.º del Prado, 18\u003Cbr>28014 Madrid\u003Cbr>Sra. Ministra:\u003Cbr>Somos el grupo Health Workers For Palestine Spain España, un grupo de profesionales de la salud  que se conformó en octubre del 2024 inspirados por otros grupos de Salud por Palestina en otros países del mundo, con quienes estamos coordinados, por la necesidad de movilizar a profesionales en todo el Estado y establecer una plataforma unificada para actuar a nivel estatal e internacional. En octubre publicamos el “Manifiesto de profesionales de la sanidad por la paz y en solidaridad con Palestina” que a día de hoy cuenta con casi 600 adhesiones individuales y más de 35 entidades sanitarias.\u003Cbr>A pesar de nuestro corto recorrido hemos estado trabajando intensamente desde los diferentes\u003Cbr>frentes, con el objetivo final de acabar con el genocidio, a día de hoy luchando por el alto el fuego permanente, la ocupación y el apartheid en Palestina. Tenemos una presencia muy intensa en Redes Sociales y en la calle. Fomentamos el boicot a productos israelíes, difundimos material e información en favor de la causa Palestina y presionamos a instituciones y gobiernos en todos los niveles de la Administración del Estado. Tenemos especial preocupación por la destrucción sistemática y deliberada del sistema sanitario gazatí.\u003Cbr>Nos ponemos en contacto con usted para trasladarle nuestra preocupación e interés por la situación de las relaciones comerciales del Ministerio de Sanidad y de las Consejerías de Salud de las Comunidades Autónomas, con empresas israelíes de materiales o tecnologías sanitarias. Nuestro grupo está especialmente preocupado por la compra de fármacos a la empresa israelí TEVA. Esta preocupación hay que enmarcarla y contextualizarla en nuestra reivindicación del fin inmediato del Genocidio en Gaza y de la ocupación colonial de Palestina por los israelíes. Esto nos lleva a exigir al Gobierno del que Usted forma parte, la interrupción inmediata y real del comercio de armas o tecnología de uso bélico con Israel e impedir el tránsito de armas provenientes de otros países hacia Israel. También solicitamos que se apliquen medidas de boicot a todas las empresas israelíes que operan en España, que se apliquen todas las disposiciones de la Corte Internacional de Justicia y de la Corte Penal Internacional, que se trabaje activamente para lograr el fin de las hostilidades y la retirada completa del Ejercito de Israel del territorio de la Franja de Gaza así como el cese de la represión y el hostigamiento de los y las palestinas de Cisjordania. En última instancia llamamos a la ruptura total de relaciones con Israel.\u003Cbr>TEVA Es una empresa farmacéutica israelí, líder en el mercado de genéricos en Europa. Su sede\u003Cbr>principal está en Tel Aviv. En 2023 ocupó el puesto 19 en el ranking de las 20 empresas farmacéuticos con mayor nivel de ingresos en el mercado mundial de fármaco. En España, en 2023 Teva fue, por volumen de ventas al SNS, el tercer laboratorio a nivel nacional con 70 millones de envases y más de 500 millones de euros en ventas. Tenemos constancia de la existencia de multitud de contratos de suministros de fármacos a hospitales en el territorio español. Son contratos públicos. Por ejemplo, basta consultar la situación de Cataluña a través del portal para encontrar cientos de contratos.\u003Cbr>En 2023 TEVA se gastó en \"transferencias de valor\" en España (pagos, congresos, viajes, etc):\u003Cbr>2.010.412 € (pagos a profesionales sanitarios 961.819 €; pagos a asociaciones: 811.811 €; pagos\u003Cbr>relacionados con I+D: 236.782 €). Además esta empresa ha sido acusada de prácticas corruptas o poco éticas en numerosas ocasiones en diferentes países: Sobornos, Competencia desleal y Crisis opioides. En nuestra página web puede usted encontrar mucha información detallada sobre esta empresa.\u003Cbr>Pero lo más importante para nosotros ahora es que TEVA financia al gobierno israelí que lleva a cabo el Genocidio en Gaza mediante transferencias de impuestos y otras formas de transferencia\u003Cbr>económica difíciles de rastrear. Por otra parte se beneficia de unas posiciones privilegiadas en el\u003Cbr>mercado farmacéutico en los territorios ocupados de Palestina, ya que no tiene que pagar aranceles ni tiene límites de circulación en los puntos fronterizos de control. Ello le permite comercializar ampliamente sus productos farmacéuticos en estos territorios, haciendo competencia directa y desleal a las pequeñas empresas farmacéuticas que operan en esos territorios. Con frecuencia venden estos fármacos a los palestinos a precios superiores a los del mercado israelí. Ya ha sido advertida por la ONU por incumplir la legislación internacional.\u003Cbr>Según la declaración de la Corte Internacional de Justicia en julio del 2024, Israel ocupa ilegalmente Palestina y, por tanto, los Estados miembros de la ONU tienen la obligación de evitar en lo posible ayudar a las actividades israelíes, tanto dentro como fuera de su territorio.\u003Cbr>Por este motivo le S O L I C I T A M O S\u003Cbr>● Que explore medidas administrativas que permitan LIMITAR la actividad de la empresa\u003Cbr>TEVA en nuestro país, tanto en el ámbito de la producción de fármacos como de su\u003Cbr>comercialización y distribución. Somos conscientes de que, al estar transferidas las\u003Cbr>competencias sanitarias a las Comunidades Autónomas, resulta difícil una acción\u003Cbr>totalmente eficaz, pero pensamos que desde el Gobierno se pueden arbitrar medidas\u003Cbr>que avancen claramente en esa dirección.\u003Cbr>● Que ANULE los contratos que mantienen los centros sanitarios públicos de su ámbito\u003Cbr>de competencia directa (INGESA y otras agencias) con empresas de material sanitario\u003Cbr>e industrias farmacéuticas de origen israelí, en concreto con la empresa TEVA.\u003Cbr>● Que establezca medidas administrativas para EVITAR que se realicen nuevos contratos\u003Cbr>con estas empresas, especialmente con TEVA, por ejemplo, incluyendo cláusulas en los\u003Cbr>pliegos de contratación que impidan a las empresas israelíes presentarse a las\u003Cbr>licitaciones argumentando su participación en el Genocidio israelí.\u003Cbr>● Que INSTE a las Consejerías de Salud de las Comunidades Autónomas a que\u003Cbr>establezcan medidas administrativas similares en su propio ámbito de competencia.\u003Cbr>Nos ponemos a su disposición para apoyar esta actividad en la manera que usted estime pertinente.\u003Cbr>Reciba un saludo muy cordial.\u003Cbr>En Madrid a 28 de Abril de 2025\u003Cbr>Health Workers For Palestine Spain (HW4PS)\u003Cbr>hcw4palestinespain@gmail.com\u003Cbr>Web: https:\u002F\u002Fhw4p.es\u002F ; Canal de Telegram:\u003Cbr>https:\u002F\u002Ft.me\u002Fhealthworkersforpalestinespain ; X: @HW4PalestSpain ; BSky:\u003Cbr>https:\u002F\u002Fbsky.app\u002Fprofile\u002Fhw4ps.bsky.social ; Instagram: @hw4p.spain\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>",{"slug":678,"title":679,"type":645,"id":680,"subtitle":12,"imageUrl":681,"timestamp":682,"content":683,"user":13,"tags":684,"videoUrl":12,"link":12},"pablo-simon-hw4ps-versus-teva-por-favor-manda-un-correo-e-al-colegio-de-medicos-de-granada-please-send-an-e-mail-to-colegio-oficial-medicos-granada-spain-esp-eng","Pablo Simón (HW4PS) versus Teva. Por favor, manda un correo-e al Colegio de Medicos de Granada. Please, send an e-mail to Colegio Oficial Médicos Granada (Spain). ESP ENG","mhyqlolrck9rok8blr","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763120847\u002Fka2lumofsyehhwpmxzgx.png",1763120883219,"\u003Cp>Los sionistas defienden Teva y el apartheid y genocidio en Palestina por Israel. Por ello persiguen a médicos honrados que consideran que la salud es también el respeto a los derechos humanos. El caso en Granada (España) de Pablo Simón Lorda versus Teva.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cem>POR FAVOR, ESCRIBA AL COLEGIO DE MÉDICOS DE GRANADA\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Te animamos a que remitas al correo corporativo del Colegio de Médicos de Granada (com@comgranada.com) tu petición de que se archive la denuncia contra Pablo Simón Lorda, al mismo tiempo que la corporación se comprometa de manera indubitable con los derechos humanos y condene el genocidio del pueblo palestino ANTES del mediodía del próximo lunes, 17 de noviembre.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>EJEMPLO\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>La cuestión planteada en el caso de Pablo Simón Lorda versus Teva resulta de todo punto insultante pues 1\u002F confunde anti-semitismo con anti-sionismo, 2\u002F niega la existencia de cuestiones éticas y morales en el uso de los recursos públicos en sanidad y 3\u002F pretende desacreditar a un profesional comprometido con su trabajo, sus pacientes y la salud, que bien entendida es cuestión social en que se refleja tanto lo bueno como lo malo, incluyendo el genocidio y el apartheid en Palestina por Israel.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Da la impresión de que Teva quiere dar un \"ejemplo\" empleando sl Colegio de Médicos de Granada de ejecutor.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Esperemos que el Colegio de Médicos de Granada no admita tal manipulación y responda apoyando el prestigio de Pablo Simón Lorda\u003Cbr>En fin\u003Cbr>Un saludo \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fenfoquejudio.es\u002Fqueja-contra-un-medico-de-granada-por-carteles-politicos-anti-israelies-y-promover-el-boicot-a-teva\u002F\">\u003Cstrong>LA DENUNCIA\u003Cbr>Enfoque judío. \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Actualidad y Cultura del Judaísmo en España.\u003Cbr>11 noviembre 2025\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>La Comisión Sanitaria contra el Antisemitismo\u003C\u002Fstrong>, grupo dentro de la \u003Cstrong>Coordinadora Estatal de Lucha contra el Antisemitismo\u003C\u002Fstrong>, ha presentado una queja al Colegio Oficial de Médicos de Granada contra un médico de la ciudad que, públicamente, ha asumido como suya la narrativa anti-israelí de grupos de izquierdas dentro del marco del servicio público de salud y promueve el boicot de medicamentos de la empresa israelí Teva, según ambas organizaciones.\u003C\u002Fp>\n\u003Cp>En una carta a la que ha tenido acceso \u003Cem>Enfoque Judío\u003C\u002Fem>, remitida el 30 de octubre a la presidenta del Colegio, \u003Cstrong>Isabel Castillo Pérez\u003C\u002Fstrong>, y al presidente de la Comisión Deontológica, \u003Cstrong>Francisco Javier García Monlleó\u003C\u002Fstrong>, ambos grupos de lucha contra el antisemitismo denuncian la conducta del doctor \u003Cstrong>Pablo Simón Lorda\u003C\u002Fstrong>, quien habría exhibido en su consulta del \u003Cstrong>Consultorio Chauchina\u003C\u002Fstrong> (Granada) carteles políticos y una bandera de Palestina con mensajes relativos a un supuesto \u003Cem>\"genocidio en Gaza\"\u003C\u002Fem>.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>EL CONTEXTO\u003C\u002Fstrong>\u003Cbr>Pablo Simón Lorda es médico rural, en Chauchina (Granada, España), especialista en Medicina de Familia, comprometido con la salud en su amplio sentido, miembro de Profesionales de la Sanidad por Palestina, España (HW4PS). Como tal promueve el antisionismo, la ideología ultraderechista y colonial del estado de Israel, y el boicot a la farmacéutica Teva que facilita el genocidio y el apartheid en Palestina por Israel.\u003C\u002Fp>\n\u003Cp>\u003Cbr>Pablo Simón Lorda ha expresado públicamente, sin afectar en modo alguno la atención sanitaria a sus pacientes, su más que justificada objeción ética al consumo y prescripción de medicamentos de empresas vinculadas a violaciones graves de derechos humanos, en este caso la compañía Teva Pharmaceutical Industries, señalada por diversas organizaciones internacionales por su participación en el suministro y financiación del aparato militar israelí. \u003C\u002Fp>\n\u003Cp>\u003Cbr>Esta objeción no constituye propaganda política ni discriminación ideológica, sino el ejercicio de un deber ético de coherencia profesional conforme a los principios de beneficencia, no maleficencia y justicia reconocidos universalmente en la bioética médica. \u003C\u002Fp>\n\u003Cp>\u003Cbr>En este sentido, el Código de Deontología Médica del Consejo General de Colegios Oficiales de Médicos reconoce expresamente que el médico tiene derecho a ejercer la objeción de conciencia en aquellos supuestos que entren en conflicto con sus convicciones éticas o científicas y obliga a las instituciones sanitarias y a los colegios profesionales a proteger ese derecho. \u003C\u002Fp>\n\u003Cp>\u003Cbr>Por tanto, el posicionamiento de Pablo Simón Lorda se encuentra plenamente amparado por el marco deontológico, constitucional e internacional que protege la libertad de conciencia del profesional sanitario. Igualmente, queremos aprovechar la ocasión para recordarle que diversas administraciones públicas autonómicas y locales han iniciado procesos de revisión o cancelación de contratos con la empresa Teva, atendiendo a criterios de responsabilidad social corporativa y derechos humanos en coherencia con las resoluciones de Naciones Unidas dictadas al efecto. \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>En este contexto, el ejercicio de objeción ética por parte de un profesional individual no solo es legítimo, sino coherente con la posición de múltiples instituciones públicas españolas y europeas que revisan su relación comercial con entidades vinculadas al conflicto y a la violación del Derecho Internacional Humanitario. \u003Cbr>Las imputaciones difundidas contra el Dr. Simón Lorda, que lo acusan falsamente de discriminación o incitación al odio, constituyen injurias graves y calumnias al atribuirle delitos inexistentes con evidente ánimo de dañar su reputación profesional. \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>El Colegio de Médicos de Granada tiene la obligación institucional de proteger el honor, la integridad moral y la libertad de conciencia de sus colegiados, especialmente cuando son objeto de campañas difamatorias por el ejercicio de valores éticos y humanitarios que forman parte del núcleo mismo de la profesión médica. \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cbr>Por tal motivo, le solicitamos expresamente que no se abra expediente alguno basado en motivaciones ideológicas o difamatorias y que, en su lugar, el Colegio se reafirme públicamente el derecho a la objeción de conciencia de los médicos andaluces, proteja el honor y la integridad profesional de Pablo Simón Lorda, víctima de una campaña de descrédito mediático y denuncie las imputaciones calumniosas vertidas en medios de comunicación y entidades privadas, que constituyen un intento de intimidar y silenciar la conciencia crítica en la profesión médica.\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Zionists defend Teva and the apartheid and genocide perpetrated by Israel in Palestine.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">For this reason, they persecute honest doctors who believe that health is also about respecting human rights.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The case of Pablo Simón Lorda versus Teva in Granada, Spai\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan class=\"ryNqvb\">PLEASE WRITE TO THE GRANADA MEDICAL ASSOCIATION BEFORE NOON NEXT MONDAY, NOVEMBER 17.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cspan class=\"ryNqvb\">We encourage you to send your request to the Granada Medical Association's corporate email address (com@comgranada.com) requesting that the complaint be dismissed and that the association unequivocally commit to human rights and condemn the genocide of the Palestinian people BEFORE noon next Monday, November 17.\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cem>\u003Cspan class=\"ryNqvb\">EXAMPLE\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv dir=\"ltr\">To whom it may concern at the Granada Medical Association\u003C\u002Fdiv>\n\u003Cdiv dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv dir=\"ltr\">I am appalled about the recent complaint against and treatment of Pablo Simón Lorda who is one of the best family doctors that I have ever met and whose moral integrity is beyond question.   \u003C\u002Fdiv>\n\u003Cdiv dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv dir=\"ltr\">I urgently request that the complaint be dismissed and that your Association publicly reaffirms its commitment to human rights and its condemnation of the genocide of the Palestinian people and the targetting of health workers in Gaza..\u003C\u002Fdiv>\n\u003Cdiv dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv dir=\"ltr\">Yours sincerely\u003C\u002Fdiv>\n\u003Cp> \u003C\u002Fp>\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">THE COMPLAINT \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Jewish Focus.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Current Affairs and Culture of Judaism in Spain.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">November 11, 2025 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Health Commission Against Antisemitism, a group within the State Coordinator for the Fight Against Antisemitism, has filed a complaint with the Official College of Physicians of Granada against a doctor in the city who has publicly adopted the anti-Israeli narrative of leftist groups within the framework of the public health service and promotes a boycott of medicines from the Israeli company Teva, according to both organizations.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In a letter obtained by Jewish Focus, sent on October 30 to the president of the College, Isabel Castillo Pérez, and the president of the Ethics Committee, Francisco Javier García Monlleó, both anti-antisemitism groups denounce the conduct of Dr. Pablo Simón Lorda, who allegedly displayed political posters and a Palestinian flag with messages related to a supposed \"genocide in Gaza\" in his office at the Chauchina Clinic (Granada).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">THE CONTEXT \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">Pablo Simón Lorda is a rural doctor in Chauchina (Granada, Spain), specialist in Family Medicine. He is committed to health in its broadest sense and is a member of Healthcare Professionals for Palestine, Spain (HW4PS). As such, he promotes anti-Zionism, opposes the far-right and colonial ideology of the State of Israel, and supports the boycott of the pharmaceutical company Teva, which facilitates genocide and apartheid in Palestine by Israel.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Pablo Simón Lorda has publicly expressed, without in any way affecting the healthcare of his patients, his more than justified ethical objection to the consumption and prescription of medications from companies linked to serious human rights violations, in this case, Teva Pharmaceutical Industries, which has been singled out by various international organizations for its involvement in supplying and financing the Israeli military apparatus.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">This objection does not constitute political propaganda or ideological discrimination, but rather the exercise of an ethical duty of professional consistency in accordance with the principles of beneficence, non-maleficence, and justice universally recognized in medical bioethics.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In this regard, the Code of Medical Ethics of the General Council of Official Colleges of Physicians expressly recognizes that physicians have the right to exercise conscientious objection in cases that conflict with their ethical or scientific convictions and obliges healthcare institutions and professional associations to protect this right.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, Pablo Simón Lorda's position is fully supported by the deontological, constitutional, and international framework that protects the freedom of conscience of healthcare professionals.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">We would also like to take this opportunity to remind him that several regional and local public administrations have initiated processes to review or cancel contracts with the company Teva, based on criteria of corporate social responsibility and human rights, in accordance with the United Nations resolutions issued for this purpose.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In this context, the exercise of ethical objection by an individual professional is not only legitimate but also consistent with the position of numerous Spanish and European public institutions that are reviewing their commercial relationships with entities linked to conflict and violations of International Humanitarian Law.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The accusations disseminated against Dr. Simón Lorda, falsely accusing him of discrimination or incitement to hatred, constitute serious defamation and slander by attributing nonexistent crimes to him with the clear intention of damaging his professional reputation.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> The Granada Medical Association has an institutional obligation to protect the honor, moral integrity, and freedom of conscience of its members, especially when they are the target of defamatory campaigns for exercising ethical and humanitarian values ​​that form part of the very core of the medical profession.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For this reason, we expressly request that no proceedings be opened based on ideological or defamatory motivations and that, instead, the College publicly reaffirm the right to conscientious objection of Andalusian doctors, protect the honor and professional integrity of Pablo Simón Lorda, victim of a media smear campaign, and denounce the slanderous accusations made in the media and private entities, which constitute an attempt to intimidate and silence critical conscience in the medical profession.\u003C\u002Fspan>\u003C\u002Fspan>\n\u003Cdiv class=\"OvtS8d\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"NQSJo\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"UdTY9 WdefRb\" aria-hidden=\"true\" data-location=\"2\">\n\u003Cdiv class=\"kO6q6e\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\">\n\u003Cdiv class=\"dig2sb\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"XL3Kf XExWNc\">\n\u003Cdiv class=\"a8FIud X0rvP\">\n\u003Cdiv data-show-delay-ms=\"250\" data-append-to-body=\"false\" data-propagate-tooltip-mouseover-events=\"true\" data-anchor-corner=\"bottom-end\" data-enable-skip-handler=\"true\" data-popup-corner=\"top-end\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"ebT7ne VOLvac sMVRZe\">\n\u003Cdiv class=\"F0pQVc\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"aJIq1d\" dir=\"ltr\" data-language-code=\"en\" data-language-name=\"inglés\" data-text=\"PLEASE WRITE TO THE GRANADA MEDICAL ASSOCIATION\nWe encourage you to send your request to the Granada Medical Association's corporate email address (com@comgranada.com) requesting that the complaint be dismissed and that the association unequivocally commit to human rights and condemn the genocide of the Palestinian people BEFORE noon next Monday, November 17.\n\nPablo Simón Lorda has publicly expressed, without in any way affecting the healthcare of his patients, his more than justified ethical objection to the consumption and prescription of medications from companies linked to serious human rights violations, in this case, Teva Pharmaceutical Industries, which has been singled out by various international organizations for its involvement in supplying and financing the Israeli military apparatus.\n\nThis objection does not constitute political propaganda or ideological discrimination, but rather the exercise of an ethical duty of professional consistency in accordance with the principles of beneficence, non-maleficence, and justice universally recognized in medical bioethics. In this regard, the Code of Medical Ethics of the General Council of Official Colleges of Physicians expressly recognizes that physicians have the right to exercise conscientious objection in cases that conflict with their ethical or scientific convictions and obliges healthcare institutions and professional associations to protect this right.\n\nTherefore, Pablo Simón Lorda's position is fully supported by the deontological, constitutional, and international framework that protects the freedom of conscience of healthcare professionals. We would also like to take this opportunity to remind him that several regional and local public administrations have initiated processes to review or cancel contracts with the company Teva, based on criteria of corporate social responsibility and human rights, in accordance with the United Nations resolutions issued for this purpose.\n\nIn this context, the exercise of ethical objection by an individual professional is not only legitimate but also consistent with the position of numerous Spanish and European public institutions that are reviewing their commercial relationships with entities linked to conflict and violations of International Humanitarian Law. The accusations disseminated against Dr. Simón Lorda, falsely accusing him of discrimination or incitement to hatred, constitute serious defamation and slander by attributing nonexistent crimes to him with the clear intention of damaging his professional reputation.\n\nThe Granada Medical Association has an institutional obligation to protect the honor, moral integrity, and freedom of conscience of its members, especially when they are the target of defamatory campaigns for exercising ethical and humanitarian values ​​that form part of the very core of the medical profession. For this reason, we expressly request that no proceedings be opened based on ideological or defamatory motivations and that, instead, the College publicly reaffirm the right to conscientious objection of Andalusian doctors, protect the honor and professional integrity of Pablo Simón Lorda, victim of a media smear campaign, and denounce the slanderous accusations made in the media and private entities, which constitute an attempt to intimidate and silence critical conscience in the medical profession.\" data-crosslingual-hint=\"\" data-location=\"2\" data-enable-toggle-playback-speed=\"true\" data-results-count=\"1\" data-result-index=\"1\">\n\u003Cdiv class=\"m0Qfkd\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"VO9ucd\">\n\u003Cdiv class=\"YJGJsb\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"HWmS8\">\n\u003Cdiv class=\"OwOEge\">\n\u003Cdiv class=\"cJ1Ndf\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cnav class=\"VlPnLc\" aria-labelledby=\"ucj-38\">\u003C\u002Fnav>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Ca class=\"mqNsCe\" href=\"https:\u002F\u002Ftranslate.google.es\u002Fhistory\" data-probe-id=\"translation_history_footer_button\">\n\u003Cdiv class=\"ySES5\"> \u003C\u002Fdiv>\n\u003C\u002Fa>\u003Ca class=\"mqNsCe\" href=\"https:\u002F\u002Ftranslate.google.es\u002Fsaved\" data-probe-id=\"saved_translations_footer_button\">\n\u003Cdiv class=\"ySES5\"> \u003C\u002Fdiv>\n\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",[15,685],"Colegio Oficial de Médicos de Granada",{"imageUrl":687,"id":688,"title":689,"slug":690,"type":645,"timestamp":691,"videoUrl":12,"content":692,"user":13,"tags":693,"link":12,"subtitle":12},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1771492908\u002Fmfnhzi9weeisriwbl2t5.jpg","mlt8ua4pdb395ge6okh","CAMPAÑA estatal \"¿Teva? No, gracias\". Desde el 1 de Marzo al 1 de Diciembre de 2026","campana-estatal-teva-no-gracias-desde-el-1-de-marzo-al-1-de-diciembre-de-2026",1771493028975,"\u003Cdiv id=\"welcome-container\" class=\"\">\n\u003Cdiv class=\"survey-description  form-heading\">\n\u003Cp>\u003Cem>\u003Cspan class=\"ryNqvb\">The English text is at the end of the Spanish version.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cstrong>CAMPAÑA estatal (España) \"¿Teva? No, gracias\"\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Ftevanogracias.limesurvey.net\u002F783363?lang=es&newtest=Y\">Aquí \u003C\u002Fa>el formulario para la adhesión de organizaciones ANTES DEL 24 DE FEBRERO DE 2026\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Ftevanogracias.limesurvey.net\u002F783363?lang=es&newtest=Y\">\u003Cem>\u003Cstrong>Adhiérete a la campaña estatal de boicot a la \u003C\u002Fstrong>\u003Cstrong>farmacéutica \u003C\u002Fstrong>\u003Cstrong>que financia el genocidio y el aparheid en Palestina\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fa>\u003C\u002Fp>\n\u003Ch3>* Esta Campaña estará activa desde el 1 de Marzo al 1 de Diciembre de 2026\u003C\u002Fh3>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"group-0\" class=\"group-outer-container  space-col\">\n\u003Cdiv class=\"group-container  space-col\">\n\u003Cdiv id=\"question23\" class=\"row equation   question-container\" role=\"group\" aria-labelledby=\"question-text-container-783363X3X23\">\n\u003Cdiv id=\"question-text-container-783363X3X23\" class=\"question-title-container   col-12\" role=\"heading\" aria-level=\"2\">\n\u003Cdiv class=\"question-text\">\n\u003Cdiv id=\"ls-question-text-783363X3X23\" class=\"ls-label-question\">\n\u003Ch2 style=\"line-height: 2;\">\u003Cspan style=\"color: #e03e2d;\">\u003Cem>\u003Cstrong>MANIFIESTO DE LA CAMPAÑA \u003C\u002Fstrong>\u003Cstrong>¿Teva? No, gracias.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fh2>\n\u003Ch3>Las organizaciones, colectivos y movimientos sociales comprometidos con los derechos humanos, abajo firmantes, promovemos esta campaña de boicot contra la farmacéutica Teva como medida de solidaridad con el pueblo palestino y por el fin del apartheid, la ocupación y el genocidio en Palestina. \u003C\u002Fh3>\n\u003Ch3>Lanzamos esta iniciativa para devolver a la sociedad civil el poder que los gobiernos le han negado frente al exterminio palestino. \u003C\u002Fh3>\n\u003Ch3>Israel es una entidad sionista ocupante que está cometiendo un genocidio en Palestina. Solo desde el 7 de octubre de 2023, Israel ha asesinado a más de 70.000 personas, aunque se estima que las cifras reales podrían ser diez veces mayores. La esperanza de vida en Gaza ha disminuido de 76 a 41 años, más de 22.000 niños y niñas han sido asesinados y hay decenas de miles de huérfanos. Israel ha destruido el 92% de las viviendas y sometido a un asedio completo a Gaza, bloqueando la entrada de comida, agua, productos sanitarios, repuestos y combustible. \u003C\u002Fh3>\n\u003Ch3>El movimiento Boicot, Desinversión y Sanciones (BDS) es un movimiento de liderazgo palestino por la libertad, la justicia y la igualdad. Inspirado en el movimiento anti-apartheid sudafricano, insta a actuar para presionar a Israel a que respete el derecho internacional.\u003C\u002Fh3>\n\u003Ch3>El BDS identifica a Teva como uno de los objetivos prioritarios para realizar boicot económico a Israel.  \u003C\u002Fh3>\n\u003Ch3>Teva es una empresa farmacéutica israelí, líder en el mercado de genéricos en Europa. En el estado español, en 2023, Teva fue por volumen de ventas al Sistema Nacional de Salud, el tercer laboratorio a nivel nacional, con 70 millones de envases y más de 500 millones de euros en ventas. En 2024, según la propia corporación, obtuvo unos ingresos de 16.500 millones de dólares por su actividad en todo el mundo.  Existen multitud de contratos de suministros de estos fármacos a centros sanitarios en el territorio español. \u003C\u002Fh3>\n\u003Ch3>Teva financia a Israel, régimen que lleva a cabo la ocupación, el apartheid y el genocidio en Palestina. Esto lo realiza mediante pago de impuestos y otras formas de financiación. \u003C\u002Fh3>\n\u003Ch3>Teva se beneficia de la ocupación ilegal, del sistema de apartheid y del mercado cautivo, ya que goza de posiciones privilegiadas en el mercado farmacéutico de los territorios palestinos ocupados. Israel controla y limita la importación y exportación de medicamentos y permite a empresas israelíes operar sin pagar aranceles ni enfrentar restricciones en los puntos fronterizos de control. Esto le permite a Teva comercializar ampliamente sus productos farmacéuticos en estos territorios, compitiendo de manera directa y desleal con el resto de empresas farmacéuticas, incluidas las palestinas, a las que a su vez Israel dificulta su desarrollo y crecimiento. \u003C\u002Fh3>\n\u003Ch3>Teva  muestra un abierto apoyo y colaboración con el genocidio que está perpetrando Israel: al menos un 10% de su plantilla en Israel se ha unido al ejército, ha donado material a las Fuerzas de Defensa de Israel, sus sedes se han establecido como espacios de recolecta de materiales para los soldados y en sus oficinas tienen colocados carteles que muestran apoyos al ejército, entre otras acciones de soporte al ejército israelí.\u003C\u002Fh3>\n\u003Ch3>El boicot es una herramienta legítima e histórica. Hacer boicot a empresas que sustentan a un régimen que perpetra crímenes contra la Humanidad es una obligación moral, ética y legal ineludible. Y lo es aún más cuando un negocio sanitario como es el de Teva es parte de un sistema que extermina a las personas palestinas. \u003C\u002Fh3>\n\u003Ch3>Por todo ello, las organizaciones firmantes \u003Cstrong>pedimos\u003C\u002Fstrong>:\u003C\u002Fh3>\n\u003Col start=\"1\" type=\"1\">\n\u003Cli class=\"MsoNormal\">\n\u003Ch3>\u003Cstrong>\u003Cu>A la ciudadanía\u003C\u002Fu>\u003C\u002Fstrong>: que pida activamente alternativas a Teva, en las recetas y en las farmacias.\u003C\u002Fh3>\n\u003C\u002Fli>\n\u003Cli class=\"MsoNormal\">\n\u003Ch3>\u003Cstrong>\u003Cu>A profesionales de la salud\u003C\u002Fu>\u003C\u002Fstrong>: que no prescriban Teva cuando existan equivalentes. Romper la cadena de complicidad desde la consulta. \u003C\u002Fh3>\n\u003C\u002Fli>\n\u003Cli class=\"MsoNormal\">\n\u003Ch3>\u003Cstrong>\u003Cu>A las farmacias\u003C\u002Fu>\u003C\u002Fstrong>: que no comercialicen o dispensen Teva. Priorizar otros laboratorios no manchados con sangre palestina.\u003C\u002Fh3>\n\u003C\u002Fli>\n\u003Cli class=\"MsoNormal\">\n\u003Ch3>\u003Cstrong>\u003Cu>A administraciones públicas, hospitales y otros compradores institucionales\u003C\u002Fu>\u003C\u002Fstrong>: que no escojan a Teva como proveedor en sus compras públicas y licitaciones sanitarias.\u003C\u002Fh3>\n\u003C\u002Fli>\n\u003Cli class=\"MsoNormal\">\n\u003Ch3>\u003Cstrong>\u003Cu>A colectivos, organizaciones y movimientos sociales\u003C\u002Fu>\u003C\u002Fstrong>: que firmen este manifiesto como acto de adhesión a la campaña y lo difundan entre sus colectivos y en la sociedad en general desde sus ámbitos de actuación. \u003C\u002Fh3>\n\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Ch3>\u003Cstrong>Por justicia para Palestina, únete a la campaña de boicot a Teva.\u003C\u002Fstrong>\u003C\u002Fh3>\n\u003Cp>______________________________\u003C\u002Fp>\n\u003Ch3>\u003Cstrong>CONSIDERACIONES A TENER EN CUENTA\u003C\u002Fstrong>\u003C\u002Fh3>\n\u003Ch3>* Esta Campaña estará activa desde el 1 de Marzo al 1 de Diciembre de 2026\u003C\u002Fh3>\n\u003Ch3>* Este FORMULARIO de adhesión es \u003Cstrong>SÓLO para organizaciones\u003C\u002Fstrong>. NO acepta adhesiones individuales.\u003C\u002Fh3>\n\u003Ch3>* La adhesión a esta Campaña mediante la firma del presente formulario implica la \u003Cstrong>aceptación íntegra de los contenidos del Manifiesto\u003C\u002Fstrong> y, en la medida de lo posible, la difusión de la información generada por la campaña y la participación activa en las actividades que se propongan\u003C\u002Fh3>\n\u003Ch3>* El nombre de la organización aparecerá en el listado público de organizaciones adheridas oficialmente a esta Campaña. \u003C\u002Fh3>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ENGLISH \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">National Campaign (Spain) “Teva? No, thanks” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Ftevanogracias.limesurvey.net\u002F783363?lang=es&newtest=Y\">Here\u003C\u002Fa> is the form for organizations to join BEFORE FEBRUARY 24, 2026 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Join the national campaign to boycott the pharmaceutical company that finances the genocide and the apartheid in Palestine. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cstrong>\u003Cspan class=\"ryNqvb\">* \u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan class=\"ryNqvb\">\u003Cem>This Campaign will be active from March 1st to December 1st, 2026.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Ca href=\"https:\u002F\u002Ftevanogracias.limesurvey.net\u002F783363?lang=es&newtest=Y\">MANIFESTO\u003C\u002Fa> OF THE CAMPAIGN “Teva? No, thanks.”\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The undersigned organizations, collectives, and social movements committed to human rights are promoting this boycott campaign against the pharmaceutical company Teva as a measure of solidarity with the Palestinian people and for the end of apartheid, occupation, and genocide in Palestine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We are launching this initiative to return to civil society the power that governments have denied it in the face of the Palestinian extermination.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Israel is an occupying Zionist entity that is committing genocide in Palestine.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Since October 7, 2023, Israel has killed more than 70,000 people, although the actual figures are estimated to be ten times higher.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Life expectancy in Gaza has fallen from 76 to 41 years, more than 22,000 children have been killed, and tens of thousands have been orphaned.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel has destroyed 92% of homes and imposed a complete siege on Gaza, blocking the entry of food, water, hygiene products, spare parts, and fuel.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The Boycott, Divestment, and Sanctions (BDS) movement is a Palestinian-led movement for freedom, justice, and equality.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Inspired by the South African anti-apartheid movement, it urges action to pressure Israel to respect international law.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> BDS identifies Teva as one of its priority targets for an economic boycott of Israel.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva is an Israeli pharmaceutical company and a leader in the European generics market.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">In Spain, in 2023, Teva was the third largest pharmaceutical company in the country in terms of sales volume to the National Health System, with 70 million packages and over €500 million in sales.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">In 2024, according to the corporation itself, it generated revenues of $16.5 billion from its global operations.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">There are numerous contracts for the supply of these drugs to healthcare facilities in Spain.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva finances Israel, the regime that carries out occupation, apartheid, and genocide in Palestine.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">It does so through tax payments and other forms of funding.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> Teva benefits from the illegal occupation, the apartheid system, and the captive market, as it enjoys privileged positions in the pharmaceutical market of the occupied Palestinian territories.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Israel controls and restricts the import and export of medicines and allows Israeli companies to operate without paying tariffs or facing restrictions at border checkpoints.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This allows Teva to widely market its pharmaceutical products in these territories, competing directly and unfairly with other pharmaceutical companies, including Palestinian ones, whose development and growth are in turn hindered by Israel.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva openly supports and collaborates with the genocide being perpetrated by Israel: at least 10% of its workforce in Israel has joined the army, it has donated equipment to the Israel Defense Forces, its headquarters have been established as collection points for soldiers' supplies, and its offices display signs showing support for the army, among other actions supporting the Israeli military.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cstrong>\u003Cspan class=\"ryNqvb\">The boycott is a legitimate and historical tool.\u003C\u002Fspan>\u003C\u002Fstrong> \u003Cspan class=\"ryNqvb\">Boycotting companies that support a regime that perpetrates crimes against humanity is an unavoidable moral, ethical, and legal obligation.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">This is even more true when a healthcare business like Teva is part of a system that exterminates Palestinians.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Therefore, the undersigned organizations call upon: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>The public:\u003C\u002Fstrong> to actively request alternatives to Teva, both on prescriptions and at pharmacies.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \u003Cstrong>Healthcare professionals:\u003C\u002Fstrong> not to prescribe Teva when equivalents exist.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Break the chain of complicity from the consultation room.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Pharmacies:\u003C\u002Fstrong> not to market or dispense Teva.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Prioritize other laboratories not stained with Palestinian blood.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Public administrations, hospitals, and other institutional buyers: not to choose Teva as a supplier in their public purchases and healthcare tenders.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cstrong>Groups, organizations, and social movements\u003C\u002Fstrong>: to sign this manifesto as an act of support for the campaign and disseminate it among their members and in society at large within their spheres of action.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">For justice for Palestine, join the Teva boycott campaign.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> ______________________________ \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">CONSIDERATIONS TO KEEP IN MIND \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">* \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">\u003Cem>This Campaign will be active from March 1st to December 1st, 2026.\u003C\u002Fem> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">*\u003Cem> This membership FORM is ONLY for organizations.\u003C\u002Fem>\u003C\u002Fspan>\u003Cem> \u003Cspan class=\"ryNqvb\">Individual memberships are NOT accepted.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Joining this Campaign by signing this form implies full acceptance of the contents of the Manifesto and, to the extent possible,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The dissemination of information generated by the campaign and active participation in proposed activities are possible. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cem>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">* The organization's name will appear on the public list of organizations officially affiliated with this Campaign.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cimg src=\"https:\u002F\u002Fcdn.bsky.app\u002Fimg\u002Ffeed_fullsize\u002Fplain\u002Fdid:plc:sijrnjskilwxv3a4lmvqw2eg\u002Fbafkreifdcwwl5yvqwa4jvtxdbmrl3iyuyt27j53coricd5ohwpfw37jpay@jpeg\" alt=\"\" width=\"621\" height=\"544\">\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Ch3>\u003Cstrong>____________________________\u003C\u002Fstrong>\u003C\u002Fh3>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>",[15],{"timestamp":695,"user":13,"tags":696,"id":697,"link":12,"subtitle":12,"videoUrl":12,"slug":698,"content":699,"type":645,"imageUrl":700,"title":701},1771854149061,[15],"mlz7u9q8yhi3vkjlao","domingo-1-marzo-madrid-la-villana-de-vallecas-12-00-14-00-h-formacion-boicot-teva","\u003Cp>Formación para la CAMPAÑ.A de boicot estatal a Teva.\u003C\u002Fp>\n\u003Cp>De doce de la mañana a dos de la tarde.\u003C\u002Fp>\n\u003Cp>Madrid.\u003C\u002Fp>\n\u003Cp>La Villana de Vallecas Calle Sierra de Alquife, nº 12\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fmadridenaccion.org\u002Fboicot-a-teva-stopteva\u002F\">\u003Cstrong>LO BÁSICO SOBRE TEVA\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>¿QUÉ ES TEVA? 4 MARCAS\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cu>TEVA es la mayor compañía farmacéutica israelí que opera en el\u003C\u002Fu>\u003Cu> mundo\u003C\u002Fu> y distribuye medicamentos bajo las denominaciones\u003Cstrong> Ratiopharm, Tevagen, Actavis, Davur y Belmac.\u003C\u002Fstrong> Está \u003Cstrong>especializada en\u003C\u002Fstrong>\u003Cstrong> medicamentos genéricos\u003C\u002Fstrong> o que han perdido la patente. Por otro lado, produce fármacos sobre todo para trastornos neurológicos aún con la patente (donde no pensamos influir en esta campaña).\u003C\u002Fp>\n\u003Cp>Pero, por ejemplo conviene saber que el dimetilfumarato 240, que se emplea para el tratamiento de adultos con formas recurrentes de Esclerosis Múltiple, no tiene ya patente de TEVA en vigor, por lo que se usan genéricos que son suministrados por otras farmacéuticas también (\u003Ca href=\"https:\u002F\u002Fwww.sanidadpublicaasturias.org\u002Fboicot-al-comercio-de-medicamentos-con-el-gobierno-de-israel\u002F\" target=\"_blank\" rel=\"noopener\">Boicot al comercio de medicamentos con el gobierno de Israel\u003C\u002Fa>. \u003Ca href=\"https:\u002F\u002Fwww.sanidadpublicaasturias.org\u002Fboicot-al-comercio-de-medicamentos-con-el-gobierno-de-israel\u002F\">20 septiembre, 2025\u003C\u002Fa>. \u003Ca href=\"https:\u002F\u002Fwww.sanidadpublicaasturias.org\u002Fboicot-al-comercio-de-medicamentos-con-el-gobierno-de-israel\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.sanidadpublicaasturias.org\u002Fboicot-al-comercio-de-medicamentos-con-el-gobierno-de-israel\u003C\u002Fa>).\u003C\u002Fp>\n\u003Cp>Teva fue fundada en 1901. Sus oficinas centrales están en Israel. Tiene una cartera de más de 3.600 medicamentos que produce en 53 plantas, en 33 países, incluyendo una planta en Zaragoza, España, con 600 trabajador@s. Es la que concentra el 8,0% de su producción mundial. \u003Cu>En España, TEVA fue en 2023 la tercera compañía por volumen de ventas\u003C\u002Fu> con un gasto de más de 500 millones de euros. A nivel mundial, obtuvo unos ingresos de más de 16.400 millones de dólares en 2024, sobre todo a expensas de medicamentos de bajo coste pero de alta demanda como los genéricos.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>¿POR QUÉ hay que hacer boicot a TEVA? \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>4 MOTIVOS\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Col>\n\u003Cli>\u003Cstrong>TEVA financia el genocidio, la ocupación y el apartheid israelíes sobre el pueblo palestino dado que genera millones de dólares en ingresos que van directamente al régimen militar y colonial israelí.\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>\u003Cstrong>Fuentes \u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-acelera-en-espana-crece-un-10-hasta-160-millones-en-el-primer-semestre\" target=\"_blank\" rel=\"noopener\">\u003Cstrong>https:\u002F\u002Fwww.plantadoce.com\u002Fempresa\u002Fteva-acelera-en-espana-crece-un-10-hasta-160-millones-en-el-primer-semestre\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Según la ONG israelí «Who Profits», especializada en verificar qué empresas se benefician del apartheid y la ocupación, Teva es cómplice de la ocupación ilegal de Palestina, de apartheid y de genocidio contra el pueblo palestino. Teva empeora de forma deliberada la calidad de vida de las mujeres palestinas, ya que colabora en la restricción de forma severa del acceso a los servicios de salud y los fármacos por parte de las mujeres embarazadas.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>\u003Cem>SEGÚN EL CODIGO ETICO que concierne a todos y el CODIGO DEONTOLÓGICO aplicable a santiarios:\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cem>“Al igual que en la salud pública, el principio de precaución exige actuar en medio de la incertidumbre. \u003Cu>Para los médicos, esto significa desvincularse de las instituciones implicadas en el genocidio y rechazar las colaboraciones que perpetúan la impunidad. Actuar con prontitud es un deber tanto humanitario como profesional: \u003C\u002Fu>el antídoto contra la parálisis que se produce en un mundo cada vez más insensible a la violencia.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cu>La desvinculación de las instituciones implicadas en genocidio sigue siendo el único medio para restablecer el equilibrio moral.\u003C\u002Fu>\u003C\u002Fem>\u003Cem> Las intervenciones de desvinculación, como las sanciones y los boicots de consumidores, pueden ejercer una fuerza tanto económica como moral. Su poder reside en influir en los mercados y la conciencia.\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cu>… En el ámbito sanitario y académico, el propósito es la desvinculación ética para evitar la complicidad”\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem> (British Medical Journal. Medicine’s reckoning with genocide and crimes against humanity. 30 October 2025. Rubin Minhas and col. \u003C\u002Fem>\u003Ca href=\"https:\u002F\u002Fwww.bmj.com\u002Fcontent\u002Fbmj\u002F391\u002Fbmj.r2277.full.pdf\" target=\"_blank\" rel=\"noopener\">\u003Cstrong>\u003Cem>https:\u002F\u002Fwww.bmj.com\u002Fcontent\u002Fbmj\u002F391\u002Fbmj.r2277.full.pdf\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003Cstrong>\u003Cem>)\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Col start=\"2\">\n\u003Cli>\u003Cstrong>Teva saca beneficios y limita el suministro de medicamentos en Palestina donde cobra más que a los israelíes por el mismo fármaco.\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>Teva disfruta del acceso total al “mercado cautivo” tanto en Cisjordania como en Gaza, donde las empresas farmacéuticas palestinas no pueden operar a causa de las restricciones legales del régimen de apartheid israelí. Israel tampoco permite que los productos farmacéuticos palestinos se distribuyan en hospitales y farmacias de Jerusalén. Los medicamentos israelíes son más asequibles económicamente a causa de los impuestos que impone Israel a los productos que ingresen en Cisjordania.\u003C\u002Fp>\n\u003Col start=\"3\">\n\u003Cli>\u003Cstrong>Teva contribuye al empeoramiento de la salud del pueblo palestino contaminando el agua en territorios ocupados y experimentando fármacos en prisioneros palestinos. \u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>TEVA, con sede en Tel Aviv, tiene cuatro centros de producción en Israel, y también opera en asentamientos ilegales en Cisjordania.\u003C\u002Fp>\n\u003Cp>Según la organización Peoples Dispatch, los Ingredientes Farmacéuticos Activos (IFA) han contaminado el agua a través de las aguas residuales sin tratar en Territorios Ocupados. Esto supone un riesgo para el medio ambiente y para la salud de las personas. Tal y como se pudo demostrar en un artículo publicado en febrero de 2022, «Pharmaceutical pollution of the world’s rivers» al PNAS, las aguas en Palestina (junto con las de Etiopía, Túnez y República Democrática del Congo) \u003Cstrong>son las más contaminadas del planeta por ingredientes activos farmacéuticos. \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Además el Ministerio de Salud de Israel ha permitido que grandes empresas farmacéuticas israelíes\u003Cstrong> prueben sus productos en prisioneros palestinos detenidos \u003C\u002Fstrong>en cárceles israelíes. En 1997, se reportó que se habían realizado más de 5,000 pruebas en prisioneros palestinos. Las autoridades israelíes se han negado históricamente a devolver los cuerpos de palestinos fallecidos, como Fares Baroud, quien murió debido a la negativa del régimen israelí a brindarle tratamiento médico. Esto ha generado sospechas de que los cuerpos palestinos están siendo utilizados para realizar experimentos médicos. \u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_edn6\" target=\"_blank\" rel=\"noopener\">[v]\u003C\u002Fa>.\u003C\u002Fp>\n\u003Col start=\"4\">\n\u003Cli>\u003Cstrong>Se han documentado procedimientos ilícitos dentro de TEVA, en forma de sobornos y estafas, con multas millonarias en EEUU y Europa \u003C\u002Fstrong>\n\u003Cul>\n\u003Cli>\u003Cstrong>Para promover las ventas de sus medicamentos, TEVA ha realizado prácticas corruptas que le han llevado a condenas judiciales:\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cul>\n\u003Cli>Así, una multa en 2016, en Estados Unidos, de 519 millones de dólares, en relación con sobornos para vender Copaxone\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_edn6\" target=\"_blank\" rel=\"noopener\">[vi]\u003C\u002Fa>.\u003C\u002Fli>\n\u003Cli>En 2022, también en Estados Unidos, Teva fue condenada a pagar 4250 millones por la promoción fuera de indicación de sus medicamentos opiodes, lo que contribuyó a la epidemia de muertes por sobredosis\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_edn7\" target=\"_blank\" rel=\"noopener\">[vii]\u003C\u002Fa>.\u003C\u002Fli>\n\u003Cli>En 2023, Teva fue multada con 225 millones de dólares por sus prácticas corruptas con pravastatina (para “el colesterol”)\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_edn8\" target=\"_blank\" rel=\"noopener\">[viii]\u003C\u002Fa>.\u003C\u002Fli>\n\u003Cli>Por sobornos, también en relación con Copaxone, una multa en Estados Unidos de 450 millones de dólares \u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_edn9\" target=\"_blank\" rel=\"noopener\">[ix]\u003C\u002Fa>.\u003C\u002Fli>\n\u003Cli>En 2024, en relación con el mismo medicamento, la Unión Europea multó a Teva con 462,6 millones de euros por abuso de posición dominante\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_edn10\" target=\"_blank\" rel=\"noopener\">[x]\u003C\u002Fa>.\u003C\u002Fli>\n\u003Cli>Entre 2010 y 2024, Teva pagó 9.000 millones de dólares por condenas y multas por corrupción demostrada en tribunales de todo el mundo\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_edn11\" target=\"_blank\" rel=\"noopener\">[xi]\u003C\u002Fa>.\u003C\u002Fli>\n\u003Cli>A finales de 2024, Teva estaba siendo investigada en Estados Unidos por incrementar los precios e impedir la libre competencia al introducir cambios en sus medicamentos genéricos para el asma y la EPOC (enfermedad pulmonar obstructiva crónica)\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_edn12\" target=\"_blank\" rel=\"noopener\">[xii]\u003C\u002Fa>.\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Además \u003C\u002Fstrong>\u003Cstrong>TEVA realiza “transferencias de valor” a asociaciones científicas, profesionales y de investigación pero no queda claro en qué marco se producen estos traspasos de dinero \u003C\u002Fstrong>(ver web de TEVA en bibliografía).\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>En el Estado español, durante el año 2023, TEVA declaró más de 2 millones de euros en “transferencias de valor” y las organizaciones que recibieron más dinero fueron:\u003C\u002Fp>\n\u003Cp>– Fundación SEN (Sociedad Española de Neurología), Barcelona, 149.645 €\u003C\u002Fp>\n\u003Cp>– Fundació Hospital Universitari Vall d’Hebron. Institut de Recerca, Barcelona 112.850 €\u003C\u002Fp>\n\u003Cp>– Fundación Investigación y Formación de la SMEG (Sociedad Española de Médicos Generales y de Familia), Madrid, 87.483  €\u003C\u002Fp>\n\u003Cp>– Fundació Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, 53.800 €\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Por tanto, las ganancias de TEVA provienen directamente de décadas de colonización y explotación de la tierra y del pueblo palestino. Es nuestro deber hacer todo lo posible, para asegurarnos de que nuestro dinero no se utilice para fomentar la opresión genocida y colonial.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Antecedes de Boicot a TEVA:\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>4 pioneros y represalias\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Desde BDS, Sanitarios con Palestina y Health Workers for Palestine Spain (HW4PS) se lleva tiempo haciendo hincapié sobre la importancia de romper relaciones con TEVA y que \u003Cu>en la Compra Pública de administraciones. se debe priorizar el respeto a los Derechos Humanos y el Derecho internacional, aplicando criterios de Compra Pública Ética. \u003C\u002Fu>\u003C\u002Fp>\n\u003Cp>En Gran Bretaña se lleva haciendo desde 2024\u003C\u002Fp>\n\u003Cp>En España, el boicot a TEVA es desde septiembre de 2025 objetivo prioritario del BDS y estos son los lugares pioneros donde se está realizando Boicot:\u003C\u002Fp>\n\u003Col>\n\u003Cli>\u003Cstrong>Navarra\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>Desde Octubre 2025, el Servicio Navarro de Salud no prorrogará el contrato de tres fármacos suministrados por empresas israelíes. Ha sido gracias al trabajo coordinado de plataformas sociales que consiguieron más de 5000 firmas por la campaña de ruptura de relaciones con TEVA. \u003Cem>Éxito de Yala Nafarroa y el pueblo navarro. https:\u002F\u002Fhw4p.es\u002Fblog\u002Fel-servicio-navarro-de-salud-deja-de-comprar-medicamentos-de-teva\u003C\u002Fem>\u003Cem>)\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>En el trabajo previo, se había dirigido: una pregunta parlamentaria en el Parlamento de Navarra “sobre relaciones de Servicio Navarro de Salud con la empresa Teva”, que fue respondida por el Consejero de Salud; y una segunda pregunta respecto a la licitación pública. Además se realizó una importante declaración parlamentaria el 6 junio 2025 \u003Ca href=\"https:\u002F\u002Fparlamentodenavarra.es\u002Fes\u002Fnoticias\u002Fel-parlamento-insta-los-ejecutivos-foral-y-central-excluir-de-obras-servicios-compras\">«El Parlamento insta a los ejecutivos foral y central a excluir de obras, servicios, compras públicas y subvenciones a personas jurídicas que participen en actividades que faciliten actos de genocidio\u003C\u002Fa>».\u003C\u002Fp>\n\u003Cp>Por último, se produjo una declaración pública de la Presidenta Chivite que expresaba que el Gobierno de Navarra “no va a mirar para otro lado ante el genocidio contra el pueblo palestino»\u003C\u002Fp>\n\u003Col start=\"2\">\n\u003Cli>\u003Cstrong>Asturias\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>En septiembre de 2025, la diputada del Grupo Mixto y portavoz de Somos Asturies, Covadonga Tomé, registró en la Junta General del Principado de Asturias una proposición no de ley que pedía al Gobierno asturiano que resolviera de manera inmediata todos los contratos que puedan existir «con empresas que, directa o indirectamente, realicen actividades comerciales o económicas en asentamientos ilegales en territorios palestinos ocupados».\u003C\u002Fp>\n\u003Cp>La Consejería de Salud del Principado de Asturias respondió que va a «analizar» los contratos que mantiene con la farmacéutica israelí \u003Ca href=\"https:\u002F\u002Fwww.elcomercio.es\u002Fasturias\u002Fprincipado-asturias-farmaceutica-israel-teva-pharma-20250918124837-nt.html\" target=\"_blank\" rel=\"noopener\">Teva Pharma\u003C\u002Fa>, a la que ha pagado dos millones de euros desde el año pasado… (\u003Ca href=\"https:\u002F\u002Fwww.sanidadpublicaasturias.org\u002Fboicot-al-comercio-de-medicamentos-con-el-gobierno-de-israel\u002F\">Boicot al comercio de medicamentos con el gobierno de Israel\u003C\u002Fa>. \u003Ca href=\"https:\u002F\u002Fwww.sanidadpublicaasturias.org\u002Fboicot-al-comercio-de-medicamentos-con-el-gobierno-de-israel\u002F\">20 septiembre, 2025\u003C\u002Fa>. \u003Ca href=\"https:\u002F\u002Fwww.sanidadpublicaasturias.org\u002Fboicot-al-comercio-de-medicamentos-con-el-gobierno-de-israel\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.sanidadpublicaasturias.org\u002Fboicot-al-comercio-de-medicamentos-con-el-gobierno-de-israel\u003C\u002Fa> y Asturias, España: todos unidos para evitar Teva. Asturias, Spain: all united to avoid Teva ESP ENG Médicos de familia, neurólogos, sociedad civil, políticos…Family doctors, neurologists, civil society, politicians… \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fasturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fasturias-espana-todos-unidos-para-evitar-teva-asturias-spain-all-united-to-avoid-teva-esp-eng\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>El 18 noviembre de 2025, el presidente del Principado de Asturias, Adrián Barbón, durante el Debate de Orientación Política, ha confirmado el no prorrogar los acuerdos con Teva Pharma y ha manifestado su «compromiso cierto» de suspender cualquier extensión contractual con la compañía. «Estamos estudiando hacerlo porque no es tan fácil. Jurídicamente necesitamos dar unos pasos. Lo que sí hemos tomado la decisión de que todas las prórrogas con la empresa farmacéutica israelí hemos renunciado a hacerlas. De hecho, la consejera [Concepción Saavedra] ha dirigido una carta a la empresa para decir que no vamos a renovar ni una sola de los contratos que tenemos con esta empresa”. Hasta el momento, se han finalizado dos contratos, uno el 30 de septiembre, cuando se cumplía la cuarta y última prórroga para el suministro de uno de los principios activos que fabrica la multinacional israelí, y otra el 14 noviembre, al vencer otra adjudicación al Hospital Universitario Central de Asturias (HUCA) y no haberse comunicado la prórroga.  El 31 de enero y el 31 de julio del 2026 vencen los contratos de otros dos medicamentos para los que hay alternativas en el mercado, por lo que no se aplicarán las prórrogas.\u003C\u002Fp>\n\u003Col start=\"3\">\n\u003Cli>\u003Cstrong>SOLICITUD DE ATENCIÓN HOSPITALIZADA en Hospitales de Bilbao (País Vasco) e Infanta Leonor en Vallecas (Madrid):\u003C\u002Fstrong> \u003Cstrong>A COMPLETAR\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>Más de 400 médicos de los hospitales de Cruces y de la zona de Vallecas han escrito a sus consejerías pidiendo restricción de medicamentos TEVA en sus hospitales. Aun están esperando respuesta.\u003C\u002Fp>\n\u003Col start=\"4\">\n\u003Cli>\u003Cstrong>SOLICITUD DE ATENCIÓN PRIMARIA en Granada \u003C\u002Fstrong>\u003Cstrong>A COMPLETAR\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>Denuncia (por no prescribir TEVA) archivada en el Colegio de Médicos Granada (España). \u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fblog\u002Fdenuncia-por-no-prescribir-teva-archivada-colegio-de-medicos-granada-espana-complaint-for-refusing-to-prescribe-teva-dismissed-granada-medical-association-spain-esp-engl\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fhw4p.es\u002Fblog\u002Fdenuncia-por-no-prescribir-teva-archivada-colegio-de-medicos-granada-espana-complaint-for-refusing-to-prescribe-teva-dismissed-granada-medical-association-spain-esp-engl\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>TEVA en el Estado español y en la contratación pública \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>TEVA está \u003Cstrong>presente en las empresas e instituciones sanitarias públicas de todo el Estado español\u003C\u002Fstrong>.\u003C\u002Fp>\n\u003Cp>“TEVA parece no dejar de expandirse dentro del país. En 2024, la entidad creció en un 10% dentro de España, y facturó 160 millones de euros en los seis primeros meses de ese año, según \u003Cem>El Economista\u003C\u002Fem>. La producción en su fábrica de Zaragoza, según la propia empresa, ha crecido un 35% desde 2020. \u003Cu>Tampoco cesan las contrataciones públicas en el territorio\u003C\u002Fu>. La Dirección del Instituto Nacional de Gestión Sanitaria (Ingensa) formalizó el pasado 25 de noviembre 2025 \u003Ca href=\"https:\u002F\u002Fcontrataciondelestado.es\u002Fwps\u002Fportal\u002Fplataforma\u002Fbuscadores\u002Fdetalle\u002F!ut\u002Fp\u002Fz1\u002FlY9LU4NAEIR_Sw5c2ckCqx4J71QwKC6EvVCbBK21WBZ5-PslCVeJzq2nuvubQQwdEGv4t_jgg1ANryddMFKa3t5x_BDDY2q4gHcupSS8SIzyq8EyHDPbZglJowAgCn13R9cWBJggtpAPrDkPv4wNf8svGNhyfY7YMgLPhqUX70GK6ciH0s68Fzt6MmC_eZ0Q2yR-SwK8BjBReuk4KamLo9Tf-anq9VZ1Q10NehZ5eeSiQoPPvtXgOPZfY3XmGviqk2PNO6E2806fHPdY5B-sczXwuq40iLlo3Ju4MlpJ6QFEImX5HNur1Q_v7O01\u002F#Z7_AVEQAI930OBRD02JPMTPG21004\">un contrato \u003C\u002Fa>por valor de cuatro millones de euros con Teva Pharma para el suministro de medicamentos a las comunidades autónomas a través de un acuerdo macro. Por su parte la Junta de Andalucía se ha gastado en medicamentos casi dos millones de euros en lo que va de 2025 de la empresa a través de \u003Ca href=\"https:\u002F\u002Fwww.juntadeandalucia.es\u002Fhaciendayadministracionpublica\u002Fapl\u002Fpdc-front-publico\u002Fperfiles-licitaciones\u002Fcontratos-menores?busquedaGlobal=&numeroExpediente=&tituloExpediente=&provinciasTM=-1&tiposContratoTM=-1&importeDesde=&importeHasta=&nombreAdjudicatario=TEVA%20PHARMA&nifAdjudicatario=&periodoContratoMenorDesde=&periodoContratoMenorHasta=&organismo=-1&organismo2=-1\">contratos menores\u003C\u002Fa>. El gasto del Gobierno andaluz en \u003Ca href=\"https:\u002F\u002Fwww.juntadeandalucia.es\u002Fhaciendayadministracionpublica\u002Fapl\u002Fpdc-front-publico\u002Fperfiles-licitaciones\u002Fdetalle-licitacion?idExpediente=464280\">licitaciones \u003C\u002Fa>y contratos menores con la empresa superaría los seis millones de euros desde 2023. Unos contratos que se repiten con cifras similares en distintas instituciones regionales y estatales.\u003C\u002Fp>\n\u003Cp>No solo en los sistemas públicos de salud, y en las farmacias tiene presencia Teva. Según un trabajo del diario \u003Ca href=\"https:\u002F\u002Fwww.publico.es\u002Finternacional\u002Fpatrocinio-proyectos-i-d-farmaceutica-israeli-teva-espana-crecido-88-2023.html\">\u003Cem>Público\u003C\u002Fem>\u003C\u002Fa>, el patrocinio de proyectos de I+D de esta farmacéutica en el Estado ha crecido un 88% desde 2023. Además, la Universidad Autónoma de Madrid ha creado una cátedra “en manejo personalizado en asma y EPOC graves y otras enfermedades respiratorias complejas” y mantiene relaciones con decenas de universidades públicas en el país”. Teva, la farmacéutica israelí que apoya el genocidio y la ocupación a la que se enfrenta un médico andaluz. \u003Ca href=\"https:\u002F\u002Fwww.elsaltodiario.com\u002Fautor\u002Faurora-baez-boza\" target=\"_blank\" rel=\"noopener\">El salto 2 dic 2025. Aurora Báez Boza\u003C\u002Fa> \u003Ca href=\"https:\u002F\u002Fbsky.app\u002Fprofile\u002Flaespigaora.bsky.social\">@laespigaora.bsky.social\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Para saber si un hospital, Equipo de Atención Primaria, residencia o cualquier otro centro sanitario tiene contratos con TEVA, solo hay que entrar \u003Cstrong>en las siguientes webs y hacer una búsqueda avanzada: \u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cstrong>Plataforma de Contratación del Sector Público [Estatal]\u003Cbr>\u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fcontrataciondelestado.es\u002Fwps\u002Fportal\u002Fplataforma\" target=\"_blank\" rel=\"noopener\">\u003Cstrong>https:\u002F\u002Fcontrataciondelestado.es\u002Fwps\u002Fportal\u002Fplataforma\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\u003Cstrong>Contratos Públicos de Galicia \u003C\u002Fstrong>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Kontratazio Publikoa Euskadin \u003C\u002Fstrong>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Portal de Contratación Navarra \u003C\u002Fstrong>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Plataforma de Serveis de Contractació Pública Catalunya. En Catalunya, las empresas públicas que contratan Teva son: Institut Català de Salut, Gestió de Serveis Sanitaris, Tribunal Català de Contractes del Servei Públic y Consorci de Salut i Social de Catalunya\u003C\u002Fstrong>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Plataforma de Contratación de la Comunidad Autónoma de la Rioja \u003C\u002Fstrong>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Contratación Pública Junta de Andalucía \u003C\u002Fstrong>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>\u003Cu>Portal de la Contratación Pública de la Comunidad de Madrid https:\u002F\u002Fcontratos-publicos.comunidad.madrid\u002F\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cstrong>En Madrid, \u003C\u002Fstrong>Audita Sanidad documenta que ha habido 30.912 contratos menores adjudicados a TEVA en la Comunidad de Madrid en el período 01\u002F01\u002F2016 a 31\u002F12\u002F2024, por un importe de 54.933.546 euros con IVA (y 52.724.839 euros sin IVA). Este colectivo denuncia al Gobierno de Ayuso, ante el Ministerio de Hacienda, por el abuso de los contratos menores:\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.elplural.com\u002Fautonomias\u002Fmadrid\u002Faudita-sanidad-denuncia-ministerio-hacienda-gobierno-ayuso-abuso-contratos-menores_366592102\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.elplural.com\u002Fautonomias\u002Fmadrid\u002Faudita-sanidad-denuncia-ministerio-hacienda-gobierno-ayuso-abuso-contratos-menores_366592102\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>Por ejemplo solo en 2024\u003C\u002Fstrong> a TEVA PHARMA se le han comprado en contratos menores:\u003C\u002Fp>\n\u003Col>\n\u003Cli>\u003Cstrong>Fármacos, por los hospitales siguientes:\u003C\u002Fstrong> Hospital Universitario de Fuenlabrada 25 contratos, Hospital Central de la Cruz Roja San José y Santa Adela, Infantil Universitario Niño Jesús, Hospital Universitario del Sureste, Hospital Universitario Fundación Alcorcón, Hospital Universitario de Móstoles (citotóxicos, antivirales, dimetilfumarato para EM, antagonistas del ligando), Hospital Universitario \u003Cstrong>La Paz 100 contratos \u003C\u002Fstrong>(inh de protein kinasas, inh proteasa y TI, triazoles, antimicoticos, \u003Ca href=\"https:\u002F\u002Fcontratos-publicos.comunidad.madrid\u002Fcontrato\u002FD981_7812\" target=\"_blank\" rel=\"noopener\">ALCALOIDES DEL OPIO Y DERIVADoS\u003C\u002Fa>, analogos de purina, antraciclinas, antiepilepticos, inh prolactica), Hospital Universitario Infanta Cristina , Hospital Dr. Rodríguez Lafora, Hospital Universitario Infanta Leonor 20 contratos (antiinfecciosos, antioncologicos e IS),  Gerencia del SUMMA 112, Hospital Universitario El Escorial (RANIBIZUMAB sc),  Hospital Universitario José Germain,  Hospital Universitario del Tajo.  Hospital Universitario del Henares 20contratos\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Pero también TECNOLOGIAS VIALES APLICADAS,\u003C\u002Fstrong> a TEVA, S.L como son las siguientes:\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cul>\n\u003Cli>MANTENIMIENTO CAMARAS LECTORAS C.SANIDAD 2025-26 Consejería de Sanidad\u003Cbr>142,74e\u003C\u002Fli>\n\u003Cli>MANTENIMIENTO PREVENTIVO Y CORRECTIVO DE LA INSTALACIÓN DEL SISTEMA DE LECTURA DE MATRICULAS PARA LOS PARKINGS UBICADOS EN LAS SEDES JUDICIALES DE GRAN VÍA, 19 Y GENERAL CASTAÑOS, 1, MADRID. Consejería de Presidencia, Justicia y Administración Local 14,000e\u003C\u002Fli>\n\u003Cli>SIST.LECTURA Y CAPT. MATRÍCULAS GARAJE ALCALA 16 Consejería de Medio Ambiente, Agricultura e Interior 15,000e\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.comunidad.madrid\u002Fpublicacion\u002Fref\u002F51698\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.comunidad.madrid\u002Fpublicacion\u002Fref\u002F51698\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong> Cumplimiento del Derecho Internacional\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Aprobada el 9 de diciembre de 1948 y puesta en vigor el 12 de enero de 1951, la Convención para la Prevención y la Sanción del Delito de Genocidio establece que el genocidio es un delito de derecho internacional. Se entiende por genocidio la matanza de personas de un grupo nacional, étnico, racial o religioso; la lesión grave a la integridad física y mental de este grupo; el sometimiento intencional del grupo a condiciones de existencia que conlleven una destrucción física (total o parcial); las medidas intencionades que impiden nacimientos de dicho grupo; y el traslado por fuerza de niños y niñas de este grupo.\u003C\u002Fp>\n\u003Cp>En el artículo III y IV de dicha convención se expone que serán castigados los actos de genocidio; la asociación para cometer genocidio; la instigación directa y pública a cometer genocidio; la tentativa de genocidio; y la complicidad en el genocidio. Las personas que hayan cometido genocidio o cualquiera de estos actos serán castigadas ya se trate de gobernantes, funcionarios o particulares.\u003C\u002Fp>\n\u003Cp>En la Constitución Española, capítulo tercero De los Tratados Internacionales, el artículo 96 expresa que\u003C\u002Fp>\n\u003Col>\n\u003Cli>Los tratados internacionales válidamente celebrados, una vez publicados oficialmente en España, formarán parte del ordenamiento interno. Sus disposiciones sólo podrán ser derogadas, modificadas o suspendidas en la forma prevista en los propios tratados o de acuerdo con las normas generales del Derecho internacional.\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>La CIJ ha declarado con toda nitidez la obligación de todos los Estados (y por ende de todas sus instituciones) de cortar todo reconocimiento, ayuda, inversión, comercio, armas y apoyo de cualquier tipo al proyecto colonial de Israel en el territorio palestino ocupado.\u003C\u002Fp>\n\u003Cp>Por lo tanto, \u003Cstrong>el Estado español está obligado a cumplir con los artículos de la Convención para la Prevención y la Sanción del Delito de Genocidio; y la sociedad civil tiene el derecho y el deber de exigir que se cumpla con el Derecho Internacional y el Derecho Humanitario Internacional.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Blanqueo de imagen de TEVA\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>TEVA tiene un premio denominado «Humanizando la Sanidad». El objetivo de este premio es, según TEVA, \u003Cstrong>reconocer la labor de aquellas instituciones públicas o privadas que desarrollan proyectos, actividades e iniciativas solidarias \u003C\u002Fstrong>que contribuyen a aliviar el sufrimiento de ciertas enfermedades. TEVA dice valorar el que los proyectos sean “de apoyo psicológico y que humanicen los procesos asistenciales”.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Este es un ejemplo de cómo las empresas israelíes intentan lavar su imagen de cara al resto del mundo\u003C\u002Fstrong>, de cómo se presentan como una empresa con valores humanistas, democráticos, feministas, ecologistas… Es otra forma de normalización de las políticas de genocidio, colonización y apartheid que ocurren en el estado donde la marca tiene su sede central y donde decide su operativa global.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Silencio de TEVA ante el asesinato \u003C\u002Fstrong>\u003Cstrong>de sanitarios y pacientes, la destrucción de las infraestructuras sanitarias en Gaza y el bloqueo de alimentos, agua, energía y medicamentos\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Una de las caras más oscuras del genocidio más allá del asesinato masivo de civiles, mayoritariamente niños y mujeres, es el convertir en objetivo de guerra contra todas las convenciones internacionales a profesores, cooperantes, periodistas, rescatistas o sanitarios. Cabría esperar de una empresa como TEVA, por su situación geográfica un mínimo de posicionamiento crítico ante el genocidio, el apartheid y la ocupación, por mucho que su operativa sea global y por mucho que pocas o ninguna de las farmacéuticas transnacionales acostumbre a posicionarse en cuestiones de conflictos y DDHH.\u003C\u002Fp>\n\u003Cp>La habitual “neutralidad” del ámbito empresarial bien puede hacer una excepción en hechos tan flagrantes como el asesinato sistemático de trabajadores y cooperantes sanitarios y trabajadores de protección civil, así como respecto al bloqueo de medicamentos y destrucción de hospitales, ambulancias y todo tipo de equipamiento sanitario. El mero silencio de TEVA sobre estos crímenes de guerra, tratándose de una empresa dedicada a la salud y con matriz y posición de privilegio en Israel hace plantearse que es una razón más para la ruptura.\u003C\u002Fp>\n\u003Cp>En un artículo del 7 de mayo del 2025 en Haaretz, el prestigioso periodista israelí Gideon Levy titula “Mi amigo en Gaza agota sus últimas gotas de insulina”. Es gravísimo que una de las mayores empresas de genéricos del mundo y que exporta a todo el planeta asuma en silencio el bloqueo de su estado sobre la población de Gaza.\u003C\u002Fp>\n\u003Cp>Según afirmaba UNWRA, en el Día Mundial de la Salud (7 de abril 2025) “ponemos en el centro que en Gaza se siguen produciendo ataques constantes contra personal e instalaciones sanitarias. Según la OMS, entre octubre de 2023 y el 14 de marzo de 2025, se han producido \u003Cstrong>670 ataques a la atención sanitaria, que han afectado a 122 centros sanitarios y 170 ambulancias\u003C\u002Fstrong>.\u003C\u002Fp>\n\u003Cp>Citamos también a MSF: “Según el Ministerio de Sanidad de Gaza, hasta el 23 de marzo de 2025: más de \u003Cstrong>50.144 personas han muerto, de entre ellos casi un tercio son menores de 18 años. Más de 113.704 han resultado herida\u003C\u002Fstrong>s.\u003C\u002Fp>\n\u003Cp>Al menos \u003Cstrong>409 miembros del personal humanitario, la gran mayoría palestinos, han muerto en Gaza\u003C\u002Fstrong> desde el comienzo de la guerra (OCHA, 4 de abril). \u003Cstrong>Más de 1.000 trabajadores sanitarios han muerto en Gaza\u003C\u002Fstrong> desde octubre de 2023 , entre ellos once miembros del personal de MSF.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>“Obligación de todos los Estados de cortar todo reconocimiento, ayuda, inversión, comercio, armas y apoyo de cualquier tipo, al proyecto colonial de Israel en el territorio palestino ocupado” (CIJ)\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>A modo de conclusión, recogemos unas palabras de un artículo del experto en DDHH Craig Mokhiber, ex-director de la oficina en Nueva York del Alto Comisionado de las Naciones Unidas para los Derechos Humanos:\u003C\u002Fp>\n\u003Cp>«La CIJ ya ha emitido una serie de medidas provisionales contra Israel por genocidio, y una lista cada vez mayor de países se están alineando detrás de Palestina y Sudáfrica en el caso de genocidio contra Israel.\u003C\u002Fp>\n\u003Cp>En la ONU se está debatiendo la creación de un tribunal internacional específico. Ya se han presentado casos en tribunales nacionales de todo el mundo y seguramente se presentarán más. También hay planes en marcha para poner en marcha un organismo internacional contra el apartheid que se focalice en Israel.\u003C\u002Fp>\n\u003Cp>Mientras tanto, las Naciones Unidas, sus mecanismos independientes de derechos humanos y las principales organizaciones internacionales, palestinas e israelíes de derechos humanos han reunido enormes cantidades de pruebas, han condenado enérgicamente a Israel por su escandalosa criminalidad y están trabajando para garantizar la rendición de cuentas.\u003C\u002Fp>\n\u003Cp>Las manifestaciones masivas contra Israel no sólo ocurren a diario en las capitales de todo el mundo, sino que en realidad están creciendo, sin que las intimiden los esfuerzos a menudo brutales (especialmente de los gobiernos occidentales) por reprimirlas.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>La CIJ ha declarado la obligación de todos los Estados de cortar todo reconocimiento, ayuda, inversión, comercio, armas y apoyo de cualquier tipo al proyecto colonial de Israel en el territorio palestino ocupado».*\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>* Fuente: El principio del fin de Israel (Craig Mokhiber)\u003Cbr>\u003Ca href=\"https:\u002F\u002Fwww.elsaltodiario.com\u002Fopinion\u002Fcraig-mokhiber-principio-fin-israel\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fwww.elsaltodiario.com\u002Fopinion\u002Fcraig-mokhiber-principio-fin-israel\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Bibliografía\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Teva, la farmacéutica israelí que apoya el genocidio y la ocupación a la que se enfrenta un médico andaluz. \u003Ca href=\"https:\u002F\u002Fwww.elsaltodiario.com\u002Fautor\u002Faurora-baez-boza\">El salto \u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fwww.elsaltodiario.com\u002Fautor\u002Faurora-baez-boza\">2 dic 2025\u003C\u002Fa>\u003Ca href=\"https:\u002F\u002Fwww.elsaltodiario.com\u002Fautor\u002Faurora-baez-boza\">. Aurora Báez Boza\u003C\u002Fa> \u003Ca href=\"https:\u002F\u002Fbsky.app\u002Fprofile\u002Flaespigaora.bsky.social\">@laespigaora.bsky.social\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"about:blank\">\u003Cstrong>[v]\u003C\u002Fstrong>\u003C\u002Fa> Las grandes farmacéuticas de propiedad israelí son ahora el objetivo de activistas británicos. Cómplice de genocidio. \u003Ca href=\"https:\u002F\u002Fwww.thecanary.co\u002Fauthor\u002Fthecanary\u002F\">The Canary\u003C\u002Fa>. \u003Ca href=\"https:\u002F\u002Fwww.thecanary.co\u002Fuk\u002Fnews\u002F2024\u002F03\u002F05\u002Fteva-uk-protest\u002F\">5 de marzo de 2024\u003C\u002Fa> \u003Cstrong> \u003C\u002Fstrong>\u003Cstrong>https:\u002F\u002Fwww.thecanary.co\u002Fuk\u002Fnews\u002F2024\u002F03\u002F05\u002Fteva-uk-protest\u002F\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref6\">[vi]\u003C\u002Fa>Teva agrees to pay US$519m to settle corruption charge. \u003Ca href=\"https:\u002F\u002Fpharmaceutical-journal.com\u002Farticle\u002Fnews\u002Fteva-agrees-to-pay-us519m-to-settle-corruption-charge\">https:\u002F\u002Fpharmaceutical-journal.com\u002Farticle\u002Fnews\u002Fteva-agrees-to-pay-us519m-to-settle-corruption-charge\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref7\">[vii]\u003C\u002Fa>Opioids Maker Teva Agrees to $4.25 billion settlement: Preliminary Agreement Will Provide Cash and Naloxone to Address Opioids Crisis. \u003Ca href=\"https:\u002F\u002Fwww.texasattorneygeneral.gov\u002Fnews\u002Freleases\u002Fopioids-maker-teva-agrees-425-billion-settlement-preliminary-agreement-will-provide-cash-and\">https:\u002F\u002Fwww.texasattorneygeneral.gov\u002Fnews\u002Freleases\u002Fopioids-maker-teva-agrees-425-billion-settlement-preliminary-agreement-will-provide-cash-and\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref8\">[viii]\u003C\u002Fa>Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges. \u003Ca href=\"https:\u002F\u002Fedition.cnn.com\u002F2023\u002F08\u002F21\u002Finvesting\u002Fteva-pharmaceuticals-price-fixing-settlement\u002Findex.html\">https:\u002F\u002Fedition.cnn.com\u002F2023\u002F08\u002F21\u002Finvesting\u002Fteva-pharmaceuticals-price-fixing-settlement\u002Findex.html\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref9\">[ix]\u003C\u002Fa>Drug Maker Teva Pharmaceuticals Agrees to Pay $450M in False Claims Act Settlement to Resolve Kickback Allegations Relating to Copayments and Price Fixing. \u003Ca href=\"https:\u002F\u002Fwww.justice.gov\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback\">https:\u002F\u002Fwww.justice.gov\u002Fopa\u002Fpr\u002Fdrug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref10\">[x]\u003C\u002Fa>Commission fines Teva €462.6 million over misuse of the patent system and disparagement to delay rival multiple sclerosis medicine. \u003Ca href=\"https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_24_5581\">https:\u002F\u002Fec.europa.eu\u002Fcommission\u002Fpresscorner\u002Fdetail\u002Fen\u002Fip_24_5581\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref11\">[xi]\u003C\u002Fa>Violation Tracker Global: Current Parent Summary. \u003Ca href=\"https:\u002F\u002Fviolationtrackerglobal.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\">https:\u002F\u002Fviolationtrackerglobal.goodjobsfirst.org\u002Fparent\u002Fteva-pharmaceutical-industries\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.nogracias.org\u002F2025\u002F01\u002F01\u002Fteva-en-espana-un-gigante-farmaceutico-cuyas-ganancias-danan-la-salud-de-la-poblacion-de-palestina-profesionales-de-la-sanidad-por-palestina-espana-healthworkers4palestinespain\u002F#_ednref12\">[xii]\u003C\u002Fa>FTC opens investigation into Teva, escalating patent fight with pharma industry. \u003Ca href=\"https:\u002F\u002Fwww.washingtonpost.com\u002Fhealth\u002F2024\u002F07\u002F01\u002Fteva-patent-pharma-generic-inhaler\u002F\">https:\u002F\u002Fwww.washingtonpost.com\u002Fhealth\u002F2024\u002F07\u002F01\u002Fteva-patent-pharma-generic-inhaler\u002F\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cstrong>ACCIÓN DE BOICOT A TEVA\u003Cbr>\u003Cbr>\u003C\u002Fstrong>\u003C\u002Fp>","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1771853583\u002Fvrsowvgswa126s66zr22.jpg","Domingo 1 marzo. Madrid. La Villana de Vallecas. 12,00-14,00 h. Formación boicot Teva",{"videoUrl":12,"link":12,"user":13,"tags":703,"id":704,"imageUrl":705,"subtitle":12,"type":645,"content":706,"slug":707,"timestamp":708,"title":709},[15,164],"mm0dr50l6nmybxyntaq","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1771924049\u002Fas5yuf3reiuarepks7da.jpg","\u003Cp>\u003Cimg src=\"https:\u002F\u002Fcdn.bsky.app\u002Fimg\u002Ffeed_fullsize\u002Fplain\u002Fdid:plc:sijrnjskilwxv3a4lmvqw2eg\u002Fbafkreiei4p2cjqtkecrzi6qg2577fc4odgllwvv7tp74swfjhfeed5o7iy@jpeg\" alt=\"\">\u003C\u002Fp>\n\u003Cp>Boicot Teva. Madrid, 27 febrero, 10,00 am, concentración, Ministerio Sanidad. Que tus medicamentos no sean sus balas.\u003C\u002Fp>\n\u003Cp>🎤\u003Cstrong>El 26 y 27 de febrero, en distintas ciudades de todo el Estado, se presentará la campaña estatal de boicot a la farmacéutica israelí Teva. \u003C\u002Fstrong>\u003Cbr>✒️La campaña liderada por múltiples grupos sanitarios y organizaciones solidarias con Palestina, cuenta ya con el apoyo de más de 200 colectivos de todo el país. \u003Cbr>💊Teva, empresa farmacéutica israelí líder en el mercado de genéricos, también a nivel español, financia el estado sionista y participa activamente en el sistema de apartheid y ocupación de Palestina, siendo cómplice del genocidio al pueblo palestino 🇵🇸.\u003Cbr>📢Por eso, os invitamos a uniros a la campaña, así como venir a apoyar en la presentación de esta.\u003Cbr>#TevaNoGracias\u003C\u002Fp>\n\u003Cp>En Madrid, nos encontraremos en:\u003Cbr>📅Viernes 27 de febrero\u003Cbr>🕘 10:00 horas\u003Cbr>📍Pº del Prado 18 (frente Mº Sanidad)\u003Cbr>❌QUE TUS MEDICAMENTOS NO SEAN SUS BALAS!\u003Cbr>❌BOICOT TEVA. BOICOT ISRAEL.\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002F\">\"¿Teva? ¡No gracias!\"\u003C\u002Fa>\u003Cbr>Campaña de boicot a los productos de Teva.\u003Cbr>De 1 de marzo a 1 de diciembre, 2026.\u003Cbr>Página oficial con toda la información.\u003Cbr>\"Que tus medicamentos no sean sus balas\"\u003Cbr>Contra la ocupación, el apartheid y el genocidio en Palestina.\u003C\u002Fp>\n\u003Cp>MATERIAL SÓLO EN ESPAÑOL\u003Cbr>https:\u002F\u002Ftevanogracias.com\u002F\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"translatable-message\">CAMPAÑA estatal \"¿Teva? No, gracias\". Desde el 1 de Marzo al 1 de Diciembre de 2026. Texto de la convocatoria. National Campaign (Spain) “Teva? No, thanks” This Campaign will be active from March 1st to December 1st, 2026. Declaration \u003Ca class=\"anchor-url\" href=\"https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fcampana-estatal-teva-no-gracias-desde-el-1-de-marzo-al-1-de-diciembre-de-2026\" target=\"_blank\" rel=\"noopener noreferrer\">https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fcampana-estatal-teva-no-gracias-desde-el-1-de-marzo-al-1-de-diciembre-de-2026 \u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fdomingo-1-marzo-madrid-la-villana-de-vallecas-12-00-14-00-h-formacion-boicot-teva\">Domingo 1 marzo. Madrid. La Villana de Vallecas. 12,00-14,00 h. Formación boicot Teva. Convocatoria y \"paquete básico\" \u003C\u002Fa> https:\u002F\u002Fhw4p.es\u002Facciones-urgentes\u002Fdomingo-1-marzo-madrid-la-villana-de-vallecas-12-00-14-00-h-formacion-boicot-teva \u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan class=\"translatable-message\">NoGracias se suma a la campaña estatal de boicot a Teva Al tiempo, pide que a la campaña se sumen los poderes públicos \"NoGracias, más allá de la campaña estatal de boicot a Teva\" \u003Ca class=\"anchor-url\" href=\"https:\u002F\u002Fwww.nogracias.org\u002F2026\u002F02\u002F21\u002Fnogracias-mas-alla-de-la-campana-estatal-de-boicot-a-teva\u002F\" target=\"_blank\" rel=\"noopener noreferrer\">https:\u002F\u002Fwww.nogracias.org\u002F2026\u002F02\u002F21\u002Fnogracias-mas-alla-de-la-campana-estatal-de-boicot-a-teva\u002F\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"_aupe copyable-text x15bjb6t x1n2onr6\">\u003Ca href=\"https:\u002F\u002Fhw4p.es\u002Fboicot\u002Ffarmaceutica\u002Fteva\">\u003Cspan class=\"_aupe copyable-text xkrh14z\" style=\"white-space: pre-wrap;\">Boicot Teva. Teva crea valor para sostener el genocidio en Palestina. Boycott Teva. \u003C\u002Fspan>\u003Cspan class=\"_aupe copyable-text xkrh14z\" style=\"white-space: pre-wrap;\">Teva creates value to sustain genocide in Palestine. Content in Spanish and English \u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>","boicot-teva-madrid-27-marzo-10-00-am-concentracion-ministerio-sanidad-que-tus-medicamentos-no-sean-sus-balas",1771924219036,"Boicot Teva. Concentraciones. En Madrid, 27 febrero, 10,00 am, concentración, Ministerio Sanidad. Que tus medicamentos no sean sus balas",{"link":12,"user":13,"tags":711,"id":714,"subtitle":12,"content":715,"timestamp":716,"videoUrl":12,"imageUrl":717,"type":645,"slug":718,"title":719},[15,164,712,713],"Campaña","Estatal","mmkhn2vu8ymybkj80hk","\u003Cp>No apoyes a Israel en la ocupación, el apartheid y el genocidio en Palestina.\u003Cbr>No mejores tu salud a costa de la muerte de mujeres, niños, ancianos y otros civiles indefensos.\u003Cbr>Di \"nogracias\" a Teva, por justicia, beneficencia y no maleficencia.\u003Cbr>Vídeo, 1 min\u003Cbr>\u003Ca class=\"text-entity-link word-break-all\" dir=\"auto\" title=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=paw248Eka20\" href=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=paw248Eka20\" target=\"_blank\" rel=\"noopener noreferrer\" data-entity-type=\"MessageEntityUrl\">https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=paw248Eka20\u003C\u002Fa>\u003C\u002Fp>",1773139971943,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1773139966\u002Fxhyeipniy4nikvblxxqz.png","boicot-a-teva-video-1-min-campana-estatal-de-1-de-marzo-a-1-de-diciembre-2026","Boicot a Teva. Vídeo 1 min. Campaña estatal de 1 de marzo a 1 de diciembre 2026.",{"link":12,"tags":721,"user":13,"subtitle":12,"timestamp":724,"videoUrl":12,"imageUrl":725,"id":726,"content":727,"type":645,"title":728,"slug":729},[15,722,723],"INFARMA","IFEMA",1773781443599,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1773777805\u002Fagtimcasnh5ky3gr9gmh.jpg","mmv1g8va4c7qilx4cks","\u003Cp>\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f4e2.png\" alt=\"📢\" data-path=\".\u002Fimg-apple-64\u002F1f4e2.png\"> \u003Cstrong data-entity-type=\"MessageEntityBold\">CONCENTRACIÓN IFEMA - Feria Internacional de Farmacia. INFARMA (entrada principal, frente a la salida del Metro \"Feria de Madrid\")\u003C\u002Fstrong>\u003Cbr>\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f5d3.png\" alt=\"🗓\" data-path=\".\u002Fimg-apple-64\u002F1f5d3.png\">\u003Cstrong data-entity-type=\"MessageEntityBold\">25 MARZO, miércoles 17:00h\u003C\u002Fstrong> - Contra la presencia de la farmaceútica TEVA\u003Cbr>\u003Cbr>\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1fa78.png\" alt=\"🩸\" data-path=\".\u002Fimg-apple-64\u002F1fa78.png\">\u003Cstrong data-entity-type=\"MessageEntityBold\"> Si te duele el genocidio, ven a nuestra consulta\u003C\u002Fstrong>.\u003Cbr>\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f915.png\" alt=\"🤕\" data-path=\".\u002Fimg-apple-64\u002F1f915.png\"> \u003Cins data-entity-type=\"MessageEntityUnderline\">Síntomas\u003C\u002Fins>: tristeza infinita, dolor agudo, impotencia y rabia.\u003Cbr>\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f469-200d-2695-fe0f.png\" alt=\"👩‍⚕️\" data-path=\".\u002Fimg-apple-64\u002F1f469-200d-2695-fe0f.png\">\u003Cins data-entity-type=\"MessageEntityUnderline\">Tratamiento\u003C\u002Fins>: boicot \u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F274c.png\" alt=\"❌\" data-path=\".\u002Fimg-apple-64\u002F274c.png\">a la farmacéutica Israeli TEVA, 24 horas al día.\u003Cbr>\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f4d1.png\" alt=\"📑\" data-path=\".\u002Fimg-apple-64\u002F1f4d1.png\"> \u003Cins data-entity-type=\"MessageEntityUnderline\">Contraindicaciones\u003C\u002Fins>: ninguna.\u003Cbr>\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f33f.png\" alt=\"🌿\" data-path=\".\u002Fimg-apple-64\u002F1f33f.png\">\u003Cins data-entity-type=\"MessageEntityUnderline\">Efectos secundarios\u003C\u002Fins>: contribuirás a acabar con el apartheid y la ocupación en Palestina, y a hacer del mundo un lugar más pacífico y seguro.\u003Cbr>\u003Cstrong data-entity-type=\"MessageEntityBold\">\u003Cins data-entity-type=\"MessageEntityUnderline\">Plan\u003C\u002Fins>\u003C\u002Fstrong>: \u003Cbr>• NO volver a comprar \u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F26d4.png\" alt=\"⛔️\" data-path=\".\u002Fimg-apple-64\u002F26d4.png\"> \u003Cstrong data-entity-type=\"MessageEntityBold\">ningún medicamento \u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f48a.png\" alt=\"💊\" data-path=\".\u002Fimg-apple-64\u002F1f48a.png\"> de\u003C\u002Fstrong> \u003Cstrong data-entity-type=\"MessageEntityBold\">Teva nunca má\u003C\u002Fstrong>s. \u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F26a0.png\" alt=\"⚠️\" data-path=\".\u002Fimg-apple-64\u002F26a0.png\"> \u003Cstrong data-entity-type=\"MessageEntityBold\">pedir cualquier otra marca\u003C\u002Fstrong>.\u003Cbr>• NO descansar hasta que Palestina sea libre. \u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f4aa-1f3fd.png\" alt=\"💪🏽\" data-path=\".\u002Fimg-apple-64\u002F1f4aa-1f3fd.png\">\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F270a-1f3fd.png\" alt=\"✊🏽\" data-path=\".\u002Fimg-apple-64\u002F270a-1f3fd.png\">\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f1f5-1f1f8.png\" alt=\"🇵🇸\" data-path=\".\u002Fimg-apple-64\u002F1f1f5-1f1f8.png\">\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f1f5-1f1f8.png\" alt=\"🇵🇸\" data-path=\".\u002Fimg-apple-64\u002F1f1f5-1f1f8.png\">\u003Cimg class=\"emoji emoji-small\" draggable=\"false\" src=\"https:\u002F\u002Fweb.telegram.org\u002Fa\u002Fimg-apple-64\u002F1f1f5-1f1f8.png\" alt=\"🇵🇸\" data-path=\".\u002Fimg-apple-64\u002F1f1f5-1f1f8.png\">\u003C\u002Fp>\n\u003Cp>Teva estará presente en Infarma 2026, que se celebrará del 24 al 26 de marzo en IFEMA, en Madrid. \u003C\u002Fp>\n\u003Ch3>\u003Cstrong>TEVA en Infarma 2026: Stand N\u003C\u002Fstrong>º3B11\u003C\u002Fh3>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"ar7uv\" data-offset-key=\"avuas-0-0\">\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"avuas-0-0\">\u003Cspan data-text=\"true\">INFARMA Madrid 2026\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"ar7uv\" data-offset-key=\"6l3ev-0-0\">\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"6l3ev-0-0\">\u003Cspan data-text=\"true\">El mayor encuentro de Farmacia que integra el Congreso Europeo de Oficina de Farmacia y el Salón de Medicamentos y Parafarmacia.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"6l3ev-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"6l3ev-0-0\">\u003Cspan data-text=\"true\">La asistencia prevista supera los 25.000 visitantes. \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"6l3ev-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"6l3ev-0-0\">\u003Cspan data-text=\"true\">Infarma Madrid 2026 tendrá lugar en el recinto ferial IFEMA del 24 al 26 de marzo bajo el lema ‘La salud empieza aquí’.\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"\" data-block=\"true\" data-editor=\"ar7uv\" data-offset-key=\"5ijdj-0-0\">\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"5ijdj-0-0\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"public-DraftStyleDefault-block public-DraftStyleDefault-ltr\" data-offset-key=\"5ijdj-0-0\">\u003Cspan data-offset-key=\"5ijdj-0-1\">\u003Cspan data-text=\"true\">Los farmacéuticos encontrarán en Infarma la oferta más extensa de productos y servicios para su oficina de farmacia que presentarán los expositores participantes.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cp>INFARMA es una feria del sector farmacéutico en Europa y tiene lugar anualmente, alternando entre Madrid y Barcelona. El nombre INFARMA significa International Pharmacy Meeting and Medicines Exhibition, lo que resalta la relevancia internacional del evento. \u003C\u002Fp>\n\u003Cp>Organizada por el Col·legi de Farmacèutics de Barcelona, en colaboración con el Colegio Oficial de Farmacéuticos de Madrid (COFM) y CloserStill Media, la feria sirve como una plataforma clave para el intercambio profesional, la presentación de innovaciones y el debate sobre los desafíos actuales de la industria farmacéutica.\u003C\u002Fp>\n\u003Cp>\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>El evento se centra en innovaciones farmacéuticas, transformación digital en el sector de la salud, gestión de farmacias, desarrollos regulatorios, farmacia clínica, salud pública y sostenibilidad en la industria farmacéutica. Empresas líderes y expertos presentan nuevos medicamentos, terapias avanzadas, soluciones digitales para farmacias y servicios innovadores diseñados para optimizar la atención al paciente.\u003C\u002Fp>\n\u003Cp>INFARMA atrae a una amplia variedad de profesionales del sector, incluidos farmacéuticos, expertos en farmacia, proveedores de servicios de salud y responsables de la toma de decisiones en la industria. Para los farmacéuticos, en particular, la feria representa una oportunidad invaluable para conocer nuevas oportunidades de negocio, ampliar redes profesionales y compartir buenas prácticas. Además de conferencias magistrales y mesas de debate, el programa incluye seminarios y conferencias sobre temas de actualidad en el sector.\u003C\u002Fp>\n\u003Cp>La INFARMA tendrá lugar en 3 días de martes, 24. marzo a jueves, 26. marzo 2026 en Madrid.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Organizador\u003Cbr>\u003C\u002Fstrong> CloserStill Media Ltd.\u003Cbr>Unit 9, Exhibition House Addison Bridge Place\u003Cbr>W14 8XP Londres, Reino Unido de Gran Bretaña e Irlanda del Norte\u003Cbr>Tel: +44 207 348 5250\u003Cbr>\u003Cspan class=\"show_hide getEmail\" data-tab=\"veranstalter\" data-id=\"6168\"> \u003Ca style=\"cursor: pointer;\"> Mostrar email \u003C\u002Fa> \u003C\u002Fspan> \u003Cbr>\u003Cspan class=\"gothere\" title=\"Sitio de los organizadores\" data-role=\"gothere\" data-target=\"%2F1o%2FLjT20J6vjmN0vu%2BPqYVlBlgRm1D9sf4rrIqJaHo%3D\"> www.closerstillmedia.com \u003C\u002Fspan>\u003C\u002Fp>","25 marzo, 17,00 h. Concentración en IFEMA, Feria Internacional Farmacia, INFARMA. #boicotTeva #TevaNoGracias","25-marzo-17-00-h-concentracion-en-ifema-feria-internacional-farmacia-infarma-boicotteva-tevanogracias",{"videoUrl":12,"tags":731,"user":13,"link":12,"imageUrl":733,"id":734,"slug":735,"type":645,"subtitle":12,"title":736,"content":737,"timestamp":738},[15,732],"Santander","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1779613950\u002Fkuuyn5ptmggzwmwwvb3f.png","mpjk0iuakyp6cjnvvtp","santander-27-de-mayo-miercoles-y-3-de-junio-miercoles-etica-y-medicamentos-teva","Santander 27 de mayo (miércoles) y 3 de junio (miércoles). Ética y medicamentos. Teva","\u003Cp>Encuentro y Solidaridad, Pasaje Seguro, Asamblea Cántabra contra el Rearme y la Militarización y Cabezón por Gaza os invitan a estas jornadas. Santander.  \u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fencuentroysolidaridad.net\u002Fevent\u002Fen-sanidad-mas-ciencia-mas-equidad-y-mas-etica\u002F\">\u003Cstrong>“En sanidad, más ciencia, más equidad y más ética”. \u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cem>Introducción general\u003C\u002Fem>, Fernando Lamata, 27 mayo.\u003C\u002Fp>\n\u003Cp>\u003Cem>Teva\u003C\u002Fem>, Juan Gérvas y Mercedes Pérez-Fernández, 3 de junio https:\u002F\u002Fencuentroysolidaridad.net\u002Fevent\u002Fen-sanidad-mas-ciencia-mas-equidad-y-mas-etica\u002F\u003C\u002Fp>\n\u003Cp>A finales de mayo y principios de junio se celebrarán en Santander las jornadas “\u003Cstrong>En sanidad, más ciencia, más equidad y más ética”. \u003C\u002Fstrong>Han sido co-organizadas por asociaciones de Cantabria adheridas al manifiesto TEVA. Se trata de una \u003Ca href=\"https:\u002F\u002Ftevanogracias.com\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">compaña de boicot\u003C\u002Fa> a la farmacéutica israelí por su complicidad en el genocidio en Palestina\u003C\u002Fp>\n\u003Cp>Las jornadas contarán con dos aportaciones y diálogo posterior\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Medicamentos, salud y sistemas sanitarios. Por Fernando Lamata.\u003Cbr>\u003C\u002Fstrong>Asociación de Acceso Justo al Medicamento. Médico Psiquiatra. Gestión de Servicios Sanitarios. Director Insalud Cantabria y Madrid (1983-1989). Director Escuela Nacional de Sanidad. (1989-1991). Consejero de Salud y Bienestar Social de Castilla-La Mancha (2000-2004 y 2008-2011). Secretario General de Sanidad (2004-2005). Miembro del Panel de Expertos en temas de Salud del Consejo de Europa (2012-2016). Ha publicado varios libros de gestión sanitaria.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Teva, una industria farmacéutica cómplice de la ocupación, el apartheid y el genocidio en Palestina. \u003C\u002Fstrong>Por Juan Gervas y Mercedes Pérez-Fernández, médicos jubilados.  Han impulsado en España la plataforma Health Workers For Palestina.\u003C\u002Fp>\n\u003Cp>Mercedes P, especialista en Medicina Interna, junto con Juan, ha publicado libros y artículos sobre la atención primaria como Equipo CESCA («Sano y salvo, y libre de intervenciones médicas innecesarias», «La expropiación de la salud» y «El encarnizamiento médico con las mujeres»).\u003C\u002Fp>\n\u003Cp>Juan G ha sido profesor en la universidad española, en torno a la salud pública y a la atención primaria, a tiempo parcial; también en Estados Unidos (Johns Hopkins, de 1991 a 2013).\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Encuentro y Solidaridad, Pasaje Seguro, Asamblea Cántabra contra el Rearme y la Militarización y Cabezón por Gaza os invitan a estas jornadas en los días, horario y lugar que se pueden ver en el\u003Ca href=\"https:\u002F\u002Fencuentroysolidaridad.net\u002Fevent\u002Fen-sanidad-mas-ciencia-mas-equidad-y-mas-etica\u002F\"> cartel\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"tribe-block tribe-block__event-price\"> \u003C\u002Fdiv>",1779613956035,{"videoUrl":12,"tags":740,"user":13,"link":12,"imageUrl":741,"id":742,"slug":743,"type":645,"subtitle":12,"title":744,"content":745,"timestamp":746},[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1780136300\u002Fs7x5kl02nz5uzwztaxx0.png","mps7238f2se3t3ofp9j","miercoles-3-junio-19-00-h-teva-apartheid-genocidio-ocupacion-en-palestina-libreria-la-voragine-santander","Miércoles 3 junio, 19,30 h Teva, apartheid, genocidio, ocupación en Palestina. Librería La Vorágine, Santander.","\u003Cp>\u003Cstrong>Teva, apartheid, genocidio, ocupación en Palestina.\u003C\u002Fstrong>\u003Cbr>3 Junio, 19,30 h. \u003Cbr>Librería La Vorágine, Cardenal Cisneros 39, Santander. \u003Cbr>Por Mercedes Pérez-Fernández y \u003Ca class=\"text-entity-link\" dir=\"auto\" data-entity-type=\"MessageEntityMention\">@JuanGrvas\u003C\u002Fa>\u003Cbr>Coorganizado por \u003Ca class=\"text-entity-link\" dir=\"auto\" data-entity-type=\"MessageEntityMention\">@__EyS\u003C\u002Fa>\u003Cbr> \u003Ca class=\"text-entity-link\" dir=\"auto\" data-entity-type=\"MessageEntityMention\">@PasajeSeguroCAN\u003C\u002Fa> Cabezón por Gaza y \u003Ca class=\"text-entity-link\" dir=\"auto\" data-entity-type=\"MessageEntityMention\">@cantcontrareame\u003C\u002Fa> \u003Cbr>En la librería La Vorágine.\u003Cbr>Espacio negado en el Colegio de Médicos y en el Hospital Valdecilla.\u003C\u002Fp>\n\u003Cp>Ver presentación de la charla en:\u003Cbr>\u003Ca class=\"text-entity-link word-break-all\" dir=\"auto\" title=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=PWLr2Ua-kPQ\" href=\"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=PWLr2Ua-kPQ\" target=\"_blank\" rel=\"noopener noreferrer\" data-entity-type=\"MessageEntityUrl\">https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=PWLr2Ua-kPQ\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Ver en directo la charla \u003Ca href=\"https:\u002F\u002Fwww.youtube.com\u002Flive\u002FT5Se7SwWFCQ\">aquí\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>",1780136308029,{"subtitle":12,"timestamp":748,"content":749,"slug":750,"type":645,"tags":751,"user":13,"link":12,"id":754,"imageUrl":755,"title":756,"videoUrl":12},1780332618240,"\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">El pasado 27 de Mayo de 2026, el programa de radio alternativa Vallekas Crítika de Madrid,entrevistó a una de las portavoces de la Campaña \"¿Teva? No, gracias\".\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">-\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">\u003Ca class=\"framer-text\" href=\"https:\u002F\u002Fgo.ivoox.com\u002Frf\u002F174510106\" target=\"_blank\" rel=\"noopener\">https:\u002F\u002Fgo.ivoox.com\u002Frf\u002F174510106 \u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cimg class=\"framer-text framer-image framer-styles-preset-ae9yzm\" style=\"aspect-ratio: 844 \u002F 496;\" src=\"https:\u002F\u002Fframerusercontent.com\u002Fimages\u002FKdYi4QKlGW4dY9WbBYTsZ05lXvc.png\" srcset=\"https:\u002F\u002Fframerusercontent.com\u002Fimages\u002FKdYi4QKlGW4dY9WbBYTsZ05lXvc.png?scale-down-to=512&width=844&height=496 512w,https:\u002F\u002Fframerusercontent.com\u002Fimages\u002FKdYi4QKlGW4dY9WbBYTsZ05lXvc.png?width=844&height=496 844w\" alt=\"\" width=\"422\" height=\"248\">\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">-\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\">En la entrevista, Mar Gimena presenta la campaña y desgrana los motivos por los que llamamos al boicot de la compañía, deteniéndose en los aspectos prácticos de la mejor manera de evitar el consumo de medicamentos de esta compañía sionista.\u003C\u002Fp>\n\u003Cp class=\"framer-text framer-styles-preset-1kmhpb8\" dir=\"auto\"> \u003C\u002Fp>","boicot-a-teva-para-difundir-entrevista-en-radio-vallekas-critika-madrid-a-mar-jimena-de-hw4ps",[15,752,753],"Entrevista radio","Mar Jimena","mpve9tbmh0woyhygt1r","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1780332589\u002Fjanojnsi2kuvesfqiljl.jpg","Boicot a Teva. Para difundir: entrevista en radio Vallekas Crítika (Madrid) a Mar Jimena, de HW4PS",{"subtitle":12,"timestamp":758,"link":12,"user":13,"tags":759,"id":761,"imageUrl":762,"type":645,"videoUrl":12,"content":763,"slug":764,"title":765},1781177231209,[15,760],"Zaragoza","mq9elqutk9dpmg0b2qh","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1781177281\u002Fnvywo3qwml9yjzt8actf.jpg","\u003Cp>\u003Cimg src=\"https:\u002F\u002Fexternal-content.duckduckgo.com\u002Fiu\u002F?u=https%3A%2F%2Faragondigital.es%2Fasset%2Fthumbnail%2C1280%2C720%2Ccenter%2Ccenter%2Fmedia%2Faragondigital%2Fimages%2F2024%2F01%2F22%2F2024012217131236291.jpg&f=1&nofb=1&ipt=8f68ca6d229da7e64f75de6f7de1eeb71c6fcd16661b1d96758bfb78f0997147\" alt=\"\" width=\"960\" height=\"720\">\u003C\u002Fp>\n\u003Cp>\u003Cstrong>ESPAÑOL\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>BOICOT A TEVA. CONCENTRACIÓN ANTE SU FÁBRICA EN ZARAGOZA (ESPAÑA) EL SÁBADO 14 DE NOVIEMBRE DE 2026\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Quizá a usted no le suene el nombre de Teva como le suenan otras compañías farmacéuticas internacionales tipo Johnson&Johnson, Roche, Pfizer, GSK, AstraZeneca, Lilly, Sanofi, Janssen, etc.\u003C\u002Fp>\n\u003Cp>Sin embargo, Teva es un gigante farmacéutico, la mayor empresa del mundo en el campo de los medicamentos genéricos (medicamentos producidos por compañías ajenas a las que desarrollaron el original, al acabar sus patentes).\u003C\u002Fp>\n\u003Cp>Teva fue fundada en 1901. Sus oficinas centrales están en Israel. Tiene una cartera de más de 3.600 medicamentos que produce en 53 plantas, en 33 países, incluyendo una planta en Zaragoza, España (con 600 trabajadores)\u003C\u002Fp>\n\u003Cp>Zaragoza concentra el seguimiento de los ensayos clínicos del mundo y mucha de su producción de Teva  (produce en torno al 8,7% del total de sus medicamentos).\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">Las ganancias de Teva, industria farmacéutica sionista, provienen directamente de décadas de colonización y explotación de la tierra y del pueblo palestino.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">Es nuestro deber hacer todo lo posible para asegurarnos de que nuestro dinero no se utiliza para fomentar la opresión genocida y el apartheid colonial.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cspan style=\"font-weight: normal;\">Tenemos que preguntarnos, f\u003C\u002Fspan>rente a Israel (causa), apartheid y genocidio (diagnóstico) y sionismo (causa de la causa) ¿qué estás haciendo?\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">“Ustedes lo vieron todo y no hicieron nada”. O, al menos “ustedes lo intentaron”. Tú eliges ahora.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">El boicot es “acción directa” para obstaculizar el desarrollo y funcionamiento de la actividad comercial y social de Teva. El boicot funciona. El boicot es ético. El boicot es legal. El boicot es legítimo. El boicot es obligación moral. El boicot es oportuno. El boicot es proporcional. El boicot es solidario.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">Hay tres argumentos éticos fundamentales para el boicot a Teva:\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">1\u002F Los beneficios de Teva sirven para pagar impuestos en Israel y financiar la actividad terrorista de su ejército, pero además Teva se implica directamente en el soporte del ejército sionista\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">2\u002F Teva monopoliza el mercado palestino de medicamentos, e impone precios abusivos y\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">3\u002F Teva es una empresa corrupta y corruptora; entre 2010 y 2024, Teva pagó unos 11.000 millones de dólares en condenas y multas por corrupción probada en tribunales de todo el mundo.\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">BOICOT A TEVA. CONCENTRACIÓN ANTE SU FÁBRICA EN ZARAGOZA EL SÁBADO 14 DE NOVIEMBRE DE 2026\u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\"> \u003C\u002Fp>\n\u003Cp class=\"western\" style=\"margin-bottom: 0cm; line-height: 100%;\" align=\"left\">\u003Cstrong>ENGLISH\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cdiv class=\"ToWKne\">\n\u003Cdiv class=\"OlSOob\">\n\u003Cdiv class=\"ccvoYb\">\n\u003Cdiv class=\"AxqVh\">\n\u003Cdiv class=\"OPPzxe\">\n\u003Cdiv class=\"QcsUad BDJ8fb BLojaf sMVRZe hCXDsb wneUed\">\n\u003Cdiv class=\"usGWQd\">\n\u003Cdiv class=\"KkbLmb\">\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cstrong>\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">BOYCOTT TEVA.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">PROTEST IN FRONT OF ITS FACTORY IN ZARAGOZA (SPAIN) ON SATURDAY, NOVEMBER 14, 2026 \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">You may not be as familiar with the name Teva as you are with other international pharmaceutical companies like Johnson & Johnson, Roche, Pfizer, GSK, AstraZeneca, Lilly, Sanofi, Janssen, etc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">However, Teva is a pharmaceutical giant, the world's largest company in the field of generic drugs (medicines produced by companies other than those that developed the original, once their patents have expired).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Teva was founded in 1901. Its headquarters are in Israel.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">It has a portfolio of more than 3,600 medicines, produced in 53 plants across 33 countries, including a plant in Zaragoza, Spain (with 600 employees). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">Zaragoza is the hub for monitoring global clinical trials and a significant portion of Teva's production (it produces around 8.7% of its total medicines).\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The profits of Teva, a Zionist pharmaceutical company, come directly from decades of colonization and exploitation of the Palestinian land and people.\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> It is our duty to do everything possible to ensure that our money is not used to fuel genocidal oppression and colonial apartheid.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">We must ask ourselves, faced with Israel (the cause), apartheid and genocide (the diagnosis), and Zionism (the root cause), what are you doing?\u003C\u002Fspan>\u003Cspan class=\"ryNqvb\"> \"You saw it all and did nothing.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">Or, at least, \"you tried.\"\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">The choice is yours now.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is “direct action” to hinder the development and operation of Teva's commercial and social activities.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott works.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is ethical.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is legal.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is legitimate.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is a moral obligation.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is timely.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is proportionate.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">The boycott is based on solidarity.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">There are three fundamental ethical arguments for boycotting Teva: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">1\u002F Teva's profits are used to pay taxes in Israel and finance the terrorist activities of its army, and Teva is also directly involved in supporting the Zionist army. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">2\u002F Teva monopolizes the Palestinian market for medicines and imposes exorbitant prices. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">3\u002F Teva is a corrupt and corrupting company;\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">between 2010 and 2024, Teva paid approximately $11 billion in judgments and fines for proven corruption in courts around the world.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\"> \u003C\u002Fdiv>\n\u003Cdiv class=\"lRu31\" dir=\"ltr\">\u003Cspan class=\"HwtZe\" lang=\"en\">\u003Cspan class=\"ryNqvb\">BOYCOTT TEVA.\u003C\u002Fspan> \u003Cspan class=\"ryNqvb\">PROTEST IN FRONT OF THEIR FACTORY IN ZARAGOZA (SPAIN) ON SATURDAY, NOVEMBER 14, 2026\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","sabado-14-noviembre-marcha-contra-teva-ante-su-fabrica-en-zaragoza","Sábado 14 noviembre, marcha contra Teva, ante su fábrica en Zaragoza",[],[],[769,777,784,791,798,805,812,819,826,833,840,847,854,861,868,875,882,889,896,903,910,917,924,931,938,945,952,959,966,973,980,987,994,1001,1008,1015,1022,1029,1036,1043,1050,1057,1066,1073,1081,1089,1098,1105,1112,1119,1126,1133,1140,1147,1154,1161,1169,1176,1183,1190,1197,1202,1210,1217,1224,1231,1238,1245],{"user":13,"tags":770,"subtitle":12,"link":12,"timestamp":771,"content":12,"imageUrl":772,"id":773,"videoUrl":12,"title":774,"slug":775,"type":776},[15],1733155483518,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1733155460\u002Fqjp3ttm6amom9i1rzb45.jpg","m477xghpvgq27z96vhp","Boicot a Teva, Tevagen, Davur, Belmac y Ratiopharm, a sus medicamentos y productos. ¡No prescribas, ni dispenses, ni consumas! Tu dinero acaba derramando sangre, matando y destruyendo Palestina","boicot-a-teva-tevagen-davur-belmac-y-ratiopharm-a-sus-medicamentos-y-productos-no-prescribas-ni-dispenses-ni-consumas-tu-dinero-acaba-derramando-sangre-matando-y-destruyendo-palestina","material",{"link":12,"user":13,"tags":778,"timestamp":779,"imageUrl":780,"content":12,"videoUrl":12,"title":781,"subtitle":12,"id":782,"type":776,"slug":783},[15],1734201432666,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1734201418\u002Fuw9vxoxppupi5gxrfsic.jpg","Medicamentos genéricos a evitar (dañan la salud en Palestina)","m4oip639nfcxzemm3gd","medicamentos-genericos-a-evitar-danan-la-salud-en-palestina",{"imageUrl":785,"content":12,"type":776,"slug":786,"videoUrl":12,"timestamp":787,"link":12,"user":13,"tags":788,"title":789,"subtitle":12,"id":790},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1734805125\u002Fqhmpyvyq6bcdbvg2o1xx.jpg","en-madrid-al-prescribir-pide-a-la-farmacia-que-no-dispense-teva-tevagen-davur-belmac-y-ratiopharm",1734805134008,[15],"En Madrid, al prescribir, pide a la farmacia que no dispense Teva, Tevagen, Davur, Belmac y Ratiopharm","m4yi570jirrpg3822jn",{"slug":792,"type":776,"id":793,"videoUrl":12,"imageUrl":794,"content":12,"title":795,"subtitle":12,"timestamp":796,"tags":797,"user":13,"link":12},"las-autoridades-sanitarias-no-advierten-que-este-medicamento-perjudica-gravemente-la-salud-palestina-boicot-a-teva-tevagen-davur-belmac-y-ratiopharm","m59zas7ad3f8iqkyfzo","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1735572014\u002Fleeziej4rzxofgisi3ng.jpg","“Las Autoridades Sanitarias NO advierten que este medicamento perjudica gravemente la salud palestina” Boicot a Teva, Tevagen, Davur, Belmac y Ratiopharm",1735499067874,[15],{"content":12,"imageUrl":799,"type":776,"slug":800,"videoUrl":12,"timestamp":801,"link":12,"user":13,"tags":802,"subtitle":12,"title":803,"id":804},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1738005587\u002Fwi6l1bhgmnu18k5oxmxg.jpg","cuitvar-vareniciclina-dejar-de-fumar-si-pero-no-a-costa-de-sangre-palestina-boicot-teva-tevagen-davur-belmac-ratiopharm",1738005641086,[15],"CuitVar, vareniciclina. Dejar de fumar, sí. Pero no a costa de sangre palestina. Boicot Teva Tevagen Davur Belmac Ratiopharm","m6ffk51g4ojqr86baa",{"id":806,"imageUrl":807,"content":12,"videoUrl":12,"tags":808,"user":13,"link":12,"subtitle":12,"slug":809,"type":776,"timestamp":810,"title":811},"m7rm90214ifbdbq0x7u","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1740919065\u002Fckgcmuyicmibor0gx2yy.jpg",[15],"no-prescribas-ni-dispenses-ni-compres-las-marcas-de-teva-teva-tevagen-ratiopharm-teva-ratio-davur-belmac",1740919071611,"NO prescribas, ni dispenses, ni compres las marcas de TEVA: Teva, TevaGen, Ratiopharm, Teva-Ratio, DAVUR, Belmac... ",{"subtitle":12,"content":12,"slug":813,"type":776,"user":13,"tags":814,"link":12,"id":815,"timestamp":816,"imageUrl":817,"title":818,"videoUrl":12},"infarma2025-infamia",[15],"m8j685yvxvvsvzk9xb",1742585350642,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1742585340\u002Flm0vpkjf78rw6zogvjeb.jpg","¿ #infarma2025? INFAMIA ",{"tags":820,"user":13,"id":821,"imageUrl":822,"link":12,"videoUrl":12,"title":823,"content":12,"timestamp":824,"subtitle":12,"slug":825,"type":776},[15],"m9h5ehqvj1ghrddqdd","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1744639798\u002Fnpyhykk1l47nwdnqov3p.jpg","Strictly apolitical (having Teva as sponsor) Estrictamente apolítico (recibiendo dinero de Teva) Strictement apolitique (reçoit de l'argent de Teva)",1744639806588,"strictly-apolitical-having-teva-as-sponsor-estrictamente-apolitico-recibiendo-dinero-de-teva-strictement-apolitique-recoit-de-l-argent-de-teva",{"slug":827,"type":776,"title":828,"imageUrl":829,"id":830,"videoUrl":12,"timestamp":831,"subtitle":12,"content":12,"user":13,"tags":832,"link":12},"rechaza-medicamentos-sangrientos-teva-tevagen-belmac-davur-ratiopharm","Rechaza medicamentos sangrientos: Teva, Tevagen, Belmac, Davur, Ratiopharm","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1744794604\u002Ffjmec1ep1qedn0ytfjbe.jpg","m9jpgmzkjeaqg9uake",1744794612467,[15],{"subtitle":12,"content":12,"slug":834,"type":776,"user":13,"tags":835,"link":12,"imageUrl":836,"title":837,"id":838,"videoUrl":12,"timestamp":839},"no-prescriba-no-dispense-no-consuma-teva-productos-criminales-do-not-prescribe-do-not-dispense-do-not-use-teva-criminal-products",[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1744985447\u002Fjgecahtq7bg3ipygsowc.jpg","No prescriba, no dispense, no consuma Teva, productos criminales. Do not prescribe, do not dispense, do not use Teva. Criminal products","m9mv6crkfvp59qzispw",1744985457371,{"slug":841,"type":776,"id":842,"imageUrl":843,"videoUrl":12,"subtitle":12,"title":844,"content":12,"timestamp":845,"user":13,"tags":846,"link":12},"boicot-a-teva-sobran-las-razones","m9xzrfyr828yy0hzj4b","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1745658129\u002Fnljhdr1fbevlww3tec2v.jpg","Boicot a TEVA. Sobran las razones",1745658141640,[15],{"content":12,"title":848,"subtitle":12,"type":776,"slug":849,"id":850,"timestamp":851,"imageUrl":852,"link":12,"user":13,"tags":853,"videoUrl":12},"#stopTEVA *¡Firma aquí!* stop-teva.yalanafarroa.com","stopteva-firma-aqui-stop-teva-yalanafarroa-com","mbkh6kjciyc3e2rerz",1749194447727,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1749194440\u002Fakxskxtvxz3plwacp5q9.jpg",[15],{"videoUrl":12,"tags":855,"user":13,"link":12,"content":12,"imageUrl":856,"timestamp":857,"slug":858,"id":859,"type":776,"subtitle":12,"title":860},[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1750230099\u002Fmrhnx7zrkpcffml7ripp.jpg",1750230110704,"boycott-teva-true-values","mc1lsdtgm4p85ymcna","Boycott Teva True values",{"imageUrl":862,"type":776,"videoUrl":12,"slug":863,"id":864,"subtitle":12,"link":12,"title":865,"tags":866,"user":13,"content":12,"timestamp":867},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1750516177\u002Fyicwmcut8gskcfsmal3s.jpg","no-te-manches-las-manos-de-sangre-teva-no","mc6c44kcjskll6r7d7","No te manches las manos de sangre. Teva no.",[15],1750516197981,{"videoUrl":12,"timestamp":869,"title":870,"id":871,"imageUrl":872,"link":12,"user":13,"tags":873,"type":776,"slug":874,"subtitle":12,"content":12},1751271056560,"Do not stain your hands with blood...","mcitjanod4d9j6a6zrk","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1751271015\u002Fi05zfmkgc7iqacmn5lko.jpg",[15],"do-not-stain-your-hands-with-blood",{"title":876,"subtitle":12,"slug":877,"type":776,"id":878,"videoUrl":12,"tags":879,"user":13,"link":12,"timestamp":880,"content":12,"imageUrl":881},"En Navarra, boicot Teva. 31 julio 2025","en-navarra-boicot-teva-31-julio-2025","mdvkucw91mdj32pmkax",[15],1754219285955,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1754219272\u002Fjbdgbzqyyy1p4dop4v8z.jpg",{"imageUrl":883,"title":884,"type":776,"slug":885,"id":886,"videoUrl":12,"content":12,"link":12,"subtitle":12,"tags":887,"user":13,"timestamp":888},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1754305242\u002Fcpqetdfgbif7imbi1lcc.jpg","Teva, no gracias (no quiero cooperar con el genocidio en Gaza). Yala Nafarroa con Palestina","teva-no-gracias-no-quiero-cooperar-con-el-genocidio-en-gaza-yala-nafarroa-con-palestina","mdwzqslagmylx6ezd7h",[15],1754305305402,{"content":12,"subtitle":12,"title":890,"link":12,"user":13,"tags":891,"timestamp":892,"imageUrl":893,"type":776,"slug":894,"id":895,"videoUrl":12},"Teva. Ez, eskerrik asko. Yala Nafarroa ",[15],1754305511412,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1754305418\u002Fp2muyqoahc4mkurk7hcb.png","teva-ez-eskerrik-asko-yala-nafarroa","mdx03z443uxt07mggeu",{"content":12,"imageUrl":897,"id":898,"slug":899,"type":776,"videoUrl":12,"subtitle":12,"tags":900,"user":13,"link":12,"title":901,"timestamp":902},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1754467050\u002Fvn19x1si7w5qw7q2y8zf.jpg","mdzod7lzqabp1m5vw1q","no-gracias",[15],"No, gracias",1754467056551,{"content":12,"imageUrl":904,"type":776,"timestamp":905,"slug":906,"videoUrl":12,"id":907,"subtitle":12,"link":12,"user":13,"tags":908,"title":909},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1754467135\u002Fuwhcl4ifbfgsl5ghiaak.png",1754467144047,"no-thanks","mdzof3vh6f9ciwj0ww",[15],"No, thanks",{"subtitle":12,"type":776,"slug":911,"link":12,"videoUrl":12,"tags":912,"user":13,"title":913,"timestamp":914,"id":915,"content":12,"imageUrl":916},"boicot-teva-4-cuestiones",[15],"Boicot Teva, 4 cuestiones",1754673295622,"me33585035mhm630dqv","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1754673288\u002Fqo8lt0egae0jnpyec4d6.jpg",{"videoUrl":12,"id":918,"user":13,"tags":919,"timestamp":920,"content":12,"link":12,"imageUrl":921,"title":922,"subtitle":12,"slug":923,"type":776},"meh5hhmxnvtks7jl4j",[15],1755523740894,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1755523736\u002Fi0ihy9ole3wdpeevggut.jpg","Teva. No thanks. 4 reasons","teva-no-thanks-4-reasons",{"timestamp":925,"content":12,"subtitle":12,"id":926,"link":12,"user":13,"tags":927,"type":776,"imageUrl":928,"slug":929,"title":930,"videoUrl":12},1755527435707,"meh7oi2371qq3bp9h38",[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1755527428\u002Fzixjx84kvsdtxjbn0vhm.jpg","boycott-teva-boycott-genocide","Boycott Teva. Boycott genocide",{"subtitle":12,"type":776,"timestamp":932,"slug":933,"content":12,"title":934,"imageUrl":935,"link":12,"id":936,"videoUrl":12,"tags":937,"user":13},1755531389578,"contra-el-genocidio-el-apartheid-y-la-ocupacion-no-a-teva-teva-tevagen-davur-belmac-ratiopharm-etc","Contra el genocidio, el apartheid y la ocupación, NO a Teva (Teva, Tevagen, Davur, Belmac, Ratiopharm, etc)","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1755531286\u002Fwxy84dnufiis53nm3eh2.jpg","meh9zcaxoke5903dyqg",[15],{"videoUrl":12,"imageUrl":939,"type":776,"timestamp":940,"slug":941,"content":12,"link":12,"user":13,"tags":942,"title":943,"id":944,"subtitle":12},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1756630667\u002Fhvcatczipciaeo0team7.jpg",1756630675370,"teva-no-no-por-favor-no",[15],"Teva, no, No, por favor no","mezgir43fuw84lctfaa",{"content":12,"videoUrl":12,"link":12,"user":13,"tags":946,"imageUrl":947,"timestamp":948,"type":776,"slug":949,"id":950,"title":951,"subtitle":12},[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1756927508\u002Fkvnidamknsuudrrt0dsd.jpg",1756927515362,"boycott-teva-priority-target-boicot-teva-objetivo-prioritario","mf4d757vr49ix60utz","Boycott Teva, priority target. Boicot Teva, objetivo prioritario.",{"timestamp":953,"link":12,"tags":954,"user":13,"id":955,"subtitle":12,"title":956,"videoUrl":12,"content":12,"type":776,"imageUrl":957,"slug":958},1758812318313,[15],"mfzjetoqr3nbc84amd9","Boicot (acción directa) a Teva. 1\u002F omeprazol, ...","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1758812312\u002Fz0a18mko7k1mwksy0set.jpg","boicot-accion-directa-a-teva-1-omeprazol",{"id":960,"imageUrl":961,"slug":962,"content":12,"type":776,"videoUrl":12,"timestamp":963,"subtitle":12,"user":13,"tags":964,"title":965,"link":12},"mfzjg12kawhv2o0kgn5","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1758812366\u002Fu4svp03xexi8am4wo4yn.jpg","boicot-accion-directa-a-teva-2-atorvastatina",1758812372398,[15],"Boicot (acción directa) a Teva. ...2\u002F atorvastatina...",{"imageUrl":967,"slug":968,"id":969,"type":776,"content":12,"videoUrl":12,"title":970,"subtitle":12,"timestamp":971,"tags":972,"user":13,"link":12},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1758812432\u002Fjgqry4wzqbpgdn2nikgn.jpg","boicot-accion-directa-a-teva-y-3-pantoprazol","mfzjh7rsds84tbo1lvm","Boicot (acción directa) a Teva. ...y 3\u002F pantoprazol",1758812437941,[15],{"title":974,"videoUrl":12,"imageUrl":975,"type":776,"timestamp":976,"slug":977,"link":12,"tags":978,"user":13,"content":12,"id":979,"subtitle":12},"No manches tus manos de sangre","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1759653472\u002Fkcsuplzhuzzryrqvj170.jpg",1759653478270,"no-manches-tus-manos-de-sangre",[15],"mgdg84n9le0hkbxi6x",{"id":981,"slug":982,"title":983,"type":776,"subtitle":12,"content":12,"videoUrl":12,"imageUrl":984,"timestamp":985,"user":13,"tags":986,"link":12},"mgsbz33lim0uhxl06f","boicot-teva-ics-vergonya","Boicot Teva. ICS vergonya","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1760553317\u002Feccz5j6ksgw72351nz3r.jpg",1760553368215,[15],{"id":988,"timestamp":989,"title":990,"tags":991,"user":13,"subtitle":12,"link":12,"slug":992,"type":776,"videoUrl":12,"content":12,"imageUrl":993},"mh90feaf8qpmozeamkx",1761561862566,"Teva desangra Palestina",[15],"teva-desangra-palestina","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1761561852\u002Ffbmggfodin4pifthtqvy.jpg",{"timestamp":995,"slug":996,"type":776,"imageUrl":997,"videoUrl":12,"title":998,"content":12,"subtitle":12,"id":999,"tags":1000,"user":13,"link":12},1763058316201,"pablo-simon-lorda-hw4ps-versus-teva","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763058286\u002Fub1zyyl1msktvjobe0sb.jpg","Pablo Simón Lorda (HW4PS) versus Teva","mhxrde4qxd7x55zvgmq",[15],{"subtitle":12,"timestamp":1002,"slug":1003,"type":776,"user":13,"tags":1004,"link":12,"imageUrl":1005,"id":1006,"title":1007,"content":12,"videoUrl":12},1763305921405,"boicot-a-medicamentos-de-teva-actavis-belmac-davur-ratiopharm-tevagen",[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763305856\u002Frrdeinwumvpotmmostzc.jpg","mi1urf7biwzqrshxy7","Boicot a medicamentos de Teva (Actavis, Belmac, Davur, Ratiopharm, Tevagen)",{"user":13,"tags":1009,"link":12,"content":12,"subtitle":12,"imageUrl":1010,"timestamp":1011,"id":1012,"slug":1013,"title":1014,"videoUrl":12,"type":776},[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763412030\u002Fgh1l6ujsc32benwuupjp.jpg",1763412040306,"mi3lyqmezntake58z3","boicot-ajovy-boicott-ajovy","Boicot Ajovy. Boicott Ajovy",{"id":1016,"imageUrl":1017,"user":13,"tags":1018,"link":12,"videoUrl":12,"timestamp":1019,"subtitle":12,"slug":1020,"type":776,"content":12,"title":1021},"mi4cziggan85z0vtr4q","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763457417\u002Fufqld49gynox7xcgzds2.jpg",[15],1763457429798,"ajovy-no-aporta-nada-bueno-nuevo-boicot-teva","Ajovy, no aporta nada bueno nuevo. Boicot Teva",{"subtitle":12,"slug":1023,"id":1024,"type":776,"content":12,"title":1025,"imageUrl":1026,"timestamp":1027,"videoUrl":12,"user":13,"tags":1028,"link":12},"teva-como-maquina-de-violencia-genocida","mi7fb3rawf2jfaxiaa","Teva como máquina de violencia genocida","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763642716\u002Fsknow5ucqfva2roigohp.jpg",1763642742451,[15],{"subtitle":12,"tags":1030,"user":13,"link":12,"content":12,"timestamp":1031,"imageUrl":1032,"id":1033,"slug":1034,"type":776,"title":1035,"videoUrl":12},[15],1763910715524,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763910708\u002Fxwcjwotqpdhtswvq87xk.jpg","mibuv8fyis23xd5z4tr","boicot-teva-boicot-ajovy","Boicot Teva. Boicot Ajovy",{"id":1037,"videoUrl":12,"tags":1038,"user":13,"link":12,"content":12,"imageUrl":1039,"timestamp":1040,"subtitle":12,"slug":1041,"type":776,"title":1042},"mibuwk9726t38pqrm8h",[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1763910947\u002Fiauiqbaj9485nqij13jb.jpg",1763910771120,"boycott-teva-boycott-ajovy","Boycott Teva. Boycott Ajovy",{"content":12,"timestamp":1044,"id":1045,"subtitle":12,"link":12,"user":13,"tags":1046,"type":776,"slug":1047,"videoUrl":12,"imageUrl":1048,"title":1049},1764186325350,"migez0ihl20kufntwzt",[15],"los-pacientes-de-chauchina-con-su-medico-pablo-simon-denunciado-por-los-sionistas-por-cumplir-con-el-codigo-deontologico-y-no-prescribir-teva","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1764186432\u002Ffurscoqdhbwpqeklaqgp.jpg","Los pacientes (de Chauchina), con su médico (Pablo Simón, denunciado por los sionistas por cumplir con el Código Deontológico y no prescribir Teva)",{"title":1051,"timestamp":1052,"subtitle":12,"slug":1053,"content":12,"type":776,"id":1054,"videoUrl":12,"tags":1055,"user":13,"link":12,"imageUrl":1056},"Boycott Boicot Teva",1764513115755,"boycott-boicot-teva","miltin5e50ee13d8o4",[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1764513107\u002Ftjgcyseimapcfjwpjdyq.jpg",{"imageUrl":1058,"id":1059,"title":1060,"slug":1061,"type":776,"content":12,"videoUrl":12,"user":13,"tags":1062,"subtitle":12,"link":12,"timestamp":1065},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1765270058\u002Fqsfdc7g4uymqbvzx6bbw.png","miyc77d9fkumj6dasld","Boicot Teva (obras son amores, y no buenas razones)","boicot-teva-obras-son-amores-y-no-buenas-razones",[15,1063,1064],"Asturias","Navarra",1765270108352,{"tags":1067,"user":13,"link":12,"subtitle":12,"content":12,"title":1068,"id":1069,"timestamp":1070,"imageUrl":1071,"videoUrl":12,"slug":1072,"type":776},[15],"Teva: un horror. Teva: a horror","mizx242vdy3z5kwwos",1765365612731,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1765365605\u002Fx2n7xdikjms7h33sri0n.png","teva-un-horror-teva-a-horror",{"link":12,"user":13,"tags":1074,"videoUrl":12,"timestamp":1076,"imageUrl":1077,"content":12,"title":1078,"subtitle":12,"type":776,"id":1079,"slug":1080},[15,1075],"Carrefour",1765913151006,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1765913063\u002Frehluaoifoc8ns9x6cfs.jpg","Teva, Carrefour...entre objetivos prioritarios de boicot...priorittery objetives of boycott...","mj8z16kappr0sov98mr","teva-carrefour-entre-objetivos-prioritarios-de-boicot-priorittery-objetives-of-boycott",{"user":13,"tags":1082,"link":12,"timestamp":1084,"videoUrl":12,"imageUrl":1085,"id":1086,"content":12,"subtitle":12,"title":1087,"slug":1088,"type":776},[15,1083],"BDS",1767517126961,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1767517102\u002Fq6k3mt5ziwutnuromsf4.jpg","mjzi0t91x1v5yq93c4i","Teva: Boicot, Desinversión, Sanción","teva-boicot-desinversion-sancion",{"link":12,"user":13,"tags":1090,"subtitle":12,"imageUrl":1093,"content":12,"timestamp":1094,"id":1095,"videoUrl":12,"title":1096,"type":776,"slug":1097},[1091,1092,15],"Corrupción","Elbit","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1768554594\u002Fbn5nfr0seysfhtmubaa3.jpg",1768554653976,"mkgnqa3q70mbu0hs9e9","Sionismo, la corrupción que no cesa: Elbit, Teva,...","sionismo-la-corrupcion-que-no-cesa-elbit-teva",{"link":12,"user":13,"tags":1099,"imageUrl":1100,"videoUrl":12,"title":1101,"subtitle":12,"timestamp":1102,"id":1103,"type":776,"content":12,"slug":1104},[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1768559058\u002Fuqn3qj8xfzun7kmphltz.jpg","Teva, boikota...BDZ",1768559070862,"mkgqdmjy0svg4tytzag","teva-boikota-bdz",{"timestamp":1106,"link":12,"content":12,"user":13,"tags":1107,"id":1108,"subtitle":12,"title":1109,"videoUrl":12,"type":776,"slug":1110,"imageUrl":1111},1768559201117,[15],"mkgqgdryc3jrwjz51jh","Teva, B Desinversió S","teva-b-desinversio-s","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1768559183\u002Ffsag1u38uat4pe4bkngu.jpg",{"type":776,"slug":1113,"subtitle":12,"id":1114,"content":12,"title":1115,"timestamp":1116,"videoUrl":12,"imageUrl":1117,"link":12,"tags":1118,"user":13},"campana-estatal-de-boicot-a-teva-que-tus-medicamentos-no-sean-sus-balas","mm1s9i47booydtfujf9","Campaña estatal de boicot a Teva, \"que tus medicamentos no sean sus balas\"",1772008822223,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1772008803\u002Fv9wuzhd2iazgcagsi9yd.png",[15,164],{"link":12,"tags":1120,"user":13,"subtitle":12,"title":1121,"id":1122,"videoUrl":12,"timestamp":1123,"content":12,"type":776,"slug":1124,"imageUrl":1125},[15,164,712,713],"Más de 300 organizaciones. Campaña estatal de boicot a Teva","mm6qf8vrfiy54wpctfk",1772308079634,"mas-de-300-organizaciones-campana-estatal-de-boicot-a-teva","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1772308021\u002Fx8ecbapjkgoghdfue5yr.png",{"user":13,"tags":1127,"link":12,"content":12,"subtitle":12,"title":1128,"timestamp":1129,"id":1130,"imageUrl":1131,"slug":1132,"videoUrl":12,"type":776},[523,15,164],"Ajovy, no. #boicotTeva #TevaNoGracias",1773777219711,"mmv149w2827qshh60bx","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1773777215\u002Fr4n5gwwwyyjjpwee9mn0.jpg","ajovy-no-boicotteva-tevanogracias",{"subtitle":12,"content":12,"timestamp":1134,"title":1135,"link":12,"id":1136,"user":13,"tags":1137,"type":776,"imageUrl":1138,"slug":1139,"videoUrl":12},1773870356808,"Infarma o, mejor, \"Infarmia\"","mmwhh4dtqpb3xidcnc",[15,722,723],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1773865145\u002Flcbfm6o1zb8wnu6733ks.jpg","infarma-o-mejor-infarmia",{"link":12,"tags":1141,"user":13,"subtitle":12,"timestamp":1142,"content":12,"videoUrl":12,"id":1143,"imageUrl":1144,"type":776,"title":1145,"slug":1146},[15],1774946868407,"mnedhol1l82vjhv22xb","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1774946857\u002Fg2kkazskacilwi0thdpe.png","30 Mar 2026. Israel. An Iranian missile strike hit the industrial zone where Teva operates and harms it. Un ataque con misiles iraníes impactó la zona industrial donde opera Teva y la dañó.","30-mar-2026-israel-an-iranian-missile-strike-hit-the-industrial-zone-where-teva-operates-and-harms-it-un-ataque-con-misiles-iranies-impacto-la-zona-industrial-donde-opera-teva-y-la-dano",{"id":1148,"subtitle":12,"user":13,"tags":1149,"link":12,"content":12,"imageUrl":1150,"timestamp":1151,"slug":1152,"type":776,"videoUrl":12,"title":1153},"mnosuuwmjtuqbrlrtkj",[15,164,471],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1775577305\u002Faeupdmh5p14evsk99mkv.jpg",1775577310211,"fijese-en-el-fabricante-boicot-teva-always-read-the-label-boycott-teva","¡Fíjese en el fabricante! Boicot Teva. Always read the label. Boycott Teva.",{"type":776,"subtitle":12,"id":1155,"slug":1156,"videoUrl":12,"link":12,"title":1157,"tags":1158,"user":13,"content":12,"imageUrl":1159,"timestamp":1160},"mnrlwq7iurfuyhgtqyb","teva-la-falsa-inocencia-de-una-industria-farmaceutica-directamente-conectada-al-genocidio","Teva, la \"falsa inocencia\" de una industria farmacéutica directamente conectada al genocidio",[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1775747010\u002Fd34g6akdkja8gdkjtbgx.jpg",1775747062062,{"imageUrl":1162,"type":776,"slug":1163,"content":12,"videoUrl":12,"title":1164,"subtitle":12,"link":12,"id":1165,"user":13,"tags":1166,"timestamp":1168},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1777480259\u002Faopdtnfm4ffewrhtvkxh.png","teva-y-la-sociedad-espanola-de-neurologia-sen-asociadas-en-el-genocidio-en-gaza","Teva y la Sociedad Española de Neurología (SEN) asociadas en el genocidio en Gaza","mok9p2if2qjwyplmt3s",[15,1167],"SEN",1777480057161,{"tags":1170,"user":13,"link":12,"imageUrl":1171,"content":12,"videoUrl":12,"title":1172,"timestamp":1173,"id":1174,"subtitle":12,"slug":1175,"type":776},[15],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1777533779\u002Fu6w2iyywqw1ox2zvh2yi.png","Genocidina. Teva",1777533784094,"mol5p7kejmgl0iuxzac","genocidina-teva",{"imageUrl":1177,"title":1178,"timestamp":1179,"type":776,"slug":1180,"videoUrl":12,"id":1181,"link":12,"content":12,"tags":1182,"user":13,"subtitle":12},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1777535608\u002Fxdlophipgip33hrwlcqc.jpg","Las Mariposas Sin Alma. VideoPotcast. Sociedad Española de Neurología (SEN)\u002FTeva. \"Entendiendo la Migraña: mucho más que dolor de cabeza” ",1777535623535,"las-mariposas-sin-alma-videopotcast-sociedad-espanola-de-neurologia-sen-teva-entendiendo-la-migrana-mucho-mas-que-dolor-de-cabeza","mol6p4lnsisrnt2b948",[15,1167],{"id":1184,"timestamp":1185,"videoUrl":12,"imageUrl":1186,"user":13,"tags":1187,"link":12,"slug":1188,"type":776,"content":12,"title":1189,"subtitle":12},"moraevlulbis8yje04e",1777904592302,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1777904482\u002Fbir1h3rclstqprmkkqo2.png",[15],"teva-priority-boycott-target-boycott-divestment-and-sanctions-bds","Teva. Priority Boycott Target. Boycott, Divestment and Sanctions (BDS)",{"timestamp":1191,"content":12,"title":1192,"link":12,"id":1193,"user":13,"tags":1194,"subtitle":12,"type":776,"slug":1195,"videoUrl":12,"imageUrl":1196},1780298601941,"¡Fíjate en el logo! ¡Teva no!","mpuvrvg3p90bnaroyl",[15],"fijate-en-el-logo-teva-no","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1780298554\u002Fgk3cmkc9dswjjyymqm71.jpg",{"link":12,"tags":1198,"user":13,"subtitle":12,"videoUrl":12,"timestamp":1199,"content":12,"id":1200,"imageUrl":1201,"type":776,"title":765,"slug":764},[15,760],1781176622342,"mq9eiriw08n150sirbur","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1781176614\u002Fqksolkbi3cwonawqe4qn.jpg",{"videoUrl":12,"user":13,"tags":1203,"link":12,"imageUrl":1205,"id":1206,"slug":1207,"timestamp":1208,"type":776,"subtitle":12,"title":1209,"content":12},[15,1204],"Marcas","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1785698821\u002Fskc6urndyhtmkm3uttc1.jpg","msc1wzd1ebp5icqe3cg","las-marcas-de-teva-todas-genocidas",1785698832007,"Las marcas de Teva. Todas genocidas.",{"content":12,"user":13,"tags":1211,"id":1212,"subtitle":12,"link":12,"timestamp":1213,"imageUrl":1214,"slug":1215,"type":776,"videoUrl":12,"title":1216},[15,1092],"mshakgf8z9jrsmtorud",1786007377532,"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1786007275\u002Fgnuqm2zbvnhk43ft3p9x.jpg","teva-nogracias-boicot-a-las-dos-companias-gigantes-de-la-bolsa-en-israel-elbit-armas-y-teva-medicamentos-teva-nothanks-boycott-the-two-giant-companies-on-the-israeli-stock-exchange-elbit-weapons-and-teva-pharmaceuticals","Teva, NoGracias. Boicot a las dos compañías gigantes de la Bolsa en Israel: Elbit (armas) y Teva (medicamentos). Teva NoThanks. Boycott the two giant companies on the Israeli Stock Exchange: Elbit (weapons) and Teva (pharmaceuticals)",{"videoUrl":12,"id":1218,"user":13,"tags":1219,"link":12,"imageUrl":1220,"slug":1221,"subtitle":12,"type":776,"content":12,"timestamp":1222,"title":1223},"msxhq7aiwt8u8rcu7j",[15,164],"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1786986689\u002Ffkvosv6edrrrybsptvpi.jpg","por-que-hacer-boicot-a-teva",1786986728832,"¿Por qué hacer boicot a Teva?",{"videoUrl":12,"link":12,"user":13,"tags":1225,"id":1226,"title":1227,"content":12,"imageUrl":1228,"type":776,"slug":1229,"subtitle":12,"timestamp":1230},[15],"mtebtnf51h8xupwuafl","Teva, #nogracias Boicot a Teva. Sus medicamentos están manchados de sangre palestina. Hay alternativas \"limpias\".","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1788004703\u002Fmjed03k2ykcskh0huxzg.png","teva-nogracias-boicot-a-teva-sus-medicamentos-estan-manchados-de-sangre-palestina-hay-alternativas-limpias",1788004715916,{"videoUrl":12,"content":12,"type":776,"imageUrl":1232,"timestamp":1233,"slug":1234,"link":12,"user":13,"tags":1235,"title":1236,"subtitle":12,"id":1237},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1790784743\u002Fj1j3dcg1iwn1wbtcflnk.png",1790784787909,"teva-una-empresa-criminal-que-corrompe-a-profesionales",[15],"Teva, una empresa criminal que corrompe a profesionales","muoaz7fvikh8q6orhzb",{"title":1239,"subtitle":12,"type":776,"slug":1240,"imageUrl":1241,"link":12,"tags":1242,"user":13,"timestamp":1243,"id":1244,"content":12,"videoUrl":12},"Patricia Pozo Rosich, a la cabeza de los \"líderes de opinión\" financiados por Teva","patricia-pozo-rosich-a-la-cabeza-de-los-lideres-de-opinion-financiados-por-teva","https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1790784814\u002Fysxddsgpuwmjmjuwouyg.png",[15,612],1790784891088,"muob139gegegnf3ta2",{"imageUrl":1246,"videoUrl":12,"slug":1247,"type":776,"subtitle":12,"tags":1248,"user":13,"id":1251,"link":12,"title":1252,"content":12,"timestamp":1253},"https:\u002F\u002Fres.cloudinary.com\u002Fdohlie6or\u002Fimage\u002Fupload\u002Fv1791550431\u002Fmn1arofxfrbvfjhxhb9g.png","boycott-teva-and-suspend-ima-from-wma-boicot-a-teva-y-fuera-la-asociacion-medica-israeli-de-la-asociacion-medica-mundial",[15,1249,1250,471,164],"IMA","WMA","mv0yt4g3j4vmzrk2lel","Boycott Teva and suspend IMA from WMA. Boicot a Teva, y fuera la Asociación Médica Israelí de la Asociación Médica Mundial",1791550483495]